PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	BOOT, RG; RENKEMA, GH; STRIJLAND, A; VANZONNEVELD, AJ; AERTS, JMFG				BOOT, RG; RENKEMA, GH; STRIJLAND, A; VANZONNEVELD, AJ; AERTS, JMFG			CLONING OF A CDNA-ENCODING CHITOTRIOSIDASE, A HUMAN CHITINASE PRODUCED BY MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; SEQUENCE; PLANT; GENE	We have recently observed that chitotriosidase, a chitinolytic enzyme, is secreted by activated human macrophages and is markedly elevated in plasma of Gaucher disease patients (Hollak, C. E, M,, van Weely, S,, van Oers, M, H. J,, and Aerts, J, M, F, G, (1994) J. Clin. Invest, 93, 1288-1292), Here, we report on the cloning of the corresponding cDNA The nucleotide sequence of the cloned cDNA predicts a protein with amino acid sequences identical to those established for purified chitotriosidase, Secretion of active chitotriosidase was obtained after transient transfection of COS-1 cells with the cloned cDNA, confirming its identity as chitotriosidase cDNA. Chitotriosidase contains several regions with high homology to those present in chitinases from different species belonging to family 18 of glycosyl hydrolases, Northern blot analysis shows that expression of chitotriosidase mRNA occurs only at a late stage of differentiation of monocytes to activated macrophages in culture, Our results show that, in contrast to previous beliefs, human macrophages can synthesize a functional chitinase, a highly conserved enzyme with a strongly regulated expression, This enzyme may play a role in the degradation of chitin-containing pathogens and can be used as a marker for specific disease states.	UNIV AMSTERDAM,ACAD MED CTR,EC SLATER INST,DEPT BIOCHEM,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam			Aerts, Johannes/A-1028-2009; van Zonneveld, Anton Jan/D-8060-2018; Renkema, Herma/L-1489-2015	Aerts, Johannes/0000-0001-8168-2565; van Zonneveld, Anton Jan/0000-0002-1676-7738; Renkema, Herma/0000-0002-8174-6538; Boot, Rolf/0000-0002-7031-3390				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BENHAMOU N, 1993, CAN J MICROBIOL, V39, P318, DOI 10.1139/m93-045; BROEKAERT WF, 1988, PHYSIOL MOL PLANT P, V33, P319, DOI 10.1016/0885-5765(88)90001-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINGE DB, 1993, PLANT J, V3, P31, DOI 10.1046/j.1365-313X.1993.t01-1-00999.x; COULSON AFW, 1994, FEBS LETT, V354, P41, DOI 10.1016/0014-5793(94)01084-6; DEJONG AJ, 1992, PLANT CELL, V4, P425, DOI 10.2307/3869444; FLACH J, 1992, EXPERIENTIA, V48, P701, DOI 10.1007/BF02124285; FUHRMAN JA, 1992, P NATL ACAD SCI USA, V89, P1548, DOI 10.1073/pnas.89.5.1548; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; HOLM L, 1994, FEBS LETT, V340, P129, DOI 10.1016/0014-5793(94)80187-8; HUBER M, 1991, P NATL ACAD SCI USA, V88, P2807, DOI 10.1073/pnas.88.7.2807; KRAMER KJ, 1993, INSECT BIOCHEM MOLEC, V23, P691, DOI 10.1016/0965-1748(93)90043-R; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; RAGHAVAN N, 1994, INFECT IMMUN, V62, P1901, DOI 10.1128/IAI.62.5.1901-1908.1994; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; ROBERTS WK, 1988, J GEN MICROBIOL, V134, P169; SAHAI AS, 1993, FEMS MICROBIOL REV, V11, P317, DOI 10.1111/j.1574-6976.1993.tb00004.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHAHABUDDIN M, 1995, PARASITOL TODAY, V11, P46, DOI 10.1016/0169-4758(95)80112-X; WATANABE T, 1993, J BIOL CHEM, V268, P18567	24	326	350	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26252	26256		10.1074/jbc.270.44.26252	http://dx.doi.org/10.1074/jbc.270.44.26252			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592832	Green Published, hybrid			2022-12-27	WOS:A1995TC97800039
J	HIPKIN, RW; LIU, XB; ASCOLI, M				HIPKIN, RW; LIU, XB; ASCOLI, M			TRUNCATION OF THE C-TERMINAL TAIL OF THE FOLLITROPIN RECEPTOR DOES NOT IMPAIR THE AGONIST-INDUCED OR PHORBOL ESTER-INDUCED RECEPTOR PHOSPHORYLATION AND UNCOUPLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; BETA-ADRENERGIC-RECEPTOR; LEYDIG TUMOR-CELLS; HUMAN CHORIO-GONADOTROPIN; EPIDERMAL GROWTH-FACTOR; SERTOLI-CELL; ADENYLYL CYCLASE; ALPHA-2-ADRENERGIC RECEPTOR; INDUCED DESENSITIZATION; CYTOPLASMIC TAIL	We have recently shown that addition of follitropin (FSH) or a phorbol ester (phorbol la-myristate 13-acetate (PMA)) to cells expressing the recombinant follitropin receptor (FSHR) results in both phosphorylation and uncoupling of the FSHR from adenylyl cyclase, In the light of findings reported with other G protein-coupled receptors we have proposed that phosphorylation of the FSHR mediates the uncoupling from adenylyl cyclase. The experiments described herein represent the first attempt to determine the location of the amino acid residues that become phosphorylated in FSHR and to test the hypothesis that phosphorylation is responsible for uncoupling of FSHR from adenylyl cyclase. As a first step in identifying which residues may be phosphorylated in response to hFSH and PMA, we constructed a mutant of the FSHR cDNA in which the C-terminal cytoplasmic tail was truncated at residue 635 (FSHR-t635), thus removing all but one of the potential phosphorylation sites present in the C-terminal tail, Cells expressing FSHR-t635 bind hFSH with the appropriate affinity and respond with increases in cAMP and inositol phosphate accumulation. The maximal cAMP and inositol phosphate responses of cells expressing FSHR-t635 are higher than those of cells expressing the wild type FSHR, but the concentration of hFSH required to elicit these responses is similar in both cell lines, Immunoprecipitation of FSHR-t635 shows that the truncated receptor is still effectively phosphorylated in response to hFSH or PMA. Phosphoamino acid analysis reveals that, like the wild-type FSHR, FSHR-t635 phosphorylation occurs on serine and threonine residues, Peptide mapping suggests that the phosphorylated residues in the FSHR and FSHR-t635 are located within the same areas of the intracellular regions of the receptors. In addition to stimulating phosphorylation of FSHR-t635, hFSH and PMA also effectively uncouple the truncated receptor from adenylyl cyclase, Taken together, these data show that hFSH and PMA can both phosphorylate and uncouple a FSH receptor species with a cytoplasmic tail truncated at residue 635.	UNIV IOWA,COLL MED,DEPT PHARMACOL,IOWA CITY,IA 52242	University of Iowa					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-28962] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; ASCOLI M, 1989, J BIOL CHEM, V264, P6674; ATTRAMADAL H, 1984, MOL CELL ENDOCRINOL, V34, P1, DOI 10.1016/0303-7207(84)90152-7; ATTRAMADAL H, 1988, ENDOCRINOLOGY, V123, P1060, DOI 10.1210/endo-123-2-1060; ATTRAMADAL H, 1984, MOL CELL ENDOCRINOL, V34, P221, DOI 10.1016/0303-7207(84)90178-3; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; Bradford M. M., 1976, ANAL BIOCHEM, V53, P304; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; FILIPPINI A, 1994, ENDOCRINOLOGY, V134, P1537, DOI 10.1210/en.134.3.1537; FLETCHER PW, 1984, MOL CELL ENDOCRINOL, V34, P39, DOI 10.1016/0303-7207(84)90157-6; HALL SH, 1988, MOL ENDOCRINOL, V2, P55; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIPKIN RW, 1995, MOL ENDOCRINOL, V9, P151, DOI 10.1210/me.9.2.151; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOELSCHER SR, 1993, ENDOCRINOLOGY, V132, P2229, DOI 10.1210/en.132.5.2229; INGLESE J, 1993, J BIOL CHEM, V268, P23735; ISHII K, 1994, J BIOL CHEM, V269, P1125; JAHNSEN T, 1982, ARCH ANDROLOGY, V8, P205, DOI 10.3109/01485018208987041; JAHNSEN T, 1980, ARCH ANDROLOGY, V5, P169, DOI 10.3109/01485018008986312; JOHANSON C, 1989, HUM REPROD, V4, P629, DOI 10.1093/oxfordjournals.humrep.a136956; KASSON BG, 1985, MOL CELL ENDOCRINOL, V42, P29, DOI 10.1016/0303-7207(85)90004-8; KIM IC, 1987, J BIOL CHEM, V262, P470; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LEGAC F, 1985, BIOL REPROD, V32, P916, DOI 10.1095/biolreprod32.4.916; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; LIU XX, 1994, ENDOCRINOLOGY, V135, P682, DOI 10.1210/en.135.2.682; MAHONEY WC, 1979, BIOCHEMISTRY-US, V18, P3810, DOI 10.1021/bi00584a026; MATUSLEIBOVITCH N, 1995, J BIOL CHEM, V270, P1041, DOI 10.1074/jbc.270.3.1041; MONACO L, 1988, ENDOCRINOLOGY, V123, P2032, DOI 10.1210/endo-123-4-2032; MONACO L, 1987, MOL CELL ENDOCRINOL, V49, P227, DOI 10.1016/0303-7207(87)90217-6; NAMBI P, 1984, J BIOL CHEM, V259, P4629; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PROSSNITZ ER, 1994, J BIOL CHEM, V270, P1130; QUINTANA J, 1993, ENDOCRINOLOGY, V133, P2098, DOI 10.1210/en.133.5.2098; QUINTANA J, 1994, J BIOL CHEM, V269, P8772; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; SANCHEZYAGUE J, 1992, J BIOL CHEM, V267, P7217; SANCHEZYAGUE J, 1993, ENDOCRINOLOGY, V132, P1007, DOI 10.1210/en.132.3.1007; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEGALOFF DL, 1981, J BIOL CHEM, V256, P1420; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TAKANO T, 1994, J BIOL CHEM, V269, P22453; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; WOODY CJ, 1989, ENDOCRINOLOGY, V124, P2261, DOI 10.1210/endo-124-5-2261	53	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26683	26689		10.1074/jbc.270.44.26683	http://dx.doi.org/10.1074/jbc.270.44.26683			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592895	hybrid			2022-12-27	WOS:A1995TC97800102
J	LAM, E; MARTIN, MM; TIMERMAN, AP; SABERS, C; FLEISCHER, S; LUKAS, T; ABRAHAM, RT; OKEEFE, SJ; ONEILL, EA; WIEDERRECHT, GJ				LAM, E; MARTIN, MM; TIMERMAN, AP; SABERS, C; FLEISCHER, S; LUKAS, T; ABRAHAM, RT; OKEEFE, SJ; ONEILL, EA; WIEDERRECHT, GJ			A NOVEL FK506 BINDING-PROTEIN CAN MEDIATE THE IMMUNOSUPPRESSIVE EFFECTS OF FK506 AND IS ASSOCIATED WITH THE CARDIAC RYANODINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM RELEASE CHANNEL; CIS-TRANS ISOMERASE; SARCOPLASMIC-RETICULUM; CYCLOSPORINE-A; SIGNAL-TRANSDUCTION; SKELETAL-MUSCLE; CALCINEURIN; FK-506; IMMUNOPHILIN; CYCLOPHILIN	FK506, an immunosuppressant that prolongs allograft survival, is a co-drug with its intracellular receptor, FKBP12. The FKBP12-FK506 complex inhibits calcineurin, a critical signaling molecule during T-cell activation, FKBP12 was, until recently, the sole FKBP known to mediate calcineurin inhibition at clinically relevant FK506 concentrations. The best characterized cellular function of FKBP12 is the modulation of ryanodine receptor isoform-1, a component of the calcium release channel of skeletal muscle sarcoplasmic reticulum. Recently, a novel protein, FKBP12.6, was found to inhibit calcineurin at clinically relevant FK506 concentrations. We have cloned the cDNA encoding human FKBP12.6 and characterized the protein. In transfected Jurkat cells, FKBP12.6 is equivalent to FKBP12 at mediating the inhibitory effects of FK506. Upon binding rapamycin, FKBP12.6 complexes with the 288-kDa mammalian target of rapamycin. In contrast to FKBP12, FKBP12.6 is not associated with ryanodine receptor isoform-1 but with the distinct ryanodine receptor isoform-a in cardiac muscle sarcoplasmic reticulum. Our results suggest that FKBP12.6 has both a unique physiological role in excitation-contraction coupling in cardiac muscle and the potential to contribute to the immunosuppressive and toxic effects of FK506 and rapamycin.	MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT IMMUNOL RES,RAHWAY,NJ 07065; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOLEC IMMUNOL,RAHWAY,NJ 07065; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905; VANDERBILT UNIV,DEPT MOLEC BIOL,NASHVILLE,TN 37235; VANDERBILT UNIV,DEPT CELL PHYSIOL,NASHVILLE,TN 37235; VANDERBILT UNIV,DEPT BIOPHYS,NASHVILLE,TN 37235	Merck & Company; Merck & Company; Mayo Clinic; Mayo Clinic; Vanderbilt University; Vanderbilt University; Vanderbilt University					NHLBI NIH HHS [P01-HL46681, HL32711] Funding Source: Medline; NIGMS NIH HHS [GM30861] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711, P01HL046681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030861] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM RT, 1996, IN PRESS ANN REV IMM; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; ARAKAWA H, 1994, BIOCHEM BIOPH RES CO, V200, P836, DOI 10.1006/bbrc.1994.1527; ASAMI M, 1993, BIOCHEM BIOPH RES CO, V192, P1388, DOI 10.1006/bbrc.1993.1570; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CALNE RY, 1989, LANCET, V2, P227; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; CHEN SRW, 1994, P NATL ACAD SCI USA, V91, P11953, DOI 10.1073/pnas.91.25.11953; CHEN YQ, 1994, BIOCHEM BIOPH RES CO, V203, P1, DOI 10.1006/bbrc.1994.2140; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COLLINS JH, 1991, BIOCHEM BIOPH RES CO, V178, P1288, DOI 10.1016/0006-291X(91)91033-9; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DUMONT FJ, 1994, J PHARMACOL EXP THER, V268, P32; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; ECKER J, 1993, J BIOL CHEM, V268, P11335; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P338; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1988, J BIOL CHEM, V263, P10872; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEBEAU MC, 1994, BIOCHEM BIOPH RES CO, V203, P750, DOI 10.1006/bbrc.1994.2246; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MARTIN M, 1995, IN PRESS IMMUNOMETHO; MAYRLEITNER M, 1994, CELL CALCIUM, V15, P99, DOI 10.1016/0143-4160(94)90048-5; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OHARA K, 1990, TRANSPLANT P, V22, P83; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OTSU K, 1990, J BIOL CHEM, V265, P13472; ROSEN MK, 1993, J AM CHEM SOC, V115, P821, DOI 10.1021/ja00055a082; ROTONDA J, 1993, J BIOL CHEM, V268, P7607; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SEWELL TJ, 1994, J BIOL CHEM, V269, P21094; SHAPIRO R, 1990, TRANSPLANT P, V22, P35; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TIMERMAN A, 1992, FASEB J, V6, P513; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; TIMMERMAN A, 1993, J BIOL CHEM, V268, P22992; UEKI K, 1992, BIOCHEM BIOPH RES CO, V187, P537, DOI 10.1016/S0006-291X(05)81527-X; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WIEDERRECHT G, 1992, J BIOL CHEM, V267, P21753; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081	61	168	171	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26511	26522		10.1074/jbc.270.44.26511	http://dx.doi.org/10.1074/jbc.270.44.26511			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592869	hybrid			2022-12-27	WOS:A1995TC97800076
J	ORA, A; HELENIUS, A				ORA, A; HELENIUS, A			CALNEXIN FAILS TO ASSOCIATE WITH SUBSTRATE PROTEINS IN GLUCOSIDASE-DEFICIENT CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VESICULAR STOMATITIS-VIRUS; ENDOPLASMIC-RETICULUM; INFLUENZA HEMAGGLUTININ; GLYCOPROTEINS; OLIGOSACCHARIDES; AGGREGATION; MATURATION; MEMBRANE; REMOVAL; INVITRO	Increasing evidence shows that calnexin, a membrane-bound chaperone in the endoplasmic reticulum, is a lectin that binds to newly synthesized glycoproteins that have partially trimmed N-linked oligosaccharides. It specifically attaches to core glycans from which two glucoses have been removed by glucosidases I and II. Several recent reports suggest, however, that it can also bind to proteins devoid of N-linked glycans. To investigate the extent of glycan-independent binding, we have analyzed two mutant cell lines (Lee 23 and Pha(R) 2.7) that are unable to process the core glycans because they lack glucosidase I or glucosidase II, respectively, In contrast to parental cell lines, calnexin binding of substrate proteins was found to be virtually nonexistent in these cells. Neither cellular nor viral proteins associated with the chaperone, It was concluded that glycans are crucial for calnexin association and that the vast majority of substrate proteins are therefore glycoproteins.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520	Yale University			ora, ari/P-5180-2015		NCI NIH HHS [CA 46128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; CARRENO BM, 1995, J IMMUNOL, V154, P5173; CHEN W, 1994, P NATL ACAD SCI USA, V92, P6229; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GETHING M J, 1991, Current Opinion in Cell Biology, V3, P610, DOI 10.1016/0955-0674(91)90030-3; GIBSON R, 1979, J BIOL CHEM, V254, P3600; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELANIUS A, 1994, MOL BIOL CELL, V5, P253; HELENIUS A, 1992, CELL BIOL BIOTECHNOL, P125; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KIM P, 1995, J CELL BIOL, V12, P29; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LOO TW, 1994, J BIOL CHEM, V269, P28683; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; METSIKKO K, 1990, J VIROL, V64, P4678; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; RABOUILLE C, 1992, J BIOL CHEM, V267, P11573; RAJOGAPALAN S, 1994, SCIENCE, V263, P387; RAY MK, 1991, J BIOL CHEM, V266, P22818; REITMAN ML, 1982, J BIOL CHEM, V257, P357; SAWYER JT, 1994, J BIOL CHEM, V269, P22440; SUH K, 1992, J BIOL CHEM, V267, P21671; WADA I, 1991, J BIOL CHEM, V266, P19599; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	33	81	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26060	26062		10.1074/jbc.270.44.26060	http://dx.doi.org/10.1074/jbc.270.44.26060			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592804	hybrid			2022-12-27	WOS:A1995TC97800011
J	BORN, TL; MYERS, JK; WIDLANSKI, TS; RUSNAK, F				BORN, TL; MYERS, JK; WIDLANSKI, TS; RUSNAK, F			4-(FLUOROMETHYL)PHENYL PHOSPHATE ACTS AS A MECHANISM-BASED INHIBITOR OF CALCINEURIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSYL PROTEIN PHOSPHATASE; CYCLOSPORINE-A; BINDING-PROTEIN; CYCLOPHILIN; TARGET; FK-506	The compound 4-(fluoromethyl)phenyl phosphate (FMPP), recently shown to be a mechanism-based inhibitor of prostatic acid phosphatase (Myers, J. K., and Widlanski, T. S. (1993) Science 262, 1451-1453), was examined for its effect on calcineurin. This compound inhibits calcineurin in a time-dependent, first order manner, Inactivation with [H-3]FMPP led to a specific labeling of the catalytic subunit with a stoichiometry of 0.75 mol of label/mol of protein. A related substrate, 4-methylphenyl phosphate, is able to protect calcineurin from FMPP-mediated inhibition. Scavenging nucleophiles, such as cysteine, do not affect the rate of inhibition when included in the reaction, In addition, extensive dialysis indicates that inhibition is essentially irreversible. These results demonstrate that FMPP inactivates calcineurin in a mechanism-based fashion by forming a covalent adduct with calcineurin A, the catalytic subunit.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405	Mayo Clinic; Indiana University System; Indiana University Bloomington					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046865, R01GM047918] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46865, GM47918] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES RH, 1976, ACCOUNTS CHEM RES, V9, P313, DOI 10.1021/ar50105a001; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN CP, 1986, J BIOL CHEM, V261, P9890; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; DONELLADEANA A, 1994, EUR J BIOCHEM, V219, P109, DOI 10.1111/j.1432-1033.1994.tb19920.x; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GUERINI D, 1991, ADV PROT PHOSPHATASE, V6, P391; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; KITZ R, 1962, J BIOL CHEM, V237, P3245; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MYERS JK, 1993, SCIENCE, V262, P1451, DOI 10.1126/science.8248785; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, P1; SIEKIERKA JJ, 1989, NATURE, V241, P755; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; WANG QP, 1994, BIOCHEM BIOPH RES CO, V200, P577, DOI 10.1006/bbrc.1994.1487; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	24	29	29	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25651	25655		10.1074/jbc.270.43.25651	http://dx.doi.org/10.1074/jbc.270.43.25651			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592741	hybrid			2022-12-27	WOS:A1995TB46600058
J	KOHZUMA, T; DENNISON, C; MCFARLANE, W; NAKASHIMA, S; KITAGAWA, T; INOUE, T; KAI, Y; NISHIO, N; SHIDARA, S; SUZUKI, S; SYKES, AG				KOHZUMA, T; DENNISON, C; MCFARLANE, W; NAKASHIMA, S; KITAGAWA, T; INOUE, T; KAI, Y; NISHIO, N; SHIDARA, S; SUZUKI, S; SYKES, AG			SPECTROSCOPIC AND ELECTROCHEMICAL STUDIES ON ACTIVE-SITE TRANSITIONS OF THE TYPE-1 COPPER PROTEIN PSEUDOAZURIN FROM ACHROMOBACTER CYCLOCLASTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA AZURIN; ALCALIGENES-FAECALIS S-6; ELECTRON-TRANSFER; RESONANCE RAMAN; NITRITE REDUCTASE; CRYSTAL-STRUCTURE; METHYLAMINE DEHYDROGENASE; POPLAR PLASTOCYANIN; COMPLEX ASSOCIATION; BLUE PROTEIN	The single type 1 copper protein pseudoazurin from Achromobacter cycloclastes gives reversible electrochemical behavior at a (4-pyridyl) disulfide-modified gold electrode. Measurements carried out at 25.0 degrees C indicate a midpoint reduction potential of E(1/2) = 260 mV versus normal hydrogen electrode at pH 7.0 and a peak-to-peak separation of Delta E(p) = 59 mV. The diffusion coefficient and heterogeneous electron transfer rate constant are estimated to be 2.23 x 10(-6) cm(2) s(-1) and 3.7 x 10(-2) cm s(-1), respectively. Also, controlled potential electrolysis indicates a 1-electron transfer process and a formal reduction potential of 259 mV versus normal hydrogen electrode for the Cu(II)/Cu(I) couple. The heterogeneous electron transfer rate constant determined at the (4-pyridyl)disulfide-modified gold electrode at pH 4.6 is 6.7 x 10(-3) cm s(-1), consistent with a slower process at the positively charged electrode surface. At pH 11.3, UV-visible, EPR, and resonance Raman spectra indicate a conversion of the distorted tetrahedral copper geometry to a trigonal structure. The trigonal form has elongated axial bonding and an axial EPR spectrum. At pH 11.3, the reduction potential is further decreased, and Cu-S bands in resonance Raman spectra at 330-460 cm(-1) are shifted to higher energy (similar to 10 cm(-1)), consistent with a stronger Cu-S bond.	UNIV NEWCASTLE UPON TYNE,DEPT CHEM,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; INST MOLEC SCI,OKAZAKI,AICHI 444,JAPAN; OSAKA UNIV,FAC ENGN,DEPT APPL CHEM,SUITA,OSAKA 565,JAPAN; HIROSHIMA UNIV,FAC INTEGRATED ARTS & SCI,DEPT ENVIRONM SCI,HIGASHIHIROSHIMA 724,JAPAN; OSAKA UNIV,FAC SCI,DEPT CHEM,TOYONAKA,OSAKA 560,JAPAN	Newcastle University - UK; National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Okazaki Institute for Integrative Bioscience (OIIB); Osaka University; Hiroshima University; Osaka University	KOHZUMA, T (corresponding author), IBARAKI UNIV,DEPT CHEM,BUNKYO 2-1-1,MITO,IBARAKI 310,JAPAN.		Kohzuma, Takamitsu/U-2966-2019	Dennison, Christopher/0000-0001-8665-052X; Nakashima, Satoru/0000-0001-8378-1153				ADMAN ET, 1989, J BIOL CHEM, V264, P87; ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; ANDREW CR, 1994, J AM CHEM SOC, V116, P11489, DOI 10.1021/ja00104a032; ARMSTRONG FA, 1988, ACCOUNTS CHEM RES, V21, P407, DOI 10.1021/ar00155a004; ARMSTRONG FA, 1989, J PHYS CHEM-US, V93, P6485, DOI 10.1021/j100354a041; BAKER EN, 1988, J MOL BIOL, V203, P1071, DOI 10.1016/0022-2836(88)90129-5; BLAIR DF, 1985, J AM CHEM SOC, V107, P5755, DOI 10.1021/ja00306a025; CHEN LY, 1992, BIOCHEMISTRY-US, V31, P4959, DOI 10.1021/bi00136a006; CHRISTENSEN HEM, 1990, INORG CHEM, V29, P2808, DOI 10.1021/ic00340a019; COLLYER CA, 1990, J MOL BIOL, V211, P617, DOI 10.1016/0022-2836(90)90269-R; DENBLAAUWEN T, 1993, BIOCHEMISTRY-US, V32, P12455, DOI 10.1021/bi00097a025; DENNISON C, 1993, J CHEM SOC DALTON, P1959, DOI 10.1039/dt9930001959; DENNISON C, 1994, J CHEM SOC DALTON, P437, DOI 10.1039/dt9940000437; DESILVA DGAH, 1992, J CHEM SOC DALTON, P2145, DOI 10.1039/dt9920002145; GRAY KA, 1988, J BIOL CHEM, V263, P13987; GROENEVELD CM, 1988, J BIOL CHEM, V263, P167; GUSS JM, 1992, ACTA CRYSTALLOGR B, V48, P790, DOI 10.1107/S0108768192004270; GUSS JM, 1986, J MOL BIOL, V192, P361, DOI 10.1016/0022-2836(86)90371-2; HAN J, 1993, J AM CHEM SOC, V115, P4256, DOI 10.1021/ja00063a048; HAN J, 1991, BIOCHEMISTRY-US, V30, P10904, DOI 10.1021/bi00109a014; HAN S, 1989, J AM CHEM SOC, V111, P3496, DOI 10.1021/ja00192a002; INOUE T, 1994, ACTA CRYSTALLOGR D, V50, P317, DOI 10.1107/S0907444994000260; INOUE T, 1993, J BIOCHEM-TOKYO, V114, P761, DOI 10.1093/oxfordjournals.jbchem.a124251; INOUE T, 1994, THESIS OSAKA U; IWASAKI H, 1973, J BIOCHEM, V73, P659, DOI 10.1093/oxfordjournals.jbchem.a130125; IWASAKI Y, 1992, ELECTROANAL, V4, P765, DOI 10.1002/elan.1140040805; KAKUTANI T, 1981, J BIOCHEM-TOKYO, V89, P463, DOI 10.1093/oxfordjournals.jbchem.a133221; KASHEM MA, 1987, BIOCHEM BIOPH RES CO, V145, P563, DOI 10.1016/0006-291X(87)91357-X; KLAULIS P, 1994, J APPL CRYSTALLOGR, V24, P946; KOHZUMA T, 1994, B CHEM SOC JPN, V67, P138, DOI 10.1246/bcsj.67.138; LAPPIN AG, 1979, J AM CHEM SOC, V101, P2302, DOI 10.1021/ja00503a009; LONG JE, 1989, BIOCHEMISTRY-US, V28, P6970, DOI 10.1021/bi00443a029; LOWERY MD, 1993, J AM CHEM SOC, V115, P3012, DOI 10.1021/ja00060a074; LU Y, 1993, J AM CHEM SOC, V115, P5907, DOI 10.1021/ja00067a003; MCGINNIS J, 1988, INORG CHEM, V27, P2306, DOI 10.1021/ic00286a018; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; NICHOLSON RS, 1965, ANAL CHEM, V37, P1351, DOI 10.1021/ac60230a016; PETRATOS K, 1988, ACTA CRYSTALLOGR B, V44, P628, DOI 10.1107/S0108768188008912; RYDEN L, 1984, COPPER PROTEINS COPP, V1, P157; SAKURAI T, 1990, INORG CHEM, V29, P4715, DOI 10.1021/ic00348a026; SEGAL MG, 1978, J AM CHEM SOC, V100, P4585, DOI 10.1021/ja00482a044; SUZUKI S, 1989, INORG CHEM, V28, P802, DOI 10.1021/ic00303a038; SYKES AG, 1990, STRUCT BOND, V75, P175; TAKAHASHI S, 1991, J AM CHEM SOC, V113, P9400, DOI 10.1021/ja00024a073; THAMANN TJ, 1982, P NATL ACAD SCI USA, V79, P6396, DOI 10.1073/pnas.79.20.6396; TOBARI J, 1984, MICROBIAL GROWTH C1, P106; VANDEKAMP M, 1993, EUR J BIOCHEM, V218, P229; VANDEKAMP M, 1990, J AM CHEM SOC, V112, P907, DOI 10.1021/ja00158a082	48	47	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25733	25738		10.1074/jbc.270.43.25733	http://dx.doi.org/10.1074/jbc.270.43.25733			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592754	hybrid			2022-12-27	WOS:A1995TB46600071
J	YEH, CH; ZONG, WX; SHATKIN, AJ				YEH, CH; ZONG, WX; SHATKIN, AJ			THE SER(36)-SER(37) PAIR IN HELA NUCLEAR-PROTEIN P21/SIIR MEDIATES SER/THR PHOSPHORYLATION AND IS ESSENTIAL FOR ROUS-SARCOMA VIRUS LONG TERMINAL REPEAT REPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION	Phosphorylation of HeLa SII (or TFIIS)-related nuclear protein p21/SIIR was demonstrated in transfected COS-1 cells. To test for a possible functional link between phosphorylation and the previously described Rous sarcoma virus (RSV) long terminal repeat (LTR) repression (Yeh, C, H., and Shatkin, A. J. (1994) Proc. Natl. Acad. Sci. U.S. A. 91, 11002-11006), p21/SIIR mutants were constructed and assayed for phosphorylation level and effect on RSV LTD-driven chloramphenicol acetyltransferase (CAT) reporter expression. A major phosphorylation target in p21/SIIR was localized to the Arg/Ser-rich region between amino acids 12 and 49. Deletion of this region impaired the ability of pB1/SIIR to down-regulate RSV LTR promoter function. Four serine pairs, all displaying the Arg/Lys-Ser-Ser motif typical of phosphorylation sites, are present in p21/SIIR between positions 31 and 48. Conversion of these individual serine pairs to alanine resulted in decreased phosphorylation in each case. Mutation of the Ser(36)-Ser(37) pair also diminished by severalfold the repression activity of p21/SIIR. The single tyrosine (Tyr(155)) in pS1/SIIR was not detectably phosphorylated in transfected COS-1 cells, suggesting that the Ser(36)-Ser(37) pair mediates Ser/Thr phosphorylation of p21/SIIR and is critical for LTR repression function.	RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick								CAMPBELL JS, 1995, RECENT PROG HORM RES, V50, P131; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOZMA SC, 1992, REV PHYSIOL BIOCH P, V119, P123; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; YEH CH, 1995, J BIOL CHEM, V270, P15815, DOI 10.1074/jbc.270.26.15815; YEH CH, 1994, GENE, V143, P285; YEH CH, 1994, P NATL ACAD SCI USA, V91, P11002, DOI 10.1073/pnas.91.23.11002	16	2	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25313	25315		10.1074/jbc.270.43.25313	http://dx.doi.org/10.1074/jbc.270.43.25313			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592688	hybrid			2022-12-27	WOS:A1995TB46600004
J	FRITZ, G; KAINA, B; AKTORIES, K				FRITZ, G; KAINA, B; AKTORIES, K			THE RAS-RELATED SMALL GTP-BINDING PROTEIN RHOB IS IMMEDIATE-EARLY INDUCIBLE BY DNA-DAMAGING TREATMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM ADP-RIBOSYLTRANSFERASE; EPIDERMAL GROWTH-FACTOR; HAMSTER OVARY CELLS; C-FOS GENE; CLOSTRIDIUM-BOTULINUM; MAMMALIAN-CELLS; UV IRRADIATION; MESSENGER-RNA; KINASE-C; SIGNAL-TRANSDUCTION	The low molecular weight GTP-binding proteins RhoA, RhoB, and RhoC are characterized as specific substrates for the ADP-ribosyltransferase C3 from Clostridium botulinum and are supposed to be involved in the organization of the microfilamental network and transformation. rhoB is known to be immediate-early inducible by growth factors and protein-tyrosine kinases. Since increasing evidence indicates overlapping of growth factor- and UV-induced signal pathways, we studied the effect of UV light and other genotoxic agents on early rhoB transcription. Within 30 min after UV irradiation of NIH3T3 cells, the amount of rhoB mRNA increased 3-4-fold. Elevated rhoB mRNA was accompanied by an increase in RhoB protein, as detected by C3-mediated [P-32]ADP-ribosylation. The transcription inhibitor actinomycin D prevented the UV-induced increase in rhoB mRNA and proved rhoB mRNA to be unstable with a half life of similar to 20 min. Transcriptional activation of rhoB by UV light was confirmed by run-on analysis. The increase in rhoB mRNA after UV irradiation was prevented by inhibitors of protein kinase A (H9) and C (H7, Go18). The tyrosine kinase inhibitor genistein did not affect UV induction of rhoB. In addition to UV, N-methyl-N-nitrosourea and the cytostatic drug cisplatin evoked rhoB response. Cycloheximide was likewise effective in increasing the amount of rhoB mRNA, whereas Bt(2)cAMP, 12-O-tetradecanoylphorbol-13-acetate, and retinoic acid were without effect. Prior down-regulation of signaling by la 12-O-tetradecanoylphorbol-13-acetate and serum pretreatment reduced UV-stimulated rhoB expression. The data indicate that rhoB represents a novel DNA damage-inducible function involved in early steps of signal transduction upon genotoxic stress.	UNIV SAARLAND,INST PHARMAKOL & TOXIKOL,D-66421 HOMBURG,GERMANY	Saarland University	FRITZ, G (corresponding author), UNIV MAINZ,INST TOXICOL,ANGEW TOXIKOL ABT,OBERE ZAHLABACHER STR 67,D-55131 MAINZ,GERMANY.		Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1985, CANCER CELL, V3, P315; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSCHER M, 1988, ONCOGENE, V3, P301; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2727; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EGAN SE, 1983, NATURE, V363, P45; FORNACE AJ, 1988, MOL CELL BIOL, V8, P4716, DOI 10.1128/MCB.8.11.4716; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; FRITZ G, 1991, MOL CELL BIOL, V11, P4660, DOI 10.1128/MCB.11.9.4660; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GHOSH R, 1993, MOL CELL BIOL, V13, P6992, DOI 10.1128/MCB.13.11.6992; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; HARRIS ELV, 1989, PROTEIN PURIFICATION, P29; HOLLANDER MC, 1989, CANCER RES, V49, P1687; JAHNER D, 1991, ONCOGENE, V6, P1259; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KAINA B, 1987, MOL CELL BIOL, V7, P2024, DOI 10.1128/MCB.7.5.2024; KAINA B, 1990, DNA REPAIR MECHANISM, P149; KASHANISABET M, 1990, J BIOL CHEM, V265, P11285; KEDAR PS, 1991, P NATL ACAD SCI USA, V88, P3729, DOI 10.1073/pnas.88.9.3729; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KOURAZIDES T, 1989, NATURE, V340, P568; KRAMER M, 1990, RADIAT ENVIRON BIOPH, V29, P303, DOI 10.1007/BF01210410; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFEBVRE P, 1993, DNA CELL BIOL, V12, P233, DOI 10.1089/dna.1993.12.233; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILLER CC, 1994, J BIOL CHEM, V269, P3529; MISKIN R, 1981, P NATL ACAD SCI-BIOL, V78, P6236, DOI 10.1073/pnas.78.10.6236; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P533; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCANLON KJ, 1991, P NATL ACAD SCI USA, V88, P10591, DOI 10.1073/pnas.88.23.10591; SCANLON KJ, 1994, P NATL ACAD SCI USA, V91, P11123, DOI 10.1073/pnas.91.23.11123; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; WIEGERS W, 1991, EUR J CELL BIOL, V54, P237; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	63	139	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25172	25177		10.1074/jbc.270.42.25172	http://dx.doi.org/10.1074/jbc.270.42.25172			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559652	hybrid			2022-12-27	WOS:A1995TB46500086
J	LI, K; WILLIAMS, RS				LI, K; WILLIAMS, RS			CLONING AND CHARACTERIZATION OF 3 NEW MURINE GENES ENCODING SHORT HOMOLOGS OF RNASE-P RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-P; ESCHERICHIA-COLI; HELA-CELLS; YEAST; COMPONENT; SUBUNIT; NUCLEAR; IDENTIFICATION; SEQUENCE; PROTEIN	Three novel genes encoding small RNAs homologous to human and mouse RNase P RNA have been isolated from a mouse genomic Library. As assessed by Northern blot analysis and nuclease protection assays, transcripts derived from one or more of these genes are expressed in murine cells and tissues. The RNA products of these RNase P RNA-homologous genes are smaller in size (238-248 nucleotides) than the 305-nucleotide transcript previously identified. These smaller transcripts are uniformly less abundant than the larger RNase P RNA, but their expression varies severalfold among different mouse tissues. Similar short homologues of RNase P RNA also are expressed in rat, rabbit, and human cells. We conclude that higher vertebrates express multiple isoforms of RNase P RNA.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; ALTMAN S, 1993, GENOMICS, V18, P418, DOI 10.1006/geno.1993.1488; ALTMAN S, 1989, ADV ENZYMOLOGY RELAT, P1; BAER M, 1985, SCIENCE, V228, P999, DOI 10.1126/science.2408335; BAER M, 1989, NUCLEIC ACIDS RES, V18, P97; BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; DANG YL, 1993, J BIOL CHEM, V268, P19791; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; DORIA M, 1991, NUCLEIC ACIDS RES, V9, P2315; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GARDINER K, 1985, J BIOL CHEM, V255, P7507; GOLD HA, 1986, CELL, V44, P243, DOI 10.1016/0092-8674(86)90758-0; GREENE JM, 1992, CURRENT PROTOCOLS MO; GROSSBERGER D, 1987, NUCLEIC ACIDS RES, V15, P6737, DOI 10.1093/nar/15.16.6737; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAAS ES, 1994, P NATL ACAD SCI USA, V91, P2527, DOI 10.1073/pnas.91.7.2527; HAAS ES, 1991, SCIENCE, V254, P853, DOI 10.1126/science.1719634; HANNON GJ, 1991, J BIOL CHEM, V266, P22796; KRUMP G, 1986, EMBO J, V5, P1697; LEE JY, 1989, MOL CELL BIOL, V9, P2536, DOI 10.1128/MCB.9.6.2536; LEE JY, 1991, MOL CELL BIOL, V11, P21; MILLER DL, 1983, CELL, V34, P911, DOI 10.1016/0092-8674(83)90548-2; MORALES MJ, 1992, P NATL ACAD SCI USA, V89, P9875, DOI 10.1073/pnas.89.20.9875; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; REILLY RM, 1986, J BIOL CHEM, V261, P2928; ROSSMANITH W, 1995, J BIOL CHEM, V270, P12885, DOI 10.1074/jbc.270.21.12885; Sambrook J, 1989, MOL CLONING LABORATO; SHIRAISHI H, 1988, EMBO J, V7, P3817, DOI 10.1002/j.1460-2075.1988.tb03266.x; SHU HH, 1991, MOL CELL BIOL, V11, P1662, DOI 10.1128/MCB.11.3.1662; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; TORRONI A, 1990, J BIOL CHEM, V265, P20589; TRANGUCH AJ, 1993, J BIOL CHEM, V268, P14045; WESTHOF E, 1994, P NATL ACAD SCI USA, V91, P5133, DOI 10.1073/pnas.91.11.5133; WISE CA, 1991, J BIOL CHEM, V266, P19154	35	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25281	25285		10.1074/jbc.270.42.25281	http://dx.doi.org/10.1074/jbc.270.42.25281			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559668	hybrid			2022-12-27	WOS:A1995TB46500102
J	CHIU, MH; THOMAS, VH; STUBBS, HJ; RICE, KG				CHIU, MH; THOMAS, VH; STUBBS, HJ; RICE, KG			TISSUE TARGETING OF MULTIVALENT LE(X)-TERMINATED N-LINKED OLIGOSACCHARIDES IN MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUCOSE-CONTAINING GLYCOPROTEINS; ISOLATED RAT HEPATOCYTES; ASIALOGLYCOPROTEIN RECEPTOR; HEPATIC LECTINS; MACROPHAGE LECTIN; ANIMAL LECTINS; BINDING LECTIN; ACETYLGALACTOSAMINE; LIVER; RECOGNITION	The target site for N-linked biantennary and triantennary oligosaccharides containing multiple terminal Le(X) determinants was analyzed in mice, N-Linked oligosaccharides containing a single tert-butoxycarbonyl-tyrosine attached to the reducing end were used as synthons for human milk alpha-3/4-fucosyltransferase to prepare multivalent Le(X) (Gal beta 1-4[Fuc alpha 1-3]GlcNAc) terminated tyrosinamide oligosaccharides. The oligosaccharides were radioiodinated and examined for their pharmacokinetics and biodistribution in mice. The liver was the major target site in mice at 30 min, which accumulated 18% of the dose for Le(X) biantennary compared with 6% for a nonfucosylated Gal biantennary, By comparison, Le(X)- and Gal-terminated triantennary accumulated in the liver with a targeting efficiency of 66 and 59%, respectively, The liver targeting of Le(X) biantennary was partially blocked by co-administration with either galactose or L-fucose whereas Le(X) triantennary targeting was only reduced by co-administration with galactose, In contrast to these results in mice, in vivo experiments performed in rats established that both Le(X) and Gal terminated biantennary target the liver with nearly identical efficiency (6-7%). It is concluded that the asialoglycoprotein receptor in mice preferentially recognize Le(X) biantennary over Gal biantennary, whereas little or no differentiation exists in rats, Thereby, the mouse asialoglycoprotein receptor apparently possesses additional binding pockets that accommodate a fucose residue when presented as Le(X).	UNIV MICHIGAN, COLL PHARM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NIDDK NIH HHS [DK45742] Funding Source: Medline; NIGMS NIH HHS [GM48048] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045742] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BAENZIGER JU, 1980, CELL, V22, P611, DOI 10.1016/0092-8674(80)90371-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIU MH, 1994, J BIOL CHEM, V269, P16195; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GUPTA D, 1994, GLYCOCONJUGATE J, V11, P558, DOI 10.1007/BF00731307; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7433; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7440; HARDY MR, 1985, BIOCHEMISTRY-US, V24, P22, DOI 10.1021/bi00322a004; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HERZIG MCS, 1989, BIOCHEMISTRY-US, V28, P600, DOI 10.1021/bi00428a028; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEE RT, 1987, GLYCOCONJUGATE J, V4, P317, DOI 10.1007/BF01048365; LEE RT, 1994, J BIOL CHEM, V269, P19617; LEE RT, 1989, BIOCHEMISTRY-US, V28, P8351, DOI 10.1021/bi00447a013; LEE YC, 1991, PURE APPL CHEM, V63, P499, DOI 10.1351/pac199163040499; LEE YC, 1983, J BIOL CHEM, V258, P199; LEE YC, 1989, CIBA F S, V145, P80; LEHRMAN MA, 1986, J BIOL CHEM, V261, P7419; LEHRMAN MA, 1986, J BIOL CHEM, V261, P7412; LEHRMAN MA, 1986, J BIOL CHEM, V261, P7426; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; MCBROOM T, 1994, ANAL BIOCHEM, V222, P243, DOI 10.1006/abio.1994.1480; MICHALSKI JC, 1991, EUR J BIOCHEM, V201, P439, DOI 10.1111/j.1432-1033.1991.tb16302.x; OZAKI K, 1992, J BIOL CHEM, V267, P9229; PALCIC MM, 1989, CARBOHYD RES, V190, P1, DOI 10.1016/0008-6215(89)84141-2; RICE KG, 1990, J BIOL CHEM, V265, P18429; SILVA M, 1994, ARCH BIOCHEM BIOPHYS, V312, P151; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; TAMURA T, 1994, ANAL BIOCHEM, V216, P335, DOI 10.1006/abio.1994.1050; TAMURA T, 1994, METHOD ENZYMOL, V247, P43; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WADHWA MS, 1995, BIOCONJUGATE CHEM, V6, P283, DOI 10.1021/bc00033a008; WADHWA MS, 1995, J DRUG TARGET, V3, P111, DOI 10.3109/10611869509059211; YAMASHITA K, 1980, J BIOL CHEM, V255, P5635; YOSHIMA H, 1981, J BIOL CHEM, V256, P5355	37	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24024	24031		10.1074/jbc.270.41.24024	http://dx.doi.org/10.1074/jbc.270.41.24024			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592600	hybrid			2022-12-27	WOS:A1995TA21700028
J	DAVLETOV, BA; KRASNOPEROV, V; HATA, Y; PETRENKO, AG; SUDHOF, TC				DAVLETOV, BA; KRASNOPEROV, V; HATA, Y; PETRENKO, AG; SUDHOF, TC			HIGH-AFFINITY BINDING OF ALPHA-LATROTOXIN TO RECOMBINANT NEUREXIN I-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							WIDOW SPIDER VENOM; TRANSMITTER RELEASE; NEUROMUSCULAR-JUNCTIONS; BRAIN SYNAPTOSOMES; PLASMA-MEMBRANE; TOXIN BINDING; RECEPTOR; PURIFICATION; STIMULATION; PROTEIN	alpha-Latrotoxin is a potent neurotoxin from black widow spider venom that stimulates neurotransmitter release. alpha-Latrotoxin is thought to act by binding to a high affinity receptor on presynaptic nerve terminals. In previous studies, high affinity alpha-latrotoxin binding proteins were isolated and demonstrated to contain neurexin I alpha as a major component. Neurexin I alpha is a cell surface protein that exists in multiple differentially spliced isoforms and belongs to a large family of neuron-specific proteins. Using a series of neurexin I-IgG fusion proteins, we now show that recombinant neurexin I alpha binds alpha-latrotoxin directly with high affinity (K-d approximate to 4 nM). Binding of alpha-latrotoxin to recombinant neurexin I alpha is dependent on Ca2+ (EC(50) approximate to 30 mu M). Our data suggest that neurexin I alpha is a Ca2+-dependent high affinity receptor for alpha-latrotoxin.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; NYU,MED CTR,DEPT ENVIRONM MED,NEW YORK,NY 10016	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; New York University			Davletov, Bazbek/ABA-8569-2021	Petrenko, Alexander/0000-0002-6689-6546; Davletov, Bazbek/0000-0003-4658-3275				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; CECCARELLI B, 1979, J CELL BIOL, V81, P163, DOI 10.1083/jcb.81.1.163; FINKELSTEIN A, 1976, SCIENCE, V193, P1009, DOI 10.1126/science.948756; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRASSO A, 1980, NATURE, V283, P774, DOI 10.1038/283774a0; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; MELDOLESI J, 1983, NEUROSCIENCE, V10, P997, DOI 10.1016/0306-4522(83)90238-5; MELDOLESI J, 1982, J NEUROCHEM, V38, P1559, DOI 10.1111/j.1471-4159.1982.tb06633.x; NICHOLLS DG, 1982, P NATL ACAD SCI-BIOL, V79, P7924, DOI 10.1073/pnas.79.24.7924; PETRENKO AG, 1993, J BIOL CHEM, V268, P1860; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; ROBELLO M, 1987, J MEMBRANE BIOL, V95, P55, DOI 10.1007/BF01869630; SCHEER H, 1985, EMBO J, V4, P323, DOI 10.1002/j.1460-2075.1985.tb03632.x; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TZENG MC, 1979, J NEUROCHEM, V33, P263, DOI 10.1111/j.1471-4159.1979.tb11728.x; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410; VALTORTA F, 1984, J CELL BIOL, V99, P124, DOI 10.1083/jcb.99.1.124; WANKE E, 1986, BIOCHEM BIOPH RES CO, V134, P320, DOI 10.1016/0006-291X(86)90565-6	23	59	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23903	23905		10.1074/jbc.270.41.23903	http://dx.doi.org/10.1074/jbc.270.41.23903			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592578	hybrid			2022-12-27	WOS:A1995TA21700006
J	SCHULTZ, SJ; WHITING, SH; CHAMPOUX, JJ				SCHULTZ, SJ; WHITING, SH; CHAMPOUX, JJ			CLEAVAGE SPECIFICITIES OF MOLONEY MURINE LEUKEMIA-VIRUS RNASE-H IMPLICATED IN THE 2ND STRAND TRANSFER DURING REVERSE TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; DEOXYRIBONUCLEIC-ACID POLYMERASE; LONG TERMINAL REPEAT; RIBONUCLEASE-H; RETROVIRAL DNA; INTEGRATION SITE; SEQUENCE; TYPE-1; PRIMER; MECHANISM	Reverse transcription of a retroviral RNA genome requires two template jumps to generate the linear double-stranded DNA required for integration. The RNase H activity of reverse transcriptase has several roles during this process. We have examined RNase H cleavages that define the maximal 3' and 5' ends of Moloney murine leukemia virus minus strand DNA prior to the second template jump. In both the endogenous reaction and on model substrates in vitro, RNase H cleaves the genomic RNA template between the second and third ribonucleotides 5' of the U5/PBS junction, but other minor cleavages between 1 and 10 nucleotides 5' of this junction are also observed. Similar experiments examining the specificity of RNase H for tRNA primer removal revealed that cleavage generally leaves a ribo A residue at the 5' end of minus strand DNA. These observations suggest that three bases are typically duplicated on the ends of the minus strands, leading to an intermediate following the second jump which contains unpaired nucleotides. Model substrates mimicking the structure of this intermediate demonstrate that reverse transcriptase has little difficulty in utilizing such a branched structure for the initiation of displacement synthesis.	UNIV WASHINGTON,SCH MED,DEPT MICROBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NCI NIH HHS [R37 CA51605, T32 CA09229] Funding Source: Medline; NIGMS NIH HHS [5T32GM07266] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009229, R37CA051605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007266] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BALTIMORE D, 1972, J BIOL CHEM, V247, P7282; BENARTZI H, 1993, J BIOL CHEM, V268, P16465; BLAIN SW, 1993, J BIOL CHEM, V268, P23585; BREWER LC, 1974, J VIROL, V14, P1494, DOI 10.1128/JVI.14.6.1494-1502.1974; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUISER RG, 1991, J BIOL CHEM, V266, P13103; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; Coffin J. M., 1990, VIROLOGY, P1437; COLICELLI J, 1985, CELL, V42, P573, DOI 10.1016/0092-8674(85)90114-X; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1991, J BIOL CHEM, V262, P7423; ELLIS J, 1989, J VIROL, V63, P2844, DOI 10.1128/JVI.63.6.2844-2846.1989; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; GARCES J, 1991, P ROY SOC B-BIOL SCI, V243, P235, DOI 10.1098/rspb.1991.0037; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; GOTTE M, 1995, EMBO J, V14, P833, DOI 10.1002/j.1460-2075.1995.tb07061.x; GRANDGENETT DP, 1974, J BIOL CHEM, V249, P5148; HUANG L, 1994, J BIOL CHEM, V269, P25922; HUBER HE, 1990, J BIOL CHEM, V265, P10565; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KELLER W, 1972, P NATL ACAD SCI USA, V69, P3360, DOI 10.1073/pnas.69.11.3360; KULKOSKY J, 1990, J ACQ IMMUN DEF SYND, V3, P852; Leis J, 1993, REVERSE TRANSCRIPTAS, P33; LEIS JP, 1973, P NATL ACAD SCI USA, V70, P466, DOI 10.1073/pnas.70.2.466; LOBEL LI, 1989, J VIROL, V63, P2629, DOI 10.1128/JVI.63.6.2629-2637.1989; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; OYAMA F, 1989, J BIOL CHEM, V264, P18808; PAUZA CD, 1990, VIROLOGY, V179, P886; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PULLEN KA, 1992, J VIROL, V66, P367, DOI 10.1128/JVI.66.1.367-373.1992; RANDOLPH CA, 1994, J BIOL CHEM, V269, P19207; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; RHIM H, 1991, J VIROL, V65, P4555, DOI 10.1128/JVI.65.9.4555-4564.1991; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SHOEMAKER C, 1980, P NATL ACAD SCI-BIOL, V77, P3932, DOI 10.1073/pnas.77.7.3932; SMITH JK, 1984, J VIROL, V52, P314, DOI 10.1128/JVI.52.2.314-319.1984; SMITH JS, 1992, J BIOL CHEM, V267, P15071; SMITH JS, 1990, J VIROL, V64, P6286, DOI 10.1128/JVI.64.12.6286-6290.1990; STARNES MC, 1989, J BIOL CHEM, V264, P7073; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; VARMUS H, 1989, MOBILE DNA, P53; WAKEFIELD JK, 1994, J VIROL, V68, P1605, DOI 10.1128/JVI.68.3.1605-1614.1994; WHITCOMB JM, 1990, J VIROL, V64, P4903, DOI 10.1128/JVI.64.10.4903-4906.1990; WHITCOMB JM, 1992, ANNU REV CELL BIOL, V8, P275, DOI 10.1146/annurev.cb.08.110192.001423; WHITING SH, 1994, J VIROL, V68, P4747, DOI 10.1128/JVI.68.8.4747-4758.1994; WOHRL BM, 1995, SCIENCE, V267, P96, DOI 10.1126/science.7528942	61	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24135	24145		10.1074/jbc.270.41.24135	http://dx.doi.org/10.1074/jbc.270.41.24135			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592616	hybrid			2022-12-27	WOS:A1995TA21700044
J	SORENSEN, T; WHITE, T; WANDALL, HH; KRISTENSEN, AK; ROEPSTORFF, P; CLAUSSEN, H				SORENSEN, T; WHITE, T; WANDALL, HH; KRISTENSEN, AK; ROEPSTORFF, P; CLAUSSEN, H			UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE-POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE - IDENTIFICATION AND SEPARATION OF 2 DISTINCT TRANSFERASE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-GLYCOSYLATION; MOLECULAR-CLONING; GALNAC; PURIFICATION; SPECIFICITY; EXPRESSION; PROTEINS; CELLS; SITES; GENE	Using a defined acceptor substrate peptide as an affinity chromatography ligand we have developed a purification scheme for a unique human polypeptide, UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase (GalNAc-transferase) (White, T., Bennett, E. P., Takio, K., Sorensen, T., Bonding, N., and Clausen, H. (1995) J, Biol. Chem, 270, 24156-24165). Here we report detailed studies of the acceptor substrate specificity of GalNAc-transferase purified by this scheme as well as the GalNAc-transferase activity, which, upon repeated affinity chromatography, evaded purification by this affinity ligand. Using a panel of acceptor peptides, a qualitative difference in specificity between these separated transferase preparations was identified. Analysis of GalNAc-transferase activities in four rat organs and two human organs also revealed qualitative differences in specificity. The results support the existence of multiple GalNAc-transferase activities and suggest that these are differentially expressed in different organs. As the number of GalNAc-transferases existing is unknown, as is the specificity of the until now cloned and expressed GalNAc-transferases (T1 and T2), it is as yet impossible to relate the results obtained to specific enzyme proteins. The identification of acceptor peptides that can be used to discriminate GalNAc-transferase activities is an important step toward understanding the molecular basis of GalNAc O-linked glycosylation in cells and organs and in pathological conditions.	UNIV COPENHAGEN, SCH DENT, FAC HLTH SCI, DK-2200 COPENHAGEN N, DENMARK; BIOMEMBRANE INST, SEATTLE, WA 98119 USA; ODENSE UNIV, DEPT MOLEC BIOL, DK-5230 ODENSE, DENMARK	University of Copenhagen; University of Southern Denmark				Wandall, Hans H./0000-0003-0240-9232; Clausen, Henrik/0000-0002-0915-5055				BIRKEN S, 1981, J BIOL CHEM, V256, P1816; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BROCKHAUSEN I, 1992, BIOCHEM CELL BIOL, V70, P99, DOI 10.1139/o92-015; CLAUSEN H, 1994, ALFRED BENZON SYMP S, V36, P297; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GOOLEY AA, 1994, GLYCOBIOLOGY, V4, P413, DOI 10.1093/glycob/4.4.413; GOOLEY AA, 1991, BIOCHEM BIOPH RES CO, V178, P1194, DOI 10.1016/0006-291X(91)91019-9; GUM JR, 1989, J BIOL CHEM, V264, P6480; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HANSEN JES, 1992, ARCH VIROL, V126, P11, DOI 10.1007/BF01309680; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HOMA FL, 1993, J BIOL CHEM, V268, P12609; ISHIOKA GY, 1992, J IMMUNOL, V148, P2446; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; MCGUIRE EJ, 1965, J BIOL CHEM, V240, P4112; MERKLE RK, 1991, ARCH BIOCHEM BIOPHYS, V290, P248, DOI 10.1016/0003-9861(91)90616-Q; MOURITSEN S, 1994, EUR J IMMUNOL, V24, P1066, DOI 10.1002/eji.1830240509; MYERS G, 1991, THEORETICAL BIOL BIO; NISHIMORI I, 1994, J BIOL CHEM, V269, P16123; NISHIMORI I, 1994, CANCER RES, V54, P3738; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; OCONNELL BC, 1993, J DENT RES, V72, P1554, DOI 10.1177/00220345930720120401; OVERBAUGH J, 1992, J VIROL, V66, P5937, DOI 10.1128/JVI.66.10.5937-5948.1992; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; STRAHLBOLSINGER S, 1993, P NATL ACAD SCI USA, V90, P8164, DOI 10.1073/pnas.90.17.8164; TAYLORPAPADIMITRIOU J, 1993, ANN NY ACAD SCI, V690, P69; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; WANG Y, 1993, J BIOL CHEM, V268, P22979; WANG YC, 1992, J BIOL CHEM, V267, P2728; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529	37	61	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24166	24173		10.1074/jbc.270.41.24166	http://dx.doi.org/10.1074/jbc.270.41.24166			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592620	hybrid			2022-12-27	WOS:A1995TA21700048
J	ARVIDSON, CG; SO, M				ARVIDSON, CG; SO, M			THE NEISSERIA TRANSCRIPTIONAL REGULATOR PILA HAS A GTPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL-RECOGNITION PARTICLE; BINDING-PROTEIN NTRC; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; ATPASE ACTIVITY; GONORRHOEAE; GENE; OPERON; MECHANISMS; EXPRESSION	The pilA gene of Neisseria gonorrhoeae encodes the response regulator of a two component regulatory system that controls pilin gene expression, Examination of the primary sequence of PilA indicates that the protein contains at least two functional domains, The N-terminal region has a proposed helix-turn-helix motif thought to be involved in DNA binding. This region also contains the residues that are presumed to form the acidic pocket involved in phosphorylation by PilB, the sensor kinase of the system. The C terminus of the protein has extensive homology to the G (GTP-binding) domains of the eukaryotic signal recognition particle (SRP) 54-kDa protein and the a! subunit of the SRP receptor, or docking protein. This homology also extends to similar regions of the bacterial SRP homologs Ffh and FtsY, Here, we demonstrate that purified PilA has significant GTPase activity, and that this activity has an absolute requirement for MgCl2 and is sensitive to KCl and low pH, We also show that PilA has a strict specificity for GTP, and that GTP hydrolysis follows first order kinetics, with a maximum velocity (V-max) of 1900 pmol of P-i produced per min per mg of protein and a K-m for GTP of 9.6 mu M at 37 degrees C.			ARVIDSON, CG (corresponding author), OREGON HLTH SCI UNIV,DEPT MOLEC MICROBIOL & IMMUNOL,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.		So, Magdalene/ABB-8918-2020	So, Magdalene/0000-0001-8301-0674	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020845] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20845] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHNN J, 1986, P NATL ACAD SCI USA, V83, P8849, DOI 10.1073/pnas.83.23.8849; ARVIDSON CG, 1995, J BACTERIOL, V177, P2497, DOI 10.1128/jb.177.9.2497-2504.1995; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BERGSTROM S, 1986, P NATL ACAD SCI USA, V83, P3890, DOI 10.1073/pnas.83.11.3890; BYSTROM AS, 1983, EMBO J, V2, P899, DOI 10.1002/j.1460-2075.1983.tb01519.x; CORNISHBOWDEN A, 1988, FOCUS; FREITAG NE, 1995, MOL MICROBIOL, V16, P575, DOI 10.1111/j.1365-2958.1995.tb02420.x; GIBBS CP, 1989, NATURE, V338, P651, DOI 10.1038/338651a0; GOLLOP N, 1991, J BACTERIOL, V173, P2265, DOI 10.1128/JB.173.7.2265-2270.1991; HAAS R, 1987, P NATL ACAD SCI USA, V84, P9079, DOI 10.1073/pnas.84.24.9079; HONDA K, 1993, J BACTERIOL, V175, P4885, DOI 10.1128/JB.175.15.4885-4894.1993; JONSSON AB, 1991, EMBO J, V10, P477, DOI 10.1002/j.1460-2075.1991.tb07970.x; KOK J, 1994, J BACTERIOL, V176, P7155, DOI 10.1128/JB.176.23.7155-7160.1994; LERNER CG, 1991, MOL MICROBIOL, V5, P951, DOI 10.1111/j.1365-2958.1991.tb00770.x; MAGASANIK B, 1982, ANNU REV GENET, V16, P135, DOI 10.1146/annurev.ge.16.120182.001031; MANNING PA, 1991, MOL MICROBIOL, V5, P917, DOI 10.1111/j.1365-2958.1991.tb00766.x; MARCH PE, 1988, ONCOGENE, V2, P239; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; Neuhard J, 1987, ESCHERICHIA COLI SAL, P445; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; OCHI K, 1982, J BACTERIOL, V151, P1062, DOI 10.1128/JB.151.2.1062-1065.1982; PALUH JL, 1986, NUCLEIC ACIDS RES, V14, P7851, DOI 10.1093/nar/14.20.7851; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SAMUELSSON T, 1992, NUCLEIC ACIDS RES, V20, P5763, DOI 10.1093/nar/20.21.5763; SEIFERT HS, 1988, VACCINE, V6, P107, DOI 10.1016/S0264-410X(88)80009-4; SOOD P, 1994, MOL MICROBIOL, V12, P201, DOI 10.1111/j.1365-2958.1994.tb01009.x; TAHA MK, 1995, MOL MICROBIOL, V15, P667, DOI 10.1111/j.1365-2958.1995.tb02376.x; TAHA MK, 1991, MOL MICROBIOL, V5, P137, DOI 10.1111/j.1365-2958.1991.tb01834.x; TAHA MK, 1988, EMBO J, V7, P4367, DOI 10.1002/j.1460-2075.1988.tb03335.x; TAHA MK, 1992, J BACTERIOL, V174, P5978, DOI 10.1128/jb.174.18.5978-5981.1992; TONJUM T, 1995, MOL MICROBIOL, V16, P451, DOI 10.1111/j.1365-2958.1995.tb02410.x; TRACH K, 1989, J BACTERIOL, V171, P1362, DOI 10.1128/jb.171.3.1362-1371.1989; WANG XD, 1993, MOL MICROBIOL, V9, P435, DOI 10.1111/j.1365-2958.1993.tb01705.x; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WELSH KM, 1994, J BACTERIOL, V176, P7161, DOI 10.1128/JB.176.23.7161-7168.1994; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4	41	11	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26045	26048		10.1074/jbc.270.44.26045	http://dx.doi.org/10.1074/jbc.270.44.26045			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592800	hybrid			2022-12-27	WOS:A1995TC97800007
J	BOLHUIS, H; POELARENDS, G; VANVEEN, HW; POOLMAN, B; DRIESSEN, AJM; KONINGS, WN				BOLHUIS, H; POELARENDS, G; VANVEEN, HW; POOLMAN, B; DRIESSEN, AJM; KONINGS, WN			THE LACTOCOCCAL LMRP GENE ENCODES A PROTON MOTIVE FORCE-DEPENDENT DRUG TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; MULTIDRUG-RESISTANCE; ANTISEPTIC RESISTANCE; LACTIC STREPTOCOCCI; BACILLUS-SUBTILIS; EFFLUX; SYSTEM; SEQUENCE; PROTEINS	To genetically dissect the drug extrusion systems of Lactococcus lactis, a chromosomal. DNA library was made in Escherichia coli and recombinant strains were selected for resistance to high concentrations of ethidium bromide. Recombinant strains were found to be resistant not only to ethidium bromide but also to daunomycin and tetraphenylphosphonium. The drug resistance is conferred by the lmrP gene, which encodes a hydrophobic polypeptide of 408 amino acid residues with 12 putative membrane-spanning segments, Some sequence elements in this novel membrane protein share similarity to regions in the transposon Tn10-encoded tetracycline resistance determinant TetA, the multidrug transporter Bmr from Bacillus subtilis, and the bicyclomycin resistance determinant Bcr from E. coli. Drug resistance associated with ImrP expression correlated with energy-dependent extrusion of the molecules. Drug extrusion was inhibited by ionophores that dissipate the proton motive force but not by the ATPase inhibitor ortho-vanadate. These observations are indicative for a drug-proton antiport system. A ImrP deletion mutant was constructed via homologous recombination using DNA fragments of the flanking region of the gene. The L. lactis (Delta lmrP) strain exhibited residual ethidium extrusion activity, which in contrast to the parent strain was inhibited by ortho-vanadate. The results indicate that in the absence of the functional drug-proton antiporter LmrP, L. lactis is able to overexpress another, ATP-dependent, drug extrusion system. These findings substantiate earlier studies on the isolation and characterization of drug-resistant mutants oft. lactis (Bolhuis, H., Molenaar, D., Poelarends, G., van Veen, H. W., Poolman, B., Driessen, A. J. M., and Konings, W. N. (1994) J. Bacteriol. 176, 6957-6964).	UNIV GRONINGEN, GRONINGEN BIOMOLEC SCI & BIOTECHNOL INST, DEPT MICROBIOL, 9751 NN HAREN, NETHERLANDS	University of Groningen			Konings, Wilhelmus N./C-7063-2013; Bolhuis, Henk/A-4308-2008; Bolhuis, Henk/H-8535-2014; Driessen, Arnold J.M./D-1876-2012; Bolhuis, Henk/S-2986-2019; van Veen, Hendrik W./A-4162-2008; Bolhuis, Henk/M-6677-2019	Bolhuis, Henk/0000-0002-4772-1898; Bolhuis, Henk/0000-0002-4772-1898; van Veen, Hendrik W./0000-0002-9658-8077; Driessen, Arnold J.M./0000-0001-9258-9104; Poelarends, Gerrit/0000-0002-6917-6368				AHMED M, 1994, J BIOL CHEM, V269, P28506; BENTLEY J, 1993, GENE, V127, P117, DOI 10.1016/0378-1119(93)90625-D; BOLHUIS H, 1994, J BACTERIOL, V176, P6957, DOI 10.1128/JB.176.22.6957-6964.1994; CULLITON BJ, 1992, NATURE, V356, P473, DOI 10.1038/356473a0; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FRANCOIS V, 1987, GENE, V56, P99, DOI 10.1016/0378-1119(87)90162-4; GASSON MJ, 1983, J BACTERIOL, V154, P1; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRINIUS LL, 1994, J BIOL CHEM, V269, P29998; HACHLER H, 1991, J BACTERIOL, V173, P5532; HAGTING A, 1994, J BIOL CHEM, V269, P11391; HENDERSON PJF, 1991, BIOSCIENCE REP, V11, P477, DOI 10.1007/BF01130216; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; HILLGINS CF, 1992, ANN REV CELL BIOL, V8, P67; KOK J, 1984, APPL ENVIRON MICROB, V48, P726, DOI 10.1128/AEM.48.4.726-731.1984; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leenhouts K, 1993, PLASMIDS PRACTICAL A, P65; LEENHOUTS KJ, 1990, APPL ENVIRON MICROB, V56, P2726, DOI 10.1128/AEM.56.9.2726-2735.1990; LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; LOMOVSKAYA O, 1995, J BACTERIOL, V177, P2328, DOI 10.1128/jb.177.9.2328-2334.1995; LOMOVSKAYA O, 1992, P NATL ACAD SCI USA, V89, P8938, DOI 10.1073/pnas.89.19.8938; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MIDGLEY M, 1987, MICROBIOL SCI, V4, P125; MIDGLEY M, 1986, J GEN MICROBIOL, V132, P3187; MIYAUCHI S, 1992, BIOCHIM BIOPHYS ACTA, V1110, P144, DOI 10.1016/0005-2736(92)90351-L; MOLENAAR D, 1992, J BACTERIOL, V174, P3118, DOI 10.1128/jb.174.10.3118-3124.1992; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; PAULSEN IT, 1993, GENE, V124, P1, DOI 10.1016/0378-1119(93)90755-R; ROUCH DA, 1990, MOL MICROBIOL, V4, P2051, DOI 10.1111/j.1365-2958.1990.tb00565.x; SAIER MH, 1994, MOL MICROBIOL, V11, P841, DOI 10.1111/j.1365-2958.1994.tb00362.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ RM, 1987, ATLAS PROTEIN SEQUEN, V5, P353; TENNENT JM, 1989, J GEN MICROBIOL, V135, P1; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; YAMAGUCHI A, 1993, J BIOL CHEM, V268, P6496; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990	40	101	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26092	26098		10.1074/jbc.270.44.26092	http://dx.doi.org/10.1074/jbc.270.44.26092			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592810	hybrid			2022-12-27	WOS:A1995TC97800017
J	HENGSTSCHLAGEROTTNAD, E; KUCHLER, K; SCHNEIDER, WJ				HENGSTSCHLAGEROTTNAD, E; KUCHLER, K; SCHNEIDER, WJ			CHICKEN LECITHIN-CHOLESTEROL ACYLTRANSFERASE - MOLECULAR CHARACTERIZATION REVEALS UNUSUAL STRUCTURE AND EXPRESSION PATTERN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA LECITHIN; DIFFERENT ALLELIC MUTATIONS; SITE-DIRECTED MUTAGENESIS; LOW-DENSITY LIPOPROTEIN; CENTRAL NERVOUS-SYSTEM; FISH EYE DISEASE; LCAT DEFICIENCY; FAMILIAL LECITHIN; ACYL TRANSFERASE; NUCLEOTIDE-SEQUENCE	Rapidly growing oocytes in the laying hen are, in addition to the liver, targets of the so-called ''reverse cholesterol transport'' (RCT) (Vieira, P, M., Vieira, A, V,, Sanders, E, J,, Steyrer, E., Nimpf, J,, and Schneider, W, J, (1995) J, Lipid Res, 36, 601-610), pointing to the importance of this process in nonplacental reproduction, We have begun to delineate the details of this unique trans port pathway branch by molecular characterization of the first nonmammalian lecithin-cholesterol acyltransferase (LCAT), the enzyme that catalyzes an early step in RCT, The biological significance of the enzyme is under scored by the high degree of protein sequence identity (73%) maintained from chicken to man, Interestingly, the conservation extends much less to the cysteine residues; in fact, two of the cysteines thought to be important in mammalian enzymes (residues 31 and 184 in man) are absent from the chicken enzyme, providing proof of their dispensability for enzymatic activity, Antibodies prepared against a chicken LCAT fusion protein cross-react with human LCAT and identify a 64-kDa protein present in enzymatically active fractions obtained by hydrophobic chromatography of chicken se rum, The developmental and tissue distribution pattern of LCAT in females is striking; during embryogenesis and adolescence, LCAT expression is extremely high in liver but undetectable in brain, Upon onset of laying, however, brain LCAT mRNA increases suddenly and is maintained at levels 5 times higher than in liver, in stark contrast to most mammals, In adult roosters, the levels of LCAT transcripts in brain are lower than in liver, Together with the molecular characterization of chicken LCAT, these newly discovered developmental changes and gender differences in its expression establish the avian oocyte/liver system as a powerful model to delineate in vivo regulatory elements of RCT.	UNIV & BIOCTR VIENNA, DEPT MOLEC GENET, A-1030 VIENNA, AUSTRIA	University of Vienna			kuchler, karl/AAL-6937-2020	kuchler, karl/0000-0003-2719-5955				AKEROYD R, 1981, EUR J BIOCHEM, V114, P385, DOI 10.1111/j.1432-1033.1981.tb05158.x; ALBERS JJ, 1976, BIOCHEMISTRY-US, V15, P1084, DOI 10.1021/bi00650a020; BORGHINI I, 1995, BBA-LIPID LIPID MET, V1255, P192, DOI 10.1016/0005-2760(94)00232-N; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BUJO H, 1991, BIOCHEM BIOPH RES CO, V181, P933, DOI 10.1016/0006-291X(91)92026-G; BURLEY RW, 1984, EUR J BIOCHEM, V142, P171, DOI 10.1111/j.1432-1033.1984.tb08266.x; CHAPMAN MJ, 1980, J LIPID RES, V21, P789; CHEN CH, 1982, J LIPID RES, V23, P680; CHONG KS, 1983, CAN J BIOCHEM CELL B, V61, P875, DOI 10.1139/o83-112; COCHRANE A, 1989, J BIOL CHEM, V264, P6495; COOPER DA, 1992, BIOCHIM BIOPHYS ACTA, V1129, P166, DOI 10.1016/0167-4781(92)90482-F; DECARO J, 1981, BIOCHIM BIOPHYS ACTA, V671, P129, DOI 10.1016/0005-2795(81)90126-4; DOCHERTY AJP, 1985, NUCLEIC ACIDS RES, V13, P1891, DOI 10.1093/nar/13.6.1891; FAROOQUI JZ, 1988, ARCH BIOCHEM BIOPHYS, V261, P330, DOI 10.1016/0003-9861(88)90348-7; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FRANCONE OL, 1991, BIOCHEMISTRY-US, V30, P10074, DOI 10.1021/bi00106a002; FRANCONE OL, 1991, P NATL ACAD SCI USA, V88, P1716, DOI 10.1073/pnas.88.5.1716; FRANCONE OL, 1993, BIOCHIM BIOPHYS ACTA, V1166, P301, DOI 10.1016/0005-2760(93)90110-U; FUNKE H, 1991, J CLIN INVEST, V87, P371, DOI 10.1172/JCI114997; FUNKE H, 1991, P NATL ACAD SCI USA, V88, P4855, DOI 10.1073/pnas.88.11.4855; FUNKE H, 1993, J CLIN INVEST, V91, P677, DOI 10.1172/JCI116248; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON DA, 1988, J BIOL CHEM, V263, P2625; GORNALL DA, 1973, J LIPID RES, V14, P197; HERMIER D, 1989, EUR J BIOCHEM, V184, P109, DOI 10.1111/j.1432-1033.1989.tb14996.x; HILL JS, 1993, BIOCHIM BIOPHYS ACTA, V1181, P321, DOI 10.1016/0925-4439(93)90039-4; HILL JS, 1993, J LIPID RES, V34, P1245; HILLYARD LA, 1972, BIOCHEMISTRY-US, V11, P511, DOI 10.1021/bi00754a005; HIXSON JE, 1993, GENE, V128, P295, DOI 10.1016/0378-1119(93)90578-Q; HUMPHRIES SE, 1988, CLIN SCI, V74, P91, DOI 10.1042/cs0740091; IGNATIUS MJ, 1987, PROG BRAIN RES, V177; ILLINGWORTH D R, 1970, Biochimica et Biophysica Acta, V220, P610, DOI 10.1016/0005-2744(70)90292-5; JAUHIAINEN M, 1988, J BIOL CHEM, V263, P6525; JAUHIAINEN M, 1986, J BIOL CHEM, V261, P7032; KIRCHGESSNER TG, 1987, GENE, V59, P241, DOI 10.1016/0378-1119(87)90332-5; KLEIN HG, 1992, J CLIN INVEST, V89, P499, DOI 10.1172/JCI115612; KLEIN HG, 1993, J LIPID RES, V34, P49; KLEIN HG, 1993, J CLIN INVEST, V92, P479, DOI 10.1172/JCI116591; KLEIN HG, 1995, J BIOL CHEM, V270, P9443, DOI 10.1074/jbc.270.16.9443; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE ME, 1989, J BIOL CHEM, V264, P20042; MAEDA E, 1991, BIOCHEM BIOPH RES CO, V178, P460, DOI 10.1016/0006-291X(91)90129-U; MCLEAN J, 1986, NUCLEIC ACIDS RES, V14, P9397, DOI 10.1093/nar/14.23.9397; MCLEAN J, 1986, P NATL ACAD SCI USA, V83, P2335, DOI 10.1073/pnas.83.8.2335; MERONI G, 1990, NUCLEIC ACIDS RES, V18, P5308, DOI 10.1093/nar/18.17.5308; MERONI G, 1991, BIOCHEM BIOPH RES CO, V180, P1469, DOI 10.1016/S0006-291X(05)81361-0; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; PUIJK WC, 1977, BIOCHIM BIOPHYS ACTA, V492, P254, DOI 10.1016/0005-2795(77)90076-9; QU SJ, 1993, BIOCHEMISTRY-US, V32, P3089, DOI 10.1021/bi00063a021; ROGNE S, 1987, BIOCHEM BIOPH RES CO, V148, P161, DOI 10.1016/0006-291X(87)91090-4; Sambrook J, 1989, MOL CLONING LABORATO; SENSEL MG, 1990, BIOCHIM BIOPHYS ACTA, V1048, P297, DOI 10.1016/0167-4781(90)90071-9; SHOJANIA AM, 1983, CLIN INVEST MED, V6, P49; SKRETTING G, 1992, FEBS LETT, V309, P307, DOI 10.1016/0014-5793(92)80795-I; Smith F R, 1977, Adv Exp Med Biol, V82, P489; STEYRER E, 1988, BIOCHIM BIOPHYS ACTA, V958, P484, DOI 10.1016/0005-2760(88)90235-4; TARAMELLI R, 1990, HUM GENET, V85, P195; TARUGI P, 1994, J LIPID RES, V34, P2019; TATA F, 1987, BIOCHIM BIOPHYS ACTA, V910, P142, DOI 10.1016/0167-4781(87)90066-2; TEISBERG P, 1981, ACTA MED SCAND, V210, P1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIEIRA AV, 1994, CELL BIOL LAB HDB, P314; VIEIRA PM, 1995, J LIPID RES, V36, P601; WARDEN CH, 1989, J BIOL CHEM, V264, P21573; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; WISKOCIL R, 1980, P NATL ACAD SCI-BIOL, V77, P4474, DOI 10.1073/pnas.77.8.4474	69	23	24	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26139	26145		10.1074/jbc.270.44.26139	http://dx.doi.org/10.1074/jbc.270.44.26139			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592817	hybrid			2022-12-27	WOS:A1995TC97800024
J	LEWENDON, A; ELLIS, J; SHAW, WV				LEWENDON, A; ELLIS, J; SHAW, WV			STRUCTURAL AND MECHANISTIC STUDIES OF GALACTOSIDE ACETYLTRANSFERASE, THE ESCHERICHIA-COLI LACA GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III CHLORAMPHENICOL ACETYLTRANSFERASE; NUCLEOTIDE-SEQUENCE ANALYSIS; SITE-DIRECTED MUTAGENESIS; THIOGALACTOSIDE TRANSACETYLASE; AFFINITY-CHROMATOGRAPHY; LACTOSE OPERON; BINDING; RESOLUTION	Escherichia coli galactoside acetyltransferase (GAT) is a member of a large family of acetyltransferases that O-acetylate dissimilar substrates but share limited sequence homology. Steady-state kinetic analysis of overexpressed GAT demonstrated that it accepted a range of substrates, including glucosides and lactosides which were acetylated at rates comparable to galactosides. GAT was shown to be a trimeric acetyltransferase by cross-linking with dimethyl suberimidate. Fluorometric analysis of coenzyme A binding showed that there is a fluorescence quench associated with acetyl-CoA binding whereas CoA has no effect. This difference was exploited to measure dissociation rates for both CoA and acetyl-CoA by stopped-flow fluorometry. The rate of dissociation of CoA (2500 s(-1)) is at least 170-fold faster than k(cat) for any substrate tested. The fluorescence response to acetyl-CoA binding is entirely due to Trp-139 since replacement by phenylalanine completely abolished the fluorescence quench. Treatment of GAT by [C-14]iodoacetamide resulted in complete inactivation of the enzyme and the incorporation of label into histidyl and cysteinyl residues to approximately equal extents. Following replacement of His-115 by alanine, label was incorporated solely into cysteinyl residues. Furthermore, the substitution results in an 1800-fold decrease in k(cat) suggesting that His-115 has an important catalytic role in GAT.			LEWENDON, A (corresponding author), UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,LEICS,ENGLAND.							ALLIGNET J, 1993, GENE, V130, P91, DOI 10.1016/0378-1119(93)90350-C; ANDREWS KJ, 1976, J BACTERIOL, V128, P510, DOI 10.1128/JB.128.1.510-513.1976; BLOEMBERG GV, 1994, MOL MICROBIOL, V11, P793, DOI 10.1111/j.1365-2958.1994.tb00357.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JL, 1967, J BIOL CHEM, V242, P4254; BROWN NF, 1994, J BIOL CHEM, V269, P19157; CARBINI LA, 1993, J NEUROCHEM, V61, P247, DOI 10.1111/j.1471-4159.1993.tb03561.x; DOWNIE JA, 1989, MOL MICROBIOL, V3, P1649, DOI 10.1111/j.1365-2958.1989.tb00150.x; ELLIS J, 1991, BIOCHEMISTRY-US, V30, P10806, DOI 10.1021/bi00108a029; ELLIS J, 1991, BIOCHEMISTRY-US, V30, P10799, DOI 10.1021/bi00108a028; FOWLER AV, 1985, BIOCHIMIE, V67, P101, DOI 10.1016/S0300-9084(85)80235-2; HEDIGER MA, 1985, P NATL ACAD SCI USA, V82, P6414, DOI 10.1073/pnas.82.19.6414; KLEANTHOUS C, 1985, BIOCHEMISTRY-US, V24, P5307, DOI 10.1021/bi00341a006; KLEANTHOUS C, 1984, BIOCHEM J, V223, P211, DOI 10.1042/bj2230211; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; LESLIE AGW, 1990, J MOL BIOL, V213, P167, DOI 10.1016/S0022-2836(05)80129-9; LEWENDON A, 1994, BIOCHEMISTRY-US, V33, P1944, DOI 10.1021/bi00173a043; LEWENDON A, 1990, BIOCHEMISTRY-US, V29, P2075, DOI 10.1021/bi00460a016; LOWE CR, 1984, METHOD ENZYMOL, V104, P97; MURRAY IA, 1988, BIOCHEM J, V252, P173, DOI 10.1042/bj2520173; MUSSO RE, 1973, BIOCHEMISTRY-US, V12, P553, DOI 10.1021/bi00727a031; PARENT R, 1992, J BACTERIOL, V174, P2891, DOI 10.1128/JB.174.9.2891-2897.1992; TENNIGKEIT J, 1991, GENE, V98, P113, DOI 10.1016/0378-1119(91)90112-O; Weber K, 1972, Methods Enzymol, V26, P3; WILSON TH, 1969, BIOCHIM BIOPHYS ACTA, V173, P501, DOI 10.1016/0005-2736(69)90014-5; ZABIN I, 1963, J BIOL CHEM, V238, P3300; ZABIN I, 1959, BIOCHEM BIOPH RES CO, V1, P289, DOI 10.1016/0006-291X(59)90040-3; ZABIN I, 1962, J BIOL CHEM, V237, P253; ZABIN I, 1984, ANAL BIOCHEM, V136, P493, DOI 10.1016/0003-2697(84)90250-1	31	20	26	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26326	26331		10.1074/jbc.270.44.26326	http://dx.doi.org/10.1074/jbc.270.44.26326			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592843	hybrid			2022-12-27	WOS:A1995TC97800050
J	NEILSON, KM; FRIESEL, RE				NEILSON, KM; FRIESEL, RE			CONSTITUTIVE ACTIVATION OF FIBROBLAST GROWTH-FACTOR RECEPTOR-2 BY A POINT MUTATION ASSOCIATED WITH CROUZON SYNDROME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEVELOPMENTAL EXPRESSION; XENOPUS DEVELOPMENT; MESODERM INDUCTION; LIGAND-BINDING; FGF; SPECIFICITY; FAMILY; MUTANT	The fibroblast growth factor receptors (FGFRs) are a family of ligand-activated, membrane-spanning tyrosine kinases. Mutations in several human FGFR genes have been identified as playing a role in certain disorders of bone growth and development. One of these, Crouzon syndrome, an autosomal dominant disorder causing craniosynostosis, has been associated with mutations in the human FGFR-2 gene. We report here that microinjection of Xenopus embryos with RNA encoding an FGFR-2 protein bearing a Cys(332) --> Tyr mutation (FGFR-2CS) found in Crouzon syndrome results in fibroblast growth factor (FGF) independent induction of mesoderm in animal pole explants. Wild-type FGFR-2 did not induce mesoderm when injected at similar doses. The effects of the mutant receptor were blocked by co-expression of dominant negative mutants of either Raf or Ras. Analysis of the mutant receptor protein expressed in Xenopus oocytes indicates that it forms covalent homodimers, does not bind radiolabeled FGF, and has increased tyrosine phosphorylation. These results indicate that FGFR-2CS forms an intermolecular disulfide bond resulting in receptor dimerization and ligand-independent activation that may play a role in the etiology of Crouzon syndrome.	AMER RED CROSS,JEROME H HOLLAND LAB,DEPT MOLEC BIOL,ROCKVILLE,MD 20855	American Red Cross					NHLBI NIH HHS [T32-HL-07698] Funding Source: Medline; NICHD NIH HHS [HD29561] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029561] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007698] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BROWN SAN, 1993, BIOCHEM BIOPH RES CO, V193, P1116, DOI 10.1006/bbrc.1993.1741; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAWID IB, 1994, J BIOL CHEM, V269, P6259; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; FRIESEL R, 1992, DEVELOPMENT, V116, P1051; GREEN JBA, 1990, DEVELOPMENT, V108, P173; HOU JZ, 1992, J BIOL CHEM, V267, P17804; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MCDONALD FJ, 1994, DEV GENET, V15, P148, DOI 10.1002/dvg.1020150205; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Moon R. T., 1989, TECHNIQUE, V1, P76; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PENG HB, 1991, XENOPUS LAEVIS PRACT; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; RUTLAND P, 1995, NAT GENET, V9, P173, DOI 10.1038/ng0295-173; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; UENO H, 1992, J BIOL CHEM, V267, P1470; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; WILKIE AOM, 1995, CURR BIOL, V5, P500; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	42	127	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26037	26040		10.1074/jbc.270.44.26037	http://dx.doi.org/10.1074/jbc.270.44.26037			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592798	hybrid			2022-12-27	WOS:A1995TC97800005
J	ADAMS, ME; DWYER, TM; DOWLER, LL; WHITE, RA; FROEHNER, SC				ADAMS, ME; DWYER, TM; DOWLER, LL; WHITE, RA; FROEHNER, SC			MOUSE ALPHA-1-SYNTROPHIN AND BETA-2-SYNTROPHIN GENE STRUCTURE, CHROMOSOME LOCALIZATION, AND HOMOLOGY WITH A DISCS LARGE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCULAR-DYSTROPHY LOCUS; NONMUSCLE TISSUES; MEMBRANE-PROTEIN; MAJOR PRODUCT; TRANSCRIPT; SEQUENCE; TORPEDO; MUSCLE; CELLS; BRAIN	The syntrophin family of dystrophin-associated proteins consists of three isoforms, alpha 1, beta 1, and beta 2, each encoded by a distinct gene. We have cloned and characterized the mouse alpha 1- and beta 2-syntrophin genes. The mouse alpha 1-syntrophin gene (>24 kilobases) is comprised of eight exons. The mouse beta 2-syntrophin gene (>33 kilobases) contains seven exons, all of which have homologues at the corresponding position in the alpha 1-syntrophin gene. Primer extension analysis reveals two transcription initiation sites in the alpha 1-syntrophin gene and a single site in the beta 2-syntrophin gene. The sequence immediately 5' of the transcription start sites of both genes lacks a TATA box but is GC-rich and has multiple putative SP1 binding sites. The alpha 1-syntrophin gene is located on human chromosome 20 and mouse chromosome 2, while the beta 2-syntrophin gene is on human chromosome 16 and mouse chromosome 8. Analysis of the amino acid sequence of the syntrophins reveals the presence of four conserved domains. The carboxyl-terminal 56 amino acids are highly conserved and constitute a syntrophin unique domain. Two pleckstrin homology domains are Located at the amino-terminal end of the protein. The first pleckstrin homology domain is interrupted by a domain homologous to repeated sequences originally found in the Drosophila discs-large protein.	UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599; UNIV MISSOURI,CHILDRENS MERCY HOSP,KANSAS CITY SCH MED,GENET SECT,KANSAS CITY,MO 64108	University of North Carolina; University of North Carolina Chapel Hill; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014871] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 14871] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; AHN AH, 1995, IN PRESS J BIOL CHEM; Blake Derek J., 1992, Human Molecular Genetics, V1, P103, DOI 10.1093/hmg/1.2.103; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CARTAUD A, 1993, J BIOL CHEM, V268, P13019; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; DSOUZA VN, 1995, HUM MOL GENET, V4, P837, DOI 10.1093/hmg/4.5.837; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FROEHNER SC, 1984, J CELL BIOL, V99, P88, DOI 10.1083/jcb.99.1.88; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GORECKI DC, 1992, HUM MOL GENET, V1, P505, DOI 10.1093/hmg/1.7.505; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HUGNOT JP, 1992, P NATL ACAD SCI USA, V89, P7506, DOI 10.1073/pnas.89.16.7506; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; LANE PW, 1976, J HERED, V67, P135, DOI 10.1093/oxfordjournals.jhered.a108687; LEDERFEIN D, 1993, HUM MOL GENET, V2, P1883, DOI 10.1093/hmg/2.11.1883; LEDERFEIN D, 1992, P NATL ACAD SCI USA, V89, P5346, DOI 10.1073/pnas.89.12.5346; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MALTAIS LJ, 1993, GBASE; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEALOCK R, 1994, CELL, V77, P617, DOI 10.1016/0092-8674(94)90045-0; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; TINSLEY JM, 1993, HUM MOL GENET, V2, P521, DOI 10.1093/hmg/2.5.521; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WHITE RA, 1992, NAT GENET, V2, P80, DOI 10.1038/ng0992-80; WOODS DF, 1991, DEV BIOL, V134, P222; YAMAMOTO H, 1993, J BIOCHEM-TOKYO, V114, P132, DOI 10.1093/oxfordjournals.jbchem.a124128; YANG B, 1994, J BIOL CHEM, V269, P6040; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	54	109	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25859	25865		10.1074/jbc.270.43.25859	http://dx.doi.org/10.1074/jbc.270.43.25859			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592771	hybrid			2022-12-27	WOS:A1995TB46600088
J	DEYST, KA; BOWE, MA; LESZYK, JD; FALLON, JR				DEYST, KA; BOWE, MA; LESZYK, JD; FALLON, JR			THE ALPHA-DYSTROGLYCAN-BETA-DYSTROGLYCAN COMPLEX - MEMBRANE ORGANIZATION AND RELATIONSHIP TO AN AGRIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-GLYCOPROTEIN COMPLEX; ACETYLCHOLINE-RECEPTOR; SKELETAL-MUSCLE; LOCALIZATION; LAMININ; PROTEIN; SARCOLEMMA; INTEGRINS; ADHESION	Aberrant expression of the dystrophin-associated protein complex is thought to underlie the pathogenesis of Duchenne dystrophy, Becker muscular dystrophy, and severe childhood autosomal recessive muscular dystrophy. Recently, our laboratory identified an agrin receptor from Torpedo electric organ postsynaptic membranes. It is a heteromer of 190- and 50-kDa subunits with similarity to two components of the dystrophin-associated protein complex of alpha- and beta-dystroglycan. We now confirm the relationship between the Torpedo agrin receptor and mammalian dystroglycans and provide further information about the structure of the alpha-dystroglycan-beta-dystroglycan complex. The sequences of three peptides from each Torpedo subunit were 69% identical to mammalian dystroglycans. An antiserum to mammalian beta-dystroglycan recognizes the Torpedo 50-kDa polypeptide. Additionally, like alpha-dystroglycan, the 190-kDa agrin receptor subunit binds laminin. Previous studies have indicated that alpha- and beta-dystroglycan arise by cleavage of a precursor protein. Tryptic peptide mapping of both subunits and amino-terminal sequencing of Torpedo beta-dystroglycan indicate a single cleavage site, corresponding to serine 654 of the mammalian dystroglycan precursor. Gel electrophoresis analysis indicates there is at least one intrachain disulfide bond in beta-dystroglycan. These results provide precise primary structures for alpha- and beta-dystroglycan.	WORCESTER FDN BIOMED RES,NEUROBIOL GRP,SHREWSBURY,MA 01545; WORCESTER FDN BIOMED RES,WM KECK PROT CHEM FACIL,SHREWSBURY,MA 01545	Worcester Foundation for Biomedical Research; Worcester Foundation for Biomedical Research					NICHD NIH HHS [R01 HD023924, HD23924] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023924] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FALLON JR, 1994, TRENDS NEUROSCI, V17, P469, DOI 10.1016/0166-2236(94)90135-X; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1993, J BIOL CHEM, V268, P14972; GORDON H, 1993, J NEUROSCI, V13, P586; HAYASHI YK, 1993, J NEUROL SCI, V119, P53, DOI 10.1016/0022-510X(93)90191-Z; HIGUCHI I, 1994, J CLIN INVEST, V94, P601, DOI 10.1172/JCI117375; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IBRAGHIMOVBESKR.O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHINOVBESKR, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; MA JY, 1993, J BIOL CHEM, V268, P25108; MCNALLY EM, 1994, P NATL ACAD SCI USA, V91, P9690, DOI 10.1073/pnas.91.21.9690; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; TOME FMS, 1994, NEUROMUSCULAR DISORD, V4, P343, DOI 10.1016/0960-8966(94)90070-1; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; YOSHIDA M, 1994, EUR J BIOCHEM, V15, P1055; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	34	56	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25956	25959		10.1074/jbc.270.43.25956	http://dx.doi.org/10.1074/jbc.270.43.25956			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592785	hybrid			2022-12-27	WOS:A1995TB46600102
J	LEECH, AP; JAMES, R; COGGINS, JR; KLEANTHOUS, C				LEECH, AP; JAMES, R; COGGINS, JR; KLEANTHOUS, C			MUTAGENESIS OF ACTIVE-SITE RESIDUES IN TYPE-I DEHYDROQUINASE FROM ESCHERICHIA-COLI - STALLED CATALYSIS IN A HISTIDINE TO ALANINE MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHIKIMATE PATHWAY ENZYME; STEREOCHEMICAL COURSES; BRONSTED ANALYSIS; SALMONELLA-TYPHI; 3-DEHYDROQUINASE; PURIFICATION; IDENTIFICATION; INTERMEDIATE; BINDING; PROTEIN	Chemical modification experiments have previously implicated four amino acid residues in the mechanism of type I dehydroquinase from Escherichia coli. To further test their importance, these residues were mutated, and the resulting mutants were expressed, purified, and characterized. When the highly conserved, Schiff base-forming lysine residue was mutated (K170A) the resulting enzyme showed a similar to 10(6)-fold reduction in catalytic activity, but was still able to bind both substrate and product, as shown by a novel fluorescence-based ligand-binding assay. This is consistent with Lys-170 playing a central role in catalysis and shows that, although forming a covalent bond with the substrate, it is not essential for ground state binding of substrate or product. Conversely, substituting leucine for the conserved, iodoacetate-reactive methionine residue (M205L) had little effect on k(cat) or K-m. Diethylpyrocarbonate experiments had previously implicated either His-143 or His-146 as the putative active site general base. Substituting alanine for each shows that H146A retains full catalytic activity while H143A shows a 10(6)-fold loss of activity. As with the K170A mutant, H143A can bind Ligand, and in addition to the predicted role of this residue as the proton-abstracting general base, our data suggest that it is also involved in the formation and breakdown of Schiff base intermediates. Isoelectric focusing, electrospray ionization mass spectrometry, and fluorescence spectroscopy show that the H143A mutant preferentially stabilizes the formation of the product Schiff base, and that this results in burst kinetics reminiscent of p-nitrophenyl acetate hydrolysis by chymotrypsin. The most striking illustration of this stabilization is the fact that the H143A mutant is isolated from overexpressing cells with a significant proportion of the enzyme monomers covalently bound to the product, 3-dehydroshikimate, via a Schiffbase linkage. Our data suggest that the H143A mutant is able to slowly transform substrate to product but that the hydrolytic release of the product is stalled. The proposed dual role of His-143 in the mechanism of type I dehydroquinase may explain why the elimination reaction catalyzed by this enzyme proceeds with syn stereochemistry.	UNIV E ANGLIA, SCH BIOL SCI, NORWICH NR4 7TJ, NORFOLK, ENGLAND; UNIV GLASGOW, DEPT BIOCHEM, GLASGOW G12 8QQ, LANARK, SCOTLAND	University of East Anglia; University of Glasgow			James, Richard/B-2252-2009	James, Richard/0000-0002-5086-788X				BENNER SA, 1981, J AM CHEM SOC, V103, P993, DOI 10.1021/ja00394a071; BONNER CA, 1994, BIOCHEM J, V302, P11, DOI 10.1042/bj3020011; BOYS CWG, 1992, J MOL BIOL, V227, P352, DOI 10.1016/0022-2836(92)90704-N; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUGG TDH, 1989, THESIS CAMBRIDGE U U; BUTLER JR, 1974, J AM CHEM SOC, V96, P1617, DOI 10.1021/ja00812a069; CHAUDHURI S, 1991, BIOCHEM J, V275, P1; CHAUDHURI S, 1986, BIOCHEM J, V239, P699, DOI 10.1042/bj2390699; CURTIS MD, 1991, MOL MICROBIOL, V5, P2727, DOI 10.1111/j.1365-2958.1991.tb01981.x; DEKA RK, 1994, FEBS LETT, V349, P397, DOI 10.1016/0014-5793(94)00710-1; DEKA RK, 1992, J BIOL CHEM, V267, P22237; DUNCAN K, 1986, BIOCHEM J, V238, P475, DOI 10.1042/bj2380475; EUVERINK GJW, 1992, J GEN MICROBIOL, V138, P2449, DOI 10.1099/00221287-138-11-2449; GARBE T, 1991, MOL GEN GENET, V228, P385, DOI 10.1007/BF00260631; GILES NH, 1967, P NATL ACAD SCI USA, V58, P1930, DOI 10.1073/pnas.58.5.1930; GOURLEY DG, 1994, J MOL BIOL, V241, P488, DOI 10.1006/jmbi.1994.1524; GREWE R, 1968, BIOCH PREP, V12, P21; HANSON KR, 1963, P NATL ACAD SCI USA, V50, P981, DOI 10.1073/pnas.50.5.981; HARRIS J, 1993, J CHEM SOC CHEM COMM, P1080, DOI 10.1039/c39930001080; HARTLEY BS, 1954, BIOCHEM J, V56, P288, DOI 10.1042/bj0560288; Haslam E., 1974, SHIKIMATE PATHWAY; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; KLEANTHOUS C, 1990, J BIOL CHEM, V265, P10929; KLEANTHOUS C, 1990, J BIOL CHEM, V265, P10935; KLEANTHOUS C, 1992, BIOCHEM J, V282, P687, DOI 10.1042/bj2820687; KLEANTHOUS C, 1991, J BIOL CHEM, V266, P10893; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; MITSUHASHI S, 1954, BIOCHIM BIOPHYS ACTA, V15, P54; MOORE JD, 1993, BIOCHEM J, V295, P277, DOI 10.1042/bj2950277; PITTARD J, 1966, J BACTERIOL, V91, P1494, DOI 10.1128/JB.91.4.1494-1508.1966; REILLY A, 1994, J BIOL CHEM, V269, P5523; REILLY A, 1993, BIOORG MED CHEM LETT, V3, P1429, DOI 10.1016/S0960-894X(01)80424-8; SCHIMMEL P, 1990, BIOCHEMISTRY-US, V29, P9495, DOI 10.1021/bi00493a001; SHNEIER A, 1991, J AM CHEM SOC, V113, P9416, DOI 10.1021/ja00024a085; SHNEIER A, 1993, BIOORG MED CHEM LETT, V3, P1399, DOI 10.1016/S0960-894X(01)80419-4; TONEY MD, 1992, PROTEIN SCI, V1, P107; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; VAZ ADN, 1979, THESIS TULANE U NEW; WHITE PJ, 1990, BIOCHEM J, V265, P735, DOI 10.1042/bj2650735	39	36	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25827	25836		10.1074/jbc.270.43.25827	http://dx.doi.org/10.1074/jbc.270.43.25827			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592767	hybrid			2022-12-27	WOS:A1995TB46600084
J	YU, L; DENG, KP; YU, CA				YU, L; DENG, KP; YU, CA			CLONING, GENE SEQUENCING, AND EXPRESSION OF THE SMALL MOLECULAR-MASS UBIQUINONE-BINDING PROTEIN OF MITOCHONDRIAL UBIQUINOL-CYTOCHROME-C REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEEF-HEART UBIQUINOL; AMINO-ACID SEQUENCE; BC1 COMPLEX; RECOMBINANT PROTEINS; INCLUSION-BODIES; ESCHERICHIA-COLI; KDA; CRYSTALLIZATION; SUBUNITS	The cDNA encoding QPc-9.5 kDa (subunit VII) of bovine heart mitochondrial ubiquinol-cytochrome c reductase was cloned and sequenced. This cDNA is 665 base pairs long with an open reading frame of 246 base pairs that encodes an 81-amino acid mature QPc-9.5 kDa, The insert contains 395 base pairs of a 3'-noncoding sequence with a poly(A) tail. The amino acid sequence of QPc-9.5 kDa deduced from this nucleotide sequence is the same as that obtained by protein sequencing except that residue 61 is tryptophan instead of cysteine, The QPc-9.5 kDa was overexpressed in Escherichia coli JM109 cells as a glutathione S-transferase fusion protein (GST-QPc) using the expression vector, pGEX/QPc, The yield of soluble active recombinant GST-QPc fusion protein depends on the induction growth time, temperature, and medium. Maximum yield of recombinant fusion protein was obtained hom cells harvested 3 h postinduction of growth at 27 degrees C on LB medium containing betaine and sorbitol, QPc-9.5 kDa was released from the fusion protein by proteolytic cleavage with thrombin. Isolated recombinant QPc-9.5 kDa showed one protein band in SDS-polyacrylamide gel electrophroesis corresponding to subunit VII of mitochondrial ubiquinol-cytochrome c reductase. Although the isolated recombinant QPc-9.5 kDa is soluble in aqueous solution, it is in a highly aggregated form, with an apparent molecular mass of over 1 million, Addition of detergent deaggreates the isolated protein to the monomeric state, suggesting that the recombinant protein exists as a hydrophobic aggregation in aqueous solution, The recombinant QPc-9.5 kDa binds ubiquinone and shows a spectral blue shift. Upon titration of the recombinant protein with ubiquinone, a saturation behavior is observed, suggesting that the binding is specific and that the recombinant protein may be in the functionally active state.			YU, L (corresponding author), OKLAHOMA STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,STILLWATER,OK 74078, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON SL, 1981, J MOL BIOL, V156, P683; ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; BARR PJ, 1966, BIOTECHNIQUES, V4, P428; BERRY EA, 1992, J MOL BIOL, V224, P1161, DOI 10.1016/0022-2836(92)90476-Z; BERRY EA, 1985, COENZYME Q, P365; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; BORCHART U, 1986, FEBS LETT, V200, P81, DOI 10.1016/0014-5793(86)80515-4; BORCHART U, 1985, FEBS LETT, V191, P125, DOI 10.1016/0014-5793(85)81007-3; BROWN AD, 1976, BACTERIOL REV, V40, P803, DOI 10.1128/MMBR.40.4.803-846.1976; COCCO T, 1991, EUR J BIOCHEM, V195, P731, DOI 10.1111/j.1432-1033.1991.tb15760.x; DARBY NJ, 1990, NATURE, V334, P715; HART RA, 1992, BIOTECHNOL BIOENG, V39, P1112, DOI 10.1002/bit.260391106; HARTLEY DL, 1988, BIOCHEM SOC T, V16, P101, DOI 10.1042/bst0160101; HARTMAN J, 1992, BIOTECHNOL BIOENG, V39, P828, DOI 10.1002/bit.260390805; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HE DY, 1994, J BIOL CHEM, V269, P2292; HOESS A, 1988, BIO-TECHNOL, V6, P1214, DOI 10.1038/nbt1088-1214; HOSOKAWA Y, 1989, J BIOL CHEM, V264, P13483; JOHNSON KS, 1989, NATURE, V338, P585, DOI 10.1038/338585a0; KUBOTA T, 1991, J MOL BIOL, V221, P379, DOI 10.1016/0022-2836(91)80059-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; SAMBROK J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1985, FEBS LETT, V190, P89, DOI 10.1016/0014-5793(85)80434-8; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SCHEIN CH, 1988, BIO-TECHNOL, V6, P291, DOI 10.1038/nbt0388-291; USUI S, 1990, BIOCHEMISTRY-US, V29, P4618, DOI 10.1021/bi00471a017; USUI S, 1990, BIOCHEM BIOPH RES CO, V167, P575, DOI 10.1016/0006-291X(90)92063-6; WAKABAYASHI S, 1982, J BIOCHEM, V91, P2077, DOI 10.1093/oxfordjournals.jbchem.a133901; WAKABAYASHI S, 1982, J BIOL CHEM, V257, P9335; YU CA, 1972, J BIOL CHEM, V247, P1012; YU L, 1985, J BIOL CHEM, V260, P963; YUE WH, 1991, BIOCHEMISTRY-US, V30, P2303, DOI 10.1021/bi00223a002; ALTERED SITESTM IN V	37	24	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25634	25638		10.1074/jbc.270.43.25634	http://dx.doi.org/10.1074/jbc.270.43.25634			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592738	hybrid			2022-12-27	WOS:A1995TB46600055
J	FAN, F; MAYO, KH				FAN, F; MAYO, KH			EFFECT OF PH ON THE CONFORMATION AND BACKBONE DYNAMICS OF A 27-RESIDUE PEPTIDE IN TRIFLUOROETHANOL - AN NMR AND CD STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLDING INITIATION SITES; MAGNETIC-RESONANCE RELAXATION; PROTEIN SECONDARY STRUCTURE; FIBRINOGEN GAMMA-CHAIN; HELIX-COIL TRANSITION; MODEL-FREE APPROACH; CIRCULAR-DICHROISM; ALIPHATIC-ALCOHOLS; WATER SOLUTION; SPECTROSCOPY	The C terminal fragment, residues 385-411, from human fibrinogen gamma-chain, i.e. KIIPFNRLTIGEGQQHHLG-GAKQAGDV, shows multiple turn conformations in aqueous solution (Mayo, K, H., Burke, C., Lindon, J, N., and Kloczewiak, M. (1990) Biochemistry 29, 3277-3286). The present study investigates the effect of pH and trifluoroethanol on the conformation and backbone dynamics of this 27-residue peptide. Both circular dichroism (CD) and H-1-NMR data indicate the normally observed increased helical conformations as a function of increasing trifluoroethanol. H-1-NMR structural studies done in the presence of 40% trifluoroethanol, pH 5.3, yield a network of nuclear Overhauser effects consistent with significant populations of helix like conformation. Distance geometry calculations based on nuclear Overhauser effect-derived distance constraints yield a family of structures with relatively well defined N- and C-terminal conformations and an ill defined mid-peptide region from Gly(397) to Gly(403). Similar conformational populations are observed at pH 2.5. CD studies, however, indicate an increase in average alpha-helix content on decreasing the pH from 6 to 2. This apparent conflict between CD and NMR results may be explained by a transition from multiple beta-turn character at pH 5.3 to increased alpha-helix structure at pH 2.5. C-13(alpha) NMR relaxation data analyzed with the Lipari-Szabo model-free approach provide order parameters that demonstrate little if any influence of pH on backbone motional restrictions within the more flexible mid-peptide domain. At low pH, however, motions become less restricted within N-terminal residues Lys(385)-Phe(389) and more restricted within C-terminal residues Ala(405)-Val(411).	UNIV MINNESOTA,CTR BIOMED ENGN,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities								AUE WP, 1975, J CHEM PHYS, V64, P2229; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BLUMENSTEIN M, 1992, BIOCHEMISTRY-US, V31, P10692, DOI 10.1021/bi00159a008; BROWN JE, 1971, BIOCHEMISTRY-US, V10, P470, DOI 10.1021/bi00779a019; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHOU PY, 1978, ADV ENZYMOL RELAT AR, V48, P45; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; CONIO G, 1970, J BIOL CHEM, V245, P3335; DYSON HJ, 1992, J MOL BIOL, V226, P819, DOI 10.1016/0022-2836(92)90634-V; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; ILYINA E, 1994, BIOCHEMISTRY-US, V33, P13436, DOI 10.1021/bi00249a032; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P2129, DOI 10.1021/bi00174a020; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kuwajima Kunihiro, 1992, Current Opinion in Biotechnology, V3, P462, DOI 10.1016/0958-1669(92)90072-Q; LEHRMAN SR, 1990, BIOCHEMISTRY-US, V29, P5590, DOI 10.1021/bi00475a025; LEIST T, 1984, BIOCHEMISTRY-US, V23, P2541, DOI 10.1021/bi00307a001; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; LLINAS M, 1975, J AM CHEM SOC, V97, P4731, DOI 10.1021/ja00849a040; LU ZX, 1984, J BIOL CHEM, V259, P7367; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MAYO KH, 1990, BIOCHEMISTRY-US, V29, P3277, DOI 10.1021/bi00465a019; MORODER L, 1975, BIOPOLYMERS, V14, P2075, DOI 10.1002/bip.1975.360141008; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; NIRMALA NR, 1988, J AM CHEM SOC, V110, P7557, DOI 10.1021/ja00230a057; PALMER AG, 1991, J AM CHEM SOC, V13, P4371; PARODI RM, 1973, J BIOL CHEM, V248, P4047; PENA MC, 1989, BIOCHIM BIOPHYS ACTA, V957, P380; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SANZ JM, 1994, BIOCHEMISTRY-US, V33, P11189, DOI 10.1021/bi00203a015; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SEGAWA SI, 1984, BIOPOLYMERS, V23, P2473; SHAKA AJ, 1983, J MAGN RESON, V51, P161; SHIN HC, 1993, BIOCHEMISTRY-US, V32, P6348, DOI 10.1021/bi00076a007; SHIN HC, 1993, BIOCHEMISTRY-US, V32, P6356, DOI 10.1021/bi00076a008; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Stewart JM, 1984, SOLID PHASE PEPTIDE; VANMIERLO CPM, 1993, J MOL BIOL, V229, P1125, DOI 10.1006/jmbi.1993.1108; WALTHO JP, 1993, BIOCHEMISTRY-US, V32, P6337, DOI 10.1021/bi00076a006; WIDER G, 1984, J MAGN RESON, V56, P207, DOI 10.1016/0022-2364(84)90099-4; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YANG YQ, 1993, J BIOL CHEM, V268, P9223	50	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24693	24701		10.1074/jbc.270.42.24693	http://dx.doi.org/10.1074/jbc.270.42.24693			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559584	hybrid			2022-12-27	WOS:A1995TB46500018
J	LI, YY; HU, ZX; JORDAN, F; INOUYE, M				LI, YY; HU, ZX; JORDAN, F; INOUYE, M			FUNCTIONAL-ANALYSIS OF THE PROPEPTIDE OF SUBTILISIN-E AS AN INTRAMOLECULAR CHAPERONE FOR PROTEIN-FOLDING - REFOLDING AND INHIBITORY ABILITIES OF PROPEPTIDE MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PRO-PEPTIDE; DENATURED SUBTILISIN; REGION; POLYMERASE; EXPRESSION; BEHAVIOR; SEQUENCE; INVITRO; ENZYME	The amino-terminal propeptide, consisting of 77 amino acid residues, is known to be required as an in tramolecular chaperone to guide the folding of mature subtilisin E, a serine protease, into active mature enzyme. Many mutations within the pro-sequence have been shown to abolish the production of active subtilisin E (Kobayashi, T., and Inouye, M. (1992) J. Mol. Biol. 226, 931-933). Here we report characterization, refolding, and inhibitory abilities of six single amino acid substitution mutations (Ile(-67) --> Val, Ile(-48) --> Thr, Gly(-44) -->) Asp, Lys(-36) --> Glu, Ala(-30) --> Thr, and Pro(-15) --> Leu) and a nonsense mutation (N59-mer) at the codon for Lys(-18). These mutant propeptides were expressed in Escherichia coli using a T7 expression system and were purified to homogeneity. Surprisingly, Lys(-36) --> Glu, Ala(-30) --> Thr and Pro(-15) --> Leu were found to still function as a chaperone for in vitro refolding of denatured subtilisin BPN' with 60, 80, and 54% efficiency compared to the wild-type propeptide, respectively. The K-i values against subtilisin BPN' were 1.6 x 10(-9) M, 1.2 x 10(-9) M, and 2.1 x 10(-9) M, respectively, almost identical to the K-i value exhibited by the wild-type propeptide (1.4 x 10(-9) M). In contrast, Ile(-67) --> Val and Gly(-44) --> Asp were able to refold denatured subtilisin BPN' with only 18 and 13% efficiencies and had K-i values of 10 and 11 x 10(-9) M, respectively. The Ile(-48) --> Thr mutant propeptide was unable to refold denatured subtilisin BPN' and gave a 100-fold higher K-i (118 x 10(-9) M) than the wild-type propeptide. The N59-mer propeptide extending from Leu(-19) to Met(-78) was unable to function as a chaperone. Like the wild-type propeptide, none of the mutant propeptides had secondary structures as judged by their circular dichroism spectra. The present results demonstrate that the ability of the propeptide as a chaperone to refold the denatured protein is well correlated with its ability as a competitive inhibitor for the active enzyme. This supports the notion that the secondary and tertiary structures of the propeptide are identical or highly homologous between the renatured propeptide-subtilisin complex and the inhibitory complex formed between the propeptide and the active enzyme.	RUTGERS STATE UNIV, DEPT CHEM, NEWARK, NJ 07102 USA	Rutgers State University Newark; Rutgers State University New Brunswick	LI, YY (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, PISCATAWAY, NJ 08854 USA.							BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; HAYASHI T, 1993, CHEM PHARM BULL, V41, P2063; HU Z, 1994, ROLE PROPEPTIDE REFO; HU ZX, 1994, BIOCHEMISTRY-US, V33, P562, DOI 10.1021/bi00168a022; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; INOUYE M, 1991, ENZYME, V45, P314, DOI 10.1159/000468904; KOBAYASHI T, 1992, J MOL BIOL, V226, P931, DOI 10.1016/0022-2836(92)91042-N; LI YY, 1994, J BIOL CHEM, V269, P4169; Maniatis T., 1982, MOL CLONING; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NAKAMURA K, 1982, Journal of Molecular and Applied Genetics, V1, P289; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; OHTA Y, 1990, MOL MICROBIOL, V4, P295, DOI 10.1111/j.1365-2958.1990.tb00596.x; RAMOS C, 1994, J BIOL CHEM, V269, P7006; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SHINDE U, 1995, J MOL BIOL, V247, P390, DOI 10.1006/jmbi.1994.0147; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; ZHU X, 1992, BIOCH LIFE SCI ADV, V11, P35; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	28	101	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25127	25132		10.1074/jbc.270.42.25127	http://dx.doi.org/10.1074/jbc.270.42.25127			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559646	hybrid			2022-12-27	WOS:A1995TB46500080
J	SCHWEITZ, H; BRUHN, T; GUILLEMARE, E; MOINIER, D; LANCELIN, JM; BERESS, L; LAZDUNSKI, M				SCHWEITZ, H; BRUHN, T; GUILLEMARE, E; MOINIER, D; LANCELIN, JM; BERESS, L; LAZDUNSKI, M			KALICLUDINES AND KALISEPTINE - 2 DIFFERENT CLASSES OF SEA-ANEMONE TOXINS FOR VOLTAGE-SENSITIVE K+ CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; DEPENDENT POTASSIUM CHANNELS; CELL DEGRANULATING PEPTIDE; AMINO-ACID-SEQUENCE; GREEN MAMBA VENOM; DENDROTOXIN-I; SODIUM-CHANNEL; PHARMACOLOGICAL PROPERTIES; RECEPTOR-SITES; MCD PEPTIDE	New peptides have been isolated from the sea anemone Anemonia sulcata which inhibit competitively the binding of I-125-dendrotoxin I (a classical ligand for K+ channel) to rat brain membranes and behave as blockers of voltage-sensitive K+ channels. Sea anemone kali-cludines are 58-59-amino acid peptides cross-linked with three disulfide bridges. They are structurally homologous both to dendrotoxins which are snake venom toxins and to the basic pancreatic trypsin inhibitor (Kunitz inhibitor) and have the unique property of expressing both the function of dendrotoxins in blocking voltage-sensitive K+ channels and the function of the Kunitz inhibitor in inhibiting trypsin. Kaliseptine is another structural class of peptide comprising 36 amino acids with no sequence homology with kalicludines or with dendrotoxins. In spite of this structural difference, it binds to the same receptor site as dendrotoxin and kalicludines and is as efficient as a K+ channel inhibitor as the most potent kalicludine.	CNRS, INST PHARMACOL MOLEC & CELLULAIRE, F-06560 VALBONNE, FRANCE; CHRISTIAN ALBRECHTS UNIV KIEL KLINIKUM, TOXIKOL ABT, W-2300 KIEL, GERMANY; CNRS, CEA, INST BIOL STRUCT JEAN PIERRE EBEL, F-38027 GRENOBLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); University of Kiel; Schleswig Holstein University Hospital; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)			Lancelin, Jean-marc/AAC-5686-2019					ANEIROS A, 1993, BIOCHIM BIOPHYS ACTA, V1157, P86, DOI 10.1016/0304-4165(93)90082-J; AWAN KA, 1991, NEUROSCIENCE, V40, P29, DOI 10.1016/0306-4522(91)90172-K; BARHANIN J, 1981, J BIOL CHEM, V256, P5764; BENISHIN CG, 1988, MOL PHARMACOL, V34, P152; BERESS L, 1975, FEBS LETT, V50, P311, DOI 10.1016/0014-5793(75)80517-5; BERESS L, 1978, DRUGS FOOD SEA MYTH, P59; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BETZ H, 1990, BIOCHEMISTRY-US, V29, P3591, DOI 10.1021/bi00467a001; BIDARD JN, 1987, BIOCHEM BIOPH RES CO, V143, P383, DOI 10.1016/0006-291X(87)90677-2; BIDARD JN, 1989, BRAIN RES, V495, P45, DOI 10.1016/0006-8993(89)91216-X; CHERUBINI E, 1987, NATURE, V328, P70, DOI 10.1038/328070a0; DREYER F, 1990, REV PHYSIOL BIOCH P, V115, P93; FRELIN C, 1984, MOL PHARMACOL, V26, P70; FRITZ H, 1972, H-S Z PHYSIOL CHEM, V353, P19, DOI 10.1515/bchm2.1972.353.1.19; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GARCIACALVO M, 1993, J BIOL CHEM, V268, P18866; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; HALLIWELL JV, 1986, P NATL ACAD SCI USA, V83, P493, DOI 10.1073/pnas.83.2.493; Harvey A.L., 1991, P131; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; KATO I, 1979, FED PROC, V38, P832; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANCELIN JM, 1994, NAT STRUCT BIOL, V1, P246, DOI 10.1038/nsb0494-246; LAZDUNSKI M, 1986, ANN NY ACAD SCI, V479, P204, DOI 10.1111/j.1749-6632.1986.tb15571.x; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MARSHALL DL, 1992, BIOL CHEM H-S, V373, P707, DOI 10.1515/bchm3.1992.373.2.707; MEVES H, 1992, HDB EXPT PHARM, V102, P739; MOCZYDLOWSKI E, 1988, J MEMBRANE BIOL, V105, P95, DOI 10.1007/BF02009164; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; PONGS O, 1992, TRENDS PHARMACOL SCI, V13, P359, DOI 10.1016/0165-6147(92)90109-J; POSSANI LD, 1982, CARLSBERG RES COMMUN, V47, P285, DOI 10.1007/BF02907789; REHM H, 1988, BIOCHEMISTRY-US, V27, P1827, DOI 10.1021/bi00406a005; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; REHM H, 1988, BIOCHEM BIOPH RES CO, V153, P231, DOI 10.1016/S0006-291X(88)81213-0; REHM H, 1991, EUR J BIOCHEM, V202, P701, DOI 10.1111/j.1432-1033.1991.tb16425.x; ROGOWSKI RS, 1994, P NATL ACAD SCI USA, V91, P1475, DOI 10.1073/pnas.91.4.1475; ROMEY G, 1976, P NATL ACAD SCI USA, V73, P4055, DOI 10.1073/pnas.73.11.4055; SCHMIDT RR, 1988, BIOCHEMISTRY-US, V27, P963, DOI 10.1021/bi00403a019; SCHWEITZ H, 1981, BIOCHEMISTRY-US, V20, P5245, DOI 10.1021/bi00521a023; SCHWEITZ H, 1994, P NATL ACAD SCI USA, V91, P878, DOI 10.1073/pnas.91.3.878; SCHWEITZ H, 1989, BIOCHEMISTRY-US, V28, P9708, DOI 10.1021/bi00451a025; SCHWEITZ H, 1985, BIOCHEMISTRY-US, V24, P3554, DOI 10.1021/bi00335a025; SCHWEITZ H, 1989, FEBS LETT, V250, P519, DOI 10.1016/0014-5793(89)80788-4; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; SKARZYNSKI T, 1992, J MOL BIOL, V224, P671, DOI 10.1016/0022-2836(92)90552-U; TARR GE, 1983, P NATL ACAD SCI-BIOL, V80, P6552, DOI 10.1073/pnas.80.21.6552; VINCENT JP, 1980, P NATL ACAD SCI-BIOL, V77, P1646, DOI 10.1073/pnas.77.3.1646; VINCENT JP, 1972, BIOCHEMISTRY-US, V11, P2967, DOI 10.1021/bi00766a007; VINCENT JP, 1974, EUR J BIOCHEM, V42, P505, DOI 10.1111/j.1432-1033.1974.tb03365.x; WACHTER E, 1987, RECEPTORS ION CHANNE, P313; WLODAWER A, 1987, J MOL BIOL, V193, P145, DOI 10.1016/0022-2836(87)90633-4	53	180	199	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25121	25126		10.1074/jbc.270.42.25121	http://dx.doi.org/10.1074/jbc.270.42.25121			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559645	hybrid			2022-12-27	WOS:A1995TB46500079
J	WANG, CN; HOBMAN, TC; BRINDLEY, DN				WANG, CN; HOBMAN, TC; BRINDLEY, DN			DEGRADATION OF APOLIPOPROTEIN-B IN CULTURED RAT HEPATOCYTES OCCURS IN A POST-ENDOPLASMIC RETICULUM COMPARTMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; HEP G2 CELLS; ALPHA-MANNOSIDASE-II; VERY-LOW-DENSITY; GOLGI-APPARATUS; INTRACELLULAR DEGRADATION; MESSENGER-RNA; SECRETORY PROTEINS; HEPATOMA-CELLS; PAUSE TRANSFER	The site of apolipoprotein B (apoB) degradation was investigated in cultured rat hepatocytes. Brefeldin A plus nocodazole completely blocked apoB degradation suggesting the involvement of a post-endoplasmic reticulum (ER) compartment. Monensin inhibited apoB degradation by 40% implying that a post-Golgi compartment could be involved in degradation of apoB. Ammonium chloride or chloroquine inhibited partially the degradation of apoB100 and apoB48, indicating some degradation in lysosomes, or in an acidic compartment such as trans-Golgi or endosomes. The degradations of apoB100 and apoB48 were blocked completely by (2S,3S)-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester (EST) during a chase of 90 min demonstrating that a cysteine protease was responsible for apoB degradation. Chymostatin, leupeptin, pepstatin, phenylmethylsulfonyl fluoride, and aprotinin had no significant effect on the degradation of apoB48. However, leupeptin and pepstatin decreased the degradation of apoB100 by 20-30%. Degradation of apoB100 and apoB48 occurred in isolated Golgi fractions with little degradation in heavy or light ER. Degradation of apoB in Golgi fractions was inhibited by EST and by preincubating hepatocytes with 10 nM dexamethasone. Immunofluorescent microscopy revealed that apoB accumulated in the Golgi region after EST treatment. it is concluded that a major part of apoB degradation in rat hepatocytes occurs in a post-ER compartment via the action of a cysteine protease that is regulated by glucocorticoids.	UNIV ALBERTA,DEPT BIOCHEM,SIGNAL TRANSDUCT LABS,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,DEPT ANAT & CELL BIOL,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta; University of Alberta								ADELI K, 1994, J BIOL CHEM, V269, P9166; AMITAY R, 1991, J BIOL CHEM, V266, P12568; AMITAY R, 1992, J BIOL CHEM, V267, P20694; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; ARION WJ, 1976, J BIOL CHEM, V251, P4901; BAMBERGER MJ, 1990, P NATL ACAD SCI USA, V87, P2390, DOI 10.1073/pnas.87.7.2390; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BERGERON JJ, 1973, J CELL BIOL, V59, P73, DOI 10.1083/jcb.59.1.73; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1993, BIOCHEM SOC T, V21, P487, DOI 10.1042/bst0210487; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; CARTWRIGHT IJ, 1992, BIOCHEM J, V285, P153, DOI 10.1042/bj2850153; CASCALES C, 1984, BIOCHEM J, V219, P911, DOI 10.1042/bj2190911; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHUCK SL, 1993, J BIOL CHEM, V268, P22794; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GIANETTO R, 1955, BIOCHEM J, V59, P433, DOI 10.1042/bj0590433; GIBBONS GF, 1994, J LIPID RES, V35, P1801; GRIFFITHS G, 1983, J CELL BIOL, V98, P835; GRINDE B, 1980, BIOCHIM BIOPHYS ACTA, V632, P73, DOI 10.1016/0304-4165(80)90250-0; HAMILTON RL, 1991, J LIPID RES, V32, P529; HAMILTON RL, 1989, BIOCHEM BIOPH RES CO, V160, P162, DOI 10.1016/0006-291X(89)91635-5; HIGGINS JA, 1988, FEBS LETT, V232, P405, DOI 10.1016/0014-5793(88)80780-4; HO WC, 1989, EUR J CELL BIOL, V48, P250; HUSSAIN MM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P901; JANERO DR, 1983, J BIOL CHEM, V258, P4496; LEONARD DA, 1987, J BIOL CHEM, V262, P7914; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLER HR, 1955, METHOD ENZYMOL, V2, P553; MARTINSANZ P, 1990, BIOCHEM J, V271, P575, DOI 10.1042/bj2710575; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RIOS RM, 1994, J CELL BIOL, V125, P997, DOI 10.1083/jcb.125.5.997; ROTUNDO RL, 1989, J BIOL CHEM, V264, P3146; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; SAKATA N, 1993, J BIOL CHEM, V268, P22967; Sambrook J., 1989, MOL CLONING LAB MANU; SATO R, 1990, J BIOL CHEM, V265, P11880; SCHWARTZ AL, 1985, EMBO J, V4, P899, DOI 10.1002/j.1460-2075.1985.tb03716.x; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; SPARKS JD, 1994, BBA-LIPID LIPID MET, V1215, P9, DOI 10.1016/0005-2760(94)90088-4; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WANG CN, 1995, ARTERIOSCL THROM VAS, V15, P1481, DOI 10.1161/01.ATV.15.9.1481; WANG HX, 1993, J CLIN INVEST, V91, P1380, DOI 10.1172/JCI116340; WANG HX, 1994, J BIOL CHEM, V269, P18514; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WILKINSON J, 1992, BIOCHEM J, V288, P413, DOI 10.1042/bj2880413; WILKINSON J, 1993, J LIPID RES, V34, P815; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YAO ZM, 1989, J BIOL CHEM, V264, P11373	72	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24924	24931		10.1074/jbc.270.42.24924	http://dx.doi.org/10.1074/jbc.270.42.24924			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559618	hybrid			2022-12-27	WOS:A1995TB46500052
J	HASHIMOTO, Y; WARE, J				HASHIMOTO, Y; WARE, J			IDENTIFICATION OF ESSENTIAL GATA AND ETS BINDING MOTIFS WITHIN THE PROMOTER OF THE PLATELET GLYCOPROTEIN IB-ALPHA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH GLYCOPROTEINS; ENDOTHELIAL-CELLS; EXPRESSION; PROTEIN; IX; ADHESIVE; CLONING; SITE; DNA	Platelet glycoprotein (GP) Ib-M-V is a multisubunit adhesion receptor that supports platelet attachment to thrombogenic surfaces at sites of vascular injury, The congenital absence of the receptor results in a bleeding disorder associated with ''giant'' platelets, a condition linking the expression of the complex to platelet morphogenesis, To understand better the expression of the GP Ib-IX-V complex, studies were undertaken to define the essential genetic elements supporting the expression of the alpha-subunit of the complex (GP Ib alpha). GP Ib alpha promoter activity was evaluated by transfection of human erythroleukemia cells with reporter plasmids coding for the enzyme, luciferase, Studies were initiated with a fragment extending 2,738 nucleotides 5' to the transcription start site and lead to the identification of 253 nucleotides retaining full promoter activity in human erythroleukemia cells. In cells of nonhematopoietic lineage, human endothelial and HeLa cells, the GP Ib alpha promoter activity was no greater than background levels obtained with promoterless constructs, Gel shift assays and site-directed mutagenesis studies defined essential GATA and Ets binding motifs 93 and 150 nucleotides upstream of the transcription start site, a finding which further substantiates these elements as important determinants of megakaryocytic gene expression. The results define essential cis-acting elements responsible for the expression of GP Ib alpha and provide insights into molecular events coinciding with the release of normal platelets into the bloodstream.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV EXPTL HEMOSTASIS & THROMBOSIS, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050545] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL050545, R01 HL050545-06, HL50545] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIRD WC, 1994, J BIOL CHEM, V269, P883; ASCH AS, 1988, J CLIN INVEST, V81, P1600, DOI 10.1172/JCI113494; BLOCK KL, 1994, BLOOD, V84, P3385; CAEN JP, 1976, J LAB CLIN MED, V87, P586; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLLER BS, 1977, J CLIN INVEST, V60, P302, DOI 10.1172/JCI108778; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HICKEY MJ, 1993, P NATL ACAD SCI USA, V90, P8327, DOI 10.1073/pnas.90.18.8327; HOWARD MA, 1973, BLOOD, V41, P687, DOI 10.1182/blood.V41.5.687.687; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KONKLE BA, 1990, J BIOL CHEM, V265, P19833; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANZA F, 1993, J BIOL CHEM, V268, P20801; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LEONARD M, 1993, BLOOD, V82, P1071; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; NURDEN AT, 1975, NATURE, V255, P720, DOI 10.1038/255720a0; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PAN JL, 1993, J BIOL CHEM, V268, P22600; PAPAYANNOPOULOU T, 1988, BLOOD, V72, P1029; RAJAGOPALAN V, 1992, BLOOD, V80, P153; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; Ruggeri Z M, 1991, Prog Hemost Thromb, V10, P35; Sambrook J, 1989, MOL CLONING LABORATO; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; TYMMS MJ, 1994, MOL REPROD DEV, V39, P208, DOI 10.1002/mrd.1080390214; UZAN G, 1991, J BIOL CHEM, V266, P8932; WARE J, 1993, J BIOL CHEM, V268, P8376; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; WENGER RH, 1989, GENE, V85, P517, DOI 10.1016/0378-1119(89)90446-0; WENGER RH, 1988, BIOCHEM BIOPH RES CO, V156, P389, DOI 10.1016/S0006-291X(88)80853-2; WHYATT DJ, 1993, EMBO J, V12, P4993, DOI 10.1002/j.1460-2075.1993.tb06193.x	40	88	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24532	24539		10.1074/jbc.270.41.24532	http://dx.doi.org/10.1074/jbc.270.41.24532			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592671	hybrid			2022-12-27	WOS:A1995TA21700099
J	HUANG, LX; ROHLFS, RJ; HILLE, R				HUANG, LX; ROHLFS, RJ; HILLE, R			THE REACTION OF TRIMETHYLAMINE DEHYDROGENASE WITH ELECTRON TRANSFERRING FLAVOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND COENZYME; DIMETHYLAMINE DEHYDROGENASE; METHYLOTROPHIC BACTERIA; PROSTHETIC GROUPS; IDENTIFICATION; SUBSTRATE; BINDING; W3A1	The kinetics of electron transfer between trimethylamine dehydrogenase (TMADH) and its physiological acceptor, electron transferring flavoprotein (ETF), has been studied by static and stopped-flow absorbance measurements. The results demonstrate that reducing equivalents are transferred from TMADH to ETF solely through the 4Fe/4S center of the former. The intrinsic limiting rate constant (k(lim)) and dissociation constant (K-d) for electron transfer from the reduced 4Fe/4S center of TMADH to ETF are about 172 s(-1) and 10 mu M, respectively. The reoxidation of fully reduced TMADH with an excess of ETF is markedly biphasic, indicating that partial oxidation of the iron-sulfur center in 1-electron reduced enzyme significantly reduces the rate of electron transfer out of the enzyme in these forms. The interaction of the two unpaired electron spins of flavin semiquinone and reduced 4Fe/4S center in 2-electron reduced TMADH, on the other hand, does not significantly slow down the electron transfer from the 4Fe/4S center to ETF. From a comparison of the limiting rate constants for the oxidative and reductive half-reactions, we conclude that electron transfer from TMADH to ETF is not rate-limiting during steady-state turnover. The overall kinetics of the oxidative half-reaction are not significantly affected by high salt concentrations, indicating that electrostatic forces are not involved in the formation and decay of reduced TMADH-oxidized ETF complex.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210	Ohio State University								BEINERT H, 1993, ARCH BIOCHEM BIOPHYS, V222, P333; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; DUPLESSIS ER, 1994, BIOCHEM MOL BIOL INT, V32, P195; HILL CL, 1977, P NATL ACAD SCI USA, V74, P547, DOI 10.1073/pnas.74.2.547; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; LEHMAN TC, 1990, BIOCHEMISTRY-US, V29, P10594, DOI 10.1021/bi00499a004; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; LIM LW, 1988, J BIOL CHEM, V263, P3075; MCINTIRE WS, 1990, METHOD ENZYMOL, V188, P250; NAGY J, 1979, J BIOL CHEM, V254, P2684; PACE CP, 1991, ARCH BIOCHEM BIOPHYS, V287, P97, DOI 10.1016/0003-9861(91)90393-W; ROHLFS RJ, 1994, J BIOL CHEM, V269, P30869; ROHLFS RJ, 1995, J BIOL CHEM, V270, P22196, DOI 10.1074/jbc.270.38.22196; ROHLFS RJ, 1991, J BIOL CHEM, V266, P15244; SINGER TP, 1980, FLAVINS FLAVOPROTEIN, P277; STEENKAMP DJ, 1982, BIOCHEM J, V207, P233, DOI 10.1042/bj2070233; STEENKAMP DJ, 1982, BIOCHEM J, V207, P241, DOI 10.1042/bj2070241; STEENKAMP DJ, 1978, BIOCHEM J, V169, P361, DOI 10.1042/bj1690361; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; STEENKAMP DJ, 1978, MECHANISMS OXIDIZING, P127; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; ZEHNDER AJB, 1976, SCIENCE, V194, P1165, DOI 10.1126/science.793008	24	33	33	4	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23958	23965		10.1074/jbc.270.41.23958	http://dx.doi.org/10.1074/jbc.270.41.23958			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592591	hybrid			2022-12-27	WOS:A1995TA21700019
J	PIKE, CJ; OVERMAN, MJ; COTMAN, CW				PIKE, CJ; OVERMAN, MJ; COTMAN, CW			AMINO-TERMINAL DELETIONS ENHANCE AGGREGATION OF BETA-AMYLOID PEPTIDES IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLAQUE CORE PROTEIN; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; INVITRO; DEPOSITION; PATHOLOGY; FRAGMENTS; TOXICITY; FIBRILS	beta-Amyloid protein, which assembles into pathological aggregates deposited in Alzheimer's disease brain tissue, exhibits N-terminal heterogeneity both in vitro and in vivo. To investigate the effects of this N-terminal heterogeneity on the assembly characteristics and biophysical properties of beta-amyloid, we synthesized a series of peptides with progressively shortened N termini (initial residues at positions beta 1, beta 4, beta 8, beta 12, and beta 17) and C termini extending to residue beta 40 or beta 42, We report that peptides with N-terminal deletions exhibit enhanced peptide aggregation relative to full-length species, as quantitatively assessed by sedimentation analyses. Overall, sedimentation levels were greater for peptides terminating at residue beta 42 than for those terminating at residue beta 40. To determine if established biophysical features of the full-length protein were maintained in the truncated peptides, structural and bioactive properties of these peptides were examined and compared. Full-length and truncated peptides exhibiting aggregation showed circular dichroism spectra consistent with predominant beta-sheet conformation, fibrillar morphology under transmission electron microscopy, and significant toxicity in cultures of rat hippocampal neurons. These data demonstrate that N-terminal deletions enhance aggregation of beta-amyloid into neurotoxic, beta-sheet fibrils and suggest that such peptides may initiate and/or nucleate the pathological deposition of beta-amyloid.			PIKE, CJ (corresponding author), UNIV CALIF IRVINE,INST BRAIN AGING & DEV,DEPT PSYCHOBIOL,IRVINE,CA 92717, USA.		Pike, Christian J/D-4013-2018	Pike, Christian/0000-0003-4577-7668	NIA NIH HHS [AG12663] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012663] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CASTANO EM, 1986, BIOCHEM BIOPH RES CO, V141, P782, DOI 10.1016/S0006-291X(86)80241-8; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOREVIC PD, 1987, BIOCHEM BIOPH RES CO, V147, P854, DOI 10.1016/0006-291X(87)91008-4; GOWING E, 1994, J BIOL CHEM, V269, P10987; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; NASLUND J, 1994, BIOCHEM BIOPH RES CO, V204, P780, DOI 10.1006/bbrc.1994.2527; PIKE CJ, 1993, NEUROSCIENCE, V56, P269, DOI 10.1016/0306-4522(93)90331-9; PIKE CJ, 1995, BRAIN RES, V671, P293, DOI 10.1016/0006-8993(94)01354-K; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PIKE CJ, 1991, EUR J PHARM-MOLEC PH, V207, P367, DOI 10.1016/0922-4106(91)90014-9; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; ROHER A, 1986, P NATL ACAD SCI USA, V83, P2662, DOI 10.1073/pnas.83.8.2662; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SARKAR PK, 1966, P NATL ACAD SCI USA, V55, P981, DOI 10.1073/pnas.55.4.981; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; ZHONG ZY, 1994, J BIOL CHEM, V269, P627	46	280	296	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23895	23898		10.1074/jbc.270.41.23895	http://dx.doi.org/10.1074/jbc.270.41.23895			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592576	hybrid			2022-12-27	WOS:A1995TA21700004
J	SIEGEL, MD; ZHANG, DH; RAY, P; RAY, A				SIEGEL, MD; ZHANG, DH; RAY, P; RAY, A			ACTIVATION OF THE INTERLEUKIN-5 PROMOTER BY CAMP IN MURINE EL-4 CELLS REQUIRES THE GATA-3 AND CLEO ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR; DNA-BINDING; MESSENGER-RNA; REGULATORY ELEMENTS; LYMPHOCYTES-T; EXPRESSION; RECEPTOR; LYMPHOKINES; PROTEIN	Interleukin-5 (IL-5) plays a central role in the growth and differentiation of eosinophils and contributes to several disease states including asthma, Accumulating evidence suggests a role for cAMP as an immunomodulator; agents that increase intracellular cAMP levels have been shown to inhibit production of cytokines predominantly produced by T helper (Th) 1 cells such as IL-2 and interferon gamma (IFN-gamma). In contrast, the production of IL-5, predominantly produced by Th2 cells, is actually enhanced by these agents, In this report, we have performed transient transfection experiments with IL-5 promoter-reporter gene constructs, DNase I footprinting assays, and electrophoretic mobility shift assays to investigate the key regulatory regions necessary for activation of the IL-5 promoter by dibutyryl cAMP and phorbol esters in the mouse thymoma line EL-4, Taken together, our data demonstrate the critical importance of two sequences within the IL-5 5'-flanking region for activation by these agents in EL-4 cells: one, a highly conserved iii-base pair element present in genes expressed by Th2 cells, called the conserved lymphokine element 0 (CLE0; located between -53 and -39 in the IL-5 promoter), and the other, two overlapping binding sites for the transcription factor GATA-3 (but not GATA-4) between -70 and -59. Taken together, our data suggest that activation via the unique sequence combination GATA/CLE0 results in selective expression of the IL-5 gene in response to elevated levels of intracellular cAMP.	YALE UNIV,SCH MED,DEPT INTERNAL MED,PULM & CRIT CARE SECT,NEW HAVEN,CT 06520	Yale University					NHLBI NIH HHS [HL52014] Funding Source: Medline; NIAID NIH HHS [AI31137] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031137] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BETZ M, 1991, J IMMUNOL, V146, P108; BIELINSKA M, 1995, BIOCHEM J, V307, P183, DOI 10.1042/bj3070183; BOHJANEN PR, 1990, P NATL ACAD SCI USA, V87, P5283, DOI 10.1073/pnas.87.14.5283; BOTTOMLY K, 1988, IMMUNOL TODAY, V9, P268, DOI 10.1016/0167-5699(88)91308-4; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; CAMPBELL HD, 1988, EUR J BIOCHEM, V174, P345, DOI 10.1111/j.1432-1033.1988.tb14104.x; DESREUMAUX P, 1992, J EXP MED, V175, P293, DOI 10.1084/jem.175.1.293; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; FARRAR JJ, 1980, J IMMUNOL, V125, P2555; GOODBOURN S, 1994, CURR BIOL, V4, P930, DOI 10.1016/S0960-9822(00)00209-8; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HENDERSON AJ, 1994, MOL CELL BIOL, V14, P4286, DOI 10.1128/MCB.14.6.4286; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LACOUR M, 1994, INT IMMUNOL, V6, P133; LAVARRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; LEE HJ, 1994, J ALLERGY CLIN IMMUN, V94, P594, DOI 10.1016/0091-6749(94)90135-X; LEE HJ, 1993, J IMMUNOL, V151, P6153; MARINE J, 1991, P NATL ACAD SCI USA, V88, P7284, DOI 10.1073/pnas.88.16.7284; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MATHEW RC, 1992, J IMMUNOL, V148, P3572; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; MIZUTA TR, 1988, ROWTH FACTORS, V1, P51; MOSSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145; MUNOZ E, 1990, J IMMUNOL, V144, P964; MUNOZ E, 1990, J EXP MED, V172, P95, DOI 10.1084/jem.172.1.95; MUNOZ E, 1992, EUR J IMMUNOL, V22, P1391, DOI 10.1002/eji.1830220610; NAORA H, 1994, J IMMUNOL, V153, P3466; NAORA H, 1994, BLOOD, V83, P3620; NAORA H, 1994, J IMMUNOL, V152, P5691; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; NIMER SD, 1988, MOL CELL BIOL, V8, P1979, DOI 10.1128/MCB.8.5.1979; ORKIN SH, 1992, BLOOD, V80, P575; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; PHIPPS RP, 1991, IMMUNOL TODAY, V12, P349, DOI 10.1016/0167-5699(91)90064-Z; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1991, P NATL ACAD SCI USA, V88, P7086, DOI 10.1073/pnas.88.16.7086; RAY P, 1995, J BIOL CHEM, V270, P10680, DOI 10.1074/jbc.270.18.10680; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SANDERSON CJ, 1988, IMMUNOL REV, V102, P29, DOI 10.1111/j.1600-065X.1988.tb00740.x; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; TAMURA S, 1993, P NATL ACAD SCI USA, V90, P10876, DOI 10.1073/pnas.90.22.10876; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; TSURUTA L, 1995, J IMMUNOL, V154, P5255; WALKER C, 1991, J IMMUNOL, V146, P1829; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG ZY, 1994, MOL CELL BIOL, V14, P2201, DOI 10.1128/MCB.14.3.2201	63	107	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24548	24555		10.1074/jbc.270.41.24548	http://dx.doi.org/10.1074/jbc.270.41.24548			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592673	hybrid			2022-12-27	WOS:A1995TA21700101
J	ASUNDI, VK; CAREY, DJ				ASUNDI, VK; CAREY, DJ			SELF-ASSOCIATION OF N-SYNDECAN (SYNDECAN-3) CORE PROTEIN IS MEDIATED BY A NOVEL STRUCTURAL MOTIF IN THE TRANSMEMBRANE DOMAIN AND ECTODOMAIN PLANKING REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; EXTRACELLULAR-MATRIX PROTEINS; CELL-SURFACE PROTEOGLYCAN; MAMMARY EPITHELIAL-CELLS; FIBROBLAST GROWTH-FACTOR; CLONING; PREDICTION; RECEPTOR; BINDING	We expressed domains of the core protein of the transmembrane heparan sulfate proteoglycan N-syndecan (syndecan-3) either individually or as maltose-binding protein fusion proteins. Biochemical characterization of the purified proteins revealed that some of them were capable of self-association and formed stable, noncovalent multimeric complexes. The formation of N-syndecan core protein complexes was also demonstrated in mammalian cells by in situ cross-linking. Identification of structural motifs in the core protein of N-syndecan responsible for the formation of these complexes was accomplished by analyzing a series of constructs comprising different regions of the protein as well as site-directed mutants. Self-association was assayed by SDS-polyacrylamide gel electrophoresis, glutaraldehyde cross-linking, and size-exclusion high pressure liquid chromatography. Our results indicated that (i) the transmembrane domain of the N-syndecan core protein was required but not sufficient for the formation of stable complexes; (ii) the minimal amino acid sequence that conferred the ability of the N-syndecan core protein to form multimeric complexes included the last four amino acids (ERKE) of the extracellular domain plus the transmembrane domain; (iii) point mutations that changed the basic residues in this sequence to alanine residues either partially or completely abolished the ability of the N-syndecan core protein to form complexes; and (iv) replacement of conserved glycine residues in the transmembrane domain with leucines abolished complex formation. This property is similar to the oligomerization activity of other transmembrane receptors and suggests that regulated self-association may be important for the biological activity of transmembrane proteoglycans.			ASUNDI, VK (corresponding author), GEISINGER MED CLIN, SIGFRIED & JANET WEIS CTR RES, 100 N ACAD AVE, DANVILLE, PA 17822 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925] Funding Source: NIH RePORTER; NINDS NIH HHS [NS21925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BERNFIELD M, 1993, DEVELOPMENT, P205; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BORMANN BJ, 1992, ANNU REV BIOPH BIOM, V21, P223, DOI 10.1146/annurev.bb.21.060192.001255; CAREY DJ, 1990, J BIOL CHEM, V265, P20627; CAREY DJ, 1994, EXP CELL RES, V214, P12, DOI 10.1006/excr.1994.1228; CAREY DJ, 1994, J CELL BIOL, V124, P161, DOI 10.1083/jcb.124.1.161; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; CHERNOUSOV MA, 1993, J BIOL CHEM, V268, P16810; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; KODA JE, 1985, J BIOL CHEM, V260, P8157; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; RAULO E, 1994, J BIOL CHEM, V269, P12999; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; SUN XJ, 1989, J BIOL CHEM, V264, P11288; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183	25	105	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26404	26410		10.1074/jbc.270.44.26404	http://dx.doi.org/10.1074/jbc.270.44.26404			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592855	hybrid			2022-12-27	WOS:A1995TC97800062
J	MCGEADY, P; KURODA, S; SHIMIZU, K; TAKAI, Y; GELB, MH				MCGEADY, P; KURODA, S; SHIMIZU, K; TAKAI, Y; GELB, MH			THE FARNESYL GROUP OF H-RAS FACILITATES THE ACTIVATION OF A SOLUBLE UPSTREAM ACTIVATOR OF MITOGEN-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; ESCHERICHIA-COLI; OOCYTES; PURIFICATION; STIMULATION; TRANSFERASE; CONTAINS; RAS-P21; CYCLASE; EGGS	To study the function of the farnesyl modification of Pas, the farnesyl group and a variety of its structural analogs, which lack one or more double bonds and/or the methyl groups, were enzymatically incorporated into recombinant H Ras in vitro. These proteins were used in a cell and membrane-free, Ras-dependent mitogen-activated protein kinase (MAP kinase) activation system derived from Xenopus laevis eggs to examine the contribution of the farnesyl group toward the activation of the kinase, Whereas non-farnesylated H-Ras is unable to activate MAP kinase, farnesylation of H-Ras alone, in the absence of further processing, is sufficient to cause the activation of MAP kinase in this system, All of the analogs of the farnesyl group, when incorporated into H-Ras, support the activation of the kinase to variable extents, These results suggest a direct but fairly nonspecific interaction of the farnesyl moiety of H-Ras with a soluble upstream activator of MAP kinase.	OSAKA UNIV, SCH MED, DEPT MOLEC BIOL & BIOCHEM, OSAKA 565, JAPAN; UNIV WASHINGTON, DEPT CHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	Osaka University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				gelb, michael/0000-0001-7000-5219	NATIONAL CANCER INSTITUTE [R01CA052874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016158] Funding Source: NIH RePORTER; NCI NIH HHS [CA52874] Funding Source: Medline; NIGMS NIH HHS [GM562, GM16158] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1993, MOL CELL BIOCHEM, V128, P201, DOI 10.1007/BF01076771; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CORNFORTH RH, 1969, METHOD ENZYMOL, V15, P359; DIEZ E, 1994, BIOCHEM J, V301, P721, DOI 10.1042/bj3010721; EIDEM A, 1975, ACTA CHEM SCAND B, V29, P1015, DOI 10.3891/acta.chem.scand.29b-1015; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; ITOH T, 1993, J BIOL CHEM, V268, P3025; KAWAHARA FK, 1968, ANAL CHEM, V40, P2073, DOI 10.1021/ac60269a044; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KURODA S, 1995, J BIOL CHEM, V270, P2460, DOI 10.1074/jbc.270.6.2460; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; NEWMAN CMH, 1993, BIOCHIM BIOPHYS ACTA, V1155, P79, DOI 10.1016/0304-419X(93)90023-6; PAWSON T, 1994, CURR OPIN GENET DEV, V4, P1, DOI 10.1016/0959-437X(94)90084-1; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAKAI Y, 1993, CIBA F S, V170, P128; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031	41	51	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26347	26351		10.1074/jbc.270.44.26347	http://dx.doi.org/10.1074/jbc.270.44.26347			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592846	hybrid, Green Published			2022-12-27	WOS:A1995TC97800053
J	SHAPIRO, DB; ESQUERRA, RM; GOLDBECK, RA; BALLAS, SK; MOHANDAS, N; KLIGER, DS				SHAPIRO, DB; ESQUERRA, RM; GOLDBECK, RA; BALLAS, SK; MOHANDAS, N; KLIGER, DS			CARBON-MONOXIDE RELIGATION KINETICS TO HEMOGLOBIN-S POLYMERS FOLLOWING LIGAND PHOTOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL HEMOGLOBIN; SINGULAR VALUE DECOMPOSITION; POLYMERIZATION; GELATION; BINDING; NUCLEATION; MECHANISM; MYOGLOBIN	The re-equilibration rate of carbon monoxide binding to hemoglobin S polymers is determined by time-resolved measurements of linear dichroism spectra. Linear dichroism is used to detect religation to hemoglobin in the polymer in the presence of rebinding to free hemoglobin S tetramers. Measurement of the linear dichroism resulting from photolysis of the small percentage of ligand bound to the polymer is accomplished through the use of an ultrasensitive, ellipsometric linear dichroism technique developed for this purpose. The major finding is that the return of the polymer phase to its equilibrium ligation state is much slower than that of the solution phase hemoglobin tetramers. Assuming all hemes in the polymer are equally likely to participate in rebinding, the re-equilibration rate for carbon monoxide religation to hemoglobin S polymers is found to be 0.14 +/- 0.07 (s(-1) m(-1)), about 1000 times slower than the rebinding rate of carbon monoxide to T-state monomer hemoglobin. Several interpretations of this result are discussed. An understanding of the ligand binding kinetics to hemoglobin S polymers could have pathophysiological significance in its relevance to polymer formation and melting during red blood cell circulation.	UNIV CALIF SANTA CRUZ,DEPT CHEM & BIOCHEM,SANTA CRUZ,CA 95064; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV LIFE SCI,BERKELEY,CA 94720; JEFFERSON MED COLL,DEPT MED,CALDEZA FDN,PHILADELPHIA,PA 19107	University of California System; University of California Santa Cruz; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Jefferson University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038632, R01HL031579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035158] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31579, HL38632] Funding Source: Medline; NIGMS NIH HHS [GM35158] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN D W, 1954, Rev Hematol, V9, P155; ALTMAN PA, 1971, RESP CIRC, P417; BERTINI I, 1994, BIORGANIC CHEM, P186; BOOKCHIN RM, 1994, J MOL BIOL, V244, P100, DOI 10.1006/jmbi.1994.1707; BRIEHL RW, 1992, J MOL BIOL, V245, P710; BRODERSEN S, 1990, J MOL SPECTROSC, V142, P122, DOI 10.1016/0022-2852(90)90296-3; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CHE DP, 1994, CHEM PHYS LETT, V224, P145, DOI 10.1016/0009-2614(94)00530-3; CHEN E, 1993, METHOD ENZYMOL, V226, P119, DOI 10.1016/0076-6879(93)26008-W; CHUNG LL, 1978, ARCH BIOCHEM BIOPHYS, V189, P535, DOI 10.1016/0003-9861(78)90244-8; DEYOUNG A, 1982, METHOD ENZYMOL, V76, P792; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; EATON WA, 1967, J CHEM PHYS, V46, P2533, DOI 10.1063/1.1841081; EATON WA, 1968, J CHEM PHYS, V49, P985, DOI 10.1063/1.1670263; FERRONE FA, 1985, J MOL BIOL, V183, P611, DOI 10.1016/0022-2836(85)90175-5; FERRONE FA, 1985, J MOL BIOL, V183, P591, DOI 10.1016/0022-2836(85)90174-3; FERRONE FA, 1978, FRONT BIOL ENERGET, V2, P1085; GERACI G, 1969, J BIOL CHEM, V244, P4664; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; GILL SJ, 1979, J MOL BIOL, V130, P175, DOI 10.1016/0022-2836(79)90425-X; GOLDBECK RA, 1993, METHOD ENZYMOL, V226, P147, DOI 10.1016/0076-6879(93)26009-X; GOLUB GH, 1970, NUMER MATH, V14, P403, DOI 10.1007/BF02163027; GROSS CT, 1991, BIOCHIM BIOPHYS ACTA, V1079, P152, DOI 10.1016/0167-4838(91)90120-O; HARRINGTON JP, 1977, P NATL ACAD SCI USA, V74, P203, DOI 10.1073/pnas.74.1.203; HASINOFF BB, 1981, BIOPHYS CHEM, V13, P173, DOI 10.1016/0301-4622(81)80016-6; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; HOFRICHTER J, 1973, P NATL ACAD SCI USA, V70, P3604, DOI 10.1073/pnas.70.12.3604; HOFRICHTER J, 1979, J MOL BIOL, V128, P335, DOI 10.1016/0022-2836(79)90092-5; HOFRICHTER J, 1994, METHOD ENZYMOL, V232, P387; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0; KLIGER DS, 1987, REV CHEM INTERMED, V8, P367, DOI 10.1007/BF03055509; MATHEWS AJ, 1994, METHOD ENZYMOL, V232, P363; MESSER MJ, 1976, DHEW NIH761007 PUBL, P225; MIZUKAMI H, 1977, P SOC EXP BIOL MED, V154, P304, DOI 10.3181/00379727-154-39659; MOFFAT K, 1974, BIOCHEM BIOPH RES CO, V61, P237, DOI 10.1016/0006-291X(74)90558-0; MOZARELLI A, 1988, SCIENCE, V237, P500; MURRAY LP, 1988, P NATL ACAD SCI USA, V85, P2151, DOI 10.1073/pnas.85.7.2151; PENNELLY RR, 1978, BIOCH CLIN ASPECTS H, P401; POILLON WN, 1993, P NATL ACAD SCI USA, V90, P5039, DOI 10.1073/pnas.90.11.5039; RUCKNAGEL DL, 1975, SICKLE CELL ANEMIA O, P1; SAMUEL RE, 1990, NATURE, V345, P833, DOI 10.1038/345833a0; SEAKINS M, 1973, J CLIN INVEST, V52, P422, DOI 10.1172/JCI107199; SHAPIRO DB, 1994, BIOCHEM BIOPH RES CO, V205, P154, DOI 10.1006/bbrc.1994.2643; SHAPIRO DB, 1995, BIOPHYS J, V68, P326, DOI 10.1016/S0006-3495(95)80191-8; SUNSHINE HR, 1979, J MOL BIOL, V133, P435, DOI 10.1016/0022-2836(79)90402-9; SUNSHINE HR, 1982, J MOL BIOL, V158, P251, DOI 10.1016/0022-2836(82)90432-6; WINSLOW RM, 1978, BIOCH CLIN ASPECTS H, P369	48	12	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26078	26085		10.1074/jbc.270.44.26078	http://dx.doi.org/10.1074/jbc.270.44.26078			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592808	hybrid			2022-12-27	WOS:A1995TC97800015
J	WANG, CC; YEH, LS; KARAM, JD				WANG, CC; YEH, LS; KARAM, JD			MODULAR ORGANIZATION OF T4 DNA-POLYMERASE - EVIDENCE FROM PHYLOGENETICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4; GENES	We describe the use of a phylogenetic approach to analyze the modular organization of the single-chained (898 amino acids) and multifunctional DNA polymerase of phage T4. We have identified, cloned in expression vectors, and sequenced the DNA polymerase gene (gene 43) of phage RB69, a distant relative of T4. The deduced primary structure of the RB69 protein (RB69 gp43) differs from that of T4 gp43 in discrete clusters of short sequence that are interspersed with clusters of high similarity between the two proteins. Despite these differences, the two enzymes can substitute for each other in phage DNA replication, although T4 gp43 does exhibit preference to its own genome. A 55-amino acid internal gp43 segment of high sequence divergence between T4 and RB69 could be replaced in RB69 gp43 with the corresponding segment from T4 without loss of replication function The reciprocal chimera and a deletion mutant of the T4 gp43 segment were both inactive for replication and specifically inhibitory (''dominant lethal'') to the T4 wild-type allele. The results show that phylogenetic markers can be used to construct chimeric and truncated forms of gp43 that, although inactive for replication, can still exhibit biological specificity.	TULANE UNIV, SCH MED, DEPT BIOCHEM, NEW ORLEANS, LA 70115 USA	Tulane University					NIGMS NIH HHS [GM18842] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018842] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRAKE M, 1988, P NATL ACAD SCI USA, V85, P7942, DOI 10.1073/pnas.85.21.7942; ANDRAKE MD, 1991, GENETICS, V128, P203; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CAI H, 1995, J BIOL CHEM, V270, P15327, DOI 10.1074/jbc.270.25.15327; CAMPBELL A, 1983, LAMBDA, V2, P365; CLYMAN J, 1992, GENE DEV, V6, P1269, DOI 10.1101/gad.6.7.1269; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; EDDY SR, 1991, GENE DEV, V5, P1032, DOI 10.1101/gad.5.6.1032; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; Henning U, 1994, MOL BIOL BACTERIOP T, P291; HSU T, 1990, J BIOL CHEM, V265, P5303; HUGHES MB, 1987, GENETICS, V115, P393; JORWIK CE, 1992, P NATL ACAD SCI USA, V89, P5053; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kornberg A., 1992, DNA REPLICATION; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; Kricker Maja S., 1994, P455; LIN TC, 1994, J BIOL CHEM, V269, P19286; MILLER ES, 1990, J BACTERIOL, V172, P5180, DOI 10.1128/jb.172.9.5180-5186.1990; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; NOSSAL NG, 1969, J BIOL CHEM, V244, P218; ODONNELL PV, 1972, J VIROL, V9, P990, DOI 10.1128/JVI.9.6.990-998.1972; PAVLOV AR, 1994, J BIOL CHEM, V269, P12968; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; Reha-Krantz Linda J., 1994, P307; Russell R.L., 1967, SPECIATION T EVEN BA; RUSSELL RL, 1974, GENETICS, V78, P989; SAMBROOK JF, 1967, NATURE, V214, P452, DOI 10.1038/214452a0; SHUB DA, 1994, CURR BIOL, V4, P555, DOI 10.1016/S0960-9822(00)00124-X; SKALKA A, 1993, REVERSE TRANSCRIPTAS; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P438; SPICER EK, 1988, J BIOL CHEM, V263, P7478; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUSSKIND MM, 1983, LAMBDA, V2, P347; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WU MQ, 1993, CELL, V75, P1371; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7	39	57	61	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26558	26564		10.1074/jbc.270.44.26558	http://dx.doi.org/10.1074/jbc.270.44.26558			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592876	hybrid			2022-12-27	WOS:A1995TC97800083
J	WEI, JY; GAUT, JR; HENDERSHOT, LM				WEI, JY; GAUT, JR; HENDERSHOT, LM			IN-VITRO DISSOCIATION OF BIP-PEPTIDE COMPLEXES REQUIRES A CONFORMATIONAL CHANGE IN BIP AFTER ATP BINDING BUT DOES NOT REQUIRE ATP HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEIN; IMMUNOGLOBULIN HEAVY-CHAIN; ESCHERICHIA-COLI DNAJ; SHOCK COGNATE PROTEIN; SITE; FRAGMENT; HSP70; GRP78; AUTOPHOSPHORYLATION; NUCLEOTIDES	In the present study, we produced single point mutations in the ATP binding site of hamster Rip, isolated recombinant proteins, and characterized them in terms of their affinity for ATP and ADP, their ability to undergo a conformational change upon nucleotide binding, and their rate of ATP hydrolysis, These analyses allowed us to classify the mutants into three groups: ATP hydrolysis (T229G), ATP binding (G226D, G227D), and ATP-induced conformation (T37G) mutants, and to test the role of these activities in the in vitro ATP-mediated release of proteins from Rip. All three classes of mutants were still able to bind peptide demonstrating that nucleotide is not involved in this function, Addition of ATP to either wild-type BiP or the T229G mutant caused the in vitro release of bound peptide, confirming that ATP hydrolysis is not required for protein release. ATP did not dissociate G226D, G227D, or T37G mutant BiP-peptide complexes, suggesting that ATP binding to Rip is not sufficient for the release of bound peptides, but that an ATP-induced conformational change in BiP is necessary, The identification of BiP mutants that are defective in each of these steps of ATP hydrolysis will allow the in vivo dissection of the role of nucleotide in BiP's activity.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; UNIV MICHIGAN, DEPT BIOL SCI, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, INST GERONTOL, ANN ARBOR, MI 48109 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Hendershot, Linda/N-8124-2018	Hendershot, Linda/0000-0002-5473-0274	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043576] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 43576] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GAUT JR, 1993, J BIOL CHEM, V268, P12691; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HENDERSHOT LM, 1995, MOL BIOL CELL, V6, P283, DOI 10.1091/mbc.6.3.283; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IKEDA E, 1994, FEBS LETT, V339, P265, DOI 10.1016/0014-5793(94)80428-1; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; LADJIMI MM, 1995, J CELL BIOCH S, V19, P198; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MCCARTY JS, 1994, J BACTERIOL, V176, P764, DOI 10.1128/jb.176.3.764-780.1994; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAYLOR DJ, 1995, BBA-PROTEIN STRUCT M, V1248, P75, DOI 10.1016/0167-4838(95)00007-H; OBRIEN MC, 1993, J BIOL CHEM, V268, P24323; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7; TOLEDO H, 1993, P NATL ACAD SCI USA, V90, P2505, DOI 10.1073/pnas.90.6.2505; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WANG TF, 1993, J BIOL CHEM, V268, P26049; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893; WILD J, 1992, P NATL ACAD SCI USA, V89, P7139, DOI 10.1073/pnas.89.15.7139	33	123	125	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26677	26682		10.1074/jbc.270.44.26677	http://dx.doi.org/10.1074/jbc.270.44.26677			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592894	hybrid			2022-12-27	WOS:A1995TC97800101
J	ALTMEYER, A; KLAMPFER, L; GOODMAN, AR; VILCEK, J				ALTMEYER, A; KLAMPFER, L; GOODMAN, AR; VILCEK, J			PROMOTER STRUCTURE AND TRANSCRIPTIONAL ACTIVATION OF THE MURINE TSG-14 GENE ENCODING A TUMOR-NECROSIS-FACTOR INTERLEUKIN-1-INDUCIBLE PENTRAXIN PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; AMYLOID-P-COMPONENT; ACUTE PHASE PROTEINS; NUCLEAR FACTOR; EXPRESSION NF-IL6; HUMAN FIBROBLASTS; DNA-SEQUENCE; C/EBP FAMILY; KAPPA-B; INTERLEUKIN-6	Human TNF-stimulated gene 14 (TSG-14) encodes a secreted 42-kDa glycoprotein that shows significant homology to proteins of the pentraxin family, which includes the acute phase reactants C-reactive protein and serum amyloid P component. Levels of TSG-14 protein (also termed PTX-3) become elevated in the serum of mice and humans after injection with bacterial Lipopolysaccharide, but in contrast to conventional acute phase proteins, the bulk of TSG-14 synthesis in the intact organism occurs outside the liver. In the present study we cloned and partially sequenced murine genomic TSG-14 DNA. Analysis of the coding region predicts a high degree of amino acid sequence homology between murine and human TSG-14 (88 and 75% identity in the first and second exons, respectively). The promoter of the TSG-14 gene lacks consensus sequences for either a TATA box or CCAAT box. Primer extension analysis and S1 nuclease protection assay revealed one major transcription start site, situated within a consensus sequence for an initiator element. Sequence analysis of a similar to 1.4-kilobase pair fragment of the 5'-flanking region of the TSG-14 gene revealed the presence of numerous potential enhancer binding elements, including six NF-IL6-like sites, four AP-1, one AP-2, one NF-kappa B, two Sp1, two interferon-gamma-activated sites (GAS), one Hox-1.3, and five binding sites for Ets family members. Transfection of BALB/c 3T3 cells with promoter DNA fragments linked to the luciferase reporter gene revealed that the 5'-flanking region of the TSG-14 gene comprises elements that can mediate a basal level of transcription and inducibility by TNF.	NYU,MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University					NCI NIH HHS [R35-CA49731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA049731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALLES VV, 1994, BLOOD, V84, P3483; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; DANOFF TM, 1994, J IMMUNOL, V152, P1182; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOWTON SB, 1991, BIOCHEMISTRY-US, V30, P9531, DOI 10.1021/bi00103a021; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; HAMADA H, 1984, MOL CELL BIOL, V4, P2622, DOI 10.1128/MCB.4.12.2622; HU SI, 1986, BIOCHEMISTRY-US, V25, P7834, DOI 10.1021/bi00372a008; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; ITOH Y, 1992, BIOCHIM BIOPHYS ACTA, V1131, P261, DOI 10.1016/0167-4781(92)90024-T; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KLAMPFER L, 1995, J BIOL CHEM, V270, P3677, DOI 10.1074/jbc.270.8.3677; KLAMPFER L, 1994, MOL CELL BIOL, V14, P6561, DOI 10.1128/MCB.14.10.6561; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMINATO Y, MOL CELL BIOL, V15, P5995; KRAMER B, 1995, J BIOL CHEM, V270, P6577; KU NO, 1993, BIOCHEM J, V295, P379, DOI 10.1042/bj2950379; LEE GW, 1994, J IMMUNOL, V153, P3700; LEE GW, 1993, J IMMUNOL, V150, P1804; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LEI KJ, 1985, J BIOL CHEM, V260, P3377; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI SP, 1990, J BIOL CHEM, V265, P4136; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; NISHIGUCHI S, 1988, BIOCHEM BIOPH RES CO, V155, P1366, DOI 10.1016/S0006-291X(88)81292-0; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; ODENWALD WF, 1989, GENE DEV, V3, P158, DOI 10.1101/gad.3.2.158; ODENWALD WF, 1987, GENE DEV, V1, P482, DOI 10.1101/gad.1.5.482; OHNISHI S, 1988, BIOCHEM BIOPH RES CO, V156, P814, DOI 10.1016/S0006-291X(88)80917-3; OHNISHI S, 1986, J BIOCHEM-TOKYO, V100, P849, DOI 10.1093/oxfordjournals.jbchem.a121797; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; RASSOULI M, 1992, J BIOL CHEM, V267, P2947; REID MS, 1994, J BIOL CHEM, V269, P32615; RUBIO N, 1993, J BIOCHEM-TOKYO, V113, P277, DOI 10.1093/oxfordjournals.jbchem.a124039; Sambrook J, 1989, MOL CLONING LABORATO; SCHLIMGEN AK, 1995, NEURON, V14, P519, DOI 10.1016/0896-6273(95)90308-9; SCIAVOLINO PJ, 1994, J BIOL CHEM, V269, P21627; SEERY LT, 1993, P ROY SOC B-BIOL SCI, V253, P263, DOI 10.1098/rspb.1993.0112; SPERGEL JM, 1992, J VIROL, V66, P1021, DOI 10.1128/JVI.66.2.1021-1030.1992; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TONIATTI C, 1990, MOL BIOL MED, V7, P199; WHITEHEAD AS, 1990, ACUTE PHASE PROTEINS, P47; WOO P, 1985, J BIOL CHEM, V260, P3384; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	53	65	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25584	25590		10.1074/jbc.270.43.25584	http://dx.doi.org/10.1074/jbc.270.43.25584			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592730	hybrid			2022-12-27	WOS:A1995TB46600047
J	KAPELLER, R; TOKER, A; CANTLEY, LC; CARPENTER, CL				KAPELLER, R; TOKER, A; CANTLEY, LC; CARPENTER, CL			PHOSPHOINOSITIDE 3-KINASE BINDS CONSTITUTIVELY TO ALPHA/BETA-TUBULIN AND BINDS TO GAMMA-TUBULIN IN RESPONSE TO INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; MIDDLE-T; TYROSINE; COMPLEXES; INVITRO	Recently we reported the localization of phosphoinositide 3-kinase (PI 3-kinase) by immunofluorescence to microtubule bundles and the centrosome (Kapeller, R., Chakrabarti, R., Cantley, L., Fay, F., and Corvera, S. (1993) Mol. Cell. Biol. 13, 6052-6063). In complementary experiments we used the recombinant p85 subunit of PI 3-kinase to identify proteins that associate with phosphoinositide 3-kinase and found that phosphoinositide 3-kinase associates with alpha/beta-tubulin. The association occurs in vivo but was not significantly affected by growth factor stimulation. We localized the region of p85 that interacts with alpha/beta-tubulin to the inter-SH2 domain. These results support the immunofluorescence data and show that p85 directly associates with alpha/beta-tubulin. We then determined whether phosphoinositide 3-kinase associates with gamma-tubulin. We found a dramatic growth factor-dependent association of phosphoinositide 3-kinase with gamma-tubulin. Phosphoinositide 3-kinase associates with gamma-tubulin in response to insulin and, to a lesser extent, in response to platelet-derived growth factor. Neither epidermal growth factor nor nerve growth factor treatment of cells results in association of phosphoinositide 3-kinase and gamma-tubulin. Phosphoinositide 3-kinase is also immunoprecipitated with antibodies to pericentrin in response to insulin, indicating that phosphoinositide 3-kinase is recruited to the centrosome. Neither phosphoinositide 3-kinase activity, nor intact microtubules are necessary for the association, Treatment of cells with 0.5 M NaCl dissociates gamma-tubulin from the centrosome and disrupts the association of phosphoinositide 3-kinase with pericentrin, but not gamma-tubulin. Recombinant p85 binds to gamma-tubulin from both insulin stimulated and quiescent cells. These results suggest that the association of phosphoinositide 3-kinase with gamma-tubulin is direct. These data suggest that phosphoinositide 3-kinase may be involved in regulating microtubule responses to insulin and platelet-derived growth factor.	BETH ISRAEL HOSP, DEPT MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NIGMS NIH HHS [GM 36624, R01 GM041890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036624, R01GM041890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1992, J BIOL CHEM, V267, P5408; Ausubel FM, 1991, CURRENT PROTOCOLS MO; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LIN CH, 1993, J CELL BIOL, V121, P1369, DOI 10.1083/jcb.121.6.1369; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; MARCHESI VT, 1993, P NATL ACAD SCI USA, V90, P3028, DOI 10.1073/pnas.90.7.3028; MASCARDO RN, 1984, DIABETES, V33, P1099, DOI 10.2337/diabetes.33.11.1099; MATTEN WT, 1990, J CELL BIOL, V111, P1959, DOI 10.1083/jcb.111.5.1959; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; TOKER A, 1994, J BIOL CHEM, V269, P32358; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANDOSELL F, 1986, J BIOL CHEM, V261, P332; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992	30	100	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25985	25991		10.1074/jbc.270.43.25985	http://dx.doi.org/10.1074/jbc.270.43.25985			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592789	hybrid			2022-12-27	WOS:A1995TB46600106
J	SZABO, MC; SOO, KS; ZLOTNIK, A; SCHALL, TJ				SZABO, MC; SOO, KS; ZLOTNIK, A; SCHALL, TJ			CHEMOKINE CLASS-DIFFERENCES IN BINDING TO THE DUFFY ANTIGEN-ERYTHROCYTE CHEMOKINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RED-BLOOD-CELLS; CYTOKINE FAMILY	The Duffy blood group antigen-erythrocyte chemokine receptor has been shown to bind to chemokines of both the C-X-C and C-C classes and to the malarial parasites Plasmodium vivax and Plasmodium knowlesi. We performed experiments to evaluate the binding properties of this receptor for the newly appreciated ''C'' and ''non-ELR C-X-C'' classes of chemokines. Binding 60 mouse erythrocytes was also evaluated for the first time. Whereas ELR C-X-C and C-C chemokines bound to human erythrocytes with high affinity, differences in the ability of non-ELR chemokines to act as competitive inhibitors were noted. While non-ELR chemokines were unable to displace C-X-C chemokines on human cells, they exhibited a low affinity interaction with the C-C chemokine binding site. The newly discovered C chemokine, lymphotactin, was unable to displace either C-X-C or C-C chemokines. On mouse erythrocytes, non-ELR chemokines exhibited a low affinity for both the C-X-C and C-C chemokines binding sites; again lymphotactin failed to bind. Binding competition studies using an anti-Duffy monoclonal antibody and chemokines suggested a common binding domain. These data show that the chemokine superfamily has at least four functional subdivisions, each interacting differently with the Duffy antigen erythrocyte chemokine receptor. In addition the chemokine binding function is conserved between mouse and man. Unlike other proteins in the superfamily C and non-ELR C-X-C chemokines do not efficiently bind red blood cells, thus their role may not require clearance from circulation.	DNAX RES INST MOLEC & CELLULAR BIOL INC, DEPT IMMUNOL, PALO ALTO, CA 94304 USA; STANFORD UNIV, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA; UCL, SCH MED, DEPT SURG, LONDON W1P 8BT, ENGLAND	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Stanford University; University of London; University College London; UCL Medical School			Zlotnik, Albert/C-3791-2011		NIAID NIH HHS [AI-07290] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHANDHURI A, 1994, J BIOL CHEM, V269, P7835; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KENNEDY J, 1995, J IMMUNOL, V155, P203; MILLER LH, 1975, SCIENCE, V189, P561, DOI 10.1126/science.1145213; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEOTE K, 1994, BLOOD, V84, P44; NEOTE K, 1993, J BIOL CHEM, V268, P12247; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHALL TJ, 1994, CYTOKINE HDB, P419	13	102	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25348	25351		10.1074/jbc.270.43.25348	http://dx.doi.org/10.1074/jbc.270.43.25348			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592697	hybrid			2022-12-27	WOS:A1995TB46600013
J	BRICKMAN, YG; FORD, MD; SMALL, DH; BARTLETT, PF; NURCOMBE, V				BRICKMAN, YG; FORD, MD; SMALL, DH; BARTLETT, PF; NURCOMBE, V			HEPARAN SULFATES MEDIATE THE BINDING OF BASIC FIBROBLAST GROWTH-FACTOR TO A SPECIFIC RECEPTOR ON NEURAL PRECURSOR CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; HIGH-AFFINITY; FGF RECEPTOR; IMMUNOGLOBULIN DOMAIN; BIOLOGICAL-ACTIVITIES; LIGAND SPECIFICITY; MESSENGER-RNA; MOUSE-BRAIN; FAMILY; EXPRESSION	Heparan sulfate proteoglycans are thought to be obligatory for receptor binding and subsequent mitogenic activity of basic fibroblast growth factor (FGF-2). In a previous study (Nurcombe V., Ford, M. D., Wildschut, J., Bartlett, P. F. (1993) Science 260, 103-106) we have shown that primary cultures of mouse neuroepithelial cells and a cell line derived from them, 2.3D, secrete a heparan sulfate proteoglycan with a high affinity for EGF-2. In this study, a combination of affinity chromatography and gel chromatography was used to further isolate heparan sulfate side chains with high affinity for FGF-2. These active chains had an average molecular weight of 18,000-20,000. In order to determine whether heparan sulfate chains with specificity for FGF-2 also displayed selectivity for the different FGF receptors, peptides designed to the heparin-binding region of the receptors were used in competitive inhibition studies. The structure of the predicted heparin-binding domain of the FGF receptor 1 was modeled on the basis of its presumed secondary and tertiary structure homology with immunoglobulin loops. These results suggested that many of the basic residues within the second immunoglobulin loop of the FGF receptor 1 form a basic domain in the molecule and therefore form part of a heparin-binding site. Peptides homologous to this region of FGF receptor 1 were shown to inhibit mitogenesis in 2.3D cells, while those to FGF receptor types 2, 3, and 4 did not. A reverse transcriptase-polymerase chain reaction assay designed to detect expression of the four FGF receptors types demonstrated that FGF receptors 1 and 3 were present on the 2.3D cell line but that receptors 2 and 4 were not. These findings indicate that unique heparan sulfate domains interact with specific cell-surface receptors to direct cellular responses.	UNIV MELBOURNE, DEPT ANAT & CELL BIOL, MELBOURNE, VIC 3052, AUSTRALIA; UNIV MELBOURNE, DEPT PATHOL, MELBOURNE, VIC 3052, AUSTRALIA; UNIV MELBOURNE, ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC 3050, AUSTRALIA	University of Melbourne; University of Melbourne; Royal Melbourne Hospital; University of Melbourne; Walter & Eliza Hall Institute			Bartlett, Perry/F-3813-2012					AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; ASAI T, 1993, MOL BRAIN RES, V17, P174, DOI 10.1016/0169-328X(93)90088-7; AVIEZER D, 1994, J BIOL CHEM, V269, P114; AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HANLEY RM, 1989, NUCLEIC ACIDS RES, V17, P3992, DOI 10.1093/nar/17.10.3992; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; LAFONT F, 1994, DEV BIOL, V165, P453, DOI 10.1006/dbio.1994.1267; Ledoux D, 1991, Growth Factors, V5, P221, DOI 10.3109/08977199109000286; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MURPHY M, 1990, J NEUROSCI RES, V25, P463, DOI 10.1002/jnr.490250404; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; POLJAK RJ, 1973, P NATL ACAD SCI USA, V70, P3305, DOI 10.1073/pnas.70.12.3305; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; RAZ V, 1991, ONCOGENE, V6, P753; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RICHARDSON JS, 1976, J MOL BIOL, V102, P221, DOI 10.1016/S0022-2836(76)80050-2; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; SAFRAN A, 1990, ONCOGENE, V5, P635; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SENSENBRENNER M, 1993, PROG NEUROBIOL, V41, P683, DOI 10.1016/0301-0082(93)90031-M; STARK KL, 1991, DEVELOPMENT, V113, P641; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1993, BIOCHEM SOC T, V21, P477, DOI 10.1042/bst0210477; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; WALKER A, 1994, J BIOL CHEM, V269, P931; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	48	82	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24941	24948		10.1074/jbc.270.42.24941	http://dx.doi.org/10.1074/jbc.270.42.24941			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559620	hybrid			2022-12-27	WOS:A1995TB46500054
J	CERVINI, R; HOUHOU, L; PRADAT, PF; BEJANIN, S; MALLET, J; BERRARD, S				CERVINI, R; HOUHOU, L; PRADAT, PF; BEJANIN, S; MALLET, J; BERRARD, S			SPECIFIC VESICULAR ACETYLCHOLINE TRANSPORTER PROMOTERS LIE WITHIN THE FIRST INTRON OF THE RAT CHOLINE-ACETYLTRANSFERASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MESSENGER-RNA; REGION; EXPRESSION; BRAIN	The sequence encoding the vesicular acetylcholine transporter (VAChT) has recently been localized within the first intron of the choline acetyltransferase (ChAT) gene in various species. In rat, we previously identified a class of VAChT mRNAs that may originate from the same promoter region as two ChAT mRNAs. Here, we demonstrate by a detailed analysis of the 5'-noncoding region of the VAChT gene, that two specific VAChT promoters lie within the first intron of the ChAT gene. Two VAChT mRNAs are generated from these promoters. These results demonstrate that the promoter regions of these two genes are intermingled, which highlight the unique organization of the ChaT/VAChT gene locus.	GRP HOSP PITIE SALPETRIERE, GENET MOLEC NEUROTRANSMISS & PROC NEURODEGENERAT, BATIMENT CERVI, F-75651 PARIS 13, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite								ALFONSO A, 1994, J MOL BIOL, V241, P627, DOI 10.1006/jmbi.1994.1538; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; BIGUET NF, 1986, EMBO J, V5, P287, DOI 10.1002/j.1460-2075.1986.tb04211.x; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; CIVELLI O, 1982, J BIOL CHEM, V257, P6783; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; HARRISON SM, 1987, NUCLEIC ACIDS RES, V15, P10267, DOI 10.1093/nar/15.24.10267; IBANEZ CF, 1991, EUR J NEUROSCI, V3, P1309, DOI 10.1111/j.1460-9568.1991.tb00063.x; KENGAKU M, 1993, MOL BRAIN RES, V18, P71, DOI 10.1016/0169-328X(93)90174-N; LONNERBERG P, 1995, P NATL ACAD SCI USA, V92, P4046, DOI 10.1073/pnas.92.9.4046; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MISAWA H, 1992, J BIOL CHEM, V267, P20392; ROGHANI A, 1994, P NATL ACAD SCI USA, V91, P10620, DOI 10.1073/pnas.91.22.10620; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SPECK NA, 1987, MOL CELL BIOL, V7, P1101, DOI 10.1128/MCB.7.3.1101; WU DH, 1994, J NEUROCHEM, V62, P1653	17	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24654	24657		10.1074/jbc.270.42.24654	http://dx.doi.org/10.1074/jbc.270.42.24654			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559575	hybrid			2022-12-27	WOS:A1995TB46500009
J	CONRADT, M; STOFFEL, W				CONRADT, M; STOFFEL, W			FUNCTIONAL-ANALYSIS OF THE HIGH-AFFINITY, NA+-DEPENDENT GLUTAMATE TRANSPORTER GLAST-1 BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; RAT-BRAIN; NEUROTRANSMITTER TRANSPORTERS; ASPARTATE TRANSPORTER; GENE FAMILY; EXPRESSION; PROTEINS; CLONING; SEQUENCE; CARRIER	The reuptake of excitatory amino acids, such as glutamate, terminates excitatory signals and prevents the persistence of excitotoxic levels of glutamate in the synaptic cleft. The L-glutamate/L-aspartate transporter (GLAST-1) is the first member of the recently discovered glutamate transporter family, which includes GLT-1 and EAAC1. The neutral amino acid carrier ASCT1 is structurally closely related to this new family of membrane proteins. Transmembrane transport of neutral amino acids is expected to differ in its binding site from that of the acidic excitatory amino acids glutamate and aspartate. Three positively charged amino acid residues, Arg-122, Arg-280, Arg-479, and one polar Tyr-405 are conserved in all glutamate transporters. They are replaced by apolar amino acid residues in the ASCT1 sequence. We exchanged these residues in the GLAST-1-specific cDNA by site-directed mutagenesis. cRNAs of these mutants were expressed in the Xenopus oocyte system. The functional characterization of the mutants R122I and R280V and the double mutant R122I,R280V revealed that the mutations have no influence on the intrinsic properties and kinetics of glutamate transport but alter the K-m-values for L-aspartate and the competitive inhibitor D,L-threo-3-hydroxy aspartate. Substitutions of Tyr-405 by Phe (Y405F) and Arg-479 (R479T) by Thr completely inactivate the glutamate transporter. Immunoprecipitations of [S-35]methionine-labeled transporter molecules indicate similar expression levels of wild-type and mutant transporters. Immunostaining of oocyte sections clearly proves the correct targeting to and integration of the mutant GLAST-1 proteins in the plasma membrane. Our results suggest the pivotal function of the hydroxy group of the highly conserved Tyr-405 and the positively charged Arg-479 in the binding of the negatively charged acidic neurotransmitter glutamate.	UNIV COLOGNE, FAC MED, INST BIOCHEM, D-50931 COLOGNE, GERMANY	University of Cologne								AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BAKER PJ, 1992, PROTEINS, V12, P75, DOI 10.1002/prot.340120109; BALCAR VJ, 1972, J NEUROCHEM, V19, P2657, DOI 10.1111/j.1471-4159.1972.tb01325.x; BENNETT JP, 1973, J NEUROCHEM, V21, P1533, DOI 10.1111/j.1471-4159.1973.tb06037.x; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; COLEMAN A, 1984, TRANSCRIPTION TRANSL, P271; CONRADT M, 1995, EUR J BIOCHEM, V229, P682, DOI 10.1111/j.1432-1033.1995.tb20514.x; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; ENGELKE T, 1989, J BACTERIOL, V171, P5551, DOI 10.1128/jb.171.10.5551-5560.1989; GORDON RD, 1983, J NEUROCHEM, V40, P1090, DOI 10.1111/j.1471-4159.1983.tb08097.x; KANAI Y, 1994, J BIOL CHEM, V269, P20599; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANAI Y, 1994, FASEB J, V8, P1450; KANNER BI, 1993, FEBS LETT, V325, P95, DOI 10.1016/0014-5793(93)81421-U; KLOCKNER U, 1993, J BIOL CHEM, V268, P14594; KLOCKNER U, 1994, J NEUROSCI, V14, P5759; KUHAR MJ, 1973, LIFE SCI, V13, P1623, DOI 10.1016/0024-3205(73)90110-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORI H, 1994, J BIOL CHEM, V269, P11578; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; RADDING W, 1991, J THEOR BIOL, V150, P239, DOI 10.1016/S0022-5193(05)80335-2; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TOLNER B, 1992, J BACTERIOL, V174, P2391, DOI 10.1128/JB.174.7.2391-2393.1992; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; ZHANG YM, 1994, J BIOL CHEM, V269, P19573	30	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25207	25212		10.1074/jbc.270.42.25207	http://dx.doi.org/10.1074/jbc.270.42.25207			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559657	hybrid			2022-12-27	WOS:A1995TB46500091
J	LAI, WS; THOMPSON, MJ; TAYLOR, GA; LIU, Y; BLACKSHEAR, PJ				LAI, WS; THOMPSON, MJ; TAYLOR, GA; LIU, Y; BLACKSHEAR, PJ			PROMOTER ANALYSIS OF ZFP-36, THE MITOGEN-INDUCIBLE GENE ENCODING THE ZINC-FINGER PROTEIN TRISTETRAPROLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; GROWTH-FACTOR; 3T3 CELLS; C-FOS; GLOBIN GENE; DNA-BINDING; ACTIN GENE; EXPRESSION; SEQUENCES; MOUSE	The gene encoding the putative zinc finger protein tristetraprolin (TTP), Zfp-36, is rapidly induced by a variety of mitogens and growth factors. We show here that 77 base pairs 5' of the transcription start site are sufficient for full serum inducibility of the mouse Zfp-36 promoter. This region of the promoter includes consensus sequences for the binding of the transcription factors EGR-1, AP2, and Sp1. In addition, we have identified a previously undescribed element, TTP promoter element 1 (TPE1); this 10-base pair sequence includes a palindrome and is identical in the human, bovine, and mouse genes. Each of the three binding elements, EGR-1, AP2, and TPE1, contribute to the serum induction of Zfp-36 and can confer serum-inducible expression on a heterologous minimal promoter. Gel mobility shift assays demonstrated the formation of complexes consisting of this region of the promoter and cellular nuclear proteins and demonstrated that the extent of complex formation could be altered by treatment of the cells with serum or insulin. These results suggest that the response of Zfp-36 to serum and other mitogens is mediated by a series of cis-acting elements acting in concert to confer full inducible transcription of this gene.	DUKE UNIV,MED CTR,DEPT MED,DIV METAB ENDOCRINOL & NUTR,DIABET & METAB SECT H,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,SARAH W STEDMAN CTR NUTR STUDIES,DURHAM,NC 27710; DUKE UNIV,DEPT MICROBIOL,DURHAM,NC 27710	Duke University; Duke University; Duke University; Duke University			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NIDDK NIH HHS [K11-DK02227-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002227] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; CAO XM, 1993, J BIOL CHEM, V268, P16949; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GEISER AG, 1993, GENE, V129, P223, DOI 10.1016/0378-1119(93)90272-5; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; HUMPHRIES RK, 1982, CELL, V30, P173; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JUVEN T, 1993, ONCOGENE, V8, P3411; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KERRIGAN LA, 1992, NUCLEIC ACIDS RES, V20, P6673, DOI 10.1093/nar/20.24.6673; LAI WS, 1990, J BIOL CHEM, V265, P16556; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAZO PS, 1992, NUCLEIC ACIDS RES, V20, P343, DOI 10.1093/nar/20.2.343; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEVENSON RM, 1989, J BIOL CHEM, V264, P11904; LIM RW, 1987, ONCOGENE, V1, P263; LOPEZRODAS G, 1993, FEBS LETT, V317, P175, DOI 10.1016/0014-5793(93)81271-Z; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOSCHONAS N, 1981, NUCLEIC ACIDS RES, V9, P4391, DOI 10.1093/nar/9.17.4391; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Sambrook J, 1989, MOL CLONING LABORATO; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; TAYLOR GA, 1995, J CELL PHYSIOL, V162, P378, DOI 10.1002/jcp.1041620310; THOMPSON MJ, 1994, J BIOL CHEM, V269, P21127; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; UNLAP T, 1992, NUCLEIC ACIDS RES, V20, P897, DOI 10.1093/nar/20.4.897; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Xie W.Q., 1991, BIOTECHNIQUES, V11, P326	39	61	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25266	25272		10.1074/jbc.270.42.25266	http://dx.doi.org/10.1074/jbc.270.42.25266			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559666	hybrid			2022-12-27	WOS:A1995TB46500100
J	LEUNG, HT; BRADSHAW, J; CLEAVELAND, JS; LINSLEY, PS				LEUNG, HT; BRADSHAW, J; CLEAVELAND, JS; LINSLEY, PS			CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED MOLECULE-4, A HIGH AVIDITY RECEPTOR FOR CD80 AND CD86, CONTAINS AN INTRACELLULAR-LOCALIZATION MOTIF IN ITS CYTOPLASMIC TAIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ACTIVATION; EXPRESSION; CTLA-4; CD28; GENE; BINDING; PROTEIN; COSTIMULATION; 3-KINASE; PATHWAY	CD28 and CTLA-4, T cell receptors for B7-1 (CD80) and B7-2 (CD86) molecules on antigen-presenting cells, transmit costimulatory signals important for optimal T cell activation. Despite sharing sequence homology and common ligands, these receptors have distinct binding properties and patterns of expression. The function of CTLA-4 during T cell activation is not well understood, although an important role is suggested by complete amino acid sequence conservation of its cytoplasmic tail in all species studied to date. We report here a role of the cytoplasmic tail of CTLA-4 in regulating its subcellular localization and cell surface expression. In activated human peripheral blood T cells, or in several transfected or transduced cell types, CTLA-4 is not primarily a cell surface protein, but rather is localized intracellularly in a region which overlaps the Golgi apparatus. Transfer of 11 cytoplasmic residues, (161)TTGVYVKMPPT, from the CTLA-4 cytoplasmic tail to the homologous position in CD28 was sufficient to confer intracellular localization. Mutation of the tyrosine residue (Tyr(165)) in this motif to phenylalanine resulted in increased sur face expression of CTLA-4. Thus, the subcellular localization of CTLA-4 is controlled by a tyrosine-containing motif within its cytoplasmic domain. Contained within this motif is a binding site for SH2 domains of the p85 subunit of phosphatidylinositol 3-kinase.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, SEATTLE, WA 98121 USA	Bristol-Myers Squibb								ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; AUGUST A, 1994, BIOCHEM BIOPH RES CO, V199, P1466, DOI 10.1006/bbrc.1994.1396; AZUMA M, 1993, J EXP MED, V177, P845, DOI 10.1084/jem.177.3.845; BALZANO C, 1992, INT J CANCER, P28; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; DAMLE NK, 1994, J IMMUNOL, V152, P2686; GUINAN EC, 1994, BLOOD, V84, P3261; HAFFAR OK, 1993, P NATL ACAD SCI USA, V90, P11094, DOI 10.1073/pnas.90.23.11094; HARPER K, 1991, J IMMUNOL, V147, P1037; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUPFER A, 1991, P NATL ACAD SCI USA, V88, P775, DOI 10.1073/pnas.88.3.775; LINDSTEN T, 1993, J IMMUNOL, V151, P3489; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1995, J BIOL CHEM, V270, P15417, DOI 10.1074/jbc.270.25.15417; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1995, J EXP MED, V182, P289, DOI 10.1084/jem.182.2.289; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, J EXP MED, V176, P1595, DOI 10.1084/jem.176.6.1595; MILLER AD, 1988, J VIROL, V62, P4337, DOI 10.1128/JVI.62.11.4337-4345.1988; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PEACH RJ, 1994, J EXP MED, V180, P2049, DOI 10.1084/jem.180.6.2049; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; POO WJ, 1988, NATURE, V332, P378, DOI 10.1038/332378a0; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; SANSOM DM, 1993, EUR J IMMUNOL, V23, P295, DOI 10.1002/eji.1830230148; SCHNEIDER H, 1995, J EXP MED, V181, P351, DOI 10.1084/jem.181.1.351; SCHREIBER KL, 1994, INT IMMUNOL, V6, P101, DOI 10.1093/intimm/6.1.101; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STEIN PH, 1994, MOL CELL BIOL, V14, P3392, DOI 10.1128/MCB.14.5.3392; STPIERRE Y, 1989, J IMMUNOL, V143, P808; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TRUITT KE, 1994, J EXP MED, V179, P1071, DOI 10.1084/jem.179.3.1071; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	132	137	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25107	25114		10.1074/jbc.270.42.25107	http://dx.doi.org/10.1074/jbc.270.42.25107			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559643	hybrid			2022-12-27	WOS:A1995TB46500077
J	SAMSON, SLA; PARAMCHUK, WJ; SHWORAK, NW; GEDAMU, L				SAMSON, SLA; PARAMCHUK, WJ; SHWORAK, NW; GEDAMU, L			FUNCTIONAL ANALYSES OF THE HUMAN METALLOTHIONEIN-IG GENE - IN-VITRO AND IN-VIVO STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL RESPONSE ELEMENT; DIFFERENTIAL EXPRESSION; DEPENDENT BINDING; CRYSTAL-STRUCTURE; PROMOTER; TRANSCRIPTION; LIVER; CELLS; ZINC; SEQUENCES	We have analyzed the human (h) metallothionein (MT)-IG proximal promoter region (-174 to +5) using a TATA box mutation (TATCA) and four trinucleotide mutants of the proximal MREa. Transient transfection of HepG2 cells was complemented by in vitro transcription with rat liver nuclear extracts. In both systems, mutations of the TATA box and conserved core of metal responsive element (MRE)a were detrimental to hMT-IG promoter activity suggesting that both elements make significant contributions to hMT-IG transcription. Although MRE binding factors were active in vitro, further metal activation of MT promoter activity was accomplished only by in vivo metal treatment rather than addition of zinc in vitro. Southwestern blotting identified nuclear proteins in rat liver and HepGa cells which physically interact with MREa in a zinc-dependent manner and could be responsible for MREa function in each system. In addition, the functional effects of the TATCA mutation correlate with altered physical interaction with TATA box-binding protein as observed using DNase I protection.	UNIV CALGARY,DEPT BIOL SCI,CALGARY,AB T2N 1N4,CANADA; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	University of Calgary; Massachusetts Institute of Technology (MIT)			Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; Ausubel FM, 1988, MOL REPROD DEV; BLALOCK TL, 1988, J NUTR, V118, P222, DOI 10.1093/jn/118.2.222; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; COUSINS RJ, 1986, AM J PHYSIOL, V251, pE688, DOI 10.1152/ajpendo.1986.251.6.E688; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; DEWET JR, 1984, MOL CELL BIOL, V7, P725; FOSTER R, 1991, J BIOL CHEM, V266, P9866; GARG LC, 1989, J BIOL CHEM, V264, P2134; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; IMBERT J, 1990, ADV INORG BIOCHEM, V8, P138; JAHROUDI N, 1990, J BIOL CHEM, V265, P6506; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Maniatis T., 1982, MOL CLONING; MAYO KE, 1981, J BIOL CHEM, V256, P2621; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; REACH M, 1991, EMBO J, V10, P3439, DOI 10.1002/j.1460-2075.1991.tb04908.x; SAMSON SLA, 1995, J BIOL CHEM, V270, P6864, DOI 10.1074/jbc.270.12.6864; SATO K, 1986, MOL CELL BIOL, V6, P1032, DOI 10.1128/MCB.6.4.1032; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHMIDT CJ, 1985, J BIOL CHEM, V260, P7731; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Searle P F, 1987, Experientia Suppl, V52, P407; SEARLE PF, 1990, NUCLEIC ACIDS RES, V18, P4683, DOI 10.1093/nar/18.16.4683; SHAPIRO SG, 1978, BIOCHEM J, V175, P833, DOI 10.1042/bj1750833; SHWORAK NW, 1993, J BIOL CHEM, V268, P24460; SHWORAK NW, 1990, THESIS U CALGARY; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; SUZUKI KT, 1993, METALLOTHIONEIN, V3, P363; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	38	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25194	25199		10.1074/jbc.270.42.25194	http://dx.doi.org/10.1074/jbc.270.42.25194			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559655	hybrid			2022-12-27	WOS:A1995TB46500089
J	TAHA, C; MITSUMOTO, Y; LIU, Z; SKOLNIK, EY; KLIP, A				TAHA, C; MITSUMOTO, Y; LIU, Z; SKOLNIK, EY; KLIP, A			THE INSULIN-DEPENDENT BIOSYNTHESIS OF GLUT1 AND GLUT3 GLUCOSE TRANSPORTERS IN L6 MUSCLE-CELLS IS MEDIATED BY DISTINCT PATHWAYS - ROLES OF P21(RAS) AND PP70 S6 KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNALING PATHWAYS; EXPRESSION; RAS; RECEPTOR; PROTEINS; CULTURE; P21RAS	Insulin binding results in rapid phosphorylation of insulin receptor substrate-1 to activate p21(ras) and mitogen-activated protein kinase. Insulin also activates the ribosomal protein S6 kinase (pp70 S6 kinase) independently of the Ras pathway. Chronic (18 h) treatment of L6 muscle cells with insulin increases glucose transport activity severalfold due to biosynthetic elevation of the GLUT1 and GLUT3 but not the GLUT4 glucose transporters. Here we investigate the roles of p21(ras) and pp70 S6 kinase in the insulin-mediated increases in GLUT1 and GLUTS expression. L6 cells were transfected with the dominant negative Ras(S17N) under the control of a dexamethasone-inducible promoter. Induction of Ras(S17N) failed to block the insulin-mediated increase in GLUT1 glucose transporter protein and mRNA; however, it abrogated the insulin-mediated increase in GLUTS glucose transporter protein and mRNA, Inhibition of pp70 S6 kinase by rapamycin, on the other hand, eliminated the insulin-mediated increase in GLUT1 but had no effect on that of GLUT3 in both parental and Ras(S17N) transfected L6 cells. These results suggest that the biosynthetic regulation of glucose transporters is differentially determined, with pp70 S6 kinase and p21(ras) playing active roles in the insulin stimulated increases in GLUT1 and GLUT3, respectively.	HOSP SICK CHILDREN,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA; NYU,MED CTR,SKIRBALL INST BIOMOLEC MED,DEPT PHARMACOL,NEW YORK,NY 10024	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); New York University								BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; GUILLETDENIAU I, 1994, J CELL SCI, V107, P487; HAINQUE B, 1990, J BIOL CHEM, V265, P7982; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KAYANO T, 1988, J BIOL CHEM, V263, P12245; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KHAN CR, 1988, J CLIN INVEST, V82, P1151; KLIP A, 1993, CELL SIGNAL, V5, P519, DOI 10.1016/0898-6568(93)90047-P; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; MAHER F, 1992, BIOCHEM BIOPH RES CO, V182, P703, DOI 10.1016/0006-291X(92)91789-S; MANCHESTER J, 1994, P NATL ACAD SCI USA, V91, P4644, DOI 10.1073/pnas.91.11.4644; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; MITSUMOTO Y, 1991, BIOCHEM BIOPH RES CO, V175, P652, DOI 10.1016/0006-291X(91)91615-J; Mitsumoto Y, 1993, ENDOCR J, V1, P307; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SARGEANT R, 1993, J ENDOCRINOL INVEST, V16, P147, DOI 10.1007/BF03347669; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SIVITZ WI, 1995, BIOCHEM BIOPH RES CO, V206, P51, DOI 10.1006/bbrc.1995.1008; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; WALKER PS, 1990, J BIOL CHEM, V265, P1516; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	34	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24678	24681		10.1074/jbc.270.42.24678	http://dx.doi.org/10.1074/jbc.270.42.24678			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559581	hybrid			2022-12-27	WOS:A1995TB46500015
J	YANG, ZH; SWEENEY, HL				YANG, ZH; SWEENEY, HL			RESTORATION OF PHOSPHORYLATION-DEPENDENT REGULATION TO THE SKELETAL-MUSCLE MYOSIN REGULATORY LIGHT-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SMOOTH-MUSCLE; ASSAY	Regulation of the ATPase activity of smooth and nonmuscle myosin II involves reversible phosphorylation of the regulatory light chain (RLC). The RLC from skeletal muscle myosin (skRLC) is unable to confer regulation (myosin is locked in an inactive state) to smooth muscle myosin when substituted for the endogenous smooth RLC (smRLC). Studies of chimeric light chains comprised of the N or C-terminal half of each skRLC and smRLC suggest that the structural basis for the loss of this regulation is within the C-terminal half of the RLC (Trybus, K. M., and Chatman, T. A. (1993) J. Biol. Chem, 268, 4412-4419). The purpose of this study is to delineate the structural elements within the C-terminal half of the smRLC that are absent in the skRLC and are necessary for regulation. By sequence comparison, six residues, Arg-103, Arg-123, Met-129, Gly-130, Arg-143, and Arg-160, which are conserved in regulated myosin RLCs but missing in nonregulated myosin RLCs, were identified in smRLC. To test whether these amino acids provide the missing structural elements necessary for phosphorylation-mediated regulation, a skRLC was engineered that replaced the corresponding skRLC amino acids (positions 100, 120, 126, 127, 140, and 157, respectively) with their smRLC counterparts. Using a newly developed RLC exchange procedure, the purified mutant protein was evaluated for its ability to regulate chicken gizzard smooth muscle myosin. Substitution of the six conserved amino acids into the skRLC completely restored phosphorylation-mediated regulation. Thus, a subset of these amino acids, including four basic arginine residues located in the E, F, G, and H helices which are missing in skRLC, may be the structural coordinates for the phosphorylserine in the N terminus, Based on this result, the regulation of glycogen phosphorylase is discussed as a model for the regulation of smooth muscle myosin.	UNIV PENN,SCH MED,DEPT PHYSIOL,PHILADELPHIA,PA 19104	University of Pennsylvania			Sweeney, H Lee/F-1862-2010					CHACKO S, 1977, P NATL ACAD SCI USA, V74, P129, DOI 10.1073/pnas.74.1.129; CHANTLER PD, 1980, J MOL BIOL, V138, P473, DOI 10.1016/S0022-2836(80)80013-1; COOK WJ, 1994, BIOCHEMISTRY-US, V33, P15259, DOI 10.1021/bi00255a006; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; HENKEL RD, 1988, ANAL BIOCHEM, V169, P312, DOI 10.1016/0003-2697(88)90290-4; IKEBE M, 1994, P NATL ACAD SCI USA, V91, P9096, DOI 10.1073/pnas.91.19.9096; IKEBE M, 1991, J BIOL CHEM, V266, P21339; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEVINE BA, 1988, BIOCHEM J, V254, P277, DOI 10.1042/bj2540277; PUTKEY JA, 1991, J BIOL CHEM, V266, P14881; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; VANDONSELAAR M, 1994, NAT STRUCT BIOL, V1, P795, DOI 10.1038/nsb1194-795; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	22	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24646	24649		10.1074/jbc.270.42.24646	http://dx.doi.org/10.1074/jbc.270.42.24646			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559573	hybrid			2022-12-27	WOS:A1995TB46500007
J	RICHARD, C; LIUZZO, JP; MOSCATELLI, D				RICHARD, C; LIUZZO, JP; MOSCATELLI, D			FIBROBLAST GROWTH FACTOR-II CAN MEDIATE CELL ATTACHMENT BY LINKING RECEPTORS AND HEPARAN-SULFATE PROTEOGLYCANS ON NEIGHBORING CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR PRODUCTION; FACTOR FGF RECEPTOR; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; PROGENITOR CELLS; LIGAND-BINDING; LEUKEMIA-CELLS; EXPRESSION; FAMILY	The myeloid 32D cell line, which grows in suspension and does not express FGF receptors or heparan sulfate proteoglycans, was transfected with the cDNA encoding FGF receptor-1 (32D-flg cells), When co cultured with glutaraldehyde-fixed Chinese hamster ovary (CHO) cells, the 32D-flg cells remained in suspension in the absence of FGF-2 but attached to the CHO monolayer in the presence of 10 ng/ml FGF-2. In contrast, 32D cells transfected with the vector alone did not attach to the CHO monolayer in the presence of FGF-2, FGF-2-dependent attachment of 32D-flg cells was prevented by inclusion of 10 mu g/ml heparin in the incubation medium and was diminished when CHO mutants in glycosaminoglycan synthesis or wild-type CHO cells treated with heparinase were used, indicating that the attachment occurred through FGF-2 interactions with heparan sulfates on the CHO cells. Attachment of 32D-flg cells to wild-type CHO cells was half-maximal at 0.4 ng/ml FGF-2 and was also observed with FGF-1 but not FGF-4, 32D-flg cells also attached to living CHO cells in a FGF-S-dependent manner, but attachment was transient at 37 degrees C. Induction of new proteins was not required for FGF-2-dependent attachment, since attachment occurred when the co cultures were incubated at 4 degrees C and when the 32D-flg cells were preincubated with cycloheximide. FGF-2-dependent attachment of 32D-flg cells was also observed with Balb/C 3T3, NIH 3T3, and bovine capillary endothelial cells. We conclude that attachment is due to FGF-2 binding simultaneously to receptors on the 32D-flg cells and heparan sulfates on the CHO monolayers; thus, the FGF-P acts as a bridge between receptor-expressing cells and heparan sulfate-bearing cells. In addition, induction of DNA synthesis in 32D-flg cells in response to FGF-2 was potentiated by the CHO-associated heparan sulfates to the same extent as by soluble heparin, indicating that this interaction has functional significance.	NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University				Moscatelli, David/0000-0002-4627-4213	NCI NIH HHS [CA42229, CA34289] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042229] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; ARMSTRONG E, 1992, CANCER RES, V52, P2004; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BENTLEY SA, 1982, BRIT J HAEMATOL, V50, P1, DOI 10.1111/j.1365-2141.1982.tb01884.x; BERGONZONI L, 1992, EUR J BIOCHEM, V210, P823, DOI 10.1111/j.1432-1033.1992.tb17485.x; BIKFALVI A, 1992, BLOOD, V80, P1905; BRUNO E, 1993, BLOOD, V82, P430, DOI 10.1182/blood.V82.2.430.bloodjournal822430; BURGER PE, 1994, BLOOD, V83, P1808; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BYERS S, 1992, DEV BIOL, V152, P411, DOI 10.1016/0012-1606(92)90149-B; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GABRILOVE JL, 1993, BLOOD, V81, P909; GABRILOVE JL, 1994, BLOOD, V83, P907; GANNOUNZAKI L, 1991, EXP CELL RES, V197, P272, DOI 10.1016/0014-4827(91)90433-U; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KATOH O, 1992, BIOCHEM BIOPH RES CO, V183, P83, DOI 10.1016/0006-291X(92)91612-T; KAUFMAN SE, 1993, ANAL BIOCHEM, V211, P261, DOI 10.1006/abio.1993.1267; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Kiefer M C, 1991, Growth Factors, V5, P115, DOI 10.3109/08977199109000276; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KODAMA H, 1994, EXP HEMATOL, V22, P979; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; LOWRY PA, 1992, BLOOD, V80, P663; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PRESTA M, 1989, J CELL PHYSIOL, V140, P68, DOI 10.1002/jcp.1041400109; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUSNATI M, 1993, J CELL PHYSIOL, V154, P152, DOI 10.1002/jcp.1041540119; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHUBERT D, 1987, J CELL BIOL, V104, P635, DOI 10.1083/jcb.104.3.635; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; SMYTH SS, 1993, BLOOD, V81, P2827; UEMURA N, 1993, BLOOD, V82, P2634; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; WILSON EL, 1991, BLOOD, V77, P954; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	57	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24188	24196		10.1074/jbc.270.41.24188	http://dx.doi.org/10.1074/jbc.270.41.24188			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592623	hybrid			2022-12-27	WOS:A1995TA21700051
J	SEUFFERLEIN, T; ROZENGURT, E				SEUFFERLEIN, T; ROZENGURT, E			SPHINGOSYLPHOSPHORYLCHOLINE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE IN SWISS 3T3 CELLS REQUIRES PROTEIN-KINASE-C AND A PERTUSSIS-TOXIN-SENSITIVE G-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; CELLULAR PROTEIN; PHORBOL ESTER; MAP KINASES; PATHWAYS; PHOSPHORYLATION; IDENTIFICATION; BOMBESIN; FIBROBLASTS	Sphingosylphosphorylcholine (SPC) is a potent mitogen for Swiss 3T3 cells, but the signaling mechanisms involved are poorly characterized, Here, we report that addition of SPC induces a rapid and transient activation of p42 mitogen-activated protein kinase (p42(MAPK)) in these cells, SPC induced p42(MAPK) activation peaked at 5 min and was undetectable after 30 min of incubation with SPC. The effect of SPC on p42(MAPK) activation was comparable to that induced by bombesin and platelet-derived growth factor. As SPC strongly induced phosphorylation of the major protein kinase C (PKC) substrate 80W/MARCKS in either intact or permeabilized cells, we examined whether PKC could be involved in SPC-induced p42(MAPK) activation. Here, we demonstrate that p42(MAPK) activation by SPC was dependent on PKC activity as shown by inhibition of PKC with the bisindolylmaleimide GF 109203X or down-regulation of PKC by prolonged treatment of Swiss 3T3 cells with phorbol esters, Activation of both PKC and p42(MAPK) by SPC was markedly inhibited by treatment with pertussis toxin, implicating a G protein(s) of the G(i)/G(o) subfamily in the action of SPC. SPC-induced rapid activation of a downstream target of p42(MAPK), p90 ribosomal S6 kinase (p90(rsh)), also required PKC and a pertussis toxin-sensitive G protein, In addition, SPC-induced mitogenesis was dependent on a G(i) protein in Swiss 3T3 cells, SPC also induced p42(MAPK) activation and DNA synthesis in secondary cultures of mouse embryo fibroblasts through a pertussis toxin-sensitive pathway, As G proteins link many cell surface receptors to effector proteins, we hypothesize, therefore, that SPC could bind to a receptor that mediates at least some of its biological effects in Swiss 3T3 cells and mouse embryo fibroblasts.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Seufferlein, Thomas TW/P-7147-2018					BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHARLESWORTH A, 1994, J BIOL CHEM, V269, P32528; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CRESPO P, 1994, J BIOL CHEM, V269, P21103; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FUJINO Y, 1968, BIOCHEM J, V109, P310, DOI 10.1042/bj1090310; FUJINO Y, 1968, BIOCHIM BIOPHYS ACTA, V152, P428, DOI 10.1016/0005-2760(68)90058-1; FUJISE A, 1994, J BIOL CHEM, V269, P31642; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KINDMAN LA, 1994, J BIOL CHEM, V269, P13088; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1983, P NATL ACAD SCI USA, V80, P7224; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEIJO L, 1994, LIPIDS, V29, P359, DOI 10.1007/BF02537190; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SOZERI O, 1992, ONCOGENE, V7, P2259; STADDON JM, 1991, J CELL BIOL, V115, P949, DOI 10.1083/jcb.115.4.949; STOFFEL W, 1980, H-S Z PHYSIOL CHEM, V361, P755, DOI 10.1515/bchm2.1980.361.1.755; STRASBERG PM, 1987, LIPID STORAGE DISORD, P601; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; YULE D, 1994, J BIOL CHEM, V268, P12353	52	77	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24334	24342		10.1074/jbc.270.41.24334	http://dx.doi.org/10.1074/jbc.270.41.24334			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592645	hybrid			2022-12-27	WOS:A1995TA21700073
J	YU, K; BAYONA, W; KALLEN, CB; HARDING, HP; RAVERA, CP; MCMAHON, G; BROWN, M; LAZAR, MA				YU, K; BAYONA, W; KALLEN, CB; HARDING, HP; RAVERA, CP; MCMAHON, G; BROWN, M; LAZAR, MA			DIFFERENTIAL ACTIVATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS BY EICOSANOIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY LIGAND; 9-CIS RETINOIC ACID; FATTY-ACIDS; ADIPOCYTE DIFFERENTIATION; NUCLEAR RECEPTOR; RESPONSE ELEMENT; GENE-EXPRESSION; HORMONE; TRANSCRIPTION; CLONING	Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that regulate gene transcription in response to peroxisome proliferators and fatty acids. PPARs also play an important role in the regulation of adipocyte differentiation. It is unclear, however, what naturally occurring compounds activate each of the PPAR subtypes. To address this issue, a screening assay was established using heterologous fusions of the bacterial tetracycline repressor to several members of the peroxisome proliferator-activated receptor (PPAR) family. This assay was employed to compare the activation of PPAR family members by known PPAR activators including peroxisome proliferators and fatty acids. Interestingly, the activation of PPARs by fatty acids was partially inhibited by the cyclooxygenase inhibitor indomethacin, which prevents prostaglandin synthesis. Indeed, prostaglandins PGA1 and 2, PGD1 and 2, and PGJ2-activated PPARs, while a number of other prostaglandins had no effect. We also screened a variety of hydroxyeicosatetraenoic acids (HETEs) for the ability to activate PPARs. 8(S)-HETE, but not other (S)-HETEs, was a strong activator of PPAR alpha. Remarkably, PPAR activation by 8(S)-HETE was stereoselective. In addition, 8(S)-HETE was able to induce differentiation of 3T3-L1 preadipocytes. These results indicate that PPARs are differentially activated by naturally occurring eicosanoids and related molecules.	UNIV PENN, SCH MED,DEPT MED,DIV ENDOCRINOL DIABET & METAB, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED,DEPT GENET, PHILADELPHIA, PA 19104 USA; SANDOZ PHARMACEUT CORP, SANDOZ RES INST,PRECLIN RES,ONCOL RES PROGRAM, E HANOVER, NJ 07936 USA; DANA FARBER CANC INST, DIV NEOPLAST DIS MECHANISMS, BOSTON, MA 02115 USA	University of Pennsylvania; University of Pennsylvania; Novartis; Sandoz; Harvard University; Dana-Farber Cancer Institute			Lazar, Mitchell A/AAF-3738-2019	Kallen, Caleb/0000-0002-4156-6719; Harding, Heather P/0000-0002-7359-7974	NIDDK NIH HHS [DK45586] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045586] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN GF, 1992, J BIOL CHEM, V267, P19513; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BRANDES R, 1987, LIFE SCI, V40, P935, DOI 10.1016/0024-3205(87)90312-2; BREGMAN MD, 1986, PROSTAGLANDINS, V26, P449; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; CHOI AMK, 1992, EXP CELL RES, V199, P85, DOI 10.1016/0014-4827(92)90464-J; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FALGUEYRET JP, 1988, BIOCHEM BIOPH RES CO, V156, P1083, DOI 10.1016/S0006-291X(88)80743-5; FUKUSHIMA M, 1982, BIOCHEM BIOPH RES CO, V105, P956, DOI 10.1016/0006-291X(82)91063-4; FURSTENBERGER G, 1991, J BIOL CHEM, V266, P15738; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOLBROOK NJ, 1992, MOL CELL BIOL, V12, P1528, DOI 10.1128/MCB.12.4.1528; HUGHES MA, 1991, BIOCHIM BIOPHYS ACTA, V1081, P347, DOI 10.1016/0005-2760(91)90292-P; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIKUCHI Y, 1992, J CANCER RES CLIN, V118, P453, DOI 10.1007/BF01629429; KIM IK, 1993, FEBS LETT, V321, P209, DOI 10.1016/0014-5793(93)80110-G; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; NATARAJAN R, 1994, HYPERTENSION, V23, pI142, DOI 10.1161/01.HYP.23.1_Suppl.I142; NEGISHI M, 1993, PROG LIPID RES, V32, P417, DOI 10.1016/0163-7827(93)90017-Q; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; PALMER CNA, 1994, J BIOL CHEM, V269, P18083; POWELL WS, 1992, J BIOL CHEM, V267, P19233; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SERHAN CN, 1991, J BIOENERG BIOMEMBR, V23, P105; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; TANG DG, 1994, ANN NY ACAD SCI, V744, P199, DOI 10.1111/j.1749-6632.1994.tb52738.x; THIERAUCH KH, 1994, J HYPERTENS, V12, P1; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	57	611	622	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23975	23983		10.1074/jbc.270.41.23975	http://dx.doi.org/10.1074/jbc.270.41.23975			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592593	hybrid			2022-12-27	WOS:A1995TA21700021
J	ZHANG, Y; FILLINGAME, RH				ZHANG, Y; FILLINGAME, RH			SUBUNITS COUPLING H+ TRANSPORT AND ATP SYNTHESIS IN THE ESCHERICHIA-COLI ATP SYNTHASE - CYS-CYS CROSS-LINKLNG OF F1 SUBUNIT-EPSILON TO THE POLAR LOOP OF F-0 SUBUNIT-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYOELECTRON MICROSCOPY; CATALYTIC SITE; COMPLEX; F1F0; DICYCLOHEXYLCARBODIIMIDE; NUCLEOTIDE; F1-ATPASE; PROTEINS	Second site suppressor mutations at position 31 of F-1 subunit epsilon recouple ATP-driven H+ translocation in the uncoupled Q42E mutant of subunit c of the Escherichia coli F1F0 ATP synthase (Zhang, Y,, Oldenburg, M,, and Fillingame, R, H, (1994) J, Biol. Chem, 269, 10221-10224), This finding suggests a functional interaction between subunit c and subunit epsilon during the coupling of H+ transport through F-0 to ATP synthesis of F-1, However, the physical proximity of the two subunits remained to be defined, In this study, Cys residues were introduced into residues in the polar loop region of subunit c surrounding Gln42 and at position 31 of subunit epsilon to see whether the subunits could be cross-linked, Disulfide bridge formation between subunit c and subunit epsilon was observed in membranes of three double mutants, i.e. cA40C/epsilon E31C, cQ42C/epsilon E31C, and cP43C/epsilon E31C, but not in wild type membranes or in membranes of the cA39C/epsilon 31C double mutant, These results indicate that the polar loop of subunit c and the region around residue 31 of subunit epsilon are physically close to each other in the F1F0 complex and support the hypothesis that these two subunits interact directly in the coupling of H+ transport to ATP synthesis, Disulfide cross-linking of the Q42C subunit c and E31C subunit epsilon leads to inhibition of ATPase coupled H+ transport, as might be expected in a model where the catalytic sites of the F-1 ATPase alternate during H+ transport-coupled ATP hydrolysis/synthesis. However, a quantitative relationship between the extent of inhibition of transport and the extent of crosslinking could not be established by the methods used here, and the possibility remains that the epsilon-C cross-linked F1F0 complex retains residual H+ transporting activity.	UNIV WISCONSIN,SCH MED,DEPT BIOMOLEC CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison			Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601	NIGMS NIH HHS [GM23105] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023105, R01GM023105] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ABRAHAMS JP, 1993, EMBO J, V12, P1775, DOI 10.1002/j.1460-2075.1993.tb05825.x; AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CAPALDI RA, 1992, J BIOENERG BIOMEMBR, V24, P435, DOI 10.1007/BF00762359; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; FILLINGAME RH, 1975, J BACTERIOL, V124, P870, DOI 10.1128/JB.124.2.870-883.1975; FILLINGAME RH, 1992, ANN NY ACAD SCI, V671, P323, DOI 10.1111/j.1749-6632.1992.tb43806.x; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1994, J BIOL CHEM, V269, P7532; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; KUKI M, 1988, J BIOL CHEM, V263, P17437; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; Miller J.H., 1972, EXPT MOL GENETICS; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER E, 1984, P NATL ACAD SCI USA, V51, P7279; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SUSS KH, 1986, FEBS LETT, V201, P63, DOI 10.1016/0014-5793(86)80571-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; ZHANG Y, 1994, J BIOL CHEM, V269, P5473; ZHANG Y, 1994, J BIOL CHEM, V269, P10221	30	102	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24609	24614		10.1074/jbc.270.41.24609	http://dx.doi.org/10.1074/jbc.270.41.24609			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592682	hybrid			2022-12-27	WOS:A1995TA21700110
J	DALY, C; REICH, NC				DALY, C; REICH, NC			CHARACTERIZATION OF SPECIFIC DNA-BINDING FACTORS ACTIVATED BY DOUBLE-STRANDED-RNA AS POSITIVE REGULATORS OF INTERFERON ALPHA/BETA-STIMULATED GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; RESPONSE ELEMENT; HUMAN-CELLS; PROMOTER; 2-AMINOPURINE; VIRUS; INHIBITION; INDUCTION; ENHANCER; LOCUS	Viral infection results in transcriptional activation of the cellular interferon alpha/beta-stimulated genes (ISGs) independent of the autocrine action of interferon alpha/beta (IFN-alpha/beta). Induction of ISG expression by virus appears to be mediated through production of viral double-stranded RNA (dsRNA). Previously, we identified two novel dsRNA-activated factors (DRAFs) that bind to the interferon-stimulated response element (ISRE), the DNA sequence that mediates transcriptional activation by IFN-alpha/beta In this report we define sequences that flank the classical ISRE to be necessary for DRAF1 binding. More significantly, it is shown that the sequences required to bind DRAF1 correlate with the ability to mediate ISG induction by virus. These results strongly suggest that DRAF1 is a positive regulator of ISG transcription. DRAF1 is shown to bind selectively to the promoters of those ISGs which are strongly induced by viral infection, again suggesting the functional significance of this factor. UV cross-linking experiments indicate that DRAF1 and DRAF2 share a common DNA-binding subunit of approximately 70 kDa which is referred to as the DRAF binding component (DRAF(B)). DRAF(B) is shown to preexist in the cytoplasm of unstimulated cells. Consistent with this observation, both DRAF1 and DRAF2 are activated in the cytoplasm prior to nuclear translocation.	SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Daly, Christopher/0000-0003-3800-8174				BAZZIGHER L, 1992, VIROLOGY, V186, P154, DOI 10.1016/0042-6822(92)90069-2; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; CANTOR CR, 1980, BIOPHYSICAL CHEM, V2, P591; COSTA RH, 1986, MOL CELL BIOL, V6, P4697, DOI 10.1128/MCB.6.12.4697; DALY C, 1993, MOL CELL BIOL, V13, P3756, DOI 10.1128/MCB.13.6.3756; DALY C, 1994, TRENDS ENDOCRIN MET, V5, P159, DOI 10.1016/1043-2760(94)90013-2; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEMAEYER E, 1988, INTERFERONS OTHER RE, P1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FUSE A, 1984, JPN J CANCER RES, V75, P379; HUANG JT, 1990, P NATL ACAD SCI USA, V87, P7115, DOI 10.1073/pnas.87.18.7115; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; MEMET S, 1991, J INTERFERON RES, V11, P131, DOI 10.1089/jir.1991.11.131; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; REICH N, 1988, J VIROL, V62, P114, DOI 10.1128/JVI.62.1.114-119.1988; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REICH NC, 1989, NUCLEIC ACIDS RES, V17, P3415, DOI 10.1093/nar/17.9.3415; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; WATHELET MG, 1987, EUR J BIOCHEM, V169, P313, DOI 10.1111/j.1432-1033.1987.tb13614.x; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; WATHELET MG, 1992, EUR J BIOCHEM, V206, P901, DOI 10.1111/j.1432-1033.1992.tb16999.x; WATHELET MG, 1988, EUR J BIOCHEM, V174, P323, DOI 10.1111/j.1432-1033.1988.tb14101.x; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WU CQ, 1994, J INTERFERON RES, V14, P357, DOI 10.1089/jir.1994.14.357	26	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23739	23746		10.1074/jbc.270.40.23739	http://dx.doi.org/10.1074/jbc.270.40.23739			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559546	hybrid			2022-12-27	WOS:A1995RY90900075
J	GARCIARAMIREZ, JJ; SANTOS, MA; REVUELTA, JL				GARCIARAMIREZ, JJ; SANTOS, MA; REVUELTA, JL			THE SACCHAROMYCES-CEREVISIAE RIB4 GENE CODES FOR 6,7-DIMETHYL-8-RIBITYLLUMAZINE SYNTHASE INVOLVED IN RIBOFLAVIN BIOSYNTHESIS - MOLECULAR CHARACTERIZATION OF THE GENE AND PURIFICATION OF THE ENCODED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION SITES; BACILLUS-SUBTILIS; TATA ELEMENTS; 2 GENES; YEAST; SEQUENCE; TRANSFORMATION; MUTAGENESIS; EF-1-ALPHA	6,7-Dimethyl-8-ribityllumazine, the immediate biosynthetic precursor of riboflavin, is synthesized by con densation of 5 amino 6-ribitylamino-2,4(1H,3H)-pyrimidinedione with 3,4-dihydroxy-2-butanone 4 phosphate. The gene coding for 6,7-dimethyl-8-ribityllumazine synthase in Saccharomyces cerevisiae (RIB4) has been cloned by functional complementation of a mutant accumulating 5-amino-6-ribitylamino-2,4( 1H, 3H) -pyrimidinedione, which can grow on riboflavin- or diacetyl-but not on 3,4-dihydroxy-2-butanone-supplemented media, Gene disruption of the chromosomal copy of RIB4 led to riboflavin auxotrophy and loss of enzyme activity, Nucleotide sequencing revealed a 169-base pair open reading frame encoding a 18.6-kDa protein. Hybridization analysis indicated that RIB4 is a single copy gene located on the left arm of chromosome XV. Overexpression of the RIB4 coding sequence in yeast cells under the control of the strong TEF1 promoter allowed ready purification of 6,7-dimethyl-8-ribityllumazine synthase to apparent homogeneity by a simple procedure. Initial structural characterization of 6,7-dimethyl-8-ribityllumazine synthase by gel filtration chromatography and both nondenaturing pore limit and SDS-polyacrylamide gel electrophoresis showed that the enzyme forms a pentamer of identical 16.8-kDa subunits. The derived amino acid sequence of RIB4 shows extensive homology to the sequences of the beta subunits of riboflavin synthase from Bacillus subtilis and other prokaryotes.	UNIV SALAMANCA, DEPT MICROBIOL & GENET, E-37007 SALAMANCA, SPAIN	University of Salamanca			Santos, Maria Angeles/H-2239-2015; Revuelta, Jose L/C-2324-2012; Revuelta, Jose Luis/ABG-1502-2020; Garcia-Ramirez, Jose J/L-2153-2014	Santos, Maria Angeles/0000-0002-1257-7611; Revuelta, Jose L/0000-0001-7838-5308; Revuelta, Jose Luis/0000-0001-7838-5308; Garcia-Ramirez, Jose J/0000-0002-8348-3727				ANDERSSON LO, 1972, FEBS LETT, V20, P199, DOI 10.1016/0014-5793(72)80793-2; BACHER A, 1980, J BIOL CHEM, V255, P632; BACHER A, 1986, J MOL BIOL, V187, P75, DOI 10.1016/0022-2836(86)90407-9; Bacher A., 1991, CHEM BIOCH FLAVOPROT, P215; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHEN W, 1985, EMBO J, V4, P3273, DOI 10.1002/j.1460-2075.1985.tb04077.x; DEMAIN AL, 1972, ANNU REV MICROBIOL, V26, P369, DOI 10.1146/annurev.mi.26.100172.002101; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FISCHER HOL, 1937, HELV CHIM ACTA, V20, P1213; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LADENSTEIN R, 1983, J BIOL CHEM, V258, P1981; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LEE CY, 1992, BIOCHEM BIOPH RES CO, V186, P690, DOI 10.1016/0006-291X(92)90802-R; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDWIG HC, 1987, J BIOL CHEM, V262, P1016; LUDWIG HC, 1984, FLAVINS FLAVOPROTEIN, P379; MIRONOV VN, 1989, DOKL AKAD NAUK SSSR+, V305, P482; NAGATA S, 1984, EMBO J, V3, P1825, DOI 10.1002/j.1460-2075.1984.tb02053.x; NAGAWA F, 1985, P NATL ACAD SCI USA, V82, P8557, DOI 10.1073/pnas.82.24.8557; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; NEUBERGER G, 1986, BIOCHEM BIOPH RES CO, V139, P1111, DOI 10.1016/S0006-291X(86)80292-3; NISHIKAWA K, 1983, BIOCHIM BIOPHYS ACTA, V748, P285, DOI 10.1016/0167-4838(83)90306-0; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; OLTMANNS O, 1972, J BACTERIOL, V110, P818, DOI 10.1128/JB.110.3.818-822.1972; OLTMANNS O, 1969, MOL GEN GENET, V105, P306, DOI 10.1007/BF00277585; OSBORNE BI, 1989, P NATL ACAD SCI USA, V86, P4097, DOI 10.1073/pnas.86.11.4097; Plaut GWE, 1971, METHODS ENZYMOL B, V18, P515; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS MA, 1995, J BIOL CHEM, V270, P437, DOI 10.1074/jbc.270.1.437; SCHIRMAIER F, 1984, EMBO J, V3, P3311, DOI 10.1002/j.1460-2075.1984.tb02295.x; SHARP PM, 1991, YEAST, V7, P657, DOI 10.1002/yea.320070702; Sherman F., 1986, METHODS YEAST GENETI; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	44	24	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23801	23807		10.1074/jbc.270.40.23801	http://dx.doi.org/10.1074/jbc.270.40.23801			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559556	hybrid			2022-12-27	WOS:A1995RY90900085
J	BONTEN, EJ; GALJART, NJ; WILLEMSEN, R; USMANY, M; VLAK, JM; DAZZO, A				BONTEN, EJ; GALJART, NJ; WILLEMSEN, R; USMANY, M; VLAK, JM; DAZZO, A			LYSOSOMAL PROTECTIVE PROTEIN CATHEPSIN-A - ROLE OF THE LINKER DOMAIN IN CATALYTIC ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPODOPTERA-FRUGIPERDA CELLS; BACULOVIRUS EXPRESSION VECTOR; BETA-GALACTOSIDASE; HUMAN-FIBROBLASTS; NEURAMINIDASE; GLYCOSYLATION; PURIFICATION; BIOSYNTHESIS; BARLEY; YEAST	Lysosomal protective protein/cathepsin A is a serine carboxypeptidase that forms a complex with beta-galactosidase and neuraminidase. The enzyme is synthesized as a 54-kDa precursor/zymogen and processed into a catalytically active 32- and 20-kDa two chain form, We have expressed in baculovirus-infected insect cells the human one chain precursor as well as the two separate subunits in order to establish the mode of catalytic activation of the zymogen and the assembly and activation of the two subunits. Infected insect cells synthesize large quantities of the exogenous proteins, which are glycosylated and secreted but not processed. Co-expression of the two subunits results in their assembly into a two-chain form of 34- and 20-kDa with negligible enzymatic activity. Limited proteolysis with trypsin of the 54-kDa precursor and the reconstituted 34- and 20-kDa form gives rise to a fully active 32- and 20-kDa product. These results enabled us to map the sites of proteolytic cleavage needed for full activation of the cathepsin A zymogen, They further indicate that the 34- and 20-kDa form is a transient processing intermediate that is converted into a mature and active enzyme by removal of a 2-kDa 'linker'' peptide from the COOH terminus of the 34-kDa subunit.	ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA; ERASMUS UNIV ROTTERDAM, DEPT CELL BIOL, 3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT CLIN GENET, 3000 DR ROTTERDAM, NETHERLANDS; AGR UNIV WAGENINGEN, DEPT VIROL, 6700 EM WAGENINGEN, NETHERLANDS	St Jude Children's Research Hospital; Erasmus University Rotterdam; Erasmus University Rotterdam; Wageningen University & Research			Galjart, Niels/D-1146-2010	Galjart, Niels/0000-0003-1964-3607	NCI NIH HHS [P30-CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOSE JA, 1991, PROTEIN EXPRES PURIF, V2, P228; BOOSE JA, 1990, PROTEIN EXPRES PURIF, V741, P111; BREDDAM K, 1986, CARLSBERG RES COMMUN, V51, P83, DOI 10.1007/BF02907561; D'Azzo A, 1995, METABOLIC MOL BASES, V2, P2825; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; DOAN NP, 1988, J BIOL CHEM, V263, P11106; ENDRIZZI JA, 1994, BIOCHEMISTRY-US, V33, P11106, DOI 10.1021/bi00203a007; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; GALJART NJ, 1991, J BIOL CHEM, V266, P14754; GALJART NJ, 1990, J BIOL CHEM, V265, P4678; GRABOWSKI GA, 1989, ENZYME, V41, P131, DOI 10.1159/000469068; HANNA WL, 1994, J IMMUNOL, V153, P4663; HASEMANN CA, 1990, P NATL ACAD SCI USA, V87, P3942, DOI 10.1073/pnas.87.10.3942; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HINK WF, 1970, NATURE, V226, P466, DOI 10.1038/226466b0; HOOGEVEEN AT, 1983, J BIOL CHEM, V258, P2143; INGLEY E, 1991, EUR J BIOCHEM, V196, P623, DOI 10.1111/j.1432-1033.1991.tb15858.x; ITOH K, 1990, BIOCHEM BIOPH RES CO, V167, P746, DOI 10.1016/0006-291X(90)92088-H; JACKMAN HL, 1992, J BIOL CHEM, V267, P2872; JACKMAN HL, 1990, J BIOL CHEM, V265, P11265; MARTIN BM, 1988, DNA-J MOLEC CELL BIO, V7, P99, DOI 10.1089/dna.1988.7.99; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; PROIA RL, 1984, J BIOL CHEM, V259, P3350; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; Sambrook J, 1989, MOL CLONING LABORATO; SMITH GE, 1978, VIROLOGY, V89, P517, DOI 10.1016/0042-6822(78)90193-9; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; SORENSEN SB, 1989, CARLSBERG RES COMMUN, V54, P193, DOI 10.1007/BF02904473; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; VANDERWILK F, 1987, J GEN VIROL, V68, P2615, DOI 10.1099/0022-1317-68-10-2615; VERHEIJEN F, 1982, BIOCHEM BIOPH RES CO, V108, P868, DOI 10.1016/0006-291X(82)90911-1; VLAK JM, 1988, J GEN VIROL, V69, P765, DOI 10.1099/0022-1317-69-4-765; WILLEMSEN R, 1986, EUR J CELL BIOL, V40, P9; ZHOU XY, 1991, EMBO J, V10, P4041, DOI 10.1002/j.1460-2075.1991.tb04980.x	35	45	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26441	26445		10.1074/jbc.270.44.26441	http://dx.doi.org/10.1074/jbc.270.44.26441			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592859	hybrid			2022-12-27	WOS:A1995TC97800066
J	CAMANI, C; KRUITHOF, EKO				CAMANI, C; KRUITHOF, EKO			THE ROLE OF THE FINGER AND GROWTH-FACTOR DOMAINS IN THE CLEARANCE OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR BY HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROLONGED CLEARANCE; HEPATIC RECEPTOR; DELETION; BINDING	The relative contribution of the finger/growth factor domains of tissue-type plasminogen activator (t-PA) and of the other t-PA domains to the clearance of t-PA by hepatocytes was investigated. A recombinant finger/growth factor construct inhibited t-PA and t-PA/plasminogen activator inhibitor type-1 degradation with an IC50 of 1800 nM, whereas a t-PA mutant lacking the finger and growth factor domains inhibited degradation with an estimated IC50 of 1200 nM. In comparison the IC50 of t-PA was found to be approximately 10 nM. Clearance of t-PA by human or rat hepatoma cells was not inhibited by high concentrations of fucose (50 mM), which suggests that the fucose on Thr-61 is not involved in clearance by these cells. These results suggest that the binding of t-PA involves several low affinity binding sites located on distinct domains of the t-PA molecule.	UNIV HOSP GENEVA,DIV ANGIOL & HEMOSTASIS,CH-1211 GENEVA,SWITZERLAND; UNIV LAUSANNE HOSP,DIV HEMATOL,LAUSANNE,SWITZERLAND	University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)			Kruithof, Egbert/AGR-4755-2022					BASSELDUBY R, 1992, J BIOL CHEM, V267, P9668; BROWNE MJ, 1988, J BIOL CHEM, V263, P1599; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CAMANI C, 1994, J BIOL CHEM, V269, P5770; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; HAJJAR KA, 1994, J CLIN INVEST, V93, P703, DOI 10.1172/JCI117023; KALYAN NK, 1988, J BIOL CHEM, V263, P3971; KRAUSE J, 1988, Fibrinolysis, V2, P133, DOI 10.1016/0268-9499(88)90026-4; LARSEN GR, 1989, BLOOD, V73, P1842, DOI 10.1182/blood.V73.7.1842.1842; LIJNEN HR, 1990, J BIOL CHEM, V265, P5677; NGUYEN G, 1992, BIOCHEM J, V287, P911, DOI 10.1042/bj2870911; NOVOKHATNY VV, 1991, J BIOL CHEM, V266, P12994; ORTH K, 1994, J BIOL CHEM, V269, P21117; SMITH BO, 1994, BIOCHEMISTRY-US, V33, P2422, DOI 10.1021/bi00175a010; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827	16	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26053	26056		10.1074/jbc.270.44.26053	http://dx.doi.org/10.1074/jbc.270.44.26053			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592802	hybrid			2022-12-27	WOS:A1995TC97800009
J	CANDI, E; MELINO, G; MEI, G; TARCSA, E; CHUNG, SI; MAREKOV, LN; STEINERT, PM				CANDI, E; MELINO, G; MEI, G; TARCSA, E; CHUNG, SI; MAREKOV, LN; STEINERT, PM			BIOCHEMICAL, STRUCTURAL, AND TRANSGLUTAMINASE SUBSTRATE PROPERTIES OF HUMAN LORICRIN, THE MAJOR EPIDERMAL CORNIFIED CELL-ENVELOPE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; EXPRESSION; DIFFERENTIATION; INVOLUCRIN; KERATIN	Loricrin is the major protein of the cornified cell envelope of terminally differentiated epidermal keratinocytes which functions as a physical barrier, In order to understand its properties and role in cornified cell envelope, we have expressed human loricrin from a full-length cDNA clone in bacteria and purified it to homogeneity. We have also isolated loricrin from newborn mouse epidermis. By circular dichroism and fluorescence spectroscopy, the in vivo mouse and bacterially expressed human loricrins possess no alpha or beta structure but have some organized structure in solution associated with their multiple tyrosines and can be reversibly denatured by either guanidine hydrochloride or temperature. The transglutaminase (TGase) 1, 2, and 3 enzymes expressed during epidermal differentiation utilized loricrin in vitro as a complete substrate, but the types of cross-linking were different. The TGase 3 reaction favored certain lysines and glutamines by forming mostly intrachain cross-links, whereas TGase 1 formed mostly large oligomeric complexes by interchain crosslinks involving different lysines and glutamines. Together, the glutamines and lysines used in vitro are almost identical to those seen in vivo. The data support a hypothesis for the essential and complementary roles of both TGase 1 and TGase 3 in cross-linking of loricrin in vivo. Failure to cross-link loricrin by TGase 1 may explain the phenotype of lamellar ichthyosis, a disease caused by mutations in the TGase 1 gene.	NIAMS,SKIN BIOL BRANCH,BETHESDA,MD 20892; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892; UNIV ROMA TOR VERGATA,IST DERMOPAT IMMACOLATA,DEPT EXPTL MED,BIOCHEM LABS,I-00167 ROME,ITALY; UNIV LAQUILA,DEPT BIOL,I-67100 LAQUILA,ITALY	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of L'Aquila								CHUNG SI, 1970, J BIOL CHEM, V245, P681; DALE BA, 1983, J CELL BIOL, V101, P1257; DESMIT MH, 1994, J MOL BIOL, V244, P144, DOI 10.1006/jmbi.1994.1714; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FRIC L, 1971, COLLECT CZECH CHEM C, V36, P2012; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GROENEN PJTA, 1994, EUR J BIOCHEM, V220, P795, DOI 10.1111/j.1432-1033.1994.tb18681.x; HIBINO Y, 1988, AGR BIOL CHEM TOKYO, V52, P329; HOHL D, 1991, J BIOL CHEM, V266, P6626; HOHL D, 1993, ARCH DERMATOL, V129, P626; HUBER M, 1995, SCIENCE, V276, P525; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; KIM SY, 1994, J BIOL CHEM, V269, P27979; LAVRIJSEN S, 1995, ARCH DERMATOL, V131, P363; MACK JW, 1988, BIOCHEMISTRY-US, V27, P5418, DOI 10.1021/bi00415a006; MATOLTSY A. GEDEON, 1965, P291; MATOLTSY AG, 1970, J CELL BIOL, V47, P593, DOI 10.1083/jcb.47.3.593; MEHREL T, 1990, CELL, V60, P1103; MICHEL S, 1992, J INVEST DERMATOL, V98, P364, DOI 10.1111/1523-1747.ep12499806; MILHAUD PG, 1980, BIOCHIM BIOPHYS ACTA, V630, P476, DOI 10.1016/0304-4165(80)90002-1; PARAMESWARAN KN, 1990, P NATL ACAD SCI USA, V87, P8472, DOI 10.1073/pnas.87.21.8472; PARRY DAD, 1995, INTERMEDIATE FILAMEN; Reichert Uwe, 1993, P107; ROTHNAGEL JA, 1994, GENOMICS, V23, P450, DOI 10.1006/geno.1994.1522; RUSSELL LJ, 1994, AM J HUM GENET, V55, P1146; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; SHVETS YP, 1990, MOL BIOL, V24, P663; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; Steinert P M, 1995, Cell Death Differ, V2, P33; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; STEINERT PM, 1979, BIOCHEMISTRY-US, V18, P5664, DOI 10.1021/bi00592a022; STEINERT PM, 1991, INT J BIOL MACROMOL, V13, P130, DOI 10.1016/0141-8130(91)90037-U; STEINERT PM, 1994, J INVEST DERMATOL S, V103, pA19; STEVEN AC, 1994, J CELL SCI, V107, P693; STEVEN AC, 1990, J STRUCT BIOL, V104, P150, DOI 10.1016/1047-8477(90)90071-J; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; WALSH F, 1963, NATURE, V198, P188; WILLIAMS ML, 1985, ARCH DERMATOL, V121, P477, DOI 10.1001/archderm.121.4.477; YONEDA K, 1992, J BIOL CHEM, V267, P18060	42	143	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26382	26390		10.1074/jbc.270.44.26382	http://dx.doi.org/10.1074/jbc.270.44.26382			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592852	hybrid			2022-12-27	WOS:A1995TC97800059
J	MCGEE, MP; TEUSCHLER, H; PARTHASARATHY, N; WAGNER, WD				MCGEE, MP; TEUSCHLER, H; PARTHASARATHY, N; WAGNER, WD			SPECIFIC REGULATION OF PROCOAGULANT ACTIVITY ON MONOCYTES - INTRINSIC PATHWAY INHIBITION BY CHONDROITIN 4,6-DISULFATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN COFACTOR-II; FACTOR-X ACTIVATION; TISSUE FACTOR; SULFATE PROTEOGLYCAN; BLOOD-COAGULATION; MACROPHAGES; GLYCOSAMINOGLYCAN; DIFFERENTIATION; BIOSYNTHESIS; CANCER	Hypercoagulability of blood, monocytic infiltration, and changes in pericellular and extracellular matrix glycosaminoglycans (GAGs)(1) are observed in atherosclerosis, inflammation, and neoplasia, In the present studies, monocyte procoagulants and different GAGs including chondroitin sulfate (CS) A, CSB, CSC, CSD, CSE, and heparan sulfate, were tested either in clotting assays with whole plasma or in chromogenic assays with purified coagulation proteases, Procoagulant activity in plasma was inhibited by three of the seven GAGs, including heparan sulfate, CSE, and CSB, In contrast, activity of purified coagulation protease was inhibited only by CSE, and the inhibition was observed with intrinsic (factor VIIIa/IXa) but not extrinsic (tissue factor/factor VII) components, Reciprocal titration experiments with enzyme and substrate and Scatchard type analyses were consistent with concentration dependent inhibitory interactions between CSE and sites on both factor VIIIa and IXa. On purified phospholipids, CSE concentration resulting in half-maximal inhibition (K-i) was 5 ng/ml for interaction with factor IXa and > 500 ng/ml for interaction with factor VIIIa, The K-i values were lower for reactions on purified lipid than for reactions on monocyte surfaces and for reactions on resting than on endotoxin-stimulated monocytes, Experiments with CSE oligosaccharides of defined size indicated that the smallest CSE fragment capable of inhibitory activity was composed of 12-18 monosaccharide units, Collectively, these results indicate that factor X-activating reactions are inhibited by GAGs expressed on monocyte membranes, Inhibition is specific with respect to the structure of both the GAG and the activating protease, Lack of inhibition by added CSA, CSB, and CSC in contrast to CSE strongly suggests a direct role of 4,6-di-O-sulfated N-acetylgalactosamine GAG structures in the inhibition of intrinsic pathway protease, These findings also suggest potential pharmacologic use of CSE as specific anticoagulant in the management of prothrombotic states mediated by intrinsic pathway coagulation reactions.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT COMPARAT MED, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	MCGEE, MP (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MED, RHEUMATOL SECT, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042812, R01HL025161] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42812, HL-25161] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1989, J BIOL CHEM, V264, P20012; BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BARROW RT, 1994, J BIOL CHEM, V269, P26789; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; BRIGG R, 1961, THROMB DIATH HAEMO, V6, P1; DIETRICH CP, 1993, LAB INVEST, V68, P439; DOUGLAS KT, 1984, CHEM ENZYME ACTION, P114; EDWARDS IJ, 1995, ATHERIOSCLEROSIS; GALLAGHER JT, 1992, ADV EXP MED BIOL, V313, P49; GALLAGHER JT, 1985, BIOCHEM J, V230, P663; KAWAI Y, 1966, J BIOCHEM-TOKYO, V60, P317, DOI 10.1093/oxfordjournals.jbchem.a128438; KOLSET SO, 1983, BIOCHEM J, V210, P661, DOI 10.1042/bj2100661; LI CY, 1973, J HISTOCHEM CYTOCHEM, V21, P1; LYON M, 1994, BIOCHEM SOC T, V22, P365, DOI 10.1042/bst0220365; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MALAR RA, 1982, BLOOD, V60, P1353; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MCGEE MP, 1991, J BIOL CHEM, V266, P8079; MCGEE MP, 1994, J EXP MED, V179, P1847, DOI 10.1084/jem.179.6.1847; MCGEE MP, 1992, J BIOL CHEM, V267, P24333; MCGEE MP, 1978, J RETICULOENDOTH SOC, V24, P253; MCGEE MP, 1990, J EXP MED, V176, P27; MCQUILLAN DJ, 1989, J BIOL CHEM, V264, P13245; OWENS RT, 1992, J LEUKOCYTE BIOL, V51, P626, DOI 10.1002/jlb.51.6.626; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; PRATT CW, 1989, ANN NY ACAD SCI, V556, P104; RICKLES FR, 1988, SEMIN THROMB HEMOST, V14, P88, DOI 10.1055/s-2007-1002760; ROSS R, 1993, ATHEROSCLER REV, V25, P195; ROTHBERGER H, 1984, J CLIN INVEST, V73, P1524, DOI 10.1172/JCI111358; SCULLY MF, 1986, BIOCHEM BIOPH RES CO, V137, P15, DOI 10.1016/0006-291X(86)91169-1; SHAKLEE PN, 1986, BIOCHEM J, V235, P225, DOI 10.1042/bj2350225; SMITH RL, 1973, J BIOL CHEM, V248, P2418; UHLINHANSEN L, 1989, J BIOL CHEM, V264, P14916; UHLINHANSEN L, 1993, BLOOD, V82, P2880; WAGNER WD, 1978, LAB INVEST, V39, P322; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; ZIMMERMAN TS, 1988, SEMIN HEMATOL, V25, P25	39	27	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26109	26115		10.1074/jbc.270.44.26109	http://dx.doi.org/10.1074/jbc.270.44.26109			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592813	hybrid			2022-12-27	WOS:A1995TC97800020
J	WAKABAYASHI, S; IKEDA, T; NOEL, J; SCHMITT, B; ORLOWSKI, J; POUYSSEGUR, J; SHIGEKAWA, M				WAKABAYASHI, S; IKEDA, T; NOEL, J; SCHMITT, B; ORLOWSKI, J; POUYSSEGUR, J; SHIGEKAWA, M			CYTOPLASMIC DOMAIN OF THE UBIQUITOUS NA+/H+ EXCHANGER NHE1 CAN CONFER CA2+ RESPONSIVENESS TO THE APICAL ISOFORM NHE3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; RAT NA/H EXCHANGER; GROWTH-FACTORS; BRUSH-BORDER; MOLECULAR-CLONING; HUMAN-FIBROBLASTS; INTRACELLULAR PH; H+ EXCHANGER; ACTIVATION; CA-2+	The Na+/H+ exchanger isoforms NHE1 and NHE3 are regulated differently by various stimuli, Calcium has been recognized as one of the major second messengers in such exchanger regulation We previously proposed that Ca2+-induced activation of NHE1 occurs via displacement of its autoinhibitory domain from the H+ modifier site due to direct binding of Ca2+/calmodulin. To further validate this hypothesis, the functional role of the cytoplasmic domain was studied in both wild-type and chimeric exchangers, i.e. NHE1, NHE3, NHE1 with the cytoplasmic domain of NHE3 (NIN3), and NHE3 with the cytoplasmic domain of NHE1 (N3N1). After expression in exchanger-deficient fibroblasts (PS120), early response (< 80 s) to external stimuli was assessed as 5-(N-ethyl-N-isopropyl)amiloride-sensitive Na-22(+) uptake. Among stimuli tested (ionomycin, alpha-thrombin, phorbol ester, hyperosmotic stress, and platelet-derived growth factor) that are all known to activate NHE1, only ionomycin and thrombin induced a significant intracellular Ca2+ mobilization and early activation of Na-22(+) uptake, implying that Ca2+ is a main regulator of NHE1 in the early phase of the agonist response. However, all the stimuli did not activate NHE3 or N1N3. In contrast, a significant stimulation of Na-22(+) uptake in response to ionomycin and thrombin was observed in N3N1, accompanied by an alkaline shift of pH, sensitivity (similar to 0.2 pH units). Deletion of the cytoplasmic calmodulin-binding domain within N3N1 resulted in a constitutive alkaline shift of pH(i) sensitivity and abolished the activation by ionomycin and thrombin. Together, these data reinforce our concept of Ca2+-induced activation of NHE1. Furthermore, they provide evidence for a functional interaction of the autoinhibitory domain of NHE1 with the H+-modifier site of a different isoform, NHE3.	UNIV NICE,CTR BIOCHIM,CNRS,F-06108 NICE 2,FRANCE; MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; McGill University	WAKABAYASHI, S (corresponding author), NATL CARDIOVASC CTR,RES INST,DEPT MOLEC PHYSIOL,SUITA,OSAKA 565,JAPAN.							ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; BOOKSTEIN C, 1994, J BIOL CHEM, V269, P29704; BORGESE F, 1994, P NATL ACAD SCI USA, V91, P5431, DOI 10.1073/pnas.91.12.5431; CHAKRABORTY M, 1994, P NATL ACAD SCI USA, V91, P2115, DOI 10.1073/pnas.91.6.2115; CHENG WY, 1980, SCIENCE, V207, P19; COHEN ME, 1990, P NATL ACAD SCI USA, V87, P8990, DOI 10.1073/pnas.87.22.8990; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; EMMER E, 1989, J MEMBRANE BIOL, V108, P207, DOI 10.1007/BF01871735; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; GRINSTEIN S, 1985, J GEN PHYSIOL, V85, P765, DOI 10.1085/jgp.85.5.765; GRINSTEIN S, 1987, J GEN PHYSIOL, V89, P185, DOI 10.1085/jgp.89.2.185; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUPTA A, 1994, AM J PHYSIOL, V266, pC1083, DOI 10.1152/ajpcell.1994.266.4.C1083; HENDEY B, 1989, J BIOL CHEM, V264, P19540; KAPUS A, 1994, J BIOL CHEM, V259, P23544; KIMURA M, 1990, J BIOL CHEM, V265, P21068; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; MA YH, 1994, J BIOL CHEM, V269, P30734; MITSUHASHI T, 1988, J BIOL CHEM, V263, P8790; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V22, P16369; PARIS S, 1984, J BIOL CHEM, V259, P989; POCH E, 1993, BIOCHEM J, V290, P617, DOI 10.1042/bj2900617; POUYSSEGUR J, 1985, TRENDS BIOCHEM SCI, V10, P453, DOI 10.1016/0968-0004(85)90030-1; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Rasmussen H, 1990, Curr Top Cell Regul, V31, P1; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SOLEIMANI M, 1994, J BIOL CHEM, V269, P15613; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; TSE CM, 1993, P NATL ACAD SCI USA, P9110; VICENTINI LM, 1985, P NATL ACAD SCI USA, V82, P8053, DOI 10.1073/pnas.82.23.8053; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WANG Z, 1993, J BIOL CHEM, V268, P11925; WEINMAN EJ, 1988, J MEMBRANE BIOL, V103, P237, DOI 10.1007/BF01993983	47	46	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26460	26465		10.1074/jbc.270.44.26460	http://dx.doi.org/10.1074/jbc.270.44.26460			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592862	hybrid			2022-12-27	WOS:A1995TC97800069
J	DENNIS, MS; HERZKA, A; LAZARUS, RA				DENNIS, MS; HERZKA, A; LAZARUS, RA			POTENT AND SELECTIVE KUNITZ DOMAIN INHIBITORS OF PLASMA KALLIKREIN DESIGNED BY PHAGE DISPLAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; BETA-PROTEIN PRECURSOR; RAY CRYSTAL-STRUCTURE; ALZHEIMERS-DISEASE; APROTININ; PROTEASES; CONTACT; SYSTEM; COAGULATION; SPECIFICITY	Phage displaying APPI Kunitz domain Libraries have been used to design potent and selective active site inhibitors of human plasma kallikrein, a serine protease that plays an important role in both inflammation and coagulation. Selected clones hom two Kunitz domain libraries randomized at or near the binding loop (positions 11-13, 15-19, and 34) were sequenced following five rounds of selection on immobilized plasma kallikrein. Invariant preferences for Arg at position 15 and His at position 18 were found, whereas His, Ala, Ala, and Pro were highly preferred residues at positions 13, 16, 17, and 19, respectively. At position 11 Pro, Asp, and Glu were favored, while hydrophobic residues were preferred at position 34. Selected variants, purified by trypsin affinity chromatography and reverse phase high performance liquid chromatography, potently inhibited plasma kallikrein, with apparent equilibrium dissociation constants (K-i*)) ranging from similar to 75 to 300 pM. From sequence and activity data, consensus mutants were constructed by site directed mutagenesis. One such mutant, KALI-DY, which differed from APPI at 6 key residues (T11D, P13H, M17A, I18H, S19P, and F34Y), inhibited plasma kallikrein with a K-i* = 15 +/- 14 pM, representing an increase in binding affinity of more than 10,000-fold compared to APPI. Similar to APPI, the variants also inhibited Factor Ma with high affinity, with K-i* values ranging from similar to 0.3 to 15 nM; KALI-DY inhibited Factor Ma with a K-i* = 8.2 +/- 3.5 nM. KALI-DY did not inhibit plasmin, thrombin, Factor Xa, Factor XIIa, activated protein C, or tissue factor-Factor VIIa. Consistent with the protease specificity profile, KALI-DY did not prolong the clotting time in a prothrombin time assay, but did prolong the clotting time in an activated partial thromboplastin time assay >3.5-fold at 1 mu M.	GENENTECH INC, DEPT PROT ENGN, San Francisco, CA 94080 USA	Roche Holding; Genentech								BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BIETH J, 1974, PROTEINASE INHIBITOR, P463; BODE W, 1984, EUR J BIOCHEM, V144, P185, DOI 10.1111/j.1432-1033.1984.tb08447.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BODE W, 1986, MOL CELLULAR BASIS D, P213; BONE RC, 1992, ARCH INTERN MED, V152, P1381, DOI 10.1001/archinte.152.7.1381; COLMAN RW, 1986, CRC CR REV ONCOL-HEM, V5, P57, DOI 10.1016/S1040-8428(86)80053-1; COLMAN RW, 1989, NEW ENGL J MED, V320, P1207, DOI 10.1056/NEJM198905043201809; CREIGHTON TE, 1987, COLD SPRING HARB SYM, V52, P511, DOI 10.1101/SQB.1987.052.01.058; DENNIS MS, 1994, J BIOL CHEM, V269, P22129; DENNIS MS, 1994, J BIOL CHEM, V269, P22137; ESPANA F, 1991, THROMB HAEMOSTASIS, V65, P46; FRITZ H, 1983, ARZNEIMITTELFORSCH, V33-1, P479; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; KIDO H, 1990, BIOCHEM BIOPH RES CO, V167, P716, DOI 10.1016/0006-291X(90)92084-D; KITAGUCHI N, 1990, BIOCHIM BIOPHYS ACTA, V1038, P105, DOI 10.1016/0167-4838(90)90017-A; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; Lowman HB., 1991, METHODS COMPANION ME, V3, P205; MACGILCHRIST A, 1994, CLIN SCI, V87, P329, DOI 10.1042/cs0870329; NORRIS K, 1989, Patent No. 339942; OLSON ST, 1993, BIOCHEMISTRY-US, V32, P12136, DOI 10.1021/bi00096a026; PERONA JJ, 1995, PROTEIN SCI, V4, P337; PETERSEN LC, 1994, FEBS LETT, V338, P53, DOI 10.1016/0014-5793(94)80115-0; ROBERTS BL, 1992, P NATL ACAD SCI USA, V89, P2429, DOI 10.1073/pnas.89.6.2429; SANGER F, 1977, P NATL ACAD SCI USA, V74, P463; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCOTT CF, 1987, BLOOD, V69, P1431; SCOTT CF, 1986, J CLIN INVEST, V77, P631, DOI 10.1172/JCI112346; SEYMOUR JL, 1994, BIOCHEMISTRY-US, V33, P3949, DOI 10.1021/bi00179a022; SIEBECK M, 1993, J TRAUMA, V34, P193, DOI 10.1097/00005373-199302000-00002; ULMER JS, 1995, FEBS LETT, V365, P159, DOI 10.1016/0014-5793(95)00466-M; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WACHTFOGEL YT, 1993, THROMB RES, V72, P1, DOI 10.1016/0049-3848(93)90168-N; WACHTFOGEL YT, 1993, J THORAC CARDIOV SUR, V106, P1; WAGNER SL, 1992, BIOCHEM BIOPH RES CO, V186, P1138, DOI 10.1016/0006-291X(92)90865-I; WESTABY S, 1993, ANN THORAC SURG, V55, P1033, DOI 10.1016/0003-4975(93)90149-C; Williams J W, 1979, Methods Enzymol, V63, P437	41	54	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25411	25417		10.1074/jbc.270.43.25411	http://dx.doi.org/10.1074/jbc.270.43.25411			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592708	hybrid			2022-12-27	WOS:A1995TB46600024
J	GANAPATHY, ME; BRANDSCH, M; PRASAD, PD; GANAPATHY, V; LEIBACH, FH				GANAPATHY, ME; BRANDSCH, M; PRASAD, PD; GANAPATHY, V; LEIBACH, FH			DIFFERENTIAL RECOGNITION OF BETA-LACTAM ANTIBIOTICS BY INTESTINAL AND RENAL PEPTIDE TRANSPORTERS, PEPT-1 AND PEPT-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; CELL-LINE; SYSTEM; OLIGOPEPTIDES	This study was initiated to determine if there are differences in the recognition of beta-lactam antibiotics as substrates between intestinal and renal peptide transporters, PEPT 1 and PEPT 2. Reverse transcription coupled polymerase chain reaction and/or Northern blot analysis have established that the human intestinal cell line Caco-2 expresses PEPT 1 but not PEPT 2, whereas the rat proximal tubule cell Line SEPT expresses PEPT 2 but not PEPT 1. Detailed kinetic analysis has provided unequivocal evidence for participation of PEPT 2 in SEPT cells in the transport of the dipeptide glycylsarcosine and the aminocephalosporin cephalexin. The substrate recognition pattern of PEPT 1 and PEPT 2 was studied with cefadroxil (a cephalosporin) and cyclacillin (a penicillin) as model substrates for the peptide transporters constitutively expressed in Caco-2 cells (PEPT 1) and SKPT cells (PEPT 2), Cyclacillin was 9-fold more potent than cefadroxil in competing with glycylsarcosine for uptake via PEPT 1. In contrast, cefadroxil was 13-fold more potent than cyclacillin in competing with the dipeptide for uptake via PEPT 2. The substrate recognition pattern of PEPT 1 and PEPT 2 was also investigated using cloned human peptide transporters functionally expressed in HeLa cells. Expression of PEPT 1 or PEPT 2 in HeLa cells was found to induce H+-coupled cephalexin uptake in these cells. As was the case with Caco-2 cells and SKPT cells, the uptake of glycylsarcosine induced in HeLa cells by PEPT 1 cDNA and PEPT 2 cDNA was inhibitable by cyclacillin and cefadroxil. Again, the PEPT 1 cDNA-induced dipeptide uptake was inhibited more potently by cyclacillin than by cefadroxil, and the PEPT 2 cDNA-induced dipeptide uptake was inhibited more potently by cefadroxil than by cyclacillin. It is concluded that there are marked differences between the intestinal and renal peptide transporters in the recognition of beta-lactam antibiotics as substrates.	MED COLL GEORGIA, DEPT BIOCHEM, AUGUSTA, GA 30912 USA; MED COLL GEORGIA, DEPT MOLEC BIOL, AUGUSTA, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	GANAPATHY, ME (corresponding author), MED COLL GEORGIA, DEPT MED, INFECT DIS SECT, AUGUSTA, GA 30912 USA.				NIDDK NIH HHS [DK 28389] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028389] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED K, 1962, CAN J BIOCHEM PHYS, V40, P1101; AMIDON GL, 1994, ANNU REV PHARMACOL, V34, P321; BRANDSCH M, 1995, AM J PHYSIOL-RENAL, V268, pF391, DOI 10.1152/ajprenal.1995.268.3.F391; BRANDSCH M, 1994, BIOCHEM J, V299, P253, DOI 10.1042/bj2990253; BRANDSCH M, 1995, IN PRESS FASEB J; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHRISTENSEN HN, 1989, METHOD ENZYMOL, V173, P576; DANIEL H, 1993, J CLIN INVEST, V92, P2215, DOI 10.1172/JCI116824; DANTZIG AH, 1994, SCIENCE, V264, P430, DOI 10.1126/science.8153632; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GANAPATHY V, 1986, AM J PHYSIOL, V251, pF945, DOI 10.1152/ajprenal.1986.251.6.F945; Ganapathy Vadivel, 1994, P1773; INUI KI, 1984, BIOCHIM BIOPHYS ACTA, V769, P449, DOI 10.1016/0005-2736(84)90329-8; KRAMER W, 1990, BIOCHIM BIOPHYS ACTA, V1027, P25, DOI 10.1016/0005-2736(90)90043-N; KULANTHAIVEL P, 1991, BIOCHEM J, V277, P53, DOI 10.1042/bj2770053; LIU W, 1995, BBA-BIOMEMBRANES, V1235, P461, DOI 10.1016/0005-2736(95)80036-F; Matthews DM, 1991, PROTEIN ABSORPTION D; OKANO T, 1986, J BIOL CHEM, V261, P14130; RAMAMOORTHY S, 1995, IN PRESS BIOCH BIOPH; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; SAITO H, 1993, AM J PHYSIOL, V265, pG289, DOI 10.1152/ajpgi.1993.265.2.G289; SCRIVER CR, 1964, NATURE, V202, P92, DOI 10.1038/202092a0; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; TSUJI A, 1987, ADV BIOSCI, V65, P125	25	236	245	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25672	25677		10.1074/jbc.270.43.25672	http://dx.doi.org/10.1074/jbc.270.43.25672			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592745	hybrid			2022-12-27	WOS:A1995TB46600062
J	KAKUMA, T; NISHIDA, J; TSUZUKI, T; SEKIGUCHI, M				KAKUMA, T; NISHIDA, J; TSUZUKI, T; SEKIGUCHI, M			MOUSE MTH1 PROTEIN WITH 8-OXO-7,8-DIHYDRO-2'-DEOXYGUANOSINE 5'-TRIPHOSPHATASE ACTIVITY THAT PREVENTS TRANSVERSION MUTATION - CDNA CLONING AND TISSUE DISTRIBUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA-SYNTHESIS; 8-HYDROXYGUANINE 7,8-DIHYDRO-8-OXOGUANINE; MUTAGENIC SUBSTRATE; NUCLEOTIDE-SEQUENCE; HUMAN-CELLS; MUTT; REPAIR; ENZYME; HYDROLYZES	8-Oxo-7,8-dihydro-2'-deoxyguanosine 5'-triphosphate (8-oxo-dGTP) is formed in the nucleotide pool of a cell during normal cellular metabolism, and when it is incorporated into DNA causes mutation. Organisms possess 8-oxo-dGTPase, an enzyme that specifically degrades 8-oxo-dGTP to 8-oxo-dGMP. We isolated cDNA for mouse 8-oxo-dGTPase, using as a probe human MTH1 (Escherichia coli mutT homolog) cDNA. The nucleotide sequence of the cDNA revealed that the mouse MTH1 protein (molecular weight of 17,896) comprises 156 amino acid residues. When the cDNA for mouse 8-oxo-dGTPase was expressed in E. coli mutT(-) mutant cells devoid of their own 8-oxo-dGTPase activity, an 18-kDa protein, which is cross-reactive with an anti-human MTH1 antibody, was formed. In such cells, the level of spontaneous mutation frequency that was elevated reverted to normal. High levels of 8-oxo-dGTPase activity were found in liver, thymus, and large intestine, whereas all other organs examined contained smaller amounts of the enzyme. In embryonic stem cells, an exceedingly high level of the enzyme was present.	KYUSHU UNIV,MED INST BIOREGULAT,DEPT BIOCHEM,FUKUOKA 81282,JAPAN	Kyushu University								AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; ARNHEIM N, 1992, MUTAT RES, V275, P157, DOI 10.1016/0921-8734(92)90020-P; BESSHO T, 1992, BIOCHEM BIOPH RES CO, V188, P372, DOI 10.1016/0006-291X(92)92395-E; BESSHO T, 1993, J BIOL CHEM, V268, P19416; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; FINANCSEK I, 1982, GENE, V18, P115; FURUICHI M, 1994, GENOMICS, V24, P485, DOI 10.1006/geno.1994.1657; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HAYAKAWA H, 1995, BIOCHEMISTRY-US, V34, P89, DOI 10.1021/bi00001a011; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; LUEDERS KK, 1980, P NATL ACAD SCI-BIOL, V77, P3571, DOI 10.1073/pnas.77.6.3571; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MATHEWS CK, 1988, TRENDS BIOCHEM SCI, V13, P394, DOI 10.1016/0968-0004(88)90182-X; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; STURDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAJIRI T, 1994, MUTAT RES, V336, P245; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; VIDMAR JJ, 1993, CAN J MICROBIOL, V39, P892, DOI 10.1139/m93-133; WEBER DJ, 1993, BIOCHEMISTRY-US, V32, P13081, DOI 10.1021/bi00211a018; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YAMAMOTO F, 1992, JPN J CANCER RES, V83, P351, DOI 10.1111/j.1349-7006.1992.tb00114.x; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274; YEH YC, 1991, J BIOL CHEM, V266, P6480	39	91	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25942	25948		10.1074/jbc.270.43.25942	http://dx.doi.org/10.1074/jbc.270.43.25942			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592783	hybrid			2022-12-27	WOS:A1995TB46600100
J	BERGAD, PL; SHIH, HM; TOWLE, HC; SCHWARZENBERG, SJ; BERRY, SA				BERGAD, PL; SHIH, HM; TOWLE, HC; SCHWARZENBERG, SJ; BERRY, SA			GROWTH-HORMONE INDUCTION OF HEPATIC SERINE-PROTEASE INHIBITOR-2.1 TRANSCRIPTION IS MEDIATED BY A STAT5-RELATED FACTOR-BINDING SYNERGISTICALLY TO 2 GAMMA-ACTIVATED SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; GENE	A growth hormone (GH)-inducible nuclear factor (GHINF) from rat liver has been purified to near homogeneity. On SDS-polyacrylamide gel electrophoresis and UV-cross-linking, a major band of mass similar to 93 kDa and a minor band of similar to 70 kDa are detected in the purified fraction. DNase I footprinting using purified GHINF yields a protected region of -149/-115 on the rat serine protease inhibitor 2.1 (Spi 2.1) promoter encompassed within the growth hormone response element (GHRE). Mutational analysis demonstrated that GHINF binds synergistically to two gamma-interferon activated sites (GAS) within the GHRE, with the 3' element being the pivotal binding domain. Functional assays show that both GAS elements are necessary for full GH response. GHINF has no immunoreactivity with either a C-terminal Stat1 antibody or an N-terminal Stat3 antibody, while cross-reacting with a C-terminal Stat5 monoclonal antibody. GHINF will bind to two GAS elements from the Stat5 binding region of the beta-casein gene. These studies indicate that GHINF is a Stat5-related factor binding synergistically to two GAS elements to activate Spi 2.1 transcription.	UNIV MINNESOTA,DEPT PEDIAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT PEDIAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,INST HUMAN GENET,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Shih, Hsiu-Ming/S-7023-2018	Berry, Susan/0000-0001-7970-688X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032817] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32817] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AUSUBEL FM, 1994, CURRENT PROTOLS MOL; Ausubel FM, 1994, CURRENT PROTOCOLS MO; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BARAHMANDPOUR F, 1995, FEBS LETT, V360, P29, DOI 10.1016/0014-5793(95)00072-H; BERRY SA, 1984, ENDOCRINOLOGY, V115, P1164, DOI 10.1210/endo-115-3-1164; BERRY SA, 1986, ENDOCRINOLOGY, V119, P2290, DOI 10.1210/endo-119-5-2290; BERRY SA, 1994, MOL ENDOCRINOL, V8, P1714, DOI 10.1210/me.8.12.1714; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; GADDYKURTEN D, 1991, MOL ENDOCRINOL, V5, P1280, DOI 10.1210/mend-5-9-1280; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KLEINBERG DL, 1990, ENDOCRINOLOGY, V126, P3274, DOI 10.1210/endo-126-6-3274; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NIIMI S, 1991, ENDOCRINOLOGY, V129, P2734, DOI 10.1210/endo-129-5-2734; PAGES G, 1990, GENE, V94, P273, DOI 10.1016/0378-1119(90)90398-B; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; RAZ R, 1994, J BIOL CHEM, V269, P24391; SCHWARZENBERG SJ, 1992, AM J PHYSIOL, V265, pC1144; SHIH HM, 1995, BIOTECHNIQUES, V18, P813; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SLIVA D, 1994, J BIOL CHEM, V269, P26208; STANDKE GJR, 1994, MOL ENDOCRINOL, V8, P469, DOI 10.1210/me.8.4.469; THOMAS MJ, 1995, MOL CELL BIOL, V15, P12, DOI 10.1128/MCB.15.1.12; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WARREN WC, 1993, MOL CELL ENDOCRINOL, V98, P27, DOI 10.1016/0303-7207(93)90232-9; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; YOON JB, 1990, J BIOL CHEM, V265, P19947	36	93	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24903	24910		10.1074/jbc.270.42.24903	http://dx.doi.org/10.1074/jbc.270.42.24903			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559615	hybrid			2022-12-27	WOS:A1995TB46500049
J	DAVIES, AA; FRIEDBERG, EC; TOMKINSON, AE; WOOD, RD; WEST, SC				DAVIES, AA; FRIEDBERG, EC; TOMKINSON, AE; WOOD, RD; WEST, SC			ROLE OF THE RAD1 AND RAD10 PROTEINS IN NUCLEOTIDE EXCISION-REPAIR AND RECOMBINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							YEAST DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; MITOTIC RECOMBINATION; GENETIC-CONTROL; RESOLUTION	In Saccharomyces cerevisiae, the RAD1 and RADIO genes are involved in DNA nucleotide excision repair (NER) and in a pathway of mitotic recombination that occurs between direct repeat DNA sequences. In this paper, we show that purified Rad1 and Rad10 interact with a synthetic bubble structure and incise the DNA at the 5'-side of the centrally unpaired region. When Rad1-Rad10 and purified XPG protein (the human homolog of yeast Rad2 protein) were co-incubated with the DNA substrate, we observed incisions at both ends of the bubble. This reaction mimics the dual incision step in nucleotide excision repair in vivo. In addition, the recent suggestion that Rad1 can act to resolve Holliday junctions (Habraken, Y., Sung, P., Prakash, L., and Prakash, S. (1994) Nature 371, 531-534), explaining the recombination defect observed in rad1 mutants, has been further investigated. However, using proteins purified in two different laboratories we were unable to show any interaction between Rad1 and synthetic Holliday junctions. The role that Rad1-Rad10 plays in recombination is likely to resemble its activity in NER by acting upon partially unpaired DNA intermediates such as those formed by recombination mechanisms involving single-strand DNA annealing.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; UNIV TEXAS,SW MED CTR,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,INST BIOTECHNOL,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Health San Antonio			Wood, Richard D/M-6319-2018	Wood, Richard D/0000-0002-9495-6892; West, Stephen/0000-0001-8848-9418				BAILIS AM, 1992, MOL CELL BIOL, V12, P4988, DOI 10.1128/MCB.12.11.4988; BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; FISHMANLOBELL J, 1992, SCIENCE, V258, P480, DOI 10.1126/science.1411547; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; FRIEDBERG EC, 1995, DNA REPAIR; HABRAKEN Y, 1994, NATURE, V371, P531, DOI 10.1038/371531a0; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; KLEIN HL, 1988, GENETICS, V120, P367; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; SAFFRAN WA, 1994, NUCLEIC ACIDS RES, V22, P2823, DOI 10.1093/nar/22.14.2823; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SCHIESTL RH, 1990, MOL CELL BIOL, V10, P2485, DOI 10.1128/MCB.10.6.2485; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; THOMAS BJ, 1989, GENETICS, V123, P725; TOMKINSON AE, 1994, BIOCHEMISTRY-US, V33, P5305, DOI 10.1021/bi00183a038; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; WEST SC, 1995, NATURE, V373, P27, DOI 10.1038/373027a0; ZEHFUS BR, 1990, GENETICS, V126, P41	30	97	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24638	24641		10.1074/jbc.270.42.24638	http://dx.doi.org/10.1074/jbc.270.42.24638			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559571	hybrid			2022-12-27	WOS:A1995TB46500005
J	FORNARO, M; ZHENG, DQ; LANGUINO, LR				FORNARO, M; ZHENG, DQ; LANGUINO, LR			THE NOVEL STRUCTURAL MOTIF GLN(795)-GLN(802) IN THE INTEGRIN BETA(1C) CYTOPLASMIC DOMAIN REGULATES CELL-PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADHESION; SUBUNIT; BETA-1; IDENTIFICATION; EXPRESSION; ANTIBODIES; RECEPTOR; FORM	Alternative splicing of the integrin beta(1) subunit mRNA generates a variant form, beta(1C), with a unique cytoplasmic domain that differs from beta(1) for a 48-amino acid COOH-terminal sequence. The potential role of this unique sequence in modulating cellular functions was investigated using Chinese hamster ovary (CHO)(1) cells transiently transfected with cDNAs coding for human integrin beta(1C) or beta(1) subunits or mutants containing truncated forms of the beta(1C) cytoplasmic domain. A differential effect of beta(1C) and beta(1) on cell proliferation was ob served. Expression of wild type beta(1) was associated with a 6-10-fold increase in cell proliferation in response to serum, as measured by [H-3]thymidine incorporation. In contrast, only a a fold increase in cell proliferation was observed in transfectants expressing comparable levels of beta(1C). Cells expressing the beta(1C) mutant truncated at Leu794 and lacking the last 31 amino acids of the cytoplasmic domain showed a 12-fold proliferation increase in response to serum. However, three beta(1C) deletion mutants, lacking the COOH-terminal 23, 13, and 8 amino acids, which all contained residues Gln(795)-Gln(802) of the variant cytoplasmic domain responded to serum stimulation with a 2-fold increase in [H-3]thymidine uptake. The effect of beta(1C) expression on cell proliferation was not associated with changes in exposure of integrin functional epitopes, as judged by the finding that CHO transfectants expressing beta(1C) full-length or deletion mutants, or beta(1) equally adhered to a functionally inhibitory monoclonal antibody against human beta(1) integrin. Expression of beta(1C) inversely correlated with the mitogenic potential of vascular cells. Absent on growing cultured endothe lial cells, surface expression of beta(1C) was induced in growth arrested, tumor necrosis factor-stimulated endothelial cells. These findings suggest that integrin alternative splicing may provide an accessory mechanism to modulate cell type-specific growth regulatory pathways during vascular cell injury in vivo.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06520 USA	Yale University				Languino, Lucia/0000-0001-9011-7031				AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; BALZAC F, 1994, J CELL BIOL, V127, P557, DOI 10.1083/jcb.127.2.557; BARTFELD NS, 1993, J BIOL CHEM, V268, P17270; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; HARLOW E, 1988, ANTIBODIES LABORATOR; HEMLER ME, 1995, INTEGRINS BIOL PROBL; HOLMES E, 1993, ANAL BIOCHEM, V214, P100, DOI 10.1006/abio.1993.1462; HOWLETT AR, 1995, J CELL SCI, V108, P1945; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MEREDITH J, 1995, IN PRESS SCIENCE; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sambrook J, 1989, MOL CLONING LABORATO; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SOLOWSKA J, 1991, J CELL BIOL, V114, P1079, DOI 10.1083/jcb.114.5.1079; STEPHENS LE, 1993, J CELL BIOL, V123, P1607, DOI 10.1083/jcb.123.6.1607; STOLPEN AH, 1986, AM J PATHOL, V123, P16; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0	35	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24666	24669		10.1074/jbc.270.42.24666	http://dx.doi.org/10.1074/jbc.270.42.24666			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559578	hybrid			2022-12-27	WOS:A1995TB46500012
J	SONG, LX; FRICKER, LD				SONG, LX; FRICKER, LD			PURIFICATION AND CHARACTERIZATION OF CARBOXYPEPTIDASE-D, A NOVEL CARBOXYPEPTIDASE E-LIKE ENZYME, FROM BOVINE PITUITARY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENKEPHALIN-SYNTHESIZING CARBOXYPEPTIDASE; MEMBRANE-BOUND CARBOXYPEPTIDASE; NEUROPEPTIDE-PROCESSING ENZYME; STRUCTURAL CHARACTERIZATION; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; HUMAN-PLASMA; CDNA; FURIN; PC2	Carboxypeptidase E (CPE) is involved in the biosynthesis of most neuropeptides and peptide hormones. Until recently, CPE was the only intracellular carboxypeptidase thought to be involved in neuroendocrine peptide processing. However, the finding that fat/fat mice, which have a mutation within the CPE gene that inactivates the enzyme, are capable of a reduced amount of insulin processing suggests that another carboxypeptidase is present within the secretory pathway. We have detected a CPE-like enzyme, designated CPD, which has many properties in common with those of CPE. Like CPE, CPD is a metallocarboxypeptidase that has a pH optimum of 5.5-6. The K-m and K-ent values for a series of short peptide substrates show only minor differences between CPD and CPE. Several active site-directed inhibitors also show generally similar potency toward the two enzymes, although guanidinoethylmercaptosuccinic acid is approximately 10-fold more potent, and hippuryl-Arg is approximately 100-fold more potent as an inhibitor of CPD than of CPE. A major difference between the two enzymes is the molecular masses; CPE is 50,000-56,000, whereas CPD is approximately 180,000. Also, CPD does not elute from a substrate affinity column when the pH is raised to 8, which elutes CPE, although CPD can subsequently be eluted by arginine. Both CPE and CPD are present in purified bovine anterior pituitary secretory vesicles, but the tissue distribution of CPD is more uniform than that of CPE. Antisera to the N- and C-terminal regions of CPE do not recognize CPD. The partial N-terminal amino acid sequence of bovine CPD shows 30-40% homology with an N-terminal region of bovine and rat CPE and 70% homology with a duck protein known as gp180, a hepatitis B virus particle binding protein that shows 47% homology to CPE. Taken together, these results suggest that CPD is a novel secretory pathway enzyme that may be the bovine homologue of gp180.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NIDA NIH HHS [R01 DA-04494] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004494] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 1995, METH NEUROSCI; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BRADSHAW RA, 1969, P NATL ACAD SCI USA, V63, P1389, DOI 10.1073/pnas.63.4.1389; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; CLAUSER E, 1988, J BIOL CHEM, V263, P17837; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DEVI L, 1991, J NEUROCHEM, V56, P320, DOI 10.1111/j.1471-4159.1991.tb02598.x; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; EATON DL, 1991, J BIOL CHEM, V266, P21833; EIPPER BA, 1986, TRENDS NEUROSCI, V9, P463, DOI 10.1016/0166-2236(86)90149-9; FOLK JE, 1960, J BIOL CHEM, V235, P2272; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; FRICKER LD, 1988, J CELL BIOCHEM, V38, P279, DOI 10.1002/jcb.240380407; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1993, J NEUROCHEM, V61, P1404, DOI 10.1111/j.1471-4159.1993.tb13634.x; FRICKER LD, 1989, MOL ENDOCRINOL, V3, P666, DOI 10.1210/mend-3-4-666; FRICKER LD, 1982, P NATL ACAD SCI-BIOL, V79, P3886, DOI 10.1073/pnas.79.12.3886; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; FRICKER LD, 1994, NEUROPROTOCOLS, V5, P151; GEBHARD W, 1989, EUR J BIOCHEM, V178, P603, DOI 10.1111/j.1432-1033.1989.tb14488.x; GREENE D, 1992, BIOCHEM J, V285, P613, DOI 10.1042/bj2850613; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JOHNSON RG, 1976, J BIOL CHEM, V251, P2189; JUNG YK, 1991, MOL ENDOCRINOL, V5, P1257, DOI 10.1210/mend-5-9-1257; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; KUROKI K, 1994, J VIROL, V68, P2091, DOI 10.1128/JVI.68.4.2091-2096.1994; MANSER E, 1990, BIOCHEM J, V267, P517, DOI 10.1042/bj2670517; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NARAHASHI Y, 1979, J BIOCHEM-TOKYO, V86, P683, DOI 10.1093/oxfordjournals.jbchem.a132572; PARKINSON D, 1990, J BIOL CHEM, V265, P17101; PLUMMER TH, 1981, METHOD ENZYMOL, V80, P442; REYNOLDS DS, 1989, P NATL ACAD SCI USA, V86, P9480, DOI 10.1073/pnas.86.23.9480; ROTH WW, 1991, MOL CELL ENDOCRINOL, V78, P171, DOI 10.1016/0303-7207(91)90120-H; RUSSELL JT, 1984, J BIOL CHEM, V259, P9496; SCHAFER MKH, 1994, J NEUROSCI, V13, P1258; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SKIDGEL RA, 1989, J BIOL CHEM, V264, P2236; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAN FL, 1989, J BIOL CHEM, V264, P13165; TITANI K, 1975, P NATL ACAD SCI USA, V72, P1666, DOI 10.1073/pnas.72.5.1666; WEBB E C, 1986, European Journal of Biochemistry, V157, P1; ZHENG M, 1994, J NEUROSCI, V14, P4656	53	130	131	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25007	25013		10.1074/jbc.270.42.25007	http://dx.doi.org/10.1074/jbc.270.42.25007			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559630	hybrid			2022-12-27	WOS:A1995TB46500064
J	XU, J; YU, WF; JAN, YN; JAN, LY; LI, M				XU, J; YU, WF; JAN, YN; JAN, LY; LI, M			ASSEMBLY OF VOLTAGE-GATED POTASSIUM CHANNELS - CONSERVED HYDROPHILIC MOTIFS DETERMINE SUBFAMILY-SPECIFIC INTERACTIONS BETWEEN THE ALPHA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROMULTIMERIC K+ CHANNELS; RAT-BRAIN; XENOPUS-OOCYTES; A-CURRENT; EXPRESSION; CLONING; SHAKER; PROTEIN; INACTIVATION; CELLS	Voltage-gated potassium (K+) channels are assembled by four identical or homologous alpha-subunits to form a tetrameric complex with a central conduction pore for potassium ions. Most of the cloned genes for the alpha-subunits are classified into four subfamilies: Kv1 (Shaker), Kv2 (Shah), Kv3 (Shaw), and Kv4 (Shal). Subfamily-specific assembly of heteromeric K+ channel complexes has been observed in vitro and in vivo, which contributes to the diversity of K+ currents. However, the molecular codes that mediate the subfamily-specific association remain unknown. To understand the molecular basis of the subfamily-specific assembly, we tested the protein-protein interactions of different regions of alpha-subunits. We report here that the cytoplasmic NH2-terminal domains of Kv1, Kv2, Rv3, and Kv4 subfamilies each associate to form homomultimers. Using the yeast two-hybrid system and eight K+ channel genes, two genes (one isolated from rat and one from Drosophila) from each subfamily, we demonstrated that the associations to form heteromultimers by the NH2-terminal domains are strictly subfamily-specific. These subfamily-specific associations suggest a molecular basis for the selective formation of heteromultimeric channels in vivo.	JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA	Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Jan, Lily/0000-0003-3938-8498				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; BUTLER A, 1990, NUCLEIC ACIDS RES, V18, P2173, DOI 10.1093/nar/18.8.2173; BYRNE JH, 1980, J NEUROPHYSIOL, V43, P651, DOI 10.1152/jn.1980.43.3.651; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P21, DOI 10.1113/jphysiol.1971.sp009365; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; DREWE JA, 1992, J NEUROSCI, V12, P538; DUBOIS JM, 1993, PROG BIOPHYS MOL BIO, V59, P1, DOI 10.1016/0079-6107(93)90005-5; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HILLE B, 1991, IONIC CHANNELS EXCIT, P58; HOPKINS WF, 1994, J NEUROSCI, V14, P1385, DOI 10.1523/JNEUROSCI.14-03-01385.1994; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LUBAN J, 1992, J VIROL, V66, P5157, DOI 10.1128/JVI.66.8.5157-5160.1992; LUNEAU C, 1991, FEBS LETT, V288, P163, DOI 10.1016/0014-5793(91)81026-5; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; PFAFFINGER PJ, 1991, J NEUROSCI, V11, P918; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; ROGAWSKI MA, 1985, TRENDS NEUROSCI, V8, P214, DOI 10.1016/0166-2236(85)90082-7; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; Sambrook J, 1989, MOL CLONING LABORATO; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; ZHAO B, 1994, NEURON, V13, P1205, DOI 10.1016/0896-6273(94)90058-2	52	162	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24761	24768		10.1074/jbc.270.42.24761	http://dx.doi.org/10.1074/jbc.270.42.24761			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559593	hybrid			2022-12-27	WOS:A1995TB46500027
J	BARBATO, R; FRISO, G; PONTICOS, M; BARBER, J				BARBATO, R; FRISO, G; PONTICOS, M; BARBER, J			CHARACTERIZATION OF THE LIGHT-INDUCED CROSS-LINKING OF THE ALPHA-SUBUNIT OF CYTOCHROME B(559) AND THE D1 PROTEIN IN ISOLATED PHOTOSYSTEM-II REACTION CENTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTER; PISUM-SATIVUM; TRANSMEMBRANE ORIENTATION; RHODOPSEUDOMONAS-VIRIDIS; PHOTOINDUCED DEGRADATION; D1-PROTEIN DEGRADATION; 3A RESOLUTION; CHLOROPLAST; POLYPEPTIDE; MEMBRANE	Illumination of the isolated reaction center of photosystem II generates a protein of 41 kDa molecular mass, Using immunoblotting, it is confirmed that the protein is an adduct of the D1 protein and the a-subunit of cytochrome b(559). Its formation seems to be photochemically induced, being independent of temperature between 4 and 20 degrees C and unaffected by a mixture of protease inhibitors. The maximum levels are detected when the pH is in the region 6.5-8.5 and when illumination intensities are moderate. Although higher light intensities induce a higher rate of formation, the accumulation of elevated levels of the 41-kDa protein does not occur due to light-induced degradation. This degradation is also unaffected by the presence of protease inhibitors, Proteolytic mapping and N-terminal sequencing indicates that the cross-linking process involves the N-terminal serine of the alpha-subunit of cytochrome b(599) and D1 residues in the 239-244 FGQEEE motif close to the Q(B) binding site. In conclusion, the results indicate that the N terminus of the cu-subunit is exposed on the stromal side of photosystem II in such a way as to undergo light-induced cross-linking in the Q(B) region of the D1 protein. They also suggest that the 41-kDa adduct may be an intermediate before the light-induced cleavage of the D1 protein in the FGQEEE region.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,WOLFSON LABS,DEPT BIOCHEM,PHOTOSYNTH RES GRP,LONDON SW7 2AY,ENGLAND	Imperial College London				Ponticos, Markella/0000-0001-5957-5851				ANDERSSON B, 1992, MOL MECHANISMS BIOEN, P121; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; ARO EM, 1990, BIOCHIM BIOPHYS ACTA, V1019, P269, DOI 10.1016/0005-2728(90)90204-H; BARBATO R, 1991, FEBS LETT, V290, P162, DOI 10.1016/0014-5793(91)81250-C; BARBATO R, 1992, FEBS LETT, V309, P165, DOI 10.1016/0014-5793(92)81087-3; BARBATO R, 1991, BIOCHEMISTRY-US, V30, P10220, DOI 10.1021/bi00106a021; BARBER J, 1987, FEBS LETT, V220, P67, DOI 10.1016/0014-5793(87)80877-3; BARBER J, 1993, P NATL ACAD SCI USA, V90, P10942, DOI 10.1073/pnas.90.23.10942; BARBER J, 1987, TRENDS BIOCHEM SCI, V12, P321, DOI 10.1016/0968-0004(87)90151-4; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; CHAPMAN DJ, 1989, PHOTOSYNTHETICA, V23, P411; CHAPMAN DJ, 1991, METHODS PLANT BIOCH, V5, P171; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; DURRANT JR, 1990, BIOCHIM BIOPHYS ACTA, V1017, P167, DOI 10.1016/0005-2728(90)90148-W; FRISO G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P265, DOI 10.1016/0005-2728(93)90110-2; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; HE WZ, 1991, BIOCHEMISTRY-US, V30, P4552, DOI 10.1021/bi00232a027; MARDER JB, 1984, J BIOL CHEM, V259, P3900; MARDER JB, 1988, BIOCHIM BIOPHYS ACTA, V932, P362, DOI 10.1016/0005-2728(88)90172-7; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTOO AK, 1981, P NATL ACAD SCI-BIOL, V78, P1572, DOI 10.1073/pnas.78.3.1572; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; RIVAS JD, 1993, BIOCHEMISTRY-US, V32, P6944, DOI 10.1021/bi00078a019; RIVAS JD, 1992, FEBS LETT, V301, P246; RUFFLE SV, 1992, PHOTOSYNTH RES, V34, P287, DOI 10.1007/BF00033446; SALTER AH, 1992, BIOCHEMISTRY-US, V31, P3990, DOI 10.1021/bi00131a014; SHIPTON CA, 1991, P NATL ACAD SCI USA, V88, P6691, DOI 10.1073/pnas.88.15.6691; SHIPTON CA, 1990, Z NATURFORSCH C, V45, P765; TAE GS, 1988, BIOCHEMISTRY-US, V27, P9075, DOI 10.1021/bi00426a002; TELFER A, 1994, J BIOL CHEM, V269, P13244; TELFER A, 1994, BIOCHEMISTRY-US, V33, P14469, DOI 10.1021/bi00252a013; TREBST A, 1987, Z NATURFORSCH C, V42, P742; VALLON O, 1989, BIOCHIM BIOPHYS ACTA, V975, P132, DOI 10.1016/S0005-2728(89)80211-7; WEBBER AN, 1989, PLANT MOL BIOL, V12, P141, DOI 10.1007/BF00020499; WEBBER AN, 1989, FEBS LETT, V242, P259, DOI 10.1016/0014-5793(89)80481-8; [No title captured]	41	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24032	24037		10.1074/jbc.270.41.24032	http://dx.doi.org/10.1074/jbc.270.41.24032			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592601	hybrid			2022-12-27	WOS:A1995TA21700029
J	CHUANG, JY; LIN, CT; WU, CW; LIN, YS				CHUANG, JY; LIN, CT; WU, CW; LIN, YS			A MOVABLE AND REGULABLE INACTIVATION FUNCTION WITHIN THE CENTRAL REGION OF A TEMPERATURE-SENSITIVE P53 MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							WILD-TYPE P53; TRANSCRIPTION ACTIVATION; GENE AMPLIFICATION; TRANSFORMATION; PROTEIN; BINDING; SUPPRESSOR; RECEPTOR	p53 is the most frequently mutated gene in human cancer. Naturally occurring mutations of p53 are mainly located within a region containing residues 100-300 and are predominantly of missense type, resulting in loss of the protein's DNA binding activity. Here we show that this type of mutation also represses the p53 N-terminal activation domain. The repression activity is localized in the central region of mutant p53 containing residues 101-318. Interestingly, the central region of a temperature-sensitive mutant p53N247I possesses a movable and regulable inactivation function. It represses other activities present on the same polypeptide chain without strict regard to the configuration of that polypeptide only at the nonpermissive temperature (37 degrees C) and not at the permissive temperature (30 degrees C). Furthermore, this mutant p53 region exhibits no other activity, and its function is independent of endogenous p53 status.	ACAD SINICA,INST BIOMED SCI,TAIPEI 11529,TAIWAN; NATL TAIWAN UNIV,COLL MED,INST PATHOL,TAIPEI 10010,TAIWAN	Academia Sinica - Taiwan; National Taiwan University								ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHEN JY, 1993, ONCOGENE, V8, P2159; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HARDY SP, 1994, FASEB J, V8, P760, DOI 10.1096/fasebj.8.10.8050676; Hay R. K. M, 1994, ATLAS HUMAN TUMOR CE; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSU YS, 1995, J BIOL CHEM, V270, P6966, DOI 10.1074/jbc.270.12.6966; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1989, NATURE, V340, P656, DOI 10.1038/340656a0; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MATTIONI T, 1994, METHOD CELL BIOL, V43, P335; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHUERMANN M, 1993, ONCOGENE, V8, P2781; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	27	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23899	23902		10.1074/jbc.270.41.23899	http://dx.doi.org/10.1074/jbc.270.41.23899			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592577	hybrid			2022-12-27	WOS:A1995TA21700005
J	KULMACZ, RJ; WANG, LH				KULMACZ, RJ; WANG, LH			COMPARISON OF HYDROPEROXIDE INITIATOR REQUIREMENTS FOR THE CYCLOOXYGENASE ACTIVITIES OF PROSTAGLANDIN-H SYNTHASE-1 AND SYNTHASE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ENDOPEROXIDE SYNTHETASE; VESICULAR GLAND; FATTY-ACIDS; PURIFICATION; BIOSYNTHESIS; KINETICS; ENCODES; TISSUES; PROTEIN	Two isoforms of prostaglandin H synthase have been described: isoform-1 (PGHS-1), which is ascribed a role in basal or housekeeping prostaglandin synthesis; and isoform-2 (PGHS-2), which has been found to be strongly inducible in many tissues and has been associated with inflammatory processes. Recent observations have indicated that cyclooxygenase catalysis by the two isoforms can be differentially regulated when both are present simultaneously (Reddy, S. T., and Herschman, H. R. (1994) J. Biol. Chem. 269, 15473-15480). The requirement of the cyclooxygenase for hydroperoxide initiator has been proposed as an important limit on cellular prostaglandin synthesis (Marshall, P. J., Kulmacz, R. J., and Lands, W. E. M. (1987) J. Biol. Chem. 262, 3510-5517). To compare the levels of hydroperoxide required for cyclooxygenase initiation in the two PGHS isoforms, we have examined the ability of a hydroperoxide scavenger, glutathione peroxidase, to suppress the cyclooxygenase activity of purified preparations of human PGHS-2, ovine PGHS-2, and ovine PGHS-1. Half-maximal prostaglandin synthetic activity was found to require a much lower hydroperoxide level with human PGHS-2 (2.3 nM) and ovine PGHS-2 (2.2 nM) than with ovine PGHS-1 (21 nM). Similar results were obtained when cyclooxygenase activity was monitored by chromatographic analyses of radiolabeled arachidonate metabolites or with oxygen electrode measurements. Mixing four parts of ovine PGHS-1 with one part of human PGHS-2 did not markedly change the sensitivity of the overall cyclooxygenase activity to inhibition by glutathione peroxidase, indicating that the PGHS-1 activity was not easily initiated by PGHS-2 activity in the same vessel. Effective catalysis by PGHS-2 can thus proceed at hydroperoxide levels too low to sustain appreciable catalysis by PGHS-1. This difference in catalytic characteristics provides a biochemical mechanism for differential control of prostaglandin synthesis by the two PGHS isoforms, even when both are present in the same intracellular compartment.			KULMACZ, RJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV HEMATOL,6431 FANNIN ST,HOUSTON,TX 77030, USA.				NIGMS NIH HHS [GM52170] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052170] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Flohe L, 1978, Ciba Found Symp, P95; HAMILTON JA, 1994, J BIOL CHEM, V269, P20852; HECKER M, 1987, BIOCHEM PHARMACOL, V36, P851, DOI 10.1016/0006-2952(87)90175-4; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HEMLER ME, 1978, BIOCHEM BIOPH RES CO, V85, P1325, DOI 10.1016/0006-291X(78)91148-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1985, BIOCHEM BIOPH RES CO, V130, P918, DOI 10.1016/0006-291X(85)90504-2; KULMACZ RJ, 1985, PROSTAGLANDINS, V29, P175, DOI 10.1016/0090-6980(85)90200-X; KULMACZ RJ, 1994, BIOCHEMISTRY-US, V33, P5428, DOI 10.1021/bi00184a011; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P502, DOI 10.1016/0003-9861(89)90317-2; KULMACZ RJ, 1994, BIOCHEMISTRY-US, V269, P5527; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE RA, 1974, EXP EYE RES, V18, P563, DOI 10.1016/0014-4835(74)90062-1; LIN AH, 1989, J BIOL CHEM, V264, P17379; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; OBANION MK, 1991, J BIOL CHEM, V266, P23261; ODENWALLER R, 1992, J BIOL CHEM, V267, P13863; PERCIVAL MD, 1994, ARCH BIOCHEM BIOPHYS, V315, P111, DOI 10.1006/abbi.1994.1478; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; REDDY ST, 1994, J BIOL CHEM, V269, P15473; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; TSAI AL, 1992, J BIOL CHEM, V267, P17753; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WEI CH, 1995, BIOCHEMISTRY-US, V34, P8499, DOI 10.1021/bi00026a034; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	39	187	188	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24019	24023		10.1074/jbc.270.41.24019	http://dx.doi.org/10.1074/jbc.270.41.24019			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592599	hybrid			2022-12-27	WOS:A1995TA21700027
J	MATHIEU, M; CHATELAIN, E; ORNITZ, D; BRESNICK, J; MASON, I; KIEFER, P; DICKSON, C				MATHIEU, M; CHATELAIN, E; ORNITZ, D; BRESNICK, J; MASON, I; KIEFER, P; DICKSON, C			RECEPTOR-BINDING AND MITOGENIC PROPERTIES OF MOUSE FIBROBLAST-GROWTH-FACTOR-3 - MODULATION OF RESPONSE BY HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; FACTOR FAMILY; SIGNAL TRANSDUCTION; CELL-TRANSFORMATION; ENDOTHELIAL-CELLS; INT-2; SPECIFICITY; EXPRESSION; AFFINITY; GENE	fgf3 has been implicated in the embryonic and fetal development of the mouse and as an oncogene in murine breast cancer. We describe a procedure to purify the product of the mouse fgf3 gene and show it to be a potent mitogen for some epithelial cell lines. Using a receptor binding competition assay, Fgf3 was shown to bind with high affinity to the IIIb isoforms of Fgf receptor (FgfR) 1 and FgfR2 (ID50 = similar to 0.8 nM) and with a lower affinity to the me variant of FgfR2 (ID50 = similar to 9 nM). NO competition for the binding of I-125-Fgf1 was observed for FgfR1 (IIIc), FgfR3 (IIIb and IIIc), or FgfR4. Mitogenicity assays using BaF3 cells containing individual Fgf receptors showed a pattern of response in agreement with the receptor binding results. A comparison of two mammary epithelial cell lines showed a marked difference of potency and dependence upon heparin in their response to mouse Fgf3, suggesting a complex interaction between the ligand and its low and high affinity receptors.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Mason, Ivor/B-1859-2008	Mason, Ivor/0000-0001-8390-3050; Ornitz, David/0000-0003-1592-7629	NATIONAL CANCER INSTITUTE [R01CA060673] Funding Source: NIH RePORTER; NCI NIH HHS [CA60673] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P753; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; COLEMANKRNACIK S, 1994, MOL ENDOCRINOL, V8, P218, DOI 10.1210/me.8.2.218; DELL KR, 1992, J BIOL CHEM, V267, P21225; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DICKSON C, 1991, FIBROBLAST GROWTH FA, P8; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; GOLDFARB M, 1991, ONCOGENE, V6, P65; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAN M, 1991, METHOD ENZYMOL C, V198, P158; KAPLOW JM, 1990, BIOCHEM BIOPH RES CO, V172, P107, DOI 10.1016/S0006-291X(05)80179-2; KIEFER P, 1993, EMBO J, V12, P4159, DOI 10.1002/j.1460-2075.1993.tb06100.x; KIEFER P, 1991, MOL CELL BIOL, V11, P5929, DOI 10.1128/MCB.11.12.5929; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; KOZAK M, 1991, J BIOL CHEM, V266, P19867; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MATHIEU M, 1995, J BIOL CHEM, V270, P6779, DOI 10.1074/jbc.270.12.6779; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1992, JNCI-J NATL CANCER I, V84, P887, DOI 10.1093/jnci/84.11.887; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PATERNO GD, 1989, DEVELOPMENT, V106, P79; PETERS G, 1991, SEMIN VIROL, V2, P319; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RON D, 1993, J BIOL CHEM, V268, P2984; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHAN X, 1987, ONCOGENE, V1, P369; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	50	51	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24197	24203		10.1074/jbc.270.41.24197	http://dx.doi.org/10.1074/jbc.270.41.24197			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592624	hybrid			2022-12-27	WOS:A1995TA21700052
J	SCHULTE, TW; BLAGOSKLONNY, MV; INGUI, C; NECKERS, L				SCHULTE, TW; BLAGOSKLONNY, MV; INGUI, C; NECKERS, L			DISRUPTION OF THE RAF-1-HSP90 MOLECULAR-COMPLEX RESULTS IN DESTABILIZATION OF RAF-1 AND LOSS OF RAF-1-RAS ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; GLUCOCORTICOID RECEPTOR; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; HSP90; INHIBITION; BINDS	Cytosolic Raf-1 exists in a high molecular weight complex with the heat shock protein Hsp90, the purpose of which is unknown. The benzoquinone ansamycin, geld-anamycin, specifically binds to Hsp90 and disrupts certain multimolecular complexes containing this protein, Using this drug, we are able to demonstrate rapid dissociation of both Raf-1-Hsp90 and Raf-1-Ras multimolecular complexes, concomitant with a markedly decreased half-life of the Raf-1 protein. Continued disruption of the Raf-1-Hsp90 complex results in apparent loss of Raf-1 protein from the cell, although Raf-1 synthesis is actually increased. Prevention of Raf-1-Hsp90 complex formation interferes with trafficking of newly synthesized Raf-1 from cytosol to plasma membrane. These data indicate that association with Hsp90 is essential for both Raf-1 protein stability and its proper localization in the cell.	NCI,CLIN PHARMACOL BRANCH,BETHESDA,MD 20892; NCI,PEDIAT BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MILLER P, 1994, BIOCHEM BIOPH RES CO, V201, P1313, DOI 10.1006/bbrc.1994.1847; MIYATA Y, 1991, J BIOL CHEM, V266, P8779; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MURAKAMI Y, 1994, BIOCHEM J, V301, P63, DOI 10.1042/bj3010063; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PRATT WB, 1993, J BIOL CHEM, V268, P21455; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TRAVERSE S, 1993, ONCOGENE, V8, P3175; UEHARA Y, 1989, CANCER RES, V49, P780; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITESELL L, 1992, CANCER RES, V52, P1721; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P9324; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	24	417	428	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24585	24588		10.1074/jbc.270.41.24585	http://dx.doi.org/10.1074/jbc.270.41.24585			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592678	hybrid			2022-12-27	WOS:A1995TA21700106
J	YANKULOV, K; YAMASHITA, K; ROY, R; EGLY, JM; BENTLEY, DL				YANKULOV, K; YAMASHITA, K; ROY, R; EGLY, JM; BENTLEY, DL			THE TRANSCRIPTIONAL ELONGATION INHIBITOR 5,6-DICHLORO-1-BETA-D-RIBOFURANOSYLBENZIMIDAZOLE INHIBITS TRANSCRIPTION FACTOR IIH-ASSOCIATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RNA POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; PHOSPHORYLATION; DISTINCT; BINDING; PURIFICATION; DETERMINANTS; ACTIVATION; INITIATION; COMPLEXES	Regulation of chain elongation by RNA polymerase II can have an important effect on gene expression (Bentley, D. (1995) Curr. Opin. Genet. Dev. 5, 210-216; Yankulov, K., Blau, J., Purton, T., Roberts, S., and Bentley, D. (1994) Cell 77, 749-759); however the mechanisms that control this step in transcription are not well understood. The adenosine analogue 5,6-dichloro-1-beta-Dribofuranosylbenzimidazole (DRB) has long been used as an inhibitor of RNA polymerase II elongation, but its target is not known. We show that DRB is a potent inhibitor of Cdk-activating kinase, associated with the general transcription factor TFIIH. Two other inhibitors of this kinase, H-7 and H-8, also inhibited transcriptional elongation. Furthermore, TFIIH kinase bound specifically to the herpes simplex virus VP16 activation domain which stimulates polymerase II elongation in addition to initiation (Yankulov, K., Blau, J., Purton, T., Roberts, S., and Bentley, D. (1994) Cell 77, 749-759). Our results suggest that DRB affects transcription by inhibiting the TFIIH-associated kinase and that this kinase functions in the control of elongation by RNA polymerase II.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; CNRS,INSERM,U184,F-67404 ILLKIRCH GRAFFENS,FRANCE	Cancer Research UK; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)				Yankulov, Krassimir/0000-0001-9440-9234; Bentley, David/0000-0002-8414-4647				BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; DUBOIS MF, 1994, EMBO J, V13, P4787, DOI 10.1002/j.1460-2075.1994.tb06804.x; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FRASER NW, 1978, NATURE, V272, P590, DOI 10.1038/272590a0; GERARD M, 1991, J BIOL CHEM, V266, P20940; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; MEGGIO F, 1990, EUR J BIOCHEM, V187, P89, DOI 10.1111/j.1432-1033.1990.tb15280.x; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; POON RYC, 1994, J CELL SCI, V107, P2789; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; ROBERTS S, 1992, EMBO J, V11, P1085, DOI 10.1002/j.1460-2075.1992.tb05147.x; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TAMM I, 1977, P NATL ACAD SCI USA, V74, P5011, DOI 10.1073/pnas.74.11.5011; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; WALKER S, 1993, MOL CELL BIOL, V13, P5233, DOI 10.1128/MCB.13.9.5233; WANG JS, 1993, MOL BIOL REP, V18, P15, DOI 10.1007/BF01006891; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414	41	159	166	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23922	23925		10.1074/jbc.270.41.23922	http://dx.doi.org/10.1074/jbc.270.41.23922			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592583	hybrid			2022-12-27	WOS:A1995TA21700011
J	BABIYCHUK, E; KUSHNIR, S; BELLESBOIX, E; VANMONTAGU, M; INZE, D				BABIYCHUK, E; KUSHNIR, S; BELLESBOIX, E; VANMONTAGU, M; INZE, D			ARABIDOPSIS-THALIANA NADPH OXIDOREDUCTASE HOMOLOGS CONFER TOLERANCE OF YEASTS TOWARD THE THIOL-OXIDIZING DRUG DIAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG LENS; DEPENDENT 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; SACCHAROMYCES-CEREVISIAE GENE; SUPEROXIDE-DISMUTASE GENE; ASCORBATE PEROXIDASE; MOLECULAR-CLONING; ZETA-CRYSTALLIN; PHYTOALEXIN BIOSYNTHESIS; ESCHERICHIA-COLI; STRESS RESPONSES	To isolate new plant genes involved in the defense against oxidative stress, an Arabidopsis cDNA library in a yeast expression vector was transformed into a yeast strain deficient in the YAP1 gene, which encodes a b-Zip transcription factor and regulates general stress response in yeasts. Cells from approximate to 10(5) primary transformants were subjected to a tolerance screen toward the thiol-oxidizing drug diamide, which depletes the reduced glutathione in the cell, Four types of Arobidopsis cDNAs were isolated, Three of these cDNAs (PI, Pa, and P4) belong to a plant zeta-crystallin family and P3 is an Arabidopsis homolog of isoflavonoid reductases. As such, all four isolated cDNAs are homologous to NADPH oxidoreductases. PI, P2, and PS steady-state mRNAs accumulated rapidly in Arabidopsis plants under various oxidative stress conditions, such as treatment with paraquat, t-butylhydroperoxide, diamide, and menadione. The data suggested that proteins encoded by the isolated cDNAs play a distinct role in plant antioxidant defense and are possibly involved in NAD(P)/NAD(P)H homeostasis.	STATE UNIV GHENT,GENET LAB,B-9000 GHENT,BELGIUM	Ghent University			kushnir, sergei/GPK-2171-2022; Inzé, Dirk/AAW-6381-2021	Inzé, Dirk/0000-0002-3217-8407; Kushnir, Sergei/0000-0002-1818-5803				ASADA K, 1992, PHYSIOL PLANTARUM, V85, P235, DOI 10.1111/j.1399-3054.1992.tb04728.x; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; AZUMA M, 1992, FEBS LETT, V307, P313, DOI 10.1016/0014-5793(92)80703-J; BOSSIER P, 1993, J BIOL CHEM, V268, P23640; BOWLER C, 1992, ANNU REV PLANT PHYS, V43, P83, DOI 10.1146/annurev.pp.43.060192.000503; BRISSON LF, 1994, PLANT CELL, V6, P1703, DOI 10.1105/tpc.6.12.1703; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; DEMURA T, 1994, PLANT CELL, V6, P967; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; DIXON RA, 1983, ADV ENZYMOL RAMB, V55, P1; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; DREWS GN, 1992, PLANT CELL, V4, P1383, DOI 10.1105/tpc.4.11.1383; ENSOR CM, 1990, J BIOL CHEM, V265, P14888; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HEILMANN HJ, 1988, EUR J BIOCHEM, V174, P485, DOI 10.1111/j.1432-1033.1988.tb14124.x; HEROUART D, 1993, P NATL ACAD SCI USA, V90, P3108, DOI 10.1073/pnas.90.7.3108; HERTLE K, 1991, CURR GENET, V19, P429, DOI 10.1007/BF00312733; HIBI N, 1994, PLANT CELL, V6, P723, DOI 10.1105/tpc.6.5.723; HUSSAIN M, 1991, GENE, V101, P149, DOI 10.1016/0378-1119(91)90238-7; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; Inze Dirk, 1995, Current Opinion in Biotechnology, V6, P153, DOI 10.1016/0958-1669(95)80024-7; KAMPFENKEL K, 1995, PLANT PHYSIOL, V107, P725, DOI 10.1104/pp.107.3.725; KREMS B, 1995, CURR GENET, V27, P427, DOI 10.1007/BF00311211; KROOK M, 1993, FEBS LETT, V322, P139, DOI 10.1016/0014-5793(93)81554-D; KUBO A, 1992, PLANT MOL BIOL, V18, P691, DOI 10.1007/BF00020011; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; LIU X, 1994, MOL BIOCHEM PARASIT, V66, P201, DOI 10.1016/0166-6851(94)90147-3; LIU XF, 1992, J BIOL CHEM, V267, P18298; LIU XF, 1994, MOL CELL BIOL, V14, P7037, DOI 10.1128/MCB.14.11.7037; MINET M, 1992, PLANT J, V2, P417; MIRONOV VN, 1994, MOL GEN GENET, V242, P201, DOI 10.1007/BF00391014; MITTLER R, 1992, J BIOL CHEM, V267, P21802; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; PAIVA NL, 1991, PLANT MOL BIOL, V17, P653, DOI 10.1007/BF00037051; PAWLOWSKI JE, 1994, J BIOL CHEM, V269, P13502; PRIVALLE CT, 1993, P NATL ACAD SCI USA, V90, P2310, DOI 10.1073/pnas.90.6.2310; RAO P, 1992, BIOCHIM BIOPHYS ACTA, V1116, P75, DOI 10.1016/0304-4165(92)90131-D; RAO PV, 1992, J BIOL CHEM, V267, P96; RODOKANAKI A, 1989, GENE, V78, P215, DOI 10.1016/0378-1119(89)90224-2; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SCHNELL N, 1991, EUR J BIOCHEM, V200, P487, DOI 10.1111/j.1432-1033.1991.tb16209.x; SHIRZADEGAN M, 1991, NUCLEIC ACIDS RES, V19, P6055, DOI 10.1093/nar/19.21.6055; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; SLABAS AR, 1992, BIOCHEM J, V283, P321, DOI 10.1042/bj2830321; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; TIEMANN K, 1991, EUR J BIOCHEM, V200, P751, DOI 10.1111/j.1432-1033.1991.tb16241.x; TUMMINIA SJ, 1993, BIOCHIM BIOPHYS ACTA, V1203, P251, DOI 10.1016/0167-4838(93)90091-5; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; [No title captured]	57	130	152	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26224	26231		10.1074/jbc.270.44.26224	http://dx.doi.org/10.1074/jbc.270.44.26224			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592828	Green Published, hybrid			2022-12-27	WOS:A1995TC97800035
J	FRENCH, PJ; BIJMAN, J; EDIXHOVEN, M; VAANDRAGER, AB; SCHOLTE, BJ; LOHMANN, SM; NAIRN, AC; DEJONGE, HR				FRENCH, PJ; BIJMAN, J; EDIXHOVEN, M; VAANDRAGER, AB; SCHOLTE, BJ; LOHMANN, SM; NAIRN, AC; DEJONGE, HR			ISOTYPE-SPECIFIC ACTIVATION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR-CHLORIDE CHANNELS BY CGMP-DEPENDENT PROTEIN-KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE ENTEROTOXIN; CYCLIC-GMP; ESCHERICHIA-COLI; INTESTINAL MICROVILLI; GUANYLATE-CYCLASE; CFTR; TRANSPORT; EXPRESSION; PHOSPHORYLATION; CLONING	Type II cGMP-dependent protein kinase (cGKII) iso isolated from pig intestinal brush borders and type I alpha cGK (cGKI) purified from bovine lung were compared for their ability to activate the cystic fibrosis transmembrane conductance regulator (CFTR)-Cl- channel in excised, inside-out membrane patches from NIH-3T3 fibroblasts and from a rat intestinal cell Line (IEC-CF7) stably expressing recombinant CFTR. In both cell models, in the presence of cGMP and ATP, cGKII was found to mimic the effect of the catalytic subunit of cAMP-dependent protein kinase (cAK) on opening CFTR-Cl- channels, albeit with different kinetics (2-3-min lag time, reduced rate of activation), By contrast, cGKI or a monomeric cGKI catalytic fragment was incapable of opening CFTR-Cl- channels and also failed to potentiate cGKII activation of the channels, The cAK activation but not the cGKII activation was blocked by a cAK inhibitor peptide, The slow activation by cGKII could not be ascribed to counteracting protein phosphatases, since neither calyculin A, a potent inhibitor of phosphatase 1 and 2A, nor ATP gamma S (adenosine 5'-O-(thiotriphosphate)), producing stable thiophosphorylation, was able to enhance the activation kinetics, Channels preactivated by cGKII closed instantaneously upon removal of ATP and kinase but reopened in the presence of ATP alone, Paradoxically, immunoprecipitated CFTR or CF-2, a cloned R domain fragment of CFTR (amino acids 645-835) could be phosphorylated to a similar extent with only minor kinetic differences by both isotypes of cGK. Phosphopeptide maps of CF-2 and CFTR, however, revealed very subtle differences in site-specificity between the cGK isoforms, These results indicate that cGKI alpha, in contrast to cGKI alpha, is a potential activator of chloride transport in CFTR-expressing cell types.	ERASMUS UNIV ROTTERDAM, FAC MED & HLTH SCI, DEPT CELL BIOL, 3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, FAC MED & HLTH SCI, DEPT BIOCHEM, 3000 DR ROTTERDAM, NETHERLANDS; UNIV WURZBURG, MED CLIN, CLIN BIOCHEM LAB, D-97080 WURZBURG, GERMANY; ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, NEW YORK, NY 10021 USA	Erasmus University Rotterdam; Erasmus University Rotterdam; University of Wurzburg; Rockefeller University				French, Pim/0000-0002-0668-9529; Nairn, Angus/0000-0002-7075-0195; Vaandrager, Arie/0000-0001-9394-9239				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; BAXTER PS, 1988, NATURE, V335, P211, DOI 10.1038/335211a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BIJMAN J, 1993, AM J PHYSIOL, V264, pL229, DOI 10.1152/ajplung.1993.264.3.L229; CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DEJONGE HR, 1976, NATURE, V262, P590, DOI 10.1038/262590a0; DEJONGE HR, 1981, ADV CYCLIC NUCL PROT, V14, P315; DEJONGE HR, 1987, PEDIATR PULM S, V1, P54; DEJONGE HR, 1990, TXB SECRETORY DIARRH, P191; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; FIELD M, 1989, NEW ENGL J MED, V321, P800; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HUGHES JM, 1978, NATURE, V271, P755, DOI 10.1038/271755a0; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KANSEN M, 1993, PFLUG ARCH EUR J PHY, V422, P539, DOI 10.1007/BF00373999; KANSEN M, 1992, BIOCHIM BIOPHYS ACTA, V1139, P49, DOI 10.1016/0925-4439(92)90081-W; KEILBACH A, 1992, EUR J BIOCHEM, V208, P467, DOI 10.1111/j.1432-1033.1992.tb17209.x; KEMP BE, 1977, J BIOL CHEM, V252, P4888; LIN MQ, 1992, AM J PHYSIOL, V262, pC1304, DOI 10.1152/ajpcell.1992.262.5.C1304; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; MONKEN CE, 1980, J BIOL CHEM, V255, P7067; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SULLIVAN SK, 1994, PEDIATR PULM S, V10, P187; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TIEN XY, 1994, J BIOL CHEM, V269, P51; UHLER MD, 1993, J BIOL CHEM, V268, P13586; Vaandrager A B, 1994, Adv Pharmacol, V26, P253, DOI 10.1016/S1054-3589(08)60057-5; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; VANDOMMELEN FS, 1986, BIOCHIM BIOPHYS ACTA, V886, P135, DOI 10.1016/0167-4889(86)90219-3; VANDOMMELEN FS, 1986, BIOCHEM J, V236, P771, DOI 10.1042/bj2360771; WALTER U, 1980, J BIOL CHEM, V255, P3757; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WIKINSON DJ, 1994, PEDIATR PULOMOL S, V10, P179	48	105	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26626	26631		10.1074/jbc.270.44.26626	http://dx.doi.org/10.1074/jbc.270.44.26626			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592887	Green Published, hybrid			2022-12-27	WOS:A1995TC97800094
J	SWANSON, HI; CHAN, WK; BRADFIELD, CA				SWANSON, HI; CHAN, WK; BRADFIELD, CA			DNA-BINDING SPECIFICITIES AND PAIRING RULES OF THE AH RECEPTOR, ARNT, AND SIM PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIOXIN-RESPONSIVE ENHANCER; PLANAR AROMATIC-COMPOUNDS; MINDED GENE ENCODES; LOOP-HELIX PROTEINS; C-MYC PROTEIN; REGULATORY ELEMENTS; INDUCIBLE EXPRESSION; DROSOPHILA; SEQUENCE; TRANSCRIPTION	The Ah receptor (AHR), the Ah receptor nuclear translocator protein (ARNT), and single-minded protein (SIM) are members of the basic helix-loop-helix-PAS (bHLH-PAS) family of regulatory proteins, In this study, we examine the DNA half-site recognition and pairing rules for these proteins using oligonucleotide selection-amplification and coprecipitation protocols, Oligonucleotide selection-amplification revealed that a variety of bHLH-PAS protein combinations could interact, with each generating a unique DNA binding specificity. To validate the selection-amplification protocol, we demonstrated the preference of the AHR ARNT complex for the sequence commonly found in dioxin-responsive enhancers in vivo (TNGCGTG). We then demonstrated that the ARNT protein is capable of forming a homodimer with a binding preference for the palindromic E-box sequence, CACGTG. Further examination indicated that ARNT may have a relaxed partner specificity, since it was also capable of forming a heterodimer with SIM and recognizing the sequence GT(G/A)CGTG, Coprecipitation experiments using various PAS proteins and ARNT were consistent with the idea that the ARNT protein has a broad range of interactions among the bHLH-PAS proteins, while the other members appear more restricted in their interactions, Comparison of this in vibro data with sites known to be bound in vivo suggests that the high affinity half-site recognition sequences for the AHR, SIM, and ARNT are T(C/T)GC, GT(G/A)C (5'-half-sites), and GTG (3'-half-sites), respectively.	NORTHWESTERN UNIV,SCH MED,DEPT MOLEC PHARMACOL & BIOL CHEM,CHICAGO,IL 60611	Northwestern University				Swanson, Hollie/0000-0002-3725-5504	NIEHS NIH HHS [ES-05703, ES-05660, F32 ES005589, ES-05589] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES005703, F32ES005589, R01ES005703, R29ES005703] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; BACSI SG, 1995, MOL PHARMACOL, V47, P432; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; CHAN WK, 1994, J BIOL CHEM, V269, P26464; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; ELLINGTON A, 1987, CURRENT PROTOCOLS MO; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; MILTON JS, 1983, STATISTICAL METHODS; MURALIDHAR MG, 1993, MECH DEVELOP, V41, P129, DOI 10.1016/0925-4773(93)90043-W; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1991, MOL PHARMACOL, V39, P20; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN ES, 1992, J BIOL CHEM, V267, P6815; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; WHARTON KA, 1994, DEVELOPMENT, V120, P3563; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505	55	300	306	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26292	26302		10.1074/jbc.270.44.26292	http://dx.doi.org/10.1074/jbc.270.44.26292			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592839	hybrid			2022-12-27	WOS:A1995TC97800046
J	DONG, LQ; CHAPLINE, C; MOUSSEAU, B; FOWLER, L; RAMSAY, K; STEVENS, JL; JAKEN, S				DONG, LQ; CHAPLINE, C; MOUSSEAU, B; FOWLER, L; RAMSAY, K; STEVENS, JL; JAKEN, S			35H, A SEQUENCE ISOLATED AS A PROTEIN-KINASE-C BINDING-PROTEIN, IS A NOVEL MEMBER OF THE ADDUCIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ADDUCIN; BETA-ADDUCIN; ASSOCIATION; CALMODULIN; PHOSPHORYLATION; REDISTRIBUTION; STAUROSPORINE; FIBROBLASTS; ACTIVATION; MEMBRANES	We recently cloned a partial cDNA (35H) for a protein kinase C (PKC) binding protein from a rat kidney cDNA library and demonstrated that it is a PKC substrate in vitro (Chapline, C., Ramsay, K., Klauck, T., and Jaken, S. (1993) J. Biol. Chem. 268, 6858-6861). Additional library screening and 5' rapid amplification of cDNA ends were used to obtain the complete open reading frame. Amino acid sequence analysis, DNA sequence analysis, and Northern analysis indicate that 35H is a unique cDNA related to alpha- and beta-adducins. Antisera prepared to the 35H bacterial fusion protein recognized two polypeptides of 80 and 90 kDa on immunoblots of kidney homogenates and cultured renal proximal tubule epithelial cell extracts. The 35H-related proteins were similar to alpha- and beta-adducins in that they were preferentially recovered in the Triton X-100-insoluble (cytoskeletal, CSK) fraction of cell extracts and were predominantly localized to cell borders. Phorbol esters stimulated phosphorylation of CSK 35H proteins, thus emphasizing that sequences isolated according to PKC binding activity in vitro are also PKC substrates in vivo. The phosphorylated forms of the 35H proteins were preferentially recovered in the soluble fraction, thus demonstrating that phosphorylation regulates their CSK association and, thereby, their function in regulating cytoskeletal assemblies, We have isolated another PKC binding protein partial cDNA (clone 45) from a rat fibroblast library with substantial homology to alpha-adducin. Antisera raised against this expressed sequence recognized a protein of 120 kDa, the reported size of alpha-adducin, on immunoblots of renal proximal tubule epithelial cell extracts. A 120-kDa protein that cross-reacts with the clone 45 (alpha-adducin) antisera coprecipitated with 35H immunecomplexes, indicating that alpha-adducin associates with 35H proteins in vivo. Taken together, these results indicate that 35H is a new, widely expressed form of adducin capable of forming heterodimers with alpha-adducin. We propose naming this adducin homologue gamma-adducin.	W ALTON JONES CELL SCI CTR INC,LAKE PLACID,NY 12946						NATIONAL CANCER INSTITUTE [R01CA053841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050152] Funding Source: NIH RePORTER; NCI NIH HHS [CA53841] Funding Source: Medline; NIEHS NIH HHS [ES05670] Funding Source: Medline; NIGMS NIH HHS [GM50152] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BIANCHI G, 1994, P NATL ACAD SCI USA, V91, P3999, DOI 10.1073/pnas.91.9.3999; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAKRAVARTHY BR, 1994, BIOCHEM J, V304, P809, DOI 10.1042/bj3040809; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DIAZGUERRA MJM, 1990, BIOCHEM J, V269, P163, DOI 10.1042/bj2690163; DONG LQ, 1994, CELL GROWTH DIFFER, V5, P881; GNEGY ME, 1993, ANNU REV PHARMACOL, V33, P45, DOI 10.1146/annurev.pa.33.040193.000401; GRABAREK J, 1993, J BIOL CHEM, V268, P5543; HINRICHSEN RD, 1993, P NATL ACAD SCI USA, V90, P1585, DOI 10.1073/pnas.90.4.1585; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; HYATT SL, 1994, CELL GROWTH DIFFER, V5, P495; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JOSHI R, 1991, J CELL BIOL, V115, P665, DOI 10.1083/jcb.115.3.665; KAISER HW, 1989, J CELL BIOL, V109, P557, DOI 10.1083/jcb.109.2.557; KILEY SC, 1992, CARCINOGENESIS, V13, P1997, DOI 10.1093/carcin/13.11.1997; KIM JY, 1994, J BIOL CHEM, V269, P28214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; OSBORN M, 1982, METHOD CELL BIOL, V24, P97; SCARAMUZZINO DA, 1993, P NATL ACAD SCI USA, V90, P3398, DOI 10.1073/pnas.90.8.3398; STABEL S, 1994, SEMIN CANCER BIOL, V5, P277; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; TRIPODI G, 1991, BIOCHEM BIOPH RES CO, V177, P939, DOI 10.1016/0006-291X(91)90629-L; WALLIN A, 1992, LAB INVEST, V66, P474; WASEEM A, 1990, J CELL SCI, V96, P93; WOLF M, 1988, BIOCHEM BIOPH RES CO, V154, P1273, DOI 10.1016/0006-291X(88)90277-X; ZHANG GH, 1991, J CELL PHYSIOL, V148, P295, DOI 10.1002/jcp.1041480216	31	102	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25534	25540		10.1074/jbc.270.43.25534	http://dx.doi.org/10.1074/jbc.270.43.25534			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592723	hybrid			2022-12-27	WOS:A1995TB46600040
J	FAVERO, TG; ZABLE, AC; ABRAMSON, JJ				FAVERO, TG; ZABLE, AC; ABRAMSON, JJ			HYDROGEN-PEROXIDE STIMULATES THE CA2+ RELEASE CHANNEL FROM SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID CALCIUM RELEASE; REACTIVE OXYGEN; DYSFUNCTION; SENSITIVITY; INHIBITION; MECHANISMS; RYANODINE; OXIDATION	Hydrogen peroxide (H2O2) at millimolar concentrations induces Ca2+ release from actively loaded sarcoplasmic reticulum vesicles and induces biphasic [H-3]ryanodine binding behavior. High affinity [H-3]ryanodine binding is enhanced at concentrations hom 100 mu M to 10 mM (3-4-fold). At H2O2 concentrations greater than 10 mM, equilibrium binding is inhibited. H2O2 decreased the k(d) for [H-3]ryanodine binding by increasing its association rate, while having no effect on the rate of dissociation of [H-3]ryanodine from its receptor. H2O2 (1 mM) also reduced the EC(50) for Ca2+ activation hom 632 nM to 335 nM. These effects were completely abolished in the presence of catalase, ruthenium red, and/or Mg2+ (mM) H2O2-stimulated [H-3]ryanodine binding is not further enhanced by either doxorubicin or caffeine. The direct interaction between H2O2 and the Ca2+ release mechanism was further demonstrated in single-channel reconstitution experiments. Peroxide, at submillimolar concentrations, activated the Ca2+ release channel following fusion of a sarcoplasmic reticulum vesicle to a bilayer lipid membrane. At millimolar concentrations of peroxide, Ca2+ channel activity was inhibited. Peroxide stimulation of Ca2+ channel activity was reversed by the thiol reducing agent dithiothreitol. Paralleling peroxide induced activation of ryanodine binding, Ca2+ transport, and single Ca2+ channel activity, it was observed that the ryanodine receptor formed large disulfide-linked protein complexes that dissociated upon addition of dithiothreitol.	PORTLAND STATE UNIV,DEPT PHYS,PORTLAND,OR 97207	Portland State University	FAVERO, TG (corresponding author), UNIV PORTLAND,DEPT BIOL,5000 N WILLIAMETTE BLVD,PORTLAND,OR 97203, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM044337] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL08388] Funding Source: Medline; NIGMS NIH HHS [1R15GM44337-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON JJ, 1988, ARCH BIOCHEM BIOPHYS, V263, P245, DOI 10.1016/0003-9861(88)90633-9; ALLEN DG, 1983, J PHYSIOL-LONDON, V339, P107, DOI 10.1113/jphysiol.1983.sp014706; BORASO A, 1994, AM J PHYSIOL, V267, pH1010, DOI 10.1152/ajpheart.1994.267.3.H1010; DAVISON A, 1988, MOL CELL BIOCHEM, V84, P199, DOI 10.1007/BF00421055; ELEY DW, 1989, CAN J PHYSL PHARM, V69, P1677; FREEMAN BA, 1982, LAB INVEST, V47, P412; HARRIS RN, 1985, BIOCHEM BIOPH RES CO, V130, P739, DOI 10.1016/0006-291X(85)90478-4; HEARSE DJ, 1987, FREE RADICALS OXIDAN, P13; KALCKAR HM, 1947, J BIOL CHEM, V196, P461; KAMINISHI T, 1989, BASIC RES CARDIOL, V84, P282, DOI 10.1007/BF01907975; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU GH, 1994, J BIOL CHEM, V269, P33028; LIU GH, 1994, MOL PHARMACOL, V45, P189; LU XY, 1994, J BIOL CHEM, V269, P6511; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; OKABE E, 1991, J PHARMACOL EXP THER, V256, P868; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797; SCHERER NM, 1986, ARCH BIOCHEM BIOPHYS, V246, P589, DOI 10.1016/0003-9861(86)90314-0; SMITH JK, 1989, AM J PHYSIOL, V256, pH789, DOI 10.1152/ajpheart.1989.256.3.H789; STUART J, 1992, ARCH BIOCHEM BIOPHYS, V292, P512, DOI 10.1016/0003-9861(92)90024-Q; SUZUKI YJ, 1992, AM J PHYSIOL, V262, pH114, DOI 10.1152/ajpheart.1992.262.1.H114; SUZUKI YJ, 1991, AM J PHYSIOL, V261, pH568, DOI 10.1152/ajpheart.1991.261.2.H568; TRIMM JL, 1986, J BIOL CHEM, V261, P6092; XIONG H, 1992, ARCH BIOCHEM BIOPHYS, V292, P522, DOI 10.1016/0003-9861(92)90025-R; YANAGISHITA T, 1989, BIOCHEM INT, V18, P1111	26	233	235	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25557	25563		10.1074/jbc.270.43.25557	http://dx.doi.org/10.1074/jbc.270.43.25557			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592726	hybrid			2022-12-27	WOS:A1995TB46600043
J	MOSIOR, M; NEWTON, AC				MOSIOR, M; NEWTON, AC			MECHANISM OF INTERACTION OF PROTEIN-KINASE-C WITH PHORBOL ESTERS - REVERSIBILITY AND NATURE OF MEMBRANE ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-VESICLES; PLASMA-MEMBRANE; MODEL MEMBRANES; HUMAN-PLATELETS; LIPID VESICLES; ACTIVATION; CALCIUM; PHOSPHATIDYLSERINE; DIACYLGLYCEROLS; FLUORESCENCE	A variety of approaches have been employed to demonstrate that the interaction of protein kinase C beta II with phorbol ester-containing membranes is reversible, is not accompanied by significant insertion of the protein into the hydrophobic core of the membrane, and is qualitatively similar to the interaction with diacylglycerol (DG), First, we show that under conditions when protein kinase C is bound with equal affinity to membranes containing either DG or phorbol myristate acetate (PMA), increasing ionic strength causes a similar reduction in membrane binding, The similar sensitivity to ionic strength indicates that the forces mediating the binding of protein kinase C to PMA are not significantly different from those mediating the binding to DG. At sufficiently high concentrations of PMA and relatively low concentrations of phosphatidylserine, the binding of protein kinase C to membranes became markedly less sensitive to ionic strength, suggesting that under these conditions direct non-electrostatic interactions with PMA dominate over electrostatic interactions with the lipid headgroups, Importantly, regardless of the strength of the interaction with PMA, protein kinase C exchanges between vesicle surfaces: protein kinase C bound first to phorbol ester-containing multilamellar vesicles exchanged to large unilamellar vesicles upon addition of an excess surface area of the latter, Lastly, the enzyme's intrinsic tryptophan fluorescence was not quenched by bromines located at various positions in the hydrophobic core of the membrane. In contrast, the enzyme's tryptophan fluorescence was significantly quenched by probes positioned at the membrane surface, In summary, our results are consistent with protein kinase C binding reversibly to PMA- or DG-containing membranes primarily via interactions at the membrane interface.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043154, R01GM043154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P3577, DOI 10.1021/bi00434a064; BELL RM, 1991, J BIOL CHEM, V266, P4661; BISHOP WR, 1986, J BIOL CHEM, V261, P2513; BLUME A, 1983, BIOCHEMISTRY-US, V22, P5436, DOI 10.1021/bi00292a027; BORNER C, 1992, J BIOL CHEM, V267, P12892; BRUMFELD V, 1990, ARCH BIOCHEM BIOPHYS, V277, P318, DOI 10.1016/0003-9861(90)90586-N; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CRABOS M, 1991, BIOCHEM BIOPH RES CO, V178, P878, DOI 10.1016/0006-291X(91)90973-B; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; EAST JM, 1982, BIOCHEMISTRY-US, V21, P4144, DOI 10.1021/bi00260a035; EPAND RM, 1992, EUR J BIOCHEM, V208, P327, DOI 10.1111/j.1432-1033.1992.tb17190.x; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FLORINCHRISTENSEN J, 1992, J BIOL CHEM, V267, P14783; FLORINE KI, 1987, BIOCHEMISTRY-US, V26, P2978, DOI 10.1021/bi00385a004; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LADOKHIN AS, 1991, BIOCHEMISTRY-US, V30, P10200, DOI 10.1021/bi00106a018; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P44; LETO TL, 1980, BIOCHEMISTRY-US, V19, P1911, DOI 10.1021/bi00550a028; MARKELLO T, 1985, BIOCHEMISTRY-US, V24, P2895, DOI 10.1021/bi00333a012; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; MOSIOR M, 1994, BIOPHYS J, V66, pA30; MOSIOR M, 1994, J BIOL CHEM, V269, P13798; NELSESTUEN GL, 1991, J BIOENERG BIOMEMBR, V23, P43; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; QUEST AFG, 1994, PROTEIN KINASE C, P64; RASMUSSEN H, 1992, PROTEIN KINASE C CUR, P216; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; SNOEK GT, 1986, BIOCHIM BIOPHYS ACTA, V860, P336, DOI 10.1016/0005-2736(86)90530-4; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TANFORD C, 1980, HYDROPHOBIC EFFECT; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; ZIDOVETZKI R, 1992, BIOCHIM BIOPHYS ACTA, V1134, P261, DOI 10.1016/0167-4889(92)90185-E	49	99	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25526	25533		10.1074/jbc.270.43.25526	http://dx.doi.org/10.1074/jbc.270.43.25526			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592722	hybrid			2022-12-27	WOS:A1995TB46600039
J	AUGUR, C; STIEFEL, V; DARVILL, A; ALBERSHEIM, P; PUIGDOMENECH, P				AUGUR, C; STIEFEL, V; DARVILL, A; ALBERSHEIM, P; PUIGDOMENECH, P			MOLECULAR-CLONING AND PATTERN OF EXPRESSION OF AN ALPHA-L-FUCOSIDASE GENE FROM PEA-SEEDLINGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUXIN-STIMULATED GROWTH; XYLOGLUCAN OLIGOSACCHARIDES; STEM SEGMENTS; CDNA; SEQUENCE; NONASACCHARIDE; INHIBITION; SEEDS; RNA	alpha-L-Fucosidase is a cell wall protein purified from pea (Pisum sativum) epicotyls. The alpha-L-fucosidase hydrolyzes terminal fucosyl residues from oligosaccharides of plant cell wall xyloglucan. alpha-L-Fucosidase may be an important factor in plant growth regulation, as it inactivates fucose-containing xyloglucan oligosaccharides that inhibit growth of pea stem segments. The amino acid sequences of the NH2-terminal region and one internal peptide were used to design redundant oligonucleotides that were utilized as primers in a polymerase chain reaction (PCR) with cDNA, generated from pea mRNA, as the template. A specific PCR amplification product containing 357 base pairs was isolated, cloned, and sequenced. The deduced amino acid sequence included the two peptides used to design the primers for PCR plus two other peptides obtained by proteinase digestion of alpha-L-fucosidase. No sequence ho homology to other alpha-L-fucosidases was apparent, although the NH2-terminal region is strongly homologous to Kunitz-type trypsin inhibitors, cDNA and genomic copies were isolated and sequenced. In pea, the gene is present in two or three copies. Its mRNA is present in roots, leaves, and elongating shoots. The spatial pattern of expression of the alpha-L-fucosidase was determined by in situ hybridization.	CSIC,CID,MOLEC GENET LAB,E-08034 BARCELONA,SPAIN; UNIV GEORGIA,COMPLEX CARBOHYDRATE RES CTR,ATHENS,GA 30602; UNIV GEORGIA,DEPT BIOCHEM & MOLEC BIOL,ATHENS,GA 30602; ORSTOM,MEXICO CITY 11530,DF,MEXICO	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Institut de Recherche pour le Developpement (IRD)								AUGUR C, 1992, PLANT PHYSIOL, V99, P180, DOI 10.1104/pp.99.1.180; AUGUR C, 1993, PLANT J, V3, P415, DOI 10.1046/j.1365-313X.1993.t01-20-00999.x; BURR B, 1981, GENETICS, V98, P143; CAROTHERS AM, 1989, BIOTECHNIQUES, V7, P494; CHEN ZX, 1991, INFECT IMMUN, V59, P2846, DOI 10.1128/IAI.59.8.2846-2850.1991; EMMERLING M, 1990, PLANTA, V182, P174, DOI 10.1007/BF00197107; FISHER KJ, 1989, BIOCHEM J, V264, P695, DOI 10.1042/bj2640695; FRY SC, 1989, J EXP BOT, V40, P1, DOI 10.1093/jxb/40.1.1; FUKUSHIMA H, 1985, P NATL ACAD SCI USA, V82, P1262, DOI 10.1073/pnas.82.4.1262; GARDINER M, 1975, PLANT PHYSIOL, V55, P536, DOI 10.1104/pp.55.3.536; HATTORI T, 1989, PLANT MOL BIOL, V13, P563, DOI 10.1007/BF00027316; HAYASHI T, 1984, PLANT PHYSIOL, V75, P596, DOI 10.1104/pp.75.3.596; Langdale Jane A., 1994, P165; MAESHIMA M, 1985, PHYTOCHEMISTRY, V24, P1899, DOI 10.1016/S0031-9422(00)83088-5; Maniatis T., 1982, MOL CLONING; MCDOUGALL GJ, 1990, PLANT PHYSIOL, V93, P1042, DOI 10.1104/pp.93.3.1042; MCDOUGALL GJ, 1988, PLANTA, V175, P412, DOI 10.1007/BF00396348; MOHNEN D, 1985, EMBO J, V4, P1631, DOI 10.1002/j.1460-2075.1985.tb03830.x; OCCHIODORO T, 1989, BIOCHEM BIOPH RES CO, V164, P439, DOI 10.1016/0006-291X(89)91739-7; RICHARDSON M, 1986, BIOCHIM BIOPHYS ACTA, V872, P134, DOI 10.1016/0167-4838(86)90156-1; Richardson MJ., 1991, METHODS PLANT BIOCH, P259; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VONHEIJNE G, 1981, EUR J BIOCHEM, V116, P419; YAMAMOTO M, 1983, J BIOCHEM, V94, P849, DOI 10.1093/oxfordjournals.jbchem.a134427; YORK WS, 1984, PLANT PHYSIOL, V75, P295, DOI 10.1104/pp.75.2.295	26	34	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24839	24843		10.1074/jbc.270.42.24839	http://dx.doi.org/10.1074/jbc.270.42.24839			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559605	hybrid			2022-12-27	WOS:A1995TB46500039
J	CHRISTOFFELS, VM; VANDENHOFF, MJB; MOORMAN, AFM; LAMERS, WH				CHRISTOFFELS, VM; VANDENHOFF, MJB; MOORMAN, AFM; LAMERS, WH			THE FAR-UPSTREAM ENHANCER OF THE CARBAMOYL-PHOSPHATE SYNTHETASE-I GENE IS RESPONSIBLE FOR THE TISSUE-SPECIFICITY AND HORMONE INDUCIBILITY OF ITS EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RAT-LIVER; CYCLIC-AMP; MESSENGER-RNAS; REPORTER GENE; CELL LINES; PROMOTER; PHOSPHORYLATION; TRANSCRIPTION; HEPATOCYTES	The role of the proximal promoter and the far-upstream enhancer in the hepatocyte-specific and hormonal regulation of the carbamoyl-phosphate synthetase I (CPS) gene was investigated in transient transfection assays using primary rat hepatocytes, hepatoma cells, and fibroblasts. These experiments revealed that the activity of the promoter is comparable in all cells tested and is, therefore, not responsible for tissue-specific expression, The 5'-untranslated region of the mRNA is a major, non-tissue specific stimulator of expression in FTO-2B hepatoma cells, acting at the post-transcriptional level. A 469-base pair DNA fragment, 6 kilobase pairs upstream of the transcription start-site in the CPS gene, confers strong hormone-dependent tissue specific expression, both in combination with the CPS promoter and a minimized viral thymidine kinase promoter. Sequences similar to a;cyclic AMP-responsive element and a glucocorticosteroid-responsive element were found in the isolated enhancer. Substitutional mutations in these sites strongly affected hormone-induced expression. Analysis of the interaction between the enhancer and parts of the CPS promoter revealed that, in addition to the TATA box, the GAG box, a motif similar to the GC box near the TATA motif, is instrumental in conferring the enhancer activity.	UNIV AMSTERDAM,DEPT ANAT & EMBRYOL,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam			Lamers, Wouter H./D-2965-2012	van den Hoff, Maurice/0000-0002-3837-8055				ADCOCK MW, 1984, J BIOL CHEM, V259, P3471; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BLOMMAART PJE, 1993, J BIOL CHEM, V268, P1610; BOTCHAN M, 1976, CELL, V9, P269, DOI 10.1016/0092-8674(76)90118-5; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COTTREZ F, 1994, NUCLEIC ACIDS RES, V22, P2712, DOI 10.1093/nar/22.13.2712; DEGROOT CJ, 1986, BIOCHIM BIOPHYS ACTA, V866, P61, DOI 10.1016/0167-4781(86)90101-6; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOPING IS, 1994, J BIOL CHEM, V269, P3891; GOPING IS, 1992, GENE, V118, P283, DOI 10.1016/0378-1119(92)90201-Y; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HARAGUCHI Y, 1991, GENE, V107, P335; HONG J, 1994, J MOL BIOL, V243, P131, DOI 10.1006/jmbi.1994.1638; JANZEN JWG, 1988, J HISTOCHEM CYTOCHEM, V36, P1223, DOI 10.1177/36.10.2458406; JANZEN JWG, 1985, J HISTOCHEM CYTOCHEM, V339, P1205; KILLARY AM, 1976, CELL, V9, P269; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAGACE M, 1987, J BIOL CHEM, V262, P10415; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LALLI E, 1994, J BIOL CHEM, V269, P17359; LAMERS WH, 1981, MECH AGEING DEV, V15, P93, DOI 10.1016/0047-6374(81)90010-5; LAMERS WH, 1987, DIFFERENTIATION, V35, P228, DOI 10.1111/j.1432-0436.1987.tb00173.x; LAMERS WH, 1984, DEV BIOL, V105, P500, DOI 10.1016/0012-1606(84)90307-5; MAJUMDER S, 1993, EMBO J, V12, P1131, DOI 10.1002/j.1460-2075.1993.tb05754.x; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MOORMAN AFM, 1990, HISTOCHEM J, V22, P457, DOI 10.1007/BF01007229; MOORMAN AFM, 1990, FEBS LETT, V276, P9, DOI 10.1016/0014-5793(90)80494-4; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; MOSSING MC, 1986, SCIENCE, V233, P889, DOI 10.1126/science.3090685; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; PINTO M, 1983, BIOL CELL, V47, P323; RYALL JC, 1986, EUR J BIOCHEM, V156, P453, DOI 10.1111/j.1432-1033.1986.tb09603.x; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; VANDEHOFF MJB, 1995, METHODS MOL BIOL; VANDENHOFF MJB, 1993, NUCLEIC ACIDS RES, V21, P4987, DOI 10.1093/nar/21.21.4987; VANDENHOFF MJB, 1995, EUR J BIOCHEM, V228, P351; VANROON MA, 1989, DIFFERENTIATION, V41, P139, DOI 10.1111/j.1432-0436.1989.tb00741.x; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	55	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24932	24940		10.1074/jbc.270.42.24932	http://dx.doi.org/10.1074/jbc.270.42.24932			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559619	hybrid			2022-12-27	WOS:A1995TB46500053
J	LIU, Y; NESHEIM, JC; LEE, SK; LIPSCOMB, JD				LIU, Y; NESHEIM, JC; LEE, SK; LIPSCOMB, JD			GATING EFFECTS OF COMPONENT-B ON OXYGEN ACTIVATION BY THE METHANE MONOOXYGENASE HYDROXYLASE COMPONENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							METHYLOCOCCUS-CAPSULATUS BATH; METHYLOSINUS-TRICHOSPORIUM OB3B; CATALYTIC CYCLE; PROTEIN-B; REDUCTASE; EPR; MOSSBAUER; IDENTIFICATION; HYDROCARBONS; OXIDATION	Component B (MMOB) of the soluble methane mono oxygenase (MMO) system accelerates the initial velocity of methane oxidation by up to 150-fold by an unknown mechanism. The active site of MMO contains a diferric, hydroxo-bridged diiron cluster located on the hydroxylase component (MMOH). This cluster is reduced by the NAD(P)H-coupled reductase component to the diferrous state, which then reacts with O-2 to yield two reaction cycle intermediates sequentially termed compounds P and Q. The rate of compound P formation is shown here to be independent of O-2 concentration, suggesting that an MMOH-O-2 complex (compound O) is (similar to irreversibly) formed before compound P. Compound Q is capable of reacting with hydrocarbons to yield the MMOH-product complex, compound T. It is shown here that MMOB accelerates catalysis by increasing similar to 1000-fold the rate of O-2 association and reaction with diferrous MMOH leading to compound P. Modeling of the single turnover reaction in the presence of substoichiometric MMOB suggests that MMOB also accelerates the compound P to Q conversion by similar to 40-fold. Due to this O-2-gating effect of MMOB, either compound Q or T becomes the dominant species during turnover, depending upon the substrate concentration and type. Because these are the species that either react with substrate (Q) or release product (T), their buildup maximizes the turnover rate. This is the first direct role in catalysis to be recognized for MMOB and represents a novel method for oxygenase regulation.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities				Lipscomb, John/0000-0002-8158-5594	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008277, R01GM040466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40466, GM08277, R01 GM040466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON KK, 1991, NEW J CHEM, V15, P411; DALTON H, 1980, ADV APPL MICROBIOL, V26, P71; DEROSE VJ, 1993, J AM CHEM SOC, V115, P6440, DOI 10.1021/ja00067a081; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1994, BIOCHEMISTRY-US, V33, P12776, DOI 10.1021/bi00209a008; FOX BG, 1989, J BIOL CHEM, V264, P10023; FOX BG, 1991, J BIOL CHEM, V266, P540; FOX BG, 1993, J AM CHEM SOC, V115, P3688, DOI 10.1021/ja00062a039; FOX BG, 1990, METHOD ENZYMOL, V188, P191; FROLAND WA, 1992, J BIOL CHEM, V267, P17588; GREEN J, 1985, J BIOL CHEM, V260, P5795; GREEN J, 1989, BIOCHEM J, V259, P167, DOI 10.1042/bj2590167; HENDRICH MP, 1990, J AM CHEM SOC, V112, P5861, DOI 10.1021/ja00171a029; HIGGINS IJ, 1980, NATURE, V286, P561, DOI 10.1038/286561a0; LEE SK, 1993, J BIOL CHEM, V268, P21569; LEE SK, 1993, J AM CHEM SOC, V115, P6450, DOI 10.1021/ja00067a086; LIPSCOMB JD, 1994, ANNU REV MICROBIOL, V48, P371, DOI 10.1146/annurev.mi.48.100194.002103; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; LIU KE, 1991, J BIOL CHEM, V266, P12836; LIU KE, 1994, J AM CHEM SOC, V116, P7465, DOI 10.1021/ja00095a083; LIU KE, 1995, J AM CHEM SOC, V117, P4997, DOI 10.1021/ja00122a032; LIU KE, 1991, J BIOL CHEM, V266, P24859; LUND J, 1985, EUR J BIOCHEM, V147, P291, DOI 10.1111/j.1432-1033.1985.tb08749.x; LUND J, 1985, EUR J BIOCHEM, V147, P297, DOI 10.1111/j.1432-1033.1985.tb08750.x; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; PAULSEN KE, 1994, BIOCHEMISTRY-US, V33, P713, DOI 10.1021/bi00169a013; PULVER S, 1993, J AM CHEM SOC, V115, P12409, DOI 10.1021/ja00079a024; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; SLIGAR SG, 1974, P NATL ACAD SCI USA, V71, P3906, DOI 10.1073/pnas.71.10.3906; THOMANN H, 1993, J AM CHEM SOC, V115, P8881, DOI 10.1021/ja00072a068	31	139	140	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24662	24665		10.1074/jbc.270.42.24662	http://dx.doi.org/10.1074/jbc.270.42.24662			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559577	hybrid			2022-12-27	WOS:A1995TB46500011
J	MORRIS, BJ				MORRIS, BJ			STIMULATION OF IMMEDIATE-EARLY GENE-EXPRESSION IN STRIATAL NEURONS BY NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS ADP-RIBOSYLATION; DEPENDENT PROTEIN-KINASE; RAT-BRAIN; NADPH-DIAPHORASE; NERVOUS-SYSTEM; MESSENGER-RNAS; C-FOS; CALCIUM; GMP; ACTIVATION	Exposure of primary cultures of embryonic rat striatal neurons to agents releasing nitric oxide (NO), including sin-1 molsidomine, S-nitroso-n-acetyl-penicillamine (SNAP), and S-nitrosoglutathione, resulted in an increase in the levels of expression of the immediate early genes c-fos and zif/268 in the cultured neurons. The membrane permeable cGMP analogue, 8-bromo-cGMP, did not significantly affect c-fos and zif/268 mRNA levels, and the highly selective inhibitor of cGMP dependent protein kinase, KT5823, was unable to inhibit the elevation in c-fos and zif/268 mRNA levels induced by SNAP. The induction of c-fos by the calcium ionophore A23187 was reduced by treatment with SNAP or 8-bromo-cGMP. Inhibitors of ADP-ribosyltransferases attenuated the stimulation of c-fos expression by SNAP. These results demonstrate for the first time that NO can induce immediate early gene expression in neurons, suggesting that NO may act as a mediator of neuronal plasticity via alterations in the expression of downstream genes. In addition, the results suggest that NO may exert these effects through a pathway that does not involve guanylate cyclase and cGMP-dependent protein kinase.			MORRIS, BJ (corresponding author), UNIV GLASGOW, INST BIOMED & LIFE SCI, PHARMACOL LABS, W MED BLDG, GLASGOW G12 8QQ, LANARK, SCOTLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BANNON MJ, 1986, J BIOL CHEM, V261, P6640; BRUNE B, 1989, J BIOL CHEM, V264, P8455; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; DRAGUNOW M, 1990, NEUROSCIENCE, V37, P287, DOI 10.1016/0306-4522(90)90399-O; DUMAN RS, 1991, J NEUROCHEM, V57, P2124, DOI 10.1111/j.1471-4159.1991.tb06431.x; EHRETHILBERER S, 1992, FEBS LETT, V309, P394, DOI 10.1016/0014-5793(92)80814-W; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GARG UC, 1991, J BIOL CHEM, V266, P9; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GRAYBIEL AM, 1986, NEUROPEPTIDES NEUROL, P135; HABY C, 1994, J NEUROCHEM, V62, P496; HOPE BT, 1989, J HISTOCHEM CYTOCHEM, V37, P653, DOI 10.1177/37.5.2703701; Ito M, 1990, Neuroreport, V1, P129; JOHANSSON JS, 1992, BIOCHIM BIOPHYS ACTA, V1105, P40, DOI 10.1016/0005-2736(92)90160-N; JOHNSTON HM, 1994, NEUROSCIENCE, V61, P435, DOI 10.1016/0306-4522(94)90423-5; JOHNSTON HM, 1994, J NEUROCHEM, V63, P379; KENDALL DA, 1984, J NEUROCHEM, V42, P1388, DOI 10.1111/j.1471-4159.1984.tb02799.x; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MERCHANT KM, 1989, BRAIN RES, V500, P21, DOI 10.1016/0006-8993(89)90295-3; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS BJ, 1989, J COMP NEUROL, V290, P358, DOI 10.1002/cne.902900305; MORRIS BJ, 1988, NEUROSCIENCE, V25, P525, DOI 10.1016/0306-4522(88)90256-4; OLIVA AM, 1995, NEUROREPORT, V6, P565, DOI 10.1097/00001756-199502000-00039; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; POZDNYAKOV N, 1993, BIOCHEM BIOPH RES CO, V192, P610, DOI 10.1006/bbrc.1993.1459; RANKIN PW, 1989, J BIOL CHEM, V264, P4312; ROBERTSON HA, 1989, BRAIN RES, V503, P346, DOI 10.1016/0006-8993(89)91689-2; RUTH P, 1993, P NATL ACAD SCI USA, V90, P2623, DOI 10.1073/pnas.90.7.2623; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SIMPSON CS, 1994, TISSUE CELL, V26, P929, DOI 10.1016/0040-8166(94)90042-6; SIMPSON CS, 1994, J NEUROCHEM, V63, P1955; SIMPSON CS, 1994, NEUROSCI LETT, V170, P281, DOI 10.1016/0304-3940(94)90338-7; SIMPSON CS, 1995, NEUROSCIENCE, V68, P97, DOI 10.1016/0306-4522(95)00122-Y; SMITH SS, 1993, MOL PHARMACOL, V43, P1; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SURMEIER DJ, 1988, DEV BRAIN RES, V42, P265, DOI 10.1016/0165-3806(88)90245-3; VACCARINO FM, 1992, MOL BRAIN RES, V12, P233, DOI 10.1016/0169-328X(92)90089-T; VINCENT SR, 1983, J COMP NEUROL, V217, P252, DOI 10.1002/cne.902170303; WILLIAMS MB, 1992, BRAIN RES, V592, P49, DOI 10.1016/0006-8993(92)91657-Z; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; YOUNG WS, 1986, P NATL ACAD SCI USA, V83, P9827, DOI 10.1073/pnas.83.24.9827; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	47	98	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24740	24744						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559590				2022-12-27	WOS:A1995TB46500024
J	WILSON, LK; BENTON, BM; ZHOU, S; THORNER, J; MARTIN, GS				WILSON, LK; BENTON, BM; ZHOU, S; THORNER, J; MARTIN, GS			THE YEAST IMMUNOPHILIN FPR3 IS A PHYSIOLOGICAL SUBSTRATE OF THE TYROSINE-SPECIFIC PHOSPHOPROTEIN PHOSPHATASE PTP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; FK506-BINDING PROTEIN; FACTOR RECEPTOR; ALPHA-FACTOR; V-SRC; KINASE; THREONINE; SERINE; GENE	The tyrosine-specific phosphoprotein phosphatase encoded by the Saccharomyces cerevisiae PTP1 gene dephosphorylates artificial substrates in vitro, but little is known about its functions and substrates in vivo. The presence of Ptp1 resulted in dephosphorylation of multiple tyrosine-phosphorylated proteins in yeast expressing a heterologous tyrosine-specific protein kinase, indicating that Ptp1 can dephosphorylate a broad range of substrates in vivo. Correspondingly, several proteins phosphorylated at tyrosine by endogenous protein kinases exhibited a marked increase in tyrosine phosphorylation in ptp1 mutant cells. One of these phosphotyrosyl proteins (p70) was also dephosphorylated in vitro when incubated with recombinant Ptp1. p70 was purified to homogeneity; analysis of four tryptic peptides revealed that p70 is identical to the recently described FPR3 gene product, a nucleolarly localized proline rotamase of the FK506- and rapamycin-binding family. The identity of p70 with Fpr3 was confirmed in the demonstration that the abundance of tyrosine-phosphorylated p70 in ptp1 mutants was strictly correlated with the level of FPR3 expression; immobilized phosphotyrosyl Fpr3 was directly dephosphorylated by recombinant Ptp1. Site-directed mutagenesis demonstrated that the site of tyrosine phosphorylation is Tyr-184, which resides within the nucleolin-like amino-terminal domain of Fpr3. Protein kinase activities from yeast cell extracts can bind to and phosphorylate the immobilized aminoterminal domain of Fpr3 on serine, threonine, and tyrosine. Fpr3 represents the first phosphotyrosyl protein identified in S. cerevisiae that is not itself a protein kinase and is as yet the only known physiological substrate of Ptp1.	UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021841, R01GM021841] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44143, GM21841] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BENTON BM, 1994, J CELL BIOL, V127, P623, DOI 10.1083/jcb.127.3.623; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BOSCHELLI F, 1993, J CELL SCI, V105, P519; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; Delidow B C, 1993, Methods Mol Biol, V15, P1, DOI 10.1385/0-89603-244-2:1; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FLORIO M, 1994, MOL BIOL CELL, V5, P283, DOI 10.1091/mbc.5.3.283; FRACKELTON AR, 1984, J BIOL CHEM, V259, P7909; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN K, 1991, J BIOL CHEM, V266, P12964; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HANNIG G, 1993, YEAST, V9, P1039, DOI 10.1002/yea.320091002; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HOEKSTRA MF, 1994, MOL BIOL CELL, V5, P877, DOI 10.1091/mbc.5.8.877; JAMES P, 1992, GENE, V122, P101, DOI 10.1016/0378-1119(92)90037-P; JORDAN G, 1987, NATURE, V329, P489, DOI 10.1038/329489a0; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBL EC, 1992, J VIROL, V66, P4315, DOI 10.1128/JVI.66.7.4315-4324.1992; LIM MY, 1993, J BIOL CHEM, V268, P21155; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANNINGKRIEG UC, 1994, FEBS LETT, V352, P98, DOI 10.1016/0014-5793(94)00927-9; MOUREY RJ, 1994, CURR OPIN GENET DEV, V4, P31, DOI 10.1016/0959-437X(94)90088-4; NIELSEN JB, 1992, P NATL ACAD SCI USA, V89, P7471, DOI 10.1073/pnas.89.16.7471; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PARTALEDIS JA, 1993, P NATL ACAD SCI USA, V90, P5450, DOI 10.1073/pnas.90.12.5450; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; SCHMIDT A, 1994, MOL CELL BIOL, V14, P6597, DOI 10.1128/MCB.14.10.6597; SHAN XY, 1994, J CELL BIOL, V126, P853, DOI 10.1083/jcb.126.4.853; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVER PA, 1988, GENE DEV, V2, P707, DOI 10.1101/gad.2.6.707; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; TONKS NK, 1988, J BIOL CHEM, V263, P6731; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WAN J, 1992, J BIOL CHEM, V267, P11274; WIEDERRECHT G, 1991, P NATL ACAD SCI USA, V88, P1029, DOI 10.1073/pnas.88.3.1029	52	41	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25185	25193		10.1074/jbc.270.42.25185	http://dx.doi.org/10.1074/jbc.270.42.25185			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559654	hybrid			2022-12-27	WOS:A1995TB46500088
J	BLACKBURN, MR; WAKAMIYA, M; CASKEY, CT; KELLEMS, RE				BLACKBURN, MR; WAKAMIYA, M; CASKEY, CT; KELLEMS, RE			TISSUE-SPECIFIC RESCUE SUGGESTS THAT PLACENTAL ADENOSINE-DEAMINASE IS IMPORTANT FOR FETAL DEVELOPMENT IN MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEOXYADENOSINE METABOLISM; S-ADENOSYLHOMOCYSTEINE; MOUSE; EXPRESSION; DEFICIENCY	Adenosine deaminase (ADA, EC 3.5.4.4) is an essential enzyme of purine metabolism that is expressed at very high levels in the murine placenta where it accounts for over 95% of the ADA present at the fetal gestation site. We have recently shown that ADA-deficient fetuses, which also lack ADA in their adjoining placentas, die during late fetal development in association with profound purine metabolic disturbances and hepatocellular impairment. We have now investigated the potential importance of placental ADA by genetically restoring the enzyme to placentas of ADA-deficient fetuses. This genetic engineering strategy corrected most of the purine metabolic disturbances, prevented serious fetal liver damage, and rescued the fetuses from perinatal lethality. Our findings suggest that placental ADA is important for murine fetal development and illustrate a general strategy for the tissue specific correction of phenotypes associated with null mutations in mice.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine				Blackburn, Michael/0000-0002-1394-9966	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042436] Funding Source: NIH RePORTER; NICHD NIH HHS [HD30302] Funding Source: Medline; NIDDK NIH HHS [DK46207] Funding Source: Medline; NIGMS NIH HHS [GM42436] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARSON DA, 1980, J IMMUNOL, V124, P8; CARSON DA, 1977, P NATL ACAD SCI USA, V74, P5677, DOI 10.1073/pnas.74.12.5677; CHINSKY JM, 1990, DIFFERENTIATION, V42, P172, DOI 10.1111/j.1432-0436.1990.tb00759.x; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; FINKELSTEIN JD, 1973, ARCH BIOCHEM BIOPHYS, V159, P160, DOI 10.1016/0003-9861(73)90440-2; GAO X, 1993, TERATOLOGY, V49, P1; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; GURTNER GC, 1995, GENE DEV, V9, P1, DOI 10.1101/gad.9.1.1; HERSHFIELD MS, 1979, J BIOL CHEM, V254, P22; HERSHFIELD MS, 1995, METABOLIC MOL BASIS, V1, P1725; Hogan B, 1994, MANIPULATING MOUSE E; JOHNSTON JM, 1979, J IMMUNOL, V123, P97; KASH SF, 1994, MOL CELL BIOL, V14, P6198, DOI 10.1128/MCB.14.9.6198; KNUDSEN TB, 1991, BIOL REPROD, V44, P171, DOI 10.1095/biolreprod44.1.171; KNUDSEN TB, 1992, TERATOLOGY, V45, P91, DOI 10.1002/tera.1420450109; MIGCHIELSEN AAJ, 1995, NAT GENET, V10, P279, DOI 10.1038/ng0795-279; Naeye RL, 1992, DISORDERS PLACENTA F; STILES GL, 1992, J BIOL CHEM, V267, P6451; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; ULLMAN B, 1978, CELL, V14, P365, DOI 10.1016/0092-8674(78)90122-8; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; WINSTON JH, 1992, J BIOL CHEM, V267, P13472; WITTE DP, 1991, J CELL BIOL, V115, P179, DOI 10.1083/jcb.115.1.179; YEUNG CY, 1985, J BIOL CHEM, V260, P299	25	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23891	23894		10.1074/jbc.270.41.23891	http://dx.doi.org/10.1074/jbc.270.41.23891			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592575	hybrid			2022-12-27	WOS:A1995TA21700003
J	COLOMBO, MI; INGLESE, J; D'SOUZA-SCHOREY, C; BERON, W; STAHL, PD				COLOMBO, MI; INGLESE, J; D'SOUZA-SCHOREY, C; BERON, W; STAHL, PD			HETEROTRIMERIC G-PROTEINS INTERACT WITH THE SMALL GTPASE ARF - POSSIBILITIES FOR THE REGULATION OF VESICULAR TRAFFIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; BETA-GAMMA-SUBUNITS; ADRENERGIC-RECEPTOR KINASE; TRIMERIC-G-PROTEINS; GOLGI MEMBRANES; BINDING PROTEINS; BREFELDIN-A; ENDOSOME FUSION; MEDIATED ENDOCYTOSIS; GUANINE-NUCLEOTIDE	Trimeric G proteins have emerged as important regulators of membrane trafficking. To explore a role for G beta gamma in endosome fusion, we have taken advantage of beta-adrenergic receptor kinase (beta ARK), an enzyme translocated to membranes by interaction with G beta gamma, The COOH terminus of beta ARK (beta ARKct) has a G beta gamma-binding domain which blocks some G beta gamma-mediated processes. We found that beta ARKct and peptide G, a peptide derived from beta ARKct, inhibit in vitro endosome fusion. Interestingly, peptide G and ARF share sequence similarity. Peptide G and beta ARKct reversed ARF-mediated inhibition of endosome fusion and blocked ARF binding to membranes. Using an ARF fusion protein, we show that both G beta gamma and G alpha s interact with the small GTPase ARF, an interaction that is regulated by nucleotide binding. We conclude that G proteins may participate in the regulation of vesicular trafficking by directly interacting with ARF, a cytosolic factor required for transport.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA	Washington University (WUSTL); Duke University; Howard Hughes Medical Institute			Stahl, Philip/D-6315-2012					BALCH WE, 1992, J BIOL CHEM, V267, P13053; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BERON W, 1995, ARCH BIOCHEM BIOPHYS, V317, P337, DOI 10.1006/abbi.1995.1172; BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BURGOYNE RD, 1992, TRENDS BIOCHEM SCI, V17, P87; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; COLOMBO MI, 1994, J BIOL CHEM, V269, P14919; COLOMBO MI, 1994, MOL MEMBR BIOL, V11, P93, DOI 10.3109/09687689409162226; COLOMBO MI, 1992, METHOD ENZYMOL, V219, P32; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1994, SCIENCE, V6, P527; FINAZZI D, 1994, J BIOL CHEM, V269, P13325; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HARAGUCHI K, 1991, P NATL ACAD SCI USA, V88, P5964, DOI 10.1073/pnas.88.14.5964; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HONG JX, 1994, J BIOL CHEM, V269, P9743; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1984, J BIOL CHEM, V259, P6235; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KREIS TE, 1994, CURR OPIN CELL BIOL, V6, P533, DOI 10.1016/0955-0674(94)90073-6; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LENHARD JM, 1994, ARCH BIOCHEM BIOPHYS, V312, P474, DOI 10.1006/abbi.1994.1334; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561	66	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24564	24571		10.1074/jbc.270.41.24564	http://dx.doi.org/10.1074/jbc.270.41.24564			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592675	hybrid			2022-12-27	WOS:A1995TA21700103
J	FORMISANO, P; NAJJAR, SM; GROSS, CN; PHILIPPE, N; ORIENTE, F; KERNBUELL, CL; ACCILI, D; GORDEN, P				FORMISANO, P; NAJJAR, SM; GROSS, CN; PHILIPPE, N; ORIENTE, F; KERNBUELL, CL; ACCILI, D; GORDEN, P			RECEPTOR-MEDIATED INTERNALIZATION OF INSULIN - POTENTIAL ROLE OF PP120/HA4, A SUBSTRATE OF THE INSULIN-RECEPTOR KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; ENDOGENOUS SUBSTRATE; ECTO-ATPASE; BETA-SUBUNIT; ENDOCYTOSIS; GLYCOPROTEIN; DOMAIN; IDENTIFICATION; LOCALIZATION; PROTEIN	pp120/HA4 is a hepatocyte membrane glycoprotein phosphorylated by the insulin receptor tyrosine kinase, In this study, we have investigated the role of pp120/HA4 in insulin action, Transfection of antisense pp120/HA4 cDNA in H35 hepatoma cells resulted in inhibition of pp120/HA4 expression and was associated with a 2-3-fold decrease in the rate of insulin internalization. Furthermore, insulin internalization in NIH 3T3 fibroblasts co-transfected with insulin receptors and pp120/HA4 was increased 2-fold compared with cells expressing insulin receptors alone. In contrast, no effect on internalization was observed in cells overexpressing a naturally occurring splice variant of pp120/HA4 that lacks the phosphorylation sites in the intracellular domain. Insulin lin internalization was also unaffected in cells expressing three site-directed mutants of pp120/HA4 in which the sites of phosphorylation by the insulin receptor kinase had been removed (Y488F, Y488F/Y513F, and S503A). Our data suggest that pp120/HA4 is part of a complex of proteins required for receptor-mediated internalization of insulin. It is possible that this function is regulated by insulin-induced phosphorylation of the intracellular domain of pp120/HA4.	NIDDK,DIABET BRANCH,BETHESDA,MD 20892; MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Formisano, Pietro/J-4237-2018; Najjar, Sonia M/GXW-2217-2022; ORIENTE, Francesco/J-6652-2018	Formisano, Pietro/0000-0001-7020-6870; ORIENTE, Francesco/0000-0003-4375-4526				ACCILI D, 1986, ENDOCRINOLOGY, V119, P1274, DOI 10.1210/endo-119-3-1274; BACKER JM, 1990, J BIOL CHEM, V265, P16450; CARPENTIER JL, 1978, J CLIN INVEST, V61, P1057, DOI 10.1172/JCI109005; CARPENTIER JL, 1995, J BIOL CHEM, V270, P5001, DOI 10.1074/jbc.270.10.5001; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CONDORELLI G, 1994, J BIOL CHEM, V269, P8510; FORMISANO P, 1994, J BIOL CHEM, V269, P16242; GEIGER D, 1989, EXP CELL RES, V185, P33, DOI 10.1016/0014-4827(89)90034-7; GORDEN P, 1978, SCIENCE, V200, P782, DOI 10.1126/science.644321; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HARI J, 1987, J BIOL CHEM, V262, P15341; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; LIN SH, 1989, J BIOL CHEM, V264, P14408; LUND KA, 1990, J BIOL CHEM, V265, P15713; MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7256, DOI 10.1073/pnas.85.19.7256; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DA, 1992, AM J MED SCI, V304, P192, DOI 10.1097/00000441-199209000-00009; MORI S, 1991, J BIOL CHEM, V266, P21158; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; RENFREWHAFT C, 1994, J BIOL CHEM, V269, P26286; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; RUSSELL DS, 1987, J BIOL CHEM, V262, P14663; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SIPPEL CJ, 1994, J BIOL CHEM, V269, P2820; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; WELSH JB, 1994, MOL BIOL CELL, V5, P539, DOI 10.1091/mbc.5.5.539; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMADA K, 1995, J BIOL CHEM, V270, P3115, DOI 10.1074/jbc.270.7.3115	35	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24073	24077		10.1074/jbc.270.41.24073	http://dx.doi.org/10.1074/jbc.270.41.24073			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592607	hybrid			2022-12-27	WOS:A1995TA21700035
J	TAO, Y; CHEN, KY				TAO, Y; CHEN, KY			MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF NEUROSPORA DEOXYHYPUSINE SYNTHASE CDNA AND IDENTIFICATION OF YEAST DEOXYHYPUSINE SYNTHASE CDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; AMPLIFICATION; PROTEIN; PCR	Deoxyhypusine synthase catalyzes the formation of deoxyhypusine residue on the eIF-5A precursor using spermidine as the substrate. We have purified deoxyhypusine synthase from Neurospora crassa to apparent homogeneity (Tao, Y., and Chen, K. Y. (1995) J. Biol. Chem. 270, 383-386). We have now cloned and characterized the deoxyhypusine synthase cDNA using a reverse genetic approach. Conceptual translation of the nucleotide sequence of the cloned 1258-base pair cDNA revealed an open reading frame containing 353 amino acids with a predicted M(r) of 38,985. The deoxyhypusine synthase cDNA was subcloned into the expression vector pQE60 to produce a 40,000-dalton recombinant protein on SDS-PAGE which exhibited deoxyhypusine synthase activity. A GenBank search showed that the Neurospora deoxyhypusine synthase cDNA possessed significant sequence homology to a previously uncharacterized yeast sequence (accession number U00061 (1994)). The yeast sequence encodes a protein of 387 amino acids that shows 69% of total amino acid identity and 80% of total amino acid similarity to the Neurospora enzyme. Sequence alignment and hydropathy analysis suggest that the yeast sequence represents deoxyhypusine synthase.	RUTGERS STATE UNIV,DEPT CHEM,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,GRAD PROGRAM BIOCHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University New Brunswick				Chen, Kuang Yu/0000-0002-5629-7785	NATIONAL CANCER INSTITUTE [R01CA049695] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA49695] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEN KY, 1988, FEBS LETT, V229, P325, DOI 10.1016/0014-5793(88)81149-9; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; DOU QP, 1990, BIOCHIM BIOPHYS ACTA, V1036, P128, DOI 10.1016/0304-4165(90)90024-Q; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; JAKUS J, 1993, J BIOL CHEM, V268, P13151; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; PARK MH, 1984, J BIOL CHEM, V259, P2123; PARK MH, 1988, J BIOL CHEM, V263, P15264; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SHULDINER AR, 1990, NUCLEIC ACIDS RES, V18, P1920, DOI 10.1093/nar/18.7.1920; TAO Y, 1994, BIOCHEM J, V302, P517, DOI 10.1042/bj3020517; TAO Y, 1995, J BIOL CHEM, V270, P383, DOI 10.1074/jbc.270.1.383; TAO Y, 1994, ANAL BIOCHEM, V221, P103, DOI 10.1006/abio.1994.1385	15	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23984	23987		10.1074/jbc.270.41.23984	http://dx.doi.org/10.1074/jbc.270.41.23984			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592594	hybrid			2022-12-27	WOS:A1995TA21700022
J	RUSSELLHARDE, D; PU, HF; BETTS, M; HARKINS, RN; PEREZ, HD; CROZE, E				RUSSELLHARDE, D; PU, HF; BETTS, M; HARKINS, RN; PEREZ, HD; CROZE, E			RECONSTITUTION OF A HIGH-AFFINITY BINDING-SITE FOR TYPE-I INTERFERONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOKINE RECEPTORS; ALPHA RECEPTOR; RECOMBINANT; BETA	The type I interferon (IFN) receptor complex is assumed to be composed of multiple protein subunits, Recently, two proteins have been identified as potential receptor components, both of which share a high degree of structural homology with the immunoglobulin superfamily, One of these proteins, referred to as the human interferon alpha receptor (IFNAR), has been shown to be involved in interferon signal transduction, but it does not bind IFN with high affinity, A second putative receptor protein, named FLP40, has been cloned from human Daudi cells, Transfection of FLP40 into murine NIH 3T3 cells does not result in high affinity IFN binding, In this study, we demonstrate that when expressed in murine L929 cells neither IFNAR nor FLP40 by themselves are capable of binding human IFN-alpha 8. Co-expression of IFNAR and FLP40 results in cells capable of binding IFN-alpha 8 and IFN-alpha 2. Scatchard analysis of binding demonstrated the presence of high (K-D 350 pM) and low (K-D 4.0 nM) affinity binding sites, Binding of radiolabeled IFN-alpha 8 can be competed with either unlabeled IFN-alpha 8 or a recombinant form of human interferon beta, IFN-beta 1b, but not with IFN-gamma. Ligand binding of LFN-alpha 8 can be inhibited by antibodies directed against IFNAR providing further support for a role for this protein in the formation of a ligand binding site, This is the first demonstration indicating that two previously identified IFN receptor proteins, which individually do not bind type I IFN with high affinity, cooperate in the formation of a type I IFN receptor ligand binding complex.	BERLEX BIOSCI INC,DEPT PROT BIOCHEM & BIOPHYS,RICHMOND,CA 94804; BERLEX BIOSCI INC,DEPT CELL & MOLEC BIOL,RICHMOND,CA 94804; BERLEX BIOSCI INC,DEPT IMMUNOL,RICHMOND,CA 94804				Eishingdrelo, Haifeng/R-8426-2019	Eishingdrelo, Haifeng/0000-0001-7205-1008				ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; BENOIT P, 1993, J IMMUNOL, V150, P707; COLAMONICI OR, 1994, J BIOL CHEM, V269, P9598; COLAMONICI OR, 1992, J IMMUNOL, V142, P2126; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; CONSTANTINESCU SN, 1995, IN PRESS P NATL ACAD; GILLIS S, 1991, CURR OPIN IMMUNOL, V3, P315, DOI 10.1016/0952-7915(91)90030-5; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; LIM JK, 1994, FEBS LETT, V350, P281, DOI 10.1016/0014-5793(94)00787-X; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PEREZ HD, 1994, J BIOL CHEM, V269, P22485; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; REHBERG E, 1982, J BIOL CHEM, V257, P1497; RUSSELLHARDE D, 1995, J INTERF CYTOK RES, V15, P31, DOI 10.1089/jir.1995.15.31; RUSSELLHARDE D, 1993, J INTERFERON RES, V13, P578; SCATCHARD G, 1965, ANN NY ACAD SCI, V51, P660; SETO MH, 1995, PROTEIN SCI, V4, P655; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1994, J MOL BIOL, V243, P245, DOI 10.1006/jmbi.1994.1651; VANDENBROECKE C, 1988, J INTERFERON RES, V8, P803; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L	28	32	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26033	26036		10.1074/jbc.270.44.26033	http://dx.doi.org/10.1074/jbc.270.44.26033			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592797	hybrid			2022-12-27	WOS:A1995TC97800004
J	SACHS, CW; SAFA, AR; HARRISON, SD; FINE, RL				SACHS, CW; SAFA, AR; HARRISON, SD; FINE, RL			PARTIAL INHIBITION OF MULTIDRUG-RESISTANCE BY SAFINGOL IS INDEPENDENT OF MODULATION OF P-GLYCOPROTEIN SUBSTRATE ACTIVITIES AND CORRELATED WITH INHIBITION OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN SPHINGOID BASES; PLASMA-MEMBRANE GLYCOPROTEIN; CALCIUM-CHANNEL BLOCKERS; BREAST CANCER-CELLS; PHORBOL ESTERS; ALTERED REGULATION; DRUG ACCUMULATION; TOPOISOMERASE-II; CARCINOMA-CELLS; MAJOR SUBSTRATE	Safingol is a lysosphingolipid protein kinase C (PKC) inhibitor that competitively interacts at the regulatory phorbol binding domain of PKC. We investigated the effects of safingol on antineoplastic drug sensitivity and PKC activity of MCF-7 tumor cell lines. Safingol treatment of P-32-labeled MCF-7 WT and MCF-7 DOX(R) cells inhibited phosphorylation of the myristoylated alanine-rich protein kinase C substrate in both cell lines, suggesting inhibition of cellular PKC. However, only in MCF-7 DOX(R) cells did safingol treatment increase accumulation of [H-3]vinblastine and enhance toxicity of Vinca alkaloids and anthracyclines. Drug accumulation changes in MCF-7 DOX(R) cells treated with safingol were accompanied by inhibition of basal and phorbol 12,13-dibutyrate stimulated phosphorylation of P-glycoprotein (P-gp). Expression of P-gp and levels of mdr1 message in MCF-7 DOX(R) cells were not altered by safingol treatment alone or in combination with vinblastine. Treatment of MCF-7 DOX(R) cell membranes with safingol did not inhibit [H-3]vinblastine binding or [H-3]azidopine photoaffinity labeling of P-gp. Furthermore, safingol did not stimulate P-gp ATPase activity in membranes pre pared from MCF-7 DOX(R) cells. We conclude that enhanced drug accumulation and sensitivity in MCF-7 DOX(R) cells treated with safingol are correlated with inhibition of PKC rather than competitive interference with P-gp drug binding through direct interaction with P-glycoprotein.	DUKE UNIV, DIV HEMATOL ONCOL, DURHAM, NC 27705 USA; VET ADM MED CTR, DURHAM, NC 27705 USA; UNIV CHICAGO, HEMATOL ONCOL SECT, CHICAGO, IL 60637 USA; UNIV CHICAGO, CANC RES CTR, CHICAGO, IL 60637 USA; SPHINX PHARMACEUT, DURHAM, NC 27710 USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Chicago; University of Chicago					NATIONAL CANCER INSTITUTE [R01CA056078] Funding Source: NIH RePORTER; NCI NIH HHS [CA-56078] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; AHMAD S, 1993, MOL PHARMACOL, V43, P858; AQUINO A, 1990, BIOCHEM BIOPH RES CO, V166, P723, DOI 10.1016/0006-291X(90)90869-O; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BATES SE, 1993, BIOCHEMISTRY-US, V32, P9156, DOI 10.1021/bi00086a022; BATIST G, 1986, J BIOL CHEM, V261, P5544; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BOREK C, 1991, P NATL ACAD SCI USA, V88, P1953, DOI 10.1073/pnas.88.5.1953; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CENTER MS, 1985, BIOCHEM PHARMACOL, V34, P1471, DOI 10.1016/0006-2952(85)90686-0; CENTER MS, 1983, BIOCHEM BIOPH RES CO, V115, P159, DOI 10.1016/0006-291X(83)90983-X; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; CHAMBERS TC, 1992, MOL PHARMACOL, V41, P1008; CHAUDHARY PM, 1992, ONCOL RES, V4, P281; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CORNWELL MM, 1987, J BIOL CHEM, V262, P2166; DEVORE RF, 1992, CANCER RES, V52, P2156; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FERGUSON PJ, 1987, CANCER RES, V47, P433; FINE RL, 1988, P NATL ACAD SCI USA, V85, P582, DOI 10.1073/pnas.85.2.582; FORD JM, 1990, PHARMACOL REV, V42, P155; FORD JM, 1990, CANCER RES, V50, P1748; GOLLAPUDI S, 1992, CANCER LETT, V62, P69, DOI 10.1016/0304-3835(92)90200-F; GOTTESMAN MM, 1993, CANCER RES, V53, P747; GUADAGNO SN, 1992, J BIOL CHEM, V267, P2697; HAMADA H, 1987, CANCER RES, V47, P2860; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1991, METHOD ENZYMOL, V201, P316; IVY SP, 1988, J BIOL CHEM, V263, P19119; JAFFREZOU JP, 1991, J BIOL CHEM, V266, P19858; KHAN WA, 1991, BIOCHEM J, V278, P387, DOI 10.1042/bj2780387; KLIGMAN D, 1986, J NEUROCHEM, V47, P298; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAMBETH JD, 1988, J BIOL CHEM, V263, P3818; MA LD, 1991, J BIOL CHEM, V266, P5593; MELLADO W, 1987, BIOCHEMISTRY-US, V26, P6900, DOI 10.1021/bi00396a005; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MIYAMOTO K, 1993, CANCER RES, V53, P1555; NAITO M, 1988, J BIOL CHEM, V263, P11887; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBRIAN CA, 1989, FEBS LETT, V246, P78, DOI 10.1016/0014-5793(89)80257-1; ORR GA, 1993, J BIOL CHEM, V268, P25054; PEARCE HL, 1989, P NATL ACAD SCI USA, V86, P5128, DOI 10.1073/pnas.86.13.5128; Posada J A, 1989, Cancer Commun, V1, P285; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SATO W, 1990, BIOCHEM BIOPH RES CO, V173, P1252, DOI 10.1016/S0006-291X(05)80921-0; SCHNEIDER E, 1994, CANCER RES, V51, P3951; SCHWARTZ GK, 1993, J NATL CANCER I, V85, P402, DOI 10.1093/jnci/85.5.402; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SMAL J, 1989, P NATL ACAD SCI USA, V86, P4705, DOI 10.1073/pnas.86.12.4705; STAATS J, 1990, J BIOL CHEM, V265, P4084; STEVENS VL, 1989, CANCER RES, V49, P3229; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; TAKANO H, 1991, CANCER RES, V51, P3951; TAMAI I, 1991, J BIOL CHEM, V266, P16796; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; YANG CPH, 1988, BIOCHEM PHARMACOL, V37, P1417; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG L, 1994, J BIOL CHEM, V269, P15973	66	95	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26639	26648		10.1074/jbc.270.44.26639	http://dx.doi.org/10.1074/jbc.270.44.26639			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592889	hybrid			2022-12-27	WOS:A1995TC97800096
J	CASSET, F; HAMELRYCK, T; LORIS, R; BRISSON, JR; TELLIER, C; DAOTHI, MH; WYNS, L; POORTMANS, F; PEREZ, S; IMBERTY, A				CASSET, F; HAMELRYCK, T; LORIS, R; BRISSON, JR; TELLIER, C; DAOTHI, MH; WYNS, L; POORTMANS, F; PEREZ, S; IMBERTY, A			NMR, MOLECULAR MODELING, AND CRYSTALLOGRAPHIC STUDIES OF LENTIL LECTIN-SUCROSE INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; RICIN-B-CHAIN; CRYSTAL-STRUCTURE; CONCANAVALIN-A; FORCE-FIELD; PEA LECTIN; RESOLUTION; COMPLEX; CARBOHYDRATE; BINDING	The conformational features of sucrose in the combining site of lentil lectin have been characterized through elucidation of a crystalline complex at 1.9-Angstrom resolution, transferred nuclear Overhauser effect experiments performed at 600 Mhz, and molecular modeling. In the crystal, the lentil lectin dimer binds one sucrose molecule per monomer. The locations of 229 water molecules have been identified. NMR experiments have provided 11 transferred NOEs. In parallel, the docking study and conformational analysis of sucrose in the combining site of lentil lectin indicate that three different conformations can be accommodated. Of these, the orientation with lowest energy is identical with the one observed in the crystalline complex and provides good agreement with the observed transferred NOEs. These structural investigations indicate that the bound sucrose has a unique conformation for the glycosidic linkage, close to the one observed in crystalline sucrose, whereas the fructofuranose ring remains relatively flexible and does not exhibit any strong interaction with the protein. Major differences in the hydrogen bonding network of sucrose are found. None of the two inter-residue hydrogen bonds in crystalline sucrose are conserved in the complex with the lectin. Instead, a water molecule bridges hydroxyl groups O2-g and O3-f of sucrose.	INRA, F-44316 NANTES 03, FRANCE; FREE UNIV BRUSSELS VIB, ULTRATRUKT LAB, B-1640 RHODE ST GENESE, BELGIUM; NATL RES COUNCIL CANADA, INST BIOL SCI, OTTAWA, ON K1A 0R6, CANADA; FAC SCI & TECH NANTES, RECH BIOCATALYSE GRP, F-44072 NANTES 03, FRANCE; VLAAMSE INSTELLING TECHNOL ONDERZOEK, B-2400 MOL, BELGIUM; FAC SCI & TECH NANTES, CNRS, SYNTH ORGAN LAB, F-44072 NANTES 03, FRANCE	INRAE; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; National Research Council Canada; Nantes Universite; VITO; Centre National de la Recherche Scientifique (CNRS); Nantes Universite			Loris, Remy/GPG-0894-2022; Imberty, Anne/P-6451-2018; Hamelryck, Thomas/A-3923-2012	Imberty, Anne/0000-0001-6825-9527; Hamelryck, Thomas/0000-0003-2917-3602; Loris, Remy/0000-0002-8862-3338				ALLINGER NL, 1989, J AM CHEM SOC, V111, P8551, DOI 10.1021/ja00205a001; AREPALLI SR, 1995, J MAGN RESON SER B, V106, P195, DOI 10.1006/jmrb.1995.1033; BALEJA JD, 1990, J MAGN RESON, V87, P375, DOI 10.1016/0022-2364(90)90015-2; BERTHOD H, 1965, J CHIM PHYS, V62, P942, DOI 10.1051/jcp/1965620942; BEVILACQUA VL, 1990, BIOCHEMISTRY-US, V29, P5529, DOI 10.1021/bi00475a017; BEVILACQUA VL, 1992, BIOCHEMISTRY-US, V31, P9339, DOI 10.1021/bi00154a003; BOURNE Y, 1990, J BIOL CHEM, V265, P18161; BOURNE Y, 1992, J BIOL CHEM, V267, P197; BOURNE Y, 1993, CURR OPIN STRUC BIOL, V3, P681, DOI 10.1016/0959-440X(93)90050-U; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; BOURNE Y, 1994, STRUCTURE, V2, P209, DOI 10.1016/S0969-2126(00)00022-8; BROWN GM, 1973, ACTA CRYSTALLOGR B, VB 29, P790, DOI 10.1107/S0567740873003353; BRUNGER AT, 1990, XPLOR VERSION 2 1; BUNDLE DR, 1994, BIOCHEMISTRY-US, V33, P5183, DOI 10.1021/bi00183a023; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; COOKE RM, 1994, BIOCHEMISTRY-US, V33, P10591, DOI 10.1021/bi00201a004; CREMER D, 1975, J AM CHEM SOC, V97, P1354, DOI 10.1021/ja00839a011; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; DIAZ CL, 1989, NATURE, V338, P579, DOI 10.1038/338579a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DUPENHOAT CH, 1991, J AM CHEM SOC, V113, P3720; ENGELSEN S, 1995, J PHYS CHEM-US, V99, P13344; FRENCH AD, 1993, CARBOHYD RES, V239, P51, DOI 10.1016/0008-6215(93)84202-H; GLAUDEMANS CPJ, 1990, BIOCHEMISTRY-US, V29, P10906, DOI 10.1021/bi00501a007; HANSON JC, 1973, ACTA CRYSTALLOGR B, V29, P797, DOI 10.1107/S0567740873003365; IMBERTY A, 1994, GLYCOBIOLOGY, V4, P351, DOI 10.1093/glycob/4.3.351; IMBERTY A, 1993, ADV BIOPH C, V0003; IMBERTY A, 1991, Glycobiology, V1, P631, DOI 10.1093/glycob/1.6.631; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; LORIS R, 1992, J MOL BIOL, V223, P579, DOI 10.1016/0022-2836(92)90672-7; LORIS R, 1994, GLYCOCONJUGATE J, V11, P507, DOI 10.1007/BF00731301; LORIS R, 1993, BIOCHEMISTRY-US, V32, P8772, DOI 10.1021/bi00085a007; LORIS R, 1994, PROTEINS, V20, P330, DOI 10.1002/prot.340200406; MARCHESSAULT RH, 1979, BIOPOLYMERS, V18, P2369, DOI 10.1002/bip.1979.360180925; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NI F, 1994, PROG NUCL MAG RES SP, V26, P517, DOI 10.1016/0079-6565(94)90000-0; OLSON WK, 1982, J AM CHEM SOC, V104, P270, DOI 10.1021/ja00365a049; PEREZ S, 1995, JERUS SYM Q, V27, P425; Perez S., 1993, Sweet-taste chemoreception., P55; Perez S., 1994, SUCROSE PROPERTIES A, P11; POPPE L, 1992, J AM CHEM SOC, V114, P1092, DOI 10.1021/ja00029a051; PRESS WH, 1986, NUMERICAL RECIPES AR; RAO VSR, 1989, J MOL STRUCT, V194, P203, DOI 10.1016/0022-2860(89)80082-1; REDDY VS, 1992, INT J BIOL MACROMOL, V14, P185, DOI 10.1016/S0141-8130(05)80025-X; RINI JM, 1993, J BIOL CHEM, V268, P10126; SCHERF T, 1993, BIOPHYS J, V64, P754, DOI 10.1016/S0006-3495(93)81436-X; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; STEVENS ES, 1991, J AM CHEM SOC, V113, P8622, DOI 10.1021/ja00023a007; TRAN VH, 1990, BIOPOLYMERS, V29, P961, DOI 10.1002/bip.360290609; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WHITE DNJ, 1975, J CHEM SOC PERK T 2, P43, DOI 10.1039/p29750000043; 1971, ARCH BIOCHEM BIOPHYS, V145, P405	58	63	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25619	25628		10.1074/jbc.270.43.25619	http://dx.doi.org/10.1074/jbc.270.43.25619			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592736	Green Published, hybrid			2022-12-27	WOS:A1995TB46600053
J	KELLENBERGER, C; BOUDIER, C; BERMUDEZ, I; BIETH, JG; LUU, B; HIETTER, H				KELLENBERGER, C; BOUDIER, C; BERMUDEZ, I; BIETH, JG; LUU, B; HIETTER, H			SERINE-PROTEASE INHIBITION BY INSECT PEPTIDES CONTAINING A CYSTEINE KNOT AND A TRIPLE-STRANDED BETA-SHEET	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; PORCINE PANCREATIC ELASTASE; CATHEPSIN-G; PROTEINASE-INHIBITORS; LOCUSTA-MIGRATORIA; REACTIVE SITE	Three insect peptides showing high sequence similarity and belonging to the same structural family incorporating a cysteine knot and a short three-stranded antiparallel beta-sheet were studied. Their inhibitory effect on two serine proteases (bovine alpha-chymotrypsin and human leukocyte elastase) is reported. One of them, PMP-C, is a strong alpha-chymotrypsin inhibitor (K-i = 0.2 nM) and interacts with leukocyte elastase with a K-i of 0.12 mu M. The other two peptides, PMP-D2 and HI, interact only weakly with alpha-chymotrypsin and do not inhibit leukocyte elastase. Synthetic variants of these peptides were prepared by solid-phase synthesis, and their action toward serine proteases was evaluated. This enabled us to locate the P1 residues within the reactive sites (Leu-30 for PMP-C and Arg-29 for PMP-D2 and HI), and, interestingly, variants of PMP-DB and RI were converted into powerful inhibitors of both alpha-chymotrypsin and leukocyte elastase, the most potent elastase inhibitor obtained in this study having a K-i of 3 nM.	UNIV STRASBOURG 1,INSERM,U392,ENZYMOL LAB,F-67400 ILLKIRCH GRAFFENS,FRANCE; OXFORD BROOKES UNIV,SCH BIOL & MOLEC SCI,OXFORD OX3 0BP,ENGLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Oxford Brookes University	KELLENBERGER, C (corresponding author), UNIV STRASBOURG 1,CHIM ORGAN SUBST NAT LAB,CNRS,URA 31,5 RUE BLAISE PASCAL,F-67084 STRASBOURG,FRANCE.		Boudier, Christian/N-3841-2018; kellenberger, christine/AAV-9304-2020	Boudier, Christian/0000-0002-5534-6389; Bermudez, Isabel/0000-0001-7692-1509				Bieth J., 1974, BAYER S, P463; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BOIGEGRAIN RA, 1992, BIOCHEM BIOPH RES CO, V189, P790, DOI 10.1016/0006-291X(92)92271-X; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; EISENBERG SP, 1990, J BIOL CHEM, V265, P7976; KELLENBERGER C, 1994, INNOVATIONS PERSPECT, P567; KROMER E, 1994, INSECT BIOCHEM MOLEC, V24, P329, DOI 10.1016/0965-1748(94)90013-2; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; MARTODAM RR, 1979, PREP BIOCHEM, V9, P15, DOI 10.1080/00327487908061669; MCRAE B, 1980, BIOCHEMISTRY-US, V19, P3973, DOI 10.1021/bi00558a013; MCWHERTER CA, 1989, BIOCHEMISTRY-US, V28, P5708, DOI 10.1021/bi00440a002; MER G, 1994, BIOCHEMISTRY-US, V33, P15397, DOI 10.1021/bi00255a021; Morisson J.F., 1988, ADV ENZYMOL RELAT AR, V61, P201; NAKAKURA N, 1992, EUR J BIOCHEM, V204, P147, DOI 10.1111/j.1432-1033.1992.tb16617.x; PEANASKY RJ, 1984, ARCH BIOCHEM BIOPHYS, V232, P135, DOI 10.1016/0003-9861(84)90529-0; POWERS JC, 1984, J BIOL CHEM, V259, P4288; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHONBAUM G, 1961, J BIOL CHEM, V236, P2930; SINHA S, 1991, J BIOL CHEM, V266, P21011; TSCHESCHE H, 1987, BIOCHIM BIOPHYS ACTA, V913, P97, DOI 10.1016/0167-4838(87)90238-X; VANIERSEL J, 1985, ANAL BIOCHEM, V151, P196, DOI 10.1016/0003-2697(85)90072-7	22	71	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25514	25519		10.1074/jbc.270.43.25514	http://dx.doi.org/10.1074/jbc.270.43.25514			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592720	hybrid			2022-12-27	WOS:A1995TB46600037
J	HOMER, MJ; DEAN, DR; ROBERTS, GP				HOMER, MJ; DEAN, DR; ROBERTS, GP			CHARACTERIZATION OF THE GAMMA-PROTEIN AND ITS INVOLVEMENT IN THE METALLOCLUSTER ASSEMBLY AND MATURATION OF DINITROGENASE FROM AZOTOBACTER-VINELANDII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; KLEBSIELLA-PNEUMONIAE; TRANSACTIVATOR MELC1; FEMO-COFACTOR; MOFE PROTEIN; NITROGENASE; APODINITROGENASE; ACTIVATION; GENE; APOTYROSINASE	Dinitrogenase, the enzyme capable of catalyzing the reduction of N2, is a heterotetramer (alpha 2 beta 2) and contains the iron-molybdenum cofactor (FeMo-co) at the active site of the enzyme. Mutant strains unable to synthesize FeMo-co accumulate an apo form of dinitrogenase, which is enzymatically inactive but can be activated in vitro by the addition of purified FeMo-co. Apodinitroge nase from certain mutant strains of Azotobacter vinelandii has a subunit composition of alpha(2) beta(2) gamma(2). The gamma subunit has been implicated as necessary for the efficient activation of apodinitrogenase in vitro. Characterization of gamma protein in crude extracts and partially pure fractions has suggested that it is a chaperone-insertase required by apodinitrogenase for the insertion of FeMo-co. There are three major forms of gamma protein detectable by Western analysis of native gels. An apodinitrogenase-associated form is found in extracts of nifB or nifNE strains and dissociates from the apocomplex upon addition of purified FeMo-co. A second form of gamma protein is unassociated with other proteins and exists as a homodimer. Both of these forms of gamma protein can be converted to a third form by the addition of purified FeMo-co. This conversion requires the addition of active FeMo-co and correlates with the incorporation of iron into gamma protein. Crude extracts that contain this form of gamma protein are capable of donating FeMo-co to apodinitrogenase, thereby activating the apodinitrogenase. These data support a model in which gamma protein is able to interact with both FeMo-co and apodinitrogenase, facilitate FeMo-co insertion into apodinitrogenase, and then dissociate from the activated dinitrogenase complex.	UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA; UNIV WISCONSIN, CTR STUDY NITROGEN FIXAT, MADISON, WI 53706 USA; VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOCHEM & ANAEROB MICROBIOL, BLACKSBURG, VA 24061 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Virginia Polytechnic Institute & State University					NIGMS NIH HHS [T32GM07215] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOLIN JT, 1993, ACS SYM SER, V535, P186; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; BUSH JA, 1959, NATURE, V184, P381, DOI 10.1038/184381a0; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; CHEN LY, 1992, J BIOL CHEM, V267, P20100; CHEN LY, 1993, J BIOL CHEM, V268, P18710; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HOMER MJ, 1993, J BACTERIOL, V175, P4907, DOI 10.1128/JB.175.15.4907-4910.1993; IMPERIAL J, 1987, J BACTERIOL, V169, P1784, DOI 10.1128/jb.169.4.1784-1786.1987; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KIM J, 1992, SCIENCE, V360, P553; KUO CF, 1988, ANAL BIOCHEM, V170, P183, DOI 10.1016/0003-2697(88)90106-6; MACNEIL T, 1978, J BACTERIOL, V136, P253, DOI 10.1128/JB.136.1.253-266.1978; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARK IS, 1994, P NATL ACAD SCI USA, V91, P3233, DOI 10.1073/pnas.91.8.3233; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAL S, 1991, J BIOL CHEM, V266, P10654; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; WHITE TC, 1992, J BIOL CHEM, V267, P24007	30	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24745	24752		10.1074/jbc.270.42.24745	http://dx.doi.org/10.1074/jbc.270.42.24745			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559591	hybrid			2022-12-27	WOS:A1995TB46500025
J	LINK, TA; VONJAGOW, G				LINK, TA; VONJAGOW, G			ZINC IONS INHIBIT THE Q(P) CENTER OF BOVINE HEART MITOCHONDRIAL BC(1) COMPLEX BY BLOCKING A PROTONATABLE GROUP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C REDUCTASE; IRON-SULFUR PROTEIN; BC1 COMPLEX; ELECTRON-TRANSPORT; BEEF-HEART; ZN2+ IONS; UBIQUINOL; BINDING; RECONSTITUTION; CLUSTER	Bovine heart bc(1) complex is reversibly inhibited by zinc ions with an inhibition constant K-I of 10(-7) M at pH greater than or equal to 7.0. Binding of zinc is at least a factor of 10 tighter than binding of any other metal ion tested. Essentially complete inhibition of ubihydroquinonecytochrome c oxidoreductase activity is observed at concentrations of [Zn2+] > 5 mu M. Zinc does not affect the K-m for the substrates, ubihydroquinone or cytochrome c, but zinc inhibits reduction of the cytochromes by ubihydroquinone through the Q(P) center. A radioactive binding assay using Zn-65 revealed one high affinity binding site per bc(1) complex with K-D less than or equal to 10(-7) M at pH = 7.0 and 3-4 additional low affinity binding sites (K-D > 2 x 10(-6) M). Zinc binding does not depend on the redox state of the high potential chain (iron sulfur protein and cytochrome c(1)). Zinc binds 3 times tighter to Fe-S-depleted bc(1) complex indicating that the zinc binding site is not on the ''Rieske'' iron-sulfur protein in contrast to a recent report by Lorusso et al, (Lorusso, M,, Cocco, T., Sardanella, A. M., Minuto, M., Bonomi, F., and Papa, S. (1991) Eur. J. Biochem. 197, 555-561). Zinc binds to a site which has the same affinity for zinc as for protons. We conclude that the zinc binding site is close to a protonatable group of the bc(1) complex with pK(a) = 7.2 which has not been identified previously. We propose that this group is part of the proton channel at the hydroquinone oxidation center of the bc(1) complex.			LINK, TA (corresponding author), UNIV FRANKFURT KLINIKUM,ZBC,THEODOR STERN KAI 7,HAUS 25B,D-60590 FRANKFURT,GERMANY.							BRANDT U, 1988, EUR J BIOCHEM, V173, P499, DOI 10.1111/j.1432-1033.1988.tb14026.x; BRANDT U, 1991, J BIOL CHEM, V266, P19958; BRANDT U, 1991, EUR J BIOCHEM, V195, P163, DOI 10.1111/j.1432-1033.1991.tb15690.x; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; ENGEL WD, 1983, EUR J BIOCHEM, V132, P395, DOI 10.1111/j.1432-1033.1983.tb07376.x; KLEINER D, 1974, ARCH BIOCHEM BIOPHYS, V165, P121, DOI 10.1016/0003-9861(74)90148-9; KLEINER D, 1972, FEBS LETT, V20, P229, DOI 10.1016/0014-5793(72)80802-0; LINK TA, 1994, BBA-BIOENERGETICS, V1185, P81, DOI 10.1016/0005-2728(94)90196-1; LINK TA, 1992, EUR J BIOCHEM, V208, P685, DOI 10.1111/j.1432-1033.1992.tb17235.x; LORUSSO M, 1991, EUR J BIOCHEM, V197, P555, DOI 10.1111/j.1432-1033.1991.tb15944.x; MARET W, 1993, METHOD ENZYMOL, V226, P52; NICHOLLS P, 1968, BIOCHEMISTRY-US, V7, P305, DOI 10.1021/bi00841a038; PIERIK AJ, 1991, EUR J BIOCHEM, V195, P505, DOI 10.1111/j.1432-1033.1991.tb15731.x; PRINCE RC, 1976, FEBS LETT, V65, P117, DOI 10.1016/0014-5793(76)80634-5; RICH PR, 1982, FARADAY DISCUSS, V74, P349, DOI 10.1039/dc9827400349; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; Rieske J. S., 1967, METHOD ENZYMOL, V10, P239; SCHAGGER H, 1987, FEBS LETT, V219, P161, DOI 10.1016/0014-5793(87)81210-3; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SKULACHE.VP, 1967, BIOCHEM BIOPH RES CO, V26, P1, DOI 10.1016/0006-291X(67)90242-2; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; TRUMPOWER BL, 1980, J BIOL CHEM, V255, P7487; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; VONJAGOW G, 1984, J BIOL CHEM, V259, P6318; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P224; WESTER PO, 1965, BIOCHIM BIOPHYS ACTA, V109, P268, DOI 10.1016/0926-6585(65)90111-1	26	148	151	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25001	25006		10.1074/jbc.270.42.25001	http://dx.doi.org/10.1074/jbc.270.42.25001			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559629	hybrid			2022-12-27	WOS:A1995TB46500063
J	LUPISELLA, JA; DRISCOLL, JE; METZLER, WJ; RECZEK, PR				LUPISELLA, JA; DRISCOLL, JE; METZLER, WJ; RECZEK, PR			THE LIGAND-BINDING DOMAIN OF THE HUMAN RETINOIC ACID RECEPTOR-GAMMA IS PREDOMINANTLY ALPHA-HELICAL WITH A TRP RESIDUE IN THE LIGAND-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; ESCHERICHIA-COLI; THYROID-HORMONE; GLUCOCORTICOID RECEPTOR; SECONDARY STRUCTURE; RESPONSIVE ELEMENT; CIRCULAR-DICHROISM; ESTROGEN-RECEPTOR; X RECEPTOR; BETA-GENE	Retinoic acid exerts its many biological effects by interaction with a nuclear protein, the retinoic acid receptor (RAR). The details of this interaction are unknown due mainly to the lack of sufficient quantities of pure functional receptor protein for biochemical and structural studies. We have recently subcloned the D and E domains of human RAR gamma for expression in Escherichia coli. Using nickel-chelation affinity chromatography with a polyhistidine amino terminal tail, purification of the DE peptide with a pI of 5.18 was accomplished to greater than 98% purity. Scatchard analysis and fluorescence quenching techniques using the purified protein indicate a very high percentage of functional molecules (>95%) with a K-d for retinoic acid (t-RA) of 0.6 +/- 0.1 nM. Circular dichroism spectra of the purified domains predict a predominantly alpha-helical structure (similar to 56%) with little beta sheet present. No significant changes in these structural characteristics were observed upon binding of t-RA. Inspection of the amino acid sequence within these domains identified a single tryptophan residue at position 227. Modeling the amino acid sequence in this region as an alpha-helical structure indicates that this tryptophan is adjacent to alanine 234, which corresponds to alanine 225 in RAR beta that has previously been linked to the ligand binding site. Fluorescence of this tryptophan was quenched in a dose-dependent manner on the addition of t-RA, confirming that Trp-227 is within the ligand binding site. Tryptophan flourescence quenching analysis also demonstrates that a single retinoic acid molecule is bound per receptor and suggests that receptor-ligand interactions occur within the amino-terminal portion of the predominantly alpha-helical ligand binding domain.	BRISTOL MYERS SQUIBB CO,RES INST,DEPT MOLEC BIOL,BUFFALO,NY 14213; SQUIBB INST MED RES,PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543	Bristol-Myers Squibb				Lupisella, John/0000-0003-1343-6412				ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; APFEL C, 1991, RETINOIDS : 10 YEARS ON, P110; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BOURGUET W, 1992, BIOCHEM BIOPH RES CO, V187, P711, DOI 10.1016/0006-291X(92)91253-M; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Clark Alfred Joseph., 1933, MODE ACTION DRUGS CE; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DAWSON MI, 1993, RETINOIDS PROGR RES, P205; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOKOH S, 1981, ANAL BIOCHEM, V116, P211, DOI 10.1016/0003-2697(81)90346-8; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FIORELLA PD, 1993, J BIOL CHEM, V268, P21545; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GODOVACZIMMERMA.J, 1988, TRENDS BIOCHEM SCI, V13, P64; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KEIDEL S, 1992, EUR J BIOCHEM, V204, P1141, DOI 10.1111/j.1432-1033.1992.tb16739.x; KNEGTEL RMA, 1993, J BIOMOL NMR, V3, P1, DOI 10.1007/BF00242472; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Lotan R, 1988, Prog Clin Biol Res, V259, P261; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MAKSYMOWYCH AB, 1992, RECEPTOR, V2, P225; MANAVALAN P, 1985, J BIOSCIENCE, V8, P141, DOI 10.1007/BF02703972; NAPOLI JL, 1990, CHEM BIOL SYNTHETIC, P229; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; OSTROWSKI J, 1995, P NATL ACAD SCI USA, V92, P1812, DOI 10.1073/pnas.92.6.1812; REDDY AP, 1992, BIOCHEM J, V287, P833, DOI 10.1042/bj2870833; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TONEY JH, 1993, BIOCHEMISTRY-US, V32, P2, DOI 10.1021/bi00052a001; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VNAHOLDE KE, 1985, PHYSICAL BIOCH, P58; WOLF G, 1984, PHYSIOL REV, V64, P873, DOI 10.1152/physrev.1984.64.3.873; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	49	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24884	24890		10.1074/jbc.270.42.24884	http://dx.doi.org/10.1074/jbc.270.42.24884			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559612	hybrid			2022-12-27	WOS:A1995TB46500046
J	MAXWELL, MM; NEARING, J; AZIZ, N				MAXWELL, MM; NEARING, J; AZIZ, N			KE-6-GENE - SEQUENCE AND ORGANIZATION AND ABERRANT REGULATION IN MURINE POLYCYSTIC KIDNEY-DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE; MODEL; DEHYDROGENASE; LOCALIZATION; REGION; H-2K; MHC	Ke 6 gene is a newly identified gene located in the major histocompatibility complex and is a candidate steroid dehydrogenase gene because of structural homology and regulatory similarities with mammalian steroid dehydrogenases. We report here the complete nucleotide sequence and intron-exon organization of the Ke 6 gene and cloning of the alternatively spliced Ke 6b transcript. We find that Ke 6 gene expression is downregulated in pcy mice which is a murine model of polycystic kidney disease (PKD). Thus far, Ke 6 gene expression is down-regulated in all murine models of PKD we have examined. Abnormal steroid metabolism as a possible cause of PKD is discussed.	CHILDRENS HOSP,DEPT MED,DIV NEPHROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK 48098] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048098] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE K, 1988, EMBO J, V7, P3441, DOI 10.1002/j.1460-2075.1988.tb03218.x; [Anonymous], 1994, CELL, V77, P881; ARTZT K, 1988, IMMUNOGENETICS, V28, P30, DOI 10.1007/BF00372526; ATALA A, 1993, KIDNEY INT, V43, P1081, DOI 10.1038/ki.1993.151; AVNER ED, 1984, EXPERIENTIA, V40, P489, DOI 10.1007/BF01952400; AZIZ N, 1993, MOL CELL BIOL, V13, P1847, DOI 10.1128/MCB.13.3.1847; AZIZ N, 1994, AM J PHYSIOL-RENAL, V267, pF791, DOI 10.1152/ajprenal.1994.267.5.F791; AZIZ N, 1994, J AM SOC NEPHROL, V5, P617; AZIZ N, 1994, IN PRESS J AM SOC NE; AZIZ N, 1995, BIOESSAYS, V17, P1; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; CROCKER JFS, 1976, AM J PATHOL, V82, P373; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FILMER RB, 1973, AM J PATHOL, V72, P461; FRY JL, 1985, J UROLOGY, V134, P828, DOI 10.1016/S0022-5347(17)47448-9; GRIDLEY T, 1991, GENOMICS, V11, P501, DOI 10.1016/0888-7543(91)90056-K; HANSON IM, 1991, IMMUNOGENETICS, V34, P5, DOI 10.1007/BF00212306; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; LORENCE MC, 1990, MOL ENDOCRINOL, V4, P1850, DOI 10.1210/mend-4-12-1850; MCDONALD ATJ, 1990, KIDNEY INT, V37, P901, DOI 10.1038/ki.1990.64; OJEDA JL, 1986, NEPHRON, V42, P240, DOI 10.1159/000183674; PATEL PI, 1986, MOL CELL BIOL, V6, P393, DOI 10.1128/MCB.6.2.393; PEREY DYE, 1967, SCIENCE, V158, P494, DOI 10.1126/science.158.3800.494; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; Sambrook J, 1989, MOL CLONING LABORATO; SMITH MW, 1988, J MOL EVOL, V27, P45, DOI 10.1007/BF02099729; STJACQUES B, 1990, MOL CELL BIOL, V10, P138, DOI 10.1128/MCB.10.1.138; TAKAHASHI H, 1991, J AM SOC NEPHROL, V1, P980; TAKAHASHI H, 1986, J UROLOGY, V135, P1280, DOI 10.1016/S0022-5347(17)46074-5; TANNIN GM, 1991, J BIOL CHEM, V266, P16653; VAN LT, 1990, MOL ENDOCRINOL, V4, P268; WELLING L, 1991, KIDNEY, V2, P1657; WHITEHOUSE RW, 1980, EXPERIENTIA, V36, P244, DOI 10.1007/BF01953758; ZERRES K, 1994, NAT GENET, V7, P429, DOI 10.1038/ng0794-429	34	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25213	25219		10.1074/jbc.270.42.25213	http://dx.doi.org/10.1074/jbc.270.42.25213			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559658	hybrid			2022-12-27	WOS:A1995TB46500092
J	WASSLER, M; ESNARD, F; FRIES, E				WASSLER, M; ESNARD, F; FRIES, E			POSTTRANSLATIONAL FOLDING OF ALPHA(1)-INHIBITOR-3 - EVIDENCE FOR A COMPACTION PROCESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; MACROGLOBULIN RAT ALPHA-1-INHIBITOR-3; ENDOPLASMIC-RETICULUM; HUMAN ALPHA-2-MACROGLOBULIN; LIMITED PROTEOLYSIS; ALPHA-MACROGLOBULINS; SECRETORY PROTEINS; BOND FORMATION; IN-VITRO; BIOSYNTHESIS	alpha(1)-Inhibitor 3 (alpha(1)I(3)) is a rodent-specific proteinase inhibitor of about 190 kDa belonging to the alpha(2)-macroglobulin family. It consists of five globular domains, three of which are connected by disulfide bridges, and contains an intramolecular thiol ester which can react with attaching proteinases. To explore the folding of newly synthesized alpha(1)I(3), We have used rat hepatocytes and pulse-chase experiments. In one of the analyses, the radiolabeled protein was isolated from cell lysates by immunoprecipitation and its Asp-Pro bonds cleaved by treatment with formic acid. The size of the major fragment, as assessed by electrophoresis under nonreducing conditions, was found to increase from 100 to 150 kDa upon the chasing. This result, together with knowledge of the positions of the cleavage sites and the disulfide arrangement, indicates that one of the interdomain disulfide bonds is formed after the synthesis of the polypeptide. Analysis of the same material by limited proteolysis and by velocity centrifugation showed that the folded regions became larger and that the protein became more compact; the thiol ester was found to be formed after these conformational changes. These results suggest that the domains of alpha(1)I(3) are only partially developed directly after the synthesis of the polypeptide and that they acquire their final structure as the protein condenses and the domains interact with one another.	UNIV UPPSALA,CTR BIOMED,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN; UNIV TOURS,BIOCHEM LAB,F-37032 TOURS,FRANCE	Uppsala University; Universite de Tours								ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CREIGHTON TE, 1993, J MOL BIOL, V232, P1176, DOI 10.1006/jmbi.1993.1470; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; ESNARD F, 1980, BIOCHIM BIOPHYS ACTA, V614, P553, DOI 10.1016/0005-2744(80)90244-2; ESNARD F, 1985, FEBS LETT, V182, P125, DOI 10.1016/0014-5793(85)81168-6; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; GEIGER T, 1987, BIOCHEM J, V245, P493, DOI 10.1042/bj2450493; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HARPEL PC, 1979, J BIOL CHEM, V254, P8669; HOWARD JB, 1980, J BIOL CHEM, V255, P3820; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HUTH JR, 1992, J BIOL CHEM, V267, P8870; HUTH JR, 1993, J BIOL CHEM, V268, P16472; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; IKAI A, 1990, FEBS LETT, V260, P291, DOI 10.1016/0014-5793(90)80126-4; ISAAC L, 1992, J BIOL CHEM, V267, P10062; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KARP DR, 1983, J BIOL CHEM, V258, P4490; Landon, 1977, Methods Enzymol, V47, P145; LAW SKA, 1990, BIOCHEM SOC T, V18, P1155; LILIE H, 1994, J BIOL CHEM, V269, P14290; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LORIMER GH, 1992, CURR OPIN STRUC BIOL, V2, P26; MARQUARDT T, 1993, J BIOL CHEM, V268, P19619; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OLSON TS, 1988, J BIOL CHEM, V263, P7342; PETERS T, 1982, J BIOL CHEM, V257, P8847; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; RUBENSTEIN DS, 1991, J BIOL CHEM, V266, P11252; RUCHEL R, 1974, H-S Z PHYSIOL CHEM, V355, P997, DOI 10.1515/bchm2.1974.355.2.997; SAITO A, 1985, J BIOCHEM-TOKYO, V98, P501, DOI 10.1093/oxfordjournals.jbchem.a135305; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SJOBERG M, 1991, EUR J BIOCHEM, V197, P61, DOI 10.1111/j.1432-1033.1991.tb15882.x; SONDEREGGER P, 1982, ANAL BIOCHEM, V122, P298, DOI 10.1016/0003-2697(82)90285-8; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STELLWAGEN E, 1962, BIOCHEMISTRY-US, V1, P1056, DOI 10.1021/bi00912a016; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369; WASSLER M, 1987, BIOCHEM J, V247, P407, DOI 10.1042/bj2470407	42	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24598	24603		10.1074/jbc.270.41.24598	http://dx.doi.org/10.1074/jbc.270.41.24598			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592680	hybrid			2022-12-27	WOS:A1995TA21700108
J	ARGRAVES, KM; BATTEY, FD; MACCALMAN, CD; MCCRAE, KR; GAFVELS, M; KOZARSKY, KF; CHAPPELL, DA; STRAUSS, JF; STRICKLAND, DK				ARGRAVES, KM; BATTEY, FD; MACCALMAN, CD; MCCRAE, KR; GAFVELS, M; KOZARSKY, KF; CHAPPELL, DA; STRAUSS, JF; STRICKLAND, DK			THE VERY-LOW-DENSITY LIPOPROTEIN RECEPTOR MEDIATES THE CELLULAR CATABOLISM OF LIPOPROTEIN-LIPASE AND UROKINASE-PLASMINOGEN ACTIVATOR INHIBITOR TYPE-I COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; LDL-RECEPTOR; ENDOTHELIAL-CELLS; BOVINE-MILK; SURFACE; BINDING; GLYCOPROTEIN-330; EXPRESSION; IDENTIFICATION; PROTEOGLYCANS	The very low density Lipoprotein (VLDL) receptor binds apolipoprotein E-rich lipoproteins as well as the 39-kDa receptor-associated protein (RAP). Ligand blotting experiments using RAP and immunoblotting experiments using an anti-VLDL receptor IgG detected the VLDL receptor in detergent extracts of human aortic endothelial cells, human umbilical vein endothelial cells, and human aortic smooth muscle cells. To gain insight into the role of the VLDL receptor in the vascular endothelium, its ligand binding properties were further characterized. In vitro binding experiments documented that lipoprotein lipase (LpL), a key enzyme in lipoprotein catabolism, binds with high affinity to purified VLDL receptor. In addition, urokinase complexed with plasminogen activator-inhibitor type I (uPA . PAI-1) also bound to the purified VLDL receptor with high affinity. To assess the capacity of the VLDL receptor to mediate the cellular internalization of ligands, an adenoviral vector was used to introduce the VLDL receptor gene into a murine embryonic fibroblast cell line deficient in the VLDL receptor and the LDL receptor-related protein, another endocytic receptor known to bind LpL and uPA . PAI-1 complexes. Infected fibroblasts that express the VLDL receptor mediate the cellular internalization of I-125-labeled LpL and uPA . PAI-1 complexes, leading to their degradation. Non-infected fibroblasts or fibroblasts infected with the lacZ gene did not internalize these ligands. These studies confirm that the VLDL receptor binds to and mediates the catabolism of LpL and uPA . PAI-1 complexes. Thus, the VLDL receptor may play a unique role on the vascular endothelium in lipoprotein catabolism by regulating levels of LpL and in the regulation of fibrinolysis by facilitating the removal of urokinase complexed with its inhibitor.	AMER RED CROSS,DEPT BIOCHEM,HOLLAND LAB,ROCKVILLE,MD 20855; UNIV PENN,SCH MED,DEPT OBSTET,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GYNECOL,PHILADELPHIA,PA 19104; TEMPLE UNIV,SCH MED,THROMBOSIS RES CTR,PHILADELPHIA,PA 19140; KAROLINSKA INST,DEPT INTERNAL MED,METAB UNIT,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,DEPT INTERNAL MED,MOLEC NUTR UNIT,S-14186 HUDDINGE,SWEDEN; HUDDINGE UNIV HOSP,DEPT INTERNAL MED,S-14186 HUDDINGE,SWEDEN; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV PENN,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MOLEC & CELLULAR ENGN,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	American Red Cross; University of Pennsylvania; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Iowa; University of Pennsylvania; University of Pennsylvania; The Wistar Institute					NHLBI NIH HHS [HL50787, HL49264] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BENSADOUN A, 1991, ANNU REV NUTR, V11, P217, DOI 10.1146/annurev.nu.11.070191.001245; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BIEMESDERFER D, 1993, AM J PHYSIOL, V264, pF1011, DOI 10.1152/ajprenal.1993.264.6.F1011; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CISAR LA, 1989, J BIOL CHEM, V264, P1767; ELLIS V, 1992, FIBRINOLYSIS, V6, P27; GAFVELS ME, 1993, SOMAT CELL MOLEC GEN, V19, P557, DOI 10.1007/BF01233382; HADDOCK RC, 1991, J BIOL CHEM, V266, P21466; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; KIRCHGESSNER TG, 1989, J BIOL CHEM, V264, P1473; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; MULTHAUPT HAB, 1994, CIRCULATION, V90, P1; NIMPF J, 1989, J BIOL CHEM, V264, P1393; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLIVECRONA T, 1987, J BIOL CHEM, V262, P10748; PLOUG M, 1991, J BIOL CHEM, V266, P1926; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SCHLEEF RR, 1988, HAEMOSTASIS, V18, P328; STINS MF, 1993, J LIPID RES, V34, P1853; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; WEBB JC, 1992, J LIPID RES, V33, P689; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; WITTMAACK FM, 1995, ENDOCRINOLOGY, V136, P340, DOI 10.1210/en.136.1.340; YAMAMOTO T, 1993, TRENDS CARDIOVAS MED, V3, P144, DOI 10.1016/1050-1738(93)90015-X; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	54	148	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26550	26557		10.1074/jbc.270.44.26550	http://dx.doi.org/10.1074/jbc.270.44.26550			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592875	hybrid			2022-12-27	WOS:A1995TC97800082
J	HARRINGTON, C; PERRINO, FW				HARRINGTON, C; PERRINO, FW			THE EFFECTS OF CYTOSINE-ARABINOSIDE OIL RNA-PRIMED DNA-SYNTHESIS BY DNA-POLYMERASE ALPHA-PRIMASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALF THYMUS; DROSOPHILA-MELANOGASTER; INITIATION SITES; INHIBITION; TEMPLATE; CELLS; 5'-TRIPHOSPHATE; FIDELITY; TRIPHOSPHATE; KINETICS	Oligonucleotides containing a specific initiation site for polymerase alpha-primase (pol alpha-primase) were used to measure the effects of cytosine arabinoside triphosphate and cytosine arabinoside monophosphate (araCMP) in DNA on RNA-primed DNA synthesis. Primase inserts araCMP at the 3' terminus of a full-length RNA primer with a 400-fold preference over GRIP. The araCMP is elongated efficiently by pol alpha in the primase-coupled reaction. Extension from RNA 3'-araCMP is 50-fold less efficient than from CMP, and extension from DNA 3'-araCMP is 1600-fold less efficient than from dCMP. Using araCMP-containing templates, primer synthesis is reduced 2-3 fold, and RNA-primed DNA synthesis is reduced 2-8-fold. The efficiency of polymerization past a template araCMP by pol alpha is reduced 180-fold during insertion of dGMP opposite araCMP and 35-fold during extension from the araCMP:dGMP 3' terminus. These results show that the pol alpha-primase efficiently incorporates araCMP as the border nucleotide between RNA and DNA and suggest that the inhibitory effects of araC most likely result from slowed elongation of pol a: and less so from inhibition of primer synthesis by primase.	WAKE FOREST UNIV,MED CTR,DEPT BIOCHEM,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,MED CTR,CTR COMPREHENS CANC,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest University					NCI NIH HHS [CA-12197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CATAPANO CV, 1993, J BIOL CHEM, V268, P7179; CATAPANO CV, 1991, CANCER RES, V51, P1829; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P2523, DOI 10.1073/pnas.79.8.2523; COTTERILL S, 1987, J BIOL CHEM, V262, P16105; DAVEY SK, 1990, J BIOL CHEM, V265, P3611; DICIOCCIO RA, 1977, EUR J BIOCHEM, V79, P411, DOI 10.1111/j.1432-1033.1977.tb11823.x; Fersht A, 1985, ENZYME STRUCTURE MEC, P105; HARRINGTON C, 1995, NUCLEIC ACIDS RES, V23, P1003, DOI 10.1093/nar/23.6.1003; Kornberg A., 1992, DNA REPLICATION; KUCHTA RD, 1992, BIOCHEMISTRY-US, V31, P4720, DOI 10.1021/bi00134a027; KUCHTA RD, 1990, J BIOL CHEM, V265, P16158; KUCHTA RD, 1991, BIOCHEMISTRY-US, V30, P797, DOI 10.1021/bi00217a033; KUFE DW, 1984, MOL PHARMACOL, V26, P128; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; MAJOR PP, 1982, BIOCHEM PHARMACOL, V31, P2937, DOI 10.1016/0006-2952(82)90266-0; MIKITA T, 1988, BIOCHEMISTRY-US, V27, P4698, DOI 10.1021/bi00413a018; PARKER WB, 1988, MOL PHARMACOL, V34, P485; PARKER WP, 1986, MOL PHARMACOL, V31, P146; PERRINO FW, 1992, J BIOL CHEM, V267, P23043; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; SHEAFF RJ, 1994, BIOCHEMISTRY-US, V33, P2247, DOI 10.1021/bi00174a035; SHEAFF RJ, 1994, J BIOL CHEM, V269, P19225; SUZUKI M, 1993, BIOCHEMISTRY-US, V32, P12782, DOI 10.1021/bi00210a030; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; TSENG BY, 1975, J MOL BIOL, V99, P339, DOI 10.1016/S0022-2836(75)80150-1; VISHWANATHA JK, 1986, NUCLEIC ACIDS RES, V14, P7305, DOI 10.1093/nar/14.18.7305; YAMAGUCHI M, 1985, MOL CELL BIOL, V5, P1170, DOI 10.1128/MCB.5.5.1170; YOSHIDA S, 1985, J BIOCHEM-TOKYO, V98, P427, DOI 10.1093/oxfordjournals.jbchem.a135297; ZHANG SS, 1990, J MOL BIOL, V216, P475, DOI 10.1016/0022-2836(90)90370-2	31	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26664	26669		10.1074/jbc.270.44.26664	http://dx.doi.org/10.1074/jbc.270.44.26664			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592892	hybrid			2022-12-27	WOS:A1995TC97800099
J	NATH, D; VANDERMERWE, PA; KELM, S; BRADFIELD, P; CROCKER, PR				NATH, D; VANDERMERWE, PA; KELM, S; BRADFIELD, P; CROCKER, PR			THE AMINO-TERMINAL IMMUNOGLOBULIN-LIKE DOMAIN OF SIALOADHESIN CONTAINS THE SIALIC-ACID BINDING-SITE - COMPARISON WITH CD22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE COMMON ANTIGEN; MONOCLONAL-ANTIBODY; ADHESION MOLECULE; HUMAN CD4; T-CELLS; RECEPTOR; SUPERFAMILY; SIALYLTRANSFERASE; ERYTHROCYTES; PURIFICATION	Sialoadhesin and CD22 are members of a recently characterized family of sialic add dependent adhesion molecules belonging to the immunoglobulin superfamily. Sialoadhesin is a macrophage-restricted receptor containing 17 extracellular Ig-like domains which recognizes oligosaccharides terminating in NeuAc alpha 2-3Gal in N- and O-linked glycans, CD22 is a B cell-restricted receptor with seven Ig-like domains which selectively recognizes oligosaccharides terminating in NeuAc alpha 2-6Gal in N-glycans, Sequence similarity between these proteins is highest within their first four amino-terminal Ig-like domains. Here we identify the domain(s) containing the binding sites of both molecules by generating a series of extracellular domain deletion mutants fused to the Fc portion of human IgG1. Binding activity was analyzed by solid phase cell adhesion assays and also by surface plasmon resonance using purified glycophorin and CD45 as Ligands for sialoadhesin and CD22, respectively. For sialoadhesin, the amino-terminal V-set Ig-like domain was both necessary and sufficient to mediate sialic acid-dependent adhesion of the correct specificity. In contrast, for murine CD22, only constructs containing both the V-set domain and the adjacent C2-set domain were able to mediate sialic acid-dependent binding. These results are consistent with the sialic acid binding site for both proteins residing in the membrane distal V-set domain, but for CD22 a direct contribution in binding from the neighboring C2-set domain cannot be excluded.	UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, IMPERIAL CANC RES FUND LABS, OXFORD OX3 9DU, ENGLAND; JOHN RADCLIFFE HOSP, SIR WILLIAM DUNN SCH PATHOL, MRC, CELLULAR IMMUNOL UNIT, OXFORD OX3 9DU, ENGLAND; CHRISTIAN ALBRECHTS UNIV KIEL, INST BIOCHEM, D-24098 KIEL, GERMANY	Cancer Research UK; University of Oxford; University of Oxford; University of Kiel			van der Merwe, P. Anton/F-8539-2011; Kelm, Soerge/C-5403-2013	Kelm, Soerge/0000-0001-5277-9421; Crocker, Paul/0000-0001-6230-0293				ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BRUMMENDORF T, 1994, PROTEIN PROFILE, V1, P951; CHAOUCHI N, 1995, J IMMUNOL, V154, P3096; CROCKER PR, 1995, J CLIN INVEST, V95, P635, DOI 10.1172/JCI117708; CROCKER PR, 1989, J EXP MED, V169, P1333, DOI 10.1084/jem.169.4.1333; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; CROCKER PR, 1990, BLOOD, V76, P1131; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; ENGEL P, 1993, J IMMUNOL, V150, P4719; ENGEL P, 1995, J EXP MED, V181, P1581, DOI 10.1084/jem.181.4.1581; FAWCETT J, 1995, J CELL BIOL, V128, P1229, DOI 10.1083/jcb.128.6.1229; FOX SB, 1994, CANCER RES, V54, P4539; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HAZLEWOOD M, 1993, CLIN EXP IMMUNOL, V93, P157; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; LAW CL, 1993, J IMMUNOL, V151, P175; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; MCEVER RP, 1994, CURR OPIN IMMUNOL, V6, P75, DOI 10.1016/0952-7915(94)90037-X; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PAULSON JC, 1987, METHOD ENZYMOL, V138, P162; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PEDRAZA L, 1990, J CELL BIOL, V111, P2651, DOI 10.1083/jcb.111.6.2651; PIGOTT R, 1991, J IMMUNOL, V147, P130; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1994, J BIOL CHEM, V269, P10628; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SGROI D, 1993, J BIOL CHEM, V268, P7011; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; SUNDERLAND CA, 1979, EUR J IMMUNOL, V9, P155, DOI 10.1002/eji.1830090212; SYMINGTON FW, 1982, IMMUNOGENETICS, V16, P381, DOI 10.1007/BF00372098; THOMAS ML, 1995, J EXP MED, V181, P1953, DOI 10.1084/jem.181.6.1953; TORRES RM, 1992, J IMMUNOL, V149, P2641; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WEIS WI, 1994, STRUCTURE, V2, P147, DOI 10.1016/S0969-2126(00)00016-2; WEN DX, 1992, J BIOL CHEM, V267, P21011; WILLIAMS AF, 1989, COLD SPRING HARB SYM, V54, P637; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951	51	91	102	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26184	26191		10.1074/jbc.270.44.26184	http://dx.doi.org/10.1074/jbc.270.44.26184			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592823	hybrid			2022-12-27	WOS:A1995TC97800030
J	CALDENHOVEN, E; VANDIJK, T; RAAIJMAKERS, JAM; LAMMERS, JWJ; KOENDERMAN, L; DEGROOT, RP				CALDENHOVEN, E; VANDIJK, T; RAAIJMAKERS, JAM; LAMMERS, JWJ; KOENDERMAN, L; DEGROOT, RP			ACTIVATION OF THE STAT3 ACUTE-PHASE RESPONSE FACTOR TRANSCRIPTION FACTOR BY INTERLEUKIN-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; COMMON BETA-SUBUNIT; SIGNAL-TRANSDUCTION; GM-CSF; HUMAN EOSINOPHILS; INTERFERON-ALPHA; CELL LINES; RECEPTOR; GENE	The receptor for interleukin-5 (IL-5R) is composed of a unique alpha chain (IL-5R alpha) expressed on eosinophils and basophils, associated with a beta c subunit, which is shared by the receptors for IL-S and granulocyte macrophage-colony stimulating factor. One of the molecular events activated via the IL-BR is the JAK/STAT signaling pathway. Recent reports have shown that IL-5 induces tyrosine phosphorylation of JAK2 followed by the subsequent cell type-specific activation of either STAT1 alpha or STAT5. To identify additional STAT proteins activated by IL-5, we co-transfected the IL-5R with STAT cDNAs in COS cells. We found that IL-5 induces binding of STAT3 to the intercellular adhesion molecule-1 pIRE, and activates STAT3-dependent transcription. Moreover, endogenous STAT3 was tyrosine phosphorylated and activated in human IL-5-stimulated BaF3 cells ectopically expressing the human IL-5R (BaF3/IL5R). These data imply that multiple STAT proteins are involved in gene regulation by IL-S in a cell type-specific manner. We further demonstrate using C-terminal truncations of the alpha and beta c subunits of the IL-5R that the membrane-proximal regions of both subunits are required for STAT activation. Interestingly, a beta c receptor mutant lacking intracellular tyrosine residues is able to mediate STAT3 activation, suggesting that tyrosine phosphorylation of the beta c receptor is not essential for STAT3 activation.	UNIV UTRECHT HOSP,DEPT PULM DIS,3584 CX UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center				Koenderman, Leo/0000-0002-5636-6453				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CAMPBELL HD, 1987, P NATL ACAD SCI USA, V84, P6629, DOI 10.1073/pnas.84.19.6629; CHIHARA J, 1990, J EXP MED, V172, P1347, DOI 10.1084/jem.172.5.1347; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; COFFER P, 1995, ONCOGENE, V10, P985; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRAHAM FL, 1973, MOL CELL BIOL, V2, P607; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HARROCH S, 1994, J BIOL CHEM, V269, P26191; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; INGLEY E, 1991, BLOOD, V78, P339; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; KITAMURA T, 1992, BLOOD, V80, P84; KRESS C, 1990, DEVELOPMENT, V109, P775; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MIYAJIMA A, 1993, BLOOD, V82, P1960; MUI ALF, 1994, P SOC EXP BIOL MED, V206, P284; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; OGAWA M, 1993, BLOOD, V81, P2844; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SANDERSON CJ, 1985, J EXP MED, V162, P60, DOI 10.1084/jem.162.1.60; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SHEN S, 1993, MECH DEVELOP, V40, P177, DOI 10.1016/0925-4773(93)90075-9; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TIAN SS, 1994, BLOOD, V84, P1760; TORIGOE T, 1992, BLOOD, V80, P617; VANDERBRUGGEN T, 1994, J IMMUNOL, V153, P2729; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; VANDERBRUGGEN T, 1993, J LEUKOCYTE BIOL, V53, P347, DOI 10.1002/jlb.53.4.347; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZANDERS ED, 1994, EUR CYTOKINE NETW, V5, P35; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	61	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25778	25784		10.1074/jbc.270.43.25778	http://dx.doi.org/10.1074/jbc.270.43.25778			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592760	Green Published, hybrid			2022-12-27	WOS:A1995TB46600077
J	DUGI, KA; DICHEK, HL; SANTAMARINAFOJO, S				DUGI, KA; DICHEK, HL; SANTAMARINAFOJO, S			HUMAN HEPATIC AND LIPOPROTEIN-LIPASE - THE LOOP COVERING THE CATALYTIC SITE MEDIATES LIPASE SUBSTRATE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; RELEASABLE LIVER LIPASE; TRIGLYCERIDE LIPASE; DIRECTED MUTAGENESIS; HUMAN-PLASMA; TRIACYLGLYCEROL LIPASE; INTERFACIAL ACTIVATION; PANCREATIC LIPASE; APOLIPOPROTEIN-E; CHIMERIC LIPASE	Hepatic lipase (HL) and Lipoprotein Lipase (LPL) are key enzymes that mediate the hydrolysis of triglycerides (TG) and phospholipids (PL) present in circulating plasma lipoproteins. Relative to triacylglycerol hydrolysis, HL displays higher phospholipase activity than LPL. The structural basis for this difference in substrate specificity has not been definitively established. We recently demonstrated that the 22-amino acid loops (''lids'') covering the catalytic sites of LPL and HL are critical for the interaction with lipid substrate (Dugi, K. A. Dichek, H. L., Talley, G. D., Brewer, H. B., Jr., and Santamarina-Fojo, S. (1992) J. Biol. Chem. 267, 25086-25091). To determine whether the Lipase lid plays a role in conferring the different substrate specificities of HL and LPL, we have generated four chimeric lipases. Characterization of these chimeric enzymes using TG (triolein and tributyrin) or PL (dioleoylphosphatidylcholine (DOPC) vesicles, DOPC proteoliposomes, and DOPC-mixed liposomes) substrates demonstrated marked differences between their relative PL/TG hydrolyzing activities. Chimeric LPL containing the lid of HL had reduced triolein hydrolyzing activity (49% of the wild type), but increased phospholipase activity in DOPC vesicle, DOPC proteoliposome, and DOPC-mixed liposome assay systems (443, 628, and 327% of wild-type LPL, respectively). In contrast, chimeric BL containing the LPL lid was more active against triolein (123% of the wild type) and less active against DOPC (23, 0, and 30%, respectively) than normal HL. Similar results were obtained when the lipase lids were exchanged in chimeric enzymes containing the NH2-terminal end of LPL and the COOH-terminal domain of HL. Exchange of the LPL and HL Lids resulted in a reversal of the phospholipase/neutral Lipase ratio, establishing the important role of this region in mediating substrate specificity. In summary, the Lid covering the catalytic domains in LPL and HL plays a crucial role in determining Lipase substrate specificity. The lid of LPL confers preferential triglyceride hydrolysis, whereas the Lid of HL augments phospholipase activity. This study provides new insight into the structural basis for the observed in vivo differences in LPL and HL function.	NHLBI,MOLEC DIS BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								AUWERX JH, 1989, ARTERIOSCLEROSIS, V9, P319, DOI 10.1161/01.ATV.9.3.319; BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BELFRAGE P, 1969, J LIPID RES, V10, P341; BOURNE Y, 1994, J MOL BIOL, V238, P709, DOI 10.1006/jmbi.1994.1331; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; CHAIT A, 1982, J CLIN INVEST, V69, P490, DOI 10.1172/JCI110473; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CH, 1982, J LIPID RES, V23, P680; CONNELLY PW, 1990, ARTERIOSCLEROSIS, V10, P40, DOI 10.1161/01.ATV.10.1.40; DATTA S, 1988, J BIOL CHEM, V263, P1107; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DAVIS RC, 1990, J BIOL CHEM, V265, P6291; DECKELBAUM RJ, 1992, BIOCHEMISTRY-US, V31, P8544, DOI 10.1021/bi00151a023; DECKELBAUM RJ, 1990, BIOCHEMISTRY-US, V29, P1136, DOI 10.1021/bi00457a006; DELSAL G, 1988, NUCLEIC ACIDS RES, V16, P9878; DEMANT T, 1988, J LIPID RES, V29, P1603; DEMANT T, 1993, J LIPID RES, V34, P147; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DICHEK HL, 1993, J LIPID RES, V34, P1393; DUGI KA, 1992, J BIOL CHEM, V267, P25086; EHNHOLM C, 1975, J BIOL CHEM, V250, P6756; EMMERICH J, 1992, J BIOL CHEM, V267, P4161; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P14418; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; GOLDBERG IJ, 1990, J CLIN INVEST, V86, P463, DOI 10.1172/JCI114732; GOLDBERG IJ, 1982, J CLIN INVEST, V70, P1184, DOI 10.1172/JCI110717; HAVEL RJ, 1973, BIOCHEMISTRY-US, V12, P1828, DOI 10.1021/bi00733a026; HIDE WA, 1992, J LIPID RES, V33, P167; HJORTH A, 1993, BIOCHEMISTRY-US, V32, P4702, DOI 10.1021/bi00069a003; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; JACKSON RL, 1983, ENZYMES, V16, P141; JAHN CE, 1983, EUR J BIOCHEM, V131, P25, DOI 10.1111/j.1432-1033.1983.tb07227.x; JANSEN H, 1980, BIOCHEM BIOPH RES CO, V92, P53, DOI 10.1016/0006-291X(80)91518-1; KEKKI M, 1980, ATHEROSCLEROSIS, V37, P143, DOI 10.1016/0021-9150(80)90102-1; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNSI T, 1979, FEBSW LETT, V804, P384; LAROSA JC, 1970, BIOCHEM BIOPH RES CO, V41, P57, DOI 10.1016/0006-291X(70)90468-7; LOOKENE A, 1993, EUR J BIOCHEM, V213, P185, DOI 10.1111/j.1432-1033.1993.tb17747.x; MARTIN GA, 1988, J BIOL CHEM, V263, P10907; MASUNO H, 1986, BIOCHIM BIOPHYS ACTA, V879, P339; MILLER CH, 1981, BIOCHIM BIOPHYS ACTA, V665, P385, DOI 10.1016/0005-2760(81)90250-2; MORLEY N, 1972, J BIOL CHEM, V247, P6389; MOWRI HO, 1992, J LIPID RES, V33, P1269; NOZAKI S, 1986, METABOLISM, V35, P53, DOI 10.1016/0026-0495(86)90095-8; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; RADLOFF R, 1967, P NATL ACAD SCI USA, V57, P1514, DOI 10.1073/pnas.57.5.1514; ROJAS C, 1991, EUR J BIOCHEM, V197, P315, DOI 10.1111/j.1432-1033.1991.tb15913.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; SHIRAI K, 1981, BIOCHEM BIOPH RES CO, V100, P591, DOI 10.1016/S0006-291X(81)80217-3; SHIRAI K, 1984, BIOCHIM BIOPHYS ACTA, V795, P9; STAHNKE G, 1987, DIFFERENTIATION, V35, P45, DOI 10.1111/j.1432-0436.1987.tb00150.x; THUREN T, 1992, BIOCHEMISTRY-US, V31, P2332, DOI 10.1021/bi00123a018; THUREN T, 1991, BIOCHIM BIOPHYS ACTA, V1083, P217, DOI 10.1016/0005-2760(91)90046-K; THUREN T, 1991, J BIOL CHEM, V266, P4853; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTOL A, 1980, BIOCHEM BIOPH RES CO, V94, P101, DOI 10.1016/S0006-291X(80)80193-8; WANG CS, 1982, LIPIDS, V17, P278, DOI 10.1007/BF02534942; WILCOX RW, 1991, LIPIDS, V26, P283, DOI 10.1007/BF02537138; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; WONG H, 1991, P NATL ACAD SCI USA, V88, P11290, DOI 10.1073/pnas.88.24.11290	67	102	114	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25396	25401		10.1074/jbc.270.43.25396	http://dx.doi.org/10.1074/jbc.270.43.25396			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592706	hybrid			2022-12-27	WOS:A1995TB46600022
J	HANNA, DE; RETHINASWAMY, A; GLOVER, CVC				HANNA, DE; RETHINASWAMY, A; GLOVER, CVC			CASEIN KINASE-II IS REQUIRED FOR CELL-CYCLE PROGRESSION DURING G(1) AND G(2)/M IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-II; PROTEIN-KINASE; CONSERVED FEATURES; DIVISION CYCLE; BUDDING YEAST; BETA-SUBUNIT; PHOSPHORYLATION; MITOSIS; IDENTIFICATION; TRANSCRIPTION	The catalytic subunit of Saccharomyces cerevisiae casein kinase II (Sc CKII) is encoded by the CKA1 and CKA2 genes, which together are essential for viability. Five independent temperature-sensitive alleles of the CKA2 gene were isolated and used to analyze the function of CHII during the cell cycle. Following a shift to the nonpermissive temperature, cka2(ts) strains arrested within a single cell cycle and exhibited a dual arrest phenotype consisting of 50% unbudded and 50% large-budded cells. The unbudded half of the arrested population contained a single nucleus and a single focus of microtubule staining, consistent with arrest in G(1). Most of the large-budded fraction contained segregated chromatin and an extended spindle, indicative of arrest in anaphase, though a fraction contained an undivided nucleus with a short thick intranuclear spindle, indicative of arrest in G(2) and/or metaphase. Flow cytometry of pheromone-synchronized cells confirmed that CKII is required in G(1), at a point which must lie at or beyond Start but prior to DNA synthesis. Similar analysis of hydroxyurea-synchronized cells indicated that CKII is not required for completion of previously initiated DNA replication but confirmed that the enzyme is again required for cell cycle progression in G(2) and/or mitosis. These results establish a role for CKII in regulation and/or execution of the eukaryotic cell cycle.	UNIV GEORGIA, DEPT BIOCHEM & MOLEC BIOL, ATHENS, GA 30602 USA	University System of Georgia; University of Georgia					NIGMS NIH HHS [GM33237] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033237] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BUSBY S, 1982, J MOL BIOL, V154, P197, DOI 10.1016/0022-2836(82)90060-2; CARDENAS ME, 1993, J CELL SCI, V104, P219; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARDENAS ME, 1993, J CELL SCI, V104, P533; CARROLL D, 1989, J BIOL CHEM, V264, P7345; DEBENEDETTE M, 1991, J IMMUNOL, V147, P2839; ELLIOTT SG, 1978, P NATL ACAD SCI USA, V75, P4384, DOI 10.1073/pnas.75.9.4384; FENG L, 1994, MOL CELL BIOL, V14, P5139, DOI 10.1128/MCB.14.8.5139; GLOVER CVC, 1994, CELL MOL BIOL RES, V40, P481; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARTWELL LH, 1973, GENETICS, V74, P267; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; MULNERLORILLON O, 1988, EUR J BIOCHEM, V171, P107, DOI 10.1111/j.1432-1033.1988.tb13765.x; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; REED SI, 1980, GENETICS, V95, P561; Rose MD., 1990, METHODS YEAST GENETI; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SIKORSKI RS, 1989, GENETICS, V122, P19; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TANG Y, 1993, GENE DEV, V7, P822, DOI 10.1101/gad.7.5.822; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x	46	187	187	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25905	25914		10.1074/jbc.270.43.25905	http://dx.doi.org/10.1074/jbc.270.43.25905			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592778	hybrid			2022-12-27	WOS:A1995TB46600095
J	LI, ML; LYON, MK; GARCEA, RL				LI, ML; LYON, MK; GARCEA, RL			IN-VITRO PHOSPHORYLATION OF THE POLYOMAVIRUS MAJOR CAPSID PROTEIN VP1 ON SERINE-66 BY CASEIN KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; LARGE T-ANTIGEN; SIMIAN VIRUS-40; MOUSE KIDNEY; CELL-GROWTH; HOST RANGE; INSULIN; GENE; PHOSPHATASE-2A; ONCOPROTEINS	Phosphorylation of the polyomavirus major capsid protein VP1 plays a role in virus assembly and may function in virus-cell recognition. Previous mapping of the in vivo phosphorylation sites on VP1 identified phosphorylation of threonine residues Thr-63 and Thr-156 (Li, M., and Garcea, R. L. (1994) J. Virol. 68, 320-327). Phosphoserine was detected in a tryptic phosphopeptide encompassing residues 58-78. Because of consensus casein kinase II (CK II) sites in this peptide, we examined the in vitro phosphorylation of the purified recombinant VP1 protein by CK II. CK II phosphorylated VP1 on serine, and the resulting tryptic phosphopeptide eluted in a 30-31 min high performance liquid chromatography fraction corresponding to residues 58-78. The VP1 tryptic phosphopeptide also co-migrated in two-dimensional peptide analysis with one of the tryptic peptides obtained from VP1 isolated after in vivo P-32 labeling of virus-infected cells. A site-directed mutant VP1 protein, Ser-66 to Ala, was phosphorylated poorly by CK II in vitro. As determined by electron microscopy, all of the mutant proteins were isolated in pentameric form similar to the mild-type protein, although the Ala-66 pentamers had a tendency to self-assemble in vitro into tubular as well as capsid-like structures. These findings identify Ser-66 as a site of VP1 phosphorylation in vitro, and suggest that VP1 may serve as a substrate for CK II in vivo.	UNIV COLORADO, HLTH SCI CTR,SCH MED,DEPT PEDIAT, PEDIAT HEMATOL ONCOL SECT, DENVER, CO 80262 USA; UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver					NATIONAL CANCER INSTITUTE [R01CA037667] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA037667, CA37667] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AEBERSOLD R, 1989, PRACTICAL GUIDE PEPT, P73; ANDERS DG, 1983, J VIROL, V48, P206, DOI 10.1128/JVI.48.1.206-217.1983; BENJAMIN TL, 1982, BIOCHIM BIOPHYS ACTA, V695, P69, DOI 10.1016/0304-419X(82)90018-X; BOLEN JB, 1981, J VIROL, V37, P80, DOI 10.1128/JVI.37.1.80-91.1981; BOLEN JB, 1979, J VIROL, V32, P679, DOI 10.1128/JVI.32.2.679-683.1979; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GARCEA RL, 1985, J VIROL, V54, P311, DOI 10.1128/JVI.54.2.311-316.1985; GARCEA RL, 1983, P NATL ACAD SCI-BIOL, V80, P3613, DOI 10.1073/pnas.80.12.3613; GARCEA RL, 1987, NATURE, V329, P86, DOI 10.1038/329086a0; GARCEA RL, 1989, VIROLOGY, V168, P312, DOI 10.1016/0042-6822(89)90271-7; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; GRESSER FA, 1988, VIROLOGY, V165, P13; GRIFFIN JD, 1979, P NATL ACAD SCI USA, V76, P2610, DOI 10.1073/pnas.76.6.2610; GROSE C, 1989, J VIROL, V63, P3912, DOI 10.1128/JVI.63.9.3912-3918.1989; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; LEAVITT AD, 1985, J BIOL CHEM, V260, P2803; LEGENDRE N, 1989, PRACTICAL GUIDE PROT, P51; LI ML, 1994, J VIROL, V68, P320, DOI 10.1128/JVI.68.1.320-327.1994; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LORENZ P, 1993, J BIOL CHEM, V268, P2733; LUDLOW JW, 1987, J VIROL, V61, P509, DOI 10.1128/JVI.61.2.509-515.1987; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MANAK JR, 1993, ONCOGENE, V8, P703; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MONTROSS L, 1991, J VIROL, V65, P4991, DOI 10.1128/JVI.65.9.4991-4998.1991; MORELAND RB, 1991, J VIROL, V65, P1168, DOI 10.1128/JVI.65.3.1168-1176.1991; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RAYMENT I, 1982, NATURE, V295, P110, DOI 10.1038/295110a0; SALUNKE DM, 1989, BIOPHYS J, V56, P887, DOI 10.1016/S0006-3495(89)82735-3; SALUNKE DM, 1986, CELL, V46, P895, DOI 10.1016/0092-8674(86)90071-1; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; STEHLE T, 1994, NATURE, V369, P160, DOI 10.1038/369160a0; TAKIO K, 1987, P NATL ACAD SCI USA, V84, P4851, DOI 10.1073/pnas.84.14.4851; TJIAN R, 1979, COLD SPRING HARB SYM, V44, P103; Tooze J, 1980, DNA TUMOR VIRUSES; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WITTERS LA, 1983, J BIOL CHEM, V258, P5643; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	49	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					26006	26011		10.1074/jbc.270.43.26006	http://dx.doi.org/10.1074/jbc.270.43.26006			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592792	hybrid			2022-12-27	WOS:A1995TB46600109
J	TJOELKER, LW; EBERHARDT, C; UNGER, J; LETRONG, H; ZIMMERMAN, GA; MCINTYRE, TM; STAFFORINI, DM; PRESCOTT, SM; GRAY, PW				TJOELKER, LW; EBERHARDT, C; UNGER, J; LETRONG, H; ZIMMERMAN, GA; MCINTYRE, TM; STAFFORINI, DM; PRESCOTT, SM; GRAY, PW			PLASMA PLATELET-ACTIVATING-FACTOR ACETYLHYDROLASE IS A SECRETED PHOSPHOLIPASE A(2) WITH A CATALYTIC TRIAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; DEPENDENT PROTEIN-KINASE; INTERFACIAL ACTIVATION; TRIACYLGLYCEROL LIPASE; TRIGLYCERIDE LIPASE; GEOTRICHUM-CANDIDUM; ENDOTHELIAL-CELLS; PANCREATIC LIPASE; REFINED STRUCTURE; ACETYLTRANSFERASE	Platelet-activating factor (PAF) is a potent pro-inflammatory autacoid with diverse physiological and pathological actions. These actions are modulated by PAF acetylhydrolase, which hydrolyzes the sn-2 ester bond to yield the biologically inactive lyso-PAF. In contrast to most secreted phospholipase A(2)s, plasma PAF acetylhydrolase is calcium-independent and contains a GXSXG motif that is characteristic of the neutral lipases and serine esterases. In this study we tested whether the serine in this motif is part of the active site of plasma PAF acetylhydrolase and, if so, what the other components of the active site are. Using site-directed mutagenesis, we demonstrated that Ser-273 (of the GXSXG motif), Asp-296, and His-351 are essential for catalysis. These residues were conserved in PAF acetylhydrolase sequences isolated from bovine, dog, mouse, and chicken. The linear orientation and spacing of these catalytic residues are consistent with the alpha/beta hydrolase conformation of other lipases and esterases. In support of this model, analysis of systematic truncations of PAF acetylhydrolase revealed that deletions beyond 54 amino acids from the NH2 terminus and 21 from the COOH terminus resulted in a loss of enzyme activity. These observations demonstrate that although plasma PAF acetylhydrolase is a phospholipase A(2) it has structural properties characteristic of the neutral lipases and esterases.	ICOS CORP, BOTHELL, WA 98021 USA; UNIV UTAH, INST CARDIOVASC RES & TRAINING, SALT LAKE CITY, UT 84112 USA	Icos Corporation; Utah System of Higher Education; University of Utah					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050153, R01HL035828] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50153, HL35828] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; BOEL E, 1988, LIPIDS, V23, P701, DOI 10.1007/BF02535672; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DATTA S, 1988, J BIOL CHEM, V263, P1107; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DEREWENDA U, 1994, NAT STRUCT BIOL, V1, P36, DOI 10.1038/nsb0194-36; DEREWENDA ZS, 1994, ADV PROTEIN CHEM, V45, P1; DOMENECH C, 1987, J BIOL CHEM, V262, P5671; ELSTAD MR, 1989, J BIOL CHEM, V264, P8467; GOMEZCAMBRONERO J, 1985, BIOCHIM BIOPHYS ACTA, V845, P516, DOI 10.1016/0167-4889(85)90219-8; GROCHULSKI P, 1994, PROTEIN SCI, V3, P82; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; Higuchi R., 1989, PCR TECHNOLOGY, P61; HJORTH A, 1993, BIOCHEMISTRY-US, V32, P4702, DOI 10.1021/bi00069a003; HOLLAND MR, 1992, J BIOL CHEM, V267, P22883; JAEGER KE, 1993, FEBS LETT, V332, P143, DOI 10.1016/0014-5793(93)80501-K; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LENIHAN DJ, 1984, BIOCHEM BIOPH RES CO, V120, P834, DOI 10.1016/S0006-291X(84)80182-5; MARTINEZ C, 1992, NATURE, V356, P615, DOI 10.1038/356615a0; NOBLE MEM, 1994, PROTEIN ENG, V7, P559, DOI 10.1093/protein/7.4.559; NOBLE MEM, 1993, FEBS LETT, V331, P123, DOI 10.1016/0014-5793(93)80310-Q; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHRAG JD, 1993, J MOL BIOL, V230, P575, DOI 10.1006/jmbi.1993.1171; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SHARP JD, 1991, J BIOL CHEM, V266, P14850; STAFFORINI DM, 1991, LIPIDS, V26, P979, DOI 10.1007/BF02536488; STAFFORINI DM, 1990, J BIOL CHEM, V265, P9682; STAFFORINI DM, 1990, METHOD ENZYMOL, V187, P344; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1992, T ASSOC AM PHYSICIAN, V105, P44; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; UPPENBERG J, 1994, STRUCTURE, V2, P293, DOI 10.1016/S0969-2126(00)00031-9; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VENABLE ME, 1993, J LIPID RES, V34, P691; WHATLEY RE, 1989, J BIOL CHEM, V264, P6325; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	53	196	212	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25481	25487		10.1074/jbc.270.43.25481	http://dx.doi.org/10.1074/jbc.270.43.25481			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592717	hybrid			2022-12-27	WOS:A1995TB46600033
J	INOUE, H; YOKOYAMA, C; HARA, S; TONE, Y; TANABE, T				INOUE, H; YOKOYAMA, C; HARA, S; TONE, Y; TANABE, T			TRANSCRIPTIONAL REGULATION OF HUMAN PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2 GENE BY LIPOPOLYSACCHARIDE AND PHORBOL ESTER IN VASCULAR ENDOTHELIAL-CELLS - INVOLVEMENT OF BOTH NUCLEAR FACTOR FOR INTERLEUKIN-6 EXPRESSION SITE AND CAMP RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; GRANULOSA-CELLS; MAMMALIAN-CELLS; CDNA CLONING; C/EBP FAMILY; H SYNTHASE; PROMOTER; CYCLOOXYGENASE; NF-IL6; IDENTIFICATION	There exist two distinct isozymes of prostaglandin-endoperoxide synthase (PES). PES-2 mRNA is synergistically induced by lipopolysaccharide (LPS) and 12-O-tetradecanoylphorbol-13-acetate (TPA) in bovine arterial endothelial cells. On the other hand, PES-1 mRNA is constitutively expressed under these conditions. Therefore, the promoter activities of the human genes for PES-1 and -2 in bovine arterial endothelial cells were examined. The 5'-flanking region of the human PES-2 gene (nucleotides -327 to +59) showed promoter activity inducible by LPS and TPA using transient transfection analysis, whereas that of the PES-1 gene (nucleotides -1010 to +69) showed constitutive promoter activity. Destruction of both consensus sequences for the nuclear factor responsible for the interleukin-6 expression (NF-IL6) site (nucleotides -132 to -124) and the cyclic AMP response element (CRE) (nucleotides -59 to -53) of the human PES-2 gene markedly reduced the promoter activity (25%) of the PES-2 gene after combined treatment with LPS and TPA, although single destruction of the NF-IL6 site or the CRE slightly reduced the promoter activity (60 or 90%, respectively). Moreover, cotransfection experiments showed that a trans-acting factor, CCAAT enhancer binding protein delta (C/EBP delta), which binds to both the NP-IL6 site and the CRE, increased the promoter activity of the PES-2 gene mainly through the CRE. C/EBP delta mRNA was rapidly induced by LPS. Collectively, these results suggest that transcription of the PES-2 gene in vascular endothelial cells is regulated through combination of the NF-IL6 site and the CRE and that C/EBP delta functions as one of the trans-acting factors.	NATL CARDIOVASC CTR,RES INST,DEPT PHARMACOL,SUITA,OSAKA 565,JAPAN	National Cerebral & Cardiovascular Center - Japan								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; CAO Z, 1991, GENE DEV, V5, P1553; Chomczynski P, 1987, ANAL BIOCHEM, V132, P6; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; INOUE H, 1993, MOL BRAIN RES, V20, P299, DOI 10.1016/0169-328X(93)90056-U; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES DA, 1992, J BIOL CHEM, V268, P9049; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LALLI E, 1994, J BIOL CHEM, V269, P17359; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEE SH, 1992, J BIOL CHEM, V267, P25934; LIN AH, 1989, J BIOL CHEM, V264, P17379; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SIROIS J, 1993, J BIOL CHEM, V268, P12199; SMITH WL, 1990, BIOCHIM BIOPHYS ACTA, V1083, P1; TANABE T, 1993, J LIPID MEDIATOR, V6, P139; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; WANG LH, 1993, BIOCHEM BIOPH RES CO, V190, P406, DOI 10.1006/bbrc.1993.1062; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; YAMAMOTO S, 1988, PROSTAGLANDINS BIOL, P37; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	36	458	460	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24965	24971		10.1074/jbc.270.42.24965	http://dx.doi.org/10.1074/jbc.270.42.24965			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559624	hybrid			2022-12-27	WOS:A1995TB46500058
J	ENGLARO, W; REZZONICO, R; DURANDCLEMENT, M; LALLEMAND, D; ORTONNE, JP; BALLOTTI, R				ENGLARO, W; REZZONICO, R; DURANDCLEMENT, M; LALLEMAND, D; ORTONNE, JP; BALLOTTI, R			MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY AND AP-1 ARE ACTIVATED DURING CAMP-INDUCED MELANOGENESIS IN B-16 MELANOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING HORMONE; SIGNAL-TRANSDUCTION; HUMAN MELANOCYTES; MAP KINASES; MAMMALIAN TYROSINASE; S6 KINASE; PHOSPHORYLATION; BIOSYNTHESIS; DIACYLGLYCEROL; PROLIFERATION	In mammalian melanocytes, melanin synthesis is controlled by tyrosinase, the critical enzyme in the melanogenic pathway. We and others showed that the stimulation of melanogenesis by cAMP is due to an increased tyrosinase expression at protein and mRNA levels, However, the molecular events connecting the rise of intracellular cAMP and the increase in tyrosinase activity remain to be elucidated, In this study, using B16 melanoma cells, we showed that cAMP-elevating agents stimulated mitogen-activated protein (MAP) kinase, p44(mapk). This effect was mediated by the activation of MAP kinase kinase, cAMP-elevating agents induced a translocation of p44(mapk) to the nucleus and an activation of the transcription factor AP-1, cAMP-induced AP-1 contained FOS-related antigen-2 in association with JunD, while after phorbol ester stimulation AP-1 complexes consist mainly of JunD/c-Fos heterodimers. In an attempt to connect these molecular events to the control of tyrosinase expression that appears to be the pivotal point of melanogenesis regulation, we hypothesized that following its activation by cAMP, p44(mapk) activates AP-1, Then AP-1 could stimulate tyrosinase expression through the interaction with specific DNA sequences present in the mouse tyrosinase promoter.	FAC MED NICE,INSERM,U385,F-06107 NICE 02,FRANCE; FAC MED NICE,INSERM,U364,F-06107 NICE 02,FRANCE; INST PASTEUR,DEPT BIOTECHNOL,ONCOGEN VIRUSES UNIT,F-75724 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			BALLOTTI, Robert/F-8825-2013; lallemand, dominique/O-7445-2017; REZZONICO, Roger/N-9626-2016	lallemand, dominique/0000-0002-0212-7342; REZZONICO, Roger/0000-0002-8460-1641; BALLOTTI, Robert/0000-0002-7322-4908				AGIN PP, 1991, PHOTODERMATOL PHOTO, V8, P51; AROCA P, 1993, J BIOL CHEM, V268, P25650; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CARSBERG CJ, 1994, J CELL SCI, V107, P2591; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P56; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; FRIEDMANN PS, 1990, J CELL PHYSIOL, V142, P334, DOI 10.1002/jcp.1041420216; FRODIN M, 1994, J BIOL CHEM, V269, P6207; FULLER BB, 1987, J BIOL CHEM, V262, P4024; FULLER BB, 1979, LIFE SCI, V24, P2405, DOI 10.1016/0024-3205(79)90448-X; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GORDON PR, 1989, J INVEST DERMATOL, V93, P700, DOI 10.1111/1523-1747.ep12319900; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; Halaban R., 1981, BIOCHIM BIOPHYS ACTA, V230, P383; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; HIBI M, 1993, GENE DEV, V7, P1031; HUNT G, 1994, J CELL SCI, V107, P205; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMOKAWA G, 1986, J INVEST DERMATOL, V87, P319, DOI 10.1111/1523-1747.ep12524388; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KORNER A, 1977, NATURE, V267, P444, DOI 10.1038/267444a0; KUZUMAKI T, 1993, EXP CELL RES, V207, P33, DOI 10.1006/excr.1993.1159; LACOUR JP, 1992, J CELL PHYSL, V15, P287; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MCNEIL S, 1992, PIGM CELL RES, V2, P154; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; OIKAWA A, 1972, ARCH BIOCHEM BIOPHYS, V148, P548, DOI 10.1016/0003-9861(72)90173-7; OKUMURA N, 1994, J BIOCHEM-TOKYO, V115, P304, DOI 10.1093/oxfordjournals.jbchem.a124333; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SETH A, 1992, J BIOL CHEM, V267, P24796; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STORM SM, 1990, ONCOGENE, V5, P345; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAMIR A, 1994, J IMMUNOL, V152, P3391; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6	49	190	193	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24315	24320		10.1074/jbc.270.41.24315	http://dx.doi.org/10.1074/jbc.270.41.24315			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592642	hybrid			2022-12-27	WOS:A1995TA21700070
J	GALLEGO, MI; LAZO, PA				GALLEGO, MI; LAZO, PA			DELETION IN HUMAN-CHROMOSOME REGION 12Q13-15 BY INTEGRATION OF HUMAN PAPILLOMAVIRUS DNA IN A CERVICAL-CARCINOMA CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELA-CELLS; HUMAN SARCOMAS; GENES; TRANSLOCATION; AMPLIFICATION; FUSION; SITES; PROTOONCOGENES; TRANSCRIPTION; LIPOSARCOMA	In human cervical carcinomas papillomavirus DNA is frequently integrated in the cell genome, We have cloned the integration site of human papillomavirus-18 DNA in human chromosome region 12q13-15 present in the SW756 cervical carcinoma cell line. Viral DNA is broken from nucleotides 2643 to 3418 in the El and E2 open reading frames, resulting in a deletion of 775 bases of viral DNA, Cloning and sequence analysis of the rearranged and germline alleles shows that there is no homology between the target cellular and viral DNA, suggesting it is a nonhomologous recombination. The target cellular region is called papillomavirus associated locus 2 (PAL2). The 5'- and 3'-flanking probes derived from the hybrid viral-cellular clone detect completely different germline restriction fragments in DNA from cells with normal chromosome 12. There is no overlap between the restriction maps of the target germline clones obtained with 5'- and 3'-flanking probes. Probes from these germline clones beyond the breakpoint position do not detect any DNA rearrangement in SW756 cells DNA. These data prove that there is a deletion of cellular DNA as consequence of the integration, with an estimated minimum size of 14 kilobases, Both cellular flanking probes are outside the amplicon of this chromosome region identified in the OSA and RMS13 sarcoma cell lines, comprising SAS-CHOP-CDK4-MDM2 genes and where translocation breakpoints are located in liposarcomas. The integration at 12q13-15 might have been selected by its contribution to the tumor phenotype.	INST SALUD CARLOS III,CTR NACL BIOL CELULAR,CSIC,GENET MOLEC UNIDAD,E-28220 MAJADAHONDA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Salud Carlos III			Lazo, Pedro A./M-6435-2014	Lazo, Pedro A./0000-0001-8997-3025; Gallego, Marta I./0000-0003-0143-2553				AMAN P, 1993, GENE CHROMOSOME CANC, V5, P278; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BERUBE NG, 1994, CANCER RES, V54, P3077; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DEMETRICK DJ, 1994, CYTOGENET CELL GENET, V66, P72, DOI 10.1159/000133669; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; GALLEGO MI, 1994, GENE CHROMOSOME CANC, V9, P28, DOI 10.1002/gcc.2870090106; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAUSEN HZ, 1991, ORIGINS OF HUMAN CANCER, P685; HOPPESEYLER F, 1994, MOL CARCINOGEN, V10, P134, DOI 10.1002/mc.2940100304; HOTTA H, 1988, CANCER RES, V48, P2955; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; JESUDASAN RA, 1995, AM J HUM GENET, V56, P705; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; KAHN T, 1994, CANCER RES, V54, P1305; KARP JE, 1995, NAT MED, V1, P309, DOI 10.1038/nm0495-309; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Kucherlapati R, 1994, Cytogenet Cell Genet, V67, P245, DOI 10.1159/000133868; LAZO PA, 1989, CANCER RES, V49, P4305; LAZO PA, 1992, FEBS LETT, V300, P109, DOI 10.1016/0014-5793(92)80175-G; LAZO PA, 1987, EUR J BIOCHEM, V165, P393, DOI 10.1111/j.1432-1033.1987.tb11452.x; LAZO PA, 1988, J BIOL CHEM, V263, P360; LAZO PA, 1988, BIOESSAYS, V9, P157; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; MELTZER PS, 1991, CELL GROWTH DIFFER, V2, P495; MITELMAN F, 1991, CATALOG HUMAN CHROMO; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; MURTY VVVS, 1994, ONCOGENE, V9, P2245; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PEDEUTOUR F, 1994, GENE CHROMOSOME CANC, V10, P85, DOI 10.1002/gcc.2870100203; PEDEUTOUR F, 1994, GENOMICS, V22, P512, DOI 10.1006/geno.1994.1424; POPESCU NC, 1987, CYTOGENET CELL GENET, V44, P58, DOI 10.1159/000132342; POPESCU NC, 1990, HUM GENET, V84, P383; POPESCU NC, 1987, J VIROL, V61, P1682, DOI 10.1128/JVI.61.5.1682-1685.1987; POPESCU NC, 1990, CANCER GENET CYTOGEN, V42, P157; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REIFENBERGER G, 1995, CANCER RES, V55, P731; REIFENBERGER G, 1994, CANCER RES, V54, P4299; ROSSL F, 1989, MOL CARCINOGEN, V2, P72; Roth D., 1988, GENETIC RECOMBINATIO, P621; Sambrook J, 1989, MOL CLONING LABORATO; SASTREGARAU X, 1995, CR ACAD SCI III-VIE, V318, P475; SASTREGARAU X, 1990, CANCER GENET CYTOGEN, V44, P243, DOI 10.1016/0165-4608(90)90053-D; Scheffner M, 1994, Curr Top Microbiol Immunol, V186, P83; SEYGER MMB, 1995, CANCER GENET CYTOGEN, V80, P23, DOI 10.1016/0165-4608(94)00157-7; SHAH KV, 1990, VIROLOGY, P1651; SHOENMAKERS EFP, 1994, GENOMICS, V20, P210; THOMAS M, 1995, ONCOGENE, V10, P261; TSICHLIS PN, 1991, CURR TOP MICROBIOL I, V171, P97; VANDEVEN WJM, 1995, GENE CHROMOSOME CANC, V12, P296; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	61	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24321	24326		10.1074/jbc.270.41.24321	http://dx.doi.org/10.1074/jbc.270.41.24321			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592643	Green Published, hybrid			2022-12-27	WOS:A1995TA21700071
J	LEE, KI; REDDY, EP; REDDY, CD				LEE, KI; REDDY, EP; REDDY, CD			CELLULAR FACTORS BINDING TO A NOVEL CIS-ACTING ELEMENT MEDIATE STEROID-HORMONE RESPONSIVENESS OF MOUSE MAMMARY-TUMOR VIRUS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTORS; FUNCTIONAL INTERFERENCE; REGULATORY ELEMENTS; PROVIRAL ACTIVATION; DNA; REGION; EXPRESSION; INDUCTION	Steroid hormone receptors regulate mouse mammary tumor virus (MMTV) gene expression by binding to hormone response DNA elements present in the long terminal repeat. Tissue-specific expression of MMTV is unlikely to be regulated by steroid hormone-receptor complex alone, and mammary cell-specific factors might play a role in the hormone-induced transcriptional activation. In this report we have investigated the function of a novel cis-acting element designated Kil (-204 to -188) which is located adjacent to the distal glucocorticoid response element, in steroid hormone-induced transcription of MMTV. Electrophoretic mobility shift assays indicate that cellular factors bind to the Kil element, and dexamethasone stimulation results in alterations in the binding pattern of proteins in this region. By transient transfection assays using wild type and deletion mutants of the Kil element, we show that this novel cis acting element is necessary for hormone-induced transcription of MMTV and functions in mammary tumor cells but not in NIH/3T3 cells. Mutagenesis of the Kil sequence suggests that the entire Kil element functioning as one unit is necessary for hormone-induced transcription of MMTV. When placed in the context of heterologous promoters, neither Kil element nor glucocorticoid response element is able to induce significant hormone-induced transcription of MMTV. The presence of both the DNA elements in tandem results in optimal induction of transcription in the presence of steroid hormones. Our results also indicate that the Kil element functions in human breast carcinoma cell lines such as T47D and MCF-7. These results suggest that Kil element in combination with distal glucocorticoid response element functions as a mammary cell-specific enhancer to regulate MMTV transcription.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA 52009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052009] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALL JK, 1988, J VIROL, V62, P2985, DOI 10.1128/JVI.62.8.2985-2993.1988; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BUETTI E, 1989, NUCLEIC ACIDS RES, V17, P3065, DOI 10.1093/nar/17.8.3065; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY J, 1984, J VIROL, V49, P92, DOI 10.1128/JVI.49.1.92-101.1984; ESPANAS ML, 1994, MOL CELL BIOL, V14, P4116; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOECK W, 1989, J BIOL CHEM, V264, P14396; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; HORWITZ KB, 1978, J BIOL CHEM, V253, P8185; HSU CLL, 1988, J VIROL, V62, P4644, DOI 10.1128/JVI.62.12.4644-4652.1988; KALFF M, 1990, NATURE, V344, P360, DOI 10.1038/344360a0; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; KWON BS, 1984, J VIROL, V52, P1000, DOI 10.1128/JVI.52.3.1000-1004.1984; LUBON H, 1987, NUCLEIC ACIDS RES, V15, P2103, DOI 10.1093/nar/15.5.2103; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MELLENTINMICHEL.J, 1994, J BIOL CHEM, V269, P31893; MEULIA T, 1990, J MOL BIOL, V216, P850; MICHALIDES R, 1985, MOL CELL BIOL, V5, P823, DOI 10.1128/MCB.5.4.823; MICHALIDES R, 1982, J VIROL, V43, P819, DOI 10.1128/JVI.43.3.819-829.1982; MINK S, 1990, NUCLEIC ACIDS RES, V18, P2017, DOI 10.1093/nar/18.8.2017; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; ONDEK B, 1988, NATURE, V33, P40; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; PONTA H, 1985, P NATL ACAD SCI USA, V82, P1020, DOI 10.1073/pnas.82.4.1020; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHEIDEREIT C, 1983, NATURE, V340, P749; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; STEWART TA, 1988, MOL CELL BIOL, V8, P473, DOI 10.1128/MCB.8.1.473; STRAHLE U, 1989, NATURE, V339, P629, DOI 10.1038/339629a0; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; THEUNISSEN HJM, 1989, J VIROL, V63, P3466, DOI 10.1128/JVI.63.8.3466-3471.1989; WELLINGER RJ, 1986, J VIROL, V60, P1; WESTLEY B, 1980, CELL, V20, P353, DOI 10.1016/0092-8674(80)90621-2; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YANAGAWA S, 1991, J VIROL, V65, P526, DOI 10.1128/JVI.65.1.526-531.1991; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	47	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24502	24508		10.1074/jbc.270.41.24502	http://dx.doi.org/10.1074/jbc.270.41.24502			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592667	hybrid			2022-12-27	WOS:A1995TA21700095
J	GOMEZMUNOZ, A; WAGGONER, DW; OBRIEN, L; BRINDLEY, DN				GOMEZMUNOZ, A; WAGGONER, DW; OBRIEN, L; BRINDLEY, DN			INTERACTION OF CERAMIDES, SPHINGOSINE, AND SPHINGOSINE 1-PHOSPHATE IN REGULATING DNA-SYNTHESIS AND PHOSPHOLIPASE-D ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LEUKEMIA HL-60 CELLS; PHOSPHATIDATE PHOSPHOHYDROLASE; 2ND MESSENGER; SPHINGOMYELINASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; CELLULAR PROLIFERATION; HUMAN FIBROBLASTS; KAPPA-B; ACTIVATION	C-2- and C-6-ceramides (N-acetylsphingosine and N-hexanoylsphingosine, respectively) abolished the stimulation of DNA synthesis by sphingosine 1-phosphate in rat fibroblasts. This inhibition by ceramide was partially prevented by insulin C-2-ceramide did not alter the stimulation of DNA synthesis by insulin and decreased the sphingosine-induced stimulation by only 16%. The ceramides did not significantly modify the actions of sphingosine or sphingosine l-phosphate in decreasing cAMP concentrations. C-2- and C-6-ceramides blocked the activation of phospholipase D by sphingosine l-phosphate, and this inhibition was not affected by insulin. Okadaic acid decreased the activation of phospholipase D by sphingosine l-phosphate and did not reverse the inhibitory effect of C-2-ceramide on this activation. Therefore, this effect of C-2-ceramide is unlikely to involve the stimulation of phosphoprotein phosphatase activity. Sphingosine did not activate phospholipase D activity significantly after 10 min. C-2-ceramide stimulated the conversion of exogenous [H-3]sphingosine 1-phosphate to sphingosine and ceramide in fibroblasts. Ceramides can inhibit some effects of sphingosine l-phosphate by stimulating its degradation via a phosphohydrolase that also hydrolyzes phosphatidate. Furthermore, C-2- and C-6-ceramides stimulated ceramide production from endogenous lipids, and this could propagate the intracellular signal. This work demonstrates that controlling the production of ceramide versus sphingosine and sphingosine l-phosphate after sphingomyelinase activation could have profound effects on signal transduction.	UNIV ALBERTA,DEPT BIOCHEM,SIGNAL TRANSDUCT LABS,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta				GOMEZ MUNOZ, ANTONIO/0000-0002-2539-016X				ABE A, 1992, EUR J BIOCHEM, V210, P765, DOI 10.1111/j.1432-1033.1992.tb17479.x; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; CHAO CP, 1994, J BIOL CHEM, V269, P5849; CHATTERJEE S, 1993, J BIOL CHEM, V268, P3401; CHEN H, 1992, BIOCHEM J, V286, P771, DOI 10.1042/bj2860771; CUADRADO A, 1993, ONCOGENE, V8, P2959; DAWSON RMC, 1987, DATA BIOCH RES, P480; DESAI NN, 1992, J BIOL CHEM, V267, P28122; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DUBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; EXTON JH, 1990, J BIOL CHEM, V265, P1; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GOMEZMUNOZ A, 1992, BIOCHIM BIOPHYS ACTA, V1127, P49, DOI 10.1016/0005-2760(92)90200-F; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883; GUPTA AK, 1991, J LIPID RES, V32, P125; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1993, ADV LIPID RES, V25, P27; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HUANG CF, 1990, J BIOL CHEM, V265, P17468; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; LISCOVITCH M, 1991, BIOCHEM J, V279, P319, DOI 10.1042/bj2790319; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MARTIN A, 1994, SIGNAL ACTIVATED PHO, P139; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1992, NUTR REV, V50, P78; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; NICULESCU F, 1993, J IMMUNOL, V150, P214; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RAMACHANDRAN CK, 1990, BIOCHEM BIOPH RES CO, V167, P607, DOI 10.1016/0006-291X(90)92068-B; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SCHROEDER JJ, 1994, J BIOL CHEM, V269, P3475; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SPIEGEL S, 1993, ADV LIPID RES, V25, P105; TOPP WC, 1981, VIROLOGY, V133, P408; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VANDERBEND RL, 1992, BIOCHEM J, V28, P235; VANVELDHOVEN PP, 1994, BIOCHEM J, V299, P597, DOI 10.1042/bj2990597; VANVELDHOVEN PP, 1989, J LIPID RES, V30, P611; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; VIETOR I, 1993, J BIOL CHEM, V268, P18994; WAGGONER DW, 1995, J BIOL CHEM, V270, P19422, DOI 10.1074/jbc.270.33.19422; WU WI, 1993, J BIOL CHEM, V268, P13830; YANG ZH, 1993, J BIOL CHEM, V268, P20520; YOUNES A, 1992, J BIOL CHEM, V267, P842; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	68	145	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26318	26325		10.1074/jbc.270.44.26318	http://dx.doi.org/10.1074/jbc.270.44.26318			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592842	hybrid			2022-12-27	WOS:A1995TC97800049
J	HERNAN, RA; SLIGAR, SG				HERNAN, RA; SLIGAR, SG			TETRAMERIC HEMOGLOBIN EXPRESSED IN ESCHERICHIA-COLI - EVIDENCE OF HETEROGENEOUS SUBUNIT ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC PROTEOLYSIS; RECOMBINANT HUMAN HEMOGLOBIN; MUTANT HUMAN HEMOGLOBINS; HUMAN DEOXYHEMOGLOBIN; SACCHAROMYCES-CEREVISIAE; INOSITOL HEXAPHOSPHATE; BACTERIAL LUCIFERASE; BETA-GLOBINS; X-RAY; BINDING	Recombinant alpha(2) beta(2) tetrameric Hb expressed and assembled in Escherichia coli has been characterized extensively, Electrospray mass spectrometry and optical and electron paramagnetic resonance spectroscopy suggest that the overexpressed protein is identical to native human Hb. Although the functional properties of this recombinant Hb are nearly identical to native Hb, crucial differences exist between the two molecules, The recombinant Hb expressed in E. coli has a lower Hill coefficient even though oxygen equilibrium binding studies indicate cooperative binding, The most significant difference observed between the recombinant and native Hb is the loss of oxygen affinity regulation by 2,3-diphosphoglyerate and protons, CO binding to the deoxy tetramer was found to be biphasic with both phases sensitive to the presence of allosteric effecters, The recombinant chains were isolated, and the ligand binding properties demonstrated that the recombinant chains behave in a similar fashion to native alpha(-sh) and beta(-sh). To investigate whether the chains were capable of forming a well behaved tetramer, the isolated chains were reassembled into a tetramer and purified to homogeneity. Oxygen binding properties of the reassembled recombinant Hb now show an increased Hill coefficient of 2.5, close to, but still slightly lower than, that ob served for native Hb. Additionally, reassembly of recombinant Hb produces a protein that is subject to regulation by allosteric effecters, Furthermore, CO binding to the reassembled recombinant deoxy tetramer was found to be monophasic under all conditions.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801; UNIV ILLINOIS,DEPT CHEM,URBANA,IL 61801; UNIV ILLINOIS,BECKMAN INST ADV SCI & TECHNOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051084] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 51084] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERS GK, 1992, SCIENCE, V54, P50; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; ARNONE A, 1974, NATURE, V249, P34, DOI 10.1038/249034a0; BALDWIN JM, 1980, J MOL BIOL, V136, P103, DOI 10.1016/0022-2836(80)90308-3; BRUNORI M, 1966, J BIOL CHEM, V241, P5238; Bucci E, 1981, Methods Enzymol, V76, P97; CARRILLO N, 1992, J BIOL CHEM, V267, P15537; COGHLAN D, 1992, EUR J BIOCHEM, V207, P931, DOI 10.1111/j.1432-1033.1992.tb17126.x; DOYLE ML, 1992, BIOCHEMISTRY-US, V31, P8629, DOI 10.1021/bi00151a033; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FRONTICELLI C, 1991, J PROTEIN CHEM, V10, P495, DOI 10.1007/BF01025477; GATENBY AA, 1985, NATURE, V314, P617, DOI 10.1038/314617a0; GRAY RD, 1971, J BIOL CHEM, V246, P7168; HAIRE RN, 1977, P NATL ACAD SCI USA, V74, P4135, DOI 10.1073/pnas.74.10.4135; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; HERNAN RA, 1992, BIOCHEMISTRY-US, V31, P8619, DOI 10.1021/bi00151a032; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; IMAI K, 1970, Biochimica et Biophysica Acta, V200, P189, DOI 10.1016/0005-2795(70)90163-7; IMAI K, 1977, BIOCHIM BIOPHYS ACTA, V490, P164, DOI 10.1016/0005-2795(77)90116-7; IMAIZUMI K, 1979, J BIOCHEM, V86, P1829, DOI 10.1093/oxfordjournals.jbchem.a132705; JOHNSON ML, 1976, BIOCHEMISTRY-US, V15, P5363, DOI 10.1021/bi00669a024; KAVANAUGH JS, 1992, BIOCHEMISTRY-US, V31, P8640, DOI 10.1021/bi00151a034; LEE AWM, 1983, P NATL ACAD SCI-BIOL, V80, P7055, DOI 10.1073/pnas.80.23.7055; LOOKER D, 1992, NATURE, V356, P258, DOI 10.1038/356258a0; LUISI B, 1989, J MOL BIOL, V206, P723, DOI 10.1016/0022-2836(89)90579-2; LUISI BF, 1986, NATURE, V320, P555, DOI 10.1038/320555a0; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NOBLE RW, 1969, J BIOL CHEM, V244, P3905; Olson J S, 1981, Methods Enzymol, V76, P631; OLSON JS, 1972, J BIOL CHEM, V247, P3662; PARKHURST LJ, 1979, ANNU REV PHYS CHEM, V30, P503, DOI 10.1146/annurev.pc.30.100179.002443; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SAWICKI CA, 1976, J BIOL CHEM, V251, P1533; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SINCLAIR JF, 1993, BIOCHEMISTRY-US, V32, P5036, DOI 10.1021/bi00070a010; WADDLE JJ, 1987, BIOCHEMISTRY-US, V26, P4917, DOI 10.1021/bi00390a004; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57	42	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26257	26264		10.1074/jbc.270.44.26257	http://dx.doi.org/10.1074/jbc.270.44.26257			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592833	hybrid			2022-12-27	WOS:A1995TC97800040
J	PIERRES, A; BENOLIEL, AM; BONGRAND, P				PIERRES, A; BENOLIEL, AM; BONGRAND, P			MEASURING THE LIFETIME OF BONDS MADE BETWEEN SURFACE-LINKED MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMINAR SHEAR-FLOW; INTERACTION FORCES; CELL-ADHESION; RECEPTOR; MODEL; DETACHMENT; ANTIBODY	It is not well known how the kinetic constants of association between soluble receptors and ligands may be used to predict the behavior of these molecules when they are bound to cell surfaces. Spherical beads were coated with varying densities of anti-rabbit immuno globulin monoclonal antibodies and driven along glass surfaces derivatized with rabbit anti-dinitrophenol. Particle motion was analyzed The velocity, attachment frequency, and duration of binding events were determined on individual particles, It was found that i) beads exhibited frequent arrests lasting between a few tenths of a second and more than one minute; ii) when antibodies were diluted, the median arrest duration remained fairly constant (approximate to 1 s) whereas binding frequency varied as the first power of the antibody concentration, suggesting that most particle arrests were due to the formation of a single bond; iii) when the shear rate was increased 7-fold, the duration of transient binding events remained constant. The disruptive force exerted on attachment points was estimated to range between about 6 and 37 piconewtons; and iv) the distribution of arrest durations suggested that binding was not a monophasic reaction but involved at least one intermediate step. Therefore, transient binding events reflected the formation of unstable associations that are not detected with standard techniques.	HOP ST MARGUERITE,INSERM,U387,IMMUNOL LAB,F-13274 MARSEILLE 09,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			Bongrand, Pierre/C-4456-2013; PIERRES, anne/F-6695-2013	Bongrand, Pierre/0000-0001-6185-6572; 				ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; ANDRE P, 1990, J CELL SCI, V200, P618; BEESON C, 1994, P NATL ACAD SCI USA, V91, P8842, DOI 10.1073/pnas.91.19.8842; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Bongrand P., 1994, STUDYING CELL ADHESI; CAPO C, 1982, J CELL SCI, V56, P21; Cochran W.G, 1957, STAT METHODS, V6th ed; COZENSROBERTS C, 1990, BIOPHYS J, V58, P841, DOI 10.1016/S0006-3495(90)82430-9; DAMMER U, 1995, SCIENCE, V267, P1173, DOI 10.1126/science.7855599; EVANS E, 1991, BIOPHYS J, V59, P838, DOI 10.1016/S0006-3495(91)82296-2; Fersht A., 1985, ENZYME STRUCTURE MEC; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; HAMMER DA, 1987, BIOPHYS J, V52, P475, DOI 10.1016/S0006-3495(87)83236-8; HUBER W, 1995, EUR J BIOCHEM, V227, P647, DOI 10.1111/j.1432-1033.1995.tb20184.x; KAPLANSKI G, 1993, BIOPHYS J, V64, P1922, DOI 10.1016/S0006-3495(93)81563-7; KUO SC, 1993, BIOPHYS J, V65, P2191, DOI 10.1016/S0006-3495(93)81277-3; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; MEGE JL, 1990, BIORHEOLOGY, V27, P433; MICHL J, 1979, J EXP MED, V150, P607, DOI 10.1084/jem.150.3.607; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; PIERRES A, 1994, CELL MECHANICS AND CELLULAR ENGINEERING, P145; PIERRES A, 1994, J CELL BIOL, V125, P945, DOI 10.1083/jcb.125.4.945; SCHMIDSCHOENBEI.GW, 1975, CIRC RES, V36, P173; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TEES DFJ, 1993, BIOPHYS J, V65, P1318, DOI 10.1016/S0006-3495(93)81180-9; TEMPELMAN LA, 1994, BIOPHYS J, V66, P1231, DOI 10.1016/S0006-3495(94)80907-5; THA SP, 1986, BIOPHYS J, V50, P1117, DOI 10.1016/S0006-3495(86)83556-1; TISSOT O, 1992, BIOPHYS J, V61, P204, DOI 10.1016/S0006-3495(92)81827-1; VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; WATTENBARGER MR, 1990, BIOPHYS J, V57, P765, DOI 10.1016/S0006-3495(90)82597-2; WILLIAMS AF, 1991, NATURE, V352, P473, DOI 10.1038/352473a0; WONG CW, 1991, INTRO MATH PHYSICS, P102; ZAFFRAN Y, 1993, BLOOD CELLS, V19, P115	35	70	73	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26586	26592		10.1074/jbc.270.44.26586	http://dx.doi.org/10.1074/jbc.270.44.26586			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592881	hybrid			2022-12-27	WOS:A1995TC97800088
J	SCHILLER, MR; MAINS, RE; EIPPER, BA				SCHILLER, MR; MAINS, RE; EIPPER, BA			A NEUROENDOCRINE-SPECIFIC PROTEIN LOCALIZED TO THE ENDOPLASMIC-RETICULUM BY DISTAL DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL ER PROTEINS; AMINO-ACID-SEQUENCE; PURKINJE NEURONS; TRANSMEMBRANE PROTEINS; PROLYL 4-HYDROXYLASE; SECRETORY GRANULES; BETA-GLUCURONIDASE; CYSTEINE PROTEASE; MOLECULAR-CLONING; LYSYL HYDROXYLASE	Regulated endocrine-specific protein, 18-kDa (RESP18), was previously cloned from rat neurointermediate pituitary based on its coordinate regulation with proopiomelanocortin and neuroendocrine specificity. RESP18 has no homology to any known protein. Although RESP18 is translocated across microsomal membranes after in vitro translation, AtT-20 pituitary tumor cells, which endogenously synthesize RESP18, do not release it into the culture medium. In this work, immunostaining and subcellular fractionation have identified RESP18 as an endoplasmic reticulum (ER) protein. Biosynthetic labeling and temperature block studies of AtT-20 cells demonstrated the localization of RESP18 to the ER lumen by a unique mechanism, degradation by proteolysis in a post-ER pre-Golgi compartment, Proteases in this compartment were saturated by exogenous RESP18 overexpression in AtT-20 cells. Furthermore, a calpain protease inhibitor enhanced secretion of RESP18 from AtT-20 cells overexpressing RESP18, Saturation and inhibition of the RESP18 degrading proteases allowed RESP18 to enter secretory granules and acquire a post-translational modification, likely O-glycosylation; this modified 21-kDa RESP18 isoform was the only RESP18 secreted. Rat anterior pituitary extracts contain 18-kDa and O-glycosylated RESP18 with similar properties. Exogenous RESP18 expression in hEK-293 cells demonstrated ER localization and RESP18 metabolism similar to AtT-20 cells, indicating that the cellular machinery involved in localizing RESP18 is not specific to neuroendocrine cells. The data implicate a novel ER localization mechanism for this neuroendocrine-specific luminal ER resident.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University				Schiller, Martin R/0000-0003-1671-6823	NATIONAL INSTITUTE ON DRUG ABUSE [F32DA005540, P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00266, DA-05540] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMITAY R, 1992, J BIOL CHEM, V267, P20694; ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BISCHOFF J, 1990, J BIOL CHEM, V265, P17110; BLOOMQUIST BT, 1994, ENDOCRINOLOGY, V135, P2714, DOI 10.1210/en.135.6.2714; BLOOMQUIST BT, 1994, J BIOL CHEM, V269, P9113; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BROADWELL RD, 1983, J HISTOCHEM CYTOCHEM, V31, P1077, DOI 10.1177/31.9.6309951; Cerundolo V, 1993, Subcell Biochem, V21, P209; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CICCARELLI E, 1993, EUR J BIOCHEM, V213, P271, DOI 10.1111/j.1432-1033.1993.tb17759.x; DAVIS R, 1993, SUBCELL BIOCH, V21, P143; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; Ericsson Johan, 1993, V21, P229; FINLEY EM, 1994, J BIOL CHEM, V269, P31259; Fra A, 1993, Subcell Biochem, V21, P143; FRICKER LD, 1993, J NEUROCHEM, V61, P1404, DOI 10.1111/j.1471-4159.1993.tb13634.x; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; HAUTALA T, 1992, GENOMICS, V13, P62, DOI 10.1016/0888-7543(92)90202-4; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; HOUGH R, 1984, P NATL ACAD SCI-BIOL, V81, P90, DOI 10.1073/pnas.81.1.90; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; HUSTEN EJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P487, DOI 10.1006/abbi.1994.1336; INOUE S, 1991, J BIOL CHEM, V266, P13311; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; KELLOKUMPU S, 1994, J BIOL CHEM, V269, P30524; Klappa P, 1993, Subcell Biochem, V21, P17; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; LAZZARINO DA, 1988, J BIOL CHEM, V263, P10118; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Lee C, 1993, Subcell Biochem, V21, P343; LI H, 1990, J BIOL CHEM, V265, P14732; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LIU CM, 1978, J BIOL CHEM, V253, P5892; LUZIO J, 1995, BIOCHEM J, V270, P97; MAREK KL, 1989, J NEUROCHEM, V52, P1807, DOI 10.1111/j.1471-4159.1989.tb07261.x; MAY V, 1986, ENDOCRINOLOGY, V118, P1284, DOI 10.1210/endo-118-4-1284; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MEDDA S, 1987, J BIOL CHEM, V262, P7248; Meldolesi J, 1993, Subcell Biochem, V21, P189; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MILGRAM SL, 1994, J CELL SCI, V107, P737; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MYLLYLA R, 1991, J BIOL CHEM, V266, P2805; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NOEL G, 1991, ENDOCRINOLOGY, V129, P1317, DOI 10.1210/endo-129-3-1317; ORCI L, 1994, P NATL ACAD SCI USA, V91, P11924, DOI 10.1073/pnas.91.25.11924; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PRESSMAN BC, 1982, ANNU REV PHARMACOL, V22, P465, DOI 10.1146/annurev.pa.22.040182.002341; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; ROSENFELD MG, 1984, J CELL BIOL, V99, P1076, DOI 10.1083/jcb.99.3.1076; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Rowling P J, 1993, Subcell Biochem, V21, P41; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SASAKI T, 1986, J BIOCHEM-TOKYO, V99, P173, DOI 10.1093/oxfordjournals.jbchem.a135457; SCHWARTZ J, 1991, AM J PHYSIOL, V261, pC793, DOI 10.1152/ajpcell.1991.261.5.C793; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Simon S M, 1993, Subcell Biochem, V21, P1; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; TAKEI K, 1992, J NEUROSCI, V12, P489; Tashiro Y, 1993, Subcell Biochem, V21, P287; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOKUNAGA F, 1995, BIOCHEMISTRY-US, V34, P1163, DOI 10.1021/bi00004a009; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; TRAPANI JA, 1994, J BIOL CHEM, V269, P18359; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; URADE R, 1993, J BIOL CHEM, V268, P22004; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; VILLA A, 1991, J CELL BIOL, V113, P779, DOI 10.1083/jcb.113.4.779; VOLPE P, 1991, EMBO J, V10, P3183, DOI 10.1002/j.1460-2075.1991.tb04880.x; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753; WILKSTROM L, 1991, J CELL BIOL, V113, P997; WILKSTROM L, 1992, J BIOL CHEM, V267, P5; WORLEY PF, 1987, NATURE, V325, P159, DOI 10.1038/325159a0; YOUNG J, 1993, J BIOL CHEM, V268, P19810; ZHEN L, 1995, J BIOL CHEM, V270, P11912, DOI 10.1074/jbc.270.20.11912	91	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26129	26138		10.1074/jbc.270.44.26129	http://dx.doi.org/10.1074/jbc.270.44.26129			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592816	hybrid			2022-12-27	WOS:A1995TC97800023
J	CROSS, MJ; STEWART, A; HODGKIN, MN; KERR, DJ; WAKELAM, MJO				CROSS, MJ; STEWART, A; HODGKIN, MN; KERR, DJ; WAKELAM, MJO			WORTMANNIN AND ITS STRUCTURAL ANALOG DEMETHOXYVIRIDIN INHIBIT STIMULATED PHOSPHOLIPASE A(2) ACTIVITY IN SWISS 3T3 CELLS - WORTMANNIN IS NOT A SPECIFIC INHIBITOR OF PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NEUTROPHIL; ACTIVATION	Wortmannin and its structural analogue demethoxy-viridin (DMV) have been reported to be specific inhibitors of phosphatidylinositol 3-kinase activity. Here we report that these compounds are not as selective as assumed and demonstrate inhibition of bombesin stimulated phospholipase A(2) activity by both wortmannin and DMV with an IC50 (2 nM) which is slightly more potent than the inhibition of insulin-stimulated phosphatidylinositol 3,4,5-trisphosphate generation in these cells (similar to 10 nM). While it has not been possible to fully block in vitro phospholipase A(2) activity with wortmannin, inhibition cannot be a consequence of inhibition of PI 3-kinase activity since bombesin fails to generate 3-phosphorylated lipids in the intact cell. Therefore, while wortmannin is indeed a PI S-kinase inhibitor, it is not as specific as previously reported, and experimental conclusions based solely on its use should be treated with caution.	UNIV BIRMINGHAM,INST CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham				Wakelam, Michael/0000-0003-4059-9276	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BONSER RW, 1991, BRIT J PHARMACOL, V103, P1237, DOI 10.1111/j.1476-5381.1991.tb12330.x; COOK SJ, 1991, BIOCHEM J, V280, P431, DOI 10.1042/bj2800431; CURRIE S, 1992, J BIOL CHEM, V267, P6056; DANA R, 1994, BIOCHEM J, V297, P217, DOI 10.1042/bj2970217; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; KIMURA K, 1994, J BIOL CHEM, V269, P18961; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014-5793(95)00153-Z; PLEVIN R, 1990, BIOCHEM J, V268, P605, DOI 10.1042/bj2680605; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Wakelam Michael J. O., 1993, Biochemical Society Transactions, V21, P874; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WONG NS, 1992, BIOCHEM J, V286, P459, DOI 10.1042/bj2860459; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6	16	249	256	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25352	25355		10.1074/jbc.270.43.25352	http://dx.doi.org/10.1074/jbc.270.43.25352			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592698	hybrid			2022-12-27	WOS:A1995TB46600014
J	FEUERBACH, D; WAELCHLI, R; FEHR, T; FEYEN, JHM				FEUERBACH, D; WAELCHLI, R; FEHR, T; FEYEN, JHM			MYCOTRIENINS - A NEW CLASS OF POTENT INHIBITORS OF OSTEOCLASTIC BONE-RESORPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESS HIGH-LEVELS; HERBIMYCIN-A; FREE-RADICALS; C-SRC; INVITRO; OSTEOPETROSIS; PP60(C-SRC); INVIVO; MICE; ANTIBIOTICS	Pharmacological intervention using selective tyrosine kinase inhibitors has been shown to be an effective approach to inhibit osteoclast function. Here, we report on the structure-activity relations of benzoquinone ansamycins isolated from Streptomyces rishirensis, which form a new class of potent inhibitors of osteoclast-mediated bone resorption. Parathyroid hormone-stimulated bone resorption was inhibited concentration dependently by both mycotrienin I and mycotrienin II, showing half-maximal inhibition in the low nanomolar range in fetal rat long bones in vitro. Structure-activity relation studies indicate that position 19 contained within the quinone/hydroquinone element and the double bonds in position 4, 6, and 8 are crucial for full bioactivity. In contrast, substitutions in position 22 are well tolerated. The lack of a similar effect of 2,6-dimethyl-p-benzoquinone and vitamin K signifies that the mechanism of action is not solely due to the oxygen scavenger capacity of the quinone/hydroquinone moiety. The inhibition of osteoclastic bone resorption is in line with the diminished activity of immunopurified pp(60c-src) from bone suggesting that pp60(c-src) is a possible target of mycotrienins in the organ culture. Thus, mycotrienins may be useful as pharmacologic inhibitors of osteoclastic bone resorption.	SANDOZ PHARMA LTD, DEPT BONE, CH-4002 BASEL, SWITZERLAND; SANDOZ PHARMA LTD, DEPT JOINTS, CH-4002 BASEL, SWITZERLAND; SANDOZ PHARMA LTD, DAT LEAD FINDING UNIT, CH-4002 BASEL, SWITZERLAND	Novartis; Sandoz; Novartis; Sandoz; Novartis; Sandoz								AKESON AL, 1991, ATHEROSCLEROSIS, V86, P261, DOI 10.1016/0021-9150(91)90222-O; ALAM ASMT, 1992, BIOSCIENCE REP, V12, P369; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DEBOER C, 1970, J ANTIBIOT, V23, P442, DOI 10.7164/antibiotics.23.442; FEYEN JHM, 1992, BIOCHEM BIOPH RES CO, V187, P8, DOI 10.1016/S0006-291X(05)81450-0; FEYEN JHM, 1991, J BIOL CHEM, V266, P19469; GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GUBLER HP, 1989, SIGFIT V1 0 IBM PC P; HALL TJ, 1994, BIOCHEM BIOPH RES CO, V199, P1237, DOI 10.1006/bbrc.1994.1363; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; IZBICKA E, 1992, J BONE MINER RES, V7, pS145; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; LORENZO JA, 1983, J CLIN INVEST, V72, P1924, DOI 10.1172/JCI111156; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; OMURA S, 1979, J ANTIBIOT, V32, P255, DOI 10.7164/antibiotics.32.255; RAISZ LG, 1965, J CLIN INVEST, V44, P103, DOI 10.1172/JCI105117; RIES WL, 1992, J BONE MINER RES, V7, P931; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUGITA M, 1982, J ANTIBIOT, V35, P1467, DOI 10.7164/antibiotics.35.1467; SUGITA M, 1982, J ANTIBIOT, V35, P1460, DOI 10.7164/antibiotics.35.1460; SUGITA M, 1982, J ANTIBIOT, V35, P1474, DOI 10.7164/antibiotics.35.1474; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; WHITESELL L, 1992, CANCER RES, V52, P1721; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whyte Michael P., 1993, P327; YONEDA T, 1993, J CLIN INVEST, V91, P2791, DOI 10.1172/JCI116521; YONEDA T, 1993, MOL ENDOCRINOL, V7, P1313, DOI 10.1210/me.7.10.1313; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	34	9	9	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25949	25955		10.1074/jbc.270.43.25949	http://dx.doi.org/10.1074/jbc.270.43.25949			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592784	hybrid			2022-12-27	WOS:A1995TB46600101
J	SPENO, H; TAHERI, MR; SIEBURTH, D; MARTIN, CT				SPENO, H; TAHERI, MR; SIEBURTH, D; MARTIN, CT			IDENTIFICATION OF ESSENTIAL AMINO-ACIDS WITHIN THE PROPOSED CU-A BINDING-SITE IN SUBUNIT-II OF CYTOCHROME-C-OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; SACCHAROMYCES-CEREVISIAE; PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; N2O REDUCTASE; COPPER SITES; LIGANDS; COMPLEX; MUTANTS; AZURIN	To explore the nature of proposed ligands to the Cu-A center in cytochrome c oxidase, site-directed mutagenesis has been initiated in subunit II of the enzyme, Mutations were introduced into the mitochondrial gene from the yeast Saccharomyces cerevisiae by high velocity microprojectile bombardment, A variety of single amino acid substitutions at each of the proposed cysteine and histidine ligands (His-161, Cys-196, Cys-200, and His-204 in the bovine numbering scheme), as well as at the conserved Met-207, all result in yeast which fails to grow on ethanol/glycerol medium. Similarly, all possible paired exchange Cys,His and Cys,Met mutants show the same phenotype. Furthermore, protein stability is severely reduced as evidenced by both the absence of an absorbance maximum at 600 nn in the spectra of mutant cells and the underaccumulation of subunit II, as observed by immunolabeling of mitochondrial extracts, In the same area of the protein, a variety of amino acid substitutions at one of the carboxylates previously implicated in binding cytochrome c, Glu-198, allow (reduced) growth on ethanol/glycerol medium, with normal intracellular levels of protein. These results suggest that a precise folding environment of the Cu-A site within subunit II is essential for assembly or stable accumulation of cytochrome c oxidase in yeast.	UNIV MASSACHUSETTS, DEPT CHEM, AMHERST, MA 01003 USA; UNIV MASSACHUSETTS, PROGRAM MOLEC & CELLULAR BIOL, AMHERST, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046517] Funding Source: NIH RePORTER; NIGMS NIH HHS [1 R01 GM46517] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTALIS TM, 1982, J BIOL CHEM, V257, P6194; ANTHOLINE WE, 1992, EUR J BIOCHEM, V209, P875, DOI 10.1111/j.1432-1033.1992.tb17360.x; Berry E.A., 1987, ANAL BIOCHEM, V161, P10; BISSON R, 1982, FEBS LETT, V144, P359, DOI 10.1016/0014-5793(82)80672-8; BROWN S, 1993, EUR J BIOCHEM, V213, P137, DOI 10.1111/j.1432-1033.1993.tb17743.x; Butler W L, 1972, Methods Enzymol, V24, P3; CALHOUN MW, 1993, BIOCHEMISTRY-US, V32, P10905, DOI 10.1021/bi00091a046; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CARLEYUSMAR VM, 1981, BIOCHEM BIOPH RES CO, V103, P1223; CHAN SI, 1982, ELECTRON TRANSPORT O, P171; CHANG TK, 1991, P NATL ACAD SCI USA, V88, P1325, DOI 10.1073/pnas.88.4.1325; COPPEE JY, 1994, FEBS LETT, V339, P1, DOI 10.1016/0014-5793(94)80373-0; CORIN AF, 1993, BIOCHEMISTRY-US, V32, P2756, DOI 10.1021/bi00062a004; COVELLO PS, 1990, FEBS LETT, V268, P5, DOI 10.1016/0014-5793(90)80958-L; DENBLAAUWEN T, 1991, J AM CHEM SOC, V113, P5050, DOI 10.1021/ja00013a046; FOX TD, 1988, P NATL ACAD SCI USA, V85, P7288, DOI 10.1073/pnas.85.19.7288; FOX TD, 1991, METHOD ENZYMOL, V194, P149; GEORGE GN, 1993, BIOCHIM BIOPHYS ACTA, V1142, P240, DOI 10.1016/0005-2728(93)90152-6; GURBIEL RJ, 1993, J AM CHEM SOC, V115, P10888, DOI 10.1021/ja00076a053; HALL J, 1988, J BIOL CHEM, V263, P8142; HILL BC, 1980, BIOCHEM J, V187, P809, DOI 10.1042/bj1870809; HILL BC, 1991, J BIOL CHEM, V266, P2219; HOLM L, 1987, EMBO J, V6, P2819, DOI 10.1002/j.1460-2075.1987.tb02578.x; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; KEILIN D, 1954, BIOCHEM J, V57, pR29; KELLY M, 1993, J BIOL CHEM, V268, P16781; KRAB K, 1987, BIOCHIM BIOPHYS ACTA, V895, P25, DOI 10.1016/S0304-4173(87)80015-0; Kroneck P M, 1990, Biol Met, V3, P103, DOI 10.1007/BF01179514; KRONECK PMH, 1990, FEBS LETT, V268, P274, DOI 10.1016/0014-5793(90)81026-K; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAPPALAINEN P, 1993, J BIOL CHEM, V268, P26416; LAPPALAINEN P, 1995, BIOCHEMISTRY-US, V34, P5824, DOI 10.1021/bi00017a014; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN CT, 1988, J BIOL CHEM, V263, P8420; MARTIN CT, 1985, J BIOL CHEM, V260, P2857; MEUNIER B, 1993, EUR J BIOCHEM, V213, P129, DOI 10.1111/j.1432-1033.1993.tb17742.x; MILLETT F, 1983, BIOCHEMISTRY-US, V22, P546, DOI 10.1021/bi00272a004; MIZOGUCHI TJ, 1992, J AM CHEM SOC, V114, P10076, DOI 10.1021/ja00051a059; MORRISON M, 1965, ANAL BIOCHEM, V12, P77, DOI 10.1016/0003-2697(65)90144-2; NILSSON T, 1992, P NATL ACAD SCI USA, V89, P6497, DOI 10.1073/pnas.89.14.6497; PAN LP, 1991, J AM CHEM SOC, V113, P5908, DOI 10.1021/ja00015a081; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; SCOTT RA, 1989, P NATL ACAD SCI USA, V86, P4082, DOI 10.1073/pnas.86.11.4082; SHAPLEIGH JP, 1992, P NATL ACAD SCI USA, V89, P4786, DOI 10.1073/pnas.89.11.4786; SHERMAN F, 1964, BIOCHIM BIOPHYS ACTA, V90, P1, DOI 10.1016/0304-4165(64)90113-8; SHERMAN F, 1986, METHODS YEAST GENETI, P125; STEVENS TH, 1982, J BIOL CHEM, V257, P2106; TAANMAN JW, 1992, J BIOL CHEM, V267, P22481; TAHA TSM, 1992, BIOCHEMISTRY-US, V31, P9090, DOI 10.1021/bi00152a053; VANDEROOST J, 1992, EMBO J, V11, P3209, DOI 10.1002/j.1460-2075.1992.tb05398.x; VONWACHENFELDT C, 1994, FEBS LETT, V340, P109, DOI 10.1016/0014-5793(94)80182-7; Wikstrom M., 1981, CYTOCHROME OXIDASE S; WITT H, 1995, BBA-BIOENERGETICS, V1230, P74, DOI 10.1016/0005-2728(95)00050-S; WITTUNG P, 1994, FEBS LETT, V349, P286, DOI 10.1016/0014-5793(94)00694-6; ZUMFT WG, 1992, EUR J BIOCHEM, V208, P31, DOI 10.1111/j.1432-1033.1992.tb17156.x	55	31	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25363	25369		10.1074/jbc.270.43.25363	http://dx.doi.org/10.1074/jbc.270.43.25363			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592701	hybrid			2022-12-27	WOS:A1995TB46600017
J	KLEFF, S; ANDRULIS, ED; ANDERSON, CW; STERNGLANZ, R				KLEFF, S; ANDRULIS, ED; ANDERSON, CW; STERNGLANZ, R			IDENTIFICATION OF A GENE ENCODING A YEAST HISTONE H4 ACETYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE; EXTENSIVE PURIFICATION; ACETYLATION; MUTANTS; NUCLEOSOMES; CHROMATIN; VECTORS; NUCLEI; CELLS; DNA	A collection of yeast temperature-sensitive mutants was screened by an enzymatic assay to find a mutant defective in the acetylation of histone H4. The assay used a fractionated cell extract and measured acetylation of a peptide corresponding to amino acids 1-28 of H4. There are at least two activities in this fraction that acetylate the peptide. A mutation, hat1-1, that eliminates one of the activities was identified and mapped to a locus near the centromere of chromosome XVI. The HAT1 gene was cloned and found to encode a protein of 374 amino acids. Analysis of the peptide used in the assay demonstrated that the HAT1 enzyme acetylates lysine 12 of histone H4. hat1 mutants have no obvious growth defects or phenotypes other than the enzyme defect itself. The HAT1 protein expressed in Escherichia coli gave histone acetyltransferase activity in vitro, demonstrating that HAT1 is the structural gene for the enzyme.	SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA; BROOKHAVEN NATL LAB, DEPT BIOL, UPTON, NY 11973 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; United States Department of Energy (DOE); Brookhaven National Laboratory					NCRR NIH HHS [RR02-427] Funding Source: Medline; NIGMS NIH HHS [GM28220] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028220, R56GM028220] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; ALLFREY VG, 1977, CHROMATIN CHROMOSOME; ALLIS CD, 1985, P NATL ACAD SCI USA, V82, P8048, DOI 10.1073/pnas.82.23.8048; ATTISANO L, 1990, J BIOL CHEM, V265, P3949; BELIKOFF E, 1980, J BIOL CHEM, V255, P1448; CHRISTENSEN ME, 1982, DEV BIOL, V93, P404, DOI 10.1016/0012-1606(82)90127-0; ERICKSON JR, 1993, GENETICS, V134, P151; GARCEA RL, 1980, J BIOL CHEM, V255, P1454; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; KLEFF S, 1992, EMBO J, V11, P699, DOI 10.1002/j.1460-2075.1992.tb05102.x; KLYCE HR, 1973, EXP CELL RES, V82, P47, DOI 10.1016/0014-4827(73)90243-7; KULKARNI MS, 1994, J BIOL CHEM, V269, P13141; LOPEZRODAS G, 1989, J BIOL CHEM, V264, P19028; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PERRY M, 1982, J BIOL CHEM, V257, P7336; RILES L, 1993, GENETICS, V134, P81; Rose MD., 1990, METHODS YEAST GENETI; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; Sambrook J, 1989, MOL CLONING LABORATO; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIKORSKI RS, 1989, GENETICS, V122, P19; TERCERO JC, 1992, J BIOL CHEM, V267, P20277; TRAVIS GH, 1984, J BIOL CHEM, V259, P4406	24	279	301	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24674	24677		10.1074/jbc.270.42.24674	http://dx.doi.org/10.1074/jbc.270.42.24674			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559580	hybrid			2022-12-27	WOS:A1995TB46500014
J	LIU, Y; LIGGITT, D; ZHONG, W; TU, GH; GAENSLER, K; DEBS, R				LIU, Y; LIGGITT, D; ZHONG, W; TU, GH; GAENSLER, K; DEBS, R			CATIONIC LIPOSOME-MEDIATED INTRAVENOUS GENE DELIVERY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MAMMALIAN-CELLS; TRANSGENIC MICE; ADULT MICE; EXPRESSION; INVIVO; ACTIVATION; EFFICIENCY; INTRON; VIRUS	Systemic gene transfer provides new opportunities for the analysis of gene function and gene regulation in vivo, as well as for human gene therapy. We used the chloramphenicol acetyltransferase reporter gene to examine several parameters important for the development of efficient, cationic liposome-mediated, intravenous (IV) gene transfer in mice. We then demonstrated that this approach can produce high level expression of biologically important genes. Specifically, we assessed the relationship of expression vector design to the level of systemic gene expression produced, and compared transfection levels produced by intravenously injecting DNA alone versus DNA liposome complexes. We found that both the position of the heterologous intron, and the promoter element used in the expression plasmid, significantly affected the level of systemic gene expression produced. Although intravenous injection of plasmid DNA alone transfected every tissue analyzed, liposome-mediated delivery was much more efficient. We also established that repeated IV injection of DNA liposome complexes produced high level systemic transfection. The second injection of DNA liposome complexes produced levels of gene expression at least as high as those following a single IV injection. Thus, unlike some viral vectors, a neutralizing host-immune response does not limit re-expression, following reinjection of DNA liposome complexes. Finally, we showed that the expression vectors which produced the highest levels of chloramphenicol acetyltransferase reporter gene expression could also produce high level expression of two colony stimulating factor genes in mice. Specifically, IV injection of liposomes complexed to expression vectors into which we had inserted either the murine granulocyte-macrophage-colony stimulating factor cDNA or the human granulocyte-CSF cDNA, produced circulating levels of the corresponding colony stimulating factor gene product comparable to levels which have been shown previously to be both biologically and therapeutically significant.	CALIF PACIFIC MED RES INST,SAN FRANCISCO,CA 94115; UNIV WASHINGTON,DEPT COMPARAT MED,SEATTLE,WA 98195; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	California Pacific Medical Center; California Pacific Medical Center Research Institute; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco					NCI NIH HHS [R01-CA 58914] Funding Source: Medline; NHLBI NIH HHS [R01-HL 53762] Funding Source: Medline; NIDDK NIH HHS [R01-DK45917] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045917] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRIGHAM KL, 1993, AM J RESP CELL MOL, V8, P209, DOI 10.1165/ajrcmb/8.2.209; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; CHENG L, 1993, P NATL ACAD SCI USA, V90, P4455, DOI 10.1073/pnas.90.10.4455; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DEBS R, 1992, AM J RESPIR CELL MOL, P406; DEBS RJ, 1990, J BIOL CHEM, V265, P10189; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; HAAS R, 1993, EXP HEMATOL, V21, P109; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; ICHIKAWA T, 1995, EXP HEMATOL, V23, P192; KAWAKAMI M, 1990, BLOOD, V76, P1962; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; LESOONWOOD LA, 1995, HUM GENE THER, V6, P365; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; PAUKSEN K, 1994, BRIT J HAEMATOL, V88, P256, DOI 10.1111/j.1365-2141.1994.tb05015.x; PERALES JC, 1994, P NATL ACAD SCI USA, V91, P4086, DOI 10.1073/pnas.91.9.4086; PETROS WP, 1992, PHARMACOTHERAPY, V12, pS32; PHILIP R, 1993, J BIOL CHEM, V268, P16087; ROSENTHAL FM, 1994, BLOOD, V84, P2960; Sambrook J, 1989, MOL CLONING LABORATO; STINSKI MF, 1985, J VIROL, V55, P431, DOI 10.1128/JVI.55.2.431-441.1985; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; TSUKAMOTO M, 1995, NAT GENET, V9, P243, DOI 10.1038/ng0395-243; WANG C, 1995, J CLIN INVEST, V95, P1710, DOI 10.1172/JCI117847; WU GY, 1991, J BIOL CHEM, V266, P14338; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073; ZHU N, 1993, Patent No. 24640	33	204	278	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24864	24870		10.1074/jbc.270.42.24864	http://dx.doi.org/10.1074/jbc.270.42.24864			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559609	hybrid			2022-12-27	WOS:A1995TB46500043
J	LORD, ST; ROONEY, MM; HOPFNER, KP; DICERA, E				LORD, ST; ROONEY, MM; HOPFNER, KP; DICERA, E			BINDING OF FIBRINOGEN A-ALPHA-1-50-BETA-GALACTOSIDASE FUSION PROTEIN TO THROMBIN STABILIZES THE SLOW FORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTITUTION	The interaction of fibrinogen A alpha 1-50-beta-galactosidase fusion protein with the slow and fast forms of thrombin was studied and compared to thrombin-fibrinogen interaction under identical solution conditions. At equilibrium, the affinity of the fusion protein for the slow form of thrombin is 3 times higher than its affinity for the fast form. The fusion protein and fibrinogen have the same affinity for the fast form. On the other hand, the affinity of the fusion protein for the slow form of thrombin is 40 times tighter than that of fibrinogen. In the transition state, binding of the fusion protein has the same properties as fibrinogen, with the fast form showing higher specificity. The N-terminal fragment of the fibrinogen A alpha chain thus contains residues that are responsible for the preferential binding of the fusion protein to the slow form at equilibrium and to the fast form in the transition state. If this fragment binds to thrombin in a similar way for fibrinogen and the fusion protein, then the N-terminal domains of the B beta and gamma chains of fibrinogen, that are not present in the fusion protein, must play a key role in the binding of fibrinogen to thrombin at equilibrium. These chains may destabilize binding to the slow form by nearly 2.4 kcal/mol, thereby favoring binding of fibrinogen to the fast form. We propose that the three chains of fibrinogen play different roles in the thrombin-fibrinogen interaction, with the A alpha chain containing residues for preferential binding to the fast form in the transition state and the B beta and gamma chains containing residues that destabilize binding to the slow form at equilibrium.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599	Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Hopfner, Karl-Peter/B-6864-2014	Hopfner, Karl-Peter/0000-0002-4528-8357	NHLBI NIH HHS [HL49413, HL45100] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, P01HL045100, R01HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024; BINNIE CG, 1993, BLOOD, V81, P3186; BODE W, 1992, PROTEIN SCI, V1, P421; DANG QD, 1994, J PROTEIN CHEM, V13, P367, DOI 10.1007/BF01901692; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; HOPFNER KP, 1992, BIOCHEMISTRY-US, V31, P11567, DOI 10.1021/bi00161a040; KACZMAREK E, 1988, J BIOL CHEM, V263, P13896; KOOPMAN J, 1992, J CLIN INVEST, V90, P238, DOI 10.1172/JCI115841; LIU CY, 1985, J BIOL CHEM, V260, P4390; LORD ST, 1989, BLOOD, V73, P166; LORD ST, 1990, J BIOL CHEM, V265, P838; MATHUR A, 1993, BIOCHEMISTRY-US, V32, P7568, DOI 10.1021/bi00080a031; NG AS, 1993, METHOD ENZYMOL, V222, P341; NIWA K, 1993, BLOOD, V82, P3658; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SIEBENLIST KR, 1990, J BIOL CHEM, V265, P18650; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; TULINSKY A, 1991, THROMB HAEMOSTASIS, V66, P16; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775	20	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24790	24793		10.1074/jbc.270.42.24790	http://dx.doi.org/10.1074/jbc.270.42.24790			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559597	hybrid			2022-12-27	WOS:A1995TB46500031
J	SEWELL, AK; YOKOYA, F; YU, W; MIYAGAWA, T; MURAYAMA, T; WINGE, DR				SEWELL, AK; YOKOYA, F; YU, W; MIYAGAWA, T; MURAYAMA, T; WINGE, DR			MUTATED YEAST HEAT-SHOCK TRANSCRIPTION FACTOR EXHIBITS ELEVATED BASAL TRANSCRIPTIONAL ACTIVATION AND CONFERS METAL RESISTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; HSP 70 GENE; SACCHAROMYCES-CEREVISIAE; METALLOTHIONEIN GENE; EXPRESSION; ELEMENT; DOMAIN; STRAIN; CELLS; ACE1	Cadmium-resistant Saccharomyces cerevisiae strain 301N exhibits high basal as well as cadmium-induced expression of the CUP1 metallothionein gene. Since regulation of CUP1 is usually restricted to copper ions, our goal was to identify the factor responsible for the high metallothionein levels in strain 301N. The gene responsible for the observed phenotype is a spontaneously mutated heat shock transcription factor gene (HSF1). A double, semidominant HSF1 mutant with substitutions at codons 206 and 256 within the DNA-binding domain of the heat shock factor (HSF) confers two phenotypes. The first phenotype is elevated transcriptional activity of the HSF mutant (HSF301), which results in constitutive thermotolerance. A second HSF301 phenotype is enhanced binding affinity for the heat shock element (HSE) within the CUP1 5'-sequences, resulting in high basal transcription of metallothionein. The CUP1 HSE is a minimal heat shock element containing only two perfectly spaced inverted repeats of the basic nGAAn block. Cells containing HSF301 are resistant to cadmium salts. The single R206S mutation is responsible for the high affinity binding to the CUP1 HSE. In addition, the R206S HSF substitution exhibits constitutive transcriptional activation from a consensus HSE (HSE2). The F256Y substitution in HSF attenuates the effects of R206S on the consensus HSE2, but not on the CUP1 HSE.	UNIV UTAH, HLTH SCI CTR, DEPT MED, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, HLTH SCI CTR, DEPT BIOCHEM, SALT LAKE CITY, UT 84132 USA; EHIME UNIV, FAC SCI, DEPT BIOL, MATSUYAMA, EHIME 790, JAPAN	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Ehime University			Sewell, Andrew/GPT-4220-2022	Sewell, Andrew/0000-0003-3194-3135	NATIONAL CANCER INSTITUTE [R01CA061286] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61286] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BONNER JJ, 1994, MOL CELL BIOL, V14, P501, DOI 10.1128/MCB.14.1.501; BONNER JJ, 1992, MOL CELL BIOL, V12, P1021, DOI 10.1128/MCB.12.3.1021; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FERNANDES M, 1994, NUCLEIC ACIDS RES, V22, P167, DOI 10.1093/nar/22.2.167; FLICK KE, 1994, J BIOL CHEM, V269, P12475; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HOJ A, 1994, EMBO J, V13, P2617; INOUHE M, 1989, BIOCHIM BIOPHYS ACTA, V993, P51, DOI 10.1016/0304-4165(89)90142-6; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NELSON HCM, 1985, CELL, V42, P549, DOI 10.1016/0092-8674(85)90112-6; NICOLET CM, 1991, METHOD ENZYMOL, V194, P710; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SEWELL AK, 1995, BIOCHEMISTRY-US, V34, P4740, DOI 10.1021/bi00014a031; SILAR P, 1991, MOL CELL BIOL, V11, P1232, DOI 10.1128/MCB.11.3.1232; SLATER MR, 1987, MOL CELL BIOL, V7, P1906, DOI 10.1128/MCB.7.5.1906; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; SORGER PK, 1989, PROTEIN FUNCTION PRA, P199; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THORVALDSEN JL, 1993, J BIOL CHEM, V268, P12512; TOHOYAMA H, 1977, AGR BIOL CHEM TOKYO, V41, P1523, DOI 10.1080/00021369.1977.10862708; TOHOYAMA H, 1992, FEMS MICROBIOL LETT, V95, P81, DOI 10.1111/j.1574-6968.1992.tb05346.x; TOHOYAMA H, 1992, CURR GENET, V21, P275, DOI 10.1007/BF00351682; TOPOL J, 1985, CELL, V42, P527, DOI 10.1016/0092-8674(85)90110-2; VUISTER GW, 1994, NAT STRUCT BIOL, V1, P605, DOI 10.1038/nsb0994-605; WELCH J, 1989, EMBO J, V8, P255, DOI 10.1002/j.1460-2075.1989.tb03371.x; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; XIAO H, 1991, CELL, V64, P585, DOI 10.1016/0092-8674(91)90242-Q; YANG WM, 1991, MOL CELL BIOL, V11, P3676, DOI 10.1128/MCB.11.7.3676	45	52	53	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25079	25086		10.1074/jbc.270.42.25079	http://dx.doi.org/10.1074/jbc.270.42.25079			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559639	hybrid			2022-12-27	WOS:A1995TB46500073
J	TYTGAT, J; DEBONT, T; CARMELIET, E; DAENENS, P				TYTGAT, J; DEBONT, T; CARMELIET, E; DAENENS, P			THE ALPHA-DENDROTOXIN FOOTPRINT ON A MAMMALIAN POTASSIUM CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDROASPIS-POLYLEPIS-POLYLEPIS; PROTEASE INHIBITOR HOMOLOGS; GREEN MAMBA VENOM; ACETYLCHOLINE-RELEASE; SUBUNIT STOICHIOMETRY; TRYPSIN-INHIBITOR; SNAKE-VENOMS; ANGUSTICEPS; TOXINS; BINDING	alpha-Dendrotoxin, a 59-amino acid basic peptide from the venom of Dendroaspis angusticeps (green mamba snake), potently blocks some but not all voltage-dependent potassium channels. Here we have investigated the relative contribution of the individual alpha-subunits constituting functional Kv1.1 potassium channels to alpha-dendrotoxin binding. Three residues critical for alpha-dendrotoxin binding and located in the loop between domains S5 and S6 were mutated (A352P, E353S, and Y379H), and multimeric cDNAs were constructed encoding homo- and heterotetrameric channels composed of all possible ratios of wild-type and mutant alpha-subunits. Complete mutant channels were about 200-fold less sensitive for the alpha-dendrotoxin block than complete wild-type channels, which is attributable to a smaller association rate. Analysis of the bimolecular reaction between alpha-dendrotoxin and the different homo- and heteromeric channel constructs revealed that the association rate depends on the number of wild-type alpha-subunits in the functional channel. Furthermore, we observed a linear relationship between the number of wild-type alpha-subunits in functional channels and the free energy for alpha-dendrotoxin binding, providing evidence that all four alpha-subunits must interact with alpha-dendrotoxin to produce a high affinity binding site.	UNIV LOUVAIN, PHYSIOL LAB, B-3000 LOUVAIN, BELGIUM		TYTGAT, J (corresponding author), UNIV LOUVAIN, TOXICOL LAB, VAN EVENST 4, B-3000 LOUVAIN, BELGIUM.		Tytgat, Jan/F-1560-2010	Tytgat, Jan/0000-0003-1778-6022				Adams P R, 1986, Adv Neurol, V44, P137; ANDERSON AJ, 1985, TOXICON, V23, P947, DOI 10.1016/0041-0101(85)90387-3; BARRETT JC, 1979, BRIT J PHARMACOL, V67, P199, DOI 10.1111/j.1476-5381.1979.tb08667.x; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BENISHIN CG, 1988, MOL PHARMACOL, V34, P152; BENOIT E, 1986, BRAIN RES, V377, P374, DOI 10.1016/0006-8993(86)90884-X; CASTLE NA, 1989, TRENDS NEUROSCI, V12, P59, DOI 10.1016/0166-2236(89)90137-9; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; DANSE JM, 1994, FEBS LETT, V356, P153, DOI 10.1016/0014-5793(94)01235-0; DREYER F, 1990, REV PHYSIOL BIOCH P, V115, P93; DREYER F, 1987, J PHYSL, V318, P455; GARCIACALVO M, 1994, P NATL ACAD SCI USA, V91, P4718, DOI 10.1073/pnas.91.11.4718; HALLIWELL JV, 1986, P NATL ACAD SCI USA, V83, P493, DOI 10.1073/pnas.83.2.493; HARVEY AL, 1982, BRIT J PHARMACOL, V77, P153, DOI 10.1111/j.1476-5381.1982.tb09281.x; HARVEY AL, 1980, N-S ARCH PHARMACOL, V312, P1, DOI 10.1007/BF00502565; HARVEY AL, 1981, TOXICON, V19, P373, DOI 10.1016/0041-0101(81)90042-8; HARVEY AL, 1985, PHARMACOL THERAPEUT, V31, P33, DOI 10.1016/0163-7258(85)90036-1; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Hille B., 1992, IONIC CHANNELS EXCIT; HUBER R, 1970, NATURWISSENSCHAFTEN, V57, P389, DOI 10.1007/BF00599976; HURST RS, 1991, MOL PHARMACOL, V40, P572; JOUBERT FJ, 1980, H-S Z PHYSIOL CHEM, V361, P661, DOI 10.1515/bchm2.1980.361.1.661; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002; PENNER R, 1986, PFLUG ARCH EUR J PHY, V407, P365, DOI 10.1007/BF00652619; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; RUSSELL SN, 1994, AM J PHYSIOL-CELL PH, V267, pC1729, DOI 10.1152/ajpcell.1994.267.6.C1729; SKARZYNSKI T, 1992, J MOL BIOL, V224, P671, DOI 10.1016/0022-2836(92)90552-U; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509; STRYDOM DJ, 1976, EUR J BIOCHEM, V69, P169, DOI 10.1111/j.1432-1033.1976.tb10870.x; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471	34	50	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24776	24781		10.1074/jbc.270.42.24776	http://dx.doi.org/10.1074/jbc.270.42.24776			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559595	hybrid			2022-12-27	WOS:A1995TB46500029
J	BJORGE, JD; BELLAGAMBA, C; CHENG, HC; TANAKA, A; WANG, JH; FUJITA, DJ				BJORGE, JD; BELLAGAMBA, C; CHENG, HC; TANAKA, A; WANG, JH; FUJITA, DJ			CHARACTERIZATION OF 2 ACTIVATED MUTANTS OF HUMAN PP60(C-SRC) THAT ESCAPE C-SRC KINASE REGULATION BY DISTINCT MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; MIDDLE-T-ANTIGEN; AUTOPHOSPHORYLATION SITE; SIGNAL-TRANSDUCTION; STABLE ASSOCIATION; CATALYTIC ACTIVITY; FAMILY KINASES; SH3 DOMAINS; PP60C-SRC; CSK	Two activated transforming mutants of human pp60(c-src) were found to possess single point mutations within the regulatory carboxyl terminus (E527K in CY CST201) and the kinase domain (E381G in WO CST1), respectively, that do not directly interfere with either the regulatory c-src kinase (CSK) phosphorylation site (Tyr(530)) Or the SH2/3 domains. In vivo, both mutant proteins are hypophosphorylated on their carboxyl terminal regulatory tyrosines and are hyperactive, In an in vitro Src kinase inactivation assay, both mutant Src proteins exhibited resistance to inactivation by CSK relative to wild-type Src. Under these in vitro conditions, E381G c-Src was found to be phosphorylated by CSK to wild-type levels, while E527K c-src was not detectably phosphorylated, The ability of CSK to phosphorylate a carboxyl-terminal peptide modelled against E527K c-Src was also impaired, suggesting that CSK is unable to recognize E527K c-Src as an efficient substrate. In the case of E381G c-Src, examination of whether its SH2/3 domains were accessible to the carboxyl-terminal regulatory phosphotyrosine revealed a highly reduced ability of autophosphorylated E381G c-Src to bind to a synthetic phosphopeptide modelled from the SH2-binding region of polyoma middle-T antigen which binds to Src SH2 with high affinity. This suggests that the E381G c-Src mutation results in an altered or reduced accessibility of the SH2 domain of the autophosphorylated form of E381G c-Src and may represent a previously undescribed mode of Src activation. Further study of these and other Src mutants may offer additional new insights into the regulation of ''Src family'' kinases.	UNIV CALGARY, CELL REGULAT GRP, CALGARY, AB T2N 4N1, CANADA; UNIV CALGARY, DEPT BIOCHEM MED, MRC, SIGNAL TRANSDUCT GRP, CALGARY, AB T2N 4N1, CANADA; UNIV MELBOURNE, RUSSELL GRIMWADE SCH BIOCHEM, PARKVILLE, VIC 3052, AUSTRALIA; CTR MOLEC MED & IMMUNOL, NEWARK, NJ 07103 USA	University of Calgary; University of Calgary; University of Melbourne				Cheng, Heung-Chin/0000-0002-4965-7148				BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; FUKAMI Y, 1993, J BIOL CHEM, V268, P1132; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU XQ, 1993, ONCOGENE, V8, P1119; MACAULEY A, 1990, New Biologist, V2, P828; MACAULEY A, 1993, ONCOGENE, V8, P117; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OCONNOR TJ, 1992, CELL GROWTH DIFFER, V3, P435; OKADA M, 1993, J BIOL CHEM, V268, P18070; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; OTTINGER EA, 1993, BIOCHEMISTRY-US, V32, P4354, DOI 10.1021/bi00067a027; PARTANEN J, 1991, ONCOGENE, V6, P2013; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SARTOR O, 1992, J BIOL CHEM, V267, P3460; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TANAKA A, 1990, ONCOGENE RES, V5, P305; TANAKA A, 1986, MOL CELL BIOL, V6, P3900, DOI 10.1128/MCB.6.11.3900; TEMIN HM, 1958, VIROLOGY, V6, P669, DOI 10.1016/0042-6822(58)90114-4; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24222	24228		10.1074/jbc.270.41.24222	http://dx.doi.org/10.1074/jbc.270.41.24222			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592628	hybrid			2022-12-27	WOS:A1995TA21700056
J	DAS, T; GUPTA, AK; SIMS, PW; GELFAND, CA; JENTOFT, JE; BANERJEE, AK				DAS, T; GUPTA, AK; SIMS, PW; GELFAND, CA; JENTOFT, JE; BANERJEE, AK			ROLE OF CELLULAR CASEIN KINASE-II IN THE FUNCTION OF THE PHOSPHOPROTEIN-(P) SUBUNIT OF RNA-POLYMERASE OF VESICULAR STOMATITIS-VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATES TRANSCRIPTION INVITRO; NS PROTEIN; PHOSPHORYLATION; DOMAIN; EXPRESSION; RESIDUES; CELLS; GENE; SITE; ACID	The phosphorylation of the P protein of vesicular stomatitis virus by cellular casein kinase II (CKII) is essential for its activity in viral transcription, Recent in vitro studies have demonstrated that CKII converts the inactive unphosphorylated form of P (P0) to an active phosphorylated form P1, after phosphorylation at two serine residues, Ser-59 and Ser-61. To gain insight into the role of CKII-mediated phosphorylation in the structure and function of the P protein, we have carried out circular dichroism (CD) and biochemical analyses of both PO and P1. The results of CD analyses reveal that phosphorylation of P0 to P1 significantly increases the predicted alpha-helical structure of the P1 protein from 27 to 48%. The phosphorylation defective double serine mutant (P59/61), which is transcriptionally inactive, possesses a secondary structure similar to that of P0, P1, at a protein concentration of 50 mu g/ml, elutes from a gel filtration column apparently as a dimer, whereas both P0 and the double serine mutant elute as a monomer at the same concentration. Interestingly, unlike wild-type P1 protein, the P mutants in which either Ser-59 or Ser-61 is altered to alanine required a high concentration of CKII for optimal phosphorylation. We demonstrate here that phosphorylation of either Ser-59 or Ser-61 is necessary and sufficient to transactivate L polymerase although alteration of one serine residue significantly decreases its affinity for CKII. We have also shown that P1 binds to the N-RNA template more efficiently than P0 and the formation of P1 is a prerequisite for the subsequent phosphorylation by L protein-associated kinase. In addition, mutant P59/61 acts as a transdominant negative mutant when used in a transcription reconstitution assay in the presence of wild-type P protein.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Case Western Reserve University					NIAID NIH HHS [AI-26585] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026585] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE AK, 1974, VIROLOGY, V61, P547, DOI 10.1016/0042-6822(74)90289-X; BANERJEE AK, 1992, VIROLOGY, V188, P417, DOI 10.1016/0042-6822(92)90495-B; BANERJEE AK, 1987, MICROBIOL REV, V51, P66, DOI 10.1128/MMBR.51.1.66-87.1987; BANERJEE AK, 1987, CELL, V48, P363, DOI 10.1016/0092-8674(87)90184-X; BARIK S, 1991, J VIROL, V65, P1719, DOI 10.1128/JVI.65.4.1719-1726.1991; BARIK S, 1992, J VIROL, V66, P1109, DOI 10.1128/JVI.66.2.1109-1118.1992; BARIK S, 1992, P NATL ACAD SCI USA, V89, P6570, DOI 10.1073/pnas.89.14.6570; BEAVEN GH, 1952, ADV PROTEIN CHEM, V7, P320; BELL JC, 1985, J VIROL, V54, P697, DOI 10.1128/JVI.54.3.697-702.1985; CHATTOPADHYAY D, 1987, CELL, V49, P407, DOI 10.1016/0092-8674(87)90293-5; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; DE BP, 1984, J VIROL, V51, P628, DOI 10.1128/JVI.51.3.628-634.1984; DE BP, 1985, BIOCHEM BIOPH RES CO, V26, P40; EMERSON SU, 1987, RHABDOVIRUSES, P167; GILL DS, 1986, P NATL ACAD SCI USA, V83, P8873, DOI 10.1073/pnas.83.23.8873; GILL DS, 1985, J VIROL, V55, P60, DOI 10.1128/JVI.55.1.60-66.1985; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HSU CH, 1982, J VIROL, V43, P104, DOI 10.1128/JVI.43.1.104-112.1982; HSU CH, 1985, J BIOL CHEM, V260, P8990; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; KINGSFORD L, 1980, J VIROL, V33, P1097, DOI 10.1128/JVI.33.3.1097-1105.1980; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MASTERS PS, 1986, VIROLOGY, V154, P259, DOI 10.1016/0042-6822(86)90452-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PAUL PR, 1988, VIROLOGY, V166, P350, DOI 10.1016/0042-6822(88)90505-3; SLEAT DE, 1993, J VIROL, V67, P1334, DOI 10.1128/JVI.67.3.1334-1339.1993; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; TAKACS AM, 1992, J VIROL, V66, P5842, DOI 10.1128/JVI.66.10.5842-5848.1992	29	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24100	24107		10.1074/jbc.270.41.24100	http://dx.doi.org/10.1074/jbc.270.41.24100			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592611	hybrid			2022-12-27	WOS:A1995TA21700039
J	MITCHELL, LW; VOLIN, M; JAFFE, EK				MITCHELL, LW; VOLIN, M; JAFFE, EK			THE PHYLOGENETICALLY CONSERVED HISTIDINES OF ESCHERICHIA-COLI PORPHOBILINOGEN SYNTHASE ARE NOT REQUIRED FOR CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOLEVULINIC-ACID DEHYDRATASE; METAL-BINDING DOMAIN; 5-AMINOLEVULINATE DEHYDRATASE; NUCLEOTIDE-SEQUENCE; 280000-DALTON PROTEIN; HEMB GENE; ZINC; CDNA; SITE; PURIFICATION	Porphobilinogen synthase (PBGS) is a metalloenzyme that catalyzes the first common step of tetrapyrrole biosynthesis, the asymmetric condensation of two molecules of 5-aminolevulinic acid (ALA) to form porphobilinogen. Chemical modification data implicate histidine as a catalytic residue of PBGS from both plants and mammals. Histidine may participate in the abstraction of two non-ionizable protons from each substrate molecule at the active site. Only one histidine is species-invariant among 17 known sequences of PBGS which have high overall sequence similarity. In Escherichia coli PBGS, this histidine is His(128). We performed site-directed mutagenesis on His(128), replacing it with alanine. The mutant protein H128A is catalytically active. His(128) is part of a histidine- and cysteine-rich region of the sequence that is implicated in metal binding. The apparent K-d for Zn(II) binding to H128A is about an order of magnitude higher than for the wild type protein. E. coli PBGS also contains His(126) which is conserved through the mammalian, fungal, and some bacterial PBGS. We mutated His(126) to, alanine, and both His(126) and His(128) simultaneously to alanine, All mutant proteins are catalytically competent; the V-max values for H128A (44 units/mg), H126A (75 units/mg), and H126/128A (61 units/mg) were similar to wild type PBGS (50 units/mg) in the presence of saturating concentrations of metal ions. The apparent K-d for Zn(II) of H126A and H126/128A is not appreciably different from wild type. The activity of wild type and mutant proteins are all stimulated by an allosteric Mg(II); the mutant proteins all have a reduced affinity for Mg(II). We observe a pK(alpha) of similar to 7.5 in the wild type PBGS k(cat)/K-m pH profile as well as in those of H128A and H126/128A, suggesting that this pK(alpha) is not the result of protonation/deprotonation of one of these histidines. H128A and H126/128A have a significantly increased K-m value for the substrate ALA. This is consistent with a role for one or both of these histidines as a ligand to the required Zn(II) of E. coli PBGS, which is known to participate in substrate binding. Past chemical modification may have inactivated the PBGS by blocking Zn(II) and ALA binding. In addition, the decreased K-m for E. coli PBGS at basic pH allows for the quantitation of active sites at four per octamer.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [CA06927] Funding Source: Medline; NCRR NIH HHS [RR05539] Funding Source: Medline; NIEHS NIH HHS [ES03654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARNOLD FH, 1991, SCIENCE, V252, P1796, DOI 10.1126/science.1648261; BISHOP TR, 1986, NUCLEIC ACIDS RES, V14, P10115, DOI 10.1093/nar/14.24.10115; BISHOP TR, 1989, NUCLEIC ACIDS RES, V17, P1775, DOI 10.1093/nar/17.4.1775; BOCK CW, 1995, J AM CHEM SOC, V117, P3754, DOI 10.1021/ja00118a012; BOESE QF, 1991, J BIOL CHEM, V266, P17060; BROCKL G, 1992, GENE, V119, P151, DOI 10.1016/0378-1119(92)90084-3; CHAUHAN S, 1993, J BACTERIOL, V175, P7222, DOI 10.1128/JB.175.22.7222-7227.1993; CHEH A, 1973, BIOCHEM BIOPH RES CO, V55, P1060, DOI 10.1016/S0006-291X(73)80002-6; DENT AJ, 1990, BIOCHEMISTRY-US, V29, P7822, DOI 10.1021/bi00486a007; ECHELARD Y, 1988, MOL GEN GENET, V214, P503, DOI 10.1007/BF00330487; FOURMY D, 1993, J MOL BIOL, V231, P1068, DOI 10.1006/jmbi.1993.1352; FUKUDA H, 1988, COMP BIOCHEM PHYS B, V91, P285, DOI 10.1016/0305-0491(88)90144-7; GIEDROC DP, 1992, BIOCHEMISTRY-US, V31, P765, DOI 10.1021/bi00118a018; HANSSON M, 1991, J BACTERIOL, V173, P2590, DOI 10.1128/jb.173.8.2590-2599.1991; JAFFE EK, 1995, BIOCHEMISTRY-US, V34, P244, DOI 10.1021/bi00001a029; JAFFE EK, 1990, BIOCHEMISTRY-US, V29, P8345, DOI 10.1021/bi00488a021; JAFFE EK, 1986, J BIOL CHEM, V261, P9348; JAFFE EK, 1987, BIOCHEMISTRY-US, V26, P4258, DOI 10.1021/bi00388a012; JAFFE EK, 1994, BIOCHEMISTRY-US, V33, P11554, DOI 10.1021/bi00204a018; JAFFE EK, 1995, J BIOENERG BIOMEMBR, V27, P169, DOI 10.1007/BF02110032; JAFFE EK, 1992, BIOCHEMISTRY-US, V31, P2113, DOI 10.1021/bi00122a032; JONES MC, 1994, PLANT MOL BIOL, V24, P435, DOI 10.1007/BF00024112; Jordan P.M., 1991, NEW COMPREHENSIVE BI, V19, P1, DOI DOI 10.1016/S0167-7306(08)60108-8; JORDAN PM, 1980, FEBS LETT, V114, P283, DOI 10.1016/0014-5793(80)81134-3; KACZOR CM, 1994, PLANT PHYSIOL, V104, P1411, DOI 10.1104/pp.104.4.1411; KAFALA B, 1994, CAN J MICROBIOL, V40, P651, DOI 10.1139/m94-103; KARLSSON C, 1993, EUR J BIOCHEM, V216, P103, DOI 10.1111/j.1432-1033.1993.tb18121.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LI JM, 1989, GENE, V75, P177, DOI 10.1016/0378-1119(89)90394-6; LINGNER B, 1983, Z NATURFORSCH C, V38, P1059; MARALIHALLI GB, 1985, PHYTOCHEMISTRY, V24, P2533, DOI 10.1016/S0031-9422(00)80662-7; MATTERS GL, 1995, PLANT MOL BIOL, V27, P607, DOI 10.1007/BF00019326; MITCHELL LW, 1993, ARCH BIOCHEM BIOPHYS, V300, P169, DOI 10.1006/abbi.1993.1024; MYERS AM, 1987, J BIOL CHEM, V262, P16822; NANDI DL, 1968, J BIOL CHEM, V243, P1236; POLKING GF, 1995, PLANT PHYSIOL, V107, P1033, DOI 10.1104/pp.107.3.1033; SCHAUMBURG A, 1992, Z NATURFORSCH C, V47, P77; SCHLOSSER M, 1987, BIOL CHEM H-S, V368, P1469, DOI 10.1515/bchm3.1987.368.2.1469; SHEMIN D, 1954, J AM CHEM SOC, V75, P4873; SPENCER P, 1993, BIOCHEM J, V290, P279, DOI 10.1042/bj2900279; SPENCER P, 1995, BIOCHEM J, V305, P151, DOI 10.1042/bj3050151; SPENCER P, 1994, BIOCHEM J, V300, P373, DOI 10.1042/bj3000373; WETMUR JG, 1986, P NATL ACAD SCI USA, V83, P7703, DOI 10.1073/pnas.83.20.7703	43	11	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24054	24059		10.1074/jbc.270.41.24054	http://dx.doi.org/10.1074/jbc.270.41.24054			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592604	hybrid			2022-12-27	WOS:A1995TA21700032
J	NORRIS, ML; MILLHORN, DE				NORRIS, ML; MILLHORN, DE			HYPOXIA-INDUCED PROTEIN-BINDING TO O-2-RESPONSIVE SEQUENCES ON THE TYROSINE-HYDROXYLASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEINS; C-FOS TRANSCRIPTION; MEMBRANE DEPOLARIZATION; CYCLIC-AMP; JUN; ELEMENT; HETERODIMERS; EXPRESSION; INDUCTION; INTERACTS	We reported recently that the gene that encodes tyrosine hydroxylase (TH), the rate-limiting enzyme in the biosynthesis of catecholamines, is regulated by hypoxia in the dopaminergic cells of the mammalian carotid body (Czyzyk-Krzeska, M. F., Bayliss, D. A., Lawson, E. E. & Millhorn, D. E. (1992) J. Neurochem, 58, 1538-1546) and in pheochromocytoma (PC12) cells (Czyzyk-Krzeska, M. F., Furnari, B. A., Lawson, E. E. & Millhorn, D. E. (1994) J. Biol. Chem. 269, 760-764). Regulation of this gene during low O-2 conditions occurs at both the level of transcription and RNA stability. Increased transcription during hypoxia is regulated by a region of the proximal promoter that extends from -284 to +27 bases, relative to transcription start site. The present study was undertaken to further characterize the sequences that confer O-2 responsiveness of the TH gene and to identify hypoxia-induced protein interactions with these sequences. Results from chloramphenicol acetyltransferase assays identified a region between bases -284 and -150 that contains the essential sequences for O-2 regulation. This region contains a number of regulatory elements including AP1, AP2, and HIF-1. Gel shift assays revealed enhanced protein interactions at the AP1 and HIF-1 elements of the native gene. Further investigations using supershift and shift-Western analysis showed that c-Fos and JunB bind to the AP1 element during hypoxia and that these protein levels are stimulated by hypoxia. Mutation of the AP1 sequence prevented stimulation of transcription of the TH-chloramphenicol acetyltransferase reporter gene by hypoxia.	UNIV CINCINNATI,COLL MED,DEPT MOLEC & CELLULAR PHYSIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028948] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL033831, R01HL033831] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33831] Funding Source: Medline; NICHD NIH HHS [HD-28948] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; DEMECZUK S, 1993, P NATL ACAD SCI USA, V90, P2574; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FOSSOM LH, 1992, MOL PHARMACOL, V42, P898; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GIZANGGINSBERG E, 1994, MOL ENDOCRINOL, V8, P249, DOI 10.1210/me.8.2.249; GONZALEZ C, 1979, J NEUROCHEM, V33, P713, DOI 10.1111/j.1471-4159.1979.tb05216.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAYASHI Y, 1990, J NEUROCHEM, V54, P1115, DOI 10.1111/j.1471-4159.1990.tb01937.x; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; KOONG AC, 1994, CANCER RES, V54, P1425; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MECHTA F, 1989, New Biologist, V1, P297; MINER LL, 1992, J NEUROSCI RES, V33, P10, DOI 10.1002/jnr.490330103; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8	33	192	198	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23774	23779		10.1074/jbc.270.40.23774	http://dx.doi.org/10.1074/jbc.270.40.23774			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559551	hybrid			2022-12-27	WOS:A1995RY90900080
J	BUREAU, MH; LASCHET, JJ				BUREAU, MH; LASCHET, JJ			ENDOGENOUS PHOSPHORYLATION OF DISTINCT GAMMA-AMINOBUTYRIC-ACID TYPE-A RECEPTOR POLYPEPTIDES BY SER/THR AND TYR KINASE-ACTIVITIES ASSOCIATED WITH THE PURIFIED RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SUBUNIT MESSENGER-RNAS; A RECEPTOR; RAT-BRAIN; BENZODIAZEPINE RECEPTORS; GABA(A) RECEPTOR; MAMMALIAN BRAIN; 2 FORMS; CAMP; BINDING	We have investigated the phosphorylation of gamma-aminobutyric acid type A (GABA(A)) receptor purified from bovine cerebral cortex in the absence of added kinases. Incubation of the affinity-purified receptor with [gamma-P-32]ATP and 500 mu M MnCl2 yielded incorporation of 0.45 mel of P-32/mol of muscimol binding sites within 2 h at 30 degrees C. Mn2+ was much more effective than Mg2+ as activator. Phosphorylation of the receptor was observed on at least three different polypeptides of 51, 53, and 55 kDa. It was predominant on 51- and 53-kDa polypeptides that co-migrate with the [H-3]flunitrazepam photoaffinity-labeled bands, suggesting that P-32 incorporation mainly occurs on alpha-subunits. A monoclonal antibody specific for alpha-subunits adsorbed the endogenously phosphorylated GABA(A) receptor with a stoichiometry close to 1 mol of phosphate/mol of muscimol. The phosphorylation of the 51-kDa polypeptide, corresponding to alpha(1)-subunit, exhibited a micromolar affinity for ATP and sigmoid kinetics (n(H) = 2). Major incorporation of phosphate occurred on serine and threonine residues in roughly equimolar ratio. By enzyme-linked immunosorbent assay and immunoblotting studies we also detected a minor incorporation on tyrosine residues; this was specific for a 55-kDa polypeptide. Comparison with molecular data suggests that at least alpha(1)- and alpha(2)-subunits (Ser and Thr residues) and possibly gamma(2)-subunits (Tyr residue) are endogenously phosphorylated by multiple kinases, with a clear preference for alpha(1)-subunit. The beta-subunits were not phosphorylated in our experimental conditions. The corresponding kinase activities are closely associated to the receptor protein, indicating a new complexity in the regulation of the GABA(A) receptor.	UNIV LIEGE,NEUROCHEM LAB,B-4020 LIEGE,BELGIUM; INSERM,CJF 9012,F-35033 RENNES,FRANCE	University of Liege; Institut National de la Sante et de la Recherche Medicale (Inserm)								BENKE D, 1991, J BIOL CHEM, V266, P4478; BROWNING MD, 1993, NEUROCHEM RES, V18, P95, DOI 10.1007/BF00966927; BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; BUREAU M, 1990, MOL PHARMACOL, V37, P497; BUREAU M, 1992, ARCH INT PHYSL BIOCH, V100, P1; BUREAU MH, 1993, J NEUROCHEM, V61, P1479, DOI 10.1111/j.1471-4159.1993.tb13643.x; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; BYLUND DB, 1976, ANAL BIOCHEM, V73, P477, DOI 10.1016/0003-2697(76)90197-4; CHEN QX, 1990, J PHYSIOL-LONDON, V420, P207, DOI 10.1113/jphysiol.1990.sp017908; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; GYENES M, 1988, MOL PHARMACOL, V34, P719; HARING P, 1985, P NATL ACAD SCI USA, V82, P4837, DOI 10.1073/pnas.82.14.4837; HEUSCHNEIDER G, 1989, P NATL ACAD SCI USA, V86, P2938, DOI 10.1073/pnas.86.8.2938; KHAN ZU, 1994, J NEUROCHEM, V63, P371; KIRKNESS EF, 1989, BIOCHEM J, V259, P613, DOI 10.1042/bj2590613; KOFUJI P, 1991, J NEUROCHEM, V56, P713, DOI 10.1111/j.1471-4159.1991.tb08209.x; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LIN YF, 1994, NEURON, V13, P1421, DOI 10.1016/0896-6273(94)90427-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MCDONALD BJ, 1994, J BIOL CHEM, V269, P18111; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; OLSEN RW, 1991, NEUROCHEM RES, V16, P317, DOI 10.1007/BF00966095; PORTER NM, 1990, NEURON, V5, P789, DOI 10.1016/0896-6273(90)90338-G; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SCHRODER H, 1993, J NEUROCHEM, V60, P1007, DOI 10.1111/j.1471-4159.1993.tb03248.x; STAUBER GB, 1987, EUR J BIOCHEM, V167, P125, DOI 10.1111/j.1432-1033.1987.tb13313.x; STELZER A, 1988, SCIENCE, V241, P339, DOI 10.1126/science.2455347; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; SWEETNAM PM, 1988, J NEUROCHEM, V51, P1274, DOI 10.1111/j.1471-4159.1988.tb03097.x; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WHITE MF, 1984, J BIOL CHEM, V259, P255; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; WISDEN W, 1992, J NEUROSCI, V12, P1040	41	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26482	26487		10.1074/jbc.270.44.26482	http://dx.doi.org/10.1074/jbc.270.44.26482			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592865	hybrid			2022-12-27	WOS:A1995TC97800072
J	DELANY, AM; JEFFREY, JJ; RYDZIEL, S; CANALIS, E				DELANY, AM; JEFFREY, JJ; RYDZIEL, S; CANALIS, E			CORTISOL INCREASES INTERSTITIAL COLLAGENASE EXPRESSION IN OSTEOBLASTS BY POSTTRANSCRIPTIONAL MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MESSENGER-RNA; GLUCOCORTICOID RECEPTOR; GROWTH-FACTORS; C-JUN; RAT; BONE; HORMONE; ACID; CULTURES	Glucocorticoids regulate both bone formation and bone resorption, In osteoblasts, they inhibit type I collagen synthesis; however, there is limited information about their effects on interstitial collagenase, the enzyme that degrades type I collagen, We used primary cultures of osteoblast-enriched cells from fetal rat calvariae (Ob cells) to study the effects of cortisol on collagenase expression, Northern blot analysis showed that cortisol increased collagenase transcript levels in a dose and time-dependent manner, which was paralleled by an increase in immunoreactive metalloproteinase in the culture medium, Cortisol increased the half-life of collagenase mRNA from 6 to 12 h in transcription-arrested Ob cells, In contrast, cortisol modestly decreased collagenase gene transcription after 24 h of treatment, The up-regulation of collagenase by cortisol is osteoblast-specific, since the glucocorticoid decreased phorbol la-myristate 13-acetate induced collagenase mRNA expression in rat fibroblasts, a result that agrees with other studies of collagenase gene regulation in fibroblastic cells, In conclusion, cortisol increases interstitial collagenase transcript levels by post-transcriptional mechanisms in osteoblastic cells, Our data demonstrate that glucocorticoids regulate collagenase gene expression in a novel tissue-specific manner, further highlighting the differences in gene regulation between osteoblastic and fibroblastic cells.	ST FRANCIS HOSP & MED CTR,DEPT MED,HARTFORD,CT 06105; UNIV CONNECTICUT,SCH MED,FARMINGTON,CT 06030; ALBANY MED COLL,DEPT MED,ALBANY,NY 12208	Saint Francis Hospital & Medical Center; University of Connecticut; Albany Medical College	DELANY, AM (corresponding author), ST FRANCIS HOSP & MED CTR,DEPT RES,114 WOODLAND ST,HARTFORD,CT 06105, USA.				NICHD NIH HHS [NICHD 05291] Funding Source: Medline; NIDDK NIH HHS [DK 09038, DK 45227] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005291, R37HD005291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045227, F32DK009038] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BELLOWS CG, 1987, ENDOCRINOLOGY, V121, P1985, DOI 10.1210/endo-121-6-1985; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BRINCKERHOFF CE, 1986, BIOCHEMISTRY-US, V25, P6378, DOI 10.1021/bi00369a006; CANALIS E, 1991, ANNU REV MED, V42, P17, DOI 10.1146/annurev.med.42.1.17; CANALIS E, 1983, ENDOCRINOLOGY, V112, P931, DOI 10.1210/endo-112-3-931; CANALIS E, 1988, CALCIFIED TISSUE INT, V43, P346, DOI 10.1007/BF02553277; CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; CHEUNG PT, 1994, ENDOCRINOLOGY, V135, P1328, DOI 10.1210/en.135.4.1328; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOHISY JC, 1994, ENDOCRINOLOGY, V135, P1447, DOI 10.1210/en.135.4.1447; DELANY AM, 1994, J CELL BIOCHEM, V56, P295, DOI 10.1002/jcb.240560304; DELANY AM, 1994, J CELL BIOCHEM, V57, P488; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOWLKES JL, 1994, ENDOCRINOLOGY, V135, P2810, DOI 10.1210/en.135.6.2810; GACK S, 1994, J BIOL CHEM, V269, P10363; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; GODFREY K, 1985, NEW ENGL J MED, V313, P1450, DOI 10.1056/NEJM198512053132305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1993, CONTROL MESSENGER RN; JEFFREY JJ, 1990, J CELL PHYSIOL, V143, P396, DOI 10.1002/jcp.1041430226; JEFFREY JJ, 1991, J CELL PHYSIOL, V146, P399, DOI 10.1002/jcp.1041460310; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOY PS, 1991, J CELL PHYSIOL, V146, P370, DOI 10.1002/jcp.1041460306; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; MARTIN TJ, 1994, J CELL BIOCHEM, V56, P357, DOI 10.1002/jcb.240560312; MATRISIAN LM, 1994, CURR TOP DEV BIOL, V24, P219; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; NAM TJ, 1994, ENDOCRINOLOGY, V135, P1385, DOI 10.1210/en.135.4.1385; OMURA TH, 1994, J BIOL CHEM, V269, P24994; PASH JM, 1995, ENDOCRINOLOGY, V136, P33, DOI 10.1210/en.136.1.33; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; QUINN CO, 1990, J BIOL CHEM, V265, P22342; RAO LG, 1977, ENDOCRINOLOGY, V100, P1233, DOI 10.1210/endo-100-5-1233; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; Sambrook J, 1989, MOL CLONING LABORATO; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P2153, DOI 10.1210/me.6.12.2153; SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411; Sokal R. R, 1981, BIOMETRY; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VARGHESE S, 1994, ENDOCRINOLOGY, V134, P2438, DOI 10.1210/en.134.6.2438; VINCENTI MP, 1994, NUCLEIC ACIDS RES, V22, P4818, DOI 10.1093/nar/22.22.4818; WALL FJ, 1986, STATISTICAL DATA ANA; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZANDOMENI R, 1983, J MOL BIOL, V167, P561, DOI 10.1016/S0022-2836(83)80098-9	51	85	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26607	26612		10.1074/jbc.270.44.26607	http://dx.doi.org/10.1074/jbc.270.44.26607			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592884	hybrid			2022-12-27	WOS:A1995TC97800091
J	DU, XP; SAIDO, TC; TSUBUKI, S; INDIG, FE; WILLIAMS, MJ; GINSBERG, MH				DU, XP; SAIDO, TC; TSUBUKI, S; INDIG, FE; WILLIAMS, MJ; GINSBERG, MH			CALPAIN CLEAVAGE OF THE CYTOPLASMIC DOMAIN OF THE INTEGRIN BETA(3) SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; CELL-ADHESION; PLATELET-AGGREGATION; PLASMA-MEMBRANE; GPIIB-IIIA; RECEPTOR; PROTEIN; PROTEOLYSIS; LIGAND; ALPHA-IIB-BETA-3	The cytoplasmic domains of integrin beta subunits are involved in bidirectional transmembrane signaling. We report that the cytoplasmic domain of the integrin beta(3) subunit undergoes limited proteolysis by calpain, an intracellular calcium-dependent protease, Calpain cleavage occurs during platelet aggregation induced by agonists such as thrombin. Five cleavage sites have been identified. Four of these sites (C-terminal to Thr(741), Tyr(747), Phe(754) and Tyr(759)) are utilized in intact platelets and flank two NXXY motifs (Asn(744)-Pro-Leu-Tyr(747) and Asn(756)-Ile-Thr-Tyr(759)). The fifth site (Ala(735)) is accessible to calpain after EDTA treatment of the alpha(IIb)beta(3) heterodimer, The NXXY motifis critical to the bidirectional signaling functions of beta(3) integrins and their association with the cytoskeleton. Thus, calpain cleavage of the beta(3) cytoplasmic domain may provide a means to regulate integrin signaling functions.	TOKYO METROPOLITAN INST MED SCI, DEPT MOLEC BIOL, BUNKYO KU, TOKYO 113, JAPAN	Tokyo Metropolitan Institute of Medical Science	DU, XP (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903	NHLBI NIH HHS [HL48728, HL52547, HL31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R29HL052547, P01HL048728] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DU XP, 1994, J BIOL CHEM, V269, P18287; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FOX JEB, 1994, BLOOD COAGUL FIBRIN, V5, P291, DOI 10.1097/00001721-199404000-00020; FOX JEB, 1983, J BIOL CHEM, V258, P9973; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1990, J CELL BIOL, V111, P483, DOI 10.1083/jcb.111.2.483; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; GINSBERG MH, 1993, THROMB HAEMOSTASIS, V70, P87; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LOFTUS JC, 1988, J BIOL CHEM, V263, P11025; NIEWIAROWSKI S, 1989, BIOCHIM BIOPHYS ACTA, V983, P91, DOI 10.1016/0005-2736(89)90384-2; ODA A, 1993, J BIOL CHEM, V268, P12603; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; POTTS AJ, 1994, EXP CELL RES, V212, P2, DOI 10.1006/excr.1994.1111; RABB H, 1993, J IMMUNOL, V151, P990; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1991, BIOMED BIOCHIM ACTA, V50, P485; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SASAKI T, 1986, J BIOCHEM-TOKYO, V99, P173, DOI 10.1093/oxfordjournals.jbchem.a135457; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; SHATTIL SJ, 1985, BLOOD, V66, P92; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; TAPLEY P, 1989, ONCOGENE, V4, P325; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	45	153	155	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26146	26151		10.1074/jbc.270.44.26146	http://dx.doi.org/10.1074/jbc.270.44.26146			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592818	hybrid			2022-12-27	WOS:A1995TC97800025
J	FRANCO, R; MOURA, JJG; MOURA, I; LLOYD, SG; HUYNH, BH; FORBES, WS; FERREIRA, GC				FRANCO, R; MOURA, JJG; MOURA, I; LLOYD, SG; HUYNH, BH; FORBES, WS; FERREIRA, GC			CHARACTERIZATION OF THE IRON-BINDING SITE IN MAMMALIAN FERROCHELATASE BY KINETIC AND MOSSBAUER METHODS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; LIVER FERROCHELATASE; MOLECULAR-CLONING; GENE; ENZYMES; PROTOPORPHYRIA; PURIFICATION; EXPRESSION; SEQUENCE; PROTEIN	All organisms utilize ferrochelatase (protoheme ferrolyase, EC 4.99.1.1) to catalyze the terminal step of the heme biosynthetic pathway, which involves the insertion of ferrous ion into protoporphyrin IX. Kinetic methods and Mossbauer spectroscopy have been used in an effort to characterize the ferrous ion-binding active site of recombinant murine ferrochelatase. The kinetic studies indicate that dithiothreitol, a reducing agent commonly used in ferrochelatase activity assays, interferes with the enzymatic production of heme. Ferrochelatase specific activity values determined under strictly anaerobic conditions are much greater than those obtained for the same enzyme under aerobic conditions and in the presence of dithiothreitol. Mossbauer spectroscopy conclusively demonstrates that, under the commonly used assay conditions, dithiothreitol chelates ferrous ion and hence competes with the enzyme for binding the ferrous substrate. Mossbauer spectroscopy of ferrous ion incubated with ferrochelatase in the absence of dithiothreitol shows a somewhat broad quadrupole doublet. Spectral analysis indicates that when 0.1 mM Fe(II) is added to 1.75 mM ferrochelatase, the overwhelming majority of the added ferrous ion is bound to the protein. The spectroscopic parameters for this bound species are delta = 1.36 +/- 0.03 mm/s and Delta E(Q) = 3.04 +/- 0.06 mm/s, distinct from the larger Delta E(Q) of a control sample of Fe(II) in buffer only. The parameters for the bound species are consistent with an active site composed of nitrogenous/oxygenous Ligands and inconsistent with the presence of sulfur ligands. This finding is in accord with the absence of conserved cysteines among the known ferrochelatase sequences. The implications these results have with regard to the mechanism of ferrochelatase activity are discussed.	EMORY UNIV, DEPT PHYS, ATLANTA, GA 30322 USA; UNIV NOVA LISBOA, FAC CIENCIAS & TECNOL, CTR QUIM FINA & BIOTECNOL, P-2825 MONTE DE CAPARICA, PORTUGAL; UNIV S FLORIDA, COLL MED, H LEE MOFFIT CANC CTR & RES INST, INST BIOMOLEC SCI, TAMPA, FL 33612 USA	Emory University; Universidade Nova de Lisboa; State University System of Florida; University of South Florida			Moura, Isabel/D-6339-2013; Moura, José J G/D-6426-2013; Ferreira, Gloria C/A-4709-2012	Moura, Isabel/0000-0003-0971-4977; Moura, José J G/0000-0002-4726-2388; Ferreira, Gloria C/0000-0001-9279-2217; Franco, Ricardo/0000-0002-5139-2871	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047295] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47295] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNER DA, 1991, P NATL ACAD SCI USA, V88, P849, DOI 10.1073/pnas.88.3.849; BRENNER DA, 1992, AM J HUM GENET, V50, P1203; CAMADRO JM, 1984, J BIOL CHEM, V259, P5678; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; CAMADRO JM, 1982, BIOCHIM BIOPHYS ACTA, V707, P280, DOI 10.1016/0167-4838(82)90362-4; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAILEY HA, 1994, J BIOL CHEM, V269, P390; DAILEY HA, 1987, ANN NY ACAD SCI, V514, P81, DOI 10.1111/j.1749-6632.1987.tb48763.x; DAILEY HA, 1994, J BIOL CHEM, V33, P403; DEBRUNNER PG, 1990, IRON PORPHYRINS 3, P139; FERREIRA GC, 1987, J BIOL CHEM, V262, P4407; FERREIRA GC, 1994, J BIOL CHEM, V269, P7062; FERREIRA GC, 1994, J BIOL CHEM, V269, P4396; FERREIRA GC, 1995, J BIOENERG BIOMEMBR, V27, P221, DOI 10.1007/BF02110037; FRUSTACI JM, 1992, J BACTERIOL, V174, P4223, DOI 10.1128/JB.174.13.4223-4229.1992; HANSSON M, 1992, J BACTERIOL, V174, P8081, DOI 10.1128/JB.174.24.8081-8093.1992; HANSSON M, 1994, EUR J BIOCHEM, V220, P201, DOI 10.1111/j.1432-1033.1994.tb18615.x; Huynh B H, 1984, Adv Inorg Biochem, V6, P163; JONES MS, 1969, BIOCHEM J, V113, P507, DOI 10.1042/bj1130507; JORDAN PM, 1991, BIOSYNTHESIS TETRAPY, P257; KOHNO H, 1994, BBA-PROTEIN STRUCT M, V1209, P95, DOI 10.1016/0167-4838(94)90142-2; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; MIYAMOTO K, 1994, PLANT PHYSIOL, V105, P769, DOI 10.1104/pp.105.2.769; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; NORDMANN Y, 1990, BIOSYNTHESIS HEME CH, P491; ORVILLE AM, 1992, BIOCHEMISTRY-US, V31, P4602, DOI 10.1021/bi00134a010; PORRA RJ, 1963, BIOCHEM J, V87, P186, DOI 10.1042/bj0870186; PORRA RJ, 1963, BIOCHEM J, V87, P181, DOI 10.1042/bj0870181; PORRA RJ, 1967, BIOCHEM J, V104, P321, DOI 10.1042/bj1040321; PUNEKAR NS, 1991, BIOTECHNOL APPL BIOC, V14, P21; RAVI N, 1994, J AM CHEM SOC, V116, P8007, DOI 10.1021/ja00097a007; SAMS JR, 1979, PORPHYRINS, V4, P425; Schulz C., 1976, J PHYS C SOLID STATE, V37, DOI DOI 10.1051/JPHYSCOL:1976633; SMITH AG, 1994, J BIOL CHEM, V269, P13405; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; TAKETANI S, 1981, J BIOL CHEM, V256, P2748; WHITCOMBE DM, 1991, GENOMICS, V11, P1152, DOI 10.1016/0888-7543(91)90044-F; White WI., 1978, PORPHYRINS, P303, DOI [10.1016/B978-0-12-220105-9.50014-X, DOI 10.1016/B978-0-12-220105-9.50014-X]	42	31	31	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26352	26357		10.1074/jbc.270.44.26352	http://dx.doi.org/10.1074/jbc.270.44.26352			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592847	hybrid			2022-12-27	WOS:A1995TC97800054
J	HECKERT, LL; SCHULTZ, K; NILSON, JH				HECKERT, LL; SCHULTZ, K; NILSON, JH			DIFFERENT COMPOSITE REGULATORY ELEMENTS DIRECT EXPRESSION OF THE HUMAN ALPHA-SUBUNIT GENE TO PITUITARY AND PLACENTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; PROTEIN-BINDING DOMAINS; CAMP RESPONSE ELEMENTS; GLYCOPROTEIN HORMONES; C-FOS; TRANSCRIPTION; ENHANCER; INTERACT; PROMOTER; PEA3	To identify elements of the human alpha subunit gene necessary for cell-specific expression, we generated an array of block mutations spanning approximately 400 base pairs (bp) of promoter proximal region and examined them using transient transfection analysis in pituitary (alpha T3) and placental (BeWo) cell lines, Comparison of promoter activity in the two cell types revealed both common and unique elements required for transcription in pituitary and placenta, Two strong elements, the cyclic AMP response element (CRE) and the upstream regulatory element (URE), regulate expression of the a subunit gene in BeWo cells, In contrast, promoter activity in alpha T3 cells requires an array of weaker elements, These include the CREs, the URE, as well as two previously described elements, pituitary glycoprotein hormore basal element (PGBE) and gonadotrope-specific element (GSE), and two new elements we designated as the a basal elements 1 and 2 (alpha BE1 and alpha BE2). These new elements reside between -316 and -302 bp (alpha BE1) and -296 and -285 bp (alpha BE2) of the human a subunit promoter and bind distinct proteins designated alpha BP1 and alpha BP2, respectively, Southwestern blot analysis revealed that alpha BE1 specifically binds 54- and 56-kDa proteins, Additional studies disclosed several potential interactions between proteins that bind the CRE and proteins that occupy PGBE, alpha BE1, and alpha BE2, suggesting that gonadotrope-specific expression occurs through a unique composite regulatory element that includes components of the placenta-specific enhancer.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106	Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028559, F32DK008975] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK08975-02, DK 28559] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABMAYR SM, 1994, CURRENT PROTOCOLS MO; ANDERSEN B, 1990, MOL ENDOCRINOL, V4, P573, DOI 10.1210/mend-4-4-573; ANDERSEN B, 1990, J BIOL CHEM, V265, P21874; BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; Bousfield George R., 1994, P1749; CHIN WW, 1984, PITUITARY GLAND, P103; CHODOSH LA, 1994, CURRENT PROTOCOLS MO; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JAMESON JL, 1989, J BIOL CHEM, V264, P16190; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; JAMESON JL, 1987, MOL CELL BIOL, V7, P3032, DOI 10.1128/MCB.7.9.3032; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; KAY TWH, 1992, MOL ENDOCRINOL, V6, P1767, DOI 10.1210/me.6.11.1767; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; MOORE WT, 1980, CHORIONIC GONADOTROP, P89; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; PITTMAN RH, 1994, J BIOL CHEM, V269, P19360; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SCHODERBEK WE, 1992, MOL ENDOCRINOL, V6, P893, DOI 10.1210/me.6.6.893; SCHODERBEK WE, 1993, J BIOL CHEM, V268, P3903; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129	35	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26497	26504		10.1074/jbc.270.44.26497	http://dx.doi.org/10.1074/jbc.270.44.26497			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592867	hybrid			2022-12-27	WOS:A1995TC97800074
J	THURIN, J; BLASZCZYKTHURIN, M				THURIN, J; BLASZCZYKTHURIN, M			PORCINE SUBMAXILLARY-GLAND GDP-L-FUCOSE-BETA-D-GALACTOSIDE ALPHA-2-L-FUCOSYL-TRANSFERASE IS LIKELY A COUNTERPART OF THE HUMAN SECRETOR GENE-ENCODED BLOOD-GROUP TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUB-MAXILLARY GLAND; HUMAN-SERUM; ANTIGEN EXPRESSION; LACTOCOCCUS-LACTIS; H-GENE; PURIFICATION; HOMOGENEITY; SEQUENCES; TISSUES; SE	Partial amino acid sequence of GDP-L-fucose:beta-D-galactoside alpha-2-L fucosyltransferase purified from porcine submaxillary glands was determined, Amino acid sequence analysis yielded 100, 93.3, and 84.2%, and 75, 46.6, and 84.2% sequence identity between 12-, 15-, and 19-amino acid tryptic peptides generated from porcine enzyme and amino acid residues 61-72, 111-125, and 308-326 and 89-100, 139-153, and 338-356 of the human Secretor and H type alpha-2-fucosyltransferases, respectively, Higher amino acid sequence homology of the porcine enzyme with the predicted sequence for the human Secretor locus as compared with H gene-encoded blood group beta-D-galactoside alpha-2-L-fucosyltransferase suggests that porcine alpha-2-fucosyltransferase highly corresponds to the human Secretor gene-encoded enzyme.	WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA	The Wistar Institute					NATIONAL CANCER INSTITUTE [R01CA045363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI028679] Funding Source: NIH RePORTER; NCI NIH HHS [CA45363] Funding Source: Medline; NIAID NIH HHS [AI28679] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BETTERIDGE A, 1985, GLYCOCONJUGATE J, V2, P61; BEYER TA, 1980, J BIOL CHEM, V255, P5364; BEYER TA, 1980, J BIOL CHEM, V255, P5373; BLASZCZYKTHURIN M, 1988, BIOCHEM BIOPH RES CO, V151, P100, DOI 10.1016/0006-291X(88)90564-5; BREIDT F, 1987, APPL ENVIRON MICROB, V53, P969, DOI 10.1128/AEM.53.5.969-973.1987; DEVOS WM, 1989, J GEN MICROBIOL, V135, P1833; GOKHALE UB, 1990, CAN J CHEM, V68, P1063, DOI 10.1139/v90-165; HITOSHI S, 1995, J BIOL CHEM, V270, P8844, DOI 10.1074/jbc.270.15.8844; HUANG DC, 1992, GENE, V118, P39, DOI 10.1016/0378-1119(92)90246-L; IUB-IUPAC Joint Commission on Biochemical Nomenclature (JCBN), 1982, J BIOL CHEM, V257, P3347, DOI [10.1016/S0021-9258(18)34777-X, DOI 10.1016/S0021-9258(18)34777-X]; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KUMAZAKI T, 1984, P NATL ACAD SCI-BIOL, V81, P4193, DOI 10.1073/pnas.81.13.4193; LANGKILDE NC, 1991, BRIT J HAEMATOL, V79, P493, DOI 10.1111/j.1365-2141.1991.tb08061.x; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEPENDU J, 1985, AM J HUM GENET, V37, P749; ORIOL R, 1981, AM J HUM GENET, V33, P421; ORIOL R, 1984, LAB INVEST, V50, P514; ORNTOFT TF, 1991, BLOOD, V77, P1389; PIAU JP, 1994, BIOCHEM J, V300, P623, DOI 10.1042/bj3000623; SADLER JE, 1979, J BIOL CHEM, V254, P4434; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; WATKINS WM, 1978, PROC R SOC SER B-BIO, V202, P31, DOI 10.1098/rspb.1978.0056; YAZAWA S, 1993, JPN J CANCER RES, V84, P989, DOI 10.1111/j.1349-7006.1993.tb00190.x	24	12	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26577	26580		10.1074/jbc.270.44.26577	http://dx.doi.org/10.1074/jbc.270.44.26577			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592879	hybrid			2022-12-27	WOS:A1995TC97800086
J	BECERRA, SP; SAGASTI, A; SPINELLA, P; NOTARIO, V				BECERRA, SP; SAGASTI, A; SPINELLA, P; NOTARIO, V			PIGMENT EPITHELIUM-DERIVED FACTOR BEHAVES LIKE A NONINHIBITORY SERPIN - NEUROTROPHIC ACTIVITY DOES NOT REQUIRE THE SERPIN REACTIVE LOOP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; CONFORMATIONAL CHANGE; ALPHA-1-PROTEINASE INHIBITOR; OVALBUMIN; BINDING; ALPHA-1-ANTITRYPSIN; ANGIOTENSINOGEN; ANTITHROMBIN; FAMILY; IDENTIFICATION	Pigment epithelium-derived factor (PEDF), a neurite-promoting factor, has an amino acid primary structure that is related to members of the serine protease inhibitor (serpin) family. Controlled proteolysis of native PEDF (50 kDa) with either trypsin, chymotrypsin, elastase, or subtilisin yields in each case one major limited product of 46 kDa as analyzed by SDS-polyacrylamide gel electrophoresis. N-terminal sequence analysis of the isolated 46-kDa products indicates a favored cleavage region located toward the C-terminal end of PEDF. A proteolyzed PEDF protein reaction mixture reveals two overlapping sequences: that of the N terminus of intact PEDF and that of an internal region, consistent with cleavage of PEDF about position 382. These data indicate that PEDF protein has a globular conformation with one protease-sensitive exposed loop that contains the homologous serpin-reactive site. Cleavage within the reactive-site loop of PEDF does not cause a conformational change in the molecules (the stressed (S) --> relaxed (R) transition) and results in heat denaturation identical to its native counterpart. This lack of conformational change is also seen upon cleavage within the reactive-site loop of the noninhibitory serpin ovalbumin. Furthermore, the PEDF neurite-promoting function is not lost with cleavage of the exposed loop, Recombinant PEDF polypeptide fragments with larger truncations from the C-terminal end show neurotrophic activity. Our results clearly indicate that integrity of the PEDF homologous serpin reactive center is dispensable for neurotrophic activity. Thus, the PEDF induction of neurites must be mediated by a mechanism other than serine protease inhibition. Altogether our data indicate that PEDF belongs to the subgroup of noninhibitory serpins and that its N-terminal region confers a neurite-promoting activity to the protein. The neurotrophic active site of PEDF is separated from the serpin reactive-site loop, not only in the primary structure, but also in the folded protein structure.	NIH,OFF INTRAMURAL RES,PROT EXPRESS LAB,BETHESDA,MD 20892; GEORGETOWN UNIV,MED CTR,DEPT RADIAT MED,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; Georgetown University	BECERRA, SP (corresponding author), NEI,RETINAL CELL & MOLEC BIOL LAB,6 CTR DR,MSC 2740,BLDG 6,RM 308,BETHESDA,MD 20892, USA.		/AAB-6461-2022; /AFP-0764-2022; Spinella, Philip/GNW-3633-2022					BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; BECERRA SP, 1993, J BIOL CHEM, V268, P23148; BOCK SC, 1990, PROTEIN ENG, V4, P107, DOI 10.1093/protein/4.2.107; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; DONOVAN FM, 1994, J BIOL CHEM, V269, P17199; DOOLITTLE RF, 1983, SCIENCE, V222, P417, DOI 10.1126/science.6604942; EVANS DL, 1991, J BIOL CHEM, V266, P22307; GETTINS P, 1989, J BIOL CHEM, V264, P3781; GLOOR S, 1986, CELL, V47, P687; HEJGAARD J, 1985, FEBS LETT, V180, P89, DOI 10.1016/0014-5793(85)80238-6; HOUENOU LJ, 1995, P NATL ACAD SCI USA, V92, P895, DOI 10.1073/pnas.92.3.895; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MONARD D, 1990, PROG BRAIN RES, V2, P167; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; PEMBERTON PA, 1995, J BIOL CHEM, V270, P18832; PIGNOLO RJ, 1993, J BIOL CHEM, V268, P8949; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SOBOL RW, 1991, BIOCHEMISTRY-US, V30, P10623, DOI 10.1021/bi00108a004; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; TANAWAKI T, 1995, J NEUROCHEM, V64, P2509; TANIWAKI T, 1994, 24 ANN M SOC NEUR MI, V20, P1691; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D; WRIGHT HT, 1990, J MOL BIOL, V213, P513; WU YQ, 1995, PROTEIN EXPRES PURIF, V6, P447, DOI 10.1006/prep.1995.1060	32	203	216	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25992	25999		10.1074/jbc.270.43.25992	http://dx.doi.org/10.1074/jbc.270.43.25992			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592790	hybrid			2022-12-27	WOS:A1995TB46600107
J	BACHHAWAT, N; OUYANG, QA; HENRY, SA				BACHHAWAT, N; OUYANG, QA; HENRY, SA			FUNCTIONAL-CHARACTERIZATION OF AN INOSITOL-SENSITIVE UPSTREAM ACTIVATION SEQUENCE IN YEAST - A CIS-REGULATORY ELEMENT RESPONSIBLE FOR INOSITOL-CHOLINE MEDIATED REGULATION OF PHOSPHOLIPID BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; SACCHAROMYCES-CEREVISIAE; INO1 PROMOTER; DNA-SEQUENCE; BINDING-SITE; GENE; ENCODES; COMPLEXES; SYNTHASE	A repeated element, the inositol-sensitive upstream activation sequence (UAS(INO)), having the consensus sequence, 5'-CATGTGAAAT-3', is present in the promoters of genes encoding enzymes of phospholipid biosynthesis that are regulated in response to the phospholipid precursors, inositol and choline. None of the naturally occurring variants of the UAS(INO) element exactly recapitulates the consensus (for review, see Carman, G. M., and Henry, S. A. (1989) Annu. Rev. Biochem. 58, 635-669 and Paltauf, F., Kolwhein, S., and Henry, S. A. (1992) in Molecular Biology of the Yeast Saccharomyces cerevisiae (Broach, J., Jones, E., and Pringle, J., eds) Vol. 2, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). The first six bases of the UAS(INO) element are homologous with canonical binding motif for proteins of the basic helix-loop helix (bHLH) family. Two bHLH regulatory proteins, Ino2p and Ino4p from yeast, were previously shown to bind to promoter fragments containing this element. In the present study, an extensive analysis of UAS(INO) function has been conducted. We report that any base substitution within the putative bHLH binding site resulted either in a dramatic reduction or in a complete obliteration of UAS(INO) function as tested in an expression assay in vivo. Base substitutions in the 5' region that flanks the 10-base pair repeat, as well as sequences within the repeat itself at its 3' end outside the bHLH core, were also assessed. The two bases immediately flanking the 5' end of the element proved to be very important to its function as a UAS element as did the two bases immediately 3' of the bHLH core motif. Substitutions of the final two bases of the original ten base pair consensus (i.e. 5'-CATGTGAAAT-3') had less dramatic effects. We also tested a subset of the altered elements for their ability to serve as competitors in an assay of Ino2p . Ino4p binding. The strength of any given sequence as a UAS(INO) element, as assayed in vivo, was strongly correlated with its strength as a competitor for Ino2p . Ino4p binding. We also tested a subset of the modified UAS(INO) elements for their effects on expression in vivo in a strain carrying an opi1 mutation. The opi1 mutation renders the coregulated enzymes of phospholipid synthesis constitutive in the presence of phospholipid precursors. All elements that retained some residual UAS(INO) activity when tested in the wild-type strain were constitutively expressed at a level comparable with the wild-type derepressed level when tested in the opi1 mutant. Thus, UAS(INO) appears to be responsible for OPI1 mediated repression, as well as Ino2p . Ino4p binding. Furthermore, each of the identified functions of the UAS(INO) element appears to have the same sequence specificity, and all require the presence of the intact bHLH motif, suggesting that transcriptional activation, repression, and Ino2p . Ino4p binding are all components of a single regulatory mechanism.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213	Carnegie Mellon University			Henry, Susan/K-5464-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019629, R37GM019629] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19629] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEX R, 1992, NUCLEIC ACIDS RES, V20, P2257, DOI 10.1093/nar/20.9.2257; AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; GREENBERG ML, 1996, IN PRESS MICROBIOL R; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOSHIZAKI DK, 1990, J BIOL CHEM, V265, P4736; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P3987, DOI 10.1093/nar/19.14.3987; LUCHE RM, 1990, MOL CELL BIOL, V10, P3884, DOI 10.1128/MCB.10.8.3884; MELLOR J, 1990, EMBO J, V9, P4017, DOI 10.1002/j.1460-2075.1990.tb07623.x; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; NIKOLOFF DM, 1994, J BIOL CHEM, V269, P7402; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; Sambrook J, 1989, MOL CLONING LABORATO; SCHWANK S, 1995, NUCLEIC ACIDS RES, V23, P230, DOI 10.1093/nar/23.2.230; SLEKAR KH, 1995, NUCLEIC ACIDS RES, V23, P1964, DOI 10.1093/nar/23.11.1964; WHITE MJ, 1991, J BIOL CHEM, V266, P863	26	100	102	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25087	25095		10.1074/jbc.270.42.25087	http://dx.doi.org/10.1074/jbc.270.42.25087			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559640	hybrid			2022-12-27	WOS:A1995TB46500074
J	JARS, MU; OSBORN, S; FORSTROM, J; MACKAY, VL				JARS, MU; OSBORN, S; FORSTROM, J; MACKAY, VL			N-GLYCOSYLATION AND O-GLYCOSYLATION AND PHOSPHORYLATION OF THE BAR SECRETION LEADER DERIVED FROM THE BARRIER PROTEASE OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY MASS-SPECTROMETRY; COLLISION-INDUCED DISSOCIATION; LIQUID-CHROMATOGRAPHY; LINKED OLIGOSACCHARIDES; POLYACRYLAMIDE GELS; PROTEINS; YEAST; GLYCOPROTEIN; SITES; GENE	A secretion leader derived from a domain of the extracellular Barrier protease of the yeast Saccharomyces cerevisiae has been expressed in wild-type and in mnn1, mnn9, and mnn1 mnn9 glycosylation mutant strains of S. cerevisiae. Structural comparison of the extracellular leader by mass spectrometry, peptide mapping, and elementary analysis proved that all strains produced a heterogeneous, heavily glycosylated polypeptide of 161 amino acids with both N- and O-glycosylation and phosphorylation. All three potential Asn N linked sites were glycosylated to some extent with the expected structures. Neither the different growth media used nor the glycosylation mutations had significant effect on O-glycosylation with respect to both site selectivity and size of the carbohydrate structures. All 33 Ser and 21 Thr residues in the polypeptide were glycosylated at least partially, with an average of more than 2 mannoses/site, Although the mnn1 mutation blocks addition of alpha 1,3-linked mannose, the bar secretion domain expressed in the mnn1 and mnn1 mnng transformants unexpectedly contained some O-linked structures with at least 4 mannoses/chain. These O-linked structures were as large as when the leader was expressed in the mnn9 and wild-type strains. The bar secretion domain also had a previously undocumented phosphorylated O-linked structure.	ZYMOGENET INC, SEATTLE, WA 98102 USA	Zymogenet Inc.								BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BORYS MC, 1993, BIO-TECHNOL, V11, P720, DOI 10.1038/nbt0693-720; CAPLAN S, 1991, J BACTERIOL, V173, P627, DOI 10.1128/jb.173.2.627-635.1991; CARR SA, 1993, PROTEIN SCI, V2, P183; CONBOY JJ, 1992, J AM SOC MASS SPECTR, V3, P804, DOI 10.1016/1044-0305(92)80003-4; COVEY TR, 1991, ANAL CHEM, V63, P1193, DOI 10.1021/ac00013a003; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; Franzusoff A, 1992, Semin Cell Biol, V3, P309, DOI 10.1016/1043-4682(92)90018-Q; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GELLERFORS P, 1989, J BIOL CHEM, V264, P11444; GOOCHEE CF, 1990, BIO-TECHNOL, V8, P421, DOI 10.1038/nbt0590-421; GOOCHEE CF, 1991, BIO-TECHNOL, V9, P1347, DOI 10.1038/nbt1291-1347; GRAHAM TR, 1994, J CELL BIOL, V127, P667, DOI 10.1083/jcb.127.3.667; GRAHAM TR, 1992, YEAST S, V8, P458; GUZZETTA AW, 1993, ANAL CHEM, V65, P2953, DOI 10.1021/ac00069a004; HASELBECK A, 1983, FEBS LETT, V158, P335, DOI 10.1016/0014-5793(83)80608-5; HAUSLER A, 1992, GLYCOBIOLOGY, V2, P77, DOI 10.1093/glycob/2.1.77; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JIANG SJ, 1988, SPECTROCHIM ACTA B, V43, P405, DOI 10.1016/0584-8547(88)80068-5; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; KONIG W, 1970, CHEM BER-RECL, V103, P788, DOI 10.1002/cber.19701030319; KRISHNA PG, 1993, METHODS PROTEIN SEQU, P167; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRIBA G, 1993, YEAST, V9, P441, DOI 10.1002/yea.320090502; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; MACKAY VL, 1990, RECOMBINANT SYSTEMS IN PROTEIN EXPRESSION, P25; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; MACKAY VL, 1991, P ASPARTIC PROTEINAS, P161; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; MUNRO S, 1984, EMBO J, V3, P3087, DOI 10.1002/j.1460-2075.1984.tb02263.x; RUSSO P, 1992, P NATL ACAD SCI USA, V89, P3671, DOI 10.1073/pnas.89.9.3671; SETTINERI CA, 1990, BIOMED ENVIRON MASS, V19, P665, DOI 10.1002/bms.1200191106; STRAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185, DOI 10.1111/j.1432-1033.1991.tb15802.x; THIM L, 1993, FEBS LETT, V318, P345, DOI 10.1016/0014-5793(93)80543-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIMBLE RB, 1992, GLYCOBIOLOGY, V2, P57, DOI 10.1093/glycob/2.1.57; TRUEHEART J, 1989, P NATL ACAD SCI USA, V86, P9916, DOI 10.1073/pnas.86.24.9916; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WANG SS, 1973, J AM CHEM SOC, V95, P1328, DOI 10.1021/ja00785a602; WANG YC, 1992, J BIOL CHEM, V267, P2728; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; YAMADA T, 1994, BIOCHEMISTRY-US, V33, P3885, DOI 10.1021/bi00179a013; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723	51	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24810	24817		10.1074/jbc.270.42.24810	http://dx.doi.org/10.1074/jbc.270.42.24810			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559601	hybrid			2022-12-27	WOS:A1995TB46500035
J	JOHNSON, WJ; FISCHER, RT; PHILLIPS, MC; ROTHBLAT, GH				JOHNSON, WJ; FISCHER, RT; PHILLIPS, MC; ROTHBLAT, GH			EFFLUX OF NEWLY SYNTHESIZED CHOLESTEROL AND BIOSYNTHETIC STEROL INTERMEDIATES FROM CELLS - DEPENDENCE ON ACCEPTOR TYPE AND ON ENRICHMENT OF CELLS WITH CHOLESTEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; PLASMA-MEMBRANE; INTRACELLULAR MEMBRANES; ENDOPLASMIC-RETICULUM; HUMAN FIBROBLASTS; COENZYME-A; PROTEIN; REDUCTASE; TRANSPORT	Previous studies suggest that during sterol synthesis in cells, cholesterol and precusor sterols are transported to the plasma membrane and that this transport is stimulated by the binding of high density lipoprotein (HDL) to its putative cell surface receptor, leading to enhanced sterol efflux. Little is known about the identities of synthesized sterols subject to efflux or whether efflux of cholesterol and precursor sterols are stimulated equally by HDL. To address these issues, cells were incubated with [H-3]acetate or [H-3]mevalonate and sterol accepters, and then the labeled sterols in cells and efflux media were analyzed by high pressure liquid chromatography methods that resolved cholesterol and precursor sterols. In non-hepatic cells (Chinese hamster ovary (CHO), fibroblasts, and smooth muscle), cholesterol and multiple precursor sterols accumulated. In CHO cells, the major products were cholesterol and des-mosterol, which together constituted 50% of labeled nonsaponifiable lipids. When media contained human HDL(3) (1 mg of protein/ml), the molar efflux of synthesized desmosterol was four times that of cholesterol, and the 8-h efflux of those sterols, each normalized to its own production, averaged 48 and 16%, respectively. When media contained egg phosphatidylcholine vesicles (1 mg/ml), the efflux of these sterols averaged 18 and 2.4%, respectively. Thus, with both accepters, desmosterol was the major synthesized sterol released from cells, and its efflux was substantially greater than that of synthesized cholesterol. High relative efflux of desmosterol (or a desmosterol-like sterol) occurred in all cell types and in both cholesterol-enriched and unenriched cells. These results demonstrated qualitatively similar efflux of synthesized sterols in the presence of HDL(3) and phospholipid vesicles, arguing against an absolute requirement for accepters that interact with the HDL receptor. To probe for possible quantitative differences in the capabilities of these two accepters, the ratios of (efflux to HDL(3))/(efflux to phosphatidylcholine vesicles) were calculated for synthesized cholesterol and desmosterol, plasma membrane cholesterol, and lysosomal cholesterol. In comparison to plasma membrane cholesterol, there was little or no HDL selectivity for lysosomal cholesterol or synthesized desmosterol, whereas there was a 2-3-fold selectivity for synthesized cholesterol, suggesting that the ability of HDL to enhance the efflux of synthesized sterols is a modest quantitative effect and confined to cholesterol.	HAHNEMANN UNIV,PHILADELPHIA,PA 19129; DUPONT MERCK PHARMACEUT CO,EXPTL STN,WILMINGTON,DE 19880	Drexel University; DuPont	JOHNSON, WJ (corresponding author), MED COLL PENN,DEPT BIOCHEM,2900 QUEEN LANE,PHILADELPHIA,PA 19129, USA.			Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL22633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARBOGAST LY, 1976, P NATL ACAD SCI USA, V73, P3680, DOI 10.1073/pnas.73.10.3680; AVIRAM M, 1989, J LIPID RES, V30, P65; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BJORKHEM I, 1987, J LIPID RES, V28, P1137; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BURKI E, 1987, J LIPID RES, V28, P1199; CAPRIOTTI AM, 1987, J TISSUE CULTURE MET, V10, P219; CLEJAN S, 1984, J BIOL CHEM, V259, P441; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; FAUST J, 1987, J BIOL CHEM, V262, P1996; FISCHER RT, 1989, J LIPID RES, V30, P1621; HANSBURY E, 1980, J LIPID RES, V21, P921; HASLAM RM, 1953, BIOCHEM J, V55, P340, DOI 10.1042/bj0550340; Hatch F T, 1968, Adv Lipid Res, V6, P1; HOKLAND BM, 1993, J BIOL CHEM, V268, P25343; ISSODORIDES CH, 1962, J ORG CHEM, V27, P4693; JOHNSON WJ, 1994, J LIPID RES, V35, P563; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; JOHNSON WJ, 1988, J BIOL CHEM, V263, P14099; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JOHNSON WJ, 1991, J LIPID RES, V32, P1993; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; LANGE Y, 1987, J BIOL CHEM, V262, P4433; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LUNDKATZ S, 1984, BIOCHEMISTRY-US, V23, P1130, DOI 10.1021/bi00301a015; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MENDEZ AJ, 1985, J BIOL CHEM, V270, P5891; ORAM JF, 1983, J CLIN INVEST, V72, P1611, DOI 10.1172/JCI111120; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; SPERRY WM, 1950, J BIOL CHEM, V187, P97; TABACIK C, 1991, ATHEROSCLEROSIS, V86, P123, DOI 10.1016/0021-9150(91)90208-K; URBANI L, 1990, J BIOL CHEM, V265, P1919; VANHANEN HT, 1993, J LIPID RES, V34, P1535	38	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25037	25046		10.1074/jbc.270.42.25037	http://dx.doi.org/10.1074/jbc.270.42.25037			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559634	hybrid			2022-12-27	WOS:A1995TB46500068
J	LIN, WH; HUANG, LH; YEH, JY; HOHEISEL, J; LEHRACH, H; SUN, YH; TSAI, SF				LIN, WH; HUANG, LH; YEH, JY; HOHEISEL, J; LEHRACH, H; SUN, YH; TSAI, SF			EXPRESSION OF A DROSOPHILA GATA TRANSCRIPTION FACTOR IN MULTIPLE TISSUES IN THE DEVELOPING EMBRYOS - IDENTIFICATION OF HOMOZYGOUS LETHAL MUTANTS WITH P-ELEMENT INSERTION AT THE PROMOTER REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; NITROGEN REGULATORY GENE; SEQUENCE-ANALYSIS; ENDOTHELIAL-CELLS; FAMILY; ENHANCER; DOMAIN; ZINC; LOCALIZATION; POLYMERASE	GATA transcription factors are DNA-binding proteins that recognize the core consensus sequence, WGATAR. Previous studies indicated that GATA factors play an important role in the development of tissue-specific functions in vertebrates, Here we report the identification of a new Drosophila melanogaster GATA factor, dGATAc, which displays a distinct expression pattern in embryos. The local concentration of dGATAc transcripts varies at different stages, being most prominent in the procephalic region at stages 6-10 and in the posterior spiracles, the gut, and the central nervous system at stages 11-13. On the basis of its predicted sequence, DNA-binding assays were performed to confirm that the dGATAc gene encodes a zinc finger protein that can bind the GATA consensus motif with predicted specificity. Two independent mutants carrying a P-element insertion at the dGATAc gene promoter region were identified that are homozygous lethal at the embryonic stage. Using a genetic scheme, it was demonstrated that the lack of dGATAc function can block normal embryonic development. Our results suggest that the dGATAc protein is a tissue-specific transcription factor that is vital to the development of multiple organ systems in D. melanogaster.	NATL YANG MING UNIV, INST GENET, TAIPEI 112, TAIWAN; ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Cancer Research UK			Sun, Y. Henry/AAZ-7966-2021; Tsai, Shih-Feng/E-3997-2010; Lin, Wen-Hsing/K-8580-2013; Sun, Y. Henry/ABC-4614-2021	Lin, Wen-Hsing/0000-0001-5023-310X; Sun, Y. Henry/0000-0001-8279-5270				ABEL T, 1993, DEVELOPMENT, V119, P623; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FU YH, 1990, MOL CELL BIOL, V10, P1056, DOI 10.1128/MCB.10.3.1056; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HOHEISEL JD, 1991, J MOL BIOL, V220, P903, DOI 10.1016/0022-2836(91)90362-A; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KARPEN GH, 1992, GENETICS, V132, P737; KELLEY C, 1993, DEVELOPMENT, V118, P817; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KULDA B, 1990, EMBO J, V9, P1355; LEE ME, 1991, J BIOL CHEM, V266, P16188; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MARINE J, 1991, P NATL ACAD SCI USA, V88, P7284, DOI 10.1073/pnas.88.16.7284; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; SPIETH J, 1991, MOL CELL BIOL, V11, P4651, DOI 10.1128/MCB.11.9.4651; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596; WINICK J, 1993, DEVELOPMENT, V119, P1055; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10642, DOI 10.1073/pnas.88.23.10642; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668	55	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25150	25158		10.1074/jbc.270.42.25150	http://dx.doi.org/10.1074/jbc.270.42.25150			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559649	hybrid			2022-12-27	WOS:A1995TB46500083
J	MILEV, P; MEYERPUTTLITZ, B; MARGOLIS, RK; MARGOLIS, RU				MILEV, P; MEYERPUTTLITZ, B; MARGOLIS, RK; MARGOLIS, RU			COMPLEX-TYPE ASPARAGINE-LINKED OLIGOSACCHARIDES ON PHOSPHACAN AND PROTEIN-TYROSINE PHOSPHATASE-ZETA/BETA MEDIATE THEIR BINDING TO NEURAL CELL-ADHESION MOLECULES AND TENASCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SODIUM DODECYL-SULFATE; CHONDROITIN SULFATE; N-GLYCOSYLATION; BRAIN; DEGLYCOSYLATION; RECOGNITION; GLYCANS; CLONING; DOMAIN	Phosphacan, a soluble nervous tissue-specific chondroitin sulfate proteoglycan, is an alternative splicing product representing the entire extracellular domain of a transmembrane receptor-type protein-tyrosine phosphatase (RPTP zeta/beta) that also occurs as a chondroitin sul fate proteoglycan in brain. We have previously demonstrated that phosphacan binds with high affinity to neural cell adhesion molecules (Ng-CAM/L1 and N-CAM) and to the extracellular matrix protein tenascin and that it is a potent inhibitor of cell adhesion and neurite outgrowth. Tryptic digests of I-125-labeled phosphacan contain two glycopeptides that bind to Ng-CAM/L1, N-CAM, and tenascin. The larger of these (17 kDa) begins at Gln-209 near the end of the carbonic anhydrase-like domain of phosphacan/RPTP zeta/beta, whereas a 13-kDa glycopeptide begins at His-361 located in the middle of the fibronectin type III-like domain. Treatment of phosphacan with peptide N-glycosidase under nondenaturing conditions reduced its binding to the neural cell adhesion molecules and tenascin by 65-75%, whereas endo-beta-N-acetylglucosaminidase H had no effect, and peptide N-glycosidase treatment both decreased the molecular sizes of the tryptic peptides to similar to 11 kDa and abolished their binding. Based on the amino acid sequence of phosphacan, it can be concluded that each of the tryptic peptides contains one potential N-glycosylation site (at Asn-232 and Asn-381), and analyses of the isolated glycopeptides demonstrated the presence of sialylated complex type oligosaccharides. Our results therefore indicate that the interactions of phosphacan/RPTP zeta/beta with neural cell adhesion molecules and tenascin are mediated by asparagine-linked oligosaccharides present in their carbonic anhydrase- and fibronectin type III-like domains.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; SUNY HLTH SCI CTR,DEPT PHARMACOL,BROOKLYN,NY 11203	New York University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009348, R01NS013876] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-00129] Funding Source: Medline; NINDS NIH HHS [NS-09348, NS-13876] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allendoerfer K. L., 1995, Society for Neuroscience Abstracts, V21, P276; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HIRANI S, 1987, ANAL BIOCHEM, V162, P485, DOI 10.1016/0003-2697(87)90424-6; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEACH BS, 1980, BIOCHEMISTRY-US, V19, P5734, DOI 10.1021/bi00566a011; Lee Y. C., 1994, NEOGLYCOCONJUGATES P; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MARGOLIS RU, 1994, METHOD ENZYMOL, V245, P105; MAUREL P, 1995, DNA SEQUENCE, V5, P323, DOI 10.3109/10425179509030989; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MEYERPUTTLITZ B, 1995, J NEUROCHEM, V65, P2327; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; NUCK R, 1990, GLYCOCONJUGATE J, V7, P279, DOI 10.1007/BF01073372; PAREKH RB, 1987, EMBO J, V6, P1233, DOI 10.1002/j.1460-2075.1987.tb02359.x; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7644, DOI 10.1021/bi00445a021; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Segrest JP, 1972, METHOD ENZYMOL, V28, P54, DOI DOI 10.1016/0076-6879(72)28007-7; SHITARA K, 1994, J BIOL CHEM, V269, P20189; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; WEITZHANDLER M, 1993, J BIOL CHEM, V268, P5121	25	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24650	24653		10.1074/jbc.270.42.24650	http://dx.doi.org/10.1074/jbc.270.42.24650			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559574	hybrid			2022-12-27	WOS:A1995TB46500008
J	ALLEGRETTO, EA; SHEVDE, N; ZOU, AB; HOWELL, SR; BOEHM, MF; HOLLIS, BW; PIKE, JW				ALLEGRETTO, EA; SHEVDE, N; ZOU, AB; HOWELL, SR; BOEHM, MF; HOLLIS, BW; PIKE, JW			RETINOID-X-RECEPTOR ACTS AS A HORMONE-RECEPTOR IN-VIVO TO INDUCE A KEY METABOLIC ENZYME FOR 1,25-DIHYDROXYVITAMIN-D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							APOLIPOPROTEIN-A-I; DIFFERENTIAL REGULATION; RESPONSE PATHWAYS; NUCLEAR RECEPTOR; ACID; EXPRESSION; BINDING; RAT; HYPERVITAMINOSIS; TISSUE	We demonstrate here that RNA levels of 25-hydroxyvitamin D-3-24-hydroxylase (24-(OH)ase), a key catabolic enzyme for 1,25-dihydroxyvitamin D-3, are increased by a highly selective retinoid X receptor (RXR) ligand, LG100268, in mice within hours. Correspondingly, upon LG100268 treatment, kidney 24-(OH)ase enzymatic activity increases 5-10-fold. The endogenous retinoid hormones, all-trans-retinoic acid and g-cis-retinoic acid, and the synthetic retinoic acid receptor-selective compound, TTNPB, also stimulate 24-(OH)ase. Additionally, we show that LG100268 stimulates transcription of a luciferase reporter plasmid driven by 24-(OH)ase promoter sequences in the presence of RXR in CV-1 cell cotransactivation assays. This first demonstration of a gene that is regulated in the intact animal through an RXR-mediated pathway confirms earlier hypotheses that RXR is a bona fide hormone receptor. Regulation of a key gene in the vitamin D signaling pathway by a retinoid transducer may provide a molecular basis for some of the documented biological effects of vitamin A on bone and vitamin D metabolism.	LIGAND PHARMACEUT INC,DEPT TRANSCRIPT RES,SAN DIEGO,CA 92121; LIGAND PHARMACEUT INC,DEPT DRUG SAFETY & DISPOSIT,SAN DIEGO,CA 92121; LIGAND PHARMACEUT INC,DEPT RETINOID CHEM,SAN DIEGO,CA 92121; MED UNIV S CAROLINA,DEPT PEDIAT,CHARLESTON,SC 29425	Ligand Pharmaceuticals; Ligand Pharmaceuticals; Ligand Pharmaceuticals; Medical University of South Carolina	ALLEGRETTO, EA (corresponding author), LIGAND PHARMACEUT INC,DEPT BIOCHEM,10255 SCI CTR RD,SAN DIEGO,CA 92121, USA.							ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; BOGUSKI MS, 1985, P NATL ACAD SCI USA, V82, P992, DOI 10.1073/pnas.82.4.992; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK L, 1971, AUST VET J, V47, P568, DOI 10.1111/j.1751-0813.1971.tb02061.x; DAVIS KD, 1994, MOL CELL BIOL, V14, P7105, DOI 10.1128/MCB.14.11.7105; ENGSTROM GW, 1986, ARCH BIOCHEM BIOPHYS, V250, P86, DOI 10.1016/0003-9861(86)90704-6; FRANKEL TL, 1986, J NUTR, V116, P578, DOI 10.1093/jn/116.4.578; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOLLIS BW, 1990, P NATL ACAD SCI USA, V87, P6009, DOI 10.1073/pnas.87.16.6009; JOWSEY J, 1968, J CLIN ENDOCR METAB, V28, P1833, DOI 10.1210/jcem-28-12-1833; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; LI H, 1991, ENDOCRINOLOGY, V128, P2844, DOI 10.1210/endo-128-6-2844; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARCHETTI MN, 1994, ANAL LETT, V27, P1847, DOI 10.1080/00032719408002636; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PIKE JW, 1994, J BONE MINER RES, V9, pS144; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; TRECHSEL U, 1984, Calcified Tissue International, V36, pS49; TRECHSEL U, 1985, VITAMIN D CHEM BIOCH, P51; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; WOLBACH S. BURT, 1952, ARCH PATHOL, V54, P30; WOLKE RE, 1969, J PATHOL, V98, P677	32	49	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23906	23909		10.1074/jbc.270.41.23906	http://dx.doi.org/10.1074/jbc.270.41.23906			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592579	hybrid			2022-12-27	WOS:A1995TA21700007
J	MCCANN, S; SULLIVAN, J; GUERRA, J; ARCINAS, M; BOXER, LM				MCCANN, S; SULLIVAN, J; GUERRA, J; ARCINAS, M; BOXER, LM			REPRESSION OF THE C-MYB GENE BY WT1 PROTEIN IN T-CELL AND B-CELL LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGATION-MEDIATED PCR; WILMS-TUMOR LOCUS; MESSENGER-RNA; SUPPRESSOR WT1; EXPRESSION; BINDING; PRODUCT; HEMATOPOIESIS; SEQUENCE; INVITRO	The c-myb gene is primarily expressed in immature hematopoietic cells, and it is overexpressed in many leukemias. We have investigated the role of negative regulatory sites in the c-myb promoter in the Molt-4 T cell line and in the DHL-9 B cell line. A potential binding site for either the EGR-1 or WT1 protein was identified by in vivo footprinting in the 5'-flanking region of c-myb in a region of negative regulatory activity in T cells. We showed by electrophoretic mobility shift assay and electrophoretic mobility shift assay Western that WT1, EGR-1, and Sp1 bound to this site. A mutation of this site which prevented protein binding increased the activity of the c myb promoter by 2.5 fold. In the DHL-9 B cell line, this site was nonfunctional; however, we found a potential EGR-1/WT1 site located more 3' in a region of negative regulatory activity. We showed that WT1, EGR-1, and Sp1 bound to this site, and that mutation of this site increased the activity of the c-myb promoter by 3.2-fold. Cotransfection of a WT1 expression vector repressed the activity of the c-myb promoter in both cell lines, and this repression was relieved when the EGR-1/WT1 sites were removed. Cotransfection of either an EGR-1 or Sp1 expression vector had no significant effect on the activity of the c-myb promoter. We conclude that WT1 is a negative regulator of c-myb expression in both T and B cell lines.	STANFORD UNIV,SCH MED,DEPT MED,DIV HEMATOL,STANFORD,CA 94305; VET AFFAIRS MED CTR,CTR MOLEC BIOL MED,PALO ALTO,CA 94304	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NCI NIH HHS [5T32 CA09302] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ARCINAS M, 1994, ONCOGENE, V9, P2699; ARCINAS M, 1994, J BIOL CHEM, V269, P21919; BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GUERRA J, 1995, IN PRESS BLOOD; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JACOBS SM, 1994, ONCOGENE, V9, P227; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maxam A M, 1980, Methods Enzymol, V65, P499; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MOUNTZ JD, 1993, MOL IMMUNOL, V30, P787, DOI 10.1016/0161-5890(93)90001-R; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REDDY C, 1989, P NATL ACAD SCI USA, V86, P7626; SEKIYA M, 1994, BLOOD, V83, P1876; WATSON R, 1988, ONCOGENE, V8, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WERNER H, 1994, J BIOL CHEM, V269, P12577	38	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23785	23789		10.1074/jbc.270.40.23785	http://dx.doi.org/10.1074/jbc.270.40.23785			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559553	hybrid			2022-12-27	WOS:A1995RY90900082
J	GRAY, AJ; PARK, PW; BROEKELMANN, TJ; LAURENT, GJ; REEVES, JT; STENMARK, KR; MECHAM, RP				GRAY, AJ; PARK, PW; BROEKELMANN, TJ; LAURENT, GJ; REEVES, JT; STENMARK, KR; MECHAM, RP			THE MITOGENIC EFFECTS OF THE B-BETA CHAIN OF FIBRINOGEN ARE MEDIATED THROUGH CELL-SURFACE CALRETICULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; MOLECULAR-CLONING; HUMAN FIBROBLASTS; GROWTH-FACTORS; EXPRESSION; RETICULUM; SEQUENCE; ALPHA	We have previously shown that soluble partially degraded fibrin(ogen) remains in solution after fibrin clot formation and is a potent fibroblast mitogen (Gray, A, J,, Bishop, J, E,, Beeves, J, T,, Mecham, R.P,, and Laurent, G.J. (1995) Am, J. Cell Mot Biol. 12, 684-690), Mitogenic sites within the fibrin(ogen) molecule are located on the Aa! and B beta chains of the protein (Gray, A. J,, Bishop, J, E,, Reeves, J, T,, and Laurent, G. J, (1993) J. Cell Sci. 104, 409-413), However, receptor pathways through which mitogenic effects are mediated are unknown, The present study sought to determine the nature of fibrin (ogen) receptors expressed on human fibroblasts which interact with the fibrinogen B beta chain, Receptor complexes were isolated from I-125-surface-labeled fibroblasts and purified on a fibrinogen B beta chain affinity column. Subsequent high performance liquid chromatography and SDS-polyacrylamide gel electrophoresis analysis indicated fibrinogen B beta chain bound specifically to a 60-kDa surface protein. Sequence analysis of the amino terminus of this protein indicated 100% homology to human calreticulin. Immunoprecipitation experiments employing a polyclonal anti-calreticulin antibody provided further evidence that the 60-kDa protein isolated in this study was calreticulin. Further, polyclonal antibodies to human calreticulin significantly inhibited the mitogenic activity of fibrinogen B beta chain on human fibroblasts. The present study has shown that cell surface calreticulin binds to the B beta chain of fibrinogen mediating its mitogenic activity.	WASHINGTON UNIV,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DIV CRIT CARE & DEV LUNG BIOL,DENVER,CO 80262	Washington University (WUSTL); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	GRAY, AJ (corresponding author), UNIV LONDON UNIV COLL,SCH MED,RAYNE INST,DIV CARDIOPULM BIOCHEM,5 UNIV ST,LONDON WC1E 6JJ,ENGLAND.		stenmark, kurt/AAH-3124-2022; stenmark, kurt/AFI-6776-2022		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROWN LF, 1989, AM REV RESPIR DIS, V140, P1104, DOI 10.1164/ajrccm/140.4.1104; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; EGGLETON P, 1994, CLIN IMMUNOL IMMUNOP, V72, P405, DOI 10.1006/clin.1994.1160; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; GRAY AJ, 1990, J CELL SCI, V96, P271; GRAY AJ, 1995, AM J RESP CELL MOL, V12, P684, DOI 10.1165/ajrcmb.12.6.7766431; GRAY AJ, 1993, J CELL SCI, V104, P409; KUWABARA K, 1995, J BIOL CHEM, V270, P8179, DOI 10.1074/jbc.270.14.8179; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; MACLENNAN DH, 1972, COLD SPRING HARB SYM, V37, P469; MALHOTRA R, 1993, IMMUNOLOGY, V78, P341; Malhotra R, 1993, Behring Inst Mitt, P254; MCCAULIFFE DP, 1990, J CLIN INVEST, V85, P1379, DOI 10.1172/JCI114582; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; OLIVER MH, 1989, J CELL SCI, V92, P513; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; SINGH NK, 1994, P NATL ACAD SCI USA, V91, P12770, DOI 10.1073/pnas.91.26.12770	19	75	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26602	26606		10.1074/jbc.270.44.26602	http://dx.doi.org/10.1074/jbc.270.44.26602			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592883	hybrid			2022-12-27	WOS:A1995TC97800090
J	WEI, JY; HENDERSHOT, LM				WEI, JY; HENDERSHOT, LM			CHARACTERIZATION OF THE NUCLEOTIDE-BINDING PROPERTIES AND ATPASE ACTIVITY OF RECOMBINANT HAMSTER BIP PURIFIED FROM BACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; SHOCK COGNATE PROTEIN; ESCHERICHIA-COLI DNAJ; UNCOATING ATPASE; INFLUENZA HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; MUTATIONAL ANALYSIS; UNFOLDED PROTEINS; CLATHRIN COATS; HOMOLOG	HSP70 family proteins bind ATP and hydrolyze it, but the precise role of these activities in their in vivo chaperoning function has not been determined. In this report, we characterized wild-type hamster BiP isolated hom bacteria in terms of its ATP binding and ATPase activities. Recombinant BiP behaved essentially the same as endogenous BiP in terms of oligomeric status, protease digestion patterns, and ATPase properties. By engineering a Factor Xa cleavable site following the His tag which was used for affinity purification, we demonstrated that the six histidines had no effect on either the structural or ATPase properties of recombinant BiP. We also found that bacteria-synthesized BiP had a tightly bound ADP that was resistant to dialysis. Removal of the bound nucleotide allowed us to directly measure the binding affinity of ATP and ADP to BiP (K-d of 0.2 mu M for ATP and 0.29 mu M for ADP) by equilibrium dialysis. Careful characterization of wild-type BiP will allow us to use this system to characterize BiP ATP binding site mutants that can be used to probe the role of ATP binding and ATPase activity in BiP functions.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Hendershot, Linda/N-8124-2018	Hendershot, Linda/0000-0002-5473-0274	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 43576] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043576] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENAROUD JN, 1994, EUR J BIOCHEM, V221, P121; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CEGIELSKA A, 1989, J BIOL CHEM, V264, P21122; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; GAO BC, 1993, J BIOL CHEM, V268, P8507; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HA JH, 1994, BIOCHEMISTRY-US, V33, P14625, DOI 10.1021/bi00252a031; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NG DTW, 1989, J CELL BIOL, V109, P3273, DOI 10.1083/jcb.109.6.3273; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; RAABE T, 1991, NUCLEIC ACIDS RES, V19, P6645, DOI 10.1093/nar/19.23.6645; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SEALS JR, 1978, ANAL BIOCHEM, V90, P785, DOI 10.1016/0003-2697(78)90169-0; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7; WANG C, 1993, BIOCHEM J, V294, P69, DOI 10.1042/bj2940069; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677	43	76	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26670	26676		10.1074/jbc.270.44.26670	http://dx.doi.org/10.1074/jbc.270.44.26670			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592893	hybrid			2022-12-27	WOS:A1995TC97800100
J	BEIGELMAN, L; MCSWIGGEN, JA; DRAPER, KG; GONZALEZ, C; JENSEN, K; KARPEISKY, AM; MODAK, AS; MATULICADAMIC, J; DIRENZO, AB; HAEBERLI, P; SWEEDLER, D; TRACZ, D; GRIMM, S; WINCOTT, FE; THACKRAY, VG; USMAN, N				BEIGELMAN, L; MCSWIGGEN, JA; DRAPER, KG; GONZALEZ, C; JENSEN, K; KARPEISKY, AM; MODAK, AS; MATULICADAMIC, J; DIRENZO, AB; HAEBERLI, P; SWEEDLER, D; TRACZ, D; GRIMM, S; WINCOTT, FE; THACKRAY, VG; USMAN, N			CHEMICAL MODIFICATION OF HAMMERHEAD RIBOZYMES - CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA; OLIGONUCLEOTIDES; OLIGODEOXYRIBONUCLEOTIDES; NUCLEOSIDE; LINKAGES	A systematic study of selectively modified, 36-mer hammerhead ribozymes has resulted in the identification of a generic, catalytically active and nuclease stable ribozyme motif containing 5 ribose residues, 29-30 2'-O-Me nucleotides, 1-2 other 2'-modified nucleotides at positions U4 and U7, and a 3'-3'-linked nucleotide ''cap.'' Eight 2'-modified uridine residues were introduced at positions U4 and/or U7. From the resulting set of ribozymes, several have almost wild-type catalytic activity and significantly improved stability. Specifically, ribozymes containing 2'-NH2 substitutions at U4 and U7, or 2'-C-allyl substitutions at U4, retain most of their catalytic activity when compared to the all-RNA parent. Their serum half-lives were 5-8 h in a variety of biological fluids, including human serum, while the all-RNA parent ribozyme exhibits a stability half-life of only similar to 0.1 min. The addition of a 3'-3'-linked nucleotide ''cap'' (inverted T) did not affect catalysis but increased the serum half-lives of these two ribozymes to >260 h at nanomolar concentrations. This represents an overall increase in stability/activity of 53,000-80,000-fold compared to the all-RNA parent ribozyme.	RIBOZYME PHARMACEUT INC,DEPT CHEM & BIOCHEM,BOULDER,CO 80301; RIBOZYME PHARMACEUT INC,DEPT CELL BIOL & ENZYMOL,BOULDER,CO 80301					Karpeisky, Alexander/0000-0002-9226-8789				BEAUCAGE SL, 1993, TETRAHEDRON, V49, P6123, DOI 10.1016/S0040-4020(01)87958-8; BRATTY J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P345, DOI 10.1016/0167-4781(93)90001-T; CAMERON FH, 1989, P NATL ACAD SCI USA, V86, P9139, DOI 10.1073/pnas.86.23.9139; CECH TR, 1992, CURR OPIN STRUC BIOL, V2, P605, DOI DOI 10.1016/0959-440X(92)90093-M; DEMESMAEKER A, 1993, SYNLETT, P677; GOODCHILD J, 1992, NUCLEIC ACIDS RES, V20, P4607, DOI 10.1093/nar/20.17.4607; HEIDENREICH O, 1994, J BIOL CHEM, V269, P2131; HEIDENREICH O, 1993, FASEB J, V7, P90, DOI 10.1096/fasebj.7.1.7678566; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; INOUE H, 1987, NUCLEIC ACIDS RES, V15, P6131, DOI 10.1093/nar/15.15.6131; IYER RP, 1990, J ORG CHEM, V55, P4693, DOI 10.1021/jo00302a039; KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; Ortigao J F, 1992, Antisense Res Dev, V2, P129; PAOLELLA G, 1992, EMBO J, V11, P1913, DOI 10.1002/j.1460-2075.1992.tb05244.x; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SHIMAYAMA T, 1993, NUCLEIC ACIDS RES, V21, P2605, DOI 10.1093/nar/21.11.2605; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; USMAN N, 1992, TRENDS BIOCHEM SCI, V17, P334, DOI 10.1016/0968-0004(92)90306-T; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677; YAMAGATA Y, 1992, NUCLEOS NUCLEOT, V11, P835, DOI 10.1080/07328319208021744; YANG JH, 1992, BIOCHEMISTRY-US, V31, P5005, DOI 10.1021/bi00136a013	26	203	300	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25702	25708		10.1074/jbc.270.43.25702	http://dx.doi.org/10.1074/jbc.270.43.25702			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592749	hybrid			2022-12-27	WOS:A1995TB46600066
J	NAGARAJAN, S; CHESLA, S; COBERN, L; ANDERSON, P; ZHU, C; SELVARAJ, P				NAGARAJAN, S; CHESLA, S; COBERN, L; ANDERSON, P; ZHU, C; SELVARAJ, P			LIGAND-BINDING AND PHAGOCYTOSIS BY CD16 (FC-GAMMA RECEPTOR-III) ISOFORMS - PHAGOCYTIC SIGNALING BY ASSOCIATED ZETA-SUBUNITS AND GAMMA-SUBUNITS IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; PROTEIN TYROSINE KINASES; CULTURED HUMAN-MONOCYTES; G-MEDIATED PHAGOCYTOSIS; RIII CD16; IGG FC; HUMAN-NEUTROPHILS; STRUCTURAL SIMILARITY; T-CELLS; EXPRESSION	CD16, the low affinity Fc gamma receptor III for IgG (Fc gamma RIII), exists as a polypeptide-anchored form (Fc gamma RIIIA or CD16A) in human natural killer cells and macrophages and as a glycosylphosphatidylinositol-anchored form (Fc gamma RIIIB or CD16B) in neutrophils. CD16A requires association of the gamma subunit of Fc epsilon RI or the zeta subunit of the TCR-CDS complex for cell surface expression. The CD16B is polymorphic and the two alleles are termed NA1 and NA2. In this study, CD16A and the two alleles of CD16B have been expressed in Chinese hamster ovary (CHO) cells and their Ligand binding and phagocytic properties analyzed. The two allelic forms of CD16B showed a similar affinity toward human IgG1. However, the NA1 allele showed approximately S-fold higher affinity for the IgG3 than the NA2 allele. Although all three forms of CD16 efficiently bound rabbit IgG-coated erythrocytes (EA), only CD16A coexpressed with the gamma subunit phagocytosed EA. The phagocytosis mediated by CD16A expressed on CHO cells was independent of divalent cations but dependent on intact microfilaments. CHO cells expressing CD16A-gamma and CD16A-zeta chimeras also phagocytosed EA. The phagocytosis was specifically inhibited by tyrphostin-23, a tyrosine kinase inhibitor. In summary, our results demonstrate that glycosylphosphatidylinositol-anchored CD16B alleles differ from CD16A in their ability to mediate phagocytosis. Furthermore, since studies with other Fc gamma Rs have shown that CHO cells lack the phagocytic pathway mediated by the cytoplasmic domain of Fc gamma Rs, the phagocytosis of EA by CHO cells stably transfected with CD16A and CD16A-subunit chimera provides an ideal system to dissect the phagocytic signaling pathways mediated by these Fc gamma R-associated subunits.	EMORY UNIV,SCH MED,DEPT PATHOL & LAB MED,ATLANTA,GA 30322; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; GEORGIA INST TECHNOL,SCH MECH ENGN,ATLANTA,GA 30332	Emory University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University System of Georgia; Georgia Institute of Technology			Zhu, Cheng/A-5724-2011		NCI NIH HHS [CA 53595] Funding Source: Medline; NIAID NIH HHS [AI30631] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030631] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; BIANCA VD, 1993, J LEUKOCYTE BIOL, V53, P427; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BONNEROT C, 1992, EMBO J, V11, P2747, DOI 10.1002/j.1460-2075.1992.tb05340.x; BROWN EJ, 1988, J CLIN INVEST, V81, P365, DOI 10.1172/JCI113328; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; EDBERG JC, 1989, J IMMUNOL, V143, P1642; EDBERG JC, 1994, J IMMUNOL, V152, P5826; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; EVANS E, 1993, J CELL BIOL, V122, P1295, DOI 10.1083/jcb.122.6.1295; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GERGELY J, 1986, MOL IMMUNOL, V23, P1203, DOI 10.1016/0161-5890(86)90152-5; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2359; HUIZINGA TWJ, 1990, J IMMUNOL, V144, P1432; INDIK ZK, 1994, EXP HEMATOL, V22, P599; JUNGI TW, 1985, J IMMUNOL METHODS, V82, P141, DOI 10.1016/0022-1759(85)90233-9; KIMBERLY RP, 1995, ARTHRITIS RHEUM, V38, P306, DOI 10.1002/art.1780380303; KIMBERLY RP, 1990, J EXP MED, V171, P1239, DOI 10.1084/jem.171.4.1239; KLAASSEN RJL, 1990, J IMMUNOL, V144, P599; KOFLER R, 1977, J IMMUNOL METHODS, V16, P201, DOI 10.1016/0022-1759(77)90198-3; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LANIER LL, 1989, EUR J IMMUNOL, V19, P775, DOI 10.1002/eji.1830190431; LANIER LL, 1988, J IMMUNOL, V141, P3478; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LENNARTZ MR, 1993, J LEUKOCYTE BIOL, V54, P389, DOI 10.1002/jlb.54.5.389; LIN CT, 1994, J CLIN IMMUNOL, V14, P1, DOI 10.1007/BF01541170; MASUDA M, 1993, J IMMUNOL, V151, P7188; NAZIRUDDIN B, 1992, J IMMUNOL, V149, P3702; NISHIKIORI N, 1993, AM J REPROD IMMUNOL, V29, P17, DOI 10.1111/j.1600-0897.1993.tb00832.x; ODIN JA, 1991, SCIENCE, V254, P1785, DOI 10.1126/science.1837175; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; PARK JG, 1993, J CLIN INVEST, V92, P1967, DOI 10.1172/JCI116790; PARK JG, 1993, J CLIN INVEST, V92, P2073, DOI 10.1172/JCI116804; PERUSSIA B, 1991, EUR J IMMUNOL, V21, P425, DOI 10.1002/eji.1830210226; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; ROSALES C, 1991, J IMMUNOL, V146, P3937; SALMON JE, 1987, J EXP MED, V166, P1798, DOI 10.1084/jem.166.6.1798; SALMON JE, 1991, J IMMUNOL, V146, P997; SALMON JE, 1990, J CLIN INVEST, V85, P1287, DOI 10.1172/JCI114566; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SANDOR M, 1993, J CLIN IMMUNOL, V13, P237, DOI 10.1007/BF00919382; SCALLON BJ, 1989, P NATL ACAD SCI USA, V86, P5079, DOI 10.1073/pnas.86.13.5079; SCHREIBER AD, 1992, CLIN IMMUNOL IMMUNOP, V62, pS66, DOI 10.1016/0090-1229(92)90043-N; SELVARAJ P, 1989, J IMMUNOL, V143, P3283; SELVARAJ P, 1988, NATURE, V333, P565, DOI 10.1038/333565a0; SELVARAJ P, 1989, LEUKOCYTE TYPING 4, P590; SHEN L, 1987, J IMMUNOL, V139, P534; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; SPIEGELBERG HL, 1976, J IMMUNOL, V117, P1464; STEFANOVA I, 1991, J IMMUNOL, V147, P1587; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; TUIJNMAN WB, 1992, SCAND J IMMUNOL, V35, P569, DOI 10.1111/j.1365-3083.1992.tb03256.x; UEDA E, 1989, J IMMUNOL, V143, P1274; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; VIVIER E, 1991, J IMMUNOL, V146, P206; VIVIER E, 1991, J IMMUNOL, V147, P4263; VIVIER E, 1992, INT IMMUNOL, V4, P1313, DOI 10.1093/intimm/4.11.1313; WERNER G, 1986, LEUKOCYTE TYPING 2, P109; WINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511; WIRTHMUELLER U, 1992, J EXP MED, V175, P1381, DOI 10.1084/jem.175.5.1381; ZHOU MJ, 1992, J IMMUNOL, V148, P3550; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407; ZHU C, 1994, CELL MECHANICS AND CELLULAR ENGINEERING, P160	72	61	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25762	25770		10.1074/jbc.270.43.25762	http://dx.doi.org/10.1074/jbc.270.43.25762			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592758	hybrid			2022-12-27	WOS:A1995TB46600075
J	SONG, RD; IKEGUCHI, M; ZHOU, G; KUO, MT				SONG, RD; IKEGUCHI, M; ZHOU, G; KUO, MT			IDENTIFICATION AND CHARACTERIZATION OF A HEPATOMA CELL-SPECIFIC ENHANCER IN THE MOUSE MULTIDRUG-RESISTANCE MDR1B PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN GENE; BACTERIAL TRANSPORT PROTEINS; TRANSCRIPTION FACTORS; REGULATORY ELEMENTS; FUNCTIONAL-ANALYSIS; BINDING-SITE; RAT-LIVER; EXPRESSION; SEQUENCE; FAMILY	The expression of multidrug resistance/P-glycoprotein genes mdr1b(mdr1) and mdr1a(mdr3) is elevated during hepatocarcinogenesis. To investigate the regulation of mdr1b gene expression, we used transient transfection expression assays of reporter constructs containing various 5'-mdr1b flanking sequences in hepatoma and non-hepatoma cells. We found that nucleotides -233 to -116 preferentially enhanced the expression of reporter gene in mouse hepatoma cell Lines in an orientation- and promoter context-independent manner. DNase I footprinting using nuclear extracts prepared from hepatoma and non-hepatoma cells identified four protein binding sites at nucleotides -205 to -186 (site A), -181 to -164 (site B), -153 to -135 (site C), and -128 to -120 (site D). Further analyses revealed that, while site B alone played a major part for the enhancer function, sites A and B combined conferred full enhancer activity, Site-directed mutagenesis results also supported these results. Gel retardation experiments using oligonucleotide competitors revealed that the site B contains a dominant binding protein. This is the first report demonstrating a cell type-specific enhancer in the mdr locus. The role of this enhancer in the activation of mdr1b gene during hepatocarcinogenesis is discussed.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA55813, CA56846] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056846, R01CA055813] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM I, 1987, MOL CELL BIOL, V7, P3089; BERNHARD HP, 1973, DEV BIOL, V35, P83, DOI 10.1016/0012-1606(73)90008-0; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; BRADLEY G, 1991, CANCER RES, V52, P5154; Chan H S, 1993, Adv Pharmacol, V24, P157, DOI 10.1016/S1054-3589(08)60937-0; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COHEN D, 1991, J BIOL CHEM, V266, P2239; COMBATES NJ, 1994, J BIOL CHEM, V269, P29715; CORNWELL MM, 1990, CELL GROWTH DIFFER, V1, P607; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DING ZM, 1995, J BIOL CHEM, V270, P3667, DOI 10.1074/jbc.270.8.3667; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; FARDEL O, 1990, EUR J BIOCHEM, V205, P847; GANT WT, 1991, NUCLEIC ACIDS RES, V20, P2841; GERMANN UA, 1994, GENE CHROMOSOME CANC, V10, P267, DOI 10.1002/gcc.2870100408; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HANKINSON O, 1979, P NATL ACAD SCI USA, V96, P373; HSU SIH, 1989, J BIOL CHEM, V264, P12053; IKEGUCHI M, 1991, DNA CELL BIOL, V10, P639, DOI 10.1089/dna.1991.10.639; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KIMURA O, 1994, HUM GENE THER, V5, P845, DOI 10.1089/hum.1994.5.7-845; KOHNO K, 1990, J BIOL CHEM, V265, P19690; KUO MT, 1990, CELL GROWTH DIFFER, V3, P531; LEE CH, 1993, J CELL PHYSIOL, V157, P392, DOI 10.1002/jcp.1041570223; LEE KAW, 1989, MOL CELL BIOL, V9, P4390, DOI 10.1128/MCB.9.10.4390; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MADDEN MJ, 1993, J BIOL CHEM, V268, P8290; MANDEL DB, 1991, SCIENCE, V254, P1762; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MORINAGA T, 1991, MOL CELL BIOL, V11, P6041, DOI 10.1128/MCB.11.12.6041; NAKATSUKASA H, 1992, MOL CARCINOGEN, V6, P190, DOI 10.1002/mc.2940060304; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYMOND M, 1990, MOL CELL BIOL, V10, P6036, DOI 10.1128/MCB.10.11.6036; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P717; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SCHUETZ JD, 1993, CELL GROWTH DIFFER, V4, P31; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; TEETER LD, 1993, MOL CARCINOGEN, V8, P67, DOI 10.1002/mc.2940080202; TEETER LD, 1990, MOL CELL BIOL, V11, P5728; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; UEDA K, 1987, J BIOL CHEM, V262, P17432; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; WANG YB, 1994, J BIOL CHEM, V269, P9137; WATANABE H, 1988, MOL CELL BIOL, V8, P1290, DOI 10.1128/MCB.8.3.1290; YASUDA H, 1994, MOL CELL BIOL, V14, P1395, DOI 10.1128/MCB.14.2.1395; YU LJ, 1993, J BIOL CHEM, V268, P7520; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	64	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25468	25474		10.1074/jbc.270.43.25468	http://dx.doi.org/10.1074/jbc.270.43.25468			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592715	hybrid			2022-12-27	WOS:A1995TB46600031
J	ETO, A; AKITA, Y; SAIDO, TC; SUZUKI, K; KAWASHIMA, S				ETO, A; AKITA, Y; SAIDO, TC; SUZUKI, K; KAWASHIMA, S			THE ROLE OF THE CALPAIN-CALPASTATIN SYSTEM IN THYROTROPIN-RELEASING HORMONE-INDUCED SELECTIVE DOWN-REGULATION OF A PROTEIN-KINASE-C ISOZYME, NPKC-EPSILON, IN RAT PITUITARY GH(4)C(1) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; PROTEOLYTIC ACTIVATION; BINDING; HETEROGENEITY; PURIFICATION; DEGRADATION; INHIBITION; SEQUENCES; MEMBRANE; DOMAINS	We have examined the mechanism for the selective down-regulation of protein kinase C epsilon (nPKC epsilon) in rat pituitary GH(4)C(1) cells responding to thyrotropin-releasing hormone (TRH) stimulation. Among various low molecular weight protease inhibitors examined, only a cysteine protease inhibitor (calpain inhibitor I, N-acetyl-Leu-Leu-norleucinal) blocked the down-regulation of nPKC epsilon. Furthermore, the introduction of a synthetic calpastatin peptide, an exclusively specific inhibitor of calpain, into the cells also reduced the down-regulation, suggesting the involvement of calpain among all the intracellular cysteine proteases in this process. In accordance, we observed TRH-induced translocation of m-calpain from the cytosol to the membrane and the concomitant up regulation of calpastatin isoforms; presumably, the former represents activation of the protease initiating the kinase degradation, while the latter constitutes a negative feedback system protecting the cells from activated calpain. These results suggest that in GH(4)C(1) cells, TRH mobilizes both protease (m-calpain) and inhibitor (calpastatin) as a strictly regulating system for the nPKC epsilon pathway mediating TRH signals.	TOKYO METROPOLITAN INST MED SCI, DEPT MOLEC BIOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN	Tokyo Metropolitan Institute of Medical Science; University of Tokyo			Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903				ADACHI Y, 1990, BIOMED RES-TOKYO, V11, P313, DOI 10.2220/biomedres.11.313; ADACHI Y, 1991, J BIOL CHEM, V266, P3968; AKITA Y, 1990, BIOCHEM BIOPH RES CO, V172, P184, DOI 10.1016/S0006-291X(05)80191-3; AKITA Y, 1994, J BIOL CHEM, V269, P4653; AL ZW, 1993, BIOCHEM J, V296, P675, DOI 10.1042/bj2960675; ALBERT PR, 1984, J BIOL CHEM, V259, P5350; ARIYOSHI H, 1992, BIOCHEM INT, V27, P335; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; CHIDA K, 1986, J BIOL CHEM, V261, P3013; Crawford C., 1990, INTRACELLULAR CALCIU, P75; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V62, P1989; Goll DE, 1990, INTRACELLULAR CALCIU, P3; HASHIMOTO E, 1989, J BIOCHEM-TOKYO, V106, P1041, DOI 10.1093/oxfordjournals.jbchem.a122961; HATA A, 1992, FEBS LETT, V304, P241, DOI 10.1016/0014-5793(92)80628-T; ISHIDA S, 1991, BIOCHIM BIOPHYS ACTA, V1088, P436; ISHIURA S, 1978, J BIOCHEM, V84, P225, DOI 10.1093/oxfordjournals.jbchem.a132111; JUNCO M, 1994, EUR J BIOCHEM, V223, P259, DOI 10.1111/j.1432-1033.1994.tb18990.x; KAWASAKI H, 1989, J BIOCHEM, V106, P274, DOI 10.1093/oxfordjournals.jbchem.a122844; KILEY S, 1990, J BIOL CHEM, V265, P15704; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; LEE WJ, 1992, J BIOL CHEM, V267, P8437; MAKI M, 1989, J BIOL CHEM, V264, P18866; MELLONI E, 1986, J BIOL CHEM, V261, P4101; NAGAO S, 1994, J BIOCHEM, V115, P1178, DOI 10.1093/oxfordjournals.jbchem.a124476; NAKAMURA M, 1992, EXP CELL RES, V200, P513, DOI 10.1016/0014-4827(92)90203-K; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1990, J BIOL CHEM, V265, P6296; OHNO S, 1994, J BIOL CHEM, V269, P17495; ORWIG KE, 1994, ENDOCRINOLOGY, V134, P78, DOI 10.1210/en.134.1.78; OSHIMA M, 1989, J BIOL CHEM, V264, P20811; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAIDO TC, 1994, FEBS LETT, V346, P263, DOI 10.1016/0014-5793(94)00487-0; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SAITO Y, 1994, FEBS LETT, V353, P327, DOI 10.1016/0014-5793(94)01075-7; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SHEA TB, 1994, FEBS LETT, V350, P223, DOI 10.1016/0014-5793(94)00769-1; SHENOY AM, 1991, CELL IMMUNOL, V138, P24, DOI 10.1016/0008-8749(91)90129-Y; SHOJIKASAI Y, 1988, P NATL ACAD SCI USA, V85, P146, DOI 10.1073/pnas.85.1.146; YAJIMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P571, DOI 10.1016/S0006-291X(05)80073-7; YAJIMA Y, 1988, MOL PHARMACOL, V33, P592; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	45	84	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25115	25120		10.1074/jbc.270.42.25115	http://dx.doi.org/10.1074/jbc.270.42.25115			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559644	hybrid			2022-12-27	WOS:A1995TB46500078
J	LAIN, B; IRIARTE, A; MATTINGLY, JR; MORENO, JI; MARTINEZCARRION, M				LAIN, B; IRIARTE, A; MATTINGLY, JR; MORENO, JI; MARTINEZCARRION, M			STRUCTURAL FEATURES OF THE PRECURSOR TO MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE RESPONSIBLE FOR BINDING TO HSP70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ESCHERICHIA-COLI; STRESS PROTEINS; IMPORT; TRANSLOCATION; CELL; POLYPEPTIDES; TRANSAMINASE; MEMBRANE; CLEAVAGE	The precursor (pmAspAT) and mature (mAspAT) forms of mitochondrial aspartate aminotransferase interact with hsp70 very early during translation when synthesized in either rabbit reticulocyte lysate or wheat germ extract (Lain, B., Iriarte, A., and Martinez-Carrion, (1994) J, Biol, Chem, 269, 15588-15596). The nature of the structural elements responsible for recognition and binding of this protein to hsp70 has been studied by examining the folding and potential association with the chaperone of several engineered forms of this enzyme, Whereas pmAspAT and mAspAT bind hsp70 very early during translation, the cytosolic form of this enzyme (cAspAT) does not interact with hsp70. A fusion protein consisting of the mitochondrial presequence peptide attached to the amino terminus of cAspAT associates with hsp70 only after the protein has acquired its native-like conformation, apparently through binding to the presequence exposed on the surface of the folded protein. Deletion of the amino-terminal segment of mAspAT or its replacement with the corresponding domain from the cytosolic isozyme eliminates the cotranslational binding of hsp70 to the mitochondrial protein, We conclude that both the presequence and NH2-terminal region of pmAspAT represent recognition signals for binding of hsp79 to the newly synthesized mitochondrial precursor. Results from competition studies with synthetic peptides support this conclusion. The ability of hsp70 to discriminate between these two highly homologous proteins probably involves the recognition of specific sequence elements in the NH2-terminal portion of the mitochondrial protein and may relate to their separate localization in the cell. A slower folding rate and higher affinity for cytosolic chaperones may represent evolutionary adaptations of translocated mitochondrial proteins to ensure their efficient importation into the organelle.	UNIV MISSOURI, SCH BIOL SCI, DIV MOLEC BIOL, KANSAS CITY, MO 64110 USA	University of Missouri System; University of Missouri Kansas City			López-Moreno, Juan Ignacio/K-2114-2014	López-Moreno, Juan Ignacio/0000-0002-7270-9313; Moreno, J. Ignacio/0000-0002-5133-7573	NHLBI NIH HHS [HL-38412] Funding Source: Medline; NIGMS NIH HHS [GM-38341] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038341] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI F, 1989, J BIOL CHEM, V264, P4782; Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FEDOROV AN, 1995, P NATL ACAD SCI USA, V92, P1227, DOI 10.1073/pnas.92.4.1227; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Freedman Robert B., 1992, P455; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HANSEN WJ, 1994, J BIOL CHEM, V269, P26610; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; IRARTE A, 1994, BIOCH VITAMIN B6 PQQ, P75; IRIARTE A, 1984, J BIOL CHEM, V259, P723; IRIARTE A, 1984, CHEM BIOL ASPECTS B, P107; IRIARTE A, 1984, CHEM BIOL ASPECTS B, P269; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; KOLB VA, 1994, EMBO J, V13, P3631, DOI 10.1002/j.1460-2075.1994.tb06670.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIN B, 1994, J BIOL CHEM, V269, P15588; MARTINEZCARRION M, 1967, BIOCHEMISTRY-US, V6, P1715, DOI 10.1021/bi00858a021; MARTINEZCARRION M, 1990, ANN NY ACAD SCI, V585, P346, DOI 10.1111/j.1749-6632.1990.tb28067.x; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MATTINGLY JR, 1995, J BIOL CHEM, V270, P1138, DOI 10.1074/jbc.270.3.1138; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MATTINGLY JR, 1993, J BIOL CHEM, V268, P26320; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; SCHMID D, 1992, EUR J BIOCHEM, V208, P699, DOI 10.1111/j.1432-1033.1992.tb17237.x; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; VERNER K, 1987, EMBO J, V6, P2449, DOI 10.1002/j.1460-2075.1987.tb02524.x; VERNER K, 1993, TRENDS BIOCHEM SCI, V18, P366, DOI 10.1016/0968-0004(93)90090-A; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229	42	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24732	24739		10.1074/jbc.270.42.24732	http://dx.doi.org/10.1074/jbc.270.42.24732			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559589	hybrid			2022-12-27	WOS:A1995TB46500023
J	SHEN, BQ; WIDDICOMBE, JH; MRSNY, RJ				SHEN, BQ; WIDDICOMBE, JH; MRSNY, RJ			EFFECTS OF LOVASTATIN ON TRAFFICKING OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IN HUMAN TRACHEAL EPITHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-METHYLATION; CHLORIDE SECRETION; TRANSPORT; CELLS; CFTR; INHIBITION; MUTATIONS; PROTEINS; CHANNEL	Genetic defects in the cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-activated chloride channel, cause cystic fibrosis. Most defective forms of CFTR show improper intracellular trafficking. Because isoprenylated, small GTP-binding proteins are involved in the vesicular trafficking of other integral membrane proteins, we have investigated the role of isoprenylation in the trafficking of CFTR to the apical membranes of primary cultures of human airway epithelium and of Calu-3 cells, a human lung carcinoma cell line, CFTR function was measured as short circuit current, I-125 efflux, and conductance of cell sheets with permeabilized basolateral membranes. Lovastatin, an inhibitor of isoprenyl lipid biosynthesis, markedly inhibited all measures of CFTR function, The lovastatin-induced declines in CFTR function were corrected by the simultaneous addition of mevalonate or the isoprenyl Lipids geranylgeranyl and farnesyl but not cholesterol. Lovastatin reduced total cellular CFTR as assessed by immunoprecipitation. Mevalonate or isoprenyl lipids protected CFTR levels from the actions of lovastatin. Together, these results suggest a role for isoprenyl lipids, presumably through the actions of small GTP-binding proteins, in the trafficking of CFTR to the apical membrane of human airway epithelium.	GENENTECH INC, DEPT PHARMACEUT RES & DEV, San Francisco, CA 94080 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; CHILDRENS HOSP, OAKLAND RES INST, OAKLAND, CA 94609 USA	Roche Holding; Genentech; University of California System; University of California San Francisco; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42368] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BIWERSI J, 1994, AM J PHYSIOL, V266, pC149, DOI 10.1152/ajpcell.1994.266.1.C149; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; CHENG SH, 1993, CYSTIC FIBROSIS CURR, V1, P175; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; ECAY TW, 1993, AM J PHYSIOL, V265, pC422, DOI 10.1152/ajpcell.1993.265.2.C422; FULLER CM, 1994, AM J PHYSIOL, V266, pC661, DOI 10.1152/ajpcell.1994.266.3.C661; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANRAHAN JW, 1993, CYSTIC FIBROSIS CURR, V1, P93; HAWS C, 1992, AM J PHYSIOL, V263, pL692, DOI 10.1152/ajplung.1992.263.6.L692; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; LEONARD S, 1990, J BIOL CHEM, V265, P5157; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; OHRUI T, 1995, J APPL PHYSIOL, V78, P1197, DOI 10.1152/jappl.1995.78.3.1197; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PIND S, 1994, J BIOL CHEM, V269, P12784; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHWIEBERT EM, 1994, AM J PHYSIOL, V267, pC272, DOI 10.1152/ajpcell.1994.267.1.C272; SHEN BQ, 1993, J BIOL CHEM, V268, P19070; SHEN BQ, 1995, IN PRESS AM J PHYSL; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; THOMAS PJ, 1992, FEBS LETT, V312, P7, DOI 10.1016/0014-5793(92)81399-7; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WAGNER JA, 1992, P NATL ACAD SCI USA, V89, P6785, DOI 10.1073/pnas.89.15.6785; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WARD CL, 1994, J BIOL CHEM, V269, P25710; WEBSTER P, 1994, AM J PHYSIOL, V267, pC340, DOI 10.1152/ajpcell.1994.267.2.C340; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WIDDICOMBE JH, 1983, AM J PHYSIOL, V245, pC388, DOI 10.1152/ajpcell.1983.245.5.C388; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713; Yang Yiping, 1994, American Journal of Respiratory Cell and Molecular Biology, V11, P7; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	41	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25102	25106		10.1074/jbc.270.42.25102	http://dx.doi.org/10.1074/jbc.270.42.25102			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559642	hybrid			2022-12-27	WOS:A1995TB46500076
J	BECKER, MM; HARROP, SA; DALTON, JP; KALINNA, BH; MCMANUS, DP; BRINDLEY, PJ				BECKER, MM; HARROP, SA; DALTON, JP; KALINNA, BH; MCMANUS, DP; BRINDLEY, PJ			CLONING AND CHARACTERIZATION OF THE SCHISTOSOMA-JAPONICUM ASPARTIC PROTEINASE INVOLVED IN HEMOGLOBIN DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CATHEPSIN-D; HETEROLOGOUS ANTISERUM; MANSONI; PROTEASES	A cDNA encoding a Schistosoma japonicum aspartic proteinase was cloned, sequenced, and found to encode a zymogen of 380 amino acid residues, and its gene was shown to be present as a single copy in the S. japonicum genome. Identity comparisons showed that the enzyme (Sjpasp) was most closely related to the cathepsin Ds. The deduced amino acid sequence has four potential glycosylation sites, two of which are in identical positions to the two glycosylation sites of human kidney lysosomal cathepsin D. Furthermore, all four disulfide bonds found in mammalian cathepsin D sequences are present in Sjpasp, although the beta-hairpin (loop 3), which is cleaved during maturation of vertebrate cathepsin Ds to yield light and heavy chain subunits, is absent from Sjpasp. While most residues involved in substrate specificity and catalysis of aspartic proteinases are preserved in Sjpasp, several residues in these regions exhibit changes that may result in a novel substrate specificity. Aspartic proteinase activity is present in extracts of adult S. japonicum and Schistosoma mansoni and in culture media in which schistosomes were maintained and was capable of digesting hemoglobin. The schistosome aspartic proteinase may play a pivotal role in the catabolism of hemoglobin obtained from host erythrocytes.	ROYAL BRISBANE HOSP, QUEENSLAND INST MED RES, MOLEC PARASITOL UNIT, BRISBANE, QLD 4029, AUSTRALIA; DUBLIN CITY UNIV, SCH BIOL SCI, DUBLIN 9, IRELAND	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Dublin City University			McManus, Donald P./G-2678-2013; Dalton, John/K-4457-2014; McManus, Don/AAC-5394-2020	McManus, Don/0000-0001-6443-1449; Brindley, Paul J./0000-0003-1765-0002				AGARWAL N, 1983, ANAL BIOCHEM, V130, P158, DOI 10.1016/0003-2697(83)90663-2; Anson ML, 1938, J GEN PHYSIOL, V22, P79, DOI 10.1085/jgp.22.1.79; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BOGITSH BJ, 1983, J PARASITOL, V69, P106, DOI 10.2307/3281284; BOGITSH BJ, 1987, EXP PARASITOL, V64, P213, DOI 10.1016/0014-4894(87)90145-7; BOGITSH BJ, 1992, J PARASITOL, V78, P454, DOI 10.2307/3283643; CHAPPELL CL, 1986, EXP PARASITOL, V61, P160, DOI 10.1016/0014-4894(86)90148-7; CHO WL, 1992, J BIOL CHEM, V267, P21823; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALTON JP, 1995, PARASITOL TODAY, V11, P299, DOI 10.1016/0169-4758(95)80045-X; DAME JB, 1994, MOL BIOCHEM PARASIT, V64, P177, DOI 10.1016/0166-6851(94)90024-8; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; GOTZ B, 1993, BIOCHEM J, V290, P801; LAWRENCE JD, 1973, J PARASITOL, V59, P60, DOI 10.2307/3278572; PEARCE EJ, 1986, PARASITE IMMUNOL, V8, P79, DOI 10.1111/j.1365-3024.1986.tb00835.x; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; SMITH AM, 1994, MOL BIOCHEM PARASIT, V67, P11, DOI 10.1016/0166-6851(94)90091-4; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; TIMMS AR, 1959, BRIT J PHARM CHEMOTH, V14, P68, DOI 10.1111/j.1476-5381.1959.tb00930.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WADA K, 1991, NUCLEIC ACIDS RES, V19, P1981, DOI 10.1093/nar/19.suppl.1981; YONEZAWA S, 1988, J BIOL CHEM, V263, P16504	24	76	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24496	24501		10.1074/jbc.270.41.24496	http://dx.doi.org/10.1074/jbc.270.41.24496			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592666	hybrid			2022-12-27	WOS:A1995TA21700094
J	FREED, EO; MARTIN, MA				FREED, EO; MARTIN, MA			THE ROLE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEINS IN VIRUS-INFECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PRINCIPAL NEUTRALIZING DETERMINANT; RECOMBINANT SOLUBLE CD4; HTLV-III/LAV ENVELOPE; AMINO-ACID CHANGES; CYTOPLASMIC DOMAIN; SYNCYTIUM FORMATION; TRANSMEMBRANE PROTEIN; MEMBRANE-FUSION; RECEPTOR-BINDING; LEUCINE ZIPPER		NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3; ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; ALLAN JS, 1990, SCIENCE, V247, P1084, DOI 10.1126/science.2309120; ANDEWEG AC, 1993, J VIROL, V67, P3232, DOI 10.1128/JVI.67.6.3232-3239.1993; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; BERGER EA, 1991, P NATL ACAD SCI USA, V88, P8082, DOI 10.1073/pnas.88.18.8082; BERMAN PW, 1988, J VIROL, V62, P3135, DOI 10.1128/JVI.62.9.3135-3142.1988; BERNSTEIN HB, 1994, J VIROL, V68, P463, DOI 10.1128/JVI.68.1.463-468.1994; BHAT S, 1991, P NATL ACAD SCI USA, V88, P7131, DOI 10.1073/pnas.88.16.7131; BOSCH ML, 1989, SCIENCE, V244, P694, DOI 10.1126/science.2541505; BRIGHTY DW, 1991, P NATL ACAD SCI USA, V88, P7802, DOI 10.1073/pnas.88.17.7802; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1994, SCIENCE, V264, P1156, DOI 10.1126/science.7909959; BUCHSCHACHER GL, 1995, J VIROL, V69, P1344, DOI 10.1128/JVI.69.2.1344-1348.1995; CALLEBAUT C, 1993, SCIENCE, V262, P2045, DOI 10.1126/science.7903479; CAMERINI D, 1994, SCIENCE, V264, P1160, DOI 10.1126/science.7909961; CANN AJ, 1990, J VIROL, V64, P4735, DOI 10.1128/JVI.64.10.4735-4742.1990; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; CHAKRABARTI L, 1989, J VIROL, V63, P4395, DOI 10.1128/JVI.63.10.4395-4403.1989; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; CHESEBRO B, 1991, J VIROL, V65, P5782, DOI 10.1128/JVI.65.11.5782-5789.1991; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; CRISE B, 1992, J VIROL, V66, P2296, DOI 10.1128/JVI.66.4.2296-2301.1992; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DELWART EL, 1990, AIDS RES HUM RETROV, V6, P703, DOI 10.1089/aid.1990.6.703; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; DRAGIC T, 1995, J VIROL, V69, P1013, DOI 10.1128/JVI.69.2.1013-1018.1995; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; DUBAY JW, 1992, J VIROL, V66, P6616, DOI 10.1128/JVI.66.11.6616-6625.1992; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; EBENBICHLER C, 1993, AIDS, V7, P639, DOI 10.1097/00002030-199305000-00005; FELSER JM, 1989, VIROLOGY, V170, P566, DOI 10.1016/0042-6822(89)90448-0; FENNIE C, 1989, J VIROL, V63, P639, DOI 10.1128/JVI.63.2.639-646.1989; FENOUILLET E, 1990, J VIROL, V64, P2841, DOI 10.1128/JVI.64.6.2841-2848.1990; FISHER AG, 1986, SCIENCE, V233, P655, DOI 10.1126/science.3014663; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FREED EO, 1992, J VIROL, V66, P5472, DOI 10.1128/JVI.66.9.5472-5478.1992; FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650; FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70; FREED EO, 1987, J VIROL, V61, P2852, DOI 10.1128/JVI.61.9.2852-2856.1987; FREED EO, 1991, AIDS RES HUM RETROV, V7, P807, DOI 10.1089/aid.1991.7.807; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; FREED EO, 1995, J VIROL, V69, P1984, DOI 10.1128/JVI.69.3.1984-1989.1995; FREED EO, 1989, J VIROL, V63, P4670, DOI 10.1128/JVI.63.11.4670-4675.1989; FREED EO, 1994, J VIROL, V68, P2503, DOI 10.1128/JVI.68.4.2503-2512.1994; FREED EO, 1990, B I PASTEUR, V88, P73; FU YK, 1993, J VIROL, V67, P3818, DOI 10.1128/JVI.67.7.3818-3825.1993; FUNG MSC, 1992, J VIROL, V66, P848, DOI 10.1128/JVI.66.2.848-856.1992; GABUZDA DH, 1992, J VIROL, V66, P3306, DOI 10.1128/JVI.66.6.3306-3315.1992; GAEDIGKNITSCHKO K, 1991, VIROLOGY, V183, P206, DOI 10.1016/0042-6822(91)90133-V; GAUDIN Y, 1995, J GEN VIROL, V76, P1541, DOI 10.1099/0022-1317-76-7-1541; GEBHARDT A, 1984, J MOL BIOL, V174, P297, DOI 10.1016/0022-2836(84)90340-1; GOMATOS PJ, 1990, J IMMUNOL, V144, P4183; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; GROENINK M, 1993, SCIENCE, V260, P1513, DOI 10.1126/science.8502996; GU RL, 1993, AIDS RES HUM RETROV, V9, P1007, DOI 10.1089/aid.1993.9.1007; HAFFAR OK, 1988, J CELL BIOL, V107, P1677, DOI 10.1083/jcb.107.5.1677; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HART TK, 1991, P NATL ACAD SCI USA, V88, P2189, DOI 10.1073/pnas.88.6.2189; HELSETH E, 1990, J VIROL, V64, P6314, DOI 10.1128/JVI.64.12.6314-6318.1990; HOXIE JA, 1986, SCIENCE, V234, P1123, DOI 10.1126/science.3095925; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; JABBAR MA, 1990, J VIROL, V64, P6297, DOI 10.1128/JVI.64.12.6297-6304.1990; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JOHNSTON PB, 1993, J VIROL, V67, P3077, DOI 10.1128/JVI.67.6.3077-3086.1993; KANG CY, 1993, J IMMUNOL, V151, P449; KAWAMURA I, 1989, J VIROL, V63, P3748, DOI 10.1128/JVI.63.9.3748-3754.1989; KLATZMANN D, 1984, NATURE, V213, P767; KOGA Y, 1991, J VIROL, V65, P5609, DOI 10.1128/JVI.65.10.5609-5612.1991; KOITO A, 1994, J VIROL, V68, P2253, DOI 10.1128/JVI.68.4.2253-2259.1994; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; LAMB RA, 1993, VIROLOGY, V197, P1, DOI 10.1006/viro.1993.1561; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LAYNE SP, 1990, NATURE, V346, P277, DOI 10.1038/346277a0; LAZARO I, 1994, J VIROL, V68, P6535, DOI 10.1128/JVI.68.10.6535-6546.1994; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; LINSLEY PS, 1988, J VIROL, V62, P3695, DOI 10.1128/JVI.62.10.3695-3702.1988; LUSSO P, 1990, SCIENCE, V247, P848, DOI 10.1126/science.2305256; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MCKEATING JA, 1993, J VIROL, V67, P4932, DOI 10.1128/JVI.67.8.4932-4944.1993; MCKEATING JA, 1992, VIROLOGY, V191, P732, DOI 10.1016/0042-6822(92)90249-O; MELTZER MS, 1990, ANNU REV IMMUNOL, V8, P169, DOI 10.1146/annurev.iy.08.040190.001125; MOORE JP, 1993, J VIROL, V67, P4785, DOI 10.1128/JVI.67.8.4785-4796.1993; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; MOORE JP, 1994, J VIROL, V68, P6836, DOI 10.1128/JVI.68.11.6836-6847.1994; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; OHNISHI Y, 1994, J VIROL, V68, P4075, DOI 10.1128/JVI.68.6.4075-4079.1994; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; PAGE KA, 1992, J VIROL, V66, P524, DOI 10.1128/JVI.66.1.524-533.1992; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PAREDES AM, 1993, P NATL ACAD SCI USA, V90, P9095, DOI 10.1073/pnas.90.19.9095; PATIENCE C, 1994, SCIENCE, V264, P1159, DOI 10.1126/science.7909960; PEREZ LG, 1987, J VIROL, V61, P2981, DOI 10.1128/JVI.61.10.2981-2988.1987; PINTER A, 1993, J VIROL, V67, P5692, DOI 10.1128/JVI.67.9.5692-5697.1993; PINTER A, 1989, J VIROL, V63, P2674, DOI 10.1128/JVI.63.6.2674-2679.1989; RITTER GD, 1993, VIROLOGY, V197, P255, DOI 10.1006/viro.1993.1586; RUBIN H, 1960, P NATL ACAD SCI USA, V46, P1105, DOI 10.1073/pnas.46.8.1105; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHWALLER M, 1989, VIROLOGY, V172, P367; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SPECTOR DH, 1990, J VIROL, V64, P2298, DOI 10.1128/JVI.64.5.2298-2308.1990; SPIES CP, 1994, VIROLOGY, V203, P8, DOI 10.1006/viro.1994.1449; STAMATATOS L, 1994, AIDS, V8, P1727, DOI 10.1097/00002030-199412000-00014; STAMATATOS L, 1994, J VIROL, V68, P4973, DOI 10.1128/JVI.68.8.4973-4979.1994; STAMATATOS L, 1993, J VIROL, V67, P5635, DOI 10.1128/JVI.67.9.5635-5639.1993; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; STEFANO KA, 1993, J VIROL, V67, P6707, DOI 10.1128/JVI.67.11.6707-6715.1993; STEFFY KR, 1992, J VIROL, V66, P4532, DOI 10.1128/JVI.66.7.4532-4535.1992; STEINEKEGROBER A, 1992, EMBO J, V11, P2407; STEPHENS PE, 1990, NATURE, V343, P219, DOI 10.1038/343219b0; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; SULLIVAN N, 1993, J VIROL, V67, P3674, DOI 10.1128/JVI.67.6.3674-3679.1993; SUOMALAINEN M, 1992, J VIROL, V66, P4737, DOI 10.1128/JVI.66.8.4737-4747.1992; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; THALI M, 1992, J VIROL, V66, P5515; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; TURNER S, 1992, P NATL ACAD SCI USA, V89, P1335, DOI 10.1073/pnas.89.4.1335; WEINER DB, 1991, PATHOBIOLOGY, V59, P361, DOI 10.1159/000163679; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILK T, 1992, VIROLOGY, V189, P167, DOI 10.1016/0042-6822(92)90692-I; WILLEY RL, 1994, J VIROL, V68, P1029, DOI 10.1128/JVI.68.2.1029-1039.1994; WILLEY RL, 1991, VIROLOGY, V184, P319, DOI 10.1016/0042-6822(91)90848-6; WILLEY RL, 1989, J VIROL, V63, P3595, DOI 10.1128/JVI.63.9.3595-3600.1989; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; WILLEY RL, 1986, P NATL ACAD SCI USA, V83, P5038, DOI 10.1073/pnas.83.14.5038; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; WYATT R, 1992, J VIROL, V66, P6997, DOI 10.1128/JVI.66.12.6997-7004.1992; YU XF, 1993, J VIROL, V67, P213, DOI 10.1128/JVI.67.1.213-221.1993; ZINGLER K, 1993, J VIROL, V67, P2824, DOI 10.1128/JVI.67.5.2824-2831.1993	150	214	221	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23883	23886		10.1074/jbc.270.41.23883	http://dx.doi.org/10.1074/jbc.270.41.23883			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592573				2022-12-27	WOS:A1995TA21700001
J	FERRER, J; NICHOLS, CG; MAKHINA, EN; SALKOFF, L; BERNSTEIN, J; GERHARD, D; WASSON, J; RAMANADHAM, S; PERMUTT, A				FERRER, J; NICHOLS, CG; MAKHINA, EN; SALKOFF, L; BERNSTEIN, J; GERHARD, D; WASSON, J; RAMANADHAM, S; PERMUTT, A			PANCREATIC-ISLET CELLS EXPRESS A FAMILY OF INWARDLY RECTIFYING K+ CHANNEL SUBUNITS WHICH INTERACT TO FORM G-PROTEIN-ACTIVATED CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; BETA-CELLS; FUNCTIONAL EXPRESSION; ADENOSINE-TRIPHOSPHATE; HUMAN CHROMOSOME-11; B-CELLS; CALCIUM; HYBRIDS; SERIES; RAT	Insulin secretion is associated with changes in pancreatic beta-cell K+ permeability, A degenerate polymerase chain reaction strategy based on the conserved features of known inwardly rectifying K+ (K-IR) channel genes was used to identify members of this family expressed in human pancreatic islets and insulinoma, Three related human K-IR transcript sequences were found: CIR (also known as cardiac KATP-1), GIRK1, and GIRK2 (KATP-2), The pancreatic islet CLR and GIRK2 full-length cDNAs were cloned, and their genes were localized to human chromosomes 11q23-ter and 21, respectively, Northern blot analysis detected CIR mRNA at similar levels in human islets and exocrine pancreas, while the abundance of GIRK2 mRNA in the two tissues was insufficient for detection by this method. Using competitive reverse-transcription polymerase chain reaction, CIR was found to be present at higher levels than GIRK2 mRNA in native purified beta-cells. Xenopus oocytes injected with M2 muscarinic receptor (M2) plus either GIRK2 or CIR cRNA expressed only very small carbachol-induced currents, while co-injection of CIR plus GIRK2 along with M2 resulted in expression of carbachol activated strong inwardly rectifying currents, Activators of K-ATP channels failed to elicit currents in the presence or absence of co expressed sulfonylurea receptor, These results show that two components of islet cell. K-IR channels, CIR and GIRK2, may interact to form heteromeric G-protein-activated inwardly rectifying K+ channels that do not possess the typical properties of K-ATP channels.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV ENDOCRINOL DIABET & METAB,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV NEUROANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Ferrer, Jorge/A-3176-2012; Nichols, Colin/D-6336-2012	Ferrer, Jorge/0000-0002-5959-5729; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024785] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK16746] Funding Source: Medline; NINDS NIH HHS [R0INS24785-01] Funding Source: Medline; PHS HHS [R01451742] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1991, PROG BIOPHYS MOL BIO, V54, P87; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DUNNE MJ, 1989, EMBO J, V8, P413, DOI 10.1002/j.1460-2075.1989.tb03392.x; FERBER S, 1994, J BIOL CHEM, V269, P11523; GERHARD DS, 1992, GENOMICS, V13, P1133, DOI 10.1016/0888-7543(92)90028-Q; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P477, DOI 10.1007/BF01534910; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; KRAPIVINSKY G, 1995, NATURE, V394, P135; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; MATSUTANI A, 1992, GENOMICS, V12, P319, DOI 10.1016/0888-7543(92)90380-B; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; PHILIPSON LH, 1991, P NATL ACAD SCI USA, V88, P53, DOI 10.1073/pnas.88.1.53; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; RORSMAN P, 1991, NATURE, V349, P77, DOI 10.1038/349077a0; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; SAKURA H, 1995, FEBS LETT, V367, P193, DOI 10.1016/0014-5793(95)00498-X; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; Sambrook J, 1989, MOL CLONING LABORATO; STOFFEL M, 1994, GENOMICS, V21, P254, DOI 10.1006/geno.1994.1253; TSAUR ML, 1995, DIABETES, V44, P592, DOI 10.2337/diabetes.44.5.592; VANDENELSEN P, 1985, P NATL ACAD SCI USA, V82, P2920, DOI 10.1073/pnas.82.9.2920; VANHEMEL JO, 1992, HUM GENET, V88, P661, DOI 10.1007/BF02265294; YANO H, 1994, MOL PHARMACOL, V45, P854	31	67	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26086	26091		10.1074/jbc.270.44.26086	http://dx.doi.org/10.1074/jbc.270.44.26086			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592809	hybrid			2022-12-27	WOS:A1995TC97800016
J	KAROOR, V; BALTENSPERGER, K; PAUL, H; CZECH, MP; MALBON, CC				KAROOR, V; BALTENSPERGER, K; PAUL, H; CZECH, MP; MALBON, CC			PHOSPHORYLATION OF TYROSYL RESIDUES-350/354 OF THE BETA-ADRENERGIC-RECEPTOR IS OBLIGATORY FOR COUNTERREGULATORY EFFECTS OF INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-MEDIATED PATHWAYS; BETA-2-ADRENERGIC RECEPTOR; CROSS-REGULATION; KINASE-ACTIVITY; EXPRESSION; BINDING; SIGNAL	Insulin stimulates a loss of function and increased phosphotyrosine content of the beta(2)-adrenergic receptor in intact cells, raising the possibility that the beta(2)-receptor itself is a substrate for the insulin receptor tyrosine kinase. Phosphorylation of synthetic peptides corresponding to cytoplasmic domains of the beta(2)-adrenergic receptor by the insulin receptor in vitro and peptide mapping of the beta(2)-adrenergic receptor phosphorylated in vivo in cells stimulated by insulin reveal tyrosyl residues 350/354 and 364 in the cytoplasmic, C-terminal region of the beta(2)-adrenergic receptor as primary targets. Mutation of tyrosyl residues 350, 354 (double mutation) to phenylalanine abolishes the ability of insulin to counterregulate beta-agonist stimulation of cyclic AMP accumulation. Phenylalanine substitution of tyrosyl reside 364, in contrast, abolishes beta-adrenergic stimulation itself.	SUNY STONY BROOK, DEPT MOLEC PHARMACOL, DIABET & METAB DIS RES PROGRAM, STONY BROOK, NY 11794 USA; UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester			malbon, craig/ABF-3604-2020					BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CZECH MP, 1980, J CLIN INVEST, V66, P574, DOI 10.1172/JCI109889; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENGLAND PJ, 1976, ANAL BIOCHEM, V75, P429, DOI 10.1016/0003-2697(76)90096-8; GEAHLEN RL, 1989, PEPTIDES PROTEIN PHO, P239; GEORGE ST, 1989, BIOCHEM BIOPH RES CO, V163, P1265, DOI 10.1016/0006-291X(89)91114-5; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; JONG YJI, 1993, P NATL ACAD SCI USA, V90, P10994, DOI 10.1073/pnas.90.23.10994; PORT JD, 1992, J BIOL CHEM, V267, P8468; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUMMERS MD, 1987, AGR EXP STN B, V1555, P16; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VALIQUETTE M, 1993, BIOCHEMISTRY-US, V32, P4979, DOI 10.1021/bi00070a002; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	19	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25305	25308		10.1074/jbc.270.43.25305	http://dx.doi.org/10.1074/jbc.270.43.25305			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592686	hybrid			2022-12-27	WOS:A1995TB46600002
J	OMOTE, H; LE, NP; PARK, MY; MAEDA, M; FUTAI, M				OMOTE, H; LE, NP; PARK, MY; MAEDA, M; FUTAI, M			BETA-SUBUNIT GLU-185 OF ESCHERICHIA-COLI H+-ATPASE (ATP SYNTHASE) IS AN ESSENTIAL RESIDUE FOR COOPERATIVE CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; HEART MITOCHONDRIAL ATPASE; GLYCINE-RICH SEQUENCE; ADENOSINE-TRIPHOSPHATASE; GAMMA-PHOSPHATE; ALPHA-SUBUNIT; MUTATIONS; F1-ATPASE; SITE; MECHANISM	Glu-beta 185 of the Escherichia coli H+-ATPase (ATP synthase) beta subunit was replaced by 19 different amino acid residues. The rates of multisite (steady state) catalysis of all the mutant membrane ATPases except Asp-beta 185 were less than 0.2% of the wild type one; the Asp-beta 185 enzyme exhibited 15% (purified) and 16% (membrane-bound) ATPase activity. The purified inactive Cys-beta 185 F-1-ATPase recovered substantial activity after treatment with iodoacetate in the presence of MgCl2; maximal activity was obtained upon the introduction of about 3 mol of carboxymethyl residues/mol of F-1. The divalent cation dependences of the S-carboxymethyl-beta 185 and Asp-beta 185 ATPase activities were altered from that of the mild type, The Asp-beta 185, Cys-beta 185, S-carboxymethyl-beta 185, and Gln-beta 185 enzymes showed about 130, 60, 20, and 50% of the mild type unisite catalysis rates, respectively. The S-carboxymethyl-beta 185 and Asp-beta 185 enzymes showed altered divalent cation sensitivities, and the S-carboxymethyl-beta 185 enzyme showed no Mg2+ inhibition. Unlike the wild type, the two mutant enzymes showed low sensitivities to azide, which stabilizes the enzyme Mg . ADP complex. These results suggest that Glu-beta 185 may form a Mg2+ binding site, and its carboxyl moiety is essential for catalytic cooperativity. Consistent with this model, the bovine glutamate residue corresponding to Glu-beta 185 is located close to the catalytic site in the higher order structure (Abrahams, J. P., Leslie, A. G. W., Lutter, R., and Walker, J. E. (1994) Nature 370, 621-628).	OSAKA UNIV, INST SCI & IND RES, DEPT BIOL SCI, OSAKA 567, JAPAN	Osaka University			OMOTE, Hiroshi/B-1635-2011					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; CROSS RL, 1982, J BIOL CHEM, V257, P2101; DUNCAN TM, 1985, J BIOL CHEM, V260, P4901; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; IDA K, 1991, J BIOL CHEM, V266, P5424; IWAMOTO A, 1993, J BIOL CHEM, V268, P3156; IWAMOTO A, 1991, J BIOL CHEM, V266, P16350; KANAZAWA H, 1980, J BIOCHEM-TOKYO, V88, P695, DOI 10.1093/oxfordjournals.jbchem.a133022; KANAZAWA H, 1979, P NATL ACAD SCI USA, V76, P1126, DOI 10.1073/pnas.76.3.1126; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RSF, 1992, ARCH BIOCHEM BIOPHYS, V297, P334, DOI 10.1016/0003-9861(92)90681-L; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; NOUMI T, 1986, J BIOL CHEM, V261, P9196; NOUMI T, 1987, J BIOL CHEM, V262, P14978; OMOTE H, 1992, J BIOL CHEM, V267, P20571; OMOTE H, 1994, J BIOL CHEM, V269, P10265; PARK MY, 1994, J BIOCHEM-TOKYO, V116, P1139, DOI 10.1093/oxfordjournals.jbchem.a124640; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; SOGA S, 1989, ARCH BIOCHEM BIOPHYS, V268, P643, DOI 10.1016/0003-9861(89)90332-9; TANAKA S, 1967, J BACTERIOL, V93, P642, DOI 10.1128/JB.93.2.642-648.1967; WEBER J, 1994, J BIOL CHEM, V269, P20462; XIAO R, 1994, J BIOL CHEM, V269, P19232; [No title captured]	32	31	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25656	25660		10.1074/jbc.270.43.25656	http://dx.doi.org/10.1074/jbc.270.43.25656			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592742	hybrid			2022-12-27	WOS:A1995TB46600059
J	ADHIKARI, P; KIRBY, SD; NOWALK, AJ; VERALDI, KL; SCHRYVERS, AB; MIETZNER, TA				ADHIKARI, P; KIRBY, SD; NOWALK, AJ; VERALDI, KL; SCHRYVERS, AB; MIETZNER, TA			BIOCHEMICAL-CHARACTERIZATION OF A HAEMOPHILUS-INFLUENZAE PERIPLASMIC IRON TRANSPORT OPERON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOFERRIN-BINDING-PROTEINS; BACTERIAL OUTER-MEMBRANE; NEISSERIA-MENINGITIDIS; SERRATIA-MARCESCENS; REGULATED PROTEIN; HUMAN TRANSFERRIN; ESCHERICHIA-COLI; HEMOPHILUS-INFLUENZAE; IDENTIFICATION; GONORRHOEAE	Bacterial iron transport is critical for growth of pathogens in the host environment, where iron is limited as a form of nonspecific immunity. For Gram-negative bacteria such as Haemophilus influenzae, iron first must be transported across the outer membrane and into the periplasmic space, then from the periplasm to the cytosol. H. influenzae express a periplasmic iron-binding protein encoded by the hitA gene. This gene is organized as the first of a three-gene operon purported to encode a classic high affinity iron acquisition system that includes hitA, a cytoplasmic permease (hitB), and a nucleotide binding protein (hitC). In this study we describe the cloning, overexpression, and purification of the H. influenzae hitA gene product. The function of this protein is unambiguously assigned by demonstrating its ability to compete for iron bound to the chemical iron chelator 2,2'-dipyridyl, both in vitro and within the periplasmic space of a siderophore-deficient strain of Escherichia coli. Finally, the importance of a functional hitABC operon for iron acquisition is demonstrated by complementation of this siderophore-deficient E. coli to growth on dipyridyl-containing medium. These studies represent a detailed genetic, biochemical, and physiologic description of an active transport system that has evolved to efficiently transport iron and consequently is widely distributed among Gram-negative pathogenic bacteria.	UNIV CALGARY, DEPT MICROBIOL & INFECT DIS, CALGARY, AB T2N 4N1, CANADA	University of Calgary	ADHIKARI, P (corresponding author), UNIV PITTSBURGH, SCH MED, DEPT MOLEC GENET & BIOCHEM, PITTSBURGH, PA 15261 USA.		Schryvers, Anthony B./AAF-3417-2020	Veraldi, Kristen/0000-0002-5580-4810	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032226] Funding Source: NIH RePORTER; NIAID NIH HHS [1R29AI32226-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ANDERSON PW, 1990, NEW GENERATION VACCI, P349; ANGERER A, 1990, J BACTERIOL, V172, P572, DOI 10.1128/jb.172.2.572-578.1990; ANGERER A, 1992, J BACTERIOL, V174, P1378, DOI 10.1128/jb.174.4.1378-1387.1992; BERISH SA, 1990, J EXP MED, V171, P1535, DOI 10.1084/jem.171.5.1535; BERISH SA, 1992, MOL MICROBIOL, V6, P2607, DOI 10.1111/j.1365-2958.1992.tb01438.x; BERISH SB, 1994, 9TH P INT PATH NEISS, P196; Bullen J J, 1978, Curr Top Microbiol Immunol, V80, P1; CHEN CY, 1993, MOL MICROBIOL, V10, P311, DOI 10.1111/j.1365-2958.1993.tb01957.x; CORNELISSEN CN, 1993, J BACTERIOL, V175, P2448, DOI 10.1128/JB.175.8.2448-2450.1993; CRICHTON RR, 1992, BIOCHEMISTRY-US, V31, P11255, DOI 10.1021/bi00161a001; CROSA JH, 1984, ANNU REV MICROBIOL, V38, P69, DOI 10.1146/annurev.mi.38.100184.000441; CROSA JH, 1989, MICROBIOL REV, V53, P517, DOI 10.1128/MMBR.53.4.517-530.1989; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FROST GE, 1975, J BACTERIOL, V124, P704, DOI 10.1128/JB.124.2.704-712.1975; GRAYOWEN SD, 1995, INFECT IMMUN, V63, P1201, DOI 10.1128/IAI.63.4.1201-1210.1995; HARKNESS RE, 1992, J BACTERIOL, V174, P2425, DOI 10.1128/jb.174.8.2425-2430.1992; HERRINGTON DA, 1985, INFECT IMMUN, V48, P248, DOI 10.1128/IAI.48.1.248-251.1985; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; MICKELSEN PA, 1981, INFECT IMMUN, V33, P555, DOI 10.1128/IAI.33.2.555-564.1981; MICKELSEN PA, 1982, INFECT IMMUN, V35, P915, DOI 10.1128/IAI.35.3.915-920.1982; MIETZNER TA, 1994, ANNU REV NUTR, V14, P471, DOI 10.1146/annurev.nu.14.070194.002351; MIETZNER TA, 1984, INFECT IMMUN, V45, P410, DOI 10.1128/IAI.45.2.410-416.1984; MIETZNER TA, 1986, INFECT IMMUN, V51, P60, DOI 10.1128/IAI.51.1.60-68.1986; MIETZNER TA, 1987, J EXP MED, V165, P1041, DOI 10.1084/jem.165.4.1041; MIETZNER TA, 1985, PATHOGENIC NEISSERIA, P406; Neilands J.B., 1987, IRON TRANSPORT MICRO, P3; NEILANDS JB, 1982, ANNU REV MICROBIOL, V36, P285, DOI 10.1146/annurev.mi.36.100182.001441; NEILANDS JB, 1980, IRON BIOCH MED, P529; Nikaido H, 1993, Trends Microbiol, V1, P5, DOI 10.1016/0966-842X(93)90016-K; NIKAIDO H, 1990, ADV MICROBIAL PHYSL, P163; NOWALK AJ, 1994, BIOCHEMISTRY-US, V33, P12769, DOI 10.1021/bi00209a007; PITTARD J, 1966, J BACTERIOL, V91, P1494, DOI 10.1128/JB.91.4.1494-1508.1966; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; SANDERS JD, 1994, INFECT IMMUN, V62, P4515, DOI 10.1128/IAI.62.10.4515-4525.1994; SCHRYVERS AB, 1992, J INFECT DIS, V165, pS103, DOI 10.1093/infdis/165-Supplement_1-S103; SCHRYVERS AB, 1989, CAN J MICROBIOL, V35, P409, DOI 10.1139/m89-063; SCHRYVERS AB, 1989, J MED MICROBIOL, V29, P121, DOI 10.1099/00222615-29-2-121; SCHRYVERS AB, 1988, MOL MICROBIOL, V2, P281, DOI 10.1111/j.1365-2958.1988.tb00029.x; SCHRYVERS AB, 1988, INFECT IMMUN, V56, P1144, DOI 10.1128/IAI.56.5.1144-1149.1988; SHEA CM, 1991, MOL MICROBIOL, V5, P1415, DOI 10.1111/j.1365-2958.1991.tb00788.x; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; WEINBERG ED, 1984, PHYSIOL REV, V64, P65, DOI 10.1152/physrev.1984.64.1.65; WILLIAMS P, 1992, MED MICROBIOL IMMUN, V181, P301; ZIMMERMANN L, 1989, J BACTERIOL, V171, P238, DOI 10.1128/jb.171.1.238-243.1989	47	77	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25142	25149		10.1074/jbc.270.42.25142	http://dx.doi.org/10.1074/jbc.270.42.25142			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559648	hybrid			2022-12-27	WOS:A1995TB46500082
J	FUHRER, DK; FENG, GS; YANG, YC				FUHRER, DK; FENG, GS; YANG, YC			SYP ASSOCIATES WITH GP130 AND JANUS KINASE-2 IN RESPONSE TO INTERLEUKIN-11 IN 3T3-L1 MOUSE PREADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; PROTEIN-TYROSINE-PHOSPHATASE; IL-6 SIGNAL TRANSDUCER; FACTOR RECEPTOR-BETA; BCR-ABL ONCOGENE; PHOSPHORYLATION; JAK2; IDENTIFICATION; CELLS; ACTIVATION	Protein tyrosine phosphorylation and thus dephosphorylation are part of the interleukin (IL)-11 response in mouse 3T3-L1 cells. We report here for the first time the involvement and interactions of the SH2-containing protein tyrosine phosphatase Syp in the IL-11 signal transduction pathway. Addition of IL-11 to 3T3-L1 cells resulted in an increase in the tyrosine phosphorylation of Syp. When cell lysates were precipitated with glutathione S transferase fusion products of Syp, the C-terminal SH2 domain of Syp was shown to precipitate several proteins of 70, 130, 150, and 200 kDa that were tyrosine phosphorylated in response to IL-11. Reciprocal immunoprecipitation experiments showed that Syp was inducibly associated with both gp130 and Janus kinase 2 (JAK2). A phosphopeptide containing the sequence for a potential Syp binding site (YXXV) was used to compete with the associations of Syp with gp130 and JAK2. The phosphopeptide reduced the Syp association with both gp130 and JAK2. To summarize, Syp has multiple interactions in IL-11 signal transduction. In addition to the IL-11-induced tyrosine phosphorylation of Syp, Syp coprecipitated with gp130, JAK2, and other tyrosine-phosphorylated proteins in response to IL-11, These findings may have extensive significance to IL-11 and related cytokine signal transduction, suggesting new pathways and mechanisms.	INDIANA UNIV, SCH MED, DEPT MED HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis					NHLBI NIH HHS [R01HL48819] Funding Source: Medline; NIDDK NIH HHS [R01DK43105] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043105] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HARPUR AG, 1992, ONCOGENE, V7, P1347; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MALEK SN, 1994, J BIOL CHEM, V269, P33009; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WANG Y, 1994, MOL BIOL CELL, V5, P819, DOI 10.1091/mbc.5.7.819; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; XIAO S, 1994, J BIOL CHEM, V269, P21244; YANG YC, 1993, STEM CELLS, V11, P474, DOI 10.1002/stem.5530110617; YIN TG, 1992, J BIOL CHEM, V267, P8347; YIN TG, 1993, J IMMUNOL, V151, P2555; YIN TG, 1994, EXP HEMATOL, V22, P467; ZAFRIRI D, 1993, P NATL ACAD SCI USA, V90, P477, DOI 10.1073/pnas.90.2.477; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24826	24830		10.1074/jbc.270.42.24826	http://dx.doi.org/10.1074/jbc.270.42.24826			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559603	hybrid			2022-12-27	WOS:A1995TB46500037
J	MARTIN, MB; GARCIAMORALES, P; STOICA, A; SOLOMON, HB; PIERCE, M; KATZ, D; ZHANG, SM; DANIELSEN, M; SACEDA, M				MARTIN, MB; GARCIAMORALES, P; STOICA, A; SOLOMON, HB; PIERCE, M; KATZ, D; ZHANG, SM; DANIELSEN, M; SACEDA, M			EFFECTS OF 12-O-TETRADECANOYLPHORBOL-13-ACETATE ON ESTROGEN-RECEPTOR ACTIVITY IN MCF-7 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CLINICAL BREAST-CANCER; RESPONSIVE ELEMENT; CARCINOMA-CELLS; MESSENGER-RNAS; PHORBOL ESTER; BINDING; PHOSPHORYLATION; ACTIVATION; TRANSCRIPTION	The effects of long term treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) on estrogen receptor (ER) expression in the human breast cancer cell line, MCF-7, were studied. This study demonstrates that treatment of cells with the phorbol ester blocked estrogen receptor activity. Treatment of cells with 100 nM TPA resulted in an 80% decrease in the level of ER protein and a parallel decrease in ER mRNA and binding capacity. Following removal of TPA from the medium, the level of ER protein and mRNA returned to control values; however, the receptor failed to bind estradiol. These cells also failed to induce progesterone receptor in response to estradiol, In addition, TPA treatment blocked transcription from an estrogen response element in transient transfection assays and inhibited ER binding to its response element in a DNA mobility shift assay. The estrogen receptor in treated cells was recognized by two monoclonal anti-ER antibodies and was not quantitatively different from ER in control cells. RNase protection analysis failed to detect any qualitative changes in the ER mRNA transcript. Mixing experiments suggest that TPA induces/activates a factor which interacts with the ER to block binding of estradiol. The effects of TPA on ER levels and binding capacity were concentration-dependent. Low concentrations of TPA inhibited estradiol binding without a decrease in the level of protein, whereas higher concentrations were required to decrease the level of ER protein. The effects of TPA appear to be mediated by activation of protein kinase C since the protein kinase C inhibitors, H-7 and bryostatin, block the effects of TPA on estradiol induction of progesterone receptor. TPA treatment had no effect on the level or binding capacity of the glucocorticoid receptor, indicating that the effects are not universal for steroid receptors. These data demonstrate that activation of the protein kinase C signal transduction pathway modulates the estrogen receptor pathway. The long term effect of protein kinase C activation is to inhibit estrogen receptor function through induction/activation of a factor which interacts with the receptor.	GEORGETOWN UNIV,VINCENT T LOMBARDI CANC RES CTR,DEPT MED ONCOL,WASHINGTON,DC 20007	Georgetown University	MARTIN, MB (corresponding author), GEORGETOWN UNIV,VINCENT T LOMBARDI CANC RES CTR,DEPT BIOCHEM & MOLEC BIOL,E411 RES BLDG,WASHINGTON,DC 20007, USA.		Danielsen, Mark/B-1606-2008; danielsen, mark/AAE-9813-2020; Garcia Morales, Pilar/ABD-4362-2021; Saceda, Miguel/A-1581-2008	Danielsen, Mark/0000-0002-0923-9945; danielsen, mark/0000-0002-0923-9945; Saceda, Miguel/0000-0002-1564-3602	NCI NIH HHS [UO1 CA51908] Funding Source: Medline; NIDDK NIH HHS [K04 DK02105, R01 DK42552] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA051908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042552, K04DK002105] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allegra J C, 1980, Recent Results Cancer Res, V71, P20; AURICCHIO F, 1984, J STEROID BIOCHEM, V20, P31, DOI 10.1016/0022-4731(84)90185-7; AURICCHIO F, 1989, J STEROID BIOCHEM, V32, P613, DOI 10.1016/0022-4731(89)90397-X; Ausubel FM, 1988, MOL REPROD DEV; BELL PA, 1973, BIOCHEM J, V136, P97, DOI 10.1042/bj1360097; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BLACKSHEAR PJ, 1984, METHOD ENZYMOL, V104, P237; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARBON JM, 1986, BIOCHEM PHARMACOL, V35, P2683, DOI 10.1016/0006-2952(86)90175-9; DENTON RR, 1992, J BIOL CHEM, V267, P7263; DESOMBRE ER, 1980, CANCER, V46, P2783, DOI 10.1002/1097-0142(19801215)46:12+<2783::AID-CNCR2820461408>3.0.CO;2-4; DOTZLAW H, 1992, MOL ENDOCRINOL, V6, P773, DOI 10.1210/me.6.5.773; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FABBRO D, 1986, CANCER RES, V46, P2720; FUQUA SAW, 1991, CANCER RES, V51, P105; FUQUA SAW, 1992, CANCER RES, V52, P483; GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GUILBAUD N, 1988, MOL CELL ENDOCRINOL, V56, P157, DOI 10.1016/0303-7207(88)90020-2; HASHIMOTO Y, 1991, JPN J CANCER RES, V82, P665, DOI 10.1111/j.1349-7006.1991.tb01902.x; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECLERCQ G, 1992, J STEROID BIOCHEM, V41, P545, DOI 10.1016/0960-0760(92)90381-R; LEE CSL, 1989, BIOCHEM BIOPH RES CO, V162, P415, DOI 10.1016/0006-291X(89)92013-5; Lippman M.E., 1985, TXB ENDOCRINOLOGY, P1309; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCGUIRE WL, 1991, MOL ENDOCRINOL, V5, P1571, DOI 10.1210/mend-5-11-1571; MCGUIRE WL, 1992, J STEROID BIOCHEM, V43, P243, DOI 10.1016/0960-0760(92)90214-4; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MIGLIACCIO A, 1986, EMBO J, V5, P2867, DOI 10.1002/j.1460-2075.1986.tb04581.x; MIGLIACCIO S, 1993, MOL ENDOCRINOL, V7, P1133, DOI 10.1210/me.7.9.1133; OSBORNE CK, 1980, CANCER-AM CANCER SOC, V46, P2884, DOI 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U; PARIDAENS R, 1980, CANCER-AM CANCER SOC, V46, P2889, DOI 10.1002/1097-0142(19801215)46:12+<2889::AID-CNCR2820461430>3.0.CO;2-4; PICCART D, 1990, NATURE, V348, P166; SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157, DOI 10.1210/mend-2-12-1157; SACEDA M, 1989, MOL ENDOCRINOL, V3, P1782, DOI 10.1210/mend-3-11-1782; SACEDA M, 1991, J BIOL CHEM, V266, P17809; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SLATER EP, 1991, MOL ENDOCRINOL, V5, P386, DOI 10.1210/mend-5-3-386; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; VACCA A, 1989, MOL ENDOCRINOL, V3, P1659, DOI 10.1210/mend-3-10-1659; VALETTE A, 1987, CANCER RES, V47, P1615; VANDERBURG B, 1990, MOL ENDOCRINOL, V4, P1720, DOI 10.1210/mend-4-11-1720; WANG YL, 1991, MOL ENDOCRINOL, V5, P1707, DOI 10.1210/mend-5-11-1707; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097	51	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25244	25251		10.1074/jbc.270.42.25244	http://dx.doi.org/10.1074/jbc.270.42.25244			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559663	hybrid			2022-12-27	WOS:A1995TB46500097
J	CHEN, XM; KOSHLAND, DE				CHEN, XM; KOSHLAND, DE			THE N-TERMINAL CYTOPLASMIC TAIL OF THE ASPARTATE RECEPTOR IS NOT ESSENTIAL IN SIGNAL-TRANSDUCTION OF BACTERIAL CHEMOTAXIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED CROSS-LINKING; ESCHERICHIA-COLI; INSULIN-RECEPTOR; SENSORY RECEPTOR; LIGAND-BINDING; TRANSMEMBRANE; CHEMORECEPTOR; QUANTITATION; ACTIVATION; DOMAINS	To determine the role in transmembrane signaling of the N-terminal peptide of the first transmembrane region of the aspartate receptor, it was subjected to extensive mutagenesis. Drastic changes did not alter the chemotactic ability of the receptor to aspartate significantly. Thus the cytoplasmic N terminus of the first transmembrane region does not play an essential role in transmembrane signaling, and the entire signal that is transmitted to the cytoplasmic domain must be sent through the second transmembrane region. This eliminates the models requiring an interaction of this N-terminal peptide with the remaining cytoplasmic portion of the receptor.	UNIV CALIF BERKELEY,DEPT CELL & MOLEC BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NIDDK NIH HHS [DK09765] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009765, R37DK009765] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARON V, 1992, J BIOL CHEM, V267, P23290; BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHELSKY D, 1984, ANAL BIOCHEM, V141, P143, DOI 10.1016/0003-2697(84)90437-8; CLARKE S, 1979, J BIOL CHEM, V254, P9695; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; HUNTER T, 1992, COLD SPRING HARB SYM, V57, P25, DOI 10.1101/SQB.1992.057.01.005; JEFFERY CJ, 1994, BIOCHEMISTRY-US, V33, P3457, DOI 10.1021/bi00178a001; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MARUYAMA I, 1995, IN PRESS J MOL BIOL; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MILLIGAN DL, 1991, THESIS U CALIFORNIA; MOE GR, 1989, P NATL ACAD SCI USA, V86, P5683, DOI 10.1073/pnas.86.15.5683; OOSAWA K, 1986, P NATL ACAD SCI USA, V83, P6930, DOI 10.1073/pnas.83.18.6930; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; ROMEO C, 1992, COLD SPRING HARB SYM, V57, P117, DOI 10.1101/SQB.1992.057.01.015; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; SCOTT WG, 1994, STRUCTURE, V2, P877, DOI 10.1016/S0969-2126(94)00088-3; SHAPIRO MJ, 1994, J BIOL CHEM, V269, P11054; STODDARD BL, 1992, COLD SPRING HARB SYM, V57, P1; STODDARD BL, 1993, BIOCHEMISTRY-US, V31, P11978; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WOLFE AJ, 1988, P NATL ACAD SCI USA, V85, P6711, DOI 10.1073/pnas.85.18.6711	30	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24038	24042		10.1074/jbc.270.41.24038	http://dx.doi.org/10.1074/jbc.270.41.24038			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592602	hybrid			2022-12-27	WOS:A1995TA21700030
J	DYHRMIKKELSEN, H; KJEMS, J				DYHRMIKKELSEN, H; KJEMS, J			INEFFICIENT SPLICEOSOME ASSEMBLY AND ABNORMAL BRANCH SITE SELECTION IN SPLICING OF AN HIV-1 TRANSCRIPT IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PRE-MESSENGER-RNA; REV PROTEIN; INTRONIC SEQUENCES; EXPRESSION; MUTATIONS; COMPLEX; INVITRO; IDENTIFICATION; TRANSLATION	Continuous replication of human immunodeficiency virus type I (HIV-1) requires balanced expression of spliced and nonspliced mRNAs in the cytoplasm. This process is regulated post-transcriptionally by the viral-encoded Rev protein. An important prerequisite for Rev responsiveness is the presence of weak splice sites in the viral mRNA, We have investigated the splicing of the second intron of the HIV-1 Tat/Rev transcript in vitro and show that the S'-splice site region is responsible for the inefficient splicing of the HIV-1 transcript. In contrast, the HIV-1 5'-splice site is highly functional in combination with a heterologous S' splice site. Incubation of the HIV-1 transcript in nuclear extract leads to a rapid accumulation of 50 S nonproductive pre-spliceosome complexes. These complexes contain mainly U1 and U2 small nuclear ribonucleoproteins and are formed independently of the presence of the downstream 3'-splice site. The HIV-1 transcripts, which do proceed through the first splicing step, utilize primarily a uridine as the branch acceptor nucleotide. Sequence comparison with other HIV-1 introns suggests that nucleotides other than adenosines are commonly used as branch points in these viruses.	AARHUS UNIV,DEPT MOLEC BIOL,DK-8000 AARHUS,DENMARK	Aarhus University			Kjems, Jorgen/I-3490-2016	Kjems, Jorgen/0000-0003-4128-9317				ADEMA GJ, 1988, NUCLEIC ACIDS RES, V16, P9513, DOI 10.1093/nar/16.20.9513; AMENDT BA, 1994, MOL CELL BIOL, V14, P3960, DOI 10.1128/MCB.14.6.3960; ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808; BERBERICH SL, 1991, J VIROL, V65, P2640, DOI 10.1128/JVI.65.5.2640-2646.1991; BRIGHTY DW, 1994, P NATL ACAD SCI USA, V91, P8314, DOI 10.1073/pnas.91.18.8314; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; COCHRANE AW, 1991, J VIROL, V65, P5305, DOI 10.1128/JVI.65.10.5305-5313.1991; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; FU XD, 1991, GENE DEV, V5, P211, DOI 10.1101/gad.5.2.211; GONTAREK RR, 1993, GENE DEV, V7, P1926, DOI 10.1101/gad.7.10.1926; HAMMARSKJOLD ML, 1994, J VIROL, V68, P951; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; HORNIG H, 1986, NATURE, V324, P589, DOI 10.1038/324589a0; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KATZ RA, 1988, J VIROL, V62, P2686, DOI 10.1128/JVI.62.8.2686-2695.1988; KATZ RA, 1990, MOL CELL BIOL, V10, P696, DOI 10.1128/MCB.10.2.696; KJEMS J, 1993, J VIROL, V67, P4769, DOI 10.1128/JVI.67.8.4769-4776.1993; KJEMS J, 1991, CELL, V67, P169, DOI 10.1016/0092-8674(91)90580-R; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; LIAO XLC, 1992, NUCLEIC ACIDS RES, V20, P4237, DOI 10.1093/nar/20.16.4237; LU XB, 1990, P NATL ACAD SCI USA, V87, P7598, DOI 10.1073/pnas.87.19.7598; MALDARELLI F, 1991, J VIROL, V65, P5732, DOI 10.1128/JVI.65.11.5732-5743.1991; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MCNALLY MT, 1991, VIROLOGY, V185, P99, DOI 10.1016/0042-6822(91)90758-4; MCNALLY MT, 1992, J VIROL, V66, P6, DOI 10.1128/JVI.66.1.6-11.1992; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M., 1993, RNA WORLD, P303; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SCHWARTZ S, 1992, J VIROL, V66, P150, DOI 10.1128/JVI.66.1.150-159.1992; STAFFA A, 1994, J VIROL, V68, P3071, DOI 10.1128/JVI.68.5.3071-3079.1994; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WASSARMAN KM, 1992, MOL CELL BIOL, V12, P1276, DOI 10.1128/MCB.12.3.1276	45	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24060	24066		10.1074/jbc.270.41.24060	http://dx.doi.org/10.1074/jbc.270.41.24060			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592605	hybrid			2022-12-27	WOS:A1995TA21700033
J	DEBELLE, L; ALIX, AJP; JACOB, MP; HUVENNE, JP; BERJOT, M; SOMBRET, B; LEGRAND, P				DEBELLE, L; ALIX, AJP; JACOB, MP; HUVENNE, JP; BERJOT, M; SOMBRET, B; LEGRAND, P			BOVINE ELASTIN AND KAPPA-ELASTIN SECONDARY STRUCTURE DETERMINATION BY OPTICAL SPECTROSCOPIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAMAN AMIDE-I; PENTAPEPTIDE SEQUENCE; CIRCULAR-DICHROISM; CHAIN DYNAMICS; MESSENGER-RNA; SOLID-STATE; PROTEINS; TRANSITION; SPECTRA	Elastin is the macromolecular polymer of tropoelastin molecules responsible for the elastic properties of tissues. The understanding of its specific elasticity is uncertain because its structure is still unknown. Here, we report the first experimental quantitative determination. of bovine elastin secondary structures as well as those of its corresponding soluble K-elastin. Using circular dichroism and Fourier transform infrared and near infrared Fourier transform Raman spectroscopic data, we estimated the secondary structure contents of elastin to be similar to 10% alpha-helices, similar to 45% beta-sheets, and similar to 45% undefined conformations. These values were very close to those we had previously determined for the free monomeric tropoelastin molecule, suggesting thus that elastin would be constituted of a closely packed assembly of globular beta structural class tropoelastin molecules crosslinked to form the elastic network (liquid drop model of elastin architecture). The presence of a strong hydration shell is demonstrated for elastin, and its possible contribution to elasticity is discussed.	UNIV REIMS,CHRU,SPECT & STRUCT BIOMOLEC LAB,INSERM,U314,F-51092 REIMS,FRANCE; UNIV SCI & TECH LILLE FLANDRES ARTOIS,SPECT INFRAROUGE & RAMAN LAB,F-59655 VILLENEUVE DASCQ,FRANCE; INSERM,U367,F-75005 PARIS,FRANCE	CHU de Reims; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Reims Champagne-Ardenne; Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm)								ALIX AJP, 1985, SPECTROSCOPY BIOL MO, P149; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; Bellamy L.J., 1975, INFRARED SPECTRA COM, P72, DOI [DOI 10.1007/978, 10.1007/978-94-011-6017-9]; BERJOT M, 1987, J RAMAN SPECTROSC, V18, P289, DOI 10.1002/jrs.1250180411; BERTOLUZZA A, 1989, CAN J SPECTROSC, V34, P13; BROWN PL, 1992, BIOCHEM BIOPH RES CO, V186, P549, DOI 10.1016/S0006-291X(05)80843-5; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; DAVIES S, 1991, MAXIMUM ENTROPY ACTI, P73; DEBELLE L, 1995, J MOL STRUCT, V348, P321, DOI 10.1016/0022-2860(95)08653-D; DEBELLE L, 1992, EUR BIOPHYS J BIOPHY, V21, P321, DOI 10.1007/BF00188344; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; FLEMING WW, 1980, BIOPOLYMERS, V19, P597, DOI 10.1002/bip.1980.360190311; FRUSHOUR BG, 1975, BIOPOLYMERS, V14, P379, DOI 10.1002/bip.1975.360140211; HOEVE CAJ, 1974, BIOPOLYMERS, V13, P677, DOI 10.1002/bip.1974.360130404; INDIK Z, 1987, P NATL ACAD SCI USA, V84, P5680, DOI 10.1073/pnas.84.16.5680; Jacob M, 1985, FRONTIERS MATRIX BIO, V10, P92; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LILLIE MA, 1993, BIORHEOLOGY, V30, P229; LILLIE MA, 1990, BIOPOLYMERS, V29, P1147, DOI 10.1002/bip.360290805; LYERLA JR, 1975, BIOCHEMISTRY-US, V14, P5175, DOI 10.1021/bi00694a024; MAMMI M, 1968, NATURE, V220, P371, DOI 10.1038/220371b0; MANAVALAN P, 1983, NATURE, V305, P831, DOI 10.1038/305831a0; Mecham R.P., 1991, CELL BIOL EXTRACELLU, V2nd, P79; MEGRET C, 1992, INT J BIOL MACROMOL, V14, P45, DOI 10.1016/S0141-8130(05)80019-4; MEGRET C, 1993, INT J BIOL MACROMOL, V15, P305, DOI 10.1016/0141-8130(93)90031-G; Miles M. J., 1993, P177; PARKER FS, 1983, APPLICATIONS INFRARE; PRESCOTT B, 1987, BIOPOLYMERS, V26, P934, DOI 10.1002/bip.360260612; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RAJU K, 1987, J BIOL CHEM, V262, P5755; RENUGOPALAKRISH.V, 1990, ELASTIN CHEM BIOL AS, P155; SERAFINIFRACASS.A, 1975, BIOCHIM BIOPHYS ACTA, V386, P80; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P3989; TAMBURRO AM, 1992, J BIOMOL STRUCT DYN, V10, P441, DOI 10.1080/07391102.1992.10508661; TAMBURRO AM, 1978, J BIOL CHEM, V253, P2893; TAMBURRO AM, 1977, BIOCHIM BIOPHYS ACTA, V492, P370, DOI 10.1016/0005-2795(77)90088-5; Tu A.T., 1982, RAMAN SPECTROSCOPY B; URRY DW, 1983, ULTRASTRUCT PATHOL, V4, P227, DOI 10.3109/01913128309140793; URRY DW, 1988, J PROTEIN CHEM, V7, P1, DOI 10.1007/BF01025411; VILLANI V, 1993, J CHEM SOC P1, V2, P1951; VILLANI V, 1992, J CHEM SOC P1, V2, P2263; WEISFOGH T, 1970, NATURE, V227, P718, DOI 10.1038/227718a0; WEISFOGH T, 1970, CHEM MOL BIOL EXTRAC, P671; WILLIAMS RW, 1986, METHOD ENZYMOL, V130, P311; YEH H, 1987, COLLAGEN REL RES, V7, P235; YU NT, 1974, PEPTIDES POLYPEPTIDE, P370; YU NT, 1973, BIOPOLYMERS, V12, P2161	48	97	97	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26099	26103		10.1074/jbc.270.44.26099	http://dx.doi.org/10.1074/jbc.270.44.26099			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592811	hybrid			2022-12-27	WOS:A1995TC97800018
J	LU, ZH; WANG, ZX; HORUK, R; HESSELGESSER, J; LOU, YC; HADLEY, TJ; PEIPER, SC				LU, ZH; WANG, ZX; HORUK, R; HESSELGESSER, J; LOU, YC; HADLEY, TJ; PEIPER, SC			THE PROMISCUOUS CHEMOKINE BINDING PROFILE OF THE DUFFY ANTIGEN RECEPTOR FOR CHEMOKINES IS PRIMARILY LOCALIZED TO SEQUENCES IN THE AMINO-TERMINAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; RED-BLOOD-CELLS; PLASMODIUM-VIVAX; FUNCTIONAL EXPRESSION; ENDOTHELIN RECEPTOR; PEPTIDE RECEPTOR; LIGAND-BINDING; CLONING; CDNA; IDENTIFICATION	The Duffy antigen (DARC) is a promiscuous chemokine receptor that also binds Plasmodium vivax. DARC belongs to a family of heptahelical chemokine receptors that includes specific (IL-8RA) and shared (IL-8RB) IL-8 receptors, Ligand binding specificity of IL-8 receptors was localized to the amino terminal extracellular (El) domain, To determine the basis for promiscuous chemokine binding by DARC, a chimeric receptor composed of the E1 domain of DARC and hydrophobic helices and loops from IL-8RB (DARC(e1)/IL-8RB) was constructed, Scatchard analysis of stable transfectants demonstrated that the DARC(e1)/IL-8RB chimeric receptor bound IL-8 and melanoma growth stimulating activity (MGSA) with K-D values almost identical to the native receptors, The hybrid receptor also bound RANTES, MCP-1, and MGSA E(6)A (which binds DARC, but not IL-8RB), but not MIP-1 alpha, similarly to DARC, Ligand binding to DARC transfectants was unaltered by anti-Fy3, but inhibited by Fy6, which binds an epitope in the El domain, The epitope recognized by Fy3 was localized to the third extracellular loop by analysis of insect cells expressing chimeric receptors composed of complementary portions of DARC and IL-8RB. These findings implicate the El domain of DARC in multispecific chemokine binding.	UNIV LOUISVILLE,HENRY VOGT CANC RES INST,DEPT PATHOL,LOUISVILLE,KY 40292; UNIV LOUISVILLE,HENRY VOGT CANC RES INST,DEPT MED,LOUISVILLE,KY 40292; BERLEX BIOSCI,DEPT IMMUNOL,RICHMOND,CA 94804	University of Louisville; University of Louisville								ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHAUDHURI A, 1993, P NATL ACAD SCI USA, V90, P10793, DOI 10.1073/pnas.90.22.10793; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HESSELGESSER J, 1995, J BIOL CHEM, V270, P11472, DOI 10.1074/jbc.270.19.11472; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1993, BIOCHEMISTRY-US, V32, P5733, DOI 10.1021/bi00073a002; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; JI IH, 1991, J BIOL CHEM, V266, P14953; KOSUGI S, 1992, MOL ENDOCRINOL, V6, P166; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE J, 1992, J BIOL CHEM, V267, P16283; LEONG SR, 1994, J BIOL CHEM, V269, P19343; MILLER LH, 1975, SCIENCE, V189, P561, DOI 10.1126/science.1145213; MILLER LH, 1986, NEW ENGL J MED, V295, P302; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1994, BLOOD, V84, P44; NEOTE K, 1993, J BIOL CHEM, V268, P12247; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NICHOLS ME, 1987, J EXP MED, V166, P776, DOI 10.1084/jem.166.3.776; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; Perez H D, 1994, Curr Opin Hematol, V1, P40; PEREZ HD, 1993, J BIOL CHEM, V268, P2292; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHALL TJ, 1994, CYTOKINE HDB, P419; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; STECK TL, 1970, SCIENCE, V168, P255, DOI 10.1126/science.168.3928.255; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723	46	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26239	26245						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592830				2022-12-27	WOS:A1995TC97800037
J	OKAMURA, H; RESH, MD				OKAMURA, H; RESH, MD			P80/85 CORTACTIN ASSOCIATES WITH THE SRC SH2 DOMAIN AND COLOCALIZES WITH V-SRC IN TRANSFORMED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; PROTEIN-TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MONOCLONAL-ANTIBODIES; PP60(SRC) SUBSTRATE; STABLE ASSOCIATION; FOCAL ADHESIONS; IDENTIFICATION; FIBROBLASTS; AFFINITY	Expression of oncogenic variants of pp60(src) leads to dramatic changes in cytoskeletal organization characteristic of transformation. Activated Src associates with the cytoskeletal matrix, resulting in tyrosine phosphorylation of specific cytoskeletal substrates. We have previously shown that stable association of Src with the cytoskeletal matrix is mediated by the Src SH2 domain in a phosphotyrosine-dependent interaction. In this report, we demonstrate that one of the cytoskeletal binding partners of Src is p80/85 cortactin. The association was observed in lysates of transformed cells but was not seen in normal fibroblasts. The interaction could be reconstituted in vitro using transformed cell extracts and a glutathione S transferase (GST) fusion protein containing the Src SH2 domain but not with GST-Src SH3 or with GST-Src SH2 containing a point mutation in the FLVRES sequence, Confocal microscopy revealed that cortactin redistributed and colocalized with v-Src and a Src SH3 deletion mutant in transformed cells. However, in cells expressing a Src SH2 deletion mutant, the redistribution of cortactin and colocalization with Src did not occur, Furthermore, biochemical fractionation of transformed cells indicated that a significant increase in cortactin distribution to the cytoskeletal fraction occurred, which correlated with a shift in the tyrosine-phosphorylated form of the protein, Cortactin fractionated from cells expressing kinase-defective or myristylation-defective Src mutants did not exhibit this shift. These data suggest a molecular mechanism by which tyrosine phosphorylation of cortactin and association with the Src SH2 domain influence the cytoskeletal reorganization induced in Src transformed cells.	MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA; PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Memorial Sloan Kettering Cancer Center; Princeton University				Resh, Marilyn/0000-0001-6118-9466	NCI NIH HHS [P30-CA-08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HOLME TC, 1986, BRIT J CANCER, V53, P465, DOI 10.1038/bjc.1986.74; JOHANSSON MW, 1994, J CELL BIOL, V126, P1299, DOI 10.1083/jcb.126.5.1299; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MAA MC, 1992, ONCOGENE, V7, P2429; MARCHISIO PC, 1987, EXP CELL RES, V169, P202, DOI 10.1016/0014-4827(87)90238-2; MIGLARESE MR, 1994, ONCOGENE, V9, P1989; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; OKAMURA H, 1994, ONCOGENE, V9, P2293; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHUURING E, 1992, ONCOGENE, V7, P355; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TANAKA S, 1993, JPN J CANCER RES, V84, P279, DOI 10.1111/j.1349-7006.1993.tb02868.x; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; WONG S, 1992, ONCOGENE, V7, P2407; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	105	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26613	26618		10.1074/jbc.270.44.26613	http://dx.doi.org/10.1074/jbc.270.44.26613			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592885	hybrid			2022-12-27	WOS:A1995TC97800092
J	TARASEVICIENE, L; BJORK, GR; UHLIN, BE				TARASEVICIENE, L; BJORK, GR; UHLIN, BE			EVIDENCE FOR AN RNA-BINDING REGION IN THE ESCHERICHIA-COLI PROCESSING ENDORIBONUCLEASE RNASE-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; RIBONUCLEASE-E; RIBOSOMAL-RNA; AMS GENE; ENDONUCLEOLYTIC CLEAVAGE; CELL-DIVISION; DECAY; STABILITY; PROTEIN; OPERON	The processing endoribonuclease RNase E (Rne), which is encoded by the me gene, is involved in the maturation process of messenger RNAs and a ribosomal RNA. A number of deletions were constructed in order to assess functional domains of the me gene product. The expression of the deletion constructs using a T7 promoter/RNA polymerase overproduction system led to the synthesis of truncated Rne polypeptides. The smallest gene fragment in this collection that was able to complement a temperature sensitive rne(ts) mutation and to restore the processing of 9 S RNA was a 2.3-kilobase pair fragment with a 1.9-kilobase pair N-terminal coding sequence that mediated synthesis of a 70.8-kDa polypeptide. Antibodies raised against a truncated 110-kDa polypeptide cross-reacted with the intact me gene product and with all of the shorter C-terminal truncated polypeptides, indicating that the N-terminal part of the molecule contained strong antigenic determinants. Furthermore, by analyzing the Rne protein and the truncated polypeptides for their ability to bind substrate RNAs, we were able to demonstrate that the central part of the Rne molecule encodes an RNA binding region. Binding to substrate RNAs correlated with the endonucleolytic activity. RNAs that are not substrates for RNase E did not bind to the protein. The two mutated Rne polypeptides expressed from the cloned gene containing either the rne-3071 or ams1 mutation also had the ability to bind 9 S RNA, while their enzymatic function was completely abolished. The data presented here suggest that the endonucleolytic activity is encoded by the N-terminal part of the Rne protein molecule and that the central part of it possesses RNA binding activity.	UMEA UNIV, DEPT MICROBIOL, S-90187 UMEA, SWEDEN	Umea University			Uhlin, Bernt Eric/AAO-6292-2021; Björk, Glenn/AAE-8219-2022	Uhlin, Bernt Eric/0000-0002-2991-8072; 				ALTMAN S, 1989, ADV ENZYMOL, V62, P1; APIRION D, 1978, GENETICS, V90, P659; APIRION D, 1993, BIOESSAYS, V15, P113, DOI 10.1002/bies.950150207; APIRION D, 1992, MOL BIOL LIFE SCI AD, V11, P221; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BARDWELL JCA, 1989, EMBO J, V8, P3401, DOI 10.1002/j.1460-2075.1989.tb08504.x; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CASAREGOLA S, 1992, J MOL BIOL, V228, P30, DOI 10.1016/0022-2836(92)90489-7; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; Court D. L., 1993, CONTROL MESSENGER RN, P71; DEUTSCHER MP, 1985, CELL, V40, P731, DOI 10.1016/0092-8674(85)90330-7; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; FAUBLADIER M, 1990, J MOL BIOL, V212, P461, DOI 10.1016/0022-2836(90)90325-G; GAMPER M, 1993, GENE, V129, P119, DOI 10.1016/0378-1119(93)90706-9; GEGENHEIMER P, 1980, NUCLEIC ACIDS RES, V8, P1873, DOI 10.1093/nar/8.8.1873; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; GINSBURG D, 1975, J BIOL CHEM, V250, P5647; GITELMAN DR, 1980, BIOCHEM BIOPH RES CO, V96, P1063, DOI 10.1016/0006-291X(80)90060-1; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAJNSDORF E, 1994, J MOL BIOL, V239, P439, DOI 10.1006/jmbi.1994.1387; HANSEN MJ, 1994, MOL MICROBIOL, V12, P707, DOI 10.1111/j.1365-2958.1994.tb01058.x; KLUG G, 1992, GENE, V121, P95, DOI 10.1016/0378-1119(92)90166-M; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MCDOWALL KJ, 1993, J BACTERIOL, V175, P4245, DOI 10.1128/JB.175.13.4245-4249.1993; MEUR MR, 1992, EMBO J, V11, P2633; MUDD EA, 1988, EMBO J, V7, P3601, DOI 10.1002/j.1460-2075.1988.tb03238.x; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; NILSSON P, 1991, MOL MICROBIOL, V5, P1791, DOI 10.1111/j.1365-2958.1991.tb01928.x; OH W, 1992, J BACTERIOL, V174, P7873, DOI 10.1128/JB.174.23.7873-7874.1992; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; REGNIER P, 1990, BIOCHIMIE, V72, P825, DOI 10.1016/0300-9084(90)90192-J; REGNIER P, 1991, J MOL BIOL, V217, P283, DOI 10.1016/0022-2836(91)90542-E; REGNIER P, 1989, J MOL BIOL, V210, P293, DOI 10.1016/0022-2836(89)90331-8; Sambrook J, 1989, MOL CLONING LABORATO; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAKIFF HE, 1989, J BACTERIOL, V171, P2581, DOI 10.1128/jb.171.5.2581-2590.1989; TALKAD V, 1978, J BACTERIOL, V135, P528, DOI 10.1128/JB.135.2.528-541.1978; TARASEVICIENE L, 1994, J BIOL CHEM, V269, P12167; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	46	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26391	26398		10.1074/jbc.270.44.26391	http://dx.doi.org/10.1074/jbc.270.44.26391			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592853	hybrid			2022-12-27	WOS:A1995TC97800060
J	BENGTSSON, E; NEAME, PJ; HEINEGARD, D; SOMMARIN, Y				BENGTSSON, E; NEAME, PJ; HEINEGARD, D; SOMMARIN, Y			THE PRIMARY STRUCTURE OF A BASIC LEUCINE-RICH REPEAT PROTEIN, PRELP, FOUND IN CONNECTIVE TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CARTILAGE PROTEOGLYCAN; KERATAN SULFATE PROTEOGLYCAN; ARTICULAR-CARTILAGE; OSTEOINDUCTIVE FACTOR; TYROSINE SULFATION; MATRIX PROTEIN; CORE PROTEIN; SEQUENCE; CDNA; FIBROMODULIN	We have determined the primary structure of a connective tissue matrix protein from the nucleotide sequence of a clone isolated from a human articular chondrocyte cDNA Library. The major part of the amino acid sequence has also been determined by direct protein sequencing. The translated primary sequence corresponds to 382 amino acid residues, including a 20-residue signal peptide. The molecular mass of the mature protein is 41,646 Da. The main part of the protein consists of 10 leucine-rich repeats ranging in length from 20 to 26 residues, with asparagine at position 10 (B-type). The N-terminal part is unusual in that it is basic and rich in arginine and proline. There are four potential N-linked glycosylation sites present. In three of these sites, post-translational modifications are likely to be present since Asn was not found by direct protein sequencing. The amino- and carboxyl-terminal parts contain four and two cysteine residues, respectively, probably forming disulfide bonds by analogy with the other members of this family. The protein shows highest identity (36%) to fibromodulin and 33% to bovine lumican, two other leucine-rich repeat connective tissue proteins. Northern blot analysis showed the presence of an similar to 3.8-kilobase mRNA in different types of bovine cartilage and cultured osteoblasts, whereas RNAs isolated from bovine kidney, skin, spleen, thymus, and trabecular bone and rat calvaria were negative. Human articular chondrocyte and rat chondrosarcoma cell RNAs contained an additional mRNA of similar to 1.6 and 1.8 kilobases, respectively.	LUND UNIV,DEPT CELLULAR & MOLEC BIOL,EXTRACELLULAR MATRIX BIOL SECT,S-22100 LUND,SWEDEN; SHRINERS HOSP CRIPPLED CHILDREN,TAMPA,FL 33612	Lund University			Bengtsson, Eva/AAA-1968-2019	Bengtsson, Eva/0000-0001-7075-1772	NIAMS NIH HHS [AR35322] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035322] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS ME, 1992, ANAL BIOCHEM, V202, P89, DOI 10.1016/0003-2697(92)90211-O; ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; Heinegard Dick, 1993, P189; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CC, 1992, METHOD ENZYMOL, V216, P69; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; MELCHING LI, 1990, BIOCHIM BIOPHYS ACTA, V1036, P213, DOI 10.1016/0304-4165(90)90037-W; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; OLDBERG A, 1987, BIOCHEM J, V243, P255, DOI 10.1042/bj2430255; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; ROSENQUIST GL, 1993, PROTEIN SCI, V2, P215; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; Sneath P.H.A., 1973, NUMERICAL TAXONOMY; SOMMARIN Y, 1989, EXP CELL RES, V184, P181, DOI 10.1016/0014-4827(89)90376-5; SOMMARIN Y, 1983, BIOCHEM J, V214, P777, DOI 10.1042/bj2140777; VASIOS G, 1988, J BIOL CHEM, V263, P2324; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726	39	101	108	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25639	25644		10.1074/jbc.270.43.25639	http://dx.doi.org/10.1074/jbc.270.43.25639			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592739	hybrid			2022-12-27	WOS:A1995TB46600056
J	LEGGETT, RW; ARMSTRONG, SA; BARRY, D; MUELLER, CR				LEGGETT, RW; ARMSTRONG, SA; BARRY, D; MUELLER, CR			SP1 IS PHOSPHORYLATED AND ITS DNA-BINDING ACTIVITY DOWN-REGULATED UPON TERMINAL DIFFERENTIATION OF THE LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; DEPENDENT PROTEIN-KINASE; TRANSCRIPTION FACTOR SP1; ZINC-FINGER PROTEINS; PROMOTER ELEMENTS; ALBUMIN GENE; EXPRESSION; CELLS; REGENERATION; SPECIFICITY	Using nuclear extracts prepared hom rat liver it was demonstrated that binding of a transcription factor to site II of the D-site binding protein promoter could be induced by dephosphorylation of these extracts. Competition band shifts and supershift assays reveal this protein to be the general transcription factor Sp1. Phosphorylation of Sp1 appears to occur as a result of terminal differentiation of the liver. Proteins from both 1-day-old rat liver and adult liver undergoing regeneration have less of the phosphorylated form of Sp1 present with consequent increased DNA binding activity. Sp1 is similarly phosphorylated in brain, kidney, and spleen with phosphatase treatment of the extracts significantly increasing the level of DNA binding activity. Dephosphorylation of Sp1 results in a 10-fold increase in the affinity of Sp1 for its cognate site. Two-dimensional gel electrophoresis reveals that approximately 20% of the detectable protein appears to be in the phosphorylated form in adult liver extracts. Another protein with similar characteristics also appears to be present in the liver, Decreasing Sp1 DNA binding activity by phosphorylation may be an important mechanism for regulating gene expression, and possibly bringing about growth arrest during terminal differentiation.	QUEENS UNIV, CANC RES LABS, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT BIOCHEM, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT PATHOL, KINGSTON, ON K7L 3N6, CANADA	Queens University - Canada; Queens University - Canada; Queens University - Canada								BORELLINI F, 1991, J BIOL CHEM, V266, P15850; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHEN XR, 1992, ONCOGENE, V7, P1805; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; DUSING MR, 1994, NUCLEIC ACIDS RES, V22, P669, DOI 10.1093/nar/22.4.669; ELBARADI T, 1991, MECH DEVELOP, V35, P155, DOI 10.1016/0925-4773(91)90015-X; GEISER AG, 1993, GENE, V129, P223, DOI 10.1016/0378-1119(93)90272-5; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUMAR AP, 1995, J BIOL CHEM, V270, P4341, DOI 10.1074/jbc.270.39.22980; LANS MS, 1994, J BIOL CHEM, V269, P14170; LEGGETT RW, 1994, DNA CELL BIOL, V13, P693, DOI 10.1089/dna.1994.13.693; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MUELLER CR, 1992, DNA CELL BIOL, V11, P559, DOI 10.1089/dna.1992.11.559; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MURATA Y, 1994, J BIOL CHEM, V269, P20674; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NAKAMURA T, 1992, J VIROL, V66, P6436, DOI 10.1128/JVI.66.11.6436-6450.1992; PANDURO A, 1986, BIOCHEMISTRY-US, V25, P1414, DOI 10.1021/bi00354a034; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SUZUKIYAGAWA Y, 1992, MOL CELL BIOL, V12, P4046, DOI 10.1128/MCB.12.9.4046; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; YEN A, 1992, P SOC EXP BIOL MED, V199, P291	44	175	175	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25879	25884		10.1074/jbc.270.43.25879	http://dx.doi.org/10.1074/jbc.270.43.25879			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592774	hybrid			2022-12-27	WOS:A1995TB46600091
J	LIANG, J; MOYEROWLEY, S; MAURER, RA				LIANG, J; MOYEROWLEY, S; MAURER, RA			IN-VIVO MUTATIONAL ANALYSIS OF THE DNA-BINDING DOMAIN OF THE TISSUE-SPECIFIC TRANSCRIPTION FACTOR, PIT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POU-SPECIFIC DOMAIN; RAT PROLACTIN GENE; GROWTH-HORMONE; HOMEODOMAIN PROTEIN; ACTIVATOR PROTEIN; ESCHERICHIA-COLI; PROXIMAL REGION; OCT-1; TRANSFORMATION; ELEMENTS	Pit-1 is a member of the POU family of transcription factors, which contain a bipartite DNA binding domain, The DNA binding domain consists of a POU-specific domain and a POU homeodomain. Each of the subdomains can interact with DNA independently, but both subdomains are required for high affinity, sequence-specific DNA binding. To examine the contributions of individual amino acids to the function of the DNA binding domain of Pit-1, we developed an approach involving random, in vitro mutagenesis followed by functional screening in Saccharomyces cerevisiae. Using this strategy, we identified a number of point mutations that altered the function of the Pit-1 DNA binding domain. Mutations that altered Pit-1 function were found in both the POU-specific and the POU homeodomain. Most of the mutations involve amino acid residues that are conserved in POU factors. One of the more frequent kinds of mutation affected residues located in the hydrophobic core of the protein. Another common mutation involved amino acids that are thought to make specific contacts with DNA. These mutations define a number of amino acid residues that are important for the function of the DNA binding domain of Pit-1.	OREGON HLTH SCI UNIV,DEPT DEV & CELL BIOL,PORTLAND,OR 97201; UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Oregon Health & Science University; University of Iowa			Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040339] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40339] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; DEMDEN MC, 1992, MOL ENDOCRINOL, V6, P581, DOI 10.1210/me.6.4.581; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DING Y, 1991, MOL ENDOCRINOL, V5, P1239, DOI 10.1210/mend-5-9-1239; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HOWARD PW, 1994, J BIOL CHEM, V268, P28662; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; OKIMURA Y, 1994, MOL ENDOCRINOL, V8, P1559, DOI 10.1210/me.8.11.1559; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; VOSS JW, 1993, MOL ENDOCRINOL, V7, P1551, DOI 10.1210/me.7.12.1551; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319	40	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25520	25525		10.1074/jbc.270.43.25520	http://dx.doi.org/10.1074/jbc.270.43.25520			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592721	hybrid			2022-12-27	WOS:A1995TB46600038
J	VANWIJK, KJ; BINGSMARK, S; ARO, EM; ANDERSSON, B				VANWIJK, KJ; BINGSMARK, S; ARO, EM; ANDERSSON, B			IN-VITRO SYNTHESIS AND ASSEMBLY OF PHOTOSYSTEM-II CORE PROTEINS - THE D1 PROTEIN CAN BE INCORPORATED INTO PHOTOSYSTEM-II IN ISOLATED-CHLOROPLASTS AND THYLAKOIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; BINDING-PROTEINS; PHOTOINHIBITION; POLYPEPTIDE; IDENTIFICATION; ORGANIZATION; ACCUMULATION; TRANSLATION; D1-PROTEIN; TURNOVER	The D1 reaction center protein of the membrane-bound photosystem II complex (PSII) has a much higher turnover rate than the other PSII proteins, Thus, the D1 protein has to be replaced while the other PSII components are not newly synthesized. In this study, this D1 protein replacement into PSII complexes was followed in two in vitro translation systems: isolated chloroplasts and a homologous run-off translation system consisting primarily of isolated thylakoids with attached ribosomes. The incorporation of newly synthesized radiolabeled products into different (sub)complexes was analyzed by sucrose density gradient centrifugation of n-dodecyl beta-D-maltoside-solubilized thylakoid membranes, This analysis allowed us to follow the release of the nascent polypeptide chains from the ribosomes and identification of at least four assembly steps of the PSII complex, as shown below. (i) Both in isolated chloroplasts and in thylakoids, newly synthesized D1 protein is predominantly incorporated into existing PSII subcomplexes, indicating that synthesis and import of nuclear-encoded factors is not needed for D1 protein replacement. (ii) In chloroplasts, D1 protein incorporation into PSII core complexes is more efficient than during translation in isolated thylakoids, In the thylakoid translation system, a large percentage of radiolabeled D1 protein is found in smaller PSII: subcomplexes, like PSII reaction center particles, and as unassembled protein in the membrane. This indicates that stromal factors are required in the replacement process of the D1 protein. (iii) Both in isolated chloroplasts and in thylakoids, the other PSII core proteins D2, CP43, and CP47 are also synthesized and released from the membrane-bound ribosomes, but incorporation into PSII complexes occurs to a much smaller extent than the D1 protein, Instead they accumulate predominantly as unassembled proteins in the thylakoid membrane. (iv) In chloroplasts, synthesis of the D1 protein seems to be adjusted according to the possibilities of incorporation into PSII complexes, while synthesis of the D2 protein, CP43, and CP47 is less regulated and their accumulation as unassembled protein in the membrane is abundant.	UNIV STOCKHOLM, ARRHENIUS LABS NAT SCI, DEPT BIOCHEM, S-10691 STOCKHOLM, SWEDEN; TURKU UNIV, DEPT BIOL, SF-20500 TURKU, FINLAND	Stockholm University; University of Turku			Andersson, Bertil/C-9328-2009; Aro, Eva-Mari/Q-8664-2017	Aro, Eva-Mari/0000-0002-2922-1435				ADIR N, 1990, J BIOL CHEM, V265, P12563; ANDERSSON B., 1991, CURR TOP BIOENERG, V16, P1; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BARBATO R, 1992, J CELL BIOL, V119, P325, DOI 10.1083/jcb.119.2.325; BASSI R, 1992, EUR J BIOCHEM, V204, P317, DOI 10.1111/j.1432-1033.1992.tb16640.x; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BOSCHETTI A, 1990, PLANT SCI, V68, P131, DOI 10.1016/0168-9452(90)90219-E; DAINESE P, 1991, J BIOL CHEM, V266, P8136; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; DEVITRY C, 1989, J CELL BIOL, V109, P999; EICHACKER LA, 1990, J BIOL CHEM, V265, P13566; ERICKSON JM, 1992, TOPICS PHOTOSYNTHESI, V11, P101; GHANOTAKIS DF, 1987, BIOCHIM BIOPHYS ACTA, V891, P15, DOI 10.1016/0005-2728(87)90078-8; GHIRARDI ML, 1989, CURRENT RES PHOTOSYN, V2, P733; HERRIN D, 1985, FEBS LETT, V184, P90, DOI 10.1016/0014-5793(85)80660-8; HUNDAL T, 1990, BIOCHIM BIOPHYS ACTA, V1017, P235, DOI 10.1016/0005-2728(90)90190-F; IKEUCHI M, 1992, RES PHOTOSYNTHESIS, V11, P175; INAGAKI N, 1989, FEBS LETT, V246, P218, DOI 10.1016/0014-5793(89)80286-8; IRRGANG KD, 1995, J BIOL CHEM, V270, P17588, DOI 10.1074/jbc.270.29.17588; JENSEN KH, 1986, J CELL BIOL, V103, P1315, DOI 10.1083/jcb.103.4.1315; KIM J, 1994, J BI0L CHEM, V266, P14931; KLEIN RR, 1988, J CELL BIOL, V106, P289, DOI 10.1083/jcb.106.2.289; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MARDER JB, 1984, J BIOL CHEM, V259, P3900; MATTOO AK, 1981, P NATL ACAD SCI-BIOL, V78, P1572, DOI 10.1073/pnas.78.3.1572; MICHEL H, 1986, ENCY PLANT PHYSL PHO, V19, P371; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; MULLET JE, 1986, EUR J BIOCHEM, V155, P331, DOI 10.1111/j.1432-1033.1986.tb09495.x; Murata N., 1986, Light emission by plants and bacteria, P137; NEALE PJ, 1990, PLANT PHYSIOL, V92, P1196, DOI 10.1104/pp.92.4.1196; NEALE PJ, 1991, BIOCHIM BIOPHYS ACTA, V1056, P195, DOI 10.1016/S0005-2728(05)80287-7; ROOBOLBOZA M, 1995, IN PRESS PHOTOSYNTH; SATOH K, 1993, PHOTOSYNTHETIC REACT, V1, P289; SAYRE RT, 1986, CELL, V47, P601, DOI 10.1016/0092-8674(86)90624-0; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P403, DOI 10.1111/j.1432-1033.1988.tb14389.x; Seibert M, 1993, PHOTOSYNTHETIC REACT, VI, P319, DOI DOI 10.1016/B978-0-12-208661-8.50016-4; TAYLOR MA, 1988, FEBS LETT, V237, P229, DOI 10.1016/0014-5793(88)80207-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANWIJK KJ, 1994, J BIOL CHEM, V269, P28382; VANWIJK KJ, 1995, FEBS LETT, V368, P263, DOI 10.1016/0014-5793(95)00668-Y; WITT HT, 1992, RES PHOTOSYNTHESIS, V1, P521; [No title captured]	45	43	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25685	25695		10.1074/jbc.270.43.25685	http://dx.doi.org/10.1074/jbc.270.43.25685			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592747	hybrid			2022-12-27	WOS:A1995TB46600064
J	NARITA, M; BU, GJ; OLINS, GM; HIGUCHI, DA; HERZ, J; BROZE, GJ; SCHWARTZ, AL				NARITA, M; BU, GJ; OLINS, GM; HIGUCHI, DA; HERZ, J; BROZE, GJ; SCHWARTZ, AL			2 RECEPTOR SYSTEMS ARE INVOLVED IN THE PLASMA-CLEARANCE OF TISSUE FACTOR PATHWAY INHIBITOR IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION INHIBITOR; 39-KDA PROTEIN; HEPARIN; DOMAINS; BINDING; IDENTIFICATION; RABBITS; LIGANDS	Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of the blood coagulation factor VIIa-tissue factor complex, as well as a direct inhibitor of factor Xa. Intravenously administered TFPI is rapidly cleared from circulation predominantly via liver. We previously reported that the low density lipoprotein receptor related protein (LRP), a multifunctional endocytic receptor, mediates the uptake and degradation of TFPI in hepatoma cells. This process is inhibited by a 39-kDa receptor-associated protein which binds to LRP and regulates its ligand binding activity. However, a distinct, low affinity binding site (perhaps heparin sulfate proteoglycans, HSPGs) on the endothelium and liver is thought to be responsible for the majority of TFPI cell surface binding. In the current study, we investigated the role of LRP and this second binding site in the clearance of I-125-TFPI in, vivo using competitors and inhibitors of the receptors. Mice overexpressing the 39-kDa protein via adenoviral-mediated gene transfer displayed diminished plasma clearance of I-125-TFPI. Blockade of cell surface HSPGs sites by incubation with the positively charged molecule, protamine, inhibited I-125-TFPI binding to the hepatoma cells in vitro. In addition, preadministration of protamine in vivo prolonged the plasma clearance of I-125-TFPI in a dose-dependent manner. However, a dramatic increase of the plasma half-life of I-125-TFPI and virtual elimination of I-125-TFPI clearance was observed in mice overexpressing the 39-kDa protein and administered protamine. Taken together, our results suggest that two receptor mechanisms are involved in the clearance of TFPI in vivo.	WASHINGTON UNIV,JEWISH HOSP,SCH MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63110; GD SEARLE & CO,DEPT CARDIOVASC DIS & RES,ST LOUIS,MO 63167; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; WASHINGTON UNIV,SCH MED,DEPT BIOL MOLEC,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Washington University (WUSTL); Washington University (WUSTL)	NARITA, M (corresponding author), WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,BOX 8116,1 CHILDRENS PL,ST LOUIS,MO 63110, USA.				NHLBI NIH HHS [HL 52040, HL 34462, HL 53280] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053280, R01HL052040, R01HL034462] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BREGENGAARD C, 1993, THROMB HAEMOSTASIS, V70, P454; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BROZE GJ, 1992, SEMIN HEMATOL, V29, P159; BU GJ, 1992, J BIOL CHEM, V267, P15595; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; DAY KC, 1990, BLOOD, V76, P1538; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; HARENBERG J, 1993, THROMB HAEMOSTASIS, V70, P942; HASKEL EJ, 1991, CIRCULATION, V84, P821, DOI 10.1161/01.CIR.84.2.821; HERZ J, 1991, J BIOL CHEM, V266, P21232; NARITA M, 1995, J CLIN INVEST, V96, P1164, DOI 10.1172/JCI118105; NOVOTNY WF, 1991, BLOOD, V78, P394; PALMIER MO, 1992, THROMB HAEMOSTASIS, V68, P33; SANDSET PM, 1988, THROMB RES, V50, P803, DOI 10.1016/0049-3848(88)90340-4; SMITH PL, 1992, J BIOL CHEM, V267, P19140; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WARSHAWSKY I, 1995, J CLIN INVEST, V95, P1773, DOI 10.1172/JCI117855; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WUN TC, 1988, J BIOL CHEM, V263, P6001; WUN TC, 1992, BLOOD, V79, P430	22	70	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24800	24804		10.1074/jbc.270.42.24800	http://dx.doi.org/10.1074/jbc.270.42.24800			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559599	hybrid			2022-12-27	WOS:A1995TB46500033
J	SASS, C; GIROUX, LM; LUSSIERCACAN, S; DAVIGNON, J; MINNICH, A				SASS, C; GIROUX, LM; LUSSIERCACAN, S; DAVIGNON, J; MINNICH, A			UNEXPECTED CONSEQUENCES OF DELETION OF THE FIRST 2 REPEATS OF THE LIGAND-BINDING DOMAIN FROM THE LOW-DENSITY-LIPOPROTEIN RECEPTOR - EVIDENCE FROM A HUMAN MUTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERCHOLESTEROLEMIA; LDL-RECEPTOR; ELECTROPHORETIC TRANSFER; GENE; CHOLESTEROL; PROTEINS; IDENTIFICATION; FIBROBLASTS; PLASMA; CELLS	Heterozygosity for a 5-kilobase (kb) deletion of the first two ligand-binding repeats (exons 2 and 3) of the low density lipoprotein (LDL) receptor (R) gene (LDL-R Delta 5kb) confers familial hypercholesterolemia (FH). The FH phenotype is unexpected based on previous site-directed mutagenesis showing that deletion of exons 2 and 3 resulted in little or no defect in LDL-R activity. In the present study, we took unique advantage of the ability to distinguish the LDL R Delta 5kb from the normal receptor on the basis of size, in order to resolve this apparent discrepancy. Fibroblasts from heterozygotes for the LDL-R Delta 5kb displayed 50% of normal capacity to bind LDL and beta-VLDL, apparently due to lower receptor number, Cellular mRNA for the Delta 5kb allele was at least as abundant as that for the normal allele. Immunoblotting and cell binding assays with anti-LDL-R antibody IgG-4A4 demonstrated normal synthesis and transport of the Delta 5kb receptor. Ligand blotting demonstrated that the Delta 5kb receptor displayed minimal or no ability to bind LDL or beta-VLDL. Thus, in contrast to transfected cell lines, in human fibroblasts, the first two cysteine-rich repeats of the LDL-R appear functionally necessary. These characteristics of the LDL-R Delta 5kb in human fibroblasts explain the in vivo phenotype of carriers.	UNIV MONTREAL,CLIN RES INST MONTREAL,DEPT MED,HYPERLIPIDEMIA & ATHEROSCLEROSIS RES GRP,MONTREAL,PQ H2W 1R7,CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal								ANDERSON RGW, 1977, NATURE, V270, P695, DOI 10.1038/270695a0; BILHEIMER DW, 1985, AM J MED GENET, V22, P593, DOI 10.1002/ajmg.1320220318; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; ESSER V, 1988, J BIOL CHEM, V263, P13282; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GUDNASON V, 1994, ARTERIOSCLER THROMB, V14, P1717, DOI 10.1161/01.ATV.14.11.1717; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HARLOW E, 1988, ANTIBODIES LAB MANUA, P245; HIMBER J, 1993, ELECTROPHORESIS, V14, P794, DOI 10.1002/elps.11501401124; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; ISHIDA BY, 1987, J LIPID RES, V28, P778; KAJINAMI K, 1988, ARTERIOSCLEROSIS, V8, P187, DOI 10.1161/01.ATV.8.2.187; KAJINAMI K, 1989, CIRICULATION, V80, P278; KIGAWA K, 1993, J BIOCHEM-TOKYO, V113, P372, DOI 10.1093/oxfordjournals.jbchem.a124053; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; LEITERSDORF E, 1988, NUCLEIC ACIDS RES, V16, P7215, DOI 10.1093/nar/16.14.7215; LEITERSDORF E, 1990, J CLIN INVEST, V85, P1014, DOI 10.1172/JCI114531; MA YH, 1989, CLIN GENET, V36, P219; MABUCHI H, 1990, ANN NY ACAD SCI, V598, P393, DOI 10.1111/j.1749-6632.1990.tb42310.x; MINNICH A, 1995, J LIPID RES, V36, P117; MOORJANI S, 1993, LANCET, V341, P1303, DOI 10.1016/0140-6736(93)90815-X; NORA JJ, 1985, AM J MED GENET, V22, P585, DOI 10.1002/ajmg.1320220317; REYMER PWA, 1995, NAT GENET, V10, P28, DOI 10.1038/ng0595-28; RHOGANI A, 1988, BIOCHEMISTRY-US, V27, P7428; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; SASS C, 1995, HUM GENET, V96, P21, DOI 10.1007/BF00214181; SCHNEIDER WJ, 1982, J BIOL CHEM, V257, P2664; SOUTAR AK, 1990, BRIT MED BULL, V46, P891, DOI 10.1093/oxfordjournals.bmb.a072445; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YOSHIMURA A, 1987, J BIOL CHEM, V262, P13299	37	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25166	25171		10.1074/jbc.270.42.25166	http://dx.doi.org/10.1074/jbc.270.42.25166			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559651	hybrid			2022-12-27	WOS:A1995TB46500085
J	SHAW, ARE; DOMANSKA, A; MAK, A; GILCHRIST, A; DOBLER, K; VISSER, L; POPPEMA, S; FLIEGEL, L; LETARTE, M; WILLETT, BJ				SHAW, ARE; DOMANSKA, A; MAK, A; GILCHRIST, A; DOBLER, K; VISSER, L; POPPEMA, S; FLIEGEL, L; LETARTE, M; WILLETT, BJ			ECTOPIC EXPRESSION OF HUMAN AND FELINE CD9 IN A HUMAN B-CELL LINE CONFERS BETA-1 INTEGRIN-DEPENDENT MOTILITY ON FIBRONECTIN AND LAMININ SUBSTRATES AND ENHANCED TYROSINE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; PLATELET ACTIVATION; MOLECULAR-CLONING; RECEPTOR; ANTIGEN; FAMILY; ASSOCIATION; PROTEINS; P24/CD9; COMPLEX	Few molecules have been shown to confer cell motility, Although the motility-arresting properties of anti-CD9 monoclonal antibody (mAb) suggest the transmembrane 4 superfamily (TM4SF) member CD9 can induce a motorgenic signal, gene transfection studies have failed to confirm this hypothesis. We report here that ectopic expression of human CD9 (CD9h) and feline CD9 (CD9f) in the CD9-negative, poorly motile, human B cell line Raji dramatically enhances migration across fibronectin- and laminin-coated polycarbonate filters. Migration of Raji/CD9h and Raji/CD9f on either substrate was inhibited by the anti-CDS mAb 50H.19 and by the anti-beta 1 integrin mAb AP-138. Migration of Raji/CD9h on laminin was potently inhibited by the anti-VLA-6 integrin mAb GoH3 and by the anti-VLA-4 integrin mAb 44H6, whereas migration of Raji/CD9h on fibronectin was inhibited only by mAb 44H6. Since CD9h-transfected Raji cells adhered to fibronectin as effectively as mock transfectants, expression of CD9 enhanced motility, but not adhesion. CD9-enhanced migration was inhibited by the protein tyrosine kinase inhibitor herbimycin A suggesting that tyrosine phosphorylation played a role in the generation of a motorgenic signal. Raji/CD9h transfectants adherent to fibronectin expressed 6-fold higher levels of phosphotyrosine than Raji. Raji/CD9f transfectants also phosphorylated proteins on tyrosine more effectively than Raji including a protein of 110 kDa which was phosphorylated on the motility-inducing substrates laminin and fibronectin, but not on bovine serum albumin. Our results support a role for CD9 in the amplification of a motorgenic signal in B cells involving beta 1 integrins and the activation of protein tyrosine kinases.	UNIV ALBERTA,DEPT ONCOL,EDMONTON,AB T6G 1Z2,CANADA; UNIV ALBERTA,DEPT PATHOL,EDMONTON,AB T6G 2E1,CANADA; UNIV ALBERTA,DEPT PEDIAT,EDMONTON,AB T6G 2E1,CANADA; HOSP SICK CHILDREN,DIV IMMUNOL & CANC RES,TORONTO,ON M5G 1X8,CANADA; UNIV GLASGOW,DEPT VET PATHOL,GLASGOW G12 8Q9,LANARK,SCOTLAND	University of Alberta; University of Alberta; University of Alberta; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Glasgow	SHAW, ARE (corresponding author), CROSS CANC INST,DEPT ONCOL,11560 UNIV AVE,EDMONTON,AB T6G 1Z2,CANADA.		Willett, Brian J/F-3396-2011; Poppema, Sibrand/D-1204-2012; Visser, Lydia/D-7675-2012		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBELDA SM, 1990, CANCER RES, V50, P6757; ARIHIRO K, 1993, ACTA PATHOL JAPON, V43, P662; BALLARD LL, 1991, CLIN EXP IMMUNOL, V84, P336; BAO L, 1993, DIFFERENTIATION, V52, P239, DOI 10.1111/j.1432-0436.1993.tb00636.x; BARDELLI A, 1992, ONCOGENE, V7, P1973; BERNARDI P, 1987, J CELL BIOL, V105, P489, DOI 10.1083/jcb.105.1.489; Bernstein Lori R., 1994, Current Opinion in Oncology, V6, P106, DOI 10.1097/00001622-199401000-00015; BOUCHEIX C, 1983, FEBS LETT, V161, P289, DOI 10.1016/0014-5793(83)81027-8; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; FREEDMAN AS, 1993, J IMMUNOL, V150, P1645; GORMAN DJ, 1985, NOUV REV FR HEMATOL, V27, P255; GRIFFITH L, 1991, BLOOD, V78, P1753; HAJIARYROU M, 1995, J NEUROSCI, V15, P574; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HEDBERG KM, 1993, CELL MOTIL CYTOSKEL, V24, P139, DOI 10.1002/cm.970240207; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; JENNINGS LK, 1990, J BIOL CHEM, V265, P3815; JENNINGS LK, 1993, ANN NY ACAD SCI, P175; KAPRIELIAN Z, 1995, J NEUROSCI, V15, P562; KEMSHEAD JT, 1982, HYBRIDOMA, V1, P109, DOI 10.1089/hyb.1.1982.1.109; KERSEY J, 1982, J EXP MED, V153, P726; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; LANZA F, 1991, J BIOL CHEM, V266, P10638; MACLEAN GD, 1982, JNCI-J NATL CANCER I, V69, P357; MAKRYNIKOLA V, 1994, LEUKEMIA, V8, P1734; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; MASELLISSMITH A, 1990, J IMMUNOL, V144, P1607; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; MOULD AP, 1994, J BIOL CHEM, V269, P27224; PATERSON DJ, 1987, J EXP MED, V165, P1, DOI 10.1084/jem.165.1.1; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; SCHWEIGHOFFER T, 1994, CELL ADHES COMMUN, V2, P403, DOI 10.3109/15419069409004451; SLUPSKY JR, 1989, J BIOL CHEM, V264, P12289; TEDDER TE, 1994, IMMUNOL TODAY, V15, P437, DOI 10.1016/0167-5699(94)90274-7; WILLETT BJ, 1995, MOL IMMUNOL, V32, P417, DOI 10.1016/0161-5890(95)00008-3; WORTHINGTON RE, 1990, BRIT J HAEMATOL, V74, P216, DOI 10.1111/j.1365-2141.1990.tb02568.x; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4	42	114	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24092	24099		10.1074/jbc.270.41.24092	http://dx.doi.org/10.1074/jbc.270.41.24092			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592610	hybrid			2022-12-27	WOS:A1995TA21700038
J	XU, YP; WARE, A				XU, YP; WARE, A			SELECTIVE-INHIBITION OF THROMBIN RECEPTOR-MEDIATED CA2+ ENTRY BY PROTEIN-KINASE-C-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-PLATELETS; CELLS; HYDROLYSIS; ACTIVATION; CHANNELS	Thrombin initiates many physiological processes in platelets and other megakaryocyte-lineage cells by interacting with surface receptors and generating rises in cytoplasmic Ca2+; these rises result from both Ca2+ release from intracellular stores and receptor-mediated Ca2+ entry. Regulators that limit Ca2+ entry after its initiation by thrombin have not been identified, In this study, prevention of expression of a single protein kinase C isoenzyme (PKC beta) by antisense cDNA overexpressed in HEL cells, a human megakaryoblastic cell line that expresses thrombin receptors, promotes thrombin receptor-mediated Ca2+ entry without altering thrombin-induced intracellular release of Ca2+, The cytoplasmic Ca2+ rise initiated by endoperoxide analogs was not affected by inhibiting PKC beta. Overexpression of a cDNA encoding wild-type PKC beta mutated to prevent recognition by the antisense cDNA abolished the enhancement of Ca2+ influx following thrombin, Thus, PKC beta appears to be a specific negative regulator of thrombin receptor-mediated Ca2+ entry.	HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED,DIV CARDIOVASC, BOSTON, MA 02215 USA; HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED, HARVARD THORNDIKE LAB, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School					NHLBI NIH HHS [HL38820, HL47032, HL02271] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047032, K04HL002271, R29HL038820, R01HL038820] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELL RM, 1991, J BIOL CHEM, V266, P4661; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHANG JD, 1993, J BIOL CHEM, V268, P14208; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COUGHLIN SR, 1994, SEMIN HEMATOL, V31, P270; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; GRABAREK J, 1992, J BIOL CHEM, V267, P10011; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; JOHNSON PC, 1989, METHOD ENZYMOL, V169, P386; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MAHAUTSMITH MP, 1990, J BIOL CHEM, V265, P10479; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PAPAYANNOPOULOU T, 1983, BLOOD, V62, P832; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; Ware J.A., 1994, WILLIAMS HEMATOLOGY, P1161; ZAVOICO GB, 1985, P NATL ACAD SCI USA, V82, P3859, DOI 10.1073/pnas.82.11.3859; ZSCHAUER A, 1988, NATURE, V334, P703, DOI 10.1038/334703a0	21	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23887	23890		10.1074/jbc.270.41.23887	http://dx.doi.org/10.1074/jbc.270.41.23887			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592574	hybrid			2022-12-27	WOS:A1995TA21700002
J	GOODMAN, OB; KEEN, JH				GOODMAN, OB; KEEN, JH			THE ALPHA-CHAIN OF THE AP-2 ADAPTER IS A CLATHRIN BINDING SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSEMBLY PROTEIN AP-2; PLASMA-MEMBRANE; COATED VESICLES; INHIBITS ENDOCYTOSIS; COMPLEX AP-2; ACIDIFICATION; DOMAIN; IDENTIFICATION; POLYPEPTIDES; AUXILIN	We have utilized a rabbit reticulocyte lysate coupled transcription-translation system to express the large subunits of the clathrin associated protein-2 (AP-2) complex so that their individual functions may be studied separately. Appropriate folding of each subunit into N-terminal core and C-terminal appendage domains was confirmed by limited proteolysis. Translated beta 2 subunit bound to both assembled clathrin cages and immobilized clathrin trimers, confirming and extending earlier studies with preparations obtained by chemical denaturation-renaturation. Translated alpha(a) exhibited rapid, reversible and specific binding to clathrin cages. As with native AP-2, proteolysis of alpha(a) bound to clathrin cages released the appendages, while cores were retained. Further digestion revealed a approximate to 29 kDa alpha(a) clathrin-binding fragment that remained tightly cage-associated. Translated alpha(a) also bound to immobilized clathrin trimers, although with greater sensitivity to increasing pH than the translated beta 2 subunit. Clathrin binding by both the alpha and beta subunits is consistent with a bivalent cross-linking model for lattice assembly (Keen, J. H. (1987) Cell Biol, 105, 1989). It also raises the possibility that the alpha clathrin interaction may have other consequences, such as modulation of lattice stability or shape, or other alpha functions.	THOMAS JEFFERSON UNIV,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University				Goodman, Oscar/0000-0002-0882-3621	NCI NIH HHS [CA09662] Funding Source: Medline; NIGMS NIH HHS [GM-28526] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028526] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; AHLE S, 1989, J BIOL CHEM, V264, P20089; BECK KA, 1991, J BIOL CHEM, V266, P4442; BECK KA, 1991, J BIOL CHEM, V266, P4437; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; COSSON P, 1989, J CELL BIOL, V108, P377, DOI 10.1083/jcb.108.2.377; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1989, BIOCHEM BIOPH RES CO, V158, P17, DOI 10.1016/S0006-291X(89)80170-6; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KEEN JH, 1991, J BIOL CHEM, V266, P7950; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; LINDNER R, 1991, BIOCHEMISTRY-US, V30, P9097, DOI 10.1021/bi00101a027; LIU Q, 1994, J BIOL CHEM, V269, P31592; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; MYERS M, 1993, J BIOL CHEM, V268, P9184; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; PRASAD K, 1993, MOL BIOL CELL, V4, P214; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZAREMBA S, 1985, J CELL BIOCHEM, V28, P47, DOI 10.1002/jcb.240280108	32	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23768	23773		10.1074/jbc.270.40.23768	http://dx.doi.org/10.1074/jbc.270.40.23768			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559550	hybrid			2022-12-27	WOS:A1995RY90900079
J	GROETTRUP, M; RUPPERT, T; KUEHN, L; SEEGER, M; STANDERA, S; KOSZINOWSKI, U; KLOETZEL, PM				GROETTRUP, M; RUPPERT, T; KUEHN, L; SEEGER, M; STANDERA, S; KOSZINOWSKI, U; KLOETZEL, PM			THE INTERFERON-GAMMA-INDUCIBLE 11S-REGULATOR (PA28) AND THE LMP2/LMP7 SUBUNITS GOVERN THE PEPTIDE PRODUCTION BY THE 20S-PROTEASOME IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR-HISTOCOMPATIBILITY-COMPLEX; LINKED LMP GENE; CLASS-II REGION; MULTICATALYTIC PROTEINASE; ANTIGEN PRESENTATION; HUMAN MHC; PROTEOLYSIS; EXPRESSION; SEQUENCE; CDNA	Antigenic peptides presented on major histocompatibility complex (MHC) class I molecules to cytotoxic T cells are generated in the cytosol by the 20 S proteasome. Upon stimulation of antigen presenting cells with interferon-gamma, two constitutive subunits of the 20 S proteasome are replaced by the MHC-encoded subunits low molecular mass polypeptide (LMP) 2 and LMP 7. In addition the expression of the two subunits of the 11 S regulator of the 20 S proteasome (PA28) are increased. As the function of LMP2 and LMP7 in antigen presentation is still controversial, we tested whether these subunits might operate by modifying proteasome activation through the 11 S regulator. We strongly overexpressed the two LMP subunits separately or together by transfection in murine fibroblasts. Isolated 20 S proteasomes from LMP transfectants were applied in digests of a 25-mer peptide in the presence or absence of a purified preparation of 11 S regulator from rabbit erythrocytes. Analysis of the cleavage products by high performance liquid chromatography and electrospray mass spectroscopy revealed marked differences in the peptide product profile in dependence on the LMP2 and LMP7 content. While the 11 S regulator did not preferentially activate LMP2 or 7 containing proteasomes, the binding of the 11 S regulator to any of the proteasome preparations markedly changed both the quality and quantity of peptides produced. These results suggest that the 11 S regulator increases the spectrum of peptides which can be generated in antigen presenting cells.	HUMBOLDT UNIV BERLIN,FAC MED CHARITE,INST BIOCHEM,D-10115 BERLIN,GERMANY; UNIV HEIDELBERG,DEPT VIROL,D-69120 HEIDELBERG,GERMANY; DIABET RES INST,D-40225 DUSSELDORF,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls University Heidelberg			Ruppert, Thomas/AAC-2467-2021	Ruppert, Thomas/0000-0001-9152-2266				AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; ANROLD D, 1993, NATURE, V360, P171; ARIZTI P, 1993, ENZYME PROTEIN, V47, P285, DOI 10.1159/000468686; BELICH MP, 1994, CURR BIOL, V4, P769, DOI 10.1016/S0960-9822(00)00174-3; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; CHEN WS, 1994, J EXP MED, V180, P1471, DOI 10.1084/jem.180.4.1471; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; COX JH, 1995, J IMMUNOL, V154, P511; DAHLMANN B, 1989, BIOCHIM BIOPHYS ACTA, V991, P253, DOI 10.1016/0304-4165(89)90113-X; DELVAL M, 1991, J VIROL, V65, P3641, DOI 10.1128/JVI.65.7.3641-3646.1991; DICK LR, 1994, J IMMUNOL, V152, P3884; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; ENGELHARD VH, 1994, CURR OPIN IMMUNOL, V6, P13, DOI 10.1016/0952-7915(94)90028-0; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FRENTZEL S, 1992, FEBS LETT, V302, P121, DOI 10.1016/0014-5793(92)80420-L; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; FRENTZEL S, 1993, EUR J BIOCHEM, V216, P119, DOI 10.1111/j.1432-1033.1993.tb18123.x; FRUH K, 1994, EMBO J, V13, P3236, DOI 10.1002/j.1460-2075.1994.tb06625.x; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; HENGEL H, 1994, J VIROL, V68, P289, DOI 10.1128/JVI.68.1.289-297.1994; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; HONORE B, 1993, EUR J BIOCHEM, V218, P421, DOI 10.1111/j.1432-1033.1993.tb18392.x; KEIL GM, 1987, J VIROL, V61, P1901, DOI 10.1128/JVI.61.6.1901-1908.1987; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KIRSTENSEN P, 1994, BIOCHEM BIOPH RES CO, V205, P1785; KOSZINOWSKI UH, 1986, J VIROL, V58, P59, DOI 10.1128/JVI.58.1.59-66.1986; KUCKELKORN U, 1995, IN PRESS EUR J IMMUN; KUEHN L, 1989, BIOCHIM BIOPHYS ACTA, V991, P263, DOI 10.1016/0304-4165(89)90114-1; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; MOMBURG F, 1993, NATURE, V360, P174; MOTT JD, 1994, J BIOL CHEM, V269, P31466; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; TANAKA K, 1992, NEW BIOL, V4, P173; USTRELL V, 1995, P NATL ACAD SCI USA, V92, P584, DOI 10.1073/pnas.92.2.584; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050; YUKAWA M, 1991, BIOCHEM BIOPH RES CO, V178, P256, DOI 10.1016/0006-291X(91)91807-O; ZWICKL P, 1994, STRUCT BIOL, V1, P765	55	204	207	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23808	23815		10.1074/jbc.270.40.23808	http://dx.doi.org/10.1074/jbc.270.40.23808			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559557	hybrid			2022-12-27	WOS:A1995RY90900086
J	CHANG, KG; HANAOKA, K; KUMADA, M; TAKUWA, Y				CHANG, KG; HANAOKA, K; KUMADA, M; TAKUWA, Y			MOLECULAR-CLONING AND FUNCTIONAL-ANALYSIS OF A NOVEL P-2 NUCLEOTIDE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SUBSTRATE-SPECIFICITY; ENDOTHELIAL-CELLS; ATP RECEPTORS; PROTEIN; EXPRESSION; P2-PURINOCEPTOR; PYRIMIDINOCEPTORS; PURINOCEPTORS; INVOLVEMENT	The cDNA encoding a novel P-2 receptor was isolated from rat aortic smooth muscle cell library and functionally characterized. The cloned P-2 receptor exhibits structural features characteristic of the G protein-coupled receptor family and shows 44 and 38% amino acid identity with previously cloned rat P-2U and chicken P-2Y receptors, respectively. The cloned P-2 receptor is functionally coupled to phospholipase C but not to adenylate cyclase in C6 rat glioma cells transfected with the cloned P-2 expression vector. The rank order of agonist potency as judged by intracellular Ca2+ mobilization responses is UTP > ADP = 2-methylthioATP > ADP beta S > ATP = ATP gamma S, which is not compatible with any of the previously characterized P-2 receptor subtypes. The nonselective P-2 antagonists, suramin and reactive blue-2, inhibit nucleotide-induced phospholipase C activation in cells expressing the cloned P-2 receptor. The cloned P-2 receptor mRNA is abundantly expressed in various rat tissues including lung, stomach, intestine, spleen, mesentery, heart, and, most prominently, aorta. The results indicate that the novel metabotropic P-2 receptor has pharmacological characteristics distinct from any of P-2 receptor subtypes thus far identified and suggest the existence of a novel regulatory system by extracellular nucleotides of potential significance.	UNIV TOKYO,FAC MED,DEPT CARDIOVASC BIOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT ANESTHESIOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT PHYSIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; University of Tokyo; University of Tokyo								BARNARD EA, 1994, TRENDS PHARMACOL SCI, V15, P67, DOI 10.1016/0165-6147(94)90280-1; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BOEYNAEMS JM, 1990, TRENDS PHARMACOL SCI, V11, P34, DOI 10.1016/0165-6147(90)90039-B; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; BURNSTOCK G, 1986, CIRC RES, V58, P319, DOI 10.1161/01.RES.58.3.319; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENS MJ, 1984, TRANSCRIPTION TRANSL, P211; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUBYAK GR, 1993, AM J PHYSIOL, pC577; ERLINGE D, 1993, AM J PHYSIOL, V265, pH1089, DOI 10.1152/ajpheart.1993.265.4.H1089; FEDAN JS, 1990, ANN NY ACAD SCI, V603, P182; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOURANI SMO, 1992, BRIT J PHARMACOL, V105, P453, DOI 10.1111/j.1476-5381.1992.tb14274.x; ISOBE K, 1993, ENDOCRINOLOGY, V132, P1757, DOI 10.1210/en.132.4.1757; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KITAJIMA S, 1994, EUR J PHARM-MOLEC PH, V266, P263, DOI 10.1016/0922-4106(94)90135-X; KOZAK M, 1983, NUCLEIC ACIDS RES, V12, P865; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MALAMSOULEY R, 1993, AM J PHYSIOL, V264, pC783, DOI 10.1152/ajpcell.1993.264.4.C783; MARTIN W, 1985, EUR J PHARMACOL, V108, P295, DOI 10.1016/0014-2999(85)90452-2; MOTTE S, 1993, CIRC RES, V72, P504, DOI 10.1161/01.RES.72.3.504; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; RALEVIC V, 1991, CIRC RES, V69, P1583, DOI 10.1161/01.RES.69.6.1583; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; RICE WR, 1995, AM J RESP CELL MOL, V12, P27, DOI 10.1165/ajrcmb.12.1.7811468; SAIAG B, 1990, BLOOD VESSELS, V27, P352; SAMBOOK J, 1989, MOL CLONING LABORATO; SEIFERT R, 1989, TRENDS PHARMACOL SCI, V10, P365, DOI 10.1016/0165-6147(89)90009-6; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; TAKUWA Y, 1990, J CLIN INVEST, V85, P653, DOI 10.1172/JCI114488; TAWADA Y, 1987, J BIOCHEM-TOKYO, V102, P1499, DOI 10.1093/oxfordjournals.jbchem.a122197; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VONKUGELGEN I, 1990, N-S ARCH PHARMACOL, V341, P538, DOI 10.1007/BF00171734; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; WILKINSON GF, 1994, J PHARMACOL EXP THER, V268, P881; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	45	224	231	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26152	26158		10.1074/jbc.270.44.26152	http://dx.doi.org/10.1074/jbc.270.44.26152			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592819	hybrid			2022-12-27	WOS:A1995TC97800026
J	NOBEL, CSI; KIMLAND, M; LIND, B; ORRENIUS, S; SLATER, AFG				NOBEL, CSI; KIMLAND, M; LIND, B; ORRENIUS, S; SLATER, AFG			DITHIOCARBAMATES INDUCE APOPTOSIS IN THYMOCYTES BY RAISING THE INTRACELLULAR LEVEL OF REDOX-ACTIVE COPPER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTACT-CELLS; SERUM COPPER; KAPPA-B; DIETHYLDITHIOCARBAMATE; GLUTATHIONE; TOXICITY; METABOLISM; DISULFIDES; PROTECTION; ACTIVATION	Dithiocarbamates are metal-chelating compounds that can exert either pro-oxidant or antioxidant effects in different situations, They have recently been found to potently inhibit apoptotic cell death, an activity attributed to their antioxidant action, However, when thymocytes were exposed to pyrrolidine dithiocarbamate, an oxidation of the glutathione pool occurred within 90 min, Longer incubation resulted in cell shrinkage, chromatin fragmentation, glutathione depletion, and eventual cell lysis, which is typical of apoptosis in these cells, These changes were inhibited by inclusion of non-permeable metal chelators in the incubation medium, suggesting that pyrrolidine dithiocarbamate exerts its toxic effect by transporting a redox-active metal into the cell. This was directly confirmed when sustained 8-fold elevations of intracellular copper were detected after addition of pyrrolidine dithiocarbamate. In agreement with this, supplementation of the incubation medium with submicromolar concentrations of copper significantly potentiated pyrrolidine dithiocarbamate toxicity, We conclude that pyrrolidine dithiocarbamate exerts a powerful pro oxidant effect on thymocytes due to its ability to transport external redox-active copper into cells, The resulting increase in glutathione disulfide may also explain the temporary anti-apoptotic activity of this compound described in other systems.	KAROLINSKA INST, INST ENVIRONM MED, DIV TOXICOL, S-17177 STOCKHOLM, SWEDEN; KAROLINSKA INST, DIV MET & HLTH, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet; Karolinska Institutet			Nobel, Stefan/F-9491-2010	Nobel, Stefan/0000-0003-1671-2291				ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; AW TY, 1990, ARCH BIOCHEM BIOPHYS, V283, P46, DOI 10.1016/0003-9861(90)90610-B; BARTOLI GM, 1983, FEBS LETT, V164, P371, DOI 10.1016/0014-5793(83)80319-6; BEAUCHAMP RO, 1983, CRC CR REV TOXICOL, V11, P169, DOI 10.3109/10408448309128255; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; BURKITT M, 1995, IN PRESS BIOCH J; DENEKE SM, 1980, BIOCHEM PHARMACOL, V29, P1367, DOI 10.1016/0006-2952(80)90432-3; DIERICKX PJ, 1984, PHARMACOL RES COMMUN, V16, P135, DOI 10.1016/S0031-6989(84)80088-0; DROGE W, 1994, FASEB J, V8, P1131; DYPBUKT JM, 1994, J BIOL CHEM, V269, P30553; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P976; GUPTA SK, 1994, J TROP PEDIATRICS, V40, P185, DOI 10.1093/tropej/40.3.185; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HART BW, 1993, BIOCHEM PHARMACOL, V46, P2285, DOI 10.1016/0006-2952(93)90619-8; HEIKKILA RE, 1976, J BIOL CHEM, V251, P2182; HOSNI M, 1992, BIOCHEM PHARMACOL, V43, P1319, DOI 10.1016/0006-2952(92)90509-H; KELLER R, 1995, CELL DEATH DIFFER, V2, P141; KELNER MJ, 1986, J BIOL CHEM, V261, P1636; KJELER MJ, 1989, FREE RADICAL BIO MED, V6, P355; KUMAR KS, 1986, INT J RADIAT ONCOL, V12, P1463; LANG JM, 1988, LANCET, V2, P702; LESKO S, 1984, FREE RADICALS MOL BI, V27, P391; LUTZ LM, 1973, BIOCHEM PHARMACOL, V22, P1729, DOI 10.1016/0006-2952(73)90386-9; MADAN A, 1993, BIOCHEM PHARMACOL, V46, P2291, DOI 10.1016/0006-2952(93)90620-C; MANSOUR H, 1986, J PHARMACOL EXP THER, V236, P476; MASSIE HR, 1993, GERONTOLOGY, V39, P136; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MOHINDRU A, 1983, NATURE, V303, P64, DOI 10.1038/303064a0; NEIMS AH, 1966, J BIOL CHEM, V241, P5941; PERRIN D, 1978, IUPAC STABILITY CONS, P330; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; SATO N, 1995, J IMMUNOL, V154, P3194; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; SUNDERMAN F. WILLIAM, 1964, J NEW DRUGS, V4, P154; Thorn G.D., 1962, DITHIOCARBAMATES REL; TOPPING RJ, 1988, MED HYPOTHESES, V27, P55, DOI 10.1016/0306-9877(88)90084-9; TROMBETTA LD, 1988, TOXICOL APPL PHARM, V93, P154, DOI 10.1016/0041-008X(88)90035-X; VALENTINE WM, 1995, CHEM RES TOXICOL, V8, P96, DOI 10.1021/tx00043a013; WOLFE JT, 1994, FEBS LETT, V352, P58, DOI 10.1016/0014-5793(94)00920-1; ZANOCCO AL, 1989, FREE RADICAL BIO MED, V7, P151, DOI 10.1016/0891-5849(89)90006-3; ZEMAITIS MA, 1979, TOXICOL APPL PHARM, V48, P343, DOI 10.1016/0041-008X(79)90041-3; ZHANG YY, 1993, J BIOL CHEM, V268, P2535; ZHIVOTOVSKY B, 1994, FEBS LETT, V351, P150, DOI 10.1016/0014-5793(94)00827-2; 1988, ENV HLTH CRITERIA	49	250	254	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26202	26208		10.1074/jbc.270.44.26202	http://dx.doi.org/10.1074/jbc.270.44.26202			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592825	hybrid			2022-12-27	WOS:A1995TC97800032
J	UELMEN, PJ; OKA, K; SULLIVAN, M; CHANG, CCY; CHANG, TY; CHAN, L				UELMEN, PJ; OKA, K; SULLIVAN, M; CHANG, CCY; CHANG, TY; CHAN, L			TISSUE-SPECIFIC EXPRESSION AND CHOLESTEROL REGULATION OF ACYLCOENZYME A-CHOLESTEROL ACYLTRANSFERASE (ACAT) IN MICE - MOLECULAR-CLONING OF MOUSE ACAT CDNA, CHROMOSOMAL LOCALIZATION, AND REGULATION OF ACAT IN-VIVO AND IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COENZYME-A; DETERMINING ATHEROSCLEROSIS SUSCEPTIBILITY; APO-B SECRETION; PREPUTIAL GLAND; DENSITY LIPOPROTEIN; ESTER SYNTHESIS; CELLS; COA; RAT; LIVER	Acyl coenzyme Archolesterol acyltransferase (ACAT) catalyzes the esterification of cholesterol with long chain fatty acids and is believed to play an important part in the development of atherosclerotic lesions. To facilitate the study of ACAT's role in this process, we have used the human ACAT K1 clone previously described (Chang, C. C. Y., Huh, H. Y., Cadigan, H. M, and Chang, T, Y. (1993) J. Biol. Chem. 268, 20747-20755) to isolate mouse ACAT cDNA from a liver cDNA library. The 3.7-kilobase cDNA clone isolated contains a 1620-base pair open reading frame which encodes a protein of 540 amino acids. The predicted mouse ACAT protein is 87% identical to the protein product of human ACAT HI and shares many of the same secondary structural features, including two transmembrane domains, a leucine heptad motif consistent with dimer or multimer formation, and five regions homologous to the ''signature sequences'' found in other enzymes that catalyze acyl adenylation followed by acyl thioester formation and acyl transfer. Using the cDNA as a hybridization probe, we mapped the gene encoding mouse ACAT to chromosome 1 in a region syntenic to human chromosome 1 where the ACAT gene is located. Northern blot analysis and RNase protection assays of mouse tissues revealed that ACAT mRNA is expressed most highly in the adrenal gland, ovary, and preputial gland and is least abundant in skeletal muscle, adipose tissue, heart, and brain. To study the dietary regulation of ACAT mRNA expression in mouse tissues, we fed C57BL/6J mice a high-fat, high-cholesterol (HF/HC) atherogenic diet for 3 weeks and measured ACAT mRNA levels in various tissues by RNase protection, The HF/HC diet had little effect on ACAT mRNA levels in the small intestine, aorta, adrenal, or peritoneal macrophages, whereas hepatic ACAT mRNA levels were doubled in mice fed the atherogenic diet, ACAT activity in liver microsomes was similarly increased in cholesterol-fed mice, suggesting that mouse ACAT is regulated at least in part at the level of mRNA abundance. Additionally, a significant positive correlation was observed between ACAT activity and microsomal free cholesterol levels in chow- and cholesterol-fed mice, supporting the concept of cholesterol availability as a regulator of ACAT. To further investigate the regulation of ACAT activity under controlled conditions, ACAT-deficient Chinese hamster ovary cells were stably transfected with the mouse ACAT cDNA clone driven by a cytomegalovirus promoter, Two transfected Chinese hamster ovary cell lines that expressed the mouse ACAT transgene regained the ability to esterify cholesterol. Cholesterol esterification activity in both of these cell lines was further increased by exposure of these cells to low density lipoprotein, Thus we have demonstrated that mouse ACAT expression in vivo and in vitro is regulated by at least two mechanisms: control of mRNA abundance and post-transcriptional regulation of the enzyme activity, probably by cholesterol availability.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; DARTMOUTH COLL SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA	Baylor College of Medicine; Baylor College of Medicine; Dartmouth College				Chang, Ta-Yuan/0000-0002-3249-0468	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016512, R37HL036709, R01HL016512, P50HL027341, P60HL027341, R01HL036709] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-27341, HL-16512, HL-36709] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALVES AM, 1986, J ENDOCRINOL, V109, P1, DOI 10.1677/joe.0.1090001; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; BEINS DM, 1982, BIOCHEM J, V202, P631, DOI 10.1042/bj2020631; BILLHEIMER JT, 1990, J BIOL CHEM, V265, P8632; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRECHER PI, 1974, CIRC RES, V35, P692, DOI 10.1161/01.RES.35.5.692; BRIND JL, 1984, J ENDOCRINOL, V100, P377, DOI 10.1677/joe.0.1000377; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BURRIER RE, 1995, J PHARMACOL EXP THER, V272, P156; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; CARR TP, 1990, ARTERIOSCLEROSIS, V10, pA823; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG CCY, 1994, SOMAT CELL MOLEC GEN, V20, P71, DOI 10.1007/BF02257489; CHANG TY, 1983, ENZYMES, V16, P523; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; ERICKSON SK, 1994, J LIPID RES, V35, P763; ERICKSON SK, 1980, J LIPID RES, V21, P930; FLINT APF, 1973, BIOCHEM J, V132, P313, DOI 10.1042/bj1320313; FREEMAN DA, 1982, J BIOL CHEM, V257, P4231; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1978, P NATL ACAD SCI USA, V75, P1877, DOI 10.1073/pnas.75.4.1877; HASHIMOTO S, 1977, ATHEROSCLEROSIS, V28, P447, DOI 10.1016/0021-9150(77)90071-5; HASHIMOTO S, 1974, P SOC EXP BIOL MED, V145, P89; HUFF MW, 1994, ARTERIOSCLER THROMB, V14, P1498, DOI 10.1161/01.ATV.14.9.1498; KRAUSE BR, 1993, J LIPID RES, V34, P279; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LICHTENSTEIN AH, 1980, J BIOL CHEM, V255, P9098; LUSIS AJ, 1983, J BIOL CHEM, V258, P5071; LUSIS AJ, 1993, TRENDS CARDIOVAS MED, V3, P135, DOI 10.1016/1050-1738(93)90014-W; PAIGEN B, 1987, BIOCHEM GENET, V25, P501, DOI 10.1007/BF00554352; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PAPE ME, 1995, J LIPID RES, V36, P823; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Seldin MF, 1988, GENOMICS, V2, P48, DOI 10.1016/0888-7543(88)90108-5; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; STEWARTPHILLIPS JL, 1991, ATHEROSCLEROSIS, V90, P211, DOI 10.1016/0021-9150(91)90117-L; SUCKLING KE, 1983, BIOCHIM BIOPHYS ACTA, V753, P422, DOI 10.1016/0005-2760(83)90066-8; SUCKLING KE, 1985, J LIPID RES, V26, P647; TAVANI DM, 1982, ENDOCRINOLOGY, V111, P794, DOI 10.1210/endo-111-3-794; WANG HX, 1994, CIRCULATION, V90, P351; WHEATLEY VR, 1979, J INVEST DERMATOL, V73, P291, DOI 10.1111/1523-1747.ep12531708; 1994, GCG SEQUENCE ANAL SO	46	114	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26192	26201		10.1074/jbc.270.44.26192	http://dx.doi.org/10.1074/jbc.270.44.26192			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592824	hybrid			2022-12-27	WOS:A1995TC97800031
J	FISHER, D; WANG, G; TOBACMAN, LS				FISHER, D; WANG, G; TOBACMAN, LS			NH2-TERMINAL TRUNCATION OF SKELETAL-MUSCLE TROPONIN-T DOES NOT ALTER THE CA2+ SENSITIVITY OF THIN FILAMENT ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; ALPHA-TROPOMYOSIN; LABELED TROPOMYOSIN; COOPERATIVE BINDING; ACTIN INTERACTIONS; CROSS-LINKING; RABBIT; CONTRACTION; FRAGMENTS; FLUORESCENCE	To investigate how Ca2+ binding to troponin C regulates muscle contraction, the Ca2+-sensitive properties of thin filament assembly were studied as the tropomyosin binding, NH2-terminal region of troponin T was progressively shortened. Troponin complexes were prepared that contained skeletal muscle troponin C, troponin I, and either intact troponin T (TnT) (residues 1-259) or fragment TnT-(70-259), TnT-(151-259), or TnT-(159-259). In the absence of Ca2+ their respective affinities for pyrene-labeled tropomyosin were 2.3 x 10(7) M(-1), 1.2 x 10(7) M(-1), 1.9 x 10(5) M(-1), and 1.9 x 10(5) M(-1). Ca2+ had only a small effect on these affinities: 1.1 x 10(7) M-1 for whole troponin, 2 x 10(5) M(-1) for troponin-(151-259), and 2.8 x 105 M-1 for troponin-(159-259). Forms of troponin that bound weakly to tropomyosin in the absence of actin increased the actin affinity of tropomyosin only 2-3-fold, even in the absence of Ca2+; weak. binding of troponin to tropomyosin correlated with weak effects on tropomyosin-actin binding. In contrast, whole troponin had an approximately 500-fold effect on tropomyosin binding to actin, regardless of whether Ca2+ was present. The small effect of Ca2+ on the energetics of thin filament assembly is not attributable to the amino-terminal region of troponin T. The results suggest that Ca2+ causes the interaction between actin and the globular region of troponin to switch between two energetically similar states.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV IOWA,DEPT ANAT,IOWA CITY,IA 52242	University of Iowa; University of Iowa	FISHER, D (corresponding author), UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.		Wang, Brant/GXM-3839-2022	Wang, Brant/0000-0002-1329-1586				CHALOVICH JM, 1992, PHARMACOL THERAPEUT, V55, P95, DOI 10.1016/0163-7258(92)90013-P; CHO YJ, 1990, J BIOL CHEM, V265, P538; CHONG PCS, 1982, J BIOL CHEM, V257, P9152; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; HASELGROVE JC, 1972, COLD SPRING HARB SYM, V37, P225; HEELEY DH, 1988, BIOCHEMISTRY-US, V27, P8227, DOI 10.1021/bi00421a036; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HILL LE, 1992, J BIOL CHEM, V267, P16106; HITCHCOCK SE, 1973, J MOL BIOL, V80, P825, DOI 10.1016/0022-2836(73)90212-X; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; INGRAHAM RH, 1985, BIOCHEMISTRY-US, V24, P5221, DOI 10.1021/bi00340a040; ISHII Y, 1991, J BIOL CHEM, V266, P6894; KRESS M, 1986, J MOL BIOL, V188, P325, DOI 10.1016/0022-2836(86)90158-0; LAMKIN M, 1983, BIOCHEMISTRY-US, V22, P3053, DOI 10.1021/bi00282a005; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; MARGOSSIAN SS, 1973, J MOL BIOL, V81, P409, DOI 10.1016/0022-2836(73)90150-2; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; OHTSUKI I, 1979, J BIOCHEM, V86, P491, DOI 10.1093/oxfordjournals.jbchem.a132549; PAN BS, 1991, J BIOL CHEM, V266, P12432; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; PATO MD, 1981, J BIOL CHEM, V256, P602; PEARLSTONE JR, 1977, CAN J BIOCHEM CELL B, V55, P1032, DOI 10.1139/o77-154; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TANOKURA M, 1984, J BIOCHEM, V95, P1417, DOI 10.1093/oxfordjournals.jbchem.a134749; TANOKURA M, 1983, J BIOCHEM, V93, P331, DOI 10.1093/oxfordjournals.jbchem.a134185; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; TAO T, 1986, BIOCHEMISTRY-US, V25, P7633, DOI 10.1021/bi00371a054; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; TSUCHIYA T, 1982, BIOPOLYMERS, V21, P979, DOI 10.1002/bip.360210510; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WHITE SP, 1988, THESIS U ILLINOIS UR; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	45	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25455	25460		10.1074/jbc.270.43.25455	http://dx.doi.org/10.1074/jbc.270.43.25455			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592713	hybrid			2022-12-27	WOS:A1995TB46600029
J	FURANO, AV; USDIN, K				FURANO, AV; USDIN, K			DNA FOSSILS AND PHYLOGENETIC ANALYSIS - USING L1 (LINE-1, LONG INTERSPERSED REPEATED) DNA TO DETERMINE THE EVOLUTIONARY HISTORY OF MAMMALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							REVERSE-TRANSCRIPTASE; MUS-DOMESTICUS; MAURICEVILLE PLASMID; CDNA SYNTHESIS; SEQUENCE; ELEMENTS; FAMILY; MOUSE; IDENTIFICATION; MICE				FURANO, AV (corresponding author), NIDDK,BIOCHEM PHARMACOL LAB,GENOM STRUCT & FUNCT SECT,BETHESDA,MD 20893, USA.							ADEY NB, 1994, P NATL ACAD SCI USA, V91, P1569, DOI 10.1073/pnas.91.4.1569; ADEY NB, 1991, J MOL BIOL, V221, P367, DOI 10.1016/0022-2836(91)80057-2; ADEY NB, 1994, MOL BIOL EVOL, V11, P778; BATZER MA, 1994, P NATL ACAD SCI USA, V91, P12288, DOI 10.1073/pnas.91.25.12288; BIRD AP, 1993, COLD SPRING HARB SYM, V58, P281, DOI 10.1101/SQB.1993.058.01.033; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BURTON FH, 1986, J MOL BIOL, V187, P291, DOI 10.1016/0022-2836(86)90235-4; CASAVANT NC, 1994, J MOL BIOL, V241, P390, DOI 10.1006/jmbi.1994.1515; CASAVANT NC, 1988, MOL CELL BIOL, V8, P4669, DOI 10.1128/MCB.8.11.4669; CASAVANT NC, 1994, GENETICS, V137, P565; CHEVRET P, 1993, P NATL ACAD SCI USA, V90, P3433, DOI 10.1073/pnas.90.8.3433; CHEVRET P, 1993, BIOCHEM SYST ECOL, V21, P123, DOI 10.1016/0305-1978(93)90017-L; DAMBROSIO E, 1987, NUCLEIC ACIDS RES, V15, P3155, DOI 10.1093/nar/15.7.3155; DOMBROSKI BA, 1993, P NATL ACAD SCI USA, V90, P6513, DOI 10.1073/pnas.90.14.6513; FANNING TG, 1983, NUCLEIC ACIDS RES, V11, P5073, DOI 10.1093/nar/11.15.5073; FURANO AV, 1994, J MOL EVOL, V38, P18; FURANO AV, 1988, NUCLEIC ACIDS RES, V16, P9215, DOI 10.1093/nar/16.19.9215; FURANO AV, 1986, NUCLEIC ACIDS RES, V14, P3717, DOI 10.1093/nar/14.9.3717; GOMBROSKI BA, 1991, SCIENCE, V254, P1805; GRAUR D, 1993, TRENDS ECOL EVOL, V8, P141, DOI 10.1016/0169-5347(93)90027-M; HANNI C, 1995, J ZOOL, V41, P131; HARDIES SC, 1986, MOL BIOL EVOL, V3, P109; HARDISON R, 1993, MOL BIOL EVOL, V10, P73; HARDISON RC, 1991, EVOLUTION AT THE MOLECULAR LEVEL, P272; HILLIS DM, 1994, SCIENCE, V264, P671, DOI 10.1126/science.8171318; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; HOLMQUIST R, 1988, MOL BIOL EVOL, V5, P201; JACOBS LL, 1989, PAPERS FOSSIL RODENT, P157; JUBIERMAURIN V, 1992, MOL BIOL EVOL, V9, P41; KUIPER MTR, 1988, CELL, V55, P693, DOI 10.1016/0092-8674(88)90228-0; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; LUAN DD, 1995, MOL CELL BIOL, V15, P3882; MARTIN SL, 1985, MOL BIOL EVOL, V2, P127; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MIKI Y, 1992, CANCER RES, V52, P643; MINAKAMI R, 1992, NUCLEIC ACIDS RES, V20, P3139, DOI 10.1093/nar/20.12.3139; Musser Guy G., 1993, P501; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; NUR I, 1988, NUCLEIC ACIDS RES, V16, P9233, DOI 10.1093/nar/16.19.9233; PADGETT RW, 1988, NUCLEIC ACIDS RES, V16, P739, DOI 10.1093/nar/16.2.739; PASCALE E, 1993, J MOL EVOL, V36, P9, DOI 10.1007/BF02407302; PASCALE E, 1990, P NATL ACAD SCI USA, V87, P9481, DOI 10.1073/pnas.87.23.9481; POCOCK TN, 1976, S AFR J SCI, V72, P58; RIKKE BA, 1991, GENOMICS, V11, P895, DOI 10.1016/0888-7543(91)90012-4; RIKKE BA, 1991, J MOL BIOL, V219, P635, DOI 10.1016/0022-2836(91)90660-X; RIKKE BA, 1995, GENETICS, V139, P901; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; SCHICHMAN SA, 1992, J MOL BIOL, V224, P559, DOI 10.1016/0022-2836(92)90544-T; SCHICHMAN SA, 1993, MOL BIOL EVOL, V10, P552; Schmid C, 1992, CURR OPIN GENET DEV, V2, P874, DOI 10.1016/S0959-437X(05)80110-8; SCOTT A F, 1987, Genomics, V1, P113, DOI 10.1016/0888-7543(87)90003-6; SEVERYNSE DM, 1992, MAMM GENOME, V2, P41, DOI 10.1007/BF00570439; SINGER MF, 1995, J BIOL CHEM, V270, P24623, DOI 10.1074/jbc.270.42.24623; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; STEWART CB, 1993, NATURE, V361, P603, DOI 10.1038/361603a0; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; TAGLE DA, 1992, GENOMICS, V13, P741, DOI 10.1016/0888-7543(92)90150-Q; USDIN K, 1989, J BIOL CHEM, V264, P20736; USDIN K, 1995, MOL BIOL EVOL, V12, P73, DOI 10.1093/oxfordjournals.molbev.a040192; USDIN K, 1988, P NATL ACAD SCI USA, V85, P4416, DOI 10.1073/pnas.85.12.4416; VANLERBERGHE F, 1993, MOL BIOL EVOL, V10, P719; VOLIVA CF, 1983, NUCLEIC ACIDS RES, V11, P8847, DOI 10.1093/nar/11.24.8847; WANG H, 1993, CELL, V75, P1071, DOI 10.1016/0092-8674(93)90317-J; WANG H, 1992, MOL CELL BIOL, V12, P5131, DOI 10.1128/MCB.12.11.5131; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	66	36	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25301	25304		10.1074/jbc.270.43.25301	http://dx.doi.org/10.1074/jbc.270.43.25301			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592685	hybrid			2022-12-27	WOS:A1995TB46600001
J	KELLER, P; ZECCA, L; BOUKAMEL, R; ZWICKER, E; GLOOR, S; SEMENZA, G				KELLER, P; ZECCA, L; BOUKAMEL, R; ZWICKER, E; GLOOR, S; SEMENZA, G			FURIN, PC1/3, AND/OR PC6A PROCESS RABBIT, BUT NOT HUMAN, PRO-LACTASE-PHLORHIZIN HYDROLASE TO THE 180-KDA INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; PHLORHIZIN HYDROLASE; SUCRASE-ISOMALTASE; FUNCTIONAL EXPRESSION; PROPROTEIN CONVERTASE; ENDOPROTEASE FAMILY; RAT; IDENTIFICATION; BIOSYNTHESIS; KEX2	Small intestinal lactase-phlorizin hydrolase (LPH) is synthesized as a large precursor (prepro-LPH) of 1926 amino acids. In the endoplasmic reticulum, prepro-LPR is split by signal protease. The resulting pro-LPH is cut to mature LPH directly (human) or via a 180-kDa intermediate (rabbit), most likely in the trans-Golgi network or in a later compartment. Antibodies directed against different regions of rabbit pro-LPH locate the cleavage site resulting in the 180-kDa intermediate between amino acid residues 79 and 286. This stretch contains the two sequences -Arg-Cys-Tyr-Arg(114)similar to and -Arg-Ala-Ser-Arg(191)similar to, which are potential cleavage sites for subtilisin-like proprotein convertases. These sites are not conserved in human pro-LPH, By coexpression in COS 7 cells of rabbit prepro-LPH and proprotein convertases (PC1/3, PC2, PC6A, PC6B, furin), we show that furin, PC1/3, and PC6A generate a processing intermediate that is immunologically indistinguishable from the one observed in vivo. Furin, PC1/3, and PC6A are all expressed in the small intestine as shown by a polymerase chain reaction-based approach and, more specifically, in enterocytes, as shown by in situ hybridization. These results suggest that furin, PC1/3, and/or PC6A are responsible for the in vivo processing of rabbit pro-LPH to the 180-kDa intermediate.	ETH ZURICH,ETH ZENTRUM,DEPT BIOCHEM,CH-8092 ZURICH,SWITZERLAND	ETH Zurich								BANZIGER R, 1990, HERSTELLUNG CHARAKTE; BEINFELD MC, 1989, J BIOL CHEM, V264, P4460; BOURDAIS J, 1991, J BIOL CHEM, V266, P23386; BRESHNAHAN PA, 1991, J CELL BIOL, V111, P2851; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; DANIELSEN EM, 1994, BIOCHEMISTRY-US, V33, P1599, DOI 10.1021/bi00172a041; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; DUDLEY MA, 1993, J BIOL CHEM, V268, P13609; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; HADDAD P, 1993, CYTOTOXIC CELLS RECO, P251; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; JIANG WP, 1992, J BIOL CHEM, V267, P9185; KELLER P, 1995, AM J PHYSIOL-GASTR L, V268, pG41, DOI 10.1152/ajpgi.1995.268.1.G41; KELLER P, 1992, FEBS LETT, V313, P265, DOI 10.1016/0014-5793(92)81206-2; KELLER P, 1995, FEBS LETT, V368, P563, DOI 10.1016/0014-5793(95)00679-4; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTTAZ D, 1992, FEBS LETT, V313, P270, DOI 10.1016/0014-5793(92)81207-3; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MONTGOMERY RK, 1989, JOINT M AM SOC BIOCH; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1991, J BIOL CHEM, V266, P12313; NAIM HY, 1994, J BIOL CHEM, V269, P26933; NAIM HY, 1992, BIOCHEM J, V285, P13, DOI 10.1042/bj2850013; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; OBERHOLZER T, 1993, FEBS LETT, V333, P127, DOI 10.1016/0014-5793(93)80389-C; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; RHOLAM M, 1995, EUR J BIOCHEM, V227, P707, DOI 10.1111/j.1432-1033.1995.tb20192.x; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROSSI M, 1993, FEBS LETT, V336, P299, DOI 10.1016/0014-5793(93)80824-E; ROSSI M, 1992, FEBS LETT, V313, P260, DOI 10.1016/0014-5793(92)81205-Z; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SKOVBJERG H, 1984, BIOCHIM BIOPHYS ACTA, V798, P247, DOI 10.1016/0304-4165(84)90312-X; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STERCHI EE, 1990, J CLIN INVEST, V86, P1329, DOI 10.1172/JCI114842; TSUJI A, 1994, BIOCHEM BIOPH RES CO, V200, P943, DOI 10.1006/bbrc.1994.1541; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; WACKER H, 1992, J BIOL CHEM, V267, P18744; WALKER JA, 1994, J VIROL, V68, P1213, DOI 10.1128/JVI.68.2.1213-1218.1994; YEH KY, 1991, GASTROENTEROLOGY, V101, P312, DOI 10.1016/0016-5085(91)90005-6; ZAMOLODCHIKOVA TS, 1995, EUR J BIOCHEM, V227, P866, DOI 10.1111/j.1432-1033.1995.tb20212.x; ZWICKER E, 1993, THESIS ETH ZURICH	60	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25722	25728		10.1074/jbc.270.43.25722	http://dx.doi.org/10.1074/jbc.270.43.25722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592752	hybrid			2022-12-27	WOS:A1995TB46600069
J	KURIBARA, H; TAGO, K; YOKOZEKI, T; SASAKI, T; TAKAI, Y; MORII, N; NARUMIYA, S; KATADA, T; KANAHO, Y				KURIBARA, H; TAGO, K; YOKOZEKI, T; SASAKI, T; TAKAI, Y; MORII, N; NARUMIYA, S; KATADA, T; KANAHO, Y			SYNERGISTIC ACTIVATION OF RAT-BRAIN PHOSPHOLIPASE-D BY ADP-RIBOSYLATION FACTOR AND RHOA P21, AND ITS INHIBITION BY CLOSTRIDIUM-BOTULINUM C3 EXOENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN; GTP; CELLS	An activator of rat brain phospholipase D (PLD) that is distinct from the already identified PLD activator, ADP-ribosylation factor (ARF), was partially purified from bovine brain cytosol by a series of chromatographic steps. The partially purified preparation contained a 22-kDa substrate for Clostridium botulinum C3 exoenzyme ADP-ribosyltransferase, which strongly reacted with anti-rhoA p21 antibody, but not with anti-rac1 p21 or anti-cdc42Hs p21 antibody. Treatment of the partially purified PLD-activating factor with both C3 exoenzyme and NAD significantly inhibited the PLD-stimulating activity. These results suggest that rhoA p21 is, at least in part, responsible for the PLD-stimulating activity in the preparation. Recombinant isoprenylated rhoA p21 expressed in and purified from Sf9 cells activated rat brain PLD in a concentration- and GTP gamma S (guanosine 5'-O-(3-thiotriphosphate))-dependent manner. In contrast, recombinant non-isoprenylated rhoA pal (fused to glutathione S-transferase) expressed in Escherichia coli failed to activate the PLD. This difference cannot be explained by a lower affinity of non-isoprenylated rhoA p21 for GTP gamma S, as the rates of [S-35]GTP gamma S binding were very similar for both recombinant preparations and the GTP gamma S-bound form of non-isoprenylated rhoA p21 did not induce PLD activation. Interestingly, recombinant isoprenylated rhoA p21 and ARF synergistically activated rat brain PLD; a similar pattern was seen with the partially purified PLD-activating factor. The synergistic activation was inhibited by C3 exoenzyme-catalyzed ADP-ribosylation of recombinant isoprenylated rhoA p21 in a NAD-dependent manner. Inhibition correlated with the extent of ADP-ribosylation. These findings suggest that rhoA pal regulates rat brain PLD in concert with ARF, and that isoprenylation of rhoA p21 is essential for PLD regulation in vitro.	TOKYO INST TECHNOL, DEPT LIFE SCI, YOKOHAMA, KANAGAWA 226, JAPAN; OSAKA UNIV, SCH MED, DEPT MOLEC BIOL & BIOCHEM, SUITA, OSAKA 565, JAPAN; KYOTO UNIV, FAC MED, DEPT PHARMACOL, SAKYO KU, KYOTO 606, JAPAN; UNIV TOKYO, FAC PHARMACEUT SCI, DEPT PHYSIOL SCI, TOKYO 113, JAPAN	Tokyo Institute of Technology; Osaka University; Kyoto University; University of Tokyo								BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; EXTON JH, 1990, J BIOL CHEM, V265, P1; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HORI Y, 1991, ONCOGENE, V6, P515; KANAHO Y, 1991, FEBS LETT, V279, P249, DOI 10.1016/0014-5793(91)80160-5; KANOH H, 1992, J NEUROCHEM, V59, P1786, DOI 10.1111/j.1471-4159.1992.tb11011.x; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; MAEHAMA T, 1990, FEBS LETT, V263, P376, DOI 10.1016/0014-5793(90)81418-N; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MORII N, 1993, J BIOL CHEM, V268, P27160; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; TSAI SC, 1988, J BIOL CHEM, V263, P1768; YANG SF, 1967, J BIOL CHEM, V242, P477	23	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25667	25671		10.1074/jbc.270.43.25667	http://dx.doi.org/10.1074/jbc.270.43.25667			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592744	hybrid			2022-12-27	WOS:A1995TB46600061
J	MCGUIRE, SL; BAJT, ML				MCGUIRE, SL; BAJT, ML			DISTINCT LIGAND-BINDING SITES IN THE I-DOMAIN OF INTEGRIN ALPHA(M)BETA(2) THAT DIFFERENTIALLY AFFECT A DIVALENT CATION-DEPENDENT CONFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT RECEPTOR TYPE-3; LEUKOCYTE ADHESION GLYCOPROTEIN; AMINO-ACID SEQUENCE; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODIES; TRANSENDOTHELIAL MIGRATION; VONWILLEBRAND-FACTOR; BETA-SUBUNIT; IIB-IIIA; MAC-1	The I domains of the leukocyte beta(2) integrins have been shown to be essential for Ligand recognition, Amino acid substitutions of Asp(140) and Ser(142), which reside in a conserved cluster of oxygenated residues, abrogate divalent cation ligand binding function of alpha(M) beta(2). Presently, we evaluated the role of two I domain regions in alpha(M) beta(2) ligand recognition: 1) the conserved cluster of oxygenated residues (Asp(134), Asp(140), Ser(142), and Ser(144)) and 2) a 7-amino acid region (Phe(246)-Tyr(252)), conserved in alpha(M), and alpha(X) but absent in alpha(L) of the beta(2) integrins. Recombinant alpha(M) beta(2) was expressed on COS-7 cells, and function was assessed by iC3b recognition. Alanine substitution at position Asp(140), Asp(140)/Ser(142), Ser(142), or Ser(144) produced a complete loss in the capacity of alpha(M) beta(2) to recognize iC3b and attenuated the binding of a divalent cation-dependent epitope recognized by monoclonal antibody 24. Moreover, alanine substitution at Asp(248) or Tyr(252) or deletion of Phe(246)-Tyr(252) abolished iCSb ligand recognition as web as the binding of a blocking antibody. In contrast, these mutations did not affect the binding of the cation-dependent epitope. These data implicate a second region within the I domain important for alpha(M) beta(2) ligand binding function and suggest that this region does not affect a divalent cation-dependent conformation of alpha(M) beta(2).	UPJOHN CO,CELL BIOL & INFLAMMAT RES,KALAMAZOO,MI 49001	Pfizer								ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; Anderson D.C., 1994, METABOLIC BASIS INHE, P3955; ANDERSON DC, 1990, BLOOD, V76, P2613; ANDERSON DC, 1986, J IMMUNOL, V137, P15; ARNAOUT MA, 1990, IMMUNOL REV, V114, P145, DOI 10.1111/j.1600-065X.1990.tb00564.x; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BAJT ML, 1992, J BIOL CHEM, V267, P22211; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V12, P3759; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; HUANG X, 1994, MOL BIOL CELL, V4, P282; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MILLER LJ, 1986, J IMMUNOL, V137, P2891; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; RANDI AM, 1994, J BIOL CHEM, V269, P12395; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Uciechowski P., 1989, LEUCOCYTE TYPING, P543; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; YONG K, 1990, BLOOD REV, V4, P211, DOI 10.1016/0268-960X(90)90001-9; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	44	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25866	25871		10.1074/jbc.270.43.25866	http://dx.doi.org/10.1074/jbc.270.43.25866			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592772	hybrid			2022-12-27	WOS:A1995TB46600089
J	MENAA, C; VRTOVSNIK, F; FRIEDLANDER, G; CORVOL, M; GARABEDIAN, M				MENAA, C; VRTOVSNIK, F; FRIEDLANDER, G; CORVOL, M; GARABEDIAN, M			INSULIN-LIKE GROWTH-FACTOR-I, A UNIQUE CALCIUM-DEPENDENT STIMULATOR OF 1,25-DIHYDROXYVITAMIN D-3 PRODUCTION - STUDIES IN CULTURED MOUSE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT-THYROID CELLS; SOMATOMEDIN-C; VITAMIN-D; PROXIMAL TUBULES; PI TRANSPORT; IGF-I; METABOLISM; 25-HYDROXYVITAMIN-D3; PHOSPHORYLATION	Previous in vivo and in vitro studies suggest that insulin-like growth factor (IGF-I) could be a regulator of the renal production of 1,25-(OH)(2)D-3. In the present work, the local effect of low nanomolar concentrations of IGF-I on the 25-OH-D-3-1 alpha-hydroxylase activity and the mechanism of its action have been investigated. To do so, an in vitro model of mouse proximal tubular cells in primary culture has been developed. These cells bear specific high affinity IGF-I binding sites (apparent K-d = 1.95 +/- 0.46 nM) and express the ability to convert [H-3]25-(OH)D-3 into [H-3]1,25-(OH)(2)D-3 (K-m = 139 +/- 15.7 nM). Human recombinant IGF-I (10-100 ng/ml) stimulated both sodium-dependent phosphate uptake and 1,25-(OH)(2)D-3 synthesis by these cells, in a time- and dose-dependent manner. IGF-I did not alter the apparent Michaelis constant but increased the maximum velocity of the 25-OH-D-3-1 alpha-hydroxylase activity. This effect required protein synthesis. It was not affected by calphostin or GF109203X, two protein kinase C inhibitors, and was not mimicked by phorbol 12-myristate 13-acetate. In contrast, it was blocked by verapamil, a calcium channel blocker. Calcium depletion of the medium blunted the IGF-I effect but not that of human 1-34 parathyroid hormone 5 x 10(-8) M. IGF-I thus appears to be the first example of a physiological calcium-dependent regulator of the renal metabolism of vitamin D.	UNIV PARIS 05,HOP ST VINCENT DE PAUL,CNRS,URA 583,F-75014 PARIS,FRANCE; HOP XAVIER BICHAT,INSERM,U251,F-75870 PARIS 18,FRANCE; HOP NECKER ENFANTS MALAD,INSERM,U30,F-75015 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite				Friedlander, Gerard/0000-0002-6854-4261; Vrtovsnik, Francois/0000-0003-1554-314X				BLANCHARD RK, 1991, VITAMIN D, P269; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNERGATI L, 1988, J CLIN INVEST, V82, P1144, DOI 10.1172/JCI113672; CAMPBELL PI, 1992, AM J PHYSIOL, V262, pE389, DOI 10.1152/ajpendo.1992.262.4.E389; CAVERZASIO J, 1990, ENDOCRINOLOGY, V127, P453, DOI 10.1210/endo-127-1-453; CAVERZASIO J, 1992, ENDOCRINOLOGY, V130, P373, DOI 10.1210/en.130.1.373; CAVERZASIO J, 1989, AM J PHYSIOL, V257, pF712, DOI 10.1152/ajprenal.1989.257.5.F712; CEJKA JC, 1994, PFLUG ARCH EUR J PHY, V427, P33, DOI 10.1007/BF00585939; CONDAMINE L, 1994, J CLIN INVEST, V94, P1673, DOI 10.1172/JCI117512; CONSTANTINO CX, 1991, ENDOCRINOLOGY, V128, P1702, DOI 10.1210/endo-128-4-1702; DAI ZH, 1992, J BIOL CHEM, V267, P19565; FLYVBJERG A, 1993, AM J PHYSIOL, V265, pF624, DOI 10.1152/ajprenal.1993.265.5.F624; FRASER DR, 1980, PHYSIOL REV, V60, P551, DOI 10.1152/physrev.1980.60.2.551; FRIEDLANDER G, 1989, J BIOL CHEM, V264, P3935; GHAZARIAN JG, 1985, BIOCHEM BIOPH RES CO, V132, P1095, DOI 10.1016/0006-291X(85)91919-9; GRAY RW, 1987, ENDOCRINOLOGY, V121, P504, DOI 10.1210/endo-121-2-504; GRAY RW, 1985, ENDOCRINOLOGY, V116, P189, DOI 10.1210/endo-116-1-189; HALLORAN BP, 1988, ENDOCRINOLOGY, V123, P1225, DOI 10.1210/endo-123-3-1225; HAMMERMAN MR, 1989, AM J PHYSIOL, V257, pF503, DOI 10.1152/ajprenal.1989.257.4.F503; HENRY HL, 1989, ENDOCRINOLOGY, V124, P2228, DOI 10.1210/endo-124-5-2228; JACOBS S, 1983, J BIOL CHEM, V258, P9581; KOJIMA I, 1993, J BIOL CHEM, V268, P10003; KOJIMA I, 1988, J BIOL CHEM, V263, P16561; KORKOR B, 1987, J BONE MINER RES, V6, P517; KUMAR R, 1986, KIDNEY INT, V30, P793, DOI 10.1038/ki.1986.258; MAGOFFIN DA, 1990, MOL ENDOCRINOL, V4, P489, DOI 10.1210/mend-4-3-489; MANDEL ML, 1990, BIOCHIM BIOPHYS ACTA, V1034, P239, DOI 10.1016/0304-4165(90)90044-W; MANDEL ML, 1990, BIOCHEM J, V266, P385, DOI 10.1042/bj2660385; MAUGER JP, 1984, BIOCHEM J, V221, P121, DOI 10.1042/bj2210121; MONTESSUIT C, 1994, AM J PHYSIOL, V267, pE24, DOI 10.1152/ajpendo.1994.267.1.E24; NASEERUDDIN SA, 1990, ENDOCRINOLOGY, V127, P1673, DOI 10.1210/endo-127-4-1673; NEMANI R, 1989, J BIOL CHEM, V264, P15361; NESBITT T, 1993, ENDOCRINOLOGY, V132, P133, DOI 10.1210/en.132.1.133; NESTLER JE, 1989, ENDOCRINOLOGY, V125, P2127, DOI 10.1210/endo-125-4-2127; OKABE T, 1985, BIOCHEM BIOPH RES CO, V127, P635, DOI 10.1016/S0006-291X(85)80208-4; PORTALE AA, 1989, J CLIN INVEST, V83, P1494, DOI 10.1172/JCI114043; RO HK, 1992, ENDOCRINOLOGY, V131, P1424, DOI 10.1210/en.131.3.1424; SHEPARD RM, 1979, BIOCHEM J, V182, P55, DOI 10.1042/bj1820055; SPENCER EM, 1981, ENDOCRINOLOGY, V108, P1064, DOI 10.1210/endo-108-3-1064; SPENCER EM, 1982, VITAMIN D MOL CELLUL, P507; TAKADA K, 1990, J CLIN INVEST, V86, P1548, DOI 10.1172/JCI114874; TANAKA Y, 1984, AM J PHYSIOL, V246, pE168, DOI 10.1152/ajpendo.1984.246.2.E168; THOMAS BR, 1993, J NUTR BIOCHEM, V4, P158, DOI 10.1016/0955-2863(93)90044-W; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRANQUE PA, 1992, ENDOCRINOLOGY, V131, P1948, DOI 10.1210/en.131.4.1948; TRECHSEL U, 1979, J CLIN INVEST, V64, P206, DOI 10.1172/JCI109441; TRIPPEL SB, 1983, ENDOCRINOLOGY, V112, P2128, DOI 10.1210/endo-112-6-2128; VELDHUIS JD, 1986, J BIOL CHEM, V261, P2499; VIETH R, 1979, J BIOL CHEM, V254, P2455; VRTOVSNIK F, 1994, J BIOL CHEM, V269, P8872; WEAVER VM, 1992, CELL SIGNAL, V4, P293, DOI 10.1016/0898-6568(92)90069-K	51	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25461	25467		10.1074/jbc.270.43.25461	http://dx.doi.org/10.1074/jbc.270.43.25461			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592714	hybrid			2022-12-27	WOS:A1995TB46600030
J	CHEN, JQ; NIKOLOVAKARAKASHIAN, M; MERRILL, AH; MORGAN, ET				CHEN, JQ; NIKOLOVAKARAKASHIAN, M; MERRILL, AH; MORGAN, ET			REGULATION OF CYTOCHROME-P450 2C11 (CYP2C11) GENE-EXPRESSION BY INTERLEUKIN-1, SPHINGOMYELIN HYDROLYSIS, AND CERAMIDES IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ACUTE PHASE RESPONSE; FACTOR-KAPPA-B; NEUTRAL SPHINGOMYELINASE; CELL-DIFFERENTIATION; PROTEIN-KINASE; HL-60 CELLS; SPHINGOSINE; DEXAMETHASONE; ACTIVATION	Interleukin-1 triggers the down-regulation of several hepatic cytochrome P450 gene products, but the cellular signaling pathways involved are not known. We have examined the role of sphingomyelin hydrolysis to ceramide in the suppression of CYP2C11, a major constitutive form of cytochrome P450, by interleukin-1. Treatment of rat hepatocytes cultured on matrigel with interleukin-1 beta caused a rapid turnover of sphingomye lin and an increase in cellular ceramide, with no change in cellular phosphatidylcholine. The ceramide was composed mainly of a D-erythro-sphingosine backbone, suggesting that it was derived from sphingolipid hydrolysis rather than from increased de novo synthesis. Treat ment of the cells with either N-acetyl-D-erythro-sphingosine (C-2-ceramide) or bacterial sphingomyelinase sup pressed the expression of CYP2C11 and induced the expression of the interleukin-1-responsive alpha(1)-acid glycoprotein mRNA. In contrast, the acute-phase gene beta fibrinogen, which is induced by interleukin-6 but not by interleukin-1, did not respond to C-2-ceramide. N-Acetyl-D-erythro-sphinganine mimicked the effect of C-2-ceramide on CYP2C11, but not on alpha(1)-acid glycoprotein expression. These results are consistent with a role for ceramide or a related sphingolipid in mediating the down-regulation of CYP2C11, the induction of alpha(1)-acid glycoprotein, and perhaps other cellular effects of interleukin-1 in hepatocytes.	EMORY UNIV,SCH MED,ROLLINS RES CTR,DEPT PHARMACOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,ROLLINS RES CTR,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University; Emory University				Morgan, Edward/0000-0003-4273-2261; Merrill, Alfred/0000-0002-6673-968X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046897, R01GM046368] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46897, GM46368] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRASIER AR, 1990, MOL ENDOCRINOL, V4, P1921, DOI 10.1210/mend-4-12-1921; CHEN JQ, 1995, MOL PHARMACOL, V47, P940; CHEN YL, 1992, BIOCHEM PHARMACOL, V44, P137, DOI 10.1016/0006-2952(92)90047-M; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; FERRARI L, 1993, BIOCHEM PHARMACOL, V45, P2269, DOI 10.1016/0006-2952(93)90198-6; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GORODISCHER R, 1976, Biochemical Pharmacology, V25, P351, DOI 10.1016/0006-2952(76)90226-4; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HOSTETLER KY, 1979, J LIPID RES, V20, P456; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRAEMER MJ, 1994, PEDIATRICS, V69, P476; KUNO K, 1994, J LEUKOCYTE BIOL, V56, P542, DOI 10.1002/jlb.56.5.542; KUROKOHCHI K, 1992, BIOCHEM PHARMACOL, V44, P1669; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LIDDLE C, 1992, ARCH BIOCHEM BIOPHYS, V298, P159, DOI 10.1016/0003-9861(92)90107-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MAHU JL, 1984, ENZYME, V31, P234, DOI 10.1159/000469532; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AH, 1988, ANAL BIOCHEM, V171, P337; MORGAN ET, 1989, MOL PHARMACOL, V36, P699; MORGAN ET, 1994, BBA-GENE STRUCT EXPR, V1219, P475, DOI 10.1016/0167-4781(94)90074-4; MORGAN ET, 1993, BIOCHEM PHARMACOL, V45, P415, DOI 10.1016/0006-2952(93)90078-B; NIKOLOVAKARAKAS.M, 1994, FASEB J, V8, P908; NIMKAR S, 1988, TETRAHEDRON LETT, V29, P3037, DOI 10.1016/0040-4039(88)85079-2; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; PORTER T, 1991, J BIOL CHEM, V269, P13469; RAMACHANDRAN CK, 1990, BIOCHEM BIOPH RES CO, V167, P607, DOI 10.1016/0006-291X(90)92068-B; RAO BG, 1976, J LIPID RES, V17, P506; RENTON KW, 1986, CLIN BIOCHEM, V19, P72, DOI 10.1016/S0009-9120(86)80051-0; RICCA GA, 1981, J BIOL CHEM, V256, P1199; SANTANA P, 1995, ENDOCRINOLOGY, V136, P2345, DOI 10.1210/en.136.5.2345; SCHUETZ EG, 1988, J CELL PHYSIOL, V134, P309, DOI 10.1002/jcp.1041340302; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; WRIGHT K, 1991, MOL PHARMACOL, V39, P468; WRIGHT K, 1990, FEBS LETT, V271, P59, DOI 10.1016/0014-5793(90)80371-O; YANG ZH, 1993, J BIOL CHEM, V268, P20520	54	83	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25233	25238		10.1074/jbc.270.42.25233	http://dx.doi.org/10.1074/jbc.270.42.25233			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559661	hybrid			2022-12-27	WOS:A1995TB46500095
J	MCKENNEY, DW; ONODERA, H; GORMAN, L; MIMURA, T; ROTHSTEIN, DM				MCKENNEY, DW; ONODERA, H; GORMAN, L; MIMURA, T; ROTHSTEIN, DM			DISTINCT ISOFORMS OF THE CD45 PROTEIN-TYROSINE-PHOSPHATASE DIFFERENTIALLY REGULATE INTERLEUKIN-2 SECRETION AND ACTIVATION SIGNAL PATHWAYS INVOLVING VAV IN T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE COMMON ANTIGENS; PHOSPHOTYROSINE PHOSPHATASE; PROTOONCOGENE PRODUCT; EXPRESSION; KINASE; PHOSPHORYLATION; RECEPTOR; SUBSETS; DOMAIN; TRANSMEMBRANE	The CD45 family of transmembrane protein-tyrosine phosphatases plays a crucial role in the regulation of lymphocyte activation by coupling activation signals from antigen receptors to the signal transduction apparatus. Multiple CD45 isoforms, generated through regulated alternative mRNA splicing, differ only in the length and glycosylation of their extracellular domains. Differential distribution of these isoforms defines subsets of T cells having distinct functions and activation requirements, While the requirement for the intracellular protein-tyrosine phosphatase domains has been documented, the physiological role of the extracellular domains remains elusive. Here we report the generation of CD45-antisense transfected Jurkat T cell clones that lack CD45 or have been reconstituted to uniquely express either the smallest, CD45(0), or the largest, CD45(ABC), isoform. These cells exhibited marked isoform-dependent differences in IL-2 production and tyrosine phosphorylation of cellular proteins, including Vav after anti-CD3 stimulation. These results demonstrate that the distinct CD45 extracellular domains differentially regulate T cell receptor-mediated signaling pathways. Furthermore, these findings suggest that alterations in CD45 isoform expression by individual T cells during thymic ontogeny and after antigen exposure in the periphery directly affects the signaling pathways utilized.	YALE UNIV, SCH MED, DEPT INTERNAL MED, NEPHROL SECT, NEW HAVEN, CT 06529 USA; UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, TOKYO 113, JAPAN	Yale University; University of Tokyo			Mimura, Toshihide/AAV-2844-2020		NIDDK NIH HHS [DK02011] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002011] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKBAR AN, 1988, J IMMUNOL, V140, P2171; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; DESAI DM, 1994, EMBO J, V13, P4002, DOI 10.1002/j.1460-2075.1994.tb06716.x; DIANZANI U, 1990, EUR J IMMUNOL, V20, P2249, DOI 10.1002/eji.1830201014; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HALL LR, 1988, J IMMUNOL, V141, P2781; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MORIMOTO C, 1985, J IMMUNOL, V134, P1508; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NOVAK TJ, 1994, IMMUNITY, V1, P109, DOI 10.1016/1074-7613(94)90104-X; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; ROTHSTEIN DM, 1993, INT IMMUNOL, V5, P409, DOI 10.1093/intimm/5.4.409; ROTHSTEIN DM, 1990, CELL IMMUNOL, V129, P449, DOI 10.1016/0008-8749(90)90220-L; ROTHSTEIN DM, 1991, J IMMUNOL, V146, P1175; ROTHSTEIN DM, 1992, J BIOL CHEM, V267, P7139; RUDD CE, 1987, J EXP MED, V166, P1758, DOI 10.1084/jem.166.6.1758; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SMITH SH, 1986, IMMUNOLOGY, V58, P63; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1988, J IMMUNOL, V141, P3910; TANAKA T, 1993, P NATL ACAD SCI USA, V90, P4586, DOI 10.1073/pnas.90.10.4586; TEDDER TF, 1985, J IMMUNOL, V134, P2983; TEDDER TF, 1985, J IMMUNOL, V134, P2989; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; WALLACE VA, 1992, J EXP MED, V176, P1657, DOI 10.1084/jem.176.6.1657; WENG WK, 1994, J BIOL CHEM, V269, P32514; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	49	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24949	24954		10.1074/jbc.270.42.24949	http://dx.doi.org/10.1074/jbc.270.42.24949			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559621	hybrid			2022-12-27	WOS:A1995TB46500055
J	PAO, CI; ZHU, JL; ROBERTSON, DG; LIN, KWM; FARMER, PK; BEGOVIC, S; WU, GJ; PHILLIPS, LS				PAO, CI; ZHU, JL; ROBERTSON, DG; LIN, KWM; FARMER, PK; BEGOVIC, S; WU, GJ; PHILLIPS, LS			TRANSCRIPTIONAL REGULATION OF THE RAT INSULIN-LIKE GROWTH-FACTOR-I GENE INVOLVES METABOLISM-DEPENDENT BINDING OF NUCLEAR PROTEINS TO A DOWNSTREAM REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; IGF-I; MOLECULAR REGULATION; LEADER EXONS; FUNCTIONAL-ANALYSIS; ADULT-RAT; EXPRESSION; PROMOTER; SOMATOMEDIN; HEPATOCYTES	Insulin-like growth factor-I (IGF I) gene transcription is mediated largely via exon 1. In an initial search for regulatory regions, rat hepatocytes were transfected with IGF-I constructs. Since omission of downstream sequences led to reduced expression, we then used in vitro transcription to evaluate potential metabolic regulation via downstream regions. With templates including 219 base pairs of downstream sequence, transcriptional activity was reduced 70-90% with hepatic nuclear extracts from diabetic versus normal rats. However, activity was comparable with templates lacking downstream sequences. The downstream region contained six DNase I footprints, and templates with deletion of either region III or V no longer provided reduced transcriptional activity with nuclear extracts from diabetic rats. Nuclear protein binding to regions III and V appeared to be metabolically regulated, as shown by reduced DNase I protection and activity in gel mobility shift assays with nuclear extracts from diabetic rats. Southwestern blotting probes corresponding to regions III and V recognized a similar to 65-kDa nuclear factor present at reduced levels in diabetic rats, These findings indicate that a downstream region in exon 1 may be important for both IGF-I expression and metabolic regulation, Altered concentration or activity of a transcription factor(s) binding to this region may contribute to reduced IGF-I gene transcription associated with diabetes mellitus.	EMORY UNIV, SCH MED, DEPT MED, DIV ENDOCRINOL & METAB, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, ATLANTA, GA 30322 USA	Emory University; Emory University					NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005364] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037261] Funding Source: NIH RePORTER; NCRR NIH HHS [SO7-RR05364] Funding Source: Medline; NIDDK NIH HHS [DK-01872] Funding Source: Medline; NIGMS NIH HHS [GM-37261] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO ML, 1991, MOL ENDOCRINOL, V5, P1677, DOI 10.1210/mend-5-11-1677; ADAMO ML, 1991, BIOCHEM BIOPH RES CO, V176, P887, DOI 10.1016/S0006-291X(05)80269-4; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; AYER DE, 1990, MOL CELL BIOL, V10, P3635, DOI 10.1128/MCB.10.7.3635; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; GINOT F, 1989, EUR J BIOCHEM, V180, P289, DOI 10.1111/j.1432-1033.1989.tb14646.x; GOLDSTEIN S, 1991, J MOL ENDOCRINOL, V6, P33, DOI 10.1677/jme.0.0060033; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; HARP JB, 1991, DIABETES, V40, P95, DOI 10.2337/diabetes.40.1.95; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; JACQUEMIN P, 1993, BIOCHEM BIOPH RES CO, V196, P376, DOI 10.1006/bbrc.1993.2259; KIM SW, 1991, MOL ENDOCRINOL, V5, P1964, DOI 10.1210/mend-5-12-1964; LOWE WL, 1987, P NATL ACAD SCI USA, V84, P8946, DOI 10.1073/pnas.84.24.8946; LOWE WL, 1988, MOL ENDOCRINOL, V2, P528, DOI 10.1210/mend-2-6-528; LOWE WL, 1994, 76TH END SOC ANN M, P330; LUND PK, 1991, MODERN CONCEPTS INSU, P111; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1279, DOI 10.1210/endo-120-4-1279; NOLTEN LA, 1994, MOL ENDOCRINOL, V8, P1636, DOI 10.1210/me.8.12.1636; PAO CI, 1993, MOL ENDOCRINOL, V7, P1561, DOI 10.1210/me.7.12.1561; PAO CI, 1992, MOL ENDOCRINOL, V6, P969, DOI 10.1210/me.6.6.969; PAO CI, 1994, GROWTH REGUL S1, V4, P126; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PELL JM, 1993, ENDOCRINOLOGY, V132, P1797, DOI 10.1210/en.132.4.1797; PHILLIPS LS, 1991, DIABETES, V40, P1525, DOI 10.2337/diabetes.40.11.1525; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; ROUSSEAU S, 1993, MOL CELL BIOL, V13, P4904, DOI 10.1128/MCB.13.8.4904; SCHWANDER JC, 1983, ENDOCRINOLOGY, V113, P297, DOI 10.1210/endo-113-1-297; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIMATSU A, 1987, J BIOL CHEM, V262, P7894; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; SUSSENBACH JS, 1994, GROWTH REGUL S1, V4, P1136; THOMAS MJ, 1994, ENDOCRINOLOGY, V135, P1584, DOI 10.1210/en.135.4.1584; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WANG X, 1994, 76TH END SOC ANN M; ZHANG ZX, 1990, J BIOL CHEM, V265, P4785	47	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24917	24923		10.1074/jbc.270.42.24917	http://dx.doi.org/10.1074/jbc.270.42.24917			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559617	hybrid			2022-12-27	WOS:A1995TB46500051
J	RODRIGUEZ, CG; CUNDELL, DR; TUOMANEN, EI; KOLAKOWSKI, LF; GERARD, C; GERARD, NP				RODRIGUEZ, CG; CUNDELL, DR; TUOMANEN, EI; KOLAKOWSKI, LF; GERARD, C; GERARD, NP			THE ROLE OF N-GLYCOSYLATION FOR FUNCTIONAL EXPRESSION OF THE HUMAN PLATELET-ACTIVATING-FACTOR RECEPTOR - GLYCOSYLATION IS REQUIRED FOR EFFICIENT MEMBRANE TRAFFICKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; ADRENERGIC-RECEPTOR; RABBIT PLATELET; HORMONE-BINDING; CLONING; PROTEIN; SITES; CELLS; LEUKOCYTES; ANTIGEN	Streptococcus pneumoniae has been shown to utilize the platelet activating factor receptor for binding and invasion of host cells (Cundell, D. R., Gerard, N. P., Gerard, C., Idanpaan-Heikkila, I., and Tuomanen, E. I. (1995) Nature, in press). Because bacterial binding is in part carbohydrate dependent, and the human platelet activating factor (PAF) receptor bears a single N-linked glycosylation sequence in the second extracellular loop, we undertook studies to determine the role of this epitope in PAF receptor function. Binding of pneumococci to COS cells transfected with the human PAF receptor is greatly reduced for a receptor mutant that bears no N-linked glycosylation site. Immunohistochemical and binding analyses show decreased expression of the non-glycosylated molecule on the cell membrane relative to the wild type receptor; however, metabolic labeling and immunopurification indicate it is synthesized intracellularly at a level similar to the native molecule. A mutant receptor encoding a functional glycosylation site at the NH2 terminus is better expressed at the cell surface compared with the non-glycosylated form, indicating that trafficking to the cell surface is facilitated by glycosylation, but its location is relatively unimportant. The binding affinity for PAF is not significantly effected by the presence or location of the carbohydrate, and variations in cell surface expression have little influence on signal transduction, as the nonglycosylated PAF receptor is equally effective for activation of phospholipase C as the native molecule. These data are supportive of pneumococcal binding on protein moiety(ies) of the PAF receptor and indicate that N-glycosylation facilitates expression of the protein on the cell membrane.	HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,BOSTON,MA 02215; HARVARD UNIV,CHILDRENS HOSP,SCH MED,INA SUE PERLMUTTER LAB,BOSTON,MA 02215; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,BOSTON,MA 02215; HARVARD UNIV,WOMENS HOSP,SCH MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,THORNDIKE LAB,BOSTON,MA 02215; ROCKEFELLER UNIV,MOLEC INFECT DIS LAB,NEW YORK,NY 10021	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Rockefeller University			Tuomanen, Elaine I/N-3081-2018; Garcia, Carmen/L-9961-2017	Tuomanen, Elaine I/0000-0003-0349-8716; Garcia, Carmen/0000-0002-7205-4572; Cundell, Diana/0000-0003-3119-180X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036162, R37HL036162, R01HL041587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023459] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36162, HL41587] Funding Source: Medline; NIAID NIH HHS [AI23459] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALI H, 1994, J BIOL CHEM, V269, P24557; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BITO H, 1994, EUR J BIOCHEM, V221, P211, DOI 10.1111/j.1432-1033.1994.tb18731.x; BRATTON DL, 1992, J IMMUNOL, V148, P514; BREITFELD PP, 1984, J BIOL CHEM, V259, P10144; CABELLOS C, 1992, J CLIN INVEST, V90, P612, DOI 10.1172/JCI115900; CHRUSCINSKI AJ, 1992, BIOCHEM BIOPH RES CO, V186, P1280, DOI 10.1016/S0006-291X(05)81544-X; CUNDELL DR, 1994, MICROB PATHOGENESIS, V17, P361, DOI 10.1006/mpat.1994.1082; CUNDELL DR, 1995, IN PRESS NATURE; DATTATREYAMURTY B, 1992, ENDOCRINOLOGY, V131, P2437, DOI 10.1210/en.131.5.2437; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GEELEN S, 1993, INFECT IMMUN, V61, P1538, DOI 10.1128/IAI.61.4.1538-1543.1993; GERARD NP, 1994, J IMMUNOL, V152, P793; HABECKER BA, 1993, LIFE SCI, V52, P429, DOI 10.1016/0024-3205(93)90298-H; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HENSON PM, 1970, J EXP MED, V131, P287, DOI 10.1084/jem.131.2.287; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1983, BIOCHEMISTRY-US, V22, P4756, DOI 10.1021/bi00289a022; HWANG SB, 1986, J BIOL CHEM, V261, P532; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LAD PM, 1985, BIOCHEM BIOPH RES CO, V129, P632, DOI 10.1016/0006-291X(85)91938-2; LIU XB, 1993, J BIOL CHEM, V268, P1513; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V57, P209; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PERRET JJ, 1992, BIOCHEM J, V228, P911; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RANDS E, 1990, J BIOL CHEM, V265, P10759; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; SNYDER F, 1987, PLATELET ACTIVATING, P1; TOMASZ A, 1989, Pediatric Infectious Disease Journal, V8, P902, DOI 10.1097/00006454-198912000-00034; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	39	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25178	25184		10.1074/jbc.270.42.25178	http://dx.doi.org/10.1074/jbc.270.42.25178			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559653	hybrid			2022-12-27	WOS:A1995TB46500087
J	CALVERT, PD; KLENCHIN, VA; BOWNDS, MD				CALVERT, PD; KLENCHIN, VA; BOWNDS, MD			RHODOPSIN KINASE INHIBITION BY RECOVERIN - FUNCTION OF RECOVERIN MYRISTOYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER SEGMENTS; TERMINUS	Recoverin is a Ca2+-binding protein that may play a role in vertebrate photoreceptor light adaptation by imparting Ca2+ sensitivity to rhodopsin kinase. It is heterogeneously acylated (mostly myristoylated) at its aminoterminal glycine. Recent studies have shown that recoverin myristoylation is necessary for its Ca2+-dependent membrane association and cooperative Ca2+ binding. We have addressed several issues concerning the role of recoverin myristoylation with respect to inhibition of rhodopsin kinase. We find that 1) myristoylation of recoverin is not necessary for inhibition of rhodopsin kinase, 2) myristoylation of recoverin induces a cooperative Ca2+-dependence for rhodopsin kinase inhibition, and 3) each Ca2+-binding site on the nonmyristoylated recoverin partially inhibits rhodopsin kinase. The available data suggest that the functions of recoverin myristoylation in the living rod are to induce a sharp Ca2+ dependence of rhodopsin kinase inhibition and to bring this dependence into the rod's physiological Ca2+ concentration range.	UNIV WISCONSIN,RM BOCK LABS,MADISON,WI 53706; UNIV WISCONSIN,NEUROSCI TRAINING PROGRAM,MADISON,WI 53706; UNIV WISCONSIN,DEPT ZOOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NEI NIH HHS [EY-00463] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; CHEN CK, 1995, J BIOL CHEM, V270, P18061; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; GORODOVIKOVA EN, 1994, FEBS LETT, V353, P171, DOI 10.1016/0014-5793(94)01030-7; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1994, BIOCHEM BIOPH RES CO, V203, P121, DOI 10.1006/bbrc.1994.2157; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KORENBROT JI, 1989, VISION RES, V29, P939, DOI 10.1016/0042-6989(89)90108-9; LAGNADO L, 1992, J PHYSIOL-LONDON, V455, P111, DOI 10.1113/jphysiol.1992.sp019293; MCCARTHY ST, 1994, BIOPHYS J, V67, P2076, DOI 10.1016/S0006-3495(94)80691-5; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; POLANS AS, 1993, METH NEUROSCI, V15, P248; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	16	67	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24127	24129		10.1074/jbc.270.41.24127	http://dx.doi.org/10.1074/jbc.270.41.24127			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592614	hybrid			2022-12-27	WOS:A1995TA21700042
J	CHERVITZ, SA; FALKE, JJ				CHERVITZ, SA; FALKE, JJ			LOCK ON OFF DISULFIDES IDENTIFY THE TRANSMEMBRANE SIGNALING HELIX OF THE ASPARTATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; DIRECTED CROSS-LINKING; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; SENSORY RECEPTOR; 2-COMPONENT REGULATORS; TAR CHEMORECEPTOR; TRANSDUCTION; METHYLATION; SULFHYDRYL	The aspartate receptor of the bacterial chemotaxis pathway regulates the autophosphorylation rate of a cytoplasmic histidine kinase in response to ligand binding, The transmembrane signal, which is transmitted from the periplasmic aspartate-binding domain to the cytoplasmic regulatory domain, is carried by an intramolecular conformational change within the homodimeric receptor structure. The present work uses engineered cysteines and disulfide bonds to probe the nature of this conformational change, focusing in particular on the role of the second transmembrane alpha-helix. Altogether 26 modifications, consisting of 13 cysteine pairs and the corresponding disulfide bonds, have been introduced into the contacts between the second transmembrane helix and adjacent helices. The effects of these modifications on the transmembrane signal have been quantified by in vitro assays which measure (i) ligand binding, (ii) receptor-mediated regulation of kinase activity, and (iii) receptor methylation. All three parameters are observed to be highly sensitive to perturbations of the second transmembrane helix. In particular, 13 of the 26 modifications (6 cysteine pairs and 7 disulfides) significantly increase or decrease aspartate affinity, while 15 of the 26 modifications (5 cysteine pairs and 10 disulfides) destroy transmembrane kinase regulation, Importantly, 3 of the perturbing disulfides are found to lock the receptor in the ''on'' or ''off' signaling state by covalently constraining the second transmembrane helix, demonstrating that it is possible to use engineered disulfides to lock the signaling function of a receptor protein. A separate aspect of the study probes the thermal motions of the second transmembrane helix: 4 disulfides designed to trap large amplitude twisting motions are observed to disrupt function but form readily, suggesting that the helix is mobile. Together the results support a model in which the second transmembrane helix is a mobile signaling element responsible for communicating the transmembrane signal.	UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040731] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM040731, GM40731, R01 GM040731-12] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; BALAJI VN, 1989, BIOCHEM BIOPH RES CO, V160, P109, DOI 10.1016/0006-291X(89)91627-6; BOGONEZ E, 1985, P NATL ACAD SCI USA, V82, P4891, DOI 10.1073/pnas.82.15.4891; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; CAREAGA CL, 1992, BIOPHYS J, V62, P209, DOI 10.1016/S0006-3495(92)81806-4; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; CLARKE S, 1979, J BIOL CHEM, V254, P9695; DANIELSON MA, 1994, BIOCHEMISTRY-US, V33, P6100, DOI 10.1021/bi00186a009; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P3576, DOI 10.1021/bi00011a012; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; FOSTER DL, 1985, J BIOL CHEM, V260, P1706; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; Hazelbauer GL, 1992, CURR OPIN STRUC BIOL, V2, P505; JEFFERY CJ, 1994, BIOCHEMISTRY-US, V33, P3457, DOI 10.1021/bi00178a001; KLEENE SJ, 1979, P NATL ACAD SCI USA, V76, P6309, DOI 10.1073/pnas.76.12.6309; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; LEE GF, 1995, P NATL ACAD SCI USA, V92, P3391, DOI 10.1073/pnas.92.8.3391; LEE GF, 1994, J BIOL CHEM, V269, P29920; LEE L, 1990, J BACTERIOL, V172, P377, DOI 10.1128/JB.172.1.377-382.1990; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MOWBRAY SL, 1990, J BIOL CHEM, V265, P15638; NINFA EG, 1991, J BIOL CHEM, V266, P9764; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PAKULA AA, 1991, METHODS COMPANION ME, V3, P175; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SCOTT WG, 1993, J MOL BIOL, V232, P555, DOI 10.1006/jmbi.1993.1411; SCOTT WG, 1994, STRUCTURE, V2, P877, DOI 10.1016/S0969-2126(94)00088-3; SPUDICH JL, 1993, J BACTERIOL, V175, P7755, DOI 10.1128/JB.175.24.7755-7761.1993; SRINIVASAN N, 1990, INT J PEPT PROT RES, V36, P147; STOCK JB, 1995, IN PRESS ESCHERICHIA; STODDARD BL, 1992, BIOCHEMISTRY-US, V31, P11978, DOI 10.1021/bi00163a004; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; WEIS RM, 1988, P NATL ACAD SCI USA, V85, P83, DOI 10.1073/pnas.85.1.83; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988; YEH JI, 1993, J BIOL CHEM, V268, P9787; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019	45	118	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24043	24053		10.1074/jbc.270.41.24043	http://dx.doi.org/10.1074/jbc.270.41.24043			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592603	hybrid, Green Accepted			2022-12-27	WOS:A1995TA21700031
J	PAN, JY; SANFORD, JC; WESSLINGRESNICK, M				PAN, JY; SANFORD, JC; WESSLINGRESNICK, M			EFFECT OF GUANINE-NUCLEOTIDE-BINDING ON THE INTRINSIC TRYPTOPHAN FLUORESCENCE PROPERTIES OF RAB5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP DISSOCIATION INHIBITOR; TRANS GOLGI NETWORK; BOVINE BRAIN CYTOSOL; SUBSEQUENT BINDING; REGULATORY PROTEIN; LATE ENDOSOMES; SMG P25A; RAS P21; GTP; MEMBRANE	To gain further insight into structural elements involved in Rab5 function, differences in the intrinsic tryptophan fluorescence of the GDP- and guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S)-bound forms of the protein were examined. When excited at 290 nm, Rab5 displays emission maxima at 339.7 nm for the GDP-bound and 336.7 nm for the GTP gamma S-bound forms. The tryptophan fluorescence intensity is quenched by similar to 25% in the GTP gamma S-bound form relative to the GDP-bound conformation. Variant Rab5 molecules were created by site-directed mutagenesis to convert the protein's two tryptophans to phenylalanine residues. Fluorescence studies reveal that the observed changes upon GDP/GTP gamma S GTP gamma S exchange are due to a blue shift in the emission spectra for both Trp(74) (342.0 to 339.5 nm) and Trp(114) (335.3 to 333.7 nm) and fluorescence quenching of Trp(114). Consistent with the blue shift in the emission spectra, both tryptophans are more resistant to oxidation by N-bromosuccinimide in the GTP gamma S-bound state. These data indicate that both of Rab5's tryptophans are brought into a more sequestered, hydrophobic environment upon conformational changes promoted by guanine nucleotide exchange. Since Trp(74) lies adjacent to Rab5's cognate switch II domain, local conformational changes would be predicted based on the known structure of Ras. However, Trp(114) lies within a region of Rab5 potentially related to the switch III domain unique to heterotrimeric G(alpha t). Thus, changes in the fluorescence properties of Trp(114) upon guanine nucleotide exchange suggest that Rab proteins may have structure-function relationships similar to those described for heterotrimeric GTP-binding proteins.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health								ADRA CN, 1993, GENE CHROMOSOME CANC, V8, P253, DOI 10.1002/gcc.2870080408; ANTONNY B, 1991, BIOCHEMISTRY-US, V30, P8287, DOI 10.1021/bi00098a002; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; GARRETT MD, 1993, FEBS LETT, V331, P233, DOI 10.1016/0014-5793(93)80343-S; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HOFFENBERG S, 1995, J BIOL CHEM, V270, P5048, DOI 10.1074/jbc.270.10.5048; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MASUDA T, 1994, J BIOL CHEM, V269, P19713; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MUSHA T, 1992, J BIOL CHEM, V267, P9821; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHAPIRO AD, 1993, J BIOL CHEM, V268, P6925; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; SKELLY JV, 1990, FEBS LETT, V262, P127, DOI 10.1016/0014-5793(90)80170-N; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; STOUTEN PFW, 1993, FEBS LETT, V320, P1, DOI 10.1016/0014-5793(93)81644-F; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; UEDA T, 1990, J BIOL CHEM, V265, P9373; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P729; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	41	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24204	24208		10.1074/jbc.270.41.24204	http://dx.doi.org/10.1074/jbc.270.41.24204			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592625	hybrid			2022-12-27	WOS:A1995TA21700053
J	BANERJEE, A; DESHAIES, RJ; CHAU, V				BANERJEE, A; DESHAIES, RJ; CHAU, V			CHARACTERIZATION OF A DOMINANT-NEGATIVE MUTANT OF THE CELL-CYCLE UBIQUITIN-CONJUGATING ENZYME CDC34	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; SACCHAROMYCES-CEREVISIAE; AFFINITY PURIFICATION; PROTEIN LIGASE; YEAST; GENE; RAD6; SEQUENCES; VECTORS; ENCODES	The yeast Saccharomyces cerevisiae CDC34 gene en codes a ubiquitin-conjugating enzyme that is required for the cell cycle G(1)/S transition. We show here that a dominant negative Cdc34 protein is generated by simultaneously replacing both Cys(95) and Leu(99) with Ser residues. Cys(95) is an essential catalytic residue that forms a transient thiol ester with ubiquitin during catalysis, and Leu(99) is highly conserved among all known ubiquitin-conjugating enzymes. Mutants that encode either an alanine or a serine at one or both of these two positions are inactive. Of these eight mutants, overexpression of CDC34-C95S,L99S in wild type strains was found to block cell growth, Although cells overexpressing Cdc34-C95S,L99S do not exhibit the characteristic multibudded phenotype of cdc34 temperature-sensitive or null mutants, this blockade is relieved by simultaneous overexpression of wild type Cdc34. Purified Cdc34-C95S,L99S protein can be shown to inhibit in vitro ubiquitination of the Cdc34-specific substrate, Cln2 protein. We suggest that Cdc34 C95S,L99S selectively sequesters a subset of Cdc34 substrates or regulators. These findings have implications for the structure/function relationships of ubiquitin-conjugating enzymes, and suggest a general method for identifying components and substrates of specific ubiquitination pathways of eukaryotes.	WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,DETROIT,MI 48201; CALTECH,DEPT BIOL 15629,PASADENA,CA 91125	Wayne State University; California Institute of Technology			Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047604] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 47604] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HARLOW E, 1988, ANTIBODIES LABORATOR; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; PTAK C, 1994, J BIOL CHEM, V269, P26539; REISS Y, 1990, J BIOL CHEM, V265, P3685; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Sherman F., 1986, METHODS YEAST GENETI; SHIESTL RH, 1989, CURR GENET, V16, P339; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SUNG P, 1991, J MOL BIOL, V221, P745, DOI 10.1016/0022-2836(91)80169-U; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	42	35	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26209	26215		10.1074/jbc.270.44.26209	http://dx.doi.org/10.1074/jbc.270.44.26209			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592826	Green Accepted, hybrid			2022-12-27	WOS:A1995TC97800033
J	DEFELICE, M; DAMANTE, G; ZANNINI, M; FRANCISLANG, H; DILAURO, R				DEFELICE, M; DAMANTE, G; ZANNINI, M; FRANCISLANG, H; DILAURO, R			REDUNDANT DOMAINS CONTRIBUTE TO THE TRANSCRIPTIONAL ACTIVITY OF THE THYROID-TRANSCRIPTION-FACTOR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; ACTIVATION DOMAIN; MAMMALIAN-CELLS; THYROGLOBULIN PROMOTER; DNA; GENE; PHOSPHORYLATION; PROTEINS; GAL4; HOMEODOMAIN	The thyroid transcription factor 1 (TTF-1) is a homeodomain-containing protein implicated in the activation of thyroid-specific gene expression. Here we report that TTF-1 is capable of activating transcription from thyroglobulin and, to a lesser extent, thyroperoxidase gene promoters in nonthyroid cells. Full transcriptional activation of the thyroglobulin promoter by TTF-1 requires the presence of at least two TTF-1 binding sites. TTF-1 activates transcription via two functionally redundant transcriptional activation domains that as suggested by competition experiments, could use a common intermediary factor.	STAZ ZOOL ANTON DOHRN, FAC MED, IST PLURIDISCIPLINARE PATOL GEN, I-80121 NAPLES, ITALY; UNIV MESSINA, I-98100 MESSINA, ITALY; DIPARTIMENTO SCI & TECNOL BIOMED, I-33100 UDINE, ITALY	Stazione Zoologica Anton Dohrn di Napoli; University of Messina; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)			Di Lauro, Roberto/A-2746-2012; Zannini, Mariastella/I-1735-2012; Damante, Giuseppe/AAC-5200-2022	Di Lauro, Roberto/0000-0001-9493-3036; Damante, Giuseppe/0000-0003-2312-4009				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Ambesi-Impiombato F S, 1979, Int Rev Cytol Suppl, P163; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANNWEILER A, 1994, NUCLEIC ACIDS RES, V22, P4250, DOI 10.1093/nar/22.20.4250; ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DAMANTE G, 1994, BBA-GENE STRUCT EXPR, V1218, P255, DOI 10.1016/0167-4781(94)90176-7; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUSTI AM, 1987, NUCLEIC ACIDS RES, V15, P8149, DOI 10.1093/nar/15.20.8149; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PFISTERER P, 1994, EMBO J, V13, P1655; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J, 1989, MOL CLONING LABORATO; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SINCLAIR AJ, 1990, EUR J BIOCHEM, V193, P311, DOI 10.1111/j.1432-1033.1990.tb19339.x; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	52	103	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26649	26656		10.1074/jbc.270.44.26649	http://dx.doi.org/10.1074/jbc.270.44.26649			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592890	hybrid			2022-12-27	WOS:A1995TC97800097
J	MOULD, AP; AKIYAMA, SK; HUMPHRIES, MJ				MOULD, AP; AKIYAMA, SK; HUMPHRIES, MJ			REGULATION OF INTEGRIN ALPHA-5-BETA-1-FIBRONECTIN INTERACTIONS BY DIVALENT-CATIONS - EVIDENCE FOR DISTINCT CLASSES OF BINDING-SITES FOR MN2+, MG2+, AND CA2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA FIBRONECTIN; CELL-ADHESION; LIGAND-BINDING; VITRONECTIN RECEPTOR; LEUKOCYTE ADHESION; PLATELET INTEGRIN; ALPHA-SUBUNIT; BETA-SUBUNIT; DOMAIN; IDENTIFICATION	Integrin-ligand interactions are known to be dependent on divalent cations, although the precise role of cations in ligand binding is still unclear. Using the interaction between alpha 5 beta 1 and fibronectin as a model system, we have performed a comprehensive analysis of the effects of Mn2+, Mg2+, and Ca2+ on Ligand binding. Each cation had distinct effects on the ligand-binding capacity of alpha 5 beta 1:Mn2+ promoted high levels of Ligand binding, Mg2+ promoted low levels of binding, and Ca2+ failed to support binding Studies of the effects of different combinations of cations on Ligand binding indicated that the cation-binding sites within alpha 5 beta 1 are not all identical, or of broad specificity, but instead each site shows a distinct preference for one or more cations, Ca2+ strongly inhibited Mn2+-supported Ligand binding, but this inhibition was noncompetitive, suggesting that Ca2+ recognizes different cation-binding sites to Mn2+. In contrast, Ca2+ acted as a direct competitive inhibitor of Mg2+-supported Ligand binding, implying that Ca2+ can displace Mg2+ from the integrin. However, low concentrations of Ca2+ greatly increased the apparent affinity of Mg2+ for its binding site, suggesting the existence of a distinct high affinity Ca2+-binding site. Taken together, our results imply that the ligand-binding capacity of alpha 5 beta 1 can be regulated in a complex manner through separate classes of binding sites for Mn2+, Mg2+, and Ca2+.	NIDR,DEV BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	MOULD, AP (corresponding author), UNIV MANCHESTER,SCH BIOL SCI,WELLCOME TRUST CTR CELL MATRIX RES,2 205 STOPFORD BLDG,OXFORD RD,MANCHESTER M13 9PT,LANCS,ENGLAND.			Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALTIERI DC, 1991, J IMMUNOL, V147, P1891; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BANAI S, 1990, CIRC RES, V67, P645, DOI 10.1161/01.RES.67.3.645; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; DAVIS GE, 1993, J IMMUNOL, V151, P7138; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; GULINO D, 1992, J BIOL CHEM, V267, P1001; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1994, CURR OPIN GENET DEV, V4, P569, DOI 10.1016/0959-437X(94)90074-D; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACKSON AM, 1994, IMMUNOLOGY, V81, P120; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LUQUE A, 1994, FEBS LETT, V346, P278, DOI 10.1016/0014-5793(94)00490-0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOULD AP, 1994, J BIOL CHEM, V269, P27224; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RUOSLAHTI E, 1994, KIDNEY INT S; SANCHEZAPARICIO P, 1993, J IMMUNOL, V150, P3506; SANK A, 1989, SURGERY, V106, P1141; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1991, J BIOL CHEM, V266, P11429; SMITH JW, 1994, J BIOL CHEM, V269, P960; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29	52	250	258	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26270	26277		10.1074/jbc.270.44.26270	http://dx.doi.org/10.1074/jbc.270.44.26270			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592835	hybrid			2022-12-27	WOS:A1995TC97800042
J	TOTA, MR; XU, L; SIROTINA, A; STRADER, CD; GRAZIANO, MP				TOTA, MR; XU, L; SIROTINA, A; STRADER, CD; GRAZIANO, MP			INTERACTION OF [FLUORESCEIN-TRP(25)]GLUCAGON WITH THE HUMAN GLUCAGON RECEPTOR EXPRESSED IN DROSOPHILA SCHNEIDER-2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; CLONING	The human glucagon receptor was expressed at high density in Drosophila Schneider 2 (S2) cells. Following selection with G418 and induction with CuSO4, the cells expressed the receptor at a level of 250 pmol/mg of membrane protein. The glucagon receptor was functionally coupled to increases in cyclic AMP in S2 cells. Protein immunoblotting with anti-peptide antibodies revealed the expressed receptor to have an apparent molecular mass of 48 kDa, consistent with low levels of glycosylation in this insect cell system. Binding of [fluorescein-Trp(25)]glucagon to 52 cells expressing the glucagon receptor was monitored as an increase in fluorescence anisotropy along with an increase in fluorescence intensity. Anisotropy data suggest that the mobility of the fluorescein is restricted when the ligand is bound to the receptor, Kinetic analysis indicates that the binding of glucagon to its receptor proceeds via a bimolecular interaction, with a forward rate constant that is several orders of magnitude slower than diffusion-controlled. These data would be consistent with a conformational change upon the binding of agonist to the receptor. The combination of [fluorescein-Trp(25)]glucagon with the 52 cell expression system should be useful for analyzing glucagon receptor structure and function.	MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT IMMUNOL RES,RAHWAY,NJ 07065	Merck & Company	TOTA, MR (corresponding author), MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOLEC PHARMACOL & BIOCHEM,BOX 2000,RAHWAY,NJ 07065, USA.							BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; BRAUN W, 1983, J MOL BIOL, V169, P921, DOI 10.1016/S0022-2836(83)80143-0; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CARRAWAY KL, 1993, BIOCHEMISTRY-US, V32, P12039, DOI 10.1021/bi00096a014; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; GRAZIANO MP, 1993, BIOCHEM BIOPH RES CO, V196, P141, DOI 10.1006/bbrc.1993.2226; HEITHIER H, 1988, BIOCHIM BIOPHYS ACTA, V971, P298; HORWITZ EM, 1985, J BIOL CHEM, V16, P9307; IWANIJ V, 1985, P NATL ACAD SCI USA, V82, P325, DOI 10.1073/pnas.82.2.325; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P145; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P88; LOK S, 1994, GENE, V140, P203, DOI 10.1016/0378-1119(94)90545-2; MACNEIL DJ, 1994, BIOCHEM BIOPH RES CO, V198, P328, DOI 10.1006/bbrc.1994.1046; MORAN EC, 1977, BIOCHEM BIOPH RES CO, V77, P1300, DOI 10.1016/S0006-291X(77)80121-6; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; SASAKI K, 1975, NATURE, V257, P751, DOI 10.1038/257751a0; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SKLAR LA, 1990, BIOCHEMISTRY-US, V29, P313, DOI 10.1021/bi00454a002; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TOTA MR, 1994, BIOCHEMISTRY-US, V33, P13079, DOI 10.1021/bi00248a017; Vetterling W.T., 1988, NUMERICAL RECIPES C; WRIGHT DE, 1983, J BIOL CHEM, V255, P10884	27	30	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26466	26472		10.1074/jbc.270.44.26466	http://dx.doi.org/10.1074/jbc.270.44.26466			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592863	hybrid			2022-12-27	WOS:A1995TC97800070
J	MEISNER, H; CZECH, MP				MEISNER, H; CZECH, MP			COUPLING OF THE PROTOONCOGENE PRODUCT C-CBL TO THE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GUANINE-NUCLEOTIDE EXCHANGE; SH3 DOMAINS; TYROSINE KINASES; V-CBL; RAS; GRB2; TRANSFORMATION; ASSOCIATION; ACTIVATION; TRUNCATION	The proto oncogene product, Cbl, is a 120-kDa protein present in lymphocytes that contains numerous PXXP motifs in its COOH-terminal region and constitutively binds the SH3-containing adaptor protein Grb2. Crosslinking of CD3 and CD4 receptors in Jurkat T cells causes tyrosine phosphorylation of Cbl and its association with phosphatidylinositol 3'-kinase (Meisner, H., Conway, B., Hartley, D., and Czech, M. P. (1995) Mol Cell. Biol. 15, 3571-3578). Here we demonstrate that Cbl is also present in nonlymphoid cells, and that epidermal growth factor (EGF) elicits its rapid tyrosine phosphorylation in human embryonic 293 cells. Immunoprecipitates of Cbl from lysates of these cells contain Grb2 in the basal state, while EGF stimulation causes co-precipitation of tyrosine-phosphorylated EGF receptors. Similarly, EGF receptor immunoprecipitates from EGF-treated 293 cells contain Cbl and Grb2. Both Grb2 and EGF receptors are released from Chl in the presence of a proline-rich peptide that binds the NH2-terminal SH3 domain of Grb2, These results indicate that autophosphorylated EGF receptors associate with the SH2 domain of Grb2, which is complexed through its SH3 domain with proline-rich regions of Cbl. Such recruitment of Cbl to EGF receptors may reflect an important mechanism for its tyrosine phosphorylation and for assembling signaling components that mediate or modulate EGF actions.	UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	MEISNER, H (corresponding author), UNIV MASSACHUSETTS,SCH MED,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30DK32520] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DONOVAN J, 1994, J BIOL CHEM, V169, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GUSTAFSON T, 1995, MOL CELL BIOL, V15, P25000; HARLOW E, 1988, ANTIBODIES LABORATOR; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI NX, 1994, ONCOGENE, V9, P3457; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUSHINSKI J, 1994, ONCOGENE, V8, P2489; MYERS M, 1994, TRENDS BIOCHEM SCI, V198, P289; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V7, P93; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SHOELSON S, 1993, J BIOL CHEM, V268, P9478; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443	36	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25332	25335		10.1074/jbc.270.43.25332	http://dx.doi.org/10.1074/jbc.270.43.25332			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592693	hybrid			2022-12-27	WOS:A1995TB46600009
J	SOLDATI, T; RANCANO, C; GEISSLER, H; PFEFFER, SR				SOLDATI, T; RANCANO, C; GEISSLER, H; PFEFFER, SR			RAB7 AND RAB9 ARE RECRUITED ONTO LATE ENDOSOMES BY BIOCHEMICALLY DISTINGUISHABLE PROCESSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; YEAST; SEC4; LOCALIZATION; YPT1	Rab GTPases are localized to the surfaces of distinct membrane-bound organelles and function in transport vesicle docking and/or fusion. Prenylated Rab9, bound to GDP dissociation inhibitor-alpha, can be recruited selectively onto a membrane fraction enriched in late endosomes; this process is accompanied by nucleotide exchange. We used this system to address whether each Rab uses a distinct machinery to associate with its cognate organelle. Purified, prenylated Rab1B, Rab7, and Rab9 proteins were each reconstituted as stoichiometric complexes with purified GDP dissociation inhibitor-alpha and their recruitment onto endosome- or ER-enriched membrane fractions was quantified. The two late endosomal proteins, Rab9 and Rab7, were each recruited onto endosome membranes with approximate apparent K-m values of 9 and 22 nM, respectively. However, while control Rab9 . GDP dissociation inhibitor-alpha complexes inhibited the initial rate of myc-tagged Rab9 recruitment with an apparent K-i of approximate to 9 nM, Rab7 complexes inhibited this process much less effectively (apparent K-i approximate to 112 nM). Similarly, complexes of the endoplasmic reticulum-localized Rab1B protein were even less potent than Rab7 complexes (apparent K-i approximate to 405 nM). Rab9 complexes inhibited Rab7 recruitment with the same low efficacy as Rab7 complexes inhibited Rab9 recruitment. These experiments distinguish, biochemically, the recruitment of different Rab proteins onto a single class of organelle. Since Rab7 and Rab9 are both localized at least in large part, to late endosomes, this suggests that a single organelle may bear multiple Rab recruitment machines.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University			SOLDATI, Thierry/A-2902-2009; SOLDATI, Thierry/U-6494-2019	SOLDATI, Thierry/0000-0002-2056-7931; SOLDATI, Thierry/0000-0002-2056-7931	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK037332, R56DK037332, R01DK037332] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37332] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CORTHESYTHEULAZ I, 1992, J CELL BIOL, V118, P1333, DOI 10.1083/jcb.118.6.1333; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PFEFFER SR, 1987, J CELL BIOL, V105, P229, DOI 10.1083/jcb.105.1.229; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHAPIRO AD, 1995, J BIOL CHEM, V270, P11085, DOI 10.1074/jbc.270.19.11085; SINGERKRUGER B, 1994, J CELL BIOL, V125, P283, DOI 10.1083/jcb.125.2.283; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; SOLDATI T, 1995, IN PRESS METHODS ENZ; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; WICHMANN H, 1992, CELL, V71, P1131, DOI 10.1016/S0092-8674(05)80062-5; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	33	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25541	25548		10.1074/jbc.270.43.25541	http://dx.doi.org/10.1074/jbc.270.43.25541			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592724	hybrid, Green Published			2022-12-27	WOS:A1995TB46600041
J	WIELES, B; VANNOORT, J; DRIJFHOUT, JW; OFFRINGA, R; HOLMGREN, A; OTTENHOFF, THM				WIELES, B; VANNOORT, J; DRIJFHOUT, JW; OFFRINGA, R; HOLMGREN, A; OTTENHOFF, THM			PURIFICATION AND FUNCTIONAL-ANALYSIS OF THE MYCOBACTERIUM-LEPRAE THIOREDOXIN THIOREDOXIN REDUCTASE HYBRID PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; THIOREDOXIN REDUCTASE; SELECTION; PLASMID	In Mycobacterium leprae, thioredoxin and thioredoxin reductase are expressed from a single gene. This results in the expression of a hybrid protein with subunits attached to each other by a hydrophilic peptide linker. In all other organisms studied so far, thioredoxin (Trx) and thioredoxin reductase (TR) are expressed as two separate proteins. This raises the question of whether the hybrid protein is enzymatically active and, if so, whether TR reduces its own Trx partner or alternatively a heterologous Trx subunit. To address this question, the hybrid TR/Trx protein of M. leprae as well as the individual parts of the hybrid gene coding for either TR or Trx were overexpressed in Escherichia coli and purified. The purified proteins were tested for their ability to catalyze NADPH-dependent insulin disulfide reduction. Here we show that the M. leprae hybrid protein is indeed enzymatically active. Compared with the enzymatic activity of the separately expressed Trx and TR proteins, the hybrid protein is shown to be more efficient, particularly at low equimolar concentrations. This suggests that the hybrid protein of M. leprae is active by itself and that its activity involves intramolecular interactions between the TR and Trx domains. The activity of the hybrid protein increases when exogenous TR or Trx is added, indicating an additional role for intermolecular interactions.	LEIDEN UNIV HOSP,BLOOD BANK,2333 AA LEIDEN,NETHERLANDS; KAROLINSKA INST,MED NOBEL INST BIOCHEM,S-17177 STOCKHOLM,SWEDEN	Leiden University; Leiden University Medical Center (LUMC); Karolinska Institutet	WIELES, B (corresponding author), LEIDEN UNIV HOSP,DEPT IMMUNOHEMATOL,RIJNSBURGERWEG 10,BLDG 1 E3Q,2333 AA LEIDEN,NETHERLANDS.		Drijfhout, Jan Wouter/ABA-6318-2021	Drijfhout, Jan Wouter/0000-0003-4808-5296; Wieles, Brigitte/0000-0001-9631-3404				BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CLARKCURTISS JE, 1985, J BACTERIOL, V161, P1093, DOI 10.1128/JB.161.3.1093-1102.1985; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOOG JO, 1985, BIOSCIENCE REP, V4, P917; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; MITSUI A, 1992, BIOCHEM BIOPH RES CO, V186, P1220, DOI 10.1016/S0006-291X(05)81536-0; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; Sambrook J, 1989, MOL CLONING LABORATO; VILLAREJO MR, 1974, J BACTERIOL, V120, P466, DOI 10.1128/JB.120.1.466-474.1974; WAKSMAN G, 1994, J MOL BIOL, V236, P800, DOI 10.1006/jmbi.1994.1190; WIELES B, 1995, MOL MICROBIOL, V16, P921, DOI 10.1111/j.1365-2958.1995.tb02318.x; YOUNG RA, 1985, NATURE, V316, P450, DOI 10.1038/316450a0	16	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25604	25606		10.1074/jbc.270.43.25604	http://dx.doi.org/10.1074/jbc.270.43.25604			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592733	hybrid			2022-12-27	WOS:A1995TB46600050
J	BUHL, AM; JOHNSON, NL; DHANASEKARAN, N; JOHNSON, GL				BUHL, AM; JOHNSON, NL; DHANASEKARAN, N; JOHNSON, GL			G-ALPHA(12) AND G-ALPHA(13) STIMULATE RHO-DEPENDENT STRESS FIBER FORMATION AND FOCAL ADHESION ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEINS; SIGNALING PATHWAYS; MOLECULAR-CLONING; ADENYLYL CYCLASE; PERTUSSIS TOXIN; GROWTH-FACTORS; GENE-PRODUCT; RECEPTOR; RAS; FIBROBLASTS	Rho, a member of the Ras superfamily of GTP-binding proteins, regulates actin polymerization resulting in the formation of stress fibers and the assembly of focal adhesions. In Swiss 3T3 cells, heterotrimeric G protein-coupled receptors for lysophosphatidic acid and gastrin releasing peptide stimulate Rho-dependent stress fiber and focal adhesion formation. The specific heterotrimeric G protein subunits mediating Rho-dependent stress fiber and focal adhesion formation have not been defined previously. We have expressed GTPase-deficient, constitutively activated G protein alpha subunits and mixtures of beta and gamma subunits in Swiss 3T3 cells. Measurement of actin polymerization and focal adhesion formation indicated that GTPase-deficient alpha(12) and alpha(13), but not the activated forms of a(i2) or a(q) stimulated stress fiber and focal adhesion assembly, Combinations of beta and gamma subunits were unable to stimulate stress fiber or focal adhesion formation. G alpha(12)- and alpha(13)-mediated stress fiber and focal adhesion assembly was inhibited by botulinum C3 exoenzyme, which ADP-ribosylates and inactivates Rho, indicating that a(12) and alpha(13), but not other G protein alpha subunits or beta gamma complexes, regulate Rho-dependent responses. The results define the integration of G(12) and G(13) with the regulation of the actin cytoskeleton.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; AARHUS UNIV,DEPT CHEM,DIV BIOSTRUCT CHEM,DK-8000 AARHUS C,DENMARK; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	National Jewish Health; Aarhus University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NCI NIH HHS [CA 58157] Funding Source: Medline; NIDDK NIH HHS [DK 37871] Funding Source: Medline; NIGMS NIH HHS [GM 30324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BAFFY G, 1994, J BIOL CHEM, V269, P8483; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HUNG DT, 1992, J BIOL CHEM, V267, P20831; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; SEKINE A, 1989, J BIOL CHEM, V264, P8602; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VOYNOYASENETSKA.T, 1994, J BIOL CHEM, V269, P4721; WILKBLASZCZAK MA, 1994, NEURON, V13, P1215, DOI 10.1016/0896-6273(94)90059-0; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	35	407	413	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24631	24634		10.1074/jbc.270.42.24631	http://dx.doi.org/10.1074/jbc.270.42.24631			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559569	hybrid			2022-12-27	WOS:A1995TB46500003
J	CHANG, J; KIM, DH; LEE, SW; CHOI, KY; SUNG, YC				CHANG, J; KIM, DH; LEE, SW; CHOI, KY; SUNG, YC			TRANSACTIVATION ABILITY OF P53 TRANSCRIPTIONAL ACTIVATION DOMAIN IS DIRECTLY RELATED TO THE BINDING-AFFINITY TO TATA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LESS PROMOTER; TFIID COMPLEX; WILD-TYPE; VP16; SEQUENCE; DNA; COACTIVATORS; ASSOCIATION; MECHANISM; ELEMENTS	Tumor suppressor protein p53 is a potent transcriptional activator and regulates cell growth negatively. To characterize the transcriptional activation domain (TAD) of p53, various point mutants were constructed in the context of Ga14 DNA binding domain and tested for their transactivation ability. Our results demonstrated that the positionally conserved hydrophobic residues shared with herpes simplex virus VP16 and other transactivators are essential for transactivation. Also, the negatively charged residues and proline residues are necessary for full activity, but not essential for the activity of p53 TAD. Deletion analyses showed that p53 TAD can be divided into two subdomains, amino acids 1-40 and 43-73. An in vitro glutathione S-transferase pull-down assay establishes a linear correlation between p53 TAD mediated transactivation in vivo and the binding activity of p53 TAD to TATA-binding protein (TBP) in vitro. Mutations that diminish the transactivation ability of Ga14-p53 TAD also impair the binding activity to TBP severely, Our results suggest that at least TBP is a direct target for p53 TAD and that the binding strength of TAD to TBP (TFIID) is an important parameter controlling activity of p53 TAD. In addition, circular dichroism spectroscopy has shown that p53 TAD peptide lacks any regular secondary structure in solution and that there is no significant difference between the spectra of the wild type TAD and that of the transactivation-deficient mutant type.	POHANG UNIV SCI & TECHNOL,CTR BIOFUNCT MOLEC,POHANG 790784,SOUTH KOREA; POHANG UNIV SCI & TECHNOL,DEPT LIFE SCI,POHANG 790784,SOUTH KOREA	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)				CHANG, JUN/0000-0002-8423-5987; Kim, Do-Hyung/0000-0002-2924-4370				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ADDISON C, 1990, ONCOGENE, V5, P423; BARGONETTI J, 1991, CELL, V65, P1063; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; CATHERINE JT, 1995, SCIENCE, V267, P100; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CRESS A, 1991, GENE, V103, P235, DOI 10.1016/0378-1119(91)90278-J; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GAUN KL, 1991, ANAL BIOCHEM, V192, P262; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HARDWICK JM, 1992, J VIROL, V66, P5500, DOI 10.1128/JVI.66.9.5500-5508.1992; HIRIKOSHI M, 1988, CELL, V54, P1033; HIRIKOSHI M, 1988, CELL, V54, P665; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; IWABUCHI K, 1993, ONCOGENE, V8, P1693; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE CW, 1994, J VIROL, V68, P2708, DOI 10.1128/JVI.68.4.2708-2719.1994; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1988, SCIENCE, V245, P371; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SOUSSI T, 1990, ONCOGENE, V5, P945; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	59	104	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25014	25019		10.1074/jbc.270.42.25014	http://dx.doi.org/10.1074/jbc.270.42.25014			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559631	hybrid			2022-12-27	WOS:A1995TB46500065
J	FERGUSON, SSG; MENARD, L; BARAK, LS; KOCH, WJ; COLAPIETRO, AM; CARON, MG				FERGUSON, SSG; MENARD, L; BARAK, LS; KOCH, WJ; COLAPIETRO, AM; CARON, MG			ROLE OF PHOSPHORYLATION IN AGONIST-PROMOTED BETA(2)-ADRENERGIC RECEPTOR SEQUESTRATION - RESCUE OF A SEQUESTRATION-DEFECTIVE MUTANT RECEPTOR BY BETA-ARK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; DEPENDENT PROTEIN-KINASE; BETA-2-ADRENERGIC RECEPTOR; DESENSITIZATION; ARRESTIN; INTERNALIZATION; MEMBRANE; BINDING; SITES; DEPHOSPHORYLATION	The beta(2)-adrenergic receptor (beta(2)AR) belongs to the large family of G protein coupled receptors. Mutation of tyrosine residue 326 to an alanine resulted in a beta(2)AR mutant (beta(2)AR-Y326A) that was defective in its ability to sequester and was less well coupled to adenylyl cyclase than the wild-type beta(2)AR. However, this mutant receptor not only desensitized in response to agonist stimulation but down-regulated normally. In an attempt to understand the basis for the properties of this mutant, we have examined the ability of this regulation-defective mutant to undergo agonist-mediated phosphorylation. When expressed in 293 cells, the maximal response for phosphorylation of the beta(2)AR-Y326A mutant was impaired by 75%. Further characterization of this phosphorylation, using either forskolin stimulation or phosphorylation site-deficient beta(2)AR-Y326A mutants, demonstrated that the beta(2)AR-Y326A mutant can be phosphorylated by cAMP-dependent protein kinase (PKA) but does not serve as a substrate for the beta-adrenergic receptor kinase 1 (beta ARK1). However, overexpression of beta ARK1 led to the agonist-dependent phosphorylation of the beta(2)AR-Y326A mutant and rescue of its sequestration. beta ARK1-mediated rescue of beta(2)AR-Y326A sequestration could be prevented by mutating putative beta ARK phosphorylation sites, but not PKA phosphorylation sites. In addition, both sequestration and phosphorylation of the wild-type beta(2)AR could be attenuated by overexpressing a dominant-negative mutant of beta ARK1 (C-20 beta ARK1-K220M). These findings implicate a role for beta ARK1 mediated phosphorylation in facilitating wild-type beta(2)AR sequestration.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL & MED,DURHAM,NC 27710	Duke University; Duke University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NINDS NIH HHS [NS19576] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BOX RJ, 1987, FEBS LETT, V214, P323, DOI 10.1016/0014-5793(87)80079-0; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; CHEUNG AH, 1989, MOL PHARMACOL, V34, P132; CLARK RB, 1989, MOL PHARMACOL, V36, P343; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; GUREVICH VV, 1994, J BIOL CHEM, V268, P16879; GURREVICH VV, 1995, J BIOL CHEM, V270, P720; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; INGLESE J, 1993, J BIOL CHEM, V268, P23735; INGLESE J, 1993, NATURE, V359, P147; KONG GH, 1994, J BIOL CHEM, V269, P13084; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P129, DOI 10.1073/pnas.82.1.129; MORO O, 1993, J BIOL CHEM, V268, P6862; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; POPPIG S, 1995, MOL PHARMACOL, V47, P666; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SCHWINN DA, 1992, HEART CARDIOVASCULAR, P1657; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; TSUGA H, 1994, J BIOL CHEM, V269, P32522; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WALDO GL, 1983, J BIOL CHEM, V258, P3900; YU SS, 1993, J BIOL CHEM, V268, P337; YUAN NY, 1994, J BIOL CHEM, V269, P23032	44	207	210	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24782	24789		10.1074/jbc.270.42.24782	http://dx.doi.org/10.1074/jbc.270.42.24782			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559596	hybrid			2022-12-27	WOS:A1995TB46500030
J	KANAMORI, K; ROSS, BD				KANAMORI, K; ROSS, BD			STEADY-STATE IN-VIVO GLUTAMATE-DEHYDROGENASE ACTIVITY IN RAT-BRAIN MEASURED BY N-15 NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOHISTOCHEMICAL DEMONSTRATION; PORTACAVAL ANASTOMOSIS; HYPERAMMONEMIC RATS; CEREBRAL-CORTEX; METABOLISM; AMMONIA; TRANSMITTER; GLUCOSE; PURIFICATION; PRECURSORS	The in vivo activity of glutamate dehydrogenase (GDH) in the direction of reductive amination was measured in rat brain at steady-state concentrations of brain ammonia and glutamate after intravenous infusion of the substrate (NH4+)-N-15. The in vivo rate was determined from the steady-state fractional. N-15 enrichment of brain ammonia, measured by selective observation of (NH4+)-N-15 protons in brain extract by H-1 -N-15 heteronuclear multiple-quantum coherence transfer MMR, and the rate of increase of brain [N-15]glutamate and [2-N-15]glutamine measured by N-15 NMR. The in vivo GDH activity was 0.76-1.17 mu mol/h/g at a brain ammonia concentration of 0.87 +/- 0,18 mu mol/g, and 1.1-1.2 mu mol/h/g at 1.0 +/- 0.17 mu mol/g. Comparison of the observed in. vivo GDH activity with the in vive rates of glutamine synthesis and of phosphate-activated glutaminase suggests that, under mild hyperammonemia, GDH-catalyzed de novo synthesis can provide a minimum of 19% of the glutamate pool that is recycled from neurons to astrocytes through the glutamate-glutamine cycle.			KANAMORI, K (corresponding author), HUNTINGTON MED RES INST,MAGNET RESONANCE SPECT LAB,660 S FAIR OAKS AVE,PASADENA,CA 91105, USA.				NINDS NIH HHS [1RO1 NS29048] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029048] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALAZS R, 1965, BIOCHEM J, V94, P131, DOI 10.1042/bj0940131; BERL S, 1961, J NEUROCHEM, V7, P186, DOI 10.1111/j.1471-4159.1961.tb13503.x; BERL S, 1962, J BIOL CHEM, V237, P2562; Bernt E., 1974, METHODS ENZYMATIC AN, P1704, DOI [10.1016/B978-0-12-091304-6.50017-3, DOI 10.1016/B978-0-12-091304-6.50017-3]; BUTTERWORTH RF, 1988, J NEUROCHEM, V51, P486, DOI 10.1111/j.1471-4159.1988.tb01064.x; CHEE PY, 1979, J NEUROCHEM, V33, P53, DOI 10.1111/j.1471-4159.1979.tb11705.x; COLON AD, 1986, J NEUROCHEM, V46, P1811; COOPER AJL, 1979, J BIOL CHEM, V254, P4982; COOPER AJL, 1985, J NEUROCHEM, V44, P1716, DOI 10.1111/j.1471-4159.1985.tb07159.x; CREMER JE, 1964, J NEUROCHEM, V11, P165, DOI 10.1111/j.1471-4159.1964.tb06127.x; DEJONG CHC, 1992, J NEUROCHEM, V59, P1071, DOI 10.1111/j.1471-4159.1992.tb08349.x; DENNIS SC, 1977, BIOCHEM J, V168, P521, DOI 10.1042/bj1680521; ERECINSKA M, 1990, PROG NEUROBIOL, V35, P245, DOI 10.1016/0301-0082(90)90013-7; ERECINSKA M, 1988, J NEUROCHEM, V51, P892, DOI 10.1111/j.1471-4159.1988.tb01826.x; FARROW NA, 1990, BIOCHEM J, V270, P473, DOI 10.1042/bj2700473; GAITONDE MK, 1965, BIOCHEM J, V94, P345, DOI 10.1042/bj0940345; GARFINKEL D, 1966, J BIOL CHEM, V241, P3918; HAMBERGER AC, 1979, BRAIN RES, V168, P513, DOI 10.1016/0006-8993(79)90306-8; KANAMORI K, 1995, BIOCHEM J, V305, P329, DOI 10.1042/bj3050329; KANAMORI K, 1993, NMR BIOMED, V6, P21, DOI 10.1002/nbm.1940060104; KANAMORI K, 1995, J MAGN RESON SER B, V107, P107, DOI 10.1006/jmrb.1995.1066; KANAMORI K, 1995, BIOCHEM J, V311, P681, DOI 10.1042/bj3110681; KANAMORI K, 1993, BIOCHEM J, V293, P461, DOI 10.1042/bj2930461; KANEKO T, 1987, NEUROSCI LETT, V77, P171, DOI 10.1016/0304-3940(87)90581-7; KUN E, 1974, METHOD ENZYMAT AN, P1802; LUND P, 1974, METHOD ENZYMAT AN, P1719; MANS AM, 1984, J NEUROCHEM, V43, P697, DOI 10.1111/j.1471-4159.1984.tb12789.x; MANS AM, 1994, J NEUROCHEM, V63, P1829; MASON GF, 1995, J CEREBR BLOOD F MET, V15, P12, DOI 10.1038/jcbfm.1995.2; MASON GF, 1992, J CEREBR BLOOD F MET, V12, P434, DOI 10.1038/jcbfm.1992.61; MILLER AL, 1973, J NEUROCHEM, V20, P1393, DOI 10.1111/j.1471-4159.1973.tb00251.x; ONEAL RM, 1966, J NEUROCHEM, V13, P835, DOI 10.1111/j.1471-4159.1966.tb05879.x; OTTERSEN OP, 1992, NEUROSCIENCE, V46, P519, DOI 10.1016/0306-4522(92)90141-N; PENG L, 1993, DEV NEUROSCI-BASEL, V15, P367, DOI 10.1159/000111357; ROTHE F, 1994, NEUROSCIENCE, V62, P1133, DOI 10.1016/0306-4522(94)90349-2; ROTHE F, 1990, NEUROSCIENCE, V39, P419, DOI 10.1016/0306-4522(90)90278-C; ROTHE F, 1983, DEV BRAIN RES, V11, P67, DOI 10.1016/0165-3806(83)90202-X; SALGANICOFF L, 1965, J NEUROCHEM, V12, P287, DOI 10.1111/j.1471-4159.1965.tb06766.x; SOMOGYI P, 1986, NEUROSCIENCE, V19, P1045, DOI 10.1016/0306-4522(86)90121-1; THANKI CM, 1983, J NEUROCHEM, V41, P611, DOI 10.1111/j.1471-4159.1983.tb04785.x; TOLEDANO A, 1979, CELL MOL BIOL, V24, P113; WARD HK, 1983, J NEUROCHEM, V40, P855, DOI 10.1111/j.1471-4159.1983.tb08058.x; YUDKOFF M, 1991, J NEUROCHEM, V57, P153, DOI 10.1111/j.1471-4159.1991.tb02110.x; YUDKOFF M, 1986, BIOCHEM J, V234, P185, DOI 10.1042/bj2340185	44	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24805	24809		10.1074/jbc.270.42.24805	http://dx.doi.org/10.1074/jbc.270.42.24805			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559600	hybrid			2022-12-27	WOS:A1995TB46500034
J	NADKARNI, AK; MCDONOUGH, VM; YANG, WL; STUKEY, JE; OZIERKALOGEROPOULOS, O; CARMAN, GM				NADKARNI, AK; MCDONOUGH, VM; YANG, WL; STUKEY, JE; OZIERKALOGEROPOULOS, O; CARMAN, GM			DIFFERENTIAL BIOCHEMICAL REGULATION OF THE URA7-ENCODED AND URA8-ENCODED CTP SYNTHETASES FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE 5'-TRIPHOSPHATE SYNTHETASE; PHOSPHATIDYLINOSITOL SYNTHASE; MUTATOR GENE; PROTEINS; MUTANTS; TUMORS; CELLS; RNA	The URA7- and URA8-encoded CTP synthetases (EC 6.3.4.2, UTP:ammonia ligase (ADP-forming)) are functionally overlapping enzymes responsible for the bio synthesis of CTP in the yeast Saccharomyces cerevisiae. URA8-encoded CTP synthetase was purified to apparent homogeneity by ammonium sulfate fractionation of the cytosolic fraction followed by chromatography with Q-Sepharose, Affi-Gel Blue, Mono Q, and Superose 6. The subunit molecular mass (67 kDa) of purified URA8-encoded CTP synthetase was in good agreement with the predicted size of the URA8 gene product. Antibodies raised against a fusion protein constructed from the coding sequences of the URA8 gene and expressed in Escherichia coli reacted with purified URA8-encoded CTP synthetase. Native URA8-encoded CTP synthetase existed as a dimer which oligomerized to a tetramer in the presence of its substrates UTP and ATP. Maximum URA8-encoded CTP synthetase activity was dependent on Mg2+ ions (K-alpha = 2.4 mM) and 2-mercaptoethanol at the pH optimum of 7.5. The enzyme followed saturation kinetics toward UTP (K-m = 74 mu M), ATP (K-m = 22 mu M), and glutamine (K-m = 0.14 mM). GTP stimulated (K-alpha = 26 mu M) URA8-encoded CTP synthetase activity 12-fold. CTP potently inhibited (IC50 = 85 mu M) URA8-encoded CTP synthetase activity and, in addition, caused the dependence of activity toward UTP to become cooperative. The URA8-encoded CTP synthetase and the previously purified URA7-encoded CTP synthetase differed significantly with respect to several biochemical properties including turnover number, pH optimum, substrate dependences, and sensitivity to inhibition by CTP. The URA7-encoded CTP synthetase mRNA was 2-fold more abundant when compared with URA8-encoded CTP synthetase mRNA. Both CTP synthetase isoforms were maximally expressed in the exponential phase of growth.	RUTGERS STATE UNIV,COOK COLL,NEW JERSEY AGR EXPT STN,DEPT FOOD SCI,NEW BRUNSWICK,NJ 08903; UNIV PARIS 06,CTR GENET MOLEC,CNRS,F-91198 GIF SUR YVETTE,FRANCE	Rutgers State University New Brunswick; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay					NIGMS NIH HHS [GM-50679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONOW B, 1984, J BIOL CHEM, V259, P9035; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHU EHY, 1984, BIOCHEM GENET, V22, P701, DOI 10.1007/BF00485854; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COEN DM, 1987, CURRENT PROTOCOLS MO; CULBERTSON MR, 1975, GENETICS, V80, P23; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; HAID A, 1983, METHOD ENZYMOL, V96, P192; Harlow E., 1988, ANTIBODIES LABORATOR, P1; KAUFMAN ER, 1986, MUTAT RES, V161, P19, DOI 10.1016/0027-5107(86)90096-5; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; KIZAKI H, 1980, CANCER RES, V40, P3921; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LIBERMAN I, 1956, J BIOL CHEM, V222, P765; LONG CW, 1967, J BIOL CHEM, V242, P4715; MEUTH M, 1979, P NATL ACAD SCI USA, V76, P6505, DOI 10.1073/pnas.76.12.6505; MEUTH M, 1982, SOMAT CELL GENET, V8, P423, DOI 10.1007/BF01538705; OZIERKALOGEROPO.O, 1991, MOL GEN GENET, V0231; OZIERKALOGEROPO.O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; ROBERTSON JG, 1993, BIOCHEMISTRY-US, V32, P3769, DOI 10.1021/bi00065a032; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SELDEN RF, 1987, CURRENT PROTOCOLS MO; TRAUT TW, 1988, CRC CR REV BIOCH MOL, V23, P121, DOI 10.3109/10409238809088318; TRUDEL M, 1984, J BIOL CHEM, V259, P2355; VINCENT BRD, 1980, BIOCHIM BIOPHYS ACTA, V610, P352; WEBER G, 1980, LIFE SCI, V27, P793, DOI 10.1016/0024-3205(80)90333-1; WEBER G, 1979, ADV ENZYME REGUL, V17, P1; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028	34	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24982	24988		10.1074/jbc.270.42.24982	http://dx.doi.org/10.1074/jbc.270.42.24982			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559626	hybrid			2022-12-27	WOS:A1995TB46500060
J	PERLMAN, JH; WANG, W; NUSSENZVEIG, DR; GERSHENGORN, MC				PERLMAN, JH; WANG, W; NUSSENZVEIG, DR; GERSHENGORN, MC			A DISULFIDE BOND BETWEEN CONSERVED EXTRACELLULAR CYSTEINES IN THE THYROTROPIN-RELEASING-HORMONE RECEPTOR IS CRITICAL FOR BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING; RHODOPSIN; RESIDUES; DOMAIN	The assumption that a disulfide bond is present between two highly conserved cysteines in the extracellular loops of G protein coupled receptors and is critical for receptor function has been cast in doubt. We undertook to determine whether a disulfide bond important for binding or activation is present in the thyrotropin-releasing hormone (TRH) receptor (TRH-R). Studies were performed with cells expressing wild-type (WT) and mutant receptors in the absence or presence of the reducing agent dithiothreitol (DTT). The affinity of WT TRH-R was 16-22-fold lower in the presence of DTT than in the absence of DTT. Mutant receptors were constructed in which Ala was substituted for conserved Cys-98 and Cys-179 of extracellular loops 1 and 2, respectively, and for the nonconserved Cys-100. C98A and C179A TRH-Rs did not exhibit high affinity binding. These mutant receptors were capable of stimulating inositol phosphate second messenger formation to the same extent as WT TRH-Rs but with a markedly lower potency. The affinities of C98A and C179A TRH-Rs, estimated from their potencies, were 4400- and 640-fold lower, respectively, than WT TRH-R. The estimated affinities of neither C98A nor C179A TRH-R were decreased by DTT. In contrast, the estimated affinity of C100A TRH-R was not different from WT TRH-R and was DTT sensitive. Moreover, the effect of mutating both Cys-98 and Cys-179 was not additive with the effects of the individual mutations. These data provide strong evidence that Cys-98 and Cys-179 form a disulfide bond. This interaction is not involved in receptor activation but is critical for maintaining the high affinity conformation of TRH-R.			PERLMAN, JH (corresponding author), CORNELL UNIV,COLL MED,DEPT MED,DIV MOLEC MED,1300 YORK AVE,NEW YORK,NY 10021, USA.							ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; GERSHENGORN MC, 1991, ENDOCRINOLOGY, V128, P1204, DOI 10.1210/endo-128-2-1204; GUSTAVSSON B, 1994, BIOCHEM BIOPH RES CO, V199, P612, DOI 10.1006/bbrc.1994.1272; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KOSUGI S, 1992, BIOCHEM BIOPH RES CO, V189, P1754, DOI 10.1016/0006-291X(92)90281-O; KURTENBACH E, 1990, BIOCHEM SOC T, V18, P442, DOI 10.1042/bst0180442; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P1; MATUSLEIBOVITCH N, 1995, J BIOL CHEM, V270, P1041, DOI 10.1074/jbc.270.3.1041; NODA K, 1994, J BIOL CHEM, V269, P6743; OGAWA N, 1982, PEPTIDES, V3, P669, DOI 10.1016/0196-9781(82)90169-3; PERLMAN JH, 1995, MOL PHARMACOL, V47, P480; PERLMAN JH, 1994, J BIOL CHEM, V269, P1610; PERLMAN JH, 1994, J BIOL CHEM, V269, P23383; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; SHARIF NA, 1984, J NEUROCHEM, V42, P209, DOI 10.1111/j.1471-4159.1984.tb09719.x; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S	27	68	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24682	24685		10.1074/jbc.270.42.24682	http://dx.doi.org/10.1074/jbc.270.42.24682			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559582	hybrid			2022-12-27	WOS:A1995TB46500016
J	BARAK, Y; COHENFIX, O; LIVNEH, Z				BARAK, Y; COHENFIX, O; LIVNEH, Z			DEAMINATION OF CYTOSINE-CONTAINING PYRIMIDINE PHOTODIMERS IN UV-IRRADIATED DNA - SIGNIFICANCE FOR UV-LIGHT MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI; ULTRAVIOLET-LIGHT; DELAYED PHOTOREVERSAL; BACTERIOPHAGE-LAMBDA; THERMAL-RESISTANCE; ACTIVATION-ENERGY; MUTATIONS; REPAIR; GENE	The realization that cytosine in cyclobutyl pyrimidine dimers rapidly deaminates to uracil raised the possibility that this chemical transformation, rather than an enzymatic polymerase error, is the major mutagenic step in UV mutagenesis. We have established a sensitive bioassay system that enabled us to determine the rate of deamination of cytosine in cyclobutyl pyrimidine dimers in plasmid DNA. This was done by in vitro UV irradiation and deamination of a plasmid carrying the cro gene, followed by photoreactivation, and assaying uracils in DNA by their ability to cause Cro(-) mutations in an indicator strain that was deficient in uracil DNA N-glycosylase, DNA sequence analysis revealed that 27 out of 29 Cro(-) mutants carried GC --> AT transitions, as expected from deamination of cytosine. Deamination of cytosines in the cro gene in UV-irradiated plasmid pOC2 proceeded at 37 degrees C with first-order kinetics, at a rate of (3.9 +/- 0.6) x 10(-5) s(-1), corresponding to a half-life of 5 h. Physiological salt conditions increased the half-life to 12 h, whereas decreasing the pH increased deamination. The temperature dependence of the rate constant yielded an activation energy of 13.6 rt 3.3 kcal/mol. These kinetics data suggest that deamination of cytosine-containing dimers is too slow to play an important role in UV mutagenesis in Escherichia coli. However, it is likely to play an important role in mammalian cells, where the mutagenic process is slower.	WEIZMANN INST SCI, DEPT BIOCHEM, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								Alberts B, 1994, MOL BIOL CELL, P508; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BRIDGES BA, 1992, MOL GEN GENET, V233, P331, DOI 10.1007/BF00265428; COHENFIX O, 1992, P NATL ACAD SCI USA, V89, P3300, DOI 10.1073/pnas.89.8.3300; COHENFIX O, 1994, J BIOL CHEM, V269, P4953; DOUKI T, 1992, J PHOTOCH PHOTOBIO B, V15, P199, DOI 10.1016/1011-1344(92)85124-D; DUNCAN BK, 1982, J BACTERIOL, V151, P750, DOI 10.1128/JB.151.2.750-755.1982; DUNCAN BK, 1985, J BACTERIOL, V164, P689, DOI 10.1128/JB.164.2.689-695.1985; FIX D, 1981, MOL GEN GENET, V182, P7, DOI 10.1007/BF00422759; FIX DF, 1986, MOL GEN GENET, V204, P452, DOI 10.1007/BF00331023; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; FRIEDBERG EC, 1995, DNA REPAIR; GREEN M, 1957, J BIOL CHEM, V228, P601; HSIA HC, 1989, J MOL BIOL, V205, P103, DOI 10.1016/0022-2836(89)90368-9; KATO T, 1977, MOL GEN GENET, V156, P121, DOI 10.1007/BF00283484; Kornberg A., 1991, DNA REPLICATION; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAWRENCE CW, 1993, MUTAT RES, V299, P157, DOI 10.1016/0165-1218(93)90093-S; LEMAIRE DGE, 1993, BIOCHEMISTRY-US, V32, P2525, DOI 10.1021/bi00061a009; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; LIVNEH Z, 1993, CRIT REV BIOCHEM MOL, V28, P465, DOI 10.3109/10409239309085136; LIVNEH Z, 1986, P NATL ACAD SCI USA, V83, P4599, DOI 10.1073/pnas.83.13.4599; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; NISHIOKA H, 1970, MUTAT RES, V9, P349, DOI 10.1016/0027-5107(70)90017-5; NISHIOKA H, 1969, MUTAT RES, V8, P215, DOI 10.1016/0027-5107(69)90001-3; Patrick M. H., 1976, PHOTOCHEM PHOTOBIOL, P35; RICHEY B, 1987, J BIOL CHEM, V262, P7157; RUIZRUBIO M, 1989, MUTAT RES, V210, P93, DOI 10.1016/0027-5107(89)90048-1; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SETLOW RB, 1965, P NATL ACAD SCI USA, V53, P1111, DOI 10.1073/pnas.53.5.1111; SKALITER R, 1992, MUTAT RES, V267, P139, DOI 10.1016/0027-5107(92)90118-L; TADMOR Y, 1992, J BACTERIOL, V174, P2517, DOI 10.1128/jb.174.8.2517-2524.1992; TEORELL TORSTEN, 1938, BIO CHEM ZEITSCHR, V299, P416; TESSMAN I, 1994, J MOL BIOL, V235, P807, DOI 10.1006/jmbi.1994.1040; TESSMAN I, 1992, P NATL ACAD SCI USA, V89, P1159, DOI 10.1073/pnas.89.4.1159; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WEISS B, 1987, ADV ENZYMOL RAMB, V60, P1; WITKIN EM, 1991, BIOCHIMIE, V73, P133, DOI 10.1016/0300-9084(91)90196-8; WITKIN EM, 1969, MUTAT RES, V8, P9, DOI 10.1016/0027-5107(69)90135-3; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976; WOODGATE R, 1992, MUTAT RES, V281, P221, DOI 10.1016/0165-7992(92)90012-7; [No title captured]	44	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24174	24179		10.1074/jbc.270.41.24174	http://dx.doi.org/10.1074/jbc.270.41.24174			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592621	hybrid			2022-12-27	WOS:A1995TA21700049
J	CALLOW, MJ; RUBIN, EM				CALLOW, MJ; RUBIN, EM			SITE-SPECIFIC MUTAGENESIS DEMONSTRATES THAT CYSTEINE-4326 OF APOLIPOPROTEIN-B IS REQUIRED FOR COVALENT LINKAGE WITH APOLIPOPROTEIN(A) IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXPRESSING HUMAN APOLIPOPROTEIN(A); PHENOTYPIC SELECTION; LIPOPROTEIN(A); DNA; PLASMA; IDENTIFICATION; SEQUENCE	In the formation of the lipoprotein(a) (Lp(a)) particle, apolipoprotein(a) (apo(a)) and apolipoprotein B (apoB) are covalently linked via a disulfide bond in both humans and human-apo(a)/apoB transgenic mice. Studies based upon fluorescent labeling of free cysteine residues have suggested that cysteine 3734 of the 4 carboxyl-terminal cysteines of apoB (Cys-3734, Cys-3890, Cys-4190, and Cys-4326) is the most likely candidate to form a disulfide bond with apo(a). However, other recent studies using truncated apoB molecules suggest that Cys-4326, the terminal cysteine of apoB, may be implicated in the binding to apo(a). In order to definitively show which of apoB's carboxyl-terminal cysteines is essential in interacting with apo(a) we have used RecA-assisted restriction enzyme digestion coupled with site-specific mutagenesis to convert Cys-3734 and Cys-4326 to serine within separate 90-kilobase pair apoB P1 phagemid clones. Transgenic mice containing the normal or mutated apoB transgenes were created, and the covalent association of mutated apoB with apo(a) was assessed in mice transgenic for both apoB and apo(a). Analysis by ultracentrifugation and immunoblotting revealed that Cys-4326, but not Cys-3734, was essential in the formation of the covalent bond between apo(a) and apoB in vivo.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,CTR HUMAN GENOME,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018574] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-18574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG VW, 1985, J LIPID RES, V26, P1314; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CALLOW MJ, 1994, NUCLEIC ACIDS RES, V22, P4348, DOI 10.1093/nar/22.20.4348; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; CHIESA G, 1992, J BIOL CHEM, V267, P24369; COLEMAN RD, 1990, BIOCHIM BIOPHYS ACTA, V1037, P129, DOI 10.1016/0167-4838(90)90111-R; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; FERRIN LJ, 1993, METH MOL G, V2, P57; FLESS GM, 1985, J LIPID RES, V26, P1224; FLESS GM, 1994, BIOCHEMISTRY-US, V33, P13492, DOI 10.1021/bi00249a038; FRAZER KA, 1995, NAT GENET, V9, P424, DOI 10.1038/ng0495-424; GABEL B, 1994, FEBS LETT, V350, P77, DOI 10.1016/0014-5793(94)00737-3; GAUBATZ JW, 1983, J BIOL CHEM, V258, P4582; GIEBEL LB, 1990, NUCLEIC ACIDS RES, V18, P4947, DOI 10.1093/nar/18.16.4947; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GUEVARA J, 1993, BIOPHYS J, V64, P686, DOI 10.1016/S0006-3495(93)81428-0; Hogan B, 1986, MANIPULATING MOUSE E, P89; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; LUDWIG EH, 1987, DNA-J MOLEC CELL BIO, V6, P363, DOI 10.1089/dna.1987.6.363; MCCORMICK SPA, 1994, J BIOL CHEM, V269, P24284; PHILLIPS ML, 1993, BIOCHEMISTRY-US, V32, P3722, DOI 10.1021/bi00065a026; PIERCE JC, 1992, P NATL ACAD SCI USA, V89, P2056, DOI 10.1073/pnas.89.6.2056; SANDHOLZER C, 1992, J CLIN INVEST, V90, P1958, DOI 10.1172/JCI116074; STEYRER E, 1994, J CLIN INVEST, V94, P2330, DOI 10.1172/JCI117598; YANG CY, 1994, CHEM PHYS LIPIDS, V67-8, P99, DOI 10.1016/0009-3084(94)90128-7	31	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23914	23917		10.1074/jbc.270.41.23914	http://dx.doi.org/10.1074/jbc.270.41.23914			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592581	hybrid			2022-12-27	WOS:A1995TA21700009
J	HELLERHARRISON, RA; MORIN, M; CZECH, MP				HELLERHARRISON, RA; MORIN, M; CZECH, MP			INSULIN REGULATION OF MEMBRANE-ASSOCIATED INSULIN-RECEPTOR SUBSTRATE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; JUXTAMEMBRANE REGION; SIGNAL TRANSMISSION; PROTEIN IRS-1; BETA-SUBUNIT; DOMAIN; PHOSPHORYLATION; INTERNALIZATION; ADIPOCYTES; ACTIVATION	Insulin stimulation of 3T3-L1 adipocytes results in rapid activation of the insulin receptor tyrosine kinase followed by autophosphorylation of the receptor and phosphorylation of insulin receptor substrate 1 (IRS-1), its major substrate. The insulin receptor resides mostly at the cell surface of 3T3-L1 adipocytes under basal conditions, while about two-thirds of IRS-1 fractionates with intracellular membranes and one-third fractionates with cytosol, To test whether insulin receptor internalization is required for optimal tyrosine phosphorylation of IRS-1, 3T3-L1 adipocytes and CHO-T cells were incubated at 4 degrees C which inhibits receptor endocytosis but not its tyrosine kinase activity. Under these conditions, tyrosine phosphorylation of IRS-1 in the low density microsome fraction in response to insulin was as intense as that observed at 37 degrees C, indicating that endocytosis of insulin receptors is not necessary for tyrosine phosphorylation of IRS-1 to occur, Surprisingly, at 37 degrees C, insulin action on 3T3-L1 adipocytes progressively decreased the amount of IRS-1 protein associated with the low density microsome fraction and increased that in the cytosol. This redistribution of IRS-1 from the low density microsome fraction to the cytosol in response to insulin was accompanied by decreased electrophoretic mobility of IRS-1 on SDS-polyacrylamide gel electrophoresis. Incubation of adipocytes at 4 degrees C blocked the appearance of tyrosine-phosphorylated IRS-1 in the cytosol, Taken together, these data indicate that insulin receptors phosphorylate IRS-1 at the cell surface, perhaps in coated pits which are included in the low density microsome fraction, The results also suggest a desensitization mechanism in which the tyrosine-phosphorylated membrane-bound IRS-1, associated with signaling molecules such as phosphatidylinositol 3-kinase, is released into the cytoplasm in concert with its serine/threonine phosphorylation.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	HELLERHARRISON, RA (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.				NIDDK NIH HHS [DK30648] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1990, J BIOL CHEM, V265, P16450; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CARPENTIER JL, 1989, DIABETOLOGIA, V32, P627; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; FAN JY, 1982, P NATL ACAD SCI-BIOL, V79, P7788, DOI 10.1073/pnas.79.24.7788; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM K, 1994, J BIOL CHEM, V269, P20648; LAMPHERE L, 1994, AM J PHYSIOL, V266, pE486, DOI 10.1152/ajpendo.1994.266.3.E486; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; MARSHALL S, 1981, DIABETES, V30, P746, DOI 10.2337/diab.30.9.746; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; OKADA T, 1994, J BIOL CHEM, V269, P3568; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; QUON MJ, 1994, J BIOL CHEM, V269, P27920; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; THIES RS, 1990, J BIOL CHEM, V265, P10132; TOBE K, 1993, J BIOL CHEM, V268, P11167; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	49	87	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24442	24450		10.1074/jbc.270.41.24442	http://dx.doi.org/10.1074/jbc.270.41.24442			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592659	hybrid			2022-12-27	WOS:A1995TA21700087
J	REN, YF; SMITH, A				REN, YF; SMITH, A			MECHANISM OF METALLOTHIONEIN GENE-REGULATION BY HEME-HEMOPEXIN - ROLES OF PROTEIN-KINASE-C, REACTIVE OXYGEN SPECIES, AND CIS-ACTING ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSIVE ELEMENT; STIMULATED LIPID-PEROXIDATION; HEPATIC METALLOTHIONEIN; OXIDATIVE STRESS; N-ACETYLCYSTEINE; DIFERRIC TRANSFERRIN; I PROMOTER; EXPRESSION; CELLS; BINDING	Heme-hemopexin or cobalt protoporphyrin (CoPP)-hemopexin (a model ligand for hemopexin receptor occupancy) is shown to increase transcription of the metallothionein-1 (MT-1) gene by activation of a signaling pathway. Promoter deletion analysis followed by transient transfection assays show that 110 base pairs (-153 to -43) of 5'-flanking region of the murine MT-1 promoter are sufficient for increasing transcription in response to heme-hemopexin or to CoPP-hemopexin in mouse hepatoma cells. The protein kinase C inhibitor, 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H7), prevented the increase in MT-1 transcription by heme-hemopexin, CoPP-hemopexin, or phorbol la-myristate 13-acetate, but the protein kinase A inhibitor, HA1004, was without effect. N-Acetylcysteine (NAC) and glutathione, as well as superoxide dismutase and catalase, inhibited both the increase in endogenous MT-1 mRNA and the activation of reporter gene activity by heme-hemopexin, CoPP-hemopexin, and phorbol 12-myristate 13-acetate. In sum, these data suggest that reactive oxygen intermediates are generated by heme-hemopexin via events associated with receptor binding, including protein kinase C activation. Induction of heme oxygenase-1 expression, in contrast to MT-1, is significantly less sensitive to NAC. Deletion and mutation analyses of the MT-1 proximal promoter revealed that the sequence 5'-GTGACTATGC-3' (from -98 to -89 base pairs) is, in part, responsible for the hemopexin-mediated regulation of MT-1 which is inhibited by H7. Regulation via this element is also induced by H2O2 showing that it is an antioxidant response element. Heme itself acts via more distal elements on the MT-1 promoter. In contrast to NAC and glutathione, diethyl dithiocarbamate and pyrrolidine dithiocarbamate, which inactivate reactive oxygen intermediates and chelate Zn(II), synergistically augment the induction of MT-1 mRNA levels and reporter gene activity in response to heme-hemopexin via the antioxidant response element by both metal-responsive element-dependent and -independent mechanisms.	UNIV MISSOURI,SCH BIOL SCI,DIV MOLEC BIOL & BIOCHEM,KANSAS CITY,MO 64110	University of Missouri System; University of Missouri Kansas City					NIDDK NIH HHS [DK-37463] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037463] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AFT RL, 1983, J BIOL CHEM, V258, P2069; AFT RL, 1984, J BIOL CHEM, V259, P301; ALAM J, 1989, J BIOL CHEM, V264, P17637; ALAM J, 1992, J BIOL CHEM, V267, P16379; ANDREWS GK, 1987, DEVELOPMENT, V100, P463; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BAUER J, 1993, J NEUROIMMUNOL, V45, P163, DOI 10.1016/0165-5728(93)90177-Z; BAUMAN JW, 1992, TOXICOL APPL PHARM, V117, P233, DOI 10.1016/0041-008X(92)90242-K; BAUMAN JW, 1991, TOXICOL APPL PHARM, V110, P347, DOI 10.1016/S0041-008X(05)80017-1; BURGUNDER JM, 1989, EUR J CLIN PHARMACOL, V36, P127, DOI 10.1007/BF00609183; CHU G, 1981, GENE, V13, P197, DOI 10.1016/0378-1119(81)90008-1; CRAIG GM, 1990, POSTGRAD MED J, V66, P1025, DOI 10.1136/pgmj.66.782.1025; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; DAVIES DM, 1979, BIOCHEM BIOPH RES CO, V91, P1504, DOI 10.1016/0006-291X(79)91235-X; DING XQ, 1994, EUR J BIOCHEM, V223, P841, DOI 10.1111/j.1432-1033.1994.tb19060.x; FAVREAU LV, 1993, J BIOL CHEM, V268, P19875; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GARRETT SH, 1992, INT J BIOCHEM, V24, P1669, DOI 10.1016/0020-711X(92)90186-5; GUTTERIDGE JMC, 1981, CRC CR REV CL LAB SC, V14, P257, DOI 10.3109/10408368109105866; GUTTERIDGE JMC, 1987, BIOCHIM BIOPHYS ACTA, V917, P219, DOI 10.1016/0005-2760(87)90125-1; GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861; GUTTERIDGE JMC, 1981, BIOCHEM J, V199, P259, DOI 10.1042/bj1990259; HALLIWELL B, 1986, TRENDS BIOCHEM SCI, V11, P372, DOI 10.1016/0968-0004(86)90207-0; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HEMMAPLARDH D, 1977, BRIT J HAEMATOL, V36, P85, DOI 10.1111/j.1365-2141.1977.tb05758.x; HIDALGO J, 1988, AM J PHYSIOL, V255, pE518, DOI 10.1152/ajpendo.1988.255.4.E518; HIDALGO J, 1994, CHEM-BIOL INTERACT, V93, P197, DOI 10.1016/0009-2797(94)90020-5; HRKAL Z, 1971, BIOCHEMISTRY-US, V10, P1746, DOI 10.1021/bi00786a002; HRKAL Z, 1974, EUR J BIOCHEM, V43, P73, DOI 10.1111/j.1432-1033.1974.tb03386.x; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; Jin N, 1993, Nihon Eiseigaku Zasshi, V48, P573; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIU J, 1991, TOXICOL APPL PHARM, V109, P235, DOI 10.1016/0041-008X(91)90171-A; LOW H, 1986, BIOCHEM BIOPH RES CO, V139, P1117, DOI 10.1016/S0006-291X(86)80293-5; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MORGAN EH, 1981, BIOCHIM BIOPHYS ACTA, V642, P119, DOI 10.1016/0005-2736(81)90143-7; MORRE DJ, 1991, BIOCHIM BIOPHYS ACTA, V1057, P140, DOI 10.1016/S0005-2728(05)80094-5; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; OLSEN KW, 1986, METHOD ENZYMOL, V123, P324; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; PLISOV SY, 1994, FEBS LETT, V352, P339, DOI 10.1016/0014-5793(94)00980-5; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; Searle P F, 1987, Experientia Suppl, V52, P407; SEARLE PF, 1990, NUCLEIC ACIDS RES, V18, P4683, DOI 10.1093/nar/18.16.4683; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; SMITH A, 1979, BIOCHEM J, V182, P47, DOI 10.1042/bj1820047; SMITH A, 1985, BIOCHEM J, V231, P663, DOI 10.1042/bj2310663; SMITH A, 1991, BIOCHEM J, V276, P417, DOI 10.1042/bj2760417; SMITH A, 1984, J BIOL CHEM, V259, P2049; SMITH A, 1993, J BIOL CHEM, V268, P7365; SMITH A, 1988, BIOCHEM J, V256, P941, DOI 10.1042/bj2560941; Smith A., 1990, BIOSYNTHESIS HEME CH, P435; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; VINCENT SH, 1988, ARCH BIOCHEM BIOPHYS, V265, P539, DOI 10.1016/0003-9861(88)90159-2; WONG JCY, 1994, INFECT IMMUN, V62, P48, DOI 10.1128/IAI.62.1.48-59.1994; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	63	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23988	23995		10.1074/jbc.270.41.23988	http://dx.doi.org/10.1074/jbc.270.41.23988			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592595	hybrid			2022-12-27	WOS:A1995TA21700023
J	SPEK, CA; GREENGARD, JS; GRIFFIN, JH; BERTINA, RM; REITSMA, PH				SPEK, CA; GREENGARD, JS; GRIFFIN, JH; BERTINA, RM; REITSMA, PH			2 MUTATIONS IN THE PROMOTER REGION OF THE HUMAN PROTEIN-C GENE BOTH CAUSE TYPE-I PROTEIN-C DEFICIENCY BY DISRUPTION OF 2 HNF-3 BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTIONAL ACTIVATOR; LIVER-SPECIFIC TRANSCRIPTION; NUCLEAR FACTOR-III; C4B-BINDING PROTEIN; CRYSTAL-STRUCTURE; HEMOPHILIA-B; GLOBIN GENE; DNA; EXPRESSION; FAMILY	Protein C is a vitamin K-dependent zymogen of a serine protease that inhibits blood coagulation by the proteolytic inactivation of factors Va and VIIIa, Individuals affected with protein C deficiency are at risk for thrombosis, Genetic analyses of affected individuals, to determine the cause of the protein C deficiency, revealed a large variety of mutations in the protein C gene, including several in the promoter region of this gene, Comparison of the region around two of these mutations, A(-32) --> G and T-27 --> A, with transcription factor consensus sequences suggested the presence of two overlapping and inversely oriented HNF-3 binding sites, Direct evidence for the presence of the two HNF-3 binding sites in the protein C promoter was obtained using electrophoretic mobility shift assays and UV crosslinking experiments, These experiments revealed that HNF-3 can bind specifically to both putative HNF-3 sites in the wild-type protein C promoter. Due to the T-27 --> A mutation, one binding site is completely lost, while the other site still binds HNF-3, but with strongly reduced affinity, As a consequence of the A(-32) --> G mutation, the protein C promoter loses all its HNF-3 binding capacity, Transient transfection experiments demonstrated that the binding of HNF-3 to the protein C promoter is of physiological significance. This followed from experiments in which the introduction of the A(-32) --> G or T-27 --> A mutation resulted in a 4-5-fold reduced promoter activity in HepG2 cells, Furthermore, transactivation of the wild-type protein C promoter construct with HNF-3 showed a 4-5-fold increased promoter activity in HepG2 cells. In HeLa cells, significant wild-type promoter activity was only observed after transactivation with HNF-3, When a promoter construct containing the T --> A mutation at position -27 was used, the transactivation potential of HNF-3 was 2-fold reduced in HepG2 cells, whereas in HeLa cells no transactivation was observed, With the promoter construct containing the A(-32) --> G mutation, no transactivation by HNF-3 was found either in HepG2 or in HeLa cells.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA	Scripps Research Institute	SPEK, CA (corresponding author), LEIDEN UNIV HOSP, CTR HEMOSTASIS & THROMBOSIS RES,DEPT HEMATOL, BLDG 1,C2-R, POB 9600, 2300 CR LEIDEN, NETHERLANDS.		Bertina, Rogier/AGQ-5246-2022; Spek, Arnold/AAC-5866-2019	Spek, Arnold/0000-0002-2149-4068	NHLBI NIH HHS [HL-52246] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052246, R37HL052246] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BERG LP, 1994, HUM MOL GENET, V3, P2147, DOI 10.1093/hmg/3.12.2147; BLAMEY SL, 1985, THROMB HAEMOSTASIS, V54, P622; BRANSON HE, 1983, LANCET, V2, P1165; BROEKMANS AW, 1983, NEW ENGL J MED, V309, P340, DOI 10.1056/NEJM198308113090604; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CARDINAUX JR, 1994, J BIOL CHEM, V269, P32947; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EFREMOV DG, 1994, BLOOD, V83, P3350; ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135; FIJNVANDRAAT K, 1995, THROMB HAEMOSTASIS, V73, P15; FOSTER DC, 1985, P NATL ACAD SCI USA, V82, P4673, DOI 10.1073/pnas.82.14.4673; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GRIFFIN JH, 1982, BLOOD, V60, P261; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HESSELVIK JF, 1991, THROMB HAEMOSTASIS, V65, P126; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; KOIVISTO UM, 1994, P NATL ACAD SCI USA, V91, P10526, DOI 10.1073/pnas.91.22.10526; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MANCA L, 1990, ANN NY ACAD SCI, V612, P485; MARLAR RA, 1989, J PEDIATR-US, V114, P528, DOI 10.1016/S0022-3476(89)80688-2; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MURRU S, 1993, BLOOD, V81, P2818; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PATRACCHINI P, 1989, HUM GENET, V81, P191, DOI 10.1007/BF00293902; PAULWEBER B, 1993, MOL CELL BIOL, V13, P1534, DOI 10.1128/MCB.13.3.1534; PLUTZKY J, 1986, P NATL ACAD SCI USA, V83, P546, DOI 10.1073/pnas.83.3.546; POORT SR, 1993, BLOOD COAGUL FIBRIN, V4, P273, DOI 10.1097/00001721-199304000-00009; QIAN XB, 1995, MOL CELL BIOL, V15, P1364; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; REITSMA PH, 1993, THROMB HAEMOSTASIS, V69, P77; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROUET P, 1995, NUCLEIC ACIDS RES, V23, P395, DOI 10.1093/nar/23.3.395; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SPEK CA, 1995, ARTERIOSCL THROM VAS, V15, P214, DOI 10.1161/01.ATV.15.2.214; STRUHL K, 1994, SCIENCE, V263, P1103, DOI 10.1126/science.8108728; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TSAY W, 1993, BLOOD COAGUL FIBRIN, V4, P791, DOI 10.1097/00001721-199304050-00017; VANHINSBERGH VWM, 1985, BLOOD, V65, P444; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WILLIS MC, 1994, NUCLEIC ACIDS RES, V22, P4947, DOI 10.1093/nar/22.23.4947	57	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24216	24221		10.1074/jbc.270.41.24216	http://dx.doi.org/10.1074/jbc.270.41.24216			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592627	hybrid			2022-12-27	WOS:A1995TA21700055
J	UOZUMI, N; GASSMANN, W; GAO, YW; SCHROEDER, JI				UOZUMI, N; GASSMANN, W; GAO, YW; SCHROEDER, JI			IDENTIFICATION OF STRONG MODIFICATIONS IN CATION SELECTIVITY IN AN ARABIDOPSIS INWARD RECTIFYING POTASSIUM CHANNEL BY MUTANT SELECTION IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNELS; PLASMA-MEMBRANE; FUNCTIONAL EXPRESSION; GUARD-CELLS; SACCHAROMYCES-CEREVISIAE; PROTOPLASTS; TRANSPORT; ION; THALIANA; CLONING	The Arabidopsis thaliana cDNA, KAT1, encodes a hyperpolarization-activated K+ channel, In the present study, we utilized a combination of random site-directed mutagenesis, genetic screening in a potassium uptake-deficient yeast strain, and electrophysiological analysis in Xenopus oocytes to identify strong modifications in cation selectivity of the inward rectifying K+ channel KAT1, Threonine at position 256 was replaced by 11 other amino acid residues, Six of these mutated KAT1 cDNAs complemented a K+ uptake-deficient yeast strain at low concentrations of potassium, Among these, two mutants (T256D and T256G) showed a sensitivity of yeast growth toward high ammonium concentrations and a dramatic increase in current amplitudes of rubidium and ammonium ions relative to K+ by 39-72-fold, These single site mutations gave rise to Rb+- and NH4+-selective channels with Rb+ and NH4+ currents that were approximately 10-13-fold greater in amplitude than K+ currents, whereas the NH4+ to K+ current amplitude ratio of wild type KAT1 was 0.28, This strong conversion in cation specificity without loss of general selectivity exceeds those reported for other mutations in the pore domain of voltage-dependent K+ channels, Yeast growth was greatly impaired by sodium in two other mutants at this site (T256E and T256Q), which were blocked by millimolar sodium (K-1/2 = 1.1 mM for T256E), although the wild type channel was not blocked by 110 mM- sodium, Interestingly, the ability of yeast to grow in the presence of toxic cations correlated to biophysical properties of KAT1 mutants, illustrating the potential for qualitative K+ channel mutant selection in yeast, These data suggest that the size of the side chain of the amino acid at position 256 in KAT1 is important for enabling cation permeation and that this site plays a crucial role in determining the cation selectivity of hyperpolarization-activated potassium channels.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR GENET MOLEC, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Uozumi, Nobuyuki/AAG-3252-2019	Schroeder, Julian/0000-0002-3283-5972; Gassmann, Walter/0000-0002-7527-0385; Uozumi, Nobuyuki/0000-0003-4268-1126				Anderson J A, 1994, Symp Soc Exp Biol, V48, P85; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BERTL A, 1995, P NATL ACAD SCI USA, V92, P2701, DOI 10.1073/pnas.92.7.2701; BUSH DS, 1988, PLANTA, V176, P368, DOI 10.1007/BF00395417; CAO YW, 1995, J BIOL CHEM, V270, P17697, DOI 10.1074/jbc.270.30.17697; COLOMBO R, 1991, PLANT PHYSIOL, V97, P1130, DOI 10.1104/pp.97.3.1130; DEBIASI M, 1993, BIOPHYS J, V65, P1235, DOI 10.1016/S0006-3495(93)81154-8; FAIRLEYGRENOT KA, 1993, PLANTA, V189, P410, DOI 10.1007/BF00194439; GASSMANN W, 1994, PLANT PHYSIOL, V105, P1399, DOI 10.1104/pp.105.4.1399; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HOSHI T, 1995, J GEN PHYSIOL, V105, P309, DOI 10.1085/jgp.105.3.309; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; KOURIE J, 1992, PLANT PHYSIOL, V98, P1087, DOI 10.1104/pp.98.3.1087; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LEE RB, 1991, PLANTA, V183, P359, DOI 10.1007/BF00197734; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; PONGS O, 1993, J MEMBRANE BIOL, V136, P1; RAINS DW, 1967, PLANT PHYSIOL, V42, P319, DOI 10.1104/pp.42.3.319; RAINS DW, 1967, PLANT PHYSIOL, V42, P314, DOI 10.1104/pp.42.3.314; RAINS DW, 1965, SCIENCE, V148, P1611, DOI 10.1126/science.148.3677.1611; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; SACHACHTMAN DP, 1994, NATURE, V370, P655; Sambrook J, 1989, MOL CLONING LABORATO; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; SCHROEDER JI, 1988, J GEN PHYSIOL, V92, P667, DOI 10.1085/jgp.92.5.667; SCHROEDER JI, 1991, P NATL ACAD SCI USA, V88, P11583, DOI 10.1073/pnas.88.24.11583; SCHROEDER JI, 1994, ANNU REV BIOPH BIOM, V23, P441, DOI 10.1146/annurev.bb.23.060194.002301; SCHROEDER JI, 1987, P NATL ACAD SCI USA, V84, P4108, DOI 10.1073/pnas.84.12.4108; SCHROEDER JI, 1995, FEBS LETT, V363, P157, DOI 10.1016/0014-5793(95)00306-T; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; TAGLIALATELA M, 1994, NEWS PHYSIOL SCI, V9, P169; VANDUIJN B, 1993, PLANT PHYSIOL, V101, P81, DOI 10.1104/pp.101.1.81; VERY AA, 1995, PLANT J, V7, P321, DOI 10.1046/j.1365-313X.1995.7020321.x; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	39	95	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24276	24281		10.1074/jbc.270.41.24276	http://dx.doi.org/10.1074/jbc.270.41.24276			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592636	hybrid			2022-12-27	WOS:A1995TA21700064
J	BERMAN, YL; JULIANO, L; DEVI, LA				BERMAN, YL; JULIANO, L; DEVI, LA			PURIFICATION AND CHARACTERIZATION OF A DYNORPHIN-PROCESSING ENDOPEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; CONVERTING ENZYME; MONOBASIC SITES; MESSENGER-RNA; SPINAL-CORD; CELL-LINE; ENDOPROTEASE; CLEAVAGE; SPECIFICITY; PITUITARY	Dynorphin B (Dyn B-13, also known as rimorphin) is generated from Dyn B-29 (leumorphin) by the cleavage at a single Arg residue. An enzymatic activity capable of processing at this monobasic site has been previously reported in neurosecretory vesicles of the bovine pituitary and pituitary-derived cell lines. This enzyme termed ''the dynorphin-converting enzyme'' (DCE) has been purified to apparent homogeneity from the neurointermediate lobe of the bovine pituitary using hydrophobic chromatography on phenyl-Sepharose, preparative isoelectrofocusing in a granulated gel between pH 4 to 6.5, and non-denaturing electrophoresis on 5% polyacrylamide gel, DCE exhibits a pI of about 5.1 and a molecular mass of about 54 kDa under reducing conditions. DCE is a metallopeptidase and exhibits a neutral pH optimum. Specific Inhibitors of soluble metallopeptidases such as enkephalinase (EC 3.4.24.11) or enkephalin generating neutral endopeptidase (EC 3.4.24.15) do not inhibit DCE activity indicating that DCE is distinct from these two enzymes. Cleavage site determination with matrix-assisted laser desorption ionization time of flight (MALDITOF) mass spectrometry shows that DCE cleaves the Dyn B-29 N terminus to the Arg(14) generating Dyn B-13 and Dyn B-(14-29). Among other peptides derived from Dyn B-29, DCE cleaves only those peptides that fit the predicted ''consensus motif'' for monobasic processing. These data are consistent with a broader role for the dynorphin converting enzyme in the biosynthesis of many peptide hormones and neuropeptides by processing at monobasic sites.	NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; ESCOLA PAULISTA MED, BR-04044020 SAO PAULO, BRAZIL	New York University; Universidade Federal de Sao Paulo (UNIFESP)			Devi P, Lakshmi/GXM-5982-2022; Juliano, Luiz/D-7204-2012	Devi P, Lakshmi/0000-0001-9274-4776; Juliano, Luiz/0000-0002-5589-2822	NIDA NIH HHS [DA 7254] Funding Source: Medline; NINDS NIH HHS [NS K04 1788, NS 26880] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026880, K04NS001788, R29NS026880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007254] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BEINFELD MC, 1989, J BIOL CHEM, V264, P4460; BERMAN YL, 1994, BIOCHIMIE, V76, P245, DOI 10.1016/0300-9084(94)90153-8; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHESNEAU V, 1994, J BIOL CHEM, V269, P2056; DAY R, 1993, NEUROSCI LETT, V149, P27, DOI 10.1016/0304-3940(93)90339-M; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; DEVI L, 1991, J NEUROCHEM, V56, P320, DOI 10.1111/j.1471-4159.1991.tb02598.x; DEVI L, 1985, BIOCHEM BIOPH RES CO, V130, P1168, DOI 10.1016/0006-291X(85)91738-3; DEVI L, 1984, P NATL ACAD SCI-BIOL, V81, P1892, DOI 10.1073/pnas.81.6.1892; DEVI L, 1993, ENDOCRINOLOGY, V132, P1139, DOI 10.1210/en.132.3.1139; DEVI L, 1994, J NEUROCHEM, V62, P2387; DEVI L, 1992, ENDOCRINOLOGY, V131, P1930, DOI 10.1210/en.131.4.1930; DIRKSEN ML, 1972, SEPAR SCI, V7, P747, DOI 10.1080/00372367208057980; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; FRICKER LD, 1995, IN PRESS PHARM OPIOI; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; GRECO L, 1992, NEUROENDOCRINOLOGY, V55, P351, DOI 10.1159/000126136; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JULIANO L, 1990, BIOCHEM BIOPH RES CO, V173, P647, DOI 10.1016/S0006-291X(05)80084-1; KRIEGER TJ, 1992, J NEUROCHEM, V59, P26, DOI 10.1111/j.1471-4159.1992.tb08871.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE LC, 1978, ANAL BIOCHEM, V86, P655, DOI 10.1016/0003-2697(78)90792-3; LINDBERG I, 1991, PEPTIDE BIOSYTHESIS, P00141; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P2263, DOI 10.1210/endo-129-4-2263; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; PETANCESKA S, 1993, MOL CELL ENDOCRINOL, V94, P37, DOI 10.1016/0303-7207(93)90049-P; RELTON JM, 1983, BIOCHEM J, V215, P519, DOI 10.1042/bj2150519; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SERIZAWA A, 1995, J BIOL CHEM, V270, P2092, DOI 10.1074/jbc.270.5.2092; SILBERRING J, 1992, J BIOL CHEM, V267, P21324; SILBERRING J, 1989, J BIOL CHEM, V264, P11082; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TEZAPSIDIS N, 1989, FEBS LETT, V246, P44, DOI 10.1016/0014-5793(89)80250-9; TEZAPSIDIS N, 1994, BIOCHEM J, V301, P607, DOI 10.1042/bj3010607; VIERECK JC, 1992, J BIOL CHEM, V267, P19475; WYPIJ DM, 1988, J BIOL CHEM, V263, P7079; YI Z, 1993, J BIOL CHEM, V268, P5615; [No title captured]	45	18	18	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23845	23850		10.1074/jbc.270.40.23845	http://dx.doi.org/10.1074/jbc.270.40.23845			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559562	hybrid			2022-12-27	WOS:A1995RY90900091
J	OLINS, PO; BAUER, SC; BRAFORDGOLDBERG, S; STERBENZ, K; POLAZZI, JO; CAPARON, MH; KLEIN, BK; EASTON, AM; PAIK, K; KLOVER, JA; THIELE, BR; MCKEARN, JP				OLINS, PO; BAUER, SC; BRAFORDGOLDBERG, S; STERBENZ, K; POLAZZI, JO; CAPARON, MH; KLEIN, BK; EASTON, AM; PAIK, K; KLOVER, JA; THIELE, BR; MCKEARN, JP			SATURATION MUTAGENESIS OF HUMAN INTERLEUKIN-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANINE-SCANNING MUTAGENESIS; HEMATOPOIETIC GROWTH-FACTORS; ESCHERICHIA-COLI; GM-CSF; RECEPTOR ACTIVATION; BIOLOGICAL-ACTIVITY; CRYSTAL-STRUCTURE; FOREIGN GENES; PROTEIN; BINDING	A deletion variant of human interleukin-3, hIL-3(15-125), was produced in the periplasmic space of Escherichia coli and had full activity in an AML193.1.3 cell proliferation assay. Libraries of random single-amino acid substitutions were constructed at each of 105 positions in the gene for hIL-3(15-125). Approximately eight single-site substitutions at each position were produced in osmotic shock fractions and screened for activity, 15 mutants were found with bioactivity of 5-26-fold greater than that of native hIL-3. The majority of amino acids in hIL-3(15-125) could be substituted without substantial loss of activity. Substitution of residues predicted to be in the hydrophobic core of the protein often resulted in reduced activity and/or low accumulation levels. Only five residues predicted to be on the surface of the protein were intolerant of substitution and hence are candidates for sites of interaction with the receptor. We therefore propose that the majority of residues in hIL-3 serve a structural role and permit the display of a few key residues in the correct configuration for recognition by the receptor.	MONSANTO CO, SEARLE RES & DEV, ST LOUIS, MO 63198 USA	Monsanto; Pfizer								BAGLEY CJ, 1994, J CELL BIOCHEM, P17; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARRY SC, 1994, J BIOL CHEM, V269, P8488; BIESMA B, 1992, BLOOD, V80, P1141; BOULAY JL, 1992, J BIOL CHEM, V267, P20525; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEMCHUK E, 1994, PROTEIN SCI, V3, P920; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DORSSERS LCJ, 1991, J BIOL CHEM, V266, P21310; EASTON AM, 1991, GENE, V101, P291, DOI 10.1016/0378-1119(91)90426-C; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FENG YQ, 1995, BIOCHEMISTRY-US, V34, P6540, DOI 10.1021/bi00019a036; GIANNI AM, 1993, ANN ONCOL, V4, P759, DOI 10.1093/oxfordjournals.annonc.a058661; GOFFIN V, 1992, MOL ENDOCRINOL, V6, P1381, DOI 10.1210/me.6.9.1381; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; GREENFIELD L, 1978, P NATL ACAD SCI USA, V75, P4724, DOI 10.1073/pnas.75.10.4724; GRUTTER MG, 1994, PROTEIN ENG, V7, P663, DOI 10.1093/protein/7.5.663; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HERCUS TR, 1994, BLOOD, V83, P3500; HUTCHISON CA, 1991, METHOD ENZYMOL, V202, P356; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KASTURI S, 1992, J BIOL CHEM, V267, P23427; KAUSHANSKY K, 1993, BLOOD, V82, P3229; KAUSHANSKY K, 1992, PROTEINS, V12, P1, DOI 10.1002/prot.340120102; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KLEIN BK, 1991, BIO-TECHNOL, V9, P869, DOI 10.1038/nbt0991-869; KRISHNAN IS, 1994, FEBS LETT, V353, P185, DOI 10.1016/0014-5793(94)01017-X; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; LEE SC, 1992, J BIOL CHEM, V267, P2849; LOKKER NA, 1991, EMBO J, V10, P2125, DOI 10.1002/j.1460-2075.1991.tb07746.x; LOKKER NA, 1991, J BIOL CHEM, V266, P10624; LOPEZ AF, 1992, P NATL ACAD SCI USA, V89, P11842, DOI 10.1073/pnas.89.24.11842; MANAVALAN P, 1992, J PROTEIN CHEM, V11, P321, DOI 10.1007/BF01024870; Messing J, 1979, RECOMBINANT DNA TECH, V2, P43; METCALF D, 1993, BLOOD, V82, P3515; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; NEU HC, 1965, J BIOL CHEM, V240, P3685; OLINS PO, 1988, GENE, V73, P227, DOI 10.1016/0378-1119(88)90329-0; OLINS PO, 1990, METHOD ENZYMOL, V185, P115; PAKULA AA, 1989, ANNU REV GENET, V23, P289, DOI 10.1146/annurev.ge.23.120189.001445; Parry D A, 1991, J Mol Recognit, V4, P63, DOI 10.1002/jmr.300040205; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; RUF W, 1994, BIOCHEMISTRY-US, V33, P1565, DOI 10.1021/bi00172a037; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANTOLI D, 1987, J IMMUNOL, V139, P3348; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; SCHREIBER G, 1993, BIOCHEMISTRY-US, V32, P5145, DOI 10.1021/bi00070a025; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHORTLE D, 1992, Q REV BIOPHYS, V25, P205, DOI 10.1017/S0033583500004674; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; THOMAS JW, 1995, P NATL ACAD SCI USA, V92, P3779, DOI 10.1073/pnas.92.9.3779; VANOSTADE X, 1994, PROTEIN ENG, V7, P5, DOI 10.1093/protein/7.1.5; WLODAWER A, 1993, PROTEIN SCI, V2, P1373, DOI 10.1002/pro.5560020902; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; ZURAWSKI SM, 1993, EMBO J, V12, P5113, DOI 10.1002/j.1460-2075.1993.tb06206.x	60	37	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23754	23760		10.1074/jbc.270.40.23754	http://dx.doi.org/10.1074/jbc.270.40.23754			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559548	hybrid			2022-12-27	WOS:A1995RY90900077
J	BOGOYEVITCH, MA; MARSHALL, CJ; SUGDEN, PH				BOGOYEVITCH, MA; MARSHALL, CJ; SUGDEN, PH			HYPERTROPHIC AGONISTS STIMULATE THE ACTIVITIES OF THE PROTEIN-KINASES C-RAF AND A-RAF IN CULTURED VENTRICULAR MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC GENE-EXPRESSION; MAP KINASE; SIGNAL-TRANSDUCTION; PARACRINE MECHANISM; CELL HYPERTROPHY; MYOCARDIAL-CELLS; PHORBOL ESTERS; ACTIVATION; PATHWAY; CAMP	We detected expression of two Raf isoforms, c-Raf and A Raf, in neonatal rat heart, Both isoforms phosphorylated, activated, and formed complexes with mitogen-activated protein kinase kinase 1 in vitro. However, these isoforms were differentially activated by hypertrophic stimuli such as peptide growth factors, endothelin-l (ET1), or 12-O-tetradecanoylphorbol-13-acetate (TPA) that activate the mitogen-activated protein kinase cascade, Exposure of cultured ventricular myocytes to acidic fibroblast growth factor activated c-Raf but not A-Raf, In contrast, TPA produced a sustained activation of A-Raf and only transiently activated c-Raf. ET1 transiently activated both isoforms. TPA and ET1 were the most potent activators of c-Raf and A-Raf. Both utilized protein kinase C dependent pathways, but stimulation by ET1 was also partially sensitive to pertussis toxin pretreatment. c-Raf was inhibited by activation of cAMP-dependent protein kinase although A-Raf was less affected. Fetal calf serum, phenylephrine, and carbachol were less potent activators of c-Raf and A-Raf. These results demonstrate that A-Raf and c-Raf are differentially regulated and that A-Raf may be an important mediator of mitogen activated protein kinase cas cade activation when cAMP is elevated.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, NATL HEART & LUNG INST, LONDON SW3 6LY, ENGLAND	Imperial College London	BOGOYEVITCH, MA (corresponding author), INST CANC RES, CHESTER BEATTY LABS, CRC, CTR CELL & MOLEC BIOL, 237 FULHAM RD, LONDON SW3 6JB, ENGLAND.			Bogoyevitch, Marie/0000-0001-9745-3716	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOGOYEVITCH MA, 1993, AM J PHYSIOL, V265, pC1247, DOI 10.1152/ajpcell.1993.265.5.C1247; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CATLING AD, 1994, J BIOL CHEM, V269, P30014; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CLERK A, 1994, J BIOL CHEM, V269, P32848; CLERK A, 1995, IN PRESS AM J PHYSL; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; FAURE M, 1994, J BIOL CHEM, V269, P7851; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GOMEZ N, 1992, FEBS LETT, V314, P461, DOI 10.1016/0014-5793(92)81527-S; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MARAIS R, 1945, MEBO J, V14, P3136; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHNEIDER MD, 1990, CIRCULATION, V81, P1443, DOI 10.1161/01.CIR.81.5.1443; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STORM SM, 1990, ONCOGENE, V5, P345; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, BIOCHEM BIOPH RES CO, V202, P1586, DOI 10.1006/bbrc.1994.2113; THORBURN J, 1994, J BIOL CHEM, V269, P30580; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VOTJEK AB, 1993, CELL, V74, P205; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069; YAN MH, 1994, NATURE, V372, P798; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031	100	86	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26303	26310		10.1074/jbc.270.44.26303	http://dx.doi.org/10.1074/jbc.270.44.26303			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592840	hybrid			2022-12-27	WOS:A1995TC97800047
J	GUICHARD, G; CALBO, S; MULLER, S; KOURILSKY, P; BRIAND, JP; ABASTADO, JP				GUICHARD, G; CALBO, S; MULLER, S; KOURILSKY, P; BRIAND, JP; ABASTADO, JP			EFFICIENT BINDING OF REDUCED PEPTIDE-BOND PSEUDOPEPTIDES TO MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VIRAL PEPTIDES; MHC MOLECULES; RECOGNITION; CHAIN; BETA-2-MICROGLOBULIN; ANTIGEN; H-2K(B)	Reduced peptide bond pseudopeptide analogues have been examined for their ability to bind murine class I molecules of the major histocompatibility complex (MHC), Eight pseudopeptide analogues of an antigenic peptide derived from Plasmodium berghei (H-Ser(252)-Tyr-Ile-Pro-Ser-Ala-Glu-Lys-Ile(260)-OH) were obtained by systematically replacing one peptide bond at a time by a reduced peptide bond Psi(CH2-NH). The resulting analogues Were then tested for their binding to a recombinant single chain SC-K-d class I molecule. The comparative results show that five analogues can efficiently mimic the parent peptide while the introduction of the reduced bond between P3-P4, P7-P8, and P8-P9 is deleterious for SC-K-d binding, The fact that more stable pseudopeptides containing reduced peptide bonds can bind major histocompatibility complex molecules is of great interest for the design of peptidomimetics with potential therapeutical properties. Such peptide analogues may prove useful for the development of peptide-based cytotoxic T lymphocyte vaccines.	INST BIOL MOLEC & CELLULAIRE,CNRS,UPR 9021,F-67000 STRASBOURG,FRANCE; INST PASTEUR,INSERM,UNITE BIOL MOLEC GENE 277,F-75724 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Muller, Sylviane/J-5319-2014; GUICHARD, Gilles/I-3858-2016	GUICHARD, Gilles/0000-0002-2584-7502				ABASTADO JP, 1995, J EXP MED, V182, P439, DOI 10.1084/jem.182.2.439; ABASTADO JP, 1993, J IMMUNOL, V151, P3569; ABASTADO JP, 1993, EUR J IMMUNOL, V23, P1776, DOI 10.1002/eji.1830230807; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FEHRENTZ JA, 1983, SYNTHESIS-STUTTGART, P676; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GILL RF, 1994, J IMMUNOL METHODS, V176, P245, DOI 10.1016/0022-1759(94)90318-2; GODEAU F, 1992, J BIOL CHEM, V267, P24223; GUICHARD G, 1994, PEPTIDE RES, V7, P308; HILL CM, 1994, J IMMUNOL, V152, P2890; HO PT, 1992, J ORG CHEM, V58, P2313; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MARRAUD M, 1993, BIOPOLYMERS, V31, P1135; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MOTTEZ E, 1991, EUR J IMMUNOL, V21, P467, DOI 10.1002/eji.1830210232; NEIMARK J, 1993, PEPTIDE RES, V6, P219; PULLEN JK, 1992, J IMMUNOL, V148, P953; ROCCA A, 1992, MOL IMMUNOL, V29, P481, DOI 10.1016/0161-5890(92)90005-I; ROMERO P, 1991, J EXP MED, V174, P603, DOI 10.1084/jem.174.3.603; SASAKI Y, 1987, PEPTIDES, V8, P119, DOI 10.1016/0196-9781(87)90174-4; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; SLINGLUFF CL, 1993, J IMMUNOL, V150, P2955; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	26	43	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26057	26059		10.1074/jbc.270.44.26057	http://dx.doi.org/10.1074/jbc.270.44.26057			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592803	hybrid			2022-12-27	WOS:A1995TC97800010
J	MONDINO, A; JENKINS, MK				MONDINO, A; JENKINS, MK			ACCUMULATION OF SEQUENCE-SPECIFIC RNA-BINDING PROTEINS IN THE CYTOSOL OF ACTIVATED T-CELLS UNDERGOING RNA DEGRADATION AND APOPTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; AU-RICH SEQUENCES; MESSENGER-RNA; CYCLOSPORINE-A; LYMPHOCYTES-T; CYCLE BLOCK; DEATH; DNA; DEOXYRIBONUCLEASE; GLUCOCORTICOIDS	Engagement of the T cell antigen receptor (TCR) causes transformed T cell hybridomas to produce lymphokines and then die by an apoptotic mechanism, Here we show that these functional effects of TCR-mediated signaling are associated with the accumulation of several cytosolic mRNA binding proteins including the previously described AU-A, -B, and -C proteins as well as a novel 70-kDa protein. The results indicate that the 70-kDa protein derived from a 90-kDa precursor present in unactivated T cells and that both proteins bound to two independent sites at the 3'-end of the interleukin-a mRNA, one in the coding region and the other in an AU-rich segment of the S'-untranslated region. Glucocorticoids, TCR engagement by monoclonal antibodies, pharmocologic mimics of TCR signaling, or high concentrations of protein or RNA synthesis inhibitors all induced apoptosis, the cytosolic appearance of the RNA-binding proteins, and an increased rate of RNA turnover, Moreover, drugs that interfere with TCR-mediated signals, such as cyclosporin A and staurosporin, prevented both apoptosis and the appearance of the RNA-binding factors. The fact that the accumulation of these factors occurred in the presence of inhibitors of transcription and translation suggested that these proteins are present in an inactive form in unstimulated T cells and are activated when apoptosis is induced.			MONDINO, A (corresponding author), UNIV MINNESOTA,SCH MED,DEPT MICROBIOL,MINNEAPOLIS,MN 55455, USA.		Mondino, Anna/K-9434-2016; Jenkins, Marc K/G-1063-2012	Mondino, Anna/0000-0003-0833-6927; Jenkins, Marc K/0000-0001-8009-7655	NIAID NIH HHS [AI-27998] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI027998, R01AI027998] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; ASHWELL JD, 1994, HDB B T LYMPHOCYTES, P63; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CIDLOWSKI JA, 1982, ENDOCRINOLOGY, V111, P184, DOI 10.1210/endo-111-1-184; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DESILVA DR, 1991, J IMMUNOL, V147, P3261; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; HECHT TT, 1983, J IMMUNOL, V131, P1049; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; HOBERT O, 1994, J BIOL CHEM, V269, P20225; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDSTEN T, 1989, SCIENCE, V144, P339; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MARTIN SJ, 1993, IMMUNOL LETT, V35, P125, DOI 10.1016/0165-2478(93)90080-L; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MERCEP M, 1989, J IMMUNOL, V142, P4085; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PERANDONES CE, 1993, J IMMUNOL, V151, P3521; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SHYU AB, 1991, GENE DEV, V3, P60; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; UCKER DS, 1989, J IMMUNOL, V143, P3461; UMLAF S, IMMUNOL REV, V133, P177; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS DL, 1993, CONTROL MESSENGER RN, P161; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1991, J IMMUNOL, V146, P3857	50	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26593	26601		10.1074/jbc.270.44.26593	http://dx.doi.org/10.1074/jbc.270.44.26593			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592882	hybrid			2022-12-27	WOS:A1995TC97800089
J	WANG, YJ; MEHTA, PP; ROSE, B				WANG, YJ; MEHTA, PP; ROSE, B			INHIBITION OF GLYCOSYLATION INDUCES FORMATION OF OPEN CONNEXIN-43 CELL-TO-CELL CHANNELS AND PHOSPHORYLATION AND TRITON X-100 INSOLUBILITY OF CONNEXIN-43	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP JUNCTION PROTEIN; MEMBRANE CHANNEL; COMMUNICATION; LIVER; EXPRESSION; GROWTH; GENE	We transfected the cDNA for the cell-to-cell channel protein connexin 43 (Cx43) into Morris hepatoma H5123 cells, which express little Cx43 and lack gap junctional communication (open cell-to-cell channels). We found that cells overexpressing Cx43 nonetheless lacked open cell-to-cell channels, but that inhibition of glycosylation by tunicamycin induced open channels in these cells. Tunicamycin also induced biochemical changes in Cx43 protein; the level increased, and a considerable fraction became phosphorylated and Triton X-100 insoluble, in contrast to untreated cells where Cx43 was non-phosphorylated and Triton X-100 soluble. Although tunicamycin caused the formation of open channels, channels were not found aggregated into gap junctional plaques, as they are when they have been induced by elevation of intracellular cAMP. The results suggest that although Cx43 itself is not glycosylated, other glycosylated proteins influence Cx43 posttranslational modification and the formation of Cx43 cell-to cell channels.	UNIV MIAMI,SCH MED,DEPT PHYSIOL & BIOPHYS,MIAMI,FL 33101; UNIV MIAMI,SCH MED,SYLVESTER COMPREHENS CANC CTR,DEPT MED,MIAMI,FL 33101; VET ADM MED CTR,CTR CLIN,MIAMI,FL 33101	University of Miami; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NCI NIH HHS [CA 14464-21] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABNEY JR, 1987, BIOPHYS J, V52, P441, DOI 10.1016/S0006-3495(87)83233-2; AZARNIA R, 1981, J MEMBRANE BIOL, V63, P133, DOI 10.1007/BF01969454; BERTHOUD VM, 1992, EUR J CELL BIOL, V57, P40; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BOREK C, 1969, J MEMBRANE BIOL, V1, P274, DOI 10.1007/BF01869786; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; DERMIETZEL R, 1987, J HISTOCHEM CYTOCHEM, V35, P387, DOI 10.1177/35.3.3029214; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FILSON AJ, 1990, CELL GROWTH DIFFER, V1, P661; GOODENOUGH DA, 1970, J CELL BIOL, V45, P272, DOI 10.1083/jcb.45.2.272; HERTZBERG EL, 1979, J BIOL CHEM, V254, P2138; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; KREUTZIGER GO, 1968, 26TH P EL MICR SOC A, P234; Kumar N M, 1992, Semin Cell Biol, V3, P3; LEVINE E, 1991, AM J PHYSIOL, V261, pC1025; LIN SS, 1987, SCIENCE, V237, P648, DOI 10.1126/science.3603045; Loewenstein W R, 1992, Semin Cell Biol, V3, P59; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; MEHTA PP, 1992, MOL BIOL CELL, V3, P839, DOI 10.1091/mbc.3.8.839; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; MICEVYCH PE, 1991, J COMP NEUROL, V305, P96, DOI 10.1002/cne.903050110; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; PERACCHIA C, 1985, ENZYMES BIOL MEMBR, V1, P81; RAHMAN S, 1993, J BIOL CHEM, V268, P1260; REVEL J. P., 1967, J CELL BIOL, V33, P7; SCHWARZMANN G, 1981, SCIENCE, V213, P551, DOI 10.1126/science.7244653; WANG YJ, 1995, EUR J CELL BIOL, V67, P285; Warner A., 1992, Seminars in Cell Biology, V3, P81	32	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26581	26585		10.1074/jbc.270.44.26581	http://dx.doi.org/10.1074/jbc.270.44.26581			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592880	hybrid			2022-12-27	WOS:A1995TC97800087
J	ZANCHIN, NIT; MCCARTHY, JEG				ZANCHIN, NIT; MCCARTHY, JEG			CHARACTERIZATION OF THE IN-VIVO PHOSPHORYLATION SITES OF THE MESSENGER-RNA-CENTER-DOT-CAP-BINDING COMPLEX PROTEINS EUKARYOTIC INITIATION FACTOR-4E AND P20 IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; RNA 5' CAP; TRANSLATIONAL CONTROL; NUCLEOTIDE-SEQUENCE; SECONDARY STRUCTURE; ESCHERICHIA-COLI; FACTOR EIF-4E; FACTOR 4E; YEAST; PURIFICATION	Eukaryotic translation is believed to be regulated via the phosphorylation of specific eukaryotic initiation factors (eIFs), including one of the cap-binding complex proteins, eIF-4E. We show that in the yeast Saccharomyces cerevisiae, both eIF-4E and another cap-binding complex protein, p20, are phosphoproteins. The major sites of phosphorylation of yeast eIF-4E are found to be located in the N-terminal region of its sequence (Ser(2) and Ser(15)) and are thus in a different part of the protein from the main phosphorylation sites (Ser(53) and Ser(209)) proposed previously for mammalian eIF-4E. The most likely sites of p20 phosphorylation are at Ser(91) and/or Ser(154). All of the major sites in the two yeast proteins are phosphorylated by casein kinase II in vitro. Casein kinase II phosphorylation of cap complex proteins should therefore be considered as potentially involved in the control of yeast protein synthesis. Mutagenesis experiments revealed that yeast eIF-4E activity is not dependent on the presence of Ser(2) or Ser(15). On the other hand, we observed variations in the amount of (phosphorylated) p20 associated with the cap binding complex as a function of cell growth conditions. Our results suggest that interactions of yeast eIF-4E with other phosphorylatable proteins, such as p20, could play a pivotal role in translational control.	NATL BIOTECHNOL RES CTR, DEPT GENE EXPRESS, D-38124 BRAUNSCHWEIG, GERMANY				Zanchin, Nilson Ivo Tonin/AAB-4907-2019	Zanchin, Nilson Ivo Tonin/0000-0002-1153-0694				ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P7520, DOI 10.1093/nar/17.18.7520; ALTMANN M, 1985, BIOCHEMISTRY-US, V24, P6085, DOI 10.1021/bi00343a009; ALTMANN M, 1989, MOL CELL BIOL, V9, P4467, DOI 10.1128/MCB.9.10.4467; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; BELEV TN, 1991, PLASMID, V26, P147, DOI 10.1016/0147-619X(91)90056-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DOBSON MJ, 1983, NUCLEIC ACIDS RES, V11, P2287, DOI 10.1093/nar/11.8.2287; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; FEIGENBLUM D, 1993, J VIROL, V67, P3027, DOI 10.1128/JVI.67.6.3027-3035.1993; FENG L, 1994, MOL CELL BIOL, V14, P5139, DOI 10.1128/MCB.14.8.5139; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; GLOVER CVC, 1983, J BIOL CHEM, V258, P3258; GOYER C, 1989, J BIOL CHEM, V264, P7603; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; JONES EW, 1977, GENETICS, V85, P23; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KAUFMAN RJ, 1993, J BIOL CHEM, V268, P11902; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG V, 1994, J BIOL CHEM, V269, P6117; LANKER S, 1992, J BIOL CHEM, V267, P21167; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1993, BIOCHIMIE, V75, P985, DOI 10.1016/0300-9084(93)90149-M; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1991, PHARMACOL THERAPEUT, V50, P291, DOI 10.1016/0163-7258(91)90047-P; MORLEY SJ, 1993, EUR J BIOCHEM, V218, P39, DOI 10.1111/j.1432-1033.1993.tb18349.x; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; PADMANABHA R, 1987, J BIOL CHEM, V262, P1829; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; RUBIN GM, 1973, J BIOL CHEM, V248, P3860; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN F, 1986, LABORATORY COURSE MA; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; VANDENHEUVEL J, 1995, BBA-GENE STRUCT EXPR, V1261, P337, DOI 10.1016/0167-4781(95)00026-D; ZHANG Y, 1994, J VIROL, V68, P7040, DOI 10.1128/JVI.68.11.7040-7050.1994	55	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26505	26510		10.1074/jbc.270.44.26505	http://dx.doi.org/10.1074/jbc.270.44.26505			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592868	hybrid			2022-12-27	WOS:A1995TC97800075
J	RAY, A; KYSELOVIC, J; LEDDY, JJ; WIGLE, JT; JASMIN, BJ; TUANA, BS				RAY, A; KYSELOVIC, J; LEDDY, JJ; WIGLE, JT; JASMIN, BJ; TUANA, BS			REGULATION OF DIHYDROPYRIDINE AND RYANODINE RECEPTOR GENE-EXPRESSION IN SKELETAL-MUSCLE - ROLE OF NERVE, PROTEIN-KINASE-C, AND CAMP PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; BETA-SUBUNIT; ELECTRICAL-ACTIVITY; MOLECULAR-CLONING; MESSENGER-RNAS; ALPHA-SUBUNIT; GAMMA-SUBUNIT; EXCITATION	The dihydropyridine (DHP) and ryanodine (RY) receptors play a critical role in depolarization-induced calcium release in skeletal muscle, yet the factors which govern their expression remain unknown. We investigated the roles of electrical activity and trophic factors in the regulation of the genes encoding the alpha(1), alpha(2), and beta subunits of the DHP receptor as well as the RY receptor in rat skeletal muscle in vivo. Muscle paralysis, induced by denervation, had no effect on the DHP receptor mRNA levels while the RY receptor mRNA was decreased. In contrast, chronic superfusion of tetrodotoxin onto the sciatic nerve resulted in a marked increase in mRNA levels and transcriptional activity of both DHP and RY receptor genes. Since nerve can induce changes in second messenger pathways which modulate muscle gene expression, we attempted to identify factors which regulate DHP and RY receptor expression using cultured myotubes. Elevated cAMP levels specifically inhibited the expression of RY receptor mRNA while 12-O-tetradecanoylphorbol-13-acetate, an activator of protein kinase C, increased the transcripts encoding the RY receptor and the alpha(1) subunit of the DHP receptor. Changes in the level of mRNAs were paralleled by altered receptor numbers. Neither cAMP nor protein kinase C altered transcriptional activity of the DHP and RY receptor genes. These results demonstrate that neural factor(s) regulate DHP and RY receptor mRNA levels in vivo via transcriptional mechanisms while protein kinase C and cAMP can modulate DHP and RY receptor transcript levels by a transcription-independent process.	UNIV OTTAWA, FAC MED, DEPT PHARMACOL, OTTAWA, ON K1H 8M5, CANADA; UNIV OTTAWA, FAC MED, DEPT PHYSIOL, OTTAWA, ON K1H 8M5, CANADA	University of Ottawa; University of Ottawa			Kyselovic, Jan/H-4858-2016; Wigle, J.t./G-2005-2014	Kyselovic, Jan/0000-0001-9208-5352; Wigle, J.t./0000-0002-4985-7684				BUONANNO A, 1986, J BIOL CHEM, V261, P1452; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHAHINE KG, 1993, J BIOL CHEM, V268, P2893; CHAPRON J, 1989, NEUROSCI LETT, V106, P19, DOI 10.1016/0304-3940(89)90195-X; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FUENTES ME, 1993, NEURON, V10, P670; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GOLDMAN D, 1988, NEURON, V1, P329, DOI 10.1016/0896-6273(88)90081-5; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; JASMIN BJ, 1995, J PHYSIOL-LONDON, V484, P155, DOI 10.1113/jphysiol.1995.sp020654; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; KYSELOVIC J, 1994, J BIOL CHEM, V269, P21770; LAVOIE PA, 1976, NATURE, V260, P349, DOI 10.1038/260349a0; LEGAY C, 1993, J NEUROCHEM, V60, P337, DOI 10.1111/j.1471-4159.1993.tb05856.x; LUO ZG, 1994, J BIOL CHEM, V269, P27216; MARKS AR, 1991, J CELL BIOL, V114, P303, DOI 10.1083/jcb.114.2.303; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARZLUFF WF, 1990, METHOD ENZYMOL, V181, P30; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MICHEL RN, 1994, J CELL BIOL, V127, P1061, DOI 10.1083/jcb.127.4.1061; MURPHY BJ, 1990, CAN J PHYSIOL PHARM, V68, P1389, DOI 10.1139/y90-211; NEW HV, 1986, NATURE, V323, P809, DOI 10.1038/323809a0; OFFORD J, 1989, NEURON, V2, P1442; OTSU K, 1990, J BIOL CHEM, V265, P13472; ROMEY G, 1989, P NATL ACAD SCI USA, V86, P2933, DOI 10.1073/pnas.86.8.2933; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SCHUETZE SM, 1987, ANNU REV NEUROSCI, V10, P403, DOI 10.1146/annurev.ne.10.030187.002155; SHIH HT, 1990, J CLIN INVEST, V85, P781, DOI 10.1172/JCI114504; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SUNAHARA RK, 1990, ANAL BIOCHEM, V185, P143, DOI 10.1016/0003-2697(90)90269-F; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUANA BS, 1988, MOL CELL BIOCHEM, V80, P133; VERGARA J, 1985, P NATL ACAD SCI USA, V82, P6352, DOI 10.1073/pnas.82.18.6352; WALKE W, 1994, J BIOL CHEM, V269, P19447; WHITE JD, 1989, METHOD ENZYMOL, V168, P681; WINTER B, 1993, J BIOL CHEM, V268, P9869; WITZEMANN V, 1991, J CELL BIOL, V114, P125, DOI 10.1083/jcb.114.1.125; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	49	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25837	25844		10.1074/jbc.270.43.25837	http://dx.doi.org/10.1074/jbc.270.43.25837			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592768	hybrid			2022-12-27	WOS:A1995TB46600085
J	WANG, LL; MUKHERJEE, S; JIA, FG; NARAYAN, O; ZHAO, LJ				WANG, LL; MUKHERJEE, S; JIA, FG; NARAYAN, O; ZHAO, LJ			INTERACTION OF VIRION PROTEIN VPR OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH CELLULAR TRANSCRIPTION FACTOR SP1 AND TRANSACTIVATION OF VIRAL LONG TERMINAL REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; GENE; PROMOTER; BINDING; AIDS; REPLICATION; INFECTION; COMPLEX; CELLS; DNA	Acquired immunodeficiency syndrome (AIDS) is a result of replication of the human immunodeficiency virus type 1 (HIV-1) predominantly in CD4(+) T lymphocytes and macrophages. However, most of these cells in vivo are immunologically quiescent, a condition restricting HIV-1 replication. Vpr is an HIV-1 virion protein suspected to enhance HIV-1 replication in vivo. We demonstrate in this report that Vpr specifically activates HIV-1 long terminal repeat (LTR)-directed transcription. This effect is most pronounced on a minimal promoter from HIV-1 LTR containing the TATA box and binding motifs for the ubiquitous cellular transcription factor Sp1. Evidence is presented that Vpr interacts with Sp1 when Sp1 is bound to the Sp1 motifs within the HIV-1 LTR. Both Vpr-Sp1 interaction and Vpr trans-activation require a central Leu/Ile-rich domain in Vpr. Our findings suggest that Vpr trans-activation through Sp1 is most critical for the immediate early transcription of HIV-1 when other positive regulators, such as NF-kappa B, are Limited or inactive, a condition presumably present in vivo. By interacting with Sp1, Vpr also has the potential to influence cellular gene expression and cellular functions. Thus, therapeutic approaches directed toward blocking the Vpr trans-activation function could prove valuable in treating AIDS.	UNIV KANSAS,MED CTR,DEPT MICROBIOL MOLEC GENET & IMMUNOL,VIRAL PATHOGENESIS LAB,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center								BALOTTA C, 1993, J VIROL, V67, P4409, DOI 10.1128/JVI.67.7.4409-4414.1993; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; CONAWAY JW, 1990, J BIOL CHEM, V265, P7564; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DEDERA D, 1989, J VIROL, V63, P3205, DOI 10.1128/JVI.63.7.3205-3208.1989; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GIULIAN D, 1993, P NATL ACAD SCI USA, V90, P2769, DOI 10.1073/pnas.90.7.2769; GREENE WC, 1990, ANNU REV IMMUNOL, V8, P453, DOI 10.1146/annurev.iy.08.040190.002321; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LEVY DN, 1995, J VIROL, V69, P1243, DOI 10.1128/JVI.69.2.1243-1252.1995; LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873; LEVY JA, 1993, MICROBIOL REV, V57, P189; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; MEEKER TC, 1990, MOL CELL BIOL, V10, P1680, DOI 10.1128/MCB.10.4.1680; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; VIRELIZIER JL, 1990, CURR OPIN IMMUNOL, V2, P409, DOI 10.1016/0952-7915(89)90151-9; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WONGSTAAL F, 1987, AIDS RES HUM RETROV, V3, P33, DOI 10.1089/aid.1987.3.33; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265; ZHAO LJ, 1994, J BIOL CHEM, V269, P32131; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1994, J BIOL CHEM, V269, P15577	33	158	161	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25564	25569		10.1074/jbc.270.43.25564	http://dx.doi.org/10.1074/jbc.270.43.25564			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592727	hybrid			2022-12-27	WOS:A1995TB46600044
J	PATTI, ME; SUN, XJ; BRUENING, JC; ARAKI, E; LIPES, MA; WHITE, MF; KAHN, CR				PATTI, ME; SUN, XJ; BRUENING, JC; ARAKI, E; LIPES, MA; WHITE, MF; KAHN, CR			4PS/INSULIN RECEPTOR SUBSTRATE (IRS)-2 IS THE ALTERNATIVE SUBSTRATE OF THE INSULIN-RECEPTOR IN IRS-1-DEFICIENT MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING COMPLEXES; INTACT-CELLS; PROTEIN; IRS-1; ASSOCIATION; RAT; PHOSPHORYLATION; 3'-KINASE; MUSCLE	Insulin receptor substrate-1 (IRS-1) is the major cytoplasmic substrate of the insulin and insulin-like growth factor (IGF)-1 receptors. Transgenic mice lacking IRS-1 are resistant to insulin and IGF-1, but exhibit significant residual insulin action which corresponds to the presence of an alternative high molecular weight substrate in liver and muscle. Recently, Sun et al. (Sun, X.-J, Wang, L. M., Zhang, Y., Yenush, L. P., Myers, M. G., Jr., Glasheen, E., Lane, W. S., Pierce, J, H., and White, M. F. (1995) Nature 377, 173-177) purified and cloned 4PS, the major substrate of the IL-4 receptor-associated tyrosine kinase in myeloid cells, which has significant structural similarity to IRS-1. To determine if 4PS is the alternative substrate of the insulin receptor in IRS-1-deficient mice, we performed immunoprecipitation, immunoblotting, and phosphatidylinositol (PI) 3-kinase assays using specific antibodies to 4PS. Following insulin stimulation, 4PS is rapidly phosphorylated in liver and muscle, binds to the p85 subunit of PI 3-kinase, and activates the enzyme. Insulin stimulation also results in the association of 4PS with Grb 2 in both liver and muscle. In IRS-1-deficient mice, both the phosphorylation of 4PS and associated PI 3-kinase activity are enhanced, without an increase in protein expression. Immunodepletion of 4PS from liver and muscle homogenates removes most of the phosphotyrosine-associated PI 3-kinase activity in IRS-1-deficient mice. Thus, 4PS is the primary alternative substrate, i.e. IRS-2, which plays a major role in physiologic insulin signal transduction via both PI 3-kinase activation and Grb 2/Sos association. In IRS-1-deficient mice, 4PS/IRS 2 provides signal transduction to these two major pathways of insulin signaling.	HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808, R01DK033201] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33201, DK43808] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, 1994, J BIOL CHEM, V269, P28937; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; FOLLI F, 1992, J BIOL CHEM, V267, P22171; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HADARI YR, 1993, J BIOL CHEM, V268, P9156; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAMPHERE L, 1994, AM J PHYSIOL, V266, pE486, DOI 10.1152/ajpendo.1994.266.3.E486; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; MYERS MG, 1994, J BIOL CHEM, V269, P28783; OKADA T, 1994, J BIOL CHEM, V269, P3568; PONS S, 1995, MOL CELL BIOL, V15, P4453; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SUNG CK, 1994, J BIOL CHEM, V269, P12503; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOBE K, 1993, J BIOL CHEM, V268, P11167; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V238, P22231; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	33	190	191	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24670	24673		10.1074/jbc.270.42.24670	http://dx.doi.org/10.1074/jbc.270.42.24670			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559579	hybrid			2022-12-27	WOS:A1995TB46500013
J	PENG, H; LEVER, JE				PENG, H; LEVER, JE			REGULATION OF NA+-COUPLED GLUCOSE-TRANSPORT IN LLC-PK1 CELLS - MESSAGE STABILIZATION INDUCED BY CYCLIC-AMP ELEVATION IS ACCOMPANIED BY BINDING OF A M(R)=48,000 PROTEIN TO A URIDINE-RICH DOMAIN IN THE 3'-UNTRANSLATED REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; C-FOS; NA+/GLUCOSE COTRANSPORTER; KINASE; LINE; PHOSPHORYLATION; DIFFERENTIATION; SPECIFICITY; LYMPHOKINE	In an exploration of the molecular basis of cyclic AMP-induced stabilization of Na+/glucose cotransporter mRNA (SGLT1 isoform) accompanying cell differentiation in the pig kidney cell line LLC-PK1, we have identified a 48-kDa cytoplasmic protein factor, designated SG-URBP, which specifically binds a 120-nucleotide sequence within the 3'-untranslated region of the SGLT1 message. A 46-nucleotide uridine-rich element within this region appears necessary for specific binding, and the presence of the 3'-untranslated region is necessary for message stabilization by cyclic AMP. The binding activity of SG-URBP is up-regulated after cyclic AMP elevation and protein kinase A activation, whereas protein dephosphorylation either in vivo or in vitro is associated with loss of binding activity. The increase in SG-URBP binding activity correlates with an increase in the half-life of the SGLT1 message, suggesting a cause and effect relationship.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225	University of Texas System					NIDDK NIH HHS [DK 27400] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027400, R01DK027400] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAVANI SR, 1987, EUR J BIOCHEM, V167, P221, DOI 10.1111/j.1432-1033.1987.tb13326.x; ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; AMSLER K, 1991, AM J PHYSIOL, V260, pC1290, DOI 10.1152/ajpcell.1991.260.6.C1290; AMSLER K, 1982, AM J PHYSIOL, V242, pC94, DOI 10.1152/ajpcell.1982.242.1.C94; ATKINS RE, 1992, BIOTECHNIQUES, V12, P496; Belasco J.G., 2012, CONTROL MESSENGER RN; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1995, IN PRESS TRENDS BIOC; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUANG LY, 1993, J BIOL CHEM, V268, P25769; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; LEVER JE, 1989, ENVIRON HEALTH PERSP, V80, P173, DOI 10.2307/3430742; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; Maniatis T, 1989, DECONTAMINATION DILU; OHTA T, 1990, MOL CELL BIOL, V10, P6491, DOI 10.1128/MCB.10.12.6491; PENG H, 1993, J CELL PHYSIOL, V154, P238, DOI 10.1002/jcp.1041540205; PENG H, 1995, J BIOL CHEM, V270, P20536, DOI 10.1074/jbc.270.35.20536; PORT JD, 1992, J BIOL CHEM, V267, P24103; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SRIVASTAVA SK, 1994, AM J PHYSIOL, V267, pF504, DOI 10.1152/ajprenal.1994.267.3.F504; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WRIGHT EM, 1993, ANNU REV PHYSIOL, V55, P575, DOI 10.1146/annurev.ph.55.030193.003043; YET SF, 1994, J CELL PHYSIOL, V158, P506, DOI 10.1002/jcp.1041580315; YONEYAMA Y, 1984, J CELL PHYSIOL, V121, P64, DOI 10.1002/jcp.1041210109; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931	40	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23996	24003		10.1074/jbc.270.41.23996	http://dx.doi.org/10.1074/jbc.270.41.23996			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592596	hybrid			2022-12-27	WOS:A1995TA21700024
J	PIO, F; NI, CZ; MITCHELL, RS; KNIGHT, J; MCKERCHER, S; KLEMSZ, M; LOMBARDO, A; MAKI, RA; ELY, KR				PIO, F; NI, CZ; MITCHELL, RS; KNIGHT, J; MCKERCHER, S; KLEMSZ, M; LOMBARDO, A; MAKI, RA; ELY, KR			COCRYSTALLIZATION OF AN ETS DOMAIN (PU.1) IN COMPLEX WITH DNA - ENGINEERING THE LENGTH OF BOTH PROTEIN AND OLIGONUCLEOTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TRANSCRIPTIONAL ACTIVATION; ONCOGENE; RECOGNITION; SEQUENCE; BINDING; C-ETS-1; MOTIF; GENE	The PU.1 transcription factor is a member of the ets gene family of regulatory proteins, These molecules play a role in normal development and also have been implicated in malignant processes such as the development of erythroid leukemia, The Ets proteins share a conserved DNA-binding domain (the ETS domain) that recognizes a purine-rich sequence with the core sequence: 5'-C/AGGAA/T-3'. This domain binds to DNA as a monomer, unlike many other DNA-binding proteins, The ETS domain of the PU.1 transcription factor has been crystallized in complex with a 16-base pair oligonucleotide that contains the recognition sequence. The crystals formed in the space group C2 with a = 89.1, b = 101.9, c = 55.6 Angstrom, and beta = 111.2 degrees and diffract to at least 2.3 Angstrom, There are two complexes in the asymmetric unit, Production of large usable crystals was dependent on the length of both protein and DNA components, the use of oligonucleotides with unpaired A and T bases at the termini, and the presence of polyethylene glycol and zinc acetate in the crystallization solutions, This is the first ETS domain to be crystallized, and the strategy used to crystallize this complex may be useful for other members of the ets family.	LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute				pio, frederic/0000-0003-2050-847X	NIAID NIH HHS [AI20194] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020194] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGGARWAL A K, 1990, Methods (Orlando), V1, P83, DOI 10.1016/S1046-2023(05)80150-1; CARTER CW, 1979, J BIOL CHEM, V254, P2219; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DOCKBREGEON AC, 1992, CRYSTALLIZATION NUCL, P145; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, BIOTECHNOLOGY, V7, P1157; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HARRISON SC, 1994, CURR OPIN STRUC BIOL, V4, P1, DOI 10.1016/S0959-440X(94)90052-3; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HIRSCH JA, 1995, PROTEINS, V21, P268, DOI 10.1002/prot.340210311; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HROMAS R, 1994, INT J HEMATOL, V59, P257; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JORDAN SR, 1985, SCIENCE, V230, P1383; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LOW BW, 1952, J AM CHEM SOC, V74, P1660, DOI 10.1021/ja01127a014; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; OUBRIDGE C, 1995, J MOL BIOL, V249, P409, DOI 10.1006/jmbi.1995.0306; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; QIU XY, 1995, STRUCTURE, V3, P87, DOI 10.1016/S0969-2126(01)00137-X; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; Sambrook J, 1989, MOL CLONING LABORATO; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURA E A, 1990, Methods (Orlando), V1, P38, DOI 10.1016/S1046-2023(05)80145-8; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9	43	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24258	24263		10.1074/jbc.270.41.24258	http://dx.doi.org/10.1074/jbc.270.41.24258			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592633	hybrid			2022-12-27	WOS:A1995TA21700061
J	TAYLOR, AF; SMITH, GR				TAYLOR, AF; SMITH, GR			MONOMERIC RECBCD ENZYME BINDS AND UNWINDS DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI K-12; EXONUCLEASE-V; ATP HYDROLYSIS; DUPLEX DNA; SUBUNIT; GENE; RECD; PURIFICATION	RecBCD enzyme is a multifunctional nuclease that is essential for the major pathway of homologous genetic recombination in Escherichia coli. It has a potent helicase activity that uses ATP hydrolysis to unwind very long stretches of DNA. The functional form of RecBCD enzyme has been unclear, since M(r) of 250,000-655,000 have been previously reported. We have isolated two oligomeric forms of the enzyme, one (monomeric) containing a single copy of the RecB, RecC, and RecD polypeptides, and the other (dimeric) containing two copies of each polypeptide. We show here that the monomeric form of the enzyme (M(r) approximate to 330,000) can form a stable initiation complex on the end of ds DNA. Depending on the nature of the ds end, K-D estimates ranged from approximate to 0.1 nM to approximate to 0.7 nM in the presence of Mg2+ ions, which enhanced but was not required for binding. We further showed that the complex of monomeric RecBCD enzyme and a ds DNA end was competent to unwind DNA. A general model for the action of helicases has been proposed that uses repeated conformational changes between two states of a complex between DNA and a dimeric form of the enzyme. Our results make such a model unlikely for RecBCD enzyme.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center				Smith, Gerald/0000-0002-8747-1352	NCI NIH HHS [P30 CA15704] Funding Source: Medline; NIGMS NIH HHS [GM32194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA015704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMUNDSEN SK, 1990, GENETICS, V126, P25; AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; BLACKSHEAR PJ, 1984, METHOD ENZYMOL, V104, P237; BOEHMER PE, 1992, J BIOL CHEM, V267, P4981; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYKSTRA CC, 1984, COLD SPRING HARB SYM, V49, P463, DOI 10.1101/SQB.1984.049.01.052; EICHLER DC, 1977, J BIOL CHEM, V252, P499; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P8583, DOI 10.1093/nar/14.21.8583; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P4437, DOI 10.1093/nar/14.11.4437; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P8573, DOI 10.1093/nar/14.21.8573; FREIFELDER D, 1982, PHYSICLA BIOCH APPLI; GANESAN S, 1993, J MOL BIOL, V229, P67, DOI 10.1006/jmbi.1993.1008; GOLDMARK PJ, 1972, J BIOL CHEM, V247, P1849; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; JULIN DA, 1987, J BIOL CHEM, V262, P9044; KORANGY F, 1992, J BIOL CHEM, V267, P3088; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; MASTERSON C, 1992, J BIOL CHEM, V267, P13564; MURPHY KC, 1994, J BIOL CHEM, V269, P22507; MUSKAVITCH KMT, 1982, J BIOL CHEM, V257, P2641; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, V1, P3; PALAS KM, 1990, J BIOL CHEM, V265, P3447; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; Sambrook J, 1989, MOL CLONING LABORATO; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; STONE SR, 1991, LAB GUIDE IN VITRO S, P164; TAL M, 1985, J BIOL CHEM, V260, P9976; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; Taylor A. F, 1980, ICN UCLA S MOL CELL, V19, P909; TAYLOR AF, 1995, J BIOL CHEM, V270, P24459, DOI 10.1074/jbc.270.41.24459; TAYLOR AF, 1990, J MOL BIOL, V211, P117, DOI 10.1016/0022-2836(90)90015-E; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; TELANDERMUSKAVI.KM, 1981, THESIS U CALIFORNIA; WILCOX KW, 1976, J BIOL CHEM, V251, P6122	37	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24451	24458		10.1074/jbc.270.41.24451	http://dx.doi.org/10.1074/jbc.270.41.24451			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592660	hybrid			2022-12-27	WOS:A1995TA21700088
J	WAN, B; MOREADITH, RW				WAN, B; MOREADITH, RW			STRUCTURAL CHARACTERIZATION AND REGULATORY ELEMENT ANALYSIS OF THE HEART ISOFORM OF CYTOCHROME-C-OXIDASE VIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE ADP/ATP TRANSLOCATOR; TISSUE-SPECIFIC REGULATION; SUBUNIT-VIIA; PARACOCCUS-DENITRIFICANS; SKELETAL-MUSCLE; 2 ISOFORMS; NUCLEAR GENES; MITOCHONDRIAL MYOPATHIES; PROTON PUMP; EXPRESSION	In order to investigate the mechanism(s) governing the striated muscle-specific expression of cytochrome c oxidase VIaH we have characterized the murine gene and analyzed its transcriptional regulatory elements in skeletal myogenic cell lines. The gene is single copy, spans 689 base pairs (bp), and is comprised of three exons, The 5'-ends of transcripts from the gene are heterogeneous, but the most abundant transcript includes a 5'-untranslated region of 30 nucleotides. When fused to the luciferase reporter gene, the 3.5-kilobase 5'-flanking region of the gene directed the expression of the heterologous protein selectively in differentiated So18 cells and transgenic mice, recapitulating the pattern of expression of the endogenous gene. Deletion analysis identified a 300-bp fragment sufficient to direct the myotube-specific expression of luciferase in So18 cells. The region lacks an apparent TATA element, and sequence motifs predicted to bind NRF-1, NRF-2, ox-box, or PPAR factors known to regulate other nuclear genes encoding mito chondrial proteins are not evident. Mutational analysis, however, identified two cis-elements necessary for the high level expression of the reporter protein: a MEF2 consensus element at -90 to -81 bp and an E-box element at -147 to -142 bp. Additional E-box motifs at closely located positions were mutated without loss of transcriptional activity. The dependence of transcriptional activation of cytochrome c oxidase VIaH on cis-elements similar to those found in contractile protein genes suggests that the striated muscle-specific expression is coregulated by mechanisms that control the lineage-specific expression of several contractile and cytosolic proteins.	UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, MOLEC CARDIOL LABS, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NHLBI NIH HHS [5T32-HL-07360] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007360] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGELER R, 1990, J BIOL CHEM, V265, P16389; ANNEX BH, 1991, AM J PHYSIOL, V260, pC266, DOI 10.1152/ajpcell.1991.260.2.C266; ANTHONY G, 1993, P NATL ACAD SCI USA, V90, P1652, DOI 10.1073/pnas.90.5.1652; ANTHONY G, 1990, FEBS LETT, V277, P97, DOI 10.1016/0014-5793(90)80817-3; ARNAUDO E, 1992, GENE, V119, P299, DOI 10.1016/0378-1119(92)90287-Y; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; CALDER KM, 1991, MOL MICROBIOL, V5, P1769, DOI 10.1111/j.1365-2958.1991.tb01926.x; CAPALDI RA, 1987, CURR TOP BIOENERG, V15, P91; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CHAN SI, 1990, BIOCHEMISTRY-US, V29, P1, DOI 10.1021/bi00453a001; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; CHOMYN A, 1987, CURR TOP BIOENERG, V15, P295; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; COOPER CE, 1991, BIOCHEM CELL BIOL, V69, P586, DOI 10.1139/o91-089; Cormack B., 1991, CURRENT PROTOCOLS MO, V1, P851; DOWHAN W, 1985, EMBO J, V4, P179, DOI 10.1002/j.1460-2075.1985.tb02334.x; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EWART GD, 1991, FEBS LETT, V292, P79, DOI 10.1016/0014-5793(91)80839-U; FABRIZI GM, 1989, NUCLEIC ACIDS RES, V17, P7107, DOI 10.1093/nar/17.17.7107; FABRIZI GM, 1992, GENE, V119, P307, DOI 10.1016/0378-1119(92)90288-Z; FABRIZI GM, 1989, NUCLEIC ACIDS RES, V17, P5845; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HALTIA T, 1988, EUR J BIOCHEM, V172, P543, DOI 10.1111/j.1432-1033.1988.tb13923.x; HARAGUCHI Y, 1994, J BIOL CHEM, V269, P9330; HEDDI A, 1994, BBA-MOL BASIS DIS, V1226, P206, DOI 10.1016/0925-4439(94)90030-2; HEDDI A, 1993, J BIOL CHEM, V268, P12156; HENDLER RW, 1991, BIOPHYS J, V60, P415, DOI 10.1016/S0006-3495(91)82067-7; HOGAN B, 1986, MANIPULATING MOUSE E; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; KADENBACH B, 1987, CURR TOP BIOENERG, V15, P113; KADENBACH B, 1990, BIOCHIM BIOPHYS ACTA, V1015, P368, DOI 10.1016/0005-2728(90)90042-3; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; KADENBACH B, 1991, J BIOENERG BIOMEMBR, V23, P321, DOI 10.1007/BF00762225; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KENNAWAY NG, 1990, PEDIATR RES, V28, P529; KLEIN SC, 1991, J BIOL CHEM, V266, P18058; KNOX BE, 1984, J BIOL CHEM, V259, P4757; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; LAMARCHE AEP, 1992, J BIOL CHEM, V267, P22473; LI K, 1990, J BIOL CHEM, V265, P20585; LIGHTOWLERS R, 1990, J BIOL CHEM, V265, P2677; LUDWIG B, 1980, P NATL ACAD SCI-BIOL, V77, P196, DOI 10.1073/pnas.77.1.196; LUDWIG B, 1987, FEMS MICROBIOL LETT, V46, P41, DOI 10.1111/j.1574-6968.1987.tb02451.x; MELL OC, 1994, GENE, V140, P179, DOI 10.1016/0378-1119(94)90542-8; MITCHELL P, 1979, EUR J BIOCHEM, V95, P1, DOI 10.1111/j.1432-1033.1979.tb12934.x; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; PARDHASARADHI K, 1991, BIOPHYS J, V60, P408, DOI 10.1016/S0006-3495(91)82066-5; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PATTERSON TE, 1986, J BIOL CHEM, V261, P7192; PATTERSON TE, 1987, CYTOCHROME SYSTEMS M, P253; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; POYTON RO, 1988, ANN NY ACAD SCI, V550, P289, DOI 10.1111/j.1749-6632.1988.tb35344.x; RACKER E, 1974, J BIOL CHEM, V249, P662; RAITIO M, 1987, EMBO J, V6, P2825, DOI 10.1002/j.1460-2075.1987.tb02579.x; RIZZUTO R, 1989, J BIOL CHEM, V264, P10595; ROHDICH F, 1993, BIOCHEMISTRY-US, V32, P8499, DOI 10.1021/bi00084a015; SAMBROOKJ, 1989, MOL CLONING LABORATO; SCHEJA K, 1992, BIOCHIM BIOPHYS ACTA, V1132, P91, DOI 10.1016/0167-4781(92)90059-9; SCHLERF A, 1988, EMBO J, V7, P2387, DOI 10.1002/j.1460-2075.1988.tb03083.x; SEELAN RS, 1991, J BIOL CHEM, V266, P19752; SMITH EO, 1993, BIOCHIM BIOPHYS ACTA, V1174, P63, DOI 10.1016/0167-4781(93)90092-R; SMITH EO, 1991, BIOCHIM BIOPHYS ACTA, V1089, P266, DOI 10.1016/0167-4781(91)90022-E; TAANMAN JW, 1992, J BIOL CHEM, V267, P22481; TAANMAN JW, 1994, BIOCHEMISTRY-US, V33, P11833, DOI 10.1021/bi00205a020; TAANMAN JW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P95, DOI 10.1016/0925-4439(93)90128-N; TAANMAN JW, 1993, J BIOL CHEM, V268, P18754; TAGER JM, 1983, FEBS LETT, V151, P1, DOI 10.1016/0014-5793(83)80330-5; TRUEBLOOD CE, 1987, MOL CELL BIOL, V7, P3520, DOI 10.1128/MCB.7.10.3520; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; VANBEEUMEN JJ, 1990, FEBS LETT, V263, P213, DOI 10.1016/0014-5793(90)81376-Y; VANKUILENBURG ABP, 1992, EUR J BIOCHEM, V203, P193; VANKUILENBURG ABP, 1988, FEBS LETT, V240, P127, DOI 10.1016/0014-5793(88)80353-3; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WIKSTROM MKF, 1977, NATURE, V266, P271, DOI 10.1038/266271a0; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; WRIGHT RM, 1986, J BIOL CHEM, V261, P7183; YANAMURA W, 1988, BIOCHEMISTRY-US, V27, P4909, DOI 10.1021/bi00413a048; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	85	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26433	26440		10.1074/jbc.270.44.26433	http://dx.doi.org/10.1074/jbc.270.44.26433			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592858	hybrid			2022-12-27	WOS:A1995TC97800065
J	KUEMMERLE, JF; MAKHLOUF, GM				KUEMMERLE, JF; MAKHLOUF, GM			AGONIST-STIMULATED CYCLIC ADP RIBOSE - ENDOGENOUS MODULATOR OF CA2+-INDUCED CA2+ RELEASE IN INTESTINAL LONGITUDINAL MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE ANTIGEN CD38; INDUCED CALCIUM-RELEASE; SEA-URCHIN EGGS; INOSITOL TRISPHOSPHATE; BETA-CELLS; RYANODINE; ENZYME; METABOLITE; RECEPTORS; NAD+	We have previously shown that agonist-induced Ca2+ mobilization in intestinal longitudinal muscle is mediated by ryanodine-sensitive, inositol 1,4,5-trisphosphate-insensitive sarcoplasmic Ca2+ channels. Ca2+ release via these channels is triggered by agonist-stimulated Ca2+ influx and results in Ca2+-induced Ca2+ release. The present study examined whether cyclic ADP-ribose (cADPR) is synthesized in response to stimulation of longitudinal muscle by agonists and modulates the activity of Ca2+ release channels. Cyclic ADPR bound with high affinity to dispersed longitudinal muscle cells (IC50 1.9 nM) and induced Ca2+ release (EC(50) 3.8 nM), increase in lCa(2+)](i) (EC(50) 2.0 nM), and contraction (EC(50) 1.1 nM); cADPR had no effect on circular muscle cells. The effects of cADPR were blocked by ruthenium red, dantrolene, and the specific antagonist, 8-amino-cADPR, and were augmented by caffeine but not affected by heparin. The binding of cADPR and its ability to stimulate Ca2+ release were dependent on the concentration of Ca2+. Cyclic ADPR was capable of stimulating Ca2+ release at subthreshold Ca2+ concentrations (25-100 nM) and of enhancing Ca2+-induced Ca2+ release. Longitudinal muscle extracts incubated with beta-NAD(+) produced a time-dependent increase in Ca2+-mobilizing activity identified as authentic cADPR by blockade of Ca2+ release with 8-amino-cADPR and ruthenium red. Ca2+ mobilizing activity was increased by cholecystokinin octapeptide (CCK-8) in a concentration-dependent fashion. The increase induced by CCK-8 was suppressed by the CCK-A antagonist, L364,718, nifedipine, and guanyl-5'-yl thiophosphate. The study shows that ADP-ribosyl cyclase can be stimulated by agonists and that cADPR can act as an endogenous modulator of Ca2+-induced Ca2+ release.			KUEMMERLE, JF (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,POB 980711,RICHMOND,VA 23298, USA.				NIDDK NIH HHS [DK-15564] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015564, R37DK015564] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON K, 1989, J BIOL CHEM, V264, P1329; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CORANADO R, 1994, AM J PHYSIOL, V35, pC1485; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; DARGIE PJ, 1990, CELL REGUL, V1, P270; FABIATO A, 1985, FED PROC, V44, P2970; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GLICK DL, 1991, CELL REGUL, V2, P211, DOI 10.1091/mbc.2.3.211; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; ISLAM MS, 1993, SCIENCE, V262, P584, DOI 10.1126/science.8211188; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; KUEMMERLE JF, 1994, AM J PHYSIOL, V266, pC1421, DOI 10.1152/ajpcell.1994.266.5.C1421; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEE HC, 1993, J BIOL CHEM, V268, P293; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MURTHY KS, 1991, AM J PHYSIOL, V261, pG937, DOI 10.1152/ajpgi.1991.261.6.G937; MURTHY KS, 1995, AM J PHYSIOL-GASTR L, V269, pG93, DOI 10.1152/ajpgi.1995.269.1.G93; MURTHY KS, 1993, AM J PHYSIOL, V265, pG660, DOI 10.1152/ajpgi.1993.265.4.G660; MURTHY KS, 1994, BIOCHEM BIOPH RES CO, V202, P1681, DOI 10.1006/bbrc.1994.2128; POGGIOLI J, 1982, PFLUEGERS ARCH EUR J, V292, P239; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; SUMMERHILL RJ, 1993, FEBS LETT, V335, P231, DOI 10.1016/0014-5793(93)80735-D; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WANG XB, 1993, BIOCHEM BIOPH RES CO, V193, P483, DOI 10.1006/bbrc.1993.1649; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X	38	135	137	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25488	25494		10.1074/jbc.270.43.25488	http://dx.doi.org/10.1074/jbc.270.43.25488			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592718	hybrid			2022-12-27	WOS:A1995TB46600034
J	MARTYS, JL; SHEVELL, T; MCGRAW, TE				MARTYS, JL; SHEVELL, T; MCGRAW, TE			STUDIES OF TRANSFERRIN RECYCLING RECONSTITUTED IN STREPTOLYSIN-O PERMEABILIZED CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; RECEPTOR-MEDIATED ENDOCYTOSIS; TRANS-GOLGI NETWORK; ENDOPLASMIC-RETICULUM; ENDOSOME FUSION; BETA-COP; VESICULAR TRAFFICKING; BREFELDIN-A; MDCK CELLS	Efficient transferrin receptor recycling is reconstituted when donor cytosol and ATP are added to the streptolysin O permeabilized cells. The rate of reconstituted recycling is dependent on the concentration of donor cytosol. The cytosol provides a factor(s) required for the transport of transferrin from the pericentriolar recycling compartment to the plasma membrane. N-Ethylmaleimide treatment of permeabilized cells inhibits both the fusion of recycling vesicles with the plasma membrane as well as the formation of functional recycling vesicles from the pericentriolar recycling compartment. Guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) does not affect reconstituted recycling in the presence of an optimal cytosol concentration. Therefore, the rate-limiting step in recycling is not regulated by GTP-hydrolyzing proteins, and hydrolysis of GTP is not required for endocytic recycling. GTP gamma S stimulates recycling when suboptimal concentrations of cytosol are used. This stimulatory effect is not mediated by a brefeldin A-sensitive ADP-ribosylation factor protein. Addition of mild-type donor cytosol to permeabilized END2 Chinese hamster ovary cells, which recycle transferrin at half the rate of mild-type cells, reconstitutes recycling to the reduced rate of intact END2 cells but not to the mild-type recycling rate. These results indicate that the defect responsible for the slowed transferrin recycling in END2 mutants is membrane associated or that the defective protein is too large to diffuse out of the cells through the streptolysin O pores.	COLUMBIA UNIV, DEPT PATHOL, NEW YORK, NY 10032 USA	Columbia University					NATIONAL INSTITUTE ON AGING [T32AG000189] Funding Source: NIH RePORTER; NIA NIH HHS [T32 AG00189] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; FITZGERALD LA, 1981, J CELL SCI, V52, P405; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; JOHNSON LS, 1994, J CELL PHYSIOL, V158, P29, DOI 10.1002/jcp.1041580105; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; KLAUSNER RD, 1984, J CELL BIOL, V98, P1098, DOI 10.1083/jcb.98.3.1098; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MCGRAW TE, 1993, J CELL PHYSIOL, V155, P579, DOI 10.1002/jcp.1041550316; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MCGRAW TE, 1991, HDB EXPT PHARM, V100, P11; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; RAUB TJ, 1990, J CELL PHYSIOL, V144, P52, DOI 10.1002/jcp.1041440108; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SALZMAN NH, 1988, J CELL BIOL, V106, P1083, DOI 10.1083/jcb.106.4.1083; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; SUDHOF TC, 1993, CELL, V75, P1; TAKIZAWA PA, 1993, CELL, V75, P593, DOI 10.1016/0092-8674(93)90477-8; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WILSON RB, 1993, J BIOL CHEM, V268, P1; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	60	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25976	25984		10.1074/jbc.270.43.25976	http://dx.doi.org/10.1074/jbc.270.43.25976			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592788	hybrid			2022-12-27	WOS:A1995TB46600105
J	MARTYTEYSSET, C; LOLKEMA, JS; SCHMITT, P; DIVIES, C; KONINGS, WN				MARTYTEYSSET, C; LOLKEMA, JS; SCHMITT, P; DIVIES, C; KONINGS, WN			MEMBRANE POTENTIAL-GENERATING TRANSPORT OF CITRATE AND MALATE CATALYZED BY CITP OF LEUCONOSTOC-MESENTEROIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-MOTIVE FORCE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; KLEBSIELLA-PNEUMONIAE; STREPTOCOCCUS-LACTIS; VESICLES; LACTOCOCCUS; ENERGY; DIACETYLACTIS; FERMENTATION	Citrate uptake in Leuconostoc mesenteroides subsp. mesenteroides 19D is catalyzed by a secondary citrate carrier (CitP). The kinetics and mechanism of CitP were investigated in membrane vesicles of L. mesenteroides. The transporter is induced by the presence of citrate in the medium and transports both citrate and malate. In spite of sequence homology to the Na+-dependent citrate carrier of Klebsiella pneumoniae, CitP is not Na+-dependent, nor is CitP Mg2+-dependent. The pH gradient (Delta pH) is a driving force for citrate and malate uptake into the membrane vesicles, whereas the membrane potential (Delta psi) counteracts transport. An inverted membrane potential (inside positive) generated by thiocyanide diffusion can drive citrate and malate uptake in membrane vesicles. Analysis of the forces involved showed that a single unit of negative charge is translocated during transport. Kinetic analysis of citrate counterflow at different pH values indicated that CitP transports the dianionic form of citrate (Hcit(2-)) with an affinity constant of similar to 20 mu M. It is concluded that CitP catalyzes Hcit(2-)/H+ symport. Translocation of negative charge into the cell during citrate metabolism results in the generation of a membrane potential that contributes to the protonmotive force across the cytoplasmic membrane, i.e. citrate metabolism in L. mesenteroides generates metabolic energy. Efficient exchange of citrate and D-lactate, a product of citrate/carbohydrate co-metabolism, is observed, suggesting that under physiological conditions, CitP may function as an electrogenic precursor/product exchanger rather than a symporter. The mechanism and energetic consequences of citrate uptake are similar to malate uptake in lactic acid bacteria.	UNIV GRONINGEN, GRONINGEN BIOTECHNOL & BIOMOLEC SCI INST, DEPT MICROBIOL, 9751 NN HAREN, NETHERLANDS; UNIV BOURGOGNE, ECOLE NATL SUPER BIOL APPL NUTR & ALIMENTAT, DEPT MICROBIOL BIOTECHNOL, F-21000 DIJON, FRANCE	University of Groningen; Universite de Bourgogne			Konings, Wilhelmus N./C-7063-2013					ANATHARAM V, 1989, J BIOL CHEM, V264, P7244; BERGSMA J, 1983, EUR J BIOCHEM, V134, P151, DOI 10.1111/j.1432-1033.1983.tb07545.x; DAMIANO E, 1984, FEBS LETT, V166, P120, DOI 10.1016/0014-5793(84)80056-3; DAVID S, 1990, J BACTERIOL, V172, P5789, DOI 10.1128/jb.172.10.5789-5794.1990; DE MAN J. C., 1960, JOUR APPL BACT, V23, P130, DOI 10.1111/j.1365-2672.1960.tb00188.x; DRIESSEN AJM, 1985, P NATL ACAD SCI USA, V82, P7555, DOI 10.1073/pnas.82.22.7555; DRIESSEN AJM, 1991, METHOD CELL BIOL, V34, P147; HUGENHOLTZ J, 1993, APPL ENVIRON MICROB, V59, P4216, DOI 10.1128/AEM.59.12.4216-4222.1993; ISHIGURO N, 1992, J BIOL CHEM, V267, P9559; KEMPLER GM, 1980, APPL ENVIRON MICROB, V39, P926, DOI 10.1128/AEM.39.4.926-927.1980; KONINGS WN, 1995, IN PRESS ARCH MICROB; LIN J, 1991, APPL MICROBIOL BIOT, V34, P628, DOI 10.1007/BF00167912; LOLKEMA JS, 1994, BBA-BIOENERGETICS, V1187, P211, DOI 10.1016/0005-2728(94)90113-9; LOLKEMA JS, 1994, EUR J BIOCHEM, V220, P469, DOI 10.1111/j.1432-1033.1994.tb18645.x; LOLKEMA JS, 1982, BIOCHIM BIOPHYS ACTA, V68, P85; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGNI C, 1994, FEMS MICROBIOL LETT, V118, P75, DOI [10.1111/j.1574-6968.1994.tb06806.x, 10.1016/0378-1097(94)90599-1]; MALONEY PC, 1982, J MEMBRANE BIOL, V66, P63, DOI 10.1007/BF01868482; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MOLENAAR D, 1993, J BACTERIOL, V175, P2864, DOI 10.1128/JB.175.10.2864-2870.1993; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; POOLMAN B, 1991, J BACTERIOL, V173, P6030, DOI 10.1128/jb.173.19.6030-6037.1991; POOLMAN B, 1993, FEMS MICROBIOL REV, V12, P125, DOI 10.1111/j.1574-6976.1993.tb00015.x; RAMOS A, 1994, J BACTERIOL, V176, P4899, DOI 10.1128/jb.176.16.4899-4905.1994; REYNOLDS CH, 1983, J BACTERIOL, V156, P1019, DOI 10.1128/JB.156.3.1019-1024.1983; SALEMA M, 1994, EUR J BIOCHEM, V225, P289, DOI 10.1111/j.1432-1033.1994.00289.x; SCHMITT P, 1992, APPL MICROBIOL BIOT, V36, P679, DOI 10.1007/BF00183249; STARRENBURG MJC, 1991, APPL ENVIRON MICROB, V57, P3535, DOI 10.1128/AEM.57.12.3535-3540.1991; VANDERREST ME, 1991, EUR J BIOCHEM, V195, P71; VANDERREST ME, 1992, J BIOL CHEM, V267, P8971; VANDERREST ME, 1992, J BACTERIOL, V174, P4892; WINTERS DA, 1991, APPL ENVIRON MICROB, V57, P3350, DOI 10.1128/AEM.57.11.3350-3354.1991	32	54	55	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25370	25376		10.1074/jbc.270.43.25370	http://dx.doi.org/10.1074/jbc.270.43.25370			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592702	hybrid			2022-12-27	WOS:A1995TB46600018
J	CRESPO, P; CACHERO, TG; XU, NZ; GUTKIND, JS				CRESPO, P; CACHERO, TG; XU, NZ; GUTKIND, JS			DUAL EFFECT OF BETA-ADRENERGIC RECEPTORS ON MITOGEN-ACTIVATED PROTEIN-KINASE - EVIDENCE FOR A BETA-GAMMA-DEPENDENT ACTIVATION AND A G-ALPHA(S)-CAMP-MEDIATED INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PROLIFERATION; ADENYLYL CYCLASE; SIGNAL TRANSDUCTION; COUPLED RECEPTORS; RAS; GENE; EXPRESSION; SUBUNITS; CAMP; PATHWAY	The enzymatic activity of mitogen-activated protein kinases (MAP kinases) increases in response to agents acting on a variety of cell surface receptors, including receptors linked to heterotrimeric G proteins of the G(i) and G(q) family. Recently, it has been shown that stimulation of beta-adrenergic receptors, which are typical of those that act through G(s) to activate adenylyl cyclases, potently activates MAP kinases in the heart, resulting in the hypertrophy of the cardiac muscle (Lazou, A., Bogoyevitch, M. A., Clerk, A., Fuller, S. J., Marshall, C. J., and Sudgen, P. H. (1994) Circ, Res, 75, 938-941). We have observed that exposure of COS-7 cells to a beta-adrenergic agonist, isoproterenol, raises intracellular levels of cAMP and effectively activates protein kinase A (PKA) and an epitope-tagged MAP kinase. However, MAP kinase stimulation by isoproterenol was neither mimicked by expression of an activated mutant of G alpha(s), nor by treatment with PKA-stimulating agents. Moreover, pretreatment of COS-7 with a permeable cAMP analog, 8-Br-cAMP, markedly decreased MAP kinase activation by either isoproterenol or epidermal growth factor. Thus, in COS-7 cells cAMP and PKA do not appear to mediate MAP kinase activation by beta-adrenergic receptors. Signaling from beta-adrenergic receptors to MAP kinase was inhibited by transfection of a chimeric molecule consisting of the CD8 receptor and the carboxyl terminus of the beta-adrenergic receptor kinase, which includes the beta gamma-binding domain. MAP kinase activation by isoproterenol was not affected by depletion of protein kinase C, but it was completely abolished by expression of Ras-inhibiting molecules. We conclude that signaling from beta-adrenergic receptors to MAP kinase involves an activating signal mediated by beta gamma subunits acting on a Ras-dependent pathway and a G alpha(s)-induced inhibitory signal mediated by cAMP and PKA. The balance between these two opposing mechanisms of regulation would be expected to control the MAP kinase response to beta-adrenergic agonists as well as to other biologically active agents known to act on G(s) coupled receptors, including a number of hormones, neurotransmitters, and lipid mediators.	NIDR,MOLEC SIGNALING UNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009; Crespo, Piero/M-3273-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Crespo, Piero/0000-0003-2825-7783				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HO AK, 1987, J BIOL CHEM, V262, P10059; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HOWE LR, 1993, J BIOL CHEM, V268, P20717; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; LAZOU A, 1994, CIRC RES, V75, P938; LEFCOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; PELECH SL, 1993, CURR BIOL, V3, P513, DOI 10.1016/0960-9822(93)90043-N; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PORRAS A, 1994, J BIOL CHEM, V269, P12741; RAY LB, 1987, P NATL ACAD SCI USA, V85, P1502; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; STEPHENS EV, 1993, ONCOGENE, V8, P19; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	49	203	205	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25259	25265		10.1074/jbc.270.42.25259	http://dx.doi.org/10.1074/jbc.270.42.25259			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559665	hybrid			2022-12-27	WOS:A1995TB46500099
J	HODITS, RA; NIMPF, J; PFISTERMUELLER, DM; HIESBERGER, T; SCHNEIDER, WJ; VAUGHAN, TJ; JOHNSON, KS; HAUMER, M; KUECHLER, E; WINTER, G; BLAAS, D				HODITS, RA; NIMPF, J; PFISTERMUELLER, DM; HIESBERGER, T; SCHNEIDER, WJ; VAUGHAN, TJ; JOHNSON, KS; HAUMER, M; KUECHLER, E; WINTER, G; BLAAS, D			AN ANTIBODY FRAGMENT FROM A PHAGE DISPLAY LIBRARY COMPETES FOR LIGAND-BINDING TO THE LOW-DENSITY-LIPOPROTEIN RECEPTOR FAMILY AND INHIBITS RHINOVIRUS INFECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; BIOSPECIFIC INTERACTION ANALYSIS; SURFACE-PLASMON RESONANCE; CHICKEN OOCYTE RECEPTOR; BY-PASSING IMMUNIZATION; PLASMINOGEN-ACTIVATOR; HIGH-AFFINITY; FILAMENTOUS PHAGE; APOLIPOPROTEIN-E; MEDIATES UPTAKE	Recently antibodies with a wide range of binding specificities have been isolated from large repertoires of antibody fragments displayed on filamentous phage, including those that are difficult to raise by immunization, We have used this approach to isolate an antibody fragment against chicken very low density lipoprotein (VLDL) receptor. It binds to the receptor with good affinity (K-aff = 2 x 10(8) M(-1)) as measured by plasmon surface resonance, and competes for binding of natural ligands (vitellogenin, VLDL, and receptor-associated protein). The antibody also binds to other members of the low density lipoprotein (LDL) receptor family including rat LDL receptor and human and rat low density lipoprotein receptor-related protein (LRP/alpha(2)MR), and it competes for binding of receptor-associated protein to LRP/alpha(2)MR. Moreover, the antibody fragment inhibits infection of human fibroblasts deficient in LDL-R but expressing LRP/alpha MR by human rhinovirus. Binding of the antibody is abolished upon reduction of the receptors and is strictly Ca2+ dependent. The phage antibody thus recognizes the ligand binding site(s) of several members of the LDL receptor family, in contrast to antibodies produced by hybridoma technology.	UNIV VIENNA,INST BIOCHEM,A-1030 VIENNA,AUSTRIA; UNIV VIENNA,INST MOLEC GENET,A-1030 VIENNA,AUSTRIA; CAMBRIDGE ANTIBODY TECHNOL LTD,MELBOURNE SG8 6EJ,CAMBS,ENGLAND; UNIV VIENNA,INST MED CHEM,A-1090 VIENNA,AUSTRIA; MRC,CTR PROT ENGN,CAMBRIDGE CB2 2QH,ENGLAND	University of Vienna; University of Vienna; AstraZeneca; University of Vienna; University of Cambridge				Nimpf, Johannes/0000-0002-9273-3492				ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; BARBER DL, 1991, J BIOL CHEM, V266, P18761; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BEISIEGEL U, 1989, NATURE, V34, P162; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; COLONNO RJ, 1986, J VIROL, V57, P7, DOI 10.1128/JVI.57.1.7-12.1986; GEORGE R, 1987, J BIOL CHEM, V262, P16838; GOLDSTEIN JL, 1979, ANNU REV GENET, V13, P259, DOI 10.1146/annurev.ge.13.120179.001355; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HAYDEN FG, 1988, ANTIVIR RES, V9, P233, DOI 10.1016/0166-3542(88)90055-1; HERZ J, 1993, CELL, V73, P428, DOI 10.1016/0092-8674(93)90130-I; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1992, J BIOL CHEM, V266, P21232; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; HOCHULI E, 1988, J CHROMATOGR, V444, P293, DOI 10.1016/S0021-9673(01)94032-4; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P; HUBER C, 1993, EUR J IMMUNOL, V23, P2868, DOI 10.1002/eji.1830231121; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOVANEN PT, 1979, J BIOL CHEM, V254, P1367; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NEUBAUER C, 1987, VIROLOGY, V158, P255, DOI 10.1016/0042-6822(87)90264-9; NIMPF J, 1989, J BIOL CHEM, V264, P1393; NIMPF J, 1994, J BIOL CHEM, V269, P212; NIMPF J, 1994, ANN NY ACAD SCI, V737, P145, DOI 10.1111/j.1749-6632.1994.tb44308.x; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SCHNEIDER WJ, 1982, J BIOL CHEM, V257, P2664; SCHNEIDER WJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P303, DOI 10.1016/0304-4157(89)90023-3; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; SKERN T, 1991, VIROLOGY, V181, P46, DOI 10.1016/0042-6822(91)90468-Q; SKERN T, 1984, VIROLOGY, V136, P125, DOI 10.1016/0042-6822(84)90253-8; SPERBER SJ, 1989, ANTIVIR RES, V12, P231, DOI 10.1016/0166-3542(89)90051-X; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STIFANI S, 1988, BIOCHEM J, V250, P467, DOI 10.1042/bj2500467; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STIFANI S, 1990, P NATL ACAD SCI USA, V87, P1955, DOI 10.1073/pnas.87.5.1955; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TOMASSINI JE, 1986, J VIROL, V58, P290, DOI 10.1128/JVI.58.2.290-295.1986; TOMLINSON IM, 1992, J MOL BIOL, V227, P776, DOI 10.1016/0022-2836(92)90223-7; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	73	23	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24078	24085		10.1074/jbc.270.41.24078	http://dx.doi.org/10.1074/jbc.270.41.24078			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592608	hybrid			2022-12-27	WOS:A1995TA21700036
J	KUTCHAN, TM; DITTRICH, H				KUTCHAN, TM; DITTRICH, H			CHARACTERIZATION AND MECHANISM OF THE BERBERINE BRIDGE ENZYME, A COVALENTLY FLAVINYLATED OXIDASE OF BENZOPHENANTHRIDINE ALKALOID BIOSYNTHESIS IN PLANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; ADENOSYL-L-METHIONINE; 6-HYDROXY-D-NICOTINE OXIDASE; ARTHROBACTER-OXIDANS; PURIFICATION; SANGUINARINE; ELICITATION; EXPRESSION; GENE	The berberine bridge enzyme ((S)-reticuline:oxygen oxidoreductase (methylene-bridge-forming), EC 1.5.3.9) catalyzes the oxidative cyclization of the N-methyl moiety of (S)-reticuline into the berberine bridge carbon, C-8, of (S)-scoulerine. This is a reaction that has neither an equivalent in organic chemistry nor a parallel in nature. The uniqueness of this catalytic reaction prompted an in depth study that began with the isolation of the cDNA encoding the berberine bridge enzyme followed by the overexpression of this cDNA in insect cell culture. The heterologously expressed enzyme has herein been shown to contain covalently attached FAD in a molar ratio of cofactor to protein of 1:1.03. Site-directed mutagenesis and laser desorption time of-flight mass spectrometry suggest that the site of covalent attachment is at His-104. The holoenzyme exhibited absorbance maxima at 380 and 442 nm and a fluorescence emission maximum at 628 nm (310 nn excitation). Enzymic transformation of a series of (S)-reticuline derivatives modified with respect to the stereochemistry at C-1 or in the aromatic ring substitution suggests that ring closure proceeds in two steps: formation of the methylene iminium ion and subsequent ring closure via an ionic mechanism.			KUTCHAN, TM (corresponding author), UNIV MUNICH,MOLEC BIOL LAB,KARLSTR 29,D-80333 MUNICH,GERMANY.		Kutchan, Toni/L-4625-2013					AMANN M, 1986, PLANTA, V167, P310, DOI 10.1007/BF00391333; AMANN M, 1988, EUR J BIOCHEM, V175, P17, DOI 10.1111/j.1432-1033.1988.tb14160.x; AUGUST PR, 1994, J BACTERIOL, V176, P4448, DOI 10.1128/jb.176.14.4448-4454.1994; BARTON DHR, 1963, P CHEM SOC LONDON, P267; BATTERSBY AR, 1963, P CHEM SOC LONDON, P268; BJORKLUND JA, 1995, J AM CHEM SOC, V117, P1533, DOI 10.1021/ja00110a009; BLECHERT S, 1995, P NATL ACAD SCI USA, V92, P4099, DOI 10.1073/pnas.92.10.4099; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; BRANDSCH R, 1985, FEBS LETT, V192, P204, DOI 10.1016/0014-5793(85)80108-3; BRANDSCH R, 1987, EUR J BIOCHEM, V167, P315, DOI 10.1111/j.1432-1033.1987.tb13338.x; CLINE SD, 1988, PLANT PHYSIOL, V86, P161, DOI 10.1104/pp.86.1.161; DECKER KF, 1993, ANNU REV NUTR, V13, P17, DOI 10.1146/annurev.nu.13.070193.000313; DITTRICH H, 1991, P NATL ACAD SCI USA, V88, P9969, DOI 10.1073/pnas.88.22.9969; DZINK JL, 1985, ANTIMICROB AGENTS CH, V27, P663, DOI 10.1128/AAC.27.4.663; FRENZEL T, 1990, PHYTOCHEMISTRY, V29, P3491, DOI 10.1016/0031-9422(90)85263-F; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; HESSE M, 1975, ALKALOIDS PROGR MASS, V3; KOSHIZAKA T, 1988, J BIOL CHEM, V263, P1619; KUTCHAN TM, 1994, PHYTOCHEMISTRY, V35, P353, DOI 10.1016/S0031-9422(00)94763-0; MUELLER MJ, 1993, LIEBIGS ANN CHEM, P557; RINK E, 1975, FEBS LETT, V49, P396, DOI 10.1016/0014-5793(75)80794-0; ROTHERA MA, 1985, J NAT PROD, V48, P802, DOI 10.1021/np50041a015; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUMACHER HM, 1987, PLANT CELL REP, V6, P410, DOI 10.1007/BF00272770; STEFFENS P, 1985, PHYTOCHEMISTRY, V24, P2577, DOI 10.1016/S0031-9422(00)80672-X; SUAU R, 1988, PHYTOCHEMISTRY, V27, P1920, DOI 10.1016/0031-9422(88)80486-2; WAT CK, 1986, Z NATURFORSCH C, V41, P126	27	104	114	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24475	24481		10.1074/jbc.270.41.24475	http://dx.doi.org/10.1074/jbc.270.41.24475			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592663	hybrid			2022-12-27	WOS:A1995TA21700091
J	PETERSOHN, D; SCHOCH, S; BRINKMANN, DR; THIEL, G				PETERSOHN, D; SCHOCH, S; BRINKMANN, DR; THIEL, G			THE HUMAN SYNAPSIN-II GENE PROMOTER - POSSIBLE ROLE FOR THE TRANSCRIPTION FACTORS ZIF268/EGR-1, POLYOMA ENHANCER ACTIVATOR-3, AND AP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; SYNAPTIC VESICLE PHOSPHOPROTEINS; IMMEDIATE EARLY GENES; AXOSPINOUS SYNAPSES; INDUCIBLE ENHANCER; MOLECULAR-CLONING; GROWTH-FACTORS; DENTATE GYRUS; FACTOR AP-2; C-FOS	Synapsin II is a neuron-specific phosphoprotein that selectively binds to small synaptic vesicles in the presynaptic synaptic nerve terminal. Here we report the cloning and sequencing of the 5'-flanking region of the human synapsin II gene. This sequence is very GC-rich and lacks a TATA or CAAT box, Two major transcriptional start sites were mapped. A hybrid gene consisting of the Escherichia coli chloramphenicol acetyltransferase gene under the control of 837 base pairs of the synapsin II 5'-upstream region was transfected into neuronal and non-neuronal cells. While reporter gene expression was low in neuroblastoma and non-neuronal cells, high chloramphenicol acetyltransferase activities were monitored in PC12 pheochromocytoma cells. However, there was no correlation between reporter gene expression in the transfected cells and endogenous synapsin II immunoreactivity, Using DNA-protein binding assays we showed that the transcription factors zif268/egr-1, polyoma enhancer activator 3 (PEA3), and AP2 specifically contact the synapsin II promoter DNA in vitro. Moreover, the zif268/egr-1 protein as well as PEA3 were shown to stimulate transcription of a reporter gene containing synapsin II promoter sequences, In the nervous system, zif268/egr-1 functions as a ''third messenger'' with a potential role in synaptic plasticity. PEA3 is expressed in the brain and its activity is regulated by proteins encoded from non-nuclear oncogenes, We postulate that zif268/egr-1 and PEA3 couple extracellular signals to long-term responses by regulating synapsin II gene expression.	UNIV COLOGNE,INST GENET,D-50674 COLOGNE,GERMANY	University of Cologne			Schoch, Susanne/F-7741-2012					ABRAHAM WC, 1993, NEUROSCIENCE, V56, P717, DOI 10.1016/0306-4522(93)90369-Q; APPLEGATE MD, 1987, BRAIN RES, V401, P401, DOI 10.1016/0006-8993(87)91429-6; ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BERG DT, 1989, MOL CELL BIOL, V9, P5248, DOI 10.1128/MCB.9.11.5248; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHILCOTE TJ, 1994, J NEUROCHEM, V63, P1568; CHIN LS, 1994, J BIOL CHEM, V269, P18507; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DESMOND NL, 1988, BRAIN RES, V453, P308, DOI 10.1016/0006-8993(88)90171-0; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GEINISMAN Y, 1991, BRAIN RES, V566, P77, DOI 10.1016/0006-8993(91)91683-R; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; JUNGLING S, 1994, EUR J BIOCHEM, V226, P925, DOI 10.1111/j.1432-1033.1994.00925.x; KROLL DJ, 1993, DNA CELL BIOL, V12, P441, DOI 10.1089/dna.1993.12.441; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; LYNCH MA, 1994, NEUROSCIENCE, V60, P1, DOI 10.1016/0306-4522(94)90197-X; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MESHUL CK, 1990, BRAIN RES, V514, P310, DOI 10.1016/0006-8993(90)91426-H; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NEDIVI E, 1992, J NEUROSCI, V12, P691; OZCELIK T, 1990, AM J HUM GENET, V47, P551; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; SAKIMURA K, 1995, MOL BRAIN RES, V28, P19, DOI 10.1016/0169-328X(94)00177-G; SAKIMURA K, 1987, GENE, V60, P103, DOI 10.1016/0378-1119(87)90218-6; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHUSTER T, 1990, BRAIN RES, V523, P171, DOI 10.1016/0006-8993(90)91654-Y; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SIOW YL, 1992, BIOCHEMISTRY-US, V31, P4268, DOI 10.1021/bi00132a017; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; THIEL G, 1994, J BIOL CHEM, V269, P15294; THIEL G, 1991, P NATL ACAD SCI USA, V88, P3431, DOI 10.1073/pnas.88.8.3431; THIEL G, 1990, J BIOL CHEM, V265, P16527; THIEL G, 1993, BRAIN PATHOL, V3, P87, DOI 10.1111/j.1750-3639.1993.tb00729.x; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WESTIN G, 1987, NUCLEIC ACIDS RES, V17, P6787; WILLE W, 1991, TECHNIQUES GENETIC A, P291; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZHONG CZ, 1992, BIOCHIM BIOPHYS ACTA, V1129, P235, DOI 10.1016/0167-4781(92)90495-L	59	118	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24361	24369		10.1074/jbc.270.41.24361	http://dx.doi.org/10.1074/jbc.270.41.24361			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592648	hybrid			2022-12-27	WOS:A1995TA21700076
J	ZHAO, YY; CHAUVET, PJP; ALPER, SL; BALTZ, JM				ZHAO, YY; CHAUVET, PJP; ALPER, SL; BALTZ, JM			EXPRESSION AND FUNCTION OF BICARBONATE CHLORIDE EXCHANGERS IN THE PREIMPLANTATION MOUSE EMBRYO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH; CL-/HCO3 EXCHANGER; CELL-LINE; KIDNEY; BAND-3; CDNA; CLONING; ANTIPORT; PROTEIN; GENE	Bicarbonate/chloride (HCO3-/Cl-) exchangers regulate intracellular pH in the alkaline range. Previously, it has been shown that mouse embryos at the two cell stage exhibit this activity, but that the otherwise ubiquitous mechanisms for regulating intracellular pH in the acid-to-neutral range are undetectable. We have examined mouse embryos during preimplantation development (one-cell zygote through blastocyst) to determine whether HCO3-/Cl- exchange activity exists at all stages, whether it is necessary for preimplantation development, and whether messenger RNAs from the known HCO3-/Cl- exchanger genes are expressed. We have found that all stages of preimplantation embryo have detectable HCO3-/Cl- exchange activity. In addition, inhibition of this activity with the stilbene anion exchange inhibitor DIDS (4,4'-diisothiocyanostilbene-2,2'-disulfonic acid) disrupts intracellular pH homeostasis and markedly inhibits embryo development from the two-cell stage to blastocysts in culture under conditions of moderately high external pH. Finally, mRNA encoding two members of the band 3 related AE anion exchanger gene family are expressed in preimplantation embryos.	OTTAWA CIVIC HOSP,LOEB MED RES INST,HORMONES GROWTH & DEV UNIT,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,DEPT OBSTET & GYNECOL,REPROD BIOL UNIT,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,DEPT PHYSIOL,OTTAWA,ON K1Y 4E9,CANADA; BETH ISRAEL HOSP,MOLEC MED UNIT,BOSTON,MA 02215; BETH ISRAEL HOSP,RENAL UNIT,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School				Baltz, Jay/0000-0002-9749-2480	NICHD NIH HHS [R01 HD29533] Funding Source: Medline; NIDDK NIH HHS [R01 DK43495] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043495] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; ALPER SL, 1994, CELL PHYSIOL BIOCHEM, V4, P265, DOI 10.1159/000154730; Baltz J. M., 1994, Molecular Biology of the Cell, V5, p102A; BALTZ JM, 1991, J BIOL CHEM, V266, P17212; BALTZ JM, 1990, DEV BIOL, V138, P421, DOI 10.1016/0012-1606(90)90208-Z; BALTZ JM, 1991, J BIOL CHEM, V266, P6052; BALTZ JM, 1993, DEVELOPMENT, V118, P1353; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; CASSEL D, 1988, J BIOL CHEM, V263, P6122; HOGAN B, 1986, MANIPULATING MOUSE E; House C. R., 1994, Zygote, V2, P37; HUMPHREYS BD, 1994, AM J PHYSIOL-CELL PH, V267, pC1295, DOI 10.1152/ajpcell.1994.267.5.C1295; HUMPHREYS BD, 1995, AM J PHYSIOL-CELL PH, V37, pC201; IRITANI A, 1971, J ANIM SCI, V33, P829; JIANG LW, 1994, AM J PHYSIOL, V267, pC845, DOI 10.1152/ajpcell.1994.267.3.C845; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; KURTZ I, 1987, J BIOL CHEM, V262, P4516; LAWITTS JA, 1993, METHOD ENZYMOL, V255, P153; LEE BS, 1991, J BIOL CHEM, V266, P11448; LINN SC, 1992, J BIOL CHEM, V267, P7927; MAAS DHA, 1977, FERTIL STERIL, V28, P981; MORGANS CW, 1993, J CELL SCI, V106, P1275; NORD EP, 1988, J BIOL CHEM, V263, P5599; OLSNES S, 1986, J CELL BIOL, V102, P967, DOI 10.1083/jcb.102.3.967; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; YANNOUKAKOS D, 1994, CIRC RES, V75, P603, DOI 10.1161/01.RES.75.4.603	30	67	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24428	24434		10.1074/jbc.270.41.24428	http://dx.doi.org/10.1074/jbc.270.41.24428			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592657	hybrid			2022-12-27	WOS:A1995TA21700085
J	ROY, SN; KUDRYK, B; REDMAN, CM				ROY, SN; KUDRYK, B; REDMAN, CM			SECRETION OF BIOLOGICALLY-ACTIVE RECOMBINANT FIBRINOGEN BY YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-BETA CHAIN; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; GAMMA-CHAIN; PROTEIN; EXPRESSION; THROMBIN; TRANSPORT; SEQUENCE; BINDING	Fibrinogen (340 kDa) is a plasma protein that plays an important role in the final stages of blood clotting, Human fibrinogen is a dimer with each half molecule com posed of three different polypeptides (A alpha, 67 kDa; B beta, 57 kDa; gamma, 47 kDa). To understand the mechanism of fibrinogen chain assembly and secretion and to obtain a system capable of producing substantial amounts of fibrinogen for structure function studies, we developed a recombinant system capable of secreting fibrinogen. An expression vector (pYES2) was constructed with individual fibrinogen chain cDNAs under the control of a Gal-1 promoter fused with mating factor F alpha 1 prepro secretion signal (SS) cascade. In addition, other constructs were prepared with combinations of cDNAs encoding two chains or all three chains in tandem. Each chain was under the control of the Gal-1 promoter. These constructs were used to transform Saccharomyces cerevisiae (INVSC1; Mat alpha his3-Delta 1 leu2 trp1-289 ura3-52) in selective media. Single colonies from transformed yeast cells were grown in synthetic media with 4% raffinose to a density of 1 x 10(8) cells/ml and induced with 2% galactose for 16 h. Yeast cells expressing all three chains contained fibrinogen precursors and nascent fibrinogen and secreted about 30 mu g/ml of fibrinogen into the culture medium. The B beta and gamma chains, but not A alpha, were glycosylated. Glycosylation of B beta and gamma chains was inhibited by treatment of transformed yeast cells with tunicamycin. Intracellular B beta and gamma chains, but not the A alpha chains in secreted fibrinogen, were cleaved by endoglycosidase H. Carbohydrate analysis indicated that secreted recombinant fibrinogen contained N-linked asialo-galactosylated biantennary oligosaccharide, Recombinant fibrinogen yielded the characteristic plasmin digestion products, fragments D and E, that were immunologically indistinct from the same fragments obtained from plasma fibrinogen. The recombinant fibrin ogen was shown to be biologically active in that it could form a thrombin-induced clot, which, in the presence of factor XIIIa, could undergo gamma chain dimerization and A alpha chain polymer formation.	NEW YORK BLOOD CTR, LINDSLEY F KIMBALL RES INST, NEW YORK, NY 10021 USA	New York Blood Center					NHLBI NIH HHS [HL37457] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BINNIE CG, 1993, BIOCHEMISTRY-US, V32, P107, DOI 10.1021/bi00052a015; BINNIE CG, 1993, BLOOD, V81, P3186; BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; BOLYARD MG, 1989, BLOOD, V73, P1202; BOLYARD MG, 1988, GENE, V66, P183, DOI 10.1016/0378-1119(88)90355-1; BOLYARD MG, 1991, BIOCHEM BIOPH RES CO, V174, P853, DOI 10.1016/0006-291X(91)91496-Y; Crabtree G. R., 1987, MOL BASIS BLOOD DISE, P631; DANISHEFSKY K, 1990, BIOCHIM BIOPHYS ACTA, V1048, P202, DOI 10.1016/0167-4781(90)90057-9; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; FARRELL DH, 1994, J BIOL CHEM, V269, P226; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FRANZUSOFF A, 1991, METHOD ENZYMOL, V194, P662; HANTGAN RR, 1994, HEMOSTASIS THROMBOSI, P277; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HUANG S, 1993, J BIOL CHEM, V26, P8919; KUDRYK B, 1982, EUR J BIOCHEM, V125, P673, DOI 10.1111/j.1432-1033.1982.tb06735.x; KUDRYK BJ, 1989, MONOCLONAL ANTIBODIE, P365; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; LORD ST, 1989, BLOOD, V73, P166; MOSESSON M W, 1992, Seminars in Hematology, V29, P177; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PROCYK R, 1992, BIOCHEMISTRY-US, V31, P2273, DOI 10.1021/bi00123a009; PROCYK R, 1993, THROMB RES, V71, P127, DOI 10.1016/0049-3848(93)90179-R; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROSE MD, 1990, METHODS YEAST GENETI, P39; ROY S, 1992, J BIOL CHEM, V267, P23151; ROY SN, 1991, J BIOL CHEM, V266, P4758; Sambrook J, 1989, MOL CLONING LABORATO; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; TOWNSEND RR, 1982, J BIOL CHEM, V257, P9704; WARREN L, 1963, METHOD ENZYMOL, V6, P463, DOI 10.1016/0076-6879(63)06207-8; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1983, J BIOL CHEM, V258, P3407; ZHANG JZ, 1994, J BIOL CHEM, V269, P652	40	13	32	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23761	23767		10.1074/jbc.270.40.23761	http://dx.doi.org/10.1074/jbc.270.40.23761			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559549	hybrid			2022-12-27	WOS:A1995RY90900078
J	HARADA, S; SMITH, RM; SMITH, JA; SHAH, N; HU, DQ; JARETT, L				HARADA, S; SMITH, RM; SMITH, JA; SHAH, N; HU, DQ; JARETT, L			INSULIN-INDUCED EGR-1 EXPRESSION IN CHINESE-HAMSTER OVARY CELLS IS INSULIN-RECEPTOR AND INSULIN-RECEPTOR SUBSTRATE-1 PHOSPHORYLATION-INDEPENDENT - EVIDENCE OF AN ALTERNATIVE SIGNAL-TRANSDUCTION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; IMMEDIATE-EARLY GENES; RAT HEPATOMA-CELLS; HYBRID RECEPTORS; NUCLEI; ACCUMULATION; STIMULATION; INTERNALIZATION; LIVER; RNA	Insulin's effects primarily are initiated by insulin binding to its plasma membrane receptor and the sequential tyrosine phosphorylation of the insulin receptor and intracellular substrates, such as insulin receptor substrate-1 (IRS-1), However, studies suggest some insulin effects, including those at the nucleus, may not be regulated by this pathway, The present study compared the levels of insulin binding, insulin receptor and IRS-1 tyrosine phosphorylation, and phosphatidylinositol 3'-kinase activity to immediate early gene c-fos and egr-1 mRNA expression in Chinese hamster ovary (CHO) cells expressing only neomycin-resistant plasmid (CHONEO), overexpressing wild type human insulin receptor (CHOHIRc) or ATP binding site-mutated insulin receptors (CHOA1018K). Insulin binding in CHONEO cells was markedly lower than that in other cell types, 10 nM insulin significantly increased tyrosine phosphorylation of insulin receptor and IRS-1 in CHOHIRc cells, Phosphorylation of insulin receptor and IRS-I in CHONEO and CHOA1018K cells was not detected in the presence or absence of insulin, Similarly, insulin increased phosphatidylinositol S-kinase activity only in CHOHIRc cells, As determined by Northern blot, nuclear run-on analysis, and in situ hybridization, insulin induced c-fos mRNA expression, through transcription, in CHOHIRc cells but not in CHONEO and CHOA1018K cells, consistent with previous reports, In contrast, all three cell types showed a similar insulin dose-dependent increase of egr-1 mRNA expression through transcription. These data indicated that insulin-induced egr-1 mRNA expression did not correlate with the levels of insulin binding to insulin receptor or phosphorylation of insulin receptor and IRS-1. These results suggest that different mechanisms are involved in induction of c-fos and egr-1 mRNA expression by insulin, the former by the more classic insulin receptor tyrosine kinase pathway and the latter by a yet to be determined alternative signal transduction pathway.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania					NIDDK NIH HHS [DK19525, DK28144, DK28143] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, R01DK028144, R01DK028143] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABLER A, 1992, J BIOL CHEM, V267, P3946; ANDO A, 1992, J BIOL CHEM, V267, P12788; ANDROLEWICZ MJ, 1989, BIOCHEMISTRY-US, V28, P9750, DOI 10.1021/bi00451a031; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BLAZERYOST BL, 1992, BIOCHEM INT, V28, P143; BURWEN SJ, 1987, TRENDS BIOCHEM SCI, V12, P159, DOI 10.1016/0968-0004(87)90074-0; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CLEVENGER CV, 1991, SCIENCE, V253, P77, DOI 10.1126/science.2063207; CONWAY BR, 1995, DIABETES, V44, pA50; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; EVELETH DD, 1992, J CELL BIOL, V117, P291, DOI 10.1083/jcb.117.2.291; FRATTALI AL, 1992, J CELL BIOCHEM, V48, P43, DOI 10.1002/jcb.240480108; FRATTALI AL, 1993, J BIOL CHEM, V268, P7393; HARADA S, 1992, J CELL PHYSIOL, V153, P607, DOI 10.1002/jcp.1041530323; HARADA S, 1994, DNA CELL BIOL, V13, P487, DOI 10.1089/dna.1994.13.487; HAWKER JR, 1992, AM J PHYSIOL, V262, pH1525, DOI 10.1152/ajpheart.1992.262.5.H1525; HEYNER S, 1989, DEV BIOL, V134, P48, DOI 10.1016/0012-1606(89)90077-8; HOPKINS CR, 1994, BIOCHEM PHARMACOL, V47, P151, DOI 10.1016/0006-2952(94)90449-9; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JUHN BH, 1995, BIOCHEMISTRY-US, V34, P7996; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI NX, 1994, ONCOGENE, V9, P3457; LIN YZJ, 1992, P NATL ACAD SCI USA, V89, P9691, DOI 10.1073/pnas.89.20.9691; LOBIE PE, 1994, J BIOL CHEM, V269, P31735; LOTEN EG, 1993, INT J BIOCHEM, V5, P653; MAGGI D, 1994, BIOCHEM BIOPH RES CO, V205, P693, DOI 10.1006/bbrc.1994.2721; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V155, P562; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MILLER DS, 1988, SCIENCE, V240, P506, DOI 10.1126/science.2451860; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MOREL G, 1994, BIOCHEM PHARMACOL, V47, P63, DOI 10.1016/0006-2952(94)90438-3; MUNDSCHAU LJ, 1994, J BIOL CHEM, V269, P16137; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; Prystowsky M B, 1994, Immunomethods, V5, P49, DOI 10.1006/immu.1994.1037; PURRELLO F, 1983, P NATL ACAD SCI-BIOL, V80, P1189, DOI 10.1073/pnas.80.5.1189; PURRELLO F, 1982, SCIENCE, V215, P1005; RAPER SE, 1987, GASTROENTEROLOGY, V92, P1243, DOI 10.1016/S0016-5085(87)91084-5; SCHUMM DE, 1983, J CELL BIOCHEM, V23, P223, DOI 10.1002/jcb.240230119; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; SMITH RM, 1987, P NATL ACAD SCI USA, V84, P459, DOI 10.1073/pnas.84.2.459; SMITH RM, 1990, DIABETES, V39, P683, DOI 10.2337/diabetes.39.6.683; SOLER AP, 1990, ENDOCRINOLOGY, V127, P595; SOLER AP, 1992, DIABETES, V41, P194, DOI 10.2337/diabetes.41.2.194; SOLER AP, 1989, P NATL ACAD SCI USA, V86, P6640, DOI 10.1073/pnas.86.17.6640; STUMPO DJ, 1991, J BIOL CHEM, V266, P455; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TAUB R, 1987, J BIOL CHEM, V262, P10893; VETTEMONY L, 1994, MOL ENDOCRINOL, V31, P623; VISA N, 1993, EXP CELL RES, V208, P19, DOI 10.1006/excr.1993.1218; WEITZMANN MN, 1992, BIOCHEM BIOPH RES CO, V187, P1166, DOI 10.1016/0006-291X(92)91319-L; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; WONG EHA, 1995, ENDOCRINOLOGY, V136, P1459, DOI 10.1210/en.136.4.1459; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YAMAUCHI K, 1995, DIABETES, V44, pA50; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	57	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26632	26638		10.1074/jbc.270.44.26632	http://dx.doi.org/10.1074/jbc.270.44.26632			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592888	hybrid			2022-12-27	WOS:A1995TC97800095
J	IM, WB; PREGENZER, JF; BINDER, JA; DILLON, GH; ALBERTS, GL				IM, WB; PREGENZER, JF; BINDER, JA; DILLON, GH; ALBERTS, GL			CHLORIDE CHANNEL EXPRESSION WITH THE TANDEM CONSTRUCT OF ALPHA-6-BETA-2 GABA(A) RECEPTOR SUBUNIT REQUIRES A MONOMERIC SUBUNIT OF ALPHA-6 OR GAMMA-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINOBUTYRIC ACIDA-RECEPTOR; A RECEPTORS; BENZODIAZEPINE SITE; BINDING-SITES; BETA-SUBUNIT; SUBTYPES; CURRENTS; ALPHA-1-BETA-2-GAMMA-2; HETEROGENEITY; PURIFICATION	Despite the presence of the multiple subunits (alpha, beta, gamma, and delta) and their isoforms for gamma-aminobutyric acid, type A (GABA(A)) receptors in mammalian brains, the alpha x beta 2 gamma 2 subtypes appear to be the prototype GABA(A) receptors sharing many properties with native neuronal receptors, In order to gain insight into their subunit stoichiometry and orientation, we prepared a tandem construct of the alpha 6 and beta 2 subunit cDNAs where the carboxyl-terminal of alpha 6 is linked to the amino terminal of beta 2 via a linker encoding 10 glutamine residues. Transfection of human embryonic kidney 293 cells with the tandem construct alone failed to induce GABA-dependent Cl- currents, but its cotransfection with the cDNA for alpha 6 or gamma 2, but not beta 2, led to the appearance of GABA currents which were picrotoxin-sensitive and, in the case of gamma 2 containing receptors, responded to a benzodiazepine agonist, U-92330. The high affinity GABA site, however, was detected with [H-3]muscimol binding in all combinations of the receptor subunits, including the tandem construct alone or with the beta 2. No appreciable differences were found in their K-d (2.5 nM) and B-max values (1.4 pmol/mg of protein), These data are consistent with the view that the polypeptides arising from the tandem construct were expressed with the high affinity GABA site, but unable to form GABA channels, The requirement of a specific monomeric subunit (alpha 6 or gamma 2) for the tandem construct to express Cl- currents supports a pentameric structure of GABA(A) receptors consisting of two alpha 6, two beta 2, and one gamma 2 for the alpha 6 beta 2 gamma 2 and three alpha 6 and two beta 2 for the alpha 6 beta 2 subtype.			IM, WB (corresponding author), UPJOHN CO,CNS DIS RES 7251209114,KALAMAZOO,MI 49001, USA.							AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; BARNARD EC, 1993, ANN NY ACAD SCI, V707, P117; BATESON AN, 1991, J NEUROCHEM, V56, P1437, DOI 10.1111/j.1471-4159.1991.tb11443.x; CARTER DB, 1992, BIO-TECHNOL, V10, P679, DOI 10.1038/nbt0692-679; DELOREY TM, 1992, J BIOL CHEM, V267, P16747; DILLON GH, 1993, MOL PHARMACOL, V44, P860; DRAGUHN A, 1990, NEURON, V5, P781, DOI 10.1016/0896-6273(90)90337-F; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARVEY RJ, 1993, FEBS LETT, V331, P211, DOI 10.1016/0014-5793(93)80339-V; HURST RS, 1992, J BIOL CHEM, V267, P23742; IM HK, 1993, MOL PHARMACOL, V44, P866; IM WB, 1994, BRIT J PHARMACOL, V112, P1025, DOI 10.1111/j.1476-5381.1994.tb13185.x; IM WB, 1993, BRIT J PHARMACOL, V110, P677, DOI 10.1111/j.1476-5381.1993.tb13864.x; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LUDDENS H, 1991, J RECEPTOR RES, V11, P535, DOI 10.3109/10799899109066426; POLLARD S, 1993, J BIOL CHEM, V268, P3753; PREGENZER JF, 1993, MOL PHARMACOL, V43, P801; PRITCHETT DB, 1991, P NATL ACAD SCI USA, V88, P1421, DOI 10.1073/pnas.88.4.1421; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; PUIA G, 1991, MOL PHARMACOL, V39, P691; Sambrook J, 1989, MOL CLONING LABORATO; SIEGHART W, 1992, TRENDS PHARMACOL SCI, V13, P446, DOI 10.1016/0165-6147(92)90142-S; STAUBER GB, 1987, EUR J BIOCHEM, V167, P125, DOI 10.1111/j.1432-1033.1987.tb13313.x; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; VERDOORN TA, 1994, MOL PHARMACOL, V45, P475; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; WANG G, 1992, MOL PHARMACOL, V42, P996; WIELAND HA, 1992, J BIOL CHEM, V267, P1426; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y	30	80	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26063	26066		10.1074/jbc.270.44.26063	http://dx.doi.org/10.1074/jbc.270.44.26063			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592805	hybrid			2022-12-27	WOS:A1995TC97800012
J	WIJKANDER, J; OFLAHERTY, JT; NIXON, AB; WYKLE, RL				WIJKANDER, J; OFLAHERTY, JT; NIXON, AB; WYKLE, RL			5-LIPOXYGENASE PRODUCTS MODULATE THE ACTIVITY OF THE 85-KDA PHOSPHOLIPASE A(2) IN HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PLATELET-ACTIVATING FACTOR; ARACHIDONATE-MOBILIZING PHOSPHOLIPASE-A2; HUMAN POLYMORPHONUCLEAR NEUTROPHILS; MOUSE PERITONEAL-MACROPHAGES; GROUP-II PHOSPHOLIPASE-A(2); TUMOR-NECROSIS-FACTOR; RAT MESANGIAL CELLS; CYTOSOLIC PHOSPHOLIPASE-A2; MEMBRANE ASSOCIATION	Addition of submicromolar concentrations of arachidonic acid (AA) to human neutrophils induced a a-fold increase in the activity of a cytosolic phospholipase A(2) (PLA(2)) when measured using sonicated vesicles of 1-stearoyl-2-[C-14]arachidonoylphosphatidylcholine as substrate, A similar increase in cytosolic PLA(2) activity was induced by stimulation of neutrophils with leukotriene B-4 (LTB(4)), 5-oxoeicosatetraenoic acid, or 5-hydroxyeicosatetraenoic acid (5-HETE), LTB(4) was the most potent of the agonists, showing maximal effect at 1 nM. Inhibition of 5-lipoxygenase with either eicosatetraynoic acid or zileuton prevented the AA-induced increase in PLA(2) activity but had no effect on the response induced by LTB(4), Furthermore, pretreatment of neutrophils with a LTB(4)-receptor antagonist, LY 255283, blocked the AA- and LTB(4)-induced activation of PLA(2) but did not influence the action of 5-HETE, Treatment of neutrophils with pancreatic PLA(2) also induced an increase in the activity of the cytosolic PLA(2); this response was inhibited by both eicosatetraynoic acid or LY 255283, The increases in PLA(2) activity in response to stimulation correlated with a shift in electrophoretic mobility of the 85-kDa PLA(2), as determined by Western blot analysis, suggesting that phosphorylation of the 85-kDa PLA(2) likely underlies its increase in catalytic activity, Although stimulation of neutrophils with individual lipoxygenase metabolites did not induce significant mobilization of endogenous AA, they greatly enhanced the N-formylmethionyl-leucyl-phenylalanine-induced mobilization of AA as determined by mass spectrometry analysis. Our findings support a positive feedback model in which stimulus-induced release of AA or exocytosis of secretory PLA(2) modulate the activity of the cytosolic 85-kDa PLA(2) by initiating the formation of LTB(4). The nascent LTB, is then released to act on the LTB(4) receptor and thereby promote further activation of the 85-kDa PLA(2). Since 5-HETE and LTB, are known to prime the synthesis of platelet-activating factor, the findings suggest that 85-kDa PLA(2) plays a role in platelet-activating factor synthesis.	WAKE FOREST UNIV,MED CTR,DEPT BIOCHEM,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,MED CTR,DEPT MED,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest University			Nixon, Andrew/AAJ-4712-2020	Nixon, Andrew/0000-0003-3971-2964; wijkander, jonny/0000-0002-2310-9039	NHLBI NIH HHS [HL 26257, HL 26818] Funding Source: Medline; NIAID NIH HHS [AI 17287] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026257, R01HL026818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017287] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BAULDRY SA, 1991, J IMMUNOL, V146, P1277; BILLAH MM, 1985, J BIOL CHEM, V260, P6899; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DECHATELET LR, 1982, INFECT IMMUN, V35, P206, DOI 10.1128/IAI.35.1.206-212.1982; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIEZ E, 1994, BIOCHEM J, V301, P721, DOI 10.1042/bj3010721; DIEZ E, 1990, J BIOL CHEM, V265, P14654; DOERFLER ME, 1994, J CLIN INVEST, V93, P1583, DOI 10.1172/JCI117138; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; FONTEH AN, 1994, J IMMUNOL, V152, P5438; GOLDMAN DW, 1982, J IMMUNOL, V129, P1600; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; GRONICH JH, 1988, J BIOL CHEM, V26, P16645; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HUBBARD WC, 1986, PROSTAGLANDINS, V32, P889, DOI 10.1016/0090-6980(86)90097-3; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KRUMP E, 1994, BBA-LIPID LIPID MET, V1213, P135, DOI 10.1016/0005-2760(94)90019-1; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MCDONALD PP, 1994, BRIT J PHARMACOL, V111, P852, DOI 10.1111/j.1476-5381.1994.tb14816.x; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NAKATANI Y, 1994, J IMMUNOL, V153, P796; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OFLAHERTY JT, 1987, J IMMUNOL, V138, P1889; OFLAHERTY JT, 1993, BIOCHEM BIOPH RES CO, V192, P129, DOI 10.1006/bbrc.1993.1391; OFLAHERTY JT, 1993, J BIOL CHEM, V268, P14708; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; POWELL WS, 1993, J BIOL CHEM, V268, P9280; QIU ZH, 1993, J BIOL CHEM, V268, P24506; RAMESHA CS, 1993, BIOCHIM BIOPHYS ACTA, V1168, P37, DOI 10.1016/0005-2760(93)90263-9; REDDY S, 1995, AM J PHYSIOL-CELL PH, V268, pC138, DOI 10.1152/ajpcell.1995.268.1.C138; REHFELDT W, 1993, BIOCHEM J, V293, P255, DOI 10.1042/bj2930255; ROSSI AG, 1989, PROSTAGLANDINS, V37, P641, DOI 10.1016/0090-6980(89)90102-0; SAITO H, 1985, PROSTA LEUKOTR MED, V18, P271, DOI 10.1016/0262-1746(85)90059-9; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V210, P169, DOI 10.1111/j.1432-1033.1992.tb17405.x; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHIKANO M, 1994, BBA-LIPID LIPID MET, V1212, P211, DOI 10.1016/0005-2760(94)90255-0; SHIMIZU T, 1994, PANCREAS, V9, P37, DOI 10.1097/00006676-199401000-00005; SUNDLER R, 1994, BIOCHEM J, V301, P455, DOI 10.1042/bj3010455; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; WIJKANDER J, 1989, FEBS LETT, V244, P51, DOI 10.1016/0014-5793(89)81160-3; WIJKANDER J, 1992, FEBS LETT, V311, P299, DOI 10.1016/0014-5793(92)81124-5; WINKLER JD, 1993, BIOCHEM J, V291, P825, DOI 10.1042/bj2910825	57	73	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26543	26549		10.1074/jbc.270.44.26543	http://dx.doi.org/10.1074/jbc.270.44.26543			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592874	hybrid			2022-12-27	WOS:A1995TC97800081
J	KOHN, WD; MONERA, OD; KAY, CM; HODGES, RS				KOHN, WD; MONERA, OD; KAY, CM; HODGES, RS			THE EFFECTS OF INTERHELICAL ELECTROSTATIC REPULSIONS BETWEEN GLUTAMIC-ACID RESIDUES IN CONTROLLING THE DIMERIZATION AND STABILITY OF 2-STRANDED ALPHA-HELICAL COILED-COILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN4 LEUCINE-ZIPPER; PERFORMANCE LIQUID-CHROMATOGRAPHY; SYNTHETIC MODEL PROTEINS; NF-KAPPA-B; TRANSCRIPTION FACTOR; GUANIDINIUM CHLORIDE; QUATERNARY STRUCTURE; HALOPHILIC PROTEINS; CIRCULAR-DICHROISM; REVERSED-PHASE	The effects of interhelical electrostatic repulsions in controlling the dimerization and stability of two-stranded alpha-helical coiled-coils have been studied using de novo designed synthetic coiled-coils. A native coiledcoil was synthesized, which consisted of two identical 35-residue polypeptide chains with a heptad repeat QgVaGbAcLdQeKf and a Cys residue at position 2 to allow formation of an interchain 2-2' disulfide bridge. This peptide, designed to contain no intrachain or interchain electrostatic interactions, forms a stable coiledcoil structure at 20 degrees C in benign medium (50 mM KCl, 25 mM PO4, pH 7) with a [urea](1/2) value of 6.1 M. Five mutant coiled-coils were designed in which Gln residues at the e and g positions of the heptad repeat were substituted with Glu systematically from the N terminus toward the C terminus, resulting in each polypeptide chain having 2, 4, 6, 8, or 10 Glu residues. These substituted Glu residues are able to form interchain i to i'+5 electrostatic repulsions across the dimer interface. As the number of interchain repulsions increases, a steady loss of helical content is observed by circular dichroism spectroscopy. The effects of the interchain Glu-Glu repulsions on the coiled-coil structure are partly overcome by the presence of an interchain disulfide bridge; the peptide with six Glu substitutions is only 15% helical in the reduced form but 85% helical in the oxidized form. The stabilities of the coiled-coils were determined by urea and guanidine hydrochloride (GdnHCl) denaturation studies at 20 degrees C. The stabilities of the coiled-coils determined by urea denaturation indicate a decrease in stability, which correlates with an increasing number of interchain repulsions ([urea](1/2) values ranging from 8.4 to 3.7 M in the presence of 3 M KCl). In contrast, all coiled-coils had similar stabilities when determined by GdnHCl denaturation (approximately 2.9 M). KCl could not effectively screen the effects of interchain repulsions on coiled-coil stability as compared to GdnHCl.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,PROT ENGN NETWORK CTR EXCELLENCE,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta								Adamson J. Gordon, 1993, Current Opinion in Biotechnology, V4, P428, DOI 10.1016/0958-1669(93)90008-K; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; ARAKAWA T, 1992, ANAL BIOCHEM, V203, P53, DOI 10.1016/0003-2697(92)90042-6; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; Cantor CR, 1980, BIOPHYSICAL CHEM 1, P290; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CARR CM, 1994, SCIENCE, V266, P234, DOI 10.1126/science.7939658; CHAKRABARTTY A, 1994, PROTEIN SCI, V3, P843; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CREIGHTON TE, 1993, PROTEINS STRUCTURE M, P262; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; ENGEL M, 1991, BIOCHEMISTRY-US, V30, P3161, DOI 10.1021/bi00227a002; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; GRADDIS TJ, 1993, BIOCHEMISTRY-US, V32, P12664, DOI 10.1021/bi00210a015; GREENE RF, 1974, J BIOL CHEM, V249, P5388; GREENFIELD NJ, 1993, PROTEIN SCI, V2, P1263, DOI 10.1002/pro.5560020809; GUO DC, 1986, J CHROMATOGR, V359, P499, DOI 10.1016/0021-9673(86)80102-9; HAGIHARA Y, 1993, J MOL BIOL, V231, P180, DOI 10.1006/jmbi.1993.1272; HAGIHARA Y, 1994, J MOL BIOL, V237, P336, DOI 10.1006/jmbi.1994.1234; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HODGES R S, 1992, Current Biology, V2, P122, DOI 10.1016/0960-9822(92)90241-2; HODGES R S, 1990, Peptide Research, V3, P123; HODGES R S, 1988, Peptide Research, V1, P19; Hodges R. S., 1972, COLD SPRING HARB SYM, V37, P299; HODGES RS, 1994, J CHROMATOGR A, V676, P3, DOI 10.1016/0021-9673(94)80452-4; HODGES RS, 1981, J BIOL CHEM, V256, P1214; HOL WGJ, 1981, NATURE, V294, P532, DOI 10.1038/294532a0; HU JC, 1993, PROTEIN SCI, V2, P1072, DOI 10.1002/pro.5560020701; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HU JC, 1992, NUCLEIC ACIDS MOL BI, V6, P82; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KAY LE, 1991, BIOCHEMISTRY-US, V30, P4323, DOI 10.1021/bi00231a031; KOHN WD, 1995, PROTEIN SCI, V4, P237; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; LANYI JK, 1974, BACTERIOL REV, V38, P272, DOI 10.1128/MMBR.38.3.272-290.1974; LAU SYM, 1984, J CHROMATOGR, V317, P129, DOI 10.1016/S0021-9673(01)91653-X; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LEHRER SS, 1991, BIOCHEMISTRY-US, V30, P5682, DOI 10.1021/bi00237a007; LEHRER SS, 1989, SCIENCE, V246, P926, DOI 10.1126/science.2814515; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; LOWEY S, 1965, J BIOL CHEM, V240, P2421; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAKHATADZE GI, 1992, J MOL BIOL, V226, P491, DOI 10.1016/0022-2836(92)90963-K; MAYR LM, 1993, BIOCHEMISTRY-US, V32, P7994, DOI 10.1021/bi00082a021; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; MONERA OD, 1994, PROTEIN SCI, V3, P1984, DOI 10.1002/pro.5560031110; MONERA OD, 1993, J BIOL CHEM, V268, P19218; MORJANA NA, 1993, P NATL ACAD SCI USA, V90, P2107, DOI 10.1073/pnas.90.6.2107; Noelken M, 1964, BIOCH MUSCLE CONTRAC, P374; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Pace C N, 1986, Methods Enzymol, V131, P266; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; POTEKHIN SA, 1994, PROTEIN ENG, V7, P1097, DOI 10.1093/protein/7.9.1097; PU WT, 1993, NUCLEIC ACIDS RES, V21, P4348, DOI 10.1093/nar/21.18.4348; RAMALINGAM K, 1992, BIOPOLYMERS, V32, P981, DOI 10.1002/bip.360320809; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; REGAN L, 1994, PROTEIN SCI, V3, P2419, DOI 10.1002/pro.5560031225; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SANCHO J, 1992, BIOCHEMISTRY-US, V31, P2253, DOI 10.1021/bi00123a006; SCHMIDTDORR T, 1991, BIOCHEMISTRY-US, V30, P9657, DOI 10.1021/bi00104a013; SCHOLTZ JM, 1993, BIOCHEMISTRY-US, V32, P9668, DOI 10.1021/bi00088a019; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SEREDA TJ, 1994, J CHROMATOGR A, V676, P139, DOI 10.1016/0021-9673(94)00371-8; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; SKOLNICK J, 1985, MACROMOLECULES, V18, P1549, DOI 10.1021/ma00150a005; SKOLNICK J, 1986, BIOCHEMISTRY-US, V25, P6192, DOI 10.1021/bi00368a054; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; STONE D, 1975, 9 P FEBS M BUD, V31, P125; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; TALBOT JA, 1982, ACCOUNTS CHEM RES, V15, P224, DOI 10.1021/ar00079a006; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; THOMPSON KS, 1993, BIOCHEMISTRY-US, V32, P5491, DOI 10.1021/bi00072a001; TSONG TY, 1975, BIOCHEMISTRY-US, V14, P1542, DOI 10.1021/bi00678a031; VONHIPPE.PH, 1965, J BIOL CHEM, V240, P3909; YANG AS, 1993, J MOL BIOL, V231, P459, DOI 10.1006/jmbi.1993.1294; ZACCAI G, 1990, TRENDS BIOCHEM SCI, V15, P333, DOI 10.1016/0968-0004(90)90068-M; ZHOU NE, 1992, BIOPOLYMERS, V32, P419, DOI 10.1002/bip.360320419; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1993, BIOCHEMISTRY-US, V32, P3178, DOI 10.1021/bi00063a033; ZHOU NE, 1992, BIOCHEMISTRY-US, V31, P5739, DOI 10.1021/bi00140a008; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365; ZHU BY, 1993, PROTEIN SCI, V2, P383; ZHU BY, 1992, INT J PEPT PROT RES, V40, P171	98	93	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25495	25506		10.1074/jbc.270.43.25495	http://dx.doi.org/10.1074/jbc.270.43.25495			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592719	hybrid			2022-12-27	WOS:A1995TB46600035
J	REZAIE, AR; COOPER, ST; CHURCH, FC; ESMON, CT				REZAIE, AR; COOPER, ST; CHURCH, FC; ESMON, CT			PROTEIN-C INHIBITOR IS A POTENT INHIBITOR OF THE THROMBIN-THROMBOMODULIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RABBIT THROMBOMODULIN; BLOOD-COAGULATION; GLYCOSAMINOGLYCAN COMPONENT; PLASMINOGEN-ACTIVATOR; HEPARIN-BINDING; PLASMA; COFACTOR; ANTITHROMBIN; SPECIFICITY; INVITRO	Protein C inhibitor (PCI), a plasma serine protease inhibitor, inhibits several proteases including the anticoagulant enzyme, activated protein C (APC), and the coagulation enzymes, thrombin and factor Xa. Previous studies have shown that thrombin and APC are inhibited at similar rates by PCI and that heparin accelerates PCI inhibition of both enzymes more than 20-fold, We now demonstrate that the thrombin-binding proteoglycan, rabbit thrombomodulin, accelerates inhibition of thrombin by PCI approximate to 140-fold (k(2) = 2.4 x 10(6) in the presence of TM compared to 1.7 x 10(4) M(-1) s(-1) in the absence of TM). Most of this effect is mediated by protein-protein interactions since the active fragment of TM composed of epidermal growth factor-like domains 4-6 (TM 4-6) accelerates inhibition by PCI approximate to 59-fold (k(2) = 1.0 x 10(6) M(-1) s(-1)). The mechanism by which TM alters reactivity with PCI appears to reside in part in an alteration of the 52 specificity pocket. Replacing Phe(353) with Pro at the P2 position in the reactive loop of PCI yields a mutant that inhibits thrombin better in the absence of TM (k(2) = 6.3 x 10(5) M(-1) s(-1)), but TM 4-6 enhances inhibition by this mutant approximate to 9-fold (k(2) = 5.8 x 10(6) M(-1) s(-1)) indicating that TM alleviates the inhibitory effect of the less favored Phe residue. These results indicate that PCI is a potent inhibitor of the protein C anticoagulant pathway at the levels of both zymogen activation and enzyme inhibition.	UNIV N CAROLINA,SCH MED,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104; HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute	REZAIE, AR (corresponding author), OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104, USA.				NHLBI NIH HHS [R37 HL30340, R01 HL29807, P01 HL54804-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804, R01HL029807, R37HL030340] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; COOPER ST, 1995, BBA-PROTEIN STRUCT M, V1246, P29, DOI 10.1016/0167-4838(94)00185-J; DEMUNK GAW, 1993, BIOCHEM J, V290, P655, DOI 10.1042/bj2900655; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESPANA F, 1991, BLOOD, V77, P1754; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GRIFFITH MJ, 1982, THROMB RES, V25, P245, DOI 10.1016/0049-3848(82)90244-4; GUINTO ER, 1994, J BIOL CHEM, V269, P18395; HEEB MJ, 1991, J BIOL CHEM, V266, P17606; HEEB MJ, 1989, BLOOD, V73, P446; HEEB MJ, 1988, J BIOL CHEM, V263, P11613; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOPKINS PCR, 1995, J BIOL CHEM, V270, P11866, DOI 10.1074/jbc.270.20.11866; LAURELL M, 1992, J CLIN INVEST, V89, P1094, DOI 10.1172/JCI115689; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LIN JH, 1994, J BIOL CHEM, V269, P25021; MAILLARD C, 1993, ENDOCRINOLOGY, V133, P668, DOI 10.1210/en.133.2.668; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MOLINARI A, 1992, THROMB HAEMOSTASIS, V67, P226; PARKINSON JF, 1992, ADV EXP MED BIOL, V313, P177; PHILLIPS JE, 1994, J BIOL CHEM, V269, P16696; PRATT CW, 1993, BLOOD COAGUL FIBRIN, V4, P479, DOI 10.1097/00001721-199306000-00013; PRATT CW, 1992, J BIOL CHEM, V267, P8789; RADTKE KP, 1994, J CLIN INVEST, V94, P2117, DOI 10.1172/JCI117566; RAIFE TJ, 1994, J CLIN INVEST, V93, P1846, DOI 10.1172/JCI117171; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; STONE SR, 1985, BIOCHEM J, V230, P497, DOI 10.1042/bj2300497; SUZUKI K, 1989, THROMB HAEMOSTASIS, V61, P337; SUZUKI K, 1987, J BIOL CHEM, V262, P611; SUZUKI K, 1984, J BIOCHEM, V95, P187, DOI 10.1093/oxfordjournals.jbchem.a134583; TAKANO S, 1990, BLOOD, V76, P2024; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1994, J BIOL CHEM, V269, P17965	38	159	164	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25336	25339		10.1074/jbc.270.43.25336	http://dx.doi.org/10.1074/jbc.270.43.25336			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592694	hybrid, Green Published			2022-12-27	WOS:A1995TB46600010
J	SHI, XY; BAI, S; FORD, AC; BURK, RD; JACQUEMIN, E; HAGENBUCH, B; MEIER, PJ; WOLKOFF, AW				SHI, XY; BAI, S; FORD, AC; BURK, RD; JACQUEMIN, E; HAGENBUCH, B; MEIER, PJ; WOLKOFF, AW			STABLE INDUCIBLE EXPRESSION OF A FUNCTIONAL-RAT LIVER ORGANIC ANION TRANSPORT PROTEIN IN HELA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; PLASMA-MEMBRANE; BINDING-PROTEIN; SERUM-ALBUMIN; BILIRUBIN; SULFOBROMOPHTHALEIN; CHLORIDE	Recently we expression cloned a rat liver organic anion transport protein in Xenopus laevis oocytes (Jacquemin, E., Hagenbuch, B., Stieger, B., Wolkoff, A. W., and Meier, P. J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 133-137). In the present study, we have stably transfected the cDNA encoding this protein into HeLa cells by using a vector containing a zinc-inducible promoter. The parent cells have virtually no baseline transport of [S-35]sulfobromophthalein, whereas the induced transfected cells express a novel 74-kDa protein and avidly transport this ligand. Transport by these cells is saturable (K-m = 3.3 mu M, V-max = 257 pmol/min/mg protein), bidirectional, and highly temperature-dependent. In the presence of albumin, uptake of [S-35]sulfobromophthalein requires the presence of extracellular Cl-, whereas in the absence of albumin, this Cl- dependence is not seen. These studies indicate that cellular uptake of sulfobromophthalein does not result hom direct interaction with the plasma membrane lipid bilayer but rather requires the presence of a specific plasma membrane transporter.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,BRONX,NY 10461; UNITE RECH,F-94275 LE KREMLIN BICETR,FRANCE; UNIV ZURICH HOSP,DIV CLIN PHARMACOL,CH-8091 ZURICH,SWITZERLAND	Yeshiva University; Albert Einstein College of Medicine; University of Zurich; University Zurich Hospital			Hagenbuch, Bruno/M-5294-2016; jacquemin, emmanuel/J-8673-2013	Hagenbuch, Bruno/0000-0002-2938-8630; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK023026, P30DK041296] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-23026, DK-41296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERK PD, 1987, HEPATOLOGY, V7, P165, DOI 10.1002/hep.1840070131; BLAUER G, 1972, BIOCHIM BIOPHYS ACTA, V278, P89, DOI 10.1016/0005-2795(72)90109-2; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; GARTNER U, 1982, GASTROENTEROLOGY, V83, P1163; GOESER T, 1990, J CLIN INVEST, V86, P220, DOI 10.1172/JCI114687; GUPTA SL, 1994, INFECT IMMUN, V62, P2277, DOI 10.1128/IAI.62.6.2277-2284.1994; HAO XY, 1994, BIOCHEM J, V297, P59, DOI 10.1042/bj2970059; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; JACQUEMIN E, 1991, J CLIN INVEST, V88, P2146, DOI 10.1172/JCI115546; KULLAKUBLICK GA, 1994, HEPATOLOGY, V20, P411; KURISU H, 1989, ANAL BIOCHEM, V179, P72, DOI 10.1016/0003-2697(89)90202-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCNEALL J, 1989, GENE, V76, P81, DOI 10.1016/0378-1119(89)90010-3; MIN AD, 1991, HEPATOLOGY, V14, P1217, DOI 10.1002/hep.1840140642; MIN AD, 1991, J CLIN INVEST, V87, P1496, DOI 10.1172/JCI115159; NOY N, 1992, BIOPHYS CHEM, V42, P177, DOI 10.1016/0301-4622(92)85007-Q; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHARSCHMIDT BF, 1975, J CLIN INVEST, V56, P1280, DOI 10.1172/JCI108204; SHNEIDER BL, 1993, J BIOL CHEM, V268, P6985; STOLLMAN YR, 1983, J CLIN INVEST, V72, P718, DOI 10.1172/JCI111021; TIRIBELLI C, 1990, BIOCHIM BIOPHYS ACTA, V1031, P261, DOI 10.1016/0304-4157(90)90012-2; Wolkoff Allan W., 1994, P179; WOLKOFF AW, 1979, AM J PHYSIOL, V236, pE638, DOI 10.1152/ajpendo.1979.236.6.E638; WOLKOFF AW, 1985, J CLIN INVEST, V76, P454, DOI 10.1172/JCI111993; WOLKOFF AW, 1987, J CLIN INVEST, V79, P1259, DOI 10.1172/JCI112946	25	88	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25591	25595		10.1074/jbc.270.43.25591	http://dx.doi.org/10.1074/jbc.270.43.25591			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592731	hybrid			2022-12-27	WOS:A1995TB46600048
J	SINGH, S; AGGARWAL, BB				SINGH, S; AGGARWAL, BB			ACTIVATION OF TRANSCRIPTION FACTOR NF-KAPPA-B IS SUPPRESSED BY CURCUMIN (DIFERULOLYLMETHANE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; FACTOR-ALPHA; PROTEIN-KINASE; INTACT-CELLS; MOUSE SKIN; BINDING; EXPRESSION; PROMOTION; DNA	When activated, NF-kappa B, a ubiquitous transcription factor, binds DNA as a heterodimeric complex composed of members of the Rel/NF-kappa B family of polypeptides. Because of its intimate involvement in host defense against disease, this transcription factor is an important target for therapeutic intervention, In the present report we demonstrate that curcumin (diferuloylmethane), a known anti-inflammatory and anticarcinogenic agent, is a potent inhibitor of NF-kappa B activation. Treatment of human myeloid ML-1a cells with tumor necrosis factor (TNF) rapidly activated NF-kappa B, which consists of p50 and p65 subunits, and this activation was inhibited by curcumin, AP-1 binding factors were also found to be down-modulated by curcumin, whereas the Sp1 binding factor was unaffected. Besides TNF, curcumin also blocked phorbol ester-and hydrogen peroxide-mediated activation of NF-kappa B. The TNF-dependent phosphorylation and degradation of I kappa B alpha was not observed in curcumin-treated cells; the translocation of p65 subunit to the nucleus was inhibited at the same time, The mechanism of action of curcumin was found to be different from that of protein tyrosine phosphatase inhibitors, Our results indicate that curcumin inhibits NF-kappa B activation pathway at a step before I kappa B alpha phosphorylation but after the convergence of various stimuli.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC ONCOL, CYTOKINE RES LAB, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Aggarwal, Bharat B/G-3388-2013					AMMON HPT, 1993, J ETHNOPHARMACOL, V38, P113, DOI 10.1016/0378-8741(93)90005-P; AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004; AZUINE MA, 1992, NUTR CANCER, V17, P77, DOI 10.1080/01635589209514174; AZUINE MA, 1992, INT J CANCER, V51, P412, DOI 10.1002/ijc.2910510313; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROUET I, 1995, BIOCHEM BIOPH RES CO, V206, P533, DOI 10.1006/bbrc.1995.1076; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; CONNEY AH, 1991, ADV ENZYME REGUL, V31, P385, DOI 10.1016/0065-2571(91)90025-H; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; EICHER DM, 1994, J IMMUNOL, V152, P2710; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GENG Y, 1993, J IMMUNOL, V151, P6692; GRILLI M, 1993, INT REV CYTOL, V143, P1; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HASSANAIN HH, 1993, ANAL BIOCHEM, V213, P162, DOI 10.1006/abio.1993.1400; HUANG MT, 1992, CARCINOGENESIS, V13, P2183, DOI 10.1093/carcin/13.11.2183; HUANG MT, 1988, CANCER RES, V48, P5941; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; KIM HK, 1995, J IMMUNOL, V154, P4741; KOONG AC, 1994, CANCER RES, V54, P1425; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LI CJ, 1993, P NATL ACAD SCI USA, V90, P1839, DOI 10.1073/pnas.90.5.1839; MAHON TM, 1995, BIOCHEM SOC T, V23, pS111, DOI 10.1042/bst023111s; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAGABHUSHAN M, 1992, J AM COLL NUTR, V11, P192; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; REDDY S, 1994, FEBS LETT, V341, P19, DOI 10.1016/0014-5793(94)80232-7; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; SATOSKAR RR, 1986, INT J CLIN PHARM TH, V24, P651; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHANNON AG, 1980, FIBONACCI QUART, V18, P73; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SINGH H, 1995, CELL, V270, P10631; TAKADA T, 1994, CANCER RES, V54, P4653; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; YANAGA F, 1994, BIOCHEM J, V298, P733, DOI 10.1042/bj2980733; YANG ZH, 1993, J BIOL CHEM, V268, P20520	50	1175	1220	2	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24995	25000		10.1074/jbc.270.42.24995	http://dx.doi.org/10.1074/jbc.270.42.24995			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559628	hybrid			2022-12-27	WOS:A1995TB46500062
J	XUI, ZJ; MOFFETT, DB; PETERS, TR; SMITH, LD; PERRY, BP; WHITMER, J; STOKKE, SA; TEINTZE, M				XUI, ZJ; MOFFETT, DB; PETERS, TR; SMITH, LD; PERRY, BP; WHITMER, J; STOKKE, SA; TEINTZE, M			THE ROLE OF THE LEADER SEQUENCE CODING REGION IN EXPRESSION AND ASSEMBLY OF BACTERIORHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; BACTERIO-OPSIN GENE; HALOBACTERIUM-HALOBIUM; HALORHODOPSIN; VESICLES; ARCHAEBACTERIUM; RECONSTITUTION; ASSOCIATION; INSERTION; BILAYERS	Bacterio-opsin is made as a precursor in Halobacterium halobium, which has 13 additional residues at the amino terminus. The codons for these residues have been proposed to form a hairpin structure in the mRNA and play a role in ribosome binding; the leader peptide sequence also has been proposed to have a role in membrane insertion of bacteriorhodopsin (BR). We have made mutations in the bop gene region coding for the leader sequence and expressed the mutant genes in an H. halobium mutant lacking wild-type BR. The leader sequence coding region was found to be important for the stability of the mRNA and for its efficient translation. Single base substitutions in this region that did not affect the amino acid sequence caused significant reductions in protein expression. Deletion of the leader region resulted in unstable mRNA and almost no BR production. Introduction of a new ribosome-binding sequence within the coding region of the mature protein restored mRNA stability and some protein expression, Protein made without the leader peptide was properly assembled in the membrane.	MONTANA STATE UNIV, DEPT CHEM & BIOCHEM, BOZEMAN, MT 59717 USA	Montana State University System; Montana State University Bozeman					NIGMS NIH HHS [GM38142] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038142] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1988, MOL REPROD DEV; BAUER U, 1992, BIOCHEM BIOPH RES CO, V187, P1480, DOI 10.1016/0006-291X(92)90469-2; BETLACH M, 1984, NUCLEIC ACIDS RES, V12, P7949, DOI 10.1093/nar/12.20.7949; BLANCK A, 1987, EMBO J, V6, P265, DOI 10.1002/j.1460-2075.1987.tb04749.x; CLINE SW, 1989, CAN J MICROBIOL, V35, P148, DOI 10.1139/m89-022; DASSARMA S, 1983, P NATL ACAD SCI-BIOL, V80, P2201, DOI 10.1073/pnas.80.8.2201; DENCHER NA, 1986, BIOCHEMISTRY-US, V25, P1195, DOI 10.1021/bi00353a038; DUNN R, 1981, P NATL ACAD SCI-BIOL, V78, P6744, DOI 10.1073/pnas.78.11.6744; GROPP R, 1992, P NATL ACAD SCI USA, V89, P1204, DOI 10.1073/pnas.89.4.1204; HEYMANN JAW, 1993, MOL MICROBIOL, V7, P623, DOI 10.1111/j.1365-2958.1993.tb01153.x; LAM WL, 1989, P NATL ACAD SCI USA, V86, P5478, DOI 10.1073/pnas.86.14.5478; NI B, 1990, GENE, V90, P169, DOI 10.1016/0378-1119(90)90456-2; Oesterhelt D, 1974, Methods Enzymol, V31, P667; Sambrook J, 1989, MOL CLONING LABORATO; SCOTTO AW, 1990, BIOCHEMISTRY-US, V29, P7244, DOI 10.1021/bi00483a012; SCOTTO AW, 1988, J BIOL CHEM, V263, P18500; SCOTTO AW, 1985, BIOCHEMISTRY-US, V24, P4066, DOI 10.1021/bi00336a040; SEEHRA JS, 1984, J BIOL CHEM, V259, P4187; SPUDICH EN, 1993, J BIOL CHEM, V268, P16095; STEINER M, 1983, EMBO J, V2, P1379, DOI 10.1002/j.1460-2075.1983.tb01595.x; VONHEIJNE G, 1987, FEBS LETT, V213, P238, DOI 10.1016/0014-5793(87)81497-7; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAKIM D, 1989, METHOD ENZYMOL, V171, P253	24	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24858	24863		10.1074/jbc.270.42.24858	http://dx.doi.org/10.1074/jbc.270.42.24858			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559608	hybrid			2022-12-27	WOS:A1995TB46500042
J	DAVIDSON, VL; JONES, LH				DAVIDSON, VL; JONES, LH			COMPLEX-FORMATION WITH METHYLAMINE DEHYDROGENASE AFFECTS THE PATHWAY OF ELECTRON-TRANSFER FROM AMICYANIN TO CYTOCHROME C-551I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							C-TYPE CYTOCHROMES; PARACOCCUS-DENITRIFICANS; CRYSTAL-STRUCTURE; PROTEIN; CONSTANTS; OXIDATION; COPPER; ENZYME	Methylamine dehydrogenase (MADH), amicyanin, and cytochrome c-551i are soluble redox proteins that form a complex in solution (Chen, L., Durley, R., Mathews, F. S., and Davidson, V. L. (1994) Science 264, 86-90), which is required for the physiologic electron transfer from the tryptophan tryptophylquinone cofactor of MADH to heme via the copper center of amicyanin. The reduction of cytochrome by amicyanin within the complex in solution has been demonstrated using rapid scanning stopped-flow spectroscopy. Electron transfer from free, uncomplexed, amicyanin to cytochrome c-551i occurs much more rapidly but only to a very small extent because the reaction is thermodynamically much less favorable when amicyanin is not associated with MADH (Gray, K. A., Davidson, V. L., and Knaff, D. B. (1988) J. Biol. Chem. 263, 13987-13990). These kinetic data suggest that amicyanin binding to cytochrome c-551i occurs at different sites when amicyanin is free and when it is in complex with MADH. A model for the interactions of these proteins is presented.			DAVIDSON, VL (corresponding author), UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,2500 N STATE ST,JACKSON,MS 39216, USA.			Davidson, Victor/0000-0002-1966-7302	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041574, R01GM041574] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41574] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROOKS HB, 1994, BIOCHEMISTRY-US, V33, P5696, DOI 10.1021/bi00185a005; CHEN LY, 1992, BIOCHEMISTRY-US, V31, P4959, DOI 10.1021/bi00136a006; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; DAVIDSON VL, 1993, BIOCHIM BIOPHYS ACTA, V1144, P39, DOI 10.1016/0005-2728(93)90028-E; DAVIDSON VL, 1990, METHOD ENZYMOL, V188, P241; DAVIDSON VL, 1991, ANAL CHIM ACTA, V249, P235, DOI 10.1016/0003-2670(91)87028-6; DAVIDSON VL, 1993, PRINCIPLES APPL QUIN, P73; GRAY KA, 1986, FEBS LETT, V207, P239, DOI 10.1016/0014-5793(86)81496-X; GRAY KA, 1988, J BIOL CHEM, V263, P13987; HUSAIN M, 1986, J BIOL CHEM, V261, P8577; HUSAIN M, 1987, BIOCHEMISTRY-US, V26, P4139, DOI 10.1021/bi00387a059; HUSAIN M, 1985, J BIOL CHEM, V260, P4626; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; VANSPANNING RJM, 1990, FEBS LETT, V275, P217, DOI 10.1016/0014-5793(90)81475-4	17	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23941	23943		10.1074/jbc.270.41.23941	http://dx.doi.org/10.1074/jbc.270.41.23941			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592588	hybrid			2022-12-27	WOS:A1995TA21700016
J	DEBERNARD, M; PAPINI, E; DEFILIPPIS, V; GOTTARDI, E; TELFORD, J; MANETTI, R; FONTANA, A; RAPPUOLI, R; MONTECUCCO, C				DEBERNARD, M; PAPINI, E; DEFILIPPIS, V; GOTTARDI, E; TELFORD, J; MANETTI, R; FONTANA, A; RAPPUOLI, R; MONTECUCCO, C			LOW PH ACTIVATES THE VACUOLATING TOXIN OF HELICOBACTER-PYLORI, WHICH BECOMES ACID AND PEPSIN RESISTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHRONIC GASTRITIS; CAMPYLOBACTER; MUCUS	The protein toxin VacA, produced by cytotoxic strains of Helicobacter pylori, causes a vacuolar degeneration of cells, which eventually die. VacA is strongly activated by a short exposure to acidic solutions in the pH 1.5-5.5 range, followed by neutralization. Activated VacA has different CD and fluorescence spectra and a limited proteolysis fragmentation pattern from VacA kept at neutral pH. Moreover, activated VacA is resistant to pH 1.5 and to pepsin. The relevance of these findings to pathogenesis of H. pylori-induced gastrointestinal ulcers is discussed.	UNIV PADUA,DIPARTIMENTO SCI BIOMED,PADUA,ITALY; UNIV PADUA,CRIBI,PADUA,ITALY; UNIV SIENA,IST RIC IMMUNOBIOL SIENNA,I-53100 SIENA,ITALY	University of Padua; University of Padua; University of Siena	DEBERNARD, M (corresponding author), UNIV PADUA,CNR,CTR BIOMEMBRANE,VIA TRIESTE 75,PADUA,ITALY.		Telford, John Laird/ABG-8144-2020; Papini, Emanuele/AAE-6961-2022	Papini, Emanuele/0000-0001-6033-4473; de Bernard, Marina/0000-0002-0091-4502				ALLEN A, 1980, GUT, V21, P249, DOI 10.1136/gut.21.3.249; BHASKAR KR, 1992, NATURE, V360, P458, DOI 10.1038/360458a0; Blaser M J, 1993, Trends Microbiol, V1, P255, DOI 10.1016/0966-842X(93)90047-U; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; COVER TL, 1994, J BIOL CHEM, V269, P10566; COVER TL, 1992, J BIOL CHEM, V287, P10570; DEFILIPPIS V, 1995, EUR J BIOCHEM, V229, P61; DEFILIPPIS V, 1995, BIOCHEMISTRY-US, V35, P9552; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; FIOCCA R, 1992, VIRCHOWS ARCH A, V420, P489, DOI 10.1007/BF01600253; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; FRIERI G, 1995, DIGESTION, V56, P107, DOI 10.1159/000201229; Guyton AC, 1991, TXB MED PHYSL; LAKOWICZ JR, 1986, PRINCIPLES FLUORESCE, P341; MARCHETTI M, 1995, SCIENCE, V1267, P1655; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MENESTRINA G, 1994, MOL ASPECTS MED, V15, P79, DOI 10.1016/0098-2997(94)90043-4; PAPINI E, 1993, MOL MICROBIOL, V7, P323, DOI 10.1111/j.1365-2958.1993.tb01123.x; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PHADNIS SH, 1994, INFECT IMMUN, V62, P1557, DOI 10.1128/IAI.62.5.1557-1565.1994; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; TELFORD JL, 1994, TRENDS BIOTECHNOL, V12, P420, DOI 10.1016/0167-7799(94)90031-0; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; VANDENBERG L, 1959, ARCH BIOCHEM BIOPHYS, V81, P319, DOI 10.1016/0003-9861(59)90209-7; VUILLEUMIER S, 1992, BIOCHEMISTRY-US, V32, P10303; WARREN JR, 1983, LANCET, V1, P1273; WILLIAMS SE, 1981, GUT, V22, P94, DOI 10.1136/gut.22.2.94; YANG JT, 1986, METHOD ENZYMOL, V130, P208; 1993, LANCET, V341, P1359	31	171	174	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23937	23940		10.1074/jbc.270.41.23937	http://dx.doi.org/10.1074/jbc.270.41.23937			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592587	hybrid, Green Published			2022-12-27	WOS:A1995TA21700015
J	FRICK, DN; TOWNSEND, BD; BESSMAN, MJ				FRICK, DN; TOWNSEND, BD; BESSMAN, MJ			A NOVEL GDP-MANNOSE MANNOSYL HYDROLASE SHARES HOMOLOGY WITH THE MUTT FAMILY OF ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOSIDE TRIPHOSPHATASE; MOLECULAR-CLONING; SEQUENCE; PROTEIN; DNA; PURIFICATION; NUCLEOTIDE; MUTATOR	The product of the Escherichia coli orf1.9, or yefc, gene (GenBank(TM) accession number L11721) has been expressed under the control of a T7 promoter, purified to apparent homogeneity, and identified as a novel enzyme that hydrolyzes GDP-mannose or GDP-glucose to GDP and the respective hexose, The enzyme has little or no activity on other nucleotides, dinucleotides, nucleotide sugars, or sugar phosphates. It has a pH optimum between 9.0 and 9.5, a K-m of 0.3 mM, and a V-max of 1.6 mu mol min(-1) mg(-1) for GDP-mannose, and it requires divalent cations for activity, This enzyme of 160 amino acids (M(r) = 18, 405) contains the consensus sequence GX(I/L/V)(E/ Q)(X)(2)ET(X)(6)R(X)(4)E(X)(2)(I/L), characteristic of the MutT family of proteins and previously shown to form part of the nucleotide-binding site of MutT (Frick, D. N., Weber, D. J., Abeygunawardana, C., Gittis, A. G., Bessman, M. J., and Mildvan, A. S. (1995) Biochemistry 34, 5577-5586). A comparison of the enzymatic reactions catalyzed by the GDP-mannose mannosyl hydrolase and the other enzymes of the MutT family suggests that the consensus signature sequence designates a novel nucleoside diphosphate binding site and catalytic motif.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University				Frick, David/0000-0002-2434-7223	NIGMS NIH HHS [GM18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEYGUNAWARDANA C, 1995, FASEB J, V9, pA1466; AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; AMES BN, 1960, J BIOL CHEM, V235, P769; AOYAMA K, 1994, MOL BIOL EVOL, V11, P829; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLIONS LC, 1993, FASEB J, V7, pA1290; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; CABIB E, 1965, J BIOL CHEM, V240, P2114; CABIB E, 1961, J BIOL CHEM, V236, P883; Cleland W W, 1979, Methods Enzymol, V63, P103; DANKERT M, 1964, BIOCHIM BIOPHYS ACTA, V81, P78, DOI 10.1016/0926-6569(64)90337-2; DESIRAJU V, 1991, THESIS U MARYLAND; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, BIOCHEMISTRY-US, V34, P5577, DOI 10.1021/bi00016a032; FURUICHI M, 1994, GENOMICS, V24, P485, DOI 10.1006/geno.1994.1657; GINSBURG V, 1964, ADV ENZYMOL REL S BI, V26, P35; GLASER L, 1965, BIOCHIM BIOPHYS ACTA, V101, P6, DOI 10.1016/0926-6534(65)90025-4; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P4847, DOI 10.1093/nar/21.20.4847; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YC, 1990, ANAL BIOCHEM, V189, P151, DOI 10.1016/0003-2697(90)90099-U; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MARKHAM R, 1952, BIOCHEM J, V52, P552, DOI 10.1042/bj0520552; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; Miller J. H., 1972, EXPT MOL GENETICS, P433; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; OHANDLEY SF, 1995, FASEB J, V9, pA1299; RAY U, 1979, MOL GEN GENET, V171, P215, DOI 10.1007/BF00270007; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHNITZLER P, 1994, NUCLEIC ACIDS RES, V22, P158, DOI 10.1093/nar/22.2.158; Silhavy TJ, 1984, EXPT GENE FUSIONS, P137; SONNINO S, 1966, J BIOL CHEM, V241, P1009; SONNINO S, 1966, ARCH BIOCHEM BIOPHYS, V116, P26, DOI 10.1016/0003-9861(66)90007-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; WEBER DJ, 1993, BIOCHEMISTRY-US, V32, P13081, DOI 10.1021/bi00211a018	42	65	69	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24086	24091		10.1074/jbc.270.41.24086	http://dx.doi.org/10.1074/jbc.270.41.24086			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592609	hybrid			2022-12-27	WOS:A1995TA21700037
J	MURASAWA, S; MATSUBARA, H; MORI, Y; KIJIMA, K; MARUYAMA, K; INADA, M				MURASAWA, S; MATSUBARA, H; MORI, Y; KIJIMA, K; MARUYAMA, K; INADA, M			IDENTIFICATION OF A NEGATIVE CIS-REGULATORY ELEMENT AND TRANS-ACTING PROTEIN THAT INHIBIT TRANSCRIPTION OF THE ANGIOTENSIN-II TYPE 1A RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; RAT; SUBTYPE; ENHANCER; CLONING; CELLS	The rat angiotensin II type la receptor (AT1a-R) gene is expressed in a cell-specific manner. We demonstrated that the negative regulatory element (NRE) between -489 and -331 is active in PC12 cells (Murasawa, S., Matsubara, H., Urakami, M., and Inada, M. (1993) J. Biol. Chem. 268, 26996-27003). Gel retardation assays confirmed that PC12 cells have a trans-acting factor bound to the NRE. By means of a DNase I footprint assay we identified the core of the NRE as an (A + T)-rich sequence (TAATCTTTTATTTTA) located at nucleotides -456 to -442. Oligonucleotides corresponding to the NRE core sequence bound to nuclear protein. Site-directed mutagenesis at nucleotides -451 to -448 eliminated the specific protein/DNA binding and restored expression of the AT1a-R in transient transfection assays (2.7-fold increase). The NRE did not negatively affect the thymidine kinase promoter. No homology was found with known NREs, suggesting that this is a novel NRE. Southwestern blotting revealed a 53-kDa, specific binding protein in PC12 cells and the rat brain, but not in the liver, spleen, adrenal gland, and kidney. These findings demonstrate that the NRE of the rat AT1a-R is an (A + T) rich sequence located at nucleotides -456 to -442 and the 53-kDa protein is a specific binding protein, and suggest that this protein may be a trans acting factor which determines the neuron-specific down-regulation of the AT1a-R gene.	KANSAI MED UNIV,DEPT INTERNAL MED 2,MORIGUCHI,OSAKA 570,JAPAN	Kansai Medical University								AUSUBEL FM, 1983, CURRENT PROTOCOL MOL; CHAMLEY JH, 1977, CELL TISSUE RES, V177, P503; ELTON TS, 1992, BIOCHEM BIOPH RES CO, V184, P1067, DOI 10.1016/0006-291X(92)90700-U; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GUO DF, 1994, BBA-GENE STRUCT EXPR, V1218, P91, DOI 10.1016/0167-4781(94)90105-8; GUO DF, 1994, BIOCHEM BIOPH RES CO, V200, P313, DOI 10.1006/bbrc.1994.1450; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; IWAI N, 1991, BIOCHEM BIOPH RES CO, V177, P299, DOI 10.1016/0006-291X(91)91982-I; IWAI N, 1992, FEBS LETT, V298, P257, DOI 10.1016/0014-5793(92)80071-N; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V183, P1090, DOI 10.1016/S0006-291X(05)80302-X; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MUGLIA L, 1986, P NATL ACAD SCI USA, V83, P7653, DOI 10.1073/pnas.83.20.7653; MURASAWA S, 1993, J BIOL CHEM, V268, P26996; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAKAMURA N, 1989, P NATL ACAD SCI USA, V86, P56, DOI 10.1073/pnas.86.1.56; NIO Y, 1995, J CLIN INVEST, V95, P46, DOI 10.1172/JCI117675; PEACH MJ, 1981, BIOCHEM PHARMACOL, V30, P2745, DOI 10.1016/0006-2952(81)90410-X; PIERCE JW, 1991, MOL CELL BIOL, V11, P1431, DOI 10.1128/MCB.11.3.1431; SANDBERG K, 1992, J BIOL CHEM, V267, P9455; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SUMMERS C, 1991, P NATL ACAD SCI USA, V88, P7567; SUZUKI J, 1993, CIRC RES, V73, P439, DOI 10.1161/01.RES.73.3.439; TAKAYANAGI R, 1994, BIOCHEM BIOPH RES CO, V200, P1264, DOI 10.1006/bbrc.1994.1587; TIMMERMANS PBMWM, 1991, TRENDS PHARMACOL SCI, V12, P55, DOI 10.1016/0165-6147(91)90498-H; WEISSMAN JD, 1991, MOL CELL BIOL, V11, P4217, DOI 10.1128/MCB.11.8.4217; ZHANG ZX, 1990, J BIOL CHEM, V265, P4785	29	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24282	24286		10.1074/jbc.270.41.24282	http://dx.doi.org/10.1074/jbc.270.41.24282			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592637	hybrid			2022-12-27	WOS:A1995TA21700065
J	PREVARSKAYA, NB; SKRYMA, RN; VACHER, P; DANIEL, N; DJIANE, J; DUFY, B				PREVARSKAYA, NB; SKRYMA, RN; VACHER, P; DANIEL, N; DJIANE, J; DUFY, B			ROLE OF TYROSINE PHOSPHORYLATION IN POTASSIUM CHANNEL ACTIVATION - FUNCTIONAL ASSOCIATION WITH PROLACTIN RECEPTOR AND JAK2 TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; RABBIT MAMMARY-GLAND; CELL-PROLIFERATION; PROTEIN; STIMULATION; PHOSPHATASE; CALCIUM; DEPHOSPHORYLATION; INHIBITION; LONG	Chinese hamster ovary (CHO) cells, stably transfected with the long form of the prolactin (PRL) receptor (PRL-R) cDNA, were used for PRL-R signal transduction studies, Patch-clamp technique in whole cell and cell-free configurations were employed. Exposure of transfected CHO cells to 5 nM PRL led to the increase of Ca2+- and voltage-dependent K+ channel (K-Ca) activity, The effect was direct as it was observed also in excised patch experiments, A series of tyrosine kinase inhibitors was studied to investigate the possible involvement of protein tyrosine kinases in K-Ca functioning and its stimulation by PRL, Genistein, lavendustin A, and herbimycin A decreased in a concentration and time-dependent manner the amplitude of the K-Ca current in whole cell and the open probability of K-Ca channels in cell-free experiments, The subsequent application of PRL was ineffective, The protein tyrosine phosphatase inhibitor orthovanadate (1 mM) stimulated K-Ca channel activity in excised patches, indicating that channels can be modulated in opposite directions by protein tyrosine kinase and protein tyrosine phosphatase. Moreover, in whole cell experiments as well as in excised patch recordings, anti-JAK2 tyrosine kinase antibody decreased the K-Ca conductance and the open probability of the K-Ca channels. Subsequent application of PRL was no longer able to stimulate K-Ca conductance. Immunoblotting studies using the same anti-JAK2 antibody, revealed the constitutive association of JAK2 kinase with PRL-R. Preincubation of anti-JAK2 antibody with the JAK2 Immunizing Peptide abolished the effects observed using anti-JAK2 antibody alone in both electrophysiological and immunoblotting studies. We conclude from these findings that these K-Ca channels are regulated through tyrosine phosphorylation/dephosphorylation; JAK2 tyrosine kinase, constitutively associated with PRL-R, is implicated in PRL stimulation of K-Ca channels.	INRA,MOLEC ENDOCRINOL UNIT,F-78352 JOUY EN JOSAS,FRANCE	INRAE; UDICE-French Research Universities; Universite Paris Saclay	PREVARSKAYA, NB (corresponding author), UNIV BORDEAUX 2,NEUROPHYSIOL LAB,CNRS,URA 1200,146 RUE LEO SAIGNAT,F-33076 BORDEAUX,FRANCE.		Vacher, Pierre/N-2243-2018	Prevarskaya, natacha/0000-0003-0316-197X; VACHER, Pierre/0000-0003-3503-7981				ABERCROMBIE RF, 1981, J GEN PHYSIOL, V78, P413, DOI 10.1085/jgp.78.4.413; AKIJAMA T, 1987, J BIOL CHEM, V262, P5592; ALEXANDER D R, 1990, New Biologist, V2, P1049; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BIGNON C, 1993, BIOTECHNIQUES, V15, P243; BORMANN J, 1988, TRENDS NEUROSCI, V11, P112, DOI 10.1016/0166-2236(88)90156-7; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; COLLIN C, 1990, SCIENCE, V250, P1743, DOI 10.1126/science.2176747; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DJIANE J, 1985, J BIOL CHEM, V260, P1430; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; ESQUERRA M, 1994, NATURE, V369, P563; FUH G, 1993, J BIOL CHEM, V268, P5376; GASSER F, 1985, IN VITRO CELL DEV B, V21, P588; GRAIER WF, 1993, BIOCHEM J, V291, P2653; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUANG Y, 1994, J BIOL CHEM, V269, P31183; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LESUEUR L, 1991, P NATL ACAD SCI USA, V88, P824, DOI 10.1073/pnas.88.3.824; LESUEUR L, 1990, MOL CELL ENDOCRINOL, V71, P7; MAGNI M, 1991, J BIOL CHEM, V266, P6329; MATSUNAGA H, 1994, AM J PHYSIOL, V267, pC456, DOI 10.1152/ajpcell.1994.267.2.C456; NESTER EJ, 1993, BASIC NEUROCHEMISTRY, V22, P449; NICOLL CS, 1980, FED PROC, V39, P2563; NILIUS B, 1992, J PHYSIOL-LONDON, V445, P3537; OBINATA A, 1991, EXP CELL RES, V193, P36, DOI 10.1016/0014-4827(91)90535-3; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; ONO K, 1994, NATURE, V370, P294; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; PARANT MR, 1990, ANAL BIOCHEM, V184, P283, DOI 10.1016/0003-2697(90)90682-Y; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PEPPELENBOSCH MP, 1991, J BIOL CHEM, V266, P19938; PEPPELENBOSCH MP, 1992, CELL, V162, P295; PREVARSKAYA N, 1994, AM J PHYSIOL, V267, pC554, DOI 10.1152/ajpcell.1994.267.2.C554; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; REPP H, 1993, P NATL ACAD SCI USA, V90, P3703; ROMERO L, 1993, PROSTATE, V22, P1, DOI 10.1002/pros.2990220102; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; RUI H, 1994, J BIOL CHEM, V269, P5364; RUI H, 1994, ENDOCRINOLOGY, V135, P1299, DOI 10.1210/en.135.4.1299; RUSSELL DH, 1989, TRENDS PHARMACOL SCI, V10, P40, DOI 10.1016/0165-6147(89)90106-5; SCHWEIZER FE, 1989, NATURE, V339, P709; SHEN SH, 1990, NATURE, V352, P736; SKRYMA R, 1994, AM J PHYSIOL, V267, pC544, DOI 10.1152/ajpcell.1994.267.2.C544; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; SYMS AJ, 1985, PROSTATE, V6, P145, DOI 10.1002/pros.2990060204; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VACHER P, 1994, ENDOCRINOLOGY, V134, P1213, DOI 10.1210/en.134.3.1213; VANDERKUUR JA, 1994, J BIOL CHEM, V34, P21709; WANG YF, 1993, ENDOCRINOLOGY, V133, P2156, DOI 10.1210/en.133.5.2156; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WATERS MJ, 1995, J BIOL CHEM, V270, P5136, DOI 10.1074/jbc.270.10.5136; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WILSON GF, 1993, NATURE, V366, P433, DOI 10.1038/366433a0; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	62	78	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24292	24299		10.1074/jbc.270.41.24292	http://dx.doi.org/10.1074/jbc.270.41.24292			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592639	Green Published, hybrid			2022-12-27	WOS:A1995TA21700067
J	SHUKLA, D; MATSUMURA, P				SHUKLA, D; MATSUMURA, P			MUTATIONS LEADING TO ALTERED CHEA BINDING CLUSTER ON A FACE OF CHEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CHEMOTAXIS; SIGNAL-TRANSDUCTION; RESPONSE REGULATOR; PROTEIN-PHOSPHORYLATION; CONSERVED ASPARTATE; COMPLEX; PHOSPHOTRANSFER; METHYLESTERASE; ACTIVATION; RESIDUES	CheY is the response regulator of Escherichia coli chemotaxis and is one of the best studied response regulators of the two-component signaling system. CheY can receive phosphate from the histidine kinase, CheA. Phospho-CheY interacts with the motor-switch complex to induce clockwise flagellar rotation, thus causing the cell to tumble. We used an enzyme-linked immunosorbent assay to study the direct interaction between the kinase, CheA, and the regulator, CheY. The products of random, suppressor, and site-specific cheY mutants were assayed for their ability to bind CheA. Nine mutants showed altered binding. We sequenced and mapped these point mutations on the crystal structure of CheY, and a high degree of spatial clustering was revealed, indicating that this region of CheY is involved in CheA binding. Interestingly, five of these altered binding mutants were previously defined as being involved in motor-switch binding interactions. This suggested a possible overlap between the motor-switch binding and CheA binding surfaces of CheY. Using CheY (Trp-58) fluorescence quenching, we determined the equilibrium dissociation constants of CheA (124-257) binding for these CheY mutants. The results from the fluorescence quenching are in close agreement with our initial enzyme-linked immunosorbent assay results. Therefore, we propose that the CheA and the motor binding surfaces on cheY partially overlap and that this overlap allows CheY to interact with either the CheA or the flagellar motor, depending on its signaling (phosphorylation) state.	UNIV ILLINOIS,DEPT MICROBIOL & IMMUNOL,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Shukla, Deepak/0000-0002-3039-6953	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018985] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18985] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM, 1988, MOL REPROD DEV; BLAT Y, 1994, BIOCHEMISTRY-US, V33, P902, DOI 10.1021/bi00170a008; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; DRAKE SK, 1993, J BIOL CHEM, V268, P13081; GANGULI S, 1995, J BIOL CHEM, V270, P17386, DOI 10.1074/jbc.270.29.17386; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; HAZELBAUER GL, 1993, CELL, V73, P15, DOI 10.1016/0092-8674(93)90156-K; Hazelbauer GL, 1992, CURR OPIN STRUC BIOL, V2, P505; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; LOWRY DF, 1994, J BIOL CHEM, V269, P26358; LUKAT GS, 1991, J BIOL CHEM, V266, P8348; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; LUKAT GS, 1990, BIOCHEMISTRY-US, V29, P5436, DOI 10.1021/bi00475a004; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; Miller J. H., 1977, EXPT MOL GENETICS; MORRISON TB, 1994, P NATL ACAD SCI USA, V91, P5485, DOI 10.1073/pnas.91.12.5485; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; ROMAN SJ, 1992, J BACTERIOL, V176, P6247; SANDERS DA, 1992, J BACTERIOL, V174, P5117, DOI 10.1128/JB.174.15.5117-5122.1992; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; STOCK JB, 1990, NATURE, V337, P745; SWANSON RV, 1993, BIOCHEMISTRY-US, V32, P7623, DOI 10.1021/bi00081a004; SWANSON RV, 1995, IN PRESS NAT STRUCT; VOLZ K, 1991, J BIOL CHEM, V266, P15511; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787	34	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24414	24419		10.1074/jbc.270.41.24414	http://dx.doi.org/10.1074/jbc.270.41.24414			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592655	hybrid			2022-12-27	WOS:A1995TA21700083
J	YONG, YQ; ROMANO, LJ				YONG, YQ; ROMANO, LJ			NUCLEOTIDE AND DNA-INDUCED CONFORMATIONAL-CHANGES IN THE BACTERIOPHAGE-T7 GENE-4-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID REPLICATION INVITRO; NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; ESCHERICHIA-COLI REP; DEOXYRIBONUCLEIC-ACID; PRIMASE HELICASE; THEORETICAL ASPECTS; BINDING; POLYMERASE; RECEPTOR; TRANSLOCATION	The bacteriophage T7 gene 4 protein is a multifunctional enzyme that has DNA helicase, primase, and deoxyribonucleotide 5'-triphosphatase activities. Prior studies have shown that in the presence of dTTP or dTDP the gene 4 protein assembles into a functionally active hexamer prior to binding to single-stranded DNA. In this study, we have examined the effects of different nucleotide cofactors on the conformation of the gene 4 protein in the presence and absence of DNA. Gel retardation analysis, partial protease digestion, and DNA footprinting all suggest that the gene 4 protein undergoes a conformational change when dTTP is hydrolyzed to dTTP and that in the presence of dTDP the complex with DNA is more open or extended. We have also found that the dissociation constant of the gene 4 protein DNA complex in the presence of dTDP was 10-fold lower than that determined in the presence of dTTP, further suggesting that these cofactors exerts different allosteric effects on the DNA-binding site of the gene 4 protein.	WAYNE STATE UNIV,DEPT CHEM,DETROIT,MI 48202	Wayne State University					NATIONAL CANCER INSTITUTE [R01CA035451, R01CA040605] Funding Source: NIH RePORTER; NCI NIH HHS [CA35451, CA40605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ALLAN GF, 1992, P NATL ACAD SCI USA, V89, P11750, DOI 10.1073/pnas.89.24.11750; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BHAT MK, 1993, BIOCHEM BIOPH RES CO, V195, P385, DOI 10.1006/bbrc.1993.2055; BOGENHAGEN DF, 1993, MOL CELL BIOL, V13, P5149, DOI 10.1128/MCB.13.9.5149; BROWN WC, 1989, J BIOL CHEM, V264, P6748; CHAO KL, 1990, J BIOL CHEM, V265, P1067; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HILL TL, 1981, P NATL ACAD SCI-BIOL, V78, P4796, DOI 10.1073/pnas.78.8.4796; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; HINKLE DC, 1975, J BIOL CHEM, V253, P5523; KOLODNER R, 1977, P NATL ACAD SCI USA, V74, P1525, DOI 10.1073/pnas.74.4.1525; KOLODNER R, 1978, J BIOL CHEM, V253, P566; KOLODNER R, 1978, J BIOL CHEM, V253, P574; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEID M, 1994, J BIOL CHEM, V269, P14175; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; PATEL SS, 1993, J BIOL CHEM, V268, P10668; ROMANO LJ, 1979, J BIOL CHEM, V254, P476; ROMANO LJ, 1979, J BIOL CHEM, V254, P483; STRATLING W, 1973, NATURE, V245, P195, DOI 10.1038/245195a0; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350	33	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24509	24517		10.1074/jbc.270.41.24509	http://dx.doi.org/10.1074/jbc.270.41.24509			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592668	hybrid			2022-12-27	WOS:A1995TA21700096
J	MEYERS, MB; PICKEL, VM; SHEU, SS; SHARMA, VK; SCOTTO, KW; FISHMAN, GI				MEYERS, MB; PICKEL, VM; SHEU, SS; SHARMA, VK; SCOTTO, KW; FISHMAN, GI			ASSOCIATION OF SORCIN WITH THE CARDIAC RYANODINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT CHINESE-HAMSTER; CALCIUM-BINDING PROTEIN; SARCOPLASMIC-RETICULUM; RELEASE CHANNELS; CELL-LINES; SKELETAL; MUSCLE; GENES; DNA; AMPLIFICATION	Sorcin is a 22 kDa calcium-binding protein initially identified in multidrug-resistant cells; however, its patterns of expression and function in normal tissues are unknown. Here we demonstrate that sorcin is widely distributed in rodent tissues, including the heart, where it was localized by immunoelectron microscopy to the sarcoplasmic reticulum. A > 500-kDa protein band immunoprecipitated from cardiac myocytes by sorcin antiserum was indistinguishable in size on gels from the 565-kDa ryanodine receptor/calcium release channel recognized by ryanodine receptor-specific antibody. Association of sorcin with a ryanodine receptor complex was confirmed by complementary co-immunoprecipitations of sorcin with the receptor antibody. Forced expression of sorcin in ryanodine receptor-negative Chinese hamster lung fibroblasts resulted in accumulation of the predicted 22-kDa protein as well as the unexpected appearance of ryanodine receptor protein. In contrast to the parental host fibroblasts, sorcin transfectants displayed a rapid and transient rise in intracellular calcium in response to caffeine, suggesting organization of the accumulated ryanodine receptor protein into functional calcium release channels. These data demonstrate an interaction between sorcin and the ryanodine receptor and suggest a role for sorcin in modulation of calcium release channel activity, perhaps by stabilizing the channel protein.	CORNELL UNIV,COLL MED,DEPT NEUROL & NEUROSCI,NEW YORK,NY 10021; UNIV ROCHESTER,MED CTR,DEPT PHARMACOL,ROCHESTER,NY 14642; MEM SLOAN KETTERING CANC CTR,MOLEC PHARMACOL & THERAPEUT PROGRAM,NEW YORK,NY 10021	Cornell University; University of Rochester; Memorial Sloan Kettering Cancer Center	MEYERS, MB (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV CARDIOL,MOLEC CARDIOL SECT,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		Sheu, Shey-Shing/Y-4009-2019	Sheu, Shey-Shing/0000-0003-3838-3601; Fishman, Glenn/0000-0002-2366-8527	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033333] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline; NHLBI NIH HHS [HL-33333] Funding Source: Medline; NIMH NIH HHS [MH-00078] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; CROW MT, 1984, EXP BIOL MED, V9, P165; DEBRUIJN MHL, 1986, MOL CELL BIOL, V6, P4717, DOI 10.1128/MCB.6.12.4717; DELEON JR, 1994, J MOL CELL CARDIOL, V26, P379, DOI 10.1006/jmcc.1994.1047; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JONGSMA APM, 1987, CANCER RES, V47, P2875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1992, AM J PHYSIOL, V263, pC365, DOI 10.1152/ajpcell.1992.263.2.C365; LERANTH C, 1989, NEUROANATOMICAL TRAC, P129; Meyers M B, 1989, Cancer Commun, V1, P233; Meyers M. B., 1991, NOVEL CALCIUM BINDIN, P385, DOI 10.1007/978-3-642-76150-8_22; MEYERS MB, 1987, BIOCHEM PHARMACOL, V36, P2373, DOI 10.1016/0006-2952(87)90606-X; MEYERS MB, 1995, FEBS LETT, V357, P230, DOI 10.1016/0014-5793(94)01338-2; MEYERS MB, 1985, J CELL BIOL, V100, P588, DOI 10.1083/jcb.100.2.588; MEYERS MB, 1990, STIMULUS RESPONSE CO, P159; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; PETERSON RHF, 1983, CANCER RES, V43, P222; SALAMA G, 1992, CELL CALCIUM, V13, P635, DOI 10.1016/0143-4160(92)90074-3; SHARP AH, 1993, J NEUROSCI, V13, P3051; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAHL F, 1992, MOL CELL BIOL, V12, P1179, DOI 10.1128/MCB.12.3.1179; SU JY, 1984, PFLUG ARCH EUR J PHY, V400, P14, DOI 10.1007/BF00670530; TEAHAN CG, 1992, BIOCHEM J, V286, P549, DOI 10.1042/bj2860549; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANDERBLIEK AM, 1986, EMBO J, V5, P3201, DOI 10.1002/j.1460-2075.1986.tb04630.x; VANDERBLIEK AM, 1988, CANCER RES, V48, P5927; VIKSTROM KL, 1993, CELL MOTIL CYTOSKEL, V26, P192, DOI 10.1002/cm.970260303; WANG SL, 1995, BBA-GENE STRUCT EXPR, V1260, P285, DOI 10.1016/0167-4781(94)00206-I; WILLIFORD DJ, 1990, CIRC RES, V66, P241, DOI 10.1161/01.RES.66.1.241; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	35	127	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26411	26418		10.1074/jbc.270.44.26411	http://dx.doi.org/10.1074/jbc.270.44.26411			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592856	hybrid			2022-12-27	WOS:A1995TC97800063
J	ROUILLE, Y; MARTIN, S; STEINER, DF				ROUILLE, Y; MARTIN, S; STEINER, DF			DIFFERENTIAL PROCESSING OF PROGLUCAGON BY THE SUBTILISIN-LIKE PROHORMONE CONVERTASES PC2 AND PC3 TO GENERATE EITHER GLUCAGON OR GLUCAGON-LIKE PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG SMALL-INTESTINE; ASPARTYL PROTEASE; MONOBASIC SITES; CLEAVAGE SITES; SOMATOSTATIN-I; MESSENGER-RNA; PANCREAS; PROPROTEIN; PROINSULIN; CELLS	Proglucagon is processed differently in the islet a cells and the intestinal endocrine L cells to release either glucagon or glucagon-like peptide 1-(7-37) (GLP1-(7-37)), peptide hormones with opposing actions in vivo. In previous studies with a transformed or cell Line (alpha TC1-6) we demonstrated that the kexin/snbtilisin-like prohormone convertase, PC2 (SPC2), is responsible for generating the typical a cell pattern of proglucagon processing giving rise to glucagon and leaving unprocessed the entire C-terminal half-molecule known as major proglucagon fragment or MPGF (Rouille, Y., Westermark, G., Martin, S. g., Steiner. D. F. (1994) Proc. Nat1 Acad, Sci. U.S.A. 91, 3242-3246). Here we present evidence, using mouse pituitary AtT-20 cells infected with a vaccinia viral vector encoding proglucagon, that PC3 (SPC3), the major neuroendocrine prohormone convertase in these cells, reproduces the intestinal L cell processing phenotype, in which MPGF is processed to release two glucagon-related peptides, GLP1 and GLP2, while the glucagon-containing N-terminal half-molecule (glicentin) is only partially processed to oxyntomodulin and small amounts of glucagon. Moreover, in AtT-20 cells stably transfected with PC2 (AtT-20/PC2 cells), glicentin was efficiently processed to glucagon, providing further support for the conclusion that PC2 is the enzyme responsible for the ar cell processing phenotype. In other cell lines expressing both PC2 and PC3 (STC-1 and beta TC-3), proglucagon was also processed extensively to both glucagon and GLP1-(7-37), although STC-1 cells express lower levels of PC2 and processed the N-terminal domain to glucagon less efficiently, In contrast, GH(4)C(1) and COS 7 cells, which express very little or no PC2 or PC3, failed to process proglucagon, aside from a low level of interdomain cleavage which occurred only in the GH(4)C(1) cells, In vibro PC3 did not cleave at the single Arg residue in GLP1 to generate GLP1-(7-37), its truncated biologically active form, indicating the likelihood that another convertase is required for this cleavage.	UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	Howard Hughes Medical Institute; University of Chicago; University of Chicago			Rouillé, Yves/P-2405-2016	Rouille, Yves/0000-0003-0788-9271	NIDDK NIH HHS [DK 20595, DK 13914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020595, R37DK013914, P60DK020595, R01DK013914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BATAILLE D, 1982, FEBS LETT, V146, P79, DOI 10.1016/0014-5793(82)80709-6; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BLACHE P, 1994, FEBS LETT, V344, P65, DOI 10.1016/0014-5793(94)00371-8; BOURBONNAIS Y, 1993, EMBO J, V12, P285, DOI 10.1002/j.1460-2075.1993.tb05655.x; BRAKCH N, 1995, FEBS LETT, V362, P143, DOI 10.1016/0014-5793(95)00229-3; CAWLEY NX, 1993, FEBS LETT, V332, P273, DOI 10.1016/0014-5793(93)80648-E; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; DEVI L, 1993, ENDOCRINOLOGY, V132, P1139, DOI 10.1210/en.132.3.1139; DRUCKER DJ, 1986, J BIOL CHEM, V261, P9637; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; Eipper B A, 1980, Endocr Rev, V1, P1; FUNCKES CL, 1983, J BIOL CHEM, V258, P8781; GALANOPOULOU AS, 1993, J BIOL CHEM, V268, P6041; HOLST JJ, 1994, J BIOL CHEM, V269, P18827; KERVRAN A, 1987, ENDOCRINOLOGY, V121, P704, DOI 10.1210/endo-121-2-704; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; Mackett M., 1985, DNA CLONING PRACTICA, P191; MAKIN RB, 1991, ENDOCRINOLOGY, V129, P1951; MINEO I, 1995, BIOCHEM BIOPH RES CO, V207, P646, DOI 10.1006/bbrc.1995.1236; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; NAGAMUNE H, 1995, ENDOCRINOLOGY, V136, P357, DOI 10.1210/en.136.1.357; NEERMANARBEZ M, 1994, BIOCHEM J, V300, P57, DOI 10.1042/bj3000057; NOVAK U, 1987, EUR J BIOCHEM, V164, P553, DOI 10.1111/j.1432-1033.1987.tb11162.x; ORSKOV C, 1989, J BIOL CHEM, V264, P12826; ORSKOV C, 1986, ENDOCRINOLOGY, V119, P1467, DOI 10.1210/endo-119-4-1467; PATZELT C, 1979, NATURE, V282, P260, DOI 10.1038/282260a0; PATZELT C, 1984, P NATL ACAD SCI-BIOL, V81, P5007, DOI 10.1073/pnas.81.16.5007; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; ROTHENBERG ME, 1995, J BIOL CHEM, V270, P10136, DOI 10.1074/jbc.270.17.10136; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; RUFAUT NW, 1993, J BIOL CHEM, V268, P20291; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCOPSI L, 1995, J CLIN ENDOCR METAB, V80, P294, DOI 10.1210/jc.80.1.294; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEVARINO KA, 1987, J BIOL CHEM, V262, P4987; SHEIKH SP, 1985, FEBS LETT, V179, P1, DOI 10.1016/0014-5793(85)80178-2; SHEN LP, 1984, SCIENCE, V224, P168, DOI 10.1126/science.6142531; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAGER HS, 1973, P NATL ACAD SCI USA, V70, P2321, DOI 10.1073/pnas.70.8.2321; THIM L, 1982, PEPTIDES S2, V2, P37; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; TSUJI A, 1994, BIOCHEM BIOPH RES CO, V200, P943, DOI 10.1006/bbrc.1994.1541; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; YANAGITA M, 1993, ENDOCRINOLOGY, V133, P639, DOI 10.1210/en.133.2.639; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHOU Y, 1994, J BIOL CHEM, V269, P18408	53	163	171	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26488	26496		10.1074/jbc.270.44.26488	http://dx.doi.org/10.1074/jbc.270.44.26488			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592866	hybrid			2022-12-27	WOS:A1995TC97800073
J	TAKAHASHI, S; NAKAGAWA, T; KASAI, K; BANNO, T; DUGUAY, SJ; VANDEVEN, WJM; MURAKAMI, K; NAKAYAMA, K				TAKAHASHI, S; NAKAGAWA, T; KASAI, K; BANNO, T; DUGUAY, SJ; VANDEVEN, WJM; MURAKAMI, K; NAKAYAMA, K			A 2ND MUTANT ALLELE OF FURIN IN THE PROCESSING-INCOMPETENT CELL-LINE, LOVO - EVIDENCE FOR INVOLVEMENT OF THE HOMO-B DOMAIN IN AUTOCATALYTIC ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS EXOTOXIN-A; FUNCTIONAL EXPRESSION; YEAST KEX2; DROSOPHILA-MELANOGASTER; KEX2-LIKE ENDOPROTEASE; PRECURSOR CLEAVAGE; DIPHTHERIA-TOXIN; FACTOR-RECEPTOR; GENE ENCODES; ENZYME FURIN	Furin is a Golgi membrane-associated endoprotease that is involved in cleavage of various precursor proteins predominantly at Arg-X-Lys/Arg-Arg sites. Furin itself is synthesized as an inactive precursor, which is activated through intramolecular autocatalytic cleavage at an Arg-X-Lys-Arg site. We previously found that human colon carcinoma LoVo cells have a frameshift mutation within the home B domain of furin and thereby lack processing activity toward Arg-X-Lys/Arg-Arg sites. In this study, however, we identified a second furin mutation in this cell line. The mutation, a replacement of a conserved Trp residue within the home B domain with Arg, results in lack of processing activity of the mutant furin. The combination of both mutations can account for the recessive nature of the processing incompetence of LoVo cells. Immunofluorescence analysis with three distinct anti-furin monoclonal antibodies revealed that neither furin mutant underwent the autocatalytic activation or left the endoplasmic reticulum for the Golgi. These data indicate that the home B domain as well as the catalytic domain is required for autocatalytic activation of furin.	UNIV TSUKUBA, INST BIOL SCI, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, INST BASIC MED SCI, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, TSUKUBA ADV RES ALLIANCE CTR, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, CTR GENE EXPT, TSUKUBA, IBARAKI 305, JAPAN; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA; CATHOLIC UNIV LEUVEN, CTR HUMAN GENET, ONCOL MOLEC LAB, B-3000 LOUVAIN, BELGIUM	University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba; Howard Hughes Medical Institute; University of Chicago; University of Chicago; KU Leuven			Nakayama, Kazuhisa/ABF-2924-2020	Nakayama, Kazuhisa/0000-0001-7701-7183				BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHAN SJ, 1992, P NATL ACAD SCI USA, V89, P6678, DOI 10.1073/pnas.89.15.6678; CHUN JY, 1994, NEURON, V12, P931; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; DAVEY J, 1994, EMBO J, V13, P5910, DOI 10.1002/j.1460-2075.1994.tb06936.x; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; GOMEZSALADIN E, 1994, CELL MOL NEUROBIOL, V14, P9, DOI 10.1007/BF02088586; HALBAN PA, 1994, BIOCHEM J, V299, P1; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HIROMOTO T, 1994, J VIROL, V68, P6074; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HOSAKA M, 1994, BIOMED RES-TOKYO, V15, P383, DOI 10.2220/biomedres.15.383; INOCENCIO NM, 1994, J BIOL CHEM, V269, P31831; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; KORNER J, 1991, P NATL ACAD SCI USA, V88, P11393, DOI 10.1073/pnas.88.24.11393; LEDUC R, 1992, J BIOL CHEM, V267, P14304; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MOEHRING JM, 1983, INFECT IMMUN, V41, P998, DOI 10.1128/IAI.41.3.998-1009.1983; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; OHNISHI Y, 1994, J VIROL, V68, P4075, DOI 10.1128/JVI.68.6.4075-4079.1994; PAQUET L, 1994, J BIOL CHEM, V269, P19279; ROEBROEK AJM, 1992, J BIOL CHEM, V267, P17208; ROEBROEK AJM, 1991, FEBS LETT, V289, P133, DOI 10.1016/0014-5793(91)81052-A; SEIDAH NG, 1991, ENZYME, V45, P271, DOI 10.1159/000468901; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMIT AB, 1992, FEBS LETT, V312, P213, DOI 10.1016/0014-5793(92)80938-D; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; TORII S, 1995, J BIOL CHEM, V270, P11574, DOI 10.1074/jbc.270.19.11574; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VANDUIJNHOVEN HLP, 1992, HYBRIDOMA, V11, P71, DOI 10.1089/hyb.1992.11.71; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; WATSON DG, 1991, J VIROL, V65, P2332, DOI 10.1128/JVI.65.5.2332-2339.1991	43	95	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26565	26569		10.1074/jbc.270.44.26565	http://dx.doi.org/10.1074/jbc.270.44.26565			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592877	hybrid			2022-12-27	WOS:A1995TC97800084
J	VENEPALLY, P; WATERMAN, MR				VENEPALLY, P; WATERMAN, MR			2 SP1-BINDING SITES MEDIATE CAMP-INDUCED TRANSCRIPTION OF THE BOVINE CYP11A GENE THROUGH THE PROTEIN-KINASE-A SIGNALING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN CLEAVAGE CYTOCHROME-P-450; CYCLIC-AMP; MAMMALIAN-CELLS; STEROID HYDROXYLASES; RESPONSE ELEMENT; PHORBOL ESTERS; P-450SCC GENE; SUBUNIT GENE; PROMOTER; EXPRESSION	Two sequence elements located at -111 to -100 base pairs and -70 to -50 base pairs in the 5'-flanking region of the bovine CYP11A gene and in closely related positions in CYP11A of other species contain G-rich regions that are similar to the consensus Sp1-binding site. These sequences bind the purified transcription factor Spl as well as nuclear proteins from mouse Y1 adrenal cells that interact with an antibody specific for Spl. Both of these CYP11A sequences support basal and cAMP-dependent transcription of reporter gene plasmids transfected into Y1 cells, and mutations within the G-rich -111/-100-base pair sequence that reduce or eliminate the binding of Sp1-related Y1 nuclear proteins also markedly reduce cAMP-induced transcription. cAMP-dependent transcription supported by both CYP11A sequence elements is mediated by protein kinase A at levels comparable to that promoted by different cAMP-response sequences and transcription factors in other genes involved in steroidogenesis. These results indicate that ACTH-dependent regulation of cholesterol side chain cleavage cytochrome P450 levels in the adrenal cortex which is mediated through cAMP involves the ubiquitous transcription factor Sp1.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-28350] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLGREN R, 1990, J BIOL CHEM, V265, P3313; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEGEOT M, 1993, J BIOL CHEM, V268, P17317; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHANG CY, 1992, MOL ENDOCRINOL, V6, P1362, DOI 10.1210/me.6.9.1362; CHEN JY, 1992, BIOCHEMISTRY-US, V31, P2400, DOI 10.1021/bi00123a027; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P475; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIMALDI P, 1993, MOL ENDOCRINOL, V7, P1217, DOI 10.1210/me.7.9.1217; GUO IC, 1994, J BIOL CHEM, V269, P6362; HUM DW, 1993, ENDOCRINOLOGY, V132, P546, DOI 10.1210/en.132.2.546; INOUE H, 1988, EUR J BIOCHEM, V171, P435, DOI 10.1111/j.1432-1033.1988.tb13808.x; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; JOHN ME, 1984, P NATL ACAD SCI-BIOL, V81, P5628, DOI 10.1073/pnas.81.18.5628; JOHN ME, 1987, MOL CELL ENDOCRINOL, V50, P263, DOI 10.1016/0303-7207(87)90025-6; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAGAWA N, 1992, J BIOL CHEM, V267, P25213; KURTEN RC, 1992, MOL ENDOCRINOL, V6, P536, DOI 10.1210/me.6.4.536; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LAUBER ME, 1993, MOL CELL ENDOCRINOL, V94, P235, DOI 10.1016/0303-7207(93)90172-G; LUND J, 1990, J BIOL CHEM, V265, P3304; LUND J, 1988, J BIOL CHEM, V263, P16195; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MIYAMOTO N, 1992, ENDOCRINOLOGY, V130, P3231, DOI 10.1210/en.130.6.3231; MOMOI K, 1992, MOL ENDOCRINOL, V6, P1682, DOI 10.1210/me.6.10.1682; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V101, P879, DOI 10.1093/oxfordjournals.jbchem.a121955; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OONK RB, 1990, J BIOL CHEM, V265, P22392; PESTELL RG, 1993, J MOL ENDOCRINOL, V10, P297, DOI 10.1677/jme.0.0100297; RAE PA, 1979, P NATL ACAD SCI USA, V76, P1896, DOI 10.1073/pnas.76.4.1896; RICE DA, 1990, J BIOL CHEM, V265, P11713; Sambrook J, 1989, MOL CLONING LABORATO; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VENEPALLY P, 1992, J BIOL CHEM, V267, P17333; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WOOD WM, 1989, J BIOL CHEM, V264, P14840	47	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25402	25410		10.1074/jbc.270.43.25402	http://dx.doi.org/10.1074/jbc.270.43.25402			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592707	hybrid			2022-12-27	WOS:A1995TB46600023
J	MCKAY, GA; WRIGHT, GD				MCKAY, GA; WRIGHT, GD			KINETIC MECHANISM OF AMINOGLYCOSIDE PHOSPHOTRANSFERASE TYPE IIIA - EVIDENCE FOR A THEORELL-CHANCE MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBIOTIC-RESISTANCE; STAPHYLOCOCCUS-AUREUS; ACETYLTRANSFERASE; SEQUENCE; GENES	Bacterial resistance to aminoglycoside-aminocyclitol antibiotics is mediated primarily by covalent modification of the drugs by a variety of enzymes. One such modifying enzyme, the 3'-aminoglycoside phosphotransferase, which is produced by Gram-positive cocci such as Enterococcus and Streptococcus inactivates a broad range of aminoglycosides by ATP-dependent phosphorylation of specific hydroxyl residues on the antibiotics. Through the use of dead-end and product inhibitor studies, we present the first detailed examination of the kinetic mechanism for the 3'-aminoglycoside phosphotransferase-IIIa, Initial velocity patterns deduced from steady-state kinetics indicate a sequential mechanism with ordered binding of ATP first followed by aminoglycoside. Dead-end inhibition by AMP and adenylyl-imidodiphosphate is competitive versus ATP and noncompetitive versus kanamycin A. Dead-end inhibition by tobramycin, a kanamycin analogue lacking a 3'-OH, is competitive versus both kanamycin A and uncompetitive versus ATP, indicative of ordered substrate binding where ATP must add prior to aminoglycoside addition, Product inhibition by kanamycin phosphate is noncompetitive versus ATP when kanamycin A is held at subsaturating concentrations (K-m(kanA)), whereas no inhibition is observed when the concentration of kanamycin A is held at 10 K-m(kanA). This is consistent with kanamycin phosphate being the first product released followed by ADP release. The patterns of inhibition observed support a mechanism where ATP binding precedes aminoglycoside binding followed by a rapid catalytic step, Product release proceeds in an ordered fashion where kanamycin phosphate is released quickly followed by a slow release of ADP. Aminoglycoside substrates, such as kanamycin A, show substrate inhibition that is uncom petitive versus ATP. This indicates binding of the aminoglycosides to the slowly dissociating (E . ADP) complex at high drug concentrations. These experiments are consistent with a Theorell-Chance kinetic mechanism for 3'-aminoglycoside phosphotransferase-IIIa.	MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA	McMaster University			Wright, G/ABB-7666-2021	Wright, Gerard/0000-0002-9129-7131				BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; Cleland W W, 1979, Methods Enzymol, V63, P500; DAVIES JE, 1991, ANTIBIOTICS LAB MED, P691; DAVIS BD, 1987, MICROBIOL REV, V51, P341, DOI 10.1128/MMBR.51.3.341-350.1987; Fromm H J, 1979, Methods Enzymol, V63, P467; GATES CA, 1988, BIOCHEMISTRY-US, V27, P3826, DOI 10.1021/bi00410a046; GRAY GS, 1983, MOL BIOL EVOL, V1, P57; LEATHERBARROW RJ, 1992, GRAFIT 3 0 ERITHACUS; MARTEL A, 1983, EUR J BIOCHEM, V133, P515, DOI 10.1111/j.1432-1033.1983.tb07494.x; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P6936, DOI 10.1021/bi00188a024; RADIKA K, 1984, J BIOL CHEM, V259, P2543; RADIKA K, 1984, ANAL BIOCHEM, V141, P413, DOI 10.1016/0003-2697(84)90063-0; RADIKA K, 1984, ANTIMICROB AGENTS CH, V25, P479, DOI 10.1128/AAC.25.4.479; Rudolph F B, 1979, Methods Enzymol, V63, P411; Segel I.H., 1975, ENZYME KINETICS; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; TRIEUCUOT P, 1983, GENE, V23, P331, DOI 10.1016/0378-1119(83)90022-7; Umezawa H., 1982, AMINOGLYCOSIDE ANTIB, P267; WILLIAMS JW, 1978, J BIOL CHEM, V253, P5902	19	70	73	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24686	24692		10.1074/jbc.270.42.24686	http://dx.doi.org/10.1074/jbc.270.42.24686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559583	hybrid			2022-12-27	WOS:A1995TB46500017
J	PLOCHOCKAZULINSKA, D; RASMUSSEN, G; RASMUSSEN, C				PLOCHOCKAZULINSKA, D; RASMUSSEN, G; RASMUSSEN, C			REGULATION OF CALCINEURIN GENE-EXPRESSION IN SCHIZOSACCHAROMYCES-POMBE - DEPENDENCE ON THE STE11 TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE; FISSION YEAST; SEXUAL-DIFFERENTIATION; CALMODULIN; SUBUNIT; ENCODES; CLONING; MOTIF	Calmodulin and its target enzymes are important regulators of numerous cellular processes, including reversible protein phosphorylation. The calmodulin-dependent protein phosphatase (calcineurin) has been suggested to play roles in activation of T cells and in the mating response of yeast. Recently, studies have shown it to be the target of immunosuppressant drugs such as cyclosporin and FK-506. In this study, we have cloned the gene for the catalytic subunit of calcineurin, CnA, from the yeast Schizosaccharomyces pombe. The gene (named ppb1(+)) has been mapped to chromosome II by analysis of the hybridization of a genomic DNA probe to an ordered library. The gene produces a single mRNA species of 2.5 kilobases, which varies during the cell cycle in exponentially growing cells. In addition, expression of ppb1(+) mRA is induced by nitrogen starvation, a condition that favors mating in S. pombe. The ppb1(+) gene promoter contains a cis-acting element for the ste11 transcription factor, and we have shown that induction of the ppb1(+) mRNA during nitrogen starvation is dependent on the ste11 gene product. Together with earlier studies showing that disruption of the ppb1(+) gene in S. pombe results in sterility (Yoshida, T., Toda, T., and Yanagida, M. (1994) J. Cell Sci., 107, 1725-1735), our studies suggest that the ppb1(+) gene plays a role in the gene expression cascade that is essential for mating and sporulation in S. pombe.	UNIV ALBERTA, DEPT ANAT & CELL BIOL, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, DEPT ONCOL, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, NATL CTR INST CANADA MOLEC MECH, GROWTH CONTROL GRP, EDMONTON, AB T6G 2H7, CANADA	University of Alberta; University of Alberta; University of Alberta; University of Alberta								ALFA C, 1992, EXPT FISSION YEAST L; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; EGEL R, 1990, TRENDS GENET, V6, P369, DOI 10.1016/0168-9525(90)90279-F; Egel R., 1989, MOL BIOL FISSION YEA, P31; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HIGUCHI S, 1991, J BIOL CHEM, V266, P18104; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Maniatis T., 1982, MOL CLONING; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MIYAMOTO M, 1994, EMBO J, V13, P1873, DOI 10.1002/j.1460-2075.1994.tb06456.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; OKAZAKI N, 1991, NUCLEIC ACIDS RES, V19, P7043, DOI 10.1093/nar/19.25.7043; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RASMUSSEN C, 1994, EMBO J, V13, P3917, DOI 10.1002/j.1460-2075.1994.tb06703.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; STEWART AA, 1983, EUR J BIOCHEM, V132, P289, DOI 10.1111/j.1432-1033.1983.tb07361.x; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; SUGIYAMA A, 1994, EMBO J, V13, P1881, DOI 10.1002/j.1460-2075.1994.tb06457.x; THORNER J, 1981, MOL BIOL YEAST SACCH, P143; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; YOSHIDA T, 1994, J CELL SCI, V107, P1725	27	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24794	24799		10.1074/jbc.270.42.24794	http://dx.doi.org/10.1074/jbc.270.42.24794			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559598	hybrid			2022-12-27	WOS:A1995TB46500032
J	WEDEL, B; HARTENECK, C; FOERSTER, J; FRIEBE, A; SCHULTZ, G; KOESLING, D				WEDEL, B; HARTENECK, C; FOERSTER, J; FRIEBE, A; SCHULTZ, G; KOESLING, D			FUNCTIONAL DOMAINS OF SOLUBLE GUANYLYL CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE DOMAIN; EXPRESSION; CONTAINS; PROTEIN; HEME	Soluble guanylyl cyclase is a heterodimer consisting of an alpha and beta subunit and stimulation occurs upon binding of NO to a prosthetic group. Little is known about the localization of catalytic and regulatory domains within the subunits of soluble guanylyl cyclase. We used deletion mutagenesis to identify the regions of alpha(1) and beta(1) subunits that are responsible for cGMP production or NO-heme-mediated activation. The amino terminus of the beta(1) subunit was necessary for NO stimulation since deletion of the 64 NH2-terminal amino acids resulted in a mutant with intact basal activity but complete loss of NO activation. The amino terminus of the alpha(1) subunit also appeared to be essential for NO sensitivity since deletion of 131 NH2-terminal amino acids of alpha(1) led to markedly reduced NO activation. These results suggest that NH2-terminal regions of alpha(1) and beta(1) are involved in NO-heme-mediated signal transduction. The NH2 terminally truncated beta(1) subunit exerted a dominant negative effect exclusively on the NO-stimulated activity of the wild type enzyme, further underlining that the regulatory domain is located within the NH2 terminus of the enzyme, Aside from the structural implications, the mutant represents a powerful tool to investigate nitric oxide-sensitive signaling pathways. Coexpression of the COOH-terminal halves of alpha(1) and beta(1) were sufficient for basal cGMP production while either of the halves expressed alone was inactive. Therefore the COOH-terminal regions appear to contain sufficient information for dimerization and basal enzymatic activity. Thus, we provide the first evidence that the regulatory and catalytic properties of soluble guanylyl cyclase can be attributed to different regions of the subunits and that the catalytic domain can be functionally expressed separately from the NH2-terminal regulatory domain. Taken together with findings on the membrane bound enzyme form, guanylyl cyclases, appear to resemble fusion proteins where different regulatory domains have been joined with a common cGMP-forming segment.	FREE UNIV BERLIN,INST PHARMAKOL,D-14195 BERLIN,GERMANY	Free University of Berlin								CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; GARBERS DL, 1992, CELL, V71, P1; GERZER R, 1981, FEBS LETT, V132, P71, DOI 10.1016/0014-5793(81)80429-2; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; KOESLING D, 1991, FASEB J, V5, P2785, DOI 10.1096/fasebj.5.13.1680765; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, J BIOL CHEM, V266, P8595; THOMPSON DK, 1995, J BIOL CHEM, V270, P425, DOI 10.1074/jbc.270.1.425; THORPE DS, 1990, J BIOL CHEM, V265, P14717; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WEDCEL B, 1994, P NATL ACAD SCI USA, V91, P2592; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; YUEN PST, 1994, J BIOL CHEM, V269, P791	15	109	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24871	24875		10.1074/jbc.270.42.24871	http://dx.doi.org/10.1074/jbc.270.42.24871			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559610	hybrid			2022-12-27	WOS:A1995TB46500044
J	YAMAGUCHI, M; HAYASHI, Y; MATSUKAGE, A				YAMAGUCHI, M; HAYASHI, Y; MATSUKAGE, A			ESSENTIAL ROLE OF E2F RECOGNITION SITES IN REGULATION OF THE PROLIFERATING CELL NUCLEAR ANTIGEN GENE PROMOTER DURING DROSOPHILA DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-ALPHA; TRANSCRIPTION FACTOR; GROWTH-REGULATION; BUDDING YEAST; MELANOGASTER; EXPRESSION; PROTEIN; CYCLE; BINDING; CLONING	We have found sequences similar to the transcription factor E2F recognition site within the Drosophila proliferating cell nuclear antigen (PCNA) gene promoter. These sequences are located at positions -43 to -36 (site I) and -56 to -49 (site II) with respect to the cap site. Glutathione S-transferase (GST)-E2F and GST-DP fusion proteins cooperate and bind to the potential E2F sites in the PCNA promoter in vitro. A binding factor(s) to these sequences that has similar binding specificity to that of E2F was detected in nuclear extracts of Drosophila Kc cells. Furthermore, transient expression of E2F in Kc cells activated the PCNA promoter, and the target site for the activation coincided with the E2F sites. These results indicate that the PCNA gene is a likely target gene of E2F. Examination of lacZ expression from PCNA-lacZ fusion genes carrying mutations in either or both of two E2F sites introduced into flies by germ line transformation revealed that site II plays a major role in the PCNA promoter activity during embryogenesis and larval development, although both sites are required for optimal promoter activity. However, for maternal expression in ovaries, either one of the two sites is essentially sufficient to direct optimal promoter activity. These results demonstrate, for the first time, an essential role for E2F sites in regulation of PCNA promoter activity during development of a multicellular organism.	AICHI CANC CTR,RES INST,CELL BIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center								BAKKENIST CJ, 1994, J BIOL CHEM, V269, P26759; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BASERGA R, 1991, J CELL SCI, V98, P433; BONDMATTHEWS B, 1988, GENE, V62, P289, DOI 10.1016/0378-1119(88)90566-5; COTTERILL S, 1992, NUCLEIC ACIDS RES, V20, P4325, DOI 10.1093/nar/20.16.4325; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; DINOCERA PP, 1983, P NATL ACAD SCI USA, P7095; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; FRIDELL YWC, 1992, MOL CELL BIOL, V12, P4571, DOI 10.1128/MCB.12.10.4571; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HIROSE F, 1991, NUCLEIC ACIDS RES, V19, P4991, DOI 10.1093/nar/19.18.4991; HIROSE F, 1994, J BIOL CHEM, V269, P2937; HIROSE F, 1993, J BIOL CHEM, V268, P2092; KARCH F, 1981, J MOL BIOL, V148, P219, DOI 10.1016/0022-2836(81)90536-2; Lee Hu-Hui, 1995, Gene Expression, V4, P95; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MATSUKAGE A, 1986, DEV BIOL, V117, P226, DOI 10.1016/0012-1606(86)90365-9; MATSUKAGE A, 1994, JPN J CANCER RES, V85, P1; MIYAZAWA H, 1993, J BIOL CHEM, V268, P8111; NEVINS JR, 1992, SCIENCE, V258, P424; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; ROBERTSON HM, 1988, GENETICS, V118, P461; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YAMAGUCHI M, 1991, MOL CELL BIOL, V11, P4909, DOI 10.1128/MCB.11.10.4909; YAMAGUCHI M, 1994, EUR J BIOCHEM, V221, P227, DOI 10.1111/j.1432-1033.1994.tb18733.x; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P15808, DOI 10.1074/jbc.270.26.15808; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773; Yamaguchi Masamitsu, 1995, Gene Expression, V4, P183; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; [No title captured]	39	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25159	25165		10.1074/jbc.270.42.25159	http://dx.doi.org/10.1074/jbc.270.42.25159			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559650	hybrid			2022-12-27	WOS:A1995TB46500084
J	ROBEY, FA; KELSONHARRIS, T; ROLLER, PP; ROBERTGUROFF, M				ROBEY, FA; KELSONHARRIS, T; ROLLER, PP; ROBERTGUROFF, M			A HELICAL EPITOPE IN THE C4 DOMAIN OF HIV GLYCOPROTEIN-120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IMMUNODEFICIENCY-VIRUS TYPE-1; SYNTHETIC PEPTIDE POLYMERS; AUTOMATED SYNTHESIS; T4 MOLECULE; PROTEIN; RECEPTOR; GP120; CD4; RETROVIRUS; AFFINITY	The fourth conserved domain of the human immunodeficiency virus type 1 (HIV-1) envelope, the C4 region of glycoprotein 120 (gp120), is an amphipathic stretch of amino acids that, based on mutational analyses, constitutes a major component of the CD4 binding region in gp120. In the absence of crystallographic and NMR data on C4 in intact gp120, we sought to gain insight into C4's conformation and accessibility in gp120 by taking an immunochemical approach. In this study, a peptomer composed of a repeat peptide of C4 amino acids 419-436 from gp120 of HIV-1(MN) was synthesized for use as a conformationally constrained immunogen. Circular dichroism studies disclosed that the polymerized peptide, peptomer-(419-436), in 0.01 M Na2HPO4 buffer, pH 7.4, at 25 degrees C contained a dominant alpha-helical structure (53 +/- 1%) compared with 2 +/- 4% alpha-helical content for the monomeric peptide-(419-436). The peptomer in Ribi's adjuvant induced the production of rabbit antibodies that recognized recombinant and native gp120 but, consistent with the literature, the C4 peptide having no conformational constraints did not. The experimental results show that only those antibodies formed against a helical immunogen from C4 will recognize recombinant and native gp120, and, therefore, the results support the notion that C4 is an alpha-helix in gp120.	NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892; NCI,DIV CANC TREATMENT,MED CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	ROBEY, FA (corresponding author), NIDR,CELLULAR DEV & ONCOL LAB,PEPTIDE & IMMUNOCHEM UNIT,BLDG 30,RM 211,BETHESDA,MD 20892, USA.							CARDONNIER A, 1989, NATURE, V340, P571; CEASE KB, 1987, P NATL ACAD SCI USA, V47, P4249; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; KALYANARAMAN VS, 1990, AIDS RES HUM RETROV, V6, P371, DOI 10.1089/aid.1990.6.371; KENNEY JS, 1989, J IMMUNOL METHODS, V121, P157, DOI 10.1016/0022-1759(89)90156-7; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LINDNER W, 1987, INT J PEPT PROT RES, V30, P794; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; POLAND D, 1970, THEORY HELIX COIL TR; POLLARD SR, 1992, EMBO J, V11, P585, DOI 10.1002/j.1460-2075.1992.tb05090.x; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Robey F A, 1994, Methods Mol Biol, V35, P73; ROBEY FA, 1989, ANAL BIOCHEM, V177, P373, DOI 10.1016/0003-2697(89)90068-7; ROBEY FA, 1992, CHIM OGGI, P27; ROBEY FA, 1992, CURRENT PROTOCOLS IM; SASTRY KJ, 1991, AIDS, V5, P699, DOI 10.1097/00002030-199106000-00009; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2	19	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23918	23921		10.1074/jbc.270.41.23918	http://dx.doi.org/10.1074/jbc.270.41.23918			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592582	hybrid			2022-12-27	WOS:A1995TA21700010
J	UDAKA, K; WIESMULLER, KH; KIENLE, S; JUNG, G; WALDEN, P				UDAKA, K; WIESMULLER, KH; KIENLE, S; JUNG, G; WALDEN, P			TOLERANCE TO AMINO-ACID VARIATIONS IN PEPTIDES BINDING TO THE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I PROTEIN H-2K(B)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; T-CELL RECOGNITION; VIRAL PEPTIDES; GLOBULAR-PROTEINS; MOLECULES; RESIDUES; ANTIGEN; SUBSTITUTIONS; ADDITIVITY; SEQUENCES	Major histocompatibility complex (MHC) class I molecules are cell-surface glycoproteins that bind peptides and present them to T cells. The formation of a peptide-MHC complex is the initial step in specific, T cell-mediated immune responses. But, unlike other receptor-iigand systems, peptides are essential for a stable conformation of the MHC proteins. To investigate the contribution of every amino acid of octapeptides to the stability and antigenic integrity of MHC proteins, complex octapeptide libraries with one defined amino acid and mixtures of 19 amino acids in the remaining seven positions were synthesized and tested for their capacity to stabilize the conformation of the mouse MHC class I molecule H-2K(b). Peptide transporter-deficient RMA-S cells were employed in this study. Amino acid preferences found for the eight sequence positions reveal constitutional, volumetric, and steric constraints that govern peptide selection by MHC molecules. The pattern of amino acid preferences indicates that the peptides behave as integral parts of the MHC proteins and follow rules established for the interrelationship of primary sequence and the conformation and stability of proteins in general.	MAX PLANCK INST BIOL, IMMUNGENET ABT, D-72076 TUBINGEN, GERMANY; UNIV TUBINGEN, INST NAT WISSENSCH & MED, D-72762 REUTLINGEN, GERMANY; UNIV TUBINGEN, INST ORGAN CHEM, D-72076 TUBINGEN, GERMANY	Max Planck Society; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen								BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BALDWIN RL, 1986, TRENDS BIOCHEM SCI, V11, P6, DOI 10.1016/0968-0004(86)90219-7; BARBER LD, 1993, ANNU REV CELL BIOL, V9, P163; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; CHEN W, 1993, J EXP MED, V177, P869, DOI 10.1084/jem.177.3.869; DOOLEY CT, 1993, LIFE SCI, V52, P1509, DOI 10.1016/0024-3205(93)90113-H; FAHNESTOCK ML, 1992, SCIENCE, V258, P1658, DOI 10.1126/science.1360705; FALK K, 1994, IMMUNOLOGY, V82, P337; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FEIERTAG S, 1994, INNOVATION PERSPECTI, P501; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; HOROVITZ A, 1987, J MOL BIOL, V196, P733, DOI 10.1016/0022-2836(87)90045-3; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JAMESON SC, 1992, EUR J IMMUNOL, V22, P2663, DOI 10.1002/eji.1830221028; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JUNG G, 1992, ANGEW CHEM INT EDIT, V31, P367, DOI 10.1002/anie.199203673; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KIENLE S, 1994, INNOVATION PERSPECTI, P863; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; LESK AM, 1980, J MOL BIOL, V136, P225, DOI 10.1016/0022-2836(80)90373-3; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; METZGER JW, 1994, ANAL BIOCHEM, V219, P261, DOI 10.1006/abio.1994.1266; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MOYLE WR, 1978, RECEPTORS HORMONE AC, V3, P221; MURPHY KP, 1990, SCIENCE, V247, P559, DOI 10.1126/science.2300815; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; ROSEMAN MA, 1988, J MOL BIOL, V200, P513, DOI 10.1016/0022-2836(88)90540-2; SAITO Y, 1993, J BIOL CHEM, V268, P21309; STEVANOVIC S, 1993, ANAL BIOCHEM, V212, P212, DOI 10.1006/abio.1993.1314; TANFORD C, 1962, J AM CHEM SOC, V84, P4240, DOI 10.1021/ja00881a009; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; UDAKA K, 1995, J EXP MED, V181, P2097, DOI 10.1084/jem.181.6.2097; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	45	56	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24130	24134		10.1074/jbc.270.41.24130	http://dx.doi.org/10.1074/jbc.270.41.24130			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592615	hybrid			2022-12-27	WOS:A1995TA21700043
J	VANTHOF, W; RODRIGUEZBOULAN, E; MENON, AK				VANTHOF, W; RODRIGUEZBOULAN, E; MENON, AK			NONPOLARIZED DISTRIBUTION OF GLYCOSYLPHOSPHATIDYLINOSITOLS IN THE PLASMA-MEMBRANE OF POLARIZED MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; MDCK CELLS; GLYCOINOSITOL PHOSPHOLIPIDS; TRYPANOSOMA-BRUCEI; THY-1 GLYCOPROTEIN; PHOSPHATIDYLINOSITOL; ANCHOR; BIOSYNTHESIS; PROTEINS; GANGLIOSIDES	Glycosylphosphatidylinositols (GPIs) are ubiquitous in eukaryotes and serve to anchor a variety of proteins to the exoplasmic leaflet of cellular membranes, GPIs are synthesized in the endoplasmic reticulum (ER), in excess of the amount needed for protein modification. The fate of the excess GPIs is unknown, but they may be retained in the ER, transported to other membranes, and/or metabolized, In relation to this problem, we were interested in determining whether GPIs were transported to the plasma membrane and whether, like GPI-anchored proteins, their presence was confined to the apical plasma membrane domain in polarized epithelial cells. Polarized Madin-Darby canine kidney epithelial cell monolayers were incubated with [H-3]mannose or [H-3]ethanolamine to label GPIs and then infected with enveloped viruses, We used influenza virus (flu) and vesicular stomatitis virus (VSV) for these experiments as these viruses are assembled at the cell surface and acquire their envelope lipids from the plasma membrane, Furthermore, flu and VSV bud specifically from the apical and basolateral plasma membrane domains, respectively, Flu and VSV were isolated from the apical and basolateral media, respectively, and subjected to lipid analysis, Radiolabeled GPIs were found in both viruses, Moreover, the membrane concentration of GPIs (i.e, GPI radioactivity normalized to membrane mass) in the two viruses was essentially the same, These observations suggest that (i) non-protein-linked GPIs are located at the plasma membrane; (ii) since GPIs are synthesized in the ER, they must be transported from the ER to the plasma membrane; and (iii) transport of nonprotein-linked GPIs is not influenced by the sorting processes that target GPI-anchored proteins exclusively to the apical plasma membrane.	UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA; CORNELL UNIV, COLL MED, DEPT ANAT & CELL BIOL, NEW YORK, NY 10021 USA	University of Wisconsin System; University of Wisconsin Madison; Cornell University				Menon, Anant Kumar/0000-0001-6924-2698	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034107, R01GM041771] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28858] Funding Source: Medline; NIGMS NIH HHS [GM-34107, GM-41771, R01 GM034107] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CALAFAT J, 1983, J GEN VIROL, V64, P1241, DOI 10.1099/0022-1317-64-6-1241; DEEG MA, 1992, J BIOL CHEM, V267, P18581; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FIELD MC, 1991, EMBO J, V10, P2731, DOI 10.1002/j.1460-2075.1991.tb07821.x; HIROSE S, 1992, J BIOL CHEM, V267, P16968; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOW MG, 1985, NATURE, V318, P62, DOI 10.1038/318062a0; LOW MG, 1985, NATURE, V318, P687, DOI 10.1038/318687a0; MAYOR S, 1992, J BIOL CHEM, V267, P754; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MENON AK, 1994, METHOD ENZYMOL, V230, P418; MENSAWILMOT K, 1994, J CELL BIOL, V124, P935, DOI 10.1083/jcb.124.6.935; NICHOLS GE, 1988, J LIPID RES, V29, P1205; Pagano RE, 1990, CURR OPIN CELL BIOL, V2, P652, DOI 10.1016/0955-0674(90)90107-P; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; RODRIGUEZBOULAN E, 1978, P NATL ACAD SCI USA, V75, P5071, DOI 10.1073/pnas.75.10.5071; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SODEIK B, 1993, J CELL BIOL, V121, P521, DOI 10.1083/jcb.121.3.521; SPIEGEL S, 1988, BIOCHIM BIOPHYS ACTA, V938, P270, DOI 10.1016/0005-2736(88)90165-4; UDENFRIEND S, 1995, METHOD ENZYMOL, V250, P571; UEDA E, 1993, J BIOL CHEM, V268, P9998; VAN GENDEREN IL, 1994, VIROLOGY, V200, P831, DOI 10.1006/viro.1994.1252; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; VAN MEER G, 1982, EMBO J, V1, P847, DOI 10.1002/j.1460-2075.1982.tb01258.x; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; WILSON JM, 1990, J CELL SCI, V96, P143	33	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24150	24155						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592618				2022-12-27	WOS:A1995TA21700046
J	ZIMMERMANN, B; SOMLYO, AV; ELLISDAVIES, GCR; KAPLAN, JH; SOMLYO, AP				ZIMMERMANN, B; SOMLYO, AV; ELLISDAVIES, GCR; KAPLAN, JH; SOMLYO, AP			KINETICS OF PREPHOSPHORYLATION REACTIONS AND MYOSIN LIGHT-CHAIN PHOSPHORYLATION IN SMOOTH-MUSCLE - FLASH-PHOTOLYSIS STUDIES WITH CAGED CALCIUM AND CAGED-ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-BRIDGE KINETICS; INOSITOL 1,4,5-TRISPHOSPHATE; SKELETAL-MUSCLE; CONTRACTION; CALMODULIN; CA2+; ACTIVATION; RELEASE; KINASE; FORCE	The pre-myosin light chain (MLC(20)) phosphorylation components of the lag phase (t(d)) of contractile activation were determined in permeabilized smooth muscles activated by photolytic release of ATP from caged ATP and/or Ca2+ from 4-(2-nitrophenyl)-EGTA (NP-EGTA). Calmodulin (CaM) shortened the t(d) (470 ms at 0 added CaM) that followed Ca2+ release, but its effect (t(d) = similar to 200 ms) saturated at 40 mu M. Photolysis of caged ATP following preequilibration with identical [Ca(4)CaM] shortened t(d) to 41 ms. The rate of phosphorylation was very fast (3.5 s(-1) at 22 degrees C in the presence of 5 mu M exogenous CaM) following photolysis of caged ATP, and, following Ca2+ release, phosphorylation was accelerated by CaM. Simultaneous photolysis of caged ATP and NP-EGTA was followed by a t(d) of 194 ms at 5 mu M CaM and a rate of MLC(20) phosphorylation intermediate between these parameters following photolysis of, respectively, NP-EGTA and caged ATP. In the presence of the normal, total endogenous CaM content (37 +/- 4 mu M) of portal vein smooth muscles t(d) was 565 ms. Steady state maximum force at pCa 5.5 was increased by much lower (100 nM) exogenous [CaM] than was required (>2.5 mu M) to shorten the t(d). We estimate the endogenous CaM available under steady state conditions in vivo to be approximately 0.25 mu M and probably less during a rapid Ca2+ transient. We conclude that the [CaM] dependence of the kinetics of MLC(20) phosphorylation and force development (t1/2 and t(d)) initiated by Ca-2+ reflects the recruitment of a slowly diffusible component of total CaM. The relatively long duration of t(d) (197 ms) at saturating [CaM] suggests the contribution to t(d) of an additional component, possibly a prephosphorylation activation/isomerization of the Ca(4)CaM myosin light chain kinase complex (Torok, K., and Trentham, D. R. (1994) Biochemistry 33, 12807-12820). The relatively short delay (108 ms in the presence of 40 mu M CaM) following simultaneous photolysis of NP-EGTA and caged ATP suggests that preincubation with ATP (prior to photolysis of NP-EGTA) may inhibit the formation of a preactive Ca(2)CaM myosin light chain kinase complex.	UNIV VIRGINIA,HLTH SCI CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOL PHYS,CHARLOTTESVILLE,VA 22908; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	University of Virginia; Oregon Health & Science University				Kaplan, Jack/0000-0002-7048-6574	NHLBI NIH HHS [HL 19242-19, HL 48807-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048807, P01HL019242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; ASHLEY CC, 1991, Q REV BIOPHYS, V24, P1, DOI 10.1017/S0033583500003267; BUTLER TM, 1989, AM J PHYSIOL, V256, pC59, DOI 10.1152/ajpcell.1989.256.1.C59; CASSIDY P, 1979, J BIOL CHEM, V254, P1148; COHEN DM, 1978, J GEN PHYSIOL, V72, P369, DOI 10.1085/jgp.72.3.369; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; FUGLSANG A, 1993, J MUSCLE RES CELL M, V15, P666; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V354, P577, DOI 10.1113/jphysiol.1984.sp015394; GONG MC, 1992, J BIOL CHEM, V267, P14662; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HIMPENS B, 1988, J PHYSIOL-LONDON, V395, P507, DOI 10.1113/jphysiol.1988.sp016932; Hiromi K., 1979, KINETICS FAST ENZYME; HORIUTI K, 1988, J PHYSIOL-LONDON, V398, P131, DOI 10.1113/jphysiol.1988.sp017034; HORIUTI K, 1989, J GEN PHYSIOL, V94, P769, DOI 10.1085/jgp.94.4.769; IIZUKA K, 1994, CELL CALCIUM, V16, P431, DOI 10.1016/0143-4160(94)90073-6; KAMM KE, 1986, SCIENCE, V232, P80, DOI 10.1126/science.3754063; KASTURI R, 1993, J BIOL CHEM, V268, P7958; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; Klee C B, 1980, Ann N Y Acad Sci, V356, P43, DOI 10.1111/j.1749-6632.1980.tb29598.x; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; KUHN H, 1990, PFLUG ARCH EUR J PHY, V416, P512, DOI 10.1007/BF00382683; LUKAS TJ, 1984, PLANT PHYSIOL, V75, P788, DOI 10.1104/pp.75.3.788; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MILLERHANCE WC, 1988, J BIOL CHEM, V263, P13979; MURALIDHARAN S, 1993, P NATL ACAD SCI USA, V90, P5199, DOI 10.1073/pnas.90.11.5199; NGAI PK, 1984, BIOCHEM J, V218, P863, DOI 10.1042/bj2180863; NISHIYE E, 1993, J PHYSIOL-LONDON, V460, P247, DOI 10.1113/jphysiol.1993.sp019470; PERSECHINI A, 1983, BIOCHEMISTRY-US, V22, P470, DOI 10.1021/bi00271a033; QUADRONI M, 1994, J BIOL CHEM, V269, P16116; RUEGG JC, 1984, FEBS LETT, V170, P383, DOI 10.1016/0014-5793(84)81349-6; SACKS DB, 1992, BIOCHEM J, V283, P21, DOI 10.1042/bj2830021; SOMLYO AP, 1989, FASEB J, V3, P2266, DOI 10.1096/fasebj.3.11.2506092; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SOMLYO AP, 1990, ANNU REV PHYSIOL, V52, P857; SOMLYO AP, 1988, PHILOS T ROY SOC B, V320, P399, DOI 10.1098/rstb.1988.0084; SOMLYO AV, 1992, J BIOL CHEM, V267, P22316; SOMLYO AV, 1988, J GEN PHYSIOL, V91, P165, DOI 10.1085/jgp.91.2.165; SPARROW MP, 1981, FEBS LETT, V125, P141, DOI 10.1016/0014-5793(81)80704-1; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; TOROK K, 1994, BIOCHEMISTRY-US, V33, P12807, DOI 10.1021/bi00209a012; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; WALKER JW, 1993, BIOCHEMISTRY-US, V32, P1338, DOI 10.1021/bi00056a020; WATTERSON DM, 1980, J BIOL CHEM, V255, P962; WEBER A, 1973, PHYSIOL REV, V53, P612, DOI 10.1152/physrev.1973.53.3.612; YAGI S, 1988, P NATL ACAD SCI USA, V85, P4109, DOI 10.1073/pnas.85.11.4109; Zimmerman B., 1995, Biophysical Journal, V68, pA417; ZUCKER RS, 1978, BIOCHIM BIOPHYS ACTA, V541, P459, DOI 10.1016/0304-4165(78)90155-1	48	58	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23966	23974		10.1074/jbc.270.41.23966	http://dx.doi.org/10.1074/jbc.270.41.23966			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592592	hybrid			2022-12-27	WOS:A1995TA21700020
J	SAPORITOIRWIN, SM; VANNOSTRAND, WE				SAPORITOIRWIN, SM; VANNOSTRAND, WE			COAGULATION-FACTOR XIA CLEAVES THE RHDS SEQUENCE AND ABOLISHES THE CELL ADHESIVE PROPERTIES OF THE AMYLOID BETA-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; NEXIN-II; INHIBITOR DOMAIN; SECRETED FORMS; PURIFICATION; CDNA; FIBROBLASTS; EXPRESSION; CONTAINS	Amyloid beta-protein (A beta) is the major constituent of senile plaques and cerebrovascular amyloid deposits in Alzheimer's disease and is proteolytically derived from its transmembrane parent protein the amyloid beta-protein precursor (A beta PP). Although the physiological role(s) of secreted A beta PPs are not fully understood, several potential functions have been described including the regulation of hemostatic enzymes factors XIa and Ma and a role in cell adhesion. In the present study, we investigated the proteolytic processing of A beta PP by factor XIa (FXIa). Incubation of the human glioblastoma cell line U138 stably transfected to overexpress the 695 isoform of A beta PP with FXIa (2.55 nM) resulted in proteolytic cleavage of secreted A beta PP. Higher concentrations of FXIa (>25 nM) resulted in loss in cell adherence. Coin cubation of FXIa with purified, recombinant Kunitz protease inhibitor domain of A beta PP blocked both the proteolytic processing of A beta PP and the loss of cell adhesion. The RHDS cell adhesion site of A beta PP resides within residues 5-8 of the A beta domain. Incubation of synthetic AP(1-40) peptide with increasing concentrations of FXIa resulted in cleavage of A beta between Arg(5) and His(6) within the cell adhesion domain of the peptide. FXIa-digested A beta(1-40) or A beta PP695 lost their abilities to serve as cell adhesion substrates consistent with cleavage through this cell adhesion site, Together, these results suggest a new potential biological function for FXIa in the modulation of cell adhesion. In addition, we have shown that FXIa can proteolytically alter A beta and therefore possibly modify its physiological and perhaps pathological properties.	UNIV CALIF IRVINE,COLL MED,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL003229, R01HL049566] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03229, HL49566] Funding Source: Medline; NIA NIH HHS [AG00096-12] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BHASIN R, 1991, P NATL ACAD SCI USA, V88, P10307, DOI 10.1073/pnas.88.22.10307; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BURDICK D, 1992, J BIOL CHEM, V267, P546; CHEN M, 1991, NEUROSCI LETT, V125, P223, DOI 10.1016/0304-3940(91)90034-Q; DAVISSALINAS J, 1994, J BIOL CHEM, V269, P22623; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GHISO J, 1992, BIOCHEM J, V288, P1053, DOI 10.1042/bj2881053; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; IGARASHI K, 1992, BIOCHEM BIOPH RES CO, V185, P1000, DOI 10.1016/0006-291X(92)91726-7; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KLIER FG, 1990, BRAIN RES, V515, P336, DOI 10.1016/0006-8993(90)90619-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; NINOMIYA H, 1993, J CELL BIOL, V121, P879, DOI 10.1083/jcb.121.4.879; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SCHMAIER AH, 1995, BIOCHEMISTRY-US, V34, P1171, DOI 10.1021/bi00004a010; SCHMAIER AH, 1993, J CLIN INVEST, V92, P2540, DOI 10.1172/JCI116863; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SMITH RP, 1992, BLOOD, V80, P2252; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; VANNOSTRAND WE, 1987, J BIOL CHEM, V262, P8508; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; VANNOSTRAND WE, 1992, ANN NY ACAD SCI, V674, P243; WAGNER SL, 1992, BIOCHEM BIOPH RES CO, V186, P1138, DOI 10.1016/0006-291X(92)90865-I; WANG R, 1991, J BIOL CHEM, V266, P16960	41	29	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26265	26269		10.1074/jbc.270.44.26265	http://dx.doi.org/10.1074/jbc.270.44.26265			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592834	hybrid			2022-12-27	WOS:A1995TC97800041
J	SARVAZYAN, NA; MODYANOV, NN; ASKARI, A				SARVAZYAN, NA; MODYANOV, NN; ASKARI, A			INTERSUBUNIT AND INTRASUBUNIT CONTACT REGIONS OF NA+/K+-ATPASE REVEALED BY CONTROLLED PROTEOLYSIS AND CHEMICAL CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; ACTIVATED ADENOSINE-TRIPHOSPHATASE; SPATIAL-ORGANIZATION; ALPHA-SUBUNIT; BETA-SUBUNIT; K+-ATPASE; CHYMOTRYPTIC CLEAVAGE; CATION OCCLUSION; MEMBRANE DOMAINS; SODIUM	To identify interfaces of alpha- and beta-subunits of Na+/K+- ATPase, and contact points between different regions of the same alpha-subunit, purified kidney enzyme preparations whose alpha-subunits were subjected to controlled proteolysis in different ways were solubilized with digitonin to disrupt intersubunit alpha,alpha-interactions, and oxidatively cross-linked. The following disulfide cross-linked products were identified by gel electrophoresis, staining with specific antibodies, and N-terminal analysis. 1) In the enzyme that was partially cleaved at Arg(438)-Ala(439), the cross-linked products were an alpha.beta-dimer, a dimer of N-terminal and C-terminal or fragments, and a trimer of beta and the two alpha fragments. 2) From an extensively digested enzyme that contained the 22-kDa C-terminal and several smaller fragments of or, two crosslinked products were obtained, One was a dimer of the 22-kDa C-terminal peptide and an 11-kDa N-terminal peptide containing the first two intramembrane helices of alpha (H-1-H-2). The other was a trimer of beta, the 11-kDa, and the 22-kDa peptides. 3) The cross-linked products of a preparation partially cleaved at Leu(266)-Ala(267) were an alpha,beta-dimer and a dimer of beta and the 83-bDa C-terminal fragment. Assuming the most likely 10-span model of alpha, these findings indicate that (a) the single intramembrane helix of beta is in contact with portions of H-8-H-10 intramembrane helices of alpha; and (b) there is close contact between N-terminal H1-H-2 and C-terminal H-8-H-10 segments of alpha; with the most probable interacting helices being the H-1,H-10-pair and the H-2,H-8-pair.	MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699						NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; ASKARI A, 1983, J BIOL CHEM, V258, P3453; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P359, DOI 10.1007/BF00768539; BALL WJ, 1987, BIOCHIM BIOPHYS ACTA, V916, P100, DOI 10.1016/0167-4838(87)90216-0; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; BROWN TA, 1987, BIOCHIM BIOPHYS ACTA, V912, P244, DOI 10.1016/0167-4838(87)90095-1; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CRAIG WS, 1982, BIOCHEMISTRY-US, V21, P5707, DOI 10.1021/bi00265a049; CRAIG WS, 1980, J BIOL CHEM, V255, P6262; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EFREMOV RG, 1992, J PROTEIN CHEM, V11, P699, DOI 10.1007/BF01024971; EFREMOV RG, 1992, J PROTEIN CHEM, V11, P665, DOI 10.1007/BF01024968; EFREMOV RG, 1993, J PROTEIN CHEM, V12, P143, DOI 10.1007/BF01026035; FAMBROUGH DM, 1994, AM J PHYSIOL, V266, pC579, DOI 10.1152/ajpcell.1994.266.3.C579; GANJEIZADEH M, 1995, J BIOL CHEM, V270, P15707, DOI 10.1074/jbc.270.26.15707; GIOTTA GJ, 1976, BIOCHEM BIOPH RES CO, V71, P776, DOI 10.1016/0006-291X(76)90898-6; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; HUANG WH, 1990, BIOCHIM BIOPHYS ACTA, V1030, P65, DOI 10.1016/0005-2736(90)90239-K; HUANG WH, 1994, BBA-BIOMEMBRANES, V1190, P108, DOI 10.1016/0005-2736(94)90039-6; HUANG WH, 1979, BIOCHIM BIOPHYS ACTA, V578, P547, DOI 10.1016/0005-2795(79)90186-7; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; JEAN DH, 1975, J BIOL CHEM, V250, P1035; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; JORGENSEN PL, 1985, BIOCHIM BIOPHYS ACTA, V821, P319, DOI 10.1016/0005-2736(85)90102-6; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P1566; KAWAMURA M, 1985, BIOCHIM BIOPHYS ACTA, V821, P115, DOI 10.1016/0005-2736(85)90161-0; KIRLEY TL, 1989, J BIOL CHEM, V264, P7185; LEMAS MV, 1994, J BIOL CHEM, V269, P18651; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LIANG SM, 1977, J BIOL CHEM, V252, P8278; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LO TN, 1978, J BIOL CHEM, V253, P4432; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PERIYASAMY SM, 1983, J BIOL CHEM, V258, P9878; PETERS K, 1977, ANNU REV BIOCHEM, V46, P523, DOI 10.1146/annurev.bi.46.070177.002515; RHEE HM, 1975, BIOCHEM BIOPH RES CO, V63, P1139, DOI 10.1016/0006-291X(75)90687-7; SARVAZYAN N, 1994, FASEB J, V8, pA299; Sarvazyan N. A., 1995, Biophysical Journal, V68, pA308; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; XIE ZJ, 1994, SODIUM PUMP, P49; ZOLOTARJOVA N, 1995, J BIOL CHEM, V270, P3989, DOI 10.1074/jbc.270.8.3989	46	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26528	26532		10.1074/jbc.270.44.26528	http://dx.doi.org/10.1074/jbc.270.44.26528			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592871	hybrid			2022-12-27	WOS:A1995TC97800078
J	MERICKEL, A; ROSANDICH, P; PETER, D; EDWARDS, RH				MERICKEL, A; ROSANDICH, P; PETER, D; EDWARDS, RH			IDENTIFICATION OF RESIDUES INVOLVED IN SUBSTRATE RECOGNITION BY A VESICULAR MONOAMINE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; BETA-ADRENERGIC-RECEPTOR; ESCHERICHIA-COLI; CHROMAFFIN GRANULES; SYNAPTIC VESICLES; AMINE TRANSPORTER; RESERPINE BINDING; TN10; RESISTANCE; SYSTEM	To identify the residues involved in substrate recognition by recently cloned vesicular monoamine transporters (VMAT1 and VMAT2), we have mutagenized the conserved residues in a cytoplasmic loop between transmembrane domains two and three of VMAT2. Although studies of related bacterial antibiotic resistance proteins indicate an important functional role for this region, we found no effect of these mutations on VMAT2 activity. However, replacement of aspartate 33 in the first predicted transmembrane domain with an asparagine (D33N) eliminates transport. D33N shows normal levels of expression and normal binding at equilibrium to the potent inhibitor reserpine. However, in contrast to wild-type VMAT2, serotonin inhibits reserpine binding to D33N very poorly, indicating a specific defect in substrate recognition. Replacement of three serine residues in transmembrane domain three with alanine (Stmd3A) shows a similarly selective but even more profound defect in substrate recognition. The results suggest that by analogy to receptors and plasma membrane transporters for monoamines, the cationic amino group of the ligand interacts with an aspartate in the first transmembrane domain of VMAT2 and hydroxyl groups on the catechol or indole ring interact with a group of serines in the third transmembrane domain. Importantly, D33N and Stmd3A retain coupling to the proton electrochemical gradient as measured by the Delta mu(H)+-induced acceleration of reserpine binding. This indicates that substrate recognition can be separated from coupling to the driving force.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF LOS ANGELES, SCH MED, INTERDEPARTMENTAL PROGRAM NEUROSCI, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT NEUROL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BARKER EL, 1994, MOL PHARMACOL, V46, P799; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; DANIELS AJ, 1988, J BIOL CHEM, V263, P5034; Edwards R H, 1992, Curr Opin Neurobiol, V2, P586, DOI 10.1016/0959-4388(92)90023-E; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; GIROS B, 1994, J BIOL CHEM, V269, P15985; HENRY JP, 1989, BIOCHEM PHARMACOL, V38, P2395, DOI 10.1016/0006-2952(89)90082-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KANEKO M, 1985, FEBS LETT, V193, P194, DOI 10.1016/0014-5793(85)80149-6; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIU Y, 1992, P NATL ACAD SCI USA, V89, P9074, DOI 10.1073/pnas.89.19.9074; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LIU YJ, 1994, J CELL BIOL, V127, P1419, DOI 10.1083/jcb.127.5.1419; MCMURRY LM, 1992, J BACTERIOL, V174, P6294, DOI 10.1128/JB.174.19.6294-6297.1992; MORIYAMA Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P271, DOI 10.1006/abbi.1993.1422; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; PETER D, 1994, J BIOL CHEM, V269, P7231; PETER D, 1995, J NEUROSCI, V15, P6179; RAMU A, 1983, P NATL ACAD SCI-BIOL, V80, P2107, DOI 10.1073/pnas.80.8.2107; ROGHANI A, 1994, P NATL ACAD SCI USA, V91, P10620, DOI 10.1073/pnas.91.22.10620; RUDNICK G, 1990, BIOCHEMISTRY-US, V29, P603, DOI 10.1021/bi00455a002; RUDNICK G, 1986, ANNU REV PHYSIOL, V48, P403; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERMAN D, 1988, EUR J PHARMACOL, V146, P359, DOI 10.1016/0014-2999(88)90317-2; SCHERMAN D, 1986, J NEUROCHEM, V47, P331; SCHULDINER S, 1993, J BIOL CHEM, V268, P29; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SHIRVAN A, 1994, FEBS LETT, V356, P145, DOI 10.1016/0014-5793(94)01252-0; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; VAROQUI H, 1994, FEBS LETT, V342, P97, DOI 10.1016/0014-5793(94)80592-X; WEAVER JA, 1982, EUR J PHARMACOL, V80, P437, DOI 10.1016/0014-2999(82)90093-0; YAMAGUCHI A, 1992, BIOCHEMISTRY-US, V31, P8344, DOI 10.1021/bi00150a031; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490	49	61	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25798	25804		10.1074/jbc.270.43.25798	http://dx.doi.org/10.1074/jbc.270.43.25798			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592763	hybrid			2022-12-27	WOS:A1995TB46600080
J	VAMBUTAS, V; KAPLAN, DR; SELLS, MA; CHERNOFF, J				VAMBUTAS, V; KAPLAN, DR; SELLS, MA; CHERNOFF, J			NERVE GROWTH-FACTOR STIMULATES TYROSINE PHOSPHORYLATION AND ACTIVATION OF SRC HOMOLOGY-CONTAINING PROTEIN-TYROSINE-PHOSPHATASE-1 IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; PHEOCHROMOCYTOMA CELLS; RECEPTOR-BETA; MOTH-EATEN; KINASE; DIFFERENTIATION; IDENTIFICATION; ASSOCIATION; CORKSCREW; MUTATIONS	Rat PC12 cells respond to extracellular peptide growth factors in at least two distinct ways, When treated with nerve growth factor (NGF) PC12 cells exit the cell cycle and differentiate to a neuronal phenotype, whereas when treated with epidermal growth factor, they proliferate, We examined the potential role of Src homology 2 (SH2)-containing protein tyrosine phosphatases (PTPs) in the differentiation process, PC12 cells express substantial amounts of both SH-PTP1 and 2. SH-PTP1, but not SH-PTP2, becomes tyrosine phosphorylated following NGF, but not epidermal growth factor treatment, The enzymatic activity of SH-PTP1 toward an exogenous substrate following NGF treatment is increased 2-fold. We found that SH-PTP1 binds to the NGF receptor TrkA in vitro and that anti-TrkA immunoprecipitates have PTP activity. These results show that SH-PTP1 is differentially phosphorylated and activated by NGF in PC12 cells and suggest that this activation may play a role in NGF-induced differentiation.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MOLEC MECHANISMS CARCINOGENESIS LAB,FREDERICK,MD 21702	Fox Chase Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NCI NIH HHS [R01 CA58836] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058836] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; APARICIO LF, 1992, CELL GROWTH DIFFER, V3, P363; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHULTZ LD, 1987, ANNU REV IMMUNOL, V5, P367; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	40	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25629	25633		10.1074/jbc.270.43.25629	http://dx.doi.org/10.1074/jbc.270.43.25629			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592737	hybrid			2022-12-27	WOS:A1995TB46600054
J	WONG, P; HAMPTON, B; SZYLOBRYT, E; GALLAGHER, AM; JAYE, M; BURGESS, WH				WONG, P; HAMPTON, B; SZYLOBRYT, E; GALLAGHER, AM; JAYE, M; BURGESS, WH			ANALYSIS OF PUTATIVE HEPARIN-BINDING DOMAINS OF FIBROBLAST GROWTH-FACTOR-I - USING SITE-DIRECTED MUTAGENESIS AND PEPTIDE ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; MITOGENIC ACTIVITY; RECEPTOR-BINDING; FACTOR FAMILY; ACIDIC FGF; PROTEINS; AFFINITY; RESIDUES; CELLS; INACTIVATION	The contribution of individual basic amino acids within three putative ''consensus sequences'' for heparin binding of fibroblast growth factor-1 have been examined by site-directed mutagenesis. The results indicate that a significant reduction in the apparent affinity of fibroblast growth factor-1 for heparin is only observed when basic residues in one of the three regions are mutated, Mutation in the other regions are without affect on heparin binding. The heparin binding properties of synthetic peptides based on the three ''consensus sequences'' paralleled the mutagenesis results. That is, synthetic peptides corresponding to regions of the protein that were affected by mutagenesis with respect to heparin binding exhibited a relatively high affinity for immobilized heparin, whereas those corresponding to regions of similar charge density that were unaffected by mutagenesis did not. In addition, amino acid substitution of a nonbasic residue in the heparin-binding peptide could abolish its heparin binding capacity. The heparin-binding peptide could antagonize the mitogenic activity of FGF-1, probably because of the heparin dependence of this activity. Together these data demonstrate that the heparin binding properties of fibroblast growth factor-1 are dictated by structural features more complex than clusters of basic amino acids. The results of these and other studies indicate that consensus motifs for heparin-binding require further definition. More importantly, the results provide a basis for the design of peptide-based inhibitors of FGF-1.	AMER RED CROSS,HOLLAND LAB,DEPT MOLEC BIOL,ROCKVILLE,MD 20855; RHONE POULENC RORER CENT RES,COLLEGEVILLE,PA 19426	American Red Cross			Hampton, Brian/G-8427-2015	Hampton, Brian/0000-0003-4650-2869	NHLBI NIH HHS [HL35762] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035762] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BURGESS WH, 1994, MOL REPROD DEV, V39, P56, DOI 10.1002/mrd.1080390110; BURGESS WH, 1991, J CELL BIOCHEM, V45, P131, DOI 10.1002/jcb.240450203; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURGESS WH, 1995, REGULATION PROLIFERA, P155; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DAMON DH, 1989, J CELL PHYSIOL, V138, P221, DOI 10.1002/jcp.1041380202; FOLKMAN J, 1991, ANN SURG, V214, P414, DOI 10.1097/00000658-199110000-00006; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HAMPTON BS, 1992, MOL BIOL CELL, V3, P85, DOI 10.1091/mbc.3.1.85; HARPER JW, 1988, BIOCHEMISTRY-US, V27, P671, DOI 10.1021/bi00402a027; HATA A, 1993, J BIOL CHEM, V268, P8447; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JAYE M, 1987, J BIOL CHEM, V262, P16612; KAPLOW JM, 1990, BIOCHEM BIOPH RES CO, V172, P107, DOI 10.1016/S0006-291X(05)80179-2; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MEHLMAN T, 1990, ANAL BIOCHEM, V188, P159, DOI 10.1016/0003-2697(90)90545-K; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOSCATELLI D, 1991, ANN NY ACAD SCI, V638, P177, DOI 10.1111/j.1749-6632.1991.tb49028.x; MUELLER SN, 1989, J CELL PHYSIOL, V140, P439, DOI 10.1002/jcp.1041400306; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PARTANEN J, 1992, Progress in Growth Factor Research, V4, P69, DOI 10.1016/0955-2235(92)90005-3; PRESTRELSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P314, DOI 10.1016/0003-9861(92)90401-H; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SLACK JMW, 1988, DEVELOPMENT, V103, P581; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WINKLES JA, 1991, CELL GROWTH DIFFER, V2, P531; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	38	53	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25805	25811		10.1074/jbc.270.43.25805	http://dx.doi.org/10.1074/jbc.270.43.25805			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592764	hybrid			2022-12-27	WOS:A1995TB46600081
J	ATAMNA, H; GINSBURG, H				ATAMNA, H; GINSBURG, H			HEME DEGRADATION IN THE PRESENCE OF GLUTATHIONE - A PROPOSED MECHANISM TO ACCOUNT FOR THE HIGH-LEVELS OF NONHEME IRON FOUND IN THE MEMBRANES OF HEMOGLOBINOPATHIC RED-BLOOD-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE ERYTHROCYTE-MEMBRANES; LIPID-PEROXIDATION; OXIDATIVE DENATURATION; FERRIPROTOPORPHYRIN IX; ASSOCIATION; HEMOLYSIS; PROTEINS; RELEASE	Unstable hemoglobins and oxidative conditions tend to produce hemichromes which demonstrably release their heme to the erythrocyte membrane, with consequent lipid peroxidation and cell lysis. High levels of non-heme iron are also found in such circumstances, but the origin of this iron is uncertain. In the present work, we show that reduced glutathione (GSH) is able to degrade heme in solution with a pH optimum of 7. Degradation depended on the presence of oxygen and on heme and GSH concentrations. It was inhibited by catalase and superoxide dismutase, implicating the involvement of perferryl reactive species in the process of heme degradation. Heme degradation at pH 7 and 37 degrees C is rapid (t(1/2) = 70 s) and results in the release of iron from heme. Heme that was dissolved in red blood cell ghosts is also degraded by GSH with a concomitant increase in non-heme iron, most of which (75%) remains associated with the cell membrane. Loading of intact erythrocytes with heme was followed by time-dependent decrease of membrane-associated heme and caused an acceleration of the hexose monophosphate shunt due to the production of H2O2 and the oxidation of intracellular GSH. Most of the activation of the hexose monophosphate pathway was due to redox cycling of iron, since iron chelators inhibited it considerably. These results explain the origin of non-heme iron found in the membrane of sickle cells and the oxidative stress that is observed in these and other abnormal erythrocytes.	HEBREW UNIV JERUSALEM, INST LIFE SCI, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL	Hebrew University of Jerusalem								AEBI H, 1982, METHOD ENZYMAT AN, V2, P673; Beutler E., 1984, RED CELL METABOLISM, P103; BROWN SB, 1968, T FARADAY SOC, V64, P999, DOI 10.1039/tf9686400999; CANNON JB, 1984, BIOCHEMISTRY-US, V23, P3715, DOI 10.1021/bi00311a022; CARTER P, 1971, ANAL BIOCHEM, V40, P450, DOI 10.1016/0003-2697(71)90405-2; CHIU D, 1989, SEMIN HEMATOL, V26, P128; CHIU D, 1989, SEMIN HEMATOL, V26, P257; CHOU AC, 1981, J CLIN INVEST, V68, P672, DOI 10.1172/JCI110302; GALARIS D, 1989, FREE RADICAL BIO MED, V6, P473, DOI 10.1016/0891-5849(89)90039-7; GUTTERIDGE JMC, 1986, FEBS LETT, V201, P291, DOI 10.1016/0014-5793(86)80626-3; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1989, FREE RADICAL BIO MED, P129; HEBBEL RP, 1990, SEMIN HEMATOL, V27, P51; HEBBEL RP, 1989, SEMIN HEMATOL, V26, P136; JAROLIM P, 1990, BLOOD, V76, P2125; KREMER ML, 1989, EUR J BIOCHEM, V185, P651, DOI 10.1111/j.1432-1033.1989.tb15162.x; KUROSS SA, 1988, BLOOD, V71, P876; KUROSS SA, 1988, BLOOD, V72, P1278; LIU SC, 1988, BLOOD, V71, P1755; MARGOLIASH E, 1960, BIOCHEM J, V74, P339, DOI 10.1042/bj0740339; MINOTTI G, 1992, LIPIDS, V27, P219, DOI 10.1007/BF02536182; MUNDAY R, 1989, BIOCHEM PHARMACOL, V38, P4349, DOI 10.1016/0006-2952(89)90641-2; PESCARMONA GP, 1982, INT J BIOCHEM, V14, P243, DOI 10.1016/0020-711X(82)90146-X; PONKA P, 1994, CAN J PHYSIOL PHARM, V72, P659, DOI 10.1139/y94-093; PONKA P, 1985, J BIOL CHEM, V260, P4717; PONKA P, 1982, BIOCHIM BIOPHYS ACTA, V718, P151, DOI 10.1016/0304-4165(82)90213-6; REPKA T, 1991, BLOOD, V78, P2753; REPKA T, 1993, BLOOD, V82, P3204; Rice-Evans C., 1990, BLOOD CELL BIOCH, P429; ROSE MY, 1985, J BIOL CHEM, V260, P6632; SHINAR E, 1990, SEMIN HEMATOL, V27, P70; SHVIRO Y, 1987, BIOCHEM PHARMACOL, V36, P3801, DOI 10.1016/0006-2952(87)90441-2; SOLAR I, 1989, FEBS LETT, V256, P225, DOI 10.1016/0014-5793(89)81753-3; SUGIHARA T, 1992, J CLIN INVEST, V90, P2327, DOI 10.1172/JCI116121; SUGIOKA Y, 1987, FEBS LETT, V223, P251, DOI 10.1016/0014-5793(87)80299-5; SULLIVAN SG, 1992, BIOCHIM BIOPHYS ACTA, V1104, P38, DOI 10.1016/0005-2736(92)90129-A; WINTERBOURN CC, 1990, SEMIN HEMATOL, V27, P41	37	184	188	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24876	24883		10.1074/jbc.270.42.24876	http://dx.doi.org/10.1074/jbc.270.42.24876			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559611	hybrid			2022-12-27	WOS:A1995TB46500045
J	LAI, KS; JIN, Y; GRAHAM, DK; WITTHUHN, BA; IHLE, JN; LIU, ET				LAI, KS; JIN, Y; GRAHAM, DK; WITTHUHN, BA; IHLE, JN; LIU, ET			A KINASE-DEFICIENT SPLICE VARIANT OF THE HUMAN JAK3 IS EXPRESSED IN HEMATOPOIETIC AND EPITHELIAL CANCER-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; EGF-RECEPTOR; BINDING-SITE; DOMAINS; FAMILY; IDENTIFICATION; GENE; SH2	Signal transduction of cytokine receptors is mediated by the JAK family of tyrosine kinases. Recently, the kinase partners for the interleukin (IL)-2 receptor have been identified as JAK1 and JAK3. In this study, we report the identification of splice variants that may modulate JAK3 signaling. Three splice variants were isolated from different mRNA sources: breast (B), spleen (S), and activated monocytes (M). Sequence analysis revealed that the splice variants contain identical NH2-terminal regions but diverge at the COOH termini. Analyses of expression of the JAK3 splice isoforms by reverse transcriptase-polymerase chain reaction on a panel of cell lines show splice preferences in different cell lines: the S-form is more commonly seen in hematopoietic lines, whereas the B- and M-forms are detected in cells both of hematopoietic and epithelial origins, Antibodies raised against peptides to the B-form splice variant confirmed that the 125-kDa JAK3B protein product is found abundantly in hematopoietic as well as epithelial cells, including primary breast cancers. The lack of subdomain XI in the tyrosine kinase core of the B-form JAK3 protein suggests that it is a defective kinase, This is supported by the lack of detected autokinase activity of the B-form JAK3. Intriguingly, both the S and B splice isoforms of JAK3 appear to co immunoprecipitate with the IL-2 receptor from HUT-78 cell lysates. This and the presence of multiple COOH-terminal splice variants coexpressed in the same cells suggest that the JAK3 splice isoforms are functional in JAK3 signaling and may enrich the complexity of the intracellular responses functional in IL-2 or cytokine signaling.	UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, DEPT MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GENET, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; St Jude Children's Research Hospital			Liu, Edison/C-4141-2008; witthuhn, bruce/GSE-3193-2022		NATIONAL CANCER INSTITUTE [P50CA058223] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA58223-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HALEY J, 1987, ONCOGENE RES, V1, P375; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARPUR AG, 1992, ONCOGENE, V7, P1347; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEMMON MA, 1994, J BIOL CHEM, V269, P31653; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; RANE SG, 1994, ONCOGENE, V9, P2415; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; TAKAHASHI T, 1994, FEBS LETT, V342, P124, DOI 10.1016/0014-5793(94)80485-0; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	35	55	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25028	25036		10.1074/jbc.270.42.25028	http://dx.doi.org/10.1074/jbc.270.42.25028			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559633	hybrid, Green Published			2022-12-27	WOS:A1995TB46500067
J	UDDIN, S; CHAMDIN, A; PLATANIAS, LC				UDDIN, S; CHAMDIN, A; PLATANIAS, LC			INTERACTION OF THE TRANSCRIPTIONAL ACTIVATOR STAT-2 WITH THE TYPE-I INTERFERON RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IFN-ALPHA RECEPTOR; TYROSINE PHOSPHORYLATION; SUBUNIT; CELLS	Binding of interferon-alpha (IFN alpha) to the multisubunit type I IFN receptor (IFNR) induces activation of the Tyk-2 and Jak-1 kinases and tyrosine phosphorylation of multiple signaling elements, including the Stat proteins that form the ISGF3 alpha complex. Although Jak kinases are required for IFN alpha-dependent activation of Stats, the mechanisms by which Stats interact with these kinases are not known. We report that Stat-2 associates with beta(s) subunit of the type I IFN receptor in an interferon-dependent manner. This association is rapid, occurring within 1 min of interferon treatment of cells, and is inducible by various type I (alpha, beta, omega) but not type II (gamma) IFNs. The kinetics of Stat-2-IFNR association are similar to the kinetics of phosphorylation of Stat-2, suggesting that during its binding to the type I IFNR, Stat-2 acts as a substrate for interferon-dependent tyrosine kinase activity. These findings support the hypothesis that the type I IFNR acts as an adaptor, linking Stat proteins to Jak kinases, Interaction of Stat-2 with the beta(s) subunit of the type I IFNR may be a critical signaling event, required for the formation of the ISGF3 alpha complex and downstream transcription of interferon-stimulated genes.	LOYOLA UNIV,DEPT MED,DIV HEMATOL ONCOL,MAYWOOD,IL 60153; EDWARD HINES JR VET ADM HOSP,HINES,IL 60141	Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital				Uddin, Shahab/0000-0003-1886-6710				COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1994, J BIOL CHEM, V269, P5660; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GUTCH MJ, 1992, P NATL ACAD SCI USA, V8, P11411; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PETSKA S, 1987, ANNU REV BIOCHEM, V56, P727; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; PLATANIAS LC, 1993, J IMMUNOL, V150, P3382; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; PLATANIAS LC, 1992, BRIT J HAEMATOL, V82, P543; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3	24	44	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24627	24630		10.1074/jbc.270.42.24627	http://dx.doi.org/10.1074/jbc.270.42.24627			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559568	hybrid			2022-12-27	WOS:A1995TB46500002
J	DING, DXH; VERA, JC; HEANEY, ML; GOLDE, DW				DING, DXH; VERA, JC; HEANEY, ML; GOLDE, DW			N-GLYCOSYLATION OF THE HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-RECEPTOR ALPHA-SUBUNIT IS ESSENTIAL FOR LIGAND-BINDING AND SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GM-CSF RECEPTORS; ASPARAGINE-LINKED OLIGOSACCHARIDES; INSULIN-RECEPTOR; BETA-SUBUNIT; EXPRESSION CLONING; CELL-LINE; AFFINITY; IDENTIFICATION; RECONSTITUTION; CARBOHYDRATE	The alpha subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein containing 11 potential N-glycosylation sites in the extracellular domain, We examined the role of N-glycosylation on alpha subunit membrane localization and function, Tunicamycin, an N-glycosylation inhibitor, markedly inhibited GM-CSF binding, GM-CSF-induced deoxyglucose uptake, and protein tyrosine phosphorylation in HL-60(eos) cells but did not affect cell surface expression of the alpha subunit as detected by an anti-alpha subunit monoclonal antibody, In COS cells expressing the alpha subunit and treated with tunicamycin, N-unglycosylated alpha subunit was expressed and transported to the cell surface but was not capable of binding GM-CSF. High affinity binding in COS cells expressing both alpha and beta subunits was also blocked by tunicamycin treatment. These studies indicate that N-linked oligosaccharides are essential for alpha subunit ligand binding and signaling by the human GM-CSF receptor.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC PHARMACOL & THERAPEUT,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [R01 CA30388, K11 CA01754] Funding Source: Medline; NHLBI NIH HHS [R01 HL42107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030388, K11CA001754] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042107] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASANO T, 1993, FEBS LETT, V324, P258, DOI 10.1016/0014-5793(93)80129-I; BALDWIN GC, 1991, BLOOD, V78, P609, DOI 10.1182/blood.V78.3.609.bloodjournal783609; BALDWIN GC, 1989, BLOOD, V73, P1033; BASTIAN W, 1993, DIABETES, V42, P966, DOI 10.2337/diabetes.42.7.966; BUDEL LM, 1993, J BIOL CHEM, V268, P10154; CHIBA S, 1990, J BIOL CHEM, V265, P19777; CHIBA S, 1990, CELL REGUL, V1, P327, DOI 10.1091/mbc.1.4.327; CHOCHOLA J, 1993, J BIOL CHEM, V268, P2312; COLLIER E, 1993, BIOCHEMISTRY-US, V32, P7818, DOI 10.1021/bi00081a029; DAVIE SJ, 1992, DIABETES, V41, P167, DOI 10.2337/diabetes.41.2.167; DING DXH, 1994, P NATL ACAD SCI USA, V91, P2537, DOI 10.1073/pnas.91.7.2537; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; FABIAN I, 1992, BLOOD, V80, P788; FEIGE JJ, 1988, J BIOL CHEM, V263, P14023; GASSON JC, 1986, P NATL ACAD SCI USA, V83, P669, DOI 10.1073/pnas.83.3.669; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; JUBINSKY PT, 1994, BLOOD, V84, P4174, DOI 10.1182/blood.V84.12.4174.bloodjournal84124174; KANAKURA Y, 1991, BLOOD, V77, P243; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KAUSHANSKY K, 1987, BIOCHEMISTRY-US, V26, P4861, DOI 10.1021/bi00389a038; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUMAGAI AK, 1994, BBA-BIOMEMBRANES, V1193, P24, DOI 10.1016/0005-2736(94)90328-X; LECONTE I, 1992, J BIOL CHEM, V267, P17415; LECONTE I, 1994, J BIOL CHEM, V269, P18062; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; METCALF D, 1990, P NATL ACAD SCI USA, V87, P4670, DOI 10.1073/pnas.87.12.4670; MOLLER LB, 1993, J BIOL CHEM, V268, P11152; MURATA Y, 1992, J EXP MED, V1765, P341; OHTA T, 1994, BIOCHEM BIOPH RES CO, V200, P1283, DOI 10.1006/bbrc.1994.1590; PRATT SE, 1994, BIOCHEM BIOPH RES CO, V200, P1313, DOI 10.1006/bbrc.1994.1594; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAINES MA, 1992, BLOOD, V79, P3350; RUSSO D, 1991, MOL ENDOCRINOL, V5, P29, DOI 10.1210/mend-5-1-29; SEMMES OJ, 1992, INT J IMMUNOPHARMACO, V14, P583, DOI 10.1016/0192-0561(92)90119-6; SHIBUYA K, 1991, EUR J BIOCHEM, V198, P659, DOI 10.1111/j.1432-1033.1991.tb16064.x; SPIELHOLZ C, 1995, BLOOD, V85, P973, DOI 10.1182/blood.V85.4.973.bloodjournal854973; SZECOWKA J, 1990, ENDOCRINOLOGY, V126, P1834, DOI 10.1210/endo-126-4-1834; TIFFT CJ, 1992, J BIOL CHEM, V267, P3268; TOMONAGA M, 1986, BLOOD, V67, P1433; VERA JC, 1990, MOL CELL BIOL, V10, P743, DOI 10.1128/MCB.10.2.743	44	43	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24580	24584		10.1074/jbc.270.41.24580	http://dx.doi.org/10.1074/jbc.270.41.24580			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592677	hybrid			2022-12-27	WOS:A1995TA21700105
J	TINTUT, Y; WANG, JT; GRALLA, JD				TINTUT, Y; WANG, JT; GRALLA, JD			ABORTIVE CYCLING AND THE RELEASE OF POLYMERASE FOR ELONGATION AT THE SIGMA-54-DEPENDENT GLNAP2 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI COMPONENTS; CORE RNA-POLYMERASE; TRANSCRIPTION INITIATION; KLEBSIELLA-PNEUMONIAE; TERNARY COMPLEXES; FACTOR SIGMA-54; PROTEIN; DNA; BINDING; ACTIVATION	Transcription initiation at the sigma 54-dependent glnAp2 promoter was studied to follow the state of polymerase as RNA synthesis begins. sigma 54 polymerase begins transcription in abortive cycling mode, i.e. after the first bond is made, approximately 75% of the time the short RNA is aborted and synthesis must be restarted. Polymerase is capable of abortive initiation until it reaches a position beyond +3 and before +7, at which stage polymerase is released from its promoter contacts and an elongation complex is formed. Initial elongation is accompanied by two transcription bubbles, one moving with the polymerase and the other remaining at the transcription start site, The sigma 54-associated polymerase shows an earlier and more efficient transition out of abortive initiation mode than prior studies of sigma 70-associated polymerase.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles	TINTUT, Y (corresponding author), UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90095 USA.		Demer, Linda L/I-5770-2013	Demer, Linda L/0000-0002-9618-6895	NIGMS NIH HHS [GM35754, GM07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035754] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CARPOUSIS AJ, 1983, THESIS U CALIF, P70; Chamberlin M J, 1992, Harvey Lect, V88, P1; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; GRALLA JD, 1985, P NATL ACAD SCI USA, V82, P3078, DOI 10.1073/pnas.82.10.3078; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HUNT TP, 1985, P NATL ACAD SCI USA, V82, P8453, DOI 10.1073/pnas.82.24.8453; JACOB GA, 1994, J BIOL CHEM, V269, P3655; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MAGASANIK B, 1989, New Biologist, V1, P247; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; MERRICK MJ, 1985, NUCLEIC ACIDS RES, V13, P7607, DOI 10.1093/nar/13.21.7607; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MUSTAEV A, 1994, P NATL ACAD SCI USA, V91, P12036, DOI 10.1073/pnas.91.25.12036; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; NORTH AK, 1993, J BACTERIOL, V175, P4267, DOI 10.1128/JB.175.14.4267-4273.1993; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; TINTUT Y, 1994, P NATL ACAD SCI USA, V91, P2120, DOI 10.1073/pnas.91.6.2120; TINTUT Y, 1995, IN PRESS J BACTERIOL; TINTUT Y, 1995, IN PRESS GENES DEV; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N	33	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24392	24398		10.1074/jbc.270.41.24392	http://dx.doi.org/10.1074/jbc.270.41.24392			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592652	hybrid			2022-12-27	WOS:A1995TA21700080
J	KANETY, H; FEINSTEIN, R; PAPA, MZ; HEMI, R; KARASIK, A				KANETY, H; FEINSTEIN, R; PAPA, MZ; HEMI, R; KARASIK, A			TUMOR-NECROSIS-FACTOR-ALPHA INDUCED PHOSPHORYLATION OF INSULIN-RECEPTOR SUBSTRATE-1 (IRS-1) - POSSIBLE MECHANISM FOR SUPPRESSION OF INSULIN-STIMULATED TYROSINE PHOSPHORYLATION OF IRS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SIGNAL TRANSDUCTION; PROTEIN-KINASE-C; OKADAIC ACID; HEPATOMA-CELLS; INTERLEUKIN-1; GLUCOSE; PHOSPHATASE; RESISTANCE; EXPRESSION; ACTIVATION	Tumor necrosis factor-alpha (TNF) has been suggested to be the mediator of insulin resistance in infection, tumor cachexia, and obesity. We have previously shown that TNF diminishes insulin-induced tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1). The current work examines potential mechanisms that mediate this event. TNF effect on IRS-1 in Fao hepatoma cells was not associated with a significant reduction in insulin receptor tyrosine kinase activity as measured in vitro but impaired the association of IRS-1 with phosphatidylinositol 3-kinase, localizing TNF impact to IRS-1. TNF did not increase protein-tyrosine phosphatase activity and protein-tyrosine phosphatase inhibition by vanadate did not change TNF effect on IRS-1 tyrosine phosphorylation, suggesting that protein-tyrosine phosphatases are not involved in this TNF effect. In contrast, TNF increased IRS-1 phosphorylation on serine residues, leading to a decrease in its electrophoretic mobility. TNF effect on IRS-1 tyrosine phosphorylation was not abolished by inhibiting protein kinase C using staurosporine, while inactivation of Ser/Thr phosphatases by calyculin A and okadaic acid mimicked it. Our data suggest that TNF induces serine phosphorylation of IRS-1 through inhibition of serine phosphatases or activation of serine kinases other than protein kinase C. This increased serine phosphorylation interferes with insulin-induced tyrosine phosphorylation of IRS-1 and impairs insulin action.	SHEBA MED CTR, INST ENDOCRINOL, IL-52621 TEL HASHOMER, ISRAEL; SHEBA MED CTR, DEPT SURG, IL-52621 TEL HASHOMER, ISRAEL; BAR ILAN UNIV, DEPT LIFE SCI, IL-52900 RAMAT GAN, ISRAEL	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Bar Ilan University								BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; CHIN JE, 1994, MOL ENDOCRINOL, V8, P51, DOI 10.1210/me.8.1.51; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; GOROSPE M, 1993, J BIOL CHEM, V268, P6214; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUY GR, 1992, J BIOL CHEM, V267, P1846; GUY GR, 1993, J BIOL CHEM, V268, P2141; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; JULLIEN D, 1993, J BIOL CHEM, V268, P15246; KANETY H, 1994, P NATL ACAD SCI USA, V91, P1853, DOI 10.1073/pnas.91.5.1853; KLETZIEN RF, 1994, DIABETES, V43, pA82; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; LANG CH, 1989, AM J PHYSIOL, V257, pE301, DOI 10.1152/ajpendo.1989.257.3.E301; MCCALL JL, 1992, BRIT J SURG, V79, P1361, DOI 10.1002/bjs.1800791240; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; OLD LJ, 1990, TUMOR NECROSIS FACTOR : STRUCTURE, MECHANISM OF ACTION, ROLE IN DISEASE AND THERAPY, P1; ROBINSON KA, 1993, AM J PHYSIOL, V265, pE36, DOI 10.1152/ajpendo.1993.265.1.E36; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SHISHEVA A, 1991, ENDOCRINOLOGY, V129, P2279; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TANTI JF, 1994, J BIOL CHEM, V269, P6051; TOTPAL K, 1992, CANCER RES, V52, P2557; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; VANDERPOLL T, 1991, AM J PHYSIOL, V261, pE457, DOI 10.1152/ajpendo.1991.261.4.E457; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VIETOR I, 1994, LYMPHOKINE CYTOK RES, V13, P315; VIETOR I, 1993, J BIOL CHEM, V268, P18994; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1994, J BIOL CHEM, V269, P1; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	41	344	357	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23780	23784		10.1074/jbc.270.40.23780	http://dx.doi.org/10.1074/jbc.270.40.23780			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559552	hybrid			2022-12-27	WOS:A1995RY90900081
J	CONTURSI, C; MINCHIOTTI, G; DINOCERA, PP				CONTURSI, C; MINCHIOTTI, G; DINOCERA, PP			IDENTIFICATION OF SEQUENCES WHICH REGULATE THE EXPRESSION OF DROSOPHILA-MELANOGASTER DOC ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; F-ELEMENTS; INTERNAL PROMOTER; MAMMALIAN LINES; START SITE; CONTAINS; RETROTRANSPOSITION; DOWNSTREAM; PROTEIN	Long interspersed nuclear elements (LINEs) are mobile DNA elements which propagate by reverse transcription of RNA intermediates. LINEs lack long terminal repeats, and their expression is controlled by promoters located inside to the transcribed region of unit-length DNA copies. Doc elements constitute one of the seven families of LINEs found in Drosophila melanogaster. Plasmids in which the chloramphenicol acetyltransferase (CAT) gene is preceded by DNA segments from different Doc family members were used as templates for transient expression assays in Drosophila S2 cells. Transcription is initiated at the 5' end of Doe elements within hexamers fitting the consensus (C/G)AYTCG and is regulated by a DNA region which is located similar to 20 base pairs (bp) downstream from the RNA start site(s). The region includes a sequence (RGACGTGY motif, or DE2) which stimulates transcription in other Drosophila LINEs, and two adjacent elements, DEI and DE3. Moving the downstream region either 4 bp away from, or 5 bp closer to the RNA start site region inhibited transcription. Sequences located similar to 200 bp downstream from the Doc 5' end repressed CAT expression in an orientation- and position-dependent manner. The inhibition reflects impaired translation of the CAT gene possibly consequent to the interaction of specific Doc RNA sequences with a cellular component.	UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC L CAL,I-80131 NAPLES,ITALY; CNR,IST INT GENET & BIOFIS,NAPLES,ITALY	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)				Minchiotti, Gabriella/0000-0003-0225-9043				ARKHIPOVA IR, 1991, EMBO J, V10, P1169, DOI 10.1002/j.1460-2075.1991.tb08057.x; AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584; BUCHETON A, 1990, TRENDS GENET, V6, P1; CHABOISSIER MC, 1990, EMBO J, V9, P3557, DOI 10.1002/j.1460-2075.1990.tb07566.x; CHEN HJ, 1994, MOL CELL BIOL, V14, P676, DOI 10.1128/MCB.14.1.676; CONTURSI C, 1993, J MOL BIOL, V234, P988, DOI 10.1006/jmbi.1993.1653; DINOCERA PP, 1988, NUCLEIC ACIDS RES, V16, P4041; DINOCERA PP, 1987, P NATL ACAD SCI USA, V84, P5843; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; DRIVER A, 1989, MOL GEN GENET, V220, P49, DOI 10.1007/BF00260854; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; EVANS JP, 1991, P NATL ACAD SCI USA, V88, P8792, DOI 10.1073/pnas.88.19.8792; FAWCETT DH, 1986, CELL, V47, P1007, DOI 10.1016/0092-8674(86)90815-9; Finnegan D J, 1986, Oxf Surv Eukaryot Genes, V3, P1; FRIDELL YWC, 1992, MOL CELL BIOL, V12, P4571, DOI 10.1128/MCB.12.10.4571; GRIMALDI G, 1988, P NATL ACAD SCI USA, V85, P5502, DOI 10.1073/pnas.85.15.5502; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; JAKUBCZAK JL, 1990, J MOL BIOL, V212, P37, DOI 10.1016/0022-2836(90)90303-4; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JENSEN S, 1991, EMBO J, V10, P1927, DOI 10.1002/j.1460-2075.1991.tb07719.x; LACHAUME P, 1992, DEVELOPMENT, V115, P729; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LIU CC, 1984, NATURE, V309, P82, DOI 10.1038/309082a0; MARTIN SL, 1993, MOL CELL BIOL, V13, P5383, DOI 10.1128/MCB.13.9.5383; MCLEAN C, 1993, MOL CELL BIOL, V13, P1042, DOI 10.1128/MCB.13.2.1042; MCMILLAN JP, 1993, P NATL ACAD SCI USA, V90, P11533, DOI 10.1073/pnas.90.24.11533; MINAKAMI R, 1992, NUCLEIC ACIDS RES, V20, P3139, DOI 10.1093/nar/20.12.3139; MINCHIOTTI G, 1991, MOL CELL BIOL, V11, P5171, DOI 10.1128/MCB.11.10.5171; MINCHIOTTI G, 1994, MOL GEN GENET, V245, P152, DOI 10.1007/BF00283262; MIZROKHI LJ, 1988, CELL, V54, P685, DOI 10.1016/S0092-8674(88)80013-8; MIZROKHI LJ, 1990, P NATL ACAD SCI USA, V87, P9216, DOI 10.1073/pnas.87.23.9216; NAKATANI Y, 1990, P NATL ACAD SCI USA, V87, P4289, DOI 10.1073/pnas.87.11.4289; OHARE K, 1991, MOL GEN GENET, V225, P17, DOI 10.1007/BF00282637; PASYUKOVA EG, 1993, MOL GEN GENET, V240, P302, DOI 10.1007/BF00277071; PELISSON A, 1991, P NATL ACAD SCI USA, V88, P4907, DOI 10.1073/pnas.88.11.4907; PERKINS KK, 1988, GENE DEV, V2, P1615, DOI 10.1101/gad.2.12a.1615; PRIIMAGI AF, 1988, GENE, V70, P253, DOI 10.1016/0378-1119(88)90197-7; Sambrook J, 1989, MOL CLONING LABORATO; SCHALET AP, 1986, MUTAT RES, V163, P115, DOI 10.1016/0027-5107(86)90042-4; SCHNEUWLY S, 1987, EMBO J, V6, P201, DOI 10.1002/j.1460-2075.1987.tb04739.x; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SINGER MF, 1985, TRENDS BIOCHEM SCI, V10, P119, DOI 10.1016/0968-0004(85)90271-3; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; THUMMEL CS, 1989, GENE DEV, V3, P782, DOI 10.1101/gad.3.6.782; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TRELOGAN SA, 1995, P NATL ACAD SCI USA, V92, P1520, DOI 10.1073/pnas.92.5.1520; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; ZENZIEGREGORY B, 1993, J BIOL CHEM, V268, P15823; [No title captured]	55	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26570	26576		10.1074/jbc.270.44.26570	http://dx.doi.org/10.1074/jbc.270.44.26570			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592878	hybrid			2022-12-27	WOS:A1995TC97800085
J	SKOWYRA, D; WICKNER, S				SKOWYRA, D; WICKNER, S			GRPE ALTERS THE AFFINITY OF DNAK FOR ATP AND MG2+ - IMPLICATIONS FOR THE MECHANISM OF NUCLEOTIDE EXCHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; REPA MONOMERIZATION; REPLICATION; CHAPERONES; BINDING; ORIGIN; GROEL	DnaK, DnaJ, and GrpE heat shock proteins of Escherichia coli activate site-specific DNA binding by the RepA replication initiator protein of plasmid P1 in a reaction dependent on ATP and Mg2+. We previously showed that GrpE is essential for in. vitro RepA activation specifically at about 1 mu m free Mg2+. In this paper, we demonstrate that GrpE lowers the requirement of DnaK ATPase for Mg2+, resulting in a large stimulation of ATP hydrolysis at about 1 mu M Mg2+ with and without DnaJ and RepA. In contrast to its effect on the Mg2+ requirement, GrpE increases the ATP requirement for DnaK ATPase and dramatically lowers the affinity of DnaK for ATP in the absence of Mg2+. We propose that GrpE not only lowers the affinity of DnaK for nucleotide but, by increasing affinity of DnaK for Mg2+, also weakens the interactions of Mg2+ with nucleotide prior to its release.			SKOWYRA, D (corresponding author), NCI, MOLEC BIOL LAB, BLDG 37, BETHESDA, MD 20892 USA.							BAKER TA, 1992, ANNU REV GENET, V26, P447; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HOLMQUIST B, 1988, METHOD ENZYMOL, V158, P6, DOI 10.1016/0076-6879(88)58042-4; IKEDA E, 1994, FEBS LETT, V339, P265, DOI 10.1016/0014-5793(94)80428-1; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MARTIN MT, 1988, METHOD ENZYMOL, V158, P15, DOI 10.1016/0076-6879(88)58044-8; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SKOWYRA D, 1993, J BIOL CHEM, V268, P25296; SKOWYRA D, 1995, SEMIN VIROL, V6, P43, DOI 10.1016/S1044-5773(05)80008-3; SOZHAMANNAN S, 1993, J BACTERIOL, V175, P3546, DOI 10.1128/jb.175.11.3546-3555.1993; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1993, PHILOS T ROY SOC B, V339, P271, DOI 10.1098/rstb.1993.0025	30	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26282	26285		10.1074/jbc.270.44.26282	http://dx.doi.org/10.1074/jbc.270.44.26282			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592837	hybrid			2022-12-27	WOS:A1995TC97800044
J	ZHAO, M; YONEDA, M; OHASHI, Y; KURONO, S; IWATA, H; OHNUKI, Y; KIMATA, K				ZHAO, M; YONEDA, M; OHASHI, Y; KURONO, S; IWATA, H; OHNUKI, Y; KIMATA, K			EVIDENCE FOR THE COVALENT BINDING OF SHAP, HEAVY-CHAINS OF INTER-ALPHA-TRYPSIN INHIBITOR, TO HYALURONAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX; CDNA SEQUENCE; CUMULUS MASS; PROTEIN; ACID; SERUM; FAMILY; CD44; GLYCOPROTEIN	We previously showed that serum derived 85-kDa proteins (SHAPs, serum derived hyaluronan associated proteins) are firmly bound to hyaluronan (HA) synthesized sized by cultured fibroblasts. SHAPs were then identified to be the heavy chains of inter-alpha-trypsin inhibitor (ITI) (Huang, L., Yoneda, M., and Kimata, K. (1993) J. Biol. Chem. 268, 26725-26730). In this study, the SHAP . HA complex was isolated from pathological synovial fluid from human arthritis patients. The SHAP . HA complex was digested with thermolysin, followed by CsCl gradient centrifugation. The HA-containing fragments thus obtained were further digested with chondroitinase AC II and subjected to TSK gel high performance liquid chromatography (HPLC), Peptide-HA disaccharide-containing fractions (the SHAP . HA binding regions) were further purified by reverse phase HPLC. Major peaks were analyzed by protein sequencing and mass spectrometry (electrospray ionization mass spectrometry and collision induced dissociation-MS/MS). By comparison with the reported C-terminal sequences of the human ITI family, the peptides were found to correspond to tetrapeptides derived from the C termini of heavy chains 1 of and 2 of inter-alpha-trypsin inhibitor (HC1 and HC2), and heavy chain 3 of pre-alpha-trypsin inhibitor (HC3), respectively, and a heptapeptide from HC1, Mass spectrometric analyses suggested that the C-terminal Asp of each heavy chain was esterified to the CG-hydroxyl group of an internal N-acetylglucosamine of HA chain. This report is the first demonstration to give evidence for the covalent binding of proteins to HA.	AICHI MED UNIV, INST MOLEC SCI MED, NAGAKUTE, AICHI 48011, JAPAN; INST PHYS & CHEM RES, FRONTIER RES PROGRAM, GLYCOBIOL GRP, WAKO, SAITAMA 35101, JAPAN; NAGOYA UNIV, SCH MED, DEPT ORTHOPED SURG, NAGOYA, AICHI 466, JAPAN; SEIKAGAKU CORP, HIGASHIYAMATO, TOKYO 207, JAPAN	Aichi Medical University; RIKEN; Nagoya University; Seikagaku Corporation								ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; BALAZS EA, 1965, AMINO SUGARS       A, V2, P401; BALDUYCK M, 1986, EUR J BIOCHEM, V158, P417, DOI 10.1111/j.1432-1033.1986.tb09769.x; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHEN L, 1993, MOL REPROD DEV, V34, P87, DOI 10.1002/mrd.1080340114; CHEN L, 1992, J BIOL CHEM, V267, P12380; CHEN L, 1994, J BIOL CHEM, V269, P28282; CHEN L, 1990, MOL REPROD DEV, V26, P236, DOI 10.1002/mrd.1080260307; DELPECH A, 1984, DEV BIOL, V101, P391, DOI 10.1016/0012-1606(84)90153-2; DELPECH B, 1985, ANAL BIOCHEM, V149, P555, DOI 10.1016/0003-2697(85)90613-X; DIARRAMEHRPOUR M, 1992, BIOCHIM BIOPHYS ACTA, V1132, P114, DOI 10.1016/0167-4781(92)90065-8; DOEGE K, 1986, P NATL ACAD SCI USA, V83, P3761, DOI 10.1073/pnas.83.11.3761; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; ENGHILD JJ, 1989, J BIOL CHEM, V264, P15975; GEBHARD W, 1989, EUR J BIOCHEM, V181, P571, DOI 10.1111/j.1432-1033.1989.tb14762.x; GEBHARD W, 1988, BIOL CHEM H-S, V369, P19; GEBHARD W, 1986, PROTEINASE INHIBITOR, P375; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HUANG L, 1993, J BIOL CHEM, V268, P26725; KNUDSON W, 1989, CIBA F SYMP, V143, P150; KOBAYASHI H, 1994, J BIOL CHEM, V269, P20642; KOBAYASHI H, 1994, CLIN EXP METASTAS, V12, P117, DOI 10.1007/BF01753978; KOBAYASHI H, 1994, CANCER RES, V54, P844; KOBAYASHI H, 1994, INT J CANCER, V57, P378, DOI 10.1002/ijc.2910570315; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; MORELLE W, 1994, EUR J BIOCHEM, V221, P881, DOI 10.1111/j.1432-1033.1994.tb18803.x; ODUM L, 1992, INT J BIOCHEM, V24, P215, DOI 10.1016/0020-711X(92)90249-Z; PERIDES G, 1989, J BIOL CHEM, V264, P5981; REISINGER P, 1985, BIOL CHEM H-S, V366, P479, DOI 10.1515/bchm3.1985.366.1.479; ROUET P, 1992, BIOL CHEM H-S, V373, P1019, DOI 10.1515/bchm3.1992.373.2.1019; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; SALIER JP, 1987, P NATL ACAD SCI USA, V84, P8272, DOI 10.1073/pnas.84.23.8272; Sandson J, 1965, Trans Assoc Am Physicians, V78, P304; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SELLOUM L, 1987, BIOL CHEM H-S, V368, P47, DOI 10.1515/bchm3.1987.368.1.47; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUNDBLAD L, 1965, AMINO SUGARS       A, V2, P229; TENGBLAD A, 1986, BIOCHEM J, V236, P521, DOI 10.1042/bj2360521; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; Toole BP, 1976, NEURONAL RECOGNITION, P275; TOOLE BP, 1984, ROLE EXTRACELLULAR M, P43; UNDERHILL C, 1992, J CELL SCI, V103, P293; WEST DC, 1989, CIBA F SYMP, V143, P187; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; YONEDA M, 1990, J BIOL CHEM, V265, P5247; YUKI Y, 1993, BIOCHIM BIOPHYS ACTA, V1203, P298, DOI 10.1016/0167-4838(93)90098-C	49	147	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26657	26663		10.1074/jbc.270.44.26657	http://dx.doi.org/10.1074/jbc.270.44.26657			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592891	hybrid			2022-12-27	WOS:A1995TC97800098
J	BRINGMANN, P; GRUBER, D; LIESE, A; TOSCHI, L; KRATZSCHMAR, J; SCHLEUNING, WD; DONNER, P				BRINGMANN, P; GRUBER, D; LIESE, A; TOSCHI, L; KRATZSCHMAR, J; SCHLEUNING, WD; DONNER, P			STRUCTURAL FEATURES MEDIATING FIBRIN SELECTIVITY OF VAMPIRE BAT PLASMINOGEN ACTIVATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CHAIN; DESMODUS-ROTUNDUS; THROMBOLYTIC PROPERTIES; MYOCARDIAL-INFARCTION; KRINGLE-2 DOMAIN; SINGLE-CHAIN; T-PA; TISSUE; BINDING; STREPTOKINASE	The distinguishing characteristic of vampire bat (Desmodus rotundus) salivary plasminogen activators (DSPAs) is their strict requirement for fibrin as a cofactor. DSPAs consist of structural modules known from urokinase (u-PA) and tissue-type plasminogen activator (t-PA) such as finger (F), epidermal growth factor (E), kringle (K), and protease (P), combining to four genetically and biochemically distinct isoenzymes, exhibiting the formulas FEKP (DSPA alpha 1 and alpha 2) and EKP and KP (DSPA beta and DSPA gamma). Only DSPA alpha 1 and alpha 2 bind to fibrin. All DSPAs are single-chain molecules, displaying substantial amidolytic activity. In a plasminogen activation assay, all four DSPAs are almost inactive in the absence of fibrin but strongly stimulated by fibrin addition. The catalytic efficiency (k(cat)/K-m) of DSPA alpha(1) increases 10(5)-fold, whereas the corresponding value of t-PA is only 550. The ratio of the bimolecular rate constants of plasminogen activation in the presence of fibrin versus fibrinogen (fibrin selectivity) of DSPA alpha 1, alpha 2, beta, gamma, and t-PA was found to be 13,000, 6500, 250, 90, and 72, respectively. Whereas all DSPAs are therefore more fibrin dependent and fibrin selective than t-PA, the extent depends on the respective presence of the various domains. The introduction of a plasmin-sensitive cleavage site in a position akin to the one in t-PA partially obliterates fibrin cofactor requirement. Fibrin dependence and fibrin selectivity of DSPAs are accordingly mediated by fibrin binding, which involves the F domain, as yet undefined determinants within the K and P domains, and by the absence of a plasmin-sensitive activation site. These findings transcend the current understanding of fibrin-mediated stimulation of plasminogen activation: in addition to fibrin binding, specific protein-protein interactions come into play, which stabilize the enzyme in its active conformation.			BRINGMANN, P (corresponding author), SCHERING AG BERLIN,RES LABS,D-13342 BERLIN,GERMANY.							ANDREASEN PA, 1991, FIBRINOLYSIS, V5, P207, DOI 10.1016/0268-9499(91)90002-L; ARNOLD AER, 1989, J AM COLL CARDIOL, V14, P581, DOI 10.1016/0735-1097(89)90096-X; ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BEARDEN JC, 1978, BIOCHIM BIOPHYS ACTA, V533, P525, DOI 10.1016/0005-2795(78)90398-7; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BERGUM PW, 1992, J BIOL CHEM, V267, P17726; BLOMBACK B, 1958, ARK KEMI, V12, P99; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; CAMIOLO SM, 1971, P SOC EXP BIOL MED, V138, P277; COLLEN D, 1991, BLOOD, V78, P3114; COLLEN D, 1994, THROMB HAEMOSTASIS, V72, P98; DEMUNK GAW, 1989, BIOCHEMISTRY-US, V28, P7318, DOI 10.1021/bi00444a026; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVRIES C, 1991, THROMB HAEMOSTASIS, V65, P280; DRAPIER JC, 1979, BIOCHIMIE, V61, P463, DOI 10.1016/S0300-9084(79)80202-3; FEARS R, 1989, BIOCHEM J, V261, P313, DOI 10.1042/bj2610313; GARDELL SJ, 1989, J BIOL CHEM, V264, P17947; GARDELL SJ, 1991, CIRCULATION, V84, P244, DOI 10.1161/01.CIR.84.1.244; HEUSSEN C, 1984, J BIOL CHEM, V259, P1635; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HIGGINS DL, 1990, ANNU REV PHARMACOL, V30, P91; HIGGINS DL, 1990, THROMB RES, V57, P527, DOI 10.1016/0049-3848(90)90070-S; HORREVOETS AJG, 1994, J BIOL CHEM, V269, P12639; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; HUSAIN SS, 1989, BLOOD, V74, P999; JONES AJS, 1990, THROMB HAEMOSTASIS, V64, P455; KEYT BA, 1994, P NATL ACAD SCI USA, V91, P3670, DOI 10.1073/pnas.91.9.3670; KRATZSCHMAR J, 1992, GENE, V116, P281, DOI 10.1016/0378-1119(92)90526-U; KRATZSCHMAR J, 1991, GENE, V105, P229, DOI 10.1016/0378-1119(91)90155-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MK, 1990, NUCLEIC ACIDS RES, V18, P3439, DOI 10.1093/nar/18.12.3439; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P88; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MELLOTT MJ, 1992, ARTERIOSCLER THROMB, V12, P212, DOI 10.1161/01.ATV.12.2.212; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUSCHICK P, 1993, FIBRINOLYSIS, V7, P284, DOI 10.1016/0268-9499(93)90137-K; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NIENABER VL, 1992, BIOCHEMISTRY-US, V31, P3852, DOI 10.1021/bi00130a017; NIEUWENHUIZEN W, 1985, FIBRINOGEN STRUCTURA, P331; PAONI NF, 1993, PROTEIN ENG, V6, P529, DOI 10.1093/protein/6.5.529; Patthy L, 1990, Blood Coagul Fibrinolysis, V1, P153; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; PETERSEN LC, 1988, BIOCHIM BIOPHYS ACTA, V952, P245, DOI 10.1016/0167-4838(88)90123-9; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; Robbins K. C., 1970, METHOD ENZYMOL, V19, P184; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEUNING WD, 1992, ANN NY ACAD SCI, V667, P395, DOI 10.1111/j.1749-6632.1992.tb51639.x; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; TATE KM, 1987, THROMB RES, V27, P175; TOPOL EJ, 1991, PROG CARDIOVASC DIS, V34, P165, DOI 10.1016/0033-0620(91)90011-A; URANO T, 1988, BIOCHEMISTRY-US, V27, P6522, DOI 10.1021/bi00417a049; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; WALLER EK, 1985, J BIOL CHEM, V260, P6354; WIRTH M, 1991, PROTEIN GLYCOSYLATIO, V15, P49; WITT W, 1992, BLOOD, V79, P1213; WITT W, 1994, CIRCULATION, V90, P421, DOI 10.1161/01.CIR.90.1.421; WU HL, 1990, J BIOL CHEM, V265, P19658	62	70	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25596	25603		10.1074/jbc.270.43.25596	http://dx.doi.org/10.1074/jbc.270.43.25596			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592732	hybrid			2022-12-27	WOS:A1995TB46600049
J	CHANG, JY				CHANG, JY			THE PROPERTIES OF SCRAMBLED HIRUDINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-A; CHYMOTRYPSIN INHIBITOR-2; TRANSITION-STATE; FOLDING PATHWAY; PROTEIN; BPTI	Scrambled hirudins serve as relevant folding intermediates during in vitro renaturation of the reduced/denatured hirudin. Eleven species of scrambled hirudins were isolated and structurally identified. Their properties, including their relative stability and the kinetics of their consolidation (disulfide reshuffling) to attain the native structure, have been investigated and are reported here.			CHANG, JY (corresponding author), CIBA GEIGY LTD,PHARMACEUT RES LABS,K-121104,CH-4002 BASEL,SWITZERLAND.							ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; CHANG JY, 1993, J BIOL CHEM, V268, P4043; CHANG JY, 1995, J BIOL CHEM, V270, P9207, DOI 10.1074/jbc.270.16.9207; CHANG JY, 1988, ANAL BIOCHEM, V170, P542, DOI 10.1016/0003-2697(88)90670-7; CHANG JY, 1995, J BIOL CHEM, V270, P11992, DOI 10.1074/jbc.270.20.11992; CHANG JY, 1994, J BIOL CHEM, V269, P22087; CHANG JY, 1994, BIOCHEM J, V300, P643, DOI 10.1042/bj3000643; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1979, J MOL BIOL, V129, P411, DOI 10.1016/0022-2836(79)90504-7; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; HABER E, 1962, J BIOL CHEM, V237, P1839; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11270, DOI 10.1021/bi00093a002; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10436, DOI 10.1021/bi00107a011; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; OTZEN DE, 1994, P NATL ACAD SCI USA, V91, P10422, DOI 10.1073/pnas.91.22.10422; PIGIET VP, 1986, P NATL ACAD SCI USA, V83, P7643, DOI 10.1073/pnas.83.20.7643; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; SCHERAGA HA, 1987, P NATL ACAD SCI USA, V84, P5740, DOI 10.1073/pnas.84.16.5740; SCHERAGA HA, 1984, ADV BIOPHYS, V18, P21, DOI 10.1016/0065-227X(84)90005-4; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	24	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25661	25666						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592743				2022-12-27	WOS:A1995TB46600060
J	CHONN, A; SEMPLE, SC; CULLIS, PR				CHONN, A; SEMPLE, SC; CULLIS, PR			BETA-2-GLYCOPROTEIN-I IS A MAJOR PROTEIN ASSOCIATED WITH VERY RAPIDLY CLEARED LIPOSOMES IN-VIVO, SUGGESTING A SIGNIFICANT ROLE IN THE IMMUNE CLEARANCE OF NON-SELF PARTICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PHOSPHOLIPID ASYMMETRY; LARGE UNILAMELLAR LIPOSOMES; PERFUSED RAT-LIVER; ANTICARDIOLIPIN ANTIBODIES; APOLIPOPROTEIN-H; SCAVENGER RECEPTOR; BLOOD COMPONENTS; UPTAKE MECHANISM; RECOGNITION; MACROPHAGES	Liposomes recovered from the blood of liposome-treated CD1 mice were previously reported to have a complex protein profile associated with their mem branes (Chonn, A., Semple, S. C., and Cullis, P. R. (1992) J. Biol. Chem. 267, 18759-18765). In this study, we have further characterized and identified the major proteins associated with very rapidly cleared large unilamellar vesicles. These liposomes contained phosphatidylcholine, cholesterol, and anionic phospholipids (phosphatidylserine, phosphatidic acid, or cardiolipin) that dramatically enhance the clearance rate of Liposomes hom the circulation. These anionic phospholipids are normally found exclusively in the interior of cells but become expressed when cells undergo apoptosis or programmed cell death, and thus, they are believed to be markers of cell senescence, Analysis of the proteins associated with these liposomes by SDS-polyacrylamide gel electrophoresis revealed that two of the major proteins associated with the liposome membranes are proteins with electrophoretic mobilities corresponding to M(r) of 66,000 and 50,000-55,000. The 66-kDa protein was identified to be serum albumin by immunoblot analysis. Using various biochemical and immunological methods, we have identified the 50-55-kDa protein as the murine equivalent of human beta(2)-glycoprotein I. beta 2-glycoprotein I has a strong affinity for phosphatidylserine, phosphatidic acid, and cardiolipin inasmuch as the levels of beta 2-glycoprotein I associated with these anionic liposomes approach or even exceed those of serum albumin, which is present in serum at a concentration 200-fold greater than beta 2-glycoprotein I. Further, we demonstrate that the amount of beta 2-glycoprotein I associated with liposomes, as quantitated by an enzyme-linked immunosorbent assay, is correlated with their clearance rates; moreover, the circulation residency time of cardiolipin-containing liposomes is extended in mice pretreated with anti-beta 2-glycoprotein I antibodies. These findings strongly suggest that beta 2-glycoprotein I plays a primary role in mediating the clearance of liposomes and, by extension, senescent cells and foreign particles.	UNIV BRITISH COLUMBIA, DEPT BIOCHEM, VANCOUVER, BC V6P 6P2, CANADA	University of British Columbia								ALLEN TM, 1988, P NATL ACAD SCI USA, V85, P8067, DOI 10.1073/pnas.85.21.8067; ANDRADE JD, 1987, ANN NY ACAD SCI, V516, P158, DOI 10.1111/j.1749-6632.1987.tb33038.x; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BONTE F, 1986, CHEM PHYS LIPIDS, V40, P359, DOI 10.1016/0009-3084(86)90079-4; BONTE F, 1987, BIOCHIM BIOPHYS ACTA, V900, P1, DOI 10.1016/0005-2736(87)90271-9; CHONN A, 1991, BIOCHIM BIOPHYS ACTA, V1070, P215, DOI 10.1016/0005-2736(91)90167-7; CHONN A, 1992, J BIOL CHEM, V267, P18759; CONNOR J, 1994, J BIOL CHEM, V269, P2399; FADOK VA, 1992, J IMMUNOL, V148, P2207; FINLAYSO.JS, 1967, BIOCHIM BIOPHYS ACTA, V147, P413, DOI 10.1016/0005-2795(67)90001-3; GALLI M, 1990, LANCET, V335, P1544, DOI 10.1016/0140-6736(90)91374-J; GHARAVI AE, 1987, ANN RHEUM DIS, V46, P1, DOI 10.1136/ard.46.1.1; HARRIS EN, 1983, LANCET, V2, P1211; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; JULIANO RL, 1980, LIPOSOMES IMMUNOBIOL, P49; KIWADA H, 1987, CHEM PHARM BULL, V35, P1189; KIWADA H, 1986, CHEM PHARM BULL, V34, P1249; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LEE KD, 1992, BIOCHIM BIOPHYS ACTA, V1111, P1, DOI 10.1016/0005-2736(92)90267-P; LEE NS, 1983, J BIOL CHEM, V258, P4765; LOZIER J, 1984, P NATL ACAD SCI-BIOL, V81, P3640, DOI 10.1073/pnas.81.12.3640; MCEVOY L, 1986, P NATL ACAD SCI USA, V83, P3311, DOI 10.1073/pnas.83.10.3311; MCNEIL HP, 1989, BRIT J HAEMATOL, V73, P506, DOI 10.1111/j.1365-2141.1989.tb00289.x; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; NONAKA M, 1992, GENOMICS, V13, P1082, DOI 10.1016/0888-7543(92)90022-K; POLZ E, 1980, INT J BIOCHEM, V11, P265, DOI 10.1016/0020-711X(80)90229-3; POLZ E, 1979, FEBS LETT, V102, P183, DOI 10.1016/0014-5793(79)80955-2; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SCHLEGEL RA, 1985, J CELL PHYSIOL, V123, P215, DOI 10.1002/jcp.1041230210; SCHROIT AJ, 1984, BIOL CELL, V51, P227, DOI 10.1111/j.1768-322X.1984.tb00303.x; SENIOR JH, 1987, CRC CR REV THER DRUG, V3, P123; SOMMERMAN EF, 1986, THESIS U BRIT COLUMB; STEIN Y, 1980, FEBS LETT, V111, P104, DOI 10.1016/0014-5793(80)80771-X; WURM H, 1982, METABOLISM, V31, P484, DOI 10.1016/0026-0495(82)90238-4; WURM H, 1984, INT J BIOCHEM, V16, P511, DOI 10.1016/0020-711X(84)90168-X	37	162	166	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25845	25849		10.1074/jbc.270.43.25845	http://dx.doi.org/10.1074/jbc.270.43.25845			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592769	hybrid			2022-12-27	WOS:A1995TB46600086
J	GRUGEL, S; FINKENZELLER, G; WEINDEL, K; BARLEON, B; MARME, D				GRUGEL, S; FINKENZELLER, G; WEINDEL, K; BARLEON, B; MARME, D			BOTH V-HA-RAS AND V-RAF STIMULATE EXPRESSION OF THE VASCULAR ENDOTHELIAL GROWTH-FACTOR IN NIH 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; B-RAF; PERMEABILITY FACTOR; FACTOR FAMILY; ONCOGENE; TRANSCRIPTION; ACTIVATION; SERUM; FOS; PHOSPHORYLATION	Stimulation of NIH 3T3 cells with platelet-derived growth factor (PDGF)-BB and 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances vascular endothelial growth factor (VEGF) gene expression. To address the question of whether Ras and Raf are involved in the induction of VEGF gene expression by PDGF and TPA, we examined the effects of both factors on NIH 3T3 cells stably transfected with v-Ha-ras or v-raf. In serum-starved NIH 3T3 cells, only low levels of mRNA expression can be detected, whereas both ras and raf transformed cell lines express enhanced levels of a 4.3-kilobase VEGF transcript. Stimulation with PDGF or TPA resulted in increased VEGF mRNA in all cell lines, with highest levels found in the transformed cells. Immunofluorescence studies confirmed that the elevated VEGF mRNA expression correlated with enhanced protein levels. Positive immunofluorescence signals could be detected in v-Ha-ras or v-raf transformed cell lines but not in unstimulated NIH 3T3 cells. VEGF from conditioned medium of v-raf transformed NIH 3T3 cells was partially purified by chromatography on heparin-Sepharose. Biological activity of this VEGF protein was demonstrated by competition with binding of recombinant I-125-VEGF(165) human umbilical vein endothelial cells and by its ability to stimulate proliferation of these cells.	TUMOR BIOL CTR,INST MOLEC MED,D-79106 FREIBURG,GERMANY									ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1990, CELL GROWTH DIFFER, V1, P653; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLENTON DJ, 1987, MOL CELL BIOL, V7, P3092; CONNOLLY DT, 1991, J CELL BIOCHEM, V47, P219, DOI 10.1002/jcb.240470306; DELAGE S, 1993, CANCER RES, V53, P2762; Ferrara N, 1991, Growth Factors, V5, P141, DOI 10.3109/08977199109000278; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KIESER A, 1994, ONCOGENE, V9, P963; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; Rapp U R, 1987, Haematol Blood Transfus, V31, P450; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1988, LUNG CANCER, V4, P162; ROSEN KM, 1990, BIOTECHNIQUES, V8, P398; Rosenthal RA, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011010; Sambrook J, 1989, MOL CLONING LABORATO; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SENGER DR, 1986, CANCER RES, V46, P5629; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; STORM SM, 1993, TOXICOL LETT, V67, P201, DOI 10.1016/0378-4274(93)90056-4; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; ZHANG K, 1990, NATURE, V3346, P754; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	52	287	290	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25915	25919		10.1074/jbc.270.43.25915	http://dx.doi.org/10.1074/jbc.270.43.25915			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592779	hybrid			2022-12-27	WOS:A1995TB46600096
J	KAPAS, S; CATT, KJ; CLARK, AJL				KAPAS, S; CATT, KJ; CLARK, AJL			CLONING AND EXPRESSION OF CDNA-ENCODING A RAT ADRENOMEDULLIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HYPOTENSIVE PEPTIDE; MOLECULAR-CLONING; PROTEIN; GLOMERULOSA; FAMILY; LUNG	Adrenomedullin is a potent vasodilator peptide that exerts major effects on cardiovascular function. Its actions are mediated through an abundant class of specific binding sites that activate adenylyl cyclase through a G protein-coupled mechanism. We report here the identification of a cDNA clone for the adrenomedullin receptor that was originally isolated as an orphan receptor from rat lung. The cDNA encodes a polypeptide of 395 residues that contains seven transmembrane domains and has a general structural resemblance to other members of the G protein-linked receptor superfamily. When expressed in COS-7 cells, this receptor mediates a cAMP response to adrenomedullin with an EC(50) of 7 x 10(-9) M, and binds I-125-adrenomedullin with a K-D of 8.2 x 10(-9) M, properties that are consistent with those observed in cardiovascular and other target tissues. The receptor gene is expressed as several mRNA species of which the most prominent is a 1.8-kilobase transcript found in the Lung, adrenal, heart, spleen, cerebellum, and other sites. Identification of this receptor cDNA should facilitate further investigation of the cellular actions of adrenomedullin and its regulatory effects in normal and disordered states of cardiovascular function.	ST BARTHOLOMEWS HOSP,COLL MED,DEPT CHEM ENDOCRINOL,LONDON EC1A 7BE,ENGLAND; NICHHD,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892	University of London; Queen Mary University London; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK AJL, 1992, MOL ENDOCRINOL, V6, P1889, DOI 10.1210/me.6.11.1889; EGUCHI S, 1994, ENDOCRINOLOGY, V135, P2454, DOI 10.1210/en.135.6.2454; EGUCHI S, 1994, FEBS LETT, V340, P226, DOI 10.1016/0014-5793(94)80143-6; EVA C, 1993, DNA CELL BIOL, V12, P393, DOI 10.1089/dna.1993.12.393; FINEBERG AP, 1983, ANAL BIOCHEM, V132, P6; HARRISON JK, 1993, FEBS LETT, V318, P17, DOI 10.1016/0014-5793(93)81318-T; ICHIKI Y, 1994, FEBS LETT, V338, P6, DOI 10.1016/0014-5793(94)80106-1; ISHIYAMA Y, 1993, EUR J PHARMACOL, V241, P271, DOI 10.1016/0014-2999(93)90214-3; KANAZAWA H, 1994, BIOCHEM BIOPH RES CO, V205, P251, DOI 10.1006/bbrc.1994.2657; KAPAS S, 1992, J MOL ENDOCRINOL, V9, P47, DOI 10.1677/jme.0.0090047; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V194, P720, DOI 10.1006/bbrc.1993.1881; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LIPPTON H, 1994, J APPL PHYSIOL, V76, P2154, DOI 10.1152/jappl.1994.76.5.2154; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY TC, 1995, ENDOCRINOLOGY, V136, P2459, DOI 10.1210/en.136.6.2459; NUKI C, 1993, BIOCHEM BIOPH RES CO, V196, P245, DOI 10.1006/bbrc.1993.2241; OWJI AA, 1995, ENDOCRINOLOGY, V136, P2127, DOI 10.1210/en.136.5.2127; SAKATA J, 1993, BIOCHEM BIOPH RES CO, V195, P921, DOI 10.1006/bbrc.1993.2132; SAKATA J, 1994, FEBS LETT, V352, P105, DOI 10.1016/0014-5793(94)00928-7; Sambrook J, 1989, MOL CLONING LABORATO; SAMSON WK, 1995, ENDOCRINOLOGY, V136, P2349, DOI 10.1210/en.136.5.2349; SHIMEKAKE Y, 1995, J BIOL CHEM, V270, P4412, DOI 10.1074/jbc.270.9.4412; SUGO S, 1994, BIOCHEM BIOPH RES CO, V201, P1160, DOI 10.1006/bbrc.1994.1827; YAMAGUCHI T, 1964, LIFE SCI, V56, P379	30	259	275	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25344	25347		10.1074/jbc.270.43.25344	http://dx.doi.org/10.1074/jbc.270.43.25344			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592696	hybrid			2022-12-27	WOS:A1995TB46600012
J	LIN, YH; SHIN, EJ; CAMPBELL, MJ; NIEDERHUBER, JE				LIN, YH; SHIN, EJ; CAMPBELL, MJ; NIEDERHUBER, JE			TRANSCRIPTION OF THE BLK GENE IN HUMAN B-LYMPHOCYTES IS CONTROLLED BY 2 PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; FACTOR-BINDING SITES; MHC CLASS-II; NUCLEOPROTEIN STRUCTURES; IMMUNOGLOBULIN ENHANCER; ANTIGEN RECEPTOR; NUCLEAR FACTOR; ETS ONCOGENE; KINASE GENE; DNA-BINDING	Genomic DNA containing the first exon and 5'-flanking region of the human protein tyrosine kinase, blk, was isolated. Sequence analysis identified a TG repeat element in this region with enhancer activity, but no TATA or CCAAT sequences were found. Two blk transcripts of 2.2 and 2.5 kilobases were identified in various B-cell lines by Northern blot analyses, and primer extension experiments demonstrated two clusters of multiple transcription start sites. Subsequent promoter analyses by transient transfection assays with a reporter gene identified two promoter elements in the human blk gene. Promoter P1 contains sequences that have been shown to regulate the expression of immunoglobulin genes and promoter P2 contains elements that are highly conserved in the promoter of major histocompatibility complex class II genes, as well as a B-cell-specific activator protein- (BSAP) binding site. Electrophoretic mobility shift assays demonstrated that the binding of a protein to the BSAP-binding site was correlated with the presence of the 2.5-kilobase blk transcript. These data suggest that the two human blk RNAs arise from the transcription of the blk gene by two distinct promoters and that these promoters may be subject to regulation by different trans-acting factors.	STANFORD UNIV, SCH MED, DEPT SURG, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, STANFORD, CA USA	Stanford University; Stanford University								ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Ausubel FM, 1988, MOL REPROD DEV; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BERG DT, 1989, MOL CELL BIOL, V9, P5248, DOI 10.1128/MCB.9.11.5248; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHEN W, 1989, EMBO J, V8, P261, DOI 10.1002/j.1460-2075.1989.tb03372.x; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; DREBIN JA, 1995, ONCOGENE, V10, P477; DYKEMA JC, 1994, ENDOCRINOLOGY, V135, P702, DOI 10.1210/en.135.2.702; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; EGGEN BJL, 1994, MOL BRAIN RES, V23, P221, DOI 10.1016/0169-328X(94)90229-1; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; GAILLARD C, 1994, SCIENCE, V264, P433, DOI 10.1126/science.8153633; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMADA H, 1984, MOL CELL BIOL, V4, P2622, DOI 10.1128/MCB.4.12.2622; HERMANSON GG, 1989, P NATL ACAD SCI USA, V86, P7341, DOI 10.1073/pnas.86.19.7341; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; INGRAHAM HA, 1986, MOL CELL BIOL, V6, P2923, DOI 10.1128/MCB.6.8.2923; ISLAM KB, 1995, J IMMUNOL, V154, P1265; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P3155, DOI 10.1128/MCB.10.6.3155; LIN JJ, 1992, J IMMUNOL, V149, P1548; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; LOCK P, 1990, MOL CELL BIOL, V10, P4603, DOI 10.1128/MCB.10.9.4603; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; NELSEN B, 1990, MOL CELL BIOL, V10, P3145, DOI 10.1128/MCB.10.6.3145; PATEL M, 1990, ONCOGENE, V5, P201; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PETERSON CL, 1988, MOL CELL BIOL, V8, P4972, DOI 10.1128/MCB.8.11.4972; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; ROSEN KM, 1990, BIOTECHNIQUES, V8, P398; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHAW P, 1985, CELL, V40, P907, DOI 10.1016/0092-8674(85)90350-2; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TEDDER TF, 1989, J IMMUNOL, V143, P712; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; UCHIUMI F, 1992, MOL CELL BIOL, V12, P3784, DOI 10.1128/MCB.12.9.3784; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZWOLLO P, 1994, J BIOL CHEM, V269, P15310	60	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25968	25975		10.1074/jbc.270.43.25968	http://dx.doi.org/10.1074/jbc.270.43.25968			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592787	hybrid			2022-12-27	WOS:A1995TB46600104
J	NOLAND, TA; GUO, XD; RAYNOR, RL; JIDEAMA, NM; AVERYHARTFULLARD, V; SOLARO, RJ; KUO, JF				NOLAND, TA; GUO, XD; RAYNOR, RL; JIDEAMA, NM; AVERYHARTFULLARD, V; SOLARO, RJ; KUO, JF			CARDIAC TROPONIN-I MUTANTS - PHOSPHORYLATION BY PROTEIN-KINASE-C AND PROTEIN-KINASE-A AND REGULATION OF CA2+-STIMULATED MGATPASE OF RECONSTITUTED ACTOMYOSIN S-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MYOSIN LIGHT CHAIN-2; RAT-HEART MYOCYTES; BIOLOGICAL-ACTIVITY; SKELETAL-MUSCLE; INHIBITORY REGION; ANGIOTENSIN-II; VENTRICULAR MYOCYTES; PHORBOL ESTERS; ADRENERGIC-STIMULATION	The significance of site-specific phosphorylation of cardiac troponin I (TnI) by protein kinase C and protein kinase A in the regulation of Ca2+-stimulated MgATPase of reconstituted actomyosin S-1 was investigated. The TnI mutants used were T144A, S43A/S45A, and S43A/S45A/T144A (in which the identified protein kinase C phosphorylation sites, Thr-144 and Ser-43/ Ser-45, were, respectively, substituted by Ala) and S23A/S24A and N32 (in which the protein kinase A phosphorylation sites Ser-23/Ser-24 were either substituted by Ala or deleted). The mutations caused subtle changes in the kinetics of phosphorylation by protein kinase C, and all mutants were maximally phosphorylated to various extents (1.3-2.7 mol of phosphate/mol of protein). Protein kinase C could cross-phosphorylate protein kinase A sites but the reverse essentially could not occur. Compared to wild-type TnI and T144A, unphosphorylated S43A/S45A, S43A/S45A/T144, S23A/ S24A, and N32 caused a decreased Ca2+ sensitivity of Ca2+-stimulated MgATPase of reconstituted actomyosin S-1. Phosphorylation by protein kinase C of wildtype and all mutants except S43A/S45A and S43A/S45A/ T144A caused marked reductions in both the maximal activity of Ca2+-stimulated MgATPase and apparent affinity of myosin S-1 for reconstituted (regulated) actin. It was further noted that protein kinase C acted in an additive manner with protein kinase A by phosphorylating Ser-23/Ser-24 to bring about a decreased Ca2+ sensitivity of the myofilament. It is suggested that Ser-43/Ser-45 and Ser-23/Ser-24 in cardiac TnI are important for normal Ca2+ sensitivity of the myofilament, and that phosphorylation of Ser-43/ Ser-45 and Ser-23/Ser-24 is primarily involved in the protein kinase C regulation of the activity and Ca(2+)sensitivity, respectively, of actomyosin S-1 MgATPase.	UNIV ILLINOIS,COLL MED,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	NOLAND, TA (corresponding author), EMORY UNIV,SCH MED,DEPT PHARMACOL,ATLANTA,GA 30322, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022231, R01HL049934, R37HL015696, R37HL022231, R01HL015696] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL15696, HL49934, HL22231] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN IS, 1988, CIRC RES, V62, P524, DOI 10.1161/01.RES.62.3.524; BAKER KM, 1988, CIRC RES, V62, P896, DOI 10.1161/01.RES.62.5.896; BAKER KM, 1989, J PHARMACOL EXP THER, V251, P578; BALL KL, 1994, BIOCHEMISTRY-US, V33, P8464, DOI 10.1021/bi00194a010; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CAPOGROSSI MC, 1990, CIRC RES, V66, P1143, DOI 10.1161/01.RES.66.4.1143; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CHONG PCS, 1982, J BIOL CHEM, V257, P1667; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DOSEMECI A, 1988, CIRC RES, V62, P347, DOI 10.1161/01.RES.62.2.347; ELSALEH SC, 1988, J BIOL CHEM, V263, P3274; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FARAH CS, 1994, J BIOL CHEM, V269, P5230; GAMBASSI G, 1992, CIRC RES, V71, P870, DOI 10.1161/01.RES.71.4.870; GIRARD PR, 1986, J BIOL CHEM, V261, P370; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GUO XD, 1994, J BIOL CHEM, V269, P15210; HELFMAN DM, 1983, CANCER RES, V43, P2955; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; INGRAHAM RH, 1988, BIOCHEMISTRY-US, V27, P5891, DOI 10.1021/bi00416a011; KAKU T, 1991, AM J PHYSIOL, V260, pC635, DOI 10.1152/ajpcell.1991.260.3.C635; KATOH N, 1983, BIOCHEM J, V209, P189, DOI 10.1042/bj2090189; KOHL C, 1990, BRIT J PHARMACOL, V101, P829, DOI 10.1111/j.1476-5381.1990.tb14165.x; KRAMER BK, 1991, CIRC RES, V68, P269, DOI 10.1161/01.RES.68.1.269; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERMAN GF, 1987, AM J PHYSIOL, V253, pH205, DOI 10.1152/ajpheart.1987.253.1.H205; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P2821, DOI 10.1021/bi00408a024; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; MARTIN AF, 1991, CIRC RES, V69, P1244, DOI 10.1161/01.RES.69.5.1244; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; NGAI SM, 1992, J BIOL CHEM, V267, P15715; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOLAND TA, 1993, J MOL CELL CARDIOL, V25, P53, DOI 10.1006/jmcc.1993.1007; NOLAND TA, 1993, BIOCHEM BIOPH RES CO, V193, P254, DOI 10.1006/bbrc.1993.1617; NOLAND TA, 1989, J BIOL CHEM, V264, P20778; NOLAND TA, 1991, J BIOL CHEM, V266, P4974; NOLAND TA, 1992, BIOCHEM J, V288, P123, DOI 10.1042/bj2880123; OISHI K, 1990, J BIOL CHEM, V265, P70; OTANI H, 1988, CIRC RES, V62, P8, DOI 10.1161/01.RES.62.1.8; OTANI H, 1990, BRIT J PHARMACOL, V100, P207, DOI 10.1111/j.1476-5381.1990.tb15783.x; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POTTER JD, 1982, METHOD ENZYMOL, V85, P164; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; PUCEAT M, 1994, PROTEIN KINASE C, P249; ROGERS TB, 1990, J BIOL CHEM, V265, P4302; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; SHENG Z, 1993, BIOPHYS J, V64, pA136; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; Solaro R.J., 1995, PHYSL PATHOPHYSIOLOG, P355; SOLARO RJ, 1986, CIRC RES, V58, P721, DOI 10.1161/01.RES.58.5.721; SOLARO RJ, 1986, PROTEIN PHOSPHORYLAT; STEINBERG SF, 1989, J PHARMACOL EXP THER, V250, P1141; STULL JT, 1977, J BIOL CHEM, V252, P851; SWIDEREK K, 1990, EUR J BIOCHEM, V190, P575, DOI 10.1111/j.1432-1033.1990.tb15612.x; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2374; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TERZIC A, 1992, J PHYSIOL-LONDON, V447, P275, DOI 10.1113/jphysiol.1992.sp019002; TOBACMAN LS, 1988, J BIOL CHEM, V263, P2668; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; VENEMA RC, 1993, J BIOL CHEM, V268, P2705; VENEMA RC, 1993, BIOCHEM J, V294, P401, DOI 10.1042/bj2940401; VENTURA C, 1992, CIRC RES, V70, P66, DOI 10.1161/01.RES.70.1.66; VIGNE P, 1989, FEBS LETT, V249, P143, DOI 10.1016/0014-5793(89)80611-8; WATTANAPERMPOOL J, 1995, AM J PHYSIOL-CELL PH, V268, pC323, DOI 10.1152/ajpcell.1995.268.2.C323; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048; WOODCOCK EA, 1987, CIRC RES, V61, P625, DOI 10.1161/01.RES.61.5.625; YUAN SH, 1987, CIRC RES, V61, P372, DOI 10.1161/01.RES.61.3.372; ZHENG B, 1994, J BIOL CHEM, V269, P12332; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	79	151	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25445	25454		10.1074/jbc.270.43.25445	http://dx.doi.org/10.1074/jbc.270.43.25445			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592712	hybrid			2022-12-27	WOS:A1995TB46600028
J	SPAIN, BH; KOO, D; RAMAKRISHNAN, M; DZUDZOR, B; COLICELLI, J				SPAIN, BH; KOO, D; RAMAKRISHNAN, M; DZUDZOR, B; COLICELLI, J			TRUNCATED FORMS OF A NOVEL YEAST PROTEIN SUPPRESS THE LETHALITY OF A G-PROTEIN ALPHA-SUBUNIT DEFICIENCY BY INTERACTING WITH THE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; SACCHAROMYCES-CEREVISIAE; PHEROMONE RESPONSE; FACTOR RECEPTOR; MATING PHEROMONE; ADENYLYL CYCLASE; GAMMA-SUBUNITS; ADAPTIVE RESPONSE; SURFACE PROTEIN; CELL-FUSION	In Saccharomyces cerevisiae, the mating pheromone-initiated signal is transduced by a heterotrimeric G protein and normally results in transient cell cycle arrest and differentiation. A null allele of the G alpha (GPA1/SCG1) subunit results in cell death due to unchecked signaling from the G beta gamma (STE4, STE18, respectively) heterodimer, We have identified three high copy suppressors of gpa1 lethality, Two of these genes encode known transcription factors, Mat alpha 2p and Mcm1p, The third is a truncated form of a novel gene, SYG1, Overexpressed wild type SYG1 is a weak suppressor of gpa1. In contrast, the isolated mutant allele SYG1-1 is a strong suppressor that completely blocks the cell cycle arrest and differentiation phenotypes of gpa1 cells of both mating types, One deletion mutant (SYG1 Delta 340) can suppress the cell cycle arrest associated with gpa1, but the cells retain a differentiated morphology, SYG1-1 can suppress the effects of overexpressed wild type G beta but is not able to suppress the lethality of an activated G beta mutant (STE4(Hpl)). Consistent with these genetic observations, the suppressing form of Syg1p can interact with the STE4 gene product, as determined by a two-hybrid assay, SYG1-1 is also capable of promoting pheromone recovery in wild type cells, as judged by halo assay. The sequence of SYG1 predicts eight membrane-spanning domains, Deletion mutants of SYG1 indicate that complete gpa1 suppression requires removal of all of these hydrophobic regions, Interestingly, this truncated protein localizes to the same plasma membrane-enriched subcellular fraction as does full-length Syg1p. Three hypothetical yeast proteins, identified by their similarity to the SYG1 primary sequence within the gpa1 suppression domain, also appear to have related structures, The properties of Syg1p are consistent with those of a transmembrane signaling component that can respond to, or transduce signals through, G beta or G beta gamma.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, STRUCT BIOL & MOLEC MED LAB, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [R01 CA 56301] Funding Source: Medline; NIGMS NIH HHS [GM-07104] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CLARK KL, 1993, MOL CELL BIOL, V13, P1; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; COLICELLI J, 1991, P NATL ACAD SCI USA, V88, P2913, DOI 10.1073/pnas.88.7.2913; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CROSS FR, 1990, GENETICS, V126, P301; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GRISHIN AV, 1994, GENETICS, V138, P1081; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGEN DC, 1991, MOL CELL BIOL, V11, P2952, DOI 10.1128/MCB.11.6.2952; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HARE JF, 1994, J BIOL CHEM, V269, P5981; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIRSCH JP, 1992, BIOESSAYS, V14, P367, DOI 10.1002/bies.950140604; HIRSCH JP, 1993, GENETICS, V135, P943; JAHNG KY, 1988, MOL CELL BIOL, V8, P2484, DOI 10.1128/MCB.8.6.2484; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KONOPKA JB, 1993, MOL CELL BIOL, V13, P6876, DOI 10.1128/MCB.13.11.6876; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE RH, 1992, J BIOL CHEM, V267, P25104; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; PAPASAVVAS S, 1992, BIOCHEM BIOPH RES CO, V184, P1378, DOI 10.1016/S0006-291X(05)80035-X; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PILLAI R, 1993, P NATL ACAD SCI USA, V90, P11970, DOI 10.1073/pnas.90.24.11970; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Schwarz R, 1979, ATLAS PROTEIN SEQUEN, P353, DOI DOI 10.2307/2408678; SIKORSKI RS, 1989, GENETICS, V122, P19; Sprague G F Jr, 1990, Adv Genet, V27, P33; SRINIVASA RT, 1994, J LEUKOCYTE BIOL, V55, P192; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; TAN PK, 1993, J CELL BIOL, V123, P1707, DOI 10.1083/jcb.123.6.1707; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WEINER JL, 1993, J BIOL CHEM, V268, P8070; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; ZHANG M, 1993, MOL MICROBIOL, V9, P813, DOI 10.1111/j.1365-2958.1993.tb01740.x	63	83	90	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25435	25444		10.1074/jbc.270.43.25435	http://dx.doi.org/10.1074/jbc.270.43.25435			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592711	hybrid			2022-12-27	WOS:A1995TB46600027
J	GERLACH, MS; KHARITONENKOV, A; VOGEL, W; ALI, S; ULLRICH, A				GERLACH, MS; KHARITONENKOV, A; VOGEL, W; ALI, S; ULLRICH, A			PROTEIN-TYROSINE-PHOSPHATASE 1D MODULATES ITS OWN STATE OF TYROSINE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; INSULIN-RECEPTOR SUBSTRATE-1; BINDING-SITE; IRS-1; CELLS; ACTIVATION; DOMAINS; CLONING; SH-PTP2; KINASE	The insulin receptor-mediated signal transduction pathway involves insulin receptor substrate 1 and a variety of proteins containing Src homology-g (SH2) domains, such as phosphatidylinositol S-kinase, Grb2, and protein-tyrosine phosphatase 1D (PTP1D). Upon insulin stimulation of baby hamster kidney cells overexpressing the IR, the catalytically inactive mutant of PTP1D, C463A, becomes tyrosine-phosphorylated and coprecipitates with Grb2. Tyrosine phosphorylation of this mutant is significantly reduced when wild type PTP1D is coexpressed. Substitution of tyrosine residues 546 and 584 with phenylalanine abrogates tyrosine phosphorylation of the catalytically inactive mutant and abolishes its interaction with Grb2.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society								ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BASTIEN L, 1993, BIOCHEM BIOPH RES CO, V196, P124, DOI 10.1006/bbrc.1993.2224; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GUAN K, 1990, SCIENCE, V269, P553; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MAEGAWA H, 1994, BIOCHEM BIOPH RES CO, V199, P780, DOI 10.1006/bbrc.1994.1297; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P108; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH RA, 1983, SCIENCE, V219, P299, DOI 10.1126/science.6849137; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780	37	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24635	24637		10.1074/jbc.270.42.24635	http://dx.doi.org/10.1074/jbc.270.42.24635			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559570	hybrid			2022-12-27	WOS:A1995TB46500004
J	BERRYMAN, DE; BENSADOUN, A				BERRYMAN, DE; BENSADOUN, A			HEPARAN-SULFATE PROTEOGLYCANS ARE PRIMARILY RESPONSIBLE FOR THE MAINTENANCE OF ENZYME-ACTIVITY, BINDING, AND DEGRADATION OF LIPOPROTEIN-LIPASE IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; LOW-DENSITY; ENDOTHELIAL-CELLS; ALPHA-2-MACROGLOBULIN RECEPTOR; INACTIVE FORMS; BOVINE-MILK; METABOLISM; ADIPOCYTES; SECRETION; BIOSYNTHESIS	Various aspects of lipoprotein lipase (LPL) metabolism, including cell surface binding, degradation, and enzymatic activity, were compared between Chinese hamster ovary (CHO) cells and two distinct proteoglycan-deficient CHO cell lines. The contribution of low density lipoprotein receptor-related protein in binding LPL was also analyzed by the use of a 39-kDa receptor associated protein expressed as a glutathione S-transferase fusion protein (GST-RAP), Equilibrium binding data with I-125-LPL revealed the presence of a class of high affinity binding sites with a K-D of 7.8 nM in CHO cells, whereas no high affinity binding was observed for proteoglycan-deficient cells. The high affinity binding of LPL in CHO cells appeared to be concentrated in cell surface projections and was not effectively inhibited by GST-RAP. Moreover, degradation of endogenous and exogenous LPL was significantly greater in control CHO cells than in proteoglycan-deficient cells. Degradation of LPL in CHO cells was not affected by GST-RAP, suggesting that proteoglycans and not low density lipoprotein receptor-related protein are responsible for the majority of binding and degradation of LPL in these cells, Our data also show that proteoglycan binding is not essential for the assembly of active LPL homodimers, although proteoglycan binding controls the distribution of LPL activity, Furthermore, LPL produced by CHO cells was more stable than LPL produced by proteoglycan-deficient cells.	CORNELL UNIV,DIV NUTR SCI,ITHACA,NY 14853; CORNELL UNIV,DIV BIOL SCI,ITHACA,NY 14853	Cornell University; Cornell University				Berryman, Darlene/0000-0003-4240-9229	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014990] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-14990] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENGTSSONOLIVEC.G, 1985, BIOCHEM J, V226, P409; BENSADOU.A, 1974, J BIOL CHEM, V249, P2220; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BERRYMAN DE, 1993, J BIOL CHEM, V268, P3272; BIERMAN EL, 1974, CIRC RES, V35, P136, DOI 10.1161/01.RES.35.1.136; CHAJEKSHAUL T, 1989, BIOCHIM BIOPHYS ACTA, V1014, P178, DOI 10.1016/0167-4889(89)90031-1; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001; CHENG CF, 1981, J BIOL CHEM, V256, P2893; CHEUNG AH, 1979, ANAL BIOCHEM, V94, P346, DOI 10.1016/0003-2697(79)90371-3; CHOI SY, 1993, J BIOL CHEM, V268, P15804; CISAR LA, 1989, J BIOL CHEM, V264, P1767; CRYER A, 1981, INT J BIOCHEM, V13, P525, DOI 10.1016/0020-711X(81)90177-4; CUPP M, 1987, J BIOL CHEM, V262, P6383; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; EVANS AJ, 1972, INT J BIOCHEM, V3, P199, DOI 10.1016/0020-711X(72)90080-8; HERZ J, 1991, J BIOL CHEM, V266, P21232; IVERIUS PH, 1972, J BIOL CHEM, V247, P6610; JI ZS, 1993, J BIOL CHEM, V268, P10160; KORN ED, 1955, J BIOL CHEM, V215, P1; KORN ED, 1956, J BIOL CHEM, V219, P833; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LIU GQ, 1993, BIOCHEM J, V292, P277, DOI 10.1042/bj2920277; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; OLIVECRONA T, 1987, J BIOL CHEM, V262, P10748; OLIVERCONA T, 1987, LIPOPROTEIN LIPASE, P71; PETERSON J, 1992, J LIPID RES, V33, P1165; ROJAS C, 1990, BIOCHEM J, V271, P11, DOI 10.1042/bj2710011; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SEHAYEK E, 1995, ATHEROSCLEROSIS, V114, P1, DOI 10.1016/0021-9150(94)05455-R; SEMB H, 1987, BIOCHIM BIOPHYS ACTA, V921, P104, DOI 10.1016/0005-2760(87)90176-7; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; SIVARAM P, 1992, J BIOL CHEM, V267, P16517; STEWART JE, 1974, J BIOL CHEM, V249, P904; WANGIVERSON P, 1982, ANN NY ACAD SCI, V401, P92, DOI 10.1111/j.1749-6632.1982.tb25710.x; WILLIAMS MP, 1983, BIOCHIM BIOPHYS ACTA, V756, P83, DOI 10.1016/0304-4165(83)90027-2; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YAMASHIRO DJ, 1989, J CELL PHYSIOL, V139, P377, DOI 10.1002/jcp.1041390221; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	51	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24525	24531		10.1074/jbc.270.41.24525	http://dx.doi.org/10.1074/jbc.270.41.24525			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592670	hybrid			2022-12-27	WOS:A1995TA21700098
J	WHITE, T; BENNETT, EP; TAKIO, K; SORENSEN, T; BONDING, N; CLAUSEN, H				WHITE, T; BENNETT, EP; TAKIO, K; SORENSEN, T; BONDING, N; CLAUSEN, H			PURIFICATION AND CDNA CLONING OF A HUMAN UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE-POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYLTRANSFERASE GENE FAMILY; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; HUMAN FIBRONECTIN; EXPRESSION; GALNAC; PROTEINS; GLYCOSYLATION; SPECIFICITY; TRANSFERASE	A UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferase (GalNAc-transferase) from human placenta was purified to apparent homogeneity using a synthetic acceptor peptide as affinity ligand. The purified GalNAc-transferase migrated as a single band with an approximate molecular weight of 52,000 by reducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Based on a partial amino acid sequence, the cDNA encoding the transferase was cloned and sequenced from a cDNA library of a human cancer cell line. The cDNA sequence has a 571-amino acid coding region in indicating a protein of 64.7 kDa with a type II domain structure. The deduced protein sequence showed significant similarity to a recently cloned bovine polypeptide GalNAc-transferase (Homa, F. L., Hollanders, T., Lehman, D. J., Thomsen, D. R., and Elhammer, Angstrom P. (1993) J. Biol. Chem, 268, 12609-12616), A polymerase chain reaction construct was expressed in insect cells using a baculovirus vector, Northern analysis of eight human tissues differed clearly from that of the bovine GalNAc-transferase. Polymerase chain reaction cloning and sequencing of the human version of the bovine transferase are presented, and 98% similarity at the amino acid level was found. The data suggest that the purified human GalNAc-transferase is a novel member of a family of polypeptide GalNAc-transferases, and a nomenclature GalNAc-T1 and GalNAc-T2 is introduced to distinguish the members.			WHITE, T (corresponding author), UNIV COPENHAGEN, SCH DENT, FAC HLTH SCI, DEPT ORAL DIAGNOST, NORRE ALLE 20, DK-2200 COPENHAGEN N, DENMARK.		Bennett, Eric/AAG-6120-2020; clausen, henrik/AAD-8016-2021	Bennett, Eric/0000-0002-4976-0647; 				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BENDIAK B, 1993, EUR J BIOCHEM, V216, P405, DOI 10.1111/j.1432-1033.1993.tb18158.x; BENNETT EP, 1995, BIOCHEM BIOPH RES CO, V206, P318, DOI 10.1006/bbrc.1995.1044; BIRKEN S, 1981, J BIOL CHEM, V256, P1816; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAUSEN H, 1990, J BIOL CHEM, V265, P1139; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GUM JR, 1989, J BIOL CHEM, V264, P6480; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOMA FL, 1993, J BIOL CHEM, V268, P12609; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JOZIASSE DH, 1991, J BIOL CHEM, V266, P6991; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MANDEL U, 1994, APMIS, V102, P695, DOI 10.1111/j.1699-0463.1994.tb05222.x; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; MATSUURA H, 1989, J BIOL CHEM, V264, P10472; MATSUURA H, 1988, J BIOL CHEM, V263, P3314; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Ruegg U T, 1977, Methods Enzymol, V47, P111; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUGIURA M, 1982, J BIOL CHEM, V257, P9501; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WANG Y, 1993, J BIOL CHEM, V268, P22979; WANG YC, 1992, J BIOL CHEM, V267, P2728; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P21011; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146	40	183	223	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24156	24165		10.1074/jbc.270.41.24156	http://dx.doi.org/10.1074/jbc.270.41.24156			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592619	hybrid			2022-12-27	WOS:A1995TA21700047
J	DEVERAUX, Q; JENSEN, C; RECHSTEINER, M				DEVERAUX, Q; JENSEN, C; RECHSTEINER, M			MOLECULAR CLONING AND EXPRESSION OF A 26-S-PROTEASE SUBUNIT ENRICHED IN DILEUCINE REPEATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT RETICULOCYTE LYSATE; UBIQUITIN; CYCLIN	The 26 S protease is a multisubunit enzyme required for ubiquitin-dependent proteolysis. Recently, we identified a 50-kDa subunit (S5) of this enzyme that binds ubiquitin polymers (Deveraux, Q., Ustrell, V., Pickart, C., and Rechsteiner, M. (1994) J. Biol. Chem. 269, 7059-7061). We have now isolated, sequenced, and expressed a cDNA encoding a novel 50-kDa subunit of the 26 S protease. The recombinant protein does not bind ubiquitin polymers. Two-dimensional electrophoresis reveals that two subunits of the 26 S protease have apparent molecular masses of 50 kDa. Antibodies specific for the recombinant protein recognize the more basic of the two subunits (S5b), whereas the more acidic subunit (S5a) binds ubiquitin chains. Thus, the 26 S protease contains at least two distinct subunits with apparent molecular masses of 50 kDa.	UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah					NIGMS NIH HHS [GM37009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVERAUX Q, 1990, J BIOL CHEM, V265, P6323; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1987, J BIOL CHEM, V262, P8303; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; MORI S, 1993, J BIOL CHEM, V268, P577; PICKART CM, 1992, J BIOL CHEM, V267, P14418; REALINI C, 1994, J BIOL CHEM, V269, P20727; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065	17	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23726	23729		10.1074/jbc.270.40.23726	http://dx.doi.org/10.1074/jbc.270.40.23726			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559544	hybrid			2022-12-27	WOS:A1995RY90900073
J	ELSON, A; LEDER, P				ELSON, A; LEDER, P			PROTEIN-TYROSINE-PHOSPHATASE-EPSILON - AN ISOFORM SPECIFICALLY EXPRESSED IN MOUSE MAMMARY-TUMORS INITIATED BY V-HA-RAS OR NEU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; GENE-PRODUCT; ONCOGENE; TRANSFORMATION; CLONING; FAMILY; MEMBER; ACID; OVEREXPRESSION; IDENTIFICATION	Transgenic mice that overexpress v-Ha-ras, c-myc, c-neu or int-2 proto-oncogenes in the mammary epithelium develop breast tumors with morphologies that are characteristic of each initiating oncogene, Since these morphological differences reflect distinctive patterns of tumor-specific gene expression, the identification of the products of these genes might shed light on the mechanisms of transformation and/or the identity of target cells that are transformed by specific classes of oncogenes, By focusing on the tyrosine phosphorylation pathway, we have found that the transmembranal protein-tyrosine phosphatase epsilon (PTP epsilon) is highly expressed in murine mammary tumors initiated by c-neu and v-Ha-ras, but not in mammary tumors initiated by c-myc or int-2. This difference is striking and occurs both in primary tumors and in epithelial cells cultured from them, Moreover, PTP epsilon overexpression appears to be mammary tumor-specific in that it is not found in other ras-based tumors and cell lines, These observations suggest that PTP epsilon either plays a role in ras- and neu-mediated transformation of mammary epithelium or marks mammary epithelial cells particularly susceptible to transformation by these oncogenes, Because of its distinctive expression in these mammary tumors, we have further characterized murine PTP epsilon, cloning and determining the complete structures of its cDNAs and showing that it is a glycoprotein that is N-glycosylated in a tissue-specific manner.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Howard Hughes Medical Institute				Elson, Ari/0000-0001-9808-9135	NATIONAL CANCER INSTITUTE [P20CA058203] Funding Source: NIH RePORTER; NCI NIH HHS [P20CA58203-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BENALLAL M, 1994, EXPERIENTIA, V50, P664, DOI 10.1007/BF01952869; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BOEHM T, 1993, ONCOGENE, V8, P1385; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; DAUM G, 1994, J BIOL CHEM, V269, P10524; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GUAN K, 1991, J BIOL CHEM, V266, P12964; HARLOW E, 1988, ANTIBODIES LABORATOR; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JANES PW, 1994, ONCOGENE, V9, P3601; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KARLUND JK, 1985, CELL, V41, P707; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MONGKOLSUK S, 1988, GENE, V70, P313, DOI 10.1016/0378-1119(88)90203-X; MORRISON BW, 1994, ONCOGENE, V9, P3417; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; REARDON DB, 1993, J BIOL CHEM, V268, P18136; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YI TL, 1991, BLOOD, V78, P2222; ZANDER NF, 1993, ONCOGENE, V8, P1175; ZHAI YF, 1993, CANCER RES, V53, P2272; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	46	84	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26116	26122		10.1074/jbc.270.44.26116	http://dx.doi.org/10.1074/jbc.270.44.26116			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592814	hybrid			2022-12-27	WOS:A1995TC97800021
J	FUKUDA, M; KOJIMA, T; ARUGA, J; NIINOBE, M; MIKOSHIBA, K				FUKUDA, M; KOJIMA, T; ARUGA, J; NIINOBE, M; MIKOSHIBA, K			FUNCTIONAL DIVERSITY OF C2 DOMAINS OF SYNAPTOTAGMIN FAMILY - MUTATIONAL ANALYSIS OF INOSITOL HIGH POLYPHOSPHATE BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTRANSMITTER RELEASE; MEMBRANE-PROTEIN; DROSOPHILA; P65; EXOCYTOSIS; MUTANTS	Synaptotagmins I and II are inositol high polyphosphate series (inositol 1,3,4,5-tetrakisphosphate (IP4), inositol 1,3,4,5,6-pentakisphosphate, and inositol 1,2,3,4,5,6-hexakisphosphate) binding proteins, which are thought to be essential for Ca2+-regulated exocytosis of neurosecretory vesicles. In this study, we analyzed the inositol high polyphosphate series binding site in the C2B domain by site-directed mutagenesis and compared the IP4 binding properties of the C2B domains of multiple synaptotagmins (II-IV). The IP4 binding domain of synaptotagmin II is characterized by a cluster of highly conserved, positively charged amino acids (321 GKRLKKKKTTVKKK 324). Among these, three lysine residues, at positions 327, 328, and 332 in the middle of the C2B domain, which is not conserved in the C2A domain, were found to be essential for IF, binding in synaptotagmin II, When these lysine residues were altered to glutamine, the IP4 binding ability was completely abolished. The primary structures of the IP4 binding sites are highly conserved among synaptotagmins I through IV. However, synaptotagmin III did not show significant binding ability, which may be due to steric hindrance by the C-terminal flanking region. These functional diversities of C2B domains suggest that not all synaptotagmins function as inositol high polyphosphate sensors at the synaptic vesicle.	UNIV TOKYO,INST MED SCI,DEPT MOLEC NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	University of Tokyo; Osaka University	FUKUDA, M (corresponding author), INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC NEUROBIOL LAB,3-1-1 KOYADAI,TSUKUBA,IBARAKI 305,JAPAN.		Aruga, Jun/H-5837-2011; Fukuda, MItsunori/I-1511-2015; Mikoshiba, Katsuhiko/N-7943-2015	Aruga, Jun/0000-0001-7936-1375; Fukuda, MItsunori/0000-0002-8620-5853; 				BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; DAMER CK, 1994, J BIOL CHEM, V269, P31115; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Hilbush B. S., 1994, Society for Neuroscience Abstracts, V20, P455; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1994, J BIOL CHEM, V269, P8576; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	28	168	168	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26523	26527		10.1074/jbc.270.44.26523	http://dx.doi.org/10.1074/jbc.270.44.26523			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592870	hybrid			2022-12-27	WOS:A1995TC97800077
J	NISHIMURA, M; UYEDA, K				NISHIMURA, M; UYEDA, K			PURIFICATION AND CHARACTERIZATION OF A NOVEL XYLULOSE 5-PHOSPHATE-ACTIVATED PROTEIN PHOSPHATASE CATALYZING DEPHOSPHORYLATION OF FRUCTOSE-6-PHOSPHATE,2-KINASE - FRUCTOSE-2,6-BISPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CATALYTIC SUBUNIT; B-SUBUNIT; TYPE-2A; FORMS; PHOSPHORYLATION; SEQUENCE; KINASE; GLYCOLYSIS; QUANTITIES	We have shown previously (Nishimura, M., Fedorov, S., and Uyeda, K, (1994) (J, Biol, Chem, 269, 26100-26106) that the administration of high concentrations of glu cose stimulates dephosphorylation of Fru-6-P,a kinase: Fru-2,6-bisphosphatase in perfused liver, and xylulose (Xu) 5-P activates the dephosphorylation reaction, To characterize the protein phosphatase, we have purified the Xu Ei-P-activated protein phosphatase to homogeneity from livers of rats injected with high glucose, Several protein phosphatases in the livers were separated by DEAE cellulose chromatography, but only one peak of the enzyme was activated by Xu 5 P. The protein phosphatase was inhibited by okadaic acid (IC50 = 1-3 nM) and did not require Mg2+ or Ca2+, suggesting that the enzyme was type 2A, The enzyme was a heterotrimer (M(r) = 150,000) and consisted of structural (A, 65 kDa), catalytic (C, 36 kDa), and regulatory (B, 52 M)a) subunits, Amino acid sequences of five tryptic peptides derived from the B subunit showed similarity with those of the B alpha isoform of rat protein phosphatase 2A, but five out of 73 residues were different, The protein phosphatase catalyzed dephosphorylation of Fru-6-P,2-kinase:Fru-2,6-Pase, phosphorylase K-m and pyruvate kinase, and the K, values were 0.8 mu M, 3.7 mu M, and 2.2 mu M, respectively, Among these substrates dephosphorylation of only the bifunctional enzyme was activated by Xu 5-P, and the K-a value for Xu 5-P was 20 ELM. Xu 5 P was the only sugar phosphate which activated the PP2A among all the sugar phosphates examined. These results demonstrated the existence and isolation of a unique heterotrimeric protein phosphatase 2A in rat liver which catalyzed the dephosphorylation of Fru-6-P,2-kinase:Fru-2,6-Pase and was activated specifically by Xu 5-P, The Xu 5-P-activated protein phosphatase 2A explains the increased Fru 2,6-P-2 level in liver after high glucose administration.	DEPT VET AFFAIRS MED CTR, DALLAS, TX 75216 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75216 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASAZZA JP, 1986, BIOCHEM J, V236, P635, DOI 10.1042/bj2360635; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; ELMAGHRABI MR, 1982, P NATL ACAD SCI-BIOL, V79, P315, DOI 10.1073/pnas.79.2.315; FURUYA E, 1982, P NATL ACAD SCI-BIOL, V79, P325, DOI 10.1073/pnas.79.2.325; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KOHL EA, 1976, ARCH BIOCHEM BIOPHYS, V176, P671, DOI 10.1016/0003-9861(76)90211-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NISHIMURA M, 1994, J BIOL CHEM, V269, P26100; ORGAD S, 1990, FEBS LETT, V275, P44, DOI 10.1016/0014-5793(90)81435-Q; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PELECH S, 1984, EUR J BIOCHEM, V145, P39, DOI 10.1111/j.1432-1033.1984.tb08519.x; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SAKAKIBARA R, 1984, J BIOL CHEM, V259, P41; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; TOMINAGA N, 1993, J BIOL CHEM, V268, P15951; USUI H, 1988, J BIOL CHEM, V263, P3752; VANSCHAFTINGEN E, 1981, BIOCHEM BIOPH RES CO, V103, P362, DOI 10.1016/0006-291X(81)91701-0; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; YUEDA K, 1991, CRC REV, V2, P445	36	92	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26341	26346		10.1074/jbc.270.44.26341	http://dx.doi.org/10.1074/jbc.270.44.26341			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592845	hybrid			2022-12-27	WOS:A1995TC97800052
J	BAZZONI, G; SHIH, DT; BUCK, CA; HEMLER, ME				BAZZONI, G; SHIH, DT; BUCK, CA; HEMLER, ME			MONOCLONAL-ANTIBODY 9EG7 DEFINES A NOVEL BETA(1) INTEGRIN EPITOPE INDUCED BY SOLUBLE LIGAND AND MANGANESE, BUT INHIBITED BY CALCIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA COMPLEX; CELL-ADHESION MOLECULE-1; PLATELET GPIIB-IIIA; FIBRONECTIN RECEPTOR; BETA-1 SUBUNIT; T-CELLS; AFFINITY MODULATION; FIBRINOGEN BINDING; CYTOPLASMIC DOMAIN; DIVALENT-CATIONS	The monoclonal antibody 9EG7 has been previously found to recognize an epitope induced by manganese on the integrin beta(1) chain (Lenter, M., Uhlig, H., Hamann, A., Jeno, P., Imhof, B., and Vestweber, D. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 9051-9055). Here we show that treatment of beta(1) integrins with manganese or soluble integrin ligands (e.g. fibronectin and RGD peptide) induced the 9EG7 epitope. This epitope was also induced upon EGTA treatment to remove calcium, and the addition of calcium inhibited 9EG7 epitope induction by manganese or by Ligand. Further emphasizing the importance of the 9EG7 epitope, the 9EG7 antibody itself stimulated adhesion mediated by multiple beta(1) integrins, and conversely, ligands for alpha(2) beta(1), alpha(3) beta(1), alpha(4) beta(1), and alpha(5) beta(1) all stimulated 9EG7 expression. Together these results support a model whereby (i) calcium inhibits beta(1) integrin function because it prevents the appearance of a conformation favorable to ligand binding and (ii) manganese enhances beta(1) integrin function because it induces the same favorable conformation that is induced by adding Ligand, or removing calcium. Notably, other beta(1)-stimulating agents (magnesium and mAb TS2/16) did not induce 9EG7 expression unless ligand was also present. Thus, although 9EG7 may reliably detect the ligand-bound conformation of beta(1) integrins, its expression does not always correlate with integrin ''activation.'' Finally, mouse/chicken beta(1) chimeric molecules were used to map the 9EG7 epitope to beta(1) residues 495-602 within the cysteine-rich region, and antibody cross-blocking studies showed that the 9EG7 epitope is distinct from all previously defined human beta(1) epitopes.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; The Wistar Institute					NATIONAL CANCER INSTITUTE [R37CA019144, R01CA019144] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER; NCI NIH HHS [CA19144] Funding Source: Medline; NHLBI NIH HHS [HLB47670] Funding Source: Medline; NIGMS NIH HHS [GM38903] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALTIERI DC, 1988, J IMMUNOL, V141, P2656; AMIOT M, 1986, SCAND J IMMUNOL, V23, P109, DOI 10.1111/j.1365-3083.1986.tb01948.x; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHARO IF, 1991, J BIOL CHEM, V266, P1415; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DETMERS PA, 1987, J CELL BIOL, V105, P1137, DOI 10.1083/jcb.105.3.1137; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DU XP, 1993, J BIOL CHEM, V268, P23087; ELEMER GS, 1994, J IMMUNOL, V152, P5836; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FITZGERALD LA, 1985, J BIOL CHEM, V260, P1366; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GAILIT J, 1988, J BIOL CHEM, V263, P12927; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GRZESIAK JJ, 1995, J CLIN INVEST, V95, P227, DOI 10.1172/JCI117644; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; HAUTANEN A, 1989, J BIOL CHEM, V264, P1437; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KASSNER PD, 1994, J BIOL CHEM, V269, P19859; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; MAKAREM R, 1994, J BIOL CHEM, V269, P4005; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MIYAKE K, 1992, J CELL BIOL, V119, P653, DOI 10.1083/jcb.119.3.653; MIYAKE K, 1994, INT IMMUNOL, V6, P1221, DOI 10.1093/intimm/6.8.1221; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; NANNINGA LB, 1971, BIOCHEMISTRY-US, V10, P2449, DOI 10.1021/bi00789a004; NEFF NT, 1982, J CELL BIOL, V95, P654, DOI 10.1083/jcb.95.2.654; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PASQUALINI R, 1993, J CELL SCI, V105, P101; PICKER LJ, 1993, EUR J IMMUNOL, V23, P2751, DOI 10.1002/eji.1830231105; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHIH DT, 1993, J CELL BIOL, V122, P1361, DOI 10.1083/jcb.122.6.1361; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SMITH JW, 1994, J BIOL CHEM, V269, P960; SMYTH SS, 1993, BLOOD, V81, P2827; SONNENBERG A, 1988, NATURE, V360, P487; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TOMINAGA S, 1988, FEBS LETT, V238, P315, DOI 10.1016/0014-5793(88)80503-9; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345	70	244	245	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25570	25577		10.1074/jbc.270.43.25570	http://dx.doi.org/10.1074/jbc.270.43.25570			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592728	hybrid			2022-12-27	WOS:A1995TB46600045
J	BORSCHHAUBOLD, AG; KRAMER, RM; WATSON, SP				BORSCHHAUBOLD, AG; KRAMER, RM; WATSON, SP			CYTOSOLIC PHOSPHOLIPASE A(2) IS PHOSPHORYLATED IN COLLAGEN-STIMULATED AND THROMBIN-STIMULATED HUMAN PLATELETS INDEPENDENT OF PROTEIN-KINASE-C AND MITOGEN-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ARACHIDONIC-ACID; SELECTIVE INHIBITORS; SIGNAL-TRANSDUCTION; INOSITOL PHOSPHATES; MOLECULAR-CLONING; PHORBOL ESTERS; MAP KINASE; RELEASE; CALCIUM	Human platelets pretreated with indomethacin release arachidonic acid predominantly through the activity of cytosolic phospholipase A(2) (cPLA(2)), an 85-kDa protein. This enzyme is regulated by an increase in intracellular Ca2+, a necessary condition for arachidonic acid liberation, and by phosphorylation. Phosphorylation of cPLA(2) enhanced the Ca2+-induced arachidonic acid release in platelets stimulated by the ionophore A23187 and phorbol ester (phorbol 12,13-dibutyrate (PDBu)). In thrombin-stimulated platelets, however, phosphorylation appeared not to be necessary for arachidonic acid release since the latter response was not impaired in the presence of staurosporine, which inhibited phosphorylation. Collagen, thrombin, and PDBu induced phosphorylation of platelet cPLA(2) as well as activation of mitogen-activated protein kinase (MAPH; p42(maph) and p44(mapk)). cPLA(2) activation was not dependent on protein kinase C (PKC) in thrombin- and collagen-stimulated platelets, as preincubation with the PKC inhibitor Ro 31-8220 neither interfered with cPLA(2) phosphorylation nor reduced arachidonic acid release, However, collagen- and thrombin-induced activation of MAPK was inhibited by Ro 31-8220, indicating that PKC is necessary for MAPK stimulation in platelets. Although MAPH may underlie phosphorylation of cPLA(2) in PDBu-activated human platelets, our results provide evidence for PKC- and MAPK-independent phosphorylation of cPLA(2) in platelets stimulated by the physiological activators collagen and thrombin.	LILLY RES LABS,INDIANAPOLIS,IN 46285	Eli Lilly	BORSCHHAUBOLD, AG (corresponding author), UNIV OXFORD,DEPT PHARMACOL,MANSFIELD RD,OXFORD OX1 3QT,ENGLAND.		Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BLAKE RA, 1993, BIOCHEM J, V290, P471, DOI 10.1042/bj2900471; BLAKE RA, 1994, FEBS LETT, V342, P15, DOI 10.1016/0014-5793(94)80575-X; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BRASS LF, 1993, THROMB HAEMOSTASIS, V70, P217; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CURRIE S, 1994, BIOCHEM J, V304, P923, DOI 10.1042/bj3040923; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; FERBY IM, 1994, J BIOL CHEM, V269, P30485; HALENDA SP, 1985, J BIOL CHEM, V260, P2484; HALENDA SP, 1989, BIOCHEMISTRY-US, V28, P7356, DOI 10.1021/bi00444a031; IMAOKA T, 1983, J BIOL CHEM, V258, P1404; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; NAKASHIMA S, 1994, BIOCHEM BIOPH RES CO, V198, P497, DOI 10.1006/bbrc.1994.1073; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; POOLE AW, 1993, BRIT J PHARMACOL, V110, pP41; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; RINK TJ, 1983, NATURE, V305, P317, DOI 10.1038/305317a0; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; SAMIEI M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P287, DOI 10.1016/0167-4889(93)90057-V; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHARP JD, 1994, J BIOL CHEM, V269, P23250; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SMITH JB, 1992, BIOCHEM J, V288, P925, DOI 10.1042/bj2880925; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; WALKER TR, 1993, BIOCHEM J, V289, P277, DOI 10.1042/bj2890277; WATERMAN AH, 1995, BIOCHEM BIOPH RES CO, V209, P271; WATSON SP, 1995, MOL PHARMACOL, V47, P823; WATSON SP, 1988, BIOCHEM J, V249, P345, DOI 10.1042/bj2490345; WATSON SP, 1985, P NATL ACAD SCI USA, V82, P2623, DOI 10.1073/pnas.82.9.2623; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; WINITZ S, 1994, J BIOL CHEM, V269, P1889; XING MZ, 1994, J BIOL CHEM, V269, P3117; XING MZ, 1992, J BIOL CHEM, V267, P25966	61	115	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25885	25892		10.1074/jbc.270.43.25885	http://dx.doi.org/10.1074/jbc.270.43.25885			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592775				2022-12-27	WOS:A1995TB46600092
J	LAEGREID, A; THOMMESEN, L; JAHR, TG; SUNDAN, A; ESPEVIK, T				LAEGREID, A; THOMMESEN, L; JAHR, TG; SUNDAN, A; ESPEVIK, T			TUMOR-NECROSIS-FACTOR INDUCES LIPOPOLYSACCHARIDE TOLERANCE IN A HUMAN ADENOCARCINOMA CELL-LINE MAINLY THROUGH THE TNF P55 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LPS BINDING-PROTEIN; MONOCLONAL-ANTIBODIES; CYTOKINE PRODUCTION; ACTIVATION; CD14; ALPHA; INTERLEUKIN-1; COMPLEXES; MONOCYTES	This study demonstrates that lipopolysaccharide (LPS) mediates induction of transcription factor NF kappa B and activation of the cytomegalovirus (CMV) promoter-enhancer in the SW480 cell Line. These cells do not express a functional membrane CD14. The LPS response in SW480 cells was weaker and markedly slower than the tumor necrosis factor (TNF) response. Pretreatment with TNF for 72 h inhibited both TNF, tumor necrosis factor receptor (TNFR) p55, TNFR p75, and LPS-mediated activation of nuclear factor -kappa B (NF kappa B), whereas pretreatment with LPS only inhibited the LPS response. TNFR p55 antibody pretreatment resulted in marked inhibition of the LPS response, while pretreatment with TNFR p75 antiserum only had a weak inhibitory effect. Flowcytometric analysis showed that LPS binding as well as expression of TNFR p55 and TNFR p75 were not affected by LPS or TNF pretreatment, indicating that the observed inhibition is not due to reduction of specific binding sites at the cell surface. The results suggest that LPS signaling in SW480 cells involves intracellular components which may be depleted or inactivated via TNFR p55, indicating that the LPS and TNFR p55 pathways overlap. We propose that TNFR p55 can mediate activation of NF kappa B and cytomegalovirus promoter-enhancer in SW480 cells via two distinct mechanisms, one which is activated only via TNFR p55 and leads to rapid activation of NF kappa B, and another which is overlapping with the LPS pathway.	UNIV TRONDHEIM,INST CANC RES & MOLEC BIOL,N-7005 TRONDHEIM,NORWAY; UNIV TRONDHEIM,CTR BIOL MOLEC,UNIGEN,N-7005 TRONDHEIM,NORWAY									BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; COUTURIER C, 1992, EUR J IMMUNOL, V22, P1461, DOI 10.1002/eji.1830220619; DAMAY BG, 1994, J BIOL CHEM, V269, P19687; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DING AH, 1988, J IMMUNOL, V141, P2407; ERROI A, 1993, INFECT IMMUN, V61, P4356, DOI 10.1128/IAI.61.10.4356-4359.1993; ESPEVIK T, 1993, EUR J IMMUNOL, V23, P255, DOI 10.1002/eji.1830230140; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GALLOWAY CJ, 1992, EUR J IMMUNOL, V22, P3045, DOI 10.1002/eji.1830221143; GENG Y, 1993, J IMMUNOL, V151, P6692; GODAMBE SA, 1994, J IMMUNOL, V153, P143; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HEITBROCK HWZ, 1993, J IMMUNOL, V151, P6986; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; JOHNS LD, 1994, J IMMUNOL, V152, P5877; JOSEPH CK, 1994, J BIOL CHEM, V269, P17606; Kronke M, 1992, Immunol Ser, V56, P189; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LIU J, 1994, J BIOL CHEM, V269, P3047; LYNN WA, 1993, INFECT IMMUN, V61, P4452, DOI 10.1128/IAI.61.10.4452-4461.1993; LYNN WA, 1992, IMMUNOL TODAY, V13, P271, DOI 10.1016/0167-5699(92)90009-V; MACHIAS S, 1994, P NATL ACAD SCI USA, V269, P13760; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEDRON T, 1994, J BIOL CHEM, V269, P2426; READ MA, 1993, P NATL ACAD SCI USA, V90, P9887, DOI 10.1073/pnas.90.21.9887; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; UPDYKE TV, 1984, J IMMUNOL METHODS, V73, P83, DOI 10.1016/0022-1759(84)90034-6; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; WAAGE A, 1987, LANCET, V1, P355; WIEGMANN K, 1994, CELL, V8, P1005; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YANG ZH, 1993, J BIOL CHEM, V268, P20520; ZHANG YH, 1994, P NATL ACAD SCI USA, V91, P2225, DOI 10.1073/pnas.91.6.2225	48	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25418	25425		10.1074/jbc.270.43.25418	http://dx.doi.org/10.1074/jbc.270.43.25418			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592709	hybrid			2022-12-27	WOS:A1995TB46600025
J	MAGENDANTZ, M; HENRY, MD; LANDER, A; SOLOMON, F				MAGENDANTZ, M; HENRY, MD; LANDER, A; SOLOMON, F			INTERDOMAIN INTERACTIONS OF RADIXIN IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEINS; CYTOSKELETON; EZRIN; PURIFICATION; LOCALIZATION; COMPONENT; BINDING; CELLS	We have assayed the domains of the ERM protein radixin for binding activities in vitro. Affinity columns bearing the amino-terminal domain of radixin selectively bound a small subset of the proteins of the chicken erythrocyte cytoskeleton. Two of those proteins were identified as radixin itself and band 4.1. In contrast, the carboxyl-terminal domain of the molecule bound neither protein, and full-length radixin did not bind band 4.1 (binding of full-length radixin to itself was not evaluated). Columns bearing a mixture of the amino- and carboxyl-terminal domains of radixin also failed to bind radixin and band 4.1. These results suggested that the amino- and carboxyl-terminal sequences can interact with one another either in cis or in trans, and so interfere with radixin's interactions with other ligands. Using affinity co-electrophoresis, we confirmed a direct interaction in solution between the two radixin domains; the data are consistent with the formation of a 1:1 complex with a dissociation constant of similar to 5 x 10(-8) M. Competition between intramolecular and intermolecular interactions may help to explain the provocative and dynamic localization of ERM proteins within cells.	MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Lander, Arthur D/C-9008-2011; Lander, Arthur/L-2827-2019	Lander, Arthur D/0000-0002-4380-5525; Lander, Arthur/0000-0002-4380-5525; Henry, Michael/0000-0002-7871-245X	NATIONAL CANCER INSTITUTE [R01CA053395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026862] Funding Source: NIH RePORTER; NCI NIH HHS [CA53395] Funding Source: Medline; NINDS NIH HHS [NS26862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ANDREOLI C, 1994, J CELL SCI, V107, P2509; BIRGBAUER E, 1991, J NEUROSCI RES, V30, P232; BIRGBAUER E, 1989, J CELL BIOL, V109, P1609, DOI 10.1083/jcb.109.4.1609; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BRETSCHER A, 1986, METHOD ENZYMOL, V134, P24; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; EDWARDS KA, 1994, P NATL ACAD SCI USA, V91, P4589, DOI 10.1073/pnas.91.10.4589; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GOSLIN K, 1989, J CELL BIOL, V109, P1621, DOI 10.1083/jcb.109.4.1621; GRANGER BL, 1984, CELL, V37, P595, DOI 10.1016/0092-8674(84)90390-8; GRANGER BL, 1985, NATURE, V313, P238, DOI 10.1038/313238a0; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LIM WA, 1991, METHOD ENZYMOL, V208, P196; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; SHUSTER CB, 1995, J CELL BIOL, V128, P837, DOI 10.1083/jcb.128.5.837; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445	24	84	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25324	25327		10.1074/jbc.270.43.25324	http://dx.doi.org/10.1074/jbc.270.43.25324			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592691	hybrid, Green Published			2022-12-27	WOS:A1995TB46600007
J	PERKINS, EB; CUNNINGHAM, JG; BRACETE, AM; ZEHNER, ZE				PERKINS, EB; CUNNINGHAM, JG; BRACETE, AM; ZEHNER, ZE			2 HOMOLOGOUS ENHANCER ELEMENTS IN THE CHICKEN VIMENTIN GENE MAY BIND A NUCLEAR FACTOR IN COMMON WITH A NEARBY SILENCER ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I TAX PROTEIN; INTERMEDIATE FILAMENTS; EPIDERMOLYTIC HYPERKERATOSIS; REGULATORY ELEMENTS; NEGATIVE ELEMENT; MESSENGER-RNA; TRANSCRIPTION; EXPRESSION; ACTIVATION; SEQUENCE	Vimentin, a cytoskeletal protein belonging to the intermediate filament protein family, exhibits a complex pattern of expression. In the case of the chicken vimentin gene, several regulatory elements within the 5' region of the gene have been characterized, including an enhancer activity between -160 and -320, which may contribute to the down-regulation of vimentin expression during myogenesis. In this study, sequences within this region were examined via transient transfections of various deletion constructs, and two distinct enhancer elements were found, one on either side of a previously described silencer element. These two enhancer elements also enhanced transcription when fused separately to the basal promoter region of the chicken vimentin gene. Gel mobility shift assays, UV cross-linking experiments, and DNase I protection studies indicate that these two enhancer elements and the silencer element all contain a common binding site for the previously described 95-kDa silencer element binding protein, suggesting that this regulatory protein can act as both an activator and a repressor.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT BIOCHEM & MOLEC BIOPHYS,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MASSEY CANC CTR,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045422] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45422] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BLOEMENDAL H, 1989, BIOCHIM BIOPHYS ACTA, V1007, P245, DOI 10.1016/0167-4781(89)90144-9; CHENG J, 1992, CELL, V70, P811, DOI 10.1016/0092-8674(92)90314-3; CHIPEV CC, 1992, CELL, V70, P821, DOI 10.1016/0092-8674(92)90315-4; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; DENTE L, 1983, NUCLEIC ACIDS RES, V6, P1645; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARRELL FX, 1990, MOL CELL BIOL, V10, P2349, DOI 10.1128/MCB.10.5.2349; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANKE WW, 1979, EXP CELL RES, V123, P25, DOI 10.1016/0014-4827(79)90418-X; GARZON RJ, 1994, MOL CELL BIOL, V14, P934, DOI 10.1128/MCB.14.2.934; GIBSON CW, 1986, MOL CELL BIOCHEM, V71, P61; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; LILIENBAUM A, 1990, J VIROL, V64, P256, DOI 10.1128/JVI.64.1.256-263.1990; LILIENBAUM A, 1993, J BIOL CHEM, V268, P2180; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OSHIMA R G, 1992, Current Opinion in Cell Biology, V4, P110, DOI 10.1016/0955-0674(92)90067-M; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; SALVETTI A, 1993, MOL CELL BIOL, V13, P89, DOI 10.1128/MCB.13.1.89; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SAX CM, 1988, NUCLEIC ACIDS RES, V16, P8057, DOI 10.1093/nar/16.16.8057; SAX CM, 1989, GENE, V78, P235, DOI 10.1016/0378-1119(89)90226-6; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STOVER DM, 1992, MOL CELL BIOL, V12, P2230, DOI 10.1128/MCB.12.5.2230; SZE JY, 1993, MOL CELL BIOL, V13, P5702, DOI 10.1128/MCB.13.9.5702; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; WANG ZY, 1993, J BIOL CHEM, V268, P9172; ZEHNER ZE, 1987, J BIOL CHEM, V262, P8112; Zehner ZE, 1991, CURR OPIN CELL BIOL, V3, P67, DOI 10.1016/0955-0674(91)90167-W	37	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25785	25791		10.1074/jbc.270.43.25785	http://dx.doi.org/10.1074/jbc.270.43.25785			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592761	hybrid			2022-12-27	WOS:A1995TB46600078
J	PENG, H; MARIANS, KJ				PENG, H; MARIANS, KJ			THE INTERACTION OF ESCHERICHIA-COLI TOPOISOMERASE-IV WITH DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOME SEGREGATION; SALMONELLA-TYPHIMURIUM; NUCLEOID SEGREGATION; SUBUNIT STRUCTURE; NALIDIXIC-ACID; PBR322 DNA; GYRASE; REPLICATION; GENE; ENZYME	The two type II topoisomerases in Escherichia coli, DNA gyrase and topoisomerase (Topo) TV, share considerable amino acid sequence similarity, yet they have distinctive topoisomerization activities. Only DNA gyrase can supercoli relaxed DNA, whereas during oriC DNA replication in vitro, only Topo IV can support the final stages of replication, processing of the late inter mediate and decatenation of the daughter molecules. In order to develop an understanding for the basis of the differential activities of these two enzymes, we have initiated a characterization of Topo TV binding to DNA. We find that unlike gyrase, Topo IV neither constrains DNA in a positive supercoli when it binds nor protects a 150-base pair region of DNA from digestion with micrococcal nuclease. Consistent with this, DNase I footprinting experiments showed that Topo IV protected a 34-base pair region roughly centered about the topoisomerase induced cleavage site. In addition, Topo IV preferentially bound supercolied rather than relaxed DNA. Thus, the DNA binding characteristics of Topo IV are more akin to those of the type II eukaryotic enzymes rather than those of its prokaryotic partner.	CORNELL UNIV, GRAD SCH MED SCI, GRAD PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA	Cornell University	PENG, H (corresponding author), MEM SLOAN KETTERING CANC CTR, MOLEC BIOL LAB, 1275 YORK AVE, NEW YORK, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; FISHER LM, 1981, P NATL ACAD SCI-BIOL, V78, P4165, DOI 10.1073/pnas.78.7.4165; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P4474, DOI 10.1073/pnas.73.12.4474; GROSS WA, 1965, J BACTERIOL, V89, P1068; HIASA H, 1994, J BIOL CHEM, V269, P16371; HIGGINS NP, 1982, NUCLEIC ACIDS RES, V10, P6833, DOI 10.1093/nar/10.21.6833; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HUSSAIN K, 1987, MOL MICROBIOL, V1, P259, DOI 10.1111/j.1365-2958.1987.tb01932.x; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1989, MOL GEN GENET, V217, P178, DOI 10.1007/BF00330959; KATO J, 1992, J BIOL CHEM, V267, P25676; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; KIRKEGAARD K, 1981, CELL, V23, P721, DOI 10.1016/0092-8674(81)90435-9; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LEE MP, 1989, J BIOL CHEM, V264, P21779; LIU LF, 1978, CELL, V15, P979, DOI 10.1016/0092-8674(78)90281-7; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; LUTTINGER AL, 1991, NEW BIOL, V3, P687; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P409, DOI 10.1093/jac/30.4.409; MORRISON A, 1981, P NATL ACAD SCI-BIOL, V78, P1416, DOI 10.1073/pnas.78.3.1416; NOLL M, 1974, NATURE, V251, P249, DOI 10.1038/251249a0; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1993, J BIOL CHEM, V268, P24481; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; RYAN MJ, 1976, BIOCHEMISTRY-US, V15, P3769, DOI 10.1021/bi00662a020; SCHMID MB, 1990, J BACTERIOL, V172, P5416, DOI 10.1128/jb.172.9.5416-5424.1990; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; STAUDENBAUER WL, 1976, EUR J BIOCHEM, V62, P491, DOI 10.1111/j.1432-1033.1976.tb10183.x; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; STERNGLANZ R, 1981, P NATL ACAD SCI-BIOL, V78, P2747, DOI 10.1073/pnas.78.5.2747; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; THOMSEN B, 1990, J MOL BIOL, V215, P237, DOI 10.1016/S0022-2836(05)80342-0; TRUCKSIS M, 1981, P NATL ACAD SCI-BIOL, V78, P2164, DOI 10.1073/pnas.78.4.2164; WASSERMAN SA, 1988, NATURE, V334, P448, DOI 10.1038/334448a0	44	73	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25286	25290		10.1074/jbc.270.42.25286	http://dx.doi.org/10.1074/jbc.270.42.25286			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559669	hybrid			2022-12-27	WOS:A1995TB46500103
J	KIM, S; NARAYANA, SVL; VOLANAKIS, JE				KIM, S; NARAYANA, SVL; VOLANAKIS, JE			CRYSTAL-STRUCTURE OF A COMPLEMENT FACTOR-D MUTANT EXPRESSING ENHANCED CATALYTIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; SERINE PROTEASES; CRYSTALLOGRAPHIC REFINEMENT; BINDING-SITE; PROTEIN-B; RESOLUTION; PATHWAY; CHYMOTRYPSIN; SEQUENCE; GAMMA	Complement factor D is a serine protease regulated by a novel mechanism that depends on conformational changes rather than cleavage of a zymogen for expression of proteolytic activity. The conformational changes are presumed to be induced by the single natural substrate, C3bB, and by result in reversible reorientation of the catalytic center and of the substrate binding site of factor D, both of which have atypical conformations. Here we report that replacement of Ser(94), Thr(214), and Ser(215) of factor D (chymotrypsinogen numbering has been used for comparison purposes) with the corresponding residues of trypsin, Tyr, Ser, and Trp, is sufficient to induce substantially higher catalytic activity associated with a typical serine protease alignment of the catalytic triad residues His(57), Asp(102), and Ser(195). These results provide a partial structural explanation for the low reactivity of ''resting-state'' factor D toward synthetic substrates.	UNIV ALABAMA, DEPT MED, DIV CLIN IMMUNOL & RHEUMATOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT MICROBIOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, CTR MACROMOLEC CRYSTALLOG, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH OPTOMETRY, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NIAID NIH HHS [AI21067, AI32949] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021067, R29AI032949] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; COHEN GH, 1981, J MOL BIOL, V148, P449, DOI 10.1016/0022-2836(81)90186-8; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; GRESHAM HD, 1986, ANAL BIOCHEM, V154, P454, DOI 10.1016/0003-2697(86)90014-X; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HEDSTROM L, 1994, BIOCHEMISTRY-US, V33, P8757, DOI 10.1021/bi00195a017; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAM CM, 1987, J BIOL CHEM, V262, P3444; KAM CM, 1992, J IMMUNOL, V149, P163; KIM S, 1994, BIOCHEMISTRY-US, V33, P14393, DOI 10.1021/bi00252a004; KIM SH, 1995, J IMMUNOL, V154, P6073; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MULLEREBERHARD HJ, 1972, J EXP MED, V135, P1003, DOI 10.1084/jem.135.4.1003; NARAYANA SVL, 1994, J MOL BIOL, V235, P695, DOI 10.1006/jmbi.1994.1021; NIEMANN MA, 1980, BIOCHEMISTRY-US, V19, P1576, DOI 10.1021/bi00549a007; NIEMANN MA, 1984, BIOCHEMISTRY-US, V23, P2482, DOI 10.1021/bi00306a025; PANGBURN MK, 1989, J IMMUNOL, V142, P202; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P2439, DOI 10.1021/bi00763a009; RUHLMANN A, 1973, J MOL BIOL, V77, P417, DOI 10.1016/0022-2836(73)90448-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEGAL DM, 1971, BIOCHEMISTRY-US, V10, P3728; SHOTTON D M, 1970, Nature (London), V225, P811, DOI 10.1038/225811a0; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; STROUD RM, 1971, COLD SPRING HARB SYM, V36, P125, DOI 10.1101/SQB.1972.036.01.018; UEDA A, 1987, J IMMUNOL, V138, P1143; VOLANAKIS JE, 1987, ANAL BIOCHEM, V163, P242, DOI 10.1016/0003-2697(87)90119-9; WHITE RT, 1992, J BIOL CHEM, V267, P9210; YAMAUCHI Y, 1994, J IMMUNOL, V152, P3645	39	27	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24399	24405		10.1074/jbc.270.41.24399	http://dx.doi.org/10.1074/jbc.270.41.24399			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592653	hybrid			2022-12-27	WOS:A1995TA21700081
J	PRAZERES, S; MOURA, JJG; MOURA, I; GILMOUR, R; GOODHEW, CF; PETTIGREW, GW; RAVI, N; HUYNH, BH				PRAZERES, S; MOURA, JJG; MOURA, I; GILMOUR, R; GOODHEW, CF; PETTIGREW, GW; RAVI, N; HUYNH, BH			MOSSBAUER CHARACTERIZATION OF PARACOCCUS-DENITRIFICANS CYTOCHROME-C PEROXIDASE - FURTHER EVIDENCE FOR REDOX AND CALCIUM BINDING-INDUCED HEME-HEME INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; MAGNETIC CIRCULAR-DICHROISM; PSEUDOMONAS-AERUGINOSA; HORSERADISH-PEROXIDASE; EPR; NMR; ION; MECHANISM; INTENSITY; SPECTRA	Mossbauer and electron paramagnetic resonance (EPR) spectroscopies were used to characterize the diheme cytochrome c peroxidase from Paracoccus denitrificans (L.M.D. 52.44). The spectra of the oxidized enzyme show two distinct spectral components characteristic of low spin ferric hemes (S = 1/2), revealing different heme environments for the two heme groups, The Paracoccus peroxidase can be non-physiologically reduced by ascorbate, Mossbauer investigation of the ascorbate-reduced peroxidase shows that only one heme (the high potential heme) is reduced and that the reduced heme is diamagnetic (S = 0), The other heme (the low potential heme) remains oxidized, indicating that the enzyme is in a mixed valence, half-reduced state, The EPR spectrum of the half-reduced peroxidase, however, shows two low spin ferric species with g(max) = 2.89 (species I) and g(max) = 2.78 (species II). This EPR observation, together with the Mossbauer result, suggests that both species are arising from the low potential heme, More interestingly, the spectroscopic properties of these two species are distinct from that of the low potential heme in the oxidized enzyme, providing evidence for heme-heme interaction induced by the reduction of the high potential heme, Addition of calcium ions to the half-reduced enzyme converts species II to species I. Since calcium has been found to promote peroxidase activity, species I may represent the active form of the peroxidatic heme.	UNIV NOVA LISBOA,FAC CIENCIAS & TECNOL,DEPT QUIM,P-2825 MONTE DE CAPARICA,PORTUGAL; UNIV EDINBURGH,ROYAL DICK SCH VET STUDIES,DEPT VET PRECLIN SCI,EDINBURGH EH9 1QH,MIDLOTHIAN,SCOTLAND; EMORY UNIV,DEPT PHYS,ATLANTA,GA 30322	Universidade Nova de Lisboa; University of Edinburgh; Emory University			Moura, Isabel/D-6339-2013; Moura, José J G/D-6426-2013	Moura, Isabel/0000-0003-0971-4977; Moura, José J G/0000-0002-4726-2388	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047295] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 47295] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		AASA R, 1981, BIOCHIM BIOPHYS ACTA, V670, P170, DOI 10.1016/0005-2795(81)90005-2; AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ARAISO T, 1980, FEBS LETT, V118, P99, DOI 10.1016/0014-5793(80)81227-0; BANCI L, 1993, BIOCHEMISTRY-US, V32, P5825, DOI 10.1021/bi00073a015; BLUMBERG WE, 1971, ADV CHEM, V100, P271; COSTA C, 1990, J BIOL CHEM, V265, P14382; DEBRUNNER PG, 1990, IRON PORPHYRINS 3, P139; DEVRIES S, 1979, BIOCHIM BIOPHYS ACTA, V546, P334; DWIVEDI A, 1979, BIOCHIM BIOPHYS ACTA, V576, P502, DOI 10.1016/0005-2795(79)90425-2; ELLFOLK N, 1991, BIOCHIM BIOPHYS ACTA, V1080, P68, DOI 10.1016/0167-4838(91)90113-E; ELLFOLK N, 1983, BIOCHIM BIOPHYS ACTA, V743, P23, DOI 10.1016/0167-4838(83)90413-2; ELLFOLK N, 1984, BIOCHIM BIOPHYS ACTA, V784, P62, DOI 10.1016/0167-4838(84)90173-0; ELLFOLK N, 1984, BIOCHIM BIOPHYS ACTA, V791, P9, DOI 10.1016/0167-4838(84)90274-7; FOOTE N, 1984, BIOCHEM J, V223, P369, DOI 10.1042/bj2230369; FOOTE N, 1985, BIOCHEM J, V230, P227, DOI 10.1042/bj2300227; FOOTE N, 1992, BIOCHEM J, V283, P839, DOI 10.1042/bj2830839; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; GILMOUR R, 1994, BIOCHEM J, V300, P907, DOI 10.1042/bj3000907; GILMOUR R, 1993, BIOCHEM J, V294, P745, DOI 10.1042/bj2940745; GOODHEW CF, 1990, BIOCHEM J, V271, P707, DOI 10.1042/bj2710707; GRIFFITH JS, 1957, NATURE, V180, P30, DOI 10.1038/180030a0; HASCHKE RH, 1978, BIOCHEM BIOPH RES CO, V80, P1039, DOI 10.1016/0006-291X(78)91350-5; HUYNH BH, 1978, BIOCHIM BIOPHYS ACTA, V534, P295, DOI 10.1016/0005-2795(78)90012-0; LANG G, 1968, J CHEM PHYS, V49, P944, DOI 10.1063/1.1670164; LIPSCOMB JD, 1982, BIOCHEMISTRY-US, V21, P3973, DOI 10.1021/bi00260a011; MORISHIMA I, 1986, J BIOL CHEM, V261, P9391; Munck E, 1978, Methods Enzymol, V54, P346; OOSTERHUIS WT, 1969, PHYS REV, V178, P439, DOI 10.1103/PhysRev.178.439; PETTIGREW GW, 1991, BIOCHIM BIOPHYS ACTA, V1058, P25, DOI 10.1016/S0005-2728(05)80261-0; POULOS TL, 1993, J BIOL CHEM, V268, P4429; PRAZERES S, 1995, NATO ADV SCI I C-MAT, V457, P141; PRAZERES S, 1993, MAGN RESON CHEM, V31, pS68, DOI 10.1002/mrc.1260311314; RAVI N, 1992, EUR J BIOCHEM, V204, P779, DOI 10.1111/j.1432-1033.1992.tb16694.x; RONNBERG M, 1980, BIOCHIM BIOPHYS ACTA, V626, P23, DOI 10.1016/0005-2795(80)90193-2; RONNBERG M, 1981, J BIOL CHEM, V256, P2471; RONNBERG M, 1981, ARCH BIOCHEM BIOPHYS, V207, P197, DOI 10.1016/0003-9861(81)90025-4; SHIRO Y, 1986, J BIOL CHEM, V261, P9382; TAYLOR CPS, 1977, BIOCHIM BIOPHYS ACTA, V491, P137, DOI 10.1016/0005-2795(77)90049-6; VILLALAIN J, 1984, EUR J BIOCHEM, V141, P305, DOI 10.1111/j.1432-1033.1984.tb08192.x; WALKER FA, 1986, J AM CHEM SOC, V108, P5288, DOI 10.1021/ja00277a038	40	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24264	24269		10.1074/jbc.270.41.24264	http://dx.doi.org/10.1074/jbc.270.41.24264			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592634	hybrid			2022-12-27	WOS:A1995TA21700062
J	SANCHEZALCAZAR, JA; HERNANDEZ, I; DELATORRE, MP; GARCIA, I; SANTIAGO, E; MUNOZYAGUE, M; SOLISHERRUZO, JA				SANCHEZALCAZAR, JA; HERNANDEZ, I; DELATORRE, MP; GARCIA, I; SANTIAGO, E; MUNOZYAGUE, M; SOLISHERRUZO, JA			DOWN-REGULATION OF TUMOR-NECROSIS-FACTOR RECEPTORS BY BLOCKADE OF MITOCHONDRIAL RESPIRATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; MANGANOUS SUPEROXIDE-DISMUTASE; FACTOR-ALPHA; HYDROGEN-PEROXIDE; PHORBOL ESTERS; BINDING-CAPACITY; CELLS-INVITRO; GENERATION; PHOSPHORYLATION; ACTIVATION	We have studied the effect of blockade of mitochondrial respiration on the binding of human I-125-TNF alpha to L929 cell receptors. Specific TNF alpha binding was decreased to about 20-40% of controls by blocking mitochondrial respiration. This effect was dose- and time-related and was observed independently of the level at which the respiration was blocked (respiratory chain, proton backflow, ATPase, anaerobiosis). This blockade had no effect on the half-life of the specific TNF alpha binding, the internalization or degradation of TNF alpha-receptor complexes, or the number of TNF alpha-binding sites. Scatchard analysis of TNF alpha binding data indicated a 2-4-fold decrease in the affinity of these binding sites. These effects did not appear to be related to the protein kinase C activity or to reactive oxygen radicals, since they were not antagonized by pretreatment of cells with oxygen radical scavengers, deferoxamine, or inhibitors of protein kinase C. Decrease in TNF alpha binding capacity correlated significantly with cellular ATP content (r = 0.94; p < 0.01) and with the cytocidal activity of TNF alpha against L929 cells. These findings suggest that blockade of mitochondrial respiration down-regulates the binding of TNF alpha to cells, most likely by changing the affinity of receptors for this cytokine. This down-regulation may increase the resistance of cells to TNF alpha cytotoxicity.	UNIV COMPLUTENSE MADRID, HOSP 12 OCTUBRE, CTR INVEST, SERV GASTROENTEROL, E-28041 MADRID, SPAIN	Complutense University of Madrid; Hospital Universitario 12 de Octubre			García-Ruiz, Inmaculada/G-8204-2015; Sanchéz-Alcázar, José A. A/L-4925-2014	García-Ruiz, Inmaculada/0000-0003-4185-8524; Sanchéz-Alcázar, José A. A/0000-0001-9705-1469				ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; AGGARWAL BB, 1987, J BIOL CHEM, V262, P16450; AGGARWAL BB, 1993, TUMOR NECROSIS FACTOR : MOLECULAR AND CELLULAR BIOLOGY AND CLINICAL RELEVANCE, P76; ALBERTS B, 1989, MOL BIOL CELL, P342; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BIDGA J, 1994, J EXP MED, V180, P445; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; Boveris A., 1977, TISSUE HYPOXIA ISCHE, P67; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BURGERS JA, 1993, BIOCHEM J, V291, P157, DOI 10.1042/bj2910157; CAMUSSI G, 1991, EUR J BIOCHEM, V202, P3, DOI 10.1111/j.1432-1033.1991.tb16337.x; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; COLTON T, 1979, ESTADISTICA MED; COSTLOW ME, 1982, J BIOL CHEM, V257, P9330; DAVIS RJ, 1984, J BIOL CHEM, V259, P8545; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; HAHN T, 1985, P NATL ACAD SCI USA, V82, P3814, DOI 10.1073/pnas.82.11.3814; HELLER RA, 1992, CELL, V70, P47; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HERTEL C, 1988, MOL PHARMACOL, V44, P364; HIGUCHI M, 1992, J IMMUNOTHER, V12, P41, DOI 10.1097/00002371-199207000-00005; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; JOHNSON SE, 1988, J BIOL CHEM, V263, P5686; KAPLAN J, 1981, SCIENCE, V212, P14, DOI 10.1126/science.6259730; KNAUER MF, 1990, J CELL PHYSIOL, V142, P469, DOI 10.1002/jcp.1041420305; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KONSTANTINOV AA, 1987, BIOCHIM BIOPHYS ACTA, V894, P1, DOI 10.1016/0005-2728(87)90206-4; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LIAO JF, 1993, MOL PHARMACOL, V44, P364; LINGE C, 1993, GROWTH FACTORS PRACT, P201; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; PERLMUTTER DH, 1986, J CLIN INVEST, V78, P1349, DOI 10.1172/JCI112721; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHEURICH P, 1986, BIOCHEM BIOPH RES CO, V141, P855, DOI 10.1016/S0006-291X(86)80251-0; SCHEURICH P, 1989, J EXP MED, V170, P947, DOI 10.1084/jem.170.3.947; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STADLER J, 1992, ANN SURG, V216, P539, DOI 10.1097/00000658-199211000-00003; SVEC F, 1985, BIOCHIM BIOPHYS ACTA, V847, P147, DOI 10.1016/0167-4889(85)90167-3; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TRACEY KJ, 1989, LANCET, V1, P1122; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; TSUJIMOTO M, 1986, J IMMUNOL, V136, P2441; UNGLAUB R, 1987, J EXP MED, V166, P1788, DOI 10.1084/jem.166.6.1788; WALLACH D, 1984, J IMMUNOL, V132, P2464; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WULFF K, 1985, METHOD ENZYMAT AN, V7, P357; YAMAUCHI N, 1989, CANCER RES, V49, P1671	60	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23944	23950		10.1074/jbc.270.41.23944	http://dx.doi.org/10.1074/jbc.270.41.23944			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592589	Green Published, hybrid			2022-12-27	WOS:A1995TA21700017
J	SEVERINOV, K; MARKOV, D; SEVERINOVA, E; NIKIFOROV, V; LANDICK, R; DARST, SA; GOLDFARB, A				SEVERINOV, K; MARKOV, D; SEVERINOVA, E; NIKIFOROV, V; LANDICK, R; DARST, SA; GOLDFARB, A			STREPTOLYDIGIN-RESISTANT MUTANTS IN AN EVOLUTIONARILY CONSERVED REGION OF THE BETA' SUBUNIT OF ESCHERICHIA-COLI RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NUCLEOTIDE-SEQUENCE; ALPHA-AMANITIN; GENE; MUTATION; TRANSCRIPTION; ENZYME; LOCALIZATION; INHIBITION; DROSOPHILA	Mutations conferring streptolydigin resistance onto Escherichia coli RNA polymerase have been found exclusively in the beta subunit (Heisler, L. M., Suzuki, H., Landick, R., and Gross, C. A. (1993) J. Biol. Chem. 268, 25369-25375). We report here the isolation of a streptolydigin-resistant mutation in the E. coli rpoC gene, encoding the beta' subunit. The mutation is the Phe(793) --> Ser substitution, which occurred in an evolutionarily conserved segment of the beta' subunit. The homologous segment in the eukaryotic RNA polymerase II largest subunit harbors mutations conferring alpha-amanitin resistance, Both streptolydigin and alpha-amanitin are inhibitors of transcription elongation. Thus, the two antibiotics may inhibit transcription in their respective systems by a similar mechanism, despite their very different chemical nature,	PUBL HLTH RES INST,NEW YORK,NY 10016; WASHINGTON UNIV,ST LOUIS,MO 63130; RUSSIAN ACAD SCI,INST MOLEC GENET,MOSCOW 123182,RUSSIA	Washington University (WUSTL); Russian Academy of Sciences	SEVERINOV, K (corresponding author), ROCKEFELLER UNIV,BOX 224,1230 YORK AVE,NEW YORK,NY 10021, USA.		Severinov, Konstantin/C-8545-2016		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038660, R37GM038660, R29GM038660, R01GM030717] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30717, GM38660] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; AUSTIN S, 1970, J MOL BIOL, V49, P263, DOI 10.1016/0022-2836(70)90394-3; BARTOLOMEI MS, 1987, MOL CELL BIOL, V7, P586, DOI 10.1128/MCB.7.2.586; BARTOLOMEI MS, 1995, MOL GEN GENET, V246, P778, DOI 10.1007/BF00290727; BERGHOFER B, 1988, NUCLEIC ACIDS RES, V16, P8113, DOI 10.1093/nar/16.16.8113; BIRD DM, 1989, MOL CELL BIOL, V9, P4119, DOI 10.1128/MCB.9.10.4119; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; BORUKHOV S, 1991, J BIOL CHEM, V266, P23932; CASSANI G, 1971, NATURE-NEW BIOL, V230, P197, DOI 10.1038/newbio230197a0; CHEN Y, 1993, MOL CELL BIOL, V13, P4214, DOI 10.1128/MCB.13.7.4214; COULTER DE, 1985, J BIOL CHEM, V260, P3190; DANILKOVICH AV, 1988, DOKL AKAD NAUK SSSR+, V303, P241; DEMERCOYROL L, 1989, BIOCHEM J, V258, P165, DOI 10.1042/bj2580165; HALLING SM, 1978, NATURE, V272, P837, DOI 10.1038/272837a0; HEIL A, 1970, FEBS LETT, V11, P165, DOI 10.1016/0014-5793(70)80519-1; HEISLER LM, 1993, J BIOL CHEM, V268, P25369; HONORE N, 1993, MOL MICROBIOL, V7, P207, DOI 10.1111/j.1365-2958.1993.tb01112.x; HUDSON GS, 1988, J MOL BIOL, V200, P639, DOI 10.1016/0022-2836(88)90477-9; IWAKURA Y, 1973, MOL GEN GENET, V121, P181, DOI 10.1007/BF00277531; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; JOB C, 1982, BIOCHEM J, V285, P85; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; LISITSYN NA, 1985, BIOORG KHIM+, V11, P132; MCCLURE WR, 1980, J BIOL CHEM, V255, P1610; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; OVCHINNIKOV YA, 1982, NUCLEIC ACIDS RES, V10, P4035, DOI 10.1093/nar/10.13.4035; PALM P, 1993, NUCLEIC ACIDS RES, V21, P4904, DOI 10.1093/nar/21.21.4904; REINES D, 1992, J BIOL CHEM, V267, P3795; RINEHART KL, 1963, J AM CHEM SOC, V85, P4038, DOI 10.1021/ja00907a034; SCHLEIF R, 1969, NATURE, V223, P1068, DOI 10.1038/2231068a0; SEVERINOV K, 1993, J BIOL CHEM, V268, P14280; SHIMADA H, 1990, MOL GEN GENET, V221, P395, DOI 10.1007/BF00259404; SIDDHIKOL C, 1969, J BACTERIOL, V99, P151, DOI 10.1128/JB.99.1.151-155.1969; VONDERHELM K, 1972, NATURE-NEW BIOL, V235, P82, DOI 10.1038/newbio235082a0; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; YANG XF, 1995, J BIOL CHEM, V270, P23930, DOI 10.1074/jbc.270.41.23930	38	49	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23926	23929		10.1074/jbc.270.41.23926	http://dx.doi.org/10.1074/jbc.270.41.23926			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592584	hybrid			2022-12-27	WOS:A1995TA21700012
J	WAYMAN, GA; HINDS, TR; STORM, DR				WAYMAN, GA; HINDS, TR; STORM, DR			HORMONE STIMULATION OF TYPE-III ADENYLYL-CYCLASE INDUCES CA2+ OSCILLATIONS IN HEK-293 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; INOSITOL TRISPHOSPHATE; CALCIUM MOBILIZATION; WHOLE CELLS; CALMODULIN; EXPRESSION; RECEPTOR; CLONING; PHOSPHORYLATION; ACTIVATION	Various forms of cross-talk between the Ca2+ and cAMP signal transduction systems can occur in animal cells depending upon the types of adenylyl cyclases present. Here, we report that Ca2+ oscillations can be generated by hormone stimulation of type III adenylyl cyclase expressed in HEK-293 cells. These Ca2+ oscillations are apparently due to the unique regulatory features of type III adenylyl cyclase, which is stimulated by hormones and inhibited by elevated Ca2+ in vivo. Ca2+ oscillations were generated by glucagon, isoproterenol, or forskolin stimulation of type III adenylyl cyclase and were dependent upon the activity of cAMP- and calmodulin-dependent protein kinases. Ca2+ oscillations were not solely dependent upon cAMP increases since dibutyryl cAMP or (S-p)-cAMP did not stimulate Ca2+ oscillations. We hypothesize that stimulation of type III adenylyl cyclase leads to increased cAMP, activation of inositol 1,4,5-trisphosphate receptors, and elevation of intracellular Ca2+. As free Ca2+ increases, type III adenylyl cyclase activity is attenuated by CaM kinase(s) and intracellular cAMP levels decrease. When cAMP levels drop below a threshold level, the inositol 1,4,5-trisphosphate receptor is dephosphorylated and Ca2+ is resequestered. This cycle is repeated if type III adenylyl cyclase is chronically exposed to an activator. This unique mechanism for generation of Ca2+ oscillations in cells is distinct from others documented in the literature.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL 44948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BEAVO JA, 1990, TRENDS NEUROCHEM SCI, V13, P65; Berridge Michael J., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P211; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V256, P9583; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CAMPBELL MD, 1990, MOL PHARMACOL, V38, P282; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DITTMAN AH, 1994, BIOCHEMISTRY-US, V33, P943, DOI 10.1021/bi00170a013; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, ANN REV PHYSL, V55, P427; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAWKINS C, 1994, J BIOL CHEM, V269, P31198; HELL JW, 1994, ANN NY ACAD SCI, V747, P282; HOENEGGER M, 1993, BIOCHEM J, V296, P303; HORN VJ, 1991, MOL CELL BIOCHEM, V101, P43; IMPEY S, 1994, MOL CELL BIOL, V14, P8272, DOI 10.1128/MCB.14.12.8272; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MASTERS SB, 1985, BIOCHEM J, V227, P933, DOI 10.1042/bj2270933; NAKADE S, 1994, J BIOL CHEM, V269, P6735; RAPP PE, 1977, J THEOR BIOL, V66, P497, DOI 10.1016/0022-5193(77)90299-5; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; SALOMON Y, 1979, ANAL BIOCHEM, V58, P541; SEAMON K, 1981, J BIOL CHEM, V256, P9799; SUBERS EM, 1988, J MOL CELL CARDIOL, V20, P131, DOI 10.1016/S0022-2828(88)80026-9; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; TANG WJ, 1991, J BIOL CHEM, V266, P8595; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU ZL, 1993, J BIOL CHEM, V268, P23766; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; XU A, 1993, J BIOL CHEM, V268, P8394; YOSHIDA A, 1992, J BIOCH TOKYO; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	52	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24108	24115		10.1074/jbc.270.41.24108	http://dx.doi.org/10.1074/jbc.270.41.24108			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592612	hybrid			2022-12-27	WOS:A1995TA21700040
J	UEDA, N; KURAHASHI, Y; YAMAMOTO, S; TOKUNAGA, T				UEDA, N; KURAHASHI, Y; YAMAMOTO, S; TOKUNAGA, T			PARTIAL-PURIFICATION AND CHARACTERIZATION OF THE PORCINE BRAIN ENZYME HYDROLYZING AND SYNTHESIZING ANANDAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANNABINOID RECEPTOR AGONIST; CONSTITUENT; BINDING	Anandamide (arachidonylethanolamide) is known as an endogenous agonist for cannabinoid receptors. An amidohydrolase, which hydrolyzed anandamide, was solubilized from the microsomal fraction of porcine brain with 1% Triton X-100. The enzyme was partially purified by Phenyl-5PW hydrophobic chromatography to a specific activity of approximately 0.37 mu mol/min/mg of protein at 37 degrees C. As assayed with C-14-labeled substrates, the apparent K-m value for anandamide was 60 mu M, and anandamide was more active than ethanol-amides of linoleic, oleic, and palmitic acids. Ceramidase and protease activities were not detected in our enzyme preparation. The purified enzyme also synthesized anandamide from free arachidonic acid in the presence of a high concentration of ethanolamine with a specific activity of about 0.16 mu mol/min/mg of protein at 37 degrees C. On the basis of cochromatographies, pH dependence, heat inactivation, and effects of inhibitors such as arachidonyl trifluoromethyl ketone, p-chloromercuribenzoic acid, diisopropyl fluorophosphate, and phenylmethylsulfonyl fluoride, it was suggested that the anandamide amidohydrolase and synthase activities were attributable to a single enzyme protein.	UNIV TOKUSHIMA,SCH MED,DEPT BIOCHEM,TOKUSHIMA 770,JAPAN; JAPAN TOBACCO INC,CENT PHARMACEUT RES INST,TAKATSUKI,OSAKA 569,JAPAN	Tokushima University; Japan Tobacco Inc.								ABADJI V, 1994, J MED CHEM, V37, P1889, DOI 10.1021/jm00038a020; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHILDERS SR, 1994, BIOCHEM PHARMACOL, V47, P711, DOI 10.1016/0006-2952(94)90134-1; CRAWLEY JN, 1993, PHARMACOL BIOCHEM BE, V46, P967, DOI 10.1016/0091-3057(93)90230-Q; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; HASSLER DF, 1993, ADV LIPID RES, V26, P49; JOHNSON DE, 1993, PROSTAG LEUKOTR ESS, V48, P429, DOI 10.1016/0952-3278(93)90048-2; KIDO H, 1993, J BIOL CHEM, V268, P13406; KOPACZYK KC, 1965, J LIPID RES, V6, P140; KOUTEK B, 1994, J BIOL CHEM, V269, P22937; KRUSZKA KK, 1994, J BIOL CHEM, V269, P14345; MACKIE K, 1993, MOL PHARMACOL, V44, P498; SATO T, 1994, SEIKAGAKU, V66, P802; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; SCHMID PC, 1985, J BIOL CHEM, V260, P4145; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; UEDA N, 1995, BBA-LIPID LIPID MET, V1254, P127, DOI 10.1016/0005-2760(94)00170-4; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x; YAVIN E, 1969, BIOCHEMISTRY-US, V8, P1692, DOI 10.1021/bi00832a052	25	278	287	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23823	23827		10.1074/jbc.270.40.23823	http://dx.doi.org/10.1074/jbc.270.40.23823			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559559	hybrid			2022-12-27	WOS:A1995RY90900088
J	ADLER, V; SCHAFFER, A; KIM, J; DOLAN, L; RONAI, Z				ADLER, V; SCHAFFER, A; KIM, J; DOLAN, L; RONAI, Z			UV IRRADIATION AND HEAT-SHOCK MEDIATE JNK ACTIVATION VIA ALTERNATE PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN-DIPLOID FIBROBLASTS; C-JUN; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATION; ULTRAVIOLET-LIGHT; TYROSINE KINASES; DNA DAMAGE; V-JUN; GENE	To elucidate cellular pathways involved in Jun-NH2-terminal kinase (JNK) activation by different forms of stress, we have compared the effects of UV irradiation, heat shock, and H2O2. Using mouse fibroblast cells (3T3-4A) we show that while H2O2 is ineffective, UV and heat shock (HS) are potent inducers of JNK. The cellular pathways that mediate JNK activation after HS or UV exposure are distinctly different as can be concluded from the following observations: (i) H2O2 is a potent inhibitor of HS-induced but not of UV-induced JNK activation; (ii) Triton X-100-treated cells abolish the ability of UV, but not HS, to activate JNK; (iii) the free radical scavenger N-acetylcysteine inhibits UV- but not HS-mediated JNK activation; (iv) N-acetylcysteine inhibition is blocked by H2O2 in a dose-dependent manner; (v) a Cockayne syndrome-derived cell line exhibits JNK activation upon UV exposure, but not upon HS treatment. The significance of Jun phosphorylation by JNK after treatment with UV, HS, or H2O2 was evaluated by measuring Jun phosphorylation in vivo and also its binding activity in gel shifts. HS and UV, which are potent inducers of JNK, increased the level of c-Jun phosphorylation when this was measured by [P-32]orthophosphate labeling of 3T3-4A cultures. H2O2 had no such effect, Although H2O2 failed to activate JNK in vitro and to phosphorylate c-Jun in vivo, all three forms of stress were found to be potent inducers of binding to the AP1 target sequence. Overall, our data indicate that both membrane associated components and oxidative damage are involved in JNK activation by UV irradiation, whereas HS-mediated JNK activation, which appears to be mitochondrial-related, utilizes cellular sensors.	AMER HLTH FDN, MOLEC CARCINOGENESIS PROGRAM, VALHALLA, NY 10595 USA	American Health Foundation				Reinhart, Lisa/0000-0001-6266-3342; RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA-51995, CA-59908] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051995, R01CA059908, R29CA051995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1994, J BIOL CHEM, V269, P11186; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADLER V, 1995, IN PRESS CELL GROWTH; ADLER V, 1995, IN PRESS P NATL ACAD; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ANGEL P, 1989, New Biologist, V1, P35; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; CARLIN C, 1994, J CELL PHYSIOL, V160, P427, DOI 10.1002/jcp.1041600305; CERUTTI P, 1992, ANN NY ACAD SCI, V663, P158, DOI 10.1111/j.1749-6632.1992.tb38659.x; CHOI HS, 1991, J BIOL CHEM, V266, P11858; CHOI HS, 1990, J BIOL CHEM, V265, P18005; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENT P, 1993, MOL BIOL CELL, V4, P483, DOI 10.1091/mbc.4.5.483; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GATES RE, 1993, J RECEPTOR RES, V13, P829, DOI 10.3109/10799899309073696; HEINECKE JW, 1990, J BIOL CHEM, V265, P7717; HERRLICH P, 1994, CURR OPIN CELL BIOL, V6, P425, DOI 10.1016/0955-0674(94)90036-1; HEYDARI AR, 1993, MOL CELL BIOL, V13, P2909, DOI 10.1128/MCB.13.5.2909; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEONARDO AD, 1994, GENE DEV, V8, P2540; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIBOI E, 1984, VIROLOGY, V135, P440, DOI 10.1016/0042-6822(84)90199-5; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU AYC, 1991, J CELL PHYSIOL, V149, P560, DOI 10.1002/jcp.1041490327; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MORGAN IM, 1993, ONCOGENE, V8, P1135; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rahmsdorf H., 1992, INDUCED EFFECTS GENO, P141; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; RONAI Z, 1994, ENVIRON MOL MUTAGEN, V23, P157, DOI 10.1002/em.2850230302; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUTBERG SE, 1992, NUCLEIC ACIDS RES, V20, P4305, DOI 10.1093/nar/20.16.4305; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SECVIST JP, 1993, J BIOL CHEM, V268, P5886; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHIOZAKI K, 1994, MOL CELL BIOL, V14, P3742, DOI 10.1128/MCB.14.6.3742; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YAN MH, 1994, NATURE, V372, P798; YANG YM, 1993, CELL GROWTH DIFFER, V4, P595; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	61	190	198	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26071	26077		10.1074/jbc.270.44.26071	http://dx.doi.org/10.1074/jbc.270.44.26071			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592807	hybrid			2022-12-27	WOS:A1995TC97800014
J	CAMPOY, FJ; MEEHAN, RR; MCKAY, S; NIXON, J; BIRD, A				CAMPOY, FJ; MEEHAN, RR; MCKAY, S; NIXON, J; BIRD, A			BINDING OF HISTONE H1 TO DNA IS INDIFFERENT TO METHYLATION AT CPG SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDINE KINASE GENE; RNA POLYMERASE-II; CHROMATIN STRUCTURE; RESTRICTION ENDONUCLEASES; CHROMOSOMAL PROTEIN; PROMOTER SEQUENCE; GLOBIN GENE; TRANSCRIPTION; EXPRESSION; INHIBITION	The possibility that histone H1 binds preferentially to DNA containing 5-methylcytosine in the dinucleotide CpG is appealing, as it could help to explain the repressive effects of methylation on gene activity, In this study, the affinity of purified H1 for methylated and non-methylated DNA sequences has been tested using both naked DNA and chromatin, Based on a variety of assays (bandshifts, filter-binding assays, Southwestern blots, and nuclease sensitivity assays), we conclude that H1 has no significant preference for binding to naked methylated DNA, Similarly, H1 showed the same affinities for methylated and non-methylated DNA when assembled into chromatin in a Xenopus oocyte extract. Thus potential cooperative interaction of H1 with polynucleosomal complexes is not enhanced by the presence of DNA methylation.	UNIV EDINBURGH,INST CELL & MOLEC BIOL,EDINBURGH EH9 3JR,MIDLOTHIAN,SCOTLAND	University of Edinburgh				Meehan, Richard/0000-0001-6471-6882; Bird, Adrian/0000-0002-8600-0372	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; BALL DJ, 1983, P NATL ACAD SCI-BIOL, V80, P5490, DOI 10.1073/pnas.80.18.5490; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; BUSCHHAUSEN G, 1985, NUCLEIC ACIDS RES, V13, P5503, DOI 10.1093/nar/13.15.5503; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; BUTKUS V, 1987, NUCLEIC ACIDS RES, V15, P7091, DOI 10.1093/nar/15.17.7091; CLARK DJ, 1986, J MOL BIOL, V187, P569, DOI 10.1016/0022-2836(86)90335-9; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DREW HR, 1987, J MOL BIOL, V197, P485, DOI 10.1016/0022-2836(87)90560-2; FELSENFELD G, 1982, COLD SPRING HARB SYM, V47, P577; HALMER L, 1995, NUCLEIC ACIDS RES, V23, P773, DOI 10.1093/nar/23.5.773; HEIERMANN R, 1985, NUCLEIC ACIDS RES, V13, P2709, DOI 10.1093/nar/13.8.2709; HIGURASHI M, 1991, J BIOL CHEM, V266, P8619; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JOHNSON CA, 1995, BIOCHEM J, V305, P791, DOI 10.1042/bj3050791; JOST JP, 1992, P NATL ACAD SCI USA, V89, P9499, DOI 10.1073/pnas.89.20.9499; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEVINE A, 1991, P NATL ACAD SCI USA, V88, P6515, DOI 10.1073/pnas.88.15.6515; LEVINE A, 1993, J BIOL CHEM, V268, P21754; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MACLEOD D, 1983, NATURE, V306, P200, DOI 10.1038/306200a0; MCCLELLAND M, 1992, NUCLEIC ACIDS RES, V20, P2145, DOI 10.1093/nar/20.suppl.2145; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MURRAY EJ, 1987, EMBO J, V6, P2329, DOI 10.1002/j.1460-2075.1987.tb02508.x; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; PAWLAK A, 1991, NUCLEIC ACIDS RES, V19, P1029; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; VARDIMON L, 1982, P NATL ACAD SCI-BIOL, V79, P1073, DOI 10.1073/pnas.79.4.1073; WAALWIJK C, 1978, NUCLEIC ACIDS RES, V5, P3231, DOI 10.1093/nar/5.9.3231; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; WOLFFE AP, 1989, EMBO J, V8, P527, DOI 10.1002/j.1460-2075.1989.tb03407.x	43	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26473	26481		10.1074/jbc.270.44.26473	http://dx.doi.org/10.1074/jbc.270.44.26473			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592864	hybrid			2022-12-27	WOS:A1995TC97800071
J	COX, MM				COX, MM			ALIGNMENT OF 3 (BUT NOT 4) DNA STRANDS WITHIN A RECA PROTEIN FILAMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ESCHERICHIA-COLI RECA; LINEAR DICHROISM SPECTROSCOPY; DUPLEX DNA; 3-STRANDED DNA; ATP HYDROLYSIS; HOMOLOGOUS RECOGNITION; GENETIC-RECOMBINATION; EXCHANGE; COMPLEXES; MOLECULES				COX, MM (corresponding author), UNIV WISCONSIN, DEPT BIOCHEM, 420 HENRY MALL, MADISON, WI 53706 USA.							ABOULELA F, 1992, NATURE, V360, P280, DOI 10.1038/360280a0; ADZUMA K, 1992, GENE DEV, V6, P1679, DOI 10.1101/gad.6.9.1679; BALIGA R, 1995, IN PRESS P NATL ACAD, V92; BEDALE WA, 1993, J BIOL CHEM, V268, P15004; BURNETT B, 1994, J MOL BIOL, V238, P540, DOI 10.1006/jmbi.1994.1313; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; CHIU SK, 1993, BIOCHEMISTRY-US, V32, P13146, DOI 10.1021/bi00211a025; CHIU SK, 1990, J BIOL CHEM, V265, P21262; CHOW SA, 1992, J MOL BIOL, V223, P79, DOI 10.1016/0022-2836(92)90717-X; CONLEY EC, 1990, J BIOL CHEM, V265, P10156; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; FISHEL RA, 1988, MECHANISMS CONSEQUEN, V83, P23; HAWLEY RS, 1993, CELL, V72, P301, DOI 10.1016/0092-8674(93)90108-3; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; JAIN SK, 1992, J BIOL CHEM, V267, P4215; JAIN SK, 1994, J BIOL CHEM, V269, P20653; JAIN SK, 1995, J BIOL CHEM, V270, P4943, DOI 10.1074/jbc.270.9.4943; KIM JI, 1992, J BIOL CHEM, V267, P16444; KONFORTI BB, 1992, J MOL BIOL, V227, P38, DOI 10.1016/0022-2836(92)90680-I; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KOWALCZYKOWSKI SC, 1987, P NATL ACAD SCI USA, V84, P3127, DOI 10.1073/pnas.84.10.3127; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KUBISTA M, 1990, J BIOL CHEM, V265, P18891; KUBISTA M, 1995, BIOL STRUCTURE FUNCT; KURUMIZAKA H, 1994, NUCLEIC ACIDS RES, V22, P3387, DOI 10.1093/nar/22.16.3387; LACKS S, 1966, GENETICS, V53, P207; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; Maher L J 3rd, 1991, Antisense Res Dev, V1, P277; MCGAVIN S, 1971, J MOL BIOL, V55, P293, DOI 10.1016/0022-2836(71)90201-4; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MULLER B, 1990, J MOL BIOL, V212, P97, DOI 10.1016/0022-2836(90)90307-8; NORDEN B, 1992, Q REV BIOPHYS, V25, P51, DOI 10.1017/S0033583500004728; PUGH BF, 1989, J MOL BIOL, V205, P487, DOI 10.1016/0022-2836(89)90219-2; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; PUGH BF, 1987, J BIOL CHEM, V262, P1326; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; RAO BJ, 1993, J MOL BIOL, V229, P328, DOI 10.1006/jmbi.1993.1038; RAO BJ, 1990, J MOL BIOL, V213, P789, DOI 10.1016/S0022-2836(05)80264-5; RAO BJ, 1995, TRENDS BIOCHEM SCI, V20, P109, DOI 10.1016/S0968-0004(00)88976-8; RAO BJ, 1994, P NATL ACAD SCI USA, V91, P6161, DOI 10.1073/pnas.91.13.6161; RAO BJ, 1993, P NATL ACAD SCI USA, V90, P6646, DOI 10.1073/pnas.90.14.6646; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; SCHUTTE BC, 1988, BIOCHEMISTRY-US, V27, P7886, DOI 10.1021/bi00420a046; SHCHYOLKINA AK, 1994, FEBS LETT, V339, P113, DOI 10.1016/0014-5793(94)80396-X; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; SMITH GR, 1991, CELL, V64, P19, DOI 10.1016/0092-8674(91)90205-D; STASIAK A, 1992, MOL MICROBIOL, V6, P3267, DOI 10.1111/j.1365-2958.1992.tb02194.x; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; STASIAK A, 1994, EXPERIENTIA, V50, P192, DOI 10.1007/BF01924002; TAKAHASHI M, 1994, ADV BIOPHYS, V30, P1, DOI 10.1016/0065-227X(94)90009-4; TAKAHASHI M, 1991, BIOCHIMIE, V73, P219, DOI 10.1016/0300-9084(91)90205-F; UMLAUF S, 1990, THESIS U WISCONSIN M; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; WEST SC, 1991, BIOESSAYS, V13, P37, DOI 10.1002/bies.950130107; WEST SC, 1984, CELL, V37, P683, DOI 10.1016/0092-8674(84)90401-X; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WILSON JH, 1979, P NATL ACAD SCI USA, V76, P3641, DOI 10.1073/pnas.76.8.3641; WU AM, 1983, P NATL ACAD SCI-BIOL, V80, P1256, DOI 10.1073/pnas.80.5.1256; ZHURKIN VB, 1994, J MOL BIOL, V239, P181, DOI 10.1006/jmbi.1994.1362; ZYSKIND JW, 1992, MOL MICROBIOL, V6, P2525	68	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26021	26024		10.1074/jbc.270.44.26021	http://dx.doi.org/10.1074/jbc.270.44.26021			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592794	hybrid			2022-12-27	WOS:A1995TC97800001
J	GANOZA, MC; CUNNINGHAM, C; GREEN, RM				GANOZA, MC; CUNNINGHAM, C; GREEN, RM			A NEW FACTOR FROM ESCHERICHIA-COLI AFFECTS TRANSLOCATION OF MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; TRANSLATION; TU; RECONSTRUCTION; PURIFICATION; TERMINATION; RIBOSOME; MODEL; GENE	Reconstitution of protein synthesis from purified translation factors on ribosomes from Escherichia coli has revealed the requirement for a protein, W, that affects chain elongation and is essential to reconstitute the process (Ganoza, M. C., Cunningham, C., and Green, R. M. (1985) Proc, Natl. Acad. Sci. U.S.A. 82, 1648-1652). We report that W has no effect on initiation complex formation by 30 or 70 S ribosomes or on the association of ribosomal subunits, peptide bond synthesis, or binding Ala-tRNA, which is the second amino acid of the coat protein of the MS2 RNA virion. W has a pronounced effect on tripeptide synthesis, and is obligatory for the synthesis of the coat protein or of the hexapeptide encoded by f2am3 RNA, Extracts from a temperature-sensitive mutant of the translocase, EF-G, were purified free of the W protein and were used to score for translocation defects, W is required for binding Ser-tRNA, the third N-terminal amino acid of the MS2 or f2 RNA coat protein to ribosomes bearing fMet-Ala-tRNA, as well as for the ejection of deacyl-tRNA from ribosomes, which occurred concomitant with the binding of the Ser-tRNA. We propose that W functions by ejecting tRNAs from ribosomes in a step that precedes the movement of mRNA during translocation.			GANOZA, MC (corresponding author), UNIV TORONTO,BANTING & BEST DEPT MED RES,112 COLL ST,TORONTO,ON M5G 1L6,CANADA.			GANOZA MELGAREJO, MICHAEL RICHARD/0000-0003-0196-8104				AOKI H, 1991, NUCLEIC ACIDS RES, V19, P6215, DOI 10.1093/nar/19.22.6215; ARAI KI, 1972, J BIOL CHEM, V247, P7029; CAPECHI M, 1967, BIOCHEM BIOPH RES CO, V28, P173; CHUNG DG, 1990, RIBOSOMES PROTEIN SY, P69; EHRENBERG M, 1990, J MOL BIOL, V211, P739, DOI 10.1016/0022-2836(90)90074-V; GANOZA MC, 1993, EUR J BIOCHEM, V217, P839, DOI 10.1111/j.1432-1033.1993.tb18312.x; GANOZA MC, 1984, J BIOL CHEM, V259, P4101; GANOZA MC, 1985, P NATL ACAD SCI USA, V82, P1648, DOI 10.1073/pnas.82.6.1648; GANOZA MC, 1976, EUR J BIOCHEM, V65, P613, DOI 10.1111/j.1432-1033.1976.tb10379.x; GANOZA MC, 1989, EUR J BIOCHEM, V178, P663, DOI 10.1111/j.1432-1033.1989.tb14496.x; GESTELAND RF, 1966, J MOL BIOL, V16, P67, DOI 10.1016/S0022-2836(66)80263-2; GORDON J, 1971, METHODS ENZYMOL    C, V20, P281; GREEN RH, 1985, BIOCHEM BIOPH RES CO, V126, P792, DOI 10.1016/0006-291X(85)90254-2; Hershey J W, 1979, Methods Enzymol, V60, P3; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V70, P4135; KALTSCHM.E, 1970, ANAL BIOCHEM, V36, P401, DOI 10.1016/0003-2697(70)90376-3; KUNG H, 1977, J BIOL CHEM, V252, P6889; KUNG HF, 1977, ARCH BIOCHEM BIOPHYS, V187, P457; KURLAND CG, 1992, ANNU REV GENET, V26, P29, DOI 10.1146/annurev.ge.26.120192.000333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILJAS A, 1990, RIBOSOME, P309; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCASLENARD J, 1974, ENZYMES, V10, P53; Miller D L, 1974, Methods Enzymol, V30, P219; MOAZED D, 1989, NATURE, V242, P142; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NIERHAUS KH, 1990, BIOCHEMISTRY-US, V29, P4997, DOI 10.1021/bi00473a001; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; PARKER J, 1989, MICROBIOL REV, V53, P273, DOI 10.1128/MMBR.53.3.273-298.1989; RYOJI M, 1981, J BIOL CHEM, V256, P5798; Sambrook J, 1989, MOL CLONING LABORATO; SUTTLE DP, 1973, BIOCHEM BIOPH RES CO, V51, P376, DOI 10.1016/0006-291X(73)91268-0; TOCCHINIVALENTI.GP, 1969, COLD SPRING HARB SYM, V34, P463; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; WEISSBACH H, 1979, RIBOSOMES STRUCTURE, P357	36	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26377	26381		10.1074/jbc.270.44.26377	http://dx.doi.org/10.1074/jbc.270.44.26377			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592851	hybrid			2022-12-27	WOS:A1995TC97800058
J	WALTNER, M; WEINER, H				WALTNER, M; WEINER, H			CONVERSION OF A NONPROCESSED MITOCHONDRIAL PRECURSOR PROTEIN INTO ONE THAT IS PROCESSED BY THE MITOCHONDRIAL PROCESSING PEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ALDEHYDE DEHYDROGENASE; TARGETING PEPTIDES; TRANSLATION SYSTEM; YEAST MITOCHONDRIA; SIGNAL PEPTIDES; BETA-SUBUNIT; IMPORT; PRESEQUENCE; CLEAVAGE	Mitochondrial processing peptidase (MPP) cleaves the signal sequence from a variety of mitochondrial pre cursor proteins. A subset of mitochondrial proteins, including rhodanese and 3-oxoacyl-CoA thiolase, are imported into the matrix space, yet are not processed. Rhodanese signal peptide and translated protein were recognized by MPP, as both were inhibitors of processing. The signal peptide of precursor aldehyde dehydrogenase consists of a helix-linker helix motif but when the RGP linker is removed, processing no longer occurs (Thornton, K., Wang, Y., Weiner, H., and Gorenstein, D. G. (1993) J. Biol. Chem. 268, 19906-19914). Disruption of the helical signal sequence of rhodanese by the addition of the RGP linker did not allow cleavage to occur. However, addition of a putative cleavage site allowed the protein to be processed. The same cleavage site was added to 3-oxoacyl-CoA thiolase, but this protein was still not processed, Thiolase and linker-deleted aldehyde dehydrogenase signal peptides were poor inhibitors of MPP. It can be concluded that both a processing site and the structure surrounding this site are important for MPP recognition.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA005812, R37AA005812] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA00028, AA05812] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ARAKAWA H, 1990, J BIOCHEM-TOKYO, V107, P160, DOI 10.1093/oxfordjournals.jbchem.a123001; ARAKAWA H, 1987, EMBO J, V6, P1361, DOI 10.1002/j.1460-2075.1987.tb02376.x; ARRETZ M, 1994, J BIOL CHEM, V269, P4959; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BELTZER JP, 1988, J BIOL CHEM, V263, P368; BRUCH MD, 1992, BIOCHIM BIOPHYS ACTA, V1159, P81, DOI 10.1016/0167-4838(92)90078-R; ENDO T, 1989, J BIOCHEM, V106, P396, DOI 10.1093/oxfordjournals.jbchem.a122864; FINOCCHIARO G, 1993, EUR J BIOCHEM, V213, P1103; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GLASER E, 1994, FEBS LETT, V346, P83, DOI 10.1016/0014-5793(94)00312-2; GLICK B, 1991, ANNU REV GENET, V25, P21; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; JARVIS JA, 1995, J BIOL CHEM, V270, P1323, DOI 10.1074/jbc.270.3.1323; KALOUSEK F, 1992, EMBO J, V8, P2803; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAARSE AC, 1984, EMBO J, V3, P2831, DOI 10.1002/j.1460-2075.1984.tb02216.x; MACLACHLAN LK, 1994, BIOCHEM J, V303, P657, DOI 10.1042/bj3030657; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MILLER DM, 1991, J BIOL CHEM, V266, P4686; OU WJ, 1994, J BIOL CHEM, V269, P24673; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; PAK YK, 1990, J BIOL CHEM, V265, P14298; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; ROISE D, 1988, J BIOL CHEM, V263, P4509; RYAN MT, 1994, FEBS LETT, V337, P152, DOI 10.1016/0014-5793(94)80263-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER G, 1995, BIOPHYS J, V68, P434, DOI 10.1016/S0006-3495(95)80205-5; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WANG TTY, 1989, ARCH BIOCHEM BIOPHYS, V272, P440, DOI 10.1016/0003-9861(89)90238-5; WANG Y, 1993, J BIOL CHEM, V268, P4759; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANG M, 1991, J BIOL CHEM, V266, P6416	42	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26311	26317		10.1074/jbc.270.44.26311	http://dx.doi.org/10.1074/jbc.270.44.26311			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592841	hybrid			2022-12-27	WOS:A1995TC97800048
J	KASHIWAGI, K; ENDO, H; KOBAYASHI, H; TAKIO, K; IGARASHI, K				KASHIWAGI, K; ENDO, H; KOBAYASHI, H; TAKIO, K; IGARASHI, K			SPERMIDINE-PREFERENTIAL UPTAKE SYSTEM IN ESCHERICHIA-COLI - ATP HYDROLYSIS BY POTA PROTEIN AND ITS ASSOCIATION WITH MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTRESCINE TRANSPORT-SYSTEM; HISTIDINE PERMEASE; NUCLEOTIDE-BINDING; MALTOSE TRANSPORT; PERIPLASMIC PERMEASES; POLYAMINE TRANSPORT; IDENTIFICATION; COMPONENTS; MUTANTS; GENE	PotA protein, one of the components of the spermidine-preferential uptake system in Escherichia coli, was purified to homogeneity, and some of its properties were examined, PotA protein showed Mg2+- and SH-dependent ATPase activity. The specific activity was approximately 400 nmol/min/mg of protein and the K-m value for ATP was 385 mu M. The nature of the ATP binding site was explored by identification of the amino acid residue photoaffinity-labeled with 8-azido-ATP. It was found that 8-azido-ATP was attached to cysteine 26. In the spermidine transport-deficient mutant E. coli NR1596, valine 135 of PotA protein, which is located between two consensus amino acid sequences for nucleotide binding (50-57 and 168-173), was replaced by methionine (Kashiwagi, K., Miyamoto, S., Nukui, E., Kobayashi, H., and Igarashi, It. (1993) J. Biol. Chem. 268, 19358-19363). This mutated PotA protein could be labeled with 8-azido-ATP, but showed very low ATPase activity. To identify which cysteine is involved in the function of potA protein, cysteines 26, 54, and 276 were replaced by alanine, threonine, and alanine, respectively. Among the three mutated PotA proteins, the mutated PotA protein C54T only lost both ATPase and spermidine uptake activities. The results taken together indicate that the adenine portion of ATP interacts with a domain close to the NH2-terminal end of PotA protein, and active centers of ATP hydrolysis are located both within and between the two consensus amino acid sequences for nucleotide binding. Association of PotA protein with membranes was strengthened by the existence of channel forming PotB and PotC proteins. ATPase of PotA protein was inhibited by spermidine, suggesting that uptake inhibition by spermidine may function during this process.	CHIBA UNIV,FAC PHARMACEUT SCI,INAGE KU,CHIBA 263,JAPAN; INST PHYS & CHEM RES,DIV BIOMOLEC CHARACTERIZAT,WAKO,SAITAMA 35001,JAPAN	Chiba University; RIKEN				Igarashi, Kazuei/0000-0003-3751-3187				AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CUNNINGHAMRUNDL.S, 1975, J BACTERIOL, V124, P791; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; FUJII S, 1981, BIOCHIM BIOPHYS ACTA, V661, P342, DOI 10.1016/0005-2744(81)90023-1; FUKUCHI J, 1994, J BIOL CHEM, V269, P22581; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; GILSON E, 1982, NUCLEIC ACIDS RES, V10, P7449, DOI 10.1093/nar/10.22.7449; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HOUNG HS, 1986, J BACTERIOL, V168, P1040, DOI 10.1128/jb.168.2.1040-1044.1986; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KASHIWAGI K, 1990, J BIOL CHEM, V265, P20893; KASHIWAGI K, 1993, J BIOL CHEM, V268, P19358; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; KASHIWAGI K, 1986, J BACTERIOL, V165, P972, DOI 10.1128/jb.165.3.972-977.1986; KASHIWAGI K, 1988, J BACTERIOL, V170, P3131, DOI 10.1128/jb.170.7.3131-3135.1988; KASHIWAGI K, 1991, J BIOL CHEM, V26, P20922; KERPPOLA RE, 1992, J BIOL CHEM, V267, P2329; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Maniatis T., 1982, MOL CLONING LAB MANU, P250; MIMURA CS, 1990, J BIOL CHEM, V265, P19535; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MUNRO GF, 1974, J BACTERIOL, V118, P952, DOI 10.1128/JB.118.3.952-963.1974; NEILSEN PJ, 1982, J BIOL CHEM, V257, P12316; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; PEGG AE, 1988, CANCER RES, V48, P759; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PISTOCCHI R, 1993, J BIOL CHEM, V268, P146; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1966, J BIOL CHEM, V241, P3714; WALTER C, 1992, J BIOL CHEM, V267, P8863; WATANABE Y, 1981, BIOCH BIPHYS ACTA, V633, P87; YAMAGUCHI K, 1985, MOL GEN GENET, V200, P362, DOI 10.1007/BF00425718; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	42	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25377	25382		10.1074/jbc.270.43.25377	http://dx.doi.org/10.1074/jbc.270.43.25377			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592703	hybrid			2022-12-27	WOS:A1995TB46600019
J	LEIPOLD, RJ; BOZARTH, TA; RACANELLI, AL; DICKER, IB				LEIPOLD, RJ; BOZARTH, TA; RACANELLI, AL; DICKER, IB			MATHEMATICAL-MODEL OF SERINE-PROTEASE INHIBITION IN THE TISSUE FACTOR PATHWAY TO THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FACTOR-VIII; COAGULATION FACTOR-X; BLOOD-COAGULATION; PROTHROMBINASE COMPLEX; PHOSPHOLIPID-VESICLES; FACTOR-IXA; FACTOR-VA; ACTIVATION; PLASMA; SIMULATION	A mathematical model has been developed to simulate the generation of thrombin by the tissue factor pathway. The model gives reasonable predictions of published experimental results without the adjustment of any parameter values. The model also accounts explicitly for the effects of serine protease inhibitors on thrombin generation, Simulations to define the optimum affinity profile of an inhibitor in this system indicate that for an inhibitor simultaneously potent against VIIa, IXa, and Xa, inhibition of thrombin generation decreases dramatically as the affinity for thrombin increases. Additional simulations show that the reason for this behavior is the sequestration of the inhibitor by small amounts of thrombin generated early in the reaction. This model is also useful for predicting the potency of compounds that inhibit thrombosis in rats, We believe that this is the first mathematical model of blood coagulation that considers the effects of exogenous inhibitors. Such a model, or extensions thereof, should be useful for evaluating targets for therapeutic intervention in the processes of blood coagulation.			LEIPOLD, RJ (corresponding author), DUPONT MERCK PHARMACEUT CO, EXPTL STN, BLDG 400, WILMINGTON, DE 19880 USA.							BAUMANN P, 1991, HAEMOSTASIS, V21, P329; BOM VJJ, 1990, THROMB HAEMOSTASIS, V63, P224; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; GIESEN PLA, 1991, J BIOL CHEM, V266, P18720; HARKER LA, 1994, BLOOD COAGUL FIBRIN, V5, pS47, DOI 10.1097/00001721-199401000-00007; HEMKER HC, 1986, THROMB HAEMOSTASIS, V56, P9; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; JESTY J, 1993, BIOCHEMISTRY-US, V32, P6266, DOI 10.1021/bi00075a021; JONES KC, 1994, J BIOL CHEM, V269, P23367; JONES KC, 1995, J BIOL CHEM, V270, P9026; KERR RA, 1994, SCIENCE, V265, P1528, DOI 10.1126/science.265.5178.1528; KESSELS H, 1994, COMPUT BIOL MED, V24, P277, DOI 10.1016/0010-4825(94)90024-8; KHANIN MA, 1991, THROMB RES, V64, P659, DOI 10.1016/0049-3848(91)90066-6; KHANIN MA, 1989, J THEOR BIOL, V136, P127, DOI 10.1016/S0022-5193(89)80220-6; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; LINIGER W, 1980, B MATH BIOL, V42, P861; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NAKAMURA M, 1994, J CLIMATE, V7, P1870, DOI 10.1175/1520-0442(1994)007<1870:DOTTCB>2.0.CO;2; NASKI MC, 1991, J BIOL CHEM, V266, P13003; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NEUENSCHWANDER P, 1988, BLOOD, V72, P1761; NEUENSCHWANDER PF, 1992, ARCH BIOCHEM BIOPHYS, V296, P426, DOI 10.1016/0003-9861(92)90593-L; POHL B, 1994, HAEMOSTASIS, V24, P325; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; TANS G, 1994, J BIOL CHEM, V269, P15969; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WILLEMS GM, 1991, HAEMOSTASIS, V21, P197; WILLEMS GM, 1991, HAEMOSTASIS, V21, P248	34	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25383	25387		10.1074/jbc.270.43.25383	http://dx.doi.org/10.1074/jbc.270.43.25383			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592704	hybrid			2022-12-27	WOS:A1995TB46600020
J	LLOYD, DB; THOMPSON, JF				LLOYD, DB; THOMPSON, JF			TRANSCRIPTIONAL MODULATORS AFFECT IN-VIVO PROTEIN FINDING TO THE LOW-DENSITY-LIPOPROTEIN RECEPTOR AND 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY ELEMENT; LEUCINE ZIPPER PROTEIN; BOX-BINDING-PROTEINS; A REDUCTASE; GENE-TRANSCRIPTION; MESSENGER-RNA; HEPG2 CELLS; IDENTIFICATION; SEQUENCE; SITE	Treatment of HepGa cells with known effecters of low density lipoprotein receptor (LDLR) gene expression altered the in vivo pattern of protein-DNA interactions in the promoter. The observed changes are consistent with proteins binding in vivo to the sterol regulatory element (SRE), to Sp1-like sites, as well as 60 other regions. Protein bound to the SRE in all conditions, but the nature of the dimethyl sulfate reactivity changed depending on the physiological state of the cell. Hypermethylation within the SRE of the low density lipoprotein receptor promoter was observed when cells were treated with cholesterol synthesis inhibitors, insulin, or phorbol 12-myristate 13-acetate, suggesting that the SRE regulates this promoter through sterol-independent as well as sterol-dependent mechanisms. No significant changes were observed in binding to the Sp1-like sites, suggesting that differential binding to these sites does not play a role in altered transcription levels. Analysis of the 3-hydroxy-3-methylglutaryl coenzyme A reductase promoter also revealed protections that varied in a cell type-specific manner. Binding to the 3-hydroxy-3-methylglutaryl coenzyme A reductase SRE and putative nuclear factor 1 sites could be observed but varied little in different physiological conditions.	PFIZER INC,DIV CENT RES,DEPT MOLEC SCI,GROTON,CT 06340	Pfizer								AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CHEN XR, 1994, ONCOGENE, V9, P3179; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; CUTHBERT JA, 1990, J LIPID RES, V31, P2067; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DIRKS RPH, 1995, NUCLEIC ACIDS RES, V23, P1119, DOI 10.1093/nar/23.7.1119; ELLSWORTH JL, 1995, J LIPID RES, V36, P383; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIL G, 1988, J BIOL CHEM, V263, P19009; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; GROVE RI, 1991, J BIOL CHEM, V266, P18194; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOIVISTO UM, 1994, P NATL ACAD SCI USA, V91, P10526, DOI 10.1073/pnas.91.22.10526; LUSKEY KL, 1987, MOL CELL BIOL, V7, P1881, DOI 10.1128/MCB.7.5.1881; MAZZONE T, 1989, J BIOL CHEM, V264, P1787; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MOORBY CD, 1992, ATHEROSCLEROSIS, V97, P21, DOI 10.1016/0021-9150(92)90047-K; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURAKAMI H, 1982, P NATL ACAD SCI-BIOL, V79, P1158, DOI 10.1073/pnas.79.4.1158; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TAKAGI K, 1989, J BIOL CHEM, V264, P12352; WADE DP, 1989, EUR J BIOCHEM, V181, P727, DOI 10.1111/j.1432-1033.1989.tb14784.x; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	42	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25812	25818		10.1074/jbc.270.43.25812	http://dx.doi.org/10.1074/jbc.270.43.25812			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592765	hybrid			2022-12-27	WOS:A1995TB46600082
J	XU, P; ZOT, AS; ZOT, HG				XU, P; ZOT, AS; ZOT, HG			IDENTIFICATION OF ACAN125 AS A MYOSIN-I-BINDING PROTEIN PRESENT WITH MYOSIN-I ON CELLULAR ORGANELLES OF ACANTHAMOEBA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SH3 DOMAINS; LOCALIZATION; ACTIN	We have discovered the first protein to bind to a nonfilamentous myosin, aside from actin. This protein, Acan125, is a 125-kDa protein from Acanthamoeba that associates with the SH3 domain of Acanthamoeba myosin-IC and not the SH3 domain of human fodrin. Antibodies raised against Acan125 recognize a single protein of 125 kDa hom a whole cell lysate of Acanthamoeba; antibodies to myosin-I (M1.7 and M1.8) do not recognize Acan125 on the same blot. Double labeling of Acanthamoeba show Acan125 and myosin-I to be present on the same intracellular organelle, most likely amoebastomes. Immunoprecipitation with either anti-myosin-I or anti-Acan125 antibodies coprecipitates both Acan125 and myosin-I from a lysate of Acanthamoeba, demonstrating that Acan125 interacts with native myosin-I.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; BAINES IC, 1992, J CELL BIOL, V119, P1193, DOI 10.1083/jcb.119.5.1193; BAINES IC, 1989, J CELL BIOL, V111, P1895; BEMENT WM, 1994, J MOL BIOL, V243, P356, DOI 10.1006/jmbi.1994.1662; CONRAD PA, 1993, J CELL BIOL, V120, P1381, DOI 10.1083/jcb.120.6.1381; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FINAN P, 1994, J BIOL CHEM, V269, P13752; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GOODSON HV, 1995, CELL MOTIL CYTOSKEL, V30, P73, DOI 10.1002/cm.970300109; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HAGAN SJ, 1986, J CELL BIOL, V103, P2121; HAMMER JA, 1994, J MUSCLE RES CELL M, V15, P1, DOI 10.1007/BF00123827; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYDEN SM, 1990, J CELL BIOL, V111, P443, DOI 10.1083/jcb.111.2.443; JUNG G, 1994, FEBS LETT, V342, P197, DOI 10.1016/0014-5793(94)80500-8; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MIKI H, 1994, J BIOL CHEM, V269, P5489; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROSENFELD SS, 1994, BIOCHEMISTRY-US, V33, P2322, DOI 10.1021/bi00174a045; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; STOFFLER HE, 1995, J CELL BIOL, V129, P819, DOI 10.1083/jcb.129.3.819; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; YONEMURA S, 1992, J CELL SCI, V102, P629; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	35	48	48	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25316	25319		10.1074/jbc.270.43.25316	http://dx.doi.org/10.1074/jbc.270.43.25316			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592689	hybrid			2022-12-27	WOS:A1995TB46600005
J	COUMAILLEAU, P; POELLINGER, L; GUSTAFSSON, JA; WHITELAW, ML				COUMAILLEAU, P; POELLINGER, L; GUSTAFSSON, JA; WHITELAW, ML			DEFINITION OF A MINIMAL DOMAIN OF THE DIOXIN RECEPTOR THAT IS ASSOCIATED WITH HSP90 AND MAINTAINS WILD-TYPE LIGAND-BINDING AFFINITY AND SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; RAT GLUCOCORTICOID RECEPTORS; LOOP-HELIX PROTEINS; AH-RECEPTOR; NUCLEAR RECEPTORS; ESCHERICHIA-COLI; HORMONE-BINDING; MR; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; EXPRESSION	The dioxin receptor is a cytoplasmic basic helix-loop-helix/Per-Arnt-Sim homology (bHLH/PAS) protein known to bind planar polycyclic ligands including polycyclic aromatic hydrocarbons, benzoflavones, heterocyclic amines, and halogenated aromatic hydrocarbons, e.g. dioxins. Ligand-induced activation of the dioxin receptor initiates a process whereby the receptor is transformed into a nuclear transcription factor complex with a specific bHLH/PAS partner protein, Arnt. In analogy to the glucocorticoid receptor, the latent dioxin receptor is found associated with the molecular chaperone hsp90. We have defined and isolated a minimal ligand binding domain of the dioxin receptor from the central PAS region, comprising of amino acids 230 to 421, and found this domain to interact with hsp90 in vitro. Expression of the minimal ligand binding domain in wheat germ lysates or bacteria, systems which harbor hsp90 homologs unable to interact with the glucocorticoid or dioxin receptors, resulted in non-ligand binding forms of this minimal 230 to 421 fragment. Importantly, affinity of the minimal ligand binding domain for dioxin was similar to the affinity inherent in the full-length dioxin receptor, and a profile of ligand structures which specifically bound the minimal ligand binding domain was found to be conserved between this domain and the native receptor. These experiments show that the minimal ligand binding domain maintains the quantitative and qualitative aspects of ligand binding exhibited by the full-length receptor, implying that the central ligand binding pocket may exist to accommodate all classes of specific dioxin receptor ligands, and that this pocket is critically dependent upon hsp90 for its ligand binding conformation.	KAROLINSKA INST, HUDDINGE UNIV HOSP F60, NOVUM, DEPT BIOSCI, S-14186 HUDDINGE, SWEDEN; KAROLINSKA INST, HUDDINGE UNIV HOSP F60, NOVUM, DEPT MED NUTR, S-14186 HUDDINGE, SWEDEN	Karolinska Institutet; Karolinska Institutet			coumailleau, pascal/K-1697-2015					ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; BARDWELL JCA, 1987, P NATL ACAD SCI USA, V84, P5177, DOI 10.1073/pnas.84.15.5177; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CAAMANO CA, 1993, BIOCHEMISTRY-US, V32, P8589, DOI 10.1021/bi00084a028; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CARVER LA, 1994, J BIOL CHEM, V269, P30109; CHAKRABORTI PK, 1991, BIOCHEM BIOPH RES CO, V176, P1338, DOI 10.1016/0006-291X(91)90433-8; CHAN WK, 1994, J BIOL CHEM, V269, P26464; CHEN HS, 1994, J BIOL CHEM, V269, P27554; CHENG L, 1994, J BIOL CHEM, V269, P18662; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; EMA M, 1994, J BIOL CHEM, V269, P27337; EUL J, 1989, EMBO J, V8, P83, DOI 10.1002/j.1460-2075.1989.tb03351.x; FRANKS RG, 1994, MECH DEVELOP, V45, P269, DOI 10.1016/0925-4773(94)90013-2; GILLNER M, 1993, MOL PHARMACOL, V44, P336; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GRADIN K, 1994, J BIOL CHEM, V269, P23800; HANKINSON O, 1994, TRENDS ENDOCRIN MET, V5, P240, DOI 10.1016/1043-2760(94)P3082-I; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HORD NG, 1994, MOL PHARMACOL, V46, P618; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; JAIN S, 1994, J BIOL CHEM, V269, P31518; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; LI H, 1994, J BIOL CHEM, V269, P28098; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; OHARANEMOTO Y, 1990, J STEROID BIOCHEM, V37, P481, DOI 10.1016/0960-0760(90)90391-W; OKINO ST, 1992, J BIOL CHEM, V267, P6991; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PERDEW GH, 1991, ARCH BIOCHEM BIOPHYS, V291, P284, DOI 10.1016/0003-9861(91)90136-7; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; PROBST MR, 1993, MOL PHARMACOL, V44, P511; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; Sambrook J, 1989, MOL CLONING LABORATO; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; WHITLOCK JP, 1994, TRENDS ENDOCRIN MET, V5, P183, DOI 10.1016/1043-2760(94)90075-2; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	63	137	141	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25291	25300		10.1074/jbc.270.42.25291	http://dx.doi.org/10.1074/jbc.270.42.25291			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559670	hybrid			2022-12-27	WOS:A1995TB46500104
J	EASON, MG; LIGGETT, SB				EASON, MG; LIGGETT, SB			IDENTIFICATION OF A G(S) COUPLING DOMAIN IN THE AMINO-TERMINUS OF THE 3RD INTRACELLULAR LOOP OF THE ALPHA(2A)-ADRENERGIC RECEPTOR - EVIDENCE FOR DISTINCT STRUCTURAL DETERMINANTS THAT CONFER G(S) VERSUS G(I) COUPLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; NUCLEOTIDE-BINDING PROTEINS; BETA-ADRENERGIC-RECEPTOR; HAMSTER OVARY CELLS; ALPHA-2-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE; PHOSPHATIDYLINOSITOL HYDROLYSIS; ALPHA(2)-ADRENERGIC RECEPTOR; CYTOPLASMIC DOMAINS; ACTIVATION	alpha(2)-Adrenergic receptors (alpha(2)AR) functionally couple not only to Gi but also to G(5). We investigated the aminoterminal portion of the third intracellular loop of the human alpha(2A)R ((alpha 2)C10) for potential G(s) coupling domains using site directed mutagenesis and recombinant expression in several different cell types. A deletion mutant and four chimeric receptors consisting of the alpha(2A)R with the analogous sequence from the 5-HT1A receptor (a G(i)-coupled receptor) and the beta(2)AR (a G(s)-coupled receptor) were expressed in Chinese hamster ovary cells, Chinese hamster fibroblasts, or COS-7 cells and examined for their ability to mediate stimulation or inhibition of membrane adenylyl cyclase activity or whole cell cAMP accumulation. In stably expressing Chinese hamster ovary cells, deletion of amino acids 221-231, which are in close proximity to the fifth transmembrane domain, eliminated alpha(2)C10-mediated stimulation of adenylyl cyclase activity, while alpha(2)C10-mediated inhibition was only moderately affected. This suggested that this region is important for G(s) coupling, prompting construction of the chimeric receptor mutants. Substitution of amino acids 218-235 with 5-HT1A receptor sequence entirely ablated agonist-promoted G(s) coupling, as compared with a 338 +/- 29% stimulation of adenylyl cyclase activity observed with the wild-type alpha(2)C10. In contrast, G(i) coupling for this mutant remained fully intact (57 +/- 2% versus 52 +/- 1% inhibition for wild-type alpha(2)C10). Similar substitution with beta(2)AR sequence had no effect on G(i) coupling but did reduce G(s) coupling. Two additional mutated alpha(2)C10 containing smaller substitutions of the amino-terminal region with 5-HT1A receptor sequence at residues 218-228 or 229-235 were then studied. While G(i) coupling remained intact with both mutants, G(s) coupling was ablated in the former but not the latter mutant receptor. Similar results were obtained using transfected Chinese hamster fibroblasts (which exclusively display alpha(2)AR-G(i) coupling) and COS-7 cells (which exclusively display alpha(2)AR-G(s) coupling). Thus, a critical determinant for G(s) coupling is contained within 11 amino acids (218-228) of the amino-terminal region of the third intracellular loop localized directly adjacent to the fifth transmembrane domain. `	UNIV CINCINNATI,COLL MED,DEPT MED PULM,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT PHARMACOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati			liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL41496, HL53436] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496, R01HL053436] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLUML K, 1994, P NATL ACAD SCI USA, V269, P7980; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CHAKRABARTI S, 1995, J NEUROCHEM, V64, P2534; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; CHEUNG AH, 1989, MOL PHARMACOL, V34, P132; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CRUCIANI RA, 1993, P NATL ACAD SCI USA, V90, P3019, DOI 10.1073/pnas.90.7.3019; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DELEAN A, 1981, MOL PHARMACOL, V21, P5; DITTMAN AH, 1994, BIOCHEMISTRY-US, V33, P943, DOI 10.1021/bi00170a013; DUMAN RS, 1986, J NEUROCHEM, V47, P800; DUZIC E, 1992, J BIOL CHEM, V267, P24045; EASON MG, 1992, J BIOL CHEM, V267, P15795; EASON MG, 1994, MOL PHARMACOL, V45, P696; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GREEN SA, 1994, J BIOL CHEM, V269, P26215; HERSHBERGER RE, 1994, ENDOCRINOLOGY, V134, P1277, DOI 10.1210/en.134.3.1277; IKEZU T, 1992, FEBS LETT, V311, P29, DOI 10.1016/0014-5793(92)81359-T; JANSSON CC, 1994, EUR J PHARM-MOLEC PH, V266, P165, DOI 10.1016/0922-4106(94)90106-6; JONES SB, 1991, MOL PHARMACOL, V39, P239; JONES SVP, 1991, MOL PHARMACOL, V40, P242; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOSUGI S, 1994, MOL ENDOCRINOL, V8, P498, DOI 10.1210/me.8.4.498; KUROSE H, 1994, J BIOL CHEM, V269, P10093; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; MALEK D, 1993, FEBS LETT, V325, P215; OCARROLL AM, 1994, MOL PHARMACOL, V46, P291; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PEPPERL DJ, 1993, MOL PHARMACOL, V44, P802; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; RAYMOND JR, 1991, J BIOL CHEM, V266, P14747; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; ULLRICH S, 1984, J BIOL CHEM, V259, P4111; VANSANDE J, 1993, EUR J PHARM-MOLEC PH, V247, P177, DOI 10.1016/0922-4106(93)90075-K; VARRAULT A, 1994, J BIOL CHEM, V269, P16720; WESS J, 1990, MOL PHARMACOL, V38, P517; WONG SKF, 1990, J BIOL CHEM, V269, P6219; YAMADA M, 1994, MOL PHARMACOL, V46, P470	47	95	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24753	24760		10.1074/jbc.270.42.24753	http://dx.doi.org/10.1074/jbc.270.42.24753			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559592	hybrid			2022-12-27	WOS:A1995TB46500026
J	GRUENKE, LD; KONOPKA, K; CADIEU, M; WASKELL, L				GRUENKE, LD; KONOPKA, K; CADIEU, M; WASKELL, L			THE STOICHIOMETRY OF THE CYTOCHROME P-450-CATALYZED METABOLISM OF METHOXYFLURANE AND BENZPHETAMINE IN THE PRESENCE AND ABSENCE OF CYTOCHROME B(5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; NUCLEAR MAGNETIC-RESONANCE; RABBIT LIVER; CATALYTIC ACTIVITY; OXYGEN ACTIVATION; HYDROGEN-PEROXIDE; CRYSTAL-STRUCTURE; RAT-LIVER; HYDROXYLATION; OXIDATION	The complete stoichiometry of the metabolism of the cytochrome b(5) (cyt b(5))-requiring substrate, methoxyflurane, by purified cytochrome P-450 2B4 was compared to that of another substrate, benzphetamine, which does not require cyt b(5) for its metabolism. Cyt b(5) invariably improved the efficiency of product formation. That is, in the presence of cyt b(5) a greater percentage of the reducing equivalents from NADPH were utilized to generate substrate metabolites, primarily at the expense of the side product, superoxide. With methoxyflurane, cyt b(5) addition always resulted in an increased rate of product formation, while with benzphetamine the rate of product formation remained unchanged, increased or decreased. The apparently contradictory observations of increased reaction efficiency but decrease in total product formation for benzphetamine can be explained by a second effect of cyt b(5). Under some experimental conditions cyt b(5) inhibits total NADPH consumption. Whether stimulation, inhibition, or no change in product formation is observed in the presence of cyt b(5) depends on the net effect of the stimulatory and inhibitory effects of cyt b(5). When total NADPH consumption is inhibited by cyt b(5), the rapidly metabolized, highly coupled (congruent to 50%) substrate, benzphetamine, undergoes a net decrease in metabolism not counterbalanced by the increase in the efficiency (2-20%) of the reaction. In contrast, in the presence of the slowly metabolized, poorly coupled (congruent to 0.5-3%) substrate, methoxyflurane, inhibition of total NADPH consumption by cyt b(5) was never sufficient to overcome the stimulation of product formation due to an increase in efficiency of the reaction.	UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143; VET ADM MED CTR,DEPT ANESTHESIA,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIGMS NIH HHS [GM35533] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035533] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYAMA T, 1990, P NATL ACAD SCI USA, V87, P5425, DOI 10.1073/pnas.87.14.5425; ATKINS WM, 1987, J AM CHEM SOC, V109, P3754, DOI 10.1021/ja00246a038; BONFILS C, 1981, J BIOL CHEM, V256, P9457; BOSTERLING B, 1982, J BIOL CHEM, V257, P4375; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRUNSTROM A, 1980, BIOCHEM BIOPH RES CO, V95, P431, DOI 10.1016/0006-291X(80)90756-1; CAMERON AD, 1993, BIOCHEMISTRY-US, V32, P13061, DOI 10.1021/bi00211a016; CANOVADAVIS E, 1985, BIOCHEM PHARMACOL, V34, P1907, DOI 10.1016/0006-2952(85)90307-7; CANOVADAVIS E, 1984, J BIOL CHEM, V259, P2541; CARTER P, 1971, ANAL BIOCHEM, V40, P450, DOI 10.1016/0003-2697(71)90405-2; CAUSEY KM, 1990, MOL PHARMACOL, V38, P134; CHIANG JYL, 1981, ARCH BIOCHEM BIOPHYS, V211, P662, DOI 10.1016/0003-9861(81)90502-6; CINTI DL, 1972, BIOCHEM PHARMACOL, V21, P3249, DOI 10.1016/0006-2952(72)90089-5; COLLINS JR, 1988, J BIOL CHEM, V263, P3164; FRENCH JS, 1979, ARCH BIOCHEM BIOPHYS, V195, P565, DOI 10.1016/0003-9861(79)90383-7; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; FRIEDEMANN TE, 1957, METHOD ENZYMOL, V3, P414, DOI 10.1016/S0076-6879(57)03406-0; GERBER NC, 1994, J BIOL CHEM, V269, P4260; GERBER NC, 1992, J AM CHEM SOC, V114, P8742, DOI 10.1021/ja00048a081; GORSKY LD, 1986, DRUG METAB DISPOS, V14, P89; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; HEINEMEYER G, 1980, N-S ARCH PHARMACOL, V314, P201, DOI 10.1007/BF00504539; HOFFMAN J, 1989, BRIT J ANAESTH, V63, P103, DOI 10.1093/bja/63.1.103; HOLADAY DA, 1970, ANESTHESIOLOGY, V33, P579, DOI 10.1097/00000542-197012000-00001; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; INGELMANSUNDBER.M, 1980, BIOCHEM BIOPH RES CO, V97, P582; KUTHAN H, 1982, BIOCHEM J, V203, P551, DOI 10.1042/bj2030551; KUTHAN H, 1978, FEBS LETT, V91, P343, DOI 10.1016/0014-5793(78)81206-X; LOIDA PJ, 1993, BIOCHEMISTRY-US, V32, P11530, DOI 10.1021/bi00094a009; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD TL, 1989, BIOCHEMISTRY-US, V28, P2071, DOI 10.1021/bi00431a016; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MORGAN ET, 1982, J BIOL CHEM, V257, P3951; MORGAN ET, 1984, DRUG METAB DISPOS, V12, P358; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NORDBLOM GD, 1977, ARCH BIOCHEM BIOPHYS, V180, P343, DOI 10.1016/0003-9861(77)90047-9; OKITA RT, 1981, J BIOL CHEM, V256, P5961; OMURA T, 1964, J BIOL CHEM, V239, P2370; OPRIAN DD, 1983, J BIOL CHEM, V258, P8684; OVENSTON TCJ, 1949, ANAL CHIM ACTA, V3, P277, DOI 10.1016/S0003-2670(00)87341-9; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PEYRONNEAU MA, 1992, EUR J BIOCHEM, V207, P109, DOI 10.1111/j.1432-1033.1992.tb17027.x; POMPON D, 1987, BIOCHEMISTRY-US, V26, P6429, DOI 10.1021/bi00394a020; POULOS TL, 1987, BIOCHEMISTRY-US, V26, P8165, DOI 10.1021/bi00399a022; RAAG R, 1993, BIOCHEMISTRY-US, V32, P4571, DOI 10.1021/bi00068a013; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; SCHWARZ D, 1984, BIOMED BIOCHIM ACTA, V43, P295; SELINSKY BS, 1988, MOL PHARMACOL, V33, P567; SELINSKY BS, 1988, MOL PHARMACOL, V33, P559; STRITTMATTER P, 1956, J BIOL CHEM, V221, P253; SWINNEY DC, 1994, BIOCHEMISTRY-US, V33, P2185, DOI 10.1021/bi00174a027; TAMBURINI PP, 1987, P NATL ACAD SCI USA, V84, P11, DOI 10.1073/pnas.84.1.11; TRETYACHENKOLAD.VG, 1993, BIOCHIM BIOPHYS ACTA, V1153, P163; VATSIS KP, 1982, J BIOL CHEM, V257, P1221; WASKELL L, 1982, ANESTH ANALG, V61, P609; WHITE RE, 1984, ARCH BIOCHEM BIOPHYS, V228, P493, DOI 10.1016/0003-9861(84)90015-8; WHITE RE, 1986, J AM CHEM SOC, V108, P6024, DOI 10.1021/ja00279a059; WHITE RE, 1991, PHARMACOL THERAPEUT, V49, P21, DOI 10.1016/0163-7258(91)90020-M; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; WINSTON GW, 1983, J BIOL CHEM, V258, P1508; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; ZHUKOV AA, 1982, BIOCHEM BIOPH RES CO, V109, P813, DOI 10.1016/0006-291X(82)92012-5	67	81	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24707	24718		10.1074/jbc.270.42.24707	http://dx.doi.org/10.1074/jbc.270.42.24707			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559586	hybrid			2022-12-27	WOS:A1995TB46500020
J	HERSHEY, JC; HAUTMANN, M; THOMPSON, MM; ROTHBLUM, LI; HAYSTEAD, TAJ; OWENS, GK				HERSHEY, JC; HAUTMANN, M; THOMPSON, MM; ROTHBLUM, LI; HAYSTEAD, TAJ; OWENS, GK			ANGIOTENSIN-II-INDUCED HYPERTROPHY OF RAT VASCULAR SMOOTH-MUSCLE IS ASSOCIATED WITH INCREASED 18S RIBOSOMAL-RNA SYNTHESIS AND PHOSPHORYLATION OF THE RIBOSOMAL-RNA TRANSCRIPTION FACTOR, UPSTREAM BINDING-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUSLY HYPERTENSIVE RAT; ACTIN MESSENGER-RNA; GROWTH-FACTOR-BETA; CASEIN KINASE-II; PROTEIN-SYNTHESIS; DNA-BINDING; ALPHA-ACTIN; FACTOR HUBF; FACTOR UBF; CELLS	Hypertrophy of vascular smooth muscle cells (VSMC) is an important adaptive response of hypertension. Drug intervention studies have implicated a role for angiotensin II (A-II) in the mediation of VSMC hypertrophy in vivo, and A-II is a potent hypertrophic agent for VSMC in culture. Our laboratory has previously shown that A-II-induced hypertrophy of cultured VSMC is due in part to generalized increases in protein synthesis and increased content of rRNA. The aim of the present study was to determine if A-II stimulates rRNA gene synthesis and whether the rRNA transcription factor, upstream binding factor (UBF), is involved. Nuclear run-on analysis demonstrated that A-II induced a greater than 5-fold increase in rRNA gene synthesis within 6 h of stimulation. A-II also stimulated a rapid increase in UBF phosphorylation as well as nucleolar localization, but no changes in the content of UBF. Phosphoamino acid analysis showed that phosphorylation occurred only on serine residue(s). Results demonstrate that increased transcription of ribosomal DNA contributes to the A-II-induced increase in protein synthesis and VSMC hypertrophy, and suggest that an important regulatory event in this pathway may be the phosphorylation and/or nucleolar localization of UBF.	UNIV VIRGINIA, SCH MED, DEPT MOLEC PHYSIOL & BIOL PHYS, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; WEIS CTR RES, GEISINGER CLIN, DANVILLE, PA 17822 USA	University of Virginia; University of Virginia					NHLBI NIH HHS [P01 HL19242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALKJAER C, 1989, J HYPERTENS, V7, P305; AZUMA H, 1992, BRIT J PHARMACOL, V106, P665, DOI 10.1111/j.1476-5381.1992.tb14392.x; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERK BC, 1987, J BIOL CHEM, V262, P5057; BLANK RS, 1990, J CELL PHYSIOL, V142, P635, DOI 10.1002/jcp.1041420325; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORJAY MH, 1989, J BIOL CHEM, V264, P10501; CORJAY MH, 1990, J CELL PHYSIOL, V145, P391, DOI 10.1002/jcp.1041450302; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GARIEPY J, 1993, HYPERTENSION, V22, P111, DOI 10.1161/01.HYP.22.1.111; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRIFFIN SA, 1991, HYPERTENSION, V17, P626, DOI 10.1161/01.HYP.17.5.626; HAHN AWA, 1991, BIOCHEM BIOPH RES CO, V178, P1451, DOI 10.1016/0006-291X(91)91056-I; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KUHN A, 1993, NUCLEIC ACIDS RES, V21, P2057, DOI 10.1093/nar/21.9.2057; KUHN A, 1992, P NATL ACAD SCI USA, V89, P7340, DOI 10.1073/pnas.89.16.7340; LICHTENSTEIN AH, 1986, HYPERTENSION, V8, P50; MONICAL PL, 1993, AM J PHYSIOL, V264, pC1466, DOI 10.1152/ajpcell.1993.264.6.C1466; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; OMAHONY DJ, 1992, NUCLEIC ACIDS RES, V20, P1301; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; OWENS GK, 1987, HYPERTENSION, V9, P178, DOI 10.1161/01.HYP.9.2.178; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; OWENS GK, 1983, CIRC RES, V53, P491, DOI 10.1161/01.RES.53.4.491; OWENS GK, 1982, CIRC RES, V51, P280, DOI 10.1161/01.RES.51.3.280; OWENS GK, 1991, CELLULAR ASPECTS HYP; PFAFF M, 1988, BIOCHIM BIOPHYS ACTA, V969, P100, DOI 10.1016/0167-4889(88)90093-6; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; ROSE KM, 1981, P NATL ACAD SCI-BIOL, V78, P2833, DOI 10.1073/pnas.78.5.2833; ROTHENBERG P, 1983, J BIOL CHEM, V258, P2644; ROUSSEL P, 1993, J CELL SCI, V104, P327; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; SMITH JB, 1984, P NATL ACAD SCI-BIOL, V81, P7812, DOI 10.1073/pnas.81.24.7812; STOUFFER GA, 1993, AM J PHYSIOL, V264, pC390, DOI 10.1152/ajpcell.1993.264.2.C390; STOUFFER GA, 1992, CIRC RES, V70, P820, DOI 10.1161/01.RES.70.4.820; TURLA MB, 1991, CIRC RES, V68, P288, DOI 10.1161/01.RES.68.1.288; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WOLINSKY H, 1970, CIRC RES, V26, P507, DOI 10.1161/01.RES.26.4.507	42	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25096	25101		10.1074/jbc.270.42.25096	http://dx.doi.org/10.1074/jbc.270.42.25096			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559641	hybrid			2022-12-27	WOS:A1995TB46500075
J	KNUTSON, VP; DONNELLY, PV; BALBA, Y; LOPEZREYES, M				KNUTSON, VP; DONNELLY, PV; BALBA, Y; LOPEZREYES, M			INSULIN-RESISTANCE IS MEDIATED BY A PROTEOLYTIC FRAGMENT OF THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED DOWN-REGULATION; SKELETAL-MUSCLE; TYROSINE KINASE; GENE; PHOSPHORYLATION; MUTATION; NIDDM; AUTOPHOSPHORYLATION; ADIPOCYTES; EXPRESSION	Insulin resistance is a common clinical feature of obesity and non-insulin-dependent diabetes mellitus, and is characterized by elevated serum levels of glucose, insulin, and lipids. The mechanism by which insulin resistance is acquired is unknown. We have previously demonstrated that upon chronic treatment of fibroblasts with insulin, conditions that mimic the hyperinsulinemia associated with insulin resistance, the membrane-associated insulin receptor beta subunit is proteolytically cleaved, resulting in the generation of a cytosolic fragment of the beta subunit, beta', and that the generation of beta' is inhibited by the thiol protease inhibitor E64 (Knutson, V. P. (1991) J. Biol. Chem. 266, 15656-15662). In this report, we demonstrate that in 3T3-L1 adipocytes: 1) cytosolic beta' is generated by chronic insulin administration to the cells, and that E64 inhibits the production of beta'; 2) chronic administration of insulin to the adipocytes leads to an insulin-resistant state, as measured by lipogenesis and glycogen synthesis, and E64 totally prevents the generation of this insulin-induced cellular insulin resistance; 3) E64 has no effect on the insulin-induced down-regulation of insulin receptor substrate-1, and therefore insulin resistance is not mediated by the down-regulation of insulin receptor substrate-1; 4) under in vitro conditions, partially purified beta' stoichiometrically inhibits the insulin-induced autophosphorylation of the insulin receptor beta subunit; and 5) administration of E64 to obese Zucker fatty rats improves the insulin resistance of the rats compared to saline-treated animals. These data indicate that beta' is a mediator of insulin resistance, and the mechanism of action of beta' is the inhibition of the insulin induced autophosphorylation of the beta subunit of the insulin receptor.			KNUTSON, VP (corresponding author), UNIV TEXAS, SCH MED, DEPT PHARMACOL, 6431 FANNIN, POB 20708, HOUSTON, TX 77225 USA.				NIDDK NIH HHS [DK35397] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035397] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAR RS, 1976, J CLIN INVEST, V58, P1123, DOI 10.1172/JCI108565; BRILLON DJ, 1989, DIABETES, V38, P397, DOI 10.2337/diabetes.38.3.397; CAMA A, 1990, J CLIN ENDOCR METAB, V70, P1155, DOI 10.1210/jcem-70-4-1155; CARO JF, 1989, DIABETES METAB REV, V5, P665, DOI 10.1002/dmr.5610050804; COBB MH, 1989, J BIOL CHEM, V264, P18701; COCOZZA S, 1992, DIABETES, V41, P521, DOI 10.2337/diabetes.41.4.521; ELBEIN SC, 1991, DIABETOLOGIA, V34, P742, DOI 10.1007/BF00401521; ELLIS L, 1990, MOL ENDORCINOL, V1, P15; HARING HU, 1991, DIABETOLOGIA, V34, P848, DOI 10.1007/BF00400192; IKEDA H, 1990, ARZNEIMITTEL-FORSCH, V40-1, P156; IMANO E, 1991, DIABETES, V40, P548, DOI 10.2337/diabetes.40.5.548; Johnson, 1990, ILAR NEWS, V32, P4, DOI [DOI 10.1093/ILAR.32.3.4, 10.1093/ilar.32.3.4]; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KASISKE BL, 1992, HYPERTENSION, V19, pI110, DOI 10.1161/01.HYP.19.1_Suppl.I110; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KNUTSON VP, 1986, J BIOL CHEM, V261, P306; KNUTSON VP, 1982, P NATL ACAD SCI-BIOL, V79, P2822, DOI 10.1073/pnas.79.9.2822; KNUTSON VP, 1991, J BIOL CHEM, V266, P15656; KNUTSON VP, 1991, ARCH BIOCHEM BIOPHYS, V285, P197, DOI 10.1016/0003-9861(91)90349-N; KOSMAKOS FC, 1980, J BIOL CHEM, V255, P9860; KRIAUCIUNAS KM, 1988, J CLIN ENDOCR METAB, V67, P1284, DOI 10.1210/jcem-67-6-1284; KRUPP M, 1981, J BIOL CHEM, V256, P1689; LEVINE BA, 1991, J BIOL CHEM, V266, P3565; LONGO N, 1992, AM J HUM GENET, V50, P998; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MOLLER DE, 1989, DIABETES, V38, P1496, DOI 10.2337/diabetes.38.11.1496; MULLERWIELAND D, 1989, DIABETES, V38, P31, DOI 10.2337/diabetes.38.1.31; OBERMAIERKUSSER B, 1989, J BIOL CHEM, V264, P9497; OJAMAA K, 1988, MOL ENDOCRINOL, V2, P242, DOI 10.1210/mend-2-3-242; ORAHILLY S, 1992, CLIN ENDOCRINOL, V36, P121, DOI 10.1111/j.1365-2265.1992.tb00945.x; ORAHILLY S, 1991, DIABETES, V40, P777, DOI 10.2337/diabetes.40.6.777; Peterson R.G., 1990, ILAR NEWS, V32, P16, DOI [10.1093/ilar.32.3.16, DOI 10.1093/ILAR.32.3.16, DOI 10.1093/ILAR.32.3.16)]; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; RONNETT GV, 1982, J BIOL CHEM, V257, P4285; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SOLL AH, 1975, J CLIN INVEST, V56, P769, DOI 10.1172/JCI108155; SOWERS JR, 1992, J CLIN PHARMACOL, V32, P529, DOI 10.1177/009127009203200607; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; TAYLOR SI, 1991, ADV EXP MED BIOL, V293, P197; TAYLOR SI, 1991, J CLIN ENDOCR METAB, V73, P1158, DOI 10.1210/jcem-73-6-1158; TAYLOR SI, 1990, DIABETES CARE, V13, P257, DOI 10.2337/diacare.13.3.257; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; VANDERVORM ER, 1992, J BIOL CHEM, V267, P66; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938	48	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24972	24981		10.1074/jbc.270.42.24972	http://dx.doi.org/10.1074/jbc.270.42.24972			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559625	hybrid			2022-12-27	WOS:A1995TB46500059
J	MANSER, E; CHONG, C; ZHAO, ZS; LEUNG, T; MICHAEL, G; HALL, C; LIM, L				MANSER, E; CHONG, C; ZHAO, ZS; LEUNG, T; MICHAEL, G; HALL, C; LIM, L			MOLECULAR-CLONING OF A NEW MEMBER OF THE P21-CDC42/RAC-ACTIVATED KINASE (PAK) FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; ACTIVATING PROTEIN; HUMAN HOMOLOG; IN-VITRO; GENE; RAS; CHIMAERIN; SEQUENCE; P21RAC; G25K	A number of ''target'' proteins for the Rho family of small GTP-binding proteins have now been identified, including the protein kinases ACK and p65(PAK) (Manser, E., Leung, T., Salihuddin, H., Zhao, Z.-S., and Lim, L. (1994) Nature 367, 40-46). The purified serine/threonine kinase p65(PAK) has been shown to be directly activated by GTP-Rac1 or GTP-Cdc42. Here we report the cDNA sequence encoding a new brain-enriched PAK isoform beta-PAK, which shares 79% amino acid identity with the previously described alpha-isoform. Their mRNAs are differentially expressed in the brain, with alpha-PAK mRNA being particularly abundant in motor-associated regions. In vitro translation products of the alpha- and beta-PAK cDNAs exhibited relative molecular masses of 68,000 and 65,000, respectively, by SDS-polyacrylamide analysis. A specific beta-PAK peptide sequence was obtained from rat brain-purified p65(PAK). Recombinant alpha- and beta-PAKs exhibited an increase in kinase activity mediated by GTP-p21 induced autophosphorylation. Cdc42 was a more potent activator in vitro of alpha-PAK kinase, and the fully activated enzyme is 300 times more active than the unphosphorylated form. Interestingly the down-regulation in the binding of p21s to recombinant beta-PAK and brain p65(PAK), which is observed upon kinase activation does not occur with recombinant alpha-PAK.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,GLAXO IMCB LAB,SINGAPORE 0511,SINGAPORE; INST NEUROL,DEPT NEUROCHEM,LONDON WC1N 1PJ,ENGLAND	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of London; University College London			Hall, Christine/C-8390-2009; Manser, Edward/ABD-2301-2020					AHMED S, 1993, J BIOL CHEM, V268, P10709; AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; HALL C, 1993, MOL CELL BIOL, V13, P4986, DOI 10.1128/MCB.13.8.4986; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEUNG T, 1994, J BIOL CHEM, V269, P12888; LEUNG T, 1993, J BIOL CHEM, V268, P3813; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MENARD L, 1992, EUR J BIOCHEM, V206, P537, DOI 10.1111/j.1432-1033.1992.tb16957.x; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SEEBURG PH, 1977, CELL, V12, P157, DOI 10.1016/0092-8674(77)90193-3; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307	30	215	224	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25070	25078		10.1074/jbc.270.42.25070	http://dx.doi.org/10.1074/jbc.270.42.25070			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559638	hybrid			2022-12-27	WOS:A1995TB46500072
J	SINGER, MF				SINGER, MF			UNUSUAL REVERSE TRANSCRIPTASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MITOCHONDRIAL PLASMIDS; MAURICEVILLE PLASMID; CDNA SYNTHESIS; DNA; DROSOPHILA; RNA; NEUROSPORA; EVOLUTION; ELEMENTS; RETROTRANSPOSON		CARNEGIE INST WASHINGTON,WASHINGTON,DC 20005; NCI,BIOCHEM LAB,BETHESDA,MD 20892	Carnegie Institution for Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AKINS RA, 1986, CELL, V47, P505, DOI 10.1016/0092-8674(86)90615-X; AUTEXIER C, 1994, GENE DEV, V8, P563, DOI 10.1101/gad.8.5.563; Berg DE, 1989, MOBILE DNA; BHATTACHARYYA A, 1994, EMBO J, V13, P5721, DOI 10.1002/j.1460-2075.1994.tb06910.x; BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; BIESSMANN H, 1994, CHROMOSOMA, V103, P90, DOI 10.1007/BF00352317; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BUCHETON A, 1990, TRENDS GENET, V6, P16, DOI 10.1016/0168-9525(90)90044-7; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DERAGON JM, 1990, EMBO J, V9, P3363, DOI 10.1002/j.1460-2075.1990.tb07537.x; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; DOMBROSKI BA, 1994, MOL CELL BIOL, V14, P4485, DOI 10.1128/MCB.14.7.4485; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; Eickbush Thomas H., 1994, P121; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; FINNEGAN DJ, 1989, MOBILE DNA, P503; GABRIEL A, 1991, P NATL ACAD SCI USA, V88, P9794, DOI 10.1073/pnas.88.21.9794; INOUYE S, 1993, CURR OPIN GENET DEV, V3, P713, DOI 10.1016/S0959-437X(05)80088-7; IVANOV VA, 1991, EMBO J, V10, P2489, DOI 10.1002/j.1460-2075.1991.tb07788.x; JAKUBCZAK JL, 1991, P NATL ACAD SCI USA, V88, P3295, DOI 10.1073/pnas.88.8.3295; JAKUBCZAK JL, 1990, J MOL BIOL, V212, P37, DOI 10.1016/0022-2836(90)90303-4; KENNELL JC, 1994, MOL CELL BIOL, V14, P3094, DOI 10.1128/MCB.14.5.3094; KUIPER MTR, 1988, CELL, V55, P693, DOI 10.1016/0092-8674(88)90228-0; KUIPER MTR, 1990, J BIOL CHEM, V265, P6936; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAMPSON BC, 1990, J BIOL CHEM, V265, P8490; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; LEVIS RW, 1993, CELL, V75, P1083, DOI 10.1016/0092-8674(93)90318-K; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; LUAN DD, 1995, MOL CELL BIOL, V15, P3882; MAIZELS N, 1993, RNA WORLD, P577; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; MIZROKHI LJ, 1990, P NATL ACAD SCI USA, V87, P9216, DOI 10.1073/pnas.87.23.9216; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; SCHWARZSOMMER Z, 1987, EMBO J, V6, P3873, DOI 10.1002/j.1460-2075.1987.tb02727.x; SHEEN FM, 1994, P NATL ACAD SCI USA, V91, P12510, DOI 10.1073/pnas.91.26.12510; SHIMADA M, 1994, J BIOL CHEM, V269, P14553; SHIMAMOTO T, 1995, J BIOL CHEM, V270, P581, DOI 10.1074/jbc.270.2.581; SHIMAMOTO T, 1993, J BIOL CHEM, V268, P2684; SHIMAMOTO T, 1995, J BACTERIOL, V177, P264, DOI 10.1128/jb.177.1.264-267.1995; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SKALKA A, 1993, REVERSE TRANSCRIPTAS; TEMIN HM, 1989, NATURE, V339, P254, DOI 10.1038/339254a0; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WANG H, 1993, CELL, V75, P1071, DOI 10.1016/0092-8674(93)90317-J; WANG H, 1992, MOL CELL BIOL, V12, P5131, DOI 10.1128/MCB.12.11.5131; WANG H, 1993, J BIOL CHEM, V268, P18951; WEINER AM, 1994, CURR BIOL, V4, P560, DOI 10.1016/S0960-9822(00)00126-3; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; XIONG Y, 1988, CELL, V55, P235, DOI 10.1016/0092-8674(88)90046-3; [No title captured]	58	16	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24623	24626		10.1074/jbc.270.42.24623	http://dx.doi.org/10.1074/jbc.270.42.24623			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559567	hybrid			2022-12-27	WOS:A1995TB46500001
J	ZHOU, Y; ROVERE, C; KITABGI, P; LINDBERG, I				ZHOU, Y; ROVERE, C; KITABGI, P; LINDBERG, I			MUTATIONAL ANALYSIS OF PC1 (SPC3) IN PC12 CELLS - 66-KDA PC1 IS FULLY FUNCTIONAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONVERTASE PC1; NEUROMEDIN-N; PROHORMONE; NEUROTENSIN; IDENTIFICATION; PRECURSOR; SEQUENCE; LINE; GENE; RNA	The proteinase mPC1, a neuroendocrine member of the mammalian family of subtilisin-like enzymes, has previously been shown to be converted to a carboxyl-terminally truncated 66-kDa form during transport through the secretory pathway. The cleavage site and the function of this carboxyl-terminal truncation event are unknown. We have performed site-directed mutagenesis of two paired basic sites in the mPC1 carboxyl-terminal tail and expressed these constructs in PC12 cells, a rat pheochromocytoma known to lack endogenous PC1. We found that the most likely site for the truncation event was at Arg(590)-Arg(591) since mutation of this site to Lys-His prevented processing of 87-kDa PC1. APC1 mutant carboxyl-terminally truncated at this site and expressed in PC12 cells was efficiently routed to the secretory pathway and stored in secretory granules, indicating that the carboxyl-terminal extension is not required for sorting of this enzyme. The function of the various PC1 constructs was assessed by analyzing proneurotensin cleavage to various forms. The carboxyl-terminally truncated PC1 mutant was found to perform most of the cleavages of this precursor as well as wild-type PC1; however, the blockade mutant processed proneurotensin much less efficiently, Differences between the site preferences of the various enzymes were noted. Our results support the notion that carboxyl terminal processing of PC1 serves to regulate PC1 activity.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, NEW ORLEANS, LA 70112 USA; CNRS, INST PHARMACOL, F-06560 VALBONNE, FRANCE	Louisiana State University System; Centre National de la Recherche Scientifique (CNRS)			Rovere-Jovene, Carole/O-4557-2016; Lindberg, Iris/Q-3825-2019	Rovere-Jovene, Carole/0000-0001-9400-7972; 	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005084, R56DA005084] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA005084, DA 05084, R56 DA005084] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BIDARD JN, 1993, BIOCHEM J, V291, P225, DOI 10.1042/bj2910225; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; CARRAWAY RE, 1993, PEPTIDES, V14, P991, DOI 10.1016/0196-9781(93)90076-S; CHUN JY, 1994, NEURON, V12, P831, DOI 10.1016/0896-6273(94)90336-0; GOODMAN LJ, 1994, BIOCHEM BIOPH RES CO, V201, P795, DOI 10.1006/bbrc.1994.1771; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; KISLAUSKIS E, 1988, J BIOL CHEM, V263, P4963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG I, 1994, MOL CELL NEUROSCI, V5, P263, DOI 10.1006/mcne.1994.1030; LINDBERG I, 1994, MOL CELL NEUROSCI, V5, P614, DOI 10.1006/mcne.1994.1075; Lindberg I., 1995, METH NEUROSCI, V23, P94; LOH YP, 1992, MECHANISMS INTRACELL, P181; MILGRAM SL, 1994, J CELL SCI, V107, P737; PALMER DJ, 1992, J BIOL CHEM, V267, P19806; ROTH WW, 1993, ENDOCRINOL J, V1, P131; ROVERE C, 1993, PEPTIDES, V14, P983, DOI 10.1016/0196-9781(93)90075-R; RUFAUT NW, 1993, J BIOL CHEM, V268, P20291; SEIDAH NG, 1992, DNA CELL BIOL, V11, P283, DOI 10.1089/dna.1992.11.283; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHOU A, 1994, J BIOL CHEM, V269, P17440; Zhou A., 1994, Society for Neuroscience Abstracts, V20, P447; ZHOU Y, 1994, ZHOU, V269, P18408	27	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24702	24706		10.1074/jbc.270.42.24702	http://dx.doi.org/10.1074/jbc.270.42.24702			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559585	hybrid			2022-12-27	WOS:A1995TB46500019
J	AZARIAN, SM; KING, AJ; HALLETT, MK; WILLIAMS, DS				AZARIAN, SM; KING, AJ; HALLETT, MK; WILLIAMS, DS			SELECTIVE PROTEOLYSIS OF ARRESTIN BY CALPAIN - MOLECULAR CHARACTERISTICS AND ITS EFFECT ON RHODOPSIN DEPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; ACTIVATED NEUTRAL PROTEINASES; 48-KDA PROTEIN; PHOSPHORYLATED RHODOPSIN; PHOTOEXCITED RHODOPSIN; BETA-ARRESTIN; S-ANTIGEN; ENDOGENOUS ACTIVATOR; TISSUE DISTRIBUTION; LIMITED AUTOLYSIS	Visual arrestin (48 kDa) plays a role in the deactivation of rhodopsin by binding to the light-activated, phosphorylated form of the receptor. In bovine rod outer segments that were prepared in the presence of protease inhibitors, two faster migrating forms of arrestin, with apparent molecular masses of 46 and 44 kDa, were observed by Western blot analysis, The 46-kDa form was more evident in rod outer segments of eyes kept in the light than those placed, in darkness and was found to be identical to that generated by in vitro proteolysis of arrestin by pure retinal calpain II. In vitro analysis showed that arrestin was proteolyzed only when bound to rhodopsin; soluble arrestin was not significantly cleaved by calpain. Proteolysis involves sequential cleavage at two, possibly three sites, resulting in the removal of 27 amino acids from the COOH terminus. The remaining 46-kDa protein was resistant to further proteolysis by calpain. Unlike intact arrestin, the 46-kDa truncated arrestin was not readily released from the receptor after the receptor had lost its chromophore, nor was it released upon the addition of 11-cis-retinal to regenerate the receptor. Truncated arrestin was found to inhibit receptor dephosphorylation to the same extent as intact arrestin. In conclusion, these results provide evidence that a 46 kDa form of arrestin in rod outer segments is a product of selective proteolysis by calpain. Furthermore, they suggest that this proteolysis may provide a mechanism for prolonging the phosphorylated state of the visual receptor.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT NEUROSCI,LA JOLLA,CA 92093; INDIANA UNIV,SCH OPTOMETRY,BLOOMINGTON,IN 47405	University of California System; University of California San Diego; University of California System; University of California San Diego; Indiana University System; Indiana University Bloomington					NEI NIH HHS [EY07042] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; AZARIAN SM, 1993, J CELL SCI, V105, P787; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BIERNBAUM MS, 1991, VISUAL NEUROSCI, V7, P499, DOI 10.1017/S0952523800009780; BRANDT H, 1974, BIOCHEM BIOPH RES CO, V61, P548; BUCZYLKO J, 1993, METH NEUROSCI, V15, P226; COOLICAN SA, 1984, J BIOL CHEM, V259, P1627; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; Dua H. S., 1993, Methods (Orlando), V5, P242, DOI 10.1006/meth.1993.1030; ERDODI F, 1992, ARCH BIOCHEM BIOPHYS, V298, P682, DOI 10.1016/0003-9861(92)90466-A; FOWLES C, 1989, BIOCHEMISTRY-US, V28, P9385, DOI 10.1021/bi00450a020; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HARLOW E, 1988, ANTIBODIES LABORATOR; HATHAWAY DR, 1982, J BIOL CHEM, V257, P9072; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; KASP E, 1987, J IMMUNOL METHODS, V100, P147, DOI 10.1016/0022-1759(87)90183-9; KAWASHIMA S, 1988, BIOCHIM BIOPHYS ACTA, V965, P130, DOI 10.1016/0304-4165(88)90048-7; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; KUHN H, 1982, BIOCHIM BIOPHYS ACTA, V679, P95, DOI 10.1016/0005-2728(82)90259-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MANGINI NJ, 1988, INVEST OPHTH VIS SCI, V29, P1221; MANGINI NJ, 1991, INVEST OPHTH VIS SCI, V32, P1150; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; MELLGREN RL, 1980, FEBS LETT, V109, P129, DOI 10.1016/0014-5793(80)81326-3; MELLGREN RL, 1982, J BIOL CHEM, V257, P7203; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; MOSIOR M, 1994, J BIOL CHEM, V269, P13798; MURACHI T, 1989, BIOCHEM INT, V18, P263; MURACHI T, 1981, BIOCHEM INT, V2, P651; NIXON RA, 1986, J NEUROSCI, V6, P1252; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P314; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P415, DOI 10.1021/bi00428a001; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; PARRUTI G, 1993, J BIOL CHEM, V268, P9753; PONTREMOLI S, 1988, P NATL ACAD SCI USA, V85, P1740, DOI 10.1073/pnas.85.6.1740; PONTREMOLI S, 1990, BIOCHEM BIOPH RES CO, V171, P569, DOI 10.1016/0006-291X(90)91184-T; RATTO GM, 1988, J NEUROSCI, V8, P3240; ROEPSTORFF P, 1994, CELL BIOL LABORATORY, V3, P399; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SMITH WC, 1994, J BIOL CHEM, V269, P15407; SMITH WC, 1995, INVEST OPHTH VIS SCI, V36, pS223; SUZUKI K, 1981, J BIOCHEM-TOKYO, V90, P275, DOI 10.1093/oxfordjournals.jbchem.a133463; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; Suzuki K., 1990, INTRACELLULAR CALCIU, P25; Takahashi K, 1990, INTRACELLULAR CALCIU, P55; TING TD, 1993, METH NEUROSCI, V15, P180; WACKER WB, 1977, J IMMUNOL, V119, P1949; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WEYAND I, 1990, EUR J BIOCHEM, V193, P459, DOI 10.1111/j.1432-1033.1990.tb19360.x; WILDEN U, 1995, BIOCHEMISTRY-US, V34, P1446, DOI 10.1021/bi00004a040; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WONG S, 1986, BIOCHEMISTRY-US, V25, P6294, DOI 10.1021/bi00368a069; ZIMMERMAN WF, 1982, METHOD ENZYMOL, V81, P52	71	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24375	24384		10.1074/jbc.270.41.24375	http://dx.doi.org/10.1074/jbc.270.41.24375			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592650	hybrid			2022-12-27	WOS:A1995TA21700078
J	SZCZESNASKORUPA, E; AHN, KS; CHEN, CD; DORAY, B; KEMPER, B				SZCZESNASKORUPA, E; AHN, KS; CHEN, CD; DORAY, B; KEMPER, B			THE CYTOPLASMIC AND N-TERMINAL TRANSMEMBRANE DOMAINS OF CYTOCHROME-P450 CONTAIN INDEPENDENT SIGNALS FOR RETENTION IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING DOMAIN; LUMINAL ER PROTEINS; GOLGI RETENTION; GLYCOSYLATION; SEQUENCES; COMPLEX; TRANSLOCATION; ORIENTATION; TRANSPORT; SECRETION	Microsomal cytochrome P450 is inserted into the membrane of the endoplasmic reticulum (ER) by its N-terminal signal/anchor sequence which also functions as an ER retention signal. To analyze further potential retention signals of cytochrome P450, topological domains of cytochrome P450 2C1 or 2C2, epidermal growth factor receptor, a plasma membrane protein, and bacterial alkaline phosphatase, a secreted protein were exchanged. The N-terminal signal/anchor of cytochrome P450 2C1 functioned as an ER retention signal when placed at the N terminus of several reporter proteins but not when fused at the C terminus of the extracellular domain of epidermal growth factor receptor, with or without a heterologous cytoplasmic domain, Chimeric proteins in which the cytoplasmic domain of cytochrome P450 2C2 was substituted for that of epidermal growth factor receptor were retained in the ER indicating that an independent retention signal is present in the cytoplasmic part of cytochrome P450 2C2, These chimeras were enzymatically active which argues against misfolding as the primary cause of retention. The ER retention signal of the cytoplasmic domain could not be localized to a single amino acid segment by deletion analysis, These results show that cytochrome P450 2C2 contains redundant, complex ER retention signals in its cytoplasmic and N-terminal hydrophobic domains and that the function of the N-terminal signal is context-dependent.	UNIV ILLINOIS,DEPT MOLEC & INTEGRAT PHYSIOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801; UNIV ILLINOIS,COLL MED,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign				Doray, Balraj/0000-0003-3347-5013	NIGMS NIH HHS [GM 35897] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN KS, 1993, J BIOL CHEM, V268, P18726; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BLACK SD, 1994, BIOCHEMISTRY-US, V33, P6945, DOI 10.1021/bi00188a025; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; CUMMINGS RD, 1985, J BIOL CHEM, V260, P1944; DELEMOSCHIARAND.C, 1987, J CELL BIOL, V104, P209; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; INGELMANSUNDBER.M, 1986, CYTOCHROME P450 STRU, P119; IVESSA NE, 1992, J CELL BIOL, V117, P949, DOI 10.1083/jcb.117.5.949; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KIM J, 1995, J BIOL CHEM, V270, P1282, DOI 10.1074/jbc.270.3.1282; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LOCKER JK, 1995, J BIOL CHEM, V270, P8815, DOI 10.1074/jbc.270.15.8815; LODISH HF, 1988, J BIOL CHEM, V263, P2107; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MURAKAMI K, 1994, J BIOCHEM, V116, P164, DOI 10.1093/oxfordjournals.jbchem.a124489; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; OHTA Y, 1992, BIOCHEMISTRY-US, V31, P12680, DOI 10.1021/bi00165a019; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; SCHWARZ D, 1990, BIOCHEM BIOPH RES CO, V171, P175, DOI 10.1016/0006-291X(90)91373-Z; SCHWEIZER A, 1994, J CELL BIOL, V126, P25, DOI 10.1083/jcb.126.1.25; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; STIRZAKER SC, 1990, J CELL BIOL, V111, P1343, DOI 10.1083/jcb.111.4.1343; STRAUB P, 1993, ARCH BIOCHEM BIOPHYS, V306, P521, DOI 10.1006/abbi.1993.1547; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; SZCZESNASKORUPA E, 1993, J BIOL CHEM, V268, P1757; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; SZCZESNASKORUPA E, 1993, ARCH BIOCHEM BIOPHYS, V340, P170; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; UVAROV VY, 1994, EUR J BIOCHEM, V222, P483, DOI 10.1111/j.1432-1033.1994.tb18889.x; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; ZAGOURAS P, 1989, J CELL BIOL, V109, P2633, DOI 10.1083/jcb.109.6.2633	38	63	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24327	24333		10.1074/jbc.270.41.24327	http://dx.doi.org/10.1074/jbc.270.41.24327			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592644	hybrid			2022-12-27	WOS:A1995TA21700072
J	TAYLOR, AF; SMITH, GR				TAYLOR, AF; SMITH, GR			STRAND SPECIFICITY OF NICKING OF DNA AT CHI-SITES BY RECBCD ENZYME - MODULATION BY ATP AND MAGNESIUM LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; RECOMBINATION HOTSPOT; PHAGE-LAMBDA; HOMOLOGOUS RECOMBINATION; DEOXYRIBONUCLEIC ACID; NUCLEASE ACTIVITY; RECD SUBUNIT; SEQUENCE; END; ORIENTATION	RecBCD enzyme is essential for the major pathway of homologous recombination of linear DNA in Escherichia coli. It is a potent nuclease and helicase and, during its unwinding of double-stranded DNA, makes single-strand scissions in the vicinity of Chi recombination hot spots. We report here that both the strand that is cut and the position of the cuts relative to Chi depended on the ATP to Mg2+ ratio. With ATP in excess, Chi-dependent nicks occurred, as we have previously reported, four to six nucleotides to the 3'-side of the Chi octamer (5'-GCTGGTGG-3') and were detected only on the strand bearing that sequence. Three differences were seen with Mg2+ in excess. 1) Chi-dependent 3'-ends were produced on the GCTGGTGG-containing strand closer to and within the Chi octamer, 2) Chi-dependent cuts occurred on the complementary DNA strand, 3) RecBCD enzyme destroyed the 3'-terminated strand of DNA from its entry point up to the vicinity of the Chi site, as others have previously reported. We show here that, with Mg2+ in excess, the enzyme continued to travel along DNA, after encountering a Chi site, releasing both strands of the DNA distal to Chi as single strands. We discuss potential biological consequences of these two modes of RecBCD enzyme-Chi interaction.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center				Smith, Gerald/0000-0002-8747-1352	NIGMS NIH HHS [GM32194, GM31693] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032194, R01GM031693, R56GM031693] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALATOSSAVA T, 1985, J BACTERIOL, V162, P413, DOI 10.1128/JB.162.1.413-419.1985; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; CHENG KC, 1987, J MOL BIOL, V194, P747, DOI 10.1016/0022-2836(87)90252-X; CHENG KC, 1989, GENETICS, V123, P5; DABERT P, 1992, P NATL ACAD SCI USA, V89, P12073, DOI 10.1073/pnas.89.24.12073; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DIXON DA, 1995, J BIOL CHEM, V270, P16360, DOI 10.1074/jbc.270.27.16360; DIXON DA, 1994, P NATL ACAD SCI USA, V91, P2980, DOI 10.1073/pnas.91.8.2980; EGGLESTON AK, 1993, J MOL BIOL, V231, P605, DOI 10.1006/jmbi.1993.1313; EICHLER DC, 1977, J BIOL CHEM, V252, P499; GUPTA RK, 1983, BIOCHEM BIOPH RES CO, V117, P210, DOI 10.1016/0006-291X(83)91562-0; HOLBECK SL, 1992, GENETICS, V132, P879; KAHRU A, 1990, MICROBIOS, V62, P83; KOBAYASHI I, 1982, P NATL ACAD SCI-BIOL, V79, P5981, DOI 10.1073/pnas.79.19.5981; KONFORTI BB, 1990, J BIOL CHEM, V265, P6916; KORANGY F, 1992, J BIOL CHEM, V267, P3088; KUZMINOV A, 1994, EMBO J, V13, P2764, DOI 10.1002/j.1460-2075.1994.tb06570.x; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; MACKAY V, 1976, J BIOL CHEM, V251, P3716; Maniatis T., 1982, MOL CLONING; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; MONCANY MLJ, 1981, EXPERIENTIA, V37, P846, DOI 10.1007/BF01985672; MORELLE B, 1994, ANAL BIOCHEM, V218, P170, DOI 10.1006/abio.1994.1156; MUSKAVITCH KMT, 1982, J BIOL CHEM, V257, P2641; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; ROMAN LJ, 1991, P NATL ACAD SCI USA, V88, P3367, DOI 10.1073/pnas.88.8.3367; ROSAMOND J, 1979, J BIOL CHEM, V254, P8646; ROSENBERG SM, 1991, BIOCHIMIE, V73, P385, DOI 10.1016/0300-9084(91)90105-A; Sambrook J, 1989, MOL CLONING LABORATO; SIMMON VF, 1972, J BACTERIOL, V112, P161, DOI 10.1128/JB.112.1.161-169.1972; Smith G. R., 1981, STADLER GENET S, V13, P25; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; SMITH GR, 1985, BIOESSAYS, V2, P244, DOI 10.1002/bies.950020603; SMITH GR, 1991, CELL, V64, P19, DOI 10.1016/0092-8674(91)90205-D; STAHL FW, 1990, GENETICS, V126, P519; STAHL FW, 1980, GENETICS, V94, P235; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TAYLOR AF, 1992, P NATL ACAD SCI USA, V89, P5226, DOI 10.1073/pnas.89.12.5226; TAYLOR AF, 1990, J MOL BIOL, V211, P117, DOI 10.1016/0022-2836(90)90015-E; TAYLOR AF, 1992, CELL, V69, P1063, DOI 10.1016/0092-8674(92)90626-N; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; UGURBIL K, 1978, P NATL ACAD SCI USA, V75, P2244, DOI 10.1073/pnas.75.5.2244; WATSON N, 1988, GENE, V70, P399, DOI 10.1016/0378-1119(88)90212-0; ZAMAN MM, 1994, J BACTERIOL, V176, P5093, DOI 10.1128/jb.176.16.5093-5100.1994	48	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24459	24467		10.1074/jbc.270.41.24459	http://dx.doi.org/10.1074/jbc.270.41.24459			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592661	hybrid			2022-12-27	WOS:A1995TA21700089
J	ZHANG, ZX; FUENTES, NL; FULLER, GM				ZHANG, ZX; FUENTES, NL; FULLER, GM			CHARACTERIZATION OF THE IL-6 RESPONSIVE ELEMENTS IN THE GAMMA-FIBRINOGEN GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE-STIMULATING FACTORS; PHASE PLASMA-PROTEINS; NUCLEAR FACTOR; INTERLEUKIN-6; TRANSCRIPTION; BINDING; EXPRESSION; CELLS; GLUCOCORTICOIDS; DEXAMETHASONE	Fibrinogen, a hepatically derived class II acute phase protein, is the product of three separate genes, (A alpha, B beta, and gamma), The fibrinogen genes are expressed constitutively; however, their transcription can be significantly up regulated by interleukin-6 (IL-6) and glucocorticoid. Inspection of the promoter region of the fibrinogen gamma gene revealed three hexanucleotide clusters of CTGGGA that are recognized as class II IL-6 responsive elements. Functional analyses of these regions (designated here as site I, site II, and site III according to their position in the promoter) were performed using luciferase reporter constructs and show a hierarchy of IL-6 response in which site II was the preferred functional site, site I was the next important site, and site III was the site least responsive to IL-6. Gel mobility shift assays using 25-base pair oligonucleotide probes derived from these three regions with the CTGGGA positioned in the middle and nuclear extracts from IL-6-treated primary hepatocytes reveal the presence of IL-6-induced high molecular weight complexes appearing 5 min after cytokine treatment, Supershift assays using anti-Stat3 antibody indicate that Stat3 is part of the IL-6-induced complex formed on the three gamma chain probes, The binding of Stat3 to the IL-6 responsive elements of the gamma probes is significantly weaker than to an alpha(2)-macroglobulin probe, These findings show for the first time that Stat3 is involved in associating with the IL-6 responsive elements of fibrinogen gamma chain, a class II acute phase gene other than alpha(2)-macroglobulin.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham				Zhang, Zhixin/0000-0003-3924-1082	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043155] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43155] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ANDERSON GM, 1993, J BIOL CHEM, V268, P22650; ANDUS T, 1988, EUR J IMMUNOL, V18, P739, DOI 10.1002/eji.1830180513; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, pCH12; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1987, J BIOL CHEM, V262, P9756; BAUMANN H, 1986, J CELL BIOL, V102, P370, DOI 10.1083/jcb.102.2.370; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BRUNN GJ, 1995, J BIOL CHEM, V270, P11628, DOI 10.1074/jbc.270.19.11628; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DOOLITTLE RF, 1983, ANN NY ACAD SCI, V408, P13, DOI 10.1111/j.1749-6632.1983.tb23231.x; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GRENETT HE, 1991, GENE, V101, P267, DOI 10.1016/0378-1119(91)90422-8; HARROCH S, 1994, J BIOL CHEM, V269, P26191; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; HUBER P, 1990, J BIOL CHEM, V265, P5695; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; LIU ZY, 1995, J BIOL CHEM, V270, P7580, DOI 10.1074/jbc.270.13.7580; MORGAN JG, 1988, MOL CELL BIOL, V8, P2628, DOI 10.1128/MCB.8.6.2628; NESBITT JE, 1991, BIOCHIM BIOPHYS ACTA, V1089, P88, DOI 10.1016/0167-4781(91)90089-5; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OTTO JM, 1987, J CELL BIOL, V105, P1067, DOI 10.1083/jcb.105.3.1067; RAZ R, 1994, J BIOL CHEM, V269, P24391; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	32	95	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24287	24291		10.1074/jbc.270.41.24287	http://dx.doi.org/10.1074/jbc.270.41.24287			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592638	hybrid			2022-12-27	WOS:A1995TA21700066
J	ZONG, RT; SCHEUERMANN, RH				ZONG, RT; SCHEUERMANN, RH			MUTUALLY EXCLUSIVE INTERACTION OF A NOVEL MATRIX ATTACHMENT REGION BINDING-PROTEIN AND THE NF-MU-NR ENHANCER REPRESSOR - IMPLICATIONS FOR REGULATION OF IMMUNOGLOBULIN HEAVY-CHAIN EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL LOOP ANCHORAGE; SUPPRESSOR SITES FLANKING; KAPPA-GENE EXPRESSION; NUCLEAR MATRIX; STABLE INTEGRATION; TOPOISOMERASE-II; TRANSGENIC MICE; INTRONIC MAR; DNA; IDENTIFICATION	The immunoglobulin heavy chain (IgH) intronic enhancer stimulates transcription from functional promoters in B lymphocytes but not other cell types. The observation that binding sites for the nuclear factor-mu negative regulator (NF-mu NR) enhancer repressor overlap nuclear matrix attachment regions (MARs) in this enhancer has lead to the hypothesis that the cell type specificity of the enhancer might be controlled by regulating nuclear matrix attachment (Scheuermann, R. H., and Chen, U. (1989) Genes & Dev. 3, 1255-1266). To understand the role of MARs in IgH enhancer regulation, we have identified a novel MAR-binding protein, MAR-BP1, from soluble nuclear matrix preparations based on its ability to bind to the MARs associated with the IgH enhancer. Purified MAR-BP1 migrates as a 33-kDa protein, and it can be found in nuclear matrix preparations from a number of different types of lymphoid cell lines. Although specific binding sites have been difficult to localize by chemical or enzymatic footprinting procedures, NF-mu NR binding sites are critical for efficient MAR-BP1 binding. Indeed, binding of the IgH enhancer to either intact nuclear matrix preparations or to MAR-BP1 is mutually exclusive to NF-mu NR binding. These results are consistent with a model for cell-type specific regulation in which binding of the NF-mu NR repressor to the IgH enhancer prevents nuclear matrix attachment in inappropriate cells by interfering with MAR-BP1/enhancer interaction.	UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ZONG, RT (corresponding author), UNIV TEXAS,SW MED CTR,MOLEC PATHOL LAB,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.			Scheuermann, Richard H./0000-0003-1355-892X				AMATI B, 1990, EMBO J, V9, P4007, DOI 10.1002/j.1460-2075.1990.tb07622.x; BEREZNEY R, 1991, J CELL BIOCHEM, V47, P109, DOI 10.1002/jcb.240470204; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BIDWELL JP, 1993, P NATL ACAD SCI USA, V90, P3162, DOI 10.1073/pnas.90.8.3162; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROTHERTON T, 1991, BIOCHEMISTRY-US, V30, P5845, DOI 10.1021/bi00238a006; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; FACKELMAYER FO, 1994, EUR J BIOCHEM, V221, P749, DOI 10.1111/j.1432-1033.1994.tb18788.x; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P3047; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GERDES MG, 1994, J CELL BIOL, V126, P289, DOI 10.1083/jcb.126.2.289; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; HAKES DJ, 1991, J BIOL CHEM, V266, P11131; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LUDERUS MEE, 1994, MOL CELL BIOL, V14, P6297, DOI 10.1128/MCB.14.9.6297; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943, DOI 10.1073/pnas.89.15.6943; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; NAKAGOMI K, 1994, MOL CELL BIOL, V14, P1852, DOI 10.1128/MCB.14.3.1852; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; SCHEUERMANN RH, 1992, J BIOL CHEM, V267, P624; SCHEUERMANN RH, 1989, GENE DEV, V3, P1255, DOI 10.1101/gad.3.8.1255; SCHEUERMANN RH, 1990, IMMUNOL METHODS, V4, P75; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; TSUTSUI K, 1993, J BIOL CHEM, V268, P12886; VONKRIES JP, 1994, NUCLEIC ACIDS RES, V22, P1215, DOI 10.1093/nar/22.7.1215; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; WEBB CF, 1991, MOL CELL BIOL, V11, P5206, DOI 10.1128/MCB.11.10.5206; XU M, 1989, J BIOL CHEM, V264, P21190; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x	48	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24010	24018		10.1074/jbc.270.41.24010	http://dx.doi.org/10.1074/jbc.270.41.24010			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592598	hybrid			2022-12-27	WOS:A1995TA21700026
J	AHMED, MU; HAZEKI, K; HAZEKI, O; KATADA, T; UI, M				AHMED, MU; HAZEKI, K; HAZEKI, O; KATADA, T; UI, M			CYCLIC AMP-INCREASING AGENTS INTERFERE WITH CHEMOATTRACTANT INDUCED RESPIRATORY BURST IN NEUTROPHILS AS A RESULT OF THE INHIBITION OF PHOSPHATIDYLINOSITOL 3-KINASE RATHER THAN RECEPTOR-OPERATED CA2+ INFLUX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-ACTIVATING PROTEIN; INDUCED TYROSINE PHOSPHORYLATION; GUINEA-PIG NEUTROPHILS; CHEMOTACTIC PEPTIDE; MAP KINASE; ADP-RIBOSYLATION; PERTUSSIS TOXIN; BINDING PROTEIN; HL-60 CELLS; CAMP	Superoxide anion and arachidonic acid were pro duced in guinea pig neutrophils in response to a chemotactic peptide formyl-methionyl leucyl-phenylalanine (fMLP). Both responses were markedly, but the former response to a phorbol ester was not at all, inhibited when the cellular cAMP level was raised by prostaglandin E(1) combined with a cAMP phosphodiesterase inhibitor. Increasing cAMP was also inhibitory to fMLP-induced activation of phosphatidylinositol (PI) 3-kinase and Ca2+ influx without any effect on the cation mobilization from intracellular stores. The fMLP-induced respiratory burst was abolished when PI 3-kinase was inhibited by wortmannin or LY294002, but was not affected when Ca2+ influx was inhibited. On the contrary, fMLP released arachidonic acid from the cells treated with the PI 3-kinase inhibitors as well as from nontreated cells, but it did not so when cellular Ca2+ uptake was prevented. The chemotactic peptide activated PI 3-kinase even in cells in which the receptor-mediated intracellular Ca2+ mobilization and respiratory burst were both abolished by exposure of the cells to a permeable Ca2+-chelating agent. Thus, stimulation of fMLP receptors gave rise to dual effects, activation of PI 3-kinase and intracellular Ca2+ mobilization; both effects were necessary for the fMLP-induced respiratory burst. Increasing cellular cAMP inhibited the respiratory burst and arachidonic acid release as a result of the inhibitions of PI 3-kinase and Ca2+ influx, respectively, in fMLP-treated neutrophils.	INST PHYS & CHEM RES,UI LAB,WAKO,SAITAMA 35101,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN	RIKEN; University of Tokyo								ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; ASAHI M, 1993, J BIOL CHEM, V268, P23334; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CURNUTTE JT, 1994, J BIOL CHEM, V269, P10813; DETOGNI P, 1984, BIOCHEM J, V224, P629, DOI 10.1042/bj2240629; DEWALD B, 1988, J BIOL CHEM, V263, P16179; DONI MG, 1994, BIOCHEM J, V303, P599, DOI 10.1042/bj3030599; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; DUSI S, 1994, BIOCHEM J, V304, P243, DOI 10.1042/bj3040243; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEEMSKERK JWM, 1994, EUR J BIOCHEM, V223, P543, DOI 10.1111/j.1432-1033.1994.tb19023.x; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; KIKUCHI A, 1986, J BIOL CHEM, V261, P1558; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LYNCH JW, 1994, J BIOL CHEM, V269, P8226; MONTERO M, 1993, J BIOL CHEM, V268, P26911; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; OHTA H, 1985, J BIOL CHEM, V260, P5771; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; OKAJIMA F, 1984, J BIOL CHEM, V259, P3863; PARK DG, 1993, J BIOL CHEM, V268, P4573; PYNE NJ, 1994, BIOCHEM J, V304, P611, DOI 10.1042/bj3040611; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TAKENAWA T, 1986, J BIOL CHEM, V261, P1092; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; THOMPSON HL, 1994, J BIOL CHEM, V269, P9486; TORRES M, 1993, J IMMUNOL, V150, P1563; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; UI M, 1986, RECEPTOR BIOCH METHO, P163; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHANG Y, 1994, J BIOL CHEM, V269, P18727	62	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23816	23822		10.1074/jbc.270.40.23816	http://dx.doi.org/10.1074/jbc.270.40.23816			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559558	hybrid			2022-12-27	WOS:A1995RY90900087
J	ALLAN, CM; WALKER, D; TAYLOR, JM				ALLAN, CM; WALKER, D; TAYLOR, JM			EVOLUTIONARY DUPLICATION OF A HEPATIC CONTROL REGION IN THE HUMAN APOLIPOPROTEIN-E GENE LOCUS - IDENTIFICATION OF A 2ND REGION THAT CONFERS HIGH-LEVEL AND LIVER-SPECIFIC EXPRESSION OF THE HUMAN APOLIPOPROTEIN-E GENE IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; C-I GENE; CHOLESTEROL HOMEOSTASIS; MESSENGER-RNAS; A-I; CLUSTER; CHROMOSOME-19; LOCALIZATION; LIPOPROTEINS; SEQUENCES	We have identified a second hepatic control region (HCR-2) in the human apolipoprotein (ape) E gene locus that confers liver expression of the human apoE gene in transgenic mice. This HCR-2 sequence is located 27 kilobases downstream of the apoE gene and 10 kilobases downstream of the previously described liver-specific enhancer (HCR-1), Nucleotide sequence analysis of the HCR-2 region revealed a sequence that shares 85% identity to the functional 319-base pair domain of HCR-1. To test its activity, transgenic mice were prepared with a fusion construct containing a human apoE gene fragment, which is not normally expressed in the liver, ligated to a 632-base pair region containing the HCR-2 sequence. This construct resulted in high levels of liver-specific apoE transgene expression, indicating that HCR-2 can function as a hepatic enhancer and has an activity similar to that of HCR-1. Hence, these findings suggest that there are at least two hepatic control regions, HCR-1 and HCR-2, capable of controlling the liver expression of this human apolipoprotein gene locus.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; University of California System; University of California San Francisco	ALLAN, CM (corresponding author), UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,POB 419100,SAN FRANCISCO,CA 94141, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037063] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-37063] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN CM, 1995, GENOMICS, V28, P291, DOI 10.1006/geno.1995.1144; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; GILMAN M, 1993, CURRENT PROTOCOLS MO, V1; HOFFER MJV, 1993, GENOMICS, V17, P45, DOI 10.1006/geno.1993.1281; HOFFER MJV, 1993, GENOMICS, V15, P62, DOI 10.1006/geno.1993.1010; LAUER SJ, 1988, J BIOL CHEM, V263, P7277; LUO CC, 1989, J LIPID RES, V30, P1735; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MYKLEBOST O, 1988, HUM GENET, V78, P244, DOI 10.1007/BF00291670; RAISONNIER A, 1991, J MOL EVOL, V32, P211; Sambrook J, 1989, MOL CLONING LABORATO; SEHAYEK E, 1991, J BIOL CHEM, V266, P18259; SHACHTER NS, 1993, J LIPID RES, V34, P1699; SHEN PY, 1992, ARCH BIOCHEM BIOPHYS, V297, P345, DOI 10.1016/0003-9861(92)90683-N; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; SMIT M, 1988, HUM GENET, V78, P90, DOI 10.1007/BF00291243; STEYRER E, 1988, BIOCHIM BIOPHYS ACTA, V958, P484, DOI 10.1016/0005-2760(88)90235-4; VANECK MM, 1994, GENOMICS, V21, P110, DOI 10.1006/geno.1994.1231; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WEISGRABER KH, 1995, ATHEROSCLEROSIS, V10, P670; WU AL, 1979, J BIOL CHEM, V254, P7316	29	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26278	26281		10.1074/jbc.270.44.26278	http://dx.doi.org/10.1074/jbc.270.44.26278			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592836	hybrid			2022-12-27	WOS:A1995TC97800043
J	GALLAGHER, PG; FORGET, BG				GALLAGHER, PG; FORGET, BG			STRUCTURE, ORGANIZATION, AND EXPRESSION OF THE HUMAN BAND 7.2B GENE, A CANDIDATE GENE FOR HEREDITARY HYDROCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; HEMOLYTIC-ANEMIA; MESSENGER-RNAS; STOMATOCYTOSIS; SEQUENCE; DNA; POLYADENYLATION; CONSERVATION; METABOLISM; EUKARYOTES	Band 7.2b is an integral membrane phosphoprotein absent from the erythrocyte membranes of patients with hereditary hydrocytosis, a hemolytic anemia inherited in an autosomal dominant fashion and characterized by stomatocytic red blood cells with abnormal permeability to Na+ and K+. The precise role of band 7.2b is unknown, but it may interact with other proteins of the junctional complex of the membrane skeleton. To gain additional insight into the structure and function of this protein and to provide the necessary tools for further genetic studies of hydrocytosis patients, we determined the sequence of the full-length human band 7.2b cDNA, characterized the genomic structure of the band 7.2b gene, studied its pattern of expression in different tissues, and characterized the promoter of the gene, The composite band 7.2b gene cDNA was 3047 base pairs in length, Northern blot analysis revealed a wide tissue distribution of expression of the band 7.2b gene, with utilization of alternative polyadenylation signals generating transcripts of 2.2 and 3.1 kilobases, Cloning of the band 7.2b chromosomal gene revealed that it is composed of seven exons distributed over 40 kilobases of DNA. The band 7.2b gene promoter was identified as a TATA-less, (G + C)-rich promoter with a typical InR recognition sequence and a single transcription initiation site. It directed high level expression of a reporter gene in both erythroid and nonerythroid cells, An imperfect simple sequence repeat polymorphism was identified in the 5'-flanking DNA, and an assay was developed for its analysis by PCR.	YALE UNIV, SCH MED, DEPT INTERNAL MED, HEMATOL SECT, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT PEDIAT, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06520 USA	Yale University; Yale University; Yale University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK019482] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08HL02857] Funding Source: Medline; NIDDK NIH HHS [R37DK19482] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMS JM, 1989, MOL CELL BIOL, V9, P620, DOI 10.1128/MCB.9.2.620; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; [Anonymous], 1994, PROGRAM MANUAL WISCO; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BUTLER AJ, 1991, J BIOL CHEM, V266, P18250; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER DN, 1993, ANN MED, V25, P11, DOI 10.3109/07853899309147851; DACIE JV, 1985, HAEMOLYTIC ANAEMIA, P259; EBER SW, 1989, BRIT J HAEMATOL, V72, P452, DOI 10.1111/j.1365-2141.1989.tb07731.x; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P365, DOI 10.1128/MCB.6.2.365; GALLAGHER PG, 1993, GENOMICS, V18, P167, DOI 10.1006/geno.1993.1449; GALLAGHER PG, 1995, BLOOD, V86, P359, DOI 10.1182/blood.V86.1.359.bloodjournal861359; GALLAGHER PG, 1994, BLOOD, V84, pA6; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1065, P195, DOI 10.1016/0005-2736(91)90230-6; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P123, DOI 10.1016/0167-4781(91)90047-P; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; HURT J, 1992, NUCLEIC ACIDS RES, V20, P2985, DOI 10.1093/nar/20.12.2985; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KANZAKI A, 1992, BRIT J HAEMATOL, V82, P133; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LABUDA D, 1989, NUCLEIC ACIDS RES, V17, P2477, DOI 10.1093/nar/17.7.2477; LANDE WM, 1985, CLIN HAEMATOL, V14, P89; LANDE WM, 1982, J CLIN INVEST, V70, P1273, DOI 10.1172/JCI110726; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LIN BY, 1993, HUM MOL GENET, V2, P1541, DOI 10.1093/hmg/2.10.1541; MASON P, 1993, GENE TRANSCRIPTION P, P47; MENTZER WC, 1975, BLOOD, V46, P659; MILLER DR, 1971, BLOOD-J HEMATOL, V38, P184, DOI 10.1182/blood.V38.2.184.184; MORLE L, 1989, BRIT J HAEMATOL, V71, P141, DOI 10.1111/j.1365-2141.1989.tb06288.x; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; OLIVIERI O, 1992, BRIT J HAEMATOL, V80, P258, DOI 10.1111/j.1365-2141.1992.tb08912.x; OSKI FA, 1969, NEW ENGL J MED, V280, P909, DOI 10.1056/NEJM196904242801701; RINCONLIMAS DE, 1991, MOL CELL BIOL, V11, P4157, DOI 10.1128/MCB.11.8.4157; SACHS A, 1993, J BIOL CHEM, V268, P22955; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sinard J. H., 1994, Molecular Biology of the Cell, V5, p421A; STEWART GW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P15, DOI 10.1016/0925-4439(93)90116-I; STEWART GW, 1992, BLOOD, V79, P1593, DOI 10.1182/blood.V79.6.1593.bloodjournal7961593; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WIERINGA B, 1984, CELL, V37, P915, DOI 10.1016/0092-8674(84)90426-4; ZARKOWSKY HS, 1968, NEW ENGL J MED, V278, P573, DOI 10.1056/NEJM196803142781101	43	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26358	26363		10.1074/jbc.270.44.26358	http://dx.doi.org/10.1074/jbc.270.44.26358			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592848	hybrid			2022-12-27	WOS:A1995TC97800055
J	LI, QQ; YOKOYAMA, S				LI, QQ; YOKOYAMA, S			INDEPENDENT REGULATION OF CHOLESTEROL INCORPORATION INTO FREE APOLIPOPROTEIN-MEDIATED CELLULAR LIPID EFFLUX IN RAT VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; COLONY-STIMULATING FACTOR; PROTEIN-KINASE-C; MONOCYTE-DERIVED MACROPHAGES; LINE THP-1; INTRACELLULAR CHOLESTEROL; CULTURED FIBROBLASTS; SCAVENGER RECEPTOR; BINDING PROTEIN; HUMAN-PLASMA	Cholesterol was poorly available to free apolipoprotein (apo)A-I-mediated cellular lipid efflux from cholesterol-loaded rat vascular smooth muscle cells generating cholesterol-poorer pre-beta-HDL particles than those generated from macrophages by the same reaction (Li, a,, Komaba, k, and Yokoyama, S. (1993) Biochemistry 32, 4597-4603). The factors known to induce transformation of the smooth muscle cells into a macrophage-like stage were used in order to modulate this reaction, such as human platelet-derived growth factor, macrophage colony-stimulating factor, and phorbol 12-myristate-13-acetate (PMA). When the cells were stimulated by PMA following the pretreatment with platelet-derived growth factor plus macrophage colony-stimulating factor, cholesterol efflux mediated by free apoA-I increased 3-foId without changing phospholipid efflux, resulting in generation of pre-beta-HDL particles more rich in cholesterol. This treatment had only a little or no effect on apparent cellular cholesterol efflux to HDL or lipid microemulsion, respectively. Overall cellular free cholesterol pool size was unaffected by the treatment, and probing by extracellular cholesterol oxidase did not detect gross change in the cellular surface cholesterol. This specific enrichment of cholesterol in the apoA-I-mediated cellular lipid efflux was reversed by protein kinase C inhibitors. Measurement of intracellular cholesterol esterification suggested that PMA. induced translocation of intracellular cholesterol to a specific pool for apoA-I-mediated efflux, and a protein kinase C inhibitor reversed this effect.	UNIV ALBERTA,DEPT MED,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta								BERNARD DW, 1992, 65TH SCI SESS AM HEA, P46; BIELICKI JK, 1992, J LIPID RES, V33, P1699; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CZARNECKA H, 1995, BIOCHEMISTRY-US, V34, P4385, DOI 10.1021/bi00013a030; FIELDING C J, 1981, Proceedings of the National Academy of Sciences of the United States of America, V78, P3911, DOI 10.1073/pnas.78.6.3911; FIELDING PE, 1982, J CELL BIOL, V94, P350, DOI 10.1083/jcb.94.2.350; FORTE TM, 1993, J LIPID RES, V34, P317; FORTE TM, 1995, J LIPID RES, V36, P148; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; GLOMSET JA, 1968, J LIPID RES, V9, P155; GRAHAM DL, 1987, J BIOL CHEM, V262, P7439; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HARA H, 1992, LIPIDS, V27, P302, DOI 10.1007/BF02536480; HARA H, 1992, BIOCHEMISTRY-US, V31, P2040, DOI 10.1021/bi00122a021; HARA H, 1991, J BIOL CHEM, V266, P3080; HARA H, 1987, BIOCHEM BIOPH RES CO, V146, P802, DOI 10.1016/0006-291X(87)90601-2; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUME DA, 1988, J IMMUNOL, V141, P3405; INABA T, 1992, J BIOL CHEM, V267, P5693; INABA T, 1992, J BIOL CHEM, V267, P13107; INABA T, 1993, J CLIN INVEST, V92, P750, DOI 10.1172/JCI116646; INOUE I, 1992, ATHEROSCLEROSIS, V93, P245, DOI 10.1016/0021-9150(92)90261-E; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; ISHII I, 1994, BBA-LIPID LIPID MET, V1212, P278, DOI 10.1016/0005-2760(94)90201-1; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; JOHNSON WJ, 1988, J BIOL CHEM, V263, P14099; KARLIN JB, 1987, J BIOL CHEM, V262, P12557; KOMABA A, 1992, J BIOL CHEM, V267, P17560; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LI Q, 1995, IN PRESS BIOCH BIOPH; LI QQ, 1993, BIOCHEMISTRY-US, V32, P4597, DOI 10.1021/bi00068a016; LISCUM L, 1992, J LIPID RES, V33, P1239; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MENJU M, 1989, J BIOCHEM-TOKYO, V106, P505, DOI 10.1093/oxfordjournals.jbchem.a122882; MIIDA T, 1992, BIOCHEMISTRY-US, V31, P11112, DOI 10.1021/bi00160a022; MIIDA T, 1990, BIOCHEMISTRY-US, V29, P10469, DOI 10.1021/bi00498a007; MORI N, 1991, ARTERIOSCLER THROMB, V11, P1315, DOI 10.1161/01.ATV.11.5.1315; MURPHY JR, 1962, J LAB CLIN MED, V60, P86; NAKOINZ I, 1988, CELL IMMUNOL, V116, P331, DOI 10.1016/0008-8749(88)90235-3; NISHIKAWA O, 1986, J BIOCHEM, V99, P295, DOI 10.1093/oxfordjournals.jbchem.a135473; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; RAY E, 1980, BIOCHIM BIOPHYS ACTA, V617, P318, DOI 10.1016/0005-2760(80)90174-5; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; SHIMADA M, 1992, J BIOL CHEM, V267, P15455; SHIMANO H, 1990, J BIOL CHEM, V265, P12869; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; TAJIMA S, 1983, J BIOL CHEM, V258, P73; TAJIMA S, 1985, BIOCHEM BIOPH RES CO, V126, P526, DOI 10.1016/0006-291X(85)90637-0; TAKATA K, 1989, BIOCHIM BIOPHYS ACTA, V986, P18, DOI 10.1016/0005-2736(89)90267-8; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THERET N, 1990, BIOCHEM BIOPH RES CO, V173, P1361, DOI 10.1016/S0006-291X(05)80938-6; VOYNOYASENETSKA.TA, 1993, P NATL ACAD SCI USA, V90, P4256; YOKOYAMA S, 1982, J BIOCHEM, V91, P1267, DOI 10.1093/oxfordjournals.jbchem.a133811; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375	61	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26216	26223		10.1074/jbc.270.44.26216	http://dx.doi.org/10.1074/jbc.270.44.26216			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592827	hybrid			2022-12-27	WOS:A1995TC97800034
J	OKAJIMA, F; KONDO, Y				OKAJIMA, F; KONDO, Y			PERTUSSIS TOXIN INHIBITS PHOSPHOLIPASE-C ACTIVATION AND CA2+ MOBILIZATION BY SPHINGOSYLPHOSPHORYLCHOLINE AND GALACTOSYLSPHINGOSINE IN HL-60 LEUKEMIA-CELLS - IMPLICATIONS OF GTP-BINDING PROTEIN-COUPLED RECEPTORS FOR LYSOSPHINGOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION SYSTEMS; PHOSPHATIDIC-ACID LEVELS; PHOSPHOINOSITIDE TURNOVER; CELLULAR PROLIFERATION; INOSITOL TRISPHOSPHATE; ARACHIDONATE RELEASE; KINASE-C; SPHINGOSINE; SPHINGOSINE-1-PHOSPHATE; SUBSTRATE	Extracellular sphingosylphosphorylcholine (SPC) and galactosylsphingosine (psychosine) induced Ca2+ mobilization in a dose-dependent manner in HL60 leukemia cells. The rapid and transient increase in intracellular Ca2+ concentration ([Ca2+](i)) elicited by SPC and psychosine at concentrations lower than 30 mu M was inhibited by treatment of the cells with pertussis toxin (PTX) and U73122, a phospholipase C inhibitor, as was the ease for UTP, a P-2-purinergic agonist. The increase in [Ca2+](i) induced by these lysosphingolipids was associated with inositol phosphate production, which was also sensitive to PTX and U73122. The inositol phosphate response is not secondary to the increase in [Ca2+](i) as evidenced by the observation that thapsigargin and ionomycin, Ca2+ mobilizing agents, never induced inositol phosphate production and, unlike lysosphingolipids, the [Ca2+], rise by these agents was totally insensitive to PTX and U73122, When HL60 cells were differentiated into neutrophil like cells by dibutyryl cyclic AMP, inositol phosphate and Ca2+ responses to AlF4- were enhanced, probably reflecting an increase in the amount of Gi, and Gi, compared with undifferentiated cells. In the neutrophil-like cells, however, the responses to SPC and psychosine were markedly attenuated, This may exclude the possibility that the lysosphingolipids activate rather directly PTX-sensitive GTP-binding proteins or the phospholipase C itself, Other lysosphingolipids including glucosylsphingosine (glucopsychosine) and sphingosylgalactosyl sulfate (lysosulfatides) at 30 mu M or lower concentrations also showed PTX- and U73122-sensitive Ca2+ mobilization and inositol phosphate response in a way similar to SPC and psychosine, However, platelet-activating factor and lysoglycerophospholipids such as lysophosphatidylcholine and lysophosphatidic acid were less effective than these lysosphingolipids in the induction of Ca2+ mobilization. Taken together, the results indicate that a group of lysosphingolipids at appropriate doses induces Ca2+ mobilization through inositol phosphate production by phospholipase C activation. The lysosphingolipids-induced enzyme activation may be mediated by PTX-sensitive GTP-binding protein-coupled receptors, which may be different from previously identified platelet-activating factor receptor or lysophosphatidic acid receptor.			OKAJIMA, F (corresponding author), GUNMA UNIV,INST MOLEC & CELLULAR REGULAT,SIGNAL TRANSDUCT LAB,MAEBASHI,GUMMA 371,JAPAN.							BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V225, P756; BREITTMAYER JP, 1994, J BIOL CHEM, V269, P5054; CHAO CP, 1994, J BIOL CHEM, V269, P5849; COWEN DS, 1990, J BIOL CHEM, V265, P16181; DESAI NN, 1992, J BIOL CHEM, V267, P23122; DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; DURIEUX ME, 1993, AM J PHYSIOL, V264, pC1360, DOI 10.1152/ajpcell.1993.264.5.C1360; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GILMAN AG, 1989, ANNU REV BIOCHEM, V56, P615; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; KANAHO Y, 1989, CELL SIGNAL, V1, P553, DOI 10.1016/0898-6568(89)90063-6; KINDMAN LA, 1994, J BIOL CHEM, V269, P13088; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MIYATAKE T, 1972, BIOCHEM BIOPH RES CO, V48, P538, DOI 10.1016/0006-291X(72)90381-6; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; OHTA H, 1985, J BIOL CHEM, V260, P5771; OINUMA M, 1987, J BIOL CHEM, V262, P8347; OKAJIMA F, 1988, ENDOCRINOLOGY, V123, P1035, DOI 10.1210/endo-123-2-1035; OKAJIMA F, 1989, J BIOL CHEM, V264, P13029; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; OKAJIMA F, 1984, J BIOL CHEM, V259, P3863; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; RITCHIE T, 1992, BIOCHEM BIOPH RES CO, V186, P790, DOI 10.1016/0006-291X(92)90815-3; SATO K, 1990, ARCH BIOCHEM BIOPHYS, V281, P298, DOI 10.1016/0003-9861(90)90447-7; STRASBERG PM, 1988, BIOCHEM CELL BIOL, V66, P1322, DOI 10.1139/o88-153; STRASBERG PM, 1988, LIPID STORAGE DISORD, P601; TORNQUIST K, 1994, BIOCHEM J, V299, P213, DOI 10.1042/bj2990213; YAMAKAWA T, 1960, J BIOCHEM-TOKYO, V48, P490, DOI 10.1093/oxfordjournals.jbchem.a127197; YULE DI, 1993, J BIOL CHEM, V268, P12353; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZHANG H, 1990, J BIOL CHEM, V265, P21309	42	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26332	26340		10.1074/jbc.270.44.26332	http://dx.doi.org/10.1074/jbc.270.44.26332			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592844	hybrid			2022-12-27	WOS:A1995TC97800051
J	BAYLE, D; WEEKS, D; SACHS, G				BAYLE, D; WEEKS, D; SACHS, G			THE MEMBRANE TOPOLOGY OF THE RAT SARCOPLASMIC AND ENDOPLASMIC-RETICULUM CALCIUM ATPASES BY IN-VITRO TRANSLATION SCANNING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; TRANSMEMBRANE DOMAIN; COMPLEMENTARY-DNA; CARBOXYL TERMINI; H+-ATPASE; AMINO; IDENTIFICATION; PROTEIN; CA-2+-ATPASE; ORGANIZATION	The membrane topology of the rat endoplasmic reticulum (ER) and sarcoplasmic reticulum (SR) Ca2+ ATPases were investigated using in vitro transcription/translation of fusion vectors containing DNA sequences encoding putative membrane-spanning domains. The sequences of these Ca2+ ATPases are identical except for the COOH-terminal end, which contains an additional predicted transmembrane segment in the ER ATPase. The MO and M1 fusion vectors (Bamberg, K., and Sachs, G. (1994) J. Biol. Chem. 269, 16909-16919) encode the NH2-terminal 101 (MO vector) or 139 (M1 vector) amino acids of the H,K-ATPase alpha subunit followed by a linker region for insertion of putative transmembrane sequences and, finally, the COOH-terminal 177 amino acids of the H,K-ATPase beta subunit containing five N-linked glycosylation consensus sequences. The linker region was replaced by the putative transmembrane domains of the Ca2+ ATPases, either individually or in pairs. Transcription and translation were performed using [S-35]methionine in a reticulocyte lysate system in the absence or presence of canine pancreatic microsomes. The translated fusion protein was identified by autoradiography following separation using SDS-polyacrylamide gel electrophoresis. When testing single transmembrane segments, this method detects signal anchor activity with MO or stop transfer activity with M1. The first four predicted SERCA transmembrane domains acted as both signal anchor and stop transfer sequences. A construct containing the fifth predicted transmembrane segment was able to act only as a stop transfer sequence. The sixth transmembrane segment did not insert cotranslationally into the membrane. The seventh was able to act as both a signal anchor and stop transfer sequence, and the eighth showed stop transfer ability in the M1 vector. The ninth transmembrane segment had both signal anchor and stop transfer capacity, whereas the tenth transmembrane segment showed only stop transfer sequence properties. The eleventh transmembrane sequence, unique to the ER Ca2+ ATPase, had both signal anchor and stop transfer properties. These translation data provide direct experimental evidence for 8 or 9 of the 10 or 11 predicted transmembrane sequences in the current topological models for the SR or ER Ca2+ ATPases, respectively.	WADSWORTH VET ADM HOSP, LOS ANGELES, CA 90073 USA; UNIV CALIF LOS ANGELES, DEPT PHYSIOL & MED, LOS ANGELES, CA 90073 USA	University of California System; University of California Los Angeles					NIDDK NIH HHS [R01 DK46917, DK40615] Funding Source: Medline; PHS HHS [41301] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046917, R01DK040615] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; CAMPBELL AM, 1992, J BIOL CHEM, V267, P9321; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1993, J BIOL CHEM, V268, P18359; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GOLDSHLEGER R, 1994, SODIUM PUMP, P309; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HOMAREDA H, 1993, BIOCHEM CELL BIOL, V71, P410, DOI 10.1139/o93-060; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lemmon MA., 1992, CURR OPIN STRUC BIOL, V2, P511; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; LIN JL, 1995, J BIOL CHEM, V270, P6942, DOI 10.1074/jbc.270.12.6942; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; MATTHEWS I, 1989, BIOCHEM BIOPH RES CO, V161, P683, DOI 10.1016/0006-291X(89)92653-3; MELCHERS K, 1995, GASTROENTEROLOGY, V106, pA881; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RAO US, 1991, J BIOL CHEM, V266, P14740; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; Sambrook J, 1989, MOL CLONING LABORATO; SHIN JM, 1994, J BIOL CHEM, V269, P8642; SHIN JM, 1994, J BIOL CHEM, V269, P22533; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SKERJANC IS, 1993, FEBS LETT, V336, P168, DOI 10.1016/0014-5793(93)81633-B; SMITH DL, 1993, J BIOL CHEM, V268, P22469; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; YOON KL, 1994, J BIOL CHEM, V269, P28249	43	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25678	25684		10.1074/jbc.270.43.25678	http://dx.doi.org/10.1074/jbc.270.43.25678			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592746	hybrid			2022-12-27	WOS:A1995TB46600063
J	BENNETT, MK; LOPEZ, JM; SANCHEZ, HB; OSBORNE, TF				BENNETT, MK; LOPEZ, JM; SANCHEZ, HB; OSBORNE, TF			STEROL REGULATION OF FATTY-ACID SYNTHASE PROMOTER - COORDINATE FEEDBACK-REGULATION OF 2 MAJOR LIPID PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LEUCINE ZIPPER PROTEIN; MOLECULAR-CLONING; RECEPTOR PROMOTER; TRANSCRIPTION; GENE; IDENTIFICATION; SEQUENCE; DIFFERENTIATION; CHOLESTEROL	The gene encoding fatty acid synthase, the essential multi-functional enzyme of fatty acid biosynthesis, is shown to be regulated by cellular sterol levels similar to genes that encode important proteins of cholesterol metabolism. me show that expression of the endogenous FAS gene is repressed when regulatory sterols are included in the culture medium of HepG2 cells and that the FAS promoter is subject to similar regulation when fused to the luciferase reporter gene. Mutational studies demonstrate that sterol regulation is mediated by binding sites for the sterol regulatory element-binding protein (SREBP) and transcription factor Sp1, making it mechanistically similar to sterol regulation of the low density lipoprotein receptor gene. It is also demonstrated that SREBP and Sp1 synergistically activate the FAS promoter in Drosophila tissue culture cells, which lack endogenous Sp1. These experiments provide key molecular evidence that directly links the metabolism of fatty acids and cholesterol together.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	University of California System; University of California Irvine			Lopez, Jose M/D-1654-2011; Lopez, Jose/AAF-3798-2020	Lopez, Jose M/0000-0002-4104-6262; Lopez, Jose/0000-0002-4104-6262	NHLBI NIH HHS [HL48044] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMY CM, 1990, BIOCHEM J, V271, P675, DOI 10.1042/bj2710675; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GLICKMAN RM, 1988, LIVER BIOL PATHOBIOL, P331; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HORTON JD, 1993, J CLIN INVEST, V92, P743, DOI 10.1172/JCI116645; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Maxam A M, 1980, Methods Enzymol, V65, P499; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MOUSTAID N, 1993, BIOCHEM J, V292, P767, DOI 10.1042/bj2920767; MOUSTAID N, 1994, J BIOL CHEM, V269, P5329; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; Sambrook J, 1989, MOL CLONING LABORATO, P545; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SPADY DK, 1993, ANNU REV NUTR, V13, P355, DOI [10.1146/annurev.nutr.13.1.355, 10.1146/annurev.nu.13.070193.002035]; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WOOLLETT LA, 1992, J LIPID RES, V33, P77; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	28	322	330	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25578	25583		10.1074/jbc.270.43.25578	http://dx.doi.org/10.1074/jbc.270.43.25578			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592729	Green Published, hybrid			2022-12-27	WOS:A1995TB46600046
J	CHO, BK; SCHODIN, BA; KRANZ, DM				CHO, BK; SCHODIN, BA; KRANZ, DM			CHARACTERIZATION OF A SINGLE-CHAIN ANTIBODY TO THE BETA-CHAIN OF THE T-CELL RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-CD3 MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR; BINDING-AFFINITY; ESCHERICHIA-COLI; INTERACTION SITE; LYMPHOCYTES-T; V-BETA; RECOGNITION; THERAPY; COMPLEX	In this report the V-H and V-H genes of the anti-T cell receptor (TCR) antibody KJ16, which recognizes the TCR V beta 8.1 and V beta 8.2 regions in mice, were cloned and expressed as a single-chain antibody (scFv) in Escherichia coli. A 29-kDa protein was obtained after renaturation from inclusion bodies. The KJ16 scFv bad a relative affinity for the native TCR that was slightly higher than KJ16 Fab fragments. The scFv and Fab fragments of the KJ16 antibody, together with monovalent forms of two other anti-TCR antibodies, were evaluated as antagonists of the T cell-mediated recognition of a peptide-class I complex or of a superantigen. Staphylococcus enterotoxin B (SEB) bound to a class II product. Each of the anti-TCR antibodies was efficient at inhibiting the recognition of the SEE-class II complex. In contrast, only the clonotypic antibody, which binds to epitopes on both the V beta and V alpha regions, inhibited the recognition of peptide-class I complex. We conclude that the TCR binding site for the SEB-class II ligand encompasses a larger surface area than the TCR binding site for the peptide-class I ligand.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035990] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35990] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; CHIOCCHIA G, 1991, EUR J IMMUNOL, V21, P2899, DOI 10.1002/eji.1830211202; CHOI YW, 1990, NATURE, V346, P471, DOI 10.1038/346471a0; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DECKHUT AM, 1994, J EXP MED, V180, P1931, DOI 10.1084/jem.180.5.1931; DIGIUSTO DL, 1994, MOL IMMUNOL, V31, P693, DOI 10.1016/0161-5890(94)90179-1; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GAUR A, 1994, ADV IMMUNOL, V56, P219, DOI 10.1016/S0065-2776(08)60453-8; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P673; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HIRSCH R, 1989, J IMMUNOL, V142, P737; HONG SC, 1992, CELL, V69, P999, DOI 10.1016/0092-8674(92)90618-M; HOO WFS, 1992, P NATL ACAD SCI USA, V89, P4759, DOI 10.1073/pnas.89.10.4759; HOO WS, 1993, J IMMUNOL, V150, P4331; HOSAKA N, 1994, CLIN EXP IMMUNOL, V96, P500; Huston J S, 1993, Int Rev Immunol, V10, P195, DOI 10.3109/08830189309061696; JANEWAY CA, 1995, IMMUNOL TODAY, V16, P223, DOI 10.1016/0167-5699(95)80163-4; KANAGAWA O, 1991, J IMMUNOL, V147, P1307; KANG JS, 1994, J IMMUNOL, V152, P5305; KAPPLER J, 1994, P NATL ACAD SCI USA, V91, P8462, DOI 10.1073/pnas.91.18.8462; KASIBHATLA S, 1993, J IMMUNOL, V151, P3140; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; LIPES MA, 1993, SCIENCE, V259, P1165, DOI 10.1126/science.8267690; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; PATTEN PA, 1993, J IMMUNOL, V150, P2281; PULLEN AM, 1991, J EXP MED, V173, P1183, DOI 10.1084/jem.173.5.1183; RAAG R, 1995, FASEB J, V9, P73, DOI 10.1096/fasebj.9.1.7821762; ROJO JM, 1988, J IMMUNOL, V140, P1081; SCHODIN BA, 1993, J BIOL CHEM, V268, P25722; SEGAL DM, 1987, METHOD ENZYMOL, V150, P478; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; STAERZ UD, 1985, J IMMUNOL, V134, P3994; SYKULEV Y, 1994, P NATL ACAD SCI USA, V91, P11487, DOI 10.1073/pnas.91.24.11487; THEOFILOPOULOS AN, 1995, IMMUNOL TODAY, V16, P90, DOI 10.1016/0167-5699(95)80095-6; VACCHIO MS, 1992, J EXP MED, V175, P1405, DOI 10.1084/jem.175.5.1405; VOSS EW, 1984, FLUORESCEIN HAPTEN I, P18; WALDMANN TA, 1992, ANNU REV IMMUNOL, V10, P675, DOI 10.1146/annurev.immunol.10.1.675; WHITLOW M, 1991, Methods (Orlando), V2, P97, DOI 10.1016/S1046-2023(05)80209-9; WOODLAND DL, 1993, J EXP MED, V177, P433, DOI 10.1084/jem.177.2.433; WOODLE ES, 1991, TRANSPLANTATION, V52, P361, DOI 10.1097/00007890-199108000-00034; YOON ST, 1994, IMMUNITY, V1, P563	48	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25819	25826		10.1074/jbc.270.43.25819	http://dx.doi.org/10.1074/jbc.270.43.25819			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592766	hybrid			2022-12-27	WOS:A1995TB46600083
J	IVESSA, NE; DELEMOSCHIARANDINI, C; GRAVOTTA, D; SABATINI, DD; KREIBICH, G				IVESSA, NE; DELEMOSCHIARANDINI, C; GRAVOTTA, D; SABATINI, DD; KREIBICH, G			THE BREFELDIN A-INDUCED RETROGRADE TRANSPORT FROM THE GOLGI-APPARATUS TO THE ENDOPLASMIC-RETICULUM DEPENDS ON CALCIUM SEQUESTERED TO INTRACELLULAR STORES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; GTP-BINDING PROTEINS; METALLOENDOPROTEASE ACTIVITY; GUANINE-NUCLEOTIDE; HELA-CELLS; MEMBRANE; CA-2+-ATPASE; THAPSIGARGIN; INVOLVEMENT; INHIBITION	Ribophorin I is a type I transmembrane glycoprotein specific to the rough endoplasmic reticulum. We have previously shown that, when expressed in transfected HeLa cells, a carboxyl-terminally truncated form of ribophorin I that contains most of the luminal domain (RI(332)) is, like the native protein, retained in the endoplasmic reticulum (ER). Brefeldin A (BFA) treatment of these HeLa cells leads to O-glycosylation of RI(332) by glycosyltransferases that are redistributed from the Golgi apparatus to the ER (Ivessa, N. E., De Lemos-Chiarandini, C., Tsao, Y.-S., Takatsuki, A. Adesnik, M., Sabatini, D. D., and Kreibich, G. (1992) J. Cell Biol. 117, 949-958). Using the state of glycosylation of RI(332) as a measure for the BFA-induced backflow of enzymes of the Golgi apparatus to the ER, we now demonstrate that the retrograde transport is inhibited when cells are treated with various agents that affect intracellular Ca2+ concentrations, such as the dipeptide benzyloxy-carbonyl (Cbz)-Gly-Phe-amide, the Ca2+ ionophore A23187, and thapsigargin, an inhibitor of the Ca2+-transporting ATPase of the ER. These treatments prevent the BFA-induced O-glycosylation of RI(332). Immunofluorescence localization of the Golgi markers, MG-160 and galactosyltransferase, shows that when BFA is applied in the presence of Ca2+ modulating agents, the markers remain confined to the Golgi apparatus and are not redistributed to the ER, as is the case when BFA alone is used. Cbz-Gly-Phe-amide does not, however, interfere with the BFA-induced release of beta-COP from the Golgi apparatus. We conclude that the maintenance of a Ca2+ gradient between the cytoplasm and the lumen of the ER and the Golgi apparatus is required for the BFA-induced retrograde transport hom the Golgi apparatus to the ER to occur.	NYU, SCH MED, NEW YORK, NY 10016 USA; NYU, KAPLAN CANC CTR, DEPT CELL BIOL, NEW YORK, NY 10016 USA	New York University; New York University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043583] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43583] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BROSTROM MA, 1991, J BIOL CHEM, V266, P7037; CARAFOLI E, 1992, CURR TOP CELL REGUL, V32, P209; COUCH CB, 1983, CELL, V32, P257, DOI 10.1016/0092-8674(83)90516-0; CROUL S, 1990, J HISTOCHEM CYTOCHEM, V38, P957, DOI 10.1177/38.7.2355176; DEFIGUEIREDO P, 1995, MOL BIOL CELL, V6, P871, DOI 10.1091/mbc.6.7.871; DELEMOSCHIARANDINI C, 1992, EUR J CELL BIOL, V58, P187; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; ECKSTEIN DJ, 1989, J CELL BIOL, V108, P2507, DOI 10.1083/jcb.108.6.2507; GONATAS JO, 1989, J BIOL CHEM, V264, P646; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; IVESSA NE, 1992, J CELL BIOL, V117, P949, DOI 10.1083/jcb.117.5.949; KELLY RB, 1995, CURR BIOL, V5, P257, DOI 10.1016/S0960-9822(95)00054-6; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; KUZNETSOV G, 1993, J BIOL CHEM, V268, P2001; LELKES PI, 1987, J BIOL CHEM, V262, P15496; LENNARZ WJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P149, DOI 10.1016/0304-4157(91)90022-O; LIPPINCOTTSCHWA.J, 1993, CELL, V3, P81; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MARCANTONIO EE, 1984, J CELL BIOL, V99, P2254, DOI 10.1083/jcb.99.6.2254; MUNDY DI, 1985, CELL, V40, P645, DOI 10.1016/0092-8674(85)90213-2; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PITT A, 1991, EUR J CELL BIOL, V55, P328; RINDLER M J, 1992, Current Opinion in Cell Biology, V4, P616, DOI 10.1016/0955-0674(92)90080-V; ROOS N, 1988, SCANNING MICROSCOPY, V2, P323; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SABATINI DD, 1994, METABOLIC MOL BASES, V1, P459; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; STROUS GJ, 1988, J BIOL CHEM, V263, P18197; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; TOOZE J, 1992, EUR J CELL BIOL, V58, P228; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; VIRK SS, 1985, BIOCHEM J, V226, P741, DOI 10.1042/bj2260741; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335	51	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25960	25967		10.1074/jbc.270.43.25960	http://dx.doi.org/10.1074/jbc.270.43.25960			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592786	hybrid			2022-12-27	WOS:A1995TB46600103
J	KOROMILAS, AE; CANTIN, C; CRAIG, AWB; JAGUS, R; HISCOTT, J; SONENBERG, N				KOROMILAS, AE; CANTIN, C; CRAIG, AWB; JAGUS, R; HISCOTT, J; SONENBERG, N			THE INTERFERON-INDUCIBLE PROTEIN-KINASE PKR MODULATES THE TRANSCRIPTIONAL ACTIVATION OF IMMUNOGLOBULIN-KAPPA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; BETA-INTERFERON; TYROSINE PHOSPHORYLATION; BINDING DOMAIN; P68 KINASE; B-LYMPHOMA; CELL-LINE; EXPRESSION; INDUCTION; LIPOPOLYSACCHARIDE	PKR is an interferon (IFN)-induced serine/threonine protein kinase that regulates protein synthesis through phosphorylation of eukaryotic translation initiation factor-2 (eIF-2). In addition to its demonstrated role in translational control, recent findings suggest that PKR plays an important role in regulation of gene transcription, as PKR phosphorylates I kappa B alpha upon double-stranded RNA treatment resulting in activation of NF-kappa B DNA binding in vitro (Kumar, A., Haque, J., Lacoste, J., Hiscott, J., and Williams, B. R. G. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 6288-6292). To further investigate the role of PKR in transcriptional signaling, we expressed the wild type human PKR and a catalytically inactive dominant negative PKR mutant in the murine pre-B lymphoma 70Z/3 cells. Here, we report that expression of wild type PKR had no effect on kappa-chain transcriptional activation induced by lipopolysaccharide or IFN-gamma. However, expression of the dominant negative PKR mutant inhibited kappa gene transcription independently of NF-kappa B activation. Phosphorylation of eIF-2 alpha was not increased by lipopolysaccharide or IFN-gamma, suggesting that PKR mediates kappa gene transcriptional activation without affecting protein synthesis. Our findings further support a transcriptional role for PKR and demonstrate that there are at least two distinct PKR-mediated signal transduction pathways to the transcriptional machinery depending on cell type and stimuli, NF-kappa B-dependent and NF-kappa B-independent.	MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3T 1E2,CANADA; CLIN RES INST MONTREAL,MONTREAL,PQ H2W 1R7,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; UNIV MARYLAND,INST BIOTECHNOL,CTR MARINE BIOTECHNOL,BALTIMORE,MD 21202; MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ H3G 1A6,CANADA	McGill University; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; McGill University; University System of Maryland; University of Maryland Baltimore; McGill University			Craig, Andrew/G-2312-2017; Craig, Andrew/AAC-6923-2019	Craig, Andrew/0000-0002-2039-2393; Craig, Andrew/0000-0002-2039-2393				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ATCHISON ML, 1988, EMBO J, V7, P4213, DOI 10.1002/j.1460-2075.1988.tb03318.x; BARBER GN, 1993, GENOMICS, V16, P765, DOI 10.1006/geno.1993.1262; BRISKIN M, 1988, SCIENCE, V242, P1036, DOI 10.1126/science.3143155; BROWN FL, 1993, MOL CELL BIOL, V13, P5245, DOI 10.1128/MCB.13.9.5245; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CARROLL K, 1993, J BIOL CHEM, V268, P12837; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DAIGNEAULT L, 1992, NUCLEIC ACIDS RES, V20, P2749, DOI 10.1093/nar/20.11.2749; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DONG ZY, 1993, J EXP MED, V177, P1071, DOI 10.1084/jem.177.4.1071; EILERS A, 1995, MOL CELL BIOL, V15, P3579; ELLIS MJC, 1994, NUCLEIC ACIDS RES, V22, P4489, DOI 10.1093/nar/22.21.4489; EMERY DW, 1989, MOL CELL BIOL, V9, P5231, DOI 10.1128/MCB.9.11.5231; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GUSELLA GL, 1995, IMMUNOLOGY, V154, P345; HANASH SM, 1993, GENE CHROMOSOME CANC, V8, P34, DOI 10.1002/gcc.2870080107; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARA H, 1990, INT IMMUNOL, V2, P691, DOI 10.1093/intimm/2.8.691; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HENRY C, 1980, SELECTED METHODS CEL, P138; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; ICELY PL, 1991, J BIOL CHEM, V266, P16073; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KATZE MG, 1992, J INTERFERON RES, V12, P241, DOI 10.1089/jir.1992.12.241; KOROMILAS A E, 1990, Technique (Philadelphia), V2, P189; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LASKY SR, 1982, J BIOL CHEM, V258, P11087; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; MUERS EF, 1993, P NATL ACAD SCI USA, V90, P232; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; NAKANO M, 1993, IMMUNOBIOLOGY, V187, P272, DOI 10.1016/S0171-2985(11)80344-X; NIELSCH U, 1991, EMBO J, V10, P4169, DOI 10.1002/j.1460-2075.1991.tb04995.x; OZES ON, 1993, J INTERFERON RES, V13, P283, DOI 10.1089/jir.1993.13.283; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RHODES LD, 1994, IMMUNOGENETICS, V40, P199, DOI 10.1007/BF00167080; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RIEMANN T, 1994, J IMMUNOL, V155, P5740; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROONEY JW, 1990, IMMUNOGENETICS, V31, P65, DOI 10.1007/BF00661215; ROONEY JW, 1990, IMMUNOGENETICS, V31, P75; ROULSTON A, 1992, J EXP MED, V175, P751, DOI 10.1084/jem.175.3.751; ROY S, 1990, SCIENCE, V247, P1216, DOI 10.1126/science.2180064; Sambrook J, 1989, MOL CLONING LABORATO; SEN GC, 1992, J BIOL CHEM, V267, P5017; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIGEKI M, 1994, P NATL ACAD SCI USA, V91, P5056; SUIRE J, 1993, GENOMICS, V16, P768; TSUDA M, 1978, J BIOCHEM-TOKYO, V84, P1285, DOI 10.1093/oxfordjournals.jbchem.a132247; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WALL R, 1986, P NATL ACAD SCI USA, V83, P295, DOI 10.1073/pnas.83.2.295; WEEKS RS, 1988, J IMMUNOL, V140, P1312; WEEKS RS, 1984, J IMMUNOL, V133, P381; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	79	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25426	25434		10.1074/jbc.270.43.25426	http://dx.doi.org/10.1074/jbc.270.43.25426			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592710	hybrid			2022-12-27	WOS:A1995TB46600026
J	LAWRENCE, DA; GINSBURG, D; DAY, DE; BERKENPAS, MB; VERHAMME, IM; KVASSMAN, JO; SHORE, JD				LAWRENCE, DA; GINSBURG, D; DAY, DE; BERKENPAS, MB; VERHAMME, IM; KVASSMAN, JO; SHORE, JD			SERPIN-PROTEASE COMPLEXES ARE TRAPPED AS STABLE ACYL-ENZYME INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CRYSTAL-STRUCTURE; INHIBITOR; MODEL; ALPHA-1-ANTITRYPSIN; ALPHA-2-ANTIPLASMIN; ANTITHROMBIN; CHYMOTRYPSIN; THROMBOSIS; MECHANISM	The serine protease inhibitors of the serpin family are an unusual group of proteins thought to have metastable native structures. Functionally, they are unique among polypeptide protease inhibitors, although their precise mechanism of action remains controversial, Conflicting results from previous studies have suggested that the stable serpin-protease complex is trapped in either a tight Michaelis-like structure, a tetrahedral intermediate, or an acyl-enzyme, In this report we show that, upon association with a target protease, the serpin reactive-center loop (RCL) is cleaved resulting in formation of an acyl-enzyme intermediate. This cleavage is coupled to rapid movement of the RCL into the body of the protein bringing the inhibitor closer to its lowest free energy state. From these data we suggest a model for serpin action in which the drive toward the lowest free energy state results in trapping of the protease-inhibitor complex as an acyl-enzyme intermediate.	UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; HENRY FORD HLTH SYST,DETROIT,MI 48202	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Henry Ford Health System; Henry Ford Hospital	LAWRENCE, DA (corresponding author), AMER RED CROSS,JEROME H HOLLAND LAB,DEPT BIOCHEM,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855, USA.			Lawrence, Daniel/0000-0003-3126-1935	NHLBI NIH HHS [HL 49184, HL 45930A] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049184, R01HL045930] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CHRISTENSEN S, 1995, J BIOL CHEM, V270, P14859, DOI 10.1074/jbc.270.25.14859; COHEN AB, 1977, P NATL ACAD SCI USA, V74, P4311, DOI 10.1073/pnas.74.10.4311; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; Fa M., 1994, Fibrinolysis, V8, P17; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P3634, DOI 10.1021/bi00410a017; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251	28	225	233	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25309	25312		10.1074/jbc.270.43.25309	http://dx.doi.org/10.1074/jbc.270.43.25309			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592687	hybrid			2022-12-27	WOS:A1995TB46600003
J	MOUILLAC, B; CHINI, B; BALESTRE, MN; ELANDS, J; TRUMPPKALLMEYER, S; HOFLACK, J; HIBERT, M; JARD, S; BARBERIS, C				MOUILLAC, B; CHINI, B; BALESTRE, MN; ELANDS, J; TRUMPPKALLMEYER, S; HOFLACK, J; HIBERT, M; JARD, S; BARBERIS, C			THE BINDING-SITE OF NEUROPEPTIDE VASOPRESSIN V1A RECEPTOR - EVIDENCE FOR A MAJOR LOCALIZATION WITHIN TRANSMEMBRANE REGIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ADRENERGIC-RECEPTOR; MOLECULAR-CLONING; LIGAND-BINDING; ANTAGONIST; OXYTOCIN; AGONIST; EXPRESSION; RAT; IDENTIFICATION	To identify receptor functional domains underlying binding of the neurohypophysial hormones vasopressin (AVP) and oxytocin (OT), we have constructed a three-dimensional (3D) model of the V1a vasopressin receptor subtype and docked the endogenous ligand AVP, To verify and to refine the 3D model, residues likely to be involved in agonist binding were selected for site-directed mutagenesis, Our experimental results suggest that AVP, which is characterized by a cyclic structure, could be completely buried into a 15-20-Angstrom deep cleft defined by the transmembrane helices of the receptor and interact with amino acids located within this region, Moreover, the AVP-binding site is situated in a position equivalent to that described for the cationic neurotransmitters, Since all mutated residues are highly conserved in AVP and OT receptors, we propose that the same agonist-binding site is shared by all members of this receptor family, In contrast, the affinity for the antagonists tested, including those with a structure closely related to AVP, is not affected by mutations, This indicates a different binding mode for agonists and antagonists in the vasopressin receptor.	CNRS, INSERM, CTR PHARMACOL ENDOCRINOL, UNITE 401, F-34094 MONTPELLIER 05, FRANCE; MARION MERRELL DOW RES INST, F-67009 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			MOUILLAC, Bernard/M-3896-2014	MOUILLAC, Bernard/0000-0002-3906-8673; Chini, Bice/0000-0002-1686-284X				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BARBERIS C, 1995, NEUROENDOCRINOLOGY, V62, P135, DOI 10.1159/000126998; BARBERIS C, 1993, VASOPRESSIN, P69; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; FATHI Z, 1993, J BIOL CHEM, V268, P14622; FONG TM, 1992, J BIOL CHEM, V267, P25664; FRASER CM, 1989, MOL PHARMACOL, V36, P840; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GORBULEV V, 1993, EUR J BIOCHEM, V215, P1, DOI 10.1111/j.1432-1033.1993.tb18000.x; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HOFLACK J, 1993, 3D QSAR DRUG DESIGN, P355; HRUBY VJ, 1987, TRENDS PHARMACOL SCI, V8, P336, DOI 10.1016/0165-6147(87)90142-8; JARD S, 1988, INT CONGR SER, V799, P1183; JARD S, 1975, PHYSIOL REV, V55, P489, DOI 10.1152/physrev.1975.55.4.489; KAUPMANN K, 1995, EMBO J, V14, P727, DOI 10.1002/j.1460-2075.1995.tb07051.x; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12383; LEE JA, 1994, P NATL ACAD SCI USA, V91, P7164, DOI 10.1073/pnas.91.15.7164; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MAHLMANN S, 1994, P NATL ACAD SCI USA, V91, P1342, DOI 10.1073/pnas.91.4.1342; MANNING M, 1993, J RECEPTOR RES, V13, P195, DOI 10.3109/10799899309073655; MANNING M, 1984, NATURE, V308, P652, DOI 10.1038/308652a0; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PEREZ HD, 1993, J BIOL CHEM, V268, P2292; PERLMAN JH, 1994, J BIOL CHEM, V269, P23383; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; TRUMPPKALLMEYER S, 1994, TACHYKININ RECEPTORS; ZIEGER G, 1991, MAGN RESON CHEM, V29, P580, DOI 10.1002/mrc.1260290608	45	205	206	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25771	25777		10.1074/jbc.270.43.25771	http://dx.doi.org/10.1074/jbc.270.43.25771			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592759	hybrid			2022-12-27	WOS:A1995TB46600076
J	NG, SW; EDER, JP; SCHNIPPER, LE; CHAN, VTW				NG, SW; EDER, JP; SCHNIPPER, LE; CHAN, VTW			MOLECULAR-CLONING AND CHARACTERIZATION OF THE PROMOTER FOR THE CHINESE-HAMSTER DNA TOPOISOMERASE II-ALPHA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDINE KINASE GENE; BOX-BINDING-PROTEINS; HUMAN-LEUKEMIC CELLS; 5'-FLANKING REGION; EXPRESSION; TRANSCRIPTION; RESISTANT; LOCALIZATION; CDNA; SEQUENCES	To investigate the mechanisms governing the expression of DNA topoisomerase II alpha, the Chinese hamster topoisomerase II alpha gene has been cloned and the promoter region analyzed. There are several transcriptional start sites clustered in a region of 30 base pairs, with the major one being 102 nucleotides upstream from the ATG translation initiation site. Sequencing data reveal one GC box and a total of five inverted CCAAT elements (ICEs) within a region of 530 base pairs upstream from the major transcription start site. Sequence comparison between the human and Chinese hamster topoisomerase II alpha gene promoter regions shows a high degree of homology centered at the ICEs and GC box. In vitro DNase I footprinting results indicate protection by binding proteins at and around each ICE on both DNA strands. However, no obvious protection was observed for the GC box, Competition gel mobility shift assays with oligonucleotides containing either the wild-type or mutated ICE sequences suggest that identical or similar proteins specifically bind at each ICE, although with different affinities for individual ICE sequences. Chloramphenicol acetyltransferase assays employing nested 5'-deletions of the 5'-flanking sequence of the gene demonstrate that the sequence between -186 and +102, which contains three proximal ICEs, is sufficient for near wild-type level of promoter activity. When these three ICEs were gradually replaced with sequences which do not interact with the binding proteins, reducing promoter activity of the resulted constructs was observed, In conjunction with results from footprinting and gel mobility shift studies, the transient gene expression finding suggests that the ICEs are functionally important for the transcriptional regulation of the topoisomerase II alpha gene.	HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,CHARLES A DANA RES INST,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,THORNDIKE LABS,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School					NCI NIH HHS [CA60154] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060154] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI N, 1992, NUCLEIC ACIDS RES, V20, P5297, DOI 10.1093/nar/20.20.5297; BECK WT, 1987, CANCER RES, V47, P5455; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; CARON PR, 1993, MOL BIOL DNA TOPOISO, P243; CHAN VTW, 1993, J BIOL CHEM, V268, P2160; CHARNAY P, 1985, MOL CELL BIOL, V5, P1498, DOI 10.1128/MCB.5.6.1498; DANKS MK, 1988, BIOCHEMISTRY-US, V27, P8861, DOI 10.1021/bi00424a026; DANKS MK, 1987, CANCER RES, V47, P1297; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; DUTTA A, 1990, GENE DEV, V4, P243, DOI 10.1101/gad.4.2.243; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; FRY AM, 1991, CANCER RES, V51, P6592; GIACCONE G, 1992, CANCER RES, V52, P1666; GODING CR, 1987, NUCLEIC ACIDS RES, V15, P7761, DOI 10.1093/nar/15.19.7761; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HOCHHAUSER D, 1992, J BIOL CHEM, V267, P18961; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; Hsieh TS, 1990, DNA TOPOLOGY ITS BIO, P243; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KAUFMANN SH, 1991, CANCER RES, V51, P3534; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KNIGHT GB, 1987, P NATL ACAD SCI USA, V84, P8350, DOI 10.1073/pnas.84.23.8350; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MATSUO K, 1990, CANCER RES, V50, P5819; Maxam A M, 1980, Methods Enzymol, V65, P499; MAXWELL A, 1985, ADV PROTEIN CHEM, V38, P69; MIRKOVITCH J, 1987, PHILOS T R SOC B, V317, P563, DOI 10.1098/rstb.1987.0081; NELSON EM, 1984, P NATL ACAD SCI-BIOL, V81, P1361, DOI 10.1073/pnas.81.5.1361; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; POMMIER Y, 1986, CANCER RES, V46, P611; POMMIER Y, 1988, CANCER RES, V48, P512; POTMESIL M, 1988, CANCER RES, V48, P3537; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; Sambrook J, 1989, MOL CLONING LABORATO; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VANWIJNEN AJ, 1988, BIOCHEMISTRY-US, V27, P6534, DOI 10.1021/bi00417a051; WOESSNER RD, 1990, CANCER RES, V50, P2901	45	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25850	25858		10.1074/jbc.270.43.25850	http://dx.doi.org/10.1074/jbc.270.43.25850			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592770	hybrid			2022-12-27	WOS:A1995TB46600087
J	QU, YS; ISOM, LL; WESTENBROEK, RE; ROGERS, JC; TANADA, TN; MCCORMICK, KA; SCHEUER, T; CATTERALL, WA				QU, YS; ISOM, LL; WESTENBROEK, RE; ROGERS, JC; TANADA, TN; MCCORMICK, KA; SCHEUER, T; CATTERALL, WA			MODULATION OF CARDIAC NA+ CHANNEL EXPRESSION IN XENOPUS OOCYTES BY BETA-1 SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; SODIUM-CHANNEL; ALPHA-SUBUNIT; FUNCTIONAL EXPRESSION; BINDING-PROTEIN; ELECTROPHORUS-ELECTRICUS; SAXITOXIN BINDING; HUMAN BRAIN; TETRODOTOXIN; HEART	Voltage-gated Na+ channels consist of a large alpha subunit of 260 kDa associated with beta 1 and/or beta 2 subunits of 36 and 33 kDa, respectively. alpha subunits of rat cardiac Na+ channels (rH1) are functional when expressed alone in Xenopus oocytes or mammalian cells. beta 1 subunits are present in the heart, and localization of beta 1 subunit mRNA by in situ hybridization shows expression in the perinuclear cytoplasm of cardiac myocytes. Coexpression of beta 1 subunits with rH1 alpha subunits in Xenopus oocytes increases Na+ currents up to 6-fold in a concentration dependent manner. However, no effects of beta 1 subunit coexpression on the kinetics or voltage dependence of the rH1 Na+ current were detected. Increased expression of Na+ currents is not observed when an equivalent mRNA encoding a nonfunctional mutant beta 1 subunit is coexpressed. Our results show that beta 1 subunits are expressed in cardiac muscle cells and that they interact with alpha subunits to increase the expression of cardiac Na+ channels in Xenopus oocytes, suggesting that beta 1 subunits are important determinants of the level of excitability of cardiac myocytes in vivo.			QU, YS (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,BOX 357280,SEATTLE,WA 98195, USA.			Isom, Lori/0000-0002-9479-6729	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL44948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGNEW WS, 1980, BIOCHEM BIOPH RES CO, V92, P860, DOI 10.1016/0006-291X(80)90782-2; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BAER M, 1976, NATURE, V263, P344, DOI 10.1038/263344a0; BARCHI RL, 1983, J NEUROCHEM, V40, P1377, DOI 10.1111/j.1471-4159.1983.tb13580.x; BENNETT PB, 1993, FEBS LETT, V326, P21, DOI 10.1016/0014-5793(93)81752-L; BLACK JA, 1994, MOL BRAIN RES, V22, P275, DOI 10.1016/0169-328X(94)90056-6; BROWN AM, 1981, J PHYSIOL-LONDON, V318, P455; CANNON SC, 1993, PFLUG ARCH EUR J PHY, V423, P155, DOI 10.1007/BF00374974; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; COHEN SA, 1993, CIRC RES, V73, P735, DOI 10.1161/01.RES.73.4.735; CRIBBS LL, 1990, FEBS LETT, V275, P195, DOI 10.1016/0014-5793(90)81470-9; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; JOHO RH, 1990, MOL BRAIN RES, V7, P105, DOI 10.1016/0169-328X(90)90087-T; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KIMITSUKI T, 1990, AM J PHYSIOL, V258, pH247, DOI 10.1152/ajpheart.1990.258.1.H247; KRAFTE DS, 1988, J NEUROSCI, V8, P2859; KRAFTE DS, 1990, J GEN PHYSIOL, V96, P689, DOI 10.1085/jgp.96.4.689; KRANER SD, 1985, J BIOL CHEM, V260, P6341; KYLE JW, 1993, BIOPHYS J, V64, pA88; LOMBET A, 1984, EUR J BIOCHEM, V141, P651, DOI 10.1111/j.1432-1033.1984.tb08241.x; Makielski Jonathan C., 1995, Biophysical Journal, V68, pA157; MAKITA N, 1994, J BIOL CHEM, V269, P7571; MCCLATCHEY AI, 1993, HUM MOL GENET, V2, P745, DOI 10.1093/hmg/2.6.745; MESSNER DJ, 1986, J BIOL CHEM, V261, P211; MESSNER DJ, 1986, J BIOL CHEM, V261, P4882; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MILLER JA, 1983, BIOCHEMISTRY-US, V22, P462, DOI 10.1021/bi00271a032; MILLER MA, 1989, METHODS NEUROSCIENCE, V1, P164; NORMAN RI, 1983, P NATL ACAD SCI-BIOL, V80, P4164, DOI 10.1073/pnas.80.13.4164; Nuss H. Bradley, 1995, Biophysical Journal, V68, pA133; OLEARY ME, 1994, J GEN PHYSIOL, V104, P507, DOI 10.1085/jgp.104.3.507; PATTON DE, 1991, NEURON, V7, P637, DOI 10.1016/0896-6273(91)90376-B; PATTON DE, 1994, J BIOL CHEM, V269, P17649; QU YS, 1994, P NATL ACAD SCI USA, V91, P3289, DOI 10.1073/pnas.91.8.3289; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; SATIN J, 1992, J MEMBRANE BIOL, V130, P11; SCHEINMAN RI, 1989, J BIOL CHEM, V264, P10660; SUTKOWSKI EM, 1990, J BIOL CHEM, V265, P12393; TONG JF, 1993, BIOCHEM BIOPH RES CO, V195, P679, DOI 10.1006/bbrc.1993.2099; WHITE MM, 1991, MOL PHARMACOL, V39, P604; WOLLNER DA, 1988, NEURON, V1, P727, DOI 10.1016/0896-6273(88)90171-7; YANG JS, 1993, NEURON, V11, P915, DOI 10.1016/0896-6273(93)90121-7	45	109	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25696	25701		10.1074/jbc.270.43.25696	http://dx.doi.org/10.1074/jbc.270.43.25696			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592748	hybrid			2022-12-27	WOS:A1995TB46600065
J	YASUKAWA, T; KANEIISHII, C; MAEKAWA, T; FUJIMOTO, J; YAMAMOTO, T; ISHII, S				YASUKAWA, T; KANEIISHII, C; MAEKAWA, T; FUJIMOTO, J; YAMAMOTO, T; ISHII, S			INCREASE OF SOLUBILITY OF FOREIGN PROTEINS IN ESCHERICHIA-COLI BY COPRODUCTION OF THE BACTERIAL THIOREDOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INCLUSION BODY FORMATION; FUNCTIONAL DOMAINS; RNA-POLYMERASE; HEAT-SHOCK; EXPRESSION; GENE; KINASE; MYB	Eukaryotic proteins are frequently produced in Escherichia coli as insoluble aggregates. This is one of the barriers to studies of macromolecular structure. We have examined the effect of coproduction of the E. coli thioredoxin (Trx) or E. coli chaperones GroESL on the solubility of various foreign proteins. The solubilities of all eight vertebrate proteins examined including transcription factors and kinases were increased dramatically by coproduction of Trx. Overproduction of E. coli chaperones GroESL increased the solubilities of four out of eight proteins examined. Although the tyrosine kinase Lck that was produced as an insoluble form and solubilized by urea treatment had a very low autophosphorylating activity, Lck produced in soluble form by coproduction of Trx had an efficient activity. These results suggest that the proteins produced in soluble form by coproduction of Trx have the native protein conformation. The mechanism by which coproduction of Trx increases the solubility of the foreign proteins is discussed.	INST PHYS & CHEM RES,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST MED SCI,TSUKUBA,IBARAKI 305,JAPAN; UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN	RIKEN; University of Tsukuba; University of Tokyo			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; KANEMORI M, 1994, J BACTERIOL, V176, P4235, DOI 10.1128/jb.176.14.4235-4242.1994; KONDO T, 1993, J BIOL CHEM, V268, P20366; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LEE SC, 1992, J BIOL CHEM, V267, P2849; LUNN CA, 1984, J BIOL CHEM, V259, P469; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NAGASE T, 1993, J BIOL CHEM, V268, P13710; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	27	260	278	3	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25328	25331		10.1074/jbc.270.43.25328	http://dx.doi.org/10.1074/jbc.270.43.25328			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592692	hybrid, Green Submitted			2022-12-27	WOS:A1995TB46600008
J	BROSE, N; HOFMANN, K; HATA, Y; SUDHOF, TC				BROSE, N; HOFMANN, K; HATA, Y; SUDHOF, TC			MAMMALIAN HOMOLOGS OF CAENORHABDITIS-ELEGANS UNC-13 GENE DEFINE NOVEL FAMILY OF C-2-DOMAIN PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE LEVELS; SYNAPTOTAGMIN; RECEPTOR; BINDING; MUTATIONS; SYNTAXIN; CLEAVAGE	The unc-13 gene in Caenorhabditis elegans is essential for normal presynaptic function and encodes a large protein with C-1- and C-2-domains. In protein kinase C and synaptotagmin, C-1- and/or C-2-domains are regulatory domains for Ca2+, phospholipids, and diacylglycerol, suggesting a role for unc-13 in regulating neurotransmitter release. To determine if a similar protein is a component of the presynaptic machinery for neurotransmitter release in vertebrates, we studied unc-13 homologues in rat. Molecular cloning revealed that three homologues of unc-13 called Munc13-1, -13-2, and -13-3 are expressed in rat brain. Munc13s are large, brain-specific proteins with divergent N termini but conserved C termini containing C-1- and C-2-domains. Specific antibodies demonstrated that Munc13-1 is a peripheral membrane protein that is enriched in synaptosomes and localized to plasma membranes but absent from synaptic vesicles. Our data suggest that the function of unc-13 in C. elegans is conserved in mammals and that Munc13s act as plasma membrane proteins in nerve terminals. The presence of C-1- and C-2-domains in these proteins and the phenotype of the C. elegans mutants raise the possibility that Munc13s may have an essential signaling role during neurotransmitter release.	UNIV TEXAS,SW MED SCH,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED SCH,HOWARD HUGHES MED INST,DALLAS,TX 75235; MAX PLANCK INST EXPTL MED,D-37075 GOTTINGEN,GERMANY; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Max Planck Society; Swiss Institute Experimental Cancer Research			Hofmann, Kay/D-6714-2011	Hofmann, Kay/0000-0002-2289-9083				AHMED S, 1992, BIOCHEM J, V287, P995, DOI 10.1042/bj2870995; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BENSON DA, 1994, NUCLEIC ACIDS RES, V22, P3441, DOI 10.1093/nar/22.17.3441; BRENNER S, 1974, GENETICS, V77, P71; BROSE N, 1993, J BIOL CHEM, V268, P22663; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1988, ANTIBODIES LABORATOR; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOFMANN K, 1995, FEBS LETT, V358, P153, DOI 10.1016/0014-5793(94)01415-W; HOSONO R, 1987, J NEUROCHEM, V49, P1820, DOI 10.1111/j.1471-4159.1987.tb02442.x; HOSONO R, 1991, NEUROSCI LETT, V128, P243, DOI 10.1016/0304-3940(91)90270-4; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; Jorgensen Erik M., 1995, Seminars in Developmental Biology, V6, P207, DOI 10.1016/S1044-5781(06)80030-7; KASANIETZ MG, 1995, J BIOL CHEM, V270, P10777; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LUTHY R, 1994, PROTEIN SCI, V3, P139; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	40	319	332	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25273	25280		10.1074/jbc.270.42.25273	http://dx.doi.org/10.1074/jbc.270.42.25273			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559667	hybrid			2022-12-27	WOS:A1995TB46500101
J	YAN, C; SEVER, Z; WHITSETT, JA				YAN, C; SEVER, Z; WHITSETT, JA			UPSTREAM ENHANCER ACTIVITY IN THE HUMAN SURFACTANT PROTEIN-B GENE IS MEDIATED BY THYROID TRANSCRIPTION FACTOR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; HOMEODOMAIN; SITES	Surfactant protein B (SP-B) is selectively expressed in bronchiolar and alveolar epithelial cells of the lung. We identified an upstream enhancer located in the 5'-flanking region of the human SP-B gene (-439 to -331 base pair, hSP-B(-439/-331)) by deletion analysis of SP-B-luciferase constructs assessed in transfection assays in vitro. The element cis-activated the expression of an SV40 promoter-luciferase reporter gene in a human pulmunary adenocarcinoma cell line (H441-4). Three distinct binding sites for the nuclear transcription protein, thyroid transcription factor 1 (TTF-1), were identified, and the purified TTF-1 homeodomain was bound to the region of hSP-B(-439/-331). Co-transfection of H441-4 cells with the expression vector pCMV-TTF-1 trans-activated the native human SP-B promoter and the SV40 promoter fused with the SP-B enhancer. Mutations of the TTF-1 binding sites in the upstream enhancer blocked TTF-1 binding and transactivation activity. In summary, TTF-1 interacts with distinct proximal (-80 to -110) and distal (-439 to -331) cis-acting elements that regulate lung epithelial cell-specific transcription of the human SP-B gene.	CHILDRENS HOSP,MED CTR,DIV PULM BIOL,CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038859, P01HL051832, R37HL038859] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38859, HL51832] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; AVERY ME, 1959, AMA J DIS CHILD, V97, P517, DOI 10.1001/archpedi.1959.02070010519001; BEACHY PA, 1993, MOL CELL BIOL, V13, P6941, DOI 10.1128/MCB.13.11.6941; BOHINSKI RJ, 1993, J BIOL CHEM, V268, P11160; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; CLEVIDENCE DE, 1994, DEV BIOL, V166, P195, DOI 10.1006/dbio.1994.1307; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; GALANG CK, 1992, NEW BIOL, V4, P558; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; IKEDA K, 1995, J BIOL CHEM, V270, P8108, DOI 10.1074/jbc.270.14.8108; KELLY SE, 1995, AM J RESP CRIT CARE, V151, P163; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PTASHNE M, 1992, GENETIC SWITCH GENE, P114; SAWAYA PL, 1994, J BIOL CHEM, V269, P22211; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WHITSETT JA, 1995, IN PRESS PHYSL REV; YAN C, 1989, J BIOL CHEM, V265, P20188; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	25	113	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24852	24857		10.1074/jbc.270.42.24852	http://dx.doi.org/10.1074/jbc.270.42.24852			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559607	hybrid			2022-12-27	WOS:A1995TB46500041
J	ZHAO, TP; BETTELHEIM, FA				ZHAO, TP; BETTELHEIM, FA			ENTHALPY AND ENTROPY OF HYDRATION OF BOVINE CRYSTALLINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-ANALYSIS; FREEZABLE WATER-CONTENT; EYE-LENS; ALPHA-CRYSTALLIN; GAMMA-CRYSTALLIN; BETA-CRYSTALLIN; OSMOTIC-PRESSURE; TRANSPARENCY; RESOLUTION; STABILITY	Transparency of the lens of the eye is the result of a short range order in the packing of crystallin molecules within the fiber cells. Short range order depends on crystallin crystallin as well as water crystallin interactions. Light scattering measurements can provide information on the hydration of crystallins. Light scattering intensities were obtained as a function of scattering angle, concentration, and temperature on dilute solutions of beta(H),beta(L), and gamma fractions of bovine lens crystallins. The temperature dependence of the second virial coefficient was negative for the beta crystallin fractions and positive for the gamma fraction as well as that for alpha crystallin (Wang, X., and Bettelheim, F. A. (1989) Proteins Struct. Funct. Genet, 5, 166-169). The partial molar enthalpy values of the solutions were negative for the beta crystallin fractions, indicating a tendency for homo- and heterodimer and -oligomer association. The enthalpy values were positive for the alpha and gamma fractions. The negative values of the enthalpy of solutions differentiate the beta crystallins from the other crystallins. The partial molar entropy values of solutions of beta(L) and gamma fractions were identical, those of the oligomeric beta(H) fraction were higher, whereas those of alpha crystallin were a magnitude larger than those of the the smaller crystallin molecules.	ADELPHI UNIV,DEPT CHEM,GARDEN CITY,NY 11530	Adelphi University					NATIONAL EYE INSTITUTE [R01EY002571] Funding Source: NIH RePORTER; NEI NIH HHS [EY-02571] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAX B, 1990, NATURE, V347, P776, DOI 10.1038/347776a0; BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; Bettelheim F. A., 1985, OCULAR LENS STRUCTUR, P265; BETTELHEIM FA, 1983, BIOPHYS J, V41, P29, DOI 10.1016/S0006-3495(83)84402-6; BETTELHEIM FA, 1986, CURR EYE RES, V5, P925, DOI 10.3109/02713688608995173; BETTELHEIM FA, 1990, EXP EYE RES, V50, P715, DOI 10.1016/0014-4835(90)90119-F; BETTELHEIM FA, 1986, INVEST OPHTH VIS SCI, V27, P122; BETTELHEIM FA, 1992, BIOCHEM BIOPH RES CO, V187, P39, DOI 10.1016/S0006-291X(05)81455-X; BETTELHEIM FA, 1991, EXP EYE RES, V52, P269, DOI 10.1016/0014-4835(91)90090-2; BLOEMENDAL H, 1981, MOL CELLULAR BIOL EY, P221; BLUNDELL T, 1981, NATURE, V289, P771, DOI 10.1038/289771a0; CASTORO JA, 1987, EXP EYE RES, V45, P191, DOI 10.1016/S0014-4835(87)80091-X; CHIRGADZE IN, 1986, DOKL AKAD NAUK SSSR+, V290, P492; FERNALD RD, 1983, NATURE, V301, P618, DOI 10.1038/301618a0; Flory PI, 1953, PRINCIPLES POLYM CHE, P495; HOPE JN, 1994, PROTEIN ENG, V7, P445, DOI 10.1093/protein/7.3.445; KENWORTHY AK, 1994, EXP EYE RES, V59, P11, DOI 10.1006/exer.1994.1077; LAHM D, 1985, INVEST OPHTH VIS SCI, V26, P1162; LAPATTO R, 1991, J MOL BIOL, V222, P1067, DOI 10.1016/0022-2836(91)90594-V; NAJMUDIN S, 1993, ACTA CRYSTALLOGR D, V49, P223, DOI 10.1107/S0907444992007601; SCHURTENBERGER P, 1991, BIOPOLYMERS, V31, P1229, DOI 10.1002/bip.360311011; SIEZEN RJ, 1978, EUR J BIOCHEM, V91, P387, DOI 10.1111/j.1432-1033.1978.tb12691.x; SLINGSBY C, 1990, BIOCHEMISTRY-US, V29, P6592, DOI 10.1021/bi00480a007; SLINGSBY C, 1985, TRENDS BIOCHEM SCI, V10, P281, DOI 10.1016/0968-0004(85)90088-X; TANFORD C, 1961, PHYSICAL CHEM MACROM, P200; THOMSON JA, 1989, CURR EYE RES, V8, P139, DOI 10.3109/02713688908995185; VERETOUT F, 1989, J MOL BIOL, V205, P713, DOI 10.1016/0022-2836(89)90316-1; VERETOUT F, 1989, EUR BIOPHYS J BIOPHY, V17, P61, DOI 10.1007/BF00257103; WANG H, 1992, EXP EYE RES, V55, P387, DOI 10.1016/0014-4835(92)90110-E; WANG XW, 1989, PROTEINS, V5, P166, DOI 10.1002/prot.340050211; WHITE HE, 1989, J MOL BIOL, V207, P217, DOI 10.1016/0022-2836(89)90452-X; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZIGLER JS, 1978, EXP EYE RES, V26, P537, DOI 10.1016/0014-4835(78)90063-5; ZIGLER JS, 1980, EXP EYE RES, V31, P41, DOI 10.1016/0014-4835(80)90089-5; ZIMM BH, 1948, J CHEM PHYS, V16, P1099, DOI 10.1063/1.1746740	35	6	6	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24961	24964		10.1074/jbc.270.42.24961	http://dx.doi.org/10.1074/jbc.270.42.24961			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559623	hybrid			2022-12-27	WOS:A1995TB46500057
J	BERTRAND, F; PHILIPPE, C; ANTOINE, PJ; BAUD, L; GROYER, A; CAPEAU, J; CHERQUI, G				BERTRAND, F; PHILIPPE, C; ANTOINE, PJ; BAUD, L; GROYER, A; CAPEAU, J; CHERQUI, G			INSULIN ACTIVATES NUCLEAR FACTOR KAPPA-B IN MAMMALIAN-CELLS THROUGH A RAF-1-MEDIATED PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE RESIDUE-1162; FACTOR NF-KAPPA; TRANSCRIPTION FACTOR; MOUSE FIBROBLASTS; GLUCOSE-TRANSPORT; GENE-EXPRESSION; REQUIRES RAF-1; DNA-BINDING; KINASE; INDUCTION	We examined the effect of insulin on nuclear factor kappa B (NF-kappa B) activity in Chinese hamster ovary (CHO) cells overexpressing wild-type (CHO-R cells) or -defective insulin receptors mutated at Tyr(1162) and Tyr(1163) autophosphorylation sites (CHO-Y2 cells). In CHO-R cells, insulin caused a specific, time-, and concentration-dependent activation of NF-kappa B. The insulin-induced DNA-binding complex was identified as the p50/p65 heterodimer. Insulin activation of NF-kappa B: 1) was related to insulin receptor number and tyrosine kinase activity since it was markedly reduced in parental CHO cells which proved to respond to insulin growth factor-1 and phorbol 12-myristate 13-acetate (PMA) activation, and was dramatically decreased in CHO-Y2 cells; 2) persisted in the presence of cycloheximide and was blocked by pyrrolidine dithiocarbamate, aspirin and sodium salicylate, three compounds interfering with I kappa B degradation and/or NF-kappa B . I kappa B complex dissociation; 3) was independent of both PMA-sensitive and atypical (zeta) protein kinases C; and 4) was dependent on Raf-1 kinase activity since insulin-stimulated NF-kappa B DNA binding activity was inhibited by 8-bromo-cAMP, a Raf-1 kinase inhibitor. Moreover, insulin activation of NF-kappa B-driven luciferase reporter gene expression was blocked in CHO-R cells expressing a Raf-1 dominant negative mutant. This is the first evidence that insulin activates NF-kappa B in mammalian cells through a post-translational mechanism requiring both insulin receptor tyrosine kinase and Raf-1 kinase activities.	UNIV PARIS 06,INSERM,U402,F-75571 PARIS 12,FRANCE; HOP ST ANTOINE,INSERM,U142,F-75571 PARIS 12,FRANCE; HOP TENON,INSERM,U64,F-75970 PARIS 20,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite								BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BARBU V, 1993, EXP CLIN ENDOCRIN S2, V10, P84; BERTRAND F, 1994, AM J PHYSIOL, V266, pC611, DOI 10.1152/ajpcell.1994.266.3.C611; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHERQUI G, 1990, J BIOL CHEM, V265, P21254; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOK SJ, 1903, SCIENCE, V262, P1069; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DESBOIS C, 1992, J BIOL CHEM, V267, P13488; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; FINCO TS, 1993, J BIOL CHEM, V268, P17676; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KASANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KOONG AC, 1994, CANCER RES, V54, P5273; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MUNOZ E, 1994, J VIROL, V68, P8035; NAKAJIMA T, 1994, BIOCHEM BIOPH RES CO, V204, P950, DOI 10.1006/bbrc.1994.2552; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OLASHAW NE, 1992, MOL BIOL CELL, V3, P1131, DOI 10.1091/mbc.3.10.1131; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; REYNET C, 1990, MOL ENDOCRINOL, V4, P304, DOI 10.1210/mend-4-2-304; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZHOU GS, 1994, EXP CELL RES, V214, P1, DOI 10.1006/excr.1994.1227	43	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24435	24441		10.1074/jbc.270.41.24435	http://dx.doi.org/10.1074/jbc.270.41.24435			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592658	hybrid			2022-12-27	WOS:A1995TA21700086
J	SCOTT, A; HAYSTEAD, CMM; HAYSTEAD, TAJ				SCOTT, A; HAYSTEAD, CMM; HAYSTEAD, TAJ			PURIFICATION OF A 12,020-DALTON PROTEIN THAT ENHANCES THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN (MAP) KINASE BY MAP KINASE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-OOCYTES; TYROSINE KINASE; PHOSPHORYLATION; RAF; CELLS; MEK; PATHWAY; CLONING; INVITRO; COMPLEX	We have purified 3500-fold from rabbit skeletal muscle a 12,020-Da mitogen-activated protein kinase kinase (MEK)-enhancing factor (MEF) that stimulates both mitogen-activated protein kinase (MAPK) autophosphorylation and the rate (24-fold) at which the enzyme is phosphorylated by MEK in vitro. This was manifest by the finding that in the presence of MEF, molar equivalents of MEK to MAPK were sufficient to produce fully phosphorylated (2.1 +/- 0.4 mol/mol; S,D., n = 3) and activated MAPK, This contrasted with the 40:1 molar excess ratio of MEK to MAPK required to produce fully phosphorylated and activated MAPK in the absence of MEF. Phosphoamino acid analysis revealed that in the presence of MEF, phosphorylation of MAPK by MEK was ordered, with Tyr-185 phosphorylation preceding Thr-183 phosphorylation. However, the rate at which Thr-183 was phosphorylated relative to Tyr-185 was greatly increased, The finding that MEF stimulated MAPK autophosphorylation and increased its ability to be phosphorylated by MEK suggests a mechanism of action in which MEF interacts with MAPK to alter its conformation.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	University of Virginia								ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; CHOI KY, 1994, CELL, V78, P499; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOZA YN, 1995, FEBS LETT, V364, P223, DOI 10.1016/0014-5793(95)00346-B; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; ERREDA B, 1995, CURR OPIN CELL BIOL, V7, P197; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GOTOH Y, 1994, ONCOGENE, V9, P1891; HAN JH, 1995, BBA-MOL CELL RES, V1265, P224, DOI 10.1016/0167-4889(95)00002-A; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; HAYSTEAD CMM, 1993, FEBS LETT, V317, P12, DOI 10.1016/0014-5793(93)81481-E; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; JAIWAL RK, 1994, MOL CELL BIOL, V14, P6944; KNIGHTON DR, 1991, SCIENCE, V407, P407; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MANSOUR SJ, 1994, SCIENCE, V265, P967; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MERRALL NW, 1993, BIOCHEM J, V295, P351, DOI 10.1042/bj2950351; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SEGAR R, 1992, J BIOL CHEM, V267, P25628; SOLOMON MJ, 1991, CELL, V63, P1013; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WU J, 1992, P NATL ACAD SCI USA, V90, P173; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHANG C, 1993, J BIOL CHEM, V268, P11435; ZHANG F, 1995, NATURE, V367, P704; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	61	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24540	24547		10.1074/jbc.270.41.24540	http://dx.doi.org/10.1074/jbc.270.41.24540			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592672	hybrid			2022-12-27	WOS:A1995TA21700100
J	SEUFFERLEIN, T; ROZENGURT, E				SEUFFERLEIN, T; ROZENGURT, E			SPHINGOSYLPHOSPHORYLCHOLINE RAPIDLY INDUCES TYROSINE PHOSPHORYLATION OF P125(FAK) AND PAXILLIN, REARRANGEMENT OF THE ACTIN CYTOSKELETON AND FOCAL CONTACT ASSEMBLY - REQUIREMENT OF P21(RHO) IN THE SIGNALING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PROTEIN-KINASE-C; EXTRACELLULAR-MATRIX; ADHESION PROTEIN; ACTIVATION; BOMBESIN; VASOPRESSIN; CALCIUM; MOBILIZATION; STIMULATION	Sphingosylphosphorylcholine (SPC), a potent mitogen for Swiss 3T3 cells, rapidly induced tyrosine phosphorylation of multiple substrates including bands of M(r) 110,000-130,000 and M(r) 70,000-80,000 in Swiss 3T3 cells, Focal adhesion kinase (p125(FAK)) and paxillin were identified as prominent substrates for SPC-stimulated tyrosine phosphorylation, An increase in tyrosine phosphorylation of p125(FAK) was detected as soon as 30 s after SPC stimulation, reaching a maximum after 2.5 min, SPC induced tyrosine phosphorylation of p125(FAK) in a concentration-dependent fashion; a half-maximum effect occurred at 250 nM. Tyrosine phosphorylation of p125(FAK) induced by SPC could be dissociated from both protein kinase C activation and Ca2+ mobilization from intracellular stores, SPC induced a unique pattern of reorganization of the actin cytoskeleton with a rapid appearance of actin microspikes at the plasma membrane that was followed by the formation of actin stress fibers, This pattern of cytoskeletal changes was clearly distinguishable from that induced by bombesin and 1-oleoyl-lysophosphatidic acid. Formation of microspikes and actin stress fibers were accompanied by striking assembly of focal adhesion plaques, Cytochalasin D, which disrupts the network of actin microfilaments, completely prevented SPC-induced tyrosine phosphorylation of p125(FAK), In addition, tyrosine phosphorylation of p125(FAK) was markedly inhibited in the presence of platelet-derived growth factor at a concentration (30 ng/ml) that disrupts actin stress fibers, Finally, microinjection of Clostridium botulinum C3 exoenzyme, which inactivates p21(rho), prevented SPC-induced formation of actin stress fibers, focal adhesion assembly, and tyrosine phosphorylation, Thus, p21(rho) is upstream of both cytoskeletal reorganization and tyrosine phosphorylation in SPC-treated cells.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Seufferlein, Thomas TW/P-7147-2018					AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN QM, 1994, J BIOL CHEM, V269, P26602; DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KINDMAN LA, 1994, J BIOL CHEM, V269, P13088; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24334, DOI 10.1074/jbc.270.41.24334; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1991, EXP CELL RES, V192, P651, DOI 10.1016/0014-4827(91)90090-H; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1994, J CELL SCI, V107, P1583; VUORI K, 1993, J BIOL CHEM, V268, P21459; YULE D, 1994, J BIOL CHEM, V268, P12353; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	42	104	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24343	24351		10.1074/jbc.270.41.24343	http://dx.doi.org/10.1074/jbc.270.41.24343			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592646	hybrid			2022-12-27	WOS:A1995TA21700074
J	TAKAGI, Y; CONAWAY, JW; CONAWAY, RC				TAKAGI, Y; CONAWAY, JW; CONAWAY, RC			A NOVEL ACTIVITY ASSOCIATED WITH RNA-POLYMERASE-II ELONGATION-FACTOR SIII - SIII DIRECTS PROMOTER-INDEPENDENT TRANSCRIPTION INITIATION BY RNA-POLYMERASE-II IN THE ABSENCE OF INITIATION-FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-PROPERTIES; FACTOR-EPSILON; WHEAT-GERM; BINDING; LIVER; ACID; DNA	General transcription factor SIII, a heterotrimer of 110-, 18-, and 15-kDa subunits, was shown previously to stimulate the overall rate of RNA chain elongation by RNA polymerase II by suppressing transient pausing by polymerase at many sites along DNA templates (Bradsher, J, N,, Jackson, K. W,, Conaway, R, C,, and Conaway, J, W. (1993) J, Biol. Chem, 268, 25587-25593), In this report, SIII is shown to possesses the novel ability to direct robust but promiscuous transcription by RNA polymerase II on duplex DNA templates in the absence of initiation factors, Mechanistic studies reveal that SIII promotes RNA synthesis by substantially increasing the efficiency with which RNA polymerase II initiates promoter-independent transcription from the ends of duplex DNA. Remarkably, SIII appears to have a negligible effect on de novo synthesis of end-to-end transcripts, Instead, analysis of reaction products indicates that SIII is capable of promoting a dramatic increase in the ability of RNA polymerase II to extend the 3'-hydroxyl termini of duplex DNA fragments, in a template-directed reaction exhibiting no strong preference for 3'-protruding, 3'-recessed, or blunt DNA ends. Although RNA polymerase II has been shown previously to catalyze primer-dependent transcription, SIII is the first eukaryotic transcription factor found to promote this reaction, Based on these findings, we propose that SIII may suppress transient pausing by RNA polymerase II by helping to maintain the 3'-hydroxyl terminus of the nascent RNA chain in its proper position in the polymerase active site.	OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation				Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P22587; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CHANDLER DW, 1980, BIOCHEMISTRY-US, V19, P1604, DOI 10.1021/bi00549a012; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DYNAN WS, 1979, BIOCHEMISTRY-US, V18, P4581, DOI 10.1021/bi00588a019; DYNAN WS, 1981, J BIOL CHEM, V256, P5866; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HENRY NL, 1992, J BIOL CHEM, V267, P23388; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KANE CM, 1994, TRANSCRIPTION MECHAN; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; LAVIALLE C, 1982, J BIOL CHEM, V257, P2458; LEWIS MK, 1980, J BIOL CHEM, V255, P4928; LEWIS MK, 1982, ENZYMES, V15, P109; PETERSON MG, 1991, NATURE, V354, P369; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; REINES D, 1994, TRANSCRIPTION MECHAN, P263; Sambrook J, 1989, MOL CLONING LABORATO; TAN SY, 1994, J BIOL CHEM, V269, P25684; TAN SY, 1994, BIOTECHNIQUES, V16, P824; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; WU C, 1995, TRANSCRIPTION MECHAN, P459	32	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24300	24305		10.1074/jbc.270.41.24300	http://dx.doi.org/10.1074/jbc.270.41.24300			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592640	hybrid			2022-12-27	WOS:A1995TA21700068
J	TIAN, GL; VAINBERG, IE; TAP, WD; LEWIS, SA; COWAN, NJ				TIAN, GL; VAINBERG, IE; TAP, WD; LEWIS, SA; COWAN, NJ			QUASI-NATIVE CHAPERONIN-BOUND INTERMEDIATES IN FACILITATED PROTEIN-FOLDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							T-COMPLEX POLYPEPTIDE-1; CYTOPLASMIC CHAPERONIN; ATP HYDROLYSIS; ALPHA-TUBULIN; IN-VIVO; GROEL; COOPERATIVITY; SUBUNITS; RING	Chaperonins are known to facilitate protein folding, but their mechanism of action is not well understood. The fact that target proteins are released from and rebind to different chaperonin molecules (''cycling'') during a folding reaction suggests that chaperonins function by unfolding aberrantly folded molecules, allowing them multiple opportunities to reach the native state in bulk solution. Here we show that the cycling of alpha-tubulin by cytosolic chaperonin (c-cpn) can be uncoupled from the action of cofactors required to complete the folding reaction. This results in the accumulation of folding intermediates which are chaperonin-bound, stable, and quasi-native in that they bind GTP nonex-changeably. We present evidence that these intermediates can be generated without the target protein leaving c-cpn. These data show that, in contrast to prevailing models, target proteins can maintain, and possibly acquire, significant native-like structure while chaperonin-bound.	NYU,MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016	New York University								AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P12424; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; ELLIS RJ, 1993, NATURE, V366, P213, DOI 10.1038/366213a0; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; ROMMELAERE H, 1993, P NATL ACAD SCI USA, V90, P11975, DOI 10.1073/pnas.90.24.11975; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SPIEGELMAN BM, 1977, CELL, V12, P587, DOI 10.1016/0092-8674(77)90259-8; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9	27	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23910	23913		10.1074/jbc.270.41.23910	http://dx.doi.org/10.1074/jbc.270.41.23910			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592580	hybrid			2022-12-27	WOS:A1995TA21700008
J	RIES, A; ENGEL, J; LUSTIG, A; KUHN, K				RIES, A; ENGEL, J; LUSTIG, A; KUHN, K			THE FUNCTION OF THE NC1 DOMAINS IN TYPE-IV COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE; ALPHA-2 CHAINS; GENES; ORGANIZATION; AGGREGATION; MOLECULES; PROMOTER; NETWORK; REGION; MODEL	At its C terminus, the collagen IV molecule bears a globular NC1 domain, to which two functions have been assigned. In the macromolecular network of collagen IV, two molecules are connected via their NC1 domains, which form a hexameric complex, stabilized by intermolecular disulfide bonds. In addition, the NC1 domains are thought to be responsible for chain selection and assembly. In order to understand the role of the NC1 domains during these steps, hexameric complexes were isolated and further investigated. SDS-polyacrylamide gel electrophoresis and Western blot revealed disulfide-linked alpha 1(IV)NC1 and alpha 2(IV)NC1 homodimers but no heterodimers. The hexamers were dissociated at low pH, separated into monomers and dimers, and submitted to reconstitution experiments. Only alpha 1(IV)NC1 dimers were able to reconstitute a hexameric complex. alpha 1(IV)-NC1 and alpha 2(IV)NC1 monomers as well as the alpha 2(IV)NC1 dimers showed only a low tendency to form complexes. It is assumed that during formation of the collagen IV network, lateral aggregation of the molecules via the triple helical domains brings the C termini of two molecules into close vicinity and that subsequently the weak interactions observed between the NC1 subdomains provide the correct alignment for a disulfide exchange. It is, however, questionable whether the low affinity between the NC1 subdomains alone is sufficient for chain assembly and alignment of the alpha(IV) chains before molecule formation.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND	Max Planck Society; University of Basel								BYERS PH, 1975, P NATL ACAD SCI USA, V72, P3009, DOI 10.1073/pnas.72.8.3009; DAVIS JM, 1989, J BIOL CHEM, V264, P8956; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; HOFMANN H, 1984, J MOL BIOL, V172, P325, DOI 10.1016/S0022-2836(84)80029-7; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; KUHN K, 1981, FEBS LETT, V125, P123, DOI 10.1016/0014-5793(81)81012-5; KUHN K, 1994, MATRIX BIOL, V14, P439; LEINONEN A, 1994, J BIOL CHEM, V269, P26172; LUKENS LN, 1976, J BIOL CHEM, V251, P3530; MARIYAMA M, 1992, GENOMICS, V13, P809, DOI 10.1016/0888-7543(92)90157-N; MORRIS NP, 1975, J BIOL CHEM, V250, P5719; OBERBAUMER I, 1982, EMBO J, V7, P805; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; REGAN L, 1994, PROTEIN SCI, V3, P2419, DOI 10.1002/pro.5560031225; SCHOFIELD JD, 1974, BIOCHEMISTRY-US, V13, P1801, DOI 10.1021/bi00706a004; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; SIEBOLD B, 1987, EUR J BIOCHEM, V168, P569, DOI 10.1111/j.1432-1033.1987.tb13455.x; SOININEN R, 1988, J BIOL CHEM, V263, P17217; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VANHOLDE KE, 1958, J PHYS CHEM-US, V62, P734, DOI 10.1021/j150564a025; WEBER S, 1984, EUR J BIOCHEM, V139, P401, DOI 10.1111/j.1432-1033.1984.tb08019.x; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449	24	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23790	23794		10.1074/jbc.270.40.23790	http://dx.doi.org/10.1074/jbc.270.40.23790			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559554	hybrid			2022-12-27	WOS:A1995RY90900083
J	CHEN, MH; SHEN, ZM; BOBIN, S; KAHN, PC; LIPKE, PN				CHEN, MH; SHEN, ZM; BOBIN, S; KAHN, PC; LIPKE, PN			STRUCTURE OF SACCHAROMYCES-CEREVISIAE ALPHA-AGGLUTININ - EVIDENCE FOR A YEAST-CELL WALL PROTEIN WITH MULTIPLE IMMUNOGLOBULIN-LIKE DOMAINS WITH ATYPICAL DISULFIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED GLYCOSYLATION; SEXUAL AGGLUTINATION; CRYSTAL-STRUCTURE; ADHESION PROTEIN; HUMAN CD4; SUPERFAMILY; MEMBRANE; ANTIGEN; EXPRESSION; CLEAVAGE	alpha-Agglutinin of Saccharomyces cerevisiae is a cell wall-associated protein that mediates cell interaction in mating. Although the mature protein includes about 610 residues, the NH2-terminal half of the protein is sufficient for binding to its ligand alpha-agglutinin alpha-Agglutinin(20-351), a fully active fragment of the protein, has been purified and analyzed. Circular dichroism spectroscopy, together with sequence alignments, suggest that alpha-agglutinin(20-351) consists of three immunoglobulin variable-like domains: domain I, residues 20-104; domain IL, residues 105-199; and domain ID. residues 200-326. Peptide sequencing data established the arrangement of the disulfide bonds in alpha-agglutinin(20-351). Cys(97) is disulfide-bonded to Cys(114), forming an interdomain bond between domains I and II. Cys(202) is bonded to Cys(300), in an atypical intradomain disulfide bond between the A and F strands of domain III, Cys(227) and Cys(256) have free sulfhydryls. Sequencing also showed that at least two of three potential N-glycosylation sites with sequence Asn-Xaa-Thr are glycosylated. At least one of three Asn-Xaa-Ser sequences is not glycosylated. No residues NH2-terminal to Ser(282) were O-glycosylated, whereas Ser(282), and all hydroxy amino acid residues COOH-terminal to this position were modified. Therefore O-glycosylated Ser and Thr residues cluster in the COOH-terminal region of domain Iii. and the O-glycosylation continues into a Sen/Thr-rich sequence that extends from domain III to the COOH-terminal of the full-length protein.	CUNY HUNTER COLL, DEPT BIOL SCI, NEW YORK, NY 10021 USA; CUNY HUNTER COLL, INST BIOMOLEC STRUCT & FUNCT, NEW YORK, NY 10021 USA; RUTGERS STATE UNIV, COOK COLL, DEPT BIOCHEM & MICROBIOL, NEW BRUNSWICK, NJ 08903 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY); Rutgers State University New Brunswick			Lipke, Peter N./AAW-4914-2020	Lipke, Peter N./0000-0003-1733-0690				BARCLAY AN, 1993, PHILOS T R SOC B, V342, P7, DOI 10.1098/rstb.1993.0129; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; CAMPBELL DG, 1979, NATURE, V282, P341, DOI 10.1038/282341a0; CANAS B, 1993, ANAL BIOCHEM, V211, P179, DOI 10.1006/abio.1993.1253; CAPPELLARO C, 1994, EMBO J, V13, P4737, DOI 10.1002/j.1460-2075.1994.tb06799.x; CAPPELLARO C, 1991, EMBO J, V10, P4081, DOI 10.1002/j.1460-2075.1991.tb04984.x; CATHOU RE, 1975, SUBUNITS BIOL SYST C, P91; CHAMOW SM, 1990, BIOCHEMISTRY-US, V29, P9885, DOI 10.1021/bi00494a019; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CRANDALL M, 1974, P NATL ACAD SCI USA, V71, P26, DOI 10.1073/pnas.71.1.26; CRANDALL MA, 1968, BACTERIOL REV, V32, P139, DOI 10.1128/MMBR.32.3.139-163.1968; DEMURA M, 1991, J MEMBRANE SCI, V59, P39, DOI 10.1016/S0376-7388(00)81220-X; DRAPEAU GR, 1978, CAN J BIOCHEM CELL B, V56, P534, DOI 10.1139/o78-082; DWEK R, 1993, PHILOS T R SOC LON B, V242, P43; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; GATTI E, 1994, J BIOL CHEM, V269, P19695; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Gribskov M., 1991, SEQUENCE ANAL PRIMER; HAGIYA M, 1977, EXP CELL RES, V104, P263, DOI 10.1016/0014-4827(77)90090-8; Hames BD., 1990, GEL ELECTROPHORESIS, P1; HARLOW E, 1988, ANTIBODIES LAB MANUA, P474; HAUSER K, 1989, FEBS LETT, V255, P290, DOI 10.1016/0014-5793(89)81108-1; HOLMGREN A, 1992, EMBO J, V11, P1617, DOI 10.1002/j.1460-2075.1992.tb05207.x; JEFFERIS R, 1977, IMMUNOCHEMISTRY, V14, P393, DOI 10.1016/0019-2791(77)90163-X; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KANG YS, 1990, MOL CELL BIOL, V10, P2582, DOI 10.1128/MCB.10.6.2582; KAPTEYN JC, 1994, EUR J CELL BIOL, V65, P402; KILLEEN N, 1988, EMBO J, V7, P3087, DOI 10.1002/j.1460-2075.1988.tb03174.x; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; KODUKULA K, 1993, J CELL BIOL, V120, P657, DOI 10.1083/jcb.120.3.657; KOZARSKY K, 1988, P NATL ACAD SCI USA, V85, P4335, DOI 10.1073/pnas.85.12.4335; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LIPKE PN, 1992, MICROBIOL REV, V56, P180, DOI 10.1128/MMBR.56.1.180-194.1992; LIPKE PN, 1989, MOL CELL BIOL, V9, P3155, DOI 10.1128/MCB.9.8.3155; LIPKE PN, 1995, PROTEIN SCI, V4, P2168, DOI 10.1002/pro.5560041023; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; LU CF, 1994, MOL CELL BIOL, V14, P4825, DOI 10.1128/MCB.14.7.4825; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MOEHLE CM, 1987, MOL CELL BIOL, V7, P4390, DOI 10.1128/MCB.7.12.4390; OSTERLUND E, 1988, BIOCHIM BIOPHYS ACTA, V955, P330, DOI 10.1016/0167-4838(88)90212-9; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; PEDRAZA L, 1990, J CELL BIOL, V111, P2651, DOI 10.1083/jcb.111.6.2651; PIERCE M, 1983, J BIOL CHEM, V258, P3576; RECNY MA, 1990, J BIOL CHEM, V265, P8542; REDDY P, 1989, J BIOL CHEM, V264, P17329; RIEDERER MA, 1991, J BACTERIOL, V173, P3539, DOI 10.1128/jb.173.11.3539-3546.1991; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SIMMONS D, 1988, J IMMUNOL, V141, P2797; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; TERRANCE K, 1981, J BACTERIOL, V148, P889, DOI 10.1128/JB.148.3.889-896.1981; TERRANCE K, 1987, J BACTERIOL, V169, P475, DOI 10.1128/jb.169.2.475-482.1987; VANBERKEL MAA, 1994, FEBS LETT, V349, P135, DOI 10.1016/0014-5793(94)00631-8; WALSH FS, 1989, DEVELOPMENT, V105, P803; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1989, COLD SPRING HARB SYM, V54, P637; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WOJCIECHOWICZ D, 1989, BIOCHEM BIOPH RES CO, V161, P46, DOI 10.1016/0006-291X(89)91557-X; WOJCIECHOWICZ D, 1993, MOL CELL BIOL, V13, P2554, DOI 10.1128/MCB.13.4.2554; YANG JT, 1986, METHOD ENZYMOL, V130, P208	61	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26168	26177		10.1074/jbc.270.44.26168	http://dx.doi.org/10.1074/jbc.270.44.26168			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592821	hybrid			2022-12-27	WOS:A1995TC97800028
J	HU, DD; LIN, ECK; KOVACH, NL; HOYER, JR; SMITH, JW				HU, DD; LIN, ECK; KOVACH, NL; HOYER, JR; SMITH, JW			A BIOCHEMICAL-CHARACTERIZATION OF THE BINDING OF OSTEOPONTIN TO INTEGRINS ALPHA(V)BETA(1) AND ALPHA(V)BETA(5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; MESSENGER-RNA; CELL-ADHESION; OSTEOCLAST PRECURSORS; VITRONECTIN RECEPTOR; MONOCLONAL-ANTIBODY; GPIIB-IIIA; EXPRESSION; ALPHA-V-BETA-3; PROTEIN	Osteopontin (OPN) is an extracellular matrix protein that binds to integrin alpha(v) beta(3), Here we demonstrate that two other integrins, alpha(v) beta(1) and alpha(v) beta(5), are also receptors for OPN. Human embryonic kidney 293 cells adhere to human recombinant osteopontin (glutathione S-transferase-osteopontin; GST-OPN) using integrin alpha(v) beta(5). When the 293 cells are transfected with the beta(5) subunit, they can also adhere to GST-OPN using integrin alpha(v) beta(5). Divalent cations regulate the binding of GST-OPN to both alpha(v) beta(1) and alpha(v) beta(5). Mg2+ and Mn2+ support the binding of GST-OPN to these integrins but Ca2+ does not, The highest affinity is observed in Mn2+, In the presence of this ion, the affinity of GST-OPN for alpha(v) beta(1), is 18 nM and the affinity for gp, is 48 nM, The antibody 8A2, which is an agonist for beta(1), promotes the adhesion of 293 cells to GST-OPN even when Ca2+ is present. This observation suggests that cellular events could modulate the affinity of alpha(v) beta(1) for OPN, Collectively, these findings prove that integrins alpha(v) beta(1), alpha(v) beta(3) and alpha(v) beta(5) have similar affinity for OPN. Therefore, all three integrins must be considered when evaluating the biological affects of OPN.	UNIV WASHINGTON,SCH MED,DIV HEMATOL,SEATTLE,WA 98195; CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104	University of Washington; University of Washington Seattle; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	HU, DD (corresponding author), LA JOLLA CANC RES FDN,CANC RES CTR,PROGRAM CELL ADHES & EXTRACELLULAR MATRIX,LA JOLLA,CA 92037, USA.				NCI NIH HHS [CA 56483] Funding Source: Medline; NIAMS NIH HHS [AR 42750] Funding Source: Medline; NIDDK NIH HHS [DK 10964] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTIERI DC, 1991, J IMMUNOL, V147, P1891; BEDNARCZK JL, 1992, J CELL BIOL, V116, P499; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BUSK M, 1992, J BIOL CHEM, V267, P5790; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; CAMPANERO MR, 1990, J CELL BIOL, V110, P2157, DOI 10.1083/jcb.110.6.2157; CLOVER J, 1992, J CELL SCI, V103, P267; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COX D, 1994, MED RES REV, V14, P195, DOI 10.1002/med.2610140203; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; EDWARDS JG, 1988, J CELL SCI, V89, P507; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GIACHELLI C, 1991, BIOCHEM BIOPH RES CO, V177, P867, DOI 10.1016/0006-291X(91)91870-I; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; HOLLY S, 1993, J BONE MINER RES, V8, pS136; HORTON MA, 1989, J BONE MINER RES, V4, P803; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; HUGHES DE, 1993, J BONE MINER RES, V8, P527; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; NESBITT S, 1993, J BIOL CHEM, V268, P16737; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PRUISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; REIDY MA, 1989, HYPERLIPIDERMIA ATHE, P149; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SAGO K, 1993, J BONE MINER RES, V8, pS121; SAITO T, 1994, J ORTHOP RES, V12, P384, DOI 10.1002/jor.1100120311; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SHIRAGA H, 1992, P NATL ACAD SCI USA, V89, P426, DOI 10.1073/pnas.89.1.426; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1994, J BIOL CHEM, V269, P960; STUIVER IS, 1995, IN PRESS HYBRIDOMA; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; WILKINS JA, 1991, EUR J IMMUNOL, V21, P517, DOI 10.1002/eji.1830210239; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V; YUE TL, 1994, EXP CELL RES, V214, P459, DOI 10.1006/excr.1994.1282; ZIMOLO Z, 1994, AM J PHYSIOL, V266, pC376, DOI 10.1152/ajpcell.1994.266.2.C376	53	225	232	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26232	26238		10.1074/jbc.270.44.26232	http://dx.doi.org/10.1074/jbc.270.44.26232			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592829	hybrid			2022-12-27	WOS:A1995TC97800036
J	MCCRIGHT, B; VIRSHUP, DM				MCCRIGHT, B; VIRSHUP, DM			IDENTIFICATION OF A NEW FAMILY OF PROTEIN PHOSPHATASE 2A REGULATORY SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIUM TUMOR-ANTIGEN; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; T-ANTIGENS; B-SUBUNIT; KINASE; DEPHOSPHORYLATES; PHOSPHORYLATION; SPECIFICITY; COMPLEXES	Protein phosphatase 2A (PP2A) is a major intracellular protein phosphatase that regulates multiple aspects of cell growth and metabolism. The ability of this widely distributed heterotrimeric enzyme to act on a diverse array of substrates is largely controlled by the nature of its regulatory B subunit. Only two gene families encoding endogenous B subunits have been cloned to date, although the existence of several additional regulatory subunits is likely. We have identified by two-hybrid interaction a new human gene family encoding PP2A B subunits. This family, denoted B56, contains three distinct genes, one of which is differentially spliced. B56 polypeptides co-immunoprecipitate with PP2A A and C subunits and with an okadaic acid-inhibitable, heparin-stimulated phosphatase activity. The three B56 family members are 70% identical to each other but share no obvious homology with previously identified B subunits. These phosphatase regulators are differentially expressed, with B56 alpha and B56 gamma highly expressed in heart and skeletal muscle and B56 beta highly expressed in brain. The identification of this novel phosphatase regulator gene family will facilitate future studies on the control of protein dephosphorylation and the role of PP2A in cellular function.	UNIV UTAH,PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT ONCOL SCI,DIV MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT PEDIAT,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah			Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X	NCI NIH HHS [P30 CA42014, T32-CA09602] Funding Source: Medline; NIAID NIH HHS [R01-AI31657] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014, T32CA009602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031657] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; AGOSTINIS P, 1990, EUR J BIOCHEM, V189, P235, DOI 10.1111/j.1432-1033.1990.tb15482.x; Altschul SF, 1990, J MOL BIOL, V215, P403; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GARDNER J, 1995, SEQVU 1 0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Hunter Tony, 1994, Seminars in Cell Biology, V5, P367, DOI 10.1006/scel.1994.1044; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MCVEY D, 1993, J VIROL, V67, P5206, DOI 10.1128/JVI.67.9.5206-5215.1993; MIYAJIMA N, 1994, DNA RES, V1, P27; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; ROSE MD, 1990, LABORATORY COURSE MA; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Sambrook J, 1989, MOL CLONING LABORATO; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; Virshup DM, 1993, ADV PROTEIN PHOSPHAT, V7, P271; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023; 1984, PROGRAM MANUAL WISCO	45	202	210	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26123	26128		10.1074/jbc.270.44.26123	http://dx.doi.org/10.1074/jbc.270.44.26123			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592815	hybrid			2022-12-27	WOS:A1995TC97800022
J	SCHWARTZ, ML; BRUCE, J; SHNEIDMAN, PS; SCHLAEPFER, WW				SCHWARTZ, ML; BRUCE, J; SHNEIDMAN, PS; SCHLAEPFER, WW			DELETION OF 3'-UNTRANSLATED REGION ALTERS THE LEVEL OF MESSENGER-RNA EXPRESSION OF A NEUROFILAMENT LIGHT SUBUNIT TRANSGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; GENE-EXPRESSION; UP-REGULATION; NF-L; MICE; CALIBER; PROTEINS; PROMOTER; SYSTEM; FAMILY	High levels of neurofilament (NF) mRNA expression are attained during early postnatal development and are a major determinant of axonal size. High level NF expression is also dependent upon axonal continuity since NF mRNA levels are down-regulated after nerve transection. This study shows that both postnatal upregulation and axotomy-induced down-regulation are altered by deletion of 3'-UTR from the mouse Light NF subunit (NF-L). Transgenes with (NF-L(+)) or without (NF-L(-)) 3'-UTR display similar patterns of neuron-specific expression but differ in their respective levels of expression. Whereas changes in the level of NF-L(+) mRNA parallel those of the endogenous mouse NF-L mRNA, changes in the level of NF-L(-) mRNA differ from the pattern of endogenous NP-L expression during postnatal up-regulation and axotomy-induced down-regulation. Specifically, the NF-L(-) transgene undergoes a 3-fold aberrant up-regulation between embryonic days 15 (E15) and 18 (E18) and has lost its susceptibility to axotomy-induced down-regulation. Studies of transfected P19 cells show that 3'-UTR deletion leads to a severalfold stabilization of NF-L mRNA and an increase in steady-state mRNA level. The findings support the working hypothesis that the 3'-UTR contains determinants that alter stability and that stabilization of NF-L mRNA regulates the levels of NF-L mRNA in neuronal tissues and cells.			SCHWARTZ, ML (corresponding author), UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, DIV NEUROPATHOL, 435 JOHNSON PAVIL, PHILADELPHIA, PA 19104 USA.				NINDS NIH HHS [R01 NS15722, T32 NS07064] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007064, R01NS015722] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATWATER JA, 1990, ANNU REV GENET, V24, P519; BEAUDET L, 1992, GENE, V116, P205, DOI 10.1016/0378-1119(92)90517-S; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1991, J CELL SCI, P85; COLE JS, 1994, J NEUROSCI, V14, P6956; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; FRIEDE RL, 1972, J COMP NEUROL, V144, P233, DOI 10.1002/cne.901440207; GOLDSTEIN ME, 1988, MOL BRAIN RES, V3, P287, DOI 10.1016/0169-328X(88)90051-4; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HSIEH ST, 1994, J NEUROSCI, V14, P6392; JULIEN JP, 1990, J PHYSIOLOGY PARIS, V84, P50; JULIEN JP, 1987, GENE DEV, V1, P1085, DOI 10.1101/gad.1.10.1085; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; LEWIS SA, 1986, MOL CELL BIOL, V6, P1529, DOI 10.1128/MCB.6.5.1529; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MONTEIRO MJ, 1990, J CELL BIOL, V111, P1543, DOI 10.1083/jcb.111.4.1543; MUMA NA, 1991, J NEUROCYTOL, V20, P844, DOI 10.1007/BF01191735; NAKAHIRA K, 1990, J BIOL CHEM, V265, P19786; OHARA O, 1993, J CELL BIOL, V121, P387, DOI 10.1083/jcb.121.2.387; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PELTZ SW, 1993, CONTROL MRNA STABILI, P291; REEBEN M, 1993, BIOCHEM BIOPH RES CO, V192, P465, DOI 10.1006/bbrc.1993.1438; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHLAEPFER WW, 1990, J NEUROSCI RES, V25, P39, DOI 10.1002/jnr.490250106; SCHWARTZ ML, 1992, J BIOL CHEM, V267, P24596; SCHWARTZ ML, 1990, J NEUROSCI RES, V27, P193, DOI 10.1002/jnr.490270209; SCHWARTZ ML, 1994, MOL BRAIN RES, V27, P215, DOI 10.1016/0169-328X(94)90003-5; SCHWARTZ ML, 1994, J BIOL CHEM, V269, P13444; SECHRIST J, 1993, DEVELOPMENT, V118, P691; SHNEIDMAN PS, 1992, MOL BRAIN RES, V13, P127, DOI 10.1016/0169-328X(92)90052-D; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; YAZDANBAKHSH K, 1993, NUCLEIC ACIDS RES, V21, P455, DOI 10.1093/nar/21.3.455	37	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26364	26369		10.1074/jbc.270.44.26364	http://dx.doi.org/10.1074/jbc.270.44.26364			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592849	hybrid			2022-12-27	WOS:A1995TC97800056
J	TSIGOS, I; BOURIOTIS, V				TSIGOS, I; BOURIOTIS, V			PURIFICATION AND CHARACTERIZATION OF CHITIN DEACETYLASE FROM COLLETOTRICHUM-LINDEMUTHIANUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCOR-ROUXII; CHITOSAN; LOCALIZATION; LEAVES; OLIGOSACCHARIDES; CALLOSE	Chitin deacetylase (EC 3.5.1.41), the enzyme that catalyzes the hydrolysis of acetamido groups of N-acetyl-D-glucosamine in chitin, has been purified to homogeneity from the culture filtrate of the fungus Colletotrichum lindemuthianum and further characterized. The enzyme is a glycoprotein, and its apparent molecular mass was determined to be similar to 150 kDa. The glycosylation pattern of the enzyme is consistent with a mixture of N-linked glycans including oligomannosidic hybrid and/or complex type, and its carbohydrate content is approximately 67% by weight. Chitin deacetylase is active on several chitinous substrates and chitin derivatives, is not considerably inhibited by carboxylic acids, especially acetic acid, and exhibits a remarkable thermostability. The enzyme requires at least two N-acetyl-D-glucosamine residues (chitobiose) for catalysis. When glycol chitin (a water-soluble chitin derivative) was used as substrate, the optimum temperature for enzyme activity was determined to be 50 degrees C, and the optimum pH was similar to 8.5.	UNIV CRETE,INST MOLEC BIOL & BIOTECHNOL,DIV ENZYME TECHNOL,GR-71110 IRAKLION,GREECE; UNIV CRETE,DEPT BIOL,DIV APPL BIOL & BIOTECHNOL,GR-71110 IRAKLION,GREECE	University of Crete; University of Crete								ALFONSO C, 1995, CURR MICROBIOL, V30, P49, DOI 10.1007/BF00294524; ARACHAMI M, 1986, CHITIN NATURE TECHNO, P263; ARAKI Y, 1975, EUR J BIOCHEM, V55, P71, DOI 10.1111/j.1432-1033.1975.tb02139.x; BARBER MS, 1989, PHYSIOL MOL PLANT P, V34, P3, DOI 10.1016/0885-5765(89)90012-X; Bartnicki-Garcia S., 1989, CHITIN CHITOSAN, P23; BENHAMOU N, 1990, PLANT PHYSIOL, V92, P1108, DOI 10.1104/pp.92.4.1108; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V1, P112; CONRATH U, 1989, PLANT CELL REP, V8, P152, DOI 10.1007/BF00716829; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; GAO XD, 1995, J BIOCHEM, V117, P257, DOI 10.1093/jb/117.2.257; GREEN ED, 1988, J BIOL CHEM, V263, P25; HIRANO S, 1989, CHITIN CHITOSAN, P37; Hirs CHW, 1967, METHOD ENZYMOL, P59, DOI [10.1016/S0076-6879(67)11008-2, DOI 10.1016/S0076-6879(67)11008-2]; JEUNIAUX C, 1982, B SOC ZOOL FR, V107, P363; JOHN M, 1993, P NATL ACAD SCI USA, V90, P625, DOI 10.1073/pnas.90.2.625; KAFETZOPOULOS D, 1993, P NATL ACAD SCI USA, V90, P8005, DOI 10.1073/pnas.90.17.8005; KAFETZOPOULOS D, 1993, P NATL ACAD SCI USA, V90, P2564, DOI 10.1073/pnas.90.7.2564; KAUSS H, 1989, PLANTA, V178, P385, DOI 10.1007/BF00391866; KAUSS H, 1983, PLANT SCI LETT, V28, P231, DOI 10.1016/S0304-4211(83)80014-5; KENDRA DF, 1984, EXP MYCOL, V8, P276, DOI 10.1016/0147-5975(84)90013-6; KNORR D, 1984, BIOTECHNOLOGY MARINE, P313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINOU A, 1995, CARBOHYD RES, V273, P235, DOI 10.1016/0008-6215(95)00111-6; MARTINOU A, 1993, J CHROMATOGR, V644, P35, DOI 10.1016/0021-9673(93)80117-Q; OCONNELL RJ, 1990, PHYSIOL MOL PLANT P, V37, P39, DOI 10.1016/0885-5765(90)90084-B; Rha C., 1984, BIOTECHNOLOGY MARINE, P283; RUIZHERRERA J, 1978, 1ST P INT C CHIT CHI, P11; SIEGRIST J, 1990, PHYSIOL MOL PLANT P, V36, P267, DOI 10.1016/0885-5765(90)90058-6; SOJAR HT, 1987, METHOD ENZYMOL, V138, P341; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; SPANU P, 1989, PLANTA, V177, P447, DOI 10.1007/BF00392612; TRUDEL J, 1990, ANAL BIOCHEM, V189, P249, DOI 10.1016/0003-2697(90)90116-Q; WALKERSIMMONS M, 1984, PLANT PHYSIOL, V76, P787, DOI 10.1104/pp.76.3.787	34	121	130	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26286	26291		10.1074/jbc.270.44.26286	http://dx.doi.org/10.1074/jbc.270.44.26286			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592838	hybrid			2022-12-27	WOS:A1995TC97800045
J	BOSC, DG; SLOMINSKI, E; SICHLER, C; LITCHFIELD, DW				BOSC, DG; SLOMINSKI, E; SICHLER, C; LITCHFIELD, DW			PHOSPHORYLATION OF CASEIN KINASE-II BY P34(CDC2) - IDENTIFICATION OF PHOSPHORYLATION SITES USING PHOSPHORYLATION SITE MUTANTS IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATURATION-PROMOTING FACTOR; PROTEIN-KINASE; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; ALPHA-SUBUNIT; BETA-SUBUNIT; MITOSIS; OOCYTES; P34CDC2; AUTOPHOSPHORYLATION	The alpha and beta subunits of casein kinase II are dramatically phosphorylated in cells that are arrested in mitosis (Litchfield, D. W., Luscher, B., Lozeman, F. J., Eisenman, R. N., and Krebs, E. G. (1992) J. Biol. Chem. 267, 13943-13951). Comparative phosphopeptide mapping experiments indicated that the mitotic phosphorylation sites on the alpha subunit of casein kinase II can be phosphorylated in vitro by p34(cdc2). In the present study, we have demonstrated that a glutathione S-transferase fusion protein encoding the C-terminal 126 amino acids of the alpha subunit is phosphorylated by p34(cdc2) at the same sites as intact casein kinase II, indicating that the mitotic phosphorylation sites are localized within the C-terminal domain of alpha. Four residues within this domain, Thr-344, Thr 360, Ser-362, and Ser-370, conform to the minimal consensus sequence for p34(cdc2) phosphorylation. Synthetic peptides corresponding to regions of alpha that contain each of these residues are phosphorylated by p34(cdc2) at these sites. Furthermore, alterations in the phosphorylation of the glutathione S-transferase proteins encoding the C-terminal domain of alpha are observed when any of the four residues are mutated to alanine, When all four residues are mutated to alanine, the fusion protein is no longer phosphorylated by p34(cdc2) at any of the sites that are phosphorylated in mitotic cells. These results indicate that Thr-344, Thr-360, Ser-362, and Ser-370 are the sites on the alpha subunit of casein kinase II that are phosphorylated in mitotic cells.	MANITOBA CANC TREATMENT & RES FDN, MANITOBA INST CELL BIOL, WINNIPEG, MB R3E 0V9, CANADA; UNIV MANITOBA, DEPT BIOCHEM & MOLEC BIOL, WINNIPEG, MB R3E 0V9, CANADA	University of Manitoba			Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620				BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; DOREE M, 1983, DEV BIOL, V99, P489, DOI 10.1016/0012-1606(83)90298-1; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FEILOTTER H, 1992, BIOCHEM CELL BIOL, V70, P954, DOI 10.1139/o92-140; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HECK MMS, 1989, J BIOL CHEM, V264, P15161; KANDROR KV, 1989, EUR J BIOCHEM, V180, P441, DOI 10.1111/j.1432-1033.1989.tb14666.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KERYER G, 1993, P NATL ACAD SCI USA, V90, P5418, DOI 10.1073/pnas.90.12.5418; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LITCHFIELD DW, 1995, IN PRESS BIOCH BIOPH; LORILLON OM, 1988, EUR J BIOCHEM, V171, P107; LORILLON OM, 1990, EUR J BIOCHEM, V193, P529; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; MALLER J, 1977, DEV BIOL, V58, P295, DOI 10.1016/0012-1606(77)90093-8; MALLER JL, 1993, MOL CELL BIOCHEM, V128, P267, DOI 10.1007/BF01076777; MARIDOR G, 1991, J BIOL CHEM, V266, P2362; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PELECH SL, 1991, BIOCHEM J, V274, P759, DOI 10.1042/bj2740759; PINES J, 1990, New Biologist, V2, P389; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	53	65	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25872	25878		10.1074/jbc.270.43.25872	http://dx.doi.org/10.1074/jbc.270.43.25872			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592773	hybrid			2022-12-27	WOS:A1995TB46600090
J	HIRAOKA, O; ANAGUCHI, H; ASAKURA, A; OTA, Y				HIRAOKA, O; ANAGUCHI, H; ASAKURA, A; OTA, Y			REQUIREMENT FOR THE IMMUNOGLOBULIN-LIKE DOMAIN OF GRANULOCYTE-COLONY-STIMULATING FACTOR-RECEPTOR IN FORMATION OF A 2/1 RECEPTOR-LIGAND COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; EXTRACELLULAR DOMAIN; SIGNAL TRANSDUCTION; EXPRESSION CLONING; DIMERIZATION; PURIFICATION; SUPERFAMILY; SECRETION; DESIGN	The extracellular portion of the granulocyte colony-stimulating factor (G-CSF) receptor has a mosaic structure of six domains (each approximately 100 amino acid residues) consisting of an immunoglobulin-like (Ig) domain, a cytokine receptor homologous region subdivided into amino-terminal (BN) and carboxyl-terminal (BC) domains, and three fibronectin type III repeats. In the present study, we expressed the Ig-BN and the BN-BC regions and purified them to homogeneity as monomers using G-CSF affinity column chromatography. Using gel filtration high performance liquid chromatography, we investigated the molecular composition of receptor-ligand complexes formed between G-CSF and purified BN-BC or Ig-BN domains. In contrast to the well characterized example of the human growth hormone (GH) receptor, in which the BN-BC . GH complex shows a 2:1 receptor-ligand complex stoichiometry, the BN-BC domain of the G-CSF receptor formed a 1:1 complex. The isolated Ig-BN domain also formed a 1:1 complex with G-CSF. However, in the presence of both Ig-BN and BN-BC domains, we detected a 1:1:1 Ig-BN . G-CSF . BN-BC complex corresponding to the 2:1 receptor: Ligand stoichiometry. These results suggest that 1) the Ig domain and both the BN and the BC domains are required for oligomerization of the G-CSF receptor, 2) G-CSF contains two binding sites for its receptor, and 3) there are two ligand binding sites on the G-CSF receptor, one site on the BN-BC domain and one on the Ig-BN domain.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN									BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1990, J BIOL CHEM, V265, P3111; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIRAOKA O, 1994, J BIOL CHEM, V269, P22412; HIRAOKA O, 1994, FEBS LETT, V356, P255, DOI 10.1016/0014-5793(94)01278-4; HOOPER KP, 1993, J BIOL CHEM, V268, P22347; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; NAGATA S, 1991, Progress in Growth Factor Research, V3, P131, DOI 10.1016/S0955-2235(05)80004-3; OTA Y, 1991, GENE, V106, P159, DOI 10.1016/0378-1119(91)90195-H; SETO Y, 1992, J IMMUNOL, V148, P259; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WELLS JA, 1993, RECENT PROG HORM RES, V48, P253; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	29	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25928	25934		10.1074/jbc.270.43.25928	http://dx.doi.org/10.1074/jbc.270.43.25928			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592781	hybrid			2022-12-27	WOS:A1995TB46600098
J	ANDERSEN, GR; KOCH, TJ; DOLMER, K; SOTTRUPJENSEN, L; NYBORG, J				ANDERSEN, GR; KOCH, TJ; DOLMER, K; SOTTRUPJENSEN, L; NYBORG, J			LOW-RESOLUTION X-RAY STRUCTURE OF HUMAN METHYLAMINE-TREATED ALPHA(2)-MACROGLOBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; FLUORESCENCE ENERGY-TRANSFER; HUMAN ALPHA-2-MACROGLOBULIN; ELECTRON-MICROSCOPY; LIPOPROTEIN RECEPTOR; BAIT REGION; CONFORMATIONAL-CHANGES; MONOCLONAL-ANTIBODIES; ALPHA-MACROGLOBULINS; COMPLEX-FORMATION	The structure of methylamine-treated human alpha(2)-macroglobulin (alpha(2)M-MA), a 720-kDa tetrameric inactivated proteinase inhibitor from plasma, has been determined to a resolution of 10 Angstrom. Data were collected with synchrotron radiation at 120 K, and phases were calculated by multiple isomorphous replacement and solvent flattening. A novel feature of the structure of alpha(2)M is present in its proteinase-binding cavity, dividing it into two compartments. The potential sites for proteinase entrap ment in these compartments are sterically restricted. The positions of the thiol groups appearing from the functional important thiol esters upon their cleavage have been determined. They are found at the walls of the compartments at the center of the structure. The overall structure of alpha(2)M-MA is much more sphere-like than previously inferred from electron microscopy studies. However, several aspects of the structure are well described by recent three-dimensional reconstructions. Possible models for the monomer, the disulfide bridged dimer, and native alpha(2)M are discussed.	AARHUS UNIV, DEPT CHEM, DK-8000 AARHUS C, DENMARK; AARHUS UNIV, DEPT MOLEC BIOL, DK-8000 AARHUS C, DENMARK	Aarhus University; Aarhus University			Dolmer, Klavs/G-5512-2012	Dolmer, Klavs/0000-0001-7359-360X; Andersen, Gregers Rom/0000-0001-6292-3319				ANDERSEN GR, 1994, ANN NY ACAD SCI, V737, P444, DOI 10.1111/j.1749-6632.1994.tb44335.x; ANDERSEN GR, 1994, ACTA CRYSTALLOGR D, V50, P298, DOI 10.1107/S0907444993013125; ANDERSEN GR, 1991, FEBS LETT, V292, P267, DOI 10.1016/0014-5793(91)80881-3; ANDERSEN GR, 1994, STRUCTURAL STUDIES A; ARAKAWA H, 1986, BIOCHEMISTRY-US, V25, P6785, DOI 10.1021/bi00370a009; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BJORK I, 1982, BIOCHEM J, V207, P347; BLOTH B, 1968, J EXP MED, V127, P749, DOI 10.1084/jem.127.4.749; BOISSET N, 1992, J STRUCT BIOL, V109, P39, DOI 10.1016/1047-8477(92)90065-I; BOISSET N, 1993, J MOL BIOL, V232, P522, DOI 10.1006/jmbi.1993.1408; BOISSET N, 1989, J BIOL CHEM, V264, P12046; BOISSET N, 1994, ANN NY ACAD SCI, V737, P229, DOI 10.1111/j.1749-6632.1994.tb44315.x; BOISSET N, 1992, J STRUCT BIOL, V108, P221, DOI 10.1016/1047-8477(92)90022-3; BOISSET N, 1991, J STRUCT BIOL, V106, P31, DOI 10.1016/1047-8477(91)90060-A; BRETAUDIERE JP, 1988, P NATL ACAD SCI USA, V85, P1437, DOI 10.1073/pnas.85.5.1437; CHEN BJ, 1992, BIOCHEMISTRY-US, V31, P8960, DOI 10.1021/bi00152a036; DELAIN E, 1988, J BIOL CHEM, V263, P2981; DELAIN E, 1992, ELECTRON MICROSC REV, V5, P231, DOI 10.1016/0892-0354(92)90012-F; DELAIN E, 1994, ANN NY ACAD SCI, V737, P202, DOI 10.1111/j.1749-6632.1994.tb44313.x; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; FUREY W, 1996, IN PRESS METHODS ENZ; GETTINS P, 1986, BIOCHEMISTRY-US, V25, P5011, DOI 10.1021/bi00366a007; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P2905, DOI 10.1021/bi00408a036; GETTINS P, 1990, BIOCHEMISTRY-US, V29, P7747, DOI 10.1021/bi00485a025; GETTINS PGW, 1993, FEBS LETT, V332, P211, DOI 10.1016/0014-5793(93)80633-6; GETTINS PGW, 1993, FEBS LETT, V325, P267, DOI 10.1016/0014-5793(93)81086-F; GONIAS SL, 1989, J BIOL CHEM, V264, P9565; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOWARD JB, 1981, P NATL ACAD SCI-BIOL, V78, P2235, DOI 10.1073/pnas.78.4.2235; HUSSAINI IM, 1990, BIOCHEM J, V270, P291, DOI 10.1042/bj2700291; IKAI A, 1990, FEBS LETT, V260, P291, DOI 10.1016/0014-5793(90)80126-4; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JACOBSON J, 1993, CLAVIER, V32, P20; JENSEN PEH, 1986, J BIOL CHEM, V261, P5863; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAPLAN J, 1981, J BIOL CHEM, V256, P7705; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LARQUET E, 1994, J STRUCT BIOL, V113, P87, DOI 10.1006/jsbi.1994.1034; MARSHALL LB, 1992, J BIOL CHEM, V267, P6347; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; OHALLORAN TV, 1987, J MOL BIOL, V194, P705, DOI 10.1016/0022-2836(87)90248-8; OTWINOWSKI Z, 1993, CCP4 STUDY WEEKEND D, P56; PICKERSGILL RW, 1991, ACTA CRYSTALLOGR B, V47, P766, DOI 10.1107/S0108768191003191; POCHON F, 1989, BIOCHIM BIOPHYS ACTA, V996, P132, DOI 10.1016/0167-4838(89)90105-2; RUBENSTEIN DS, 1993, BIOCHEM J, V290, P85, DOI 10.1042/bj2900085; SCHNEIDER G, 1994, ACTA CRYSTALLOGR D, V50, P186, DOI 10.1107/S0907444993009679; SCHROETER JP, 1992, J STRUCT BIOL, V109, P235, DOI 10.1016/1047-8477(92)90036-A; SORENSEN AH, 1994, ACTA CRYSTALLOGR D, V50, P786, DOI 10.1107/S0907444994003689; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SOTTRUPJENSEN L, 1990, J BIOL CHEM, V265, P17727; SOTTRUPJENSEN L, 1981, FEBS LETT, V128, P123, DOI 10.1016/0014-5793(81)81096-4; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STOOPS JK, 1994, ANN NY ACAD SCI, V737, P212, DOI 10.1111/j.1749-6632.1994.tb44314.x; STOOPS JK, 1991, J STRUCT BIOL, V106, P172, DOI 10.1016/1047-8477(91)90086-C; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STROTHKAMP KG, 1978, P NATL ACAD SCI USA, V75, P1181, DOI 10.1073/pnas.75.3.1181; TAPONBRETAUDIERE J, 1985, EMBO J, V4, P85, DOI 10.1002/j.1460-2075.1985.tb02321.x; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369; VANLEUVEN F, 1986, J BIOL CHEM, V261, P6933; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WELINDER KG, 1984, J BIOL CHEM, V259, P8328; ZHAO BL, 1988, BIOCHEMISTRY-US, V27, P5304, DOI 10.1021/bi00414a053; 1979, SUITE PROGRAMS PROTE	71	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25133	25141		10.1074/jbc.270.42.25133	http://dx.doi.org/10.1074/jbc.270.42.25133			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559647	hybrid			2022-12-27	WOS:A1995TB46500081
J	DIZHOOR, AM; OLSHEVSKAYA, EV; HENZEL, WJ; WONG, SC; STULTS, JT; ANKOUDINOVA, I; HURLEY, JB				DIZHOOR, AM; OLSHEVSKAYA, EV; HENZEL, WJ; WONG, SC; STULTS, JT; ANKOUDINOVA, I; HURLEY, JB			CLONING, SEQUENCING, AND EXPRESSION OF A 24-KDA CA2+-BINDING PROTEIN ACTIVATING PHOTORECEPTOR GUANYLYL CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; MOLECULAR-CLONING; RECOVERIN; TRANSDUCTION; MEMBRANES; TERMINUS; FAMILY	Two vertebrate photoreceptor-specific membrane guanylyl cyclases, RetGC-1 and RetGC-2, are activated by a soluble 24-kDa retinal protein, p24, in a Ca2+-sensitive manner (Dizhoor, A. M., Lowe, D. G., Olshevskaya, E. V., Laura, R. P., and Hurley, J. B. (1994) Neuron 12, 1345-1352; Lowe, D. G., Dizhoor, A. M., Liu, K., Gu, O., Laura, R., Lu, L., and Hurley, J. B. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5535-5539). The primary structure of bovine p24 has been derived from peptide sequencing and from its cDNA. p24 is a new EF-hand-type Ca2+ binding protein, related but not identical to another guanylyl cyclase-activating protein, GCAP (Palczewski, K., Subbaraya, I., Gorczyca, W. A., Helekar, B. S., Ruiz, C. C., Ohguro, H. Huang, J., Zhao, X., Crabb, J. W., Johnson, R. S., Walsh, K. A., Gray-Keller, M. P., Detwiler, P. B., and Baehr, W. (1994) Neuron 13, 395-404) and other members of the recoverin family of Ca2+-binding proteins. Antibodies against a truncated fusion protein and against a p24-specific synthetic peptide specifically recognize retinal p24 on immunoblot. Both antibodies inhibit activation of photoreceptor membrane guanylyl cyclase by purified p24. p24 is found only in retina, and it copurifies with outer segment membranes. Immunocytochemical analysis shows that it is present in rod photoreceptor cells. An immobilized antibody column was used to purify p24 from a heat-treated retinal extract. Purified p24 appears on SDS-polyacrylamide gel electrophoresis as a homogenous protein not contaminated with GCAP, and it activates photoreceptor guanylyl cyclase in vitro at submicromolar concentrations. Ca2+ inhibits this activation with an EC(50) near 200 nM and a Hill coefficient of 1.7. Recombinant p24 expressed in 293 cells effectively stimulates photoreceptor guanylyl cyclase. These findings demonstrate that p24, like GCAP, imparts Ca2+ sensitivity to photoreceptor membrane guanylyl cyclase. We propose that p24 be referred to as GCAP-2 and that GCAP be referred to as GCAP-1.	UNIV WASHINGTON, SCH MED, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; GENENTECH INC, S SAN FRANCISCO, CA 94080 USA	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Roche Holding; Genentech				Dizhoor, Alexander/0000-0001-6770-9186; Henzel, William/0000-0003-2940-3797	NEI NIH HHS [EYO6641] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4746, DOI 10.1073/pnas.88.11.4746; Henzel William J., 1994, Methods (Orlando), V6, P239, DOI 10.1006/meth.1994.1026; HENZEL WJ, 1987, J CHROMATOGR, V404, P41, DOI 10.1016/S0021-9673(01)86835-7; HENZEL WJ, 1990, ANAL BIOCHEM, V187, P228, DOI 10.1016/0003-2697(90)90448-I; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; HURLEY JB, 1993, SCIENCE, V260, P740, DOI 10.1126/science.8097896; JOHNSON RS, 1994, J BIOL CHEM, V269, P21067; KOBAYASHI M, 1993, BIOCHEM BIOPH RES CO, V196, P1017, DOI 10.1006/bbrc.1993.2351; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOCH KW, 1991, J BIOL CHEM, V266, P8634; KRUTZSCH HC, 1993, ANAL BIOCHEM, V209, P109, DOI 10.1006/abio.1993.1089; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LI X, 1994, EXP EYE RES, V59, P761; LOLLEY RN, 1982, VISION RES, V22, P1481, DOI 10.1016/0042-6989(82)90213-9; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MARGULIS A, 1993, BIOCHEM BIOPH RES CO, V194, P855, DOI 10.1006/bbrc.1993.1900; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCDOWELL JH, 1977, BIOCHEMISTRY-US, V16, P4054, DOI 10.1021/bi00637a018; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; STRYER L, 1991, J BIOL CHEM, V266, P10711; TENG DHF, 1994, J BIOL CHEM, V269, P31900; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	39	270	274	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25200	25206		10.1074/jbc.270.42.25200	http://dx.doi.org/10.1074/jbc.270.42.25200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559656	hybrid			2022-12-27	WOS:A1995TB46500090
J	DINOIA, JM; SANCHEZ, DO; FRASCH, ACC				DINOIA, JM; SANCHEZ, DO; FRASCH, ACC			THE PROTOZOAN TRYPANOSOMA-CRUZI HAS A FAMILY OF GENES RESEMBLING THE MUCIN GENES OF MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM REPEATS; INTESTINAL MUCIN; ANTIGEN GENES; REGION; GLYCOPROTEINS; SEQUENCES; MEMBRANE; PROTEIN; DOMAINS; RICH	Mucins are heavily O-glycosylated Thr/Ser/Pro-rich molecules. Given their relevant functions, mucins and their genes have been mainly studied in higher eukaryotes. In the protozoan parasite Trypanosoma cruzi, mucin-like glycoproteins were shown to play an important role in the interaction with the surface of the mammalian cell during the invasion process, We show now that this parasite has a family of putative mucin genes, whose organization resembles the one present in mammalian cells. Different parasite isolates have different sets of genes, as defined by their central domain. Central domains, rich in codons for Thr and/or Ser and Pro residues, are made up of either a variable number of repeat units in tandem or non-repetitive sequences. Conversely, 5'- and 3'-ends from different genes in different isolates have similar sequences, suggesting their common origin. Comparison of deduced amino acid sequences revealed that all members of the family have the same putative signal peptide on the N terminus and a putative sequence for glycophosphatidylinositol anchoring on the C terminus. The deduced molecular mass of the core proteins is small (from 17 to 21 kDa), in agreement with the 1-kilobase size of the mRNA detected. Putative mucin genes in T. cruzi are located on large chromosomal bands of about 1.6-2.2 megabase pairs.	FDN CAMPOMAR, INST INVEST BIOQUIM, RA-1405 BUENOS AIRES, DF, ARGENTINA; UNIV BUENOS AIRES, FAC CIENCIAS EXACTAS & NAT, BUENOS AIRES, DF, ARGENTINA	Leloir Institute; University of Buenos Aires			Di Noia, Javier Marcelo/D-2285-2012	Di Noia, Javier Marcelo/0000-0003-2896-0321; sanchez, daniel/0000-0002-5427-7764; Frasch, Alberto Carlos/0000-0001-7532-653X				BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BRENER Z, 1963, Rev Inst Med Trop Sao Paulo, V5, P220; CAPPA SMG, 1981, MEDICINA-BUENOS AIRE, V41, P549; CAZZULO JJ, 1985, MOL BIOCHEM PARASIT, V16, P329, DOI 10.1016/0166-6851(85)90074-X; COWMAN AF, 1985, CELL, V40, P775, DOI 10.1016/0092-8674(85)90337-X; DEVINE PL, 1992, BIOESSAYS, V14, P619, DOI 10.1002/bies.950140909; DUFOSSE J, 1993, BIOCHEM J, V293, P329, DOI 10.1042/bj2930329; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FOURNEY RM, 1978, FOCUS, V10, P5; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GONZALEZCAPPA SM, 1980, MEDICINA-BUENOS AIRE, V40, P63; GUM JR, 1992, AM J RESP CELL MOL, V7, P557, DOI 10.1165/ajrcmb/7.6.557; GUM JR, 1992, J BIOL CHEM, V267, P21375; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; HEI J, 1990, METHOD ENZYMOL, V183, P626; HENRIKSSON J, 1990, MOL BIOCHEM PARASIT, V42, P213, DOI 10.1016/0166-6851(90)90164-H; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; KHATRI IA, 1993, BIOCHEM J, V294, P391, DOI 10.1042/bj2940391; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; MURRAY PJ, 1991, J BIOL CHEM, V266, P24477; REYES MB, 1994, GENE, V140, P139, DOI 10.1016/0378-1119(94)90745-5; RUIZ RD, 1993, PARASITE IMMUNOL, V15, P121, DOI 10.1111/j.1365-3024.1993.tb00591.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; SCHENKMAN S, 1994, ANNU REV MICROBIOL, V48, P499, DOI 10.1146/annurev.mi.48.100194.002435; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; XU G, 1992, BIOCHEM BIOPH RES CO, V183, P821, DOI 10.1016/0006-291X(92)90557-2; XU GQ, 1992, J BIOL CHEM, V267, P5401; YOSHIDA N, 1989, INFECT IMMUN, V57, P1663, DOI 10.1128/IAI.57.6.1663-1667.1989; ZINGALES B, 1985, MOL BIOCHEM PARASIT, V16, P21, DOI 10.1016/0166-6851(85)90046-5	34	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24146	24149		10.1074/jbc.270.41.24146	http://dx.doi.org/10.1074/jbc.270.41.24146			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592617	hybrid			2022-12-27	WOS:A1995TA21700045
J	LAWN, RM; BOONMARK, NW; SCHWARTZ, K; LINDAHL, GE; WADE, DP; BYRNE, CD; FONG, KJ; MEER, K; PATTHY, L				LAWN, RM; BOONMARK, NW; SCHWARTZ, K; LINDAHL, GE; WADE, DP; BYRNE, CD; FONG, KJ; MEER, K; PATTHY, L			THE RECURRING EVOLUTION OF LIPOPROTEIN(A) - INSIGHTS FROM CLONING OF HEDGEHOG APOLIPOPROTEIN(A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA-LIPOPROTEIN; NONHUMAN-PRIMATES; BLOOD-COAGULATION; HUMAN-PLASMINOGEN; SEQUENCE; QUANTIFICATION; ACTIVATION; BINDING; COMPLEX; LP(A)	The lipoprotein Lp(a), a major inherited risk factor for atherosclerosis, consists of a low density lipoprotein-like particle containing apolipoprotein B-100 plus the distinguishing component apolipoprotein(a) (apo(a)). Human apo(a) contains highly repeated domains related to plasminogen kringle four plus single kringle five and protease-like domains, Apo(a) is virtually confined to primates, and the gene may have arisen during primate evolution. One exception is the occurrence of an Lp(a)like particle in the hedgehog. Cloning of the hedgehog apo(a)-like gene shows that it is distinctive in form and evolutionary history from human apo(a), but that it has acquired several common features. It appears that the primate and hedgehog apo(a) genes evolved independently by duplication and modification of different domains of the plasminogen gene, providing a novel type of ''convergent'' molecular evolution.	HUNGARIAN ACAD SCI, INST ENZYMOL, H-1502 BUDAPEST, HUNGARY	Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences	LAWN, RM (corresponding author), STANFORD UNIV, SCH MED, FALK CARDIOVASC RES CTR, 300 PASTEUR DR, STANFORD, CA 94305 USA.		Patthy, Laszlo/Q-6058-2019; Patthy, Laszlo/A-2353-2013	Byrne, Christopher D/0000-0001-6322-7753	NHLBI NIH HHS [HL-48638] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048638] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOSTOM AG, 1994, CIRCULATION, V90, P1688, DOI 10.1161/01.CIR.90.4.1688; BROWN MS, 1987, NATURE, V330, P113, DOI 10.1038/330113a0; BYRNE CD, 1994, ARTERIOSCLER THROMB, V14, P534, DOI 10.1161/01.ATV.14.4.534; BYRNE CD, 1995, ARTERIOSCL THROM VAS, V15, P65, DOI 10.1161/01.ATV.15.1.65; CASTELLINO FJ, 1987, J MOL EVOL, V26, P358, DOI 10.1007/BF02101155; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; DAVIE EW, 1981, METHOD ENZYMOL, V80, P153; DOOLITTLE RF, 1993, THROMB HAEMOSTASIS, V70, P24; DOOLITTLE RF, 1994, TRENDS BIOCHEM SCI, V19, P15, DOI 10.1016/0968-0004(94)90167-8; DOUCET C, 1994, J LIPID RES, V35, P263; FLESS GM, 1984, J BIOL CHEM, V259, P1470; FRIEZNERDEGEN S, 1987, BIOCHEMISTRY-US, V26, P8270; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIXSON JE, 1989, J BIOL CHEM, V264, P6013; ICHINOSE A, 1992, BIOCHEMISTRY-US, V31, P3113, DOI 10.1021/bi00127a011; JAUHIAINEN M, 1991, BIOCHEM J, V274, P491, DOI 10.1042/bj2740491; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KREUZER J, 1994, CHEM PHYS LIPIDS, V67-8, P175, DOI 10.1016/0009-3084(94)90137-6; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LAPLAUD PM, 1988, J LIPID RES, V29, P1157; Liu Alexander C., 1994, Current Opinion in Lipidology, V5, P269, DOI 10.1097/00041433-199408000-00005; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MACDONALD DW, 1984, ENCY MAMMALS, P738; MAGNAGHI P, 1994, HUM MOL GENET, V3, P437, DOI 10.1093/hmg/3.3.437; MAKINO K, 1989, ATHEROSCLEROSIS, V78, P81, DOI 10.1016/0021-9150(89)90161-5; MALGARETTI N, 1992, P NATL ACAD SCI USA, V89, P11584, DOI 10.1073/pnas.89.23.11584; MCCANCE SG, 1994, J BIOL CHEM, V269, P32405; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1990, THROMB HAEMOSTASIS, V63, P331; NACHMAN RL, 1991, ARTERIOSCLER THROMB, V11, P32, DOI 10.1161/01.ATV.11.1.32; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PEPIN JM, 1991, J LIPID RES, V32, P317; PESOLE G, 1994, GENETICS, V136, P255; PHILLIPS ML, 1993, BIOCHEMISTRY-US, V32, P3722, DOI 10.1021/bi00065a026; PHILLIPS ML, 1994, CHEM PHYS LIPIDS, V67-8, P91, DOI 10.1016/0009-3084(94)90127-9; PICCININI M, 1991, BIOL CHEM H-S, V372, P975, DOI 10.1515/bchm3.1991.372.2.975; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; RATH M, 1990, P NATL ACAD SCI USA, V87, P9338; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROUY D, 1992, ARTERIOSCLER THROMB, V12, P146, DOI 10.1161/01.ATV.12.2.146; SALONEN EM, 1989, EMBO J, V8, P4035, DOI 10.1002/j.1460-2075.1989.tb08586.x; SCANU AM, 1994, BBA-MOL BASIS DIS, V1227, P41, DOI 10.1016/0925-4439(94)90104-X; SCANU AM, 1995, BBA-LIPID LIPID MET, V1256, P1, DOI 10.1016/0005-2760(95)00012-2; STEWART CB, 1987, COLD SPRING HARB SYM, V52, P891, DOI 10.1101/SQB.1987.052.01.097; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; TRIEU VN, 1991, J BIOL CHEM, V266, P5480; TSENG H, 1988, CELL, V54, P491, DOI 10.1016/0092-8674(88)90070-0; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; WU TP, 1991, BIOCHEMISTRY-US, V30, P10589, DOI 10.1021/bi00107a030	53	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24004	24009		10.1074/jbc.270.41.24004	http://dx.doi.org/10.1074/jbc.270.41.24004			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592597	hybrid			2022-12-27	WOS:A1995TA21700025
J	YANG, W; BOGGS, KP; JACKOWSKI, S				YANG, W; BOGGS, KP; JACKOWSKI, S			THE ASSOCIATION OF LIPID ACTIVATORS WITH THE AMPHIPATHIC HELICAL DOMAIN OF CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE ACCELERATES CATALYSIS BY INCREASING THE AFFINITY OF THE ENZYME FOR CTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER OVARY; PHOSPHOLIPASE-C TREATMENT; RAT-LIVER CTP; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; FEEDBACK-REGULATION; INDUCED INHIBITION; FATTY-ACIDS; CELLS; TRANSLOCATION	The biochemical mechanism for the regulation of enzyme activity by lipid modulators and the role of the amphipathic alpha-helical domain of CTP:phosphocholine cytidylyltransferase (CT) was investigated by analyzing the kinetic properties of the wild-type protein and two truncation mutants isolated from a baculovirus expression system. The CT[Delta 312-367] mutant protein lacked the carboxyl-terminal phosphorylation domain and retained high catalytic activity along with both positive and negative regulation by lipid modulators. The CT[Delta 257-367] deletion removed in addition the region containing three consecutive amphipathic alpha-helical repeats The CT[Delta 257-367] mutant protein exhibited a significantly lower specific activity compared to CT or CT[Delta 312-367] when expressed in either insect or mammalian cells; however, CT[Delta 257-367] activity was refractory to either stimulation or inhibition by lipid regulators. Lipid activators accelerated CT activity by decreasing the K-m for CTP from 24.7 mM in their absence to 0.7 mM in their presence. The K-m for phosphocholine was not affected by lipid activators. The activity of CT[Delta 257-367] was comparable to the activity of wildtype CT in the absence of lipid activators and the CTP K-m for CT[Delta 257-367] was 13.9 mM. The enzymatic properties of the CT[Delta 231-367] mutant were comparable to those exhibited by the CT[257-367] mutant indicating that removal of residues 231 through 257 did not have any additional influence on the lipid regulation of the enzyme. Thus, the region between residues 257 and 312 was required to confer lipid regulation on CT, and the association of activating lipids with this region of the protein stimulated catalysis by increasing the affinity of the enzyme for CTP.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NCI NIH HHS [T32 CA09346, CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM45737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009346, P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOY PC, 1979, CAN J BIOCHEM CELL B, V57, P605, DOI 10.1139/o79-076; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P37, DOI 10.1016/0005-2760(87)90215-3; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5881, DOI 10.1021/bi00238a011; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P573; CRAIG L, 1994, J BIOL CHEM, V269, P3311; Dixon M., 1979, ENZYMES, Vthird; HATCH GM, 1992, J BIOL CHEM, V267, P15751; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; JAMIL H, 1990, J BIOL CHEM, V265, P4332; JAMIL H, 1992, J BIOL CHEM, V267, P1752; JAMIL H, 1990, BIOCHEM J, V270, P749, DOI 10.1042/bj2700749; JONES GA, 1992, ARCH BIOCHEM BIOPHYS, V288, P331; KALMAR GB, 1994, BBA-GENE STRUCT EXPR, V1219, P328, DOI 10.1016/0167-4781(94)90056-6; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; LIANG P, 1994, CURRENT PROTOCOLS MO; LOPEZ G, 1992, J NEUROCHEM, V59, P338; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MORAND JN, 1989, J BIOL CHEM, V264, P13785; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; PELECH SL, 1982, J BIOL CHEM, V257, P4198; PELECH SL, 1983, J BIOL CHEM, V258, P6782; RUTHERFORD MS, 1993, GENOMICS, V18, P698, DOI 10.1016/S0888-7543(05)80377-5; SAVCI V, 1995, J NEUROCHEM, V64, P378; SLEIGHT R, 1983, J BIOL CHEM, V258, P831; SOHAL PS, 1990, J BIOL CHEM, V265, P11746; SWEITZER TD, 1994, ARCH BIOCHEM BIOPHYS, V311, P107, DOI 10.1006/abbi.1994.1215; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P225; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; WIEDER T, 1994, FEBS LETT, V345, P207, DOI 10.1016/0014-5793(94)00433-1; WRIGHT PS, 1985, J BIOL CHEM, V260, P7919; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503; YAO ZM, 1990, J BIOL CHEM, V265, P4326	42	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23951	23957		10.1074/jbc.270.41.23951	http://dx.doi.org/10.1074/jbc.270.41.23951			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592590	hybrid			2022-12-27	WOS:A1995TA21700018
J	YANG, XF; PRICE, CW				YANG, XF; PRICE, CW			STREPTOLYDIGIN RESISTANCE CAN BE CONFERRED BY ALTERATIONS TO EITHER THE BETA-SUBUNIT OR BETA'-SUBUNITS OF BACILLUS-SUBTILIS RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; RIFAMPICIN RESISTANCE; GENE; INHIBITION; MUTANTS; RPOB; TERMINATION; ELONGATION	Rifampicin and streptolydigin are antibiotics which inhibit prokaryotic RNA polymerase at the initiation and elongation steps, respectively. In Escherichia coli, resistance to each antibiotic results from alterations in the beta subunit of the core enzyme. However, in Bacillus subtilis, reconstitution studies found rifampicin resistance (Rif(R)) associated with the beta subunit and streptolydigin resistance (Stl(R)) with beta'. To understand the basis of bacterial Stl(R), we isolated the B. subtilis rpoC gene, which encodes a 1,199-residue product that is 53% identical to E. coli beta'. Two spontaneous Stl(R) mutants carried the same D796G substitution in rpoC, and this substitution alone was sufficient to confer Stl(R) in vivo. D796 falls within Region F, which is conserved among the largest subunits of prokaryotic and eukaryotic RNA polymerases. Among eukaryotes, alterations in Region F promote resistance to alpha-amanitin, a toxin which inhibits transcription elongation; among prokaryotes, alterations in Region F cause aberrant termination. To determine whether alterations in the beta subunit of B. subtilis could also confer Stl(R), we made three Stl(R) substitutions (A499V, G500R, and E502V) in the rif region of rpoB. Together these results suggest that beta and beta' interact to form an Stl binding site, and that this site is important for transcription elongation.	UNIV CALIF DAVIS, DEPT FOOD SCI & TECHNOL, DAVIS, CA 95616 USA	University of California System; University of California Davis			Price, Chester/M-6900-2019		NIGMS NIH HHS [GM42077] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042077] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOSHKIWA M, 1992, J GEN MICROBIOL, V138, P1875, DOI 10.1099/00221287-138-9-1875; Anagnostopoulos C., 1993, P425; ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; BARTOLOMEI MS, 1995, MOL GEN GENET, V246, P778, DOI 10.1007/BF00290727; BOOR KJ, 1995, J BIOL CHEM, V270, P20329, DOI 10.1074/jbc.270.35.20329; CASSANI G, 1971, NATURE-NEW BIOL, V230, P197, DOI 10.1038/newbio230197a0; CHAFIN DR, 1995, J BIOL CHEM, V270, P19114, DOI 10.1074/jbc.270.32.19114; COCHETME.M, 1974, BIOCHIM BIOPHYS ACTA, V353, P160, DOI 10.1016/0005-2787(74)90182-8; COULTER DE, 1985, J BIOL CHEM, V260, P3190; DEMERCOYROL L, 1989, BIOCHEM J, V258, P165, DOI 10.1042/bj2580165; HALLING SM, 1978, NATURE, V272, P837, DOI 10.1038/272837a0; HALLING SM, 1977, J BIOL CHEM, V252, P9024; HEISLER LM, 1993, J BIOL CHEM, V268, P25369; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONORE N, 1993, MOL MICROBIOL, V7, P207, DOI 10.1111/j.1365-2958.1993.tb01112.x; JIN DJ, 1989, J BACTERIOL, V171, P5229, DOI 10.1128/jb.171.9.5229-5231.1989; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JIN DJ, 1994, J MOL BIOL, V236, P72, DOI 10.1006/jmbi.1994.1119; JOHNSTON DE, 1976, RNA POLYM, P101; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KIMURA M, 1987, FEBS LETT, V210, P91, DOI 10.1016/0014-5793(87)81304-2; KRAKOW JS, 1970, COLD SPRING HARB SYM, V35, P73, DOI 10.1101/SQB.1970.035.01.013; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LISITSYN NA, 1985, BIOORG KHIM+, V11, P132; MCCLURE WR, 1980, J BIOL CHEM, V255, P1610; OVCHINNIKOV YA, 1982, NUCLEIC ACIDS RES, V10, P4035, DOI 10.1093/nar/10.13.4035; OVCHINNIKOV YA, 1981, EUR J BIOCHEM, V116, P621, DOI 10.1111/j.1432-1033.1981.tb05381.x; OZAKI M, 1969, NATURE, V222, P333, DOI 10.1038/222333a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PUHLER G, 1989, NUCLEIC ACIDS RES, V17, P4517, DOI 10.1093/nar/17.12.4517; ROTHSTEIN DM, 1976, RNA POLYMERASE, P601; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SEVERINOV K, 1995, J BIOL CHEM, V270, P23926, DOI 10.1074/jbc.270.41.23926; SONENSHEIN AL, 1974, J BACTERIOL, V120, P253, DOI 10.1128/JB.120.1.253-265.1974; SUH JW, 1986, J BACTERIOL, V168, P65, DOI 10.1128/jb.168.1.65-71.1986; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315	38	31	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23930	23933		10.1074/jbc.270.41.23930	http://dx.doi.org/10.1074/jbc.270.41.23930			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592585	hybrid			2022-12-27	WOS:A1995TA21700013
J	ZHANG, SJ; HAN, JH; SELLS, MA; CHERNOFF, J; KNAUS, UG; ULEVITCH, RJ; BOKOCH, GM				ZHANG, SJ; HAN, JH; SELLS, MA; CHERNOFF, J; KNAUS, UG; ULEVITCH, RJ; BOKOCH, GM			RHO-FAMILY GTPASES REGULATE P38 MITOGEN-ACTIVATED PROTEIN-KINASE THROUGH THE DOWNSTREAM MEDIATOR PAK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUTAGENESIS	The stress-activated p38 mitogen-activated protein (MAP) kinase defines a subgroup of the mammalian MAP kinases that appear to play a key role in regulating inflammatory responses. Co-expression of constitutively active forms of Rac and Cdc42 leads to activation of p38 while dominant negative Rac and Cdc42 inhibit the ability of interleukin-1 to increase p38 activity. p21-activated kinase 1 (Pak1) is a potential mediator of Rac/Cdc42 signaling, and we observe that Pak1 stimulates p38 activity. A dominant negative Pak1 suppresses both interleukin-1- and Rac/Cdc42-induced p38 activity. Rac and Cdc42 appear to regulate a protein kinase cascade initiated at the level of Pak and leading to activation of p38 and JNK.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA	Scripps Research Institute; Scripps Research Institute; Fox Chase Cancer Center			Chernoff, Jonathan/I-7631-2014; Ulevitch, Richard J/Q-3393-2017; Han, J/G-4671-2010	Chernoff, Jonathan/0000-0002-4803-7836; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48008] Funding Source: Medline; NIAID NIH HHS [AI35947] Funding Source: Medline; NIGMS NIH HHS [GM39434] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V219, P470; DEIJARD B, 1995, SCIENCE, V267, P682; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; QUI RG, 1995, NATURE, V374, P457; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639	25	653	666	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					23934	23936		10.1074/jbc.270.41.23934	http://dx.doi.org/10.1074/jbc.270.41.23934			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592586	hybrid, Green Published			2022-12-27	WOS:A1995TA21700014
J	BIERHAUS, A; ZHANG, YM; DENG, YH; MACKMAN, N; QUEHENBERGER, P; HAASE, M; LUTHER, T; MULLER, M; BOHRER, H; GRETEN, J; MARTIN, E; BAEUERLE, PA; WALDHERR, R; KISIEL, W; ZIEGLER, R; STERN, DM; NAWROTH, PP				BIERHAUS, A; ZHANG, YM; DENG, YH; MACKMAN, N; QUEHENBERGER, P; HAASE, M; LUTHER, T; MULLER, M; BOHRER, H; GRETEN, J; MARTIN, E; BAEUERLE, PA; WALDHERR, R; KISIEL, W; ZIEGLER, R; STERN, DM; NAWROTH, PP			MECHANISM OF THE TUMOR-NECROSIS-FACTOR ALPHA-MEDIATED INDUCTION OF ENDOTHELIAL TISSUE FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; FACTOR MESSENGER-RNA; NF-KAPPA-B; C-JUN; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL-ANALYSIS; GENE-EXPRESSION; MAMMALIAN-CELLS; PROTO-ONCOGENE; E-SELECTIN	This study examines the regulation of the human tissue factor (TF) promotor in vitro and in vivo. Transient transfections were performed in bovine aortic endothelial cells to investigate the role of two fundamentally different AP-1 sites and a closely located NF-kappa B site in the human TF promotor, The NF-kappa B site is functionally active, since overexpression of NF-kappa B(p65) resulted in induction of TF mRNA and activity, Promotor analysis showed that NF-kappa B induction was dependent on the integrity of the region from base pair -188 to -181. Overexpression of Jun/Fos resulted in TF induction of transcription and protein/activity. Functional studies revealed that the proximal AP-1 site, but not the distal, was inducible by Jun/Fos heterodimers. The distal AP-1 site, which has a G --> A switch at position 4, was inducible by Jun homodimers. Electrophoretic mobility shift assays, using extracts of tumor necrosis factor alpha (TNF alpha)-stimulated bovine aortic endothelial cells, demonstrated TNF alpha-inducible binding to the proximal AP-1 site, comprising JunD/Fos heterodimers. At the distal AP-1 site, only minor induction of binding activity, characterized as proteins of the Jun and ATF family, was observed. Consistently, this site only marginally participates in TNF alpha induction. Functional studies with TF promotor plasmids confirmed that deletion of the proximal AP-1 or the NF-kappa B site decreased TNF alpha-mediated TF induction to a higher extend than loss of the distal AP-1 site. However, integrity of both AP-1 sites and the NF-kappa B site was required for optimal TNF alpha stimulation. The relevance of these in vitro data was confirmed in vivo in a mouse tumor model. Expression plasmids for a dominant negative Jun mutant or I-KB were packaged in liposomes. When either mutated Jun or I-KB were injected intravenously 48 h before TNF alpha, a reduction in TNF alpha-mediated TF expression in the tumor endothelial cells was observed. Simultaneously, fibrin/fibrinogen deposition decreased and free blood flow could be re stored, Thus, TNF alpha-induced up-regulation of endothelial cell TF depends on a concerted action of members of the bZIP and NF-kappa B family.	UNIV HEIDELBERG, DEPT MED, D-69115 HEIDELBERG, GERMANY; UNIV HEIDELBERG, DEPT PATHOL, D-69115 HEIDELBERG, GERMANY; UNIV HEIDELBERG, DEPT ANESTHESIOL, D-69115 HEIDELBERG, GERMANY; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; TECH UNIV DRESDEN, DEPT PATHOL, D-01307 DRESDEN, GERMANY; INST BIOCHEM, D-79106 FREIBURG, GERMANY; UNIV NEW MEXICO, DEPT PATHOL, ALBUQUERQUE, NM 87131 USA; COLUMBIA UNIV, DEPT PHYSIOL, NEW YORK, NY 10032 USA	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Scripps Research Institute; Technische Universitat Dresden; University of New Mexico; Columbia University			Greten, Henry/A-3248-2012	Greten, Johannes/0000-0003-0196-4584				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; BERGER I, 1991, ONCOGENE, V6, P561; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BIERHAUS A, 1995, THROMB HAEMOSTASIS, V73, P39; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COLUCCI M, 1983, J CLIN INVEST, V71, P1893, DOI 10.1172/JCI110945; CONWAY EM, 1989, THROMB RES, V53, P231, DOI 10.1016/0049-3848(89)90098-4; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; CUNNINGHAM PR, 1990, BIOTECHNIQUES, V9, P713; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; DETOGNI P, 1988, MOL CELL BIOL, V8, P2251, DOI 10.1128/MCB.8.5.2251; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONOVANPALUSO O, 1994, J BIOL CHEM, V269, P1361; DRAKE TA, 1993, AM J PATHOL, V142, P1458; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; EDGINGTON TS, 1992, NOUV REV FR HEMATOLS, V34, P15; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAGEMEYER BM, 1993, EMBO J, V12, P3559; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HEMMER CJ, 1994, THROMB HAEMOSTASIS, V72, P457; HENTSCH B, 1992, NUCLEIC ACIDS RES, V20, P2675; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KONDO S, 1987, BLOOD, V70, P1947; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEE ME, 1991, J BIOL CHEM, V266, P19034; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MACKMAN N, 1993, AM J PATHOL, V143, P76; MANDECKI W, 1988, DNA-J MOLEC CELL BIO, V7, P57, DOI 10.1089/dna.1988.7.57; Maniatis T, 1989, DECONTAMINATION DILU; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P94; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAWROTH P, 1988, J EXP MED, V168, P637, DOI 10.1084/jem.168.2.637; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; NAWROTH PP, 1985, THROMB RES, V40, P677, DOI 10.1016/0049-3848(85)90305-6; NAWROTH PP, 1984, BLOOD, V64, P801; NEMERSON Y, 1988, BLOOD, V71, P1; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; PARRY GCN, 1994, FASEB J, V8, P5902; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; SCARPATI EM, 1987, BIOCHEMISTRY-US, V26, P5234, DOI 10.1021/bi00391a004; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHWARTZ SM, 1978, IN VITRO CELL DEV B, V14, P966, DOI 10.1007/BF02616210; SMITH SE, 1993, NUCLEIC ACIDS RES, V21, P1581, DOI 10.1093/nar/21.7.1581; Solberg S, 1990, Blood Coagul Fibrinolysis, V1, P595; STERN DM, 1985, J EXP MED, V162, P1223, DOI 10.1084/jem.162.4.1223; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WEIS JR, 1991, FASEB J, V5, P2459, DOI 10.1096/fasebj.5.10.2065893; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; ZHANG Y, 1995, IN PRESS J CLIN INVE; ZHANG YM, 1994, AM J PATHOL, V144, P51; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	80	128	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26419	26432		10.1074/jbc.270.44.26419	http://dx.doi.org/10.1074/jbc.270.44.26419			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592857	hybrid			2022-12-27	WOS:A1995TC97800064
J	LOFERER, H; WUNDERLICH, M; HENNECKE, H; GLOCKSHUBER, R				LOFERER, H; WUNDERLICH, M; HENNECKE, H; GLOCKSHUBER, R			A BACTERIAL THIOREDOXIN-LIKE PROTEIN THAT IS EXPOSED TO THE PERIPLASM HAS REDOX PROPERTIES COMPARABLE WITH THOSE OF CYTOPLASMIC THIOREDOXINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; DISULFIDE-ISOMERASE DSBA; BOND FORMATION INVIVO; REDUCTION OXIDATION; ACTIVE-SITE; SUBSTITUTION; EQUILIBRIUM; GLUTATHIONE; BIOGENESIS; MUTATION	The membrane-anchored thioredoxin-like protein (TlpA) from the Gram-negative soil bacterium Bradyrhizobium japonicum was initially discovered due to its essential role in the maturation of cytochrome aa,, A soluble form of TlpA lacking the N-terminal membrane anchor acts as a protein thiol:disulfide oxidoreductase. TlpA possesses an active-site disulfide bond common to all members of the thiol:disulfide oxidoreductase family, In addition, it contains two non-active-site cysteines that form a structural disulfide bond (Loferer, H,, Bott, M., and Hennecke, H, (1993) EMBO J. 12, 3373-3383 Loferer, H,, and Hennecke, H, (1994) fur. J, Biochem. 223, 339-344). Here, we compare the far- and near-UV CD spectra of TlpA before and after reduction of both disulfides by dithiothreitol and show that the non-active-site disulfide bond is not required for the integrity of TlpA's native conformation In contrast to dithiothreitol, reduced glutathione (GSH) selectively reduces the active-site disulfide and leaves the non active-site disulfide bond intact, even at high molar excess over TlpA The selective reduction of the active-site disulfide bond leads to a 10-fold increase of the intrinsic tryptophan fluorescence of TlpA at 555 nm, which may be interpreted as a quenching of tryptophan fluorescence by the active-site disulfide bond, Using the specific fluorescence of TlpA as a measure of its redox state, a value of 1.9 +/- 0.2 FA was determined for the TlpA:glutathione equilibrium constant at pH 7.0, demonstrating that TlpA is a reductant, like cytoplasmic thioredoxins. The DsbA protein, which acts as the final oxidant of periplasmic secretory proteins in Escherichia coli, is not capable of oxidizing the active-site cysteines of TlpA This suggests that TlpA's primary role in vivo is keeping the thiols of certain proteins reduced and that TIpA's active, reduced state may be maintained owing to its kinetically restricted oxidation by other periplasmic disulfide oxidoreductases such as DsbA.	ETH ZURICH,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND; ETH ZURICH,INST MIKROBIOL,CH-8093 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich								BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BECKMAN DL, 1993, P NATL ACAD SCI USA, V90, P2179, DOI 10.1073/pnas.90.6.2179; BERGLUND O, 1970, J BIOL CHEM, V245, P6030; BOTT M, 1990, MOL MICROBIOL, V4, P2147, DOI 10.1111/j.1365-2958.1990.tb00576.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Gilbert HF, 1994, MECH PROTEIN FOLDING, P104; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLEASON FK, 1992, PROTEIN SCI, V1, P609, DOI 10.1002/pro.5560010507; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOLMGREN A, 1980, BIOCHEMISTRY-US, V20, P3204; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KELLY M, 1993, J BIOL CHEM, V268, P16781; KRAUSE G, 1991, J BIOL CHEM, V266, P4056; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOFERER H, 1993, EMBO J, V12, P3373, DOI 10.1002/j.1460-2075.1993.tb06011.x; LOFERER H, 1994, EUR J BIOCHEM, V223, P339, DOI 10.1111/j.1432-1033.1994.tb18999.x; LOFERER H, 1994, TRENDS BIOCHEM SCI, V19, P169, DOI 10.1016/0968-0004(94)90279-8; LUNDSTROM J, 1993, BIOCHEMISTRY-US, V32, P6649, DOI 10.1021/bi00077a018; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; THONYMEYER L, 1994, MOL MICROBIOL, V12, P1, DOI 10.1111/j.1365-2958.1994.tb00988.x; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, J BIOL CHEM, V268, P24547; WUNDERLICH M, 1993, J MOL BIOL, V233, P559, DOI 10.1006/jmbi.1993.1535; WUNDERLICH M, 1993, BIOCHEMISTRY-US, V32, P12251, DOI 10.1021/bi00096a039; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	36	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26178	26183		10.1074/jbc.270.44.26178	http://dx.doi.org/10.1074/jbc.270.44.26178			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592822	hybrid			2022-12-27	WOS:A1995TC97800029
J	OOSTVEEN, FG; AU, HC; MEIJER, PJ; SCHEFFLER, IE				OOSTVEEN, FG; AU, HC; MEIJER, PJ; SCHEFFLER, IE			A CHINESE-HAMSTER MUTANT-CELL LINE WITH A DEFECT IN THE INTEGRAL MEMBRANE-PROTEIN C-II-3 OF COMPLEX-II OF THE MITOCHONDRIAL ELECTRON-TRANSPORT CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCCINATE-DEHYDROGENASE ACTIVITY; HUMAN CHROMOSOME-1; CENTROMERE; GENE	In this study, a respiration-deficient Chinese hamster cell line with a defect in succinate dehydrogenase activity is shown to result from a single base change in a codon in the coding sequence for the membrane anchor protein C-II-3 (also referred to as QPs-1). A premature translation stop results in the truncation of 33 amino acids from the C terminus. Bovine cDNA encoding this peptide complements the mutation. There is about 82% identity between these two mammalian proteins. The gene for C-II-3 was mapped on human chromosome 1, and because it is also found on minichromosomes characterized by our laboratory, we can localize it on the short arm within 1-2 megabases from the centromere.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033752] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33752] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKRELL BAC, 1992, CHEM BIOCH FLAVOENZY, P229; AU HC, 1995, GENE, V159, P249, DOI 10.1016/0378-1119(95)00162-Y; CARINE K, 1986, SOMAT CELL MOLEC GEN, V12, P479, DOI 10.1007/BF01539919; CARINE K, 1989, SOMAT CELL MOLEC GEN, V15, P445, DOI 10.1007/BF01534895; COCHRAN B, 1994, BBA-BIOENERGETICS, V1188, P162, DOI 10.1016/0005-2728(94)90035-3; CROCE CM, 1976, P NATL ACAD SCI USA, V73, P3248, DOI 10.1073/pnas.73.9.3248; DITTA G, 1976, SOMAT CELL GENET, V2, P331, DOI 10.1007/BF01538838; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOULD SJ, 1989, P NATL ACAD SCI USA, V86, P1934, DOI 10.1073/pnas.86.6.1934; GREEN JD, 1980, J HISTOCHEM CYTOCHEM, V28, P408, DOI 10.1177/28.5.6966645; Hatefi Y, 1979, Methods Enzymol, V56, P577; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; LECKSCHAT S, 1993, SOMAT CELL MOLEC GEN, V19, P505, DOI 10.1007/BF01233256; Maniatis T., 1982, MOL CLONING; MASCARELLO JT, 1980, CYTOGENET CELL GENET, V28, P121, DOI 10.1159/000131520; MILPETZ F, 1995, TRENDS BIOCHEM SCI, V20, P204, DOI 10.1016/S0968-0004(00)89009-X; OHNISHI T, 1987, CURR TOP BIOENERG, V15, P37; PILZ RB, 1990, J BIOL CHEM, V265, P8880; SAGHBINI M, 1994, BIOCHEMISTRY-US, V33, P159, DOI 10.1021/bi00167a021; Scheffler I E, 1989, Prog Clin Biol Res, V318, P19; SCHEFFLER IE, 1986, CARBOHYD METABOL, P77; SCHEFFLER LE, 1981, BIOMEDICAL CLIN ASPE, P245; SCHMIDT DM, 1992, BIOCHEMISTRY-US, V31, P86442; SINGER TP, 1985, FEBS LETT, V190, P189, DOI 10.1016/0014-5793(85)81282-5; SODERBERG K, 1979, SOMAT CELL GENET, V5, P225, DOI 10.1007/BF01539163; SODERBERG KL, 1977, CELL, V10, P697, DOI 10.1016/0092-8674(77)90103-9; YU L, 1992, J BIOL CHEM, V267, P24508	28	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26104	26108		10.1074/jbc.270.44.26104	http://dx.doi.org/10.1074/jbc.270.44.26104			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592812	hybrid			2022-12-27	WOS:A1995TC97800019
J	CHARRON, G; JULIEN, JP; BIBORHARDY, V				CHARRON, G; JULIEN, JP; BIBORHARDY, V			NEURON SPECIFICITY OF THE NEUROFILAMENT LIGHT PROMOTER IN TRANSGENIC MICE REQUIRES THE PRESENCE OF DNA UNWINDING ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAFFOLD-ATTACHED REGIONS; BETA-GLOBIN GENE; NUCLEAR MATRIX; DROSOPHILA-MELANOGASTER; REGULATORY ELEMENTS; CHROMOSOMAL DOMAINS; REPLICATION ORIGIN; TORSIONAL STRESS; CHAIN GENE; EXPRESSION	Three reporter genes, the chloramphenicol acetyltransferase (CAT), the lacZ, and the intronless NF-L DNA, were used to test the activity of the proximal promoter region (-292 bp) of the human neurofilament light (hNF-L) gene in transgenic mice. Surprisingly, the hNF-L/CAT construct was highly sensitive to position effect, and its expression was found at low levels in several tissues of adult transgenic mice (Beaudet, L., Charron, G., Houle, D., Tretjakoff, I. Peterson, A., and Julien, J.-P. (1992) Gene (Amst,) 116, 205-214). In contrast, the hNF-L/lacZ or the hNF-L/intronless constructs were expressed exclusively in the nervous system during embryonic development and in adult animals, The DNA sequences analysis of the different reporter genes revealed the presence of matrix attachment regions (MARs) within the 3'-untranslated regions of all three transgenes, DNA unwinding elements were found within the MARs of lacZ and hNF-L gene constructs but not in the CAT gene construct, When this element was removed hom the lacZ construct, expression of the hNF-L/lacZ transgene became susceptible to position effect and was no longer tissue-specific. These results indicate that DNA unwinding elements are essential for position effect independence conferred by MARs to the hNF-L basal promoter.	CTR RECH LOUIS CHARLES SIMARD,INST CANC MONTREAL,MONTREAL,PQ H2L 4M1,CANADA; MONTREAL GEN HOSP,RES INST,MONTREAL,PQ H3G 1A4,CANADA	Universite de Montreal; McGill University								ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; ALLEN ND, 1988, NATURE, V333, P852, DOI 10.1038/333852a0; AMATI B, 1990, MOL CELL BIOL, V10, P5442, DOI 10.1128/MCB.10.10.5442; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BEAUDET L, 1992, GENE, V116, P205, DOI 10.1016/0378-1119(92)90517-S; BEAUDET L, 1992, BIOCHEM CELL BIOL, V70, P279, DOI 10.1139/o92-044; BEREZNEY R, 1991, J CELL BIOCHEM, V47, P109, DOI 10.1002/jcb.240470204; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; CANTOR CR, 1984, NUCLEIC ACIDS RES, V12, P8059, DOI 10.1093/nar/12.21.8059; CAO SX, 1988, EUR J BIOCHEM, V173, P517, DOI 10.1111/j.1432-1033.1988.tb14028.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOPHE D, 1985, NUCLEIC ACIDS RES, V13, P5127, DOI 10.1093/nar/13.14.5127; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; FRIED M, 1983, P NATL ACAD SCI-BIOL, V80, P2117, DOI 10.1073/pnas.80.8.2117; GARRARD WT, 1990, NUCL ACIDS MOL BIOL, P163; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GORMAN C, 1985, DNA CLONING PRACTICA, V1, P143; GOULD SJ, 1988, ANAL BIOCHEM, V175, P5, DOI 10.1016/0003-2697(88)90353-3; HAMADA H, 1986, MOL CELL BIOL, V6, P4179, DOI 10.1128/MCB.6.12.4179; HOPE IA, 1991, DEVELOPMENT, V113, P399; HUANG RY, 1993, EMBO J, V12, P4521, DOI 10.1002/j.1460-2075.1993.tb06141.x; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JULIEN JP, 1987, GENE DEV, V1, P1085, DOI 10.1101/gad.1.10.1085; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KOHWISHIGEMATSU T, 1985, CELL, V43, P199, DOI 10.1016/0092-8674(85)90024-8; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; KOWALSKI D, 1989, EMBO J, V8, P4335, DOI 10.1002/j.1460-2075.1989.tb08620.x; KUSMIEREK JT, 1982, BIOCHEMISTRY-US, V21, P5717, DOI 10.1021/bi00265a050; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; MARGOT JB, 1985, J MOL BIOL, V184, P195, DOI 10.1016/0022-2836(85)90373-0; MCCARTHY JG, 1987, NUCLEIC ACIDS RES, V15, P8069, DOI 10.1093/nar/15.19.8069; MCKEON C, 1984, J BIOL CHEM, V259, P6636; MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943, DOI 10.1073/pnas.89.15.6943; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MIRKOVITCH J, 1988, J MOL BIOL, V200, P101, DOI 10.1016/0022-2836(88)90336-1; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; NATALE DA, 1993, NUCLEIC ACIDS RES, V21, P555, DOI 10.1093/nar/21.3.555; NICKOL JM, 1983, CELL, V35, P467, DOI 10.1016/0092-8674(83)90180-0; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; POMMIER Y, 1990, J VIROL, V64, P419, DOI 10.1128/JVI.64.1.419-423.1990; REYNOLDS WF, 1985, P NATL ACAD SCI USA, V82, P4018, DOI 10.1073/pnas.82.12.4018; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; RUIZCARRILLO A, 1984, NUCLEIC ACIDS RES, V12, P6473, DOI 10.1093/nar/12.16.6473; Sambrook J, 1989, MOL CLONING LABORATO; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SILHAVY TJ, 1984, EXPT GENE FUSIONS LA, P266; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; UMEK RM, 1988, CANCER CELL, V6, P473; URDEA MS, 1988, NUCLEIC ACIDS RES, V16, P4937, DOI 10.1093/nar/16.11.4937; WANG JNC, 1985, J BIOL CHEM, V260, P8194; WEBER F, 1984, CELL, V36, P983, DOI 10.1016/0092-8674(84)90048-5; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791; YAZDANBAKHSH K, 1993, NUCLEIC ACIDS RES, V21, P455, DOI 10.1093/nar/21.3.455	70	11	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25739	25745		10.1074/jbc.270.43.25739	http://dx.doi.org/10.1074/jbc.270.43.25739			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592755	hybrid			2022-12-27	WOS:A1995TB46600072
J	KHISTY, VJ; MUNSKE, GR; RANDALL, LL				KHISTY, VJ; MUNSKE, GR; RANDALL, LL			MAPPING OF THE BINDING FRAME FOR THE CHAPERONE SECB WITHIN A NATURAL LIGAND, GALACTOSE-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MALTOSE-BINDING; LEADER PEPTIDE; EXPORT; RECOGNITION; RECEPTOR; INVIVO	The chaperone SecB selectively binds polypeptides that are in a non-native state; however, the details of the interaction between SecB and its ligands are unknown. As a step in elucidation of the molecular mechanism of binding, we have mapped the region of a physiologic ligand (galactose-binding protein) that is in contact with SecB. The binding frame comprises similar to 160 amino-acyl residues and is located in the central portion of the primary sequence. Comparison to the binding frame within maltose-binding protein, which is similarly long and positioned around the center of that polypeptide, reveals no similarity in sequence or in folding motif. The results are consistent with the proposal that the selectivity in binding exhibited by SecB is based on the simultaneous occupancy of multiple binding sites, each of which demonstrates low specificity, by flexible stretches of polypeptide that are only accessible in nonnative proteins.	WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164	Washington State University					NIGMS NIH HHS [GM 29798] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029798, R37GM029798] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; COLLIER DN, 1993, ADV PROTEIN CHEM, V44, P151, DOI 10.1016/S0065-3233(08)60567-7; FLORES TP, 1994, PROTEIN ENG, V7, P31, DOI 10.1093/protein/7.1.31; HEPPEL LA, 1971, STRUCTURE FUNCTION B, P223; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; KHISTY VJ, 1995, J BACTERIOL, V177, P3277, DOI 10.1128/jb.177.11.3277-3282.1995; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; Mowbray S L, 1990, Receptor, V1, P41; POWERS EL, 1995, J BACTERIOL, V177, P1906, DOI 10.1128/jb.177.7.1906-1907.1995; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; RANDALL LL, 1977, EUR J BIOCHEM, V75, P43, DOI 10.1111/j.1432-1033.1977.tb11502.x; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; TOPPING TB, 1994, PROTEIN SCI, V3, P730; WEISS JB, 1990, J BACTERIOL, V172, P3023, DOI 10.1128/jb.172.6.3023-3029.1990	22	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25920	25927		10.1074/jbc.270.43.25920	http://dx.doi.org/10.1074/jbc.270.43.25920			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592780	hybrid			2022-12-27	WOS:A1995TB46600097
J	ROSSAK, M; TIETJE, C; HEINZ, E; BENNING, C				ROSSAK, M; TIETJE, C; HEINZ, E; BENNING, C			ACCUMULATION OF UDP-SULFOQUINOVOSE IN A SULFOLIPID-DEFICIENT MUTANT OF RHODOBACTER-SPHAEROIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLASTS; BIOSYNTHESIS	The sulfolipid 6-sulfo-alpha-D-quinovosyl diacylglycerol is found in the photosynthetic membranes of all plants and most photosynthetic bacteria. Progress toward the elucidation of the pathway for sulfolipid biosynthesis has been slow in the past. However, the recent isolation of three genes of the photosynthetic bacterium Rhodobacter sphaeroides known to be involved in sulfo-lipid biosynthesis provides promising new opportunities. Two of the genes flank an open reading frame predicted to encode a protein with amino acid sequence similarity to sugar nucleotide-dependent glycosyltransferases. The UDP-sulfoquinovose:diacylglycerol sulfoquinovosyltransferase thought to catalyze the last step of sulfolipid biosynthesis belongs to this group of glycosyltransferases. To test whether this open reading frame encodes the sulfoquinovosyltransferase of R. sphaeroides, it was inactivated by gene replacement avoiding polar mutagenesis. The resulting sulfolipid-deficient mutant defines a new gene, designated sqdD. Mutant cells grown in the presence of [S-35]sulfate accumulate a water-soluble S-35-labeled compound. The purified compound was tentatively identified by co-chromatography with standards and enzymatic conversion as UDP-sulfoquinovose, the final precursor of sulfolipid biosynthesis. This result strongly suggests that the inactivation of sqdD causes a metabolic block in the last step of sulfolipid biosynthesis.	INST GENBIOL FORSCH BERLIN GMBH,D-14195 BERLIN,GERMANY; UNIV HAMBURG,INST ALLGEMEINE BOT,D-22609 HAMBURG,GERMANY	University of Hamburg			Benning, Christoph/Y-2528-2019	Benning, Christoph/0000-0001-8585-3667				BENNING C, 1992, J BACTERIOL, V174, P6479, DOI 10.1128/JB.174.20.6479-6487.1992; BENNING C, 1992, J BACTERIOL, V174, P2352, DOI 10.1128/JB.174.7.2352-2360.1992; BENSON AA, 1959, P NATL ACAD SCI USA, V45, P1582, DOI 10.1073/pnas.45.11.1582; BENSON AA, 1963, ADV LIPID RES, V1, P387; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; DALDAL F, 1986, P NATL ACAD SCI USA, V83, P2012, DOI 10.1073/pnas.83.7.2012; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; HAAS R, 1980, PLANTA, V148, P238, DOI 10.1007/BF00380033; Harwood J. L., 1980, The biochemistry of plants. A comprehensive treatise. Volume 4. Lipids: structure and function., P301; HEINZ E, 1989, EUR J BIOCHEM, V184, P445, DOI 10.1111/j.1432-1033.1989.tb15037.x; HOCH M, 1989, CARBOHYD RES, V191, P21, DOI 10.1016/0008-6215(89)85043-8; IMHOFF JF, 1982, J BACTERIOL, V150, P1192, DOI 10.1128/JB.150.3.1192-1201.1982; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MILLS WR, 1980, PLANTA, V148, P75, DOI 10.1007/BF00385445; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, V2, P1190; SEIFERT U, 1992, BOT ACTA, V105, P197, DOI 10.1111/j.1438-8677.1992.tb00287.x; SHIBUYA ISAO, 1963, P627; Simon R., 1983, BIOTECHNOLOGY, V1, P37; SISTROM WR, 1962, J GEN MICROBIOL, V28, P607, DOI 10.1099/00221287-28-4-607; SISTROM WR, 1960, J GEN MICROBIOL, V22, P778, DOI 10.1099/00221287-22-3-778; van Niel CB, 1944, BACTERIOL REV, V8, P1	22	27	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25792	25797		10.1074/jbc.270.43.25792	http://dx.doi.org/10.1074/jbc.270.43.25792			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592762	hybrid			2022-12-27	WOS:A1995TB46600079
J	ARGAUD, D; LANGE, AJ; BECKER, TC; OKAR, DA; ELMAGHRABI, MR; NEWGARD, CB; PILKIS, SJ				ARGAUD, D; LANGE, AJ; BECKER, TC; OKAR, DA; ELMAGHRABI, MR; NEWGARD, CB; PILKIS, SJ			ADENOVIRUS-MEDIATED OVEREXPRESSION OF LIVER 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE IN GLUCONEOGENIC RAT HEPATOMA-CELLS - PARADOXICAL EFFECT ON FRU-2,6-P(2) LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE; MESSENGER-RNA; PYRUVATE-KINASE; HEPATOCYTES; INHIBITION; GLYCOLYSIS; METABOLISM; INSULIN	6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase has been postulated 60 be a metabolic signaling enzyme, which acts as a switch between glycolysis and gluconeogenesis in mammalian liver by regulating the level of fructose 2,6-bisphosphate, The effect of overexpressing the bifunctional enzyme was studied in FAO cells transduced with recombinant adenoviral constructs of either the wild-type enzyme or a double mutant that has no bisphosphatase activity or protein kinase phosphorylation site, With both constructs, the mRNA and protein were overexpressed by 150- and 40-fold, respectively, Addition of cAMP to cells overexpressing the wild-type enzyme increased the S-0.5 for fructose 6-phosphate of the kinase by 1.5 fold but had no effect on the overexpressed double mutant, When the wild-type enzyme was overexpressed, there was a decrease in fructose 2,6-bisphosphate levels, even though 6-phosphofructo-2-kinase maximal activity increased more than 22 fold and was in excess of fructose 2,6-bisphosphatase maximal activity, The kinase:bisphosphatase maximal activity ratio was decreased, indicating that the overexpressed enzyme was phosphorylated by cAMP-dependent protein kinase, Overexpression of the double mutant resulted in a 28-fold increase in kinase maximal activity and a 3-4 fold increase in fructose 2,6-bisphosphate levels, Overexpression of this form inhibited the rate of glucose production from dihydroxyacetone by 90% and stimulated the rate of lactate plus pyruvate production by 200%, In contrast, overexpression of the wild-type enzyme enhanced glucose production and inhibited lactate plus pyruvate production, These results provide direct support for fructose 2,6-bisphosphate as a regulator of gluconeogenic/glycolytic pathway flux and suggest that regulation of bifunctional enzyme activities by covalent modification is more important than the amount of the protein.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM & INTERNAL MED,DALLAS,TX 75235	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ARGAUD, D (corresponding author), UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038354, R01DK038354, R01DK046492, R37DK046492] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38354, DK-46492] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGAUD D, 1991, BIOCHEM J, V280, P663, DOI 10.1042/bj2800663; ARGAUD D, 1993, EUR J BIOCHEM, V213, P1341, DOI 10.1111/j.1432-1033.1993.tb17886.x; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BECKER TC, 1994, J BIOL CHEM, V269, P21234; Bergmeyer H., 1974, METHOD ENZYMAT AN, V3, P1125; BERTOLOTTI R, 1977, SOMAT CELL GENET, V3, P365, DOI 10.1007/BF01542966; CLAUS TH, 1984, BIOCHEM BIOPH RES CO, V125, P655, DOI 10.1016/0006-291X(84)90589-8; CLEVELAND DW, 1980, CELL, V20, P85; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DESCHATRETTE J, 1979, SOMAT CELL GENET, V5, P697, DOI 10.1007/BF01542636; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; ELMAGHRABI MR, 1982, J BIOL CHEM, V257, P7603; ESPINET C, 1993, BIOCHEM J, V293, P173, DOI 10.1042/bj2930173; EXTON JH, 1967, J BIOL CHEM, V242, P2622; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Gluzman Y., 1982, EUKARYOTIC VIRAL VEC, P187; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HALESTRAP AP, 1986, HORMONAL CONTROL GLU, P31; HOD Y, 1984, J BIOL CHEM, V259, P5603; HOD Y, 1992, BIOTECHNIQUES, V13, P852; ISHIHARA H, 1994, J BIOL CHEM, V269, P3081; KAHN CR, 1989, MOL ENDOCRINOL, V3, P840, DOI 10.1210/mend-3-5-840; KURLAND IJ, 1992, J BIOL CHEM, V267, P4416; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MURRAY KJ, 1984, J BIOL CHEM, V259, P7673; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PILKIS SJ, 1987, J BIOL CHEM, V262, P12672; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; PILKIS SJ, 1981, J BIOL CHEM, V256, P3171; PROBST I, 1985, EUR J BIOCHEM, V153, P347, DOI 10.1111/j.1432-1033.1985.tb09309.x; RIOU JP, 1978, J BIOL CHEM, V253, P656; ROSA JL, 1995, IN PRESS BIOCH J; ROSELLA G, 1993, MOL ENDOCRINOL, V7, P1456, DOI 10.1210/me.7.11.1456; SCHAMHART DHJ, 1979, CANCER RES, V39, P1051; TAULER A, 1990, J BIOL CHEM, V265, P15617; VALERA A, 1994, EUR J BIOCHEM, V222, P533, DOI 10.1111/j.1432-1033.1994.tb18895.x; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P2861; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VANSCHAFTINGEN E, 1990, FRUCTOSE 2 6 BISPHOS, P65; VARGAS AM, 1994, DIABETES, V43, P792, DOI 10.2337/diabetes.43.6.792; VENEZIALE CM, 1976, GLUCONEOGENESIS ITS, P463; WEINHOUSE S, 1972, CANCER RES, V32, P2007	47	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24229	24236		10.1074/jbc.270.41.24229	http://dx.doi.org/10.1074/jbc.270.41.24229			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592629	hybrid			2022-12-27	WOS:A1995TA21700057
J	BACOLLA, A; ULRICH, MJ; LARSON, JE; LEY, TJ; WELLS, RD				BACOLLA, A; ULRICH, MJ; LARSON, JE; LEY, TJ; WELLS, RD			AN INTRAMOLECULAR TRIPLEX IN THE HUMAN GAMMA-GLOBIN 5'-FLANKING REGION IS ALTERED BY POINT MUTATIONS ASSOCIATED WITH HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOPURINE-HOMOPYRIMIDINE SEQUENCES; SUPERCOILED PLASMID DNA; PURINE-PURINE TRIPLEX; SIMIAN VIRUS 40; MYOTONIC-DYSTROPHY; CTG REPEAT; B-DNA; GENE; STABILITY; HELIX	The properties of an intramolecular tripler formed in vitro at the 5'-flanking region of the human gamma-globin genes were studied by chemical and physical probes, Chemical modifications performed with osmium tetroxide, chloroacetaldehyde, and diethyl pyrocarbonate revealed the presence of non-paired nucleotides on the ''coding strand'' at positions -209 through -217, These reactivities were induced by negative supercoiling, low pH, and magnesium ions, Downstream point mutations associated with hereditary persistence of fetal hemoglobin (HPFH) altered the extent of the modifications and some of the patterns, Specifically, C-202 --> G and C-202 --> T significantly decreased the reactivities, whereas the patterns were increased and altered in the T-198 --> C, C-196 --> T and C-195 --> G caused local decreases in reactivity, Modifications at the upstream flanking duplex were modulated by the composition of the vector sequence, In summary, our data indicates the formation of an intramolecular tripler between nucleotides -209 to -217 of the ''non-coding strand'' and the downstream sequence containing the HPFH mutations, All of the HPFH point mutations altered the structure, More than one sequence alignment is possible for each of the triplexes, In addition, a consequence of some of the point mutations may be to facilitate slippage of the third strand relative to the Watson-Crick duplex.	TEXAS A&M UNIV,TEXAS MED CTR,INST BIOSCI & TECHNOL,HOUSTON,TX 77030; WASHINGTON UNIV,MED CTR,DEPT MED,DIV BONE MARROW TRANSPLANTAT & STEM CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,MED CTR,DEPT GENET,ST LOUIS,MO 63110	Baylor College of Medicine; Texas A&M University System; Washington University (WUSTL); Washington University (WUSTL)			Bacolla, Albino/N-3877-2013; Bacolla, Albino/AAP-1727-2020	Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49786] Funding Source: Medline; NIGMS NIH HHS [GM52982] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACOLLA A, 1991, NUCLEIC ACIDS RES, V19, P1639, DOI 10.1093/nar/19.7.1639; BEHE MJ, 1995, NUCLEIC ACIDS RES, V23, P689, DOI 10.1093/nar/23.4.689; BENEZRA R, 1986, CELL, V44, P697, DOI 10.1016/0092-8674(86)90835-4; BERRY M, 1992, NATURE, V358, P499, DOI 10.1038/358499a0; BOWATER RP, 1994, BIOCHEMISTRY-US, V33, P9266, DOI 10.1021/bi00197a030; BRESNICK EH, 1994, P NATL ACAD SCI USA, V91, P1314, DOI 10.1073/pnas.91.4.1314; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BRUKNER I, 1994, J MOL BIOL, V236, P26, DOI 10.1006/jmbi.1994.1115; BUCKLE M, 1991, METHOD ENZYMOL, V208, P236; CARBONNAUX C, 1991, BIOCHEMISTRY-US, V30, P5449, DOI 10.1021/bi00236a018; COCKELL M, 1994, NUCLEIC ACIDS RES, V22, P32, DOI 10.1093/nar/22.1.32; COLLIER DA, 1988, J BIOL CHEM, V263, P7397; COLLINS FS, 1984, PROG NUCLEIC ACID RE, V31, P315, DOI 10.1016/S0079-6603(08)60382-7; DITTRICH K, 1994, BIOCHEMISTRY-US, V33, P4111, DOI 10.1021/bi00180a003; DURLAND RH, 1994, NUCLEIC ACIDS RES, V22, P3233, DOI 10.1093/nar/22.15.3233; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GIFFIN W, 1994, J BIOL CHEM, V269, P1449; GIMBLE JM, 1988, BLOOD, V72, P606; HANVEY JC, 1989, J BIOL CHEM, V264, P5950; HORWITZ EM, 1994, J BIOL CHEM, V269, P14130; HUISMAN THJ, 1992, HEMOGLOBIN, V16, P237, DOI 10.3109/03630269208998865; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; INMAN RB, 1964, J MOL BIOL, V9, P624, DOI 10.1016/S0022-2836(64)80171-6; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG S, 1992, J BIOL CHEM, V267, P1259; KANG S, 1995, IN PRESS J BIOL CHEM; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KLYSIK J, 1995, J MOL BIOL, V245, P499, DOI 10.1006/jmbi.1994.0041; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWISHIGEMATSU T, 1992, METHOD ENZYMOL, V212, P155; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEE JS, 1989, GENE, V82, P191, DOI 10.1016/0378-1119(89)90044-9; LEONARD GA, 1990, NUCLEIC ACIDS RES, V18, P5617, DOI 10.1093/nar/18.19.5617; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; LU GH, 1993, INT J BIOCHEM, V25, P1529, DOI 10.1016/0020-711X(93)90508-C; LUKOMSKI S, 1994, P NATL ACAD SCI USA, V91, P9980, DOI 10.1073/pnas.91.21.9980; MACAYA RF, 1991, SCIENCE, V254, P270, DOI 10.1126/science.1925581; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MALKOV VA, 1993, NUCLEIC ACIDS RES, V21, P585, DOI 10.1093/nar/21.3.585; MALKOV VA, 1993, NUCLEIC ACIDS RES, V21, P105, DOI 10.1093/nar/21.1.105; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PALECEK E, 1992, METHOD ENZYMOL, V212, P139; RADHAKRISHNAN I, 1994, BIOCHEMISTRY-US, V33, P11405, DOI 10.1021/bi00204a001; REDDY PMS, 1994, J BIOL CHEM, V269, P8287; ROONEY SM, 1995, P NATL ACAD SCI USA, V92, P2141, DOI 10.1073/pnas.92.6.2141; Sambrook J, 1989, MOL CLONING LABORATO; SHIMIZU M, 1994, J MOL BIOL, V235, P185, DOI 10.1016/S0022-2836(05)80025-7; SINDEN RR, 1994, DNA STRUCTURE FUNCTI, P134; STARCK J, 1994, BLOOD, V84, P1656; TATE VE, 1986, BLOOD, V68, P1389; TUNG CH, 1993, NUCLEIC ACIDS RES, V21, P5489, DOI 10.1093/nar/21.23.5489; ULRICH MJ, 1992, J BIOL CHEM, V267, P18649; WASHBROOK E, 1994, NUCLEIC ACIDS RES, V22, P3977, DOI 10.1093/nar/22.19.3977; WELLS RD, 1972, J BIOL CHEM, V247, P3405; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; YAMAZOE M, 1994, J BIOL CHEM, V269, P15244; 1993, CELL, V72, P971	64	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24556	24563		10.1074/jbc.270.41.24556	http://dx.doi.org/10.1074/jbc.270.41.24556			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592674	hybrid			2022-12-27	WOS:A1995TA21700102
J	DELL, A; MORRIS, HR; EASTON, RL; PANICO, M; PATANKAR, M; OEHNINGER, S; KOISTINEN, R; KOISTINEN, H; SEPPALA, M; CLARK, GF				DELL, A; MORRIS, HR; EASTON, RL; PANICO, M; PATANKAR, M; OEHNINGER, S; KOISTINEN, R; KOISTINEN, H; SEPPALA, M; CLARK, GF			STRUCTURAL-ANALYSIS OF THE OLIGOSACCHARIDES DERIVED FROM GLYCODELIN, A HUMAN GLYCOPROTEIN WITH POTENT IMMUNOSUPPRESSIVE AND CONTRACEPTIVE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLACENTAL PROTEIN-14; LINKED OLIGOSACCHARIDES; MASS-SPECTROMETRY; CARBOHYDRATE-STRUCTURE; CELL ACTIVATION; ADHESION; CD22; RECOGNITION; PP14; PHYTOHEMAGGLUTININ	Glycodelin, also known as placental protein 14 (PP14) or progesterone-associated endometrial protein (PAEP), is a human glycoprotein with potent immunosuppressive and contraceptive activities. In this paper we report the first characterization of glycodelin-derived oligosaccharides. Using strategies based upon fast atom bombardment and electrospray mass spectrometry we have established that glycodelin is glycosylated at Asn-28 and Asn-63. The Asn-28 site carries high mannose, hybrid and complex-type structures, whereas the second site is exclusively occupied by complex-type glycans. The major non-reducing epitopes in the complex-type glycans are: Gal beta 1-4GlcNAc (lacNAc), GalNAc beta 1-4GlcNAc (lacdiNAc), NeuAc alpha 2-GGal beta 1-4GlcNAc (sialylated lacNAc), NeuAc alpha 2-6GalNAc beta 1-4GlcNAc (sialylated lacdiNAc), Gal beta 1-4(Fuc alpha 1-3)GlcNAc (Lewis(x)), and GalNAc beta 1-4(Fuc alpha 1-3)GlcNAc (lacdiNAc analogue of Lewis(x)). It is possible that the oligosaccharides bearing sialylated lacNAc or lacdiNAc antennae may manifest immunosuppressive effects by specifically blocking adhesive and activation-related events mediated by CD22, the human B cell associated receptor. Oligosaccharides with fucosylated lacdiNAc antennae have previously been shown to potently block selectin-mediated adhesions and may perform the same function in glycodelin, The potent inhibitory effect of glycodelin on initial human sperm-zona pellucida binding is consistent with our previous suggestion that this cell adhesion event requires a selectin-like adhesion process. This result also raises the possibility that a convergence between immune and gamete recognition processes may have occurred in the types of carbohydrate ligands recognized in the human.	EASTERN VIRGINIA MED SCH, DEPT BIOCHEM, NORFOLK, VA 23501 USA; EASTERN VIRGINIA MED SCH, DEPT OBSTET & GYNECOL, NORFOLK, VA 23501 USA; UNIV HELSINKI, CENT HOSP, DEPT OBSTET & GYNECOL, SF-00290 HELSINKI, FINLAND	Eastern Virginia Medical School; Eastern Virginia Medical School; University of Helsinki; Helsinki University Central Hospital	DELL, A (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND.		Oehninger, Sergio/AAZ-8443-2020; Koistinen, Hannu/AGU-1279-2022; Seppala, Markku/AAT-6618-2021	Koistinen, Hannu/0000-0003-0926-3109; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BERG EL, 1991, J BIOL CHEM, V266, P14869; BERGWERFF AA, 1992, FEBS LETT, V314, P389, DOI 10.1016/0014-5793(92)81512-K; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; Bohn H, 1982, Placenta Suppl, V4, P67; BOLTON AE, 1987, LANCET, V1, P593; CHAN A L, 1991, Glycobiology, V1, P173, DOI 10.1093/glycob/1.2.173; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; CLARK EA, 1993, J IMMUNOL, V150, P4715; CLARK GF, 1995, J ASSIST REPROD GEN, V12, P475; CLARK GF, 1995, IN PRESS HUM REPROD; CODDEVILLE B, 1992, CARBOHYD RES, V236, P145, DOI 10.1016/0008-6215(92)85013-P; DELL A, 1983, CARBOHYD RES, V115, P41, DOI 10.1016/0008-6215(83)88133-6; DELL A, 1994, METHOD ENZYMOL, V230, P108; DELL A, 1993, CURR OPIN STRUC BIOL, V3, P687, DOI 10.1016/0959-440X(93)90051-L; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; GEDDES AJ, 1969, BIOCHEM J, V114, P695, DOI 10.1042/bj1140695; GRINNELL BW, 1994, GLYCOBIOLOGY, V4, P221, DOI 10.1093/glycob/4.2.221; JULKUNEN M, 1986, FERTIL STERIL, V45, P47; JULKUNEN M, 1986, ENDOCRINOLOGY, V118, P1782, DOI 10.1210/endo-118-5-1782; JULKUNEN M, 1988, P NATL ACAD SCI USA, V85, P8845, DOI 10.1073/pnas.85.23.8845; JULKUNEN M, 1985, BRIT J OBSTET GYNAEC, V92, P1145, DOI 10.1111/j.1471-0528.1985.tb03027.x; KAMARAINEN M, 1994, BLOOD, V84, P467; KHOO KH, 1993, CARBOHYD RES, V244, P205, DOI 10.1016/0008-6215(83)85002-2; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEDBETTER JA, 1993, CURR OPIN IMMUNOL, V5, P334, DOI 10.1016/0952-7915(93)90050-3; LEMAIRE S, 1982, BIOCHEM BIOPH RES CO, V108, P51, DOI 10.1016/0006-291X(82)91830-7; LOCHNIT G, 1995, EUR J BIOCHEM, V228, P805, DOI 10.1111/j.1432-1033.1995.tb20326.x; MACEK MB, 1988, GAMETE RES, V20, P93, DOI 10.1002/mrd.1120200109; MAHONY MC, 1991, CONTRACEPTION, V44, P657, DOI 10.1016/0010-7824(91)90085-T; MERKLE RK, 1994, METHOD ENZYMOL, V230, P1; MILLER DJ, 1990, MOL REPROD DEV, V26, P184, DOI 10.1002/mrd.1080260213; MORRIS HR, 1971, BIOCHEM J, V125, P189, DOI 10.1042/bj1250189; MORRIS HR, 1983, BIOCHEM BIOPH RES CO, V117, P299, DOI 10.1016/0006-291X(83)91575-9; MORRIS HR, 1978, J BIOL CHEM, V253, P5155; MORROW DM, 1994, AM J PATHOL, V145, P1485; NAKATA N, 1993, BIOCHEMISTRY-US, V32, P4369, DOI 10.1021/bi00067a029; OEHNINGER S, 1995, FERTIL STERIL, V63, P377; OEHNINGER S, 1991, FERTIL STERIL, V55, P165; OKAMOTO N, 1991, AM J REPROD IMMUNOL, V26, P137, DOI 10.1111/j.1600-0897.1991.tb00713.x; Patankar M., 1993, Glycobiology, V3, P521; PATANKAR MS, 1993, J BIOL CHEM, V268, P21770; PEAKER CJG, 1994, CURR OPIN IMMUNOL, V6, P359, DOI 10.1016/0952-7915(94)90113-9; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; PFEIFFER G, 1992, EUR J BIOCHEM, V205, P961, DOI 10.1111/j.1432-1033.1992.tb16863.x; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POCKLEY AG, 1988, J REPROD IMMUNOL, V13, P31, DOI 10.1016/0165-0378(88)90046-0; POCKLEY AG, 1989, CLIN EXP IMMUNOL, V77, P252; POCKLEY AG, 1990, IMMUNOLOGY, V69, P277; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; POWELL LD, 1994, J BIOL CHEM, V269, P10628; RIITTINEN L, 1991, J IMMUNOL METHODS, V136, P85, DOI 10.1016/0022-1759(91)90253-C; SATO T, 1995, J BIOCHEM-TOKYO, V117, P147, DOI 10.1093/oxfordjournals.jbchem.a124702; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TOMIYA N, 1993, J BIOL CHEM, V268, P113; VANDENEIJNDEN DH, 1995, BIOCHEM SOC T, V23, P175, DOI 10.1042/bst0230175; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WASSARMAN PM, 1990, DEVELOPMENT, V108, P1; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; YAN SB, 1993, GLYCOBIOLOGY, V3, P597, DOI 10.1093/glycob/3.6.597; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003	65	233	241	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24116	24126		10.1074/jbc.270.41.24116	http://dx.doi.org/10.1074/jbc.270.41.24116			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592613	hybrid			2022-12-27	WOS:A1995TA21700041
J	JURIVICH, DA; PACHETTI, C; QIU, L; WELK, JF				JURIVICH, DA; PACHETTI, C; QIU, L; WELK, JF			SALICYLATE TRIGGERS HEAT-SHOCK FACTOR DIFFERENTLY THAN HEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; PROTEIN HSP70; ACTIVATION; EXPRESSION; CELLS; RESISTANCE; STRESS	Sodium salicylate has the unusual property of partially inducing the human heat shock response (Jurivich, D. A., Sistonen, L., Kroes, R., and Morimoto, R.I. (1992) Science 255, 1243-1245). Salicylate induces the DNA binding state of the human heat shock transcription factor (HSF), but this is insufficient to elevate heat shock gene expression. Because it is not known how HSF enhances heat shock gene expression, further analysis of the transcriptionally inert, salicylate-induced HSF was undertaken to potentially identify components of the heat shock response that are necessary for full transcriptional induction. Like thermal stress, exposure of HeLa cells to salicylate led to the induction of HSF1 into a DNA-bound state. Despite continued exposure of cells to salicylate, HSF1 DNA binding attenuated much more rapidly than a continuous heat shock. Western blot analysis revealed that the salicylate-induced form of HSF1 was not hyperphosphorylated like the heat-induced form. Furthermore, supershifts of the HSF1 bound to an heat shock element (HSE) oligonucleotide by monoclonal antibodies to phosphoamino acids revealed that salicylate induced threonine phosphorylation of HSF1, whereas heat led to a predominance of HSF1 serine phosphorylation. These data suggest that salicylate-independent signals are necessary to convert HSF1 into a transactivator of heat shock gene expression and that brief acquisition of DNA binding by this factor is insufficient to maximally enhance transcription.			JURIVICH, DA (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,GERIATR MED SECT,CHICAGO,IL 60611, USA.				NIAMS NIH HHS [AR30692] Funding Source: Medline; NIA NIH HHS [AG00509] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR030692] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMSON SB, 1991, BIOCHEM PHARMACOL, V41, P1567, DOI 10.1016/0006-2952(91)90155-X; ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; Baeuerle P. A., 1991, MOL ASPECTS CELLULAR, P409; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; COHEN SP, 1993, J BACTERIOL, V175, P7856, DOI 10.1128/JB.175.24.7856-7862.1993; CROTTY B, 1992, GUT, V33, P59, DOI 10.1136/gut.33.1.59; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; ENYEDI AJ, 1992, CELL, V70, P879, DOI 10.1016/0092-8674(92)90239-9; GOODSON ML, 1995, J BIOL CHEM, V270, P2447, DOI 10.1074/jbc.270.6.2447; HOJ A, 1994, EMBO J, V13, P2617; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LI N, 1992, PLANT MOL BIOL, V18, P477, DOI 10.1007/BF00040664; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RABINDRAN SK, 1994, MOL CELL BIOL, V14, P6552, DOI 10.1128/MCB.14.10.6552; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; UKNES S, 1993, PLANT CELL, V5, P159, DOI 10.1105/tpc.5.2.159; VERNOOIJ B, 1994, CURR OPIN CELL BIOL, V6, P275, DOI 10.1016/0955-0674(94)90147-3; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; Yalpani Nasser, 1993, Trends in Microbiology, V1, P88, DOI 10.1016/0966-842X(93)90113-6	32	92	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24489	24495		10.1074/jbc.270.41.24489	http://dx.doi.org/10.1074/jbc.270.41.24489			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592665	hybrid			2022-12-27	WOS:A1995TA21700093
J	LEHMANN, S; HARRIS, DA				LEHMANN, S; HARRIS, DA			A MUTANT PRION PROTEIN DISPLAYS AN ABERRANT MEMBRANE ASSOCIATION WHEN EXPRESSED IN CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB DISEASE; SCRAPIE AGENT PROTEIN; NEURO-BLASTOMA CELLS; TRANSGENIC MICE; PHOSPHOLIPASE-C; PRP 27-30; GENE; RESISTANT; SURFACE; IDENTIFICATION	Inherited forms of prion disease have been linked to mutations in the gene encoding PrP, a neuronal and glial protein that is attached to the plasma membrane by a glycosyl-phosphatidylinositol (GPI) anchor, One familial form of Creutzfeldt-Jakob disease is associated with a mutant PrP containing six additional octapeptide repeats. We report here our analysis of cultured Chinese hamster ovary cells expressing a murine homologue of this mutant PrP. We find that, like wild-type PrP, the mutant protein is glycosylated, GPI-anchored, and expressed on the cell surface. Surprisingly, however, cleavage of the GPI anchor using phosphatidylinositol-specific phospholipase C fails to release the mutant PrP from the surface of intact cells, suggesting that it has an additional mode of membrane attachment. The phospholipase-treated protein is hydrophobic, since it partitions into the detergent phase of Triton X-114 lysates; and it is tightly membrane associated, since it is not extractable in carbonate buffer at pH 11.5. Whether membrane attachment of the mutant PrP involves integration of the polypeptide into the lipid bilayer, self-association, or binding to other membrane proteins remains to be determined. Our results suggest that alterations in the membrane association of PrP may be an important feature of prion diseases.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Lehmann, Sylvain/P-1301-2017	Lehmann, Sylvain/0000-0001-6117-562X; Harris, David/0000-0002-6985-5790				Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHESEBRO B, 1985, NATURE, V315, P331, DOI 10.1038/315331a0; COLLINGE J, 1992, BRAIN, V115, P685; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DEFEA KA, 1994, J BIOL CHEM, V269, P16810; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GAJDUSEK DC, 1990, VIROLOGY, P2289; GIBBONS RA, 1967, NATURE, V215, P1041, DOI 10.1038/2151041a0; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HAY B, 1987, MOL CELL BIOL, V7, P914, DOI 10.1128/MCB.7.2.914; HITT AL, 1994, J CELL BIOL, V126, P1421, DOI 10.1083/jcb.126.6.1421; HOWELL S, 1994, J BIOL CHEM, V269, P16993; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HUNTER GD, 1964, J GEN MICROBIOL, V34, P319, DOI 10.1099/00221287-34-2-319; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KOSTER B, 1994, ARCH BIOCHEM BIOPHYS, V310, P108, DOI 10.1006/abbi.1994.1146; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; NICHOLL D, 1995, J NEUROL NEUROSUR PS, V58, P65, DOI 10.1136/jnnp.58.1.65; ODA T, 1995, ACTA NEUROPATHOL, V90, P80; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OWEN F, 1990, MOL BRAIN RES, V7, P273, DOI 10.1016/0169-328X(90)90038-F; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; PRUSINER SB, 1978, BIOCHEMISTRY-US, V17, P4993, DOI 10.1021/bi00616a021; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523; PRUSINER SB, 1994, ANN NEUROL, V35, P385, DOI 10.1002/ana.410350404; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; ROSENBERRY TL, 1991, CELL BIOL INT REP, V15, P1133, DOI 10.1016/0309-1651(91)90060-V; SAFAR J, 1991, J INFECT DIS, V163, P488, DOI 10.1093/infdis/163.3.488; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; SHYNG SL, 1995, J BIOL CHEM, V270, P14793, DOI 10.1074/jbc.270.24.14793; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; ULRICH MJ, 1990, BLOOD, V75, P990; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0	60	147	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24589	24597		10.1074/jbc.270.41.24589	http://dx.doi.org/10.1074/jbc.270.41.24589			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592679	hybrid			2022-12-27	WOS:A1995TA21700107
J	FLETCHER, TM; HANSEN, JC				FLETCHER, TM; HANSEN, JC			CORE HISTONE TAIL DOMAINS MEDIATE OLIGONUCLEOSOME FOLDING AND NUCLEOSOMAL DNA ORGANIZATION THROUGH DISTINCT MOLECULAR MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TERMINAL TAIL; CHROMATIN; INVOLVEMENT; INTERACTS; H2B	Defined oligonucleosome model systems have been used to investigate the molecular mechanisms through which the core histone tail domains modulate chromatin structure. In low salt conditions, the tail domains function at the nucleosome level to facilitate proper organization of nucleosomal DNA, i.e. wrapping of DNA around the histone octamer. Mg2+ ions can substitute for the tail domains to yield a trypsinized oligonucleosome structure that is indistinguishable from that of an intact nucleosomal array in low salt. However, Mg2+-dependent formation of highly folded oligonucleosome structures absolutely requires the histone tail domains, and is associated with rearrangement of the tails to a non-nucleosomal location, We conclude that the tail domains mediate oligonucleosome folding and nucleosomal DNA organization through fundamentally different molecular mechanisms.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045916, R01GM045916] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45916] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1981, J CELL BIOL, V90, P279, DOI 10.1083/jcb.90.2.279; ALLEN MJ, 1993, BIOCHEMISTRY-US, V32, P8390, DOI 10.1021/bi00084a002; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; FLETCHER TM, 1994, BIOCHEMISTRY-US, V33, P10859, DOI 10.1021/bi00202a002; FLETCHER TM, 1994, BIOCHEMISTRY-US, V33, P2226, DOI 10.1021/bi00174a032; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GRIESS GA, 1989, BIOPOLYMERS, V28, P1475, DOI 10.1002/bip.360280811; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HANSEN JC, 1993, J BIOL CHEM, V268, P5840; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; HANSEN JC, 1994, BIOCHEMISTRY-US, V33, P13155, DOI 10.1021/bi00249a001; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; HILL CS, 1990, EUR J BIOCHEM, V187, P145, DOI 10.1111/j.1432-1033.1990.tb15288.x; ICHIMURA S, 1982, BIOCHEMISTRY-US, V21, P5329, DOI 10.1021/bi00264a032; LEWIS EA, 1976, BIOCHEMISTRY-US, V15, P186, DOI 10.1021/bi00646a029; LINDSEY GG, 1991, J MOL BIOL, V218, P805, DOI 10.1016/0022-2836(91)90268-B; MORSE RH, 1986, NUCLEIC ACIDS RES, V14, P3293, DOI 10.1093/nar/14.8.3293; RENZ M, 1977, P NATL ACAD SCI USA, V74, P1879, DOI 10.1073/pnas.74.5.1879; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; SHAW DJ, 1969, ELECTROPHORESIS, P10; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SXTRATLING W, 1979, BIOCHEMISTRY-US, V18, P596; THOMA F, 1977, CELL, V12, P101, DOI 10.1016/0092-8674(77)90188-X; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; VANHOLDE KE, 1978, BIOPOLYMEERS, V17, P1981; WALKER IO, 1984, BIOCHEMISTRY-US, V23, P5622, DOI 10.1021/bi00318a037; WOLFFE AP, 1995, CHROMATIN STRUCTURE, P225; YANG GL, 1994, NAT STRUCT BIOL, V1, P761, DOI 10.1038/nsb1194-761	31	149	151	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25359	25362		10.1074/jbc.270.43.25359	http://dx.doi.org/10.1074/jbc.270.43.25359			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592700	hybrid			2022-12-27	WOS:A1995TB46600016
J	GERSTEN, KM; NATSUKA, S; TRINCHERA, M; PETRYNIAK, B; KELLY, RJ; HIRAIWA, N; JENKINS, NA; GILBERT, DJ; COPELAND, NG; LOWE, JB				GERSTEN, KM; NATSUKA, S; TRINCHERA, M; PETRYNIAK, B; KELLY, RJ; HIRAIWA, N; JENKINS, NA; GILBERT, DJ; COPELAND, NG; LOWE, JB			MOLECULAR-CLONING, EXPRESSION, CHROMOSOMAL ASSIGNMENT, AND TISSUE-SPECIFIC EXPRESSION OF A MURINE ALPHA-(1,3)-FUCOSYL-TRANSFERASE LOCUS CORRESPONDING TO THE HUMAN ELAM-1 LIGAND FUCOSYL-TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; ELAM-1-DEPENDENT CELL-ADHESION; EMBRYONIC ANTIGEN SSEA-1; FULL-LENGTH CDNA; LEWIS-X; MONOCLONAL-ANTIBODIES; DETERMINES EXPRESSION; LEUKEMIA-VIRUS; MOUSE EMBRYOS	Terminal Fuc alpha 1-3GlcNAc moieties are displayed by mammalian cell surface glycoconjugates in a tissue-specific manner. These oligosaccharides participate in selectin-dependent leukocyte adhesion and have been implicated in adhesive events during murine embryogenesis. Other functions for these molecules remain to be defined, as do the tissue-specific expression patterns of the corresponding alpha-(1-3)-fucosyltransferase (alpha 1-3FT) genes. This report characterizes a murine alpha 1-3FT that shares 77% amino acid sequence identity with human ELAM ligand fucosyltransferase (ELFT, also termed Fuc-TIV). The corresponding gene maps to mouse chromosome 9 in a region of homology with the Fuc-TIV locus on human chromosome 11q. In vitro, the murine (alpha 1-3FT can efficiently fucosylate the trisaccharide Gal alpha 1-3Gal beta 1-4GlcNAc (apparent K-m of 0.71 mM) to form an unusual tetrasaccharide (Gal alpha 1-3Gal beta 1-4[Fuc alpha 1-3]GlcNAc) described in periimplantation mouse tissues. The enzyme can also form the Lewis x determinant from Gal beta 1-4GlcNAc (K-m = 2.05 mM), and the sialyl Lewis x determinant from NeuNAc alpha 2-3Gal beta 1-4GlcNAc (K-m = 1.78 mM). However, it does not yield sialyl Lewis x determinants when expressed in a mammalian cell line that maintains sialyl Lewis x precursors. Transcripts from this gene accumulate to low levels in hematopoietic organs, but are unexpectedly abundant in epithelia that line the stomach, small intestine, colon, and epididymus. Epithelial cell-specific expression of this gene suggests function(s) in addition to, and distinct from, its proposed role in selectin ligand synthesis.	UNIV MICHIGAN, SCH MED, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT CELL & MOLEC BIOL PROGRAM, ANN ARBOR, MI 48109 USA; NCI, FREDERICK CANC RES & DEV CTR,ABL INC, BASIC RES PROGRAM,MAMMALIAN GENET LAB, FREDERICK, MD 21702 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Natsuka, Shunji/L-9330-2018	Natsuka, Shunji/0000-0003-1726-8946	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047455] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NCRR NIH HHS [M01RR00042] Funding Source: Medline; NIGMS NIH HHS [1R01GM47455] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; BERG EL, 1991, J BIOL CHEM, V266, P14869; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; CHIA D, 1985, CANCER RES, V45, P435; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; CUMMINGS RD, 1988, J BIOL CHEM, V263, P511; Dayhoff M.O., 1978, ATLAS PROTEIN SEQ ST; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EGGENS I, 1989, J BIOL CHEM, V264, P9476; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENDERSON BA, 1986, DEV BIOL, V114, P12, DOI 10.1016/0012-1606(86)90379-9; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; Fitch W.M., 1970, EVOL BIOL, V4, P67; FOX N, 1981, DEV BIOL, V83, P391, DOI 10.1016/0012-1606(81)90487-5; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GALTON J, 1985, P117; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; Green EL, 1981, GENETICS PROBABILITY, P77; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HAMANO T, 1983, J IMMUNOL, V130, P2027; HUMMEL M, 1987, J IMMUNOL, V138, P3539; ITO K, 1994, GLYCOCONJUGATE J, V11, P232, DOI 10.1007/BF00731223; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1991, J BIOL CHEM, V266, P6991; JOZIASSE DH, 1993, BIOCHEM BIOPH RES CO, V194, P358, DOI 10.1006/bbrc.1993.1828; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KOREN HS, 1975, J IMMUNOL, V114, P894; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANCE P, 1989, BIOCHEM BIOPH RES CO, V164, P225, DOI 10.1016/0006-291X(89)91706-3; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; Lowe J B, 1991, Semin Cell Biol, V2, P289; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; Maniatis T., 1982, MOL CLONING; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MELLIS SJ, 1983, ANAL BIOCHEM, V134, P442, DOI 10.1016/0003-2697(83)90320-2; MOLLICONE R, 1992, CARBOHYD RES, V228, P265, DOI 10.1016/S0008-6215(00)90564-0; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; NAKAZAWA K, 1988, J BIOCHEM-TOKYO, V104, P165, DOI 10.1093/oxfordjournals.jbchem.a122434; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; OHANLON TP, 1989, J BIOL CHEM, V264, P17389; OLD LJ, 1965, CANCER RES, V25, P813; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PENNINGTON JE, 1985, J EMBRYOL EXP MORPH, V90, P335; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; RALPH P, 1977, J IMMUNOL, V119, P950; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; REGUIGNE I, 1994, CYTOGENET CELL GENET, V66, P104, DOI 10.1159/000133677; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SINGER D, 1974, P NATL ACAD SCI USA, V71, P2668, DOI 10.1073/pnas.71.7.2668; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SUEYOSHI S, 1994, J BIOL CHEM, V269, P32342; SZULMAN AE, 1973, LAB INVEST, V28, P565; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; VALANILA RP, 1989, J BIOL CHEM, V19, P11158; VANKESSEL AG, 1984, J IMMUNOL, V133, P1265; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; 1972, SPECIFICATIONS CRITE	78	90	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25047	25056		10.1074/jbc.270.42.25047	http://dx.doi.org/10.1074/jbc.270.42.25047			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559635	hybrid			2022-12-27	WOS:A1995TB46500069
J	LI, C; DAVLETOV, BA; SUDHOF, TC				LI, C; DAVLETOV, BA; SUDHOF, TC			DISTINCT CA2+ AND SR2+ BINDING-PROPERTIES OF SYNAPTOTAGMINS - DEFINITION OF CANDIDATE CA2+ SENSORS FOR THE FAST AND SLOW COMPONENTS OF NEUROTRANSMITTER RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN; P65	Ca2+-dependent neurotransmitter release consists of at least two components: a major fast component that is insensitive to Sr2+ and a minor slow component that is potentiated by Sr2+ (Goda, Y., and Stevens, C. F. (1994) Proc. Natl. Acad. U. S. A. 91, 12942-12946). These results suggest that at least two Ca2+ sensors act in synaptic vesicle fusion with distinct Ca2+ and Sr2+ binding properties. We have now investigated the relative Ca2+ and Sr2+ binding activities of synaptotagmins to evaluate their potential roles as Ca2+ sensors for the fast and slow components. Our results demonstrate that the first C-2 domains of synaptotagmins I, II, III, V, and VII have very similar Ca2+ requirements for phospholipid binding (range of EC(50) = 2.6 mu M to 5.0 mu M), but distinct Sr2+ requirements (EC(50) range = 23 mu M to 133 mu M); synaptotagmin I and II had the lowest Sr2+ affinity, and synaptotagmin III the highest Sr2+ affinity. Purified synaptotagmin I from bovine brain exhibited similar properties as its recombinant first C-2 domain, suggesting that the first C-2 domain fully accounts for its Ca2+-dependent phospholipid binding properties. Sr2+ was unable to trigger syntaxin binding by synaptotagmin I at all concentrations tested, whereas it was effective for synaptotagmin III. These results suggest that different C-2 domains have distinct Sr2+ binding properties. They support the hypothesis that synaptotagmins localized on the same vesicle perform distinct functions, with synaptotagmins I and II serving as candidate Ca2+ sensors for the fast component in release and synaptotagmin III for the slow component.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Davletov, Bazbek/ABA-8569-2021	Davletov, Bazbek/0000-0003-4658-3275				BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CRAXTON M, 1995, FEBS LETT, V361, P196, DOI 10.1016/0014-5793(95)00176-A; DAMER CK, 1994, J BIOL CHEM, V269, P31115; DAVLETOV BA, 1994, J BIOL CHEM, V269, P28547; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; FUKUDA M, 1994, J BIOL CHEM, V269, P26206; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	26	132	134	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24898	24902		10.1074/jbc.270.42.24898	http://dx.doi.org/10.1074/jbc.270.42.24898			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559614	hybrid			2022-12-27	WOS:A1995TB46500048
J	LIANG, YZ; PATEL, SS; DEAN, DH				LIANG, YZ; PATEL, SS; DEAN, DH			IRREVERSIBLE BINDING-KINETICS OF BACILLUS-THURINGIENSIS CRYIA DELTA-ENDOTOXINS TO GYPSY-MOTH BRUSH-BORDER MEMBRANE-VESICLES IS DIRECTLY CORRELATED TO TOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUTTERFLY PIERIS-BRASSICAE; BOMBYX-MORI; HELIOTHIS-VIRESCENS; MIDGUT; SPECIFICITY; PROTEINS; RECEPTORS; LEPIDOPTERA; INHIBITION; RESISTANCE	To examine the binding of Bacillus thuringiensis delta-endotoxins, CryIAa, CryIAb, and CryIAc, to Lymantria dispar (gypsy moth) brush border membrane vesicles (BBMV), saturation kinetic analyses were conducted according to a two-step interaction scheme [GRAPHICS] for delta-endotoxin binding to BBMV, rather than the one-step reversible binding presented in prior reports. The order of toxicity of the delta-endotoxins, as measured by the dose required for a 50% inhibition of weight gain (ID50), was CryIAa (77.3 ng) > CryIAb (157 ng) > CryIAc (187 ng). While both the maximum extent of binding, B-max and the half-maximum insertion rate concentration, K-1/2 was observed to be indirectly related to toxicity, the rate constant of irreversible binding, k(2), was found to be directly correlated to toxicity.	OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University					NIAID NIH HHS [R01 AI29092] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029092] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELFIORE CJ, 1994, BIOCHEM BIOPH RES CO, V200, P359, DOI 10.1006/bbrc.1994.1456; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN XJ, 1993, P NATL ACAD SCI USA, V90, P9041, DOI 10.1073/pnas.90.19.9041; CHEN XJ, 1995, J BIOL CHEM, V270, P6412, DOI 10.1074/jbc.270.11.6412; DENOLF P, 1993, APPL ENVIRON MICROB, V59, P1828, DOI 10.1128/AEM.59.6.1828-1837.1993; FERRE J, 1991, P NATL ACAD SCI USA, V88, P5119, DOI 10.1073/pnas.88.12.5119; GARCZYNSKI SF, 1995, INSECT BIOCHEM MOLEC, V25, P409, DOI 10.1016/0965-1748(94)00072-7; GILL SS, 1992, ANNU REV ENTOMOL, V37, P615, DOI 10.1146/annurev.en.37.010192.003151; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; HOFMANN C, 1988, EUR J BIOCHEM, V173, P85, DOI 10.1111/j.1432-1033.1988.tb13970.x; HONEE G, 1993, ENTOMOL EXP APPL, V69, P145, DOI 10.1007/BF02380641; IHARA H, 1993, BIOSCI BIOTECH BIOCH, V57, P200, DOI 10.1271/bbb.57.200; JOHNSTON L, 1992, INT J SOCIOL LAW, V20, P1; KEENA M, 1993, P US DEP AGR INT GYP, P13; KLOTZ IM, 1989, PROTEIN FUNCTION PRA, P42; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; LEE MK, 1992, J BIOL CHEM, V267, P3115; LIANG Y, 1994, MOL MICROBIOL, V13, P569, DOI 10.1111/j.1365-2958.1994.tb00451.x; MACINTOSH SC, 1991, P NATL ACAD SCI USA, V88, P8930, DOI 10.1073/pnas.88.20.8930; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ODDOU P, 1991, EUR J BIOCHEM, V202, P673, DOI 10.1111/j.1432-1033.1991.tb16422.x; ODDOU P, 1993, EUR J BIOCHEM, V212, P145, DOI 10.1111/j.1432-1033.1993.tb17644.x; SANGADALA S, 1994, J BIOL CHEM, V269, P10088; VANFRANKENHUYZEN K, 1991, APPL ENVIRON MICROB, V57, P1650, DOI 10.1128/AEM.57.6.1650-1655.1991; VANRIE J, 1990, SCIENCE, V247, P72, DOI 10.1126/science.2294593; VANRIE J, 1989, EUR J BIOCHEM, V186, P239, DOI 10.1111/j.1432-1033.1989.tb15201.x; VANRIE J, 1990, APPL ENVIRON MICROB, V56, P1378, DOI 10.1128/AEM.56.5.1378-1385.1990; WEILAND GA, 1981, LIFE SCI, V29, P313, DOI 10.1016/0024-3205(81)90324-6; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; WOLFERSBERGER MG, 1991, J EXP BIOL, V161, P519; WOLFERSBERGER MG, 1990, EXPERIENTIA, V46, P475; WOLFERSBERGER MG, 1986, ZENTRALBL BAKTERIO S, V15, P237; WU D, 1992, J BIOL CHEM, V267, P2311; 1992, 28666X PIERC TECHN B	35	76	84	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24719	24724		10.1074/jbc.270.42.24719	http://dx.doi.org/10.1074/jbc.270.42.24719			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559587	hybrid			2022-12-27	WOS:A1995TB46500021
J	BREUER, W; EPSZTEJN, S; CABANTCHIK, ZI				BREUER, W; EPSZTEJN, S; CABANTCHIK, ZI			IRON ACQUIRED FROM TRANSFERRIN BY K562 CELLS IS DELIVERED INTO A CYTOPLASMIC POOL OF CHELATABLE IRON(II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; RETICULOCYTES; MOBILIZATION; METABOLISM; TRANSPORT; CHELATORS; PROTEIN; RNA	The release of iron from transferrin (Tf) in the acidic milieu of endosomes and its translocation into the cytosol are integral steps in the process of iron acquisition via receptor-mediated endocytosis (RME), The translocated metal is thought to enter a low molecular weight cytoplasmic pool, presumed to contain the form of iron which is apparently sensed by iron responsive proteins and is the direct target of iron chelators, The process of iron delivery into the cytoplasmic chelatable pool of K562 cells was studied in situ by continuous monitoring of the fluorescence of cells loaded with the metal-sensitive probe calcein, Upon exposure to Tf at 37 degrees C, intracellular fluorescence decayed, corresponding to an initial iron uptake of 40 nM/min, The Tf-mediated iron uptake was profoundly inhibited by weak, bases, the protonophore monensin, energy depletion, or low temperatures (<25 degrees C), all properties characteristic of RME, Cell iron levels were affected by the slowly permeating chelator desferrioxamine only after prolonged incubations, Conversely, rapidly penetrating, lipophilic iron(II) chelators such as 2,2'-bipyridyl, evoked swift increases in cell calcein fluorescence, equivalent to sequestration of 0.2-0.5 mu M cytosolic iron, depending on the degree of pre-exposure to Tf, Addition of iron(III) chelators to permeabilized 2,2'-bipyridyl-treated cells, failed to reveal significant levels of chelatable iron(III), The finding that the bulk of the in situ cell chelatable pool is comprised of iron(II) was corroborated by pulsing K562 cells with Tf-Fe-55, followed by addition of iron(II) and/or iron(III) chelators and extraction of chelator-Fe-55 complexes into organic solvent. Virtually all of the accumulated Fe-55 in the chelatable pool could be complexed by iron(II) chelators, The cytoplasmic concentration of iron(II) fluctuated between 0.3 and 0.5 mu M, and its mean transit time through the chelatable pool was 1-2 h, me conclude that after iron is translocated from the endosomes, it is maintained in the cytosol as a transit pool of chelatable iron(II), The ostensible absence of chelatable iron(III) implicates the intracellular operation of vigorous reductive mechanisms.			BREUER, W (corresponding author), HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI020342, R01AI020342] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20342] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER E, 1990, HEPATOLOGY, V15, P492; BAKKER GR, 1986, J BIOL CHEM, V261, P3182; BREUER W, 1995, AM J PHYSIOL-CELL PH, V268, pC1354, DOI 10.1152/ajpcell.1995.268.6.C1354; BRIDGES KR, 1984, J BIOL CHEM, V259, P2970; BURKITT MJ, 1991, FREE RADICAL RES COM, V14, P107, DOI 10.3109/10715769109094123; CONRAD ME, 1990, J BIOL CHEM, V265, P5273; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; Crichton R.R, 1992, IRON HUMAN DIS, P23; DAILEY HA, 1994, J BIOL CHEM, V269, P390; DEIGHTON N, 1989, BIOCHEM SOC T, V17, P490, DOI 10.1042/bst0170490; FONTECAVE M, 1991, BIOL MET, V4, P133, DOI 10.1007/BF01141302; HERSHKO C, 1988, CRC CR REV CL LAB SC, V26, P303, DOI 10.3109/10408368809105894; JACOBS A, 1977, BLOOD, V50, P4331; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LAW FY, 1983, AM J PHYSIOL, V244, pC68, DOI 10.1152/ajpcell.1983.244.1.C68; LOYEVSKY M, 1993, J CLIN INVEST, V91, P218, DOI 10.1172/JCI116174; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCCORD JM, 1992, IRON HUMAN DISEASE, P509; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; NUNEZ MT, 1980, BLOOD, V55, P1051; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; POLLACK S, 1992, AM J HEMATOL, V39, P113, DOI 10.1002/ajh.2830390208; PONKA P, 1984, BIOCHIM BIOPHYS ACTA, V802, P477, DOI 10.1016/0304-4165(84)90367-2; ROBERTS S, 1988, J BIOL CHEM, V263, P19181; ROTHMAN RJ, 1992, MOL PHARMACOL, V42, P703; STPIERRE TG, 1992, BIOCHIM BIOPHYS ACTA, V1135, P154; THORSTENSEN K, 1988, J BIOL CHEM, V263, P16837; YEGOROV DY, 1993, FREE RADICAL BIO MED, V15, P565, DOI 10.1016/0891-5849(93)90158-Q; YOUNG SP, 1994, BIOCHEM J, V298, P165, DOI 10.1042/bj2980165	31	268	272	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24209	24215		10.1074/jbc.270.41.24209	http://dx.doi.org/10.1074/jbc.270.41.24209			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592626	hybrid			2022-12-27	WOS:A1995TA21700054
J	ORIMO, A; INOUE, S; IKEDA, K; NOJI, S; MURAMATSU, M				ORIMO, A; INOUE, S; IKEDA, K; NOJI, S; MURAMATSU, M			MOLECULAR-CLONING, STRUCTURE, AND EXPRESSION OF MOUSE ESTROGEN-RESPONSIVE FINGER PROTEIN EFP - COLOCALIZATION WITH ESTROGEN-RECEPTOR MESSENGER-RNA IN TARGET ORGANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; MYC TRANSGENIC MICE; INSITU HYBRIDIZATION; ZINC FINGER; MESSENGER-RNA; PROGESTERONE RECEPTORS; RAR-ALPHA; GENE; CELLS; TRANSCRIPTION	We have previously identified a human estrogen-responsive gene, efp (estrogen-responsive finger protein), which encodes a putative transcription regulator (Inoue, S., Orimo, A., Hosoi, T., Kondo, S., Toyoshima, H., Kondo, T., Ikegami, A., Ouchi, Y., Orimo, H., and Muramatsu, M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 11117-11121). Here, we report isolation of mouse Efp cDNA and its structure containing three cysteine-rich domains (RING finger and B1 and B2 boxes), a coiled-coil domain, and a C-terminal domain. High levels of Efp mRNA were detected in uterus, ovary, and placenta by RNase protection assay. By in situ hybridization histochemistry the transcripts of efp, were also detected in uterus, mammary gland, ovary, and brain, and the colocalization of Efp and estrogen receptor mRNA was particularly demonstrated in these female organs. Moreover, the level of Efp mRNA in uterus and brain, which are known as target organs for estrogen, was up-regulated in vivo by 17 beta-estradiol. Furthermore, both the Efp and estrogen receptor mRNA were stained in the brain vesicles of 11.5-day embryos by whole mount in situ hybridization. These findings raise the possibility that efp is an estrogen responsive gene that mediates estrogen action in various target organs.	SAITAMA MED SCH, DEPT BIOCHEM, MOROYAMA, SAITAMA 35004, JAPAN; UNIV TOKUSHIMA, FAC ENGN, DEPT BIOL SCI & TECHNOL, TOKUSHIMA 770, JAPAN	Saitama Medical University; Tokushima University			Noji, Sumihare/E-3047-2010					Agthoven TV, 1994, AM J PATHOL, V144, P1238; BELLINI M, 1993, EMBO J, V12, P107, DOI 10.1002/j.1460-2075.1993.tb05636.x; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BILLIAR RB, 1992, J CLIN ENDOCR METAB, V75, P1159, DOI 10.1210/jc.75.4.1159; BLAKE TJ, 1991, ONCOGENE, V6, P653; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; CHRISTIANSEN C, 1985, LANCET, V2, P800; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; INOUE S, 1991, NUCLEIC ACIDS RES, V19, P4091, DOI 10.1093/nar/19.15.4091; INOUE S, 1995, GENOMICS, V25, P581, DOI 10.1016/0888-7543(95)80064-S; ITOH K, 1991, J CLIN INVEST, V87, P177, DOI 10.1172/JCI114968; IWAI T, 1991, ENDOCRINOLOGY, V129, P1840, DOI 10.1210/endo-129-4-1840; JACK LJW, 1990, J BIOL CHEM, V265, P14481; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOJI T, 1993, ENDOCRINOLOGY, V132, P382, DOI 10.1210/en.132.1.382; KOMM BS, 1988, SCIENCE, V241, P81, DOI 10.1126/science.3164526; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MULLER H, 1980, EUR J BIOCHEM, V112, P235, DOI 10.1111/j.1432-1033.1980.tb07199.x; NELSON KG, 1994, CELL GROWTH DIFFER, V5, P595; NOJI S, 1990, ACTA HISTOCHEM CYTOC, V23, P353, DOI 10.1267/ahc.23.353; ORIMO A, 1993, BIOCHEM BIOPH RES CO, V195, P730, DOI 10.1006/bbrc.1993.2106; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PETERSEN OW, 1987, CANCER RES, V47, P5748; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sambrook J, 1989, MOL CLONING LABORATO; SIMERLY RB, 1990, J COMP NEUROL, V294, P76, DOI 10.1002/cne.902940107; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STUMPF WE, 1977, SCIENCE, V196, P319, DOI 10.1126/science.847474; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; TORANALLERAND CD, 1992, BRAIN RES, V576, P25; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735; Wilkinson DG, 1992, SITU HYBRIDIZATION P; YAMASHITA S, 1989, ENDOCRINOLOGY, V125, P2888, DOI 10.1210/endo-125-6-2888; ZAINO RJ, 1989, ENDOCRINOLOGY, V125, P2728, DOI 10.1210/endo-125-5-2728	59	71	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24406	24413		10.1074/jbc.270.41.24406	http://dx.doi.org/10.1074/jbc.270.41.24406			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592654	hybrid			2022-12-27	WOS:A1995TA21700082
J	SEABRA, MC; HO, YK; ANANT, JS				SEABRA, MC; HO, YK; ANANT, JS			DEFICIENT GERANYLGERANYLATION OF RAM/RAB27 IN CHOROIDEREMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; CDNA CLONING; COMPONENT-A; RAB; TRANSFERASE; GENE; TRANSPORT; PURIFICATION; INVITRO; HOMOLOG	Choroideremia, an X-linked form of retinal degeneration, results from defects in the Rab escort protein-1 (REP-1) gene. REP-1 and REP-2 assist in the attachment of geranylgeranyl groups to Rab GTPases, a modification essential for their action as molecular switches regulating intracellular vesicular transport. If Rabs that depend preferentially on REP-1 for prenylation exist, they will accumulate unprenylated in choroideremia cells. Using recombinant Rab geranylgeranyl transferase and REPs to label unprenylated cytosolic proteins, we identified one unprenylated protein in choroideremia lymphoblasts that was prenylated in vitro more efficiently by REP-1 than by REP-2. This protein was purified and identified as Ram (renamed Rab27), a previously cloned Rab of unknown function, Immunohistochemistry of rat retina showed that Ram/Rab27 is expressed in the pigment epithelium and choriocapillaris, the two retinal cell layers that degenerate earliest in choroideremia. These results raise the possibility that the retinal degeneration in choroideremia results from the deficient geranylgeranylation of Ram/Rab27 or a closely related protein.			SEABRA, MC (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.		Seabra, Miguel C/M-3280-2013; Seabra, Miguel/AAC-3099-2019	Seabra, Miguel C/0000-0002-6404-4892; 	NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FUJIMURA K, 1994, J BIOL CHEM, V269, P9205; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Heckenlively JR, 1988, RETINITIS PIGMENTOSA, P176; HUBER LA, 1994, P NATL ACAD SCI USA, V91, P7874, DOI 10.1073/pnas.91.17.7874; JIANG Y, 1994, P NATL ACAD SCI USA, V91, P4377, DOI 10.1073/pnas.91.10.4377; JIANG Y, 1993, NATURE, V366, P84, DOI 10.1038/366084a0; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MERRY DE, 1992, P NATL ACAD SCI USA, V89, P2135, DOI 10.1073/pnas.89.6.2135; NAGATA K, 1990, FEBS LETT, V275, P29, DOI 10.1016/0014-5793(90)81431-M; NAGATA K, 1989, J BIOL CHEM, V264, P17000; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; REISS Y, 1991, J BIOL CHEM, V266, P10672; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; WALDHERR M, 1993, NAT GENET, V3, P193, DOI 10.1038/ng0393-193; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x	33	182	190	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24420	24427		10.1074/jbc.270.41.24420	http://dx.doi.org/10.1074/jbc.270.41.24420			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592656	hybrid			2022-12-27	WOS:A1995TA21700084
J	THURIAUX, P; MARIOTTE, S; BUHLER, JM; SENTENAC, A; VU, L; LEE, BS; NOMURA, M				THURIAUX, P; MARIOTTE, S; BUHLER, JM; SENTENAC, A; VU, L; LEE, BS; NOMURA, M			GENE RPA43 IN SACCHAROMYCES-CEREVISIAE ENCODES AN ESSENTIAL SUBUNIT OF RNA-POLYMERASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTATIONS; COMMON SUBUNITS; SUPPRESSOR ANALYSIS; YEAST; TRANSCRIPTION; MUTANTS; ANTIBODIES; COMPLEX; RPA190	Yeast RNA polymerase I contains 14 distinct polypeptides, including A43, a component of about 43 kDa. The corresponding gene, RPA43, encodes a 326-amino acid polypeptide matching the peptidic sequence of two tryptic fragments isolated from A43. Gene inactivation leads to a lethal phenotype that is rescued by a plasmid containing the S-35 ribosomal RNA gene fused to the GAL7 promoter, which allows the synthesis of S-35 rRNA by RNA polymerase II in the presence of galactose. A screening for mutants rescued by the presence of GAL7-(35)SrDNA identified a nonsense rpa43 allele truncating the protein at amino acid position 217. [H-3]Uridine pulse labeling showed that this mutation abolishes S-35 rRNA synthesis without significant effects on the synthesis of 5 S RNA and tRNAs. These properties establish that A43 is an essential component of RNA polymerase I. This highly hydrophilic phosphoprotein has a strongly acidic carboxyl-terminal domain, and shows no homology to entries in current sequence data banks, including all the genetically identified components of the other two yeast RNA polymerases. RPA43 mapped next to RPA190, encoding the largest subunit of polymerase I, These genes are divergently transcribed and may thus share upstream regulatory elements ensuring their co-regulation.	UNIV CALIF IRVINE,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine	THURIAUX, P (corresponding author), CEA SACLAY,SERV BIOCHIM & GENET MOLEC,BAT 142,F-91191 GIF SUR YVETTE,FRANCE.				NIGMS NIH HHS [R37GM35949] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035949] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BREANT B, 1983, EUR J BIOCHEM, V130, P247; BUHLER JM, 1976, J BIOL CHEM, V251, P1712; CARLES C, 1991, J BIOL CHEM, V266, P24092; DEQUARDCHABLAT M, 1991, J BIOL CHEM, V266, P15300; EBERHARD D, 1993, NUCLEIC ACIDS RES, V21, P4180, DOI 10.1093/nar/21.18.4180; HAGER GL, 1977, BIOCHEMISTRY-US, V16, P1, DOI 10.1021/bi00620a001; HUET J, 1982, J BIOL CHEM, V257, P2613; HUET J, 1985, J BIOL CHEM, V260, P5304; KEYS DA, 1994, GENE DEV, V8, P2349, DOI 10.1101/gad.8.19.2349; KRAAKMAN LS, 1989, NUCLEIC ACIDS RES, V17, P9693, DOI 10.1093/nar/17.23.9693; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; LILJELUND P, 1992, P NATL ACAD SCI USA, V89, P9302, DOI 10.1073/pnas.89.19.9302; LUE NF, 1990, J BIOL CHEM, V265, P18091; MANN C, 1987, CELL, V48, P627, DOI 10.1016/0092-8674(87)90241-8; MCCUSKER JH, 1991, MOL CELL BIOL, V11, P746, DOI 10.1128/MCB.11.2.746; MEMET S, 1988, J BIOL CHEM, V263, P2830; MOSRIN C, 1990, MOL CELL BIOL, V10, P4737, DOI 10.1128/MCB.10.9.4737; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P7026, DOI 10.1073/pnas.88.16.7026; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P3962, DOI 10.1073/pnas.88.9.3962; NOGI Y, 1993, MOL CELL BIOL, V13, P114, DOI 10.1128/MCB.13.1.114; NOMURA M, 1993, TRANSLATIONAL APPARATUS, P89; ORRWEAVER TL, 1988, METHOD ENZYMOL, V101, P228; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; REEDER RH, 1992, TRANSCRIPTIONAL REGU, V2, P315; RIGGS DL, 1990, J BIOL CHEM, V265, P7596; RIVA M, 1986, P NATL ACAD SCI USA, V83, P1554, DOI 10.1073/pnas.83.6.1554; RIVA M, 1982, J BIOL CHEM, V257, P4570; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SADHALE PP, 1994, MOL CELL BIOL, V14, P6164, DOI 10.1128/MCB.14.9.6164; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SMID A, 1995, J BIOL CHEM, V270, P13534, DOI 10.1074/jbc.270.22.13534; THUILLIER V, 1995, EMBO J, V14, P351, DOI 10.1002/j.1460-2075.1995.tb07009.x; THURIAUX P, 1992, MOL CELLULAR BIOL YE, V2, P1; Treich Isabelle, 1992, Gene Expression, V2, P31; VALENZUELA P, 1979, BIOCHEM BIOPH RES CO, V71, P1319; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WERNER M, 1993, J BIOL CHEM, V268, P20721; WITTEKIND M, 1988, MOL CELL BIOL, V8, P3997, DOI 10.1128/MCB.8.10.3997; WOYCHIK NA, 1990, J BIOL CHEM, V265, P17816; WOYCHIK NA, 1991, J BIOL CHEM, V266, P19053; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZOMERDIJK JCBM, 1994, SCIENCE, V266, P2015, DOI 10.1126/science.7801130	46	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24252	24257		10.1074/jbc.270.41.24252	http://dx.doi.org/10.1074/jbc.270.41.24252			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592632	hybrid			2022-12-27	WOS:A1995TA21700060
J	FOWLER, GJS; GARDINER, AT; MACKENZIE, RC; BARRATT, SJ; SIMMONS, AE; WESTERHUIS, WHJ; COGDELL, RJ				FOWLER, GJS; GARDINER, AT; MACKENZIE, RC; BARRATT, SJ; SIMMONS, AE; WESTERHUIS, WHJ; COGDELL, RJ			HETEROLOGOUS EXPRESSION OF GENES ENCODING BACTERIAL LIGHT-HARVESTING COMPLEXES IN RHODOBACTER-SPHAEROIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT-PROTEIN COMPLEXES; POLYACRYLAMIDE-GEL-ELECTROPHORESIS; PUC OPERON; ANTENNA COMPLEXES; B800-850 COMPLEX; LH2 GENES; CAPSULATUS; MUTANT; COMPLEMENTATION; ORGANIZATION	One of the major problems in structural work on membrane-spanning proteins is the identification of an expression system which will allow the production of enough pure protein for structural studies; an inadequate expression system can lead, for example, to the formation of unwanted protein inclusion bodies. In the present work we report the expression of genes encoding the light-harvesting 2 (LH2) membrane spanning proteins from a number of species of purple bacteria in mutants of Rhodobacter sphaeroides that lack the native LH2 antenna. The LH2 structural genes (pucBA) from the photosynthetic bacteria Rhodopseudomonas acidophila and Rubrivivax gelatinosus were amplified and tailed by polymerase chain reaction, and cloned into an LH2 expression vector, which was then introduced into three LH2-minus Rb, sphaeroides mutants; DBC Omega/G5 and DD13 (DD13/G1); the resulting transconjugant strains synthesized LH2 complexes that were examined using absorption and fluorescence spectroscopy, and Western blotting. Thus, we have created a heterologous expression system which supports the assembly of a functional ''foreign'' light-harvesting complex. This work opens up the possibility of creating site-directed LH2 mutants from bacteria for which no genetic system is available; this is particularly significant in the case of Rps, acidophila, since this bacterium has been the source of the LH2 complex that has recently been structurally resolved to atomic resolution.	UNIV GLASGOW, DEPT BIOCHEM, GLASGOW G12 8QQ, LANARK, SCOTLAND	University of Glasgow	FOWLER, GJS (corresponding author), UNIV SHEFFIELD, DEPT MOLEC BIOL & BIOTECHNOL, SHEFFIELD S10 2TN, S YORKSHIRE, ENGLAND.		Gardiner, Alastair T/N-8385-2017	Fowler, Gregory/0000-0002-0420-7661	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROGLIE RM, 1980, P NATL ACAD SCI-BIOL, V77, P87, DOI 10.1073/pnas.77.1.87; BRUNISHOLZ RA, 1992, J PHOTOCH PHOTOBIO B, V15, P113, DOI 10.1016/1011-1344(92)87010-7; BURGESS JG, 1989, J GEN MICROBIOL, V135, P1809; BYLINA EJ, 1988, ISRAEL J CHEM, V28, P73; CODGELL RJ, 1993, PHOTOSYNTHETIC REACT, V1, P23; CRIELAARD W, 1994, BBA-BIOENERGETICS, V1183, P473, DOI 10.1016/0005-2728(94)90074-4; DEMARCUCCI OL, 1985, BIOCHEM J, V226, P509, DOI 10.1042/bj2260509; DREWS G, 1981, ADV MICROB PHYSIOL, V22, P1, DOI 10.1016/S0065-2911(08)60325-2; FOWLER GJS, 1992, NATURE, V355, P848, DOI 10.1038/355848a0; FOWLER GJS, 1994, BIOCHEM J, V299, P695, DOI 10.1042/bj2990695; GARDINER AT, 1993, PHOTOSYNTH RES, V38, P159, DOI 10.1007/BF00146415; GARDINER AT, 1992, THESIS U GLASGOW GLA; GIBSON LCD, 1992, MOL MICROBIOL, V6, P3171, DOI 10.1111/j.1365-2958.1992.tb01773.x; GOLECKI JR, 1991, FEMS MICROBIOL LETT, V77, P335, DOI 10.1111/j.1574-6968.1991.tb04372.x; Hawthornthwaite-Lawless A. M., 1991, CHLOROPHYLLS, P493; HUNTER CN, 1988, BIOCHEMISTRY-US, V27, P3459, DOI 10.1021/bi00409a050; HUNTER CN, 1988, J GEN MICROBIOL, V134, P1471; HUNTER CN, 1989, BIOCHIM BIOPHYS ACTA, V973, P383, DOI 10.1016/S0005-2728(89)80379-2; HUNTER CN, 1994, J BACTERIOL, V176, P3693; JIRSAKOVA V, 1993, BIOCHIM BIOPHYS ACTA, V1183, P301, DOI 10.1016/0005-2728(93)90231-4; JONES MR, 1992, MOL MICROBIOL, V6, P1173, DOI 10.1111/j.1365-2958.1992.tb01556.x; KILEY PJ, 1988, J BACTERIOL, V170, P1103, DOI 10.1128/jb.170.3.1103-1115.1988; LANG HP, 1994, BIOCHEM J, V298, P197, DOI 10.1042/bj2980197; LEE JK, 1989, J BACTERIOL, V171, P3391, DOI 10.1128/jb.171.6.3391-3405.1989; Loach P.A., 1995, ANOXYGENIC PHOTOSYNT; LOMMEN MAJ, 1978, ARCH MICROBIOL, V118, P305, DOI 10.1007/BF00429122; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; PAPIZ MZ, 1989, J MOL BIOL, V209, P833, DOI 10.1016/0022-2836(89)90612-8; Sambrook J, 1989, MOL CLONING LABORATO; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SUNDSTROM V, 1990, J OPT SOC AM, V7, P1596; TADROS MH, 1990, FEMS SYMP, V53, P181; TADROS MH, 1993, EUR J BIOCHEM, V217, P867, DOI 10.1111/j.1432-1033.1993.tb18315.x; TICHY HV, 1989, J BACTERIOL, V171, P4914, DOI 10.1128/jb.171.9.4914-4922.1989; TICHY HV, 1991, EMBO J, V10, P2949, DOI 10.1002/j.1460-2075.1991.tb07845.x; VISSCHERS RW, 1994, BBA-BIOENERGETICS, V1183, P483, DOI 10.1016/0005-2728(94)90075-2; Young A., 1993, CAROTENOIDS PHOTOSYN, P16, DOI DOI 10.1007/978-94-011-2124-8_2	37	23	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23875	23882		10.1074/jbc.270.40.23875	http://dx.doi.org/10.1074/jbc.270.40.23875			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559566	hybrid			2022-12-27	WOS:A1995RY90900095
J	LIANG, F; JASIN, M				LIANG, F; JASIN, M			STUDIES ON THE INFLUENCE OF CYTOSINE METHYLATION ON DNA RECOMBINATION AND END-JOINING IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE L-CELLS; HOMOLOGOUS RECOMBINATION; GENE; REPLICATION; PROTEIN; REPAIR; MODEL; LOCI	To test the influence of cytosine methylation on homologous recombination and the rejoining of DNA double strand breaks in mammalian cells, we developed a sensitive and quantitative assay system using extrachromosomal substrates. First, methylation was introduced into substrates in vitro with the prokaryotic SssI methylase, which specifically methylates the C-5 position of cytosine bases within CpG dinucleotides, mimicking the mammalian DNA methyltransferase. Next, methylated substrates were incubated in mammalian cells for a sufficient length of time to recombine or rejoin prior to substrate recovery. Results from bacterial transformation of the substrates and from direct Southern analysis demonstrate that cytosine methylation has no detectable effect on either DNA end-joining or homologous recombination. Thus, the components of the protein machinery involved in these complex processes are unaffected by the major DNA modification in mammalian cells. These results leave open the possibility that methylation may modulate the accessibility of these components to chromosomal DNA by altering local chromatin structure.	SLOAN KETTERING INST,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University					NCI NIH HHS [P30CA-08748-26] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BURGER C, 1990, EUR J IMMUNOL, V20, P2285, DOI 10.1002/eji.1830201018; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; GILL JE, 1974, BIOCHIM BIOPHYS ACTA, V335, P330, DOI 10.1016/0005-2787(74)90157-9; HABER J E, 1992, Current Opinion in Cell Biology, V4, P401, DOI 10.1016/0955-0674(92)90005-W; HODGESGARCIA Y, 1995, J BIOL CHEM, V270, P197, DOI 10.1074/jbc.270.1.197; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; JASIN M, 1988, GENE DEV, V2, P1353, DOI 10.1101/gad.2.11.1353; JASIN M, 1985, CELL, V43, P695, DOI 10.1016/0092-8674(85)90242-9; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIN FL, 1984, MOL CELL BIOL, V4, P1020, DOI 10.1128/MCB.4.6.1020; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; Maniatis T., 1982, MOL CLONING; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MONK M, 1987, DEVELOPMENT, V99, P371; MORISHIMA A, 1962, P NATL ACAD SCI USA, V48, P756, DOI 10.1073/pnas.48.5.756; MURCHIE AI, 1993, J MOL BIOL, V205, P593; NUR I, 1985, J BACTERIOL, V164, P19, DOI 10.1128/JB.164.1.19-24.1985; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; PUCHTA H, 1992, MOL CELL BIOL, V12, P3372, DOI 10.1128/MCB.12.8.3372; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SEIDMAN MM, 1987, MOL CELL BIOL, V7, P3561, DOI 10.1128/MCB.7.10.3561; SERGHINI MA, 1989, NUCLEIC ACIDS RES, V17, P3604, DOI 10.1093/nar/17.9.3604; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUBRAMANI S, 1988, GENETIC RECOMBINATIO, P549; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VALANCIUS V, 1991, MOL CELL BIOL, V11, P4389, DOI 10.1128/MCB.11.9.4389; WILLARD HF, 1976, AM J HUM GENET, V28, P213; ZACHARIAS W, 1993, DNA METHYLATION MOL, P27	34	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23838	23844		10.1074/jbc.270.40.23838	http://dx.doi.org/10.1074/jbc.270.40.23838			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559561	hybrid			2022-12-27	WOS:A1995RY90900090
J	DELEO, FR; NAUSEEF, WM; JESAITIS, AJ; BURRITT, JB; CLARK, RA; QUINN, MT				DELEO, FR; NAUSEEF, WM; JESAITIS, AJ; BURRITT, JB; CLARK, RA; QUINN, MT			A DOMAIN OF P47(PHOX) THAT INTERACTS WITH HUMAN NEUTROPHIL FLAVOCYTOCHROME B(558)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; NADPH OXIDASE; MICROBICIDAL OXIDASE; PLASMA-MEMBRANE; SUPEROXIDE PRODUCTION; CYTOSOLIC COMPONENTS; CYTOCHROME-B; BINDING SITE	The NADPH-dependent oxidase of human neutrophils is a multicomponent system including cytosolic and membrane proteins. Activation requires translocation of cytosolic proteins p47(phox), p67(phox) ,and Rac2 to the plasma membrane and association with the membrane flavocytochrome b to assemble a functioning oxidase. We report the location of a region in p47(phox) that mediates its interaction with flavocytochrome b. From a random peptide phage display Library, we used biopanning with purified flavocytochrome b to select phage peptides that mimicked potential p47(phox) binding residues. Using this approach, we identified a region of p47(phox) from residue 323 to 342 as a site of interaction with flavocytochrome b. Synthetic peptides (315)SRKRLSQD-AYRRNS(328), (323)AYRRNSVRFL(332) and (334)QRRRQARPG-PQSPG(347) inhibited superoxide (O-2(radical anion)) production in the broken cell system with IC, of 18, 57, and 15 mu M, respectively. (323)AYRRNSVRFL(332) and its derivative peptides inhibited phosphorylation of p47(phox). However, the functional importance of this peptide was independent of its effects on phosphorylation, since (323)AYRRNA-VRFL(332) inhibited O-2(radical anion) production, but had no effect on phosphorylation. None of the peptides blocked O-2(radical anion) production when added after enzyme activation, suggesting that they inhibited the assembly, rather than the activity, of the oxidase. Furthermore these peptides inhibited membrane association of p47(phox), the broken cell translocation assay and O-2(radical anion) production by electropermeabilized neutrophils, thereby supporting the interpretation that this region of p47(phox) interacts with flavocytochrome b.	MONTANA STATE UNIV,DEPT VET MOLEC BIOL,BOZEMAN,MT 59717; MONTANA STATE UNIV,DEPT MICROBIOL,BOZEMAN,MT 59717; UNIV IOWA,IOWA CITY,IA 52242; DEPT VET AFFAIRS MED CTR,DEPT MED,IOWA CITY,IA 52242; UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284; AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital			Clark, Robert/Q-6764-2019	Clark, Robert/0000-0002-4892-3619; Nauseef, William/0000-0003-4032-757X; DeLeo, Frank/0000-0003-3150-2516; Quinn, Mark/0000-0001-8114-5073; Jesaitis, Algirdas/0000-0001-9001-5617	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028412, R01AI020866, R37AI020866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040929] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI020866, R37 AI020866, AI20866, AI28412] Funding Source: Medline; NIAMS NIH HHS [AR40929] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Veterans Affairs(US Department of Veterans Affairs); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); BLRD VA		ABO A, 1991, J BIOL CHEM, V266, P23577; BADWEY JA, 1993, FASEB J, V7, P1004; BAGGIOLINI M, 1993, FASEB J, V7, P1004, DOI 10.1096/fasebj.7.11.8396540; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FINAN P, 1994, J BIOL CHEM, V269, P13752; FUJITA I, 1987, BIOCHIM BIOPHYS ACTA, V931, P41, DOI 10.1016/0167-4889(87)90048-6; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; IYER SS, 1994, J BIOL CHEM, V269, P22405; JOSEPH G, 1994, J BIOL CHEM, V269, P29024; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J CLIN INVEST, V93, P2120, DOI 10.1172/JCI117207; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MALY FE, 1994, J BIOL CHEM, V269, P18743; NAKANISHI A, 1992, J BIOL CHEM, V267, P19072; NAUSEEF WM, 1993, EUR J HAEMATOL, V51, P301; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; PARK JW, 1992, J BIOL CHEM, V267, P19901; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; QUINN MT, 1995, METHOD ENZYMOL, V255, P476; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; Sambrook J, 1989, MOL CLONING LABORATO; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SMITH RM, 1991, BLOOD, V77, P673; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; VERHOEVEN AJ, 1993, J BIOL CHEM, V268, P18593; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557	49	70	71	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26246	26251		10.1074/jbc.270.44.26246	http://dx.doi.org/10.1074/jbc.270.44.26246			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592831	hybrid			2022-12-27	WOS:A1995TC97800038
J	FOSSATI, G; LUCIETTO, P; GIULIANI, P; COATES, AR; HARDING, S; COLFEN, H; LEGNAME, G; CHAN, E; ZALIANI, A; MASCAGNI, P				FOSSATI, G; LUCIETTO, P; GIULIANI, P; COATES, AR; HARDING, S; COLFEN, H; LEGNAME, G; CHAN, E; ZALIANI, A; MASCAGNI, P			MYCOBACTERIUM-TUBERCULOSIS CHAPERONIN-10 FORMS STABLE TETRAMERIC AND HEPTAMERIC STRUCTURES - IMPLICATIONS FOR ITS DIVERSE BIOLOGICAL-ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; PROTEIN; ANTIGENS; PEPTIDES	The chaperonin activity of sequence related chaperonin 10 proteins requires their aggregation into heptameric structures. We describe size-exclusion chromatography and ultracentrifugation studies that reveal that while Escherichia coli chaperonin 10 exists as a heptamer, the Mycobacterium tuberculosis chaperonin 10 is tetrameric in dilute solutions and in whole M. tuberculosis lysate. At high protein concentration and in the presence of saturating amounts of divalent ions, the protein is heptameric. Human chaperonin 10 is predominantly heptameric, although smaller oligomers were detected, These differences in structural assembly between species may explain differences in biological activity such as antigenicity. Using C-terminal and N-terminal fragments, sequence 1-25 was identified as indispensable for aggregation. CD spectroscopy studies revealed that (i) a minimum at 202-204 nm correlates with aggregation and characterizes not only the spectrum of the mycobacterial protein, but also those of E. coli and human chaperonin 10 proteins; (ii) the interactions between subunits are of the hydrophobic type; and (iii) the anti-parallel beta-pleated sheet is the main secondary structure element of subunits in both tetrameric and heptameric proteins.	UNIV NOTTINGHAM,DEPT APPL BIOCHEM & FOOD SCI,NOTTINGHAM LE12 5RD,ENGLAND; ITALFARMACO RES CTR,DEPT CHEM,I-20092 MILAN,ITALY; ST GEORGE HOSP,SCH MED,DEPT MED MICROBIOL,LONDON SW17 0RE,ENGLAND	University of Nottingham; Italfarmaco; St Georges University London			Zaliani, Andrea/ABC-9236-2021; Legname, Giuseppe/C-1723-2012	Zaliani, Andrea/0000-0002-1740-8390; Legname, Giuseppe/0000-0003-0716-4393; Harding, Stephen E./0000-0002-7798-9692; Coates, Anthony/0000-0001-8052-3175				ATKINS D, 1994, GENE, V150, P145, DOI 10.1016/0378-1119(94)90874-5; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; Ball H. L., 1995, BIOCH PEPT PROTEINS, V1, P39; BALL HL, 1992, INT J PEPT PROT RES, V40, P370; BALL HL, 1994, J CHROMATOGR A, V686, P73, DOI 10.1016/S0021-9673(94)89010-2; BARNES PF, 1992, J IMMUNOL, V148, P1835; CAVANAGH AC, 1994, EUR J BIOCHEM, V222, P551, DOI 10.1111/j.1432-1033.1994.tb18897.x; CHAN E, 1995, BIOCHEM BIOPH RES CO, V211, P14, DOI 10.1006/bbrc.1995.1771; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COATES ARM, 1995, CHAPERONINS; DEBRUYN J, 1987, INFECT IMMUN, V5, P245; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FOSSATI G, 1993, 2ND P JAP S PEPT CHE, P238; FRIEDLAND JS, 1993, CLIN EXP IMMUNOL, V91, P58; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HARDING SE, 1992, ANAL ULTRACENTRIFIGU; Kratky O, 1973, Methods Enzymol, V27, P98; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LEGNAME G, 1995, FEBS LETT, V361, P211, DOI 10.1016/0014-5793(95)00184-B; MANAVALAN P, 1983, NATURE, V305, P831, DOI 10.1038/305831a0; MASCAGNI P, 1994, 13TH P AM PEPT S, P763; MEHRA V, 1992, J EXP MED, V175, P275, DOI 10.1084/jem.175.1.275; MINDEN P, 1986, INFECT IMMUN, V53, P560, DOI 10.1128/IAI.53.3.560-564.1986; OFTUNG F, 1987, J IMMUNOL, V138, P927; ORME IM, 1988, J IMMUNOL, V140, P3589; PERCZEL A, 1992, PROTEINS, V13, P57, DOI 10.1002/prot.340130106; PERKINS SJ, 1986, EUR J BIOCHEM, V57, P169; PETERMANS WE, 1994, SCAN J IMMUNOL, V39, P613; PRATT LR, 1977, J CHEM PHYS, V67, P3683, DOI 10.1063/1.435308; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SAIBIL H, 1993, CURR OPIN STRUC BIOL, V3, P207, DOI 10.1016/S0959-440X(05)80154-X; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1994, NAT STRUCT BIOL, V1, P838, DOI 10.1038/nsb1294-838; Teller D C, 1973, Methods Enzymol, V27, P346; VERBON A, 1991, CLIN EXP IMMUNOL, V86, P6; Woody R. W., 1992, ADV BIOPHYS CHEM, V2, P37; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	40	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26159	26167		10.1074/jbc.270.44.26159	http://dx.doi.org/10.1074/jbc.270.44.26159			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592820	hybrid			2022-12-27	WOS:A1995TC97800027
J	JANCIAUSKIENE, S; DE FRUTOS, PG; CARLEMALM, E; DAHLBACK, B; ERIKSSON, S				JANCIAUSKIENE, S; DE FRUTOS, PG; CARLEMALM, E; DAHLBACK, B; ERIKSSON, S			INHIBITION OF ALZHEIMER BETA-PEPTIDE FIBRIL FORMATION BY SERUM AMYLOID-P COMPONENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COMPLEMENT C4B-BINDING PROTEIN; ASSOCIATION; DISEASE; PATHOGENESIS; DEPOSITS; SULFATE; BINDING; PATHWAY; HEPARIN	A 39-43-amino acid residue-long fragment (beta-peptide) from the amyloid precursor protein is the predominant component of amyloid deposits in the brain of individuals with Alzheimer's disease, Serum amyloid P component (SAP) is present in all types of amyloid, including that of Alzheimer's disease, We have used an in vitro model to study the effects of purified SAP on the fibril formation of synthetic Alzheimer beta-peptide 1-42, SAP was found to inhibit fibril formation and to increase the solubility of the peptide in a dose-dependent manner, At a 5:1 molar ratio of A beta 1-42 peptide to SAP, fibril formation was completely inhibited, and approximately 80% of the peptide remained in solution even after 4 days of incubation, At lower SAP concentrations, e,g, at peptide to SAP ratio of 1000:1, short fibrillar like structures, lacking amyloid characteristics, were formed, These structures frequently contained associated SAP molecules, suggesting that SAP binds to the polymerizing peptide in a reaction which prevented further fibril formation.	UNIV LUND HOSP, ELECTRONMICROSCOPY UNIT, S-22185 LUND, SWEDEN; UNIV LUND HOSP, DEPT MED, S-22185 LUND, SWEDEN; UNIV LUND HOSP, DEPT CLIN CHEM, S-22185 LUND, SWEDEN	Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital			de Frutos, Pablo García/B-8594-2011	de Frutos, Pablo García/0000-0003-1547-1190; Dahlback, Bjorn/0000-0003-1546-0328				BREATHNACH SM, 1989, J EXP MED, V170, P1433, DOI 10.1084/jem.170.4.1433; BREATHNACH SM, 1981, NATURE, V293, P652, DOI 10.1038/293652a0; CHRISTNER RB, 1994, J BIOL CHEM, V269, P9760; DE FRUTOS PG, 1994, J IMMUNOL, V152, P2430; DEBEER FC, 1981, J EXP MED, V154, P1134, DOI 10.1084/jem.154.4.1134; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; ERIKSSON S, 1995, P NATL ACAD SCI USA, V92, P2313, DOI 10.1073/pnas.92.6.2313; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; GALLO G, 1994, AM J PATHOL, V145, P526; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAMAZAKI H, 1995, J BIOL CHEM, V270, P10392, DOI 10.1074/jbc.270.18.10392; HAMAZAKI H, 1987, J BIOL CHEM, V262, P1456; HAMAZAKI H, 1989, BIOCHIM BIOPHYS ACTA, V998, P231, DOI 10.1016/0167-4838(89)90279-3; HICKS PS, 1992, J IMMUNOL, V149, P3689; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JANCIAUSKIENE S, 1995, BIOL CHEM H-S, V376, P415, DOI 10.1515/bchm3.1995.376.7.415; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; PEPYS MB, 1979, CLIN EXP IMMUNOL, V38, P284; PEPYS MB, 1987, BIOCHEM BIOPH RES CO, V148, P308, DOI 10.1016/0006-291X(87)91111-9; PEPYS MB, 1995, SAMTERS IMMUNOLOGIC, V2, P637; PERLMUTTER LS, 1995, J COMP NEUROL, V352, P92, DOI 10.1002/cne.903520107; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; RUBIO N, 1993, J BIOCHEM-TOKYO, V113, P277, DOI 10.1093/oxfordjournals.jbchem.a124039; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SCHWALBE RA, 1991, J BIOL CHEM, V266, P12896; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SNOW AD, 1989, NEUROBIOL AGING, V10, P481, DOI 10.1016/0197-4580(89)90108-5; STENSTAD T, 1993, CLIN EXP IMMUNOL, V94, P189; TENNENT GA, 1995, P NATL ACAD SCI USA, V92, P763; Thorell JL, 1978, RADIOIMMUNOASSAY REL; YING SC, 1993, J IMMUNOL, V150, P169	33	72	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26041	26044		10.1074/jbc.270.44.26041	http://dx.doi.org/10.1074/jbc.270.44.26041			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592799	hybrid			2022-12-27	WOS:A1995TC97800006
J	MIYASHITA, T; KITADA, S; KRAJEWSKI, S; HORNE, WA; DELIA, D; REED, JC				MIYASHITA, T; KITADA, S; KRAJEWSKI, S; HORNE, WA; DELIA, D; REED, JC			OVEREXPRESSION OF THE BCL-2 PROTEIN INCREASES THE HALF-LIFE OF P21(BAX)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL	Bcl-2 and Bax are homologous proteins which can heterodimerize with each other, These proteins have opposing effects on cell survival when overexpressed in cells, with Bcl-2 blocking and Bax promoting apoptosis, Here we demonstrate that gene transfer-mediated elevations in Bcl-2 protein levels result in a marked increase in the steady state levels of endogenous p21(Bax) protein as determined by immunoblotting in the Jurkat T-cell and 697 pre-B-cell leukemia cell lines, but not in several other cell lines including CEM T-cell leukemia, 32D.3 myeloid progenitor, PC12 pheochromocytoma, and NIH-3T3 fibroblasts. Steady-state levels of p21(Bax) protein were also elevated in the lymph nodes of Bcl-2 transgenic mice in which a BCL-2 transgene is expressed at high levels in B-cells. Northern blot analysis of BCL-2-transfected and control-transfected Jurkat and 697 leukemia cells revealed no Bcl-2-induced alterations in the steady-state levels of BAX mRNAs, In contrast, L-[S-35]methionine pulse-chase analysis indicated a marked increase in the half-life (t(1/2)) of the p21(Bax) protein in BCL-2-transfected 697 cells compared to control-transfected cells (t(1/2) > 24 h versus similar to 4 h), whereas the rate of Bax degradation was unaltered in Bcl-2-transfected CEM cells, The results demonstrate that levels of the proapoptotic p21(Bax) protein can be post-translationally regulated by Bcl-2, probably in a tissue-specific fashion, and suggest the existence of a feedback mechanism that may help to maintain the ratio of Bcl-2 to Bax protein in physiologically appropriate ranges.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037; IDUN PHARMACEUT INC,SAN DIEGO,CA 92121; IST NAZL TUMORI,DIV OSA,I-20133 MILAN,ITALY	Sanford Burnham Prebys Medical Discovery Institute; Fondazione IRCCS Istituto Nazionale Tumori Milan					NCI NIH HHS [CA-60381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BEHL C, 1993, BIOCHEM BIOPH RES CO, V197, P949, DOI 10.1006/bbrc.1993.2571; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; BOYD JM, 1993, CELL, V79, P341; Exley M, 1991, Semin Immunol, V3, P283; KATSUMATA M, 1992, P NATL ACAD SCI USA, V89, P11376, DOI 10.1073/pnas.89.23.11376; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1995, IN PRESS J NEUROSCI; KRAJEWSKI S, 1995, IN PRESS CANCER RES; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1983, BLOOD, V81, P151; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REED JC, 1991, EXP CELL RES, V195, P277, DOI 10.1016/0014-4827(91)90374-4; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TORIGOE T, 1994, CANCER RES, V54, P4851; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZHAN QM, 1994, ONCOGENE, V9, P3743	24	111	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26049	26052		10.1074/jbc.270.44.26049	http://dx.doi.org/10.1074/jbc.270.44.26049			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592801	hybrid			2022-12-27	WOS:A1995TC97800008
J	SONGYANG, Z; GISH, G; MBAMALU, G; PAWSON, T; CANTLEY, LC				SONGYANG, Z; GISH, G; MBAMALU, G; PAWSON, T; CANTLEY, LC			A SINGLE-POINT MUTATION SWITCHES THE SPECIFICITY OF GROUP-III SRC HOMOLOGY (SH) 2 DOMAINS TO THAT OF GROUP-I SH2 DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AFFINITY PHOSPHOTYROSYL PEPTIDE; BINDING	Src homology 2 (SH2) domains recognize phosphotyrosine-containing sequences, and thereby mediate the association of specific signaling proteins in response to tyrosine phosphorylation (Pawson, T., and Schlessinger, J. (1993) Curr. Biol. 3, 434-442). We have shown that specific binding of SH2 domains to tyrosine-phosphorylated sites is determined by sequences adjacent to the phosphotyrosine. Eased on the phosphopeptide specific ity and crystal structures, SH2 domains were classified into four different groups (Songyang, Z., Shoelson, S. E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W. G., King, F., Roberts, T., Ratnofsky, S., Lechleider, R. J., Neel, E. G., R. E. E., Fajardo, J. E., Chou, M. M., Hanafusa, H., Schaffhausen, E., and Cantley, L. C. (1993) Cell 72, 767-778). The beta D5 residues of SH2 domains were predicted to be critical in distinguishing these groups (Songyang, Z., Shoelson, S. E., Chaudhuri, M., Gish, G., Pawson, T., I-laser, W. G., King, F., Roberts, T., Ratnofsky, S., Lechleider, R. J., Neel, E. G., R. E. E., Fajardo, J. E., Chou, M. Ri., Hanafusa, H., Schaffhausen, E., and Cantley, L. C. (1993) Cell 72, 767-778; Eck, M. J., Shoelson, S. E., and Harrison, S. C. (1993) Nature 362, 87-91). We report here that replacing the aliphatic residues at the beta D5 positions of two Group III SH2 domains (phosphoinositide 3-kinase N-terminal SH2 domain and phospholipase C-gamma C-terminal SH2 domain) with Tyr (as found in Group I SH2 domains) results in a switch in phosphopeptide selectivity, consistent with the specificities of Group I SH2 domains. These results establish the importance of the beta D5 residue in determining specificities of SH2 domains.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAM MOLEC BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; MT SINAI HOSP, PROT ENGN NETWORK CTR EXCELLENCE, TORONTO, ON M5G 1X5, CANADA	Harvard University; Harvard Medical School; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	SONGYANG, Z (corresponding author), HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA.		Cantley, Lewis C/D-1800-2014; Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013	Cantley, Lewis C/0000-0002-1298-7653; 	NIGMS NIH HHS [GM36624] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036624] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; HENSMANN M, 1994, PROTEIN SCI, V3, P1020, DOI 10.1002/pro.5560030704; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; YOAKIM M, 1994, MOL CELL BIOL, V14, P5929, DOI 10.1128/MCB.14.9.5929; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	13	75	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26029	26032		10.1074/jbc.270.44.26029	http://dx.doi.org/10.1074/jbc.270.44.26029			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592796	hybrid			2022-12-27	WOS:A1995TC97800003
J	HAQUE, SJ; FLATI, V; DEB, A; WILLIAMS, BRG				HAQUE, SJ; FLATI, V; DEB, A; WILLIAMS, BRG			ROLES OF PROTEIN-TYROSINE PHOSPHATASES IN STAT1-ALPHA-MEDIATED CELL SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; INTERFERON-GAMMA; GENE-EXPRESSION; TRANSDUCTION PATHWAYS; INVITRO ACTIVATION; ALPHA-INTERFERON; VANADATE; KINASE; PHOSPHORYLATION; LINE	Different Stat proteins are activated through phosphorylation of unique tyrosine residues in response to different cytokines and growth factors. Interferon-gamma activates Stat1 molecules that form homodimers and bind cognate DNA elements. Here we show that treatment of permeabilized cells with 200-500 mu M peroxo-derivatives of vanadium, molybdenum, and tungsten results in the accumulation of constitutively phosphorylated Stat1 alpha molecules, In contrast, treatment of permeabilized cells with orthovanadate, vanadyl sulfate, molybdate, and tungstate at the same range of concentrations does not result in the accumulation of activated Stat1 alpha molecules in the absence of ligand. However, these compounds inhibit the inactivation of interferon-gamma-induced DNA-binding activity of Stat1 alpha. A 4-6-h exposure of the permeabilized cells to orthovanadate, molybdate, and tungstate, but not vanadyl sulfate, results in a ligand-independent activation of Stat1 alpha, which is blocked by the inhibition or depletion of NADPH oxidase activity in the cells, indicating that NADPH oxidase-catalyzed superoxide formation is required for the bioconversion of these metal oxides to the corresponding peroxo-compounds. Interestingly, Ligand-independent Stat1 alpha activation by peroxo-derivatives of these transition metals does not require Jak1, Jak2, or Tyk2 kinase activity, suggesting that other kinases can phosphorylate Stat1 alpha on tyrosine 701.			HAQUE, SJ (corresponding author), CLEVELAND CLIN FDN, RES INST, DEPT CANC BIOL, RM NN1-12, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.		Williams, Bryan R. G./A-5021-2009; FLATI, VINCENZO/R-6231-2018	Williams, Bryan R. G./0000-0002-4969-1151; FLATI, VINCENZO/0000-0003-1014-297X	NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA62220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BERNIER M, 1994, BIOCHEMISTRY-US, V33, P4343, DOI 10.1021/bi00180a031; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; Cotton F.A., 1972, ADV INORGANIC CHEM, Vthird, P1145; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; ELBERG G, 1994, J BIOL CHEM, V269, P9521; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRINSTEIN S, 1990, J BIOL CHEM, V265, P318; HAQUE SJ, 1994, J BIOL CHEM, V269, P19523; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LAMB P, 1994, J INTERFERON RES, V14, P365, DOI 10.1089/jir.1994.14.365; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NEWBURGER PE, 1979, J CELL BIOL, V82, P315, DOI 10.1083/jcb.82.2.315; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAI K, 1993, NATURE, V366, P508; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; XIAO S, 1994, J BIOL CHEM, V269, P21244; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	57	87	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25709	25714		10.1074/jbc.270.43.25709	http://dx.doi.org/10.1074/jbc.270.43.25709			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592750	hybrid			2022-12-27	WOS:A1995TB46600067
J	HERBST, JJ; ANDREWS, GC; CONTILLO, LG; SINGLETON, DH; GENEREUX, PE; GIBBS, EM; LIENHARD, GE				HERBST, JJ; ANDREWS, GC; CONTILLO, LG; SINGLETON, DH; GENEREUX, PE; GIBBS, EM; LIENHARD, GE			EFFECT OF THE ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE BY A THIOPHOSPHOTYROSINE PEPTIDE ON GLUCOSE-TRANSPORT IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONHYDROLYZABLE GTP ANALOGS; ALPHA-TOXIN; INSULIN; LOCALIZATION; MEMBRANE; RAT; TRANSLOCATION; KINASE; CELLS	Insulin causes the activation of phosphatidylinositol 3-kinase (PI 3-kinase) through complexation of tyrosine-phosphorylated YMXM motifs on insulin receptor substrate 1 with the Src homology 2 domains of PI 3-kinase. Previous studies with inhibitors have indicated that activation of PI 3-kinase is necessary for the stimulation of glucose transport in adipocytes. Here, we investigate whether this activation is sufficient for this effect. Short peptides containing two tyrosine-phosphorylated or thiophosphorylated YMXM motifs potently activated PI 3-kinase in the cytosol from 3T3-L1 adipocytes. Introduction of the phosphatase-resistant thiophosphorylated peptide into 3T3-L1 adipocytes through permeabilization with Staphylococcus aureus alpha-toxin stimulated PI 3-kinase as strongly as insulin. However, under the same conditions the peptide increased glucose transport into the permeabilized cells only 20% as well as insulin. Determination of the distribution of the glucose transporter isotype GLUT4 by confocal immunofluorescence showed that GLUT4 translocation to the plasma membrane can account for the effect of the peptide. These results suggest that one or more other insulin-triggered signaling pathways, besides the PI 3-kinase one, participate in the stimulation of glucose transport.	DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755; PFIZER INC,PFIZER CENT RES,GROTON,CT 06340	Dartmouth College; Pfizer					NIDDK NIH HHS [DK 42816] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042816, R01DK042816] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDINI G, 1991, J BIOL CHEM, V266, P4037; BEUSCH JEB, 1995, J BIOL CHEM, V270, P2036; BIRNBAUM MJ, 1992, INT REV CYTOL, V137, P29; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; FINGAR DC, 1994, ENDOCRINOLOGY, V134, P728, DOI 10.1210/en.134.2.728; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FROST SC, 1985, J BIOL CHEM, V260, P2646; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GOULD GW, 1994, J BIOL CHEM, V269, P26622; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KITAS E, 1994, INT J PEPT PROT RES, V43, P146; KLARLUND JK, 1993, J BIOL CHEM, V268, P7646; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; LAMPHERE L, 1994, AM J PHYSIOL, V266, pE486, DOI 10.1152/ajpendo.1994.266.3.E486; LAVAN BE, 1994, BIOCHEM SOC T, V22, P676, DOI 10.1042/bst0220676; LAZAR DF, 1995, DIABETES, V44, P206; OKADA T, 1994, J BIOL CHEM, V269, P3568; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROSEN OM, 1978, J BIOL CHEM, V253, P7579; SHIBATA H, 1991, ARCH BIOCHEM BIOPHYS, V285, P97, DOI 10.1016/0003-9861(91)90333-E; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; TOKER A, 1994, J BIOL CHEM, V269, P32358; TONKS NK, 1988, J BIOL CHEM, V263, P6722; VANDENBERGHE N, 1994, MOL CELL BIOL, V14, P2372, DOI 10.1128/MCB.14.4.2372; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	40	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					26000	26005		10.1074/jbc.270.43.26000	http://dx.doi.org/10.1074/jbc.270.43.26000			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592791	hybrid			2022-12-27	WOS:A1995TB46600108
J	HORI, O; BRETT, J; SLATTERY, T; CAO, R; ZHANG, JH; CHEN, JX; NAGASHIMA, M; LUNDH, ER; VIJAY, S; NITECKI, D; MORSER, J; STERN, D; SCHMIDT, AM				HORI, O; BRETT, J; SLATTERY, T; CAO, R; ZHANG, JH; CHEN, JX; NAGASHIMA, M; LUNDH, ER; VIJAY, S; NITECKI, D; MORSER, J; STERN, D; SCHMIDT, AM			THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS (RAGE) IS A CELLULAR-BINDING SITE FOR AMPHOTERIN - MEDIATION OF NEURITE OUTGROWTH AND COEXPRESSION OF RAGE AND AMPHOTERIN IN THE DEVELOPING NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADVANCED GLYCOSYLATION; PLASMINOGEN ACTIVATION; PROTEIN AMPHOTERIN; GLUCOSE; COMPLICATIONS; LOCALIZATION; COLLAGEN; MEMBRANE; SEQUENCE; SURFACE	The receptor for advanced glycation end products (RAGE), a newly-identified member of the immunoglobulin superfamily, mediates interactions of advanced glycation end product (AGE)-modified proteins with endothelium and other cell types. Survey of normal tissues demonstrated RAGE expression in situations in which accumulation of AGEs would be unexpected, leading to the hypothesis that under physiologic circumstances, RAGE might mediate interaction with ligands distinct from AGEs. Sequential chromatography of bovine lung extract identified polypeptides with M(r) values of approximate to 12,000 (p12) and approximate to 23,000 (p23) which bound RAGE. NH2-terminal and internal protein sequence data for p23 matched that reported previously for amphoterin. Amphoterin purified from rat brain or recombinant rat amphoterin bound to purified sRAGE in a saturable and dose-dependent manner, blocked by anti-RAGE IgG or a soluble form of RAGE (sRAGE). Cultured embryonic rat neurons, which express RAGE, displayed dose-dependent binding of I-125-amphoterin which was prevented by blockade of RAGE using antibody to the receptor or excess soluble receptor (sRAGE). A functional correlate of RAGE-amphoterin interaction was inhibition by anti-RAGE F(ab')(2) and sRAGE of neurite formation by cortical neurons specifically on amphoterin-coated substrates. Consistent with a potential role for RAGE-amphoterin interaction in development, amphoterin and RAGE mRNA/antigen were co-localized in developing rat brain. These data indicate that RAGE has physiologically relevant ligands distinct from AGEs which are likely, via their interaction with the receptor, to participate in physiologic processes outside of the context of diabetes and accumulation of AGEs.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT SURG,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; BERLEX BIOSCI,RICHMOND,CA 94804	Columbia University; Columbia University; Columbia University					NHLBI NIH HHS [HL21006] Funding Source: Medline; NIA NIH HHS [AG00602] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BRETT J, 1993, AM J PATHOL, V143, P1699; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELKHOURY J, 1994, J BIOL CHEM, V269, P10197; HICKS M, 1988, BIOCHEM BIOPH RES CO, V151, P649, DOI 10.1016/S0006-291X(88)80330-9; Hunt J, 1990, DIABETES, V30, P1420; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KLOTZ I, 1984, J BIOL CHEM, V258, P11442; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; MOHAN PS, 1992, BIOCHEM BIOPH RES CO, V182, P689, DOI 10.1016/0006-291X(92)91787-Q; MOHANTY JG, 1989, COMP IMMUNOL MICROB, V12, P153, DOI 10.1016/0147-9571(89)90064-7; NEEPER M, 1992, J BIOL CHEM, V267, P14998; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; PARKKINEN J, 1991, J BIOL CHEM, V266, P16730; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; SALMIVIRTA M, 1992, EXP CELL RES, V200, P444, DOI 10.1016/0014-4827(92)90194-D; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1994, J BIOL CHEM, V269, P9882; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHMIDT AM, 1994, FASEB J, V8, pA662; SCHMIDT AM, 1993, J CLIN INVEST, V92, P2155; SELL DR, 1989, J BIOL CHEM, V264, P21597; SLATTERY TK, 1992, TECHNIQUES PROTEIN C, V4; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; YAN SD, 1994, J BIOL CHEM, V269, P9889; YANG Z, 1991, J EXP MED, V174, P515, DOI 10.1084/jem.174.3.515	33	968	1038	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25752	25761		10.1074/jbc.270.43.25752	http://dx.doi.org/10.1074/jbc.270.43.25752			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592757	hybrid			2022-12-27	WOS:A1995TB46600074
J	KISSELEV, O; ERMOLAEVA, M; GAUTAM, N				KISSELEV, O; ERMOLAEVA, M; GAUTAM, N			EFFICIENT INTERACTION WITH A RECEPTOR REQUIRES A SPECIFIC TYPE OF PRENYL GROUP ON THE G-PROTEIN GAMMA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEIN; METARHODOPSIN-II; RHODOPSIN; TRANSDUCIN; MEMBRANES	Post-translational prenylation of the carboxyl-terminal cysteine is a characteristic feature of the guanine nucleotide-binding protein (G protein) gamma subunits. Recent findings show that the farnesylated COOH-terminal tail of the gamma 1 subunit is a specific determinant of rhodopsin-transducin coupling. We show here that when synthetic peptides specific to the COOH-terminal tail of gamma 1 are chemically modified with geranyl, farnesyl, or geranylgeranyl groups and tested for their ability to interact with light activated rhodopsin, the farnesylated peptide is significantly more effective. These results show that an appropriate isoprenoid on the G protein gamma subunit serves not only a membrane anchoring function but in combination with the COOH-terminal domain specifies receptor-G protein coupling.	WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								BENNETT N, 1982, EUR J BIOCHEM, V127, P97, DOI 10.1111/j.1432-1033.1982.tb06842.x; CALDWELL GA, 1994, P NATL ACAD SCI USA, V91, P1275, DOI 10.1073/pnas.91.4.1275; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KALMAN VK, 1995, J BIOL CHEM, V270, P14835, DOI 10.1074/jbc.270.24.14835; KISSELEV O, 1995, IN PRESS P NATL ACAD; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MATSUDA T, 1994, J BIOL CHEM, V269, P30358; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; ONG OC, 1995, J BIOL CHEM, V270, P8495, DOI 10.1074/jbc.270.15.8495; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; SCHEER A, 1995, BIOCHEMISTRY-US, V34, P4952, DOI 10.1021/bi00015a006; SIMON MI, 1991, SCIENCE, V52, P802; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WILLARDSON BM, 1993, J BIOL CHEM, V268, P6371	24	104	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25356	25358		10.1074/jbc.270.43.25356	http://dx.doi.org/10.1074/jbc.270.43.25356			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592699	hybrid			2022-12-27	WOS:A1995TB46600015
J	OSUSKY, M; TAYLOR, SJ; SHALLOWAY, D				OSUSKY, M; TAYLOR, SJ; SHALLOWAY, D			AUTOPHOSPHORYLATION OF PURIFIED C-SRC AT ITS PRIMARY NEGATIVE REGULATION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-TRANSFORMING PROTEIN; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; PP60C-SRC; ACTIVATION; CSK; PP60V-SRC; P60C-SRC; KINASES	The phosphorylating and transforming activities of c-Src are negatively regulated by phosphorylation at Tyr-527 near its carboxyl terminus, Previous studies have indicated that c-Src preferentially autophosphorylates Tyr-416, a residue in the middle of the catalytic domain, in vitro, and that Tyr-527 is phosphorylated by the carboxyl-terminal Src kinase, Csk. However, indirect evidence suggests that c-Src may also autophosphorylate Tyr-527 as part of a negative feedback loop, While some in vivo evidence suggests that Tyr-527 can be autophosphorylated in an intermolecular interaction, it has not previously been possible to directly demonstrate significant autophosphorylation in vitro, Here we show that c-Src purified from recombinant bacteria can autophosphorylate Tyr-527 to high levels in vitro when incubated with sufficiently high concentrations of ATP (K-m(Mg2+/ATP) approximate to 20 mu M) that are well above those that have been used previously. In vitro Tyr-527 autophosphorylation can occur both as an intra- and intermolecular interaction; higher enzyme concentrations are required for intermolecular Tyr-527 phosphorylation than for Tyr-416 autophosphorylation, These results support the possibility that, Like G-proteins, c-Src can switch itself off in vivo by its own enzymatic activity.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University					NATIONAL CANCER INSTITUTE [R01CA032317] Funding Source: NIH RePORTER; NCI NIH HHS [CA32317] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FEDER D, 1990, J BIOL CHEM, V265, P8205; GILMER TM, 1982, P NATL ACAD SCI-BIOL, V79, P2152, DOI 10.1073/pnas.79.7.2152; GILMER TM, 1981, NATURE, V294, P771, DOI 10.1038/294771a0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MACAULEY A, 1993, ONCOGENE, V8, P117; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; REVISGUPTA S, 1991, P NATL ACAD SCI USA, V88, P5954, DOI 10.1073/pnas.88.14.5954; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SUGIMOTO Y, 1985, J BIOL CHEM, V260, P3838; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; ZHANG S, 1991, Cellular Physiology and Biochemistry, V1, P24, DOI 10.1159/000154590	23	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25729	25732		10.1074/jbc.270.43.25729	http://dx.doi.org/10.1074/jbc.270.43.25729			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592753	hybrid			2022-12-27	WOS:A1995TB46600070
J	REGNIER, CH; TOMASETTO, C; MOOGLUTZ, C; CHENARD, MP; WENDLING, C; BASSET, P; RIO, MC				REGNIER, CH; TOMASETTO, C; MOOGLUTZ, C; CHENARD, MP; WENDLING, C; BASSET, P; RIO, MC			PRESENCE OF A NEW CONSERVED DOMAIN IN CART1, A NOVEL MEMBER OF THE TUMOR-NECROSIS-FACTOR RECEPTOR-ASSOCIATED PROTEIN FAMILY, WHICH IS EXPRESSED IN BREAST-CARCINOMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER; TARGETING SEQUENCES; CANCER; GENES; NUCLEAR; BINDING; MOTIF; CELLS; ALIGNMENT; ONCOGENE	CART1, a novel human gene, encodes a putative protein exhibiting three main structural domains: first, a cysteine-rich domain located at the amino-terminal part of the protein, which corresponds to an unusual RING finger motif; second, an original cysteine-rich domain located at the core of the protein and constituted by three repeats of an HC3HC3 consensus motif that we designated the CART motif, and which might interact with nucleic acid; third, the carboxyl-terminal part of the CART1 protein corresponds to a TRAF domain known to be involved in protein-protein interactions. Similar association of RING, CART, and TRAF domains was observed in the human CD40-binding protein and in the mouse tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2), both involved in signal transduction mediated by the TNF receptor family and in the developmentally regulated Dictyostelium discoideum DG17 protein. CART1 is specifically expressed by epithelial cells in breast carcinomas and metastases. Moreover, in these malignant cells, the CART1 protein is localized in the nucleus. Altogether, these observations indicate that CART1 may be involved in TNF-related cytokine signal transduction in breast carcinoma.	UNIV STRASBOURG 1, INST GENET & BIOL MOLEC & CELLULAIRE, CNRS, INSERM, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; CHU HAUTEPIERRE, SERV ANAT PATHOL GEN, F-67098 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg			Chenard, Marie-Pierre/O-2373-2016; MOOG-LUTZ, Christel/F-1975-2011; Tomasetto, Catherine Laure/J-2783-2014	Tomasetto, Catherine Laure/0000-0002-1811-5848; Regnier, Catherine/0000-0002-4386-1324				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Asano H, 1993, DNA Seq, V3, P369, DOI 10.3109/10425179309020838; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DANG CV, 1989, J BIOL CHEM, V264, P18019; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; DRISCOLL DM, 1987, MOL CELL BIOL, V7, P4482, DOI 10.1128/MCB.7.12.4482; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FLETCHER SW, 1994, J NATL CANCER I, V86, P558, DOI 10.1093/jnci/86.7.558-a; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; FROST P, 1992, LANCET, V339, P1458, DOI 10.1016/0140-6736(92)92040-M; GOEBL MG, 1991, CELL, V66, P623, DOI 10.1016/0092-8674(91)90106-9; Hoskins Kent, 1994, Current Opinion in Oncology, V6, P554, DOI 10.1097/00001622-199411000-00004; HU HM, 1994, J BIOL CHEM, V269, P30069; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PUSZTAI L, 1994, BRIT J CANCER, V70, P289, DOI 10.1038/bjc.1994.294; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; RIO MC, 1987, P NATL ACAD SCI USA, V84, P9243, DOI 10.1073/pnas.84.24.9243; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; RUSCIANO D, 1992, BIOESSAYS, V14, P185, DOI 10.1002/bies.950140309; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHMIEDESKAMP M, 1994, CURR OPIN STRUC BIOL, V4, P28, DOI 10.1016/S0959-440X(94)90056-6; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; ZHOU C, 1990, BIOTECHNIQUES, V8, P172	54	202	215	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25715	25721		10.1074/jbc.270.43.25715	http://dx.doi.org/10.1074/jbc.270.43.25715			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592751	hybrid			2022-12-27	WOS:A1995TB46600068
J	ZHOU, D; LUINI, W; BERNASCONI, S; DIOMEDE, L; SALMONA, M; MANTOVANI, A; SOZZANI, S				ZHOU, D; LUINI, W; BERNASCONI, S; DIOMEDE, L; SALMONA, M; MANTOVANI, A; SOZZANI, S			PHOSPHATIDIC-ACID AND LYSOPHOSPHATIDIC ACID INDUCE HAPTOTACTIC MIGRATION OF HUMAN MONOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVATION; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; HUMAN-NEUTROPHILS; SUPEROXIDE GENERATION; NADPH OXIDASE; PHOSPHATIDYLCHOLINE BREAKDOWN; INTRACELLULAR TRANSLOCATION; PHOSPHOHYDROLASE ACTIVITY; SIGNAL TRANSDUCTION; ENDOTHELIAL-CELLS	The present study was aimed at defining the chemotactic activity of phosphatidic acid, which is rapidly produced by phagocytes in response to chemotactic agonists. Exogenously added phosphatidic acid induced human monocyte directional migration across polycarbonate filters with an efficacy (number of cell migrated) comparable to that of ''classical'' chemotactic factors. In lipid specificity studies, activity of phosphatidic acid decreased with increasing acyl chain length but was restored by introducing unsaturation in the acyl chain with the most active form being the natural occurring 18:0,20:4-phosphatidic acid. Lysophosphatidic acid was also active in inducing monocyte migration. No other phospholipid and lysophospholipid tested was effective in this response. Monocyte migration was regulated by a gradient of phosphatidic acid and lysophosphatidic acid bound to the polycarbonate filter, in the absence of detectable soluble chemoattractant. Migration was also observed if phospholipids were bound to fibronectin-coated polycarbonate filters. Thus, phosphatidic acid and lysophosphatidic acid, similarly to other physiological chemoattractants (e.g. C5a and interleukin-8), induce cell migration by an haptotactic mechanism. Phosphatidic acid caused a rapid increase of filamentous actin and, at higher concentrations, induced a rise of intracellular calcium concentration. Monocyte migration to phosphatidic acid and lysophosphatidic acid, but not to diacylglycerol, was inhibited in a concentration-dependent manner by Bordetella pertussis toxin, while cholera toxin was ineffective. In the chemotactic assay, phosphatidic acid and lysophosphatidic acid induced a complete homologous desensitization and only partially cross-desensitized one with each other, or with diacylglycerol and monocyte chemotactic protein-1. Suramine inhibited monocyte chemotaxis with a different efficiency: phosphatidic acid > lysophosphatidic acid >> diacylglycerol. On the contrary, monocyte chemotactic protein-1-induced chemotaxis was not affected by the drug. Collectively, these data show that phosphatidic acid induces haptotactic migration of monocytes that is at least in part receptor-mediated. These results support a role for phosphatidic acid and lysophosphatidic acid in the regulation of leukocyte accumulation into tissues.	IST RIC FARMACOL MARIO NEGRI,I-20157 MILAN,ITALY; UNIV BRESCIA,DEPT BIOTECHNOL,PATHOL & IMMUNOL SECT,I-25100 BRESCIA,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Brescia			Sozzani, Silvano/C-1447-2009; salmona, mario/ABI-4066-2020; Diomede, Luisa/P-3417-2014; Mantovani, Alberto/HCI-7449-2022; salmona, mario/AAA-7116-2020	Sozzani, Silvano/0000-0002-3144-8743; Diomede, Luisa/0000-0002-2258-0531; Mantovani, Alberto/0000-0001-5578-236X; salmona, mario/0000-0002-9098-9873				ABRAHAM E, 1995, J EXP MED, V181, P569, DOI 10.1084/jem.181.2.569; AGWU DE, 1989, BIOCHEM BIOPH RES CO, V159, P79, DOI 10.1016/0006-291X(89)92407-8; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P99; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DIERICH MP, 1977, NATURE, V270, P351, DOI 10.1038/270351a0; DURIEUX ME, 1993, TRENDS PHARMACOL SCI, V14, P249, DOI 10.1016/0165-6147(93)90021-B; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; EXTON JH, 1990, J BIOL CHEM, V265, P1; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FERNANDEZ B, 1994, J BIOL CHEM, V269, P26711; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; GILAT D, 1994, J IMMUNOL, V153, P4899; GISMONDI A, 1991, J IMMUNOL, V146, P384; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HA KS, 1994, BIOCHEM J, V303, P55, DOI 10.1042/bj3030055; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HIGGINS CF, 1994, CELL, V79, P393, DOI 10.1016/0092-8674(94)90248-8; HOFFMAN RD, 1982, P NATL ACAD SCI-BIOL, V79, P3285, DOI 10.1073/pnas.79.10.3285; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWARD TH, 1984, J CELL BIOL, V98, P1265, DOI 10.1083/jcb.98.4.1265; HOWE LR, 1993, J BIOL CHEM, V268, P20717; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JALINK K, 1993, P NATL ACAD SCI USA, V90, P1857, DOI 10.1073/pnas.90.5.1857; JALINK K, 1990, J BIOL CHEM, V265, P12232; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JONES GA, 1993, J BIOL CHEM, V268, P20845; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KHAN WA, 1994, J BIOL CHEM, V269, P9729; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; KOUL O, 1987, ARCH BIOCHEM BIOPHYS, V253, P453, DOI 10.1016/0003-9861(87)90199-8; KROLL MH, 1989, J CELL PHYSIOL, V139, P558, DOI 10.1002/jcp.1041390315; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MANTOVANI A, 1989, IMMUNOL TODAY, V10, P370, DOI 10.1016/0167-5699(89)90270-3; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; MCPHAIL LC, 1993, NATURAL IMMUNE SYSTE, P63; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; PAGANO RE, 1983, J BIOL CHEM, V258, P2034; PERRY DK, 1993, J BIOL CHEM, V268, P25302; PIAZZA GA, 1995, EXP CELL RES, V216, P51, DOI 10.1006/excr.1995.1007; PLEVIN R, 1991, BIOCHEM J, V280, P609, DOI 10.1042/bj2800609; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; PUTNEY JW, 1980, NATURE, V284, P345, DOI 10.1038/284345a0; QUALLIOTINEMANN D, 1993, J BIOL CHEM, V268, P23843; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150; SALMON DM, 1980, NATURE, V284, P344, DOI 10.1038/284344a0; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2; SMYTH SS, 1992, J BIOL CHEM, V267, P15568; SNYDERMAN R, 1981, METHODS STUDYING MON, P535; SOZZANI S, 1994, J IMMUNOL, V152, P3615; SOZZANI S, 1993, J IMMUNOL, V150, P1544; SOZZANI S, 1991, J IMMUNOL, V147, P2215; SOZZANI S, 1995, J LEUKOCYTE BIOL, V57, P788, DOI 10.1002/jlb.57.5.788; SOZZANI S, 1995, BLOOD, V84, P3895; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STUTCHFIELD J, 1993, BIOCHEM J, V293, P649, DOI 10.1042/bj2930649; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TAYLOR GS, 1993, BIOCHIM BIOPHYS ACTA, V1175, P219, DOI 10.1016/0167-4889(93)90026-L; THOMSON FJ, 1994, MOL PHARMACOL, V45, P718; TRUETT AP, 1992, FASEB J, V6, P2720, DOI 10.1096/fasebj.6.9.1612297; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; VOELKER DR, 1990, EXPERIENTIA, V46, P569, DOI 10.1007/BF01939695; WANG JM, 1990, BIOCHEM BIOPH RES CO, V169, P165, DOI 10.1016/0006-291X(90)91449-3; WEBSTER RO, 1980, EXP CELL RES, V129, P55, DOI 10.1016/0014-4827(80)90330-4; WRIGHT TM, 1988, P NATL ACAD SCI USA, V85, P1869, DOI 10.1073/pnas.85.6.1869; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447; ZHOU HL, 1993, BIOCHEM PHARMACOL, V46, P139; ZIMMERMAN GA, 1995, IMMUNOL TODAY, V13, P93	90	84	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25549	25556		10.1074/jbc.270.43.25549	http://dx.doi.org/10.1074/jbc.270.43.25549			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592725	hybrid			2022-12-27	WOS:A1995TB46600042
J	DUAN, CM; CLEMMONS, DR				DUAN, CM; CLEMMONS, DR			TRANSCRIPTION FACTOR AP-2 REGULATES HUMAN INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-5 GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-I; MYOBLAST DIFFERENTIATION; INDUCIBLE ENHANCER; RETINOIC ACID; CYCLIC-AMP; CLONING; CELLS; RAT; IDENTIFICATION; ACTIVATION	Insulin-like growth factor binding protein-5 (IGFBP-5) is an important modulator of IGF actions. IGFBP-5 mRNA is abundant in human fibroblasts and is regulated by cAMP. To understand the molecular mechanism underlying this cell type-specific expression and regulation, we isolated the 5'-flanking region of the human IGFBP-5 gene and fused it to a promoter-less reporter plasmid encoding luciferase. Transient transfection of the construct into fibroblasts displayed both constitutive and cAMP-induced promoter activity in an orientation-specific manner. Sequence analysis revealed the existence of distal and proximal consensus AP-2 recognition sites located 5' from the TATA box. Both sequences bound specifically to human AP-2 in vitro by gel shift mobility assay. The possible role of AP-2 was examined by cotransfection of AP-2-deficient HepG2 cells with the IGFBP-5 promoter construct and a human AP-2 expression construct. Cotransfection with AP-2 significantly elevated IGFBP-5 promoter activity. This trans-activation was IGFBP-5 promoter and AP-2 specific. In AP-2 abundant fibroblasts, expression of AP-2B, a dominant-negative inhibitor of AP-2, suppressed IGFBP-5 promoter activity. In HepG2 cells, AP-2B alone had no significant effect, but the AP a-induced activation of promoter activity was inhibited by AP-2B in a dose-dependent manner. The relative functional importance of the putative AP-2 binding sites was examined using a number of deletion mutants and point mutations. When the first two distal CCCCACCC-like putative AP-2 sites were deleted or mutated, there was no change in AP-2-induced trans-activation. Deletion or mutation of the proximal GCCNNNGGC-like sequences, however, abolished the AP-2-induced activation. These results suggest that AP-2 regulates the IGFBP-5 gene expression through the proximal GCCNNNGGC-like sequences. This AP-2-mediated trans-activation contributes at least in part to the constitutively high expression of IGFBP-5 in fibroblasts and to the cAMP responsiveness of this gene.			DUAN, CM (corresponding author), UNIV N CAROLINA,DEPT MED,CB 7170 MACNIDER,CHAPEL HILL,NC 27599, USA.				NIA NIH HHS [AG02331] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG002331, R01AG002331] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLANDER SV, 1994, J BIOL CHEM, V269, P10891; ANDERSSON G, 1994, CELL GROWTH DIFFER, V5, P27; BACKELJAUW PF, 1993, ENDOCRINOLOGY, V132, P1677, DOI 10.1210/en.132.4.1677; BERNARDINI S, 1994, J NEUROENDOCRINOL, V6, P409, DOI 10.1111/j.1365-2826.1994.tb00601.x; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; CONOVER CA, 1993, ENDOCRINOLOGY, V132, P2525, DOI 10.1210/en.132.6.2525; DONG Y, 1995, ENDOCRINOLOGY, V136, P2000, DOI 10.1210/en.136.5.2000; FELDMAN EL, 1993, ANN NY ACAD SCI, V692, P262; GREEN BN, 1994, ENDOCRINOLOGY, V134, P954, DOI 10.1210/en.134.2.954; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAMES PL, 1993, J BIOL CHEM, V268, P22305; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KOU K, 1994, GENOMICS, V20, P412, DOI 10.1006/geno.1994.1195; KOU K, 1995, DNA CELL BIOL, V3, P241; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; PAHLMAN S, 1991, P NATL ACAD SCI USA, V88, P9994, DOI 10.1073/pnas.88.22.9994; PERKINS ND, 1994, J VIROL, V68, P6820, DOI 10.1128/JVI.68.10.6820-6823.1994; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SHEIKH MS, 1993, BIOCHEM BIOPH RES CO, V188, P1122; SHEMER J, 1993, J CLIN ENDOCR METAB, V77, P1246, DOI 10.1210/jc.77.5.1246; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; ZHU X, 1993, BIOCHEM BIOPH RES CO, V190, P1045, DOI 10.1006/bbrc.1993.1154	36	88	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24844	24851		10.1074/jbc.270.42.24844	http://dx.doi.org/10.1074/jbc.270.42.24844			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559606	Green Published, hybrid			2022-12-27	WOS:A1995TB46500040
J	FILATOV, D; THELANDER, L				FILATOV, D; THELANDER, L			ROLE OF A PROXIMAL NF-Y BINDING PROMOTER ELEMENT IN S-PHASE-SPECIFIC EXPRESSION OF MOUSE RIBONUCLEOTIDE REDUCTASE R2 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION; PROTEINS; DEOXYRIBONUCLEOTIDE; SUBUNITS; CLONING; TYPE-1	Cell cycle-regulated transcription of the R2 gene of mouse ribonucleotide reductase was earlier shown to be controlled at the level of elongation by an S phase-specific release from a transcriptional block. However, the R2 promoter is activated very early when quiescent cells start to proliferate, and this activation is dependent on three upstream sequences located nucleotide -672 to nucleotide -527 from the transcription start. In this study, we use R2-luciferase reporter gene constructs and gel shift assays to demonstrate that, in addition to the upstseam sequences, a proximal CCAAT element specifically binding the transcription factor NF-Y is required for continuous activity of the R2 promoter through the S phase. When the CCAAT element is deleted or mutated, promoter activity induced by the upstream elements decays before cells enter S phase, and the transcriptional block is released. This is a clear example of how changing of a proximal sequence element can alter not only the quantitative but also the qualitative response to upstream transcription activation domains.	UMEA UNIV,DEPT MED BIOCHEM & BIOPHYS,S-90187 UMEA,SWEDEN	Umea University								ARCOT SS, 1989, J BIOL CHEM, V264, P2343; BJORKLUND S, 1992, EMBO J, V11, P4953, DOI 10.1002/j.1460-2075.1992.tb05602.x; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BJORKLUND S, 1993, P NATL ACAD SCI USA, V90, P11322, DOI 10.1073/pnas.90.23.11322; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; KAWAMOTO T, 1989, NUCLEIC ACIDS RES, V17, P523, DOI 10.1093/nar/17.2.523; MAIRE P, 1989, SCIENCE, V246, P343; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; NORDENSKJOLD BA, 1970, J BIOL CHEM, V245, P5360; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THELANDER M, 1989, EMBO J, V8, P2475, DOI 10.1002/j.1460-2075.1989.tb08383.x; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525	24	37	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25239	25243		10.1074/jbc.270.42.25239	http://dx.doi.org/10.1074/jbc.270.42.25239			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559662	hybrid			2022-12-27	WOS:A1995TB46500096
J	LAMBALOT, RH; WALSH, CT				LAMBALOT, RH; WALSH, CT			CLONING, OVERPRODUCTION, AND CHARACTERIZATION OF THE ESCHERICHIA-COLI HOLO-ACYL CARRIER PROTEIN SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PDXJ OPERON; PURIFICATION; SYNTHETASE; GENES	Holo-acyl carrier protein synthase (ACPS) transfers the 4'-phosphopantetheine (4'-PP) moiety from coenzyme A (CoA) to Ser-36 of acyl carrier protein (ACP) in Escherichia coli. This post-translational modification renders holo-ACP capable of acyl group activation via thioesterification of the cysteamine thiol of 4'-PP. We have purified E. coli ACPS to near homogeneity by exploiting the ability to refold ACPS and reconstitute its activity after elution from an apo-ACP affinity column under denaturing conditions. N-terminal sequencing of ACPS allowed us to identify dpj, an essential gene of previously unknown function, as the structural gene for ACPS. We report herein the 70,000-fold purification of wild-type ACPS and the overproduction and initial characterization of recombinant ACPS from E. coli.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NIGMS NIH HHS [GM20011, GM16583-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020011, F32GM016583, R37GM020011] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BALDWIN JE, 1991, J ANTIBIOT, V44, P241, DOI 10.7164/antibiotics.44.241; ELHUSSEIN SA, 1988, BIOCHEM J, V252, P39, DOI 10.1042/bj2520039; ELOVSON J, 1968, J BIOL CHEM, V243, P3603; FISCHL AS, 1990, J BACTERIOL, V172, P5445, DOI 10.1128/jb.172.9.5445-5449.1990; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GEIGER O, 1991, J BACTERIOL, V173, P2872, DOI 10.1128/JB.173.9.2872-2878.1991; GERNGROSS TU, 1994, BIOCHEMISTRY-US, V33, P9311, DOI 10.1021/bi00197a035; HEATON MP, 1994, J BACTERIOL, V176, P681, DOI 10.1128/jb.176.3.681-690.1994; HOLAK TA, 1988, EUR J BIOCHEM, V175, P9, DOI 10.1111/j.1432-1033.1988.tb14159.x; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; Jones A. Lesley, 1993, Biochemical Society Transactions, V21, p202S; LAM HM, 1992, J BACTERIOL, V174, P1554, DOI 10.1128/jb.174.5.1554-1567.1992; MAJERUS PW, 1965, P NATL ACAD SCI USA, V53, P410, DOI 10.1073/pnas.53.2.410; PEREGO M, 1995, J BIOL CHEM, V270, P15598, DOI 10.1074/jbc.270.26.15598; POLACCO ML, 1981, J BIOL CHEM, V256, P5750; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; Rock C O, 1981, Methods Enzymol, V71 Pt C, P341; RUSNAK F, 1991, BIOCHEMISTRY-US, V30, P2916, DOI 10.1021/bi00225a027; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT B, 1992, FEBS LETT, V307, P355, DOI 10.1016/0014-5793(92)80712-P; SHEN B, 1992, J BACTERIOL, V174, P3818, DOI 10.1128/JB.174.11.3818-3821.1992; TAKIFF HE, 1992, J BACTERIOL, V174, P1544, DOI 10.1128/jb.174.5.1544-1553.1992	24	175	188	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24658	24661		10.1074/jbc.270.42.24658	http://dx.doi.org/10.1074/jbc.270.42.24658			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559576	hybrid			2022-12-27	WOS:A1995TB46500010
J	TANHAUSER, SM; LAIPIS, PJ				TANHAUSER, SM; LAIPIS, PJ			MULTIPLE DELETIONS ARE DETECTABLE IN MITOCHONDRIAL-DNA OF AGING MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-CHAIN FUNCTION; DEGENERATIVE DISEASES; SKELETAL-MUSCLE; EXTERNAL OPHTHALMOPLEGIA; HUMAN BRAIN; SEQUENCE; MUTATION; TISSUES; ACCUMULATION; MYOPATHIES	Mutational damage to human mitochondrial DNA (mtDNA) can cause disorders in oxidative phosphorylation; speculation that such damage is involved in degenerative diseases and aging is common. We have detected deletions in mouse mtDNA which resemble those found in elderly humans or patients with certain mtDNA disorders. Five different mtDNA deletions, predicted from the positions of short, direct DNA repeats, were present in aged, but not young, mice. Deleted regions were surrounded by either exact or inexact repeats and occurred in both the major and minor regions of the mtDNA genome, The abundance of a particular deletion was generally related to the thermodynamic stability of the bounding repeat sequence. Deletions in aged mice were present at low levels (less than 0.01% of total mtDNA). However, in contrast to results from aged humans, deletions were more abundant in liver than in brain, heart, or skeletal muscle. These results make it possible to predict the location and relative abundance of deletions in any sequenced mtDNA, including inbred mouse strains differing in inherent natural lifespan. The inbred mouse model will allow a critical examination of the relationship between the presence and abundance of mtDNA deletions and the aging process.	UNIV FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida					NIGMS NIH HHS [GM33537] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033537] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; ARNOLD FH, 1987, BIOCHEMISTRY-US, V26, P4068, DOI 10.1021/bi00387a049; BAKER GT, 1988, EXP GERONTOL, V23, P223, DOI 10.1016/0531-5565(88)90025-3; BAUMER A, 1994, AM J HUM GENET, V54, P618; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BLOCH W, 1992, AMPLIFICATIONS, V8, P1; BOURSOT P, 1987, MOL BIOL EVOL, V4, P46; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BROSSAS JY, 1994, BIOCHEM BIOPH RES CO, V202, P654, DOI 10.1006/bbrc.1994.1980; CHUNG SS, 1994, AGING-CLIN EXP RES, V6, P193, DOI 10.1007/BF03324239; COOPER JM, 1992, J NEUROL SCI, V113, P91, DOI 10.1016/0022-510X(92)90270-U; CORRALDEBRINSKI M, 1992, MUTAT RES, V275, P169, DOI 10.1016/0921-8734(92)90021-G; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; DEGOUL F, 1991, NUCLEIC ACIDS RES, V19, P493, DOI 10.1093/nar/19.3.493; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GADALETA MN, 1992, MUTAT RES, V275, P181, DOI 10.1016/0921-8734(92)90022-H; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603; KATAYAMA M, 1991, BIOCHEM INT, V25, P47; LINNANE AW, 1992, MUTAT RES, V275, P195, DOI 10.1016/0921-8734(92)90023-I; LINNANE AW, 1990, BIOCHEM INT, V22, P1067; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731; MASORO EJ, 1992, LAB ANIM SCI, V42, P132; MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; MUNSCHER C, 1993, FEBS LETT, V317, P27, DOI 10.1016/0014-5793(93)81484-H; NEWSHOLME EA, 1983, BIOCH MED SCI, P146; PERITZ AE, 1991, BIOCHEMISTRY-US, V30, P6428, DOI 10.1021/bi00240a013; PIKO L, 1992, ANN NY ACAD SCI, V663, P450, DOI 10.1111/j.1749-6632.1992.tb38698.x; PIKO L, 1988, MECH AGEING DEV, V43, P279, DOI 10.1016/0047-6374(88)90037-1; ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881; Sambrook J, 1989, MOL CLONING LABORATO; SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184; SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952; SIMONETTI S, 1992, BIOCHIM BIOPHYS ACTA, V1180, P113, DOI 10.1016/0925-4439(92)90059-V; SOONG NW, 1992, NAT GENET, V2, P318; SPROTT RL, 1991, NEUROBIOL AGING, V12, P635, DOI 10.1016/0197-4580(91)90113-X; SUGIYAMA S, 1991, BIOCHEM BIOPH RES CO, V180, P894, DOI 10.1016/S0006-291X(05)81149-0; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; YEN TC, 1991, BIOCHEM BIOPH RES CO, V178, P124, DOI 10.1016/0006-291X(91)91788-E; ZHANG C, 1992, FEBS LETT, V297, P34, DOI 10.1016/0014-5793(92)80321-7	49	124	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24769	24775		10.1074/jbc.270.42.24769	http://dx.doi.org/10.1074/jbc.270.42.24769			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559594	hybrid			2022-12-27	WOS:A1995TB46500028
J	ENGELAND, K; ANDREWS, NC; MATHEYPREVOT, B				ENGELAND, K; ANDREWS, NC; MATHEYPREVOT, B			MULTIPLE PROTEINS INTERACT WITH THE NUCLEAR INHIBITORY PROTEIN REPRESSOR ELEMENT IN THE HUMAN INTERLEUKIN-3 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HUMAN IL-3; TRANSCRIPTION FACTOR; GENE-EXPRESSION; MESSENGER-RNA; CELLS; IDENTIFICATION; INDUCTION; REQUIRES; REGION	T cell expression of interleukin 3 (IL-3) is directed by positive and negative cis-acting DNA elements clustered within 300 base pairs of the transcriptional start site, A strong repressor element, termed nuclear inhibitory protein (NIP), was previously mapped to a segment of the IL-3 promoter between nucleotides -271 and -250. Functional characterization of this element demonstrates that it can mediate repression when linked in cis to a heterologous promoter, DNA binding experiments were carried out to characterize the repressor activity, Using varying conditions, three distinct complexes were shown to interact specifically with the NIP region, al though only one correlates with repressor activity, Complex 1 results from binding of a ubiquitous polypeptide that recognizes the 3' portion of this sequence and is not required for repression, Complex 2 corresponds to binding of transcription factor (upstream stimulatory factor) to an E-box motif in the 5' portion of the NIP region, DNA binding specificity of complex 3 overlaps with that of upstream stimulatory factor but is clearly distinct, To determine which of the latter two complexes represents NIP activity, we incorporated small alterations into the NIP site of an IL-3 promoter-linked reporter construct and examined their effects on NIP-mediated repression, Functional specificity for repression matches the DNA binding specificity of complex 3; both repressor activity and complex 3 binding require the consensus sequence CTCACNTNC.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT PEDIAT ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, BOSTON, MA 02115 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute			Engeland, Kurt/AAW-9965-2020	Engeland, Kurt/0000-0003-3525-0440; Andrews, Nancy/0000-0003-0243-4462	NIDDK NIH HHS [R01 DK41758] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041758] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DAVIES K, 1993, BLOOD, V81, P928; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; KAWAKAMI TG, 1972, NATURE-NEW BIOL, V235, P170, DOI 10.1038/newbio235170a0; KOYANONAKAGAWA N, 1994, MOL CELL BIOL, V14, P5099, DOI 10.1128/MCB.14.8.5099; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; METCALF D, 1992, TRENDS BIOCHEM SCI, V17, P286, DOI 10.1016/0968-0004(92)90436-D; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; NIEMEYER CM, 1987, BLOOD, V73, P945; NIMER SD, 1988, MOL CELL BIOL, V8, P1979, DOI 10.1128/MCB.8.5.1979; OTSUKA T, 1988, J IMMUNOL, V140, P2288; RYAN GR, 1991, BLOOD, V77, P1195; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; WILLIAMS TM, 1991, SCIENCE, V254, P1791, DOI 10.1126/science.1840704; WIMPERIS JZ, 1989, BLOOD, V74, P1525; WOLIN M, 1993, ONCOGENE, V8, P1905; Yang Y. C., 1988, LYMPHOKINES, V15, P375; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0	29	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24572	24579		10.1074/jbc.270.41.24572	http://dx.doi.org/10.1074/jbc.270.41.24572			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592676	hybrid			2022-12-27	WOS:A1995TA21700104
J	JOHNSON, EM; CHEN, PL; KRACHMAROV, CP; BARR, SM; KANOVSKY, M; MA, ZW; LEE, WH				JOHNSON, EM; CHEN, PL; KRACHMAROV, CP; BARR, SM; KANOVSKY, M; MA, ZW; LEE, WH			ASSOCIATION OF HUMAN PUR-ALPHA WITH THE RETINOBLASTOMA PROTEIN, RB, REGULATES BINDING TO THE SINGLE-STRANDED-DNA PUR-ALPHA RECOGNITION ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F; LARGE T-ANTIGEN; D-TYPE CYCLINS; GENE-PRODUCT; CELL-CYCLE; SUSCEPTIBILITY GENE; REPLICATION ORIGIN; MOLECULAR-CLONING; EXPRESSION; SEQUENCE	The retinoblastoma protein, Rb, is detected in extracts of monkey CV-1 cells complexed with Pur alpha, a Sequence-specific single-stranded DNA-binding protein implicated in control of gene transcription and DNA replication, These complexes can be immunoextracted from cell lysates using monoclonal antibodies to either Pur alpha or Rb. The Pur alpha . Rb complexes contain a form of Pur alpha with extensive post-synthetic modification, as demonstrated following expression of Pur alpha cDNA fused to a 9-amino acid epitope tag. Human Pur alpha, expressed as a glutathione S-transferase fusion protein, specifically binds to the hypophosphorylated form of Rb with an affinity as high as that of SV40 large T-antigen, In the absence of DNA, glutathione S-transferase-Pur alpha binds to p56(RB), an NH2-terminal-truncated Rb protein purified from Escherichia coli, containing the T-antigen binding domain, to form multimeric complexes, The single-stranded DNA Pur alpha recognition element disrupts these complexes, Conversely, high concentrations of p56(RB) prevent Pur alpha binding to DNA, Through use of a series of deletion mutants, the DNA binding activity of Pur alpha is localized to a series of modular amino acid repeats, Rb binding involves a Pur alpha region with limited homology to the Rb-binding region of SV40 large T-antigen, Binding of Pur alpha to p56(RB), the COOH-terminal portion of Rb, is inhibited by a synthetic peptide containing the T-antigen Rb-binding motif.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,SAN ANTONIO,TX 78245	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Texas System; University of Texas Health San Antonio	JOHNSON, EM (corresponding author), CUNY MT SINAI SCH MED,DEPT PATHOL,NEW YORK,NY 10029, USA.			Krachmarov, Chavdar/0000-0003-1100-5096	NATIONAL CANCER INSTITUTE [R01CA055219, R55CA055219] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY005758] Funding Source: NIH RePORTER; NCI NIH HHS [CA55219] Funding Source: Medline; NEI NIH HHS [EY05758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; CADDLE MS, 1990, J MOL BIOL, V211, P19, DOI 10.1016/0022-2836(90)90008-A; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHANG CF, 1994, GENE, V148, P309; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN PL, 1992, CELL GROWTH DIFFER, V3, P119; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHOWDHURY M, 1993, ONCOGENE, V8, P887; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ECKDAHL TT, 1990, NUCLEIC ACIDS RES, V18, P1609, DOI 10.1093/nar/18.6.1609; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GALE JM, 1992, J MOL BIOL, V224, P343, DOI 10.1016/0022-2836(92)90999-Z; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; HERAULT Y, 1993, CELL MOL BIOL RES, V39, P717; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JACKS T, 1992, NATURE, V359, P328; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KILBOURNE ED, 1993, J GEN VIROL, V74, P1311, DOI 10.1099/0022-1317-74-7-1311; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LYNCH KJ, 1990, J VIROL, V64, P5812, DOI 10.1128/JVI.64.12.5812-5822.1990; MA ZW, 1994, GENE, V149, P311, DOI 10.1016/0378-1119(94)90167-8; MA ZW, 1995, CYTOGENET CELL GENET, V71, P64, DOI 10.1159/000134065; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MAYOL X, 1993, ONCOGENE, V8, P2561; MORROW JS, 1983, METHOD ENZYMOL, V96, P298; PATI UK, 1992, GENE, V114, P285, DOI 10.1016/0378-1119(92)90589-H; PEDERSEN B, 1993, ANTICANCER RES, V13, P1913; SAVRANSKY E, 1994, LAB INVEST, V70, P676; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TODOROV IT, 1994, J CELL SCI, V107, P253; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; VIRTAPEARLMAN VJ, 1993, MOL CELL BIOL, V13, P5931, DOI 10.1128/MCB.13.10.5931; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG NP, 1990, CELL GROWTH DIFFER, V1, P429; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	60	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24352	24360		10.1074/jbc.270.41.24352	http://dx.doi.org/10.1074/jbc.270.41.24352			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592647	hybrid			2022-12-27	WOS:A1995TA21700075
J	PERI, KG; HARDY, P; LI, DY; VARMA, DR; CHEMTOB, S				PERI, KG; HARDY, P; LI, DY; VARMA, DR; CHEMTOB, S			PROSTAGLANDIN G/H SYNTHASE-2 IS A MAJOR CONTRIBUTOR OF BRAIN PROSTAGLANDINS IN THE NEWBORN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBRAL BLOOD-FLOW; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MITOGEN-INDUCIBLE CYCLOOXYGENASE; RAT PREOVULATORY FOLLICLES; SWISS 3T3 CELLS; ENDOPEROXIDE SYNTHASE; MESSENGER-RNA; CEREBROVASCULAR PROSTAGLANDINS; H SYNTHASE; EXPRESSION	In order to understand the molecular basis of the elevated cerebral prostaglandin levels in the newborn, we compared the expression of the mRNAs and proteins of prostaglandin G/H synthases (PGHS), PGHS-1 and PGHS-2, in various regions of the brain and the microvasculature of newborn (1-2-day-old) and juvenile (4-7-week-old) pigs and also measured the relative contribution of PGHS-2 to cerebral prostaglandin synthesis both in vivo and in vitro by using a novel inhibitor of PGHS-2, NS-398. Ribonuclease protection assays using total RNA isolated from various regions of the porcine brain revealed that, unlike PGHS-1 mRNA, PGHS-2 mRNA was abundantly expressed in the cortex and the microvasculature of the newborn compared with those of the juvenile animal. PGHS-2 immunoreactive protein comprised the majority of total PGHS enzyme in neonatal cerebral microvasculature due to a 2-3-fold lower expression of immunoreactive PGHS-1 protein, Inhibition of PGHS-2 by NS-398 decreased the rate of prostaglandin synthesis by purified cerebral microvessels of the newborn by approximately 65% and of juvenile pigs by 30%, The decrease in brain tissue prostaglandin concentrations following intravenous administration of NS-398 was greater in newborn pigs (greater than or equal to 90%) than in the juvenile animals (less than or equal to 30%). Furthermore, NS-398 substantially reduced the net in vivo cerebrovascular production of prostaglandins in newborn pigs, Taken together, these results indicate that PGHS-2 is the predominant form of prostaglandin G/H synthase in the newborn brain and cerebral microvasculature and the main contributor to the brain prostaglandin levels in the newborn animal.	UNIV MONTREAL,ST JUSTINE HOSP,RES CTR,DEPT PEDIAT,MONTREAL,PQ H3T 1C5,CANADA; UNIV MONTREAL,ST JUSTINE HOSP,RES CTR,DEPT OPHTHALMOL,MONTREAL,PQ H3T 1C5,CANADA; UNIV MONTREAL,ST JUSTINE HOSP,RES CTR,DEPT PHARMACOL,MONTREAL,PQ H3T 1C5,CANADA; MCGILL UNIV,DEPT PHARMACOL & EXPTL THERAPEUT,MONTREAL,PQ H3T 1C5,CANADA	Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; McGill University								ABRAN D, 1995, AM J PHYSIOL-HEART C, V268, pH628, DOI 10.1152/ajpheart.1995.268.2.H628; AKAI Y, 1994, AM J PHYSIOL, V267, pC482, DOI 10.1152/ajpcell.1994.267.2.C482; BARNETT J, 1994, BIOCHIM BIOPHYS ACTA, V16, P130; BORDONARO M, 1994, BIOTECHNIQUES, V16, P428; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAZEVIEILLE C, 1994, NEUROCHEM INT, V24, P395, DOI 10.1016/0197-0186(94)90118-X; CHEMTOB S, 1991, PEDIATR RES, V30, P106, DOI 10.1203/00006450-199107000-00021; CHEMTOB S, 1990, STROKE, V21, P777, DOI 10.1161/01.STR.21.5.777; CHEMTOB S, 1990, CIRC RES, V67, P674, DOI 10.1161/01.RES.67.3.674; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DILDY GA, 1994, AM J OBSTET GYNECOL, V171, P679, DOI 10.1016/0002-9378(94)90081-7; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GAUDET RJ, 1980, J NEUROCHEM, V35, P653, DOI 10.1111/j.1471-4159.1980.tb03704.x; GOLDSTEIN GW, 1975, J NEUROCHEM, V25, P715, DOI 10.1111/j.1471-4159.1975.tb04395.x; HAYAISHI O, 1991, FASEB J, V5, P2575, DOI 10.1096/fasebj.5.11.1907936; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; JONES SA, 1993, AM J PHYSIOL, V264, pR135, DOI 10.1152/ajpregu.1993.264.1.R135; KAWASAKI M, 1993, MOL BRAIN RES, V19, P39, DOI 10.1016/0169-328X(93)90146-G; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LEAVER HA, 1984, PROSTA LEUKOTR MED, V13, P179, DOI 10.1016/0262-1746(84)90009-X; LEE SH, 1992, J BIOL CHEM, V267, P25934; LI DY, 1995, J PHARMACOL EXP THER, V272, P15; Li S.-R., 1993, Biological Signals, V2, P77; MALCOLM DD, 1993, J APPL PHYSIOL, V74, P1672, DOI 10.1152/jappl.1993.74.4.1672; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MEADE EA, 1993, J LIPID MEDIATOR, V6, P119; MITCHELL MD, 1978, PROSTAGLANDINS, V16, P319, DOI 10.1016/0090-6980(78)90033-3; MYERS SI, 1988, J SURG RES, V45, P154, DOI 10.1016/0022-4804(88)90035-2; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; OTTO JC, 1993, J BIOL CHEM, V268, P18234; PERI KG, 1993, BIOCHIM BIOPHYS ACTA, V1171, P281, DOI 10.1016/0167-4781(93)90066-M; POWELL WS, 1982, METHOD ENZYMOL, V86, P467; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SLATER D, 1994, BIOCHEM BIOPH RES CO, V203, P67, DOI 10.1006/bbrc.1994.2149; SMITH WL, 1994, ANN NY ACAD SCI, V744, P50, DOI 10.1111/j.1749-6632.1994.tb52723.x; TEIXEIRA FJ, 1994, J CLIN ENDOCR METAB, V78, P1396, DOI 10.1210/jc.78.6.1396; WIMSATT J, 1993, ENDOCRINOLOGY, V133, P1068, DOI 10.1210/en.133.3.1068; WOLFE LS, 1979, ANNU REV PHYSIOL, V41, P669, DOI 10.1146/annurev.ph.41.030179.003321; WONG WYL, 1992, ENDOCRINOLOGY, V130, P3512, DOI 10.1210/en.130.6.3512; XIE WL, 1992, DRUG DEVELOP RES, V25, P249, DOI 10.1002/ddr.430250402; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	53	134	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24615	24620		10.1074/jbc.270.41.24615	http://dx.doi.org/10.1074/jbc.270.41.24615			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592683	hybrid			2022-12-27	WOS:A1995TA21700111
J	RATNAM, K; SHIRAISHI, N; CAMPBELL, WH; HILLE, R				RATNAM, K; SHIRAISHI, N; CAMPBELL, WH; HILLE, R			SPECTROSCOPIC AND KINETIC CHARACTERIZATION OF THE RECOMBINANT WILD-TYPE AND C242S MUTANT OF THE CYTOCHROME-B REDUCTASE FRAGMENT OF NITRATE REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NADH-CYTOCHROME-B5 REDUCTASE; PHTHALATE DIOXYGENASE REDUCTASE; FERREDOXIN-NADP+ REDUCTASE; SITE-DIRECTED MUTAGENESIS; MO-PTERIN CENTERS; ESCHERICHIA-COLI; CYSTEINE RESIDUES; EXPRESSION; FLAVIN; DOMAIN	Spectroscopic and kinetic studies comparing the behavior of the recombinant cytochrome b reductase fragment of corn leaf nitrate reductase and a mutant in which cysteine 242 is replaced with a serine residue (C242S) have been carried out. The visible and circular dichroism spectra of the wild-type and mutant protein are virtually identical and compare well with those reported for nitrate reductases from other sources, The reduced wild-type protein forms a charge-transfer complex with NAD(+) that has an absorption envelope that extends into the near infrared, with a maximum around 800 nm, The C2425 mutant forms a similar charge-transfer complex with NAD(+) but to a lesser extent than the mild-type, The reduction potential of the flavin for the wild-type protein is -287 mV, and that for the mutant is -279 mV. The rate of reduction by NADH of the C2425 mutant is 7-fold slower than that for the wild-type protein, and the K-d is larger by a factor of 2. These results indicate that the cysteine 242 residue plays a role principally in facilitating electron transfer from NADH to the flavin rather than in binding of NADH to the enzyme.	MICHIGAN TECHNOL UNIV,PHYTOTECHNOL RES CTR,HOUGHTON,MI 49931; MICHIGAN TECHNOL UNIV,DEPT BIOL SCI,HOUGHTON,MI 49931	Michigan Technological University; Michigan Technological University	RATNAM, K (corresponding author), OHIO STATE UNIV,DEPT BIOCHEM MED,COLUMBUS,OH 43210, USA.			Campbell, Wilbur/0000-0001-6432-7537				ALIVERTI A, 1993, BIOCHEMISTRY-US, V32, P6374, DOI 10.1021/bi00076a010; AMY NK, 1977, BIOCHIM BIOPHYS ACTA, V480, P83; ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; BARBER MJ, 1990, J BIOL CHEM, V265, P20912; BATIE CJ, 1992, CHEM BIOCH FLAVOENZY, V3, P543; BURLEIGH BD, 1969, ANAL BIOCHEM, V84, P75; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; CAMPBELL WH, 1992, PLANT PHYSIOL, V99, P693, DOI 10.1104/pp.99.2.693; CAMPBELL WH, 1989, MOL GENETIC ASPECTS, P123; CANNONS AC, 1993, J BIOL CHEM, V268, P3268; CLARK WM, 1972, OXIDATION REDUCTION, P415; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V83, P8073; DWIVEDI UN, 1994, J BIOL CHEM, V269, P13785; HYDE GE, 1990, BIOCHEM BIOPH RES CO, V168, P1285, DOI 10.1016/0006-291X(90)91168-R; HYDE GE, 1991, J BIOL CHEM, V266, P23542; IYANAGI T, 1984, BIOCHEMISTRY-US, V23, P1418, DOI 10.1021/bi00302a013; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KAY CJ, 1990, BIOCHEMISTRY-US, V29, P10823, DOI 10.1021/bi00500a015; KAY CJ, 1988, BIOCHEMISTRY-US, V27, P6142, DOI 10.1021/bi00416a047; KAY CJ, 1989, BIOCHEM J, V263, P285, DOI 10.1042/bj2630285; KUBO Y, 1988, J BIOL CHEM, V263, P19684; LU GG, 1995, J MOL BIOL, V248, P931, DOI 10.1006/jmbi.1995.0273; LU GG, 1994, STRUCTURE, V2, P809, DOI 10.1016/S0969-2126(94)00082-4; Massey V, 1990, FLAVINS FLAVOPROTEIN, P59; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; ROUZE P, 1992, SOC EXP BIOL SEMIN S, V49, P45, DOI 10.1017/CBO9780511600395.004; SHIRABE K, 1991, J BIOL CHEM, V266, P7531; SOLOMONSON LP, 1990, ANNU REV PLANT PHYS, V41, P225, DOI 10.1146/annurev.pp.41.060190.001301; SOLOMONSON LP, 1984, FLAVINS FLAVOPROTEIN, P47; Takano T, 1994, FLAVINS AND FLAVOPROTEINS 1993, P409; WILLIAMS CH, 1976, ENZYMES, V8, P154	33	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24067	24072		10.1074/jbc.270.41.24067	http://dx.doi.org/10.1074/jbc.270.41.24067			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592606	hybrid			2022-12-27	WOS:A1995TA21700034
J	WILSON, DM; BINDER, LI				WILSON, DM; BINDER, LI			POLYMERIZATION OF MICROTUBULE-ASSOCIATED PROTEIN-TAU UNDER NEAR-PHYSIOLOGICAL CONDITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMER NEUROFIBRILLARY TANGLES; NEUROPIL THREADS; ASSEMBLY INVITRO; DISEASE; BRAIN; TUBULIN; DEMENTIA; SENILE; PHOSPHORYLATION	Neurofibrillary tangles, which form in certain degenerating neurons in the brains of patients with Alzheimer's disease, are amassed from filaments having a straight or paired helical morphology. Solubilization of these filaments reveals that they are composed of the microtubule-associated protein tau. It has not previously been shown, however, that tan win assemble to form filaments of similar morphology under conditions representative of the intracellular environment. We have succeeded in forming such filaments using tau purified from porcine or rat microtubules. The filaments are relatively straight with narrowing at irregular intervals, and are about 10 nn wide, a morphology similar to that of straight filaments seen in Alzheimer's disease neurofibrillary tangles. At tau concentrations of 1-10 mu M, in vitro assembly occurs at physiological pH, ionic strength, temperature, and reducing potential, and each one of these factors modulates the reaction, Assembly is judged to be only slowly reversible by the exponential rather than normal distribution of filament lengths, and by the limited disassembly observed under conditions which inhibit polymerization. Tau purified directly from whole brain tissue rather than from microtubules does not polymerize under conditions described in this report.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NIA NIH HHS [P01-AG06569, AG09031] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG006569, R01AG009031] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AEBI U, 1988, PROTOPLASMA, V145, P73, DOI 10.1007/BF01349341; BERKOWITZ SA, 1977, BIOCHEMISTRY-US, V16, P5610, DOI 10.1021/bi00644a035; BRAAK H, 1986, NEUROSCI LETT, V65, P351, DOI 10.1016/0304-3940(86)90288-0; BUGIANI O, 1979, ACTA NEUROPATHOL, V45, P147, DOI 10.1007/BF00691893; BURNS RG, 1991, BIOCHEM J, V277, P231, DOI 10.1042/bj2770231; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; CROWTHER RA, 1991, P NATL ACAD SCI USA, V88, P2288, DOI 10.1073/pnas.88.6.2288; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; CROWTHER RA, 1994, FEBS LETT, V337, P135, DOI 10.1016/0014-5793(94)80260-2; DEGARCINI EM, 1986, BIOCHEM BIOPH RES CO, V141, P790, DOI 10.1016/S0006-291X(86)80242-X; DEGARCINI EM, 1987, J BIOCHEM-TOKYO, V102, P1415, DOI 10.1093/oxfordjournals.jbchem.a122187; DUDEK SM, 1993, J NEUROCHEM, V61, P1159, DOI 10.1111/j.1471-4159.1993.tb03636.x; GEISLER N, 1981, J MOL BIOL, V151, P565, DOI 10.1016/0022-2836(81)90011-5; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; HAGESTEDT T, 1989, J CELL BIOL, V109, P1643, DOI 10.1083/jcb.109.4.1643; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HIRANO A, 1968, J NEUROPATH EXP NEUR, V27, P167, DOI 10.1097/00005072-196804000-00001; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; IQBAL K, 1984, ACTA NEUROPATHOL, V62, P167, DOI 10.1007/BF00691849; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; KIDD M, 1963, NATURE, V197, P192, DOI 10.1038/197192b0; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; KOWALL NW, 1987, ANN NEUROL, V22, P639, DOI 10.1002/ana.410220514; KSIEZAKREDING H, 1992, BRAIN RES, V597, P209, DOI 10.1016/0006-8993(92)91476-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1990, CELL MOTIL CYTOSKEL, V15, P199, DOI 10.1002/cm.970150402; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; METUZALS J, 1981, CELL TISSUE RES, V214, P455; PAPASOZOMENOS SC, 1987, CELL MOTIL CYTOSKEL, V8, P210, DOI 10.1002/cm.970080303; PAPASOZOMENOS SC, 1989, LAB INVEST, V60, P375; PERRY G, 1987, J NEUROSCI, V7, P3736; PROBST A, 1989, ACTA NEUROPATHOL, V77, P430, DOI 10.1007/BF00687379; RUBEN GC, 1993, BRAIN RES, V602, P1, DOI 10.1016/0006-8993(93)90234-E; RUBEN GC, 1991, J BIOL CHEM, V266, P22019; SANDOVAL IV, 1980, J BIOL CHEM, V255, P8952; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; SYMMONS MF, 1991, BIOCHEM J, V277, P245, DOI 10.1042/bj2770245; TELLEZNAGEL I, 1973, ARCH NEUROL-CHICAGO, V29, P324, DOI 10.1001/archneur.1973.00490290064007; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUYAMA S, 1986, J BIOL CHEM, V261, P4110; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WISHIK CM, 1985, J CELL BIOL, V100, P1905; WISNIEWSKI HM, 1984, J NEUROPATH EXP NEUR, V43, P643, DOI 10.1097/00005072-198411000-00008; WISNIEWSKI K, 1979, ANN NEUROL, V5, P288, DOI 10.1002/ana.410050311; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; YAGISHITA S, 1981, ACTA NEUROPATHOL, V54, P239, DOI 10.1007/BF00687747; YAMAGUCHI H, 1990, ACTA NEUROPATHOL, V80, P368, DOI 10.1007/BF00307689	59	81	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24306	24314		10.1074/jbc.270.41.24306	http://dx.doi.org/10.1074/jbc.270.41.24306			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592641	hybrid			2022-12-27	WOS:A1995TA21700069
J	YOKOKURA, H; PICCIOTTO, MR; NAIRN, AC; HIDAKA, H				YOKOKURA, H; PICCIOTTO, MR; NAIRN, AC; HIDAKA, H			THE REGULATORY REGION OF CALCIUM CALMODULIN-DEPENDENT PROTEIN-KINASE-I CONTAINS CLOSELY ASSOCIATED AUTOINHIBITORY AND CALMODULIN-BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT-CHAIN; SMOOTH-MUSCLE; PEPTIDE COMPLEX; RAT-BRAIN; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION; SEQUENCE; RECOGNITION; CELLS	The mechanism for the regulation of Ca2+/calmodulin-dependent protein kinase I (CaM kinase I) was investigated using a series of COOH-terminal truncated mutants. These mutants were expressed in bacteria as fusion proteins with glutathione S-transferase and purified by affinity chromatography using glutathione Sepharose 4B. A mutant (residues 1-332) showed complete Ca2+/CaM-dependent activity. Truncation mutants (residues 1-321, 1-314, and 1-309) exhibited decreasing affinities for Ca2+/CaM and also exhibited decreasing Ca2+/CaM-dependent activities. Truncation mutants (residues 1-305 or 1-299) were unable to bind Ca2+/CaM and were inactive. In contrast, truncation mutants (residues 1-293 or 1-277) were constitutively active at a slightly higher level (a fold) than fully active CaM kinase I. These results indicate the location of the Ca2+/ CaM-binding domain on CaM kinase I (residues 294-321) and predict the existence of an autoinhibitory domain near, or overlapping, the Ca2+/CaM-binding domain. These conclusions were supported by studies which showed that a synthetic peptide (CaM kinase I(294-321)) corresponding to residues 294-321 of CaM kinase I inhibited the fully active kinase in a manner that was competitive with Ca2+/CaM and also inhibited the constitutively active mutant (residues 1-293) in a manner that was competitive with Syntide-2, a peptide substrate, (K-i = 1.2 mu M) but was non-competitive with ATP. Thus, these results suggest that CaM kinase I is regulated through an intrasteric mechanism common to other members of the family of Ca2+/CaM-dependent protein kinases.	NAGOYA UNIV, SCH MED, DEPT PHARMACOL, SHOWA KU, NAGOYA, AICHI 466, JAPAN; INST PASTEUR, F-75724 PARIS, FRANCE; ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, NEW YORK, NY 10021 USA	Nagoya University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Rockefeller University			Picciotto, Marina R./F-8747-2012	Picciotto, Marina R./0000-0002-4404-1280; Nairn, Angus/0000-0002-7075-0195				ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; Beavo J A, 1974, Methods Enzymol, V38, P299; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell A.K, 1983, INTRACELLULAR CALCIU; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHO FS, 1994, BBA-MOL CELL RES, V1224, P156, DOI 10.1016/0167-4889(94)90123-6; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7519; DAVIS TN, 1992, CELL, V71, P557, DOI 10.1016/0092-8674(92)90590-9; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; ENDO T, 1981, J BIOL CHEM, V256, P2485; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; GLENNEY JR, 1980, J BIOL CHEM, V255, P551; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIDAKA H, 1983, METHOD ENZYMOL, V102, P185; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; INAGAKI M, 1987, ARCH BIOCHEM BIOPHYS, V254, P136, DOI 10.1016/0003-9861(87)90089-0; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; ITO T, 1994, ARCH BIOCHEM BIOPHYS, V312, P278, DOI 10.1006/abbi.1994.1310; ITO T, 1994, BIOCHEM BIOPH RES CO, V201, P1561, DOI 10.1006/bbrc.1994.1882; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P6247, DOI 10.1021/bi00239a024; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PEARSON RB, 1984, FEBS LETT, V168, P108, DOI 10.1016/0014-5793(84)80216-1; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; PICCIOTTO MR, 1995, J BIOL CHEM, V270, P10358; ROSKOSKI R, 1985, METHOD ENZYMOL, V99, P3; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; SUGITA R, 1994, BIOCHEM BIOPH RES CO, V203, P694, DOI 10.1006/bbrc.1994.2238; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016; ZHANG MJ, 1994, J BIOL CHEM, V269, P981	56	56	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23851	23859		10.1074/jbc.270.40.23851	http://dx.doi.org/10.1074/jbc.270.40.23851			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559563	hybrid			2022-12-27	WOS:A1995RY90900092
J	ZUCKER, S; CONNER, C; DIMASSMO, BI; ENDE, H; DREWS, M; SEIKI, M; BAHOU, WF				ZUCKER, S; CONNER, C; DIMASSMO, BI; ENDE, H; DREWS, M; SEIKI, M; BAHOU, WF			THROMBIN INDUCES THE ACTIVATION OF PROGELATINASE-A IN VASCULAR ENDOTHELIAL-CELLS - PHYSIOLOGICAL REGULATION OF ANGIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE INHIBITOR; IV COLLAGENASE; 72-KDA GELATINASE; MATRIX METALLOPROTEINASES; MEMBRANE; PROTEINASES; FIBROBLASTS; EXPRESSION; DOMAIN; PLASMA	Angiogenesis requires degradation of vascular base ment membrane prior to migration and proliferation of endothelial cells; proteinases are essential ingredients in this process. Because of thrombin's multiple effects on endothelium, we have examined its role in matrix metalloproteinase activation using human umbilical vein endothelial cells. Gelatin zymography of endothelial conditioned media revealed a prominent 72-kDa progelatinase A band. Addition of alpha-thrombin to endothelial cells resulted in the generation of 64 and 62 kDa gelatinolytic bands which is consistent with the activation of progelatinase A; thrombin had no effect in the absence of cells. This effect requires the proteolytic site of thrombin since progelatinase A activation was abolished by specific inhibitors of thrombin. Matrix metalloproteinase inhibitors diminished thrombin-induced activation of progelatinase A. Pretreatment of endothelial cells with excess tissue inhibitor of metalloproteinase-2 or a COOH-terminal fragment of progelatinase A abrogated thrombin mediated activation of progelatinase A presumably by competing with the COOH terminus of native progelatinase A for interaction with an activator site on endothelial plasma membranes. Although membrane-type matrix metalloproteinase was demonstrated in endothelial cells by Northern and Western blotting, the receptor function of this molecule in thrombin-induced activation of progelatinase A needs to be clarified. Progelatinase A activation did not require intracellular signal transduction events mediated by the thrombin receptor. These data demonstrate that 1) endothelial cells express a novel activation mechanism for progelatinase A, 2) proteolytically active thrombin regulates this activation mechanism, and 3) activation occurs independently of the functional thrombin receptor.	DEPT VET AFFAIRS MED CTR, DEPT MED, NORTHPORT, NY 11768 USA; DEPT VET AFFAIRS MED CTR, DEPT RES, NORTHPORT, NY 11768 USA; SUNY STONY BROOK, STONY BROOK, NY 11794 USA; KANAZAWA UNIV, CANC RES INST, KANAZAWA, ISHIKAWA 920, JAPAN	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Kanazawa University			Seiki, Motoharu/K-9443-2015		NHLBI NIH HHS [HL-02431, HL-49141] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049141, K08HL002431] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BAHOU WF, 1992, J BIOL CHEM, V267, P13986; BELLONI PN, 1992, MICROVASC RES, V43, P20, DOI 10.1016/0026-2862(92)90004-9; BROWN PD, 1993, KIDNEY INT, V43, P163, DOI 10.1038/ki.1993.27; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WT, 1990, CELL DIFFER DEV, V32, P329, DOI 10.1016/0922-3371(90)90047-Z; COOKSLEY S, 1990, MATRIX, V10, P285, DOI 10.1016/S0934-8832(11)80183-6; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; EMONARD HP, 1992, CANCER RES, V52, P5845; FISHER C, 1994, DEV BIOL, V162, P499, DOI 10.1006/dbio.1994.1104; FOLKMAN J, 1986, CANCER RES, V46, P467; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; GALARDY RE, 1994, CANCER RES, V54, P4715; GARCIA JGN, 1990, J CELL PHYSIOL, V142, P186, DOI 10.1002/jcp.1041420123; GOLIGORSKY MS, 1989, J BIOL CHEM, V264, P16771; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HUREWITZ AN, 1992, CHEST, V102, P1808, DOI 10.1378/chest.102.6.1808; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; KALEBIC T, 1983, SCIENCE, V221, P281, DOI 10.1126/science.6190230; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; KLEINER DE, 1993, BIOCHEMISTRY-US, V32, P1583, DOI 10.1021/bi00057a024; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MOUTSIAKIS D, 1992, CONNECT TISSUE RES, V28, P213, DOI 10.3109/03008209209015038; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y; SALO T, 1991, J BIOL CHEM, V266, P11436; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; STERN D, 1985, P NATL ACAD SCI USA, V82, P2523, DOI 10.1073/pnas.82.8.2523; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TSOPANOGLOU NE, 1993, AM J PHYSIOL, V264, pC1302, DOI 10.1152/ajpcell.1993.264.5.C1302; UNEMORI EN, 1990, J BIOL CHEM, V265, P445; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; ZUCKER S, 1992, INT J CANCER, V52, P366, DOI 10.1002/ijc.2910520307; ZUCKER S, 1994, CLIN EXP METASTAS, V12, P13, DOI 10.1007/BF01784329; ZUCKER S, 1987, CANCER RES, V47, P1608	45	173	181	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23730	23738		10.1074/jbc.270.40.23730	http://dx.doi.org/10.1074/jbc.270.40.23730			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559545	hybrid			2022-12-27	WOS:A1995RY90900074
J	FARGNOLI, J; BURKHARDT, AL; LAVERTY, M; KUT, SA; VANOERS, NSC; WEISS, A; BOLEN, JB				FARGNOLI, J; BURKHARDT, AL; LAVERTY, M; KUT, SA; VANOERS, NSC; WEISS, A; BOLEN, JB			SYK MUTATION IN JURKAT E6-DERIVED CLONES RESULTS IN LACK OF P72(SYK) EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CELL ANTIGEN RECEPTOR; ZETA-CHAIN; ASSOCIATION; ACTIVATION; ZAP-70	The human leukemic Jurkat cell line is commonly used as a model cellular system to study T lymphocyte signal transduction. Various clonal derivatives of Jurkat T cells exist which display different characteristics with regard to responses to external stimuli, Among these, the E6-1 clone of Jurkat T cells has been used as a parental line from which numerous important somatic mutant clones have been generated, During the course of experiments examining signals initiated by the T cell antigen receptor in an E6-1-derived Jurkat cell clone J.CaM1, we observed that the 72-kilodalton Syk protein tyrosine kinase previously found in other Jurkat cells was not detected, Upon further analysis it was determined that Syk transcripts from the J.CaM1 cells as well as the parental E6-1 cells contain a single guanine nucleotide insertion at position 92. This nucleotide insertion results in a shift in the Syk open reading frame leading to alternate codon usage as well as the generation of a termination codon at position 109. Thus, Syk transcripts in E6-1 cells and E6-1-derived clones are predicted to be capable of encoding only the first 33 amino acids of the 630-amino acid wild type Syk, These findings are incompatible with a recently proposed model of T cell antigen receptor signal transduction based, in part, on experiments conducted using E6-1-derived cells, suggesting that Syk might play a role upstream of Lck and Zap70.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT CELLULAR SIGNALING,PALO ALTO,CA 94304; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT ONCOL,PRINCETON,NJ 08543; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94066; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MED,SAN FRANCISCO,CA 94066	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Bristol-Myers Squibb; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco			Van+Oers, Nicolai/ABA-2437-2021	van Oers, Nicolai/0000-0002-6545-8405	NIGMS NIH HHS [GM39553] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHENG AM, 1995, IN PRESS NATURE; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; DARBY C, 1994, J IMMUNOL, V152, P5429; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IWASHIMA M, 1993, SCIENCE, V263, P1136; KAINZ P, 1992, ANAL BIOCHEM, V202, P46, DOI 10.1016/0003-2697(92)90203-J; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LAW CL, 1994, J BIOL CHEM, V269, P12310; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; RETH M, 1992, NATURE, V338, P383; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROWLEY RB, 1995, J BIOL CHEM, V270, P12659, DOI 10.1074/jbc.270.21.12659; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Sambrook J, 1989, MOL CLONING LABORATO; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169	32	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26533	26537		10.1074/jbc.270.44.26533	http://dx.doi.org/10.1074/jbc.270.44.26533			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592872	hybrid			2022-12-27	WOS:A1995TC97800079
J	HEATH, RJ; ROCK, CO				HEATH, RJ; ROCK, CO			ENOYL-ACYL CARRIER PROTEIN REDUCTASE (FABI) PLAYS A DETERMINANT ROLE IN COMPLETING CYCLES OF FATTY-ACID ELONGATION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS; INVIVO	The role of enoyl-acyl carrier protein (ACP) reductase (E.C, 1.3.1.9), the product of the fabI gene, was investigated in the type II, dissociated, fatty acid synthase system of Escherichia coli. All of the proteins required to catalyze one cycle of fatty acid synthesis from acetyl-CoA plus malonyl-CoA to butyryl-ACP in vitro were purified. These proteins were malonyl-CoA:ACP transacylase (fabD), beta-ketoacyl-ACP synthase III (fabH), beta-ketoacyl-ACP reductase (fabG), beta-hydroxydecanoyl-ACP dehydrase (fabA), and enoyl-ACP reductase (fabI). Unlike the other enzymes in the cycle, FabA did not efficiently convert its substrate beta-hydroxybutyryl-ACP to crotonyl-ACP, but rather the equilibrium favored formation of beta-hydroxybutyryl-ACP over crotonyl-ACP by a ratio of 9:1, The amount of butyryl-ACP formed depended on the amount of FabI protein added to the assay, Extracts from fabI(Ts) mutants accumulated beta-hydroxybutyryl-ACP, and the addition of FabI protein to the fabI(Ts) extract restored both butyryl-ACP and long-chain acyl-ACP synthesis. FabI was verified to be the only enoyl-ACP reductase required for the synthesis of fatty acids by demonstrating that purified FabI was required for the elongation of both long chain saturated and unsaturated fatty acids, These results were corroborated by analysis of the intracellular ACP pool composition in fabr(Ts) mutants that showed beta-hydroxybutyryl-ACP and crotonyl-ACP accumulated at the nonpermissive temperature in the same ratio found in the fabI(Ts) extracts and in the in vitro reconstruction experiments that lacked FabI. We conclude that FabI is the only enoyl-ACP reductase involved in fatty add synthesis in E, coli and that the activity of this enzyme plays a determinant role in completing cycles of fatty acid biosynthesis.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center				Heath, Richard/0000-0002-1795-1254	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BERGLER H, 1992, J GEN MICROBIOL, V138, P2093, DOI 10.1099/00221287-138-10-2093; BERGLER H, 1994, J BIOL CHEM, V269, P5493; Bloch K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHO HS, 1995, J BIOL CHEM, V270, P4216, DOI 10.1074/jbc.270.9.4216; CLARK DP, 1983, BIOCHEMISTRY-US, V22, P5897, DOI 10.1021/bi00294a032; CLEWELL DB, 1969, P NATL ACAD SCI USA, V62, P1159, DOI 10.1073/pnas.62.4.1159; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; DORMANN P, 1995, ARCH BIOCHEM BIOPHYS, V316, P612, DOI 10.1006/abbi.1995.1081; EGAN AF, 1973, GENET RES, V21, P3603; HEATH RJ, 1994, J BIOL CHEM, V269, P26584; HEATH RJ, 1995, J BIOL CHEM, V270, P15531, DOI 10.1074/jbc.270.26.15531; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; JACKOWSKI S, 1994, J BIOL CHEM, V269, P2921; JIANG P, 1994, J BACTERIOL, V176, P2814, DOI 10.1128/JB.176.10.2814-2821.1994; MAGNUSON K, 1995, J BACTERIOL, V177, P3593, DOI 10.1128/jb.177.12.3593-3595.1995; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Miller J. H., 1972, EXPT MOL GENETICS, P431; MOHAN S, 1994, J BIOL CHEM, V269, P32896; OHLROGGE J, 1995, ARCH BIOCHEM BIOPHYS, V317, P185, DOI 10.1006/abbi.1995.1152; PETTY KJ, 1994, CURRENT PROTOCOLS MO; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; ROCK CO, 1979, J BIOL CHEM, V254, P7123; ROCK CO, 1982, J BIOL CHEM, V257, P10759; SIGGAARDANDERSEN M, 1994, P NATL ACAD SCI USA, V91, P11027, DOI 10.1073/pnas.91.23.11027; TURNOWSKY F, 1989, J BACTERIOL, V171, P6555, DOI 10.1128/jb.171.12.6555-6565.1989; VOELKER TA, 1994, J BACTERIOL, V176, P7320, DOI 10.1128/JB.176.23.7320-7327.1994; WEEKS G, 1968, J BIOL CHEM, V243, P1180	31	295	333	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26538	26542		10.1074/jbc.270.44.26538	http://dx.doi.org/10.1074/jbc.270.44.26538			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592873	hybrid			2022-12-27	WOS:A1995TC97800080
J	LAING, JG; BEYER, EC				LAING, JG; BEYER, EC			THE GAP JUNCTION PROTEIN CONNEXIN43 IS DEGRADED VIA THE UBIQUITIN PROTEASOME PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING ENZYME; DEGRADATION; PHOSPHORYLATION; LIVER; CARDIOMYOCYTES; RECEPTOR; INVITRO; E1	We investigated the degradation of the gap junction protein connexin43 in E36 Chinese hamster ovary cells and rat cardiomyocyte derived BWEM cells. Treatment of E36 cells with the lysosomotropic amine, primaquine, for 16 h doubled the amount of connexin43 detected by immunoblotting and modestly increased the half-life of connexin43 in pulse-chase studies, suggesting that the lysosome played a minor role in connexin43 proteolysis, In contrast, treatment with the proteasomal inhibitor N-acetyl-L-leucyl-L-leucinyl-norleucinal led to a B-fold accumulation of connexin43 and increased the half-life of connexin43 to similar to 9 h. The role of ubiquitin in connexin43 degradation was examined in an E36-derived mutant, ts20, which contains a thermolabile ubiquitin-activating enzyme, E1, E36 and ts20 cells grown at the permissive temperature contained similar amounts of connexin43 detectable by immunoblotting, Heat treatment dramatically reduced the amount of connexin43 detected in E36 cells, while connexin43 levels in heat-treated ts20 cells did not change, E36 cells that were heat-treated in the presence of N-acetyl-L-leucyl-L-leucinyl-norleucinal did not lose their connexin43. Pulse-chase experiments showed the reversibility of the block to connexin43 degradation in ts20 cells that were returned to the permissive temperature. Finally, sequential immunoprecipitation using anti-connexin43 and anti-ubiquitin antibodies demonstrated polyubiquitination of connexin43. These results indicate that ubiquitin mediated proteasomal proteolysis may be the major mechanism of degradation of connexin43.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Beyer, Eric/V-1317-2019	Beyer, Eric/0000-0001-8044-1356	NATIONAL EYE INSTITUTE [R01EY008368, R29EY008368] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045466] Funding Source: NIH RePORTER; NEI NIH HHS [EY08368] Funding Source: Medline; NHLBI NIH HHS [HL45466] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; Beyer E C, 1993, Int Rev Cytol, V137C, P1; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Cole W.C., 1985, GAP JUNCTIONS, P215; DARROW BJ, 1995, CIRC RES, V76, P381, DOI 10.1161/01.RES.76.3.381; ELVIRA M, 1993, J BIOL CHEM, V268, P14294; FALLON RF, 1981, J CELL BIOL, V90, P521, DOI 10.1083/jcb.90.2.521; GINZBERG RD, 1979, DEV BIOL, V68, P110, DOI 10.1016/0012-1606(79)90247-1; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; GROPPER R, 1991, J BIOL CHEM, V266, P3602; HANDLEYGEARHART PM, 1994, BIOCHEM J, V304, P1015, DOI 10.1042/bj3041015; HILENSKI LL, 1992, J HISTOCHEM CYTOCHEM, V40, P1037, DOI 10.1177/40.7.1318894; HOU D, 1994, J BIOL CHEM, V269, P14244; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAING JG, 1994, J MEMBRANE BIOL, V139, P31; LAIRD DW, 1991, BIOCHEM J, V273, P67, DOI 10.1042/bj2730067; LARSEN WJ, 1979, J CELL BIOL, V83, P576, DOI 10.1083/jcb.83.3.576; LENK SE, 1992, J CELL BIOL, V118, P301, DOI 10.1083/jcb.118.2.301; LUKE RA, 1991, J CLIN INVEST, V87, P1594, DOI 10.1172/JCI115173; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MANDELBOIM O, 1994, NATURE, V369, P67, DOI 10.1038/369067a0; MANJUNATH CK, 1987, BIOCHEM BIOPH RES CO, V142, P228, DOI 10.1016/0006-291X(87)90475-X; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1992, J BIOL CHEM, V267, P6429; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; RECHSTEINER M, 1988, CURRENT TRENDS STUDY, P235; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHWARTZ AL, 1986, J BIOL CHEM, V261, P5225; SEVERS NJ, 1989, CIRC RES, V65, P22, DOI 10.1161/01.RES.65.1.22; TOWBIN H, 1970, P NATL ACAD SCI USA, V76, P4350; TRAUB O, 1983, P NATL ACAD SCI-BIOL, V80, P755, DOI 10.1073/pnas.80.3.755; TRAUB O, 1989, J CELL BIOL, V108, P1039, DOI 10.1083/jcb.108.3.1039; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	40	205	207	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26399	26403		10.1074/jbc.270.44.26399	http://dx.doi.org/10.1074/jbc.270.44.26399			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592854	hybrid			2022-12-27	WOS:A1995TC97800061
J	PETRITSCH, C; WOSCHOLSKI, R; EDELMANN, HML; BALLOU, LM				PETRITSCH, C; WOSCHOLSKI, R; EDELMANN, HML; BALLOU, LM			ACTIVATION OF P70 S6 KINASE AND ERK-ENCODED MITOGEN-ACTIVATED PROTEIN-KINASES IS RESISTANT TO HIGH CYCLIC-NUCLEOTIDE LEVELS IN SWISS 3T3 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; RAPAMYCIN; CELLS; S6-KINASE; P70(S6K); PROGRESSION; EXPRESSION; INHIBITORS; SITES	Treatment of Swiss mouse 3T3 fibroblasts with certain cyclic nucleotide phosphodiesterase inhibitors (theophylline, SQ 20,006, and MY-5445) prevents the activation of the M(r) 70,000 S6 kinase (p70(S6k)) induced by a variety of external stimuli, Concentrations giving half-maximal inhibition were 800, 50, and 25 mu M, respectively, Western blot analysis and immunocomplex kinase assays showed that these compounds inhibit the phosphorylation and activation of p70(S6k) without affecting the erk-encoded mitogen-activated protein (MAP) kinases or the rsk-encoded S6 kinase (p90(rsk)). A distinct collection of cAMP and cGMP agonists and analogues did not suppress p70(S6k) activation, indicating that 1) high intracellular cyclic nucleotide concentrations do not antagonize the p70(S6k) pathway and 2) phosphodiesterase inhibitors block p70(S6k) activation by a mechanism that is independent of cAMP or cGMP production. The effect of theophylline and SQ 20,006, but not MY-5445, on p70(S6k) signaling may be due in part to the inhibition of a phosphatidylinositol 3-kinase that acts upstream of p70(S6k). Finally, in contrast to many other cell types, cAMP and cGMP were also found to have no inhibitory effect on the MAP kinase/p90(rsk) signaling pathway in Swiss 3T3 fibroblasts.	INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Cancer Research UK			Petritsch, Claudia/AAP-9597-2021					ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHASIN M, 1972, BIOCHEM PHARMACOL, V21, P2443, DOI 10.1016/0006-2952(72)90414-5; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; FREDHOLM BB, 1982, EUR J PHARMACOL, V81, P673, DOI 10.1016/0014-2999(82)90359-4; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JOHNSON KW, 1988, P NATL ACAD SCI USA, V85, P6072, DOI 10.1073/pnas.85.16.6072; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KRIEG J, 1988, METHOD ENZYMOL, V164, P575; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MAGANIELLO V, 1972, P NATL ACAD SCI USA, V69, P269, DOI 10.1073/pnas.69.1.269; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; ROTHERMEL JD, 1984, J BIOL CHEM, V259, P8151; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SADLER SE, 1991, MOL ENDOCRINOL, V5, P1947, DOI 10.1210/mend-5-12-1947; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; STEINBERG RA, 1978, CELL, V15, P1351, DOI 10.1016/0092-8674(78)90060-0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS G, 1980, CELL, V19, P1015, DOI 10.1016/0092-8674(80)90092-6; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; WOSCHOLSKI R, 1994, J BIOL CHEM, V269, P25067; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	52	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26619	26625		10.1074/jbc.270.44.26619	http://dx.doi.org/10.1074/jbc.270.44.26619			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592886	hybrid			2022-12-27	WOS:A1995TC97800093
J	ROSE, T; SEBO, P; BELLALOU, J; LADANT, D				ROSE, T; SEBO, P; BELLALOU, J; LADANT, D			INTERACTION OF CALCIUM WITH BORDETELLA-PERTUSSIS ADENYLATE-CYCLASE TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI HEMOLYSIN HLYA; PROTEIN SECONDARY STRUCTURE; ESCHERICHIA-COLI; CIRCULAR-DICHROISM; ERYTHROCYTE-MEMBRANES; BINDING; PURIFICATION; ACTIVATION; SECRETION; DOMAINS	The adenylate intrinsic hemolytic activity that is independent hom the ATP cycling catalytic activity of the toxin, Both the cytotoxic and hemolytic activities are calcium-dependent. In this work, we have analyzed the calcium interacting properties of CyaA. We have shown that CyaA exposed to CaCl2 could retain membrane binding capability and hemolytic activity when it was further assayed in the presence of an excess of EGTA. Determination of the calcium content of CyaA exposed first to calcium and subsequently to EGTA indicated that some (3-5) calcium ions remained bound to the protein, suggesting the existence of Ca2+ binding sites of high affinity, finding of Ca2+ to these sites might be necessary for both the membrane binding capability and the hemolytic activity of the toxin. In addition, CyaA possesses a large number (about 45) of low affinity (K-D = 0.5-0.8 mM) Ca2+ binding sites that are located in the C terminus of the toxin, between amino acids 1007 and 1706. This region mainly consists of about 45 repeated sequences of the type GGXGXDXLX (where X represents any amino acid) that are characteristic of the RTX (Repeat: in ToXin) bacterial protein family. Our data suggest that each one can bind one calcium ion, Circular dichroism spectroscopy analysis showed that calcium binding to the low affinity sites induces a large conformational change of CyaA, as revealed by an important increase in the content of alpha-helical structures. This conformational change might be directly involved in the Ca2+-dependent translocation of the catalytic domain of CyaA through the plasma membrane of target cells.	INST PASTEUR, UNITE BIOCHIM REGULAT CELLULAIRES, F-75724 PARIS 15, FRANCE; INST PASTEUR, RESONANCE MAGNET NUCL LAB, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			SEBO, Peter/F-7423-2011; SEBO, Peter/N-2043-2019	SEBO, Peter/0000-0002-9755-7715; SEBO, Peter/0000-0002-9755-7715; ROSE, Thierry/0000-0001-8863-0207; LADANT, Daniel/0000-0003-1955-548X				BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BELLALOU J, 1990, INFECT IMMUN, V58, P1195, DOI 10.1128/IAI.58.5.1195-1200.1990; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BENZ R, 1994, J BIOL CHEM, V269, P27231; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; BOEHM DF, 1990, INFECT IMMUN, V58, P1959, DOI 10.1128/IAI.58.6.1959-1964.1990; BOEHM DF, 1990, INFECT IMMUN, V58, P1951, DOI 10.1128/IAI.58.6.1951-1958.1990; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; DORMAN BP, 1973, P NATL ACAD SCI USA, V70, P255, DOI 10.1073/pnas.70.1.255; EHRMANN IE, 1992, FEBS LETT, V304, P51, DOI 10.1016/0014-5793(92)80587-7; GENTILE F, 1990, J BIOL CHEM, V265, P10686; GLASER P, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P239; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HANSKI E, 1985, J BIOL CHEM, V260, P5526; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LADANT D, 1995, J BIOL CHEM, V270, P3179; LADANT D, 1992, J BIOL CHEM, V267, P2244; LADANT D, 1989, J BIOL CHEM, V264, P4015; LADANT D, 1986, J BIOL CHEM, V261, P6264; LUDWIG A, 1988, MOL GEN GENET, V214, P553, DOI 10.1007/BF00330494; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MASURE HR, 1987, MICROBIOL REV, V51, P60, DOI 10.1128/MMBR.51.1.60-65.1987; Mock M, 1993, Trends Microbiol, V1, P187, DOI 10.1016/0966-842X(93)90089-A; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; ROGEL A, 1991, J BIOL CHEM, V266, P3154; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; Sambrook J, 1989, MOL CLONING LABORATO; SEBO P, 1993, MOL MICROBIOL, V9, P999, DOI 10.1111/j.1365-2958.1993.tb01229.x; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; SHATTUCK RL, 1985, BIOCHEMISTRY-US, V24, P6323, DOI 10.1021/bi00344a001; SZABO G, 1994, J BIOL CHEM, V269, P22496; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841	40	136	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26370	26376		10.1074/jbc.270.44.26370	http://dx.doi.org/10.1074/jbc.270.44.26370			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592850	hybrid			2022-12-27	WOS:A1995TC97800057
J	TEO, M; MANSER, E; LIM, L				TEO, M; MANSER, E; LIM, L			IDENTIFICATION AND MOLECULAR-CLONING OF A P21(CDC42/RAC1)-ACTIVATED SERINE THREORNINE KINASE THAT IS RAPIDLY ACTIVATED BY THROMBIN IN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; CELL CYCLE GENE; HUMAN HOMOLOG; ENCODES; P21RAC; RHO; BCR; REGION; CDC42; G25K	The brain-enriched p21(cdc42/rac1)-activated serine/threonine kinase, p65(PAK), was identified and purified on the basis of overlays with [gamma-P-32]GTP-Cdc42 onto SDS-fractionated proteins (Manser, E., Leung, T., Salihuddin, H., Zhao, Z.-S., and Lim, L. (1994) Nature 367, 40-46). In this study, the ubiquitously expressed p21(cdc42/rac1) binding protein with relative molecular weight of 62,000 was purified from rat testes and shown to contain peptides related to PAK. It has thus been designated as the gamma-PAK isoform (alpha- and beta-isoforms being brain enriched). Isolation of gamma-PAK cDNAs show that the kinase is highly conserved with alpha-PAK in both the p21 binding and kinase domains. The purified protein exhibited kinase activity that was activated by GTP-Cdc42 or GTP-Rac1 in vitro. In platelets, a p62 in situ. renaturable kinase was recognized by antibodies raised against gamma-PAK. This thrombin-activated protein kinase appears to coprecipitate with another kinase of M(r) 86,000, suggesting that PAK may be part of a thrombin-responsive signaling complex.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,GLAXO IMCB GRP,SINGAPORE 0511,SINGAPORE; INST NEUROL,DEPT NEUROCHEM,LONDON WC1N 1PJ,ENGLAND	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of London; University College London			Manser, Edward/ABD-2301-2020					ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V9, P4263; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL C, 1993, MOL CELL BIOL, V13, P4986, DOI 10.1128/MCB.13.8.4986; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KROLL MH, 1989, BLOOD, V74, P1181; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEUNG T, 1994, J BIOL CHEM, V269, P12888; LEUNG T, 1993, J BIOL CHEM, V268, P3813; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MORII N, 1992, J BIOL CHEM, V267, P20921; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; SHINE J, 1977, NATURE, V270, P494, DOI 10.1038/270494a0; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; TAN EC, 1993, J BIOL CHEM, V268, P27291; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	37	121	130	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26690	26697		10.1074/jbc.270.44.26690	http://dx.doi.org/10.1074/jbc.270.44.26690			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592896	hybrid			2022-12-27	WOS:A1995TC97800103
J	BERVEN, LA; CROUCH, MF; KATSIS, F; KEMP, BE; HARLAND, LM; BARRITT, GJ				BERVEN, LA; CROUCH, MF; KATSIS, F; KEMP, BE; HARLAND, LM; BARRITT, GJ			EVIDENCE THAT THE PERTUSSIS-TOXIN-SENSITIVE TRIMERIC GTP-BINDING PROTEIN G(I2) IS REQUIRED FOR AGONIST-ACTIVATED AND STORE-ACTIVATED CA2+ INFLOW IN HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; RAT-LIVER; INHIBITION; PHOSPHORYLATION; THAPSIGARGIN; VASOPRESSIN; MESSENGER; MECHANISM; RELEASE	The role of a trimeric GTP-binding protein (G-protein) in the mechanism of vasopressin-dependent Ca2+ inflow in hepatocytes was investigated using both antibodies against the carboxyl termini of trimeric G-protein alpha subunits, and carboxyl-terminal alpha-subunit synthetic peptides. An anti-G(i1-2 alpha) antibody and a G(i2 alpha) peptide (G(i2 alpha) ILe(345)-Phe(355)), but not a Gi(3 alpha) peptide (G(i3 alpha) Ile(344)-Phe(354)), inhibited vasopressin- and thapsigargin-stimulated Ca2+ inflow, had no effect on vasopressin-stimulated release of Ca2+ from intracellular stores, and caused partial inhibition of thapsigargin-stimulated release of Ca2+. An anti-G(q alpha) antibody also inhibited vasopressin-stimulated Ca2+ inflow and partially inhibited vasopressin-induced release of Ca2+ from intracellular stores. Immunofluorescence measurements showed that G(i2 alpha) is distributed throughout much of the interior of the hepatocyte as well as at the periphery of the cell. By contrast, G(q/11 alpha) was found principally at the cell periphery. It is concluded that the trimeric G-protein, G(i2) is required for store-activated Ca2+ inflow in hepatocytes and acts between the release of Ca2+ from the endoplasmic reticulum (presumably adjacent to the plasma membrane) and the receptor-activated Ca2+ channel protein(s) in the plasma membrane.	FLINDERS UNIV S AUSTRALIA,SCH MED,DEPT MED BIOCHEM,ADELAIDE,SA 5001,AUSTRALIA; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV NEUROSCI,CANBERRA,ACT 2601,AUSTRALIA; ST VINCENTS INST MED RES,MELBOURNE,VIC 3065,AUSTRALIA	Flinders University South Australia; Australian National University; John Curtin School of Medical Research; St. Vincent's Institute of Medical Research			Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082				ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; BAFFY G, 1994, J BIOL CHEM, V269, P8483; BERVEN LA, 1994, BIOCHEM J, V299, P399, DOI 10.1042/bj2990399; BERVEN LA, 1994, FEBS LETT, V346, P235, DOI 10.1016/0014-5793(94)00481-1; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BUSHFIELD M, 1990, BIOCHEM J, V271, P365, DOI 10.1042/bj2710365; BUTTA N, 1993, J BIOL CHEM, V268, P6081; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CROUCH MF, 1993, CELL SIGNAL, V5, P41, DOI 10.1016/0898-6568(93)90006-8; DAWSON AP, 1985, FEBS LETT, V185, P147, DOI 10.1016/0014-5793(85)80759-6; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FERNANDO KC, 1994, BIOCHEM J, V303, P351, DOI 10.1042/bj3030351; GILL DL, 1986, NATURE, V320, P461, DOI 10.1038/320461a0; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HOTH M, 1993, ANN NY ACAD SCI, V707, P198, DOI 10.1111/j.1749-6632.1993.tb38053.x; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; JACONI MEE, 1993, J BIOL CHEM, V268, P26075; JENNER S, 1994, BIOCHEM J, V303, P337, DOI 10.1042/bj3030337; KIM HY, 1995, J BIOL CHEM, V270, P9706, DOI 10.1074/jbc.270.17.9706; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LIEVREMONT JP, 1994, BIOCHEM J, V300, P419, DOI 10.1042/bj3000419; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; POBINER BF, 1991, MOL PHARMACOL, V40, P156; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; YANG LJ, 1993, J BIOL CHEM, V268, P3739	30	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25893	25897		10.1074/jbc.270.43.25893	http://dx.doi.org/10.1074/jbc.270.43.25893			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592776	hybrid			2022-12-27	WOS:A1995TB46600093
J	GOTOH, Y; MASUYAMA, N; DELL, J; SHIRAKABE, K; NISHIDA, E				GOTOH, Y; MASUYAMA, N; DELL, J; SHIRAKABE, K; NISHIDA, E			INITIATION OF XENOPUS OOCYTE MATURATION BY ACTIVATION OF THE MITOGEN-ACTIVATED PROTEIN-KINASE CASCADE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN SOMATIC-CELLS; MAP KINASE; MEIOTIC MATURATION; SIGNAL-TRANSDUCTION; ONCOGENIC RAS; TYROSINE PHOSPHORYLATION; AMPHIBIAN OOCYTES; FROG OOCYTES; IN-VITRO; MOS	Mitogen-activated protein kinase (MAPK) and MAPK kinase (MAPKK) are activated during Xenopus oocyte maturation concomitant with the activation of maturation promoting factor (MPF). We reported previously that an anti-MAPKK neutralizing antibody inhibited progesterone- or Mos- induced initiation of oocyte maturation. Here, we show that injection of CL100 (also called MAPK phosphatase-1) into immature oocytes inhibited progesterone-induced oocyte maturation as well as MAPK activation and that injection of mRNA encoding a constitutively active MAPKK induced activation of histone H1 kinase and germinal vesicle breakdown in the absence of progesterone. Injection of recombinant STE11 protein (a yeast MAPKK kinase) also induced initiation of oocyte maturation. These data support the idea that the MAPKK/MAPK cascade plays an important role in oocyte maturation. Interestingly, injection of the active MAPKK mRNA or the STE11 protein resulted in induction and accumulation of Mos protein. Furthermore, in the presence of cycloheximide, the STE11-induced activation of MPF as well as the induction and accumulation of Mos was blocked, and the activation of MAPK was greatly reduced. The increase in Mos protein and the activation of MAPK by injecting cyclin A protein into immature oocytes were both blocked also by cycloheximide treatment. These results are consistent with an idea that there may exist a positive feedback loop consisting of Mos, the MAPKK/MAPK cascade, and MPF, which may be important for the initiation of oocyte maturation induced by progesterone.			GOTOH, Y (corresponding author), KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN.							Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALLENDE CC, 1988, FEBS LETT, V234, P426, DOI 10.1016/0014-5793(88)80130-3; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; DAAR I, 1993, J CELL BIOL, V120, P1197, DOI 10.1083/jcb.120.5.1197; DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; ELETR M, 1979, SCIENCE, V205, P1297; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GOTOH Y, 1994, ONCOGENE, V9, P1891; HACCARDO, 1995, DEV BIOL, V168, P677; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MALLER J, 1977, DEV BIOL, V58, P295, DOI 10.1016/0012-1606(77)90093-8; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MALLER JL, 1981, DEV BIOL, V85, P309, DOI 10.1016/0012-1606(81)90262-1; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Masui Y, 1979, Int Rev Cytol, V57, P185, DOI 10.1016/S0074-7696(08)61464-3; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; Moon R. T., 1989, TECHNIQUE, V1, P76; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEBREDA AR, 1993, ONCOGENE, V8, P467; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OPRESKO LK, 1990, P NATL ACAD SCI USA, V79, P2937; PARIS J, 1991, GENE DEV, V5, P1697, DOI 10.1101/gad.5.9.1697; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; RIME H, 1992, DEV BIOL, V151, P105, DOI 10.1016/0012-1606(92)90217-5; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	65	156	158	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25898	25904		10.1074/jbc.270.43.25898	http://dx.doi.org/10.1074/jbc.270.43.25898			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592777	hybrid			2022-12-27	WOS:A1995TB46600094
J	OGO, A; WATERMAN, MR; KAMPS, MP; KAGAWA, N				OGO, A; WATERMAN, MR; KAMPS, MP; KAGAWA, N			PROTEIN-KINASE A-DEPENDENT TRANSACTIVATION BY THE E2A-PBX1 FUSION PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; PRE-B; DNA-BINDING; TRANSCRIPTION FACTOR; ADENOSINE-MONOPHOSPHATE; TRANSLOCATION PROTEIN; CAMP RESPONSIVENESS; GENE; E2A	The chimeric gene E2A-PBX1 is formed by the t(1;19) chromosomal translocation exclusively associated with pediatric pre-B cell acute lymphoblastic leukemia (pre-B ALL). The resultant fusion protein from this chimeric gene contains the DNA-binding homeodomain of Pbx1. The first and only functional Pbx1 binding site has been localized in bovine CYP17 to a sequence (CRS1) that participates in cAMP-dependent transcription of this gene encoding the steroid hydroxylase, 17 alpha-hydroxylase cytochrome P450. Because Pbx1 is not expressed in pre-B cells, it may be possible that the E2a-Pbx1 fusion protein expressed in pre-B cells having this translocation will activate, in response to cAMP, transcription of genes not normally expressed in these cells leading to arrest of differentiation at the pre-B cell stage. We have now shown that reporter genes comprising CRS1 are activated transcriptionally by protein kinase A (PKA) in the pre-B cell line 697, which endogenously expresses the fusion protein, and that overexpression of E2A-Pbx1 in additional cell lines enhances transcription of reporter genes in a PKA-dependent fashion. Thus, it seems plausible that arrest in the pre-B stage leading to pre-B ALL includes cAMP-dependent activation of E2A-Pbx1.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,LA JOLLA,CA 92093	Vanderbilt University; University of California System; University of California San Diego					NIDDK NIH HHS [DK28350] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AHLGREN R, 1990, J BIOL CHEM, V265, P3313; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BARKER PE, 1987, CANCER GENET CYTOGEN, V25, P379, DOI 10.1016/0165-4608(87)90204-4; BAUM C, 1994, BIOTECHNIQUES, V17, P1058; CARROLL AJ, 1984, BLOOD, V63, P721; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DENNIG D, 1991, LYMPHOKINE CYTOK RES, V10, P27; HOFFMANN MK, 1988, J IMMUNOL, V140, P580; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; KAGAWA N, 1992, J BIOL CHEM, V267, P25213; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; KAGAWA N, 1994, J BIOL CHEM, V269, P18716; KAGAWA N, 1991, J BIOL CHEM, V266, P11199; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; LU QA, 1995, MOL CELL BIOL, V15, P3786; LUND J, 1990, J BIOL CHEM, V256, P3304; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	36	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25340	25343		10.1074/jbc.270.43.25340	http://dx.doi.org/10.1074/jbc.270.43.25340			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592695	hybrid			2022-12-27	WOS:A1995TB46600011
J	ROGERO, O; TEJEDOR, FJ				ROGERO, O; TEJEDOR, FJ			IMMUNOCHEMICAL CHARACTERIZATION AND DEVELOPMENTAL EXPRESSION OF SHAKER POTASSIUM CHANNELS FROM THE NERVOUS-SYSTEM OF DROSOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+-CHANNEL; BINDING-PROPERTIES; XENOPUS-OOCYTES; PROTEINS; SUBUNIT; LOCUS; MELANOGASTER; BRAIN; GENE; CDNA	We have raised antisera against recombinant peptides expressed from cDNAs fragments common to all splicing variants generated at the Shaker locus of Drosophila and used them as a tool to biochemically characterize these channel proteins, This antisera succeeded in detecting the expression of multiple Shaker potassium channels (Sh Kch), proteins with variable molecular mass (65-85 kDa) and pi (5.5-7), Additionally, for first time, specific Sh proteins of 40-45 kDa most probably corresponding to some of the so called short Sh cDNAs previously isolated by others have been identified, Using genetic criteria, it has been determined that at least a good part of this variety of proteins is generated by alternative splicing, Developmental experiments show a double wave of Sh Hch channel expression with a first pick at the third instar larvae stage, a minimum at the beginning of puparation, and the highest plateau 36 h after hatching of adult flies, The pattern of Sh splice variants changes dramatically throughout development. A detergent-resistant fraction with about 50% of Sh Kch which seems to be anchored to submembranous structures has been found, Finally, other biochemical properties of Sh Kch, like membrane fractionation and glycosylation, are also described.	CSIC, INST CAJAL, E-28002 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)				Tejedor, Francisco J/0000-0003-1942-2580				ATTALI B, 1993, J BIOL CHEM, V268, P24283; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BARBAS JA, 1989, MOL BRAIN RES, V5, P171, DOI 10.1016/0169-328X(89)90008-9; BAUMANN A, 1987, EMBO J, V6, P3419, DOI 10.1002/j.1460-2075.1987.tb02665.x; Breer H., 1985, Springer Series in Experimental Entomology, V1985, P125; BROADIE KS, 1993, J NEUROSCI, V13, P167; FERRUS A, 1990, GENETICS, V125, P383; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; GISSELMANN G, 1989, EMBO J, V8, P2359, DOI 10.1002/j.1460-2075.1989.tb08364.x; HARDIE RC, 1991, NEURON, V6, P477, DOI 10.1016/0896-6273(91)90255-X; HARLOW E, 1988, ANTIBODIES LABORATOR; Hille B., 1992, IONIC CHANNELS EXCIT; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KYTE J, 1983, ANAL BIOCHEM, V133, P515, DOI 10.1016/0003-2697(83)90118-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MOTTES JR, 1995, NEURON, V14, P613, DOI 10.1016/0896-6273(95)90318-6; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARCEJ DN, 1989, BIOCHEM J, V257, P899, DOI 10.1042/bj2570899; PASSAFARO M, 1994, NEURON, V12, P317, DOI 10.1016/0896-6273(94)90274-7; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; REHM H, 1989, FEBS LETT, V247, P28, DOI 10.1016/0014-5793(89)81233-5; REHM H, 1984, J BIOL CHEM, V259, P6865; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; Sambrook J, 1989, MOL CLONING LABORATO; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; SANTAREN JF, 1986, EMBO J, V5, P877, DOI 10.1002/j.1460-2075.1986.tb04298.x; SCHMIDT J, 1985, P NATL ACAD SCI USA, V82, P4847, DOI 10.1073/pnas.82.14.4847; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; SCHULTEIS CT, 1995, BIOCHEMISTRY-US, V34, P1725, DOI 10.1021/bi00005a029; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SCHWARZ TL, 1990, NEURON, V4, P119, DOI 10.1016/0896-6273(90)90448-O; SHEN NV, 1993, NEURON, V11, P67; SPITZER NC, 1991, J NEUROBIOL, V22, P659, DOI 10.1002/neu.480220702; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; SUN TY, 1994, BIOCHEMISTRY-US, V33, P9992, DOI 10.1021/bi00199a024; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; TSENGCRANK J, 1991, J NEUROGENET, V7, P229, DOI 10.3109/01677069109167435; Whittaker V P, 1965, Prog Biophys Mol Biol, V15, P39, DOI 10.1016/0079-6107(65)90004-0	49	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25746	25751		10.1074/jbc.270.43.25746	http://dx.doi.org/10.1074/jbc.270.43.25746			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592756	hybrid			2022-12-27	WOS:A1995TB46600073
J	VONKOCH, CS; LAHIRI, DK; MAMMEN, AL; COPELAND, NG; GILBERT, DJ; JENKINS, NA; SISODIA, SS				VONKOCH, CS; LAHIRI, DK; MAMMEN, AL; COPELAND, NG; GILBERT, DJ; JENKINS, NA; SISODIA, SS			THE MOUSE APLP2 GENE - CHROMOSOMAL LOCALIZATION AND PROMOTER CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN PRECURSOR; ALZHEIMERS-DISEASE; REGULATORY ELEMENTS; MAMMALIAN-CELLS; MESSENGER-RNA; REGION; EXPRESSION; CDNA; DNA; IDENTIFICATION	Senile plaques are primarily comprised of deposits of the beta-amyloid protein derived from larger amyloid precursor proteins (APPs). APP is a member of a gene family, including amyloid precursor-like proteins APLP1 and APLP2. Using interspecific mouse backcross mapping, we localized the mouse APLP2 gene to the proximal region of mouse chromosome 9, syntenic with a region of human 11q. We cloned an similar to 1.2-kilobase mouse genomic fragment containing the APLP2 gene promoter. The APLP2 promoter lacks a typical TATA box, is CC-rich, and contains several sequences for transcription factor binding. S1 nuclease protection analysis revealed the presence of multiple transcription start sites. The lack of a TATA box, the presence of a high GC content, and multiple transcription start sites place the APLP2 promoter in the class of promoters of ''housekeeping genes.'' Regulatory regions within the promoter were assayed by transfection of mouse N2a and Ltk(-) cells with constructs containing progressive 5'-deletions of the APLP2 promoter fused to the bacterial chloramphenicol acetyl transferase (CAT) reporter gene. A minimal region that includes sequences 99 bp upstream of the predominant transcription start site of the APLP2 promoter was sufficient to direct high levels of CAT expression.	JOHNS HOPKINS UNIV, SCH MED, NEUROPATHOL LAB, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA; INDIANA UNIV, SCH MED, DEPT PSYCHIAT, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED & MOLEC GENET, INDIANAPOLIS, IN 46202 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MAMMALIAN GENET LAB, FREDERICK, MD 21702 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Lahiri, Debomoy/AAZ-3322-2020; Mammen, Andrew/AAF-2885-2021		NATIONAL INSTITUTE ON AGING [P50AG005146] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO046000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-46000] Funding Source: Medline; NIA NIH HHS [AG 05146] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHERNAK JM, 1993, GENE, V133, P255, DOI 10.1016/0378-1119(93)90648-M; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; CROUSE GF, 1982, J BIOL CHEM, V257, P7887; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Green EL, 1981, GENETICS PROBABILITY, P77; HANES J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P154, DOI 10.1016/0167-4781(93)90055-I; HOFFMAN PW, 1994, BIOCHEM BIOPH RES CO, V201, P610, DOI 10.1006/bbrc.1994.1745; IZUMI R, 1992, GENE, V112, P189, DOI 10.1016/0378-1119(92)90375-Y; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; LAFAUCI G, 1989, BIOCHEM BIOPH RES CO, V159, P297, DOI 10.1016/0006-291X(89)92437-6; LORENT K, 1995, NEUROSCIENCE, V65, P1009, DOI 10.1016/0306-4522(94)00555-J; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANNINEN I, 1993, BIOTECHNIQUES, V14, P174; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SANDBRINK R, 1994, BBA-GENE STRUCT EXPR, V1219, P167, DOI 10.1016/0167-4781(94)90263-1; SANDBRINK R, 1994, J BIOL CHEM, V269, P14227; Sandbrink R, 1994, Neurobiol Dis, V1, P13, DOI 10.1006/nbdi.1994.0003; SISODIA SS, 1987, MOL CELL BIOL, V7, P3602, DOI 10.1128/MCB.7.10.3602; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; THINAKARAN G, 1995, IN PRESS J NEUROSCI; TREJO J, 1994, J BIOL CHEM, V269, P21682; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; VONDERKAMMER H, 1994, GENOMICS, V20, P308, DOI 10.1006/geno.1994.1174; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WILKIE TM, 1993, GENOMICS, V18, P175, DOI 10.1006/geno.1993.1452; YANG-YEN H-F, 1990, New Biologist, V2, P351	40	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25475	25480		10.1074/jbc.270.43.25475	http://dx.doi.org/10.1074/jbc.270.43.25475			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592716	hybrid			2022-12-27	WOS:A1995TB46600032
J	WANG, YX; SANTINI, F; QIN, KF; HUANG, CY				WANG, YX; SANTINI, F; QIN, KF; HUANG, CY			MG2+-DEPENDENT, CA2+-INHIBITABLE SERINE/THREONINE PROTEIN PHOSPHATASE FROM BOVINE BRAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE PHOSPHATASE; GLYCOGEN-SYNTHASE PHOSPHATASE; RABBIT SKELETAL-MUSCLE; RAT-LIVER; PHOSPHOPROTEIN PHOSPHATASE; MOLECULAR-CLONING; OKADAIC ACID; PURIFICATION; KINASE; IDENTIFICATION	The Mg2+-dependent serine/threonine protein phosphatases, also known as type 2C phosphatases (PP2C), belong to a gene family distinct from the other serine/ threonine phosphatases and tyrosine phosphatases. Here we report the purification to apparent homogeneity of a novel Mg2+-dependent, Ca2+-inhibitable serine/ threonine protein phosphatase from bovine brain. It is a type 2C enzyme in view of its Mg2+ requirement, resistance to okadaic acid and calyculin A, inability to use phosphorylase a as substrate, and a segment of amino acid sequence typical of all PP2C type phosphatases known to date. However, it differs from the other PP2C enzymes, particularly the mammalian PP2C alpha and -beta isoforms, in that its molecular weight, 76,000, is considerably larger and that it is inhibited by Ca2+, NaF, and polycations, but not by orthovanadate. The Ca2+ inhibition may not be related to its cellular regulation because of K-i values in the 20-90 mu M range, but this property permits distinction of this enzyme from the other phosphatases. Although the precise physiological role of this phosphatase is not yet known, its ability to dephosphorylate a wide variety of phosphoproteins and its broad distribution, as shown by a survey of mouse tissues for its activity, suggest that it may serve an important cellular function.	NHLBI, BIOCHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUTIGAN DL, 1994, RECENT PROG HORM RES, V132, P255; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; HIRAGA A, 1981, EUR J BIOCHEM, V119, P503, DOI 10.1111/j.1432-1033.1981.tb05636.x; HOU EW, 1994, BIOCHEM MOL BIOL INT, V32, P773; HUANG KP, 1976, ANAL BIOCHEM, V72, P593, DOI 10.1016/0003-2697(76)90571-6; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KATO S, 1994, GENE, V145, P311, DOI 10.1016/0378-1119(94)90026-4; KING MM, 1983, J BIOL CHEM, V258, P9925; KING MM, 1984, J BIOL CHEM, V259, P8847; LAWSON JE, 1993, BIOCHEMISTRY-US, V32, P8987, DOI 10.1021/bi00086a002; LI HC, 1978, EUR J BIOCHEM, V84, P215, DOI 10.1111/j.1432-1033.1978.tb12159.x; MACKINTOSH C, 1991, BIOCHEM J, V273, P733, DOI 10.1042/bj2730733; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MANN DJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P100, DOI 10.1016/0167-4781(92)90471-B; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MCGOWAN CH, 1987, EUR J BIOCHEM, V166, P713, DOI 10.1111/j.1432-1033.1987.tb13570.x; MIESKES G, 1984, EUR J BIOCHEM, V140, P375, DOI 10.1111/j.1432-1033.1984.tb08112.x; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; MORGAN M, 1976, BIOCHEM J, V157, P687, DOI 10.1042/bj1570687; MVUMBI L, 1985, BIOCHEM J, V232, P697, DOI 10.1042/bj2320697; PATO MD, 1983, J BIOL CHEM, V258, P7055; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHERENS B, 1993, YEAST, V9, P1355, DOI 10.1002/yea.320091210; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHIOZAKI K, 1994, MOL CELL BIOL, V14, P3742, DOI 10.1128/MCB.14.6.3742; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; TEAGUE WM, 1982, BIOCHEMISTRY-US, V21, P5585, DOI 10.1021/bi00265a031; TITANJI VPK, 1977, BIOCHIM BIOPHYS ACTA, V481, P140, DOI 10.1016/0005-2744(77)90145-0; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WENK J, 1992, FEBS LETT, V297, P135, DOI 10.1016/0014-5793(92)80344-G	38	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25607	25612		10.1074/jbc.270.43.25607	http://dx.doi.org/10.1074/jbc.270.43.25607			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592734	hybrid			2022-12-27	WOS:A1995TB46600051
J	CAO, L; WU, JM; GARDNER, DG				CAO, L; WU, JM; GARDNER, DG			ATRIAL-NATRIURETIC-PEPTIDE SUPPRESSES THE TRANSCRIPTION OF ITS GUANYLYL CYCLASE-LINKED RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; RAT RENAL GLOMERULI; DOWN-REGULATION; ENDOTHELIAL-CELLS; C-RECEPTOR; CLEARANCE RECEPTOR; ADENYLATE-CYCLASE; EXPRESSION; ANP; PROLIFERATION	Atrial natriuretic peptide (ANP) treatment of rat aortic smooth muscle cells suppressed both I-125-ANP binding and ANP dependent cGMP accumulation, suggesting reductions in the type C (NPR-C) and type A (NPR-A) natriuretic peptide receptor populations, respectively. NPR-A, but not NPR-C, mRNA levels were reduced in a dose-dependent fashion by ANP. The latter effect appeared to be due, at least in part, to suppression of NPR-A gene promoter activity. ANP effected a dose and time-dependent reduction in a transiently transfected NPR-A luciferase reporter (-1575LUC). Analysis of 5' deletion mutants of the NPR-A promoter demonstrated that the ANP-dependent sequence lies between -1575 and -1290 relative to the transcription start site. Inhibition of the ANP promoter was also effected by brain natriuretic peptide, type C natriuretic peptide, and 8-bromo-cGMP, but not by the NPR-C-selective ligand cANF. In the case of 8-bromo-cGMP, the responsive element(s) was localized to the same 285-base pair region linked to the ANP effect above. These findings indicate that ANP autoregulates its own receptors in these cells and, at least in the ease of NPR-A, it does so through suppression of receptor gene expression and receptor synthesis. This suppression may operate through a cGMP-dependent element located more than a kilobase upstream from the transcription start site.	UNIV CALIF SAN FRANCISCO, METAB RES UNIT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL 45637, HL 35753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045637, R01HL035753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMEIDA FA, 1989, AM J PHYSIOL, V256, pR469, DOI 10.1152/ajpregu.1989.256.2.R469; ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; ANANDSRIVASTAVA MB, 1987, J BIOL CHEM, V262, P4931; BALLERMANN BJ, 1985, J CLIN INVEST, V76, P2049, DOI 10.1172/JCI112207; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CACHOFEIRO V, 1989, AM J PHYSIOL, V256, pR1250, DOI 10.1152/ajpregu.1989.256.6.R1250; CAHILL PA, 1990, J BIOL CHEM, V265, P21896; CAO L, 1994, HYPERTENSION, V24, P329, DOI 10.1161/01.HYP.24.3.329; CAO L, 1995, HYPERTENSION, V25, P227, DOI 10.1161/01.HYP.25.2.227; CHABRIER PE, 1988, J BIOL CHEM, V263, P13199; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUJIO N, 1994, HYPERTENSION, V23, P908, DOI 10.1161/01.HYP.23.6.908; FULLER F, 1988, J BIOL CHEM, V263, P9395; GARDNER DG, 1986, P NATL ACAD SCI USA, V83, P6697, DOI 10.1073/pnas.83.18.6697; GAUQUELIN G, 1988, AM J PHYSIOL, V254, pF51, DOI 10.1152/ajprenal.1988.254.1.F51; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; HIRATA Y, 1987, EUR J PHARMACOL, V135, P439, DOI 10.1016/0014-2999(87)90697-2; HIRATA Y, 1985, BIOCHEM BIOPH RES CO, V128, P538, DOI 10.1016/0006-291X(85)90080-4; HIRATA Y, 1989, EUR J PHARMACOL, V164, P603, DOI 10.1016/0014-2999(89)90273-2; HUGHES RJ, 1987, AM J PHYSIOL, V253, pC809, DOI 10.1152/ajpcell.1987.253.6.C809; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; ITOH H, 1992, HYPERTENSION, V19, P758, DOI 10.1161/01.HYP.19.6.758; KATAFUCHI T, 1992, J BIOL CHEM, V267, P7624; KATO J, 1993, EUR J PHARM-MOLEC PH, V244, P153, DOI 10.1016/0922-4106(93)90021-Z; KATO J, 1991, J BIOL CHEM, V266, P14681; KISHIMOTO I, 1993, AM J PHYSIOL, V265, pH1373, DOI 10.1152/ajpheart.1993.265.4.H1373; KISHIMOTO I, 1994, J BIOL CHEM, V269, P28300; KOHNO M, 1993, AM J PHYSIOL, V265, pE673, DOI 10.1152/ajpendo.1993.265.5.E673; LANIERSMITH KL, 1991, ENDOCRINOLOGY, V129, P2311, DOI 10.1210/endo-129-5-2311; LEITMAN DC, 1988, J BIOL CHEM, V263, P3720; LEVIN ER, 1991, AM J PHYSIOL, V261, pR453, DOI 10.1152/ajpregu.1991.261.2.R453; LEVIN ER, 1993, AM J PHYSIOL, V264, pE483, DOI 10.1152/ajpendo.1993.264.4.E483; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MARTIN ER, 1989, AM J PHYSIOL, V257, pF649, DOI 10.1152/ajprenal.1989.257.4.F649; PAUL RV, 1993, J BIOL CHEM, V268, P18205; POTTER LR, 1992, J BIOL CHEM, V267, P14531; POTTER LR, 1994, J BIOL CHEM, V269, P14636; ROUBERT P, 1987, BIOCHEM BIOPH RES CO, V148, P61, DOI 10.1016/0006-291X(87)91076-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHIFFRIN EL, 1991, AM J PHYSIOL, V260, pH58, DOI 10.1152/ajpheart.1991.260.1.H58; SUGA SI, 1992, CIRC RES, V71, P34, DOI 10.1161/01.RES.71.1.34; TSUTAMOTO T, 1993, CIRCULATION, V87, P70, DOI 10.1161/01.CIR.87.1.70; WEI CM, 1993, AM J PHYSIOL, V264, pH71, DOI 10.1152/ajpheart.1993.264.1.H71; WINQUIST RJ, 1984, EUR J PHARMACOL, V102, P169, DOI 10.1016/0014-2999(84)90353-4; YAMAGUCHI M, 1990, J BIOL CHEM, V265, P20414; YASUNARI K, 1992, HYPERTENSION, V19, P314, DOI 10.1161/01.HYP.19.4.314; ZHANG LM, 1993, AM J PHYSIOL, V264, pH1753, DOI 10.1152/ajpheart.1993.264.6.H1753	51	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24891	24897		10.1074/jbc.270.42.24891	http://dx.doi.org/10.1074/jbc.270.42.24891			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559613	hybrid			2022-12-27	WOS:A1995TB46500047
J	CHAKRAVARTHY, BR; ISAACS, RJ; MORLEY, P; WHITFIELD, JF				CHAKRAVARTHY, BR; ISAACS, RJ; MORLEY, P; WHITFIELD, JF			CA2+-CALMODULIN PREVENTS MYRISTOYLATED ALANINE-RICH KINASE-C SUBSTRATE PROTEIN-PHOSPHORYLATION BY PROTEIN-KINASE CS IN C6 RAT GLIOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING; MARCKS PROTEIN; DIFFERENTIATION; ACTIVATION; KERATINOCYTES; FAMILY; DOMAIN; IDENTIFICATION; NEUROMODULIN; GROWTH	Ionomycin stimulated membrane-associated protein kinase Cs (PKCs) activity in C6 rat glioma cells as much as the potent PKCs stimulator 12-O-tetradecanoyl phorbol 13-acetate (TPA). However, while TPA, as expected, powerfully stimulated the phosphorylation of the PKCs' 85-kDa myristoylated alanine-rich protein kinase C substrate (MARCKS) protein, ionomycin unexpectedly did not. Instead, ionomycin reduced the basal MARCKS phosphorylation. Pretreating the glioma cells with ionomycin prevented TPA-stimulated PKCs from phosphorylating the MARCKS protein. The stimulation of membrane PKCs activity and the prevention of MARCKS phosphorylation by ionomycin required external Ca2+ because they were both abolished by adding 5 mM EGTA to the culture medium, Recently (Chakravarthy, B. R., Isaacs, R. J., Morley, P., Durkin, J. P., and Whitfield, J. F. (1995) J, Biol. Chem, 270, 1362-1368), we proposed that Ca2+ calmodulin complexes block MARCKS phosphorylation by the activated PKCs in keratinocytes stimulated by raising the external Ca2+ concentration. In the present experiments calmodulin prevented MARCKS phosphorylation by TPA-stimulated PKCs in glioma cell lysates, and this blockade was lifted by a calmodulin antagonist, the calmodulin-binding domain peptide. But, physiologically more significant, pretreating intact glioma cells with a cell-permeable calmodulin antagonist, calmidazolium, prevented ionomycin from blocking MARCKS phosphorylation by PKCs in unstimulated and TPA-stimulated cells. The effect of ionomycin on MARCKS phosphorylation was not due to the stimulation of Ca2+ calmodulin-dependent phosphoprotein phosphatase, calcineurin, because cyclosporin A, a potent inhibitor of this phosphatase, did not stop ionomycin from preventing MARCKS phosphorylation. The ability of ionomycin to prevent TPA-stimulated PKCs hom phosphorylating MARCKS depended on whether ionomycin was added before, with, or after TPA. Maximum blockade occurred when ionomycin was added before TPA but was less effective when added with or after TPA. These results indicate that Ca2+ calmodulin can profoundly affect PKCs' signaling at the substrate level.			CHAKRAVARTHY, BR (corresponding author), NATL RES COUNCIL CANADA, INST BIOL SCI, BLDG M-54, MONTREAL RD CAMPUS, OTTAWA, ON K1A 0R6, CANADA.							ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BAUDIER J, 1987, BIOCHEMISTRY-US, V26, P2886, DOI 10.1021/bi00384a033; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUELT MK, 1994, J BIOL CHEM, V269, P29367; BYERS DM, 1993, J NEUROCHEM, V60, P1414, DOI 10.1111/j.1471-4159.1993.tb03303.x; CHAKRAVARTHY BR, 1989, BIOCHEM BIOPH RES CO, V160, P340, DOI 10.1016/0006-291X(89)91661-6; CHAKRAVARTHY BR, 1992, BIOCHIM BIOPHYS ACTA, V1136, P83, DOI 10.1016/0167-4889(92)90088-S; CHAKRAVARTHY BR, 1995, J BIOL CHEM, V270, P1362, DOI 10.1074/jbc.270.3.1362; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; CHAKRAVARTHY BR, 1994, BIOCHEM J, V304, P809, DOI 10.1042/bj3040809; CHIDA K, 1986, J BIOL CHEM, V261, P3013; FALCO JP, 1988, ONCOGENE, V2, P573; FUJISE A, 1994, J BIOL CHEM, V269, P31642; GROBLEWSKI GE, 1994, J BIOL CHEM, V269, P15111; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEEMSKERK FMJ, 1993, BIOCHEM BIOPH RES CO, V190, P236, DOI 10.1006/bbrc.1993.1036; HOFMANN F, 1994, J BIOL CHEM, V269, P24298; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN WW, 1993, NEUROCHEM RES, V18, P681, DOI 10.1007/BF00966782; LIN WW, 1992, J NEUROSCI, V12, P1077; LIN WW, 1990, BIOCHEM BIOPH RES CO, V168, P512, DOI 10.1016/0006-291X(90)92351-Y; MORLEY P, 1993, J CELL PHYSIOL, V156, P219, DOI 10.1002/jcp.1041560202; MOSCAT J, 1989, J BIOL CHEM, V264, P11228; NAIRN AC, 1992, CIBA F SYMP, V164, P145; ORR JW, 1992, J BIOL CHEM, V267, P15263; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; ROBINSON PJ, 1993, ANAL BIOCHEM, V210, P172, DOI 10.1006/abio.1993.1169; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WEISSMANN BE, 1985, MOL CELL BIOL, V51, P3386; WHITFIELD JF, 1995, J CELL BIOCHEM, P74; WHITFIELD JF, 1992, J CELL PHYSIOL, V150, P299, DOI 10.1002/jcp.1041500212; WHITFIELD JF, 1995, CALCIUM CELL CYCLES; WILLIAMS RE, 1992, PEPTIDES CHEM BIOL, P923	42	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24911	24916		10.1074/jbc.270.42.24911	http://dx.doi.org/10.1074/jbc.270.42.24911			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559616	hybrid			2022-12-27	WOS:A1995TB46500050
J	DURICK, K; YAO, VJ; BORRELLO, MG; BONGARZONE, I; PIEROTTI, MA; TAYLOR, SS				DURICK, K; YAO, VJ; BORRELLO, MG; BONGARZONE, I; PIEROTTI, MA; TAYLOR, SS			TYROSINES OUTSIDE THE KINASE CORE AND DIMERIZATION ARE REQUIRED FOR THE MITOGENIC ACTIVITY OF RET/PTC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEPENDENT PROTEIN-KINASE; REGULATORY SUBUNIT; SIGNAL TRANSDUCTION; RET; DNA; RECEPTOR; SEQUENCE; DOMAINS; CAMP	Defects in the c-ret proto-oncogene, a member of the protein tyrosine kinase receptor family, have recently been linked to two types of genetic syndromes, Hirschsprung's disease and the multiple endocrine neoplasia family of inherited cancers. RET/ptc2 is the product of a papillary thyroid carcinoma translocation event between the genes coding for c-ret and the type I alpha regulatory subunit of protein kinase A (RI alpha) (Lanzi, C., Borrello, M., Bongarzone, I., Migliazza, A., Fusco, A., Grieco, M., Santoro, M., Gambetta, R., Zunino, F., Della Porta, G., and Pierotti, M. (1992) Oncogene 7, 2189-2194). The resulting 596-residue protein contains the first two thirds of RI alpha and the entire tyrosine kinase domain of c-ret (RET(tk)). An in vivo assay of growth stimulatory effects was developed, which consisted of microinjecting a RET/ptc2 expression plasmid into the nuclei of 10T1/2 mouse fibroblasts and observing the incorporation of 5-bromodeoxyuridine. This assay was used to determine that only the dimerization domain of RI alpha fused to RET(tk) is required for RET/ptc2's mitogenic activity. In addition, all of the reported Hirschsprung's disease point mutations in the RET(tk) (S289P, R421Q, and R496G) inactivate RET/ptc2 in our assay, confirming that these are loss of function mutations. Two tyrosines outside the conserved kinase core were also identified that are essential for full mitogenic activity of RET/ptc2. These two tyrosines, Tyr-350 and Tyr-586, are potential sites for Src homology 2 and phosphotyrosine binding domain interactions.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; IST NAZL TUMORI, DIV ONCOL SPERIMENTALE A, I-20133 MILAN, ITALY	University of California System; University of California San Diego; Fondazione IRCCS Istituto Nazionale Tumori Milan			Bongarzone, Italia/B-9544-2017; Borrello, Maria Grazia/C-3161-2017; Pierotti, Marco Alessandro/AAC-4728-2022	Bongarzone, Italia/0000-0003-2530-9170; Borrello, Maria Grazia/0000-0002-6854-2848; Pierotti, Marco Alessandro/0000-0002-7431-8332	NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09523] Funding Source: Medline; NIDDK NIH HHS [DK0704417] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; BUBIS J, 1988, J BIOL CHEM, V263, P9668; BUBIS J, 1987, J BIOL CHEM, V262, P14961; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LANZI C, 1992, ONCOGENE, V7, P2189; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; REDDY CC, 1994, BIOTECHNOL PROGR, V10, P377, DOI 10.1021/bp00028a006; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WHITE MF, 1988, J BIOL CHEM, V263, P2969	28	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24642	24645		10.1074/jbc.270.42.24642	http://dx.doi.org/10.1074/jbc.270.42.24642			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559572	hybrid			2022-12-27	WOS:A1995TB46500006
J	SHOJI, W; INOUE, T; YAMAMOTO, T; OBINATA, M				SHOJI, W; INOUE, T; YAMAMOTO, T; OBINATA, M			MIDA1, A PROTEIN ASSOCIATED WITH ID, REGULATES CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; SACCHAROMYCES-CEREVISIAE; GENE; DIFFERENTIATION; HSP70; TRANSCRIPTION; INHIBITION; EXPRESSION; SEQUENCE; FAMILY	We have isolated cDNA clone encoding a protein that can associate with Id, a helix-loop-helix (HLH) protein, This protein is named MIDA1 (mouse Id associate 1), and its predicted amino acid sequence consists of Zuotin (a putative Z-DNA binding protein in yeast) homology region and tryptophan-mediated repeats similar to c-Myb oncoprotein. MIDA1 associates with the HLH region of Id with the conserved region adjacent to eukaryotic DnaJ conserved motif within the Zuotin homology region, although it does not have any canonical HLH motif. The addition of antisense oligonucleotide of MIDA1 inhibited growth of murine erythroleukemia cells without interfering with erythroid differentiation, indicating that it regulates cell growth.	TOHOKU UNIV,INST DEV AGING & CANC,DEPT CELL BIOL,AOBA KU,SENDAI,MIYAGI 98077,JAPAN	Tohoku University			Yamamoto, Tohru/A-3801-2012	Yamamoto, Tohru/0000-0002-1652-0233				BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CRAIG EA, 1987, P NATL ACAD SCI USA, V84, P4156, DOI 10.1073/pnas.84.12.4156; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAWE KM, 1990, EMBO J, V9, P161; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MILARSKI KL, 1989, J CELL BIOL, V108, P413, DOI 10.1083/jcb.108.2.413; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MURRAY SS, 1992, J BONE MINER RES, V7, P1131; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHOJI W, 1994, J BIOL CHEM, V268, P5078; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WAHLS WP, 1990, MOL CELL BIOL, V10, P785, DOI 10.1128/MCB.10.2.785; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WITTIG B, 1991, P NATL ACAD SCI USA, V88, P2259, DOI 10.1073/pnas.88.6.2259; ZHANG SG, 1992, EMBO J, V11, P3787, DOI 10.1002/j.1460-2075.1992.tb05464.x	33	74	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24818	24825		10.1074/jbc.270.42.24818	http://dx.doi.org/10.1074/jbc.270.42.24818			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559602	hybrid			2022-12-27	WOS:A1995TB46500036
J	VENER, AV; VANKAN, PJM; GAL, A; ANDERSSON, B; OHAD, I				VENER, AV; VANKAN, PJM; GAL, A; ANDERSSON, B; OHAD, I			ACTIVATION DEACTIVATION CYCLE OF REDOX-CONTROLLED THYLAKOID PROTEIN-PHOSPHORYLATION - ROLE OF PLASTOQUINOL BOUND TO THE REDUCED CYTOCHROME BF COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC ELECTRON-TRANSPORT; MAIZE MESOPHYLL CHLOROPLASTS; MEMBRANE POLYPEPTIDES; SPINACH-CHLOROPLASTS; EXCITATION-ENERGY; PHOTOSYSTEM-II; KINASE; STATE; PHOTOINHIBITION; INHIBITION	Signal transduction via light-dependent redox control of reversible thylakoid protein phosphorylation has evolved in plants as a unique mechanism for controlling events related to light energy utilization. Here we report for the first time that protein phosphorylation can be activated without light or the addition of reducing agents by a transient exposure of isolated thylakoid membranes to low pH in darkness. The activation of the kinase after incubation of dark-adapted thylakoids at pH 4.3 coincides with an increase in the plastoquinol: plastoquinone ratio up to 0.25. However, rapid plastoquinol reoxidation (<1 min) at pH 7.4 contrasts with the slow kinase deactivation (t(1/2) = 4 min), which indicates that the redox control is not directly dependent on the plastoquinone pool. Use of inhibitors and a cytochrome bf-deficient mutant of Lemna demonstrate the involvement of the cytochrome bf complex in the low-pH induced protein phosphorylation. EPR spectroscopy shows that subsequent to the transient low pH treatment and transfer of the thylakoids to pH 7.4, cytochrome f, the Rieske Fe-S center, and plastocyanin become reduced and are not reoxidized while the kinase is slowly deactivated. However, the deactivation correlates with a decrease of the EPR g(z) signal of the reduced Rieske Fe-S center, which is also affected by quinone analogues that inhibit the kinase. Our data point to an activation mechanism of thylakoid protein phosphorylation that involves the binding of plastoquinol to the cytochrome bf complex in the vicinity of the reduced Rieske Fe-S center.	UNIV STOCKHOLM,ARRHENIUS LABS NAT SCI,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN; HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL	Stockholm University; Hebrew University of Jerusalem			Andersson, Bertil/C-9328-2009					ABERG F, 1992, ARCH BIOCHEM BIOPHYS, V295, P230, DOI 10.1016/0003-9861(92)90511-T; ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; Andersson B., 1994, P143; ANDERSSON B, 1976, BIOCHIM BIOPHYS ACTA, V423, P122, DOI 10.1016/0005-2728(76)90106-7; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; ARO EM, 1992, FEBS LETT, V297, P29, DOI 10.1016/0014-5793(92)80320-G; BENNETT J, 1977, NATURE, V269, P344, DOI 10.1038/269344a0; BENNETT J, 1988, EUR J BIOCHEM, V171, P95, DOI 10.1111/j.1432-1033.1988.tb13763.x; BENNETT J, 1987, FEBS LETT, V210, P22, DOI 10.1016/0014-5793(87)81290-5; BENNETT J, 1991, ANNU REV PLANT PHYS, V42, P281, DOI 10.1146/annurev.pp.42.060191.001433; BENNETT J, 1980, P NATL ACAD SCI-BIOL, V77, P5253, DOI 10.1073/pnas.77.9.5253; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; COUGHLAN SJ, 1986, J BIOL CHEM, V261, P14062; COUGHLAN SJ, 1988, BIOCHIM BIOPHYS ACTA, V933, P413, DOI 10.1016/0005-2728(88)90076-X; EBBERT V, 1994, BBA-BIOENERGETICS, V1187, P335, DOI 10.1016/0005-2728(94)90007-8; ELICH TD, 1992, J BIOL CHEM, V267, P3523; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FARCHAUS J, 1985, BIOCHIM BIOPHYS ACTA, V809, P17, DOI 10.1016/0005-2728(85)90162-8; FERNYHOUGH P, 1984, FEBS LETT, V176, P133, DOI 10.1016/0014-5793(84)80927-8; FRANK K, 1995, PHOTOCHEM PHOTOBIOL, V61, P2, DOI 10.1111/j.1751-1097.1995.tb09237.x; FRID D, 1992, J BIOL CHEM, V267, P25908; GAL A, 1988, J BIOL CHEM, V263, P7785; GAL A, 1987, FEBS LETT, V221, P205, DOI 10.1016/0014-5793(87)80926-2; GAL A, 1990, J BIOL CHEM, V265, P19742; GAL A, 1990, CURRENT RES PHOTOSYN, V2, P783; HALLIWELL B, 1981, CHLOROPLAST METABOLI, P1; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; HORTON JP, 1981, FEBS LETT, V125, P193; HORTON P, 1990, BIOCHIM BIOPHYS ACTA, V1017, P160, DOI 10.1016/0005-2728(90)90147-V; HORTON P, 1985, PLANTA, V165, P37, DOI 10.1007/BF00392209; HOUCHINS JP, 1983, BIOCHIM BIOPHYS ACTA, V725, P138, DOI 10.1016/0005-2728(83)90233-5; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; HURT E, 1981, FEBS LETT, V134, P1, DOI 10.1016/0014-5793(81)80537-6; HURT E, 1981, EUR J BIOCHEM, V117, P591; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; KRAMER DM, 1994, BBA-BIOENERGETICS, V1184, P251, DOI 10.1016/0005-2728(94)90230-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM E, 1984, FEBS LETT, V172, P255, DOI 10.1016/0014-5793(84)81136-9; LARSSON UK, 1987, BIOCHIM BIOPHYS ACTA, V894, P69, DOI 10.1016/0005-2728(87)90213-1; MALKIN R, 1973, BIOCHIM BIOPHYS ACTA, V292, P169, DOI 10.1016/0005-2728(73)90261-2; MALKIN R, 1982, BIOCHEMISTRY-US, V21, P2945, DOI 10.1021/bi00541a022; MILLNER PA, 1982, J BIOL CHEM, V257, P1736; OXBOROUGH K, 1987, FEBS LETT, V221, P211, DOI 10.1016/0014-5793(87)80927-4; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; REIDEL A, 1991, J BIOL CHEM, V266, P17838; RICH PR, 1991, BIOCHIM BIOPHYS ACTA, V1058, P312, DOI 10.1016/S0005-2728(05)80252-X; SELAK MA, 1982, FEBS LETT, V150, P286, DOI 10.1016/0014-5793(82)80753-9; SHAHAK Y, 1976, PLANT PHYSIOL, V57, P577, DOI 10.1104/pp.57.4.577; SIEGENTHALER PA, 1976, EUR J BIOCHEM, V61, P573, DOI 10.1111/j.1432-1033.1976.tb10052.x; SILVERSTEIN T, 1993, BIOCHIM BIOPHYS ACTA, V1183, P215, DOI 10.1016/0005-2728(93)90022-8; STAEHELIN LA, 1983, J CELL BIOL, V97, P1327, DOI 10.1083/jcb.97.5.1327; WOLLMAN FA, 1988, BIOCHIM BIOPHYS ACTA, V933, P85, DOI 10.1016/0005-2728(88)90058-8	54	90	92	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25225	25232		10.1074/jbc.270.42.25225	http://dx.doi.org/10.1074/jbc.270.42.25225			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559660	hybrid			2022-12-27	WOS:A1995TB46500094
J	ZHOU, MY; WU, XJ; HUANG, LS; GINSBERG, HN				ZHOU, MY; WU, XJ; HUANG, LS; GINSBERG, HN			APOPROTEIN B100, AN INEFFICIENTLY TRANSLOCATED SECRETORY PROTEIN, IS BOUND TO THE CYTOSOLIC CHAPERONE, HEAT-SHOCK-PROTEIN-70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CONTAINING LIPOPROTEINS; HEP G2 CELLS; APOLIPOPROTEIN-B; ENDOPLASMIC-RETICULUM; PAUSE TRANSFER; BIOSYNTHESIS; MICROSOMES; FRACTIONS; MEMBRANE; SEQUENCE	Apoprotein B100 (apoB) is a secretory protein that appears to be constitutively translated but inefficiently translocated into the lumen of the endoplasmic reticulum. Using several experimental approaches, we found that apoB is bound to the cytosolic chaperone protein, heat shock protein 72/73 (commonly referred to as Hsp7O). Similar to other chaperone-protein interactions, this binding was transient and ATP-sensitive. The binding of apoB to Hsp70 in HepG2 cells was decreased by treatment with oleic acid, which increases both translocation and secretion of apoB, and was increased by N-acetyl-leucyl-leucyl-norleucinal, a protease inhibitor which efficiently protects apoB from cellular degradation without affecting translocation. The N-terminal 16% of apoB, which is efficiently translocated into the endoplasmic reticulum lumen in stably transfected Chinese hamster ovary (CHO) cells, showed minimal, if any, binding to Hsp70. The N-terminal 50% of apoB, which is very poorly translocated in CHO cells, was found to bind significantly to Hsp7O. These results suggest that domains of nascent apoB localized on the C-terminal regions of the molecule are transiently exposed to the cytosol during translation and/or translocation, and that Hsp70 functions as a molecular chaperone to maintain apoB in a translocational competent conformation until translocation is completed.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021	Columbia University; Rockefeller University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036000, P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36000, HL 21006] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHUCK SL, 1993, J BIOL CHEM, V268, P22794; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V26, P10005; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DIERKS T, 1993, PHILOS T ROY SOC B, V339, P335, DOI 10.1098/rstb.1993.0032; DIXON JL, 1992, J CELL BIOL, V117, P1161, DOI 10.1083/jcb.117.6.1161; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DU EZ, 1994, J BIOL CHEM, V269, P24169; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GILMORE R, 1991, Current Opinion in Cell Biology, V3, P580, DOI 10.1016/0955-0674(91)90026-U; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEINEMANN T, 1994, J LIPID RES, V35, P2200; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P525, DOI 10.1073/pnas.79.2.525; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WILKINSON J, 1993, J LIPID RES, V34, P815; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x	35	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25220	25224		10.1074/jbc.270.42.25220	http://dx.doi.org/10.1074/jbc.270.42.25220			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559659	hybrid			2022-12-27	WOS:A1995TB46500093
J	BORRAS, FE; LLOBERAS, J; MAKI, RA; CELADA, A				BORRAS, FE; LLOBERAS, J; MAKI, RA; CELADA, A			REPRESSION OF I-A-BETA GENE-EXPRESSION BY THE TRANSCRIPTION FACTOR PU.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTOCOMPATIBILITY COMPLEX; INTERFERON-GAMMA; DNA-BINDING; REGULATES EXPRESSION; CD11B PROMOTER; NUCLEAR FACTOR; MICE LACKING; ETS ONCOGENE; CHAIN GENE; B-CELL	The PU.1 protein is an ets-related transcription factor that is expressed in macrophages and B lymphocytes. We present evidence that PU.1 binds to the promoter of the I-A beta gene, i.e. a PU box located next to the Y box. Transfection of PU.1 in B lymphocytes or in interferon-gamma-treated macrophages represses I-A beta gene expression. The inhibitory effect of PU.1 was obtained with the DNA binding domain of the protein, but not with the activation domain. Using the gel shift retardation assay we found that in vitro transcribed/translated NF-YA and NF-YB bind to the Y box of the I-A beta promoter. When PU.1 was added to the assay, a supershifted DNA band was found, indicating that PU.1 and NFY proteins bind to the same DNA molecule. We conclude that I-A beta gene expression is repressed by PU.1 binding to the PU box domain.	UNIV BARCELONA, FAC BIOL, DEPT FISIOL IMMUNOL, E-08028 BARCELONA, SPAIN; UNIV BARCELONA, FDN AUGUST PI & SUNYER, E-08028 BARCELONA, SPAIN; LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Sanford Burnham Prebys Medical Discovery Institute			Celada, Antonio/I-1714-2016; Lloberas, Jorge/D-4303-2014; Borràs, Francesc E/P-2287-2017	Lloberas, Jorge/0000-0001-7075-4201; Borràs, Francesc E/0000-0003-4038-1912; Celada, Antonio/0000-0003-3883-2171	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030656] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 30656] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERT SE, 1994, J EXP MED, V180, P233, DOI 10.1084/jem.180.1.233; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; CELADA A, 1989, EUR J IMMUNOL, V19, P205, DOI 10.1002/eji.1830190134; CELADA A, 1989, EUR J IMMUNOL, V19, P1103, DOI 10.1002/eji.1830190621; CELADA A, 1993, J EXP MED, V177, P691, DOI 10.1084/jem.177.3.691; CELADA A, 1988, J IMMUNOL, V140, P3995; CELADA A, 1989, MOL CELL BIOL, V9, P3097, DOI 10.1128/MCB.9.7.3097; CHEN HM, 1993, J BIOL CHEM, V268, P8230; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DELLABONA P, 1989, J IMMUNOL, V142, P2902; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FELDHAUS AL, 1992, MOL CELL BIOL, V12, P1126, DOI 10.1128/MCB.12.3.1126; FINN PW, 1990, J EXP MED, V171, P2159, DOI 10.1084/jem.171.6.2159; FINN PW, 1990, EMBO J, V9, P1543, DOI 10.1002/j.1460-2075.1990.tb08273.x; FLAVELL RA, 1986, SCIENCE, V233, P437, DOI 10.1126/science.3726537; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; Griscelli C, 1989, Immunodefic Rev, V1, P135; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HROMAS R, 1993, BLOOD, V82, P2998; JACKSON ME, 1991, J CELL SCI, V100, P1; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KISHI F, 1993, GENE, V133, P243; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MORIMOTO R I, 1992, Current Opinion in Cell Biology, V4, P480, DOI 10.1016/0955-0674(92)90015-5; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; OROURKE D, 1993, J VIROL, V67, P7201, DOI 10.1128/JVI.67.12.7201-7214.1993; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; REITH W, 1994, J BIOL CHEM, V269, P20020; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; Schwartz R H, 1986, Adv Immunol, V38, P31, DOI 10.1016/S0065-2776(08)60006-1; SHACKELFORD R, 1995, J IMMUNOL, V154, P1374; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; STUART PM, 1989, CELL IMMUNOL, V122, P391, DOI 10.1016/0008-8749(89)90086-5; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; TSONIS PA, 1988, NUCLEIC ACIDS RES, V16, P7745, DOI 10.1093/nar/16.15.7745; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VILEN BJ, 1992, J BIOL CHEM, V267, P23728; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; VIVILLE S, 1991, J IMMUNOL, V146, P3211; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	56	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24385	24391		10.1074/jbc.270.41.24385	http://dx.doi.org/10.1074/jbc.270.41.24385			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592651	hybrid			2022-12-27	WOS:A1995TA21700079
J	FAVREAU, LV; PICKETT, CB				FAVREAU, LV; PICKETT, CB			THE RAT QUINONE REDUCTASE ANTIOXIDANT RESPONSE ELEMENT - IDENTIFICATION OF THE NUCLEOTIDE-SEQUENCE REQUIRED FOR BASAL AND INDUCIBLE ACTIVITY AND DETECTION OF ANTIOXIDANT RESPONSE ELEMENT-BINDING PROTEINS IN HEPATOMA AND NON-HEPATOMA CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YA-SUBUNIT GENE; PLACENTAL GLUTATHIONE TRANSFERASE; PLANAR AROMATIC-COMPOUNDS; CHEMICAL HEPATOCARCINOGENESIS; TRANSCRIPTIONAL REGULATION; FUNCTIONAL-ANALYSIS; 3RD MEMBER; P GENE; JUN-B; INDUCTION	The antioxidant response element (ARE) found in the 5'-flanking region of the rat quinone reductase gene has been further characterized by mutational and deletion analysis. The results indicate that the 31-base pair ARE, which contains a 13-base pair palindromic sequence, can be further separated into three regions, all three of which are required for elevated basal level gene expression. These three regions include the proximal. and distal half-sites as well as a 3'-flanking region consisting of 4 adenine nucleotides. Neither the proximal nor the distal half-site alone mediates transcriptional activation by beta-naphthoflavone. However, when placed together the two half-sites restore responsiveness to the inducer, Interestingly, the presence of only 1 of the 4 adenine nucleotides in the 3'-flanking region of the proximal half-site is required for responsiveness to the inducer. Point mutations within the ARE indicate that several nucleotides in both the proximal and distal half-sites are required for basal level gene expression. Electrophoretic mobility shift analysis using the ARE as the probe indicates that enhancers found in the glutathione S-transferase Ya and P genes recognize a similar trans acting factor(s) found in crude nuclear extracts from human Hep G2 cells. Further, this complex can be detected in nuclear extracts from rat liver and rat hepatoma cells but not in mouse Hepa 1c1c7 cells or in human HeLa cells. The ARE-nucleoprotein complex can also be detected in F9 cells which lack significant levels of Jun/Fos proteins. Although the rat ARE resembles the human quinone reductase ARE which contains a consensus TRE, the 2-nucleotide change in the core sequence (TGACTCA versus TGACTTG) eliminates the high affinity TRE motif in the rat ARE. The rat ARE forms a nucleoprotein complex in Hep G2 and other cells with different properties than AP-1.	MERCK FROSST CTR THERAPEUT RES,DEPT BIOL MOLEC,POINTE CLAIRE,PQ H9R 4P8,CANADA	Merck & Company								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DICCIANNI MB, 1992, NUCLEIC ACIDS RES, V20, P5153, DOI 10.1093/nar/20.19.5153; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERNSTER L, 1960, BIOCHEM BIOPH RES CO, V2, P88, DOI 10.1016/0006-291X(60)90193-5; FAVREAU LV, 1993, J BIOL CHEM, V268, P19875; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1992, BIOCHEM BIOPH RES CO, V188, P992, DOI 10.1016/0006-291X(92)91329-O; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MORIMURA S, 1993, P NATL ACAD SCI USA, V90, P2065, DOI 10.1073/pnas.90.5.2065; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; OKUDA A, 1989, J BIOL CHEM, V264, P16919; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PICKETT CB, 1984, P NATL ACAD SCI-BIOL, V81, P5091, DOI 10.1073/pnas.81.16.5091; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; PROCHASKA HJ, 1988, CANCER RES, V48, P4776; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; SATOH K, 1985, P NATL ACAD SCI USA, V82, P3964, DOI 10.1073/pnas.82.12.3964; Suzuki T., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P611; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894; YANG-YEN H-F, 1990, New Biologist, V2, P351; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972	38	143	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24468	24474		10.1074/jbc.270.41.24468	http://dx.doi.org/10.1074/jbc.270.41.24468			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592662	hybrid			2022-12-27	WOS:A1995TA21700090
J	HORAN, T; WEN, J; ARAKAWA, T; LIU, NL; BRANKOW, D; HU, S; RATZKIN, B; PHILO, JS				HORAN, T; WEN, J; ARAKAWA, T; LIU, NL; BRANKOW, D; HU, S; RATZKIN, B; PHILO, JS			BINDING OF NEU DIFFERENTIATION FACTOR WITH THE EXTRACELLULAR DOMAIN OF HER2 AND HER3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR FAMILY; BREAST-CANCER; LIGAND; HEREGULIN; PROTEIN; MEMBER; HER4/P180(ERBB4); OVEREXPRESSION	The interaction of neu differentiation factor (NDF) with the extracellular domains of Her2 (sHer2) and Her3 (sHer3) have been studied using native gels, light scattering, and sedimentation equilibrium. The full-length NDF beta 2 was shown to bind sHer3 with a dissociation constant of 26 +/- 9 nM, while it showed a 1000-fold weaker binding to sHer2. Taken together, these results demonstrate that NDF is a high affinity ligand for Her3, but not for Hera. No increase in affinity of the NDF beta 2 for sHer3 was observed upon addition of sHer2 to the NDF beta 2-sHer3 mixture. Binding of NDF beta 2 to sHer3 did not induce receptor dimerization or oligomerization, the stoichiometry being one sHer3 per one NDF molecule. This finding suggests that transmembrane and/or intracellular domains of receptor family members or perhaps additional unidentified components may be involved in NDF induced dimerization and autophosphorylation, or alternatively, that dimerization is not the mechanism for Her3 autophosphorylation and signal transduction.			HORAN, T (corresponding author), AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320, USA.		Philo, John S/A-8804-2009	Philo, John S/0000-0003-3418-0356				ARAKAWA T, 1994, ARCH BIOCHEM BIOPHYS, V308, P267, DOI 10.1006/abbi.1994.1037; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; HARTMANN LC, 1994, CANCER, V74, P2956, DOI 10.1002/1097-0142(19941201)74:11<2956::AID-CNCR2820741111>3.0.CO;2-V; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LU HS, 1995, J BIOL CHEM, V270, P4784, DOI 10.1074/jbc.270.9.4784; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PHILO J, 1994, J BIOL CHEM, V269, P27840; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TAKAGI T, 1990, J CHROMATOGR, V506, P409, DOI 10.1016/S0021-9673(01)91596-1; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WRIGHT C, 1989, CANCER RES, V49, P2087	26	64	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24604	24608		10.1074/jbc.270.41.24604	http://dx.doi.org/10.1074/jbc.270.41.24604			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592681	hybrid			2022-12-27	WOS:A1995TA21700109
J	LI, SC; WU, YY; SUGIYAMA, E; TAKI, T; KASAMA, T; CASELLATO, R; SONNINO, S; LI, YT				LI, SC; WU, YY; SUGIYAMA, E; TAKI, T; KASAMA, T; CASELLATO, R; SONNINO, S; LI, YT			SPECIFIC RECOGNITION OF N-ACETYLNEURAMINIC ACID IN THE G(M2) EPITOPE BY HUMAN G(M2) ACTIVATOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS CALCULATIONS; ENZYMIC-HYDROLYSIS; GM2 GANGLIOSIDOSIS; HEXOSAMINIDASE-A; 3-DIMENSIONAL STRUCTURE; SULFATIDE ACTIVATOR; HUMAN-BRAIN; DEGRADATION; GENE; GLYCOLIPIDS	G(M2) Activator is a low molecular weight protein cofactor that stimulates the enzymatic conversion of G(M2) into G(M3) by human beta-hexosaminidase A and also the conversion of G(M2) into G(A2) by clostridial sialidase (Wu, Y.-Y., Lockyer, J. M., Sugiyama, E., Pavlova, N. V., Li, Y.-T., and Li, S.- C. (1994) J. Biol. Chem. 269, 16276-16283). Among the five known activator proteins for the enzymatic hydrolysis of glycosphingolipids, only G(M2) activator is effective in stimulating the hydrolysis of G(M2). However, the mechanism of action of G(M2) activator is still not well understood, Using a unique disialosylganglioside, GalNAc-G(D1a), as the substrate, we were able to show that in the presence of G(M2) activator, GalNAc-G(D1a) was specifically converted into GalNAc-G(M1a) by clostridial sialidase, while in the presence of saposin B, a nonspecific activator protein, GalNAc-G(D1a) was converted into both GalNAc-G(M1a) and GalNAc-G(M1b). individual products generated from GalNAc-G(D1a) by clostridial sialidase were identified by thin layer chromatography, negative secondary ion mass spectrometry, and immunostaining with a monoclonal IgM that recognizes the G(M2) epitope. Our results clearly show that G(M2) activator recognizes the G(M2) epitope in GalNAc-G(D1a). Thus, G(M2) activator may interact with the trisaccharide structure of the G(M2) epitope and render the GalNAc and NeuAc residues accessible to beta-hexosaminidase A and sialidase, respectively.	TOKYO MED & DENT UNIV,DEPT BIOCHEM,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,BIOMED ANAL LAB,TOKYO 113,JAPAN; UNIV MILAN,SCH MED,DEPT MED CHEM & BIOCHEM,I-20133 MILAN,ITALY	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); University of Milan	LI, SC (corresponding author), TULANE UNIV,SCH MED,DEPT BIOCHEM,1430 TULANE AVE,NEW ORLEANS,LA 70112, USA.		Sonnino, Sandro/R-4154-2017	Sonnino, Sandro/0000-0001-8180-5908	NINDS NIH HHS [NS 09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACQUOTTI D, 1994, EUR J BIOCHEM, V225, P271, DOI 10.1111/j.1432-1033.1994.00271.x; ACQUOTTI D, 1990, J AM CHEM SOC, V112, P7772, DOI 10.1021/ja00177a043; ACQUOTTI D, 1991, CHEM PHYS LIPIDS, V59, P107, DOI 10.1016/0009-3084(91)90001-R; ANDO S, 1978, ANAL BIOCHEM, V89, P437, DOI 10.1016/0003-2697(78)90373-1; BURG J, 1985, ANN HUM GENET, V49, P41, DOI 10.1111/j.1469-1809.1985.tb01674.x; CHRISTOMANOU H, 1985, BIOL CHEM H-S, V366, P245, DOI 10.1515/bchm3.1985.366.1.245; CONZELMANN E, 1978, P NATL ACAD SCI USA, V75, P3979, DOI 10.1073/pnas.75.8.3979; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; Corfield A.P., 1981, PERSPECTIVES INHERIT, V4, P3; FUJIBAYASHI S, 1985, AM J HUM GENET, V37, P741; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; HARRIS G, 1954, CHEM IND-LONDON, P249; HECHTMAN P, 1982, PEDIATR RES, V16, P217, DOI 10.1203/00006450-198203000-00011; HIRABAYASHI Y, 1983, J NEUROCHEM, V40, P168, DOI 10.1111/j.1471-4159.1983.tb12667.x; ILYAS AA, 1985, P NATL ACAD SCI USA, V82, P6697, DOI 10.1073/pnas.82.19.6697; INUI K, 1985, HUM GENET, V69, P197, DOI 10.1007/BF00293023; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; LI SC, 1988, J BIOL CHEM, V263, P6588; LI SC, 1979, J BIOL CHEM, V254, P592; LI SC, 1981, J BIOL CHEM, V256, P6234; LI SC, 1976, J BIOL CHEM, V251, P1159; LI YT, 1984, LYSOSOM BIOL PATHOL, P99; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; SIEBERT HC, 1992, BIOCHEMISTRY-US, V31, P6962, DOI 10.1021/bi00145a014; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; SVENNERHOLM L, 1972, METHODS CARBOHYD CHE, V6, P464; TAKI T, 1994, ANAL BIOCHEM, V221, P312, DOI 10.1006/abio.1994.1418; TAKI T, 1995, ANAL BIOCHEM, V225, P24, DOI 10.1006/abio.1995.1102; TAKI T, 1994, ANAL BIOCHEM, V223, P232, DOI 10.1006/abio.1994.1579; WENGER DA, 1982, BIOCHIM BIOPHYS ACTA, V712, P639, DOI 10.1016/0005-2760(82)90293-4; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; WU YY, 1994, J BIOL CHEM, V269, P16276; ZHOU B, 1989, J BIOL CHEM, V264, P12272	38	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24246	24251		10.1074/jbc.270.41.24246	http://dx.doi.org/10.1074/jbc.270.41.24246			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592631	hybrid			2022-12-27	WOS:A1995TA21700059
J	PURI, RN; KUMAR, A; CHEN, HY; COLMAN, RF; COLMAN, RW				PURI, RN; KUMAR, A; CHEN, HY; COLMAN, RF; COLMAN, RW			INHIBITION OF ADP-INDUCED PLATELET RESPONSES BY COVALENT MODIFICATION OF AGGREGIN, A PUTATIVE ADP RECEPTOR, BY 8-(4-BROMO-2,3-DIOXOBUTYLTHIO)ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC FREE CALCIUM; GLYCOPROTEIN-IIB-IIIA; BLOOD-PLATELETS; SHAPE CHANGE; ADENYLATE-CYCLASE; 8-<(4-BROMO-2,3-DIOXOBUTYL)THIO>ADENOSINE 5'-DIPHOSPHATE; BINDING-SITE; CYCLIC-AMP; ACTIVATION; AGGREGATION	ADP is an important platelet agonist which initiates platelet shape change, aggregation, exposure of fibrinogen receptors, and calcium mobilization. Because of the limitations of previously used affinity analogs and photolabeling studies as well as controversies surrounding the identity of an ADP receptor on platelets, we have used an affinity label capable of alkylating a putative exofacial receptor on platelets. We now report that 8-(4-bromo-2,3-dioxobutylthio)adenosine-5'-diphosphate (8-BDB-TADP), which is an analog of the natural ligand ADP, blocked ADP-induced platelet shape change, aggregation, exposure of fibrinogen-binding sites, secretion, and calcium mobilization. Following modification by 8-BDB-TADP, the rates of aggregation of platelets induced by thrombin, a calcium ionophore (A23187) or a stimulator of protein kinase C (phorbol myristate acetate) were minimally affected. However, the 8-BDB-TADP-modified platelets exhibited decreased rates of aggregation in response to ADP, as well as collagen and a thromboxane mimetic (U46619), both of which partially require ADP. Autoradiograms of the gels obtained by sodium dodecyl sulfate-polyacrylamide gel electrophoresis of solubilized platelets modified by either [beta-P-32]8-BDB-TADP, or 8-BDB-TADP and NaB[H-3](4) showed the presence of a single radiolabeled protein band at 100 kDa. The intensity of this band was reduced when platelets were preincubated with ADP, ATP, and 8-bromo-ADP prior to labeling by the radioactive 8-BDB-TADP. The results show that 8-BDB-TADP selectively and covalently labeled aggregin (100 kDa), a putative ADP receptor, resulting in a loss of ADP-induced platelet responses.	UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716	University of Delaware	PURI, RN (corresponding author), TEMPLE UNIV,SCH MED,SOL SHERRY THROMBOSIS RES CTR,3400 N BROAD ST,PHILADELPHIA,PA 19140, USA.				NHLBI NIH HHS [HL 46431] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT JS, 1978, J BIOL CHEM, V253, P7346; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; BOYER JL, 1990, J BIOL CHEM, V265, P13515; BRASS LF, 1986, J BIOL CHEM, V263, P5210; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; COLMAN RF, 1989, PROTEIN FUNCTION PRA, P77; COLMAN RF, 1994, BIOCHEMISTRY-US, V23, P3281; COLMAN RW, 1986, BLOOD, V68, P565; COLMAN RW, 1990, FASEB J, V4, P1425, DOI 10.1096/fasebj.4.5.2407587; COLMAN RW, 1992, NEWS PHYSIOL SCI, V7, P274; CRISTALLI G, 1993, BIOCHEM J, V291, P875, DOI 10.1042/bj2910875; DECAMP DL, 1988, BIOCHEMISTRY-US, V27, P7651, DOI 10.1021/bi00420a012; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUBYAK GR, 1991, AM J RESP CELL MOL, V4, P295, DOI 10.1165/ajrcmb/4.4.295; ELMAOTASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31; FIGURES WR, 1981, J BIOL CHEM, V258, P7789; GARRDER A, 1961, NATURE, V192, P531; GRECO NJ, 1991, J BIOL CHEM, V266, P13627; GRECO NJ, 1995, BBA-BIOMEMBRANES, V1236, P142, DOI 10.1016/0005-2736(95)00038-5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haslam R. J., 1981, PURINERGIC RECEPTORS, P223; HOURANI SMO, 1991, PHARMACOL REV, V43, P243; HUANG Y, 1986, J BIOL CHEM, V261, P14100; KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187; KALAMBAKAS SA, 1993, BLOOD, V81, P2652; KIKKAWA U, 1988, ADV CYCLIC NUCLEOTID, V17, P437; KOZARICH JW, 1973, BIOCHEMISTRY-US, V12, P4458, DOI 10.1021/bi00746a024; KUMAR A, 1994, ARCH BIOCHEM BIOPHYS, V308, P357, DOI 10.1006/abbi.1994.1051; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACFARLANE DE, 1982, BIOCHEMISTRY-US, V21, P544, DOI 10.1021/bi00532a020; MACFARLANE DE, 1983, J CLIN INVEST, V71, P420, DOI 10.1172/JCI110786; MAYINGER P, 1992, BIOCHIM BIOPHYS ACTA, V1137, P77, DOI 10.1016/0167-4889(92)90103-I; MILLS DCB, 1985, J BIOL CHEM, V260, P8078; MILLS DCB, 1972, ANN NY ACAD SCI, V201, P391, DOI 10.1111/j.1749-6632.1972.tb16312.x; MORINELLI TA, 1983, BLOOD, V61, P41; OZTURK DH, 1990, BIOCHEMISTRY-US, V29, P7112, DOI 10.1021/bi00482a024; OZTURK DH, 1991, BIOCHEMISTRY-US, V30, P7112; POWLING MJ, 1985, BLOOD, V66, P731; PURI RN, 1989, ARCH BIOCHEM BIOPHYS, V271, P346, DOI 10.1016/0003-9861(89)90284-1; PURI RN, 1991, ARCH BIOCHEM BIOPHYS, V286, P419, DOI 10.1016/0003-9861(91)90060-V; PURI RN, 1994, FASEB J, V8, pA1407; PURI RN, 1994, BLOOD S, V81, pA690; PURI RN, 1989, BLOOD, V77, P500; RAO AK, 1987, BLOOD, V70, P751; RINK TJ, 1984, TRENDS BIOCHEM SCI, V9, P215, DOI 10.1016/0968-0004(84)90067-7; SAVI P, 1994, THROMB RES, V76, P157, DOI 10.1016/0049-3848(94)90186-4; SCHIEVEN GL, 1993, J IMMUNOTHER, V14, P221, DOI 10.1097/00002371-199310000-00009; SCHIEVEN GL, 1993, MOL BIOL CELL, V4, P523, DOI 10.1091/mbc.4.5.523; SHI XP, 1995, THROMB RES, V77, P235, DOI 10.1016/0049-3848(95)91611-N; SUGATANI J, 1987, J BIOL CHEM, V262, P16995; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; WHITE J G, 1974, American Journal of Pathology, V77, P135; YAMADA M, 1995, BIOCHEMISTRY-US, V34, P481, DOI 10.1021/bi00002a012	54	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24482	24488		10.1074/jbc.270.41.24482	http://dx.doi.org/10.1074/jbc.270.41.24482			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592664	hybrid			2022-12-27	WOS:A1995TA21700092
J	DEBLANDRE, GA; MARINX, OP; EVANS, SS; MAJJAJ, S; LEO, O; CAPUT, D; HUEZ, GA; WATHELET, MG				DEBLANDRE, GA; MARINX, OP; EVANS, SS; MAJJAJ, S; LEO, O; CAPUT, D; HUEZ, GA; WATHELET, MG			EXPRESSION CLONING OF AN INTERFERON-INDUCIBLE 17-KDA MEMBRANE-PROTEIN IMPLICATED IN THE CONTROL OF CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAUDI CELLS; GENE-EXPRESSION; MESSENGER-RNA; ANTIPROLIFERATIVE ANTIBODY; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; B-LYMPHOCYTES; ALPHA; LEU-13; ANTIGEN	Interferon-inducible membrane proteins of approximately 17 kDa have been suggested to play a role in the antiproliferative activity of interferons based on (1) their pattern of induction in interferon-sensitive and -resistant cell lines and (2) the ability of a membrane fraction enriched in 17-kDa proteins to inhibit cell growth. To gain insight into the nature of the proteins that mediate the antiproliferative activity of interferons, a monoclonal antibody, 13A5, was generated that reacted specifically with a 17-kDa interferon-inducible cell surface protein. The expression pattern of this 17-kDa protein by human cell lines correlated with sensitivity to the antiproliferative activity of interferons. To obtain information regarding the structure of this protein, the 13A5 antibody was used to screen COS cells transfected with a human cDNA expression library. Sequence analysis of a full-length cDNA clone revealed identity with the 9-27 cDNA, previously isolated on the basis of its interferon inducibility by differential screening. In addition, the 17-kDa protein encoded by the 9-27 gene was shown to be identical to the Leu-13 antigen. Leu-13 was previously identified as a 16-kDa interferon-inducible protein in leukocytes and endothelial cells and is a component of a multimeric complex involved in the transduction of antiproliferative and homotypic adhesion signals. These results suggest a novel level of cellular regulation by interferons involving a membrane protein, encoded by the interferon-inducible 9-27 gene, which associates with other proteins at the cell surface, forming a complex relaying growth inhibitory and aggregation signals.	SANOFI RECH,F-31676 LABEGE,FRANCE; ROSWELL PK CANC INST,BUFFALO,NY 14263; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Sanofi-Aventis; Sanofi France; Roswell Park Cancer Institute; Harvard University	DEBLANDRE, GA (corresponding author), FREE UNIV BRUSSELS,DEPT BIOL MOLEC,67 RUE CHEVAUX,B-1640 RHODE ST GENESE,BELGIUM.							AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; BRADBURY LE, 1993, J IMMUNOL, V151, P2915; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHEN YX, 1984, J IMMUNOL, V133, P2496; DEBLANDRE GA, 1992, CYTOKINE, V4, P36, DOI 10.1016/1043-4666(92)90034-O; DEMAEYER E, 1988, INTERFERONS OTHER RE, P91; DRON M, 1983, J GEN VIROL, V64, P2641, DOI 10.1099/0022-1317-64-12-2641; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVANS SS, 1993, J IMMUNOL, V150, P736; EVANS SS, 1990, BLOOD, V76, P2583; FRANSSEN JD, 1981, PROTIDES BIOL FLUIDS, V29, P645; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; GIL ML, 1992, J IMMUNOL, V148, P2826; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILLMAN MC, 1987, BIOCHEM BIOPH RES CO, V148, P140, DOI 10.1016/0006-291X(87)91087-4; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JAFFE EA, 1989, J IMMUNOL, V143, P3961; KNIGHT E, 1985, J INTERFERON RES, V5, P305, DOI 10.1089/jir.1985.5.305; KNIGHT E, 1985, P NATL ACAD SCI USA, V82, P1151, DOI 10.1073/pnas.82.4.1151; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; LEWIN AR, 1991, EUR J BIOCHEM, V199, P417, DOI 10.1111/j.1432-1033.1991.tb16139.x; LLOYD RE, 1983, SCIENCE, V221, P953, DOI 10.1126/science.6192500; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; MATTHEW WD, 1987, J IMMUNOL METHODS, V100, P73, DOI 10.1016/0022-1759(87)90174-8; MEURS E, 1988, EMBO J, V7, P1689, DOI 10.1002/j.1460-2075.1988.tb02997.x; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; Sambrook J, 1989, MOL CLONING LABORATO; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEN GC, 1992, J BIOL CHEM, V267, P5017; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; WATHELET MG, 1992, EUR J BIOCHEM, V206, P901, DOI 10.1111/j.1432-1033.1992.tb16999.x	42	146	158	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23860	23866		10.1074/jbc.270.40.23860	http://dx.doi.org/10.1074/jbc.270.40.23860			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559564	hybrid			2022-12-27	WOS:A1995RY90900093
J	TSAO, PW; MOUSA, SA				TSAO, PW; MOUSA, SA			THROMBOSPONDIN MEDIATES CALCIUM MOBILIZATION IN FIBROBLASTS VIA ITS ARG-GLY-ASP AND CARBOXYL-TERMINAL DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; GLYCOPROTEIN-IIIA COMPLEX; HUMAN-ENDOTHELIAL-CELLS; HUMAN CARCINOMA-CELLS; SIGNAL TRANSDUCTION; INTRACELLULAR PH; BINDING DOMAIN; ADHESION; RECEPTOR; ATTACHMENT	Thrombospondin is a matrix glycoprotein found in various cells that can modulate cell attachment, migration, and proliferation. We now show that intact soluble thrombospondin causes a transient [Ca2+](i) increase in IMR-90 fibroblasts. This [Ca2+](i) increase is mediated partly by the RGD containing domain of thrombospondin that binds to the integrin alpha v beta 3 as demonstrated by inhibitor studies using anti-alpha v beta 3 antibody and RGD-containing peptides. A non-RGD and non-alpha v beta 3 component of this [Ca2+](i) increase is mediated by the carboxyl-terminal domain of thrombospondin through an unidentified receptor on fibroblasts as shown by the antibody to the carboxyl terminal of thrombospondin, C6.7. In addition, the carboxyl terminal derived peptide, RFYVVMWK, also triggers [Ca2+](i) increase in similar to 35% of fibroblasts. Both EGTA and Ni2+ block the entire [Ca2+](i) increase indicating that this is due to an influx of extracellular Ca2+. B6H12, an antibody to the integrin-associated protein, blocks this [Ca2+](i) increase by 50%, suggesting that some of the Ca2+ might be entering through an integrin-associated calcium channel. The current findings demonstrate that multiple domains on thrombospondin can trigger signal transduction events by increasing [Ca2+](i) through their interactions with different cell receptors.	DUPONT MERCK PHARMACEUT CO,EXPTL STN,DIV CARDIOVASC DIS,WILMINGTON,DE 19880	DuPont			Mousa, Shaker A/A-7151-2017	Mousa, Shaker A/0000-0002-9294-015X				ALESSIO M, 1993, BLOOD, V82, P3637; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLEZARDIN P, 1989, EUR J BIOCHEM, V181, P721, DOI 10.1111/j.1432-1033.1989.tb14783.x; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DARDIK R, 1987, EUR J BIOCHEM, V168, P347, DOI 10.1111/j.1432-1033.1987.tb13426.x; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GAN ZR, 1988, J BIOL CHEM, V263, P19827; GAO AG, 1994, J BIOL CHEM, V269, P29650; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KOSFELD MD, 1993, J BIOL CHEM, V268, P8808; KOSFELD MD, 1992, J BIOL CHEM, V267, P16230; KOSFELD MD, 1991, J BIOL CHEM, V266, P24257; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; NGSIKORSKI J, 1991, EXP CELL RES, V195, P204; NICOSIA RF, 1994, J CELL BIOL, V124, P183, DOI 10.1083/jcb.124.1.183; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; ROBERTS DD, 1988, CANCER RES, V48, P6785; RYBAK MEM, 1989, J BIOL CHEM, V264, P14617; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SCHUEPP BJ, 1991, BIOCHEM BIOPH RES CO, V175, P263, DOI 10.1016/S0006-291X(05)81229-X; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCHWARTZ MA, 1991, EXP CELL RES, V195, P533, DOI 10.1016/0014-4827(91)90407-L; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SHANKAR G, 1993, J CELL SCI, V105, P61; SJAASTAD MD, 1994, P NATL ACAD SCI USA, V91, P8214, DOI 10.1073/pnas.91.17.8214; SMITH JW, 1994, J BIOL CHEM, V269, P960; STEINER B, 1989, J BIOL CHEM, V264, P13102; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TSAO PW, 1995, THROMB RES, V77, P543, DOI 10.1016/0049-3848(95)00029-1; TUSZYNSKI GP, 1992, J CELL BIOL, V116, P209, DOI 10.1083/jcb.116.1.209; WELDER CA, 1993, J IMMUNOL, V150, P2203; YABKOWITZ R, 1993, J CELL PHYSIOL, V157, P24, DOI 10.1002/jcp.1041570104; YABKOWITZ R, 1991, CANCER RES, V51, P3648; YABKOWITZ R, 1993, CANCER RES, V53, P378; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; ZIMOLO Z, 1994, AM J PHYSIOL, V266, pC376, DOI 10.1152/ajpcell.1994.266.2.C376	51	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23747	23753		10.1074/jbc.270.40.23747	http://dx.doi.org/10.1074/jbc.270.40.23747			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559547	hybrid			2022-12-27	WOS:A1995RY90900076
J	HARDY, DM; GARBERS, DL				HARDY, DM; GARBERS, DL			A SPERM MEMBRANE-PROTEIN THAT BINDS IN A SPECIES-SPECIFIC MANNER TO THE EGG EXTRACELLULAR-MATRIX IS HOMOLOGOUS TO VON-WILLEBRAND-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACROSOME REACTION; ZONA-PELLUCIDA; HAMSTER SPERMATOZOA; EXPRESSION; AGGREGATION; RECEPTORS; SEQUENCE; CYCLASE	We have purified a sperm membrane protein, designated zonadhesin, that binds in a species-specific manner to the extracellular matrix (zona pellucida) of the egg, and cloned its cDNA, The cDNA encodes a novel protein with a single transmembrane segment separating a 36 amino acid, highly basic intracellular C terminus from a 2418 amino acid extracellular region. The extracellular sequence specifies a mosaic protein comprising a unique N-terminal domain, a mucin-like domain, and five tandem domains proximal to the membrane that are homologous to prepro von Willebrand factor. The N-terminal and mucin-like domains were absent from zonadhesin that bound to the egg extracellular matrix, suggesting that processing occurs during sperm maturation and/or capacitation, By Northern blotting and in situ hybridization, zonadhesin mRNA was detected only within the testis, where it was expressed primarily in haploid spermatids. The unique domain structure of zonadhesin suggests multiple functions, one of which is to mediate sperm adhesion to the zona pellucida.	UNIV TEXAS,SW MED SCH,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED SCH,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Hardy, Daniel/AAP-5823-2020	Hardy, Daniel/0000-0002-7297-3093				BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BOOKBINDER LH, 1995, SCIENCE, V269, P86, DOI 10.1126/science.7604284; BURKS DJ, 1995, SCIENCE, V269, P83, DOI 10.1126/science.7541556; CHANG MC, 1951, NATURE, V168, P697, DOI 10.1038/168697b0; CHERR GN, 1986, DEV BIOL, V114, P119, DOI 10.1016/0012-1606(86)90388-X; CHOMCZYNSKI P, 1988, ANAL BIOCHEM, V162, P156; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; DUNBAR BS, 1980, BIOCHEMISTRY-US, V2, P356; FULLE HJ, 1995, P NATL ACAD SCI USA, V92, P3571, DOI 10.1073/pnas.92.8.3571; GUM JR, 1994, J BIOL CHEM, V269, P2440; Hardy Daniel M., 1994, Seminars in Developmental Biology, V5, P217, DOI 10.1006/sedb.1994.1029; HARDY DM, 1994, J BIOL CHEM, V269, P19000; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; MACEK MB, 1991, DEV BIOL, V147, P440, DOI 10.1016/0012-1606(91)90301-I; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MEYER D, 1993, THROMB HAEMOSTASIS, V70, P99; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; PARRISH JJ, 1989, GAMETE RES, V24, P403, DOI 10.1002/mrd.1120240407; PETERSON RN, 1980, SCIENCE, V207, P73, DOI 10.1126/science.7188647; PRIMAKOFF P, 1988, NATURE, V335, P543, DOI 10.1038/335543a0; Ramarao Chodavarapu S., 1994, Seminars in Developmental Biology, V5, P265, DOI 10.1006/sedb.1994.1034; SALING PM, 1981, P NATL ACAD SCI-BIOL, V78, P6231, DOI 10.1073/pnas.78.10.6231; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHUR BD, 1989, BIOCHIM BIOPHYS ACTA, V988, P389, DOI 10.1016/0304-4157(89)90012-9; SMITH TT, 1991, J REPROD FERTIL, V91, P567, DOI 10.1530/jrf.0.0910567; UTO N, 1988, J EXP ZOOL, V248, P113, DOI 10.1002/jez.1402480115; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; YANAGIMACHI R, 1976, J REPROD FERTIL, V46, P49; Yanagimachi R., 1981, FERTILIZATION EMBRYO, P81; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002	36	147	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26025	26028		10.1074/jbc.270.44.26025	http://dx.doi.org/10.1074/jbc.270.44.26025			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592795	hybrid			2022-12-27	WOS:A1995TC97800002
J	CHOU, WY; TSAI, WP; LIN, CC; CHANG, GG				CHOU, WY; TSAI, WP; LIN, CC; CHANG, GG			SELECTIVE OXIDATIVE MODIFICATION AND AFFINITY CLEAVAGE OF PIGEON LIVER MALIC ENZYME BY THE CU2+-ASCORBATE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; MESSENGER-RNA; EXPRESSION; MECHANISM; CLONING; COMPLEXES; PROTEINS; SITES; GENE	Pigeon liver malic enzyme was rapidly inactivated by micromolar concentration of Fe2+ in the presence of ascorbate at neutral pH. The inactivated enzyme was subsequently cleaved by the Fe2+-ascorbate system at the chemical bond between Asp(258) and Ile(259) (Wei, C. H., Chou, W. Y., Huang, S. M., Lin, C. C., and Chang, G. G. (1994) Biochemistry, 33, 7931-7936), which was confirmed by site-specific mutagenesis (Wei, C. H., Chou, W. Y., and Chang, G. G. (1995) Biochemistry 34, 7949-7954). In the present study, at neutral pH, Cu2+ was found to be more reactive in the oxidative modification of malic enzyme and the enzyme was cleaved in a similar manner as Fe2+ did. At acidic pH, however, Fe2+ was found to be ineffective in oxidative modification of the enzyme. Nevertheless, Cu2+ still caused enzyme inactivation and cleaved the enzyme at Asp(141)-Gly(142), Asp(194)-Pro(195), or Asp(464)-Asp(465). Mn2+ and L-malate synergistically protect the enzyme hom Cu2+ inactivation at acidic pH. Cu2+ is also a competitive inhibitor versus Mn2+ in the malic enzyme-catalyzed reaction with K-i value 70.3 +/- 5.8 mu M. The above results indicated that, in addition to the previously determined Asp(258) at neutral pH, Asp(141), Asp(194), and Asp(464) are also the coordination sites for the metal binding of malic enzyme. We suggest that the mechanism of affinity modification and cleavage of malic enzyme by the Cu2+-ascorbate system proceed in the following sequence. First, Cu2+ binds with the enzyme at the Mn2+ binding site and reduces to Cu+ by ascorbate. Next, the local oxygen molecules are reduced by Cu+, thereby generating superoxide or other reactive free radicals. These radicals interact with the susceptible essential amino acid residues at the metal-binding site, ultimately causing enzyme inactivation. Finally, the modified enzyme is cleaved into several peptide fragments, allowing the identification of metal site of the enzyme. The pH-dependent different specificities of metal-catalyzed oxidation system may be generally applicable for other enzymes or proteins.	ACAD SINICA,INST ZOOL,TAIPEI 100,TAIWAN	Academia Sinica - Taiwan	CHOU, WY (corresponding author), NATL DEF MED CTR,DEPT BIOCHEM,POB 90048,TAIPEI 100,TAIWAN.							BAGCHI S, 1987, J BIOL CHEM, V262, P1558; BORSCH D, 1990, FEBS LETT, V273, P111, DOI 10.1016/0014-5793(90)81063-T; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHANG GG, 1992, ARCH BIOCHEM BIOPHYS, V296, P468, DOI 10.1016/0003-9861(92)90599-R; CHANG JT, 1982, ANAL BIOCHEM, V121, P366, DOI 10.1016/0003-2697(82)90494-8; CHOU WY, 1994, ARCH BIOCHEM BIOPHYS, V310, P158, DOI 10.1006/abbi.1994.1152; HERMES JD, 1982, BIOCHEMISTRY-US, V21, P5106, DOI 10.1021/bi00263a040; HIGAKI JN, 1992, TRENDS BIOCHEM SCI, V17, P100, DOI 10.1016/0968-0004(92)90245-5; HSU RY, 1992, BIOCHEM J, V284, P869, DOI 10.1042/bj2840869; HSU RY, 1976, J BIOL CHEM, V251, P6574; HSU RY, 1982, MOL CELL BIOCHEM, V43, P3; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; KOBAYASHI K, 1989, J BIOL CHEM, V264, P3200; KUFEL J, 1994, J MOL BIOL, V244, P511, DOI 10.1006/jmbi.1994.1749; KULKARNI G, 1993, ARCH BIOCHEM BIOPHYS, V300, P231, DOI 10.1006/abbi.1993.1032; LOEBER G, 1994, FEBS LETT, V344, P181, DOI 10.1016/0014-5793(94)00386-6; LOEBER G, 1991, J BIOL CHEM, V266, P3016; MAGNUSON MA, 1986, J BIOL CHEM, V261, P1183; MURRAY RK, 1990, HARPERS BIOCH, P682; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OLEARY MH, 1992, ENZYMES, V20, P236; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; REGAN L, 1993, ANNU REV BIOPH BIOM, V22, P257, DOI 10.1146/annurev.bb.22.060193.001353; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROTHERMEL BA, 1989, J BIOL CHEM, V264, P19587; SALLES JBV, 1950, J BIOL CHEM, V187, P849; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; VALLEE BL, 1993, BIOCHEMISTRY-US, V32, P6493, DOI 10.1021/bi00077a001; Villafranca JJ., 1992, ENZYMES, V20, P63; WEI CH, 1994, BIOCHEMISTRY-US, V33, P7931, DOI 10.1021/bi00191a021; WEI CH, 1995, BIOCHEMISTRY-US, V34, P7949, DOI 10.1021/bi00024a020	33	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25935	25941		10.1074/jbc.270.43.25935	http://dx.doi.org/10.1074/jbc.270.43.25935			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592782	hybrid			2022-12-27	WOS:A1995TB46600099
J	HAN, SJ; YOO, YJ; KANG, HS				HAN, SJ; YOO, YJ; KANG, HS			CHARACTERIZATION OF A BIFUNCTIONAL CELLULASE AND ITS STRUCTURAL GENE - THE CEL GENE OF BACILLUS SP D04 HAS EXOGLUCANASE AND ENDOGLUCANASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; TRICHODERMA-REESEI QM-9414; ESCHERICHIA-COLI; NEOCALLIMASTIX-PATRICIARUM; CELLULOLYTIC ENZYMES; PURIFICATION; CELLOBIOHYDROLASES; EXPRESSION; SUBTILIS; CLONING	Bacillus sp. D04 secreted a bifunctional cellulase that had a molecular weight of 35,000. This cellulase degraded Cm-cellulose, cellotetraose, cellopentaose, p-nitrophenyl-beta-D-cellobioside, and avicel PH101. Based on the high performance Liquid chromatography analysis of the degradation products, this cellulase randomly cleaved internal beta-1,4-glycosidic bonds in cellotetraose and cellopentaose as an endoglucanase. It also hydrolyzed the aglycosidic bond in p-nitrophenyl-beta-D-cellobioside and cleaved avicel to cellobiose as an exoglucanase. Cellobiose competitively inhibited the p-nitrophenyl-beta-D-cellobioside degrading activity but not Cm-cellulose degrading activity. Ten mM p-chloromercuribenzoate inhibited p-nitrophenyl-beta-D-cellobioside degrading activity completely, but Cm-cellulose degrading activity incompletely. Cm-cellulose increased p-nitrophenyl-beta-D-cellobioside degrading activity, and vice versa, whereas methylumbelliferyl-beta-D-cellobiose strongly inhibited p-nitrophenyl-beta-D-cellobioside degrading activity. The cellulase gene (eel gene), 1461 base pairs, of Bacillus sp. D04 was cloned. The nucleotide sequence of the eel gene was highly homologous to those of Bacillus subtilis DLG and B. subtilis BSE616. The eel gene was overexpressed in Escherichia coli, and its product was purified. The substrate specificity and substrate competition pattern of the purified recombinant cellulase were the same as those of the purified cellulase from Bacillus sp. D04. These results suggest that a single polypeptide cellulase had both endo- and exoglucanase activities and each activity exists in a separate site.	SEOUL NATL UNIV, COLL NAT SCI, DEPT MICROBIOL, SEOUL 151742, SOUTH KOREA; SEOUL NATL UNIV, COLL ENGN, DEPT CHEM ENGN, SEOUL 151742, SOUTH KOREA	Seoul National University (SNU); Seoul National University (SNU)								ALPENFELS WF, 1981, ANAL BIOCHEM, V114, P153, DOI 10.1016/0003-2697(81)90466-8; BELDMAN G, 1985, EUR J BIOCHEM, V146, P301, DOI 10.1111/j.1432-1033.1985.tb08653.x; DESHPANDE MV, 1984, ANAL BIOCHEM, V138, P481, DOI 10.1016/0003-2697(84)90843-1; DHILLON N, 1985, BIOTECHNOL LETT, V7, P695, DOI 10.1007/BF01040212; FAGERSTAM LG, 1980, FEBS LETT, V119, P97, DOI 10.1016/0014-5793(80)81006-4; FOGARTY W M, 1973, Biochemical Society Transactions, V1, P1297; GILKES NR, 1984, J BIOL CHEM, V259, P455; GRANDER RM, 1987, J BACTERIOL, V169, P4581; HEPTINSTALL J, 1986, ENZYME MICROB TECH, V8, P70, DOI 10.1016/0141-0229(86)90073-6; KALRA MK, 1986, J APPL BACTERIOL, V61, P73, DOI 10.1111/j.1365-2672.1986.tb03760.x; MCGINNIS GD, 1978, J CHROMATOGR, V153, P107, DOI 10.1016/S0021-9673(00)89861-1; OKADA G, 1975, J BIOCHEM-TOKYO, V78, P297, DOI 10.1093/oxfordjournals.jbchem.a130908; PARK SH, 1991, AGR BIOL CHEM TOKYO, V55, P441, DOI 10.1080/00021369.1991.10870613; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; ROBSON LM, 1989, ENZYME MICROB TECH, V11, P626, DOI 10.1016/0141-0229(89)90001-X; ROBSON LM, 1986, J BACTERIOL, V165, P612, DOI 10.1128/jb.165.2.612-619.1986; ROBSON LM, 1984, APPL ENVIRON MICROB, V47, P1039, DOI 10.1128/AEM.47.5.1039-1046.1984; SAUL DJ, 1990, APPL ENVIRON MICROB, V56, P3117, DOI 10.1128/AEM.56.10.3117-3124.1990; SHRAM P, 1990, ENZYME MICROB TECHNO, V12, P132; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; TAKEMOTO H, 1985, ANAL BIOCHEM, V145, P245, DOI 10.1016/0003-2697(85)90357-4; THAYER DW, 1978, J GEN MICROBIOL, V106, P13, DOI 10.1099/00221287-106-1-13; TOMME P, 1988, EUR J BIOCHEM, V170, P575, DOI 10.1111/j.1432-1033.1988.tb13736.x; VERHAAR LAT, 1981, J CHROMATOGR, V220, P313, DOI 10.1016/S0021-9673(00)81928-7; XUE GP, 1992, J GEN MICROBIOL, V138, P2397, DOI 10.1099/00221287-138-11-2397; XUE GP, 1992, J GEN MICROBIOL, V138, P1413, DOI 10.1099/00221287-138-7-1413	26	84	92	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					26012	26019		10.1074/jbc.270.43.26012	http://dx.doi.org/10.1074/jbc.270.43.26012			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592793	hybrid			2022-12-27	WOS:A1995TB46600110
J	NIIMURA, Y; POOLE, LB; MASSEY, V				NIIMURA, Y; POOLE, LB; MASSEY, V			AMPHIBACILLUS XYLANUS NADH OXIDASE AND SALMONELLA-TYPHIMURIUM ALKYL-HYDROPEROXIDE REDUCTASE FLAVOPROTEIN COMPONENTS SHOW EXTREMELY HIGH SCAVENGING ACTIVITY FOR BOTH ALKYL HYDROPEROXIDE AND HYDROGEN-PEROXIDE IN THE PRESENCE OF SALMONELLA-TYPHIMURIUM ALKYL-HYDROPEROXIDE REDUCTASE 22-KDA PROTEIN-COMPONENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE; THIOREDOXIN REDUCTASE; ESCHERICHIA-COLI; DISULFIDE OXIDOREDUCTASES; SACCHAROMYCES-CEREVISIAE; LACKING CYTOCHROME; PURIFICATION; CATALASE; QUINONE; DISTINCT	The flavoprotein NADH oxidase from Amphibacillus xylanus consumes oxygen to produce hydrogen peroxide, The amino acid sequence of this flavoprotein shows 51.2% identity to the F-52a component, denoted AhpF, of the alkyl-hydroperoxide reductase hom Salmonella typhimurium, AhpF also catalyzes NADH-dependent hydrogen peroxide formation under aerobic conditions, albeit at a somewhat slower rate than the Amphibacillus protein. In the presence of the 22-kDa colorless component (AhpC) of tbe Salmonella alkyl-hydroperoxide reductase, both proteins catalyze the 4-electron reduction of oxygen to water. Both flavoproteins are active as AhpC reductases and mediate electron transfer, resulting in the NADH-dependent reduction of hydrogen peroxide and cumene hydroperoxide. Both enzymes' K-m values for hydrogen peroxide, cumene hydroperoxide, and NADH are so low that they could not be determined accurately, V-max values for hydrogen peroxide or cumene hydroperoxide reduction are >10,000 min(-1) at 25 degrees C, These values are almost the same as the reduction rate of the flavoprotein component by NADH. The involvement in catalysis of a redox-active disulfide of the A. xylanus flavoprotein was shown by construction of three mutant enzymes, C337S, C340S, and C337S/C340S. Very little activity for hydrogen peroxide or cumene hydroperoxide was found with the single mutants (C337S and C340S), and none with the double mutant (C337S/C340S). Analysis of the DNA sequence upstream of the Amphibacillus flavoprotein structural gene indicated the presence of a partial open reading frame homologous to the Salmonella ahpC structural gene (64.3% identical at the amino acid sequence level), suggesting that the NADH oxidase protein of A. xylanus is also part of a functional alkyl-hydroperoxide reductase system within these catalase-lacking bacteria.	WAKE FOREST UNIV, MED CTR, DEPT BIOCHEM, WINSTON SALEM, NC 27157 USA; UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	Wake Forest University; University of Michigan System; University of Michigan	NIIMURA, Y (corresponding author), TOKYO UNIV AGR, DEPT FOOD SCI & TECHNOL, 196 YASAKA, ABASHIRI, HOKKAIDO 09924, JAPAN.			Poole, Leslie/0000-0003-0334-7328	NIGMS NIH HHS [GM-50389, GM-11106, R01 GM050389] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050389, R37GM011106, R01GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAUDIERE J, 1983, ARCH BIOCHEM BIOPHYS, V226, P448, DOI 10.1016/0003-9861(83)90314-4; COCCO D, 1988, EUR J BIOCHEM, V174, P267, DOI 10.1111/j.1432-1033.1988.tb14093.x; ENGLARD S, 1990, METHOD ENZYMOL, V182, P285; FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987; HIGUCHI M, 1993, J GEN MICROBIOL, V139, P2343, DOI 10.1099/00221287-139-10-2343; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; KOIKE K, 1985, J BIOCHEM, V97, P1279, DOI 10.1093/oxfordjournals.jbchem.a135179; KOYAMA N, 1988, FEMS MICROBIOL LETT, V49, P123, DOI 10.1016/0378-1097(88)90113-9; LITTLE C, 1972, BIOCHIM BIOPHYS ACTA, V284, P375, DOI 10.1016/0005-2744(72)90133-7; NIIMURA Y, 1993, J BACTERIOL, V175, P7945, DOI 10.1128/JB.175.24.7945-7950.1993; NIIMURA Y, 1987, AGR BIOL CHEM TOKYO, V51, P2271; NIIMURA Y, 1990, INT J SYST BACTERIOL, V40, P297, DOI 10.1099/00207713-40-3-297; NIIMURA Y, 1989, FEMS MICROBIOL LETT, V61, P79, DOI 10.1016/S0378-1097(98)00072-X; OGURA Y, 1955, ARCH BIOCHEM BIOPHYS, V57, P288, DOI 10.1016/0003-9861(55)90291-5; OHNISHI K, 1995, J BIOL CHEM, V270, P5812, DOI 10.1074/jbc.270.11.5812; OHNISHI K, 1994, J BIOL CHEM, V269, P31418; PARK HJ, 1992, EUR J BIOCHEM, V205, P881, DOI 10.1111/j.1432-1033.1992.tb16853.x; PARSONAGE D, 1993, J BIOL CHEM, V268, P3161; Poole LB, 1994, FLAVINS AND FLAVOPROTEINS 1993, P583; PRONGAY AJ, 1989, J BIOL CHEM, V264, P2656; REINARDS R, 1981, EUR J BIOCHEM, V120, P329, DOI 10.1111/j.1432-1033.1981.tb05708.x; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; SAEKI Y, 1985, J BIOCHEM-TOKYO, V98, P1433, DOI 10.1093/oxfordjournals.jbchem.a135411; SCHMIDT HL, 1986, EUR J BIOCHEM, V156, P149, DOI 10.1111/j.1432-1033.1986.tb09560.x; TAKAGI T, 1978, LIPIDS, V13, P147, DOI 10.1007/BF02533257; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; 1972, WORTHINGTON ENZYME M, P41	35	99	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25645	25650		10.1074/jbc.270.43.25645	http://dx.doi.org/10.1074/jbc.270.43.25645			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592740	hybrid			2022-12-27	WOS:A1995TB46600057
J	SHASHKIN, P; KOSHKIN, A; LANGLEY, D; REN, JM; WESTERBLAD, H; KATZ, A				SHASHKIN, P; KOSHKIN, A; LANGLEY, D; REN, JM; WESTERBLAD, H; KATZ, A			EFFECTS OF CGS 9343B (A PUTATIVE CALMODULIN ANTAGONIST) ON ISOLATED SKELETAL-MUSCLE - DISSOCIATION OF SIGNALING PATHWAYS FOR INSULIN-MEDIATED ACTIVATION OF GLYCOGEN-SYNTHASE AND HEXOSE-TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SOLEUS MUSCLE; GLUCOSE-TRANSPORT; DIABETES-MELLITUS; INDUCED INCREASE; PHOSPHORYLATION; INHIBITION; CELLS; STIMULATION; EPINEPHRINE; METABOLISM	The role of calmodulin in control of carbohydrate metabolism in the absence and presence of insulin in isolated mouse soleus muscle was investigated, The calmodulin antagonist CGS 9343B had no effect on basal glycogen synthase activity, the contents of high energy phosphates, glucose-6-P, or glycogen synthesis. However, CGS 9343B inhibited the basal rates of 2-deoxyglucose uptake and 3-O-methylglucose transport by 30% (p < 0.05) and 40% (p < 0.001), respectively, Insulin activated glycogen synthase by almost 40% (p < 0.01) and this increase was not altered in the presence of CGS 9343B. Insulin increased the muscle content of glucose-6-P (approximate to 2-fold), as well as glycogen synthesis (approximate to 8-fold), 2-deoxyglucose uptake (approximate to 3-fold), and 3-O-methylglucose transport (approximate to 2-fold), and these increases were inhibited by CGS 9343B, In additional experiments on isolated rat epitrochlearis muscle, it was found that the hypoxia-mediated activation of 3-O-methylglucose transport was also inhibited by CGS 9343B. These data demonstrate that: 1) hexose transport, both in the absence and presence of external stimuli (insulin and hypoxia), requires functional calmodulin; and 2) insulin-mediated activation of glycogen synthase does not require functional calmodulin, nor can it be accounted for by increases in glucose transport or glucose-6-P.	KAROLINSKA INST,KAROLINSKA HOSP,DEPT SURG SCI,DIV CLIN PHYSIOL,S-17176 STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT PHYSIOL & PHARMACOL,S-17177 STOCKHOLM,SWEDEN; BAYER CORP,DIV PHARMACEUT,W HAVEN,CT 06516	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Bayer AG				Westerblad, Hakan/0000-0002-8180-3029				BEITNER R, 1993, INT J BIOCHEM, V25, P297, DOI 10.1016/0020-711X(93)90616-M; BOGARDUS C, 1990, NEW ENGL J MED, V322, P262, DOI 10.1056/NEJM199001253220409; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; CHENZION M, 1992, INT J BIOCHEM, V24, P1661, DOI 10.1016/0020-711X(92)90185-4; CHIASSON JL, 1981, J CLIN INVEST, V68, P706, DOI 10.1172/JCI110306; DEFRONZO RA, 1985, J CLIN INVEST, V76, P149, DOI 10.1172/JCI111938; GUARNER V, 1993, EUR J PHARMACOL, V237, P139, DOI 10.1016/0014-2999(93)90103-O; HANSEN PA, 1994, J APPL PHYSIOL, V76, P979, DOI 10.1152/jappl.1994.76.2.979; HENRIKSEN EJ, 1989, J BIOL CHEM, V264, P21536; ISHIBASHI O, 1989, DIABETES RES CLIN PR, V6, P109, DOI 10.1016/0168-8227(89)90114-9; JORGENSEN AO, 1986, J BIOL CHEM, V261, P3775; KATZ A, 1995, BBA-GEN SUBJECTS, V1244, P229, DOI 10.1016/0304-4165(95)00050-L; KIPNIS DM, 1960, J BIOL CHEM, V235, P3070; LARNER J, 1960, ARCH BIOCHEM BIOPHYS, V86, P56, DOI 10.1016/0003-9861(60)90367-2; LAWRENCE JC, 1978, J BIOL CHEM, V253, P2104; LEMARCHANDBRUST.Y, 1981, BIOCHIM BIOPHYS ACTA, V677, P13; LEMARCHANDBRUST.Y, 1979, J CLIN INVEST, V64, P1505; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; NEUHAUS R, 1992, EUR J PHARM-MOLEC PH, V226, P183, DOI 10.1016/0922-4106(92)90182-U; NORMAN JA, 1987, MOL PHARMACOL, V31, P535; ORON Y, 1980, MOL CELL BIOCHEM, V32, P153; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; REN JM, 1993, J BIOL CHEM, V268, P16113; SACKS DB, 1992, BIOCHEM J, V283, P21, DOI 10.1042/bj2830021; SACKS DB, 1992, BIOCHEM J, V286, P211, DOI 10.1042/bj2860211; SATOH S, 1993, J BIOL CHEM, V268, P17820; SHECHTER Y, 1984, P NATL ACAD SCI-BIOL, V81, P327, DOI 10.1073/pnas.81.2.327; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; TAN AWH, 1975, BIOCHIM BIOPHYS ACTA, V410, P45, DOI 10.1016/0005-2744(75)90206-5; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VILLARPALASI C, 1960, BIOCHIM BIOPHYS ACTA, V39, P171, DOI 10.1016/0006-3002(60)90142-6; VILLARPALASI C, 1991, BIOCHIM BIOPHYS ACTA, V1095, P261, DOI 10.1016/0167-4889(91)90109-B; VITTONE L, 1994, MOL CELL BIOCHEM, V124, P33; WILSON CM, 1994, BIOCHEM J, V299, P755, DOI 10.1042/bj2990755; XU A, 1994, J BIOL CHEM, V268, P8394; YOUN JH, 1994, AM J PHYSIOL-REG I, V267, pR888, DOI 10.1152/ajpregu.1994.267.4.R888; YOUNG DA, 1986, J BIOL CHEM, V261, P6049	37	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25613	25618		10.1074/jbc.270.43.25613	http://dx.doi.org/10.1074/jbc.270.43.25613			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592735	hybrid			2022-12-27	WOS:A1995TB46600052
J	CANTATORE, P; DADDABBO, L; FRACASSO, F; GADALETA, MN				CANTATORE, P; DADDABBO, L; FRACASSO, F; GADALETA, MN			IDENTIFICATION BY IN ORGANELLO FOOTPRINTING OF PROTEIN CONTACT SITES AND OF SINGLE-STRANDED-DNA SEQUENCES IN THE REGULATORY REGION OF RAT MITOCHONDRIAL-DNA - PROTEIN-BINDING SITES AND SINGLE-STRANDED-DNA REGIONS IN ISOLATED RAT-LIVER MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RNASE MRP; RIBOSOMAL-RNA; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; INITIATION EVENTS; DISPLACEMENT LOOP; GENE ORGANIZATION; SENESCENT RAT; HEAVY-STRAND; IN-VIVO	Footprinting studies with the purine-modifying reagent dimethyl sulfate and with the single-stranded DNA probing reagent potassium permanganate were carried out in isolated mitochondria from rat liver. Dimethyl sulfate footprinting allowed the detection of protein-DNA interactions within the rat analogues of the human binding sites for the transcription termination factor mTERF and for the transcription activating factor mt-TFA. Although mTERF contacts were localized only at the boundary between the 16S rRNA/tRNA(UUR)(Leu) genes, multiple mtTFA contacts were detected, Contact sites were located in the light and the heavy strand promoters and, in agreement with in nitro footprinting data on human mitochondria, between the conserved sequence blocks (CSB) 1 and 2 and inside CSB-1. Potassium permanganate footprinting allowed detection of a 25-base pair region entirely contained in CSB-1 in which both strands were permanganate-reactive. No permanganate reactivity was associated with the other regions of the D-loop, including CSB-2 and -3, and with the mTERF contact site. We hypothesize that the single-stranded DNA at CSB-1 may be due to a profound helix distortion induced by mtTFA binding or be associated with a RNA polymerase pause site. In any case the location in CSB-1 of the 3' end of the most abundant replication primer and of the 5' end of the prominent D-loop DNA suggests that protein-induced DNA conformational changes play an important role in directing the transition from transcription to replication in mammalian mitochondria.	CNR,CTR STUDI MITOCONDRI & METAB ENERGET,I-70126 BARI,ITALY	Consiglio Nazionale delle Ricerche (CNR)	CANTATORE, P (corresponding author), UNIV BARI,DEPT BIOCHEM & MOLEC BIOL,VIA ORABONA 4A,I-70126 BARI,ITALY.							ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; [Anonymous], MITOCHONDRIAL DNA HU; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; ATTARDI G, 1982, MITOCHONDRIAL GENES, P51; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BOROWIEC JA, 1986, BIOCHEMISTRY-US, V25, P5051, DOI 10.1021/bi00366a012; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; CAIRNS SS, 1986, J BIOL CHEM, V261, P8481; CANTATORE P, 1980, NUCLEIC ACIDS RES, V8, P2605, DOI 10.1093/nar/8.12.2605; CANTATORE P, 1988, CURR GENET, V14, P477, DOI 10.1007/BF00521272; CANTATORE P, 1987, INT REV CYTOL, V108, P149, DOI 10.1016/S0074-7696(08)61438-2; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHANG DD, 1986, MOL CELL BIOL, V6, P294, DOI 10.1128/MCB.6.1.294; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CHRISTIANSON TW, 1988, MOL CELL BIOL, V8, P4502, DOI 10.1128/MCB.8.10.4502; CHU S, 1994, P NATL ACAD SCI USA, V91, P659, DOI 10.1073/pnas.91.2.659; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; DESJARDINS P, 1990, J MOL BIOL, V212, P599, DOI 10.1016/0022-2836(90)90225-B; DOERSEN CJ, 1985, J BIOL CHEM, V260, P5942; ENRIQUEZ JA, 1991, FEBS LETT, V280, P32, DOI 10.1016/0014-5793(91)80197-B; ENRIQUEZ JA, 1994, NUCLEIC ACIDS RES, V22, P1861, DOI 10.1093/nar/22.10.1861; ENRIQUEZ JA, 1992, FEBS LETT, V304, P285, DOI 10.1016/0014-5793(92)80639-X; FABER S, 1993, J BIOL CHEM, V268, P24976; FERNANDEZSILVA P, 1991, BIOCHEM BIOPH RES CO, V176, P645, DOI 10.1016/S0006-291X(05)80233-5; FISHER RP, 1992, J BIOL CHEM, V267, P3358; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; FISHER RP, 1989, GENE DEV, V3, P2202, DOI 10.1101/gad.3.12b.2202; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GADALETA MN, 1990, EUR J BIOCHEM, V187, P501, DOI 10.1111/j.1432-1033.1990.tb15331.x; GAINES G, 1984, MOL CELL BIOL, V4, P1605, DOI 10.1128/MCB.4.8.1605; GAINES G, 1984, J MOL BIOL, V172, P451, DOI 10.1016/S0022-2836(84)80017-0; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GHIVIZZANI SC, 1994, MOL CELL BIOL, V14, P7717, DOI 10.1128/MCB.14.12.7717; GHIVIZZANI SC, 1993, J BIOL CHEM, V268, P8675; GHIVIZZANI SC, 1993, J MOL EVOL, V37, P36, DOI 10.1007/BF00170460; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HSIEH DJ, 1993, EMBO J, V12, P4933, DOI 10.1002/j.1460-2075.1993.tb06187.x; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KARWAN R, 1991, GENE DEV, V5, P1264, DOI 10.1101/gad.5.7.1264; KING TC, 1987, J BIOL CHEM, V262, P6204; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; KISS T, 1992, CELL, V70, P11, DOI 10.1016/0092-8674(92)90528-K; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; Lawley P D, 1966, Prog Nucleic Acid Res Mol Biol, V5, P89, DOI 10.1016/S0079-6603(08)60232-9; LAWLEY PD, 1963, BIOCHEM J, V89, P127, DOI 10.1042/bj0890127; LI K, 1994, J CELL BIOL, V124, P871, DOI 10.1083/jcb.124.6.871; MONTOYA J, 1983, CELL, V34, P151, DOI 10.1016/0092-8674(83)90145-9; MONTOYA J, 1982, P NATL ACAD SCI-BIOL, V79, P7195, DOI 10.1073/pnas.79.23.7195; MUKHOPADHYAY G, 1993, EMBO J, V12, P4547, DOI 10.1002/j.1460-2075.1993.tb06143.x; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; SACCONE C, 1991, J MOL EVOL, V33, P83, DOI 10.1007/BF02100199; Sambrook J, 1989, MOL CLONING LABORATO; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V84, P8934; SCHMITT ME, 1993, MOL CELL BIOL, V13, P7935, DOI 10.1128/MCB.13.12.7935; SHANG J, 1994, J BIOL CHEM, V269, P29112; SHISA E, 1990, CURR GENET, V17, P247; TOPPER JN, 1992, CELL, V70, P16, DOI 10.1016/0092-8674(92)90529-L; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; TOPPER JN, 1989, MOL CELL BIOL, V9, P1200, DOI 10.1128/MCB.9.3.1200; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; YANOFSKY C, 1988, J BIOL CHEM, V263, P609	72	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25020	25027		10.1074/jbc.270.42.25020	http://dx.doi.org/10.1074/jbc.270.42.25020			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559632	hybrid			2022-12-27	WOS:A1995TB46500066
J	LUCARELLI, E; KAPLAN, DR; THIELE, CJ				LUCARELLI, E; KAPLAN, DR; THIELE, CJ			SELECTIVE REGULATION OF TRKA AND TRKB RECEPTORS BY RETINOIC ACID AND INTERFERON-GAMMA IN HUMAN NEUROBLASTOMA CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEURO-BLASTOMA; NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; NEUROTROPHIC FACTOR; MESSENGER-RNA; PROTOONCOGENE PRODUCT; EXPRESSION; DIFFERENTIATION; NGF; GENE	Trk receptors are a family of genes implicated in the survival, differentiation, and growth of certain neurons and tumors of the nervous system. A better understanding of the regulation of Trk receptors is relevant for developmental and oncological studies. Human neuroblastoma (NB) cell lines constitutively express low levels of TrkA mRNA, while TrkB mRNA is not readily detectable. Differentiation of NB cells is accompanied by a differential modulation of Trk expression in human NE cells. Nanomolar concentrations of RA induce a stable increase of TrkB mRNk. A transient induction of TrkA mRNA levels requires micromolar concentrations of RA. Induction of both TrkA and TrkB mRNA does not require new protein synthesis. However, RA-induced TrkB mRNA expression is transcriptionally regulated, while the transient RA-induced increase of TrkA mRNA is a consequence of extended mRNA stability. Interferon gamma (IFN-gamma) selectively increases TrkA mRNA without affecting TrkB mRNA levels. Similar to RA, IFN-gamma does not modify the transcriptional rate of TrkA mRNA, but rather increases TrkA mRNA stability. Thus, RA and IFN-gamma differentially regulate TrkA or TrkB expression in the same cell type by predominantly transcriptional (TrkB) or post transcriptional (TrkA) mechanisms. Such experiments indicate the complexity of Trk mRNA regulation and also indicate compounds that may affect neurotrophin responsiveness in developing neural cells.	NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MOLEC MECHANISMS CARCINOGENESIS LAB, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	LUCARELLI, E (corresponding author), NCI, PEDIAT BRANCH,CELLULAR & MOLEC BIOL SECT,BLDG 10, ROOM 13C218, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.		Enrico, Lucarelli/G-3588-2015; Lucarelli, Enrico/AAF-1612-2021	Enrico, Lucarelli/0000-0002-6681-6374; Lucarelli, Enrico/0000-0002-6681-6374				BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BIRREN SJ, 1992, SCIENCE, V257, P395, DOI 10.1126/science.1321502; BOSCO MC, 1994, BLOOD, V83, P537; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; DAVIES AM, 1994, CURR BIOL, V4, P273, DOI 10.1016/S0960-9822(00)00064-6; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DICICCOBLOOM E, 1993, NEURON, V11, P1101, DOI 10.1016/0896-6273(93)90223-E; GAETANO C, 1991, CELL GROWTH DIFFER, V2, P487; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HOLTZMAN DM, 1992, NEURON, V9, P465, DOI 10.1016/0896-6273(92)90184-F; HUNTER K, 1991, P NATL ACAD SCI USA, V88, P3666, DOI 10.1073/pnas.88.9.3666; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JELSMA TN, 1993, J NEUROBIOL, V24, P1207, DOI 10.1002/neu.480240907; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KRISHNAMURTHY S, 1963, J NUTR, V79, P503, DOI 10.1093/jn/79.4.503; KUMAR S, 1993, MOL BRAIN RES, V17, P163, DOI 10.1016/0169-328X(93)90086-5; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LOPRESTI P, 1992, CELL GROWTH DIFFER, V3, P627; LUCARELLI E, 1994, ADV NEUROBLASTOMA RE, V4, P185; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MASANA Y, 1993, J NEUROSCI RES, V35, P468, DOI 10.1002/jnr.490350503; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7772, DOI 10.1073/pnas.91.16.7772; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7194, DOI 10.1073/pnas.91.15.7194; MCCAFFERY P, 1993, DEV BIOL, V158, P390, DOI 10.1006/dbio.1993.1197; MCCAFFERY P, 1993, ENZYMOLOGY MOL BIOL, V4, P181; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NAKAGAWARA A, 1995, GENOMICS, V25, P538, DOI 10.1016/0888-7543(95)80055-Q; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; OKAZAWA H, 1994, ONCOGENE, V9, P1813; OLSSON T, 1994, EUR J IMMUNOL, V24, P308, DOI 10.1002/eji.1830240205; PASTOR R, 1994, ONCOGENE, V9, P1081; RADZIOCH D, 1991, MOL CELL BIOL, V11, P2718, DOI 10.1128/MCB.11.5.2718; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; RODRIGUEZTEBAR A, 1991, DEVELOPMENT, V112, P813; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SHIKATA A, 1994, JPN J CANCER RES, V85, P122, DOI 10.1111/j.1349-7006.1994.tb02070.x; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SOHRABJI F, 1994, J NEUROSCI, V14, P459; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VERDI JM, 1994, NEURON, V13, P1359, DOI 10.1016/0896-6273(94)90421-9; VILCEK J, 1994, INT ARCH ALLERGY IMM, V104, P311; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WANG SY, 1985, DEV BIOL, V107, P75, DOI 10.1016/0012-1606(85)90377-X	63	54	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24725	24731		10.1074/jbc.270.42.24725	http://dx.doi.org/10.1074/jbc.270.42.24725			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559588	hybrid			2022-12-27	WOS:A1995TB46500022
J	RAO, PV; PUGAZHENTHI, S; KHANDELWAL, RL				RAO, PV; PUGAZHENTHI, S; KHANDELWAL, RL			THE EFFECTS OF STREPTOZOTOCIN-INDUCED DIABETES AND INSULIN SUPPLEMENTATION ON EXPRESSION OF THE GLYCOGEN-PHOSPHORYLASE GENE IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE; ENZYME-ACTIVITY; MESSENGER-RNA; CYCLIC-AMP; TRANSCRIPTIONAL REGULATION; PARTICULATE FRACTIONS; GLUCOKINASE GENE; SKELETAL-MUSCLE; PYRUVATE-KINASE; PROTEIN-KINASE	We have previously observed that the chronic effects of streptozotocin-induced diabetes cause a decrease in the total hepatic glycogen phosphorylase activity with a corresponding reduction in the phosphorylase protein levels. These effects were normalized by insulin administration to diabetic rats. There was no change in the total glycogen synthase activity as a result of diabetes or insulin supplementation. These results are extended to examine the effects of diabetes and insulin administration to diabetic animals on the expression of phosphorylase and glycogen synthase enzymes. The expression (i.e. mRNA levels) of phosphorylase was down-regulated (45% of normal levels) in diabetic livers, and this was normalized by insulin supplementation to diabetic animals. Diabetes or insulin supplementation to diabetic rats showed no effect on the transcription rate of phosphorylase. As expected, diabetes (or insulin administration to diabetic animals) did not cause any alteration in the mRNA levels or in the transcription rate of hepatic glycogen synthase. The stability of phosphorylase mRNA was then examined using hepatocytes prepared from normal and diabetic rats. Diabetes caused a decrease in the half-life of phosphorylase mRNA from 14 h in normal hepatocytes to 6.5 h in diabetic hepatocyte. Insulin supplementation to the medium of diabetic hepatocytes increased the half-life of phosphorylase mRNA to a level comparable with normal values. This study indicates that the chronic effect of insulin on the activation of the total hepatic phosphorylase activity (and protein) is mediated through the stabilization of its mRNA levels.	UNIV SASKATCHEWAN,COLL MED,DEPT BIOCHEM,SASKATOON,SK S7N 5E5,CANADA	University of Saskatchewan								ALEXANDER MC, 1988, P NATL ACAD SCI USA, V85, P5092, DOI 10.1073/pnas.85.14.5092; BAHNAK BR, 1982, J BIOL CHEM, V257, P8775; BAI G, 1990, J BIOL CHEM, V265, P7843; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; CASCALES C, 1984, BIOCHEM J, V219, P911, DOI 10.1042/bj2190911; CHAUHAN J, 1991, J BIOL CHEM, V266, P10035; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIMBALA MA, 1982, J BIOL CHEM, V257, P7629; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; GABBAY RA, 1984, J BIOL CHEM, V259, P6052; GIFFIN BF, 1993, J HISTOCHEM CYTOCHEM, V41, P1849, DOI 10.1177/41.12.8245433; GORIN F, 1989, AM J PHYSIOL, V257, pC495, DOI 10.1152/ajpcell.1989.257.3.C495; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; HOD Y, 1988, J BIOL CHEM, V263, P7747; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; KHANDELWAL RL, 1977, BIOCHEM J, V168, P541, DOI 10.1042/bj1680541; LARNER J, 1988, DIABETES, V37, P262, DOI 10.2337/diab.37.3.262; LAVOIE L, 1991, METABOLISM, V40, P1031, DOI 10.1016/0026-0495(91)90125-G; LEYLAND DM, 1991, BIOCHEM J, V278, P113, DOI 10.1042/bj2780113; MILLER TB, 1978, LIFE SCI, V23, P1083, DOI 10.1016/0024-3205(78)90670-7; MILLER TB, 1986, J IBOL CHEM, V261, P735; MOORE PS, 1989, MOL ENDOCRINOL, V3, P1724, DOI 10.1210/mend-3-11-1724; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; NEWGARD CB, 1986, P NATL ACAD SCI USA, V83, P8132, DOI 10.1073/pnas.83.21.8132; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; NUTTALL FQ, 1989, ANAL BIOCHEM, V178, P311, DOI 10.1016/0003-2697(89)90644-1; OKUBO M, 1991, ARCH BIOCHEM BIOPHYS, V288, P126, DOI 10.1016/0003-9861(91)90173-G; PUGAZHENTHI S, 1990, BIOCHEM INT, V21, P651; PUGAZHENTHI S, 1993, MOL CELL BIOCHEM, V122, P77, DOI 10.1007/BF00925740; PUGAZHENTHI S, 1990, DIABETES, V39, P821, DOI 10.2337/diabetes.39.7.821; PUGAZHENTHI S, 1993, BIOCHIM BIOPHYS ACTA, V1179, P271, DOI 10.1016/0167-4889(93)90082-Z; RAABO E, 1960, SCAND J CLIN LAB INV, V12, P402; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROESLER WJ, 1986, FEBS LETT, V195, P344, DOI 10.1016/0014-5793(86)80190-9; ROESLER WJ, 1986, ARCH BIOCHEM BIOPHYS, V244, P397, DOI 10.1016/0003-9861(86)90130-X; ROESLER WJ, 1990, MOL CELL BIOCHEM, V92, P99; ROESLER WJ, 1989, MOL CELL BIOCHEM, V87, P147; ROESLER WJ, 1987, ENDOCRINOLOGY, V121, P127; RULFS J, 1989, AM J PHYSIOL, V257, pE74, DOI 10.1152/ajpendo.1989.257.1.E74; SIDDLE K, 1973, BIOCHEM J, V132, P765, DOI 10.1042/bj1320765; STALFORS P, 1985, EUR J BIOCHEM, V149, P295; STALMANS W, 1987, Diabetes Metabolism Reviews, V3, P127; TAN AWH, 1975, BIOCHIM BIOPHYS ACTA, V410, P45, DOI 10.1016/0005-2744(75)90206-5; THOMAS JA, 1973, BIOCHIM BIOPHYS ACTA, V293, P84, DOI 10.1016/0005-2744(73)90378-1; van de Werve G, 1987, Diabetes Metab Rev, V3, P47	48	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24955	24960		10.1074/jbc.270.42.24955	http://dx.doi.org/10.1074/jbc.270.42.24955			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559622	hybrid			2022-12-27	WOS:A1995TB46500056
J	TANIMURA, A; KURIHARA, K; RESHKIN, SJ; TURNER, RJ				TANIMURA, A; KURIHARA, K; RESHKIN, SJ; TURNER, RJ			INVOLVEMENT OF DIRECT PHOSPHORYLATION IN THE REGULATION OF THE RAT PAROTID NA+-K+-2CL(-) COTRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHARK RECTAL GLAND; K-CL COTRANSPORT; FLUID SECRETION; ACINAR-CELLS; BUMETANIDE-BINDING; NA/K/CL COTRANSPORTER; PROTEIN; PURIFICATION; INHIBITORS	We identify a 175-kDa membrane phosphoprotein (pp175) in rat parotid acini whose properties correlate well with the Na+-K+-2Cl(-) cotransporter previously characterized functionally and biochemically in this tissue. pp175 was the only phosphoprotein immunoprecipitated by an anti-Na+-K+-2Cl(-) cotransporter antibody and the only membrane protein whose phosphorylation state was conspicuously altered after a brief (45-s) exposure of acini to the beta-adrenergic agonist isoproterenol. Phosphopeptide mapping provided evidence for three phosphorylation sites on pp175, only one of which was labeled in response to isoproterenol treatment. The half-maximal effect of isoproterenol on phosphorylation of pp175 (approximate to 20 nM) was in excellent agreement with its previously demonstrated up regulatory effect on cotransport activity. Increased phosphorylation of pp175 was also seen following acinar treatment with a permeant cAMP analogue and with forskolin, conditions that have likewise been shown to up-regulate the cotransporter. Combined with earlier results from our laboratory, these data provide strong evidence that the up-regulation of the cotransporter by these agents is due to direct phosphorylation mediated by protein kinase A. ALF(4)(-) treatment, which results in an up regulation of cotransport activity comparable with that observed with isoproterenol (similar to 6-fold), caused a similar increase in phosphorylation of pp175. However, hypertonic shrinkage and treatment with the protein phosphatase inhibitor calyculin A, which also up-regulate the cotransporter (similar to 3-fold and similar to 6-fold, respectively) caused no change in the phosphorylation level. Furthermore, although acinar treatment with the muscarinic agonist carbachol results in a dramatic up-regulation of cotransport activity and a concomitant phosphorylation of pp175, no phosphorylation of pp175 was seen with the Ca2+-mobilizing agent thapsigargin, which is able to fully mimic the up-regulatory effect of carbachol on transport activity. Taken together, these results indicate that direct phosphorylation is only one of the mechanisms involved in secretagogue-induced regulation of the rat parotid Na+K+-2Cl(-) cotransporter.	NIDR,CLIN INVEST & PATIENT CARE BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Reshkin, Stephan/AAI-6680-2020	Reshkin, Stephan/0000-0001-9757-5908				CORCELLI A, 1991, J MEMBRANE BIOL, V120, P125, DOI 10.1007/BF01872395; Evans R. L., 1994, Molecular Biology of the Cell, V5, p116A; FORBUSH B, 1992, AM J PHYSIOL, V262, pC1000, DOI 10.1152/ajpcell.1992.262.4.C1000; HAAS M, 1988, BIOCHIM BIOPHYS ACTA, V939, P131, DOI 10.1016/0005-2736(88)90054-5; HAAS M, 1987, AM J PHYSIOL, V253, pC243, DOI 10.1152/ajpcell.1987.253.2.C243; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JOHNSON D A, 1987, P135; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYTLE C, 1992, AM J PHYSIOL, V262, pC1009, DOI 10.1152/ajpcell.1992.262.4.C1009; LYTLE C, 1992, J BIOL CHEM, V267, P25438; MELVIN JE, 1992, AM J PHYSIOL, V262, pG393, DOI 10.1152/ajpgi.1992.262.3.G393; MELVIN JE, 1987, BIOCHEM BIOPH RES CO, V145, P754, DOI 10.1016/0006-291X(87)91029-1; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; PAULAIS M, 1992, J CLIN INVEST, V89, P1142, DOI 10.1172/JCI115695; PAULAIS M, 1992, J BIOL CHEM, V267, P21558; PETERSEN OH, 1984, NATURE, V307, P693, DOI 10.1038/307693a0; RESHKIN SJ, 1993, J MEMBRANE BIOL, V136, P243, DOI 10.1007/BF02505766; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TORCHIA J, 1992, J BIOL CHEM, V267, P25444; TORCHIA J, 1994, J BIOL CHEM, V269, P29778; TURNER RJ, 1993, ANN NY ACAD SCI, V694, P24, DOI 10.1111/j.1749-6632.1993.tb18339.x; TURNER RJ, 1990, J MEMBRANE BIOL, V113, P203, DOI 10.1007/BF01870072; TURNER RJ, 1988, J MEMBRANE BIOL, V102, P71, DOI 10.1007/BF01875354	23	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25252	25258		10.1074/jbc.270.42.25252	http://dx.doi.org/10.1074/jbc.270.42.25252			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559664	hybrid			2022-12-27	WOS:A1995TB46500098
J	ZHU, DH; CARDENAS, ME; HEITMAN, J				ZHU, DH; CARDENAS, ME; HEITMAN, J			MYRISTOYLATION OF CALCINEURIN-B IS NOT REQUIRED FOR FUNCTION OR INTERACTION WITH IMMUNOPHILIN-IMMUNOSUPPRESSANT COMPLEXES IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; CYCLOSPORINE-A; CATALYTIC SUBUNIT; GENE-PRODUCT; MOLECULAR CHARACTERIZATION; TYROSINE KINASES; BINDING SUBUNIT; AMINO TERMINUS; CYCLOPHILIN-A; SARCOMA-VIRUS	Calcineurin is a heterodimeric Ca2+/calmodulin-dependent protein phosphatase that regulates signal transduction and is the target of immunophilin-immunosuppressive drug complexes in T-lymphocytes and in yeast. Calcineurin is composed of a catalytic A subunit and a regulatory B subunit that is myristoylated at its amino terminus. We employed genetic and biochemical approaches to investigate the functional roles of myristoylation of calcineurin B (CNB1) in Saccharomyces cerevisiae, A calcineurin B mutant in which glycine 2 was substituted by alanine (CNB1-G2A) did not incorporate [H-3]myristate when expressed in yeast. Both wild-type calcineurin B and the CNB1-G2A mutant protein are partially associated with membranes and cytoskeletal structures; hence, myristoylation is not required for these associations. In several independent genetic assays of calcineurin functions (recovery from alpha-factor arrest, survival during cation stress, and viability of a calcineurin dependent strain), the nonmyristoylated CNB1-G2A mutant protein exhibited full biological activity. In vitro, both wild-type and CNB1-G2A mutant proteins formed complexes with both cyclophilin A-cyclosporin A (CsA) and FKBP12-FK506 that contained calcineurin A. Interestingly, expression of the nonmyristoylated CNB1-G2A mutant protein rendered yeast cells partially resistant to the immunosuppressant CsA, but not to FK506. This study demonstrates that calcineurin B myristoylation is not required for function, but may participate in inhibition by the cyclophilin A-CsA complex.	DUKE UNIV, MED CTR, DEPT GENET, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University; Howard Hughes Medical Institute			Heitman, Joseph/ABC-6006-2021					AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; ANGLISTER J, 1994, BIOCHEMISTRY-US, V33, P3540, DOI 10.1021/bi00178a010; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; BOSS MA, 1981, J VIROL, V40, P472, DOI 10.1128/JVI.40.2.472-481.1981; BREUDER T, 1994, P NATL ACAD SCI USA, V91, P5372, DOI 10.1073/pnas.91.12.5372; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; Cardenas Maria E., 1994, Perspectives in Drug Discovery and Design, V2, P103, DOI 10.1007/BF02171739; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; EGERTON M, 1993, YEAST, V9, P703, DOI 10.1002/yea.320090704; ENG WK, 1994, GENE, V151, P61, DOI 10.1016/0378-1119(94)90633-5; ETZKORN FA, 1994, BIOCHEMISTRY-US, V33, P2380, DOI 10.1021/bi00175a005; FERREIRA A, 1993, MOL BIOL CELL, V4, P1225, DOI 10.1091/mbc.4.12.1225; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FOOR F, 1992, NATURE, V360, P682; FUKUI Y, 1989, ONCOGENE RES, V4, P283; HADDY A, 1992, FEBS LETT, V314, P37, DOI 10.1016/0014-5793(92)81456-V; HADDY A, 1994, BIOCHEM BIOPH RES CO, V200, P1221, DOI 10.1006/bbrc.1994.1581; HAENDLER B, 1989, GENE, V83, P39, DOI 10.1016/0378-1119(89)90401-0; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HARLOW E, 1988, ANTIBODIES LABORATOR; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1992, NEW BIOL, V4, P448; Heitman Joseph, 1993, Methods (Orlando), V5, P176, DOI 10.1006/meth.1993.1022; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUSI H, 1994, J BIOL CHEM, V269, P14199; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JONES DH, 1991, BIOTECHNIQUES, V10, P62; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; JOTTE RM, 1994, J BIOL CHEM, V269, P16388; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAMINCHIK J, 1994, AIDS RES HUM RETROV, V10, P1003, DOI 10.1089/aid.1994.10.1003; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KUNO T, 1991, BIOCHEM BIOPH RES CO, V180, P1159, DOI 10.1016/S0006-291X(05)81188-X; LI W, 1993, J BIOL CHEM, V268, P14040; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; MANGER R, 1986, J VIROL, V59, P66, DOI 10.1128/JVI.59.1.66-72.1986; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; NIEDERMAN TMJ, 1993, VIROLOGY, V197, P420, DOI 10.1006/viro.1993.1605; OLSON EN, 1986, J BIOL CHEM, V261, P2458; PAPADOPOULOS V, 1989, MOL CELL ENDOCRINOL, V63, P23, DOI 10.1016/0303-7207(89)90078-6; PAPADOPOULOS V, 1990, MOL CELL ENDOCRINOL, V74, P109, DOI 10.1016/0303-7207(90)90113-M; PARENT SA, 1993, J GEN MICROBIOL, V139, P2973, DOI 10.1099/00221287-139-12-2973; PARSONS JN, 1994, J BIOL CHEM, V269, P19610; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; POLITINO M, 1990, J BIOL CHEM, V265, P7619; POLITINO M, 1987, J BIOL CHEM, V262, P10109; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RYFFEL B, 1993, BIOCHEM BIOPH RES CO, V194, P1074, DOI 10.1006/bbrc.1993.1931; Schiestl Robert H., 1993, Methods (Orlando), V5, P79, DOI 10.1006/meth.1993.1011; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVERMAN L, 1993, CELL GROWTH DIFFER, V4, P475; SILVERMAN L, 1992, J CELL BIOL, V119, P415, DOI 10.1083/jcb.119.2.415; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; UEKI K, 1993, J BIOL CHEM, V268, P6554; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; YE RR, 1992, EUR J BIOCHEM, V204, P713, DOI 10.1111/j.1432-1033.1992.tb16686.x; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	90	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24831	24838		10.1074/jbc.270.42.24831	http://dx.doi.org/10.1074/jbc.270.42.24831			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559604	hybrid			2022-12-27	WOS:A1995TB46500038
J	ITO, M; KURITA, T; KITA, K				ITO, M; KURITA, T; KITA, K			A NOVEL ENZYME THAT CLEAVES THE N-ACYL LINKAGE OF CERAMIDES IN VARIOUS GLYCOSPHINGOLIPIDS AS WELL AS SPHINGOMYELIN TO PRODUCE THEIR LYSO FORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; ENDOGLYCOCERAMIDASE; CHROMATOGRAPHY; GANGLIOSIDES; BRAIN	We describe a novel enzyme that hydrolyzes the N-acyl linkage between fatty acids and sphingosine bases in ceramides of various sphingolipids. The enzyme was purified about 300-fold with 5% recovery from the culture filtrate of a newly isolated bacterium (Pseudomonas sp. TK4) by ammonium sulfate precipitation followed by several steps of high performance liquid chromatography. The purified enzyme preparation was completely free of exoglycosidases, sphingomyelinase, and proteases, and showed a single protein band corresponding to a molecular mass of 52 kDa on SDS-polyacrylamide slab gel electrophoresis after staining with Coomassie Brilliant Blue, The enzyme shows quite wide specificity, i.e. it hydrolyzes both neutral and acidic glycosphingolipids, and simple glycosphingolipid cerebrosides to polysialogangliosides such as GQ1b, Furthermore the enzyme also hydrolyzes sphingomyelin to produce the respective lyse form. However, the enzyme shows hardly any activity on ceramides, indicating that it is completely different from the ceramidase (EC 3.5.1.23) reported previously, This enzyme, which is tentatively named sphingolipid ceramide N-deacylase, should greatly facilitate the further study of sphingolipids as well as lysosphingolipids.			ITO, M (corresponding author), KYUSHU UNIV, FAC AGR, MARINE BIOCHEM LAB, HIGASHI KU, HAKOZAKI 6-10-1, FUKUOKA 812, JAPAN.			ito, Makoto/0000-0003-3159-7818				BARNHOLZ Y, 1966, J BIOL CHEM, V241, P3731; DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; FARRER RG, 1990, J BIOL CHEM, V265, P22217; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANAI N, 1988, J BIOL CHEM, V263, P10915; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1987, J BIOL CHEM, V262, P13620; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HIRABAYASHI Y, 1988, J BIOCHEM, V103, P1; ITO M, 1989, J BIOL CHEM, V264, P9510; ITO M, 1989, METHOD ENZYMOL, V179, P488; KATO N, 1991, J CHROMATOGR, V549, P133, DOI 10.1016/S0021-9673(00)91424-9; KITAMIKADO M, 1981, J BIOL CHEM, V256, P3906; KOBAYASHI T, 1988, ANN NEUROL, V24, P517, DOI 10.1002/ana.410240407; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; MOORE GL, 1959, ANAL BIOCHEM, V32, P122; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; NEUENHOFER S, 1985, BIOCHEMISTRY-US, V24, P525, DOI 10.1021/bi00323a042; NEUENHOFER S, 1986, BIOL CHEM H-S, V367, P241, DOI 10.1515/bchm3.1986.367.1.241; OHASHI Y, 1984, BIOMED MASS SPECTROM, V11, P383, DOI 10.1002/bms.1200110803; PUSHKAREVA MY, 1994, BBA-MOL CELL RES, V1221, P54, DOI 10.1016/0167-4889(94)90215-1; RAGHAVAN SS, 1974, J LIPID RES, V15, P484; ROSENGREN B, 1987, J NEUROCHEM, V49, P834, DOI 10.1111/j.1471-4159.1987.tb00969.x; SVANNERHOLM L, 1963, J NEUROCHEM, V10, P613; YAMAGUCHI Y, 1994, J BIOCHEM-TOKYO, V116, P704, DOI 10.1093/oxfordjournals.jbchem.a124584; YAVIN E, 1969, BIOCHEMISTRY-US, V8, P1692, DOI 10.1021/bi00832a052; ZHANG H, 1990, J BIOL CHEM, V265, P76	29	97	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24370	24374		10.1074/jbc.270.41.24370	http://dx.doi.org/10.1074/jbc.270.41.24370			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592649	hybrid			2022-12-27	WOS:A1995TA21700077
J	RON, D; LUO, JH; MOCHLYROSEN, D				RON, D; LUO, JH; MOCHLYROSEN, D			C2 REGION-DERIVED PEPTIDES INHIBIT TRANSLOCATION AND FUNCTION OF BETA-PROTEIN KINASE-C IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; INTRACELLULAR RECEPTORS; REGULATORY DOMAIN; RAT-LIVER; IDENTIFICATION; FAMILY; PHOSPHATIDYLSERINE; CONTAINS; HETEROGENEITY; SYNAPTOTAGMIN	RACK1 is a protein kinase C (PKC)-binding protein that fulfills the criteria previously established for a receptor for activated C kinase (RACK). If binding of PKC to RACK anchors the activated enzyme near its protein substrates, then inhibition of this binding should inhibit translocation and function of the enzyme irt vivo. Here, we have identified such inhibitors that mimic the RACK1-binding site on beta PKC. We first found that a C2-containing fragment, but not a C1-containing fragment of beta PKC, bound to RACK1 and inhibited subsequent beta PKC binding. The RACK1-binding site was further mapped; peptides beta C2-1 (beta PKC(209-216)), beta C2-2 (beta PKC(186-198)), and beta C2-4 (beta PKC(218-226), but not a number of control peptides, bound to RACK1 and inhibited the C2 fragment binding to RACK1, Peptides beta C2-1, beta C2-2, and beta C2-4 specifically inhibited phorbol ester-induced translocation of the C2-containing isozymes in cardiac myocytes and insulin-induced beta PKC translocation and function in Xenopus oocytes, Therefore, peptides corresponding to amino acids 186-198, and 209-226 within the C2 region of the beta PKC are specific inhibitors for functions mediated by beta PKC.	STANFORD UNIV, SCH MED, DEPT MOLEC PHARMACOL, STANFORD, CA 94305 USA; COLUMBIA UNIV, COLUMBIA PRESBYTERIAN MED CTR, NEW YORK, NY 10032 USA	Stanford University; Columbia University; NewYork-Presbyterian Hospital				Mochly-Rosen, Daria/0000-0002-6691-8733	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043380] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43380] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CHEN ZZ, 1987, J IMMUNOL, V138, P2345; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DISATNIK MH, 1994, P NATL ACAD SCI USA, V91, P559, DOI 10.1073/pnas.91.2.559; DISATNIK MH, 1994, CELL GROWTH DIFFER, V5, P873; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FORDHUTCHINSON AW, 1991, TRENDS PHARMACOL SCI, V12, P68, DOI 10.1016/0165-6147(91)90500-R; GAWLER DJ, 1995, ONCOGENE, V10, P817; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P6438; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; JACOB MC, 1991, CYTOMETRY, V12, P550, DOI 10.1002/cyto.990120612; JAKEN S, 1992, PROTEIN KINASE C CUR, P237; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LIU SH, 1993, NUCLEIC ACIDS RES, V21, P4005, DOI 10.1093/nar/21.17.4005; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LUO JH, 1993, J BIOL CHEM, V268, P3715; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; MOSIOR M, 1991, BIOPHYS J, V60, P149, DOI 10.1016/S0006-3495(91)82038-0; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NEHER E, 1994, NATURE, V372, P316, DOI 10.1038/372316a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1988, J BIOL CHEM, V263, P6927; PADFIELD PJ, 1992, P NATL ACAD SCI USA, V89, P1656, DOI 10.1073/pnas.89.5.1656; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; RON D, 1994, J BIOL CHEM, V269, P21395; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SMITH BL, 1992, BIOCHEM BIOPH RES CO, V188, P1235, DOI 10.1016/0006-291X(92)91363-U; SMITH LD, 1989, DEVELOPMENT, V107, P685; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; WOLF M, 1990, BIOCHEM J, V269, P723, DOI 10.1042/bj2690723; WOLF M, 1986, J BIOL CHEM, V261, P3327; YANAI S, 1991, PHARMACEUT RES, V8, P557, DOI 10.1023/A:1015836219502; ZALEWSKI PD, 1988, BIOCHEM PHARMACOL, V37, P1415, DOI 10.1016/0006-2952(88)90802-7	53	264	283	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24180	24187		10.1074/jbc.270.41.24180	http://dx.doi.org/10.1074/jbc.270.41.24180			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592622	hybrid			2022-12-27	WOS:A1995TA21700050
J	DEXAERDE, AD; SUPPLY, P; DUFOUR, JP; BOGAERTS, P; THINES, D; GOFFEAU, A; BOUTRY, M				DEXAERDE, AD; SUPPLY, P; DUFOUR, JP; BOGAERTS, P; THINES, D; GOFFEAU, A; BOUTRY, M			FUNCTIONAL COMPLEMENTATION OF A NULL MUTATION OF THE YEAST SACCHAROMYCES-CEREVISIAE PLASMA-MEMBRANE H+-ATPASE BY A PLANT H+-ATPASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTIANA-PLUMBAGINIFOLIA; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; SHUTTLE VECTORS; EXPRESSION; PROLIFERATION; OVEREXPRESSION; IDENTIFICATION; CA-2+-ATPASE; MODULATION	In plants, the proton pump-ATPase (H+-ATPase) of the plasma membrane is encoded by a multigene family. The presence within an organ of several isoforms prevents a detailed enzymatic characterization of individual H+-ATPases. We therefore used the yeast Saccharomyces cerevisiae as a heterologous host for the expression of PMA2, an H+-ATPase isoform of Nicotiana plumbagini-folia. Yeast transformed by the plant pma2 was still able to grow under conditions where the yeast ATPase gene (PMA1) was either repressed or deleted. The transformed yeast strain was resistant to hygromycin, and its growth was prevented when the medium pH was lowered to 5.0. The N. plumbaginifolia PMA2 expressed in S. cerevisiae has unusual low K-m for ATP (23 mu M) and high pH optimum (6.8). Electron microscopic examination revealed PMA2 in internal structures of the karmellae type which proliferated when cell growth was arrested, either at a nonpermissive pH or at the stationary phase in a minimal medium. Under the latter conditions, subcellular fractionation on sucrose gradients revealed, in addition to the expected plant PMA2 peak linked to the plasma membrane fraction, a low density peak containing PMA2 and KAR2, an endoplasmic reticulum marker. These observations suggest that the partial internal accumulation of PMA2 occurs in membranes derived from the endoplasmic reticulum and largely depends on growth conditions.	UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM	Universite Catholique Louvain			de Kerchove d'Exaerde, Alban/R-6984-2019; Supply, Philip/A-9580-2019	de Kerchove d'Exaerde, Alban/0000-0002-0682-5877; Boutry, Marc/0000-0002-2315-6900; Supply, Philip/0000-0003-3690-3853				AMMERER G, 1983, METHOD ENZYMOL, V101, P192; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BOUTRY M, 1989, BIOCHEM BIOPH RES CO, V162, P567, DOI 10.1016/0006-291X(89)92348-6; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; DEXAERDE AD, 1995, METHODS MOL GENETICS; DUFOUR JP, 1982, J BIOL CHEM, V257, P9365; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; HARLOW E, 1988, ANTIBODIES LABORATOR, P490; HARRIS S, 1993, GENETICS, V135, P5; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MICHELET B, 1994, PLANT CELL, V6, P1375, DOI 10.1105/tpc.6.10.1375; MICHELET B, 1995, PLANT PHYSIOL, V108, P1, DOI 10.1104/pp.108.1.1; MORIAU L, 1993, PLANT MOL BIOL, V21, P955, DOI 10.1007/BF00023594; PALMGREN MG, 1988, PHYSIOL PLANTARUM, V74, P11, DOI 10.1111/j.1399-3054.1988.tb04934.x; PALMGREN MG, 1993, FEBS LETT, V317, P216, DOI 10.1016/0014-5793(93)81279-9; PALMGREN MG, 1994, J BIOL CHEM, V269, P3027; PEREZ C, 1992, J BIOL CHEM, V267, P1204; PETERS PH, 1978, PHYSIOL PLANTARUM, V46, P330; PORTILLO F, 1989, FEBS LETT, V247, P381, DOI 10.1016/0014-5793(89)81375-4; RAMBOURG A, 1993, ANAT REC, V237, P441, DOI 10.1002/ar.1092370402; RAMOS RS, 1994, PLANT PHYSIOL, V105, P853, DOI 10.1104/pp.105.3.853; RAO R, 1992, ANN NY ACAD SCI, V671, P195, DOI 10.1111/j.1749-6632.1992.tb43796.x; ROBERTS G, 1991, BIOCHIM BIOPHYS ACTA, V1064, P131, DOI 10.1016/0005-2736(91)90419-9; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; SCHLESSER A, 1988, J BIOL CHEM, V263, P19480; SCHUNCK WH, 1991, EUR J CELL BIOL, V55, P336; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SIKORSKI RS, 1989, GENETICS, V122, P19; SUPPLY P, 1993, J BIOL CHEM, V268, P19744; SUSSMAN MR, 1994, ANNU REV PLANT PHYS, V45, P211, DOI 10.1146/annurev.pp.45.060194.001235; TRECO DA, 1989, CURRENT PROTOCOLS MO; VANTUINEN E, 1987, J HISTOCHEM CYTOCHEM, V35, P327, DOI 10.1177/35.3.3546482; VENEMA K, 1993, BIOCHIM BIOPHYS ACTA, V1146, P87, DOI 10.1016/0005-2736(93)90342-W; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; WACH A, 1990, EUR J BIOCHEM, V189, P675, DOI 10.1111/j.1432-1033.1990.tb15536.x; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101	49	78	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23828	23837		10.1074/jbc.270.40.23828	http://dx.doi.org/10.1074/jbc.270.40.23828			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559560	hybrid			2022-12-27	WOS:A1995RY90900089
J	NAKAE, K; NAKAJIMA, K; INAZAWA, J; KITAOKA, T; HIRANO, T				NAKAE, K; NAKAJIMA, K; INAZAWA, J; KITAOKA, T; HIRANO, T			ERM, A PEA3 SUBFAMILY OF ETS TRANSCRIPTION FACTORS, CAN COOPERATE WITH C-JUN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; LONG TERMINAL REPEAT; AMP RESPONSE ELEMENT; DNA-BINDING; CYCLIC-AMP; ONCOGENE FAMILY; SOMATOSTATIN GENE; LEUKEMIA-VIRUS; NUCLEAR FACTOR; FACTOR P62TCF	A human cDNA clone for ERM, a member of the ets gene family, has been obtained by polymerase chain reaction with degenerate primers corresponding to highly conserved regions within an Ets DNA binding domain. ERM mRNA is expressed ubiquitously. The gene was mapped to chromosome 3q27. In in vivo transient-expression assays, ERM induced transcription more efficiently from a synthetic element containing both an ets-binding site (EBS) and a cyclic AMP response element (CRE) than from one containing an EBS alone. The activation of a synthetic EBS-CRE site by ERM was likely to involve a leucine zipper protein capable of dimerizing with CRE-BP1 leucine zipper. Indeed, ERM and c-Jun synergistically activated the EBS-CRE without making an apparent ternary complex. The synergy between c-Jun and ERM may be attributed to the enhancing effect of c-Jun on the transcription activity of ERM, because c Jun increased ERM transcription activity by more than 20-fold in an assay system using a variety of fusion proteins between a Ga14 DNA-binding domain and a portion of ERM. This enhancing effect of c-Jun required the amino-terminal portion of ERM.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT ONCOL,DIV MOLEC ONCOL,SUITA,OSAKA 565,JAPAN; KYOTO PREFECTURAL UNIV,DEPT HYG,KYOTO 602,JAPAN	Osaka University; Kyoto Prefectural University			Hirano, Toshio/C-8194-2009					ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1993, ONCOGENE, V8, P3375; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIEDEN JM, 1993, ANNU REV IMMUNOL, V11, P539; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTE D, 1994, ONCOGENE, V9, P1397; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; Sambrook J, 1989, MOL CLONING LABORATO; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	67	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	1995	270	40					23795	23800		10.1074/jbc.270.40.23795	http://dx.doi.org/10.1074/jbc.270.40.23795			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RY909	7559555	hybrid			2022-12-27	WOS:A1995RY90900084
J	POLVERINO, A; FROST, J; YANG, PR; HUTCHISON, M; NIEMAN, AM; COBB, MH; MARCUS, S				POLVERINO, A; FROST, J; YANG, PR; HUTCHISON, M; NIEMAN, AM; COBB, MH; MARCUS, S			ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE CASCADES BY P21-ACTIVATED PROTEIN-KINASES IN CELL-FREE-EXTRACTS OF XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MAP KINASE; SIGNAL TRANSDUCTION; RAS; FAMILY; YEAST; CDNA	In the evolutionarily distant yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe, genetic evidence suggests that activation of pheromone induced mitogen-activated protein kinase (MAPK) cascades involves the function of the p21(cdc42/rac1)-activated protein kinases (PAKs) Ste20 and Shk1, respectively. In this report, we show that purified Ste20 and Shk1 were each capable of inducing p42(MAPK) activation in cell-free extracts of Xenopus laevis oocytes, while a mammalian Ste20/Shk1-related protein kinase, p65(pak) (Pak1), did not induce activation of p42(MAPK). In contrast to p42(MAPK), activation of JNK/SAPK in Xenopus oocyte ex tracts was induced by both the yeast Ste20 and Shk1 kinases, as well as by mammalian Pak1. Our results demonstrate that MAPK cascades that are responsive to PAKs are conserved in higher eukaryotes and suggest that distinct PAKs may regulate distinct MAPK modules.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030; AMGEN INC,DEPT PROT STRUCT,THOUSAND OAKS,CA 91320; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	University of Texas System; UTMD Anderson Cancer Center; Amgen; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Frost, Jeffrey/0000-0001-9722-1536; Neiman, Aaron/0000-0002-6600-6996; Cobb, Melanie/0000-0003-0833-5473				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COOK S, 1994, NATURE, V369, P361, DOI 10.1038/369361a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ENGLISH JM, 1995, IN PRESS J BIOL CHEM, V270; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MAUSER E, 1994, NATURE, V367, P40; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PORRAS A, 1994, J BIOL CHEM, V269, P12741; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rose MD., 1990, METHODS YEAST GENETI; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	41	92	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26067	26070		10.1074/jbc.270.44.26067	http://dx.doi.org/10.1074/jbc.270.44.26067			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592806	hybrid			2022-12-27	WOS:A1995TC97800013
J	REDDY, SPM; CHUU, YJ; LAO, PN; DONN, J; ANN, DK; WU, R				REDDY, SPM; CHUU, YJ; LAO, PN; DONN, J; ANN, DK; WU, R			EXPRESSION OF HUMAN SQUAMOUS-CELL DIFFERENTIATION MARKER, SPR1, IN TRACHEOBRONCHIAL EPITHELIUM DEPENDS ON JUN AND TRE MOTIFS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; PHORBOL ESTER; GENE-TRANSCRIPTION; DNA-BINDING; FOS; AP-1; COLLAGENASE; TPA; KERATINOCYTES; INDUCTION	Tracheobronchial epithelial (TBE) cells that normally do not express the squamous cell differentiation marker gene, SPR1, can be induced to produce it by 12-O-tetradecanoylphorbol-13-acetate (TPA), The regulation of SPR1 gene expression by TPA occurs, in part, at the transcriptional level in primary human and monkey TBE cells, Using a transient transfection assay, we observed that TPA stimulates the activity of the reporter gene, chloramphenicol acetyltransferase, by 2-4-fold in transfected TBE cells, However, this chloramphenicol acetyltransferase activity is cell type specific with significantly less activity in transformed epithelial cell lines and no activity in non-epithelial cell types, TPA-dependent stimulation can also be demonstrated by cotransfection with plasmid DNAs that overexpress the JUN family of proteins, especially c-JUN. Overexpression of c-JUN and TPA treatment synergistically stimulate the SPR1 promoter activity by more than 40-fold. Deletion analysis of the promoter region demonstrates that the DNA fragment of the first 98 base pairs of the 5'-flanking region contains the basal promoter activity, while the region between -162 and -96 contains the cis-enhancer elements for both the basal and TPA/c-JUN-stimulating promoter activities, This observation is supported by in vivo genomic footprinting studies that reveal persistent protections in the following motifs of this region: -141 TRE, -131 GT, -123 ETS-like, and -111 TRE-like motifs and in the enhanced protections in -141 TRE and -111 TRE-like motifs in cells after the TPA treatment. Site directed mutagenesis in this region demonstrates the involvement of both -141 TRE and -111 THE-like motifs in TPA/c-JUN-dependent stimulation as well as enhanced basal transcriptional activity, However, it is primarily the -111 TRE-like motif that is involved in the mediation of the enhanced basal promoter activity of the human SPR1 gene, These results are further supported by gel mobility shift assays that demonstrate the involvement of c-JUN and these TRE motifs in the formation of the DNA-protein complex.	UNIV CALIF DAVIS, CALIF REG PRIMATE RES CTR, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, SCH MED, DEPT INTERNAL MED, DAVIS, CA 95616 USA; UNIV SO CALIF, DEPT MOLEC PHARMACOL & TOXICOL, LOS ANGELES, CA 90033 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Southern California					NHLBI NIH HHS [HL35635] Funding Source: Medline; NIDCR NIH HHS [DE10742] Funding Source: Medline; NIEHS NIH HHS [ES06230] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL035635, R01HL035635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006230] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AN G, 1993, J CELL PHYSIOL, V157, P562, DOI 10.1002/jcp.1041570316; AN G, 1993, J BIOL CHEM, V268, P10977; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BACKENDORF C, 1992, NAT GENET, V2, P91, DOI 10.1038/ng1092-91; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1991, MOL ASPECTS CELLULAR, V6, P295; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS DR, 1986, NUCLEIC ACIDS RES, V14, P8863, DOI 10.1093/nar/14.22.8863; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRISCH SM, 1987, P NATL ACAD SCI USA, V84, P2600, DOI 10.1073/pnas.84.9.2600; GANG A, 1992, AM J RESP CELL MOL, V7, P104, DOI 10.1165/ajrcmb/7.1.104; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; GIBBS S, 1993, GENOMICS, V16, P630, DOI 10.1006/geno.1993.1240; HARRIS CC, 1972, JNCI-J NATL CANCER I, V48, P743; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; JETTEN AM, 1989, ENVIRON HEALTH PERSP, V80, P149, DOI 10.2307/3430740; JETTEN AM, 1992, J NATL CANCER INVSTM, V18, P93; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2204, DOI 10.1128/MCB.8.5.2204; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; RADZIOCH D, 1987, MOL CELL BIOL, V7, P595, DOI 10.1128/MCB.7.2.595; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REDDY PMS, 1994, J BIOL CHEM, V269, P8287; ROBINSON CB, 1991, J TISSUE CULTURE MET, V13, P95; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; TESFAIGZI J, 1995, J CELL PHYSIOL, V164, P571, DOI 10.1002/jcp.1041640315; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WU R, 1986, IN VITRO MODELS RESP, P1	42	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26451	26459		10.1074/jbc.270.44.26451	http://dx.doi.org/10.1074/jbc.270.44.26451			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592861	hybrid			2022-12-27	WOS:A1995TC97800068
J	SCHORK, SM; THUMM, M; WOLF, DH				SCHORK, SM; THUMM, M; WOLF, DH			CATABOLITE INACTIVATION OF FRUCTOSE-1,6-BISPHOSPHATASE OF SACCHAROMYCES-CEREVISIAE - DEGRADATION OCCURS VIA THE UBIQUITIN PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; CONJUGATING ENZYMES; PROTEIN-DEGRADATION; MULTIFUNCTIONAL PROTEINASE; INVIVO FUNCTION; CELL-SURVIVAL; YEAST; PROTEASOME; MUTANTS; COMPLEX	Catabolite inactivation of fructose-1,6-bisphosphatase (EBPase), a key enzyme in gluconeogenesis, is due to phosphorylation and subsequent degradation in the yeast Saccharomyces cerevisiae. The degradation process of the enzyme had been shown to depend on the action of the proteasome. Here we report that components of the ubiquitin pathway target FBPase to proteolysis. Upon glucose addition to yeast cells cultured on nonfermentable carbon sources FBPase is ubiquitinated in vivo. A multiubiquitin chain containing isopeptide linkages at Lys(48) of ubiquitin is attached to FBPase. Formation of a multiubiquitin chain is a prerequisite for the degradation of FBPase. Catabolite degradation of FBPase is dependent on the ubiquitin-conjugating enzymes Ubc1, Ubc4, and Ubc5. The 26 S proteasome is involved in the degradation process.	UNIV STUTTGART,INST BIOCHEM,D-70569 STUTTGART,GERMANY	University of Stuttgart			Thumm, Michael/A-8033-2015	Thumm, Michael/0000-0003-3238-4857				ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; CIECHANOVER A, 1994, BIOL CHEM H-S, V375, P565; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FINLEY D, 1992, MOL CELLULAR BIOL YE, P539; FUNAYAMA S, 1980, EUR J BIOCHEM, V109, P61, DOI 10.1111/j.1432-1033.1980.tb04767.x; GANCEDO C, 1971, J BACTERIOL, V107, P401, DOI 10.1128/JB.107.2.401-405.1971; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOLZER H, 1976, TRENDS BIOCHEM SCI, V1, P178, DOI 10.1016/S0968-0004(76)80018-7; HOUGH R, 1986, J BIOL CHEM, V261, P2400; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; MAMROUDKIDRON E, 1994, FEBS LETT, V337, P239, DOI 10.1016/0014-5793(94)80199-1; MAZON MJ, 1982, J BIOL CHEM, V257, P1128; MOLANO J, 1974, EUR J BIOCHEM, V44, P213, DOI 10.1111/j.1432-1033.1974.tb03475.x; MULLER D, 1981, BIOCHEM BIOPH RES CO, V103, P926, DOI 10.1016/0006-291X(81)90899-8; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHORK SM, 1994, FEBS LETT, V349, P270, DOI 10.1016/0014-5793(94)00668-7; SCHORK SM, 1994, NATURE, V369, P283, DOI 10.1038/369283a0; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; WOLF DH, 1979, EUR J BIOCHEM, V98, P375, DOI 10.1111/j.1432-1033.1979.tb13197.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; ZUBENKO GS, 1979, P NATL ACAD SCI USA, V76, P4581, DOI 10.1073/pnas.76.9.4581	49	95	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26446	26450		10.1074/jbc.270.44.26446	http://dx.doi.org/10.1074/jbc.270.44.26446			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592860	hybrid			2022-12-27	WOS:A1995TC97800067
J	LANGLOIS, WJ; SASAOKA, T; SALTIEL, AR; OLEFSKY, JM				LANGLOIS, WJ; SASAOKA, T; SALTIEL, AR; OLEFSKY, JM			NEGATIVE FEEDBACK-REGULATION AND DESENSITIZATION OF INSULIN-STIMULATED AND EPIDERMAL GROWTH FACTOR-STIMULATED P21(RAS) ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NUCLEOTIDE EXCHANGE FACTOR; GUANINE-NUCLEOTIDES; TYROSINE KINASE; SUBSTRATE RECOGNITION; SIGNAL TRANSDUCTION; RAS; PROTEIN; RECEPTOR; GRB2; P21RAS	Insulin and epidermal growth factor receptors transmit signals for cell proliferation and gene regulation through formation of active GTP-bound p21(ras) mediated by the guanine nucleotide exchange factor Sos. Sos is constitutively bound to the adaptor protein Grb2 and growth factor stimulation induces association of the Grb2/Sos complex with She and movement of Sos to the plasma membrane location of p21(ras). Insulin or epidermal growth factor stimulation induces a rapid increase in p21(ras) levels, but after several minutes levels decline toward basal despite ongoing hormone stimulation. Here we show that deactivation of p21(ras) correlates closely with phosphorylation of Sos and dissociation of Sos from Grb2, and that inhibition of mitogen-activated protein (MAP) kinase kinase (also known as extracellular signal-related kinase (ERK) kinase, or MEK) blocks both events, resulting in prolonged p21(ras) activation. These data suggest that a negative feedback loop exists whereby activation of the Raf/MEK/MAP kinase cascade by p21(ras) causes Sos phosphorylation and, therefore, Sos/Grb2 dissociation, Limiting the duration of p21(ras) activation by growth factors. A serine/threonine kinase downstream of MEK (probably MAP kinase) mediates this desensitization feedback pathway.	UNIV CALIF SAN DIEGO,DEPT MED 0673,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; VET ADM MED CTR,RES SERV,SAN DIEGO,CA 92161; TOYAMA MED & PHARMACEUT UNIV,DEPT MED 1,TOYAMA 93001,JAPAN; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Toyama; Pfizer			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NIDDK NIH HHS [DK33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BOS JL, 1989, CANCER RES, V49, P4682; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1991, EMBO J, V5, P1103; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; DUDLEY DT, 1995, IN PRESS P NATL ACAD; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; JHUN BH, 1994, J BIOL CHEM, V269, P5699; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WATERS SB, 1995, MOL CELL BIOL, V15, P2791	36	161	161	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25320	25323		10.1074/jbc.270.43.25320	http://dx.doi.org/10.1074/jbc.270.43.25320			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592690	hybrid			2022-12-27	WOS:A1995TB46600006
J	RUETZ, S; GROS, P				RUETZ, S; GROS, P			ENHANCEMENT OF MDR2-MEDIATED PHOSPHATIDYLCHOLINE TRANSLOCATION BY THE BILE-SALT TAUROCHOLATE - IMPLICATIONS FOR HEPATIC BILE FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; BACTERIAL TRANSPORT PROTEINS; PRODUCT P-GLYCOPROTEIN; SECRETORY VESICLES; EXPRESSION; CELLS; CHOLESTEROL; COLCHICINE; TISSUES; YEAST	Expression of the Mdra-protein in secretory vesicules (SVs) from the yeast mutant sec6-4 causes a time- and temperature-dependent enhancement of phosphatidylcholine (PC) translocation from the outer to the inner leaflet of the SV lipid bilayer. We show that this activity is independent of changes either in the membrane potential or the pH gradient (inside positive) generated in these SVs by the yeast proton-translocating PMA1 ATPase. However, loading of the SVs with the primary bile salt taurocholate results in an apparent enhancement of Mdr2-mediated PC translocation activity. Reducing the intravesicular taurocholate (TC) concentration by dissipating the electrochemical potential across the SV membranes eliminates the enhancing effect of TC. Three Lines of evidence suggest that the enhanced Mdr2-mediated PC translocation activity is not caused by a regulatory effect of TC on Mdr2 but rather reflected the formation of TC/PC aggregates or micelles in the lumen of SVs. First, significantly higher detergent concentrations are required to reveal the fluorescence of (7-niaro-2-1,3-benzoxadiazol-4-yl)amino- molecules translocated in Mdr2-SV under conditions of TC stimulation than under control conditions; second, the nonmicelle-forming bile salt taurodehydrocholate does not cause enhancement of PC translocation in Mdr2-SVs; third, enzyme marker studies indicate that TC behaves as a potent lipid solubilizer directly extracting PC molecules out of the bilayer without causing leakage. This results in the formation of intravesicular aggregates or mixed micelles, and provokes the apparent stimulation of Mdr2 activity. These data demonstrate a unique relationship between Mdr2, PC, and TC in the process of bile formation and secretion.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA	McGill University								ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; BALINT JA, 1971, J LAB CLIN MED, V77, P122; BARNWELL SG, 1984, BIOCHEM J, V220, P723, DOI 10.1042/bj2200723; BOYER JL, 1992, ANNU REV PHYSIOL, V54, P415, DOI 10.1146/annurev.ph.54.030192.002215; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAREY MC, 1972, ARCH INTERN MED, V130, P506, DOI 10.1001/archinte.130.4.506; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COLEMAN R, 1992, BIOCHIM BIOPHYS ACTA, V1125, P113, DOI 10.1016/0005-2760(92)90036-U; COLEMAN R, 1987, BIOCHEM J, V244, P249, DOI 10.1042/bj2440249; COLEMAN R, 1989, BIOCHEM J, V258, P17, DOI 10.1042/bj2580017; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVAUX PF, 1994, CHEM PHYS LIPIDS, V73, P107, DOI 10.1016/0009-3084(94)90177-5; FELLE H, 1980, BIOCHEMISTRY-US, V19, P3585, DOI 10.1021/bi00556a026; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gros P, 1993, Int Rev Cytol, V137C, P169; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HARDISON WG, 1972, AM J PHYSIOL, V222, P61, DOI 10.1152/ajplegacy.1972.222.1.61; HAYAKAWA T, 1990, GASTROENTEROLOGY, V99, P216, DOI 10.1016/0016-5085(90)91251-Z; HIGGINS CF, 1994, CELL, V79, P393, DOI 10.1016/0092-8674(94)90248-8; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; JONES AL, 1979, LAB INVEST, V40, P512; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; LOWE PJ, 1984, BIOCHEM J, V222, P631, DOI 10.1042/bj2220631; MAZER NA, 1979, BIOCHEMISTRY-US, V18, P3064, DOI 10.1021/bi00581a024; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; RODA A, 1983, J BIOL CHEM, V258, P6362; ROEPE PD, 1993, BIOCHEMISTRY-US, V32, P11042, DOI 10.1021/bi00092a014; RUETZ S, 1993, P NATL ACAD SCI USA, V90, P11588, DOI 10.1073/pnas.90.24.11588; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SAGAWA H, 1993, AM J PHYSIOL, V264, pG835, DOI 10.1152/ajpgi.1993.264.5.G835; SAKISAKA S, 1988, GASTROENTEROLOGY, V95, P793, DOI 10.1016/S0016-5085(88)80030-1; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SCHLEMMER SR, 1994, J BIOL CHEM, V269, P31059; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; STPIERRE MV, 1994, P NATL ACAD SCI USA, V91, P9476, DOI 10.1073/pnas.91.20.9476; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163	49	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25388	25395		10.1074/jbc.270.43.25388	http://dx.doi.org/10.1074/jbc.270.43.25388			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592705	hybrid			2022-12-27	WOS:A1995TB46600021
J	HAGEN, G; DENNIG, J; PREISS, A; BEATO, M; SUSKE, G				HAGEN, G; DENNIG, J; PREISS, A; BEATO, M; SUSKE, G			FUNCTIONAL ANALYSES OF THE TRANSCRIPTION FACTOR SP4 REVEAL PROPERTIES DISTINCT FROM SP1 AND SP3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; DNA-BINDING; GEL-ELECTROPHORESIS; MAMMALIAN-CELLS; ACTIVATION; DROSOPHILA; CLONING; DOMAINS; EXPRESSION; ELEMENT	Sp4 is a human sequence-specific DNA binding protein with structural features similar to those described for the transcription factors Sp1 and Sp3. These three proteins contain two glutamine-rich regions and a highly conserved DNA binding domain composed of three zinc fingers. Consistently, Sp1, Sp3, and Sp4 do have the same DNA binding specificities. In this report, we have embarked on a detailed analysis of the transcriptional properties of Sp4 in direct comparison to Sp1 and Sp3. Cotransfection experiments into Drosophila SL2 cells lacking endogenous Sp factors demonstrate that Sp4 is an activator protein like Sp1. However, in contrast to Sp1, Sp4 is not able to act synergistically through adjacent binding sites. The transactivation function of Sp4 resides, like that of Sp1, in the N-terminal glutamine-rich region. Sp4 can function as a target for the Sp1 activation domains in a superactivation assay, suggesting that the activation domains of Sp1 and Sp4 are functionally related. Furthermore, we show that Sp4-mediated transcriptional activation can be repressed by Sp3. Taken together, our results demonstrate that the transcription factor Sp4 exhibits specific functional properties distinct from Sp1 and Sp3.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY	Philipps University Marburg			Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222; Suske, Guntram/0000-0002-4807-0513				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1986, TRENDS BIOCHEM SCI, V11, P395, DOI 10.1016/0968-0004(86)90149-0; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; IMATAKA H, 1992, EMBO J, V11, P3653; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; Suske Guntram, 1992, Gene Expression, V2, P339	29	190	190	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					24989	24994		10.1074/jbc.270.42.24989	http://dx.doi.org/10.1074/jbc.270.42.24989			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559627	hybrid			2022-12-27	WOS:A1995TB46500061
J	HOE, MH; SLUSAREWICZ, P; MISTELI, T; WATSON, R; WARREN, G				HOE, MH; SLUSAREWICZ, P; MISTELI, T; WATSON, R; WARREN, G			EVIDENCE FOR RECYCLING OF THE RESIDENT MEDIAL/TRANS GOLGI ENZYME, N-ACETYLGLUCOSAMINYLTRANSFERASE-I, IN LDLD-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; O-LINKED GLYCOSYLATION; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; CYTOPLASMIC DOMAIN; MANNOSIDASE-II; OKADAIC ACID; FREE SYSTEM; TRANSPORT; APPARATUS	ldlD cells, which lack the UDP-Gal/UDP-GalNAc 4-epimerase, were stably transfected with a Myc-tagged version of N-acetylglucosaminyltransferase I (Myc-Glc-NAc-T I). In the absence of GalNAc and Gal, newly synthesized GlcNAc-T I did not acquire O-linked oligosaccharides but was catalytically active and was transported to the Golgi region as defined using both immunofluorescence and immunoelectron microscopy. After addition of cycloheximide to prevent further synthesis, GalNAc and Gal were added, and the unglycosylated GlcNAc-T I was found to acquire mature, O-linked oligosaccharides with a half-time of about 150 min. The addition of these sugars was sensitive to N-ethylmaleimide and okadaic acid, both inhibitors of vesicle-mediated traffic. Together, these results suggest that Myc-GlcNAc-T I undergoes retrograde transport to the early part of the Golgi apparatus where the first O-linked sugar, GalNAc, is added followed by anterograde transport back to the Golgi stack, where addition of Gal and sialic acid occurs.	IMPERIAL CANC RES FUND, CELL BIOL LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ALCALDE J, 1994, J CELL BIOL, V124, P649, DOI 10.1083/jcb.124.5.649; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BRETZ R, 1977, EUR J BIOCHEM, V77, P181, DOI 10.1111/j.1432-1033.1977.tb11656.x; CANAANI D, 1982, P NATL ACAD SCI-BIOL, V79, P5166, DOI 10.1073/pnas.79.17.5166; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DESCHUYTENEER M, 1988, J BIOL CHEM, V263, P2452; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GONATAS JO, 1989, J BIOL CHEM, V264, P646; GREEN J, 1981, J MOL BIOL, V152, P663, DOI 10.1016/0022-2836(81)90122-4; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; Huttner WB, 1989, CURR OPIN CELL BIOL, V1, P648, DOI 10.1016/0955-0674(89)90029-X; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JOHNSTON PA, 1994, J CELL SCI, V107, P529; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; Kornfeld R., 1980, BIOCH GLYCOPROTEINS, P1; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOZARSKY K, 1988, P NATL ACAD SCI USA, V85, P4335, DOI 10.1073/pnas.85.12.4335; KRIEGER M, 1989, METHOD CELL BIOL, V32, P57; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; LUCOCQ J, 1991, J CELL SCI, V100, P753; MISTELI T, 1995, J CELL SCI, V108, P2715; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NIEMANN H, 1982, EMBO J, V1, P1499, DOI 10.1002/j.1460-2075.1982.tb01346.x; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1987, J BIOL CHEM, V262, P12502; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; SOUTHERN PJ, 1981, IN VITRO, V18, P315; STROUS GJAM, 1982, J BIOL CHEM, V257, P7623; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VISCHER P, 1981, EUR J BIOCHEM, V117, P275, DOI 10.1111/j.1432-1033.1981.tb06334.x; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WARREN G, 1987, NATURE, V327, P17, DOI 10.1038/327017a0; WATTENBERG BW, 1990, J CELL BIOL, V111, P421, DOI 10.1083/jcb.111.2.421; WEIBEL ER, 1969, J CELL BIOL, V42, P68, DOI 10.1083/jcb.42.1.68; WERTZ GW, 1989, J VIROL, V63, P4767, DOI 10.1128/JVI.63.11.4767-4776.1989; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WONG SH, 1993, J BIOL CHEM, V268, P22853; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	67	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25057	25063		10.1074/jbc.270.42.25057	http://dx.doi.org/10.1074/jbc.270.42.25057			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559636	hybrid			2022-12-27	WOS:A1995TB46500070
J	YAMADA, K; HARADA, N; HONDA, S; TAKAGI, Y				YAMADA, K; HARADA, N; HONDA, S; TAKAGI, Y			REGULATION OF PLACENTA-SPECIFIC EXPRESSION OF THE AROMATASE CYTOCHROME-P-450 GENE - INVOLVEMENT OF THE TROPHOBLAST-SPECIFIC ELEMENT-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; TISSUE-SPECIFIC EXPRESSION; HUMAN SKIN FIBROBLASTS; ADIPOSE STROMAL CELLS; MESSENGER-RNA; GRANULOSA-CELLS; MAMMALIAN-CELLS; ALTERNATIVE USE; PHORBOL ESTERS; CYCLIC-AMP	The aromatase (cytochrome P-450(AROM)) gene contains multiple untranslated exons I that are differentially transcribed in a tissue-specific manner. DNA sequences within the initial -301 upstream of placenta-specific exon I (exon Ia) are sufficient for placenta-specific expression of aromatase. In gel mobility shift assay, three separate domains in this region form specific binding complexes with proteins extracted from choriocarcinoma JEG-3 nuclei. A fragment containing these domains activates transcription driven by a heterologous promoter in a cell type-specific manner. Two of the binding domains that form major complexes in gel shift assay compete with each other and with a DNA fragment containing the trophoblast-specific element (TSE), which is derived from the enhancer region of the human chorionic gonadotropin alpha-subunit gene and is believed to confer placenta-specific expression of the gene. The core sequence RNCCTNNRG is sufficient for recognition of the TSE-binding protein, which is detected only in nuclear extracts prepared from placenta and choriocarcinoma. A mutation introduced in the distal TSE core in aromatase promoter resulted in marked reduction of transcriptional activity, although TSE region by itself did not show enhancer activity as that in human chorionic gonadotropin alpha-subunit gene.			YAMADA, K (corresponding author), FUJITA HLTH UNIV,SCH MED,INST COMPREHENS MED SCI,DIV MOLEC GENET,TOYOAKE,AICHI 47011,JAPAN.							ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; BERKOVITZ GD, 1992, J CLIN ENDOCR METAB, V74, P629, DOI 10.1210/jc.74.3.629; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; CROSS JC, 1994, MOL BIOL CELL S, V5, P453; DANIEL SAJ, 1980, ENDOCRINOLOGY, V107, P1027, DOI 10.1210/endo-107-4-1027; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DORRINGTON JH, 1975, P NATL ACAD SCI USA, V72, P2677, DOI 10.1073/pnas.72.7.2677; EVANS CT, 1987, J BIOL CHEM, V262, P6914; GARZO VG, 1984, AM J OBSTET GYNECOL, V148, P657, DOI 10.1016/0002-9378(84)90769-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P757; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HARADA N, 1988, J BIOCHEM-TOKYO, V103, P106, DOI 10.1093/oxfordjournals.jbchem.a122213; HARADA N, 1992, BIOCHEM BIOPH RES CO, V189, P1001, DOI 10.1016/0006-291X(92)92303-F; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; HOLLENBERG AN, 1994, MOL CELL ENDOCRINOL, V106, P111, DOI 10.1016/0303-7207(94)90192-9; HONDA S, 1994, BIOCHEM BIOPH RES CO, V198, P1153, DOI 10.1006/bbrc.1994.1163; ITO A, 1990, BIOCHEM INT, V22, P235; JAMESON JL, 1989, J BIOL CHEM, V264, P16190; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KILGORE MW, 1992, MOL CELL ENDOCRINOL, V83, pR9, DOI 10.1016/0303-7207(92)90202-H; KRASNOW JS, 1990, MOL ENDOCRINOL, V4, P13, DOI 10.1210/mend-4-1-13; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAHENDROO MS, 1991, J BIOL CHEM, V266, P11276; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005, DOI 10.1210/mend-5-12-2005; MENDELSON CR, 1982, ENDOCRINOLOGY, V111, P1077, DOI 10.1210/endo-111-4-1077; MENDELSON CR, 1986, ENDOCRINOLOGY, V118, P968, DOI 10.1210/endo-118-3-968; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; NAFTOLIN F, 1972, ENDOCRINOLOGY, V90, P295, DOI 10.1210/endo-90-1-295; PITTMAN RH, 1994, J BIOL CHEM, V269, P19360; RITVOS O, 1992, ENDOCRINOLOGY, V130, P61, DOI 10.1210/en.130.1.61; ROSELLI CE, 1985, ENDOCRINOLOGY, V117, P2471, DOI 10.1210/endo-117-6-2471; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; THOMPSON EA, 1974, J BIOL CHEM, V249, P5373; TJAN R, 1994, CELL, V77, P5; TODA K, 1992, EUR J BIOCHEM, V205, P303, DOI 10.1111/j.1432-1033.1992.tb16781.x; TODA K, 1993, EUR J BIOCHEM, V213, P383, DOI 10.1111/j.1432-1033.1993.tb17772.x; TODA K, 1990, EUR J BIOCHEM, V193, P559, DOI 10.1111/j.1432-1033.1990.tb19372.x; UCHIUMI F, 1992, MOL CELL BIOL, V12, P3784, DOI 10.1128/MCB.12.9.3784; VALLADARES LE, 1979, P NATL ACAD SCI USA, V76, P4460, DOI 10.1073/pnas.76.9.4460; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; YAMADA K, 1994, CYTOCHROME P450, P651	44	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	1995	270	42					25064	25069		10.1074/jbc.270.42.25064	http://dx.doi.org/10.1074/jbc.270.42.25064			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB465	7559637	hybrid			2022-12-27	WOS:A1995TB46500071
J	ANDRIEU, N; SALVAYRE, R; JAFFREZOU, JP; LEVADE, T				ANDRIEU, N; SALVAYRE, R; JAFFREZOU, JP; LEVADE, T			LOW-TEMPERATURES AND HYPERTONICITY DO NOT BLOCK CYTOKINE-INDUCED STIMULATION OF THE SPHINGOMYELIN PATHWAY BUT INHIBIT NUCLEAR FACTOR-KAPPA-B ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; RECEPTOR-MEDIATED ENDOCYTOSIS; CELL-FREE SYSTEM; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; HL-60 CELLS; PROTEIN-KINASE; CYTOSOLIC PROTEIN; PHOSPHOLIPASE-C; GENE-EXPRESSION	In order to better understand the significance of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta)-receptor internalization in the sphingomyelin pathway signal transduction, we investigated receptor signaling under conditions in which receptor internalization is blocked. We demonstrate that human recombinant TNF-alpha and IL-1 beta both induced sphingomyelin and phosphatidylcholine hydrolysis at either 4, 14, or 37 degrees C in human skin fibroblasts and U937 monocytic cells. Cytokine-induced sphingomyelin degradation also occurred when endocytosis was inhibited by incubating the cells in hypertonic medium. While internalization was not required for the production of ceramide, activation of the transcription factor NF-kappa B was strongly reduced when cells were stimulated with TNF at low temperature or in hypertonic medium. Under these conditions, activation of NF-kappa B by the cell-permeant C-2-ceramide (N-acetylsphingosine), by exogenous sphingomyelinase or by phorbol myristate acetate was also inhibited. These results suggest that low temperature and hypertonicity, two inhibitors of receptor internalization: (i) do not affect the TNF-alpha- or IL-1 beta-induced sphingomyelin hydrolysis, but (ii) do inhibit a step distal to ceramide of the intracellular signaling pathway leading to NF-kappa B activation.	CHU RANGUEIL,INST LOUIS BUGNARD,INSERM,CJF 9206,BIOCHIM MALAD METAB LAB,F-31054 TOULOUSE,FRANCE; CNRS,CTR CLAUDIUS REGAUD,TOULOUSE,FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Institut Claudius Regaud			Andrieu-Abadie, Nathalie/N-6793-2013; Levade, Thierry/O-8948-2014	Andrieu-Abadie, Nathalie/0000-0003-2698-1970; 				Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BRADLEY JR, 1993, J IMMUNOL, V150, P5544; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FALK W, 1989, LYMPHOKINE RES, V8, P263; FOLCH J, 1957, J BIOL CHEM, V226, P497; GRABER D, 1994, J NEUROCHEM, V63, P1060; HAIMOVITZFRIEDM.A, 1994, J EXP MED, V180, P525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HIGUCHI M, 1994, J IMMUNOL, V152, P3550; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JOHNS LD, 1994, J IMMUNOL, V152, P5877; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRALL JF, 1985, J BIOL CHEM, V260, P9685; KRONKE M, 1992, TUMOR NECROSIS FACTO, P189; KULL FC, 1981, CANCER RES, V41, P4885; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; LANGIN D, 1993, P NATL ACAD SCI USA, V90, P4897, DOI 10.1073/pnas.90.11.4897; LE JM, 1987, LAB INVEST, V56, P234; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MOHANDAS DV, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OKUDA K, 1991, BLOOD, V78, P1928; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; RAINES MA, 1993, J BIOL CHEM, V268, P14572; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; RIVAS CI, 1994, BLOOD, V83, P2191; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1989, J BIOL CHEM, V264, P3562; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SILVERSTEIN SC, 1977, ANNU REV BIOCHEM, V46, P669, DOI 10.1146/annurev.bi.46.070177.003321; SMITH MR, 1990, J IMMUNOL, V144, P162; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOLARI R, 1994, BIOCHEM PHARMACOL, V47, P93, DOI 10.1016/0006-2952(94)90441-3; SUFFYS P, 1987, BIOCHEM BIOPH RES CO, V149, P735, DOI 10.1016/0006-291X(87)90429-3; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; UNGLAUB R, 1987, J EXP MED, V166, P1788, DOI 10.1084/jem.166.6.1788; Via D P, 1986, Methods Enzymol, V129, P848; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; YANAGA F, 1992, FEBS LETT, V314, P297, DOI 10.1016/0014-5793(92)81493-6; YANG ZH, 1993, J BIOL CHEM, V268, P20520	65	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24518	24524		10.1074/jbc.270.41.24518	http://dx.doi.org/10.1074/jbc.270.41.24518			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592669	hybrid			2022-12-27	WOS:A1995TA21700097
J	FENG, XH; FILVAROFF, EH; DERYNCK, R				FENG, XH; FILVAROFF, EH; DERYNCK, R			TRANSFORMING GROWTH-FACTOR-BETA (TGF-BETA)-INDUCED DOWN-REGULATION OF CYCLIN-A EXPRESSION REQUIRES A FUNCTIONAL TGF-BETA RECEPTOR COMPLEX - CHARACTERIZATION OF CHIMERIC AND TRUNCATED TYPE-I AND TYPE-II RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; CELL-CYCLE; ACTIVIN RECEPTOR; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; PROTEIN; CLONING; FACTOR-BETA-1; INHIBITION; BINDING	Transforming growth factor-beta (TGF-beta) inhibits the proliferation of epithelial cells by altering the expression or function of various components of the cell cycle machinery, Expression of one of these components, cyclin A, is inhibited by TGF-beta treatment, We have identified a 760-base pair fragment of the human cyclin A gene promoter that is sufficient to confer TGF-beta responsiveness, Using this promoter fragment, we have developed a cyclin A-based luciferase reporter assay that quantitates the growth inhibitory effect of TGF-beta in transient transfection assays, This assay was used to determine which domains of the type I (RI) and type II (RII) receptors were required for the antiproliferative effect of TGF-beta. In parallel, the functionality of chimeric receptors, between RI and RII (RI-RII: or RII-RI), was tested for TGF-beta effect on gene expression using a reporter assay based on the plasminogen activator inhibitor type 1 (PAI-1) promoter, We found that TGF-beta-induced inhibition of cyclin A expression was absent in RI or RII-deficient Mv1Lu cells and that this response was restored by expression of wild-type type I or type II receptors in these cells, Furthermore, expression of a single chimeric receptor, either RI-RII or RII-RI, did not confer cyclin A regulation by TGF-beta, However, expression of two reciprocal chimeras (RI-RII and RII-RI) resulted in growth inhibition, similarly to wildtype receptors, In addition, chimeric receptors as well as mutant receptors with a deleted cytoplasmic domain and kinase-negative receptors inhibited TGF-beta responsiveness. in the cyclin A reporter assay in a dominant negative fashion, Finally, in both receptor types, the juxtamembrane domain preceding the kinase-domain was essential for receptor function but the cytoplasmic tail was dispensable, Our results suggest that a functional TGF-beta receptor complex is required for TGF-beta-dependent down-regulation of cyclin A gene expression and illustrate the identical receptor requirements for TGF-beta-induced growth inhibition and gene expression.	UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,PROGRAM CELL & DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM CELL & DEV BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA63101] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATAYAKULCHANT.S, 1994, J BIOL CHEM, V269, P27687; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BASSING CH, 1994, J BIOL CHEM, V269, P14861; BRAND T, 1995, J BIOL CHEM, V270, P8274, DOI 10.1074/jbc.270.14.8274; BRAND T, 1993, J BIOL CHEM, V268, P11500; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Derynck R, 1994, CYTOKINE HDB, P319; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; EBLEN ST, 1994, CELL GROWTH DIFFER, V5, P109; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FAFEUR V, 1993, MOL BIOL CELL, V4, P135, DOI 10.1091/mbc.4.2.135; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LANDESMAN Y, 1992, ONCOGENE, V7, P1661; LAWLER S, 1994, DEVELOPMENT, V120, P165; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; OKADOME T, 1994, J BIOL CHEM, V269, P30753; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RALPH D, 1993, P NATL ACAD SCI USA, V90, P10710, DOI 10.1073/pnas.90.22.10710; REDDY KB, 1994, J CELL BIOCHEM, V56, P418, DOI 10.1002/jcb.240560318; SATTERWHITE DJ, 1994, CELL GROWTH DIFFER, V5, P789; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TENDIJKE P, 1993, ONCOGENE, V8, P2879; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, COLD SPRING HARB SYM, V57, P81, DOI 10.1101/SQB.1992.057.01.011; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZINDY F, 1991, BIOCHEM BIOPH RES CO, V182, P1144	73	147	154	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24237	24245		10.1074/jbc.270.41.24237	http://dx.doi.org/10.1074/jbc.270.41.24237			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592630	hybrid			2022-12-27	WOS:A1995TA21700058
J	KIRK, K; HORNER, HA				KIRK, K; HORNER, HA			NOVEL ANION DEPENDENCE OF INDUCED CATION-TRANSPORT IN MALARIA-INFECTED ERYTHROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNEL; PLASMODIUM-FALCIPARUM; CELL MEMBRANE; PERMEABILITY; PARASITES; LACTATE; BLOOD	Following invasion by the malaria parasite there appear in the parasitized erythrocyte new (''induced''') permeation pathways that mediate the transport of a wide variety of small solutes, Although anion-selective, these pathways have a significant cation permeability and cause a substantial increase in the basal leak of cations into and out of the infected cell. In this study of human erythrocytes infected in vitro with Plasmodium falciparum it was shown that the transport of monovalent cations (Rb+ and choline), but not that of a nonelectrolyte (sorbitol) or a monovalent anion (lactate), via the malaria induced pathways is strongly dependent on the nature of the anion in the suspending medium. Substitution of NO3- for Cl- resulted in a 4-6-fold increase in the unidirectional influx and efflux of Rb+, and a 2-3-fold increase in the influx of choline via the induced pathways, By contrast, replacement of Cl- with NO3- caused a slight (although not significant) decrease in the malaria-induced influx of sorbitol and lactate, Hemolysis experiments with a range of K+ salts revealed that the net influx of K+ into infected cells showed the same novel anion dependence as seen for the unidirectional flux of Rb+ and choline, with hemolysis occurring much faster in iso-osmotic KNO3 and KSCN solutions than in KCl, KBr, or KI solutions, Hemolysis in the corresponding Na+ salt solutions was very much slower, consistent with the induced pathways being selective for K+ over Na+, and raising the possibility that the efflux of cell K+ via these pathways may play a role in host cell volume regulation. A number of models that would account for the anion dependence of malaria-induced cation transport are considered.			KIRK, K (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.		Kirk, Kiaran/C-8299-2009	Kirk, Kiaran/0000-0002-5613-2622	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; CABANTCHIK ZI, 1990, BLOOD CELLS, V16, P421; ELFORD BC, 1995, BIOCHEM J, V308, P361, DOI 10.1042/bj3080361; ELLORY JC, 1992, FEBS LETT, V296, P219, DOI 10.1016/0014-5793(92)80383-R; FRANCIOLINI F, 1990, BIOCHIM BIOPHYS ACTA, V1031, P247, DOI 10.1016/0304-4157(90)90009-2; GERO AM, 1992, PARASITOL TODAY, V8, P283, DOI 10.1016/0169-4758(92)90147-T; GERO AM, 1994, PARASITOL TODAY, V10, P395, DOI 10.1016/0169-4758(94)90231-3; GINSBERG H, 1990, COMP BIOCHEM PHYS A, V95, P31, DOI 10.1016/0300-9629(90)90006-E; GINSBURG H, 1988, P188; GINSBURG H, 1983, MOL BIOCHEM PARASIT, V8, P177, DOI 10.1016/0166-6851(83)90008-7; GINSBURG H, 1987, J MEMBRANE BIOL, V96, P1, DOI 10.1007/BF01869329; GINSBURG H, 1994, BIOCHEM PHARMACOL, V48, P1847, DOI 10.1016/0006-2952(94)90582-7; GINSBURG H, 1985, MOL BIOCHEM PARASIT, V14, P315; KANAANI J, 1991, J CELL PHYSIOL, V149, P469, DOI 10.1002/jcp.1041490316; KIRK K, 1993, FEBS LETT, V323, P123, DOI 10.1016/0014-5793(93)81462-9; KIRK K, 1992, J BIOL CHEM, V267, P23475; KIRK K, 1994, J BIOL CHEM, V269, P3339; KIRK K, 1992, BIOCHIM BIOPHYS ACTA, V1135, P8, DOI 10.1016/0167-4889(92)90159-9; KIRK K, 1995, IN PRESS BIOCH J, V311; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; PASVOL G, 1978, ANN TROP MED PARASIT, V72, P87, DOI 10.1080/00034983.1978.11719283; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; UPSTON JM, 1995, BBA-BIOMEMBRANES, V1236, P249, DOI 10.1016/0005-2736(95)00055-8; ZARCHIN S, 1986, BIOCHEM PHARMACOL, V35, P2435, DOI 10.1016/0006-2952(86)90473-9	24	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	1995	270	41					24270	24275		10.1074/jbc.270.41.24270	http://dx.doi.org/10.1074/jbc.270.41.24270			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TA217	7592635	hybrid			2022-12-27	WOS:A1995TA21700063
